Benign Neoplasms

Synonym
Benign Neoplasms
Neoplasms, Benign
Neoplasia
Malignancy
Tumors
Cancer
Malignant Neoplasms
Neoplasm

Synonym

Benign Neoplasms

Neoplasms, Benign

Neoplasia

Malignancy

Tumors

Cancer

Malignant Neoplasms

Neoplasm

Research Excerpts

Overview

Excerpt	Reference
"Patients with solid tumors are more likely to be deficient only in the response to newly encountered antigens."	( Burdick, JF; Herberman, RB; Wells, SA, 1975)
"Cancer is unable to go into the radical state."	( Szent-Györgyi, A, 1977)
"Cancers are a broad spectrum of diseases in which there are altered growth fractions and cell-turnover fractions, and therefore cancer chemotherapeutic agents have been developed to take tumor kinetics into account."	( Russell, DH, 1977)
"Human tumors are in general more efficient producers of fluorodeoxyuridylate than murine tumors."	( Ardalan, B; Cooney, D; Macdonald, JS; Schein, PS, 1979)
"Malignant tumors are known to have a "remote" or nonmetastatic effect on the central and peripheral nervous systems."	( Barron, SA; Heffner, RR, 1978)
"Different types of cancer are not necessarily affected by dietary components in the same manner."	( Alcantara, EN; Speckmann, EW, 1976)
"Two kinds of neoplasm are now known to be associated with human exposure to anabolic agents: vaginal adenocarcinoma and liver-cell tumours."	( Rose, FJ, 1976)
"Cancer is described as a disease of abnormal cell and tissue differentiation, and its underlying cause is identified in the process of blocked reontogeny."	( Longenecker, JP; Williams, JF, 1977)
"Lung cancer is excessive in curing workers."	( Burgess, WA; Fine, LJ; Monson, RR; Peters, JM, 1976)
"Tumors are chemically active and the important concept which has had great impact on the diagnosis, treatment, and basic understanding of mechanisms, which are important to endocrinologists and oncologists has been stated by Liddle: "Certain tumors of nonendocrine tissue can produce hormones that are similar to normal hormones except that their production is not appropriately controlled by normal physiologic mechanisms."	( Bartuska, DG, 1975)
"Mortality due to cancers is generally negatively correlated to serum cholesterol levels with a significant increase in mortality in patients with a low serum cholesterol."	( Bruckert, E; Delahaye, F; Emmerich, J; Richard, JL; Thomas, D, 1992)
"Pain from cancer is said to be poorly relieved."	( Lied, VF; Manger, AT; Ottesen, S, 1992)
"Since human cancers are of the insulin-producing/secreting or insulin-dependent types, it is suggested that screening of individuals for blood insulin level and reducing the insulin status by dietary means may lead to a decreased risk of cancer."	( Yam, D, 1992)
"Hypercalcemia of malignancy is a commonly encountered serious clinical problem that often requires aggressive therapy."	( Fatemi, S; Rude, RK; Singer, FR, 1992)
"Advanced cancer is often accompanied by anaemia, which may worsen with concomitant administration of chemotherapy."	( Abels, RI, 1992)
"Cancer is frequently complicated by anemia, and a survey of serum erythropoietin concentrations in anemic cancer patients showed inappropriately low concentrations for the degree of anemia."	( Spivak, JL, 1992)
"Ovarian cancer is unique in that neoplasms arise from the epithelium, not the hormone-sensitive tissue."	( King, RJ, 1991)
"These stage I tumors are highly curable when they first present but, if allowed to recur, chemotherapy may not offer the patient such a favorable response and cure rate."	( Exelby, P; Ghavimi, F; Luks, E; Wachtel, A; Wollner, N; Woodruff, J, 1991)
"Cancer is now being appreciated in India as an emerging public health problem."	( Mathew, B; Mayadevi, S; Nair, MK; Sankaranarayanan, R; Wesley, R, 1992)
"Cancer is characterized primarily by an increase in the number of abnormal cells derived from a given normal tissue, invasion of adjacent tissues by these abnormal cells, and lymphatic or blood-borne spread of malignant cells to regional lymph nodes and to distant sites (metastasis)."	( Clemens, MR, 1991)
"Mutations in lung cancer are therefore caused by a different mechanism than colorectal cancer and this presumably requires the direct interaction of carcinogens with DNA."	( Coetzee, GA; Jones, PA; Olumi, AF; Rideout, WM; Spruck, CH, 1991)
"These cancers are putatively promoted by estradiol, bile acids and androgens."	( Troll, W, 1991)
"Colon cancer is also etiologically linked to cholesterol oxidation products."	( Hu, B; Morin, RJ; Peng, SK; Sevanian, A, 1991)
"At present, cancer is responsible for almost half of all deaths among women 45-64 years of age, and about 30% of all deaths among men in the same age group (1)."	( Feuer, G; Kerenyi, NA; Pandula, E, 1990)
"Patients with solid tumors are often anemic even before they undergo cytotoxic therapy."	( Abeloff, MD; Jones, RJ; Miller, CB; Piantadosi, S; Spivak, JL, 1990)
"Since cancer is essentially a cell surface problem with loss of contact inhibition, effort might be directed to restoring such inhibition by interfering with activity of new determinants on the cancer cell surface associated with the contact inhibition loss."	( Field, EJ, 1986)
"Most human cancers are resistant to bleomycin a priori, however, and those which are initially sensitive frequently develop resistance to the drug during therapy."	( Sikic, BI, 1986)
"If bladder cancer is caused by agents present in the urine, as is widely believed, this mechanism may also protect against carcinogenesis."	( Anderson, K; Kaufman, JE; Parsons, CL, 1987)
"The notion that cancer is a genetic disease has gained increasing credence from the now numerous studies in which specific alterations of chromosome and of gene structure and activity in a variety of cancers have been identified, and, in particular, with the increasing awareness of the heritability of factors that predispose to the development of early, specific cancers in the offspring of parents carrying these predisposing genes."	( Evans, HJ, 1989)
"Cancer is a process of acquisition of an increased variety of cell functions by originally differentiated cells due to the failure of other organs to maintain their specific functions."	( Bok, SW, 1989)
"Hypercalcaemia in malignancy is a major clinical problem."	( Eisman, JA; Kelly, PJ, 1989)
"Tumors are likely to be highly heterogeneous for these dynamic properties."	( Coleman, CN, 1988)
"Cancer is the second leading cause of death in the United States."	( Kinzel, T, 1988)
"If stress and cancer are related by coping failure, that connection presumably involves the immune system."	( Brand, RJ; Fox, BH; Ragland, DR; Rosenman, RH, 1987)
"Patients with cancer are especially predisposed to the development of antibiotic-associated hypoprothrombinemia."	( Bodey, GP; Fainstein, V; Jones, PG; Rolston, KV; Strother, SV, 1986)
"Neoplasms are characterized by increased perfusion, increased permeability of their capillary beds to macromolecules, and a delay in new lymphatic vessel growth."	( Scheffel, U; Tsan, MF, 1986)
"Cancer is one of the most serious illnesses of the elderly."	( Neilan, BA, 1985)
"Since endometrial cancer is probably, and cervical cancer certainly, not enhanced by the pill, the maternal death rate among pill users is about 5% of the rate among unprotected sexually active women."	( Lecart, C, 1973)
"Certain cancers are able to synthesize, store, and secrete peptide hormones."	( Borer, WZ, 1984)
"Cervical cancer is the most common, accounting for 28% of diagnosed tumours and 47% of genital tumours in women."	( Séraphin, JJ, 1984)
"Cancers are clones of abnormal cells, arising presumably as the result of mutational or epignetic alterations of gene expression."	( Cairns, J, 1980)
"When gynecologic cancer is treated by either surgery or radiation therapy, definitive infertility usually results."	( Barber, HR, 1981)
"Cancer is characterized by a relatively autonomous growth of cells due to a reduced responsiveness to normal controls of proliferation and differentiation."	( Hull, LA, 1981)
"Cancer is occasionally associated with an increase in serum TBG."	( Hachiya, T; Ijichi, H; Ishida, M; Kajita, Y; Miyazaki, T; Ochi, Y; Yoshimura, M, 1981)
"Cancer is thought also to produce substances which are structurally different in minute points."	( Hattori, N, 1983)
"These tumors are unique in that they require a trypsin-sensitive surface protein for activity."	( Ambrogio, C; Karpatkin, S; Lerner, WA; Pearlstein, E, 1983)
"The tumors are often associated with the site(s) of deposition of the metal."	( Weinberg, ED, 1983)
"Cancer is a disease that requires follow-up and, in some areas, like breast cancer, a long follow-up."	( Fletcher, GH, 1983)
"Solid tumors are known to contain hypoxic cells and are relatively resistant to ionizing radiation and some chemotherapeutic agents."	( Beaudry, JN; Ludwig, CU; Peng, YM; Salmon, SE, 1984)
"Individuals with cancer are subject to fluid and electrolyte imbalances because of the original disease process, therapy, and complications resulting from both the disease process and from therapy."	( Cunningham, SG, 1982)
"Several tumors are characterized by elevated levels of polyamines involved in vital cell proliferation processes."	( Ali-Osman, F; Maurer, HR, 1983)
"Most of the neoplasms are large, and present as masses in the mediastinum or retroperitoneal space."	( Kahn, CR, 1980)
"Benign tumors are dangerous because they tend to rupture spontaneously."	( Huggins, GR, 1981)
"Malignant tumors are the second most common cause of death in children 0 to 15 years old."	( Ivankovic, S, 1982)
"Malignancy is the most common cause of hypercalcemia, which may result from direct involvement of bone or from local or distant production of substances that enhance bone resorption."	( Flueck, JA; Reynolds, LR, 1981)
"Drug treatment for cancer is now widely utilized and in selected neoplasms offers the opportunity for prolonged remission or even cure."	( Kiely, JM, 1981)
"Human tumors are thus different from tumors from other species which have been reported to be deficient or very low in Mn superoxide dismutase."	( Marklund, SL; Westman, NG, 1981)
"These unusual tumors are located chiefly on the scalp and consists of areas of squamous epithelium with non-epidermal keratinization and moderate cellular polymorphism."	( Janitz, J; Wiedersberg, H, 1980)
"Hypercalcaemia of malignancy is usually the result of both increased bone destruction and decreased urinary calcium excretion."	( Hosking, DJ; Lyons, AR; Patel, S, 1993)
"Gastric cancer is the major cancer in Japan."	( Canzian, F; Inoue, R; Nagao, M; Ohgaki, H; Sugimura, T; Ushijima, T, 1995)
"Cancer is a major world health problem."	( Kodiath, A; Kodiath, MF, 1995)
"Since cancer is mainly a disease of older persons, the incidence of malignancies of all types is expected to increase during the coming decades."	( Urushizaki, I, 1993)
"Hypercalcemia of malignancy is due either to local osteolysis at the site of bone metastases or to production by the malignancy of parathyroid hormone-related peptide, which shares some of the effects of parathyroid hormone."	( Audran, M; Boasson, M; Giraud, P; Jallet, P; Legrand, E; Lortholary, A; Minebois-Villégas, A; Pascaretti, C; Subra, JF, 1995)
"Several human cancers are associated with chronic bacterial, viral and parasitic infections."	( Hotchkiss, JH; Liu, RH, 1995)
"The recurrent tumors are suggested to be sensitive to the agents as follows: locally recurrent solid tumors, 5-FU; distantly recurrent solid tumors, 5-FU and CDDP; locally recurrent effusion, CDDP; distantly recurrent effusion, ADR."	( Araya, S; Hayashi, H; Imamura, M; Ishigami, S; Kawabata, K; Masai, Y; Nio, Y; Tamura, K; Tsubono, M, 1995)
"Cancer is not a notifiable disease in India, and hence registration per force has to be active."	( Gajalakshmi, CK; Ravichandran, K; Shanta, V; Swaminathan, R; Vasanthi, L, 1994)
"Malignant tumors are often complicated by hypercalcemia (malignancy associated hypercalcemia: MAHC) which causes various clinical symptoms."	( Eto, S, 1994)
"As cancer is diagnosed at earlier stages of the disease and survival improves after cancer treatment, hand therapy may improve the functional outcomes of persons with cancer."	( Burkhardt, A; Cook, A, 1994)
"Increasingly, cancer is managed on an outpatient basis with pain management responsibility assumed by the family at home."	( Ahn, C; Ferrell, BA; Ferrell, BR; Tran, K, 1994)
"Evidence for breast cancer is more limited but protective associations with vitamin A from both carotenoid and preformed sources have been seen in several studies."	( Willett, WC, 1994)
"Urinary bladder cancer is the most common form of cancer caused by exposure to benzidine."	( Choudhary, G, 1996)
"Cancer is a genetic disorder of somatic cells."	( Venitt, S, 1996)
"Only bladder tumors are produced in dogs and in humans who have been occupationally exposed, possibly related to the slow rate of liver detoxification by acetylation, allowing activation of BZ or its metabolites in urine."	( Verna, L; Whysner, J; Williams, GM, 1996)
"The anemia of malignancy is common and is related to several etiologic factors, a major one being relative erythropoietin (Epo) deficiency."	( Mittelman, M, 1996)
"Cancer is currently regarded to be the phenotypic expression of an accumulation of heritable alterations in the regulators of cell growth and differentiation."	( Mark, SD, 1996)
"Cancer is often viewed as a genetic process in which the developing cancer cell acquires successive mutational lesions that each provide the cell with a growth or survival advantage."	( Laird, PW, 1997)
"Cancer is primarily a disease of the elderly and the palliation of both disease- and treatment-related symptoms is of importance in the practice of cancer medicine in all patients."	( Carbone, PP; Cleary, JF, 1997)
"Cancer is often associated with chronic anemia which frequently requires blood transfusions."	( Barona, P; Jiménez, M; León, P; Sierrasesúmaga, L, 1998)
"Neoplasia is characterised by abnormal regulation of the cell cycle."	( Chetty, R; Donnellan, R, 1998)
"Cancer is frequently associated with anemia and may be related to inadequate erythropoietin production."	( Barona Zamora, P; Castro Paz, L; Jiménez Monteagudo, M; León Molinari, P; Riol Diego, M; Sierrasesúmaga Ariznavarreta, L, 1998)
"Advanced cancer is commonly associated with significant anemia which worsens with the administration of cytotoxic drugs."	( Hakimali, A; Khan, ZK; Malik, IA; Rehman, G; Sabih, M, 1998)
"If tumors are resistant to methotrexate because of decreased transport of drug (and also folate), then the same pharmacological principle used to develop TMTX/LV for the treatment of P."	( Holcenberg, JS; Hum, M; Kamen, BA; Tkaczewski, I; Weaver, JW; Wilson, J, 1998)
"Patients with cancer are clearly at high risk for the development of venous thromboembolism (VTE), particularly during chemotherapy and surgery."	( Levine, MN; Rickles, FR, 1998)
"Chronic anaemia of cancer is often characterized by inappropriately low levels of endogenous erythropoietin for the degree of anaemia, and manifests clinically with generalized hypoxia and resultant severe fatigue."	( Ludwig, H, 1999)
"In studies where cancer is the endpoint, only three effects have been replicated: (a) selenium supplementation and decreased liver cancer incidence, (b) treatment by the retinoid etretinate and reduced bladder tumours in susceptible individuals, and (c) beta-carotene supplementation and increased lung cancer incidence."	( Lee, PN; Young, KJ, 1999)
"These neoplasms are rare in mice and suggest endocrine dysfunction as a component of preconception carcinogenesis."	( Anderson, LM; Birely, L; Diwan, BA; Haines, DC; Kasprzak, KS; Riggs, CW; Sipowicz, MA; Yu, W, 1999)
"Since cancer is incurable in many patients, palliation of symptoms and quality-of-life issues are important aspects of therapy."	( Bokemeyer, C; Hartmann, JT; Kanz, L; Kollmannsberger, C; Mayer, F, 1999)
"Malignancy is associated with diffuse enlargement of the adrenal glands and resistance to dexamethasone-induced suppression of the HPA axis, which is not due to ectopic ACTH secretion."	( Besser, GM; Jenkins, PJ; Lister, TA; Reznek, R; Sohaib, SA; Trainer, PJ, 1999)
"Most tumors are resistant to therapy by thymidylate synthase (TS) inhibitors due to their high levels of TS."	( Collins, JM; Katki, AG; Klecker, RW, 1999)
"Pediatric cancer is rife with psychological and social issues for both patients and families."	( Gunderman, RB, 2000)
"Trapping of 5-FU in tumors is a necessary, albeit not a sufficient condition, for response."	( Presant, CA; Waluch, V; Wolf, W, 2000)
"Susceptibility to cancer is determined at different levels such as the genetic polymorphism of enzymes involved in the activation and detoxification of carcinogens, the polymorphism of genes that maintains the genome stability, like those involved in DNA repair or recombination processes, and finally the polymorphism in oncogenes or tumour suppressor genes."	( Burnouf, DY; Fuchs, RP, 2000)
"Cancer is a strong risk factor for hospital-acquired thrombosis in the medical ward."	( den Heijer, M; Nijs, AM; Schuurman, B, 2000)
"When tumors are prepared for in vitro assays against drugs, they are routinely treated with proteolytic enzymes (e."	( Egyud, LG; Lipinski, B, 2000)
"As persons with malignancy are at a high risk for developing zoster itself, PHN is a complication that will be faced by many of these patients and their caregivers."	( Mackey, JR; Modi, S; Pereira, J, 2000)
"Cancer is a common life-threatening disease."	( Shudo, K, 2000)
"Hypoxia in tumors is primarily a pathophysiologic consequence of structurally and functionally disturbed microcirculation and the deterioration of diffusion conditions."	( Höckel, M; Vaupel, P, 2001)
"Most neoplasms are dependent on glucose as their primary fuel, and their ambient glucose levels tend to be rather low owing to wasteful aerobic glycolysis and poor perfusion."	( McCarty, MF, 2001)
"Pancreatic cancer is among the most fatal cancers worldwide and one for which few preventable risk factors have been established."	( Albanes, D; Blaser, MJ; Limburg, PJ; Perez-Perez, G; Stolzenberg-Solomon, RZ; Taylor, PR; Virtamo, J, 2001)
"The cancer care team can initiate interventions including patient education and treatments for altered desire, erectile dysfunction, and estrogen deficiency."	( McKee, AL; Schover, LR, 2001)
"Patients with cancer are at risk for developing a variety of fluid and electrolyte disturbances caused by the disease process or by complications from therapy."	( Chan, GZ; Kapoor, M, 2001)
"Cancers are often refractile to this growth inhibition either because of genetic loss of TGF-beta signaling components or, more commonly, because of downstream perturbation of the signaling pathway, such as by Ras activation."	( Akhurst, RJ; Derynck, R, 2001)
"Both AIDS and cancer are linked to immune dysfunctions of the body which are characterized by the persistence of disease-afflicted cells."	( Chang, LJ; He, J, 2001)
"Hypoxia in tumors is associated with malignant progression, metastatic spread, and increased resistance to radiotherapy and chemotherapy."	( Adams, MA; Gofton, TE; Graham, CH; Matthews, NE; Maxwell, LR, 2001)
"Therapy for neoplasma is limited by hematological side effects of tumor-destructive therapy and, in part, makes expensive supportive care necessary to overcome and treat leukopenia and thrombocytopenia and their consequences."	( Dziambor, H; Hager, ED; Höhmann, D; Strama, H; Winkler, P, 2001)
"The hallmark of cancer is genomic instability."	( Fransson, LA, 2001)
"Its use in other tumors is under evaluation, with promise in renal cell carcinoma, prostate cancer, glioma, and Kaposi's sarcoma."	( Anderson, K; Hideshima, T; Richardson, P, 2002)
"Treatment of cancer is increasingly effective but is associated with short and long-term side effects."	( Clarkson, JE; Eden, OB; Worthington, HV, 2002)
"Human cancers are generally characterized by acquisition of a series of somatic mutations."	( Mills, K, 2002)
"Lung cancer is the most frequent of occupational cancers."	( Brochard, P; Matrat, M; Pairon, JC, 2002)
"Nevertheless, cancer is not a frequent disease for the Indian population."	( Desai, PB, 2002)
"Many of cancers are caused by lifestyle elements."	( Chung, FL; Weisburger, JH, 2002)
"Since cancer is not a notifiable disease in India, registration is carried out by active data collection by the registry staff."	( Mandal, S; Parkin, DM; Ramanakumar, AV; Sankaranarayanan, R; Sen, U; Siddiqi, M, 2002)
"In Nigeria, breast cancer is rare, while deaths due to pregnancy and childbirth are common, indicating that OC use can prevent many female deaths."	( Ibekwe, J, 1993)
"Cancer is the 2nd largest cause of death."	( Barros, FC; Lokschin, F, 1984)
"A tar cancer is recorded in 1 control rat."	( Mceuen, CS, 1939)
"Prostate cancer is the growth of malignant cells in the prostate gland, the gland at the base of the urinary bladder in men which helps to create semen."	( , 1996)
"Benign liver tumors are very rare and should not affect prescription of OCs."	( Hecht, Y, 1991)
"30-40% of breast cancers are hormone dependent or sensitive."	( Petit, JC, 1972)
"The risk of breast cancer is increased by an early menarche, late age at 1st birth, and by a late menopause which implicates ovarian steroids in the initiation or promotion of breast cancer, as some breast cancers are estrogen dependent."	( Chandran, R, 1992)
"Hypercalcemia of malignancy is a serious complication of cancer that affects patients with and without bone metastases."	( Major, P, 2002)
"Cancer is the culmination of the chronic disease process, and can be attributed the interactions of environment and genes."	( Zhong, W, 2002)
"Tumors are visible as early as 0."	( Barrett, J; Bartis, J; Bozarth, J; Edwards, S; Ellars, C; Harris, TD; Kalogeropoulos, S; Lazewatsky, J; Liu, S; Nguyen, T; Onthank, D; Robinson, S; Silva, P; Yalamanchili, P, 2003)
"As many tumors are driven by autocrine or paracrine growth through the type-I insulin-like growth factor receptor, mTOR is potentially an attractive target for molecular-targeted treatment."	( Houghton, PJ; Huang, S, 2004)
"Chemoprevention of cancer is reviewed from the viewpoints of action mechanisms and methodology of clinical trials in order to introduce promising agents discovered by in vitro and/or in vivo studies to applications in humans."	( Kakizoe, T, 2003)
"The prevalence of cancer is rising markedly due to increased survival rates."	( Bosanquet, N; Tolley, K, 2003)
"Colorectal cancer is the second most common cause of cancer-related mortality in the west."	( Burgaud, JL; Del Soldato, P; Lavagna, C; Rampal, P, 2003)
"Results for other cancers are sparse."	( Boffetta, P; Nyberg, F, 2003)
"Treatment of cancer is increasingly effective but is associated with short and long-term side effects."	( Clarkson, JE; Eden, OB; Worthington, HV, 2004)
"Cancer is the second leading cause of death in industrialised countries like the United States, where a significant proportion of workers engage in shift work, making a hypothesised relation between light exposure at night and cancer risk relevant."	( Schernhammer, ES; Schulmeister, K, 2004)
"As cancer is predominantly a disease of disordered balance between proliferation, differentiation, and apoptosis, disruptions in the function of the CaR could contribute to the progression of neoplastic disease."	( Rodland, KD, 2004)
"Kidney tumors are heterogeneous in their histology, genetics, and clinical behavior."	( Al-Saleem, T; Babb, JS; Cairns, P; Dulaimi, E; Greenberg, RE; Grizzle, WE; Ibanez de Caceres, I; Polascik, TJ; Uzzo, RG, 2004)
"Cancer is one of the leading causes of death in children."	( Agarwal, S; Khanna, G; Mishra, K; Sharma, S, 2004)
"Cancer is the second leading cause of death in the western world."	( Ganesan, TS; Madhusudan, S, 2004)
"Breast cancer is the only other cancer demonstrating endogenous functional NIS expression."	( Adelman, D; Carrasco, N; Dohan, O; Goris, M; Nowels, K; Wapnir, IL; Yudd, A, 2004)
"Cancer is one of the major health problems around the world."	( Li, Y; Sarkar, FH, 2004)
"Not a few of the cancers are of transitional cell type, that is to say are expressive of an intermediate stage in the metaplasia."	( SMITH, WE, 1950)
"The ICC tumors are called gastrointestinal stromal tumors (GISTs), and GISTs are a good target for the Kit inhibitor imatinib mesylate."	( Hirotab, S; Kitamura, Y, 2004)
"Hypercalcemia of malignancy is a serious complication of cancer."	( Inoue, K; Kawada, K; Minami, H; Okabe, K; Sasaki, T; Sawamura, M; Takashima, S; Watanabe, T; Yagi, Y, 2005)
"Patients with cancer are a recognized group at high risk of VTE, and those undergoing major surgery for their malignancy are at particular risk."	( Kher, A; Samama, MM, 2005)
"Advanced cancer is associated with a hypercoagulable state, and tissue factor expression by cancer cells has received widespread attention because of its significant contribution to the pathogenesis of cancer progression and metastasis."	( Ahamed, J; Belting, M; Ruf, W, 2005)
"Solid tumors are characterized by a fast growth that eventually pushes cells away from their natural source of oxygen and nutrients from the capillaries."	( Martínez, A, 2006)
"Virtually all human tumors are deficient in gap junctional communication (GJC) and the restoration of GJC by forced expression of connexins reduces indices of neoplasia."	( Bertram, JS; Vine, AL, 2005)
"Tumors are generally characterized by an increased glucose uptake and a high rate of glycolysis."	( Hoekman, K; Niessen, HW; Schalkwijk, CG; van Heijst, JW, 2005)
"Childhood cancers are strongly determined by prenatal or early postnatal exposures to oil based combustion gases, especially from engine exhausts."	( Knox, EG, 2005)
"Cancer is a major morbidity and mortality concern in Malaysia."	( Cheah, PL; Cheong, SK; Gudum, HR; Iekhsan, O; Ikram, SI; Jamal, R; Looi, LM; Mak, JW; Othman, NH; Puteri, JN; Rosline, H; Sabariah, AR; Seow, HF; Sharifah, NA; Zubaidah, Z, 2004)
"Advanced cancer is a leading cause of death in the developed world."	( Hickson, ID; Madhusudan, S, 2005)
"Cancer is becoming an increasingly significant disease worldwide."	( Abdulah, R; Koyama, H; Miyazaki, K; Nakazawa, M, 2005)
"These tumors are marked by increased angiogenesis and an activation of the Akt pathway."	( Bader, AG; Kang, S; Vogt, PK, 2006)
"Tumors are angiogenesis dependent."	( Albertsson, P; Lennernäs, B; Norrby, K, 2006)
"Cancer is the second leading cause of death worldwide."	( Doble, M; HemaIswarya, S, 2006)
"Breast cancer is the oncological disease entity whose relationship to circadian rhythm fluctuations has perhaps been most extensively studied."	( Blask, DE; Brainard, GC; Jasser, SA, 2006)
"Cancer is a multi-factorial process involving genetic and epigenetic events which result in neoplastic transformation."	( Dashwood, RH; Myzak, MC, 2006)
"Cancers are diverse and often resistant to therapeutic strategies."	( Kaneda, Y; Tabata, Y, 2006)
"Cancer is an epigenetic disease, a combination of DNA modifications, chromatin organization and variations in its associated proteins, configure a new entity that regulates gene function throughout methylation, acetylation and chromatin remodelling."	( Esteller, M; Herranz, M, 2006)
"Advanced cancer is associated with a hypercoagulable state that is triggered by tissue factor (TF)."	( Mueller, BM; Ruf, W, 2006)
"Metastatic cancer is one of the main causes of cancer-related death since they rarely respond to available treatments."	( Cheung, HW; Chu, Q; Feng, H; Ling, MT; Tsao, SW; Wang, X; Wong, YC, 2006)
"When cancer is not curable, the focus of care shifts from cure to care."	( , 2006)
"When cancer is not curable, the focus of care shifts from cure to care."	( , 2006)
"The growth of tumors is facilitated by low expressions of MHC and co-stimulatory antigens on tumor cells and the induction of suppressor cells and other inhibitory products by tumors."	( Artym, J, 2006)
"The perfusion of tumors is a surrogate parameter of their viability and may mirror their response to therapy."	( Delorme, S; Krix, M, 2006)
"Accurate staging of cancer is of fundamental importance to treatment selection and planning."	( Hicks, RJ; Lau, EW; Ware, RE, 2006)
"Cancer is the second leading cause of death in the USA, with metastatic disease proving a particular management challenge."	( Eller, MS; Gilchrest, BA; Ohashi, N; Truzzi, F; Yaar, M, 2007)
"Cancer is one of the major public health burdens in the United States and in other developed countries, causing approximately 7 million deaths every year worldwide."	( Gupta, S; Patel, D; Shukla, S, 2007)
"Cancers are assumed to be multivariate, multifactorial diseases that occur when a complex and prolonged process involving genetic and environmental factors interact in a multistage sequence."	( Buka, I; Koranteng, S; Osornio Vargas, AR, 2007)
"Malignancy is an uncommon cause of ALF, and thus imaging studies may not be useful in this setting, but liver biopsy may be beneficial in selected cases."	( Khashab, M; Kwo, PY; Tector, AJ, 2007)
"It was aimed at cancer care in general practice by creating interaction between patients, students, and teachers, thus making the emphasis and focus of teaching student and patient centered rather then teacher centered."	( de Vries, J; Haagedoorn, EM; Kapoor, N, 2006)
"Most PET-negative cancers are early stage cancers, and thus can be detected using other conventional examinations such as endoscopy."	( Kitagawa, M; Kobayashi, H; Ochiai, R; Omagari, J; Ono, K; Yamashita, Y; Yoshida, T, 2007)
"Treatment of cancer is increasingly effective but is associated with short and long term side effects."	( Clarkson, JE; Eden, OB; Worthington, HV, 2007)
"Tumors are associated with immunosuppression and anemia."	( Al-Waili, NS, 2007)
"Cancer is a risk factor for venous thromboembolism (VTE)."	( Agnelli, G; Caprini, JA, 2007)
"Cancer is a cause of venous thromboembolism."	( Berthier, S; Bonnotte, B; Falvo, N; Ghiringhelli, F; Lorcerie, B, 2007)
"Cancer is a genetic disease and carcinogenesis is the process whereby the relevant genetic alterations are acquired."	( Kaufmann, WK, 2007)
"Hypoxic tumors are significantly more malignant, metastatic, radio- and chemoresistant and have a poor prognosis."	( Airley, RE; Mobasheri, A, 2007)
"Cancer is a complex, multi-step process characterized by misregulated signal transduction and altered metabolism."	( Ben-Bassat, H; Klein, S; Kravchenko-Balasha, N; Levitzki, A; Mizrachy-Schwartz, S, 2007)
"Individuals with cancer are living longer, and the number of cancer treatment options provided at various points in the cancer continuum is growing; however, many treatments contribute to anemia."	( Bush, NJ; Hurter, B, 2007)
"Cancer is a serious worldwide health threat, killing almost seven million people per year."	( Bieber, LW; Brondani, DJ; de M Moreira, DR; de Souza, IA; Lima Leite, AC; Nascimento, CR, 2007)
"However, cancer is no longer such an explosive disease, and many cancer sufferers can now expect to have a prolonged, even normal, lifespan."	( Ballantyne, JC, 2007)
"Social burden of cancer is the greatest in persons aged from 15 to 59 years."	( Luo, SQ; Yang, CY; Zhang, MB; Zou, H, 2007)
"Cancer is characterized by uncontrolled cell division resulting from multiple mutagenic events."	( Blumen, S; Dmitrovsky, E; Dragnev, KH; Feng, Q; Freemantle, SJ; Galimberti, F; Kitareewan, S; Liu, X; Sekula, D, 2007)
"Cancer is often burdened by psychological comorbidity, mainly represented by depression, anxiety and adjustment disorders."	( Caldera, P; Siri, I; Torta, R, 2008)
"Most cancers are characterized by excessive transforming growth factor-beta production by tumors, which can promote tumor growth and mediate epithelial-to-mesenchymal transition."	( Pasche, B; Pennison, M, 2007)
"The development of cancer is associated with disorders in the regulation of the cell cycle."	( Katiyar, SK; Meeran, SM, 2008)
"Human solid tumors are invariably less well-oxygenated than the normal tissues from which they arose."	( Brown, JM, 2007)
"Cancer is the leading cause of mortality in Japan, accounting for about 30 percent of all deaths."	( Otsuka, K; Yasuhara, H, 2007)
"Cancer is a simplistic, yet complicated, process that promotes uncontrolled growth."	( Bilfinger, TV; Cadet, P; Esch, T; Kream, RM; Mantione, KJ; Sheehan, M; Stefano, GB; Zhu, W, 2008)
"Cancer is one of the most dreaded diseases with a complex pathogenesis, which threats human life greatly."	( Li, X; Xu, W, 2006)
"when the cancer is considered to be rapidly evolving or as terminal."	( Laval, G; Paris, A, 2008)
"Cancer is primarily a disease of old age, and that life style plays a major role in the development of most cancers is now well recognized."	( Aggarwal, BB; Anand, P; Jhurani, S; Kunnumakkara, AB; Sundaram, C, 2008)
"Because most cancers are caused by dysregulation of as many as 500 different genes, agents that target multiple gene products are needed for prevention and treatment of cancer."	( Aggarwal, BB; Anand, P; Kunnumakkara, AB, 2008)
"Cancer is a major risk factor for the development of venous thromboembolism (VTE)."	( Linkins, LA, 2008)
"These cancers are potential targets for selective chemotherapy with inhibitors of de novo adenine synthesis such as L-alanosine [L-2-amino-3-(N-hydroxy-N-nitrosamino) propionic acid]."	( Burris, HA; Kindler, HL; Oliff, IA; Sandler, AB, 2009)
"O(2) delivery to tumors is constantly changing in all tumors, resulting in continuous reoxygenation events throughout the tumor."	( Cárdenas-Navia, LI; Dewhirst, MW; Mace, D; Richardson, RA; Shan, S; Wilson, DF, 2008)
"Clam cancer is the best characterized, naturally occurring malignancy with a known molecular basis remarkably similar to those observed in several unrelated human cancers where both genotoxic and non-genotoxic strategies can restore the function of wild-type p53."	( Böttger, SA; Walker, CW, 2008)
"Cancer is one of the most common diseases for which a beneficial role of vitamin C has been claimed."	( Calderon, PB; Verrax, J, 2008)
"Breast cancer is the most common female malignancy, for which HRT is one of many modifiable risk factors, often attracting disproportionate attention."	( Marsden, J; Sturdee, D, 2009)
"As cancer is a disease of ageing, targeting Sirtuins is emerging as a promising antitumour strategy."	( Altucci, L; Calvanese, V; Esteller, M; Fraga, MF; Imhof, A; Inhof, A; Lara, E; Lopez-Nieva, P; Mai, A; Martinez-Chantar, ML; Mato, JM; Montoya, G; Nebbioso, A; Oyarzabal, J; Ropero, S; Rotili, D; Serrano, M; Varela-Rey, M; Velasco, S; Villar-Garea, A; Witt, M, 2009)
"Cancer is a disease state in which the cells in our body undergo mutations at the genetic level and are transformed, acquiring the ability to replicate limitlessly."	( Choong, PF; Dass, CR; Tan, ML, 2009)
"Cancer is the result of sequential genetic changes over time that transform a cell into a malignant and ultimately invasive entity."	( Moreno, E; Rhiner, C, 2009)
"Treatment of cancer is increasingly effective, but associated with oral complications such as mucositis, fungal infections, bacterial infections and viral infections such as the herpes simplex virus (HSV)."	( Fernandez Mauleffinch, LM; Glenny, AM; Pavitt, S; Walsh, T, 2009)
"Cancer is linked with hypercoagulability and risk of thrombosis and this close association was recognized by Armand Trousseau in 1865."	( Elalamy, I; Gerotziafas, GT; Hatmi, M; Papageorgiou, C; Samama, MM, 2008)
"Cancer is one of the leading causes of death in the world."	( Aggarwal, P; Burman, AC; Hirpara, KV; Joshi, N; Mukherjee, AJ, 2009)
"The targeting of tumors is made possible through establishing protein signatures specific for each cancer type."	( Atay, C; Ozören, N; Ugurlu, S, 2009)
"Cancer is a leading health hazard, and lung cancer is its most common form."	( Feng, X; Haick, H; Müllen, K; Pisula, W; Tisch, U; Zilberman, Y, 2009)
"Cancer is a pathology that is associated with aberrant gene expression and an altered metabolism."	( Domann, FE; Hitchler, MJ, 2009)
"Malignancy is characterized by a systemic deficiency of glutamine (GLN)."	( Belabed, L; Darmon, P; Pichard, C, 2009)
"These cancers are characterized by length alterations in ubiquitous simple sequence repeats, a phenotype called microsatellite instability."	( de Wind, N; Ferrás, C; Oude Vrielink, JA; te Riele, H; Tsaalbi-Shtylik, A; Verspuy, JW, 2009)
"Many cancers are known to produce high amounts of PGE(2), which is involved in both tumor progression and tumor-induced immune dysfunction."	( Buchsbaum, D; Daurkin, I; Eruslanov, E; Kaliberov, S; Kaliberova, L; Kusmartsev, S; Vieweg, J, 2009)
"Human cancer is likewise significantly determined by the interactions of selenium with other elements, as evidenced by epidemiological, ecological and case-control studies."	( Schrauzer, GN, 2009)
"Although cancer is considered to be a disease caused by DNA alterations, the high genetic variability of tumor cells makes it difficult to exploit these alterations for the treatment of cancer."	( López-Lázaro, M, 2009)
"Hypoxic tumors are often resistant to conventional cancer therapies, and tumor hypoxia correlates with advanced stages of malignancy."	( Glazer, PM; Kim, Y; Lin, Q; Yun, Z, 2009)
"Cancer is a frequent finding in patients with thrombosis, and thrombosis is much more prevalent in patients with cancer, with important clinical consequences."	( Khorana, AA, 2009)
"Aggressive cancers are metabolically active and highly glycolytic; an MRI contrast agent that enters cells with high glycolytic activity could provide high-resolution functional images of tumor boundaries and internal structure, which cannot be achieved by conventional contrast agents."	( Ejnik, J; Foxley, S; Karczmar, GS; Makinen, MW; Martin, H; Mustafi, D; Peng, B; Zamora, M, 2009)
"Cancer is a hyperproliferative disorder that is usually treated by chemotherapeutic agents that are toxic not only to tumor cells but also to normal cells, so these agents produce major side effects."	( Aggarwal, BB; Prasad, S; Ravindran, J, 2009)
"Cancer is one of the leading causes of death in Europe and United States."	( Demopoulos, CA; Frangia, C; Iatrou, C; Tsoupras, AB, 2009)
"Patients with cancer are increasingly at risk for venous thromboembolism (VTE)."	( Connolly, GC; Khorana, AA, 2009)
"Patients with cancer are members of a unique patient population because of their high risk for thrombosis and the risk of anticoagulant-related bleeding."	( Levine, MN, 2009)
"Malignancy is a dreaded complication following organ transplantation."	( Boffa, DJ; Hojo, M; Luan, FL; Maluccio, M; Suthanthiran, M, 2009)
"Many tumors are associated with decreased cellular immunity and elevated levels of prostaglandin E2 (PGE2), a known inhibitor of CD4+ T cell activation and inducer of type-2 cytokine bias."	( Banerjee, S; Bhattacharyya, S; Chakraborty, J; Chattopadhyay, S; Das, K; Das, T; Mohanty, S; Sa, G; Saha, B; Sakib Hossain, DM, 2009)
"Because most cancers are caused by deregulation of as many as 500 different genes, agents that target multiple gene products are needed for prevention and treatment of cancer."	( Das, K; Das, T; Sa, G; Saha, B, 2010)
"Consequently, the malignancy is maintained with the aid of Hsp90 upon which the mutated proteins have become particularly dependent for their activity."	( Prodromou, C, 2009)
"Hence, such tumors are selectively sensitized to DNA-damaging agents by Wee1 inhibition."	( Arai, T; Arakawa, H; Fukasawa, K; Hirai, H; Itadani, H; Iwasawa, Y; Jiang, J; Kaneko, N; Kimura, T; Kobayashi, M; Kotani, H; Mizuarai, S; Nambu, T; Nishibata, T; Ohtani, J; Okada, M; Oki, H; Sagara, T; Sakai, T; Sakamoto, T; Takahashi-Suzuki, I; Yamanaka, K; Yoshizumi, T, 2009)
"In India, cervical cancer is a leading cancer among women and almost all cases of cervical cancer show prevalence of High Risk (HR)-HPV infection."	( Bharti, AC; Das, BC; Hedau, S; Hussain, S; Kumar, R; Mahata, S; Shukla, S, 2009)
"Microscopic tumors are useful models for the validation of hypoxia radiotracers, and digital autoradiography is an appropriate technique for studying the distribution of hypoxia radiotracers in microscopic tumors."	( Humm, JL; Li, XF; Ling, CC; Ma, Y; O'Donoghue, JA; Russell, J; Suehiro, M; Sun, X; Zhang, M, 2010)
"Neonatal neoplasms are rare tumours notorious for their atypical presentation and unpredictable behaviour."	( Yeap, BH; Zahari, Z, 2010)
"Cancer is a limiting factor for long-term survival after heart transplantation."	( Chang, HH; Chen, IM; Chen, PL; Hsieh, YC; Lai, ST; Shih, CC; Weng, ZC; Yang, AH, 2009)
"New treatments for malignancy are greatly needed."	( Bromley, E; Chen, JC; Keltner, L; Wang, S; Xu, L, 2010)
"Development of cancer is a long-term and multistep process which comprises initiation, progression, and promotion stages of carcinogenesis."	( Cheung, KL; Kong, AN, 2010)
"Finally, if cancer is a consequence of excessive nighttime light, it is likely that other diseases/conditions may also be exaggerated by the widespread use of light after darkness onset."	( Erren, TC; Fuentes-Broto, L; Paredes, SD; Reiter, RJ; Tan, DX, 2009)
"Risk of cancer is increased in conditions associated with insulin resistance, but this could be secondary to subclinical inflammation."	( Godsland, IF; Johnston, DG; Loh, WJ; North, BV, 2010)
"In (18)F-FDG PET, tumors are often characterized by their metabolically active volume and standardized uptake value (SUV)."	( Buvat, I; Doyeux, K; Gardin, I; Grotus, N; Hapdey, S; Stute, S; Tylski, P; Vanderlinden, B, 2010)
"Many cancers are deficient in catalase activity, and maintain a moderate level of oxidative stress to aid their proliferation and survival."	( Barroso-Aranda, J; Contreras, F; McCarty, MF, 2010)
"Cancer is well known to be associated with alterations in membrane protein glycosylation (Bird, N."	( Baker, MS; Chick, JM; Clarke, SJ; Haynes, PA; Jankova, L; Kolarich, D; Lee, A; Packer, NH; Robertson, GR; Tsoli, M, 2011)
"Cancer is a leading cause of death in the United States and contributes to yearly rising health care costs."	( Day, ES; Halas, NJ; Morton, JG; West, JL, 2010)
"As lung cancer is the No."	( Supaibulwatana, K; Zhai, DD; Zhong, JJ, 2010)
"Malignancy is one of the comorbidities linked to golimumab, a biological TNF-α blocker."	( Bartegi, A; Ben Amor, N; Bouaziz, A; Mnif, W; Zidi, I, 2011)
"Furthermore, tumors are constantly evolving entities, and are heterogeneous in their cellular makeup, compounding the challenge."	( Klein, S; Levitzki, A, 2010)
"Cancer is a multistep process characterized by altered signal transduction, cell growth, and metabolism."	( Kravchenko-Balasha, N; Levine, RD; Levitzki, A; Remacle, F, 2010)
"As far as cancer is concerned, naturally occurring compounds have been reported to prevent tumorigenesis and also to suppress the growth of established tumors."	( Fulda, S, 2010)
"CCancer is an automatically collected database of gene lists, which were reported mostly by experimental studies in various biological and clinical contexts."	( Antonov, AV; Dietmann, S; Lee, W; Rodchenkov, I; Wong, P, 2010)
"Solid tumors are often poorly vascularized, with cells that can be 100 microm away from blood vessels."	( Caruso, M; Cottin, S; de Campos-Lima, PO; Ghani, K, 2010)
"Cancer is a leading cause of death worldwide, and the numbers of new cancer cases are expected to continue to rise."	( Barnes, S; Nagy, TR; Virk-Baker, MK, 2010)
"Because many cancers are thought to derive from a subpopulation of cancer stem-like cells, which may re-express embryonic genes, Cripto-1 signaling may drive tumor growth through the generation or expansion of tumor initiating cells bearing stem-like characteristics."	( Bianco, C; Castro, NP; Gonzales, M; Nagaoka, T; Rangel, MC; Rollman, K; Salomon, DS, 2010)
"Lung cancer is the leading cause of cancer death, developing over prolonged periods through genetic and epigenetic changes induced and exacerbated by tobacco exposure."	( Fujimoto, J; Hong, WK; Kong, M; Lee, JJ; Lotan, R, 2010)
"Cancer is one of the leading causes of death worldwide."	( Ahmed, R; Mosavel, M; Simon, C, 2010)
"Depression in cancer is associated with increased plasma IL-6 concentrations and dysfunction of the HPA axis."	( Bartholomae, A; Flath, BC; Jehn, CF; Kühnhardt, D; Lüftner, D; Pfeiffer, S; Possinger, K; Schmid, P, 2010)
"Cancer is a major health problem around the world."	( Agarwal, R; Deep, G, 2010)
"Diabetes and cancer are common conditions, and their co-diagnosis in the same individual is not infrequent."	( Chowdhury, TA, 2010)
"These neoplasms are characterized by the presence of neuroamine uptake mechanisms and/or peptide receptors at the cell membrane."	( Baum, RP; Howman-Giles, R; Schmidt, M; Simon, T, 2010)
"Tumors are commonly found during senescence of several strains of mice."	( Bondy, SC; Sharman, EH; Sharman, KG, 2011)
"AIDS-associated cancers are seen in advanced stage of HIV infection."	( Badakh, DK; Gosavi, VS; Jagdale, RV; Joshi, R; Phatak, JU; Phatak, UA, 2010)
"Cancer is frequently caused by altered protein expression."	( De Rosa, G; De Stefano, D; Galeone, A, 2010)
"Metastasis of cancer is a multifactorial disease and is the main cause of death in patients with malignancy."	( Geliebter, J; Moscatello, A; Rajoria, S; Schantz, SP; Suriano, R; Tiwari, RK; Wilson, YL, 2011)
"Human cancers are characterized by widespread changes in their genomic DNA methylation and histone modification patterns."	( Lyko, F; Mund, C, 2010)
"Cancer is one of the leading causes of death worldwide and there is an increasing need for novel anti-tumor therapeutics with greater selectivity and potency."	( Bernhardt, PV; Kalinowski, DS; Kovacevic, Z; Lovejoy, DB; Richardson, DR; Sharpe, PC; Suryo Rahmanto, Y; Yu, Y, 2011)
"Cancer is a prothrombotic state, with an increased prevalence of venous thromboembolism (VTE)."	( Bulato, C; Campello, E; Castelli, M; Gavasso, S; Radu, CM; Simioni, P; Spiezia, L, 2011)
"Cancer is one of the leading causes of death in the United States and around the world."	( Kannaiyan, R; Sethi, G; Shanmugam, MK, 2011)
"Cancer is a disease marked by genetic instability."	( Agrawal, V; Bhasme, D; Bisaria, VS; Grover, A; Pratik, P; Shandilya, A; Sundar, D, 2011)
"Cancer is the leading cause of death in Japan."	( Ebihara, T; Kushida, K; Shiraishi, T, 2010)
"Cancer is connected with mitochondrial malfunction (the Warburg effect) suggesting disrupted physical mechanisms."	( Cifra, M; Kučera, O; Pokorný, J; Vedruccio, C, 2011)
"Cancer is a leading cause of death worldwide."	( Boukamp, P; Chong, HC; Ding, JL; Huang, RL; Kersten, S; Lam, CR; Li, HY; Pal, M; Pan, JY; Tan, CK; Tan, MJ; Tan, NS; Tan, SH; Zhu, P, 2011)
"Cancer is an increasing problem in the Middle Eastern (ME) countries."	( Daher, M, 2011)
"Cancer is one of the leading causes of death in the United States and accounts for approximately 8 million deaths per year worldwide."	( Anant, S; Dhar, A; Gutheil, WG; Ray, A; Reed, G, 2012)
"Epithelial malignancy is common in older age group but it is also an Important cause of morbidity and mortality in young adults."	( Mukhopadhyay, S; Ray, S; Sadhu, A; Sinha, SK, 2010)
"Patients with lung cancer are at a higher risk for severe pulmonary side effects with docetaxel-gemcitabine than are patients with breast cancer."	( Binder, D; Hübner, RH; Schlattmann, P; Temmesfeld-Wollbrück, B, 2011)
"Anxiety in terminal cancer is linked to diminished quality of life, yet overall it is poorly understood with regard to prevalence and relationship to other aspects of psychological distress."	( Breitbart, W; Brescia, R; Kolva, E; Pessin, H; Rosenfeld, B, 2011)
"Cancer is a major killer in today's world accounting for around 13% of all deaths according to the World Health Organisation (W."	( Gibbons, JA; Kanwar, JR; Kanwar, RK, 2011)
"Advanced tumors are often immunosuppressive which results in lack of tumor eradication despite abnormal epitopes being present."	( Cerullo, V; Diaconu, I; Dotti, G; Escutenaire, S; Guse, K; Haavisto, E; Hannuksela, P; Hemminki, A; Holm, SL; Joensuu, T; Kanerva, A; Kangasniemi, L; Karioja-Kallio, A; Karli, E; Kauppinen, S; Laasonen, L; Nokisalmi, P; Oksanen, M; Partanen, K; Pesonen, S; Raki, M, 2012)
"To date cancer is considered as one of the most devastating diseases due to its high rate of mortality."	( Mohanty, C; Parhi, P; Sahoo, SK, 2011)
"Cancer is characterized by bidirectional interrelations between tumour progression, coagulation activation, and inflammation."	( Bokemeyer, C; Langer, F, 2012)
"Cancer is a world-wide health problem and the implication rate as well as the death rate increase year to year."	( Bhattacharya, R; Kudgus, RA; Mukherjee, P, 2011)
"Basal-like breast cancer is an aggressive disease with limited therapeutic options because these tumors frequently express the 'triple-negative' phenotype."	( Ambs, S; Cheng, RY; Glynn, SA; Ridnour, LA; Switzer, CH; Vitek, MP; Wink, DA, 2011)
"Hypercalcemia of malignancy is a common paraneoplastic syndrome and a frequent complication of advanced breast and lung cancer, and multiple myeloma."	( Clines, GA, 2011)
"Most cancers are characterized by multiple molecular alterations, but identification of the key proteins involved in these signaling pathways is currently beyond reach."	( Ahn, JH; Alpaugh, M; Beebe, K; Caldas-Lopes, E; Cerchietti, L; Chiosis, G; Erdjument-Bromage, H; Gomes DaGama, EM; Gross, SS; Guzman, ML; Hatzi, K; Ku, T; Larson, SM; Levine, R; Lewis, JS; Melnick, A; Moulick, K; Neckers, L; Nimer, SD; Perna, F; Pillarsetty, N; Rodina, A; Smith-Jones, P; Taldone, T; Vu, LP; Zatorska, D; Zhao, X; Zong, H, 2011)
"Cancer is one of the main causes of death in the world, and according to the WHO it is projected to continue rising."	( De La Peña, H; Pastorin, G; Rajadas, J; Seifalian, A; Tan, A; Yildirimer, L, 2011)
"Cancer is often accompanied with inflammatory, thrombotic, and diabetic complications."	( Pace-Asciak, CR, 2011)
"Cancer is a major public health problem worldwide."	( Charles, C; Duez, P; Guissou, IP; Ouédraogo, M; Stévigny, C, 2011)
"Cancer is a major cause of death throughout the world."	( Athar, MA; Dar, N; Pervaiz, S; Samra, ZQ; Shaheen, S, 2011)
"Because each cancer is a heterogeneous mix of cancer cells at different stages of development, we are faced with trying to treat many different diseased cells all at once."	( Perkins, G; Yamaguchi, R, 2012)
"Cancer is a genetic disease that is caused by mutations in oncogenes, tumor suppressor genes and stability genes."	( Aguilar-Cazares, D; Báez-Viveros, JL; Lopez-Gonzalez, JS; Prado-Garcia, H; Romero-Garcia, S, 2011)
"As cancer is a multifactor disease, it may require treatment with compounds able to target multiple intracellular components."	( Dicato, M; Diederich, M; Eifes, S; Teiten, MH, 2010)
"Metastasis of tumors is promoted by lactate-induced secretion of hyaluronan by tumor-associated fibroblasts that create a milieu favorable for migration."	( Hirschhaeuser, F; Mueller-Klieser, W; Sattler, UG, 2011)
"Malignant neoplasms are associated with a wide variety of paraneoplastic rheumatological syndromes."	( Bahiri, R; Hajjaj-Hassouni, N; Hakkou, J; Rostom, S, 2012)
"Early detection of cancer is a major problem throughout the world, which is why many researchers are still looking for specific and sensitive markers of malignant tumors."	( Choromańska, B; Dadan, J; Janica, J; Kępka, A; Ladny, JR; Luto, M; Myśliwiec, P; Szajda, SD; Waszkiewicz, N; Zwierz, K, 2011)
"Tumors are multifaceted; in fact, numerous things happen in synchrony to enable tumor promotion and progression."	( Bhattacharyya, S; Das, T; Hossain, DM; Sa, G, 2012)
"Tumors are often sensitive to chemotherapy upon initial treatment, but repeated treatments can select for those cells that were able to survive initial therapy and have acquired cellular mechanisms to enhance their resistance to subsequent chemotherapy treatment."	( Eblen, ST, 2012)
"Because cancers are caused by deregulation of hundreds of genes, an ideal anticancer agent should target multiple gene products or signaling pathways simultaneously."	( Maioli, E; Torricelli, C; Valacchi, G, 2012)
"Cancer is known to be a complex disease and its therapy is difficult."	( Daskalaki, A; Hache, H; Herwig, R; Kühn, A; Lehrach, H; Li, J; Maschke-Dutz, E; Peycheva, S; Wierling, C, 2012)
"Cancers are associated with varying degrees of an increased risk of venous thromboembotic events (VTE) occurring."	( Greenman, J; Madden, LA; Maraveyas, A; Smith, JD; Welsh, J; Yates, KR, 2012)
"Malignant cancer is the leading cause of death in man, exceeding cerebrovascular disease and heart disease."	( Hu, GJ; Lai, ZF; Li, J; Li, YL; Yan, CY, 2014)
"The risk of breast cancer is generally increased by MHT, particularly in lean women with no previous MHT who start estrogen-progestin therapy near the menopause and continue for several years, but there is no increased risk 5 years after stopping MHT."	( Davey, DA, 2012)
"Cancer is a major public health problem in the world."	( Chen, Z; Liu, Y; Mao, R, 2012)
"Lung cancer is the leading cause of cancer-related deaths worldwide."	( El-Ghamry, MN; Kloecker, GH; Sethi, TK, 2012)
"Most solid tumors are known to rely on glycolysis for energy production and this activity leads to production of important amounts of lactate, which are exported into the extracellular milieu, contributing to the acidic microenvironment."	( Azevedo-Silva, J; Baltazar, F; Casal, M; Longatto-Filho, A; Pinheiro, C; Schmitt, FC, 2012)
"Cancer is one of the leading causes of deaths in the world."	( Aluyen, JK; Bellanger, RA; Gottlieb, HB; Ton, QN; Tran, T; Yang, AE, 2012)
"Such cancers are very receptive to cytotoxic therapy because of increased mitotic rates."	( Mackiewicz, T, 2012)
"Cancer is the second cause of death in the world after cardiovascular diseases."	( González, DR; González, E; Ibacache, A; Leiva, E; Monsalve, FA; Rodríguez, JA; Valderrama, JA; Vásquez, D, 2012)
"Cancer is responsible for millions of immature deaths every year and is an economical burden on developing countries."	( Chaudhary, K; Gautam, A; Kapoor, P; Kumar, R; Raghava, GP; Singh, H, 2012)
"Cancer is rapidly becoming the worldwide leading cause of premature death."	( Ceelen, W; Debergh, I; Vanhove, C, 2012)
"Cancer is a major burden worldwide but there are marked geographical variations in frequency and incidence overall."	( Pandith, AA; Siddiqi, MA, 2012)
"Risk for oral cancer is debated, with more studies showing an increased risk than showing no risk; risk also exists for cancer of esophagus, stomach and pancreas."	( Ainamo, A; Lahtinen, A; Rautalahti, M; Wickholm, S, 2012)
"Cancer is the major effect of concern."	( Brugge, D; Buchner, V, 2012)
"Cancer is a complex biological occurrence which is difficult to describe clearly and explain its growth development."	( Chen, YY; Hu, GM; Lee, CY; Pang, NN; Tzeng, WJ, 2012)
"Cancer is no longer considered a "terminal disease"; 50% to 65% of patients survive for at least 2 years, and there are about 12 million cancer survivors in the United States."	( Bruel, BM; Bruera, E; Burton, AW; Koyyalagunta, D; Manchikanti, L; Nouri, KH; Solanki, DR; Toro, MP, 2012)
"Pancreatic cancer is a relatively rare malignancy with a very aggressive natural course, not restrained by the existing current treatments."	( Saif, MW; Strimpakos, AS; Syrigos, KN, 2012)
"Cancer is the current leading cause of death worldwide, responsible for approximately one quarter of all deaths in the USA and UK."	( Austin, LA; Dreaden, EC; El-Sayed, MA; Mackey, MA, 2012)
"Hypoxic tumors are resistant to radiation, chemotherapy, and surgery."	( Maguire, D; O'Dell, W; Okunieff, P; Zhang, L; Zhang, M, 2013)
"Cancer is one of the most serious and lethal diseases around the world."	( Chen, C; Jiang, J; Yu, R; Zhang, L; Zhao, J, 2012)
"Cancer is emerging as a key disease in India, but there has been virtually no research exploring understandings of cancer and practices of communication within oncology settings."	( Broom, AF; Doron, A, 2013)
"Cancer is one of the most life-threatening diseases, which causes 7."	( Fan, Z; Ray, PC; Senapati, D; Singh, AK, 2013)
"Cancer is the second leading cause of death in the United States."	( Chauhan, SC; Jaggi, M; Yallapu, MM, 2013)
"Deaths from cancer are expected to continue to rise because of ageing populations and modifiable risk factors such as tobacco and alcohol use, diet, and obesity."	( Chan, N; Connor, S; Davies, A; Goh, C; Payne, S; Poon, E, 2012)
"Cancer is a growing co-morbidity among HIV-infected patients worldwide."	( Adoubi, I; Akakpo, J; Bissagnene, E; Dabis, F; Diomande, I; Eholie, SP; Ekouevi, DK; Houngbe, F; Jaquet, A; Sasco, AJ; Tanon, A; Zannou, MD, 2012)
"Common cancer is an age-related disease."	( Blagosklonny, MV, 2012)
"Pancreatic cancer is a deadly disease and has the worst prognosis among almost all cancers and is in dire need of new and improved therapeutic strategies."	( Azmi, A; Banerjee, S; Lum, LG; Mohommad, R; Sarkar, FH; Schalk, D; Thakur, A, 2012)
"against cancer are commonly matured by pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and prostaglandin E(2) although the absence of Toll-like receptor mediated activation prevents secretion of IL-12 from DCs and subsequent efficient induction of type 1 effector T cells."	( Andersen, MH; Donia, M; Hansen, M; Hjortø, GM; Larsen, NB; Met, Ö; Svane, IM; thor Straten, P, 2013)
"Cancer is frequently complicated by venous thromboembolic events (VTE), which pose a significant health burden due to the associated high morbidity and mortality rates, yet the exact details of the pathophysiological mechanisms underlying their development are yet to be fully elucidated."	( Date, K; Greenman, J; Hall, J; Madden, LA; Maraveyas, A, 2013)
"Walker-256 tumors are divided into 2 groups, hypovascular and hypervascular tumors that arise 2 and 4 days after tumor inoculation, respectively."	( Kawaguchi, T; Satou, T; Shibata, M; Takenoshita, S, 2012)
"Cancer is a chronic disease and its pathogenesis is well correlated with infection and inflammation."	( Kumar, V, 2013)
"The pH of solid tumors is acidic due to increased fermentative metabolism and poor perfusion."	( Bailey, K; Balagurunathan, Y; Chen, T; Cornnell, HH; Estrella, V; Gatenby, RA; Gillies, RJ; Ibrahim-Hashim, A; Johnson, J; Lloyd, M; Rothberg, JM; Sloane, BF; Wojtkowiak, J, 2013)
"Cancer is caused by defects in the mechanisms underlying cell proliferation, death and migration."	( Prevarskaya, N; Shuba, Y; Skryma, R, 2013)
"Treated tumors are better differentiated as compared with those established in the control mice."	( Basavaraj, C; Chivukula, IV; James, R; Melarkode, R; Montero, E; Nair, P; Vishwakarma, S, 2012)
"Cancer is a cell disease, characterized by a deviation of the control mechanisms of proliferation and differentiation of cells."	( Baggio Gnoatto, SC; Bergold, AM; Froehlich, PE; Kaiser, S; Muller, JJ, 2013)
"Certain cancers are more common, including hepatocellular and pancreatic carcinoma, colorectal cancer, renal cancer, and breast and endometrial cancer, and non-Hodgkin's lymphoma."	( Akturk, HK; Rendell, M; Tella, SH, 2013)
"Cancer is considered as one of the most serious health problems."	( El-Nassan, HB, 2013)
"Aging and advanced cancer are characterized by similar neuroendocrine and immune deficiencies; the most important of them consist of diminished nocturnal production of the pineal hormone melatonin (MLT) and decreased production of IL-2."	( Lissoni, P; Messina, G; Rovelli, F, 2012)
"The burden of cancer is growing globally and is one of the top leading causes of death."	( Hussain, MA; Kadam, S; Nayak, S; Pati, S; Prusty, M; Swain, S, 2012)
"As an important cancer care team member, oncology nurses need to communicate effectively with cancer patients."	( Krauss, SE; Maskor, NA; Muhamad, M; Nik Mahmood, NH, 2013)
"Most hypoxic tumors are insensitive to radiation, which is a major obstacle in the development of conventional radiotherapy for tumor treatment."	( Bu, W; Chen, F; Fan, W; He, Q; Liu, J; Ni, D; Peng, W; Shen, B; Shi, J; Xiao, Q; Xing, H; Zhang, S; Zhao, K; Zhou, L, 2013)
"Cancer is expected to be a major medical issue among this population."	( Bee, PC; Gan, GG; Razali, RM, 2013)
"Cancer is the second leading cause of death in the United States."	( Robbins, D; Zhao, Y, 2014)
"Tumors are characterized by a high degree of diversity and heterogeneity in receptor expression."	( Choyke, PL; Kobayashi, H; Nakajima, T; Sano, K, 2013)
"Lung cancers are increasing rapidly in Kolkata and West Bengal, whereas head and neck cancer has shown a declining trend."	( Gangopadhyay, S; Maiti, PK, 2012)
"However, cancer is still considered as a disease of genetic and metabolic disorders; hence, attacking both aspects of the disease can give better results as compared to contemporary treatment modalities."	( Chibber, S; Hassan, I; Naseem, I, 2013)
"Indeed various cancers are concerned such as prostate, breast, glioblastoma, colorectal, and ovary tumors, and leukemia."	( Alioui, A; Baron, S; De Boussac, H; Dufour, J; Guy, L; Lobaccaro, JM; Trousson, A; Vega, A; Viennois, E; Volle, DH, 2013)
"Patients with cancer are particularly susceptible to drug interactions (DIs), but the extent of the problem has received limited attention."	( D'Hondt, L; Kerger, J; Mouzon, A; Spinewine, A, 2013)
"The onset of cancer is anticipated by changes in the hormonalimmune coordination resulting in chronic quantitative alterations in the synthesis and release of hormones and the loss of the natural synchronicity of that release, which occurs according to circadian rhythms in the healthy organism, principally under the control of the pineal network."	( Pierpaoli, W, 2013)
"Childhood cancers are a special entity with different genetic, environmental factors playing a role in their aetiology."	( Ganguly, S; Gayen, S; Pal, S; Purkait, R; Roy, BN; Samanta, T, 2012)
"Patients with cancer are not protected from the problems of opioid abuse/misuse, and the multidisciplinary cancer treatment team should coordinate an evaluation of risk and the monitoring of aberrant behaviors as part of the comprehensive care plan."	( Anghelescu, DL; Ehrentraut, JH; Faughnan, LG, 2013)
"Imaging pO2 in tumors is now a robust pre-clinical imaging modality with potential for implementation clinically."	( Ardenkjaer-Larsen, JH; Krishna, MC; Matsumoto, S; Matsuo, M; Mitchell, JB; Saito, K, 2013)
"Many patients with cancer are at risk for therapy-induced bone loss, with resultant osteoporotic fractures, or skeletal metastases, which may result in pathologic fractures, hypercalcemia, bone pain, and decline in motility and performance status."	( Biermann, JS; Farooki, A; Fornier, MN; Gagel, RF; Gralow, JR; Kumar, R; Litsas, G; McKay, R; Podoloff, DA; Srinivas, S; Van Poznak, CH, 2013)
"Studies in thyroid cancer are still in their initial stage, but promising."	( Chiovato, L; Coperchini, F; Rotondi, M, 2013)
"Most solid tumors are characterized by unstable perfusion patterns, creating regions of hypoxia that are detrimental to radiotherapy treatment response."	( Danhier, P; De Preter, G; De Saedeleer, CJ; Gallez, B; Jordan, BF; Karroum, O; Porporato, PE; Sonveaux, P, 2013)
"Tumors are characterized by an inefficient and disorganized vasculature which leads to tumor regions that are transiently or chronically undersupplied with oxygen (hypoxia) and nutrients (e."	( Busk, M; Horsman, MR, 2013)
"Prostate cancer is one of the most frequently diagnosed cancers among men."	( Li, J; Li, X; Qin, H; Rasul, A; Yang, N; Zhao, B, 2013)
"Gynecological cancers are among the most common in women and are directly related to a variety of hormonal factors."	( Bazzan, AJ; Newberg, AB; Zabrecky, GP, 2013)
"Cancer is a complex disease characterized by multiple genetic and molecular alterations involving transformation, deregulation of apoptosis, proliferation, invasion, angiogenesis, and metastasis."	( Fimognari, C; Hrelia, P; Lenzi, M, 2014)
"As patients with cancer are living longer, there is a need to ensure that treatments used for palliative care are well tolerated and effective during long-term use."	( Ellershaw, JE; Perelman, M; Radbruch, L; Revnic, J; Taylor, D; Torres, LM, 2014)
"Solid tumors are composed of both cancer cells and various types of accessory cells, mainly fibroblasts, that collectively compose the so called tumor-microenvironment."	( Camici, G; Caselli, A; Chiarugi, P; Cirri, P; Corti, D; Paoli, P; Pieraccini, G; Santi, A; Serni, S; Taddei, ML, 2013)
"Cancer is characterized by uncontrolled growth of abnormal cells leading to the formation of tumors."	( Patil, SP, 2013)
"Cancer is a leading cause of mortality worldwide."	( Chauhan, AS; Hussain, MA; Mallick, D; Nayak, S; Pati, S, 2013)
"Cancer is a complex disease that is dictated by both cancer cell-intrinsic and cell-extrinsic processes."	( Antonioli, L; Blandizzi, C; Haskó, G; Pacher, P, 2013)
"Obesity and cancer are preeminent health care challenges in the 21st century, with obese persons being at an increased risk of cancer."	( Hall, RG; Jean, GW; Shah, S; Sigler, M, 2013)
"Cancer is one of the most significant diseases associated with chronic alcohol consumption, and chronic drinking is a strong risk factor for cancer, particularly of the upper aerodigestive tract, liver, colorectum, and breast."	( Lu, SC; Martinez-Chantar, ML; Mato, JM; Varela-Rey, M; Woodhoo, A, 2013)
"Many types of cancer are now curable or, if not cured, becoming a chronic illness."	( Carver, JR; Liu, J; Manrique, C; Steingart, RM; Yadav, N, 2013)
"Cancer is becoming the largest threat to human health."	( Li, F; Shi, X; Sun, Y; Wu, P; Zhang, Y; Zhu, Z, 2013)
"Because lung cancer is a leading cause of cancer death with limited curative therapy options, careful elucidation of the mechanism and consequences of disordered cancer metabolism in lung cancer is warranted."	( Deng, X; Khuri, FR; Mohamed, A; Owonikoko, TK, 2014)
"Cancer is a leading cause of death worldwide."	( Misra, S; Sharma, K, 2014)
"Cancer is a major public health issue and, despite recent advances, effective clinical management remains elusive due to intra-tumoural heterogeneity and therapeutic resistance."	( Kalinowski, DS; Kovacevic, Z; Lane, DJ; Merlot, AM; Mills, TM; Richardson, DR; Saleh Moussa, R; Shafie, NH, 2014)
"Early detecting of cancer is critical to provide proper treatment and to improve survival of patients."	( Han, J; Kim, JH; Kim, JS; Lee, J; Lee, JH; Lim, JY; Pradhan, T; Ren, WX, 2014)
"Cancer is the second leading cause of death, and chemoprevention is defined as the use of natural or synthetic substances to prevent cancer initiation or progression."	( Becceneri, AB; Cominetti, MR; Filho, JC; Fuzer, AM; Martin, AC; Poltronieri, J; Pouliot, N; Vieira, PC, 2014)
"Cancer is a leading cause of death worldwide."	( Cheng, AS; Huang, M; Luo, T; Xie, H; Zeng, Y, 2014)
"Cancer is a major public health burden in both developed and developing countries."	( Abegaz, B; Mukanganyama, S; Tambama, P, 2014)
"A hallmark of cancer is resistance to apoptosis, with both the loss of proapoptotic signals and the gain of anti-apoptotic mechanisms contributing to tumorigenesis."	( Chen, J; Chen, WD; Wang, FL, 2014)
"Ras-driven cancers are among the most difficult to treat and often excluded from therapies."	( Bagni, RK; Esposito, D; McCormick, F; Stephen, AG, 2014)
"Late diagnosis of cancer is a problem which requires further research."	( Blaney, JM; Crawford, G; Elder, TR; Gavin, AT; Johnston, G, 2011)
"Cancer is one of the major non-communicable diseases posing a threat to world health."	( Adilbay, D; Badovinac-Crnjevic, T; Badwe, R; Banavali, SD; Chan, A; Chaturvedi, P; Chavarri-Guerra, Y; Chen, Z; Chow, LW; Danishevskiy, KD; Digumarti, R; Fan, D; Fan, L; Goss, PE; He, J; Hurlbert, M; Iyer, S; Kaidarova, D; Kumar, L; Lee-Bychkovsky, BL; Li, J; Liedke, PE; Nair, R; Orlov, S; Parikh, P; Pramesh, CS; Purushotham, A; Qiao, YL; Semiglazov, V; Shao, Z; Shastri, SS; Sheikine, Y; Shen, G; Soto-Perez-de-Celis, E; St Louis, J; Strasser-Weippl, K; Subramanian, S; Sullivan, R; Tatishchev, S; Tsimafeyeu, I; Vail, C; Wang, J; Wu, YL; Yu, S; Zhang, Q, 2014)
"Active cancer is the major predictor of venous thromboembolism (VTE) recurrence, but further stratification of recurrence risk is uncertain."	( Ashrani, AA; Bailey, KR; Chee, CE; Heit, JA; Marks, RS; Melton, LJ; Petterson, TM, 2014)
"Burden of cancer is progressively increasing in developing countries like India which has also led to a steep rise in toxicity due to anti-cancer therapy."	( Gupta, S; Haresh, KP; Julka, PK; Mallick, S; Rath, GK; Raza, MW; Roy, S; Sharma, DN, 2014)
"Cancer is a multifactorial and multistep disease, so the treatment effect of combination formulas and prescriptions in TCMs involving multi-targets and multi-signal pathways on tumor may be superior than that of agents targeting a single molecular target alone."	( Bai, XY; Wang, CH; Wang, CY, 2014)
"Diabetes and cancer are common chronic disorders."	( Badrick, E; Renehan, AG, 2014)
"Breast cancer is the most common cancer among women worldwide and novel therapeutic agents are needed to treat this disease."	( Ismail, P; Jabbarzadeh Kaboli, P; Ling, KH; Rahmat, A, 2014)
"GGT in tumors is expressed over the entire cell membrane and provides tumors with access to additional cysteine and cystine from reduced and oxidized glutathione in the blood and interstitial fluid."	( Hanigan, MH, 2014)
"Cancer is a leading cause of death worldwide and an estimated 1 in 4 deaths in the United States is due to cancer."	( Botting, GM; Crees, Z; Devito, JT; Girard, J; Harrington, K; Puri, N; Rios, Z; Shearrow, C; Stone, AL; Uppada, SB; Wojdyla, L, 2014)
"Cancer is the second leading cause of death worldwide."	( Chen, K; Johnston, N; Liu, Q; Ma, Z; Wang, W; Zhang, F; Zheng, X, 2014)
"Reducing fear of cancer is significant in developing cancer screening interventions, but the levels of fear may vary depending on the degrees of media exposure as well as individuals' socioeconomic positions (SEP)."	( Chan, CK; Jung, M; Viswanath, K, 2014)
"A large variety of cancers are associated with a high incidence of lymph node metastasis, which leads to a high risk of cancer death."	( Chen, Q; He, J; Li, Y; Liang, C; Liu, Z; Wang, X, 2014)
"Cancer is now recognized to be a disease arising from both genetic and metabolic abnormalities."	( Adekola, KU; Batra, S; Rosen, ST; Shanmugam, M, 2013)
"Malignant tumors are the major disease that cause serious damage to human health, and have been listed as the premier diseases which seriously threatened human health by World Health Organization (WHO)."	( Song, Z; Xu, X, 2014)
"Hypoxic regions in tumors are known to be resistant to chemotherapy and radiotherapy."	( Saji, H; Ueda, M, 2014)
"Patients with cancer are at risk of venous thromboembolism (VTE)."	( Ay, C; Königsbrügge, O; Lötsch, F; Pabinger, I; Posch, F; Zielinski, C, 2014)
"Cancer is an increasing cause of mortality and morbidity throughout the world."	( Kanwar, SS; Sharma, B; Singh, S, 2014)
"Cancer is a life-threatening disease, which is rapidly becoming a global pandemic."	( Chavva, SR; Fan, Z; Grennell, J; Hamme, AT; Kanchanapally, R; Pramanik, A; Ray, PC; Robinson, C; Sinha, SS; Viraka Nellore, BP; Weaver, I, 2014)
"Childhood cancers are relatively uncommon in comparison to adult cancers."	( Bhuyan, C; Hazarika, M; Kataki, AC; Krishnatreya, M; Nandy, P; Roy, PS; Saikia, BJ, 2014)
"Cancer is the most dreadful disease worldwide in terms of morbidity and mortality."	( Al Zohairy, MA; Aly, SM; Khan, MA; Rahmani, AH, 2014)
"Cancer is one of the leading causes of death worldwide."	( Che, CM; Leung, KW; Wong, AS, 2015)
"Patients with cancer are at high risk for infections caused by antibiotic resistant gram-negative bacteria."	( Adachi, J; Bonomo, RA; Perez, F, 2014)
"Gastric cancer is a major cause of mortality and morbidity around world."	( Feng, XL; Hu, P; Jin, W; Li, YS; Liu, XL; Liu, ZS; Lu, SY; Ren, HL; Tong, W; Wang, Q; Yan, DM; Zhang, S; Zhou, Y, 2015)
"Cancer is one of the major malignant diseases in the world."	( Abbaspour-Aghdam, F; Anarjan, N; Berenjian, A; Ghaz-Jahanian, MA; Jafarizadeh-Malmiri, H, 2015)
"Diabetes, much like cancer, is defined by significant metabolic changes."	( Arshad, OA; Datta, A; Venkatasubramani, PS; Venkatraj, J, 2016)
"Cancer is the third leading cause of death in Iran and its incidence has been increasing in recent years."	( Rassouli, M; Sajjadi, M, 2016)
"Cancer is a multifactorial disease that requires treatments able to target multiple intracellular components and signaling pathways."	( Dicato, M; Diederich, M; Teiten, MH, 2014)
"Cancer is one of the major causes of deaths in developed countries and is emerging as a major public health burden in developing countries too."	( Mir, IA; Tiku, AB, 2015)
"Cancer is a significant disease burden in the world."	( He, Y; Hu, W; Liang, C; Liu, L; Pan, E; Xu, Q; Zhang, Q, 2014)
"Cancer is one of the dreadful chronic diseases, and many drugs are available for its treatment."	( Bansal, G; Bansal, Y; Kaur, M; Kohli, S; Sandhu, S, 2015)
"Cancer is one of the most common and deadly diseases around the world."	( Durfee, R; Kairdolf, B; Ren, J; Venugopalan, J; Wang, MD; Xu, J, 2014)
"Neoplasms are highly dependent on glucose as their substrate for energy production and are generally not able to catabolize other fuel sources such as ketones and fatty acids."	( Kapelner, A; Vorsanger, M, 2015)
"Cancer is the most dangerous disease that causes deaths all over the world."	( Shen, X; Shi, Y; Su, P; Wang, J; Zhang, J, 2015)
"End-of-life (EOL) cancer care in general hospitals and home care has not previously been evaluated in Japan."	( Miyashita, M; Morita, T; Sato, K; Shima, Y; Tsuneto, S, 2015)
"Hypoxia in solid tumors is one of the seminal mechanisms for developing aggressive trait and treatment resistance in solid tumors."	( Krohn, KA; Rajendran, JG, 2015)
"Cancer is a major threat to human health."	( Cao, YW; Jiang, HP; Niu, HT; Shao, SX; Wang, XS; Wang, YH; Wang, YL; Xu, XD; Yang, XC, 2015)
"Cancer is a multifaceted and genomically complex disease and rapidly accumulating high impact research is deepening our understanding related to the mechanisms underlying cancer development, progression and resistance to therapeutics."	( Aslam, A; Attar, R; Farooqi, AA; Hasnain, S; Ismail, M; Mansoor, Q; Wang, Z, 2015)
"In other mice when tumors are not eradicated by the current cycle of therapy, it serves as a starting point for the subsequent cycles of treatment to generate higher levels of antitumor immunity and greater antitumor response."	( Feng, D; Hu, Y; Norton, JA; Tsung, K; Zhang, L, 2015)
"Cancer is a group of diseases characterized by uncontrolled cell proliferation, evasion of cell death and the ability to invade and disrupt vital tissue function."	( Di Santo, N; Ehrisman, J, 2014)
"Cancer is an unnatural type of tissue growth in which the cells exhibit unrestrained division, leading to a progressive increase in the number of dividing cells."	( Keskin, C, 2015)
"Cancer is well known as a leading cause of death in the world."	( Jiang, Y; Wang, D; Wang, S; Wang, Y; Wu, K, 2015)
"Because childhood cancer is vastly different from cancer in adults, a thorough understanding of the underlying molecular mechanisms specific to childhood cancer is essential."	( Li, W; Yiu, TT, 2015)
"Cancer is characterized by the uncontrolled growth of cells with the ability of invading local organs and/or tissues and of spreading to other sites."	( Costa, JM; Cotta, RM; da Cunha Neto, SH; de Pinho, ST; Dulikravich, GS; Orlande, HR; Velho, HF, 2015)
"Cancer is a multi-factorial disease and is a major cause of morbidity and mortality worldwide."	( Brasili, E; Filho, VC, 2017)
"Cancer is the one of the leading causes of death, whose incidences is increasing day by day."	( Bhaskar, A; Chandra, S; Kumar, A; Kumar, M; Mukhopadhyay, K; Sasmal, D; Sharma, N, 2015)
"Cancer is a leading cause of death worldwide and novel chemotherapeutic agents with better efficacy and safety profiles are much needed."	( Bracke, ME; Firuzi, O; Khakdan, F; Mathur, D; Miri, R; Nejati, M; Parmar, VS; Parshad, B; Prasad, AK; Saso, L; Sharma, SK, 2016)
"Cancer is the major cause of fatality and the number of new cases is increasing incessantly."	( Alexander, A; Barman, TK; Giri, TK; Maity, S, 2016)
"Patients with cancer are at increased risk of (recurrent) venous thromboembolism."	( Bleker, SM; Büller, HR; Di Nisio, M; Kamphuisen, PW; Van Es, N; Wilts, IT, 2015)
"Cancer is a disease of remarkable importance in the world today and is projected to become the primary cause of death within the coming years, therefore the design and development of new antitumor agents is one of the most pressing research areas in medicinal chemistry."	( Leoni, A; Locatelli, A; Morigi, R; Rambaldi, M, 2015)
"Cancer is one of the main causes of death for human beings."	( Fan, C; Liang, M; Mei, X; Wu, X; Zhang, T, 2015)
"Cancer is the second leading cause of deaths worldwide."	( Khan, M; Ma, T; Maryam, A; Qazi, JI, 2015)
"Cancer is a problem of global importance, since the incidence is increasing worldwide and therapeutic options are generally limited."	( Abrantes, AM; Botelho, MF; Brito, AF; Pires, AS; Ribeiro, M; Teixo, RJ; Tralhão, JG, 2015)
"Also altered in cancer are components of the machinery which sense amino acid sufficiency, nucleated by the mechanistic target of rapamycin (mTOR), a key regulator of cell growth via modulation of key processes including protein synthesis and autophagy."	( Possemato, R; Tsun, ZY, 2015)
"Cancer is responsible for millions of deaths throughout the world every year."	( Jaitak, V, 2016)
"Cancer is known to be a genetic disease, which is caused by abnormalities of oncogenes and/or tumor-suppressor genes."	( Sakai, T; Sowa, Y, 2015)
"Cancer is characterized by abnormal energy metabolism shaped by nutrient deprivation that malignant cells experience during various stages of tumor development."	( Ahmed, H; AlSadek, DM; Badr, HA; Djansugurova, LB; Li, CZ; Mathew, MP; Yarema, KJ, 2015)
"Cancer is a leading cause of death worldwide."	( Bumb, D; Dey, S; Dhillon, PK; Govil, J; Gupta, A; Krishnan, S, 2015)
"Immunotherapy of cancer is a promising therapeutic approach which aims to eliminate malignancies by inducing or enhancing an immune response against the tumor."	( Amidi, M; Fransen, MF; Hennink, WE; Kleinovink, JW; Ossendorp, F; Rahimian, S, 2015)
"Human cancer is becoming a leading cause of death in the world and the development of a straightforward strategy for early detection of cancer is urgently required."	( Chen, Z; Lu, J; Sun, D; Wang, Y; Yu, Y; Zhang, B; Zhong, Y, 2016)
"Cancer is the third cause of death worldwide, with complex etiology, and is defined as an uncontrolled growth of cells."	( Ahmadi, A; Shadboorestan, A, 2016)
"Cancer is often associated with an increased risk of thrombotic events which are exacerbated by treatment with chemotherapeutics such as cyclosphosphamide (CP)."	( Alexander, ET; Gilmour, SK; Goss, A; Hayes, CS; Minton, AR; Van Ryn, J, 2015)
"Patients with cancer are fragile and there is reluctance on the part of health professionals to take multiple plasma samples for PK/PD studies."	( Bista, SR; Good, P; Hardy, J; Haywood, A; Lobb, M; Norris, R; Tapuni, A, 2015)
"Cancer is rapidly becoming a major public health concern in India as well, with the number of new cancer cases anticipated to double within the next 20 years."	( Abid, M; Azam, A; Shamsi, F, 2016)
"Cancer is a manifestation of aberrant cellular proliferation, and the cell cycle is one of the most successfully drugged targets in oncology."	( Gad, Y; Helgason, T; Hong, DS; Jain, RK; Kurzrock, R; Naing, A; Shi, NY; Wheler, J, 2015)
"Cancer is still a clinical challenge, with many efforts invested in order to achieve timely detection."	( Chen, T; Cheng, D; Li, W; Ou, R; Xie, D; Xiong, L; Xu, Y; Yin, W; Zhao, L; Zheng, X, 2016)
"Cancer is one of the deadliest diseases nowadays and is a great topic for research as the challenging task is to develop new entities with selectivity towards cancerous cells."	( Kaur, H; Narasimhan, B; Yadav, S, 2016)
"Cancer is considered as a prevalent cause of human deaths and undoubtedly, is the most complex disease with multiple cellular physiological systems involved."	( Alexiou, A; Ashraf, GM; Tsiamis, V; Vairaktarakis, C, 2015)
"The tumors are not recurrent within the observation time (19 days), and the normal or main organs are not obviously pathological."	( Fei, J; Li, J; Qin, C; Wang, A; Yang, Y, 2015)
"Cancers are characterized by a high metabolic plasticity resulting from mutations and the selection of metabolic phenotypes conferring growth and invasive advantages."	( Baselet, B; Payen, VL; Porporato, PE; Sonveaux, P, 2016)
"Cancer is a multi-faceted disease comprised of a combination of genetic, epigenetic, metabolic and signalling aberrations which severely disrupt the normal homoeostasis of cell growth and death."	( Khan, M; Ma, T; Maryam, A; Mehmood, T; Zhang, H, 2016)
"Transmissible tumors are those that have transcended the bounds of their incipient hosts by evolving the ability to infect another individual through direct transfer of cancer cells, thus becoming parasitic cancer clones."	( Davis, BW; Ostrander, EA; Ostrander, GK, 2016)
"Cancer is a diverse class of diseases characterized by uncontrolled cell growth that constitutes the greatest cause of mortality and morbidity worldwide."	( Bukhari, SN; Jantan, I; Seyed, MA; Vijayaraghavan, K, 2016)
"The 'hallmarks of cancer' are generally accepted as a set of genetic and epigenetic alterations that a normal cell must accrue to transform into a fully malignant cancer."	( Delbridge, AR; Grabow, S; Strasser, A; Vaux, DL, 2016)
"Cancer is a cell dysfunction disease."	( Chen, J; Chen, S; Cui, J; Gao, L; Li, H; Xu, P, 2016)
"The development of cancer is often accompanied by a loss of the primary cilium, a microtubule-based cellular protrusion that functions as a cellular antenna and that puts a break on cell proliferation."	( Bagadi, M; Binda, MM; Chaltin, P; Daniels, VW; Dehairs, J; Khan, NA; Marchand, A; Munck, S; Rueda-Rincon, N; Swinnen, JV; Talebi, A; Thimiri Govinda Raj, DB; Vanderhoydonc, F; Willemarck, N, 2016)
"Cancer is a multifaceted and genomically complex disease."	( Aydin, T; Cakir, A; Farooqi, AA; Fayyaz, S; Gasparri, ML; Panici, PB, 2016)
"Cancer is known as abnormal cell division and consisting of a group of diseases on various organ tissues."	( Coşkun, GP; Küçükgüzel, ŞG, 2016)
"Cancer is a disease caused by the abnormal proliferation and differentiation of cells governed by tumorigenic factors."	( Li, W; Liu, T; Liu, X, 2016)
"Given that tumors are often resistant to apoptosis, it is important to identify alternative molecular mechanisms that elicit immunogenic cell death."	( Aaes, TL; Agostinis, P; Bertrand, MJ; Berx, G; De Craene, B; De Groote, P; De Koker, S; Declercq, W; Delrue, I; Delvaeye, T; Garg, AD; Grooten, J; Heyndrickx, L; Kaczmarek, A; Krysko, DV; Leybaert, L; Taminau, J; Vandenabeele, P; Wiernicki, B, 2016)
"Cancer is the second leading cause of death in the United States."	( Anderson, ML; Buist, DS; Burda, BU; Chubak, J; Kamineni, A; Whitlock, EP; Williams, SB, 2016)
"Pancreatic cancer is the most used animal model, due to its high rate of cancer-associated VTE."	( Dignat-George, F; Dubois, C; Mege, D; Mezouar, S; Panicot-Dubois, L, 2016)
"Many types of cancer are hypermetabolic on PET/CT scans, but normal structures and areas of inflammation are also hypermetabolic, so knowledge of normal imaging and cytologic or histopathologic evaluation of lesions is essential."	( Randall, EK, 2016)
"However, cancer is one of the top causes of death, and its incidence continues to increase in many countries, including Japan."	( Toyokuni, S, 2016)
"Muscle wasting in cancer is a common and often occult condition that can occur prior to overt signs of weight loss and before a clinical diagnosis of cachexia can be made."	( Crawford, J; Dalton, JT; Gralla, RJ; Hancock, ML; Johnston, MA; Prado, CM; Taylor, RP, 2016)
"Cancer is a major cause of death worldwide despite significant advances in surgery and biology."	( Lao, X; Yu, T; Zheng, H, 2016)
"Treating cancer is one of the big challenges of this century and it has become evident that single chemotherapeutic treatment is rarely effective."	( Lehr, T; Menche, D; Müller, R; Schneider, LS; Ulrich, M; von Schwarzenberg, K, 2016)
"Inflammation and cancer are tightly linked."	( Allin, KH; Bojesen, SE; Nordestgaard, BG, 2016)
"Cancer is one of the leading causes of morbidity and mortality all over the world."	( Granja, A; Pinheiro, M; Reis, S, 2016)
"Cancer is now one of the leading causes of death worldwide, and excisional surgery is an essential treatment for the four most common adult cancers."	( Buggy, DJ; Connolly, C, 2016)
"Cancer is one of the major leading causes of death worldwide and its prevalence will be higher in the coming years due to the progressive aging of the population."	( Baeza, A; Vallet-Regi, M, 2018)
"Cancer is a leading cause of death in the world."	( Duan, H; Wang, L; Xiao, F; Xiong, Q, 2017)
"Cancer is a collection of proliferative diseases marked by malignant transformation, dysregulated mitosis, invasion and metastasis."	( Engel, PA, 2016)
"Cancer is predominantly a somatic disease."	( Chandrani, P; Desai, S; Dutt, A; Gardi, N; Gupta, S; Iyer, P; Prasad, R; Sahoo, B; Singh, A; Togar, T; Upadhyay, P, 2016)
"Hypoxic tumors are resistant to radiotherapy, motivating the development of tools to image local oxygen concentrations."	( Christodoulou, AG; Clifford, B; Epel, B; Halpern, HJ; Liang, ZP; Redler, G, 2016)
"Cancer is the fourth leading cause of death in Sabah Malaysia with a reported agestandardized incidence rate was 104."	( Hassan, MR; Ibrahim, MY; Jeffree, SM; Kamaludin, F; Kaur, N; Lukman, KA; Mihat, O; Myint, T, 2016)
"Cancer is a class of formidable disease with high degree of mortality."	( Lal, K; Yadav, P, 2018)
"Advanced colorectal cancer is one of the deadliest cancers, with a 5-year survival rate of only 12% for patients with the metastatic disease."	( Chan, C; Duan, X; Guo, N; He, C; Lin, W; Poon, C; Weichselbaum, RR, 2016)
"Research related to cancer is vast, and continues in earnest in many directions."	( Bloch, N; Harel, D, 2016)
"Cancer is a leading cause of death and major health concern worldwide."	( Ansari, MN; Gautam, S; Kaithwas, G; Roy, S; Saeedan, AS; Saraf, SA, 2017)
"Hypercalcaemia of malignancy is well recognised, but hypocalcaemia in cancer patients is not, although it is increasingly encountered."	( Dubin, I; Gelber, M; Huber, R; Schattner, A, 2016)
"Patients with cancer are a specific high-risk group for development of infection."	( Hebbard, AI; Reed, C; Slavin, MA; Teh, BW; Thursky, KA; Trubiano, JA; Worth, LJ, 2016)
"Various cancers are related to obesity and proper understanding of their aetiology, especially their molecular tumour biology is important for early diagnosis and better treatment."	( Das, S; Teoh, SL, 2016)
"Cancer is one of the leading causes of deaths worldwide."	( Chen, M; Dong, J; Luo, Q; Lyu, Y; Mo, S; Wei, Y; Wu, J, 2016)
"Cancer is a multifactorial disease and most of its types still remain incurable, in spite of enormous efforts to explicate various tumor pathophysiology."	( Kamath, PR; Sunil, D, 2017)
"Cancer is one of the leading causes of death worldwide and a major global health problem."	( Chen, A; Cheng, P; Dong, Y; Du, Z; Gao, Y; Huang, H; Liu, H; Wang, Y, 2016)
"Cancer is a major public health problem and the second leading cause of mortality around the world."	( Chiosi, E; Gallo, M; Illiano, M; Naviglio, D; Naviglio, S; Sapio, L; Spina, A, 2017)
"A hallmark of cancer is the evasion of apoptosis, which is often associated with the upregulation of the antiapoptotic members of the Bcl-2 family of proteins."	( Chen, L; Fletcher, S; Lanning, ME; Yap, JL, 2017)
"These tumors are sensitive to Arg-starvation therapy using pegylated arginine deiminase (ADI-PEG20) which digests extracellular Arg."	( Chang, JT; Chen, HH; Estecio, M; Feun, LG; Kuo, MT; Long, Y; Savaraj, N; Tsai, WB; Wangpaichitr, M, 2016)
"Radioresistant tumors are perceived as-principal indications for carbon ions in 39."	( Carrara, M; Ciardo, D; Fossati, P; Giandini, T; Jereczek-Fossa, BA; Marvaso, G; Morlino, S; Orecchia, R; Romanelli, P; Russi, E; Valdagni, R; Valvo, F; Vischioni, B, 2017)
"Children with cancer are potentially at a high risk of plasma 25-hydroxyvitamin D (25(OH)D) inadequacy, and despite UK vitamin D supplementation guidelines their implementation remains inconsistent."	( Brand, C; Brougham, MF; Chin, RF; Davidson, I; Iniesta, RR; McKenzie, JM; Paciarotti, I; Wilson, DC, 2016)
"Malignant tumors are one of the main causes of death in Poland."	( Krokosz, A; Lichota, A, 2016)
"Development of malignancy is accompanied by a complete metabolic reprogramming closely related to the acquisition of most of cancer hallmarks."	( Cascante, M; de Atauri, P; Tarrado-Castellarnau, M, 2016)
"Yet, cancer is a highly heterogeneous disease in which the global pattern of DNA methylation and gene expression, especially across diverse cancers, is not well understood."	( He, YH; Kong, QP; Li, QG; Liu, J; Wang, XX; Xiao, FH, 2017)
"Cancer is a life-threatening disease with an alarmingly increased annual mortality rate globally."	( Duan, X; Sun, M; Xiao, L; Ye, Y; Zhang, H; Zhang, Y, 2017)
"Patients with cancer are at increased risk of venous thromboembolism, and emergency physicians can play a significant role in addressing one of the leading causes of morbidity and mortality in this patient population."	( Coyne, CJ; Nene, RV, 2017)
"The risk of colon cancer is increased in patients with Crohn's disease and ulcerative colitis."	( Bakthavatchalu, V; Bryant, EM; Conaway, EA; Fox, JG; Gong, G; Holcombe, H; Horwitz, BH; Muthupalani, S; Parry, NAP; Puglisi, DA; Sheh, A; Short, SP; Tannenbaum, SR; Wang, C; Williams, CS; Wogan, GN, 2017)
"Contagious cancers are malignant cells that are physically transferred between individuals as a natural allograft, forming new clonal tumours."	( Siddle, HV, 2017)
"Cancer is one of the most awful lethal diseases all over the world and the success of its current chemotherapeutic treatment strategies is limited due to several associated drawbacks."	( Kamath, PR; Sunil, D, 2017)
"Cancers are able to grow by subverting immune suppressive pathways, to prevent the malignant cells as being recognized as dangerous or foreign."	( Allard, B; Longhi, MS; Robson, SC; Stagg, J, 2017)
"Patients with cancer are at increased risk of recurrent venous thromboembolism (VTE) and bleeding."	( Bauersachs, R; Martínez-Zapata, MJ; Mathioudakis, AG; Mousa, SA, 2018)
"Cancer is a great threat of human health worldwide due to the uncontrollable spread of malignant cells throughout the body."	( Bi, J; Tan, M; Wang, H; Zhu, BW, 2018)
"Cancer is one of the leading causes of death worldwide (approximately 8."	( Berenger, ALR; Brito, LC; Figueiredo, MR, 2017)
"Cancers are usually treated by anticancer agents that are toxic for both normal and cancer cells, so these drugs have major side effects and they are not suitable and enough effective for cancer prevention."	( Kalalinia, F; Karimi-Sani, I, 2017)
"When initiation of cancer is blocked, promotion, progression and development of the disease cannot occur."	( Cavalieri, EL; Rogan, EG; Zahid, M, 2017)
"Cancer is a heterogeneous and complex "organ" containing multiple components, therefore, cancer needs to be investigated from systems biology point of view, we proposed the concept of "systems molecular imaging" for much better understanding systems biology of cancer."	( Huang, T; Jin, Z; Li, XF; Shen, B; Sun, Y, 2017)
"Patients with cancer are at increased risk of thrombosis, particularly those with central venous catheter (CVC) placement, which may predispose to the development of upper extremity deep vein thrombosis (UEDVT)."	( Corpuz, R; Davies, GA; Gandara, E; Kovacs, MJ; Lazo-Langner, A; Louzada, M; Rodger, M; Tagalakis, V, 2018)
"The fight against cancer is hindered by its highly heterogeneous nature."	( Gauran, IIM; Kann, MG; Park, D; Park, J; Peterson, TA, 2017)
"Cancer is an extremely complex disease comprising of a multitude of characteristic hallmarks that continue to evolve with time."	( Dai, X; Kumar, AP; Magae, J; Min-Wen, JC; Mishra, S; Sethi, G; Shyh-Chang, N; Yan-Jiang, BC, 2017)
"Cancer is defined as the abnormal cell growth that can cause life-threatening malignancies with high financial costs for patients as well as the health care system."	( Abdollahi, M; Bahramsoltani, R; Davatgaran-Taghipour, Y; Farzaei, MH; Karimi-Soureh, Z; Masoomzadeh, S; Rahimi, R, 2017)
"Cancer is one of the most common causes of death and remains the first in China and the second in the US."	( Pu, X; Wei, Y; Zhao, L, 2017)
"Cancer is a rapidly growing disease of current era which poses a major life threaten situation to human beings."	( Bajaj, S; Roy, PP; Singh, J, 2018)
"Cancer is a disease whose treatment is often limited due to the development of a phenomenon known as multidrug resistance (MDR)."	( Anreddy, N; Chen, ZS; Cheng, C; Gadhia, S; Kathawala, R; Li, TW; Patel, A; Sodani, K; Wang, DS; Yang, DH, 2017)
"Cancer is now becoming a leading cause of death."	( Akhtari-Zavare, M; Fadhilah, SI; Mahmud, R; Mohd Sidik, S; Periasamy, U; Rampal, L, 2017)
"Cancer is a major health concern and leading burden on economy worldwide."	( Chen, BA; Jacob, JA; Salmani, JMM; Zhang, XP, 2017)
"Atherosclerosis and cancer are chronic diseases considered two of the main causes of death all over the world."	( Delgado-Coello, B; Mas-Oliva, J; Tapia-Vieyra, JV, 2017)

Excerpt

Reference

"Patients with solid tumors are more likely to be deficient only in the response to newly encountered antigens."

( Burdick, JF; Herberman, RB; Wells, SA, 1975)

"Cancer is unable to go into the radical state."

( Szent-Györgyi, A, 1977)

"Cancers are a broad spectrum of diseases in which there are altered growth fractions and cell-turnover fractions, and therefore cancer chemotherapeutic agents have been developed to take tumor kinetics into account."

( Russell, DH, 1977)

"Human tumors are in general more efficient producers of fluorodeoxyuridylate than murine tumors."

( Ardalan, B; Cooney, D; Macdonald, JS; Schein, PS, 1979)

"Malignant tumors are known to have a "remote" or nonmetastatic effect on the central and peripheral nervous systems."

( Barron, SA; Heffner, RR, 1978)

"Different types of cancer are not necessarily affected by dietary components in the same manner."

( Alcantara, EN; Speckmann, EW, 1976)

"Two kinds of neoplasm are now known to be associated with human exposure to anabolic agents: vaginal adenocarcinoma and liver-cell tumours."

( Rose, FJ, 1976)

"Cancer is described as a disease of abnormal cell and tissue differentiation, and its underlying cause is identified in the process of blocked reontogeny."

( Longenecker, JP; Williams, JF, 1977)

"Lung cancer is excessive in curing workers."

( Burgess, WA; Fine, LJ; Monson, RR; Peters, JM, 1976)

"Tumors are chemically active and the important concept which has had great impact on the diagnosis, treatment, and basic understanding of mechanisms, which are important to endocrinologists and oncologists has been stated by Liddle: "Certain tumors of nonendocrine tissue can produce hormones that are similar to normal hormones except that their production is not appropriately controlled by normal physiologic mechanisms."

( Bartuska, DG, 1975)

"Mortality due to cancers is generally negatively correlated to serum cholesterol levels with a significant increase in mortality in patients with a low serum cholesterol."

( Bruckert, E; Delahaye, F; Emmerich, J; Richard, JL; Thomas, D, 1992)

"Pain from cancer is said to be poorly relieved."

( Lied, VF; Manger, AT; Ottesen, S, 1992)

"Since human cancers are of the insulin-producing/secreting or insulin-dependent types, it is suggested that screening of individuals for blood insulin level and reducing the insulin status by dietary means may lead to a decreased risk of cancer."

( Yam, D, 1992)

"Hypercalcemia of malignancy is a commonly encountered serious clinical problem that often requires aggressive therapy."

( Fatemi, S; Rude, RK; Singer, FR, 1992)

"Advanced cancer is often accompanied by anaemia, which may worsen with concomitant administration of chemotherapy."

( Abels, RI, 1992)

"Cancer is frequently complicated by anemia, and a survey of serum erythropoietin concentrations in anemic cancer patients showed inappropriately low concentrations for the degree of anemia."

( Spivak, JL, 1992)

"Ovarian cancer is unique in that neoplasms arise from the epithelium, not the hormone-sensitive tissue."

( King, RJ, 1991)

"These stage I tumors are highly curable when they first present but, if allowed to recur, chemotherapy may not offer the patient such a favorable response and cure rate."

( Exelby, P; Ghavimi, F; Luks, E; Wachtel, A; Wollner, N; Woodruff, J, 1991)

"Cancer is now being appreciated in India as an emerging public health problem."

( Mathew, B; Mayadevi, S; Nair, MK; Sankaranarayanan, R; Wesley, R, 1992)

"Cancer is characterized primarily by an increase in the number of abnormal cells derived from a given normal tissue, invasion of adjacent tissues by these abnormal cells, and lymphatic or blood-borne spread of malignant cells to regional lymph nodes and to distant sites (metastasis)."

( Clemens, MR, 1991)

"Mutations in lung cancer are therefore caused by a different mechanism than colorectal cancer and this presumably requires the direct interaction of carcinogens with DNA."

( Coetzee, GA; Jones, PA; Olumi, AF; Rideout, WM; Spruck, CH, 1991)

"These cancers are putatively promoted by estradiol, bile acids and androgens."

( Troll, W, 1991)

"Colon cancer is also etiologically linked to cholesterol oxidation products."

( Hu, B; Morin, RJ; Peng, SK; Sevanian, A, 1991)

"At present, cancer is responsible for almost half of all deaths among women 45-64 years of age, and about 30% of all deaths among men in the same age group (1)."

( Feuer, G; Kerenyi, NA; Pandula, E, 1990)

"Patients with solid tumors are often anemic even before they undergo cytotoxic therapy."

( Abeloff, MD; Jones, RJ; Miller, CB; Piantadosi, S; Spivak, JL, 1990)

"Since cancer is essentially a cell surface problem with loss of contact inhibition, effort might be directed to restoring such inhibition by interfering with activity of new determinants on the cancer cell surface associated with the contact inhibition loss."

( Field, EJ, 1986)

"Most human cancers are resistant to bleomycin a priori, however, and those which are initially sensitive frequently develop resistance to the drug during therapy."

( Sikic, BI, 1986)

"If bladder cancer is caused by agents present in the urine, as is widely believed, this mechanism may also protect against carcinogenesis."

( Anderson, K; Kaufman, JE; Parsons, CL, 1987)

"The notion that cancer is a genetic disease has gained increasing credence from the now numerous studies in which specific alterations of chromosome and of gene structure and activity in a variety of cancers have been identified, and, in particular, with the increasing awareness of the heritability of factors that predispose to the development of early, specific cancers in the offspring of parents carrying these predisposing genes."

( Evans, HJ, 1989)

"Cancer is a process of acquisition of an increased variety of cell functions by originally differentiated cells due to the failure of other organs to maintain their specific functions."

( Bok, SW, 1989)

"Hypercalcaemia in malignancy is a major clinical problem."

( Eisman, JA; Kelly, PJ, 1989)

"Tumors are likely to be highly heterogeneous for these dynamic properties."

( Coleman, CN, 1988)

"Cancer is the second leading cause of death in the United States."

( Kinzel, T, 1988)

"If stress and cancer are related by coping failure, that connection presumably involves the immune system."

( Brand, RJ; Fox, BH; Ragland, DR; Rosenman, RH, 1987)

"Patients with cancer are especially predisposed to the development of antibiotic-associated hypoprothrombinemia."

( Bodey, GP; Fainstein, V; Jones, PG; Rolston, KV; Strother, SV, 1986)

"Neoplasms are characterized by increased perfusion, increased permeability of their capillary beds to macromolecules, and a delay in new lymphatic vessel growth."

( Scheffel, U; Tsan, MF, 1986)

"Cancer is one of the most serious illnesses of the elderly."

( Neilan, BA, 1985)

"Since endometrial cancer is probably, and cervical cancer certainly, not enhanced by the pill, the maternal death rate among pill users is about 5% of the rate among unprotected sexually active women."

( Lecart, C, 1973)

"Certain cancers are able to synthesize, store, and secrete peptide hormones."

( Borer, WZ, 1984)

"Cervical cancer is the most common, accounting for 28% of diagnosed tumours and 47% of genital tumours in women."

( Séraphin, JJ, 1984)

"Cancers are clones of abnormal cells, arising presumably as the result of mutational or epignetic alterations of gene expression."

( Cairns, J, 1980)

"When gynecologic cancer is treated by either surgery or radiation therapy, definitive infertility usually results."

( Barber, HR, 1981)

"Cancer is characterized by a relatively autonomous growth of cells due to a reduced responsiveness to normal controls of proliferation and differentiation."

( Hull, LA, 1981)

"Cancer is occasionally associated with an increase in serum TBG."

( Hachiya, T; Ijichi, H; Ishida, M; Kajita, Y; Miyazaki, T; Ochi, Y; Yoshimura, M, 1981)

"Cancer is thought also to produce substances which are structurally different in minute points."

( Hattori, N, 1983)

"These tumors are unique in that they require a trypsin-sensitive surface protein for activity."

( Ambrogio, C; Karpatkin, S; Lerner, WA; Pearlstein, E, 1983)

"The tumors are often associated with the site(s) of deposition of the metal."

( Weinberg, ED, 1983)

"Cancer is a disease that requires follow-up and, in some areas, like breast cancer, a long follow-up."

( Fletcher, GH, 1983)

"Solid tumors are known to contain hypoxic cells and are relatively resistant to ionizing radiation and some chemotherapeutic agents."

( Beaudry, JN; Ludwig, CU; Peng, YM; Salmon, SE, 1984)

"Individuals with cancer are subject to fluid and electrolyte imbalances because of the original disease process, therapy, and complications resulting from both the disease process and from therapy."

( Cunningham, SG, 1982)

"Several tumors are characterized by elevated levels of polyamines involved in vital cell proliferation processes."

( Ali-Osman, F; Maurer, HR, 1983)

"Most of the neoplasms are large, and present as masses in the mediastinum or retroperitoneal space."

( Kahn, CR, 1980)

"Benign tumors are dangerous because they tend to rupture spontaneously."

( Huggins, GR, 1981)

"Malignant tumors are the second most common cause of death in children 0 to 15 years old."

( Ivankovic, S, 1982)

"Malignancy is the most common cause of hypercalcemia, which may result from direct involvement of bone or from local or distant production of substances that enhance bone resorption."

( Flueck, JA; Reynolds, LR, 1981)

"Drug treatment for cancer is now widely utilized and in selected neoplasms offers the opportunity for prolonged remission or even cure."

( Kiely, JM, 1981)

"Human tumors are thus different from tumors from other species which have been reported to be deficient or very low in Mn superoxide dismutase."

( Marklund, SL; Westman, NG, 1981)

"These unusual tumors are located chiefly on the scalp and consists of areas of squamous epithelium with non-epidermal keratinization and moderate cellular polymorphism."

( Janitz, J; Wiedersberg, H, 1980)

"Hypercalcaemia of malignancy is usually the result of both increased bone destruction and decreased urinary calcium excretion."

( Hosking, DJ; Lyons, AR; Patel, S, 1993)

"Gastric cancer is the major cancer in Japan."

( Canzian, F; Inoue, R; Nagao, M; Ohgaki, H; Sugimura, T; Ushijima, T, 1995)

"Cancer is a major world health problem."

( Kodiath, A; Kodiath, MF, 1995)

"Since cancer is mainly a disease of older persons, the incidence of malignancies of all types is expected to increase during the coming decades."

( Urushizaki, I, 1993)

"Hypercalcemia of malignancy is due either to local osteolysis at the site of bone metastases or to production by the malignancy of parathyroid hormone-related peptide, which shares some of the effects of parathyroid hormone."

( Audran, M; Boasson, M; Giraud, P; Jallet, P; Legrand, E; Lortholary, A; Minebois-Villégas, A; Pascaretti, C; Subra, JF, 1995)

"Several human cancers are associated with chronic bacterial, viral and parasitic infections."

( Hotchkiss, JH; Liu, RH, 1995)

"The recurrent tumors are suggested to be sensitive to the agents as follows: locally recurrent solid tumors, 5-FU; distantly recurrent solid tumors, 5-FU and CDDP; locally recurrent effusion, CDDP; distantly recurrent effusion, ADR."

( Araya, S; Hayashi, H; Imamura, M; Ishigami, S; Kawabata, K; Masai, Y; Nio, Y; Tamura, K; Tsubono, M, 1995)

"Cancer is not a notifiable disease in India, and hence registration per force has to be active."

( Gajalakshmi, CK; Ravichandran, K; Shanta, V; Swaminathan, R; Vasanthi, L, 1994)

"Malignant tumors are often complicated by hypercalcemia (malignancy associated hypercalcemia: MAHC) which causes various clinical symptoms."

( Eto, S, 1994)

"As cancer is diagnosed at earlier stages of the disease and survival improves after cancer treatment, hand therapy may improve the functional outcomes of persons with cancer."

( Burkhardt, A; Cook, A, 1994)

"Increasingly, cancer is managed on an outpatient basis with pain management responsibility assumed by the family at home."

( Ahn, C; Ferrell, BA; Ferrell, BR; Tran, K, 1994)

"Evidence for breast cancer is more limited but protective associations with vitamin A from both carotenoid and preformed sources have been seen in several studies."

( Willett, WC, 1994)

"Urinary bladder cancer is the most common form of cancer caused by exposure to benzidine."

( Choudhary, G, 1996)

"Cancer is a genetic disorder of somatic cells."

( Venitt, S, 1996)

"Only bladder tumors are produced in dogs and in humans who have been occupationally exposed, possibly related to the slow rate of liver detoxification by acetylation, allowing activation of BZ or its metabolites in urine."

( Verna, L; Whysner, J; Williams, GM, 1996)

"The anemia of malignancy is common and is related to several etiologic factors, a major one being relative erythropoietin (Epo) deficiency."

( Mittelman, M, 1996)

"Cancer is currently regarded to be the phenotypic expression of an accumulation of heritable alterations in the regulators of cell growth and differentiation."

( Mark, SD, 1996)

"Cancer is often viewed as a genetic process in which the developing cancer cell acquires successive mutational lesions that each provide the cell with a growth or survival advantage."

( Laird, PW, 1997)

"Cancer is primarily a disease of the elderly and the palliation of both disease- and treatment-related symptoms is of importance in the practice of cancer medicine in all patients."

( Carbone, PP; Cleary, JF, 1997)

"Cancer is often associated with chronic anemia which frequently requires blood transfusions."

( Barona, P; Jiménez, M; León, P; Sierrasesúmaga, L, 1998)

"Neoplasia is characterised by abnormal regulation of the cell cycle."

( Chetty, R; Donnellan, R, 1998)

"Cancer is frequently associated with anemia and may be related to inadequate erythropoietin production."

( Barona Zamora, P; Castro Paz, L; Jiménez Monteagudo, M; León Molinari, P; Riol Diego, M; Sierrasesúmaga Ariznavarreta, L, 1998)

"Advanced cancer is commonly associated with significant anemia which worsens with the administration of cytotoxic drugs."

( Hakimali, A; Khan, ZK; Malik, IA; Rehman, G; Sabih, M, 1998)

"If tumors are resistant to methotrexate because of decreased transport of drug (and also folate), then the same pharmacological principle used to develop TMTX/LV for the treatment of P."

( Holcenberg, JS; Hum, M; Kamen, BA; Tkaczewski, I; Weaver, JW; Wilson, J, 1998)

"Patients with cancer are clearly at high risk for the development of venous thromboembolism (VTE), particularly during chemotherapy and surgery."

( Levine, MN; Rickles, FR, 1998)

"Chronic anaemia of cancer is often characterized by inappropriately low levels of endogenous erythropoietin for the degree of anaemia, and manifests clinically with generalized hypoxia and resultant severe fatigue."

( Ludwig, H, 1999)

"In studies where cancer is the endpoint, only three effects have been replicated: (a) selenium supplementation and decreased liver cancer incidence, (b) treatment by the retinoid etretinate and reduced bladder tumours in susceptible individuals, and (c) beta-carotene supplementation and increased lung cancer incidence."

( Lee, PN; Young, KJ, 1999)

"These neoplasms are rare in mice and suggest endocrine dysfunction as a component of preconception carcinogenesis."

( Anderson, LM; Birely, L; Diwan, BA; Haines, DC; Kasprzak, KS; Riggs, CW; Sipowicz, MA; Yu, W, 1999)

"Since cancer is incurable in many patients, palliation of symptoms and quality-of-life issues are important aspects of therapy."

( Bokemeyer, C; Hartmann, JT; Kanz, L; Kollmannsberger, C; Mayer, F, 1999)

"Malignancy is associated with diffuse enlargement of the adrenal glands and resistance to dexamethasone-induced suppression of the HPA axis, which is not due to ectopic ACTH secretion."

( Besser, GM; Jenkins, PJ; Lister, TA; Reznek, R; Sohaib, SA; Trainer, PJ, 1999)

"Most tumors are resistant to therapy by thymidylate synthase (TS) inhibitors due to their high levels of TS."

( Collins, JM; Katki, AG; Klecker, RW, 1999)

"Pediatric cancer is rife with psychological and social issues for both patients and families."

( Gunderman, RB, 2000)

"Trapping of 5-FU in tumors is a necessary, albeit not a sufficient condition, for response."

( Presant, CA; Waluch, V; Wolf, W, 2000)

"Susceptibility to cancer is determined at different levels such as the genetic polymorphism of enzymes involved in the activation and detoxification of carcinogens, the polymorphism of genes that maintains the genome stability, like those involved in DNA repair or recombination processes, and finally the polymorphism in oncogenes or tumour suppressor genes."

( Burnouf, DY; Fuchs, RP, 2000)

"Cancer is a strong risk factor for hospital-acquired thrombosis in the medical ward."

( den Heijer, M; Nijs, AM; Schuurman, B, 2000)

"When tumors are prepared for in vitro assays against drugs, they are routinely treated with proteolytic enzymes (e."

( Egyud, LG; Lipinski, B, 2000)

"As persons with malignancy are at a high risk for developing zoster itself, PHN is a complication that will be faced by many of these patients and their caregivers."

( Mackey, JR; Modi, S; Pereira, J, 2000)

"Cancer is a common life-threatening disease."

( Shudo, K, 2000)

"Hypoxia in tumors is primarily a pathophysiologic consequence of structurally and functionally disturbed microcirculation and the deterioration of diffusion conditions."

( Höckel, M; Vaupel, P, 2001)

"Most neoplasms are dependent on glucose as their primary fuel, and their ambient glucose levels tend to be rather low owing to wasteful aerobic glycolysis and poor perfusion."

( McCarty, MF, 2001)

"Pancreatic cancer is among the most fatal cancers worldwide and one for which few preventable risk factors have been established."

( Albanes, D; Blaser, MJ; Limburg, PJ; Perez-Perez, G; Stolzenberg-Solomon, RZ; Taylor, PR; Virtamo, J, 2001)

"The cancer care team can initiate interventions including patient education and treatments for altered desire, erectile dysfunction, and estrogen deficiency."

( McKee, AL; Schover, LR, 2001)

"Patients with cancer are at risk for developing a variety of fluid and electrolyte disturbances caused by the disease process or by complications from therapy."

( Chan, GZ; Kapoor, M, 2001)

"Cancers are often refractile to this growth inhibition either because of genetic loss of TGF-beta signaling components or, more commonly, because of downstream perturbation of the signaling pathway, such as by Ras activation."

( Akhurst, RJ; Derynck, R, 2001)

"Both AIDS and cancer are linked to immune dysfunctions of the body which are characterized by the persistence of disease-afflicted cells."

( Chang, LJ; He, J, 2001)

"Hypoxia in tumors is associated with malignant progression, metastatic spread, and increased resistance to radiotherapy and chemotherapy."

( Adams, MA; Gofton, TE; Graham, CH; Matthews, NE; Maxwell, LR, 2001)

"Therapy for neoplasma is limited by hematological side effects of tumor-destructive therapy and, in part, makes expensive supportive care necessary to overcome and treat leukopenia and thrombocytopenia and their consequences."

( Dziambor, H; Hager, ED; Höhmann, D; Strama, H; Winkler, P, 2001)

"The hallmark of cancer is genomic instability."

( Fransson, LA, 2001)

"Its use in other tumors is under evaluation, with promise in renal cell carcinoma, prostate cancer, glioma, and Kaposi's sarcoma."

( Anderson, K; Hideshima, T; Richardson, P, 2002)

"Treatment of cancer is increasingly effective but is associated with short and long-term side effects."

( Clarkson, JE; Eden, OB; Worthington, HV, 2002)

"Human cancers are generally characterized by acquisition of a series of somatic mutations."

( Mills, K, 2002)

"Lung cancer is the most frequent of occupational cancers."

( Brochard, P; Matrat, M; Pairon, JC, 2002)

"Nevertheless, cancer is not a frequent disease for the Indian population."

( Desai, PB, 2002)

"Many of cancers are caused by lifestyle elements."

( Chung, FL; Weisburger, JH, 2002)

"Since cancer is not a notifiable disease in India, registration is carried out by active data collection by the registry staff."

( Mandal, S; Parkin, DM; Ramanakumar, AV; Sankaranarayanan, R; Sen, U; Siddiqi, M, 2002)

"In Nigeria, breast cancer is rare, while deaths due to pregnancy and childbirth are common, indicating that OC use can prevent many female deaths."

( Ibekwe, J, 1993)

"Cancer is the 2nd largest cause of death."

( Barros, FC; Lokschin, F, 1984)

"A tar cancer is recorded in 1 control rat."

( Mceuen, CS, 1939)

"Prostate cancer is the growth of malignant cells in the prostate gland, the gland at the base of the urinary bladder in men which helps to create semen."

( , 1996)

"Benign liver tumors are very rare and should not affect prescription of OCs."

( Hecht, Y, 1991)

"30-40% of breast cancers are hormone dependent or sensitive."

( Petit, JC, 1972)

"The risk of breast cancer is increased by an early menarche, late age at 1st birth, and by a late menopause which implicates ovarian steroids in the initiation or promotion of breast cancer, as some breast cancers are estrogen dependent."

( Chandran, R, 1992)

"Hypercalcemia of malignancy is a serious complication of cancer that affects patients with and without bone metastases."

( Major, P, 2002)

"Cancer is the culmination of the chronic disease process, and can be attributed the interactions of environment and genes."

( Zhong, W, 2002)

"Tumors are visible as early as 0."

( Barrett, J; Bartis, J; Bozarth, J; Edwards, S; Ellars, C; Harris, TD; Kalogeropoulos, S; Lazewatsky, J; Liu, S; Nguyen, T; Onthank, D; Robinson, S; Silva, P; Yalamanchili, P, 2003)

"As many tumors are driven by autocrine or paracrine growth through the type-I insulin-like growth factor receptor, mTOR is potentially an attractive target for molecular-targeted treatment."

( Houghton, PJ; Huang, S, 2004)

"Chemoprevention of cancer is reviewed from the viewpoints of action mechanisms and methodology of clinical trials in order to introduce promising agents discovered by in vitro and/or in vivo studies to applications in humans."

( Kakizoe, T, 2003)

"The prevalence of cancer is rising markedly due to increased survival rates."

( Bosanquet, N; Tolley, K, 2003)

"Colorectal cancer is the second most common cause of cancer-related mortality in the west."

( Burgaud, JL; Del Soldato, P; Lavagna, C; Rampal, P, 2003)

"Results for other cancers are sparse."

( Boffetta, P; Nyberg, F, 2003)

"Treatment of cancer is increasingly effective but is associated with short and long-term side effects."

( Clarkson, JE; Eden, OB; Worthington, HV, 2004)

"Cancer is the second leading cause of death in industrialised countries like the United States, where a significant proportion of workers engage in shift work, making a hypothesised relation between light exposure at night and cancer risk relevant."

( Schernhammer, ES; Schulmeister, K, 2004)

"As cancer is predominantly a disease of disordered balance between proliferation, differentiation, and apoptosis, disruptions in the function of the CaR could contribute to the progression of neoplastic disease."

( Rodland, KD, 2004)

"Kidney tumors are heterogeneous in their histology, genetics, and clinical behavior."

( Al-Saleem, T; Babb, JS; Cairns, P; Dulaimi, E; Greenberg, RE; Grizzle, WE; Ibanez de Caceres, I; Polascik, TJ; Uzzo, RG, 2004)

"Cancer is one of the leading causes of death in children."

( Agarwal, S; Khanna, G; Mishra, K; Sharma, S, 2004)

"Cancer is the second leading cause of death in the western world."

( Ganesan, TS; Madhusudan, S, 2004)

"Breast cancer is the only other cancer demonstrating endogenous functional NIS expression."

( Adelman, D; Carrasco, N; Dohan, O; Goris, M; Nowels, K; Wapnir, IL; Yudd, A, 2004)

"Cancer is one of the major health problems around the world."

( Li, Y; Sarkar, FH, 2004)

"Not a few of the cancers are of transitional cell type, that is to say are expressive of an intermediate stage in the metaplasia."

( SMITH, WE, 1950)

"The ICC tumors are called gastrointestinal stromal tumors (GISTs), and GISTs are a good target for the Kit inhibitor imatinib mesylate."

( Hirotab, S; Kitamura, Y, 2004)

"Hypercalcemia of malignancy is a serious complication of cancer."

( Inoue, K; Kawada, K; Minami, H; Okabe, K; Sasaki, T; Sawamura, M; Takashima, S; Watanabe, T; Yagi, Y, 2005)

"Patients with cancer are a recognized group at high risk of VTE, and those undergoing major surgery for their malignancy are at particular risk."

( Kher, A; Samama, MM, 2005)

"Advanced cancer is associated with a hypercoagulable state, and tissue factor expression by cancer cells has received widespread attention because of its significant contribution to the pathogenesis of cancer progression and metastasis."

( Ahamed, J; Belting, M; Ruf, W, 2005)

"Solid tumors are characterized by a fast growth that eventually pushes cells away from their natural source of oxygen and nutrients from the capillaries."

( Martínez, A, 2006)

"Virtually all human tumors are deficient in gap junctional communication (GJC) and the restoration of GJC by forced expression of connexins reduces indices of neoplasia."

( Bertram, JS; Vine, AL, 2005)

"Tumors are generally characterized by an increased glucose uptake and a high rate of glycolysis."

( Hoekman, K; Niessen, HW; Schalkwijk, CG; van Heijst, JW, 2005)

"Childhood cancers are strongly determined by prenatal or early postnatal exposures to oil based combustion gases, especially from engine exhausts."

( Knox, EG, 2005)

"Cancer is a major morbidity and mortality concern in Malaysia."

( Cheah, PL; Cheong, SK; Gudum, HR; Iekhsan, O; Ikram, SI; Jamal, R; Looi, LM; Mak, JW; Othman, NH; Puteri, JN; Rosline, H; Sabariah, AR; Seow, HF; Sharifah, NA; Zubaidah, Z, 2004)

"Advanced cancer is a leading cause of death in the developed world."

( Hickson, ID; Madhusudan, S, 2005)

"Cancer is becoming an increasingly significant disease worldwide."

( Abdulah, R; Koyama, H; Miyazaki, K; Nakazawa, M, 2005)

"These tumors are marked by increased angiogenesis and an activation of the Akt pathway."

( Bader, AG; Kang, S; Vogt, PK, 2006)

"Tumors are angiogenesis dependent."

( Albertsson, P; Lennernäs, B; Norrby, K, 2006)

"Cancer is the second leading cause of death worldwide."

( Doble, M; HemaIswarya, S, 2006)

"Breast cancer is the oncological disease entity whose relationship to circadian rhythm fluctuations has perhaps been most extensively studied."

( Blask, DE; Brainard, GC; Jasser, SA, 2006)

"Cancer is a multi-factorial process involving genetic and epigenetic events which result in neoplastic transformation."

( Dashwood, RH; Myzak, MC, 2006)

"Cancers are diverse and often resistant to therapeutic strategies."

( Kaneda, Y; Tabata, Y, 2006)

"Cancer is an epigenetic disease, a combination of DNA modifications, chromatin organization and variations in its associated proteins, configure a new entity that regulates gene function throughout methylation, acetylation and chromatin remodelling."

( Esteller, M; Herranz, M, 2006)

"Advanced cancer is associated with a hypercoagulable state that is triggered by tissue factor (TF)."

( Mueller, BM; Ruf, W, 2006)

"Metastatic cancer is one of the main causes of cancer-related death since they rarely respond to available treatments."

( Cheung, HW; Chu, Q; Feng, H; Ling, MT; Tsao, SW; Wang, X; Wong, YC, 2006)

"When cancer is not curable, the focus of care shifts from cure to care."

( , 2006)

"When cancer is not curable, the focus of care shifts from cure to care."

( , 2006)

"The growth of tumors is facilitated by low expressions of MHC and co-stimulatory antigens on tumor cells and the induction of suppressor cells and other inhibitory products by tumors."

( Artym, J, 2006)

"The perfusion of tumors is a surrogate parameter of their viability and may mirror their response to therapy."

( Delorme, S; Krix, M, 2006)

"Accurate staging of cancer is of fundamental importance to treatment selection and planning."

( Hicks, RJ; Lau, EW; Ware, RE, 2006)

"Cancer is the second leading cause of death in the USA, with metastatic disease proving a particular management challenge."

( Eller, MS; Gilchrest, BA; Ohashi, N; Truzzi, F; Yaar, M, 2007)

"Cancer is one of the major public health burdens in the United States and in other developed countries, causing approximately 7 million deaths every year worldwide."

( Gupta, S; Patel, D; Shukla, S, 2007)

"Cancers are assumed to be multivariate, multifactorial diseases that occur when a complex and prolonged process involving genetic and environmental factors interact in a multistage sequence."

( Buka, I; Koranteng, S; Osornio Vargas, AR, 2007)

"Malignancy is an uncommon cause of ALF, and thus imaging studies may not be useful in this setting, but liver biopsy may be beneficial in selected cases."

( Khashab, M; Kwo, PY; Tector, AJ, 2007)

"It was aimed at cancer care in general practice by creating interaction between patients, students, and teachers, thus making the emphasis and focus of teaching student and patient centered rather then teacher centered."

( de Vries, J; Haagedoorn, EM; Kapoor, N, 2006)

"Most PET-negative cancers are early stage cancers, and thus can be detected using other conventional examinations such as endoscopy."

( Kitagawa, M; Kobayashi, H; Ochiai, R; Omagari, J; Ono, K; Yamashita, Y; Yoshida, T, 2007)

"Treatment of cancer is increasingly effective but is associated with short and long term side effects."

( Clarkson, JE; Eden, OB; Worthington, HV, 2007)

"Tumors are associated with immunosuppression and anemia."

( Al-Waili, NS, 2007)

"Cancer is a risk factor for venous thromboembolism (VTE)."

( Agnelli, G; Caprini, JA, 2007)

"Cancer is a cause of venous thromboembolism."

( Berthier, S; Bonnotte, B; Falvo, N; Ghiringhelli, F; Lorcerie, B, 2007)

"Cancer is a genetic disease and carcinogenesis is the process whereby the relevant genetic alterations are acquired."

( Kaufmann, WK, 2007)

"Hypoxic tumors are significantly more malignant, metastatic, radio- and chemoresistant and have a poor prognosis."

( Airley, RE; Mobasheri, A, 2007)

"Cancer is a complex, multi-step process characterized by misregulated signal transduction and altered metabolism."

( Ben-Bassat, H; Klein, S; Kravchenko-Balasha, N; Levitzki, A; Mizrachy-Schwartz, S, 2007)

"Individuals with cancer are living longer, and the number of cancer treatment options provided at various points in the cancer continuum is growing; however, many treatments contribute to anemia."

( Bush, NJ; Hurter, B, 2007)

"Cancer is a serious worldwide health threat, killing almost seven million people per year."

( Bieber, LW; Brondani, DJ; de M Moreira, DR; de Souza, IA; Lima Leite, AC; Nascimento, CR, 2007)

"However, cancer is no longer such an explosive disease, and many cancer sufferers can now expect to have a prolonged, even normal, lifespan."

( Ballantyne, JC, 2007)

"Social burden of cancer is the greatest in persons aged from 15 to 59 years."

( Luo, SQ; Yang, CY; Zhang, MB; Zou, H, 2007)

"Cancer is characterized by uncontrolled cell division resulting from multiple mutagenic events."

( Blumen, S; Dmitrovsky, E; Dragnev, KH; Feng, Q; Freemantle, SJ; Galimberti, F; Kitareewan, S; Liu, X; Sekula, D, 2007)

"Cancer is often burdened by psychological comorbidity, mainly represented by depression, anxiety and adjustment disorders."

( Caldera, P; Siri, I; Torta, R, 2008)

"Most cancers are characterized by excessive transforming growth factor-beta production by tumors, which can promote tumor growth and mediate epithelial-to-mesenchymal transition."

( Pasche, B; Pennison, M, 2007)

"The development of cancer is associated with disorders in the regulation of the cell cycle."

( Katiyar, SK; Meeran, SM, 2008)

"Human solid tumors are invariably less well-oxygenated than the normal tissues from which they arose."

( Brown, JM, 2007)

"Cancer is the leading cause of mortality in Japan, accounting for about 30 percent of all deaths."

( Otsuka, K; Yasuhara, H, 2007)

"Cancer is a simplistic, yet complicated, process that promotes uncontrolled growth."

( Bilfinger, TV; Cadet, P; Esch, T; Kream, RM; Mantione, KJ; Sheehan, M; Stefano, GB; Zhu, W, 2008)

"Cancer is one of the most dreaded diseases with a complex pathogenesis, which threats human life greatly."

( Li, X; Xu, W, 2006)

"when the cancer is considered to be rapidly evolving or as terminal."

( Laval, G; Paris, A, 2008)

"Cancer is primarily a disease of old age, and that life style plays a major role in the development of most cancers is now well recognized."

( Aggarwal, BB; Anand, P; Jhurani, S; Kunnumakkara, AB; Sundaram, C, 2008)

"Because most cancers are caused by dysregulation of as many as 500 different genes, agents that target multiple gene products are needed for prevention and treatment of cancer."

( Aggarwal, BB; Anand, P; Kunnumakkara, AB, 2008)

"Cancer is a major risk factor for the development of venous thromboembolism (VTE)."

( Linkins, LA, 2008)

"These cancers are potential targets for selective chemotherapy with inhibitors of de novo adenine synthesis such as L-alanosine [L-2-amino-3-(N-hydroxy-N-nitrosamino) propionic acid]."

( Burris, HA; Kindler, HL; Oliff, IA; Sandler, AB, 2009)

"O(2) delivery to tumors is constantly changing in all tumors, resulting in continuous reoxygenation events throughout the tumor."

( Cárdenas-Navia, LI; Dewhirst, MW; Mace, D; Richardson, RA; Shan, S; Wilson, DF, 2008)

"Clam cancer is the best characterized, naturally occurring malignancy with a known molecular basis remarkably similar to those observed in several unrelated human cancers where both genotoxic and non-genotoxic strategies can restore the function of wild-type p53."

( Böttger, SA; Walker, CW, 2008)

"Cancer is one of the most common diseases for which a beneficial role of vitamin C has been claimed."

( Calderon, PB; Verrax, J, 2008)

"Breast cancer is the most common female malignancy, for which HRT is one of many modifiable risk factors, often attracting disproportionate attention."

( Marsden, J; Sturdee, D, 2009)

"As cancer is a disease of ageing, targeting Sirtuins is emerging as a promising antitumour strategy."

( Altucci, L; Calvanese, V; Esteller, M; Fraga, MF; Imhof, A; Inhof, A; Lara, E; Lopez-Nieva, P; Mai, A; Martinez-Chantar, ML; Mato, JM; Montoya, G; Nebbioso, A; Oyarzabal, J; Ropero, S; Rotili, D; Serrano, M; Varela-Rey, M; Velasco, S; Villar-Garea, A; Witt, M, 2009)

"Cancer is a disease state in which the cells in our body undergo mutations at the genetic level and are transformed, acquiring the ability to replicate limitlessly."

( Choong, PF; Dass, CR; Tan, ML, 2009)

"Cancer is the result of sequential genetic changes over time that transform a cell into a malignant and ultimately invasive entity."

( Moreno, E; Rhiner, C, 2009)

"Treatment of cancer is increasingly effective, but associated with oral complications such as mucositis, fungal infections, bacterial infections and viral infections such as the herpes simplex virus (HSV)."

( Fernandez Mauleffinch, LM; Glenny, AM; Pavitt, S; Walsh, T, 2009)

"Cancer is linked with hypercoagulability and risk of thrombosis and this close association was recognized by Armand Trousseau in 1865."

( Elalamy, I; Gerotziafas, GT; Hatmi, M; Papageorgiou, C; Samama, MM, 2008)

"Cancer is one of the leading causes of death in the world."

( Aggarwal, P; Burman, AC; Hirpara, KV; Joshi, N; Mukherjee, AJ, 2009)

"The targeting of tumors is made possible through establishing protein signatures specific for each cancer type."

( Atay, C; Ozören, N; Ugurlu, S, 2009)

"Cancer is a leading health hazard, and lung cancer is its most common form."

( Feng, X; Haick, H; Müllen, K; Pisula, W; Tisch, U; Zilberman, Y, 2009)

"Cancer is a pathology that is associated with aberrant gene expression and an altered metabolism."

( Domann, FE; Hitchler, MJ, 2009)

"Malignancy is characterized by a systemic deficiency of glutamine (GLN)."

( Belabed, L; Darmon, P; Pichard, C, 2009)

"These cancers are characterized by length alterations in ubiquitous simple sequence repeats, a phenotype called microsatellite instability."

( de Wind, N; Ferrás, C; Oude Vrielink, JA; te Riele, H; Tsaalbi-Shtylik, A; Verspuy, JW, 2009)

"Many cancers are known to produce high amounts of PGE(2), which is involved in both tumor progression and tumor-induced immune dysfunction."

( Buchsbaum, D; Daurkin, I; Eruslanov, E; Kaliberov, S; Kaliberova, L; Kusmartsev, S; Vieweg, J, 2009)

"Human cancer is likewise significantly determined by the interactions of selenium with other elements, as evidenced by epidemiological, ecological and case-control studies."

( Schrauzer, GN, 2009)

"Although cancer is considered to be a disease caused by DNA alterations, the high genetic variability of tumor cells makes it difficult to exploit these alterations for the treatment of cancer."

( López-Lázaro, M, 2009)

"Hypoxic tumors are often resistant to conventional cancer therapies, and tumor hypoxia correlates with advanced stages of malignancy."

( Glazer, PM; Kim, Y; Lin, Q; Yun, Z, 2009)

"Cancer is a frequent finding in patients with thrombosis, and thrombosis is much more prevalent in patients with cancer, with important clinical consequences."

( Khorana, AA, 2009)

"Aggressive cancers are metabolically active and highly glycolytic; an MRI contrast agent that enters cells with high glycolytic activity could provide high-resolution functional images of tumor boundaries and internal structure, which cannot be achieved by conventional contrast agents."

( Ejnik, J; Foxley, S; Karczmar, GS; Makinen, MW; Martin, H; Mustafi, D; Peng, B; Zamora, M, 2009)

"Cancer is a hyperproliferative disorder that is usually treated by chemotherapeutic agents that are toxic not only to tumor cells but also to normal cells, so these agents produce major side effects."

( Aggarwal, BB; Prasad, S; Ravindran, J, 2009)

"Cancer is one of the leading causes of death in Europe and United States."

( Demopoulos, CA; Frangia, C; Iatrou, C; Tsoupras, AB, 2009)

"Patients with cancer are increasingly at risk for venous thromboembolism (VTE)."

( Connolly, GC; Khorana, AA, 2009)

"Patients with cancer are members of a unique patient population because of their high risk for thrombosis and the risk of anticoagulant-related bleeding."

( Levine, MN, 2009)

"Malignancy is a dreaded complication following organ transplantation."

( Boffa, DJ; Hojo, M; Luan, FL; Maluccio, M; Suthanthiran, M, 2009)

"Many tumors are associated with decreased cellular immunity and elevated levels of prostaglandin E2 (PGE2), a known inhibitor of CD4+ T cell activation and inducer of type-2 cytokine bias."

( Banerjee, S; Bhattacharyya, S; Chakraborty, J; Chattopadhyay, S; Das, K; Das, T; Mohanty, S; Sa, G; Saha, B; Sakib Hossain, DM, 2009)

"Because most cancers are caused by deregulation of as many as 500 different genes, agents that target multiple gene products are needed for prevention and treatment of cancer."

( Das, K; Das, T; Sa, G; Saha, B, 2010)

"Consequently, the malignancy is maintained with the aid of Hsp90 upon which the mutated proteins have become particularly dependent for their activity."

( Prodromou, C, 2009)

"Hence, such tumors are selectively sensitized to DNA-damaging agents by Wee1 inhibition."

( Arai, T; Arakawa, H; Fukasawa, K; Hirai, H; Itadani, H; Iwasawa, Y; Jiang, J; Kaneko, N; Kimura, T; Kobayashi, M; Kotani, H; Mizuarai, S; Nambu, T; Nishibata, T; Ohtani, J; Okada, M; Oki, H; Sagara, T; Sakai, T; Sakamoto, T; Takahashi-Suzuki, I; Yamanaka, K; Yoshizumi, T, 2009)

"In India, cervical cancer is a leading cancer among women and almost all cases of cervical cancer show prevalence of High Risk (HR)-HPV infection."

( Bharti, AC; Das, BC; Hedau, S; Hussain, S; Kumar, R; Mahata, S; Shukla, S, 2009)

"Microscopic tumors are useful models for the validation of hypoxia radiotracers, and digital autoradiography is an appropriate technique for studying the distribution of hypoxia radiotracers in microscopic tumors."

( Humm, JL; Li, XF; Ling, CC; Ma, Y; O'Donoghue, JA; Russell, J; Suehiro, M; Sun, X; Zhang, M, 2010)

"Neonatal neoplasms are rare tumours notorious for their atypical presentation and unpredictable behaviour."

( Yeap, BH; Zahari, Z, 2010)

"Cancer is a limiting factor for long-term survival after heart transplantation."

( Chang, HH; Chen, IM; Chen, PL; Hsieh, YC; Lai, ST; Shih, CC; Weng, ZC; Yang, AH, 2009)

"New treatments for malignancy are greatly needed."

( Bromley, E; Chen, JC; Keltner, L; Wang, S; Xu, L, 2010)

"Development of cancer is a long-term and multistep process which comprises initiation, progression, and promotion stages of carcinogenesis."

( Cheung, KL; Kong, AN, 2010)

"Finally, if cancer is a consequence of excessive nighttime light, it is likely that other diseases/conditions may also be exaggerated by the widespread use of light after darkness onset."

( Erren, TC; Fuentes-Broto, L; Paredes, SD; Reiter, RJ; Tan, DX, 2009)

"Risk of cancer is increased in conditions associated with insulin resistance, but this could be secondary to subclinical inflammation."

( Godsland, IF; Johnston, DG; Loh, WJ; North, BV, 2010)

"In (18)F-FDG PET, tumors are often characterized by their metabolically active volume and standardized uptake value (SUV)."

( Buvat, I; Doyeux, K; Gardin, I; Grotus, N; Hapdey, S; Stute, S; Tylski, P; Vanderlinden, B, 2010)

"Many cancers are deficient in catalase activity, and maintain a moderate level of oxidative stress to aid their proliferation and survival."

( Barroso-Aranda, J; Contreras, F; McCarty, MF, 2010)

"Cancer is well known to be associated with alterations in membrane protein glycosylation (Bird, N."

( Baker, MS; Chick, JM; Clarke, SJ; Haynes, PA; Jankova, L; Kolarich, D; Lee, A; Packer, NH; Robertson, GR; Tsoli, M, 2011)

"Cancer is a leading cause of death in the United States and contributes to yearly rising health care costs."

( Day, ES; Halas, NJ; Morton, JG; West, JL, 2010)

"As lung cancer is the No."

( Supaibulwatana, K; Zhai, DD; Zhong, JJ, 2010)

"Malignancy is one of the comorbidities linked to golimumab, a biological TNF-α blocker."

( Bartegi, A; Ben Amor, N; Bouaziz, A; Mnif, W; Zidi, I, 2011)

"Furthermore, tumors are constantly evolving entities, and are heterogeneous in their cellular makeup, compounding the challenge."

( Klein, S; Levitzki, A, 2010)

"Cancer is a multistep process characterized by altered signal transduction, cell growth, and metabolism."

( Kravchenko-Balasha, N; Levine, RD; Levitzki, A; Remacle, F, 2010)

"As far as cancer is concerned, naturally occurring compounds have been reported to prevent tumorigenesis and also to suppress the growth of established tumors."

( Fulda, S, 2010)

"CCancer is an automatically collected database of gene lists, which were reported mostly by experimental studies in various biological and clinical contexts."

( Antonov, AV; Dietmann, S; Lee, W; Rodchenkov, I; Wong, P, 2010)

"Solid tumors are often poorly vascularized, with cells that can be 100 microm away from blood vessels."

( Caruso, M; Cottin, S; de Campos-Lima, PO; Ghani, K, 2010)

"Cancer is a leading cause of death worldwide, and the numbers of new cancer cases are expected to continue to rise."

( Barnes, S; Nagy, TR; Virk-Baker, MK, 2010)

"Because many cancers are thought to derive from a subpopulation of cancer stem-like cells, which may re-express embryonic genes, Cripto-1 signaling may drive tumor growth through the generation or expansion of tumor initiating cells bearing stem-like characteristics."

( Bianco, C; Castro, NP; Gonzales, M; Nagaoka, T; Rangel, MC; Rollman, K; Salomon, DS, 2010)

"Lung cancer is the leading cause of cancer death, developing over prolonged periods through genetic and epigenetic changes induced and exacerbated by tobacco exposure."

( Fujimoto, J; Hong, WK; Kong, M; Lee, JJ; Lotan, R, 2010)

"Cancer is one of the leading causes of death worldwide."

( Ahmed, R; Mosavel, M; Simon, C, 2010)

"Depression in cancer is associated with increased plasma IL-6 concentrations and dysfunction of the HPA axis."

( Bartholomae, A; Flath, BC; Jehn, CF; Kühnhardt, D; Lüftner, D; Pfeiffer, S; Possinger, K; Schmid, P, 2010)

"Cancer is a major health problem around the world."

( Agarwal, R; Deep, G, 2010)

"Diabetes and cancer are common conditions, and their co-diagnosis in the same individual is not infrequent."

( Chowdhury, TA, 2010)

"These neoplasms are characterized by the presence of neuroamine uptake mechanisms and/or peptide receptors at the cell membrane."

( Baum, RP; Howman-Giles, R; Schmidt, M; Simon, T, 2010)

"Tumors are commonly found during senescence of several strains of mice."

( Bondy, SC; Sharman, EH; Sharman, KG, 2011)

"AIDS-associated cancers are seen in advanced stage of HIV infection."

( Badakh, DK; Gosavi, VS; Jagdale, RV; Joshi, R; Phatak, JU; Phatak, UA, 2010)

"Cancer is frequently caused by altered protein expression."

( De Rosa, G; De Stefano, D; Galeone, A, 2010)

"Metastasis of cancer is a multifactorial disease and is the main cause of death in patients with malignancy."

( Geliebter, J; Moscatello, A; Rajoria, S; Schantz, SP; Suriano, R; Tiwari, RK; Wilson, YL, 2011)

"Human cancers are characterized by widespread changes in their genomic DNA methylation and histone modification patterns."

( Lyko, F; Mund, C, 2010)

"Cancer is one of the leading causes of death worldwide and there is an increasing need for novel anti-tumor therapeutics with greater selectivity and potency."

( Bernhardt, PV; Kalinowski, DS; Kovacevic, Z; Lovejoy, DB; Richardson, DR; Sharpe, PC; Suryo Rahmanto, Y; Yu, Y, 2011)

"Cancer is a prothrombotic state, with an increased prevalence of venous thromboembolism (VTE)."

( Bulato, C; Campello, E; Castelli, M; Gavasso, S; Radu, CM; Simioni, P; Spiezia, L, 2011)

"Cancer is one of the leading causes of death in the United States and around the world."

( Kannaiyan, R; Sethi, G; Shanmugam, MK, 2011)

"Cancer is a disease marked by genetic instability."

( Agrawal, V; Bhasme, D; Bisaria, VS; Grover, A; Pratik, P; Shandilya, A; Sundar, D, 2011)

"Cancer is the leading cause of death in Japan."

( Ebihara, T; Kushida, K; Shiraishi, T, 2010)

"Cancer is connected with mitochondrial malfunction (the Warburg effect) suggesting disrupted physical mechanisms."

( Cifra, M; Kučera, O; Pokorný, J; Vedruccio, C, 2011)

"Cancer is a leading cause of death worldwide."

( Boukamp, P; Chong, HC; Ding, JL; Huang, RL; Kersten, S; Lam, CR; Li, HY; Pal, M; Pan, JY; Tan, CK; Tan, MJ; Tan, NS; Tan, SH; Zhu, P, 2011)

"Cancer is an increasing problem in the Middle Eastern (ME) countries."

( Daher, M, 2011)

"Cancer is one of the leading causes of death in the United States and accounts for approximately 8 million deaths per year worldwide."

( Anant, S; Dhar, A; Gutheil, WG; Ray, A; Reed, G, 2012)

"Epithelial malignancy is common in older age group but it is also an Important cause of morbidity and mortality in young adults."

( Mukhopadhyay, S; Ray, S; Sadhu, A; Sinha, SK, 2010)

"Patients with lung cancer are at a higher risk for severe pulmonary side effects with docetaxel-gemcitabine than are patients with breast cancer."

( Binder, D; Hübner, RH; Schlattmann, P; Temmesfeld-Wollbrück, B, 2011)

"Anxiety in terminal cancer is linked to diminished quality of life, yet overall it is poorly understood with regard to prevalence and relationship to other aspects of psychological distress."

( Breitbart, W; Brescia, R; Kolva, E; Pessin, H; Rosenfeld, B, 2011)

"Cancer is a major killer in today's world accounting for around 13% of all deaths according to the World Health Organisation (W."

( Gibbons, JA; Kanwar, JR; Kanwar, RK, 2011)

"Advanced tumors are often immunosuppressive which results in lack of tumor eradication despite abnormal epitopes being present."

( Cerullo, V; Diaconu, I; Dotti, G; Escutenaire, S; Guse, K; Haavisto, E; Hannuksela, P; Hemminki, A; Holm, SL; Joensuu, T; Kanerva, A; Kangasniemi, L; Karioja-Kallio, A; Karli, E; Kauppinen, S; Laasonen, L; Nokisalmi, P; Oksanen, M; Partanen, K; Pesonen, S; Raki, M, 2012)

"To date cancer is considered as one of the most devastating diseases due to its high rate of mortality."

( Mohanty, C; Parhi, P; Sahoo, SK, 2011)

"Cancer is characterized by bidirectional interrelations between tumour progression, coagulation activation, and inflammation."

( Bokemeyer, C; Langer, F, 2012)

"Cancer is a world-wide health problem and the implication rate as well as the death rate increase year to year."

( Bhattacharya, R; Kudgus, RA; Mukherjee, P, 2011)

"Basal-like breast cancer is an aggressive disease with limited therapeutic options because these tumors frequently express the 'triple-negative' phenotype."

( Ambs, S; Cheng, RY; Glynn, SA; Ridnour, LA; Switzer, CH; Vitek, MP; Wink, DA, 2011)

"Hypercalcemia of malignancy is a common paraneoplastic syndrome and a frequent complication of advanced breast and lung cancer, and multiple myeloma."

( Clines, GA, 2011)

"Most cancers are characterized by multiple molecular alterations, but identification of the key proteins involved in these signaling pathways is currently beyond reach."

( Ahn, JH; Alpaugh, M; Beebe, K; Caldas-Lopes, E; Cerchietti, L; Chiosis, G; Erdjument-Bromage, H; Gomes DaGama, EM; Gross, SS; Guzman, ML; Hatzi, K; Ku, T; Larson, SM; Levine, R; Lewis, JS; Melnick, A; Moulick, K; Neckers, L; Nimer, SD; Perna, F; Pillarsetty, N; Rodina, A; Smith-Jones, P; Taldone, T; Vu, LP; Zatorska, D; Zhao, X; Zong, H, 2011)

"Cancer is one of the main causes of death in the world, and according to the WHO it is projected to continue rising."

( De La Peña, H; Pastorin, G; Rajadas, J; Seifalian, A; Tan, A; Yildirimer, L, 2011)

"Cancer is often accompanied with inflammatory, thrombotic, and diabetic complications."

( Pace-Asciak, CR, 2011)

"Cancer is a major public health problem worldwide."

( Charles, C; Duez, P; Guissou, IP; Ouédraogo, M; Stévigny, C, 2011)

"Cancer is a major cause of death throughout the world."

( Athar, MA; Dar, N; Pervaiz, S; Samra, ZQ; Shaheen, S, 2011)

"Because each cancer is a heterogeneous mix of cancer cells at different stages of development, we are faced with trying to treat many different diseased cells all at once."

( Perkins, G; Yamaguchi, R, 2012)

"Cancer is a genetic disease that is caused by mutations in oncogenes, tumor suppressor genes and stability genes."

( Aguilar-Cazares, D; Báez-Viveros, JL; Lopez-Gonzalez, JS; Prado-Garcia, H; Romero-Garcia, S, 2011)

"As cancer is a multifactor disease, it may require treatment with compounds able to target multiple intracellular components."

( Dicato, M; Diederich, M; Eifes, S; Teiten, MH, 2010)

"Metastasis of tumors is promoted by lactate-induced secretion of hyaluronan by tumor-associated fibroblasts that create a milieu favorable for migration."

( Hirschhaeuser, F; Mueller-Klieser, W; Sattler, UG, 2011)

"Malignant neoplasms are associated with a wide variety of paraneoplastic rheumatological syndromes."

( Bahiri, R; Hajjaj-Hassouni, N; Hakkou, J; Rostom, S, 2012)

"Early detection of cancer is a major problem throughout the world, which is why many researchers are still looking for specific and sensitive markers of malignant tumors."

( Choromańska, B; Dadan, J; Janica, J; Kępka, A; Ladny, JR; Luto, M; Myśliwiec, P; Szajda, SD; Waszkiewicz, N; Zwierz, K, 2011)

"Tumors are multifaceted; in fact, numerous things happen in synchrony to enable tumor promotion and progression."

( Bhattacharyya, S; Das, T; Hossain, DM; Sa, G, 2012)

"Tumors are often sensitive to chemotherapy upon initial treatment, but repeated treatments can select for those cells that were able to survive initial therapy and have acquired cellular mechanisms to enhance their resistance to subsequent chemotherapy treatment."

( Eblen, ST, 2012)

"Because cancers are caused by deregulation of hundreds of genes, an ideal anticancer agent should target multiple gene products or signaling pathways simultaneously."

( Maioli, E; Torricelli, C; Valacchi, G, 2012)

"Cancer is known to be a complex disease and its therapy is difficult."

( Daskalaki, A; Hache, H; Herwig, R; Kühn, A; Lehrach, H; Li, J; Maschke-Dutz, E; Peycheva, S; Wierling, C, 2012)

"Cancers are associated with varying degrees of an increased risk of venous thromboembotic events (VTE) occurring."

( Greenman, J; Madden, LA; Maraveyas, A; Smith, JD; Welsh, J; Yates, KR, 2012)

"Malignant cancer is the leading cause of death in man, exceeding cerebrovascular disease and heart disease."

( Hu, GJ; Lai, ZF; Li, J; Li, YL; Yan, CY, 2014)

"The risk of breast cancer is generally increased by MHT, particularly in lean women with no previous MHT who start estrogen-progestin therapy near the menopause and continue for several years, but there is no increased risk 5 years after stopping MHT."

( Davey, DA, 2012)

"Cancer is a major public health problem in the world."

( Chen, Z; Liu, Y; Mao, R, 2012)

"Lung cancer is the leading cause of cancer-related deaths worldwide."

( El-Ghamry, MN; Kloecker, GH; Sethi, TK, 2012)

"Most solid tumors are known to rely on glycolysis for energy production and this activity leads to production of important amounts of lactate, which are exported into the extracellular milieu, contributing to the acidic microenvironment."

( Azevedo-Silva, J; Baltazar, F; Casal, M; Longatto-Filho, A; Pinheiro, C; Schmitt, FC, 2012)

"Cancer is one of the leading causes of deaths in the world."

( Aluyen, JK; Bellanger, RA; Gottlieb, HB; Ton, QN; Tran, T; Yang, AE, 2012)

"Such cancers are very receptive to cytotoxic therapy because of increased mitotic rates."

( Mackiewicz, T, 2012)

"Cancer is the second cause of death in the world after cardiovascular diseases."

( González, DR; González, E; Ibacache, A; Leiva, E; Monsalve, FA; Rodríguez, JA; Valderrama, JA; Vásquez, D, 2012)

"Cancer is responsible for millions of immature deaths every year and is an economical burden on developing countries."

( Chaudhary, K; Gautam, A; Kapoor, P; Kumar, R; Raghava, GP; Singh, H, 2012)

"Cancer is rapidly becoming the worldwide leading cause of premature death."

( Ceelen, W; Debergh, I; Vanhove, C, 2012)

"Cancer is a major burden worldwide but there are marked geographical variations in frequency and incidence overall."

( Pandith, AA; Siddiqi, MA, 2012)

"Risk for oral cancer is debated, with more studies showing an increased risk than showing no risk; risk also exists for cancer of esophagus, stomach and pancreas."

( Ainamo, A; Lahtinen, A; Rautalahti, M; Wickholm, S, 2012)

"Cancer is the major effect of concern."

( Brugge, D; Buchner, V, 2012)

"Cancer is a complex biological occurrence which is difficult to describe clearly and explain its growth development."

( Chen, YY; Hu, GM; Lee, CY; Pang, NN; Tzeng, WJ, 2012)

"Cancer is no longer considered a "terminal disease"; 50% to 65% of patients survive for at least 2 years, and there are about 12 million cancer survivors in the United States."

( Bruel, BM; Bruera, E; Burton, AW; Koyyalagunta, D; Manchikanti, L; Nouri, KH; Solanki, DR; Toro, MP, 2012)

"Pancreatic cancer is a relatively rare malignancy with a very aggressive natural course, not restrained by the existing current treatments."

( Saif, MW; Strimpakos, AS; Syrigos, KN, 2012)

"Cancer is the current leading cause of death worldwide, responsible for approximately one quarter of all deaths in the USA and UK."

( Austin, LA; Dreaden, EC; El-Sayed, MA; Mackey, MA, 2012)

"Hypoxic tumors are resistant to radiation, chemotherapy, and surgery."

( Maguire, D; O'Dell, W; Okunieff, P; Zhang, L; Zhang, M, 2013)

"Cancer is one of the most serious and lethal diseases around the world."

( Chen, C; Jiang, J; Yu, R; Zhang, L; Zhao, J, 2012)

"Cancer is emerging as a key disease in India, but there has been virtually no research exploring understandings of cancer and practices of communication within oncology settings."

( Broom, AF; Doron, A, 2013)

"Cancer is one of the most life-threatening diseases, which causes 7."

( Fan, Z; Ray, PC; Senapati, D; Singh, AK, 2013)

"Cancer is the second leading cause of death in the United States."

( Chauhan, SC; Jaggi, M; Yallapu, MM, 2013)

"Deaths from cancer are expected to continue to rise because of ageing populations and modifiable risk factors such as tobacco and alcohol use, diet, and obesity."

( Chan, N; Connor, S; Davies, A; Goh, C; Payne, S; Poon, E, 2012)

"Cancer is a growing co-morbidity among HIV-infected patients worldwide."

( Adoubi, I; Akakpo, J; Bissagnene, E; Dabis, F; Diomande, I; Eholie, SP; Ekouevi, DK; Houngbe, F; Jaquet, A; Sasco, AJ; Tanon, A; Zannou, MD, 2012)

"Common cancer is an age-related disease."

( Blagosklonny, MV, 2012)

"Pancreatic cancer is a deadly disease and has the worst prognosis among almost all cancers and is in dire need of new and improved therapeutic strategies."

( Azmi, A; Banerjee, S; Lum, LG; Mohommad, R; Sarkar, FH; Schalk, D; Thakur, A, 2012)

"against cancer are commonly matured by pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and prostaglandin E(2) although the absence of Toll-like receptor mediated activation prevents secretion of IL-12 from DCs and subsequent efficient induction of type 1 effector T cells."

( Andersen, MH; Donia, M; Hansen, M; Hjortø, GM; Larsen, NB; Met, Ö; Svane, IM; thor Straten, P, 2013)

"Cancer is frequently complicated by venous thromboembolic events (VTE), which pose a significant health burden due to the associated high morbidity and mortality rates, yet the exact details of the pathophysiological mechanisms underlying their development are yet to be fully elucidated."

( Date, K; Greenman, J; Hall, J; Madden, LA; Maraveyas, A, 2013)

"Walker-256 tumors are divided into 2 groups, hypovascular and hypervascular tumors that arise 2 and 4 days after tumor inoculation, respectively."

( Kawaguchi, T; Satou, T; Shibata, M; Takenoshita, S, 2012)

"Cancer is a chronic disease and its pathogenesis is well correlated with infection and inflammation."

( Kumar, V, 2013)

"The pH of solid tumors is acidic due to increased fermentative metabolism and poor perfusion."

( Bailey, K; Balagurunathan, Y; Chen, T; Cornnell, HH; Estrella, V; Gatenby, RA; Gillies, RJ; Ibrahim-Hashim, A; Johnson, J; Lloyd, M; Rothberg, JM; Sloane, BF; Wojtkowiak, J, 2013)

"Cancer is caused by defects in the mechanisms underlying cell proliferation, death and migration."

( Prevarskaya, N; Shuba, Y; Skryma, R, 2013)

"Treated tumors are better differentiated as compared with those established in the control mice."

( Basavaraj, C; Chivukula, IV; James, R; Melarkode, R; Montero, E; Nair, P; Vishwakarma, S, 2012)

"Cancer is a cell disease, characterized by a deviation of the control mechanisms of proliferation and differentiation of cells."

( Baggio Gnoatto, SC; Bergold, AM; Froehlich, PE; Kaiser, S; Muller, JJ, 2013)

"Certain cancers are more common, including hepatocellular and pancreatic carcinoma, colorectal cancer, renal cancer, and breast and endometrial cancer, and non-Hodgkin's lymphoma."

( Akturk, HK; Rendell, M; Tella, SH, 2013)

"Cancer is considered as one of the most serious health problems."

( El-Nassan, HB, 2013)

"Aging and advanced cancer are characterized by similar neuroendocrine and immune deficiencies; the most important of them consist of diminished nocturnal production of the pineal hormone melatonin (MLT) and decreased production of IL-2."

( Lissoni, P; Messina, G; Rovelli, F, 2012)

"The burden of cancer is growing globally and is one of the top leading causes of death."

( Hussain, MA; Kadam, S; Nayak, S; Pati, S; Prusty, M; Swain, S, 2012)

"As an important cancer care team member, oncology nurses need to communicate effectively with cancer patients."

( Krauss, SE; Maskor, NA; Muhamad, M; Nik Mahmood, NH, 2013)

"Most hypoxic tumors are insensitive to radiation, which is a major obstacle in the development of conventional radiotherapy for tumor treatment."

( Bu, W; Chen, F; Fan, W; He, Q; Liu, J; Ni, D; Peng, W; Shen, B; Shi, J; Xiao, Q; Xing, H; Zhang, S; Zhao, K; Zhou, L, 2013)

"Cancer is expected to be a major medical issue among this population."

( Bee, PC; Gan, GG; Razali, RM, 2013)

"Cancer is the second leading cause of death in the United States."

( Robbins, D; Zhao, Y, 2014)

"Tumors are characterized by a high degree of diversity and heterogeneity in receptor expression."

( Choyke, PL; Kobayashi, H; Nakajima, T; Sano, K, 2013)

"Lung cancers are increasing rapidly in Kolkata and West Bengal, whereas head and neck cancer has shown a declining trend."

( Gangopadhyay, S; Maiti, PK, 2012)

"However, cancer is still considered as a disease of genetic and metabolic disorders; hence, attacking both aspects of the disease can give better results as compared to contemporary treatment modalities."

( Chibber, S; Hassan, I; Naseem, I, 2013)

"Indeed various cancers are concerned such as prostate, breast, glioblastoma, colorectal, and ovary tumors, and leukemia."

( Alioui, A; Baron, S; De Boussac, H; Dufour, J; Guy, L; Lobaccaro, JM; Trousson, A; Vega, A; Viennois, E; Volle, DH, 2013)

"Patients with cancer are particularly susceptible to drug interactions (DIs), but the extent of the problem has received limited attention."

( D'Hondt, L; Kerger, J; Mouzon, A; Spinewine, A, 2013)

"The onset of cancer is anticipated by changes in the hormonalimmune coordination resulting in chronic quantitative alterations in the synthesis and release of hormones and the loss of the natural synchronicity of that release, which occurs according to circadian rhythms in the healthy organism, principally under the control of the pineal network."

( Pierpaoli, W, 2013)

"Childhood cancers are a special entity with different genetic, environmental factors playing a role in their aetiology."

( Ganguly, S; Gayen, S; Pal, S; Purkait, R; Roy, BN; Samanta, T, 2012)

"Patients with cancer are not protected from the problems of opioid abuse/misuse, and the multidisciplinary cancer treatment team should coordinate an evaluation of risk and the monitoring of aberrant behaviors as part of the comprehensive care plan."

( Anghelescu, DL; Ehrentraut, JH; Faughnan, LG, 2013)

"Imaging pO2 in tumors is now a robust pre-clinical imaging modality with potential for implementation clinically."

( Ardenkjaer-Larsen, JH; Krishna, MC; Matsumoto, S; Matsuo, M; Mitchell, JB; Saito, K, 2013)

"Many patients with cancer are at risk for therapy-induced bone loss, with resultant osteoporotic fractures, or skeletal metastases, which may result in pathologic fractures, hypercalcemia, bone pain, and decline in motility and performance status."

( Biermann, JS; Farooki, A; Fornier, MN; Gagel, RF; Gralow, JR; Kumar, R; Litsas, G; McKay, R; Podoloff, DA; Srinivas, S; Van Poznak, CH, 2013)

"Studies in thyroid cancer are still in their initial stage, but promising."

( Chiovato, L; Coperchini, F; Rotondi, M, 2013)

"Most solid tumors are characterized by unstable perfusion patterns, creating regions of hypoxia that are detrimental to radiotherapy treatment response."

( Danhier, P; De Preter, G; De Saedeleer, CJ; Gallez, B; Jordan, BF; Karroum, O; Porporato, PE; Sonveaux, P, 2013)

"Tumors are characterized by an inefficient and disorganized vasculature which leads to tumor regions that are transiently or chronically undersupplied with oxygen (hypoxia) and nutrients (e."

( Busk, M; Horsman, MR, 2013)

"Prostate cancer is one of the most frequently diagnosed cancers among men."

( Li, J; Li, X; Qin, H; Rasul, A; Yang, N; Zhao, B, 2013)

"Gynecological cancers are among the most common in women and are directly related to a variety of hormonal factors."

( Bazzan, AJ; Newberg, AB; Zabrecky, GP, 2013)

"Cancer is a complex disease characterized by multiple genetic and molecular alterations involving transformation, deregulation of apoptosis, proliferation, invasion, angiogenesis, and metastasis."

( Fimognari, C; Hrelia, P; Lenzi, M, 2014)

"As patients with cancer are living longer, there is a need to ensure that treatments used for palliative care are well tolerated and effective during long-term use."

( Ellershaw, JE; Perelman, M; Radbruch, L; Revnic, J; Taylor, D; Torres, LM, 2014)

"Solid tumors are composed of both cancer cells and various types of accessory cells, mainly fibroblasts, that collectively compose the so called tumor-microenvironment."

( Camici, G; Caselli, A; Chiarugi, P; Cirri, P; Corti, D; Paoli, P; Pieraccini, G; Santi, A; Serni, S; Taddei, ML, 2013)

"Cancer is characterized by uncontrolled growth of abnormal cells leading to the formation of tumors."

( Patil, SP, 2013)

"Cancer is a leading cause of mortality worldwide."

( Chauhan, AS; Hussain, MA; Mallick, D; Nayak, S; Pati, S, 2013)

"Cancer is a complex disease that is dictated by both cancer cell-intrinsic and cell-extrinsic processes."

( Antonioli, L; Blandizzi, C; Haskó, G; Pacher, P, 2013)

"Obesity and cancer are preeminent health care challenges in the 21st century, with obese persons being at an increased risk of cancer."

( Hall, RG; Jean, GW; Shah, S; Sigler, M, 2013)

"Cancer is one of the most significant diseases associated with chronic alcohol consumption, and chronic drinking is a strong risk factor for cancer, particularly of the upper aerodigestive tract, liver, colorectum, and breast."

( Lu, SC; Martinez-Chantar, ML; Mato, JM; Varela-Rey, M; Woodhoo, A, 2013)

"Many types of cancer are now curable or, if not cured, becoming a chronic illness."

( Carver, JR; Liu, J; Manrique, C; Steingart, RM; Yadav, N, 2013)

"Cancer is becoming the largest threat to human health."

( Li, F; Shi, X; Sun, Y; Wu, P; Zhang, Y; Zhu, Z, 2013)

"Because lung cancer is a leading cause of cancer death with limited curative therapy options, careful elucidation of the mechanism and consequences of disordered cancer metabolism in lung cancer is warranted."

( Deng, X; Khuri, FR; Mohamed, A; Owonikoko, TK, 2014)

"Cancer is a leading cause of death worldwide."

( Misra, S; Sharma, K, 2014)

"Cancer is a major public health issue and, despite recent advances, effective clinical management remains elusive due to intra-tumoural heterogeneity and therapeutic resistance."

( Kalinowski, DS; Kovacevic, Z; Lane, DJ; Merlot, AM; Mills, TM; Richardson, DR; Saleh Moussa, R; Shafie, NH, 2014)

"Early detecting of cancer is critical to provide proper treatment and to improve survival of patients."

( Han, J; Kim, JH; Kim, JS; Lee, J; Lee, JH; Lim, JY; Pradhan, T; Ren, WX, 2014)

"Cancer is the second leading cause of death, and chemoprevention is defined as the use of natural or synthetic substances to prevent cancer initiation or progression."

( Becceneri, AB; Cominetti, MR; Filho, JC; Fuzer, AM; Martin, AC; Poltronieri, J; Pouliot, N; Vieira, PC, 2014)

"Cancer is a leading cause of death worldwide."

( Cheng, AS; Huang, M; Luo, T; Xie, H; Zeng, Y, 2014)

"Cancer is a major public health burden in both developed and developing countries."

( Abegaz, B; Mukanganyama, S; Tambama, P, 2014)

"A hallmark of cancer is resistance to apoptosis, with both the loss of proapoptotic signals and the gain of anti-apoptotic mechanisms contributing to tumorigenesis."

( Chen, J; Chen, WD; Wang, FL, 2014)

"Ras-driven cancers are among the most difficult to treat and often excluded from therapies."

( Bagni, RK; Esposito, D; McCormick, F; Stephen, AG, 2014)

"Late diagnosis of cancer is a problem which requires further research."

( Blaney, JM; Crawford, G; Elder, TR; Gavin, AT; Johnston, G, 2011)

"Cancer is one of the major non-communicable diseases posing a threat to world health."

( Adilbay, D; Badovinac-Crnjevic, T; Badwe, R; Banavali, SD; Chan, A; Chaturvedi, P; Chavarri-Guerra, Y; Chen, Z; Chow, LW; Danishevskiy, KD; Digumarti, R; Fan, D; Fan, L; Goss, PE; He, J; Hurlbert, M; Iyer, S; Kaidarova, D; Kumar, L; Lee-Bychkovsky, BL; Li, J; Liedke, PE; Nair, R; Orlov, S; Parikh, P; Pramesh, CS; Purushotham, A; Qiao, YL; Semiglazov, V; Shao, Z; Shastri, SS; Sheikine, Y; Shen, G; Soto-Perez-de-Celis, E; St Louis, J; Strasser-Weippl, K; Subramanian, S; Sullivan, R; Tatishchev, S; Tsimafeyeu, I; Vail, C; Wang, J; Wu, YL; Yu, S; Zhang, Q, 2014)

"Active cancer is the major predictor of venous thromboembolism (VTE) recurrence, but further stratification of recurrence risk is uncertain."

( Ashrani, AA; Bailey, KR; Chee, CE; Heit, JA; Marks, RS; Melton, LJ; Petterson, TM, 2014)

"Burden of cancer is progressively increasing in developing countries like India which has also led to a steep rise in toxicity due to anti-cancer therapy."

( Gupta, S; Haresh, KP; Julka, PK; Mallick, S; Rath, GK; Raza, MW; Roy, S; Sharma, DN, 2014)

"Cancer is a multifactorial and multistep disease, so the treatment effect of combination formulas and prescriptions in TCMs involving multi-targets and multi-signal pathways on tumor may be superior than that of agents targeting a single molecular target alone."

( Bai, XY; Wang, CH; Wang, CY, 2014)

"Diabetes and cancer are common chronic disorders."

( Badrick, E; Renehan, AG, 2014)

"Breast cancer is the most common cancer among women worldwide and novel therapeutic agents are needed to treat this disease."

( Ismail, P; Jabbarzadeh Kaboli, P; Ling, KH; Rahmat, A, 2014)

"GGT in tumors is expressed over the entire cell membrane and provides tumors with access to additional cysteine and cystine from reduced and oxidized glutathione in the blood and interstitial fluid."

( Hanigan, MH, 2014)

"Cancer is a leading cause of death worldwide and an estimated 1 in 4 deaths in the United States is due to cancer."

( Botting, GM; Crees, Z; Devito, JT; Girard, J; Harrington, K; Puri, N; Rios, Z; Shearrow, C; Stone, AL; Uppada, SB; Wojdyla, L, 2014)

"Cancer is the second leading cause of death worldwide."

( Chen, K; Johnston, N; Liu, Q; Ma, Z; Wang, W; Zhang, F; Zheng, X, 2014)

"Reducing fear of cancer is significant in developing cancer screening interventions, but the levels of fear may vary depending on the degrees of media exposure as well as individuals' socioeconomic positions (SEP)."

( Chan, CK; Jung, M; Viswanath, K, 2014)

"A large variety of cancers are associated with a high incidence of lymph node metastasis, which leads to a high risk of cancer death."

( Chen, Q; He, J; Li, Y; Liang, C; Liu, Z; Wang, X, 2014)

"Cancer is now recognized to be a disease arising from both genetic and metabolic abnormalities."

( Adekola, KU; Batra, S; Rosen, ST; Shanmugam, M, 2013)

"Malignant tumors are the major disease that cause serious damage to human health, and have been listed as the premier diseases which seriously threatened human health by World Health Organization (WHO)."

( Song, Z; Xu, X, 2014)

"Hypoxic regions in tumors are known to be resistant to chemotherapy and radiotherapy."

( Saji, H; Ueda, M, 2014)

"Patients with cancer are at risk of venous thromboembolism (VTE)."

( Ay, C; Königsbrügge, O; Lötsch, F; Pabinger, I; Posch, F; Zielinski, C, 2014)

"Cancer is an increasing cause of mortality and morbidity throughout the world."

( Kanwar, SS; Sharma, B; Singh, S, 2014)

"Cancer is a life-threatening disease, which is rapidly becoming a global pandemic."

( Chavva, SR; Fan, Z; Grennell, J; Hamme, AT; Kanchanapally, R; Pramanik, A; Ray, PC; Robinson, C; Sinha, SS; Viraka Nellore, BP; Weaver, I, 2014)

"Childhood cancers are relatively uncommon in comparison to adult cancers."

( Bhuyan, C; Hazarika, M; Kataki, AC; Krishnatreya, M; Nandy, P; Roy, PS; Saikia, BJ, 2014)

"Cancer is the most dreadful disease worldwide in terms of morbidity and mortality."

( Al Zohairy, MA; Aly, SM; Khan, MA; Rahmani, AH, 2014)

"Cancer is one of the leading causes of death worldwide."

( Che, CM; Leung, KW; Wong, AS, 2015)

"Patients with cancer are at high risk for infections caused by antibiotic resistant gram-negative bacteria."

( Adachi, J; Bonomo, RA; Perez, F, 2014)

"Gastric cancer is a major cause of mortality and morbidity around world."

( Feng, XL; Hu, P; Jin, W; Li, YS; Liu, XL; Liu, ZS; Lu, SY; Ren, HL; Tong, W; Wang, Q; Yan, DM; Zhang, S; Zhou, Y, 2015)

"Cancer is one of the major malignant diseases in the world."

( Abbaspour-Aghdam, F; Anarjan, N; Berenjian, A; Ghaz-Jahanian, MA; Jafarizadeh-Malmiri, H, 2015)

"Diabetes, much like cancer, is defined by significant metabolic changes."

( Arshad, OA; Datta, A; Venkatasubramani, PS; Venkatraj, J, 2016)

"Cancer is the third leading cause of death in Iran and its incidence has been increasing in recent years."

( Rassouli, M; Sajjadi, M, 2016)

"Cancer is a multifactorial disease that requires treatments able to target multiple intracellular components and signaling pathways."

( Dicato, M; Diederich, M; Teiten, MH, 2014)

"Cancer is one of the major causes of deaths in developed countries and is emerging as a major public health burden in developing countries too."

( Mir, IA; Tiku, AB, 2015)

"Cancer is a significant disease burden in the world."

( He, Y; Hu, W; Liang, C; Liu, L; Pan, E; Xu, Q; Zhang, Q, 2014)

"Cancer is one of the dreadful chronic diseases, and many drugs are available for its treatment."

( Bansal, G; Bansal, Y; Kaur, M; Kohli, S; Sandhu, S, 2015)

"Cancer is one of the most common and deadly diseases around the world."

( Durfee, R; Kairdolf, B; Ren, J; Venugopalan, J; Wang, MD; Xu, J, 2014)

"Neoplasms are highly dependent on glucose as their substrate for energy production and are generally not able to catabolize other fuel sources such as ketones and fatty acids."

( Kapelner, A; Vorsanger, M, 2015)

"Cancer is the most dangerous disease that causes deaths all over the world."

( Shen, X; Shi, Y; Su, P; Wang, J; Zhang, J, 2015)

"End-of-life (EOL) cancer care in general hospitals and home care has not previously been evaluated in Japan."

( Miyashita, M; Morita, T; Sato, K; Shima, Y; Tsuneto, S, 2015)

"Hypoxia in solid tumors is one of the seminal mechanisms for developing aggressive trait and treatment resistance in solid tumors."

( Krohn, KA; Rajendran, JG, 2015)

"Cancer is a major threat to human health."

( Cao, YW; Jiang, HP; Niu, HT; Shao, SX; Wang, XS; Wang, YH; Wang, YL; Xu, XD; Yang, XC, 2015)

"Cancer is a multifaceted and genomically complex disease and rapidly accumulating high impact research is deepening our understanding related to the mechanisms underlying cancer development, progression and resistance to therapeutics."

( Aslam, A; Attar, R; Farooqi, AA; Hasnain, S; Ismail, M; Mansoor, Q; Wang, Z, 2015)

"In other mice when tumors are not eradicated by the current cycle of therapy, it serves as a starting point for the subsequent cycles of treatment to generate higher levels of antitumor immunity and greater antitumor response."

( Feng, D; Hu, Y; Norton, JA; Tsung, K; Zhang, L, 2015)

"Cancer is a group of diseases characterized by uncontrolled cell proliferation, evasion of cell death and the ability to invade and disrupt vital tissue function."

( Di Santo, N; Ehrisman, J, 2014)

"Cancer is an unnatural type of tissue growth in which the cells exhibit unrestrained division, leading to a progressive increase in the number of dividing cells."

( Keskin, C, 2015)

"Cancer is well known as a leading cause of death in the world."

( Jiang, Y; Wang, D; Wang, S; Wang, Y; Wu, K, 2015)

"Because childhood cancer is vastly different from cancer in adults, a thorough understanding of the underlying molecular mechanisms specific to childhood cancer is essential."

( Li, W; Yiu, TT, 2015)

"Cancer is characterized by the uncontrolled growth of cells with the ability of invading local organs and/or tissues and of spreading to other sites."

( Costa, JM; Cotta, RM; da Cunha Neto, SH; de Pinho, ST; Dulikravich, GS; Orlande, HR; Velho, HF, 2015)

"Cancer is a multi-factorial disease and is a major cause of morbidity and mortality worldwide."

( Brasili, E; Filho, VC, 2017)

"Cancer is the one of the leading causes of death, whose incidences is increasing day by day."

( Bhaskar, A; Chandra, S; Kumar, A; Kumar, M; Mukhopadhyay, K; Sasmal, D; Sharma, N, 2015)

"Cancer is a leading cause of death worldwide and novel chemotherapeutic agents with better efficacy and safety profiles are much needed."

( Bracke, ME; Firuzi, O; Khakdan, F; Mathur, D; Miri, R; Nejati, M; Parmar, VS; Parshad, B; Prasad, AK; Saso, L; Sharma, SK, 2016)

"Cancer is the major cause of fatality and the number of new cases is increasing incessantly."

( Alexander, A; Barman, TK; Giri, TK; Maity, S, 2016)

"Patients with cancer are at increased risk of (recurrent) venous thromboembolism."

( Bleker, SM; Büller, HR; Di Nisio, M; Kamphuisen, PW; Van Es, N; Wilts, IT, 2015)

"Cancer is a disease of remarkable importance in the world today and is projected to become the primary cause of death within the coming years, therefore the design and development of new antitumor agents is one of the most pressing research areas in medicinal chemistry."

( Leoni, A; Locatelli, A; Morigi, R; Rambaldi, M, 2015)

"Cancer is one of the main causes of death for human beings."

( Fan, C; Liang, M; Mei, X; Wu, X; Zhang, T, 2015)

"Cancer is the second leading cause of deaths worldwide."

( Khan, M; Ma, T; Maryam, A; Qazi, JI, 2015)

"Cancer is a problem of global importance, since the incidence is increasing worldwide and therapeutic options are generally limited."

( Abrantes, AM; Botelho, MF; Brito, AF; Pires, AS; Ribeiro, M; Teixo, RJ; Tralhão, JG, 2015)

"Also altered in cancer are components of the machinery which sense amino acid sufficiency, nucleated by the mechanistic target of rapamycin (mTOR), a key regulator of cell growth via modulation of key processes including protein synthesis and autophagy."

( Possemato, R; Tsun, ZY, 2015)

"Cancer is responsible for millions of deaths throughout the world every year."

( Jaitak, V, 2016)

"Cancer is known to be a genetic disease, which is caused by abnormalities of oncogenes and/or tumor-suppressor genes."

( Sakai, T; Sowa, Y, 2015)

"Cancer is characterized by abnormal energy metabolism shaped by nutrient deprivation that malignant cells experience during various stages of tumor development."

( Ahmed, H; AlSadek, DM; Badr, HA; Djansugurova, LB; Li, CZ; Mathew, MP; Yarema, KJ, 2015)

"Cancer is a leading cause of death worldwide."

( Bumb, D; Dey, S; Dhillon, PK; Govil, J; Gupta, A; Krishnan, S, 2015)

"Immunotherapy of cancer is a promising therapeutic approach which aims to eliminate malignancies by inducing or enhancing an immune response against the tumor."

( Amidi, M; Fransen, MF; Hennink, WE; Kleinovink, JW; Ossendorp, F; Rahimian, S, 2015)

"Human cancer is becoming a leading cause of death in the world and the development of a straightforward strategy for early detection of cancer is urgently required."

( Chen, Z; Lu, J; Sun, D; Wang, Y; Yu, Y; Zhang, B; Zhong, Y, 2016)

"Cancer is the third cause of death worldwide, with complex etiology, and is defined as an uncontrolled growth of cells."

( Ahmadi, A; Shadboorestan, A, 2016)

"Cancer is often associated with an increased risk of thrombotic events which are exacerbated by treatment with chemotherapeutics such as cyclosphosphamide (CP)."

( Alexander, ET; Gilmour, SK; Goss, A; Hayes, CS; Minton, AR; Van Ryn, J, 2015)

"Patients with cancer are fragile and there is reluctance on the part of health professionals to take multiple plasma samples for PK/PD studies."

( Bista, SR; Good, P; Hardy, J; Haywood, A; Lobb, M; Norris, R; Tapuni, A, 2015)

"Cancer is rapidly becoming a major public health concern in India as well, with the number of new cancer cases anticipated to double within the next 20 years."

( Abid, M; Azam, A; Shamsi, F, 2016)

"Cancer is a manifestation of aberrant cellular proliferation, and the cell cycle is one of the most successfully drugged targets in oncology."

( Gad, Y; Helgason, T; Hong, DS; Jain, RK; Kurzrock, R; Naing, A; Shi, NY; Wheler, J, 2015)

"Cancer is still a clinical challenge, with many efforts invested in order to achieve timely detection."

( Chen, T; Cheng, D; Li, W; Ou, R; Xie, D; Xiong, L; Xu, Y; Yin, W; Zhao, L; Zheng, X, 2016)

"Cancer is one of the deadliest diseases nowadays and is a great topic for research as the challenging task is to develop new entities with selectivity towards cancerous cells."

( Kaur, H; Narasimhan, B; Yadav, S, 2016)

"Cancer is considered as a prevalent cause of human deaths and undoubtedly, is the most complex disease with multiple cellular physiological systems involved."

( Alexiou, A; Ashraf, GM; Tsiamis, V; Vairaktarakis, C, 2015)

"The tumors are not recurrent within the observation time (19 days), and the normal or main organs are not obviously pathological."

( Fei, J; Li, J; Qin, C; Wang, A; Yang, Y, 2015)

"Cancers are characterized by a high metabolic plasticity resulting from mutations and the selection of metabolic phenotypes conferring growth and invasive advantages."

( Baselet, B; Payen, VL; Porporato, PE; Sonveaux, P, 2016)

"Cancer is a multi-faceted disease comprised of a combination of genetic, epigenetic, metabolic and signalling aberrations which severely disrupt the normal homoeostasis of cell growth and death."

( Khan, M; Ma, T; Maryam, A; Mehmood, T; Zhang, H, 2016)

"Transmissible tumors are those that have transcended the bounds of their incipient hosts by evolving the ability to infect another individual through direct transfer of cancer cells, thus becoming parasitic cancer clones."

( Davis, BW; Ostrander, EA; Ostrander, GK, 2016)

"Cancer is a diverse class of diseases characterized by uncontrolled cell growth that constitutes the greatest cause of mortality and morbidity worldwide."

( Bukhari, SN; Jantan, I; Seyed, MA; Vijayaraghavan, K, 2016)

"The 'hallmarks of cancer' are generally accepted as a set of genetic and epigenetic alterations that a normal cell must accrue to transform into a fully malignant cancer."

( Delbridge, AR; Grabow, S; Strasser, A; Vaux, DL, 2016)

"Cancer is a cell dysfunction disease."

( Chen, J; Chen, S; Cui, J; Gao, L; Li, H; Xu, P, 2016)

"The development of cancer is often accompanied by a loss of the primary cilium, a microtubule-based cellular protrusion that functions as a cellular antenna and that puts a break on cell proliferation."

( Bagadi, M; Binda, MM; Chaltin, P; Daniels, VW; Dehairs, J; Khan, NA; Marchand, A; Munck, S; Rueda-Rincon, N; Swinnen, JV; Talebi, A; Thimiri Govinda Raj, DB; Vanderhoydonc, F; Willemarck, N, 2016)

"Cancer is a multifaceted and genomically complex disease."

( Aydin, T; Cakir, A; Farooqi, AA; Fayyaz, S; Gasparri, ML; Panici, PB, 2016)

"Cancer is known as abnormal cell division and consisting of a group of diseases on various organ tissues."

( Coşkun, GP; Küçükgüzel, ŞG, 2016)

"Cancer is a disease caused by the abnormal proliferation and differentiation of cells governed by tumorigenic factors."

( Li, W; Liu, T; Liu, X, 2016)

"Given that tumors are often resistant to apoptosis, it is important to identify alternative molecular mechanisms that elicit immunogenic cell death."

( Aaes, TL; Agostinis, P; Bertrand, MJ; Berx, G; De Craene, B; De Groote, P; De Koker, S; Declercq, W; Delrue, I; Delvaeye, T; Garg, AD; Grooten, J; Heyndrickx, L; Kaczmarek, A; Krysko, DV; Leybaert, L; Taminau, J; Vandenabeele, P; Wiernicki, B, 2016)

"Cancer is the second leading cause of death in the United States."

( Anderson, ML; Buist, DS; Burda, BU; Chubak, J; Kamineni, A; Whitlock, EP; Williams, SB, 2016)

"Pancreatic cancer is the most used animal model, due to its high rate of cancer-associated VTE."

( Dignat-George, F; Dubois, C; Mege, D; Mezouar, S; Panicot-Dubois, L, 2016)

"Many types of cancer are hypermetabolic on PET/CT scans, but normal structures and areas of inflammation are also hypermetabolic, so knowledge of normal imaging and cytologic or histopathologic evaluation of lesions is essential."

( Randall, EK, 2016)

"However, cancer is one of the top causes of death, and its incidence continues to increase in many countries, including Japan."

( Toyokuni, S, 2016)

"Muscle wasting in cancer is a common and often occult condition that can occur prior to overt signs of weight loss and before a clinical diagnosis of cachexia can be made."

( Crawford, J; Dalton, JT; Gralla, RJ; Hancock, ML; Johnston, MA; Prado, CM; Taylor, RP, 2016)

"Cancer is a major cause of death worldwide despite significant advances in surgery and biology."

( Lao, X; Yu, T; Zheng, H, 2016)

"Treating cancer is one of the big challenges of this century and it has become evident that single chemotherapeutic treatment is rarely effective."

( Lehr, T; Menche, D; Müller, R; Schneider, LS; Ulrich, M; von Schwarzenberg, K, 2016)

"Inflammation and cancer are tightly linked."

( Allin, KH; Bojesen, SE; Nordestgaard, BG, 2016)

"Cancer is one of the leading causes of morbidity and mortality all over the world."

( Granja, A; Pinheiro, M; Reis, S, 2016)

"Cancer is now one of the leading causes of death worldwide, and excisional surgery is an essential treatment for the four most common adult cancers."

( Buggy, DJ; Connolly, C, 2016)

"Cancer is one of the major leading causes of death worldwide and its prevalence will be higher in the coming years due to the progressive aging of the population."

( Baeza, A; Vallet-Regi, M, 2018)

"Cancer is a leading cause of death in the world."

( Duan, H; Wang, L; Xiao, F; Xiong, Q, 2017)

"Cancer is a collection of proliferative diseases marked by malignant transformation, dysregulated mitosis, invasion and metastasis."

( Engel, PA, 2016)

"Cancer is predominantly a somatic disease."

( Chandrani, P; Desai, S; Dutt, A; Gardi, N; Gupta, S; Iyer, P; Prasad, R; Sahoo, B; Singh, A; Togar, T; Upadhyay, P, 2016)

"Hypoxic tumors are resistant to radiotherapy, motivating the development of tools to image local oxygen concentrations."

( Christodoulou, AG; Clifford, B; Epel, B; Halpern, HJ; Liang, ZP; Redler, G, 2016)

"Cancer is the fourth leading cause of death in Sabah Malaysia with a reported agestandardized incidence rate was 104."

( Hassan, MR; Ibrahim, MY; Jeffree, SM; Kamaludin, F; Kaur, N; Lukman, KA; Mihat, O; Myint, T, 2016)

"Cancer is a class of formidable disease with high degree of mortality."

( Lal, K; Yadav, P, 2018)

"Advanced colorectal cancer is one of the deadliest cancers, with a 5-year survival rate of only 12% for patients with the metastatic disease."

( Chan, C; Duan, X; Guo, N; He, C; Lin, W; Poon, C; Weichselbaum, RR, 2016)

"Research related to cancer is vast, and continues in earnest in many directions."

( Bloch, N; Harel, D, 2016)

"Cancer is a leading cause of death and major health concern worldwide."

( Ansari, MN; Gautam, S; Kaithwas, G; Roy, S; Saeedan, AS; Saraf, SA, 2017)

"Hypercalcaemia of malignancy is well recognised, but hypocalcaemia in cancer patients is not, although it is increasingly encountered."

( Dubin, I; Gelber, M; Huber, R; Schattner, A, 2016)

"Patients with cancer are a specific high-risk group for development of infection."

( Hebbard, AI; Reed, C; Slavin, MA; Teh, BW; Thursky, KA; Trubiano, JA; Worth, LJ, 2016)

"Various cancers are related to obesity and proper understanding of their aetiology, especially their molecular tumour biology is important for early diagnosis and better treatment."

( Das, S; Teoh, SL, 2016)

"Cancer is one of the leading causes of deaths worldwide."

( Chen, M; Dong, J; Luo, Q; Lyu, Y; Mo, S; Wei, Y; Wu, J, 2016)

"Cancer is a multifactorial disease and most of its types still remain incurable, in spite of enormous efforts to explicate various tumor pathophysiology."

( Kamath, PR; Sunil, D, 2017)

"Cancer is one of the leading causes of death worldwide and a major global health problem."

( Chen, A; Cheng, P; Dong, Y; Du, Z; Gao, Y; Huang, H; Liu, H; Wang, Y, 2016)

"Cancer is a major public health problem and the second leading cause of mortality around the world."

( Chiosi, E; Gallo, M; Illiano, M; Naviglio, D; Naviglio, S; Sapio, L; Spina, A, 2017)

"A hallmark of cancer is the evasion of apoptosis, which is often associated with the upregulation of the antiapoptotic members of the Bcl-2 family of proteins."

( Chen, L; Fletcher, S; Lanning, ME; Yap, JL, 2017)

"These tumors are sensitive to Arg-starvation therapy using pegylated arginine deiminase (ADI-PEG20) which digests extracellular Arg."

( Chang, JT; Chen, HH; Estecio, M; Feun, LG; Kuo, MT; Long, Y; Savaraj, N; Tsai, WB; Wangpaichitr, M, 2016)

"Radioresistant tumors are perceived as-principal indications for carbon ions in 39."

( Carrara, M; Ciardo, D; Fossati, P; Giandini, T; Jereczek-Fossa, BA; Marvaso, G; Morlino, S; Orecchia, R; Romanelli, P; Russi, E; Valdagni, R; Valvo, F; Vischioni, B, 2017)

"Children with cancer are potentially at a high risk of plasma 25-hydroxyvitamin D (25(OH)D) inadequacy, and despite UK vitamin D supplementation guidelines their implementation remains inconsistent."

( Brand, C; Brougham, MF; Chin, RF; Davidson, I; Iniesta, RR; McKenzie, JM; Paciarotti, I; Wilson, DC, 2016)

"Malignant tumors are one of the main causes of death in Poland."

( Krokosz, A; Lichota, A, 2016)

"Development of malignancy is accompanied by a complete metabolic reprogramming closely related to the acquisition of most of cancer hallmarks."

( Cascante, M; de Atauri, P; Tarrado-Castellarnau, M, 2016)

"Yet, cancer is a highly heterogeneous disease in which the global pattern of DNA methylation and gene expression, especially across diverse cancers, is not well understood."

( He, YH; Kong, QP; Li, QG; Liu, J; Wang, XX; Xiao, FH, 2017)

"Cancer is a life-threatening disease with an alarmingly increased annual mortality rate globally."

( Duan, X; Sun, M; Xiao, L; Ye, Y; Zhang, H; Zhang, Y, 2017)

"Patients with cancer are at increased risk of venous thromboembolism, and emergency physicians can play a significant role in addressing one of the leading causes of morbidity and mortality in this patient population."

( Coyne, CJ; Nene, RV, 2017)

"The risk of colon cancer is increased in patients with Crohn's disease and ulcerative colitis."

( Bakthavatchalu, V; Bryant, EM; Conaway, EA; Fox, JG; Gong, G; Holcombe, H; Horwitz, BH; Muthupalani, S; Parry, NAP; Puglisi, DA; Sheh, A; Short, SP; Tannenbaum, SR; Wang, C; Williams, CS; Wogan, GN, 2017)

"Contagious cancers are malignant cells that are physically transferred between individuals as a natural allograft, forming new clonal tumours."

( Siddle, HV, 2017)

"Cancer is one of the most awful lethal diseases all over the world and the success of its current chemotherapeutic treatment strategies is limited due to several associated drawbacks."

( Kamath, PR; Sunil, D, 2017)

"Cancers are able to grow by subverting immune suppressive pathways, to prevent the malignant cells as being recognized as dangerous or foreign."

( Allard, B; Longhi, MS; Robson, SC; Stagg, J, 2017)

"Patients with cancer are at increased risk of recurrent venous thromboembolism (VTE) and bleeding."

( Bauersachs, R; Martínez-Zapata, MJ; Mathioudakis, AG; Mousa, SA, 2018)

"Cancer is a great threat of human health worldwide due to the uncontrollable spread of malignant cells throughout the body."

( Bi, J; Tan, M; Wang, H; Zhu, BW, 2018)

"Cancer is one of the leading causes of death worldwide (approximately 8."

( Berenger, ALR; Brito, LC; Figueiredo, MR, 2017)

"Cancers are usually treated by anticancer agents that are toxic for both normal and cancer cells, so these drugs have major side effects and they are not suitable and enough effective for cancer prevention."

( Kalalinia, F; Karimi-Sani, I, 2017)

"When initiation of cancer is blocked, promotion, progression and development of the disease cannot occur."

( Cavalieri, EL; Rogan, EG; Zahid, M, 2017)

"Cancer is a heterogeneous and complex "organ" containing multiple components, therefore, cancer needs to be investigated from systems biology point of view, we proposed the concept of "systems molecular imaging" for much better understanding systems biology of cancer."

( Huang, T; Jin, Z; Li, XF; Shen, B; Sun, Y, 2017)

"Patients with cancer are at increased risk of thrombosis, particularly those with central venous catheter (CVC) placement, which may predispose to the development of upper extremity deep vein thrombosis (UEDVT)."

( Corpuz, R; Davies, GA; Gandara, E; Kovacs, MJ; Lazo-Langner, A; Louzada, M; Rodger, M; Tagalakis, V, 2018)

"The fight against cancer is hindered by its highly heterogeneous nature."

( Gauran, IIM; Kann, MG; Park, D; Park, J; Peterson, TA, 2017)

"Cancer is an extremely complex disease comprising of a multitude of characteristic hallmarks that continue to evolve with time."

( Dai, X; Kumar, AP; Magae, J; Min-Wen, JC; Mishra, S; Sethi, G; Shyh-Chang, N; Yan-Jiang, BC, 2017)

"Cancer is defined as the abnormal cell growth that can cause life-threatening malignancies with high financial costs for patients as well as the health care system."

( Abdollahi, M; Bahramsoltani, R; Davatgaran-Taghipour, Y; Farzaei, MH; Karimi-Soureh, Z; Masoomzadeh, S; Rahimi, R, 2017)

"Cancer is one of the most common causes of death and remains the first in China and the second in the US."

( Pu, X; Wei, Y; Zhao, L, 2017)

"Cancer is a rapidly growing disease of current era which poses a major life threaten situation to human beings."

( Bajaj, S; Roy, PP; Singh, J, 2018)

"Cancer is a disease whose treatment is often limited due to the development of a phenomenon known as multidrug resistance (MDR)."

( Anreddy, N; Chen, ZS; Cheng, C; Gadhia, S; Kathawala, R; Li, TW; Patel, A; Sodani, K; Wang, DS; Yang, DH, 2017)

"Cancer is now becoming a leading cause of death."

( Akhtari-Zavare, M; Fadhilah, SI; Mahmud, R; Mohd Sidik, S; Periasamy, U; Rampal, L, 2017)

"Cancer is a major health concern and leading burden on economy worldwide."

( Chen, BA; Jacob, JA; Salmani, JMM; Zhang, XP, 2017)

"Atherosclerosis and cancer are chronic diseases considered two of the main causes of death all over the world."

( Delgado-Coello, B; Mas-Oliva, J; Tapia-Vieyra, JV, 2017)

"Tumors are strongly influenced by the surrounding normal tissue, which forms a specialized niche termed the tumor microenvironment (TME)."

( Diaz-Meco, M; Moscat, J; Reina-Campos, M, 2017)

"Work-related cancer is an important public health issue with a large financial impact on society."

( Cherrie, JW; Corden, C; Gorman Ng, M; Hutchings, S; Lamb, J; Mistry, R; Rushton, L; Sánchez Jiménez, A; Shafrir, A; Sobey, M; van Tongeren, M, 2017)

"Patients with cancer are at highest risk, and this increases morbidity, mortality and costs."

( Alexandrou, E; Castillo, MI; Chan, RJ; Chopra, V; Choudhury, MA; Cooke, M; Corley, A; Gavin, NC; Geoffrey Playford, E; Hallahan, A; Keogh, S; Kleidon, T; Larsen, E; Marsh, NM; McCarthy, AL; McGrail, MR; McMillan, DJ; Mervin, MC; Mollee, P; Paterson, DL; Ray-Barruel, G; Rickard, CM; Ullman, AJ; Webster, J; Zhang, L, 2017)

"Although cancer is a life-threatening condition, oncology medication adherence-the extent to which a patient follows the drug regimen that is intended by the prescriber-can be suboptimal in the long term, as in any other chronic disease."

( Cardoso, E; Csajka, C; Schneider, MP; Widmer, N, 2018)

"Cancer is the 2nd leading cause of death worldwide."

( Ghramh, HA; Khan, M; Ma, T; Maryam, A; Mehmood, T, 2017)

"Cancer is the principal cause of human death and occurs through highly complex processes that involve the multiple coordinated mechanisms of tumorigenesis."

( Han, SJ; Kim, IC; Kim, S; Lee, SG; Suh, SS; Yang, EJ; Youn, UJ, 2017)

"Similarly, tumors are a multicellular mass with distinct cellular phenotypes."

( Erez, A; Kolodkin-Gal, I, 2017)

"Cancer is one of the major causes of mortality in organ transplant patients receiving immunosuppressive regimen based on Cyclosporin A (CsA)."

( Bodeau, S; Choukroun, G; Galmiche, A; Pluquet, O; Sauzay, C, 2017)

"Cancer is a complex disease that involves several genetic and environmental factors."

( Freiesleben, S; Gupta, SK; Shukla, Y; Singh, N; Wolkenhauer, O, 2017)

"Cancer is the leading cause of non-accidental death among adolescents and young adults (AYAs; those aged 15-39 years)."

( Chamberlain, LJ; Johnston, EE; Rajeshuni, N; Sanders, LM; Saynina, O, 2017)

"Tumors are dynamic pseudoorgans that contain numerous cell types interacting to create a unique physiology."

( Kimmelman, AC; Lyssiotis, CA, 2017)

"In 2007, Cancer Care Ontario introduced a provincial symptom screening program, which included pain, for cancer patients."

( Atzema, C; Barbera, L; Chu, A; DeAngelis, C; Dudgeon, D; Earle, CC; Howell, D; Husain, A; Liu, Y; O'Brien, MA; Seow, H; Sutradhar, R, 2017)

"Neonatal tumors are different from tumors of the older children and knowledge gained from treating older children can not be extrapolated to neonates."

( Chandrasekaran, A, 2018)

"Neonatal tumors are defined as tumors which are diagnosed before the first month of life."

( Chandrasekaran, A, 2018)

"Cancer is associated with a prothrombotic state and increases the risk of thrombotic events in patients with atrial fibrillation."

( Alexander, JH; Douglas, PS; Dunning, A; Garcia, DA; Gersh, BJ; Granger, CB; Hanna, M; Hylek, EM; Khouri, MG; Lopes, RD; Melloni, C; Thomas, L; Wallentin, L, 2017)

"Cancer is caused by uncontrollable growth of neoplastic cells, leading to invasion of adjacent and distant tissues resulting in death."

( Chan, GC; Fung, MKL, 2017)

"Cancer is well established as a multifactorial disease and requires multi-module therapeutics."

( Kaul, SC; Putri, JF; Sakamoto, K; Wadhwa, R; Widodo, N, 2017)

"Cancer is a primary public health problem and the second leading cause of death worldwide."

( Ganesan, K; Xu, B, 2017)

"Cancer is an enormous global health burden, and should be effectively addressed with better therapeutic strategies."

( Galadari, S; Pallichankandy, S; Rahman, A; Thayyullathil, F, 2017)

"Patients with cancer are vulnerable to infection and fever, and the causes of these are frequently unclear using conventional diagnostic methods leading to high morbidity and mortality, length of stay and costs of care."

( Douglas, A; Lau, E; Slavin, M; Thursky, K, 2017)

"Cancer is a leading cause of mortality in the world and metastasis is to blame."

( Chik, WI; Sze, LP; Tsang, NY; Tsang, SW; Wang, MZ; Zhang, HJ, 2018)

"Cancer is associated with hypercoagulability."

( Ageno, W; Campiotti, L; Dentali, F; Grandi, AM; Guasti, L; Maresca, AM; Moretto, P; Passi, A; Squizzato, A; Vigetti, D, 2017)

"Cancer is associated with an increased risk of venous thromboembolism (VTE); the exact mechanisms for the induction of VTE remain to be fully elucidated, but it is widely acknowledged that tissue factor (TF)-bearing microparticles (TF-MPs) may play a significant role."

( Date, K; Ettelaie, C; Maraveyas, A, 2017)

"Cancer is a known hypercoagulable state that leads to an increased risk of venous thromboembolism (VTE)."

( Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E, 2018)

"Cancer is a complex disease where cancer stem cells (CSCs) maintain unlimited replicative potential, but evade chemotherapy drugs through cellular quiescence."

( Diwakar, BT; Korwar, AM; Paulson, RF; Prabhu, KS, 2017)

"Cancer is a multifactorial disease, causing behavioral and metabolic alterations, leading to uncontrolled cell proliferation with collateral weakening of immune system."

( Gill, BS; Kumar, S; Kumar, V; Mehra, R, 2018)

"Cancer is a major health problem worldwide and still lacks fully effective treatments."

( Gutiérrez-Rodríguez, AG; Juárez-Portilla, C; Olivares-Bañuelos, T; Zepeda, RC, 2018)

"Cancer is one of the most important healthcare matters, with the worst prognosis but the best possibilities for scientific development."

( Garg, S; Kaul, SC; Wadhwa, R, 2018)

"Malignant tumors are currently the leading cause of death worldwide, followed by cardiovascular and cerebrovascular diseases."

( Chan, MH; Liu, RS, 2017)

"Cancer is one of the most serious illnesses of our civilization."

( Pinto, DCGA; Silva, AMS, 2017)

"Its effect on cancer is the result of gene-nutrient interaction between the genes in folate metabolic pathway and dietary folate availability; mutations in genes of folate metabolism have been shown to alter individual susceptibility to certain childhood cancers as well as response to cancer chemotherapy."

( Agrawal, S; Kumar, A; Moulik, NR, 2017)

"Cancer is one of the leading groups of threatened caused by abnormal state cell growth and second leading diseases involved in the major global death."

( Asiri, AM; Manukumar, HM; Marwani, HM; Qin, HL; Rakesh, KP; Shantharam, CS; Zhang, X, 2018)

"Oral cancers are extremely common among adults with increasing incidences due to human papillomavirus, while treatment modalities are limited."

( Abu El-Naaj, I; Bianco-Peled, H; Ghantous, Y; Goldfeder, M; Prinz, H; Schroeder, A; Shainsky, J; Shtenberg, Y, 2018)

"Cancer is caused by uncontrolled cell proliferation which has the potential to occur in different tissues and spread into surrounding and distant tissues."

( Bazvandi, L; Bhattacharyya, P; Bishayee, A; Chow, N; Farooqi, AA; Farzaei, MH; Hosseinzadeh, L; Jafari, F; Mohammadi, Z; Nabavi, SM; Shokoohinia, Y; Yerer, MB, 2018)

"Cancers are mostly affecting 0-4 years age group, and there is a rising trend of Non-Hodgkin's lymphoma."

( Anshu, K; Bhakta, S; Das, S; Paul, DK, 2017)

"Cancer is a major cause of death."

( Chang, WT; Chen, RJ; Cheng, HC; Cheng, LH; Kuo, HC; Lee, YH; Wang, BJ; Wang, YJ, 2018)

"Cancer is one of the top three causes of death in the United States."

( Valentovic, MA, 2018)

"Vascular supply of tumors is one of the main targets for cancer therapy."

( Akhmanova, A; Aviles, P; Bouchet, BP; Galmarini, CM; Guillen-Navarro, MJ; Martin, M; Martínez-Diez, M; Martinez-Leal, JF, 2018)

"Cancer is a well-established DNA mutation-linked disease; however, epigenetic events are perhaps more important and harmful than genetic alterations."

( Capitanio, N; Piccoli, C; Ricciardi, N; Scrima, R; Zefferino, R, 2017)

"Up to 30% of solid tumors are known to have a mutated (abnormal) KRAS gene."

( Aguilera, Ó; García-Foncillas, J; Sanz-Álvarez, M; Serna-Blasco, R, 2019)

"All cancer care reimbursement schemes in India were identified and three highly utilized schemes (VAS, RAS, CMCHS) were selected."

( Gurumurthy, P; Haitsma, G; Patel, H; Postma, MJ, 2018)

"Both depression and cancer are related to a dysregulation of inflammatory and immune pathways."

( Barreto, FS; Chaves Filho, AJM; de Araújo, MCCR; de Lucena, DF; de Moraes, MEA; de Moraes, MO; Macedo, DS; Maes, M, 2018)

"Cancer is believed to arise through the perturbation of pathways and the order of pathway perturbation events can enhance understanding and evaluation of carcinogenicity."

( Degli Esposti, D; Demetriou, CA; Pullen Fedinick, K; Robinson, O; Russo, F; Vineis, P, 2018)

"Although cancer is known to be predominantly a disease of the elderly, it is also thought that aging and cancer may occur either via similar or opposing cellular mechanisms."

( Papageorgis, P, 2017)

"Cancer is a complex disease, which not only involves the tumor but its microenvironment comprising different immune cells as well."

( Anderson, SK; Basudhar, D; Bharadwaj, G; Cheng, RYS; Fujita, M; McVicar, DW; No, JH; Ridnour, LA; Somasundaram, V; Thomas, DD; Wink, DA, 2019)

"Cancer is considered as one of the most serious health problems today."

( Bhardwaj, TR; Kumar, S; Prasad, DN; Singh, RK, 2018)

"Cancer is a disease of multicellularity; it originates when cells become dysregulated due to mutations and grow out of control, invading other tissues and provoking discomfort, disability, and eventually death."

( Albuquerque, TAF; de Magalhães, JP; Doherty, A; Drummond do Val, L, 2018)

"Cancer is a widespread and life-threatening disease and its early-stage diagnosis is vital."

( Heikkinen, S; Horkka, K; Kavakka, J; Moilanen, JO; Soikkeli, M; Timonen, M, 2018)

"Cancer is a widespread disease and has a high mortality rate."

( Dilnawaz, F, 2019)

"Tumors are easily spread through the lymphatic system while the traditional NPs (~100 nm) can hardly reach lymph nodes for the treatment of metastasis."

( He, Q; Li, M; Liu, Y; Mei, L; Rao, J; Zhang, Z, 2018)

"Tumors are characterized by leaky blood vessels, and by an abnormal and heterogeneous vascular network."

( Barz, M; Baues, M; Gremse, F; Jahnen-Dechent, W; Kiessling, F; Koynov, K; Lammers, T; Negwer, I; Pechar, M; Pola, R; Storm, G; Theek, B; Weber, B, 2018)

"Cancer is a global problem with no sign that incidences are reducing."

( Fakih, O; Kane, D; Sanver, D; Thorne, JL, 2018)

"As most cancers are thought to have defective circadian rhythms, these results suggest that future research on timed dosage of cisplatin could potentially reduce damage to healthy tissue and improve its therapeutic index."

( Adebali, O; Chiou, YY; Hogenesch, JB; Hu, J; Rashid, N; Sancar, A; Selby, CP; Wu, G; Yang, Y, 2018)

"Cancer is one of the leading causes of death worldwide and evergrowing number of scientific research on the topic only confirms that the needs have not been completed yet and that there is a wide platform for improvement."

( Borišev, I; Djordjevic, A; Jović, D; Latinovic, N; Mrđanovic, J; Petrovic, D; Seke, M; Srđenović, B, 2018)

"Cancer is the second leading cause of death worldwide."

( Blanco-Vaca, F; Cedó, L; Julve, J, 2019)

"Recently, pancreas cancers are shown to elevate dopamine receptor-2 synthesis, which is blocked by pimozide leading growth inhibition."

( Altinoz, MA; Elmaci, I, 2018)

"Cancer is one of the most dangerous diseases that are rapidly increasing globally."

( Abroon, S; Aliarab, A; Aziz, SG; Babaei, G; Rasmi, Y, 2018)

"Many cancers are variably resistant to radiation treatment: some patients die within months, while others with the same tumour type and equivalent radiation protocol, survive for years."

( Doble, PA; Miklos, GLG, 2018)

"Cancer is a major burden of disease in low- and middle-income countries (LMICs) yet financial barriers limit access to life-saving oncology drugs."

( Garcia-Gonzalez, P; Novakowski, AK; Stergachis, A; Wrigglesworth, M, 2018)

"Cancer is one of the most troublesome diseases and a leading cause of death worldwide."

( Chao, CY; Chen, WT; Hsieh, CH; Kuo, YY; Lu, CH, 2018)

"Cancer is a major cause of death."

( Chalmers, SB; Monteith, GR, 2018)

"Cancer is highly prevalent and one of the leading causes of global morbidity and mortality."

( Ross, S, 2018)

"Cancer is a serious public health problem not only in Malaysia, also worldwide."

( Akhtari-Zavare, M; Fadhilah, SI; Mahmud, R; Mohd-Sidik, S; Periasamy, U; Rampal, L, 2018)

"Cancer is an uncontrolled division of cells that results in the formation of tumour which have the potential to migrate to other parts of the body (metastasis) finally becoming a major threat to human population."

( Alam, MI; Alam, O; Goel, P; Iqbal, M; Naim, MJ; Nawaz, F, 2018)

"Inpatients with cancer are at higher likelihood of developing acute renal AEs following CT with iodinated CM compared to those without a cancer."

( Baker, ER; Gunnarsson, C; Kalva, SP; Mehta, RL; Ng, CS; Ryan, MP, 2018)

"The tumors are further damaged by the phototoxicity of GCNCs/CS after loading with 5-Fluorouracil (5FU)."

( Chen, Y; Chu, M; Guo, Y; Han, P; Li, D; Li, W; Wu, Y; Yue, Y, 2018)

"Prostate cancer is a serious disease in terms of its high incidence and mortality rate in the USA and around the world."

( Banerjee, HN; Kahan, W; Kumar, V; Verma, M, 2018)

"Cancer is one of the most serious threats to human health."

( Cao, Y; Chen, Y; Gong, Y; Guo, Y; Li, P; Li, Y; Liu, F; Ran, H; Wang, Z, 2018)

"Cancer is one of the major causes of morbidity and mortality in the world."

( Ji, R; Jiang, X; Liu, Y; Lv, G; Ma, L; Qu, Y; Xin, Y, 2018)

"Cancers are complex diseases having several unique features, commonly described as ‘hallmarks of cancer’."

( Kma, L; Marbaniang, C, 2018)

"Cancer is the second cause of death worldwide."

( Farhood, B; Goradel, NH; Khanlarkhani, N; Mortezaee, K; Najafi, M; Nashtaei, MS; Sahebkar, A; Salehi, E, 2019)

"Cancer is a growing health problem worldwide."

( Fan, RP; Han, H; Hu, Y; Kou, JP; Yu, BY; Zhang, YY; Zhao, YZ; Zhong, L, 2018)

"Cancer is a complex disorder extremely dependent on its microenvironment and highly regulated by multiple intracellular and extracellular stimuli."

( Lutsenko, SV; Moldogazieva, NT; Terentiev, AA, 2018)

"Cancer is the second leading cause of mortality, only overcome by cardiovascular diseases, and has caused more than 8."

( Jiang, J; Muhammad, Y; Rashid, HU; Wang, L; Xu, Y, 2019)

"Cancer is one of the important causes of morbidity and mortality in India."

( Behera, P; Patro, BK, 2018)

"Cancer is a complex and tenacious disease."

( Lee, SY; Shieh, MJ; Tsai, MH; Tu, TY; Wang, CH; Yang, SJ; Young, TH, 2019)

"Unresponsive tumors are characterized as being immunologically "cold," indicating that these tumors lack tumor antigen-specific primed cytotoxic T cells."

( Brekken, RA; Du, W; Huang, H; Sorrelle, N, 2018)

"Cancer is a major global health problem with large therapeutic challenges."

( Balusu, R; Björkling, F; Kankala, S; Taylor, MK; Thota, N; Vadde, R, 2019)

"A major hallmark of cancer is a perturbed metabolism resulting in high demand for various metabolites, glucose being the most well studied."

( Gu, W; Herring, J; Ou, Y; Sowers, ML; Tang, H; Zhang, K; Zhang, W, 2019)

"Such tumors are often associated with an intrinsic chemoresistance and thus a poor prognosis."

( Classen, CF; Fiedler, T; Junghanss, C; Kreikemeyer, B; Maletzki, C; Riess, C; Shokraie, F, 2018)

"Cancer is associated with an increased risk of venous thromboembolism of four to sixfold."

( Cabezón-Gutiérrez, L; Franco-Moreno, A; García-Navarro, M; Palka-Kotlowsa, M; Villamayor-Delgado, M, 2019)

"Lung cancer is the worldwide leading cause of cancer-related death."

( Han, B; Jiang, P; Li, X; Liu, L; Liu, W; Ma, W; Wu, S; Xu, H; Ye, X; Zhang, J, 2019)

"Cancer is a leading cause of death and a major health problem worldwide."

( Mathias, F; Montana, M; Terme, T; Vanelle, P, 2019)

"Cancer is the second cause of death worldwide, exceeded only by cardiovascular diseases."

( Aserin, A; Ezrahi, S; Garti, N, 2019)

"Among males, common cancers are lung (12."

( George, PS; James, FV; K M, JK; Mathew, A; Vasudevan, D, 2019)

"Cancers are heterogeneous at the cell level, and the mechanisms leading to cancer heterogeneity could be clonal evolution or cancer stem cells."

( Angeli, E; Bousquet, G; Di Benedetto, M; El Bouchtaoui, M; Gapihan, G; Hamdan, D; Janin, A; Leboeuf, C; Lu, H; Meles, S; Nguyen, TT; Nunes, T; Ratajczak, P, 2018)

"Cancer is one of the major health problem globally, responsible for high morbidity and mortality."

( Agrewala, JN; Sajid, M, 2019)

"Cancer is a disorder which has a powerful impact on the quality life and life expectancy despite the increase in drugs and treatments available for cancer patients."

( Colapietro, A; D'Alessandro, AM; Festuccia, C; Mancini, A, 2019)

"The development of tumors is conditioned by genetic changes in cancer-transformed cells, immunological tolerance and immunosuppression."

( Danielak, A; Kruszewski, WJ; Szefel, J, 2019)

"Cancer is a major cause of morbidity and mortality worldwide."

( Faustino, C; Fonte, P; Macedo, A; Neto, Í, 2018)

"Cancer is one of the death causing disease is always being a public health concern due to its rapid increase in the world population."

( Liu, L; Ma, Y; Sun, J; Wei, W; Yan, F; Zhao, Z, 2019)

"The incidence of cancer is rapidly increasing around the world not only because of continual aging and growth in global population, but also due to the adaptation of Western lifestyle behaviours, including intake of high fat diets and low physical activity."

( Aggarwal, V; Chaudhary, A; Garg, VK; Jain, A; Kashyap, D; Sak, K; Sethi, G; Tuli, HS; Yerer, MB, 2019)

"Cancer is the second leading cause of mortality worldwide."

( Lordan, R; Tsoupras, A; Zabetakis, I, 2019)

"Cancer is a disease that effects cell metabolism causing an imbalance in the health of the patient."

( Alves, S; Azzalis, LA; Figueiredo, FWS; Fonseca, FLA; Fonseca, RLA; Fudimura, KA; Hallack, ML; Junqueira, VBC; Rocha, KC; Sonego, DRN, 2019)

"Currently cancer is the second leading cause of death globally and worldwide incidence and mortality rates of all cancers of males and females are rising tremendously."

( Anant, S; Hegde, MV; Kadam, SS; Mali, AV; Padhye, SB, 2019)

"Cancer is becoming a major reason for death troll worldwide due to the difficulty in finding an efficient, cost effective and target specific method of treatment or diagnosis."

( Edison, TNJI; Kumar, P; LewisOscar, F; Pugazhendhi, A; Shanmugam, S; Shanmuganathan, R, 2019)

"Cancer is one of the major growing public health problems making the development of new anti-cancer treatment strategies still compulsory."

( Klimpel, A; Lützenburg, T; Neundorf, I, 2019)

"Cancer is the second most important cause of death worldwide."

( Moku, B; Qin, HL; Rakesh, KP; Ravindar, L, 2019)

"Cancer is considered a fetal disease caused by uncontrolled proliferation and progression of abnormal cells."

( Arnold, M; Huang, YW; Oshima, K; Pan, P; Wang, LS; Yearsley, M; Yu, J; Zhang, J, 2019)

"Cancer is associated with a prothrombotic state as well as an increased bleeding risk."

( Fujita, M; Oboshi, M; Oka, T; Shioyama, W; Yasui, T, 2019)

"Cancer is one of the major world public health problems and the currently available treatments are nonspecific and ineffective."

( Correia, IJ; Ferreira, P; Jacinto, TA; Moreira, AF; Reis, CA; Rodrigues, CF, 2019)

"Cancer is the second leading cause of death in the world and one of the major public health problems."

( Hadianamrei, R; Tomeh, MA; Zhao, X, 2019)

"Cancer is considered as one of the highly mortal diseases globally."

( Fang, J; Han, X; Liu, T; Wu, Y; Xu, J; Zhang, J, 2019)

"Tumors are known to modulate the immune system by immune-editing the microenvironment."

( Banerjee, S; Bose, D; Chatterjee, N; Das, S; Saha, KD; Saha, M, 2019)

"Cancer is a multi-factorial disease including alterations in the cell signalling pathways."

( Almatroodi, SA; Almatroudi, A; Alsahli, MA; Rahmani, AH, 2019)

"Cancer is a significant disease burden worldwide."

( Jiang, S; Wang, K; Wang, M; Yu, F; Zhou, L, 2019)

"Cancer is still a leading cause of death worldwide, while most chemotherapies induce nonselective toxicity and severe systemic side effects."

( Coricovac, D; Dehelean, C; Ghiulai, R; Mioc, A; Mioc, M; Racoviceanu, R; Soica, C; Trandafirescu, C; Voicu, M, 2019)

"Microtumors are widely applied in the fields of fundamental cancer research, drug discovery, and precision medicine."

( Demir, K; Haitz, P; Kuodyte, K; Levkin, PA; Popova, AA; Starkuviene, V; Tronser, T; Wajda, P, 2019)

"Since tumors are complex systems, in which cancer cells coexist and interact with several different types of non-malignant cells, it is not surprising that anti-cancer drugs affect not only cancer cells, but also the abundance and functions of cells of the tumor microenvironment."

( Gasparre, G; Iorio, M; Kurelac, I; Porcelli, AM; Umesh Ganesh, N, 2020)

"TF expression in cancer is associated with poor prognosis."

( Hisada, Y; Mackman, N, 2019)

"Cancer is typically treated through surgical resection, radiotherapy, and small-molecule chemotherapy."

( Revia, RA; Stephen, ZR; Zhang, M, 2019)

"Malignancy is a major cause of late post-heart transplantation (HT) mortality."

( Alnsasra, H; Asleh, R; Briasoulis, A; Clavell, AL; Daly, RC; Edwards, BS; Habermann, TM; Kremers, WK; Kushwaha, SS; Li, X; Otley, CC; Pereira, NL; Smith, B; Stulak, JM, 2019)

"Malignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome."

( Connell, NT; Connors, JM, 2019)

"Cancer is a problem with worldwide importance and is the second leading cause of death globally."

( Carrasco-Pozo, C; Reyes-Farias, M, 2019)

"Cancer is among the leading causes of death worldwide."

( Mangieri, D; Tataranni, T; Zadorozhna, M, 2019)

"Cancer is known as one of the main causes of death in the world; and many compounds have been synthesized to date with potential use in cancer therapy."

( Ayati, A; Emami, S; Foroumadi, A; Moghimi, S, 2019)

"Malignant tumors are often multifactorial."

( Li, W; Sang, H; Shang, C; Wang, Y; Zhang, X; Zhou, Y; Zhu, H, 2019)

"Cancer is a major burden of disease and a public health problem, as it is one of the main causes of morbidity and mortality worldwide."

( Adriana, PN; Edith, MC; Emma, VA; Laura, GG; Silvia, AP, 2021)

"Cancer is the second cause of death worldwide, but current therapies are often insufficient or linked with toxicity."

( Baiardo Redaelli, M; Ciceri, F; Dagna, L; Gregorc, V; Landoni, G; Navalesi, P; Tshomba, Y; Zangrillo, A, 2019)

"Tumors are highly plastic metabolic entities composed of cancer and host cells that can adopt different metabolic phenotypes."

( Mina, E; Payen, VL; Porporato, PE; Sonveaux, P; Van Hée, VF, 2020)

"Cancer is now the second leading cause of death in the Caribbean."

( Andall-Brereton, G; Anderson, BO; Argentieri, MA; Bodkyn, C; Bray, F; Duggan, C; Garcia, WG; Gibson, T; Greaves, N; Gupta, S; Hobday, V; McLean, F; Mery, L; Nimrod, M; Ocho, O; Quee-Brown, CS; Shields, AE; Spence, D; Tortolero-Luna, G, 2019)

"Cancer is the second leading cause of death worldwide, and it results in around 9 million deaths annually."

( Xu, Z; Zhang, L, 2019)

"Childhood cancer is a leading non-communicable cause of death in children aged 0-14 years worldwide."

( Alcasabas, T; Antillon, F; Arora, R; Atun, R; Denburg, AE; Force, L; Friedrich, P; Fuentes-Alabi, S; Galindo, CR; Lam, C; Maser, B; McCann, E; Pavuluri, S; Ramirez, A; Renner, L; Shah, S, 2019)

"The core of solid tumors is characterized by hypoxia and a nutrient-starved microenvironment and has gained much attention as targets of anti-cancer drugs."

( Arai, M; Ishida, R; Kimishima, A; Setiawan, A; Tang, R, 2020)

"Breast cancer is second most leading cause of death in all over the world and not only limited to the females."

( Kohli, K; Mangla, B; Neupane, YR; Singh, A, 2019)

"Cancer is a life-threatening disease afflicting human health worldwide."

( Bhagat, M; Rather, RA, 2020)

"Early detection of cancer is very critical because it can reduce the treatment risk and cost."

( Jahanian, A; Sanjabi, M, 2019)

"Malaria and cancer are chronic diseases."

( Aderibigbe, BA; Peter, S, 2019)

"Breast cancer is a heterogeneous disease with different morphological and molecular subtypes and responses to therapy, and breast cancer cells are known to rewire glutamine metabolism to support survival and proliferation."

( Alfarsi, L; Craze, ML; El Ansari, R; Green, AR; Masisi, BK; Rakha, EA, 2020)

"Tumors are major chronic diseases and seriously threaten human health all over the world."

( Chen, L; Fu, CM; Li, J; Li, JX; Luo, RF; Luo, YY; Shi, JF; Zhang, JM, 2019)

"Cancer is a disease of high complexity."

( Farhood, B; Mirtavoos-Mahyari, H; Mortezaee, K; Motevaseli, E; Musa, AE; Najafi, M; Potes, Y; Shabeeb, D, 2019)

"Cancer is the second most important cause of death and new therapy modalities continue to be developed and evolved."

( Abbaszadeh, Z; Biray Avcı, Ç; Çeşmeli, S, 2020)

"Breast cancer is the most common type of cancer in women worldwide."

( Ardestani, MS; Ebrahimi, SES; Farzaneh, J; Hadadian, S; Hamedani, MP; Karimpourfard, N; Mojarrad, P; Omoomi, FD; Seyedhamzeh, M; Zamani, S, 2020)

"Liver cancer is a leading cause of cancer morbidity and mortality worldwide, especially in China."

( Gu, D; He, J; Jin, H; Lv, Y; Qin, W; Sun, J; Sun, L; Wan, J; Wang, C; Wang, H; Wang, S; Wu, H; Yang, C; Yao, M; Yu, C; Zhang, Z, 2019)

"Solid tumors are typically supplied nutrients by a network of irregular blood vessels."

( Fadhel, MN; Hysi, E; Kolios, MC; Zalev, J, 2019)

"Cancer is a disease of uncontrolled cell growth and a major cause of death worldwide."

( Eich, ML; Robinson, AD; Varambally, S, 2020)

"Cancer is one of the most complicated diseases in present-day medical science."

( Ahmadi, A; Farhood, B; Mortezaee, K; Musa, AE; Najafi, M; Shabeeb, D, 2020)

"Cancer is the leading cause of death by disease in developed countries."

( Cata, JP; Kapoor, R; Lonnqvist, PA; Owusu-Agyemang, P, 2019)

"Cancer is a global health problem and the continuous rise in incidence and mortality due to cancer carries a real economic burden to all countries."

( Khan, MA; Siddique, HR; Singh, D, 2019)

"Cancer is a major health problem in the United States with extremely high mortality."

( Andarge, H; Dong, Z; Li, W; Pappas, D; Zhou, Y, 2019)

"Cancer is one of the leading causes of death worldwide and, as such, efforts are being done to find new chemotherapeutic drugs or, alternatively, novel approaches for the delivery of old ones."

( Gonçalves, M; Mignani, S; Rodrigues, J; Tomás, H, 2020)

"Cancer is the second leading cause of death worldwide."

( Cho, WC; Kobarfard, F; Kumar, P; Martins, N; Martorell, M; Pezzani, R; Rajabi, S; Redaelli, M; S Mileski, K; Salehi, B; Selamoglu, Z; Sharifi-Rad, J; Subhra Santra, T, 2019)

"Cancer is a huge challenge humanity facing today, and single chemical treatments inevitably have shortcomings such as poor selectivity and large side effects."

( Cheng, J; Deng, T; Feng, C; Li, Y; Xie, M; Yang, M; Yang, N, 2020)

"Advanced cancers are associated with a chronic inflammation, especially high interleukin-6 (IL-6) and with various levels of adipokines (leptin and adiponectin), while ghrelin counteracts the anorexigenic effect of leptin in cancer-induced anorexia-cachexia syndrome."

( Bautmans, I; De Breucker, S; Decoster, L; Luce, S; Mets, T; Njemini, R; Pepersack, T, 2020)

"Cancer is a disease receiving an outstanding input of funds for basic and clinical research but is, nevertheless, still the second leading cause of death in the developed world and a great burden for health systems."

( Kos, J; Mitrović, A, 2019)

"Cancer is the leading cause of death worldwide."

( Farahani, AM; Maleki, F; Sadeghzadeh, N, 2020)

"Cancer is a disease that involves impaired genome stability with a high mortality index globally."

( Arias-Calderón, M; Cancino, P; Rodríguez-Arce, E; Saldías, M; Silva-Matus, P, 2019)

"Cancer is one of the leading causes of death worldwide and requires intense and growing research investments from the public and private sectors."

( Andrade, CH; Custodio, JMF; D'Oliveira, GDC; Filho, JTM; Junior, PSC; Napolitano, HB; Neves, BJ; Perez, CN; Silveira-Lacerda, EP; Vaz, WF, 2021)

"Breast cancer is a serious public health problem that causes thousands of deaths annually."

( Boni, FI; Callan, JF; Chorilli, M; de Freitas, LM; de Oliveira, KT; Fontana, CR; McHale, A; Nicholas, D; Oshiro-Junior, JA; Santos, KLM; Sato, MR, 2020)

"Cancer is a preventable disease if detected at an early stage; however, most of the cases of cancer are diagnosed at an incurable advanced or metastatic stage."

( Banik, K; Deshpande, V; Fan, L; Girisa, S; Harsha, C; Kunnumakkara, AB; Nalawade, SP; Nitesh, T; Ranaware, AM; Sethi, G, 2020)

"Nevertheless, cancers are often able to circumvent chemotherapeutic interventions and become therapy resistant."

( Bayram, S; Forbes, M; Fürst, S; Kempa, S, 2020)

"Cancer is one of the major threats to human health and current cancer therapies have been unsuccessful in eradicating it."

( Han, W; Hou, H; Lv, H; Shaikh, AB; Shang, P; Wang, S; Wei, Y; Zhang, Z, 2020)

"Cancer is a severe threat to human health."

( Han, W; Hou, H; Lv, H; Shaikh, AB; Shang, P; Wang, S; Wei, Y; Zhang, Z, 2020)

"Cancer is a key cause of death worldwide."

( Gao, X; Gou, X; Guo, N; Hu, Z; Luan, J; Mi, Y; Wang, N; Xu, H; Xu, L; Zhang, D, 2020)

"As most cancers are aneuploid, targeting aneuploidy or CIN may be an effective way to target a broad spectrum of cancers."

( Bakker, PL; Bastians, H; Colomé-Tatché, M; Foijer, F; Lin, YC; Preuss, SF; Schubert, M; Schukken, KM; Simon, JE; Spierings, DC; Storchova, Z; van den Bos, H, 2020)

"Patients with cancer are at an increased risk of developing and dying from sepsis."

( Chen, CW; Chihade, DB; Coopersmith, CM; Ford, ML; Liang, Z; Ramonell, KM; Xie, J; Zhang, W, 2020)

"Cancer is a condition where there is an uncontrolled growth of cells resulting in high mortality."

( Jaafari, MR; Korani, M; Korani, S; Sahebkar, A; Sathyapalan, T; Zendehdel, E, 2020)

"Cancer is the one of the fatal and dreaded disease responsible for huge number of morbidity and mortality across the globe."

( Batool, S; Shahzad, F; Zaidi, SA, 2020)

"Cancer is one of the leading causes of death all over the world."

( Chen, H; Liang, K, 2020)

"Cancer is a kind of malignant diseases that threatens human health and the research application of anti-tumor drug therapeutics is growingly always been focused on."

( Chaurasiya, B; Chen, D; Li, Y; Shen, Y; Sun, R; Tang, B; Tu, J; Yu, C; Yu, Y; Zu, C, 2020)

"Cancer is a multifaceted global disease."

( Göbel, A; Hofbauer, LC; Rachner, TD; Rauner, M, 2020)

"Globally, cancer is the second leading cause of death."

( Abotaleb, M; Büsselberg, D; Kubatka, P; Liskova, A, 2020)

"Cancer is a frequent finding in ischaemic stroke patients."

( Berkowitz, SD; Chamorro, A; Demchuk, A; Hart, RG; Joensuu, H; Kasner, SE; Liu, YY; Marti-Fabregas, J; Martinez-Majander, N; Mundl, H; Ntaios, G; Perera, KS; Prats-Sanchez, L; Rudilosso, S; Saarinen, J; Tatlisumak, T; Themeles, E; Tiainen, M; Ylikotila, P, 2020)

"Metabolic demand of cancer is quite unique compared to normal tissues and this is an emerging hallmark of cancer, which brings a potential opportunity to discover drugs that target cancer cell metabolism."

( Duan, Z; Gong, M; Gong, Q; Gu, Z; Li, Z; Luo, K; Pan, D; Zhang, H; Zhang, Q; Zheng, W; Zheng, X; Zhu, H, 2020)

"Cancer is a prevalent disease in the world and is becoming more widespread as time goes on."

( Abdullah, Y; Dou, QP; Khan, H; Khan, R, 2020)

"Cancer is one of the prominent global causes of death and the foremost worldwide health concern."

( Chaubey, P; Murahari, M; Singh, V; Suvarna, V, 2020)

"The roles of SFE in cancers are mainly through the regulation of potential biomarkers to activate or inhibit related signaling pathways."

( Duan, Y; Lin, W; Ou, C; Wang, X; Wu, G; Xu, Z; Yan, Y; Zeng, S; Zhou, J; Zhou, Y, 2020)

"Cancer is not a single disease but it constitutes a large variety of different types that are also different from each other phenotypically and molecularly."

( Bonavida, B, 2020)

"Early detection of cancer is likely to be one of the most effective means of reducing the cancer mortality rate."

( Behi, M; Chandrawati, R; Dehghani, F; Naficy, S, 2020)

"However, tumors are known to be complex tissues in which non-cancerous cells are also critical for tumorigenesis."

( Hölzen, L; Parigiani, MA; Reinheckel, T, 2020)

"Cancer is the second most common cause of death, and nanomedicine is regarded as one of the strategies that may revolutionize cancer treatments."

( Appelhans, D; Feng, S; Hao, P; Peng, B; Yang, D; Zan, X; Zhang, L; Zhang, T, 2019)

"Cancer is one of the major causes of death and is difficult to cure using existing clinical therapies."

( Deng, J; Shen, P; Shen, Y; Wang, J; Webster, TJ; Wu, X, 2020)

"Cancer is not just one disease; it is a group of diseases either genetic or metabolic due to the malfunction of mitochondria."

( Ahmed, I; Yousef, H; Zam, W, 2021)

"Cancer is the leading cause of death worldwide and the current mode of cancer treatment causes side effects on normal cells and are still the key challenges in its' treatment."

( Almatroodi, SA; Almatroudi, A; Alsahli, MA; Khan, AA; Rahmani, AH, 2020)

"Cancer is a major cause of death in low- and middle-income countries."

( Azizi, F; Hadaegh, F; Ramezankhani, A, 2020)

"Cancer is the second life-threatening disease worldwide, and it resulted in around 9."

( Bharath, RD; Goud, NS; Kumar, P, 2020)

"Older patients with cancer are at high risk of developing venous thromboembolism (VTE) and bleeding."

( Cai, P; Dixon, RAF; Hadley, M; Li, M; Li, P; Liu, EY; Liu, Q; Ning, Y; Pan, S; Siddiqui, AD; Wu, F, 2020)

"Cancer is among the leading causes of mortality worldwide."

( El Haouari, M; Quintero, JE; Rosado, JA, 2020)

"Cancer is a worldwide disease that causes millions of cases of mortality and morbidity."

( Al Jaouni, SK; El-Far, AH; Mousa, SA; Tantawy, MA, 2020)

"Cancer is driven by genetic mutations in oncogenes and tumor suppressor genes and by cellular events that develop a misregulated molecular microenvironment in the growing tumor tissue."

( Moustakas, A; Papoutsoglou, P, 2020)

"Cancer is one of the most dangerous diseases worldwide, the treatment of which is still a great problem."

( Sun, S; Wen, J; Yang, K, 2020)

"Heart disease and cancer are the leading causes of death in the United States."

( Brodman, M; Gallagher, EJ; Gretz Friedman, E; Kang, C; Kase, NG; LeRoith, D, 2020)

"Cancer is a significant medical issue, being one of the main causes of mortality around the world."

( Brebi, P; de La Fuente, M; Hermoso, M; Ili, CG; Reyes, ME, 2020)

"Some tumors are infiltrated by the different cells of immune system but are able to use adenosine as an immunosuppressive molecule and thus inhibit immune anticancer response."

( Cadassou, O; Cros-Perrial, E; Jordheim, LP; Strakhova, R, 2020)

"Cancer is the second leading cause of mortality globally."

( Agarwal, P; He, X; Lin, J; Lu, X; Shamul, JG; Sun, M; Tkaczuk, KHR; Wang, H; Xu, J, 2020)

"Dealing with cancer is of importance due to enhanced incidence rate of this life-threatening disorder."

( Ashrafizadeh, M; Entezari, M; Hashemi, F; Hushmandi, K; Moghadam, ER; Mohammadinejad, R; Najafi, M; Zarrabi, A, 2020)

"Cancer is one of most the significant threats to human health worldwide, and the primary method of treating solid tumours is surgery."

( Jiang, W; Pan, S; Xu, Y; Xue, F; Zhu, X, 2020)

"Cancer is the world's second-largest cause of death, with an estimated 9."

( Aggarwal, G; Dhingra, GA; Jindal, M; Nagpal, M; Singh, M, 2020)

"Patients with cancer are at higher risk of atrial fibrillation, thromboembolic complications and bleeding events compared with the general population."

( Casula, M; Fabris, F; Fortuni, F; Gnecchi, M; Greco, A; Leonardi, S; Rordorf, R; Sanzo, A, 2020)

"Cancer is a leading cause of death worldwide."

( Dhiman, N; Jaitak, V; Kaur, K, 2020)

"Cancer is a complex expression of an altered state of cellular differentiation associated with severe clinical repercussions."

( Campos-Contreras, ADR; Díaz-Muñoz, M; Vázquez-Cuevas, FG, 2020)

"Cancer is the second leading cause of death-1 in 6 deaths globally is due to cancer."

( Maniam, S, 2020)

"Cancer is the world's second-largest cause of mortality and one of the biggest global health concerns."

( Kumar, N; Mishra, I; Mishra, R; Sachan, N, 2020)

"Cancer is the leading cause of morbidity and mortality, and about one in six people die from cancer globally."

( Bie, R; Hu, H; Pang, NI; Ung, COL, 2020)

"Cancer is a preeminent threat to the human race, causing millions of deaths each year on the Earth."

( Naz, F; Wu, Y; Yang, Z; Yu, C; Zhang, N, 2020)

"Cancer is becoming an important public health problem in the country, but a systematic plan to cancer control is lacking."

( Booth, CM; Dulal, S; Gyawali, B; Pariyar, J; Sharma Poudyal, B; Sharma, S; Shilpakar, R, 2020)

"Cancer is a leading cause of death globally."

( Gibbs, P; Haydon, A; Kirpach, B; Lockery, JE; McNeil, JJ; Murray, AM; Nelson, MR; Orchard, SG; Polekhina, G; Reid, CM; Wolfe, R; Woods, RL; Zalcberg, J, 2020)

"Cancer is one of the most serious health concerns in the 21st century whose prevalence is beyond boundaries and can affect any organ of the human body."

( Bhatia, R; Narang, RK; Rawal, RK; Sharma, A, 2021)

"Cancer is one of the leading causes of death worldwide."

( Gul, S; Hassan, SH; Irfan, M; Khan, M; Maryam, A; Shakir, HA; Zahra, HS, 2021)

"Cancer is a condition in which some cells in the body grow uncontrollably and can also spread in other parts of the body."

( Gupta, A; Kushwaha, SS; Mishra, A, 2020)

"To date, cancer is the second leading cause of death worldwide after cardiac arrest."

( Luqman, S; Meena, A; Raza, W, 2020)

"Cancer is one of the most devastating disease and leading cause of death worldwide."

( Ashaq, A; Irfan, M; Khan, M; Li, Y; Ma, T; Maqbool, MF; Maryam, A; Qazi, JI; Shakir, HA, 2021)

"Cancer is one of the most lethal diseases in the world."

( Khan, MA; Mehdi, SH; Nafees, S; Rizvi, MA; Zafaryab, M; Zia, B, 2021)

"Cancer is a rapidly growing non-communicable disease worldwide that is responsible for high mortality rates, which account for 9."

( Abubakar, IB; Alhassan, AM; Bunza, AM; Etti, IC; Malami, I; Muhammad, A; Waziri, PM; Yunusa, A, 2022)

"Cancer is an abnormal growth of cells due to the uncontrolled division of the cells and it is the second leading cause of death globally."

( Abd El-Salam, HM; Ahmed, OM; Kamel, EM, 2020)

"Since cancer is a major problem for public health with high mortality and morbidity worldwide, experiments have focused on revealing the anti-tumor activity of natural products."

( Ang, HL; Ashrafizadeh, M; Asnaf, SE; Esmaeili, H; Kumar, AP; Moghadam, ER; Saleki, H; Yavari, M; Zabolian, A; Zarrabi, A, 2020)

"Unfortunately, cancer is characterized by genetic alterations in the host's cells, leading to uncontrolled cellular proliferation and evasion of immune surveillance."

( Aikins, ME; Moon, JJ; Xu, C, 2020)

"Cancer is an unpleasant, painful disease."

( Kumari, S; Muthusamy, S, 2020)

"Cancer is the second most prevalent disease worldwide and it presents characteristic hallmarks common to all its types."

( Minzer, S, 2021)

"Cachexia induced by cancer is a systemic wasting syndrome and it accompanies continuous body weight loss with the exhaustion of skeletal muscle and adipose tissue."

( Choi, BM; Han, YH; Hong, SH; Jeon, HD; Kee, JY; Mun, JG; Yoon, DH, 2020)

"Cancer care is likely to affect the patient's financial well-being, putting huge financial pressure to the families."

( Chew, KS; Kueh, JS; Siew, KL; Wong, SS; Yap, SL, 2020)

"Cancer is defined as an abnormal/uncontrolled cell growth that shows rapid cell division."

( Alizadeh, SR; Ebrahimzadeh, MA, 2021)

"Cancer is one of the highest prevalent diseases in humans."

( Clemente, SM; Martínez-Costa, OH; Monsalve, M; Samhan-Arias, AK, 2020)

"Older adults with cancer are increasingly inquiring about and using cannabis."

( Bromberg, HS; Chang, YD; Donovan, KA; Haas, MF; Portman, DG; Rajasekhara, S; Randich, AL; Rashid, S, 2022)

"Cancer is one of the main causes of mortality in the world."

( Annas, D; Bae, SJ; Cheon, SY; Ha, KT; Park, KH; Yusuf, M, 2020)

"Cancer is a deadly disease, which has significantly increased in both developed and developing nations."

( Roy, A, 2021)

"Cancer is a major health problem worldwide, and the most extensive treatment can be obtained by using chemotherapy in the clinic."

( Guo, J; Hu, C; Peng, H; Wang, M, 2020)

"Patients with cancer are at high risk of venous thromboembolic events, and this risk can be further increased in patients with certain cancer types and by cancer treatments."

( Carrier, M; Cohen, AT; Kavan, P; Khorana, AA; Meyer, G; Pabinger, I; Wells, P, 2020)

"Cancer is the deadliest disease worldwide and the development of safer chemical entities to treat cancer is one of the major challenges of medicinal chemistry."

( Goyal, K; Gulati, S; Guliya, N; Kumar, S; Sharma, V; Shukla, S; Singh, A; Sood, AK, 2021)

"Presently cancer is a grave health issue with predominance beyond restrictions."

( Bansal, R; Malhotra, A, 2021)

"Cancer is one of the leading causes of death worldwide."

( Efferth, T; Fischer, N; Fleischer, E; Klinger, A; Seo, EJ, 2021)

"Cancer is a widespread fatal disease associated with the abnormal growth of cells in the body."

( Sharma, R; Srivastava, N, 2021)

"Cancer is the second most common cause of deaths worldwide."

( Das, B; Nath, UK; Pasricha, RK; Ramasubbu, SK; Rawat, VS, 2021)

"Cancer is a major disease burden worldwide."

( Chen, K; Du, JX; Ren, SZ; Zhu, D; Zhu, HL; Zhu, XH, 2020)

"Cancer is the second leading cause of death globally, and researchers seek to identify modifiable risk factors Over the past several decades, there has been ongoing debate whether opioids are associated with cancer development, metastasis, or recurrence."

( Davis, MA; Goodrich, ME; Havidich, JE; Low, YH; Onega, TL; Sites, BD; Weiss, JE, 2021)

"Cancer is a multifactorial disease and the second leading cause of death worldwide."

( Bardaweel, SK; Hajjo, R; Haroon, RA; Sabbah, DA; Sweidan, K, 2020)

"Metastatic cancer is a persistent clinical enigma, which requires combination of several treatment modules."

( Diao, D; Huang, Y; Li, S; Luo, Z; Ren, P; Sun, J; Wan, Z; Xu, J; Zhang, B, 2021)

"Cancer is one of the most devastating diseases, and recently, a variety of natural compounds with preventive effects on cancer developments have been reported."

( Du, M; Gu, HF; Mao, XY, 2022)

"Cancer is a major health issue worldwide and the global burden of cancer is expected to reduce the costs of treatment as well as prolong the survival time."

( Li, X; Lu, C; Ren, Y; Zhang, X, 2021)

"Globally, cancer is considered as the major leading cause in burdening the patient's health care system globally."

( Das, R; Mehta, DK; Sahu, RK; Sharma, D; Sharma, V, 2022)

"Cancer is a broad-spectrum disease which is spread globally, having high mortality rates."

( George, SM; Kandasubramanian, B; McIntyre, R; Tandon, S, 2020)

"Cancer is considered as the main challenge of human communities, and it annually imposes a significant economic burden on society."

( Babaei, G; Gholizadeh-Ghaleh Aziz, S; Khadem Ansari, MH; Rajabi Bazl, M, 2021)

"Cancer is currently the second most common cause of death worldwide."

( Jendryczko, K; Krzyscik, MA; Nawrocka, D; Opalinski, L; Otlewski, J; Porebska, N; Pozniak, M; Sokolowska-Wedzina, A; Szlachcic, A; Zakrzewska, M, 2021)

"Cancer is the most incurable pernicious disease to date after cardiovascular disease with an immeasurable rate of mortality."

( Bose, B; Gauthaman, A; Moharana, P; Moorthy, A; Muthukumar, V; Paira, P; Ray Chaudhuri, S; Roy, N; Sen, U, 2021)

"Cancer is often accompanied by worsening of the patient's iron profile, and the resulting anemia could be a factor that negatively impacts antineoplastic treatment efficacy and patient survival."

( Agostini, D; Barbieri, E; Calcagnoli, F; Emili, R; Natalucci, V; Valli, G; Virgili, E; Zeppa, SD, 2021)

"Cancer is one of the leading causes of death worldwide, with a mortality rate of more than 9 million deaths reported in 2018."

( Abdullah, NA; Ammar, A; Md Hashim, NF; Muhamad Zakuan, N, 2021)

"Cancer is driven by somatic mutations that result in a cellular fitness advantage."

( Claeys, A; Luijts, T; Marchal, K; Van den Eynden, J, 2021)

"Tumors are one of the most life-threatening diseases, and a variety of cancer treatment options have been continuously introduced in order to overcome cancer and improve conventional therapy."

( Hur, S; Jang, E; Lee, JH, 2021)

"Cancer is a group of diseases with major societal impact and accounts for approximately 55 percent of mortality in India."

( Dey, B; Shenoy, SR, 2021)

"Cancer is an anomalous growth and differentiation of cells known to be governed by oncogenic factors."

( Aggarwal, D; Aggarwal, V; Bishayee, A; Kaur, G; Kumar, M; Loka, M; Masurkar, A; Mittal, S; Sak, K; Sethi, G; Tuli, HS; Varol, M, 2021)

"Delivering quality cancer care in low to middle-income countries is a challenge even in normal times."

( Akhtar, N; Chaturvedi, A; Gupta, S; Kumar, V; Mishra, P; Misra, S; Rajan, S; Sharma, S; Singh, M; Tripathi, A, 2021)

"The incidence of cancer is increasing worldwide, which has led to greater public health focus on primary prevention."

( Condon, L; Curejova, J; Fenlon, D; Miles, G; Morgan, DL, 2021)

"As of 2018 cancer is responsible for almost 9."

( Alam, A; Hana, Z; Ma, D; Patel, S; Rampes, S, 2021)

"Cancer is an important threat to public health because of its high morbidity and mortality."

( Liu, M; Liu, W; Luo, J; Luo, Z; Wang, Y, 2020)

"Cancer is a serious threat to human health."

( Deng, T; Li, J; Shen, H; Xie, M, 2021)

"Cancer is the first or second leading cause of premature death in 134 of 183 countries in the world."

( Ahsan, MJ, 2022)

"As cancer is associated with changes in the systemic trace element status and distribution, serum concentrations of selenium, iron, copper, and zinc could contribute to an early diagnosis."

( Kipp, AP; Lossow, K; Schwarz, M, 2021)

"Early diagnosis of tumors is crucial in selecting appropriate treatment options to achieve the desired therapeutic effect, but it is difficult to accurately diagnose cancer by a single imaging modality due to technical constraints."

( Cheng, Y; Cui, D; Fan, S; He, Y; Liu, Y; Niu, J; Tan, H; Wei, X; Xue, C; Zha, Y; Zhang, Y, 2021)

"Cancer is a disease characterized by aberrant proliferative and apoptotic signaling pathways, leading to uncontrolled proliferation of cancer cells combined with enhanced survival and evasion of cell death."

( Albano, A; O'Neill, EJ; Termini, D; Tsiani, E, 2021)

"Pancreatic cancer is one of the most malignant cancers around the world."

( Jerald, MK; Kommalapati, VK; Kumar, D; Tangutur, AD, 2021)

"Cancer is an uncontrolled cell growth that can generate diverse types of cancer, in which these will also present a different behavior in the face of pharmacological treatment."

( da Silva-Júnior, EF; Silva, LR, 2022)

"Cancer is a public health problem worldwide, and one of the crucial steps within tumor progression is the invasion and metastasis of cancer cells, which are directly related to cancer-associated deaths in patients."

( Cayetano-Salazar, L; Fernández-Tilapa, G; Mendoza-Catalán, MA; Navarro-Tito, N; Olea-Flores, M; Ortiz-Ortiz, J; Ortuño-Pineda, C; Weinstein-Oppenheimer, C; Zacapala-Gómez, AE; Zuñiga-Eulogio, MD, 2021)

"Cancer is a fatal disease with high mortality and low survival rate worldwide."

( Chen, J; Chen, Y; Fu, C; Gao, T; Liao, W; Limsila, B; Lu, M; Yang, Q; Zheng, Y; Zhu, Z, 2021)

"Malignant neoplasms are the leading cause of death in Korea."

( Bae, YJ; Choi, EA; Han, YE; Kang, HT; Kim, HS; Kim, J; Kim, Y; Kim, YS; Lee, JW; You, HS, 2021)

"Prostate cancer is a major cause of death in males."

( Chen, CS; Chen, SC; Chou, YT; Gao, GL; Ho, DR; Huang, MC; Kao, WY; Lin, CY; Su, JJ, 2021)

"Children with cancer are vulnerable to severe infections."

( Boddu, D; John, RR; Joseph, LL; Mathew, LG; Moorthy, M; Srinivasan, HN; Suresh Kochath, P; Totadri, S, 2022)

"Cancer is a leading cause of disabling morbidities and death worldwide."

( Al-Tel, TH; Alhamad, DW; Elgendy, SM; Omar, HA, 2021)

"Cancer is the second leading cause of death worldwide, and the World Health Organization estimates that one in six deaths globally is due to cancer."

( Barbolina, MV, 2021)

"Cancer is the second leading cause of death worldwide and even though the prognosis of patients is improving, it is still poor in the substantial part of the cases."

( Ruml, T; Vrzáčková, N; Zelenka, J, 2021)

"Cancer is one of the deadliest diseases in human history with extremely poor prognosis."

( Chen, JP; Dash, BS; Jose, G; Lu, YJ, 2021)

"Cancer is a complex and multistage disease that causes suffering worldwide."

( Beyaz, S; Bozkurt, BT; Bülbül, B; Hayal, TB; Kırbaş, OK; Şahin, F; Taşlı, PN, 2022)

"Cancer is the second-leading cause of death worldwide."

( Bhalerao, M; Bhatia, M; Cruz-Martins, N; Kumar, D, 2021)

"Cancer is a multi-factorial health condition involving uncontrolled cell divisions."

( Ali, S; Almarshad, FM; Arafah, A; Rashid, S; Rehman, MU; Shoaib, A; Tabish, M; Wahab, S, 2021)

"Cancer is a serious public health problem worldwide responsible for more than 70% of all deaths globally."

( Cadoná, FC; Dantas, RF; de Mello, GH; Silva-Jr, FP, 2022)

"Solid tumors are a common predisposing factor for invasive candidiasis (IC) or candidemia due to IC."

( Aram, JA; Busca, A; Capparella, MR; De Rosa, FG; Yan, JL, 2021)

"The commencement of cancer is attributed to one or a few cells that become rogue and attain the property of immortality."

( Dhamdhere, SG; Pandkar, MR; Shukla, S, 2021)

"Targeted therapy of cancer is considered as promising alternative approach to conventional chemotherapy and radiotherapy."

( Altmann, A; Giesel, F; Haberkorn, U; Kratochwil, C, 2021)

"Cancer is known as one of the leading causes of morbidity and fatality, currently faced by our society."

( Aldakheel, FM; Alshaghdali, K; Anwar, S; Kausar, MA; Mishra, D; Saeed, A; Singh, R; Srivastava, M, 2022)

"Although race and cancer are related to chronic pain in patients, psychological well-being is also strongly related to this same pain."

( Allsop, MJ; Azizoddin, DR; Beck, MR; Boyer, E; Darnall, BD; Edwards, RR; Enzinger, AC; Hruschak, V; Mackey, S; Schreiber, K; Tulsky, JA, 2021)

"Cancer is one of the leading causes of death globally."

( Huang, Q; Jiang, Y; Jiang, Z; Ma, L, 2021)

"Cancer is currently a major threat to public health, being among the principal causes of death to the global population."

( Jia, L; Lugoloobi, I; Maniriho, H; Namulinda, T; Shi, X; Zhao, Y, 2021)

"Cancer is still a major threat to human health at present."

( Cheng, H; Cheng, Y; Liu, X; Shen, Y; Tang, R; Wang, X; Wen, H; Xie, A; Zhu, M, 2021)

"Cancer is one of the leading causes of death worldwide and also the main obstacle of accelerating anticipation."

( Thakur, PK; Verma, V, 2021)

"Metastatic breast cancer is a major cause of cancer-related mortality worldwide."

( Gu, Y; Hu, C; Huo, M; Li, L; Liu, J; Tong, Y; Wang, H; Yin, T, 2021)

"The incidence of cancer is increasing worldwide, affecting a vast majority of the human population, therefore, new different anticancer agents are being developed now and their safety still needs to be evaluated."

( Kumar, A; Kumar, R; Majee, C; Mazumder, A; Mishra, R; Sahu, R, 2022)

"Cancer is a leading cause of death which imposes a substantial financial burden."

( Ahmadi, M; Amir, A; Ebrahimi Nik, M; Gardanova, ZR; Gholizadeh Navashenaq, J; Gowhari Shabgah, A; Olegovna Zekiy, A; Thangavelu, L, 2021)

"Cancer is a second leading cause of death worldwide, and metastasis is the major cause of cancer-related mortality."

( Bang, C; Jang, EH; Kim, GL; Kim, JH; Koo, J; Lee, DE; Lee, DH; Lee, S; Na, JH; Yoon, SY, 2021)

"Cancer is one of the major causes of death worldwide, and its prevalence is rising every day."

( Hassanzadeh-Tabrizi, SA; Koupaei, N; Salmanian, G, 2021)

"Cancer is a major public health concern due to high mortality and poor quality of life of patients."

( Ahn, KS; Banik, K; Bordoloi, D; Daimary, UD; Girisa, S; Kunnumakkara, AB; Monisha, J; Saikia, Q; Verma, E, 2021)

"Although cancer is traditionally considered a genetic disease, the epigenetic abnormalities, including DNA hypermethylation, histone deacetylation, and/or microRNA dysregulation, have been demonstrated as a hallmark of cancer."

( Dennison, G; Liu, S; Mueller, S, 2021)

"Globally, cancer is the second (to cardiovascular diseases) leading cause of death."

( Makgopa, K; Manicum, AE; Mkhatshwa, M; Moremi, JM, 2021)

"Early detection of cancer is the only window of hope that allows for appreciable management and possible limited survival."

( Boye, A, 2021)

"Arsenic induced cancer is a major public health issue in Indo-Gangetic plains of Bihar, India where 22 out of 38 districts report arsenic contamination of groundwater."

( Bharti, DA; Kesh Kumar, S, 2023)

"Cancer is a collection of diseases caused by specific changes at the genomic level that support cell proliferation indefinitely."

( Banderali, U; Eskandari, N; Gentile, S; Leanza, L, 2022)

"Lung cancer is one of the most commonly occurring cancer mortality worldwide."

( Niu, Y; Shen, XJ; Sheng, J; Su, FW; Wang, LX; Wang, XJ; Wang, Y; Wu, YL; Xie, YR; Zhang, DY; Zhang, N; Zi, CT, 2021)

"Cancer is the second leading cause of death globally."

( Bansal, S; Kumari, N, 2021)

"Cancer is among the leading causes of mortality worldwide."

( Chung, IM; Rebezov, M; Rengasamy, KRR; Samynathan, R; Shariati, MA; Subramanian, U; Thirupathi, P; Thiruvengadam, M; Venkidasamy, B, 2023)

"Economic impact of cancer care on household financial risk protection will be assessed by estimating prevalence of catastrophic health expenditures and impoverishment."

( Dixit, J; Gupta, D; Gupta, N; Gupta, S; Kalaiyarasi, JP; Kataki, A; Krishnamurthy, MN; Kumar, L; Malhotra, P; Malik, PS; Mathew, A; Mehra, N; Pandey, A; Prinja, S; Rajsekar, K; Roy, PS; Singh, A; Singh, G, 2021)

"On the other hand, cancer is a highly heterogeneous disease and precision oncology as the most effective cancer therapy is gaining attraction."

( Dlamini, Z; Hull, R; Makhafola, TJ; Marima, R; Mbele, M, 2021)

"Cancer is considered one of the gruelling challenges and poses a grave health hazard across the globe."

( Karati, D; Kumar, D; Mahadik, KR; Trivedi, P, 2022)

"Cancer is a leading cause of death worldwide."

( Ahumada-Castro, U; Bustos, G; Cesar Cardenas, J; Lovy, A; Puebla, A; Silva-Pavez, E, 2021)

"Advanced cancer is accompanied by a substantial burden of symptoms, and palliative care (PC) plays an essential role, especially at the end of life (EOL)."

( Moncho, MEI; Palomar-Abril, V; Soria-Comes, T, 2022)

"Patients with cancer are using cannabis for self-treatment."

( Brønnum, D; Dalton, SO; Eckhoff, L; Herrstedt, J; Nielsen, SW; Ruhlmann, CH, 2022)

"Cancer is known as a second major cause of death globally."

( Najafi, M; Yang, B; Yu, C, 2021)

"Cancer is reported to be one of the most life-threatening diseases."

( Bhandari, S; Patil, S, 2022)

"The oxygen level in tumors is significantly promoted to about 52."

( Duan, Z; Gong, Q; Gu, L; Gu, Z; Li, X; Luo, K; Luo, Q; Zhang, H; Zhu, H, 2021)

"Cancer is the world's third deadliest disease."

( Jaitak, V; Kaur, K; Kulkarni, S, 2022)

"Cancer is still an insurmountable problem for humans and critically attacking human health."

( Cao, X; Chen, G; Chen, J; Chen, Y; Li, G; Peng, C; Peng, F; Qin, J; Xie, X; Yu, L, 2021)

"Cancer is a heterogeneous disease characterized by an abnormal and uncontrolled division of the cells leading to tumors that invade the adjacent normal tissues."

( Alam, O; Azam, F; Husain, A; Imran, M; Khan, IA; Manaithiya, A; Mittal, S; Naim, MJ; Sharma, V; Sheikh, AA, 2021)

"Worldwide, cancer is a serious threat to the health of citizens of every country, with the incidence and mortality increasing year by year."

( Cheng, Y; Hu, XR; Mu, C; Ruan, Y; Sun, JJ; Wang, XL, 2021)

"Cancer is the second leading cause of death worldwide."

( Arenas, M; Baiges-Gaya, G; Camps, J; Castañé, H; Joven, J; Rodríguez-Tomàs, E, 2021)

"Cancer is a leading cause of morbidity and mortality, with up to 9."

( Chan, H; Hsu, E; Ing, J; Wong, S, 2021)

"Cancer is the second leading cause of death worldwide."

( Ahn, KS; Ang, HL; Ashrafizadeh, M; Hashemi, F; Hushmandi, K; Khan, H; Kumar, AP; Makvandi, P; Mirzaei, S; Nabavi, N; Samarghandian, S; Sethi, G; Varma, RS; Zabolian, A; Zarrabi, A, 2021)

"Cancer is the second death cause worldwide, with breast and colon cancer among the most prevalent types."

( Aguilar, LF; Coddou, C; Jara-Gutierrez, C; Mellado, M; Reyna-Jeldes, M; Villena, J; Weinstein-Oppenheimer, C, 2022)

"Cancer is a life-threatening disease, and the challenges in accepting the diagnosis can bring a devastating emotional impact on the patient's mental and psychological wellbeing."

( Azmi, NA; Chan, CMH; Leong, WC; Rajah, HDA; Wee, LH, 2021)

"Cancer is the second leading cause of death globally and its incidence and mortality are rapidly increasing worldwide."

( Medina, VA; Nicoud, MB; Sarasola, MP; Táquez Delgado, MA, 2021)

"Cancer is a global disease involving transformation of normal cells into tumor types via numerous mechanisms, with mortality among all generations, in spite of the breakthroughs in chemotherapy, radiotherapy and/or surgery for cancer treatment."

( Asemi, Z; Homayoonfal, M; Yousefi, B, 2021)

"Malignant tumors are life-threatening, and chemotherapy is one of the common treatment methods."

( Li, J; Liu, M; Luo, R; Tan, T; Wang, R; Xie, T; Yin, L; Zeng, Y; Zeng, Z, 2021)

"Cancer is the second leading cause of death in the world."

( Akter, R; Bibi, P; Hassan, SSU; Mubin, S; Najda, A; Rahman, MH; Saeeda, S; Shah, M; Wesołowska, S, 2021)

"Cancer is a silent killer and remains to pose major health problems globally."

( Jhingran, S; K Rao, V; Laxmikeshav, K; Mone, S; Shankaraiah, N, 2022)

"Children with cancer are increasingly using cannabis therapeutically."

( Ananth, P; Balneaves, LG; Chapman, S; Crooks, B; Decker, K; Kelly, LE; Oberoi, S; Protudjer, JLP; Rapoport, A; Rassekh, SR; Siden, H; Vanan, MI, 2022)

"Cancer is a long-known incurable disease, and the medical use of cisplatin has been a significant discovery."

( Dai, X; Gao, H; Mu, M; Zhan, J, 2022)

"Patients with cancer are at increased risk of myocardial infarction (MI) and stroke."

( Chan, MY; Chng, WJ; Chong, JH; Foo, LL; Hausenloy, DJ; Koo, CY; Lee, CH; Richards, AM; Seet, R; Tan, LL; Zheng, H, 2021)

"Cancer is one of the most important reasons for mortality worldwide."

( Adibi, H; Eskandari, E; Ghadami, SA; Hosseinzadeh, L; Yarmohammadi, N, 2021)

"Moreover, cancer is a kind of multifactorial disease, and therefore manipulating a single target may result in treatment failure."

( Fan, M; He, H; Hu, L; Qi, B; Shi, S; Song, X; Wang, F, 2022)

"Cancer is a heterogeneous disease with high morbidity and mortality rate involving changes in redox balance and deregulation of redox signalling."

( Goh, BH; Phua, CYH; Tang, YQ; Teoh, ZL; Yap, WH, 2021)

"Prostate cancer is the most common cancer in men."

( Amiche, M; Couty, M; de la Taille, A; Delbe, J; Dusaud, M; Hamma-Kourbali, Y; Lequin, O; Miro-Padovani, M; Zadigue, P; Zargarian, L; Zhang, L, 2021)

"Cancer is a condition caused by many mechanisms (genetic, immune, oxidation, and inflammatory)."

( Constantinescu, T; Lungu, CN, 2021)

"Cancer is one of the leading causes of death in both developed and developing countries."

( Has, ATC; Hassan, Z; Juvale, IIA, 2021)

"Cancer is one of the top life-threatening dangers to the human survival, accounting for over 10 million deaths per year."

( Agarwal, T; Ambrosio, L; Ashrafizadeh, M; Bigham, A; Boccaccini, AR; Burvill, C; Dabbagh Moghaddam, F; Esmaeili, Y; Ghomi, M; Maiti, TK; Makvandi, P; Maleki, A; Mattoli, V; Nikfarjam, N; Raucci, MG; Samadi, P; Sartorius, R; Sharifi, E; Sharifi, S; Song, H; Trovato, M; Yousefiasl, S; Zarrabi, A; Zheng, K, 2022)

"Cancer is a serious threat to human health, and there is an urgent need to develop new treatment methods to overcome it."

( Li, M; Li, X; Liu, C; Rong, X; Sheng, W; Su, M; Wang, K; Wang, X; Yu, M; Zhang, Y; Zhu, B; Zhu, H, 2021)

"Blood cancers are difficult to cure completely and frequently show a poor prognosis."

( Kim, H; Lee, SY; Seo, B; Shin, MG; Yang, S; Yun, YR, 2022)

"The incidence of cancer is significantly higher in patients with DM than in those without DM."

( Lam, BQ; Morvant, J; Shankar, S; Srivastava, R; Srivastava, RK, 2021)

"Cancer is a prevalent disease worldwide, and treatments such as radiotherapy and chemotherapy sometimes lead to adverse events."

( Cabañas-Alite, L; García-Gozalbo, B, 2021)

"Hand tumors are a very common problem in hand surgery."

( Chammas, M; Coulet, B; Degeorge, B; Lazerges, C, 2022)

"Cancer is a complex disease with very high incidence and mortality rates every year."

( Chen, L; Fu, L; Huang, Y; Lu, P; Wang, X; Zhang, C, 2022)

"Older adults with cancer are at an elevated risk of death from their illness, and it is essential they understand how advance care planning can improve their quality of life, facilitate goal congruent care and ultimately decrease medical expenditures at end of life."

( Kozlov, E; Llaneza, DH; Trevino, K, 2022)

"Cancer is still among the leading causes of death globally, although cancer treatments have improved over the past decades."

( Bibá, GCC; de Souza, PS; Melo, EDDN; Muzitano, MF, 2022)

"Cancer is a complex group of diseases initiated by abnormal cell division with the potential of spreading to other parts of the body."

( Addae-Mensah, I; Amewu, RK; Osei-Safo, D; Sakyi, PO, 2021)

"These tumors are commonly diagnosed either non-invasively or intraoperatively using different modalities of fluorescence spectroscopy and imaging, which makes them ideal candidates for our feasibility test."

( Alekseeva, AI; Dolganova, IN; Karalkin, PA; Katyba, GM; Kurlov, VN; Kuznetsov, MR; Mukhina, EE; Nikitin, PV; Shikunova, IA; Tuchin, VV; Varvina, DA; Zaytsev, KI; Zotov, AK, 2022)

"As cancer is one of the main leading causes of mortality, a series of monotherapies such as chemotherapy, gene therapy and radiotherapy have been developed to overcome this thorny problem."

( Chen, X; Han, Z; Hua, Y; Kang, X; Liu, JQ; Wang, Y; Wang, ZY; Xu, F; Zang, SQ; Zhang, C; Zhao, X, 2021)

"Cancer care provided through public institutions had a low direct medical cost, but the indirect cost seemed to be extremely high."

( Jayaseelan, V; Maurya, PK; Murali, S; Pandjatcharam, J; Thulasingam, M, 2021)

"Cancer is a destructive disease that causes high levels of morbidity and mortality."

( Guo, Z; Kong, CY; Song, P; Tang, QZ; Teng, T; Yan, L; Yuan, YP; Zhang, X, 2022)

"Head and neck cancer is a growing worldwide public health problem, accounting for approximately 1,500,000 new cases and 500,000 deaths annually."

( Esteban, F; González-Moles, MÁ; Muñoz, M; Ramos-García, P, 2021)

"Cancer is defined by unrestrained cell proliferation due to impaired protein activity."

( Evan Prince, S; Panchal, NK, 2023)

"Cancer is one of the leading causes of death, with a heavy socio-economical burden for countries."

( Dong, H; Jia, S; Yang, R; Yang, Z, 2022)

"Patients with cancer are living longer, and many experience pain secondary to tumor invasion or as a consequence of cancer-directed therapies."

( Lowry, S, 2022)

"Cancer is a prime example derived from a loss of homeostasis, primarily caused by genetic alterations both in the genomic and epigenetic landscape, which results in deregulation of the gene networks."

( Aránega, A; Dueñas, Á; Franco, D; García-López, V; Garcia-Martínez, V; García-Padilla, C; López-Sánchez, C, 2022)

"Cancer is a multifaceted global health problem that requires continuous action to develop next-generation cancer theranostics."

( Dong, H; Gao, Y; Huang, X; Wu, X, 2022)

"Cancer is one of the leading causes of death in the modern world."

( Koszła, O; Koziorowska, A; Koziorowski, M; Majchrowicz, L; Mytych, J; Sołek, P; Łannik, E, 2022)

"Cancer is one of the leading causes of death globally and the number of cancer deaths is rising as a result of increased longevity."

( Chattipakorn, N; Chattipakorn, SC; Shinlapawittayatorn, K, 2022)

"Cancer is one of the important causes of death worldwide."

( Bahadır Acıkara, Ö; Küpeli Akkol, E; Şeker Karatoprak, G; Sobarzo-Sánchez, E; Yücel, Ç, 2022)

"Cancer is the second leading cause of death in people with chronic kidney disease (CKD) after cardiovascular disease."

( Elyan, BMP; Herrmann, SM; Jones, RJ; Lang, NN; Lees, JS; Mark, PB, 2023)

"Because cancer is one of the highest causes of death globally, the discovery of immune checkpoint inhibitors by Honjo and Allison in cancer immunotherapy earned a Nobel Prize in 2018."

( Chen, W; MaruYama, T; Shibata, H, 2022)

"Three out of five tumors are completely eliminated under photoacoustic imaging-guided 2nd NIR irradiation."

( Cui, K; Cui, Y; Li, M; Li, R; Liu, L; Xiao, Z; Xie, W; Zhang, Y, 2022)

"Cancer is one of the main causes of human mortality and brain tumors, including invasive pituitary adenomas, medulloblastomas and glioblastomas are common brain malignancies with poor prognosis."

( Altinoz, MA; Ozpinar, A, 2022)

"Cancer is one of the diseases with the highest morbidity and mortality rates worldwide, and its therapeutic options are inadequate."

( Gan, L; He, J; Huang, Y; Li, L; Mo, T; Na, J; Tang, C; Zhong, L, 2022)

"The risk of cancer is higher in patients with MS who received 1."

( Askari, M; Ghaffary, EM; Ghajarzadeh, M; Ghoshouni, H; Mirmosayyeb, O; Shaygannejad, V, 2022)

"As breakthroughs in cancer care are leading to improved long-term outcomes in a subset of advanced cancers, there is a growing population of long-term cancer survivors that are at risk of long-term complications."

( Deshpande, P; Eswarappa, M; Lee, M; Sise, ME; Wanchoo, R; Wang, Q, 2021)

"Cervical cancer is the fourth leading cause of cancer death among women worldwide."

( Islam, N; Shoaib, S; Yusuf, N, 2022)

"Childhood cancers are usually treated with chemotherapy and radiation."

( Bahadoram, M; Bahadoram, S; Hassanzadeh, S; Keikha, A; Keikhaei, B; Mahmoudian-Sani, MR, 2023)

"Cancer is a life-threatening disease and is the second leading cause of death worldwide."

( Bhandare, RR; Natarajan, R; Shaik, AB; Sivaperuman, A; Subramani, AK, 2022)

"Cancer is claimed as a prevalent cause of mortality throughout the world."

( Zou, Y, 2022)

"Cancer is characterized by the continuous multiplication of cells in the human, which is unable to control."

( Das, A; Gogoi, U; Pathak, K; Pathak, MP; Sahariah, JJ; Saikia, R; Samanta, A; Zothantluanga, JH, 2022)

"Cancer is one of the leading causes of death worldwide."

( Hegde, N; Juvale, K; Kalave, S, 2022)

"Patients with cancer are at risk for opportunistic infections, frequently experience cardiovascular complications, and often receive classes of medications that cause or exacerbate hypomagnesemia."

( Jhaveri, KD; Rondon-Berrios, H; Uppal, NN; Workeneh, BT, 2021)

"According to WHO, cancer is the second leading cause of global deaths and accounted for approximately 9."

( Goel, N; Kumar, N, 2022)

"Cancer is the world's second leading cause of death, but a significant advancement in cancer treatment has been achieved within the last few decades."

( Bishayee, A; Priya, A; Tewari, D, 2022)

"Cancer is a leading cause of morbidity and mortality worldwide."

( Mehmood, T; Muanprasat, C, 2022)

"Cancer is the most devastating disease and second leading cause of death around the world."

( Dhuguru, J; Ghoneim, OA, 2022)

"Breast cancer is one of the leading causes of cancer-related death."

( Cha, BS; Hashkavayi, AB; Lee, ES; Park, KS, 2022)

"Tumors are composed by a heterogeneous population of cells."

( Gomez, LJ; Jardin, I; Lopez, JJ; Rosado, JA; Salido, GM; Sanchez-Collado, J, 2022)

"Cancer is one of the most widespread diseases globally and one of the leading causes of death."

( Bosco, F; Cardamone, A; Carresi, C; Cognetti, F; Coppoletta, AR; Gliozzi, M; Guarnieri, L; Ilari, S; Macrì, R; Maiuolo, J; Mollace, A; Mollace, V; Muscoli, C; Musolino, V; Nucera, S; Oppedisano, F; Ruga, S; Scarano, F; Scicchitano, M, 2022)

"Cancer is a major health problem across the globe, and is expeditiously growing at a faster rate worldwide."

( Alam, W; Albrakati, A; Alsharif, KF; Khan, H; Mir, RH; Mohi-Ud-Din, R; Saso, L; Wani, TU, 2022)

"Cancer is the disease of uncontrollably dividing cells in the body."

( İlhan, M, 2022)

"Cancer is a leading risk of death globally."

( Kumar, D; Kumar, S; Sharma, P; Shri, R, 2022)

"Cancer is the second leading cause of death following ischemic heart disease in the world and the primary clinical, social and economic burden."

( Chen, Q; Chen, S; Deng, S; Hu, P; Hu, X; Ling, C; Liu, X; Luo, B; Qiu, L; Wu, Q; Yuan, M, 2022)

"Cancer is one of the major diseases threatening human life and health worldwide."

( Bao, Z; Chu, Q; Jiang, S; Li, L; Lu, J; Su, Y; Xue, C; Zheng, Q, 2022)

"Aggressive cancer care at the end-of-life (ACEOL) is considered poor quality care."

( Behm, B; Correa Ordonez, ID; Davis, MP; Digwood, G; Elder, A; Ellison, H; Fernandez, C; Mehta, Z; Panikkar, R; Vanenkevort, EA; Wojtowicz, MJ; Young, A, 2023)

"Cancer is a worldwide public health issue that has not been conquered."

( Chen, H; Feng, C; Gao, Y; Li, X; Wang, Y, 2022)

"Cancer is a significant public health problem worldwide."

( Bhoir, S; Cata, JP; Dougherty, PM; Gorur, A; Ilsin, N; Uhelski, ML, 2022)

"Tumors are heterogeneous cellular environments with entwined metabolic dependencies."

( Baruah, P; Ghoshdastider, U; Kulshrestha, T; Rohatgi, N; Skanderup, AJ, 2022)

"Cancer is the major cause of morbidity and mortality worldwide."

( Basavarajappa, D; Kulothungan, V; Leburu, S; Mathur, P; Menon, GR; Mohan, R; Ramamoorthy, T; Sathishkumar, K; Stephen, S; Tomy, N, 2022)

"Cancer is a long-term and deadly pandemic that affects nearly a third of the world's population."

( Shi, Y; Wang, J; Yan, H, 2022)

"Cancer is one of the deadliest diseases involving dysregulated cell proliferation and has been the leading cause of death worldwide."

( Chandrasekar, MJN; Nagarjuna, P; Patnaik, SK; Ramamurthi, D; Swaroop, AK, 2022)

"Cancer is among the most prominent causes of mortality worldwide."

( A Alsahli, M; Alhumaydhi, FA; Almatroodi, SA; Babiker, AY; Khan, AA; Rahmani, AH; S M Aljohani, A, 2022)

"Cancer is a disorder that rigorously affects the human population worldwide."

( Ahmed, F; Aktar, A; Bachar, SC; Biswas, B; Fukase, K; Hossain, ME; Mazumder, K; Monjur-Al-Hossain, ASM; Roy, P; Sarkar, KK, 2022)

"Cancer is the second leading cause of death in the world, behind only cardiovascular diseases, and is one of the most serious diseases threatening human health nowadays."

( Chen, L; Duan, X; Gong, X; Yang, H; Yang, Y; Zheng, X; Zhu, Y, 2022)

"Patients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes."

( Albiges, L; Angelakas, A; Armstrong, AC; Arnold, D; Aung, T; Banfill, K; Barlesi, F; Baxter, M; Bayle, A; Besse, B; Bhogal, T; Boyce, H; Britton, F; Calles, A; Castelo-Branco, L; Cooksley, T; Copson, E; Croitoru, AE; Dani, SS; Dickens, E; Dive, C; Eastlake, L; Fitzpatrick, P; Foulon, S; Frederiksen, H; Freitas, A; Frost, H; Ganatra, S; Gennatas, S; Glenthøj, A; Gomes, F; Graham, DM; Hague, C; Harrington, K; Harrison, M; Horsley, L; Hoskins, R; Huddar, P; Hudson, Z; Jakobsen, LH; Joharatnam-Hogan, N; Khan, K; Khan, S; Khan, UT; Landers, D; Lee, RJ; Lever, L; Massard, C; Maynard, A; McKenzie, H; Michielin, O; Mosenthal, AC; Obispo, B; Palmieri, C; Patel, R; Pentheroudakis, G; Peters, S; Rieger-Christ, K; Robinson, T; Rogado, J; Romano, E; Rowe, M; Sekacheva, M; Sheehan, R; Shotton, R; Stevenson, J; Stockdale, A; Thomas, A; Tivey, A; Turtle, L; Viñal, D; Weaver, J; Williams, S; Wilson, C; Woodcock, J; Wysocki, O; Zhou, C, 2022)

"Cancer is one of the deadliest diseases worldwide, and there is a critical need for diagnostic platforms for applications in early cancer detection."

( Hoorfar, M; Janfaza, S; Khassi, K; Pourmadadi, M; Saeidi Tabar, F; Soleimani Dinani, H; Tasnim, N, 2022)

"Currently, cancer is ranked among the top ten causes of death worldwide."

( Asemi, Z; Homayoonfal, M; Maleki Dana, P; Sadoughi, F; Sharifi, M, 2022)

"Cancer is a fatal disease with a collection of related diseases in various body parts."

( Bhatt, A; Narwal, S; Rani, N; Redhu, R; Singla, RK, 2022)

"Cancer is the leading cause of death and the most significant determinant of life expectancy in almost every country in this twenty-first century."

( Agarwal, S; Asati, V; Chourasia, P; Das, R; Kashaw, SK; Kashaw, V, 2023)

"Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020."

( Kumar, A; Mazumder, A; Mazumder, R; Mishra, R; Varshney, S, 2023)

"Globally, breast cancer is one of the leading invasive cancers in women."

( Mohaideen, NSMH; Ravindranath, KJ; Srinivasan, H, 2022)

"Cancer is becoming a global threat as its treatment accounts for many challenges."

( Asati, V; Bhattacharya, S; Bhupal, R; Gupta, GD; Kaur, K; Mahapatra, DK; Pathak, A, 2023)

"Cancer is a life-threatening and multifaceted disease."

( Attar, R; Farooqi, AA; Xu, B, 2022)

"Cancer is one of the major causes of global deaths and needs immediate therapeutic development."

( Elasbali, AM; Haque, QMR; Hassan, MI; Khan, P; Khan, S; Shahwan, M; Shamsi, A; Yousuf, M, 2022)

"Cancer is a disease of high mortality, and its prevalence has increased steadily in the last few years."

( Altieri, F; Chichiarelli, S; Eufemi, M; González-Montero, J; Rodrigo, R; Saso, L, 2022)

"Cancer is one of the significant threats to human life."

( Alle, M; Kim, JC; Lee, SH; Sharma, G, 2022)

"Breast cancer is one of the most common cancers among women that is associated with high mortality."

( Alamdari, SG; Amini, M; Baradaran, B; Jalilzadeh, N; Mohammadzadeh, R; Mokhtarzadeh, A; Oroojalian, F, 2022)

"Cancer is a most common cause of mortality globally."

( DCruz, CEM; Fernandes, NB; Kajampady, MK; Kumar, L; Shenoy, RUK; Shirodkar, RK; Verma, R, 2022)

"Cancer is one of the most common causes of death globally."

( Ahmed, MB; Alghamdi, AAA; Islam, SU; Lee, JS; Lee, YS, 2022)

"Cancer is a disease that seriously threatens human health."

( Huang, H; Ju, M; Shen, B; Sun, W; Wu, J; Zheng, X, 2022)

"Cancer is a complex pathology of great heterogeneity and difficulty that makes the constant search for new therapies necessary."

( Araya-Valdés, G; Bastidas, H; Catalán, M; Cortés, G; Jara, JA, 2022)

"Cancer is a life-threatening disease that has claimed the lives of many people worldwide."

( Borisova, E; Boyko, A; Chakrabarti, S; Gopal, D; Ivanov, D; K, SP; Kaniyala Melanthota, S; Kistenev, YV; Mazumder, N; Vrazhnov, D; Zakharova, O, 2022)

"Gynecologic cancers are one of the main health concerns of women throughout the world, and the early diagnosis and effective therapy of gynecologic cancers will be particularly important for the survival of female patients."

( Hu, J; Li, C; Xiao, C; Zhu, L, 2022)

"Patients with cancer are prone to anemia and receive transfusions frequently; the condition which results in iron overload, contributing to serious therapeutic complications."

( Abedi, M; Rahgozar, S, 2022)

"Cancer is one of the main causes of death worldwide."

( Alessio, E; Burckel, P; Gandioso, A; Gasser, G; Vidal, A, 2022)

"Cancer is known as a notorious disease responsible for threatening millions of lives every year."

( Gaur, A; Gulati, S; Kumar, S; Pandey, E; Sagar, B; Shukla, S, 2023)

"Some breast cancers are caused by hormonal imbalances, such as estrogen and progesterone."

( Maurya, P; Mishra, N; Nisha, R; Pal, RR; Parashar, P; Saraf, SA; Singh, N; Singh, P, 2023)

"Patients with cancer are at higher risk of atrial fibrillation (AF)."

( Al Kasasbeh, M; Al-Abdouh, A; Barbarawi, M; Barbarawi, O; Corcoran, J; Mhanna, M; Obeidat, K; Pickett, CC, 2022)

"Lung cancer is a significant public health concern in low- and middle-income countries such as India."

( Das, P; Mathur, P; Nath, A; Sathishkumar, K; Sudarshan, KL, 2022)

"Cancer is a type of human cell degenerative disease that has afflicted a large number of people for years."

( Abdulah, MM; Chauhan, B; Kumar, R; Mazumder, A; Singh, H; Yadav, RK, 2023)

"Cancer is the second cause of human mortality after cardiovascular disease around the globe."

( Ahmadi, F; Asare-Addo, K; Ebrahimnejad, F; Ebrahimnejad, P; Nokhodchi, A; Pouya Hadipour Moghaddam, S; Sodagar-Taleghani, A, 2022)

"Breast cancer is the leading cause of cancer-related deaths in women and remains a formidable therapeutic challenge."

( Chen, J; Du, M; Gu, L; Liu, D; Liu, S; Peng, Q; Shen, S; Tian, Y; Wang, J; Xiao, W; Zhang, J, 2022)

"Cancer is replacing cardiovascular-disease as a leading cause of death in type 2 diabetes (T2D)."

( Chan, JC; Chow, E; Fan, B; Kong, AP; Lau, ESH; Luk, AO; Ma, RC; Shi, M; Wu, H; Yang, A, 2022)

"Tumors are the biggest opponents in the history of human diseases, and they cannot be eliminated so far."

( Li, P; Wei, J; Zhang, H; Zhu, R, 2022)

"Shortly after cancer is diagnosed, a phenomenon develops in cancer cells called multidrug resistance (MDR), in which cell sensitivity against anti-cancer drugs is significantly reduced."

( Alipourfard, I; Beyrami Aghbash, E; Hemmati-Dinarvand, M; Kheirandish, S; Khodadadian, A; Mokhtari, H; Seghatoleslam, A, 2023)

"Cancer is one of the most common and dreaded diseases affecting the vastness of society."

( Kleczkowska, P; Laskowska, AK, 2022)

"Cancer is a devastating disease and the second most cause of mortality."

( Aziz, T; Nawaz, T; Ullah, A; Ullah, N, 2023)

"Breast cancer is a prevalent female malignancy and tamoxifen remains the first-line treatment for breast cancer, but tamoxifen resistance is a frequent clinical problem."

( Dai, Z; Li, F; Li, M; Liu, J; Wang, B; Zhang, M; Zhang, W; Zhang, X, 2022)

"Cancer is one of the most intractable diseases in the world because of its high recurrence rate, high metastasis rate and high lethality rate."

( Cao, D; Kuang, Y; Liu, X; Lu, J; Luo, Y; Wang, J; Wang, X; Xia, W; Yuan, C; Zhang, Z, 2022)

"Cancer is a horrific disease that, to date, has no cure."

( Abusaliya, A; Bhosale, PB; Ha, SE; Heo, JD; Jeong, SH; Kim, GS; Kim, HH; Kim, HW; Park, KI; Park, MY, 2022)

"Globally, cancer is the second leading cause of mortality and morbidity."

( Alomar, SY; Hashmi, MA; Imran, MA; Qais, FA, 2022)

"The chemotherapy of tumors is frequently limited by the development of resistance and severe side effects."

( Bahramimehr, F; Boulos, JC; Dawood, M; Drif, A; Efferth, T; Khalid, SA; Shahhamzehei, N; Shan, L; Wasfi, M, 2022)

"Cancer is the most commonly diagnosed type of disease and a major cause of death worldwide."

( Almatroodi, SA; Alsahli, MA; Rahmani, AH, 2022)

"Cancer is the leading cause of death worldwide."

( Almatroodi, SA; Almatroudi, A; Almogbel, MA; Alsahli, MA; Anwar, S; Khan, AA; Rahmani, AH, 2022)

"Breast cancer is the number one cause of cancer-related deaths among females."

( Bagwe, P; Bansal, A; D'Souza, MJ; Gala, RP; Zaman, RU, 2022)

"Cancer is imposing a global health burden because of the steady increase in new cases."

( Al-Shar'i, NA; Islam, MK; Jayanthi, S; Nwaefulu, ON; Owolabi, JO; Sagineedu, SR; Stanslas, J; Wai, LK; Woei, LC, 2022)

"Breast cancer is the second most common malignancy in females worldwide and poses a great challenge that necessitates the identification of novel therapeutic agents from several sources."

( Achar, RR; Amruthesh, KN; Anandan, S; Flores-Holguín, N; Frau, J; Glossman-Mitnik, D; Gowtham, HG; Kollur, SP; Murali, M; Ortega-Castro, J; Pradeep, S; Shivakumar, CS; Shivamallu, C; Silina, E; Singh, SB; Stupin, V; Thampy, A, 2022)

"Cancer is one of the biggest public enemies of global health with its high morbidity and mortality."

( Chen, JT; Fei, J; Hou, MJ; Li, CY; Mao, GJ; Tan, ZK; Wang, ZQ, 2022)

"Cancer is the second leading cause of death in the world."

( Arabpour, Z; Hasani, M; Khodabakhshi, A; Monfared, V; Vahid, F, 2023)

"Cancer is one of the deadliest diseases in the world."

( Belete, TM, 2022)

"Breast cancer is a multifactorial disease, and among the many factors which are involved in the onset, progression, and invasion of the disease, oxidative stress plays a significant role."

( Abbasalipourkabir, R; Barartabar, Z; Mesbah-Namin, SA; Moini, N; Ziamajidi, N, 2023)

"Cancer is still one of the leading causes of death worldwide."

( Kumar, K; Rathod, B, 2022)

"Cancer is a major risk factor for venous thromboembolism (VTE), and cancer-associated thrombosis (CAT) constitutes approximately 15-25% of all VTE cases."

( Attard, LM; Bertoletti, L; Delluc, A; Gatt, A; Riva, N, 2022)

"When cancer is found at later stages, the pain can become severe and constant; reducing their quality of life and significantly affecting mental and physical well-being."

( Amatya, S; Cornett, EM; Cruz-Topete, D; Kaye, AD; Kelkar, N; Rosa, CM; Tran, A; Urits, I; Virgen, CG; Viswanath, O, 2022)

"The occurrence of tumors is associated with the upregulation or downregulation of certain genes."

( Guo, L; Huang, J; Liang, D; Meng, Q; Pan, H; Wang, J; Wang, P; Wang, T; Wu, J; Zhu, S, 2022)

"Hypercalcemia of malignancy is associated with poor survival."

( Shane, E; Walker, MD, 2022)

"Tumors are usually associated with oxygen-deficient regions (hypoxia) which results from reduced and disorganized intratumoral vasculature, increased diffusion distances, and growing tumor masses."

( Kumar, R; Saha, G; Saudagar, P; Tiwari, K, 2023)

"Cancer is currently the second leading cause of death globally."

( Fuentes-Soriano, P; Herold-Mende, C; Romero-Nieto, C; Wolfram, A, 2022)

"Colon and breast cancer are among the diseases for which data suggest that modified pectin (MP), specifically modified citrus pectin (MCP), has beneficial effects on the development and spread of malignancies, in addition to its benefits as a soluble dietary fiber."

( Alhasaniah, AH; Almazni, IA; Awadh, AAA; Chandran, D; Das, R; Emran, TB; Guiné, RPF; Islam, F; Khan, Z; Lima, CMG; Mitra, S; Nath, N; Paul, S; Sharma, R, 2022)

"Breast cancer is the type of cancer with the highest incidence in women around the world."

( Aleixo, DT; Corrêa, JODA; Costa, DS; da Silva Filho, AA; Ferreira, KCB; Gameiro, J; Gualberto, ACM; Oliveira, LL; Pittella, F; Santos, MM; Silva, LM; Tavares, GD; Valle, ABCDS, 2022)

"Cancer is a major reason for concurrent prescription of opioids with other sedating medications-particularly benzodiazepines and gabapentinoids-yet population-based assessments of the extent and predictors of concurrent prescribing among clinically and demographically diverse patients with cancer are lacking."

( Baggett, CD; Check, DK; Dinan, MA; Kim, K; Merlin, JS; Oeffinger, KC; Roberts, MC; Robinson, T; Winn, AN, 2022)

"Breast cancer is the most frequent malignant neoplasm in females."

( do Carmo Neto, JR; Franco, PIR; Machado, JR; Miguel, MP; Milhomem, AC, 2023)

"Breast cancer is the most frequent malignant neoplasm in females."

( do Carmo Neto, JR; Franco, PIR; Machado, JR; Miguel, MP; Milhomem, AC, 2023)

"Breast cancer is the most frequent malignant neoplasm in females."

( do Carmo Neto, JR; Franco, PIR; Machado, JR; Miguel, MP; Milhomem, AC, 2023)

"Cancer is a worldwide problem afflicting 19 million people."

( Tamanoi, F; Yoshikawa, K, 2022)

"Cancer is a worldwide problem afflicting 19 million people."

( Tamanoi, F; Yoshikawa, K, 2022)

"Cancer is a worldwide problem afflicting 19 million people."

( Tamanoi, F; Yoshikawa, K, 2022)

"Pancreatic cancer is the most severe among other cancers due to its late detection and less chance of survivability."

( Achur, R; Kumaraswamy, HM; Ningegowda, NB; Pargi, M; Rahman, A; Satyanarayan, ND; Siddappa, MK, 2023)

"Pancreatic cancer is the most severe among other cancers due to its late detection and less chance of survivability."

( Achur, R; Kumaraswamy, HM; Ningegowda, NB; Pargi, M; Rahman, A; Satyanarayan, ND; Siddappa, MK, 2023)

"Pancreatic cancer is the most severe among other cancers due to its late detection and less chance of survivability."

( Achur, R; Kumaraswamy, HM; Ningegowda, NB; Pargi, M; Rahman, A; Satyanarayan, ND; Siddappa, MK, 2023)

"Cancer is one of the most challenging diseases to manage."

( Alvandi, M; Dehbanpour, MR; Farzipour, S; Nosrati, S; Shaghaghi, Z, 2022)

"Cancer is one of the most challenging diseases to manage."

( Alvandi, M; Dehbanpour, MR; Farzipour, S; Nosrati, S; Shaghaghi, Z, 2022)

"Breast cancer is heterogenous in development and cell population with prognoses being highly dependent on numerous factors from driving mutations, biomarker expression and variation in extracellular environment, all affecting response to therapies."

( Doddapaneni, R; Lu, PJ; Lu, QL; Tucker, JD, 2022)

"Cancer is the most important acquired risk factor for VTE in Asians."

( Angchaisuksiri, P; Boonyawat, K, 2022)

"Cancer is the most important acquired risk factor for VTE in Asians."

( Angchaisuksiri, P; Boonyawat, K, 2022)

"Cancer is one of the most common diseases throughout the world, with many treatment modalities currently being used, and new treatment strategies being sought."

( Johnston, TP; Kesharwani, P; Sahebkar, A; Shahriari, M, 2023)

"Cancer is one of the most common diseases throughout the world, with many treatment modalities currently being used, and new treatment strategies being sought."

( Johnston, TP; Kesharwani, P; Sahebkar, A; Shahriari, M, 2023)

"Cancer is responsible for about one in six deaths in the world."

( Ahmadifard, M; Fatemi, S; Kamali, MJ; Khoshghiafeh, A; Moradi, F; Salehi, M, 2023)

"Cancer is responsible for about one in six deaths in the world."

( Ahmadifard, M; Fatemi, S; Kamali, MJ; Khoshghiafeh, A; Moradi, F; Salehi, M, 2023)

"Many patients with cancer are taking dietary supplements and may not disclose such to their care teams."

( Bauer, BA; Burckhard, JL; D'Andre, SD; Hofmann, MB; Loprinzi, CL; Montane, HN, 2022)

"Many patients with cancer are taking dietary supplements and may not disclose such to their care teams."

( Bauer, BA; Burckhard, JL; D'Andre, SD; Hofmann, MB; Loprinzi, CL; Montane, HN, 2022)

"Cancer is currently the most important problem endangering human health."

( He, T; Li, Z; Mi, L; Su, A; Wu, W; Xing, Z; Zhang, Y; Zhou, F, 2023)

"Cancer is currently the most important problem endangering human health."

( He, T; Li, Z; Mi, L; Su, A; Wu, W; Xing, Z; Zhang, Y; Zhou, F, 2023)

"Cancers are among the leading causes of death currently."

( Li, X; Liu, W; Qi, K; Wang, J; Wang, Y; Xu, H, 2023)

"Cancer is the most serious problem for public health."

( Guo, T; Hu, Z; Li, M; Luo, F; Tang, Y; Wu, X; Xie, T, 2023)

"Cancer is a main culprit and the second-leading cause of death worldwide."

( Allemailem, KS; Almatroodi, SA; Almatroudi, A; Khan, AA; Rahmani, AH, 2022)

"On the other hand, cancer is the most significant cause of mortality globally, accounting for over 10 million fatalities in 2020, or nearly one in every six deaths."

( Ali, Q; Khalid, A; Khan, MA; Nadeem, T; Zubair, M, 2022)

"The fact that cancer is one of the leading causes of death requires researchers to create new systems of effective treatment for malignant tumors."

( Abashkin, V; Bryszewska, M; Horodecka, K; Pędziwiatr-Werbicka, E; Shcharbin, D; Shmanai, V; Ulashchik, E; Zhogla, V, 2023)

"Cancer is the second leading cause of death worldwide, and effective removal of tumour cells while protecting normal cells is the key to tumour treatment."

( Wang, D, 2023)

"Cancer is one of the leading causes of death worldwide."

( Abbas, FH; Azeez, NF; Faris, M; Hasan, HH; Madlool, HA; Mohammed, DF; Shalan, BH, 2022)

"Early detection of cancer is critical in medical sciences, as the sooner a cancer is diagnosed, the higher are the chances of recovery."

( d'Ettorre, P; Devienne, P; Leroy, C; Marangoni, E; Montaudon, É; Piqueret, B; Sandoz, JC, 2023)

"Cancer is the world's second leading cause of death, and there are no approved herbal therapies."

( Baitharu, I; Ekka, NJ; Mir, SA; Muhammad, A; Naik, PK; Nayak, B; Padhiary, A, 2023)

"Patients with cancer are at an increased risk of developing atrial fibrillation (AF) and often need to undergo procedures or surgery that requires periprocedural interruption of anticoagulation."

( Aziz, J; Carrier, M; Douketis, J; Le Gal, G; Shaw, JR; Siegal, D; Wang, TF, 2023)

"Malignancy is often associated with therapeutic resistance and metastasis, usually arising after therapeutic treatment."

( Asai, H; Fujimori, H; Hyodo, M; Kusumoto-Matsuo, R; Manaka, Y; Matsuno, Y; Shiroishi, M; Suzuki, M; Wakatsuki, K; Yoshioka, KI, 2023)

"Cancer is a complicated malignancy controlled by numerous intrinsic and extrinsic pathways."

( Khan, F; Pandey, P; Upadhyay, TK, 2023)

"Cancer is the leading cause of mortality and morbidity worldwide, and its cases are rapidly increasing every year."

( Ahmad, R; Khan, A; Khan, AU; Khan, M; Khan, S; Riaz, M; Shal, B, 2023)

"Cancer is characterized by a perturbed immune landscape."

( Mishra, V; Singh, MP; Tripathi, V; Yadav, P, 2023)

"Cancer is a deadly disease associated with abnormal cell growth and invasion to various parts of the body."

( Rani J, J; Roy, S, 2023)

"Cancer is one of the acute life-threatening diseases endangering the whole of humanity."

( Chai, J; Luan, J; Tian, Y; Wang, Y; Yang, K; Zhu, J, 2023)

"Cancer is the second leading cause of death in the world after cardiovascular diseases."

( Alizadeh-Navaei, R; Rahavi, H; Tehrani, M, 2023)

"Many types of human cancers are being treated with small molecule ATP-competitive inhibitors targeting the kinase domain of receptor tyrosine kinases."

( Besch, A; Marsiglia, WM; Mohammadi, M; Traaseth, NJ; Zhang, Y, 2023)

"Cancer is one of the major causes of death worldwide."

( Cheng, S; Huo, D; Jing, T; Lv, J; Ma, X; Meng, T; Wen, R; Yang, J, 2023)

"Cancer is a leading cause of death worldwide, posing a huge burden upon society and individuals."

( Gu, K; Zhou, F; Zhou, Y, 2023)

"Cancer is one of the most deadly diseases involving dysregulated cell proliferation."

( Chandrasekar, MJN; Nagarjuna, P; Nanjan, MJ; Patnaik, SK; Swaroop, AK, 2024)

"Cancer is the second leading reason of death in many countries, and its burden and prognosis are highly dependent on disease stage at diagnosis."

( Garg, SK; Goel, GS; Kamboj, D; Kumar, K; Mittal, A, 2023)

"Colorectal cancer is the third leading cause of death in patients with cancers in America."

( Deng, Y; He, TC; Qiao, M; Wang, J; Wei, Q; Yan, Z; Ye, J; Zhang, J; Zhou, Y, 2023)

"Liver cancer is one of the most common causes of cancer death worldwide."

( Armentano, MF; Bisaccia, F; Caddeo, C; Chiummiento, L; D'Orsi, R; Fadda, AM; Funicello, M; Lamorte, D; Lupattelli, P; Miglionico, R; Nigro, I; Rinaldi, R; Santoro, V; Valenti, D; Vassallo, A, 2023)

"As cancer is an insurmountable challenge, no miracle drug is currently available."

( Gu, C; Huang, P; Liu, Y; Lu, L; Qian, J; Song, F; Yang, Y; Zhang, Y; Zheng, X; Zou, X, 2023)

"Emerging cancers are sculpted by neo-Darwinian selection for superior growth and survival but minimal immunogenicity; consequently, metastatic cancers often evolve common genetic and epigenetic signatures to elude immune surveillance."

( Al Haddad, E; Andersen, RJ; Caspani, G; Dada, S; Dreier, C; Ellis, SLS; Eyford, BA; Garcia, NH; Garrovillas, E; Gray, PW; Jefferies, WA; Kari, S; Lack, NA; Morova, T; Munro, L; Nohara, LL; Pfeifer, CG; Saranchova, I; Tjoelker, L; Wood, C, 2022)

"Cancer is a major cause of death worldwide."

( Amini, SM; Dinarvand, R; Jaafari, MR; Kharrazi, S; Rezayat, SM, 2023)

"Female breast cancer is the most common malignancy worldwide, with a high disease burden."

( Chen, Y; Luo, Y; Ou, J; Sun, Y; Wang, C; Ye, Y; Zhang, C, 2023)

"Most tumors are easily missed and misdiagnosed due to the lack of specific clinical signs and symptoms in the early stage."

( Chen, Z; Liu, Y; Luo, J; Yang, S; Yang, X; Zhan, X, 2023)

"Cancer is an escalating global issue, with 19."

( Fagbohun, OF; Gillies, CR; Murphy, KPJ; Rupasinghe, HPV, 2023)

"Cancer is still the leading cause of death worldwide, burdening the global medical system."

( Abbasi, BA; Almarhoon, ZM; Calina, D; Cho, WC; Hano, C; Ijaz, S; Iqbal, J; Kanwal, S; Mahmood, T; Sharifi-Rad, J; Sydykbayeva, S; Ullah, Z; Yaseen, T; Ydyrys, A, 2023)

"The prime cause of cancer is essential for the prevention and diagnosis, yet the effects that influence tumor growth are more important for cancer treatment."

( Menchikov, LG; Popov, AV; Shestov, AA, 2023)

"Cancer is prevalent among vascular amputees, with a large proportion being occult diagnoses."

( Azhar, B; Budge, J; Holt, P; Kolli, V; Loftus, I; Moxey, P; Poole, G; Wafi, A, 2023)

"Airway tumors are rare in children."

( Gipsman, AI; Piccione, J; Treat, JR, 2023)

"Solid tumors are regarded as complex evolving systems rather than simple diseases."

( He, Z; Kong, Z; Li, S; Luo, C; Sun, J; Wang, Z; Ye, H; Zhang, S; Zheng, Y, 2023)

"Breast cancer is the most common malignant tumor and one of the leading causes of cancer-related death in women throughout the world."

( Arsic, A; Jakovljevic, V; Krstic, P; Nedovic, J; Paunovic, M; Vucic, V, 2023)

"Cancer is a complex genetic disorder due to uncontrolled growth of abnormal cells in the body, causes damage to the immune system, and may lead to life-threatening situations."

( Amala Dev, AR; Sonia Mol, J, 2023)

"Cancer is one of the deadliest diseases, and current treatment regimens suffer from limited efficacy, nonspecific toxicity, and chemoresistance."

( Chen, Y; Xie, W; Yang, H, 2023)

"Cancer is one of the most common causes of human death worldwide; thus, numerous therapies, including chemotherapy, have been and are being continuously developed."

( Borys, F; Fabczak, H; Joachimiak, E; Krawczyk, H; Poterała, M; Tobiasz, P, 2023)

"Patients with brain cancer are at a high risk of developing venous thromboembolism (VTE) and are underrepresented in clinical trials."

( Alfred, T; Bruette, R; Cohen, A; Dhamane, A; Hines, DM; Luo, X; Noxon, V; Shah, S, 2023)

"Cancer is considered as the major public health scourge of the 21st century."

( Hegde, M; Kumar, A; Kunnumakkara, AB; Parama, D, 2022)

"Cancer is a disease in which repeated rounds of mutations cause uncontrolled growth of cells, which prospers at the expense of their neighbor cells and then eventually leads to the destruction of the whole cellular community."

( Arshad, M; Khan, H; Rais, J, 2023)

"Most solid tumors are clinically treated using surgical resection, and the presence of residual tumor tissues at the surgical margins often determines tumor survival and recurrence."

( Qian, X; Qu, J; Teng, X; Xu, Y; Yang, J; Yang, Y; Zhu, W, 2023)

"Cancer is the leading cause of death worldwide and several anticancer therapies take advantage of the ability of reactive oxygen species to kill cancer cells."

( Curia, MC; D'Antonio, DL; Piattelli, A; Pignatelli, P; Umme, S, 2023)

"Cancer is threatening the survival of human beings all over the world."

( Cao, D; Lai, B; Ran, X; Tang, H; Wang, L, 2023)

"Cancer is a major burden of disease worldwide and increasing evidence shows that inflammation contributes to cancer development and progression."

( Attaya, A; Deng, J; Fan, D; Fan, W; Kelly, A; Panigrahy, D; Rothenberger, E; Yang, H; Zhao, T, 2023)

"Cancer is one of the world's major causes of death."

( Gulle, K; Ilhan, I; Sarman, E, 2023)

"However, most solid cancers are seemingly resistant to PIs."

( Hido, M; Ishii, K; Sakamura, M; Virgona, N; Yano, T, 2023)

"Cancer is a major public health concern worldwide and main burden of the healthcare system."

( Alharbi, BF; Allemailem, KS; Almatroodi, SA; Almatroudi, A; Alrumaihi, F; Alwanian, WM; Khan, AA; Rahmani, AH, 2023)

"Cancer is one of the main causes of death in all developed and developing countries."

( Almatroodi, SA; Almatroudi, A; Khan, AA; Rahmani, AH, 2023)

"Cancer is the abnormal division and multiplication of cells in an organ or tissue."

( Conradie, J; Ugwu, DI, 2023)

"The solid tumors are characterized with oxidative stress and metabolic reprogramming, which has been independently used for targeted tumor monotherapy."

( Dai, Y; Jing, W; Man, S; Meng, X; Shen, Y; Wang, L; Yao, Y; Zhao, D; Zhao, N; Zhao, Y, 2023)

"Cancer is a grievous disease whose treatment requires a more efficient, non-invasive therapy, associated with minimal side effects."

( Abourehab, MAS; Chen, ZS; Fatima, M; Gupta, N; Kesharwani, P; Ma, R; Sang, L; Sheikh, A; Zhou, Y, 2023)

"Cancer is one of the major diseases that seriously endanger the health of all mankind."

( Chen, DH; Chen, JT; Hou, MJ; Li, CY; Li, Y; Mao, GJ; Tan, ZK; Wang, ZQ, 2023)

"Colorectal cancer is a highly prevalent malignancy that threatens human health worldwide."

( Cai, J; Feng, Y; Han, H; Li, S; Li, W; Tian, J; Zhang, X; Zhao, H; Zhu, W, 2023)

"Breast cancer is one of the most common cancers."

( Hadinedoushan, H; Tahoori, MT; Yavari, A; Zare, F, 2023)

"Cancer is one of the most expensive medical conditions to treat worldwide, affecting national and local spending, as well as household budgets for patients and their families."

( Yabroff, KR; Zhao, J, 2023)

"Cancer is one of the leading causes of death worldwide, and it is well known that an early detection of cancer in a human body will provide an opportunity to cure the cancer."

( Gollapalli, R; Paul, P; Phillips, J, 2023)

"Breast cancer is a significant public health problem globally and prevention strategies have become of great interest as its incidence rises."

( Chang, TM; Chu, CH; Dai, MS; Feng, AC; Fu, CY; Hong, ZJ; Hsu, HM; Hsu, KF; Liao, GS; Tsai, HH; Yu, JC, 2023)

"Cancer is one of the leading causes of death."

( ALaqeel, NK, 2023)

"Since cancer is a continuously increasing concern for the general population, more efficient treatment alternatives ought to be developed."

( Andronescu, E; Bîrcă, AC; Chircov, C; Dănciulescu, LA; Neacșu, IA; Oprea, OC; Trușcă, RD, 2023)

"Cancer is the world's leading cause of death and a key hindrance to extending life expectancy."

( Huang, J; Lai, W; Li, G; Liao, J; Liu, W; Wang, F; Xie, D; Xu, R; Zhang, R; Zhang, Z; Zhou, M, 2023)

"People with cancer are not exempt from the opioid epidemic and may be at risk for nonmedical opioid use (NMOU) and substance use disorders."

( Baiocchi, R; McLaughlin, EM; McNally, GA; Ridgway-Limle, E; Rosselet, R, 2023)

"CancerCare Manitoba (CCMB) introduced virtual visits at the beginning of the COVID-19 pandemic to replace many in-person visits."

( Czaykowski, P; Decker, K; Lambert, P; Musto, G; Thiessen, M, 2023)

"Breast cancer is not highly thrombogenic but is highly prevalent, resulting in increased VTE cases."

( Bucciol, R; Othman, M, 2023)

"Depression and cancer are both prevalent diseases worldwide."

( Dong, ZR; Li, T; Tan, SY; Wang, DX; Yan, LJ; Yan, YC; Yang, LS; Zhang, ZY, 2023)

"Cancer is a multifactorial disorder with extremely complex genetics and progression."

( Alanazi, AS; Alanazi, MM, 2023)

"Cancer is still a leading cause of deaths worldwide, especially due to those cases diagnosed at late stages with metastases that are still considered untreatable and are managed in such a way that a lengthy chronic state is achieved."

( Agaj, A; Bulog, A; Čolić, M; Kraljević Pavelić, S; Pavelić, K; Rojnić, B; Trivanović, D, 2023)

"Breast cancer is the most common tumor among women throughout the world."

( Chesney, MA; El-Amir, A; El-Baiomy, EM; Kassem, L; Sabry, NA; Wallston, KA, 2023)

"Cancer is one of the deadliest and most heterogeneous diseases."

( Alam, W; Aschner, M; Ghanbari, F; Hassani, S; Khan, H; Lotfi, M; Popović-Djordjević, J; Shahcheraghi, SH, 2023)

"Cancer is a leading cause of death globally and has been associated with Mycobacterium tuberculosis (Mtb)."

( Abdel-Aziz, LM; Abdel-Aziz, MM; El-Shanawani, AA; Elbaramawi, SS; Elbatreek, MH; Zawal, AG, 2023)

"Transmissible cancers are infectious parasitic clones that metastasize to new hosts, living past the death of the founder animal in which the cancer initiated."

( Arriagada, G; Beal, BF; Davis, BW; Garrett, FES; Giersch, RM; Goff, SP; Hart, SFM; Metzger, MJ; Ostrander, EA; Yonemitsu, MA, 2023)

"Cancers are complex, heterogeneous, dynamic and aggressive diseases exhibiting a series of characteristic biophysical traits which complement the original biological hallmarks of cancers favouring progressive growth, metastasis, and contributing to immune evasion and treatment resistance."

( Piazena, H; Vaupel, P, 2023)

"Cancer is one of the leading causes of death."

( Zhao, DF, 2023)

"Currently, cancer is one of the main research topics, due to its high incidence and drug resistance to existing anti-cancer drugs."

( Alhammadi, M; Aliya, S; Han, YK; Huh, YS; Lee, JH; Park, U; Tiwari, JN, 2023)

"Cancer is a complex and multifaceted disease with a high global incidence and mortality rate."

( Bardelčíková, A; Čižmáriková, M; Michalková, R; Mirossay, L; Mojžiš, J; Mojžišová, G; Zigová, M, 2023)

"Cancer is a major global public health problem with high morbidity."

( Bao, J; Ding, RB; Fu, Y; He, L; Qi, X; Tian, Y; Wang, X; Zhou, X, 2023)

"Cancer is a disease that is notoriously difficult to treat due its heterogeneous nature which makes it the deadliest disease in the developed world."

( Eskandari, N; Gentile, S, 2023)

"Cancer is one of the major causes of death worldwide affecting more than 19 million people."

( Bonilla-Vidal, L; Espina, M; García, ML; Gliszczyńska, A; Sánchez López, E; Souto, EB; Świtalska, M; Wietrzyk, J, 2023)

Context

Excerpt	Reference
"Renal cancer has been often treated by medroxyprogesterone acetate or testosterone propionate, with little success."	( Stoll, BA, 1979)
"At the same time, tumors have been shown to produce superoxide radicals."	( Buettner, GR; Oberley, LW, 1979)
"Liver neoplasms have been described in three strains of mice."	( Reuber, MD, 1979)
"Children with malignancy have a high incidence of pneumonia and pneumonitis and death is rare if the patient does not have terminal malignant disease."	( Eden, OB; Elton, R; Shaw, NJ, 1992)
"Cancer has been closely associated with human immunodeficiency virus (HIV) infection but this is less frequent in children."	( Aricò, M; Caselli, D; D'Argenio, P; Del Mistro, AR; DeMartino, M; Livadiotti, S; Santoro, N; Terragna, A, 1991)
"Cancers have a formidable capacity to develop resistance to a large and diverse array of chemical, biologic, and physical anti-neoplastic agents."	( Kerbel, RS, 1991)
"Other cancers have about the same-distribution."	( Alexander, JW; Bhat, G; Bolce, R; First, MR; Hariharan, S; Munda, R; Penn, I; Ryckman, F; Schroeder, T, 1991)
"Cancer has become a chronic disease for many patients."	( Ganz, PA, 1990)
"Studies on sporadic cancers have revealed a wide range of different oncogenes in which mutation or abnormal regulation is a cardinal factor leading to a neoplastic state."	( Evans, HJ, 1989)
"Superficial human tumors have been studied by MRS to characterize their 31P spectra, and to measure metabolic changes during therapy."	( Boska, MD; Karczmar, GS; Meyerhoff, DJ; Shine, N; Speder, A; Valone, F; Weiner, MW; Wilkinson, M, 1989)
"Patients with cancer have an increased incidence of thromboembolic disease and haemostatic abnormalities, and there is considerable evidence that the haemostatic system is involved in the growth and spread of malignant disease."	( Francis, JL, 1989)
"Liver cancers have been reported in users of androgenic anabolic steroids, and both hepatic cell adenomas and carcinomas have been associated with use of combined oral contraceptives."	( Thomas, DB, 1988)
"Studies on cancer have found increased risks of 5."	( Arundel, AV; Sterling, TD, 1986)
"Patients with liver neoplasms have a significantly lower stearic to oleic ratio (SI) in tumour (x = 0."	( Apostolov, K; Barker, W; Coutilno, J; Habib, NA; Hershman, M; Mentha, G; Thompson, A; Wood, CB, 1987)
"Human esophageal cancer has been epidemiologically associated with riboflavin deficiency, but the precise role of riboflavin in this tumor remains to be defined."	( Rivlin, RS, 1986)
"The pattern of cancers has not changed much since 1966 and the findings of the present study are very similar to the series from the Institute of Medical Research, Kuala Lumpur, in 1969 to 1971."	( Dawie Usop, AK, 1985)
"Cancer has a profound psychological impact upon the patient and his family, and the psychological responses, primarily of the patient himself, the close family, physician and nursing personnel, but also of the extended family, and society in general, become a complex interrelationship."	( Christakis, J; Manos, N, 1985)
"In females, breast cancer has the highest incidence followed by cancer of the cervix, leukaemia, and cancers of the ovary and thyroid."	( Jussawalla, DJ; Yeole, BB, 1985)
"IF typing of a few tumors has already led to a revision or reconsideration of the original light microscopic diagnosis."	( Osborn, M; Weber, K, 1983)
"Some tumors have a slow growth rate, with a few proliferating cells, while others grow faster and have higher proportions of proliferative cells (Charbit et al."	( Carlsson, J; Yuhas, JM, 1984)
"Four of these tumors have been tested in tissue culture for in vitro production of endocrine active substances."	( Arps, H; Dietel, M; Otto, U, 1984)
"While lung cancer has a greater excess in the Sudbury sinter plant than at Port Colborne, the reverse is true for mortality from nasal cancer, which is ten times more frequent at Port Colborne than at Sudbury."	( Julian, JA; Muir, DC; Roberts, RS; Shannon, HS, 1984)
"The study of human cancers has provided evidence that malignant progression is associated with genetic change."	( McMahon, G, 1994)
"Patients with cancer have an increased incidence of thrombosis and abnormal haemostasis detectable by sophisticated laboratory tests."	( Francis, DA; Francis, JL; Gunathilagan, GJ, 1994)
"Patients with cancer have inappropriately low levels of endogenous erythropoietin for the degree of anemia and further suppression of erythropoiesis results from chemotherapy."	( Thatcher, N, 1998)
"Although excess cancers have been found among workers in the smelting of aluminium, the exposure assessment methods in future studies need to be improved to better characterise possible causative agents."	( Abramson, M; Benke, G; Sim, M, 1998)
"Patients with cancer have diverse symptoms, impairments in physical and psychological functioning, and other difficulties that can undermine their quality of life."	( Lesage, P; Portenoy, RK, 1999)
"More than 180 human tumors have been reported to contain p53 with mutations within the region that encompasses T81 and the JNK binding site (amino acids 81 to 116)."	( Alarcon-Vargas, D; Bar-Shira, A; Buschmann, T; Fried, VA; Fuchs, SY; Gaarde, WA; Henderson, S; Holbrook, NJ; Ivanov, VN; Minamoto, T; Pincus, MR; Potapova, O; Ronai, Z; Shiloh, Y, 2001)
"Cancer has been described as a nitrogen trap."	( Medina, MA, 2001)
"The fact that most cancers have poor vascular systems has led cancer scientists to assume that such cells are deprived of a normal supply of oxygen."	( John, AP, 2001)
"Few true cancers have been reported for non-isogeneic members of Xenopus laevis, despite their widespread use in laboratories around the world."	( Clothier, RH; Johnson, RO; Ruben, LN; Taylor, SJ, 2003)
"The occurrence of cancer has been recently described by many investigators as an event that fulfills the DSM-IV criteria for a "traumatic event" that has been demonstrated in some cases to be linked with the subsequent development of PTSD."	( Yehuda, R, 2003)
"Cancers have developed numerous mechanisms for escaping the immune response, either by successfully evading a fully functional immune system or by actively suppressing the immune system so that they are no longer recognised or effectively eliminated."	( Blobe, GC; Kirkbride, KC, 2003)
"Patients with cancer have a substantial risk of recurrent thrombosis despite the use of oral anticoagulant therapy."	( Baker, RI; Bowden, C; Gent, M; Haley, S; Julian, JA; Kakkar, AK; Kovacs, MJ; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2003)
"Different tumors have different aberrations in signaling and growth stimulation pathways that drive cancer growth."	( Herbst, RS; Khuri, FR, 2003)
"Most cancers have an occupational, viral, nutritional, behavioral or iatrogenic etiology."	( Beaubier, J; Chiu, A; Chiu, N; Katz, AJ; Shi, X, 2004)
"While some types of cancer have been suppressed significantly, others are either stagnating or on the increase."	( Alleva, R; Birringer, M; Fariss, MW; Mellick, AS; Neuzil, J; Salvatore, BA; Tomasetti, M, 2004)
"Patients with malignancy have a prothrombotic state due to the ability of almost all type of cancer cells to activate the coagulation system."	( De Cicco, M, 2004)
"Cancer has a negative systemic impact on its host in addition to its local or metastatic effects, and no cancer complication is more ubiquitous than anaemia, a condition for which there is now a specific remedy, the recombinant growth factor erythropoietin."	( Spivak, JL, 2005)
"Where death from cancer has been studied, the focus has been mainly on psychological outcomes."	( Bond, JB; Daeninck, PJ; Dean, M; McClement, S; Nelson, F, 2005)
"Cancer has been reported to be more common among kidney transplant recipients than waiting-list patients or the general population."	( Alfaro, C; Arellano, EM; Burgos, FJ; Fernández, A; Galeano, C; Marcén, R; Ocaña, J; Ortuño, J; Pascual, J; Villafruela, JJ, 2006)
"While cases of malignancy have been reported in patients who have used pimecrolimus cream 1%, there is no clinical evidence to establish that treatment with pimecrolimus cream 1% increases the risk of malignancy."	( Cork, MJ; Langley, RG; Luger, TA; Paul, C; Schneider, D, 2007)
"SIRs from lung cancer have greatly diminished whereas bladder cancer SIRs remain elevated in all but one cohort."	( Gibbs, GW; Sevigny, M, 2007)
"Patients with cancer have an impaired T-cell response that can decrease the potential therapeutic benefit of cancer vaccines and other forms of immunotherapy."	( Ochoa, AC; Rodríguez, PC, 2008)
"The incidence of malignancy has been estimated at 20% after 10 years of chronic immunosuppression."	( Kapoor, A, 2008)
"Cancer has been shown to be an independent risk factor for the development of venous thromboembolism (VTE; deep vein thrombosis and pulmonary embolism)."	( Engman, CA; Zacharski, LR, 2008)
"Cancer has become a major problem in public health and the resulting bone metastases a worsening factor."	( Baslé, MF; Chappard, D; Cincu, C; Filmon, R; Nyangoga, H; Zecheru, T, 2009)
"Patients with malignancy have a 4-fold increase in the risk of developing a venous thrombosis and a 3-fold increase in risk of bleeding."	( Louzada, ML; Majeed, H; Wells, PS, 2009)
"These tumors have also responded well to boron neutron capture therapy."	( Johnson, A; Kabalka, GW; McCormack, MT; Miller, LF; Nichols, TL, 2009)
"Although cancers have altered glucose metabolism, termed the Warburg effect, which describes the increased uptake and conversion of glucose to lactate by cancer cells under adequate oxygen tension, changes in the metabolism of glutamine and fatty acid have also been documented."	( Dang, CV; Gao, P; Le, A, 2009)
"Epithelial tumors have been readily obtained by the implantation of embryo stomach tissue together with olive oil containing methylcholanthrene (with or without Scharlach R) in adult mice of homologous strain."	( Smith, WE, 1947)
"Cancer has become the number one cause of death amongst Americans, killing approximately 1,600 people per day."	( Brown, KC, 2010)
"A number of cancers have increased expression of Nampt/PBEF/visfatin, which regulates a variety of different signaling pathways such as PI3K/Akt, ERK1/2 and STAT3."	( Bi, TQ; Che, XM, 2010)
"Children with cancer have an increased susceptibility to influenza infection."	( Bate, J; Heath, PT; Hoschler, K; Miller, E; Morden, J; Sheasby, L; Taj, M; Yung, CF, 2010)
"Patients with cancer have an increased risk of VTE."	( Abletshauser, C; Bauersachs, R; Bramlage, P; Gerlach, HE; Haas, S; Melzer, N; Riess, H; Schellong, SM; Sieder, C; Tebbe, U, 2011)
"Cells of most human cancers have supernumerary centrosomes."	( Castiel, A; Cohen-Armon, M; Dantzer, F; Izraeli, S; Mittelman, L; Visochek, L, 2011)
"Many studies in cancer have identified alterations in the expression of proteins involved in the movement of Ca(2+) across the plasma membrane and subcellular organelles."	( Davis, FM; Monteith, GR; Roberts-Thomson, SJ, 2012)
"Patients with cancer have an impaired T cell response that can decrease the potential therapeutic benefit of cancer vaccines and other forms of immunotherapy."	( Ochoa, AC; Raber, P; Rodríguez, PC, 2012)
"Studies on HBO and cancer have up to recently focused on whether enhanced oxygen acts as a cancer promoter or not."	( Moen, I; Stuhr, LE, 2012)
"Cancer has become the leading cause of human death worldwide."	( He, Z; Luo, C; Sun, J; Wang, Y, 2013)
"The incidence of cancer has been rising steadily in the third world countries including India."	( Ganguly, S; Jana, U; Karmakar, R; Maiti, PK; Mitra, TN; Ray, A, 2012)
"Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cell lung cancer (NSCLC), and neuroblastoma."	( Adamson, PC; Ahern, C; Balis, FM; Blaney, SM; Ingle, AM; Laliberte, J; Lim, MS; Maris, JM; Mossé, YP; Rolland, D; Ruffner, K; Voss, SD; Weigel, BJ; Wilner, K, 2013)
"The incidence of cancer has been slowly declining in the developed countries, but increasing in the less developed and developing countries."	( Gangopadhyay, S; Maiti, PK, 2012)
"Patients with cancer have an increased risk for venous thrombosis."	( Geddings, JE; Mackman, N, 2013)
"Tumors have a greater reliance on anaerobic glycolysis for energy production than normal tissues."	( Arstad, E; Golay, X; Gonçalves, M; Johnson, SP; Lythgoe, MF; Parkes, HG; Pedley, RB; Rajkumar, V; Ramasawmy, R; Rega, M; Richardson, S; Thomas, DL; Torrealdea, F; Walker-Samuel, S, 2013)
"KDM4A-amplified tumors have increased copy gains for these same regions."	( Allis, CD; Black, JC; Cho, J; Daniels, DL; Dyson, NJ; Getz, G; Glass, K; Kim, J; Ladd, B; Lewis, PW; Manning, AL; Montagna, C; Murphy, N; Pineda, CM; Van Rechem, C; Whetstine, JR, 2013)
"Cancer has been a big challenge in the clinical research arena for many years."	( Chibber, S; Hassan, I; Naseem, I, 2013)
"Most malignant tumors have elevated levels of Tn, an O-GalNAc glycan."	( Bard, FA; Bard-Chapeau, EA; Chia, J; Clausen, H; Gill, DJ; Steentoft, C; Tham, KM; Wang, SC, 2013)
"The incidence of cancer has been increasing steadily in the developing world including India."	( Ganguly, S; Gayen, S; Pal, S; Purkait, R; Roy, BN; Samanta, T, 2012)
"Because many cancers have acquired mutations in DNA damage checkpoints or repair pathways, we hypothesized that these cancers may be susceptible to treatments that target compensatory pathways."	( Choi, K; Choi, Y; Fox, J; Hendrickson, EA; Kim, S; Li, L; Mejia, M; Muller, M; Myung, K; Oh, S; Ruangpradit, W; Saberi, A; Smith, S; Takeda, S; Wang, Y, 2014)
"Patients with cancer have an anabolic potential to be exploited early on in cachexia development."	( Chevalier, S; Winter, A, 2014)
"Several human tumors have been shown to have high levels of expression of OATP1B3 but not OATP1B1, the main transporter in liver cells."	( Daily, A; Moscow, JA; Niedermeyer, TH; Swiatecka-Hagenbruch, M, 2014)
"Cancers have dysfunctional redox regulation resulting in reactive oxygen species production, damaging both DNA and free dNTPs."	( Almlöf, I; Altun, M; Artursson, P; Axelsson, H; Baranczewski, P; Berglund, UW; Berntsson, RP; Bräutigam, L; Desroses, M; Djureinovic, T; Einarsdottir, BO; Eshtad, S; Evers, B; Gad, H; Gaugaz, FZ; Göktürk, C; Granelli, I; Gustafsson, R; Gustavsson, AL; Hagenkort, A; Häggblad, M; Hammarström, LG; Helleday, T; Henriksson, M; Höglund, A; Homan, EJ; Jacques, SA; Jacques-Cordonnier, MC; Jemth, AS; Jensen, AJ; Jeppsson, F; Johansson, F; Johansson, L; Kalderén, C; Koolmeister, T; Loseva, O; Lundbäck, T; Lundgren, B; Lundin, C; Martens, U; Nilsson, JA; Olofsson, R; Pham, T; Puigvert, JC; Saleh, A; Sanjiv, K; Schultz, N; Scobie, M; Stenmark, P; Ström, CE; Strömberg, K; Svensson, LM; Svensson, R; Vallin, KS; Vikingsson, S; Wallner, OA; Wiita, E, 2014)
"Because tumors have the added stress of hypoxia, the metabolic response to low oxygen may represent such a tumor-specific metabolic program."	( Denko, NC, 2014)
"Tumors have evolved numerous mechanisms by which they can escape from immune surveillance."	( Jia, ZH; Li, Z; Mao, XL; Meng, ZY; Tian, GF; Tian, J; Wu, ZZ; Yin, ZN; Zhang, HR; Zhang, LJ; Zhao, LQ, 2014)
"Patients with cancer have different immune profile in sepsis when compared with patients without cancer, as demonstrated for levels of cytokines, sTREM-1 and HMGB-1."	( Moura, AD; Pedroso, ÊR; Ravetti, CG; Teixeira, AL; Vieira, ÉL, 2015)
"Solid tumors have chaotic organization of blood vessels, disruptive nerve paths and muscle fibers that result in a hostile and heterogeneous microenvironment."	( Epel, B; Halpern, H; Kotecha, M; Majumdar, S; Triplett, W, 2014)
"Several types of tumors have abnormalities in arginine metabolism enzymes and completely rely on extracellular arginine to support necessary biological processes."	( Huang, J; Qiu, F; Sui, M, 2015)
"Cancers have been the leading cause of death worldwide and poor diet and physical inactivity are major risk factors in cancer-related deaths."	( Singh, S; Sunil Kumar, BV; Verma, R, 2017)
"Intriguingly, these cancers have changes in the global levels of the H3K27me2 and H3K27me3 modifications as well as genome-wide redistributions."	( Bracken, AP; Conway, E; Healy, E, 2015)
"The landscape of cancer has changed considerably in past several years, due mainly to aggressive screening, accumulation of data from basic and epidemiological studies, and the advances in translational research."	( Ahmad, A; Li, Y; Sarkar, FH, 2016)
"However, many tumors have developed adaptive mechanisms to circumvent the requirement for exogenous growth factors."	( Chen, Q; Chen, Y; Li, J; Li, X; Lin, Y; Ruan, Q; Wan, X; Yu, G; Zhang, G, 2016)
"In this context, cancer has become one of the most deadly diseases around the world, and despite many advances in theranostics techniques the treatment of cancer still remains an important problem."	( Augustine, S; Das, A; Malhotra, BD; Sharma, M; Singh, J; Srivastava, M, 2017)
"Cancers have increased threat to human health due to the limited treatment efficacy of chemotherapy and radiotherapy with a series of toxicity and side effects; therefore, the development and utilization of natural products with potential preventive and therapeutic efficacy, and less toxicity and side effects will be beneficial to promote the health of cancer patients."	( Chen, N; Fan, J; Kou, X, 2017)
"Therefore, cancer has been the main focus of recent research to uncover possible mitochondrial targets for therapeutic benefit."	( Dickerson, T; Jauregui, CE; Teng, Y, 2017)
"Given that many cancers have an environmental component, their occupational exposure to products of carbon combustion such as polycyclic aromatic hydrocarbons (PAHs) is of concern."	( Dickens, KE; Hewitt, FE; Houldsworth, PE; Martin, FL; Salden, M; Stec, AA; Watts, DP, 2018)
"Genomic analyses of cancer have identified recurrent point mutations in the RNA splicing factor-encoding genes SF3B1, U2AF1, and SRSF2 that confer an alteration of function."	( Abdel-Wahab, O; Agrawal, AA; Buonamici, S; Caleb, B; Chan, B; Csibi, A; Darman, R; Fekkes, P; Karr, C; Keaney, G; Klimek, V; Kumar, P; Lai, G; Lee, L; Lee, SC; Liu, X; Mackenzie, C; Meeske, C; Mizui, Y; Padron, E; Park, E; Pazolli, E; Peng, S; Prajapati, S; Sean, E; Seiler, M; Smith, PG; Taylor, J; Teng, T; Thomas, M; Wang, J; Warmuth, M; Yao, H; Yoshimi, A; Yu, L; Zhu, P, 2018)
"Breast cancer has led the way and endocrine agents used to treat it-notably tamoxifen and the aromatase inhibitors-have now been shown to have a substantial preventive effect as well."	( Cuzick, J, 2018)
"Information about cancer has to be delivered in an understandable form and to places where it reaches these communities."	( Berlin, J; Newton, P; Smith, D, 2018)
"Cancer has become an important public health issue in India."	( Keditsu, K; Meshram, N; Shankar, A; Srinivas, P; Thakur, R, 2018)
"Immunotherapy of cancer has finally materialized following the success of immune checkpoint blockade."	( Ohta, A, 2018)
"In recent years, cancer has become the most common human disease worldwide, and great attentions have been paid to clarifying the carcinogenesis and identifying new effective antitumor therapy."	( Sun, X; Yan, P, 2018)
"Patients whose tumors have genetic, metabolic, or imaging biomarker evidence of glutamine dependence should be prioritized as candidates for future clinical evaluations of novel DON prodrugs, given either as monotherapy or in rationally directed pharmacologic combinations."	( Lemberg, KM; Rais, R; Slusher, BS; Vornov, JJ, 2018)
"Cancer has been a significant threat to human health with more than eight million deaths each year in the world."	( Crawford, BM; Liu, Y; Vo-Dinh, T, 2018)
"Cancer has become the leading cause of death in many countries."	( Andersen, MØ; Arnspang, EC; Code, C; Notabi, MK; Popova, P, 2019)
"Tumors have evolved a variety of methods to reprogram conventional metabolic pathways to favor their own nutritional needs, including glutaminolysis, the first step of which is the hydrolysis of glutamine to glutamate by the amidohydrolase glutaminase 1 (GLS1)."	( Anderton, M; Bailey, A; Boyd, S; Brookfield, J; Cairnduff, C; Charles, M; Cheasty, A; Critchlow, SE; Culshaw, J; Ekwuru, T; Finlay, MRV; Hollingsworth, I; Jones, N; Leroux, F; Littleson, M; McCarron, H; McKelvie, J; Mooney, L; Nissink, JWM; Perkins, D; Powell, S; Quesada, MJ; Raubo, P; Sabin, V; Smith, J; Smith, PD; Stark, A; Ting, A; Wang, P; Wilson, Z; Winter-Holt, JJ; Wood, JM; Wrigley, GL; Yu, G; Zhang, P, 2019)
"We conclude that cancer has been recognized in India since antiquity."	( Mallath, MK; Smith, RD, 2019)
"Most people with cancer have a combination of treatments, such as surgery with chemotherapy and/or radiation therapy."	( Abdul Aziz, SA; Ismail, F; Lew, YL; Mohamed Shah, N, 2021)
"While research in cancer has largely focused on the neoplasm/tumor and the cancerous cells that make up the tumor, more recently, the existence, proliferation, differentiation, migration and invasion of cancer stem cells (CSCs) and the role that CSCs play in tumor initiation, progression, metastasis, drug resistance and relapse/recurrence of the disease has gained widespread interest in cancer research."	( Büsselberg, D; Samuel, SM; Satheesh, NJ, 2020)
"Chelating Cu from tumors has been verified as an effective and promising strategy for cancer therapy through antiangiogenesis."	( Chen, H; Chen, Q; Chu, Y; Guo, Q; Guo, Z; Jiang, C; Jiang, L; Li, C; Liu, P; Sun, T; Yu, H; Zhang, G; Zhang, Y; Zhou, W, 2020)
"Both these cancers have several risk factors, among which the claimed exposure presents only a minor, if any, increased risk."	( Dragani, TA, 2020)
"Liver cancer has become the third type of cancer that causes death; this is why the design of new chemotherapeutic drugs against this disease is a major need."	( Belhassan, A; Benlyas, M; Bouachrine, M; Lakhlifi, T; Zaki, H, 2021)
"In recent decades, cancer has been one of the leading causes of death worldwide."	( Ho, CT; Lai, CS; Pan, MH, 2020)
"Cancer has the ability to escape the immune system using different molecular actors."	( Cadassou, O; Cros-Perrial, E; Jordheim, LP; Strakhova, R, 2020)
"Tumors have increasingly been a spotlight because of their terrible trends and refractory characteristic."	( Lu, L; Tian, C; Tuo, Y; Xiang, M, 2020)
"Paradoxically, many cancers have increased dependency on NAD+."	( Allison, SJ; Griffiths, HBS; King, SJ; Williams, C, 2020)
"A number of cancers have been associated with inflammatory processes."	( Iqbal, A; Marszałek, K; Miękus, N; Podlacha, M; Puchalski, C; Świergiel, AH, 2020)
"Solid tumors have abnormal microcirculation that limits oxygen delivery and leads to a hypoxic tumor microenvironment."	( Spiess, BD, 2020)
"Cancer has been the second heath killer being next only to cardiovascular diseases in human society."	( Gao, H; Long, J; Tang, Z; Wan, Y, 2021)
"For their part, cancers have evolved to create conditions around their cells that eliminate their active apoptotic forms."	( Tsanov, H; Tsanov, V, 2021)
"Treatment of cancers has always been a challenge for physicians."	( Ala, M, 2021)
"Patients with cancer have played a key role in advocating for legal access to cannabis, but little is known about links between cancer and cannabis use or cannabis-related beliefs."	( Coughlin, LN; Cousins, MM; Ilgen, MA; Jagsi, R; Jannausch, ML, 2021)
"If, however, those cancers have functional GABA receptors that participate in GABAergic signaling, it raises an important question whether these signaling pathways might be targetable for therapeutic benefit."	( Bhattacharya, D; Gawali, VS; Kallay, L; Koehler, A; Krummel, DP; Sengupta, S; Stambrook, P; Toukam, DK, 2021)
"Cancer has become a serious disease threatening human health."	( Abu-Serie, MM; El Fawal, G; Mo, X; Wang, H, 2021)
"Cancer has become one of the main reasons for human death in recent years."	( Aramesh, N; Bagheri, AR; Bilal, M; Kim, HW; Xiao, J; Yan, B, 2021)
"Many neoplasms have been shown to have over activated Nrf2, strongly suggesting that it is responsible for tumors with a poor prognosis."	( Alam, W; Ayatollahi, J; Khan, H; Peirovi, N; Salemi, F; Saso, L; Shahcheraghi, SH, 2021)
"Breast cancer has strong developmental origins and maternal nutrition composition may influence later-life breast cancer risk in the offspring."	( Chen, M; Li, S; Li, Y; Li, Z; Sharma, M; Srinivasasainagendra, V; Tiwari, H; Tollefsbol, TO, 2022)
"Patients with cancer have a higher risk of renal dysfunction, which may be associated with increased risks of thrombotic or bleeding complications."	( Carrier, M; Mallick, R; Wang, TF; Wells, PS, 2022)
"Cancer has been one of the leading causes of death in India in the past decade."	( Bhadelia, A, 2021)
"Many cancers have an unusual dependence on glutamine."	( Alexander, PB; Li, QJ; Liang, Y; Mudgal, P; Pan, C; Qin, D; Tan, L; Thompson, JW; Wan, Y; Wang, XF; Wang, Y; Wu, H; Yin, T; Yuan, L, 2022)
"Cancer has long been considered a genetic disease characterized by a myriad of mutations that drive cancer progression."	( Choi, J; Gyamfi, J; Kim, J, 2022)
"The incidence of cancer has been increasing worldwide."	( Das, U; Dimmock, JR; Okudaira, N; Roayapalley, PK; Sakagami, H; Sharma, RK, 2022)
"Cancer has been identified as one of the leading causes of death worldwide."	( Alonso, C; Martín-Encinas, E; Palacios, F; Selas, A, 2022)
"Many tumors have increased sialic acid incorporation."	( Belmonte, P; Dong, H; Friedman, DJ; Kim Lee, HS; Kizerwetter, M; Rajcula, M; Shapiro, MJ; Shapiro, VS; Theodore, K, 2022)
"Accordingly, many cancers have been documented to silence expression of the ISYNA1 gene, which encodes the rate-limiting enzyme of inositol synthesis."	( Case, KC; Greenberg, ML; Schmidtke, MW, 2022)
"Cancer has become one of the leading causes of death worldwide."	( Gong, X; Guo, Y; Li, Y; Shi, L; Xu, J; Zhang, S, 2022)
"Tumors have a series of clinical biological signs with the following five main features: postoperative pain and cancerous pain; suppression of antitumor immunity; angiogenesis in tumors; proliferation, growth and metastasis of tumors; and mental depression."	( Chen, Q; Chen, S; Deng, S; Hu, P; Hu, X; Ling, C; Liu, X; Luo, B; Qiu, L; Wu, Q; Yuan, M, 2022)
"Tumors have developed the ability to survive at elevated ROS levels with significantly higher H2O2 levels than normal tissues."	( Amaldoss, MJN; Sorrell, CC, 2022)
"Since cancer has emerged as one of the most serious threats to human health, the highly sensitive determination of cancer cells is of significant importance to improve the accuracy of early clinical diagnosis."	( Lin, X; Qian, C; Sohan, ASMMF; Sun, X; Wan, X; Yin, B; Yue, W; Zeng, S, 2022)
"Cancer has presented to be the most challenging disease, contributing to one in six mortalities worldwide."	( Guha, S; Hazarika, S; Sivalingam, N; Sritharan, S, 2022)
"Tumors have long been known to rewire their metabolism to endorse their proliferation, growth, survival, and invasiveness."	( Bononi, G; Di Bussolo, V; Granchi, C; Masoni, S; Minutolo, F; Tuccinardi, T, 2022)
"Cancer has been recognized as one of the non-communicable diseases with an increasing number of new cases, higher morbidity, and higher mortality rates at the global level."	( Kaur, N; Kumar, D; Kumar, V; Sahu, S; Sharma, A; Sharma, V; Wadhwa, P, 2023)
"The incidence of cancer has been growing worldwide."	( Ansari, MJ; Jafarzadeh, E; Jalil, AT; Jawad, MA; Moslehi, M; Najafi, M; Rastegar-Pouyani, N; Rezaei, S; Taeb, S; Talebzadeh, P, 2023)
"Cancer has become a major challenge in the global disease burden."	( Cui, W; Li, B; Liu, L; Liu, S; Yan, F; Yan, S, 2022)
"Multiple cancers have been reported to be associated with angiogenesis and are sensitive to anti-angiogenic therapies."	( Chen, H; Gao, X; Li, J; Li, Y; Liu, J; Liu, P; Ren, Y; Song, S; Wang, B; Wang, H; Wang, R; Wang, Y; Zhang, M, 2023)
"Children with cancer have an increased risk for developing a venous thromboembolism (VTE) during their treatment course."	( Branchford, B; Liegl, M; Malec, L; Scheuermann, A; Simpson, P, 2023)
"Patients with cancer have increased risks of venous and arterial thromboembolism and/or atrial fibrillation, for which anticoagulation is commonly used."	( Wang, TF, 2022)
"Patients with cancer have a high risk of recurrent VTE and bleeding."	( Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Yamashita, A, 2023)
"Cancer has been a major health problem in the world in the past decades."	( Chen, D; Chen, L; Gu, Z; He, B; Li, Y; Lin, S; Yan, W; Zeng, Z, 2022)
"Patients with cancer have been reported to show elevated plasma concentrations of vitamin B12, thus causing uncertainties regarding safety of vitamin B12."	( Obeid, R, 2022)
"Cancer has recently increased the death toll worldwide owing to inadequate therapy and decreased drug bioavailability."	( Alalikhan, A; Hashemian, P; Hashemzadeh, A; Javid, H; Karimi-Shahri, M, 2023)
"Lactate in tumors has long been considered "metabolic junk" derived from the glycolysis of cancer cells and utilized only as a biomarker of malignancy, but is presently believed to be a pivotal regulator of tumor development, maintenance and metastasis."	( Chen, J; Shi, J; Wu, C; Zhu, Y, 2023)
"Patients with malignancy have higher risk of developing venous thromboembolism."	( Bodnar, L; Bodnar, P; Bodnar, T; Bodnar, Y; Klishch, I, 2022)
"Cancer has been considered as complex malignant consequence of genetic mutations that control the cellular proliferation, differentiation and homeostasis, thus making tumor treatment extremely challenging."	( Guo, Q; Meng, Y; Qiu, C; Shi, Q; Wang, C; Wang, J; Wu, Y; Xia, F; Xu, C; Zhang, J, 2023)
"Cancer has remained to be one of the major challenges in medicine and regarded as the second leading cause of death worldwide."	( AliAshrafzadeh, H; Jafarzadeh, E; Khodamoradi, E; Moazamiyanfar, R; Mouludi, K; Najafi, M; Rastegar-Pouyani, N; Rezaei, S; Taeb, S; Zhaleh, M, 2023)
"Tumors have considerable cellular heterogeneity that is impossible to explore with simple cell cultures."	( Beller, NC; Hummon, AB; Wang, Y, 2023)
"Cancer has become the primary cause of death worldwide, and anticancer drugs are used to combat this disease."	( Ahmad, FB; Woon, CK; Zamakshshari, NH, 2023)
"Solid tumors have developed robust ferroptosis resistance."	( Guan, Q; Qin, C; Qu, S; Su, W; Wang, Y; Wei, X; Xiang, J; Yang, Z; Yao, B; Zen, K; Zhao, D; Zhou, J, 2023)
"Malignant tumors have a unique tumor microenvironment (TME), which includes mild acidity, hypoxia, overexpressed reactive oxygen species (ROS), and high glutathione (GSH) levels, among others."	( Chen, L; Wang, Y; Yang, R; Yang, Y; Zhang, L; Zheng, X; Zhu, Y, 2023)
"Cancer has always posed a significant threat to human health, prompting extensive research into new treatment strategies due to the limitations of traditional therapies."	( Fu, Y; Li, W; Sun, J; Wang, Y, 2023)

Excerpt

Reference

"Renal cancer has been often treated by medroxyprogesterone acetate or testosterone propionate, with little success."

( Stoll, BA, 1979)

"At the same time, tumors have been shown to produce superoxide radicals."

( Buettner, GR; Oberley, LW, 1979)

"Liver neoplasms have been described in three strains of mice."

( Reuber, MD, 1979)

"Children with malignancy have a high incidence of pneumonia and pneumonitis and death is rare if the patient does not have terminal malignant disease."

( Eden, OB; Elton, R; Shaw, NJ, 1992)

"Cancer has been closely associated with human immunodeficiency virus (HIV) infection but this is less frequent in children."

( Aricò, M; Caselli, D; D'Argenio, P; Del Mistro, AR; DeMartino, M; Livadiotti, S; Santoro, N; Terragna, A, 1991)

"Cancers have a formidable capacity to develop resistance to a large and diverse array of chemical, biologic, and physical anti-neoplastic agents."

( Kerbel, RS, 1991)

"Other cancers have about the same-distribution."

( Alexander, JW; Bhat, G; Bolce, R; First, MR; Hariharan, S; Munda, R; Penn, I; Ryckman, F; Schroeder, T, 1991)

"Cancer has become a chronic disease for many patients."

( Ganz, PA, 1990)

"Studies on sporadic cancers have revealed a wide range of different oncogenes in which mutation or abnormal regulation is a cardinal factor leading to a neoplastic state."

( Evans, HJ, 1989)

"Superficial human tumors have been studied by MRS to characterize their 31P spectra, and to measure metabolic changes during therapy."

( Boska, MD; Karczmar, GS; Meyerhoff, DJ; Shine, N; Speder, A; Valone, F; Weiner, MW; Wilkinson, M, 1989)

"Patients with cancer have an increased incidence of thromboembolic disease and haemostatic abnormalities, and there is considerable evidence that the haemostatic system is involved in the growth and spread of malignant disease."

( Francis, JL, 1989)

"Liver cancers have been reported in users of androgenic anabolic steroids, and both hepatic cell adenomas and carcinomas have been associated with use of combined oral contraceptives."

( Thomas, DB, 1988)

"Studies on cancer have found increased risks of 5."

( Arundel, AV; Sterling, TD, 1986)

"Patients with liver neoplasms have a significantly lower stearic to oleic ratio (SI) in tumour (x = 0."

( Apostolov, K; Barker, W; Coutilno, J; Habib, NA; Hershman, M; Mentha, G; Thompson, A; Wood, CB, 1987)

"Human esophageal cancer has been epidemiologically associated with riboflavin deficiency, but the precise role of riboflavin in this tumor remains to be defined."

( Rivlin, RS, 1986)

"The pattern of cancers has not changed much since 1966 and the findings of the present study are very similar to the series from the Institute of Medical Research, Kuala Lumpur, in 1969 to 1971."

( Dawie Usop, AK, 1985)

"Cancer has a profound psychological impact upon the patient and his family, and the psychological responses, primarily of the patient himself, the close family, physician and nursing personnel, but also of the extended family, and society in general, become a complex interrelationship."

( Christakis, J; Manos, N, 1985)

"In females, breast cancer has the highest incidence followed by cancer of the cervix, leukaemia, and cancers of the ovary and thyroid."

( Jussawalla, DJ; Yeole, BB, 1985)

"IF typing of a few tumors has already led to a revision or reconsideration of the original light microscopic diagnosis."

( Osborn, M; Weber, K, 1983)

"Some tumors have a slow growth rate, with a few proliferating cells, while others grow faster and have higher proportions of proliferative cells (Charbit et al."

( Carlsson, J; Yuhas, JM, 1984)

"Four of these tumors have been tested in tissue culture for in vitro production of endocrine active substances."

( Arps, H; Dietel, M; Otto, U, 1984)

"While lung cancer has a greater excess in the Sudbury sinter plant than at Port Colborne, the reverse is true for mortality from nasal cancer, which is ten times more frequent at Port Colborne than at Sudbury."

( Julian, JA; Muir, DC; Roberts, RS; Shannon, HS, 1984)

"The study of human cancers has provided evidence that malignant progression is associated with genetic change."

( McMahon, G, 1994)

"Patients with cancer have an increased incidence of thrombosis and abnormal haemostasis detectable by sophisticated laboratory tests."

( Francis, DA; Francis, JL; Gunathilagan, GJ, 1994)

"Patients with cancer have inappropriately low levels of endogenous erythropoietin for the degree of anemia and further suppression of erythropoiesis results from chemotherapy."

( Thatcher, N, 1998)

"Although excess cancers have been found among workers in the smelting of aluminium, the exposure assessment methods in future studies need to be improved to better characterise possible causative agents."

( Abramson, M; Benke, G; Sim, M, 1998)

"Patients with cancer have diverse symptoms, impairments in physical and psychological functioning, and other difficulties that can undermine their quality of life."

( Lesage, P; Portenoy, RK, 1999)

"More than 180 human tumors have been reported to contain p53 with mutations within the region that encompasses T81 and the JNK binding site (amino acids 81 to 116)."

( Alarcon-Vargas, D; Bar-Shira, A; Buschmann, T; Fried, VA; Fuchs, SY; Gaarde, WA; Henderson, S; Holbrook, NJ; Ivanov, VN; Minamoto, T; Pincus, MR; Potapova, O; Ronai, Z; Shiloh, Y, 2001)

"Cancer has been described as a nitrogen trap."

( Medina, MA, 2001)

"The fact that most cancers have poor vascular systems has led cancer scientists to assume that such cells are deprived of a normal supply of oxygen."

( John, AP, 2001)

"Few true cancers have been reported for non-isogeneic members of Xenopus laevis, despite their widespread use in laboratories around the world."

( Clothier, RH; Johnson, RO; Ruben, LN; Taylor, SJ, 2003)

"The occurrence of cancer has been recently described by many investigators as an event that fulfills the DSM-IV criteria for a "traumatic event" that has been demonstrated in some cases to be linked with the subsequent development of PTSD."

( Yehuda, R, 2003)

"Cancers have developed numerous mechanisms for escaping the immune response, either by successfully evading a fully functional immune system or by actively suppressing the immune system so that they are no longer recognised or effectively eliminated."

( Blobe, GC; Kirkbride, KC, 2003)

"Patients with cancer have a substantial risk of recurrent thrombosis despite the use of oral anticoagulant therapy."

( Baker, RI; Bowden, C; Gent, M; Haley, S; Julian, JA; Kakkar, AK; Kovacs, MJ; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2003)

"Different tumors have different aberrations in signaling and growth stimulation pathways that drive cancer growth."

( Herbst, RS; Khuri, FR, 2003)

"Most cancers have an occupational, viral, nutritional, behavioral or iatrogenic etiology."

( Beaubier, J; Chiu, A; Chiu, N; Katz, AJ; Shi, X, 2004)

"While some types of cancer have been suppressed significantly, others are either stagnating or on the increase."

( Alleva, R; Birringer, M; Fariss, MW; Mellick, AS; Neuzil, J; Salvatore, BA; Tomasetti, M, 2004)

"Patients with malignancy have a prothrombotic state due to the ability of almost all type of cancer cells to activate the coagulation system."

( De Cicco, M, 2004)

"Cancer has a negative systemic impact on its host in addition to its local or metastatic effects, and no cancer complication is more ubiquitous than anaemia, a condition for which there is now a specific remedy, the recombinant growth factor erythropoietin."

( Spivak, JL, 2005)

"Where death from cancer has been studied, the focus has been mainly on psychological outcomes."

( Bond, JB; Daeninck, PJ; Dean, M; McClement, S; Nelson, F, 2005)

"Cancer has been reported to be more common among kidney transplant recipients than waiting-list patients or the general population."

( Alfaro, C; Arellano, EM; Burgos, FJ; Fernández, A; Galeano, C; Marcén, R; Ocaña, J; Ortuño, J; Pascual, J; Villafruela, JJ, 2006)

"While cases of malignancy have been reported in patients who have used pimecrolimus cream 1%, there is no clinical evidence to establish that treatment with pimecrolimus cream 1% increases the risk of malignancy."

( Cork, MJ; Langley, RG; Luger, TA; Paul, C; Schneider, D, 2007)

"SIRs from lung cancer have greatly diminished whereas bladder cancer SIRs remain elevated in all but one cohort."

( Gibbs, GW; Sevigny, M, 2007)

"Patients with cancer have an impaired T-cell response that can decrease the potential therapeutic benefit of cancer vaccines and other forms of immunotherapy."

( Ochoa, AC; Rodríguez, PC, 2008)

"The incidence of malignancy has been estimated at 20% after 10 years of chronic immunosuppression."

( Kapoor, A, 2008)

"Cancer has been shown to be an independent risk factor for the development of venous thromboembolism (VTE; deep vein thrombosis and pulmonary embolism)."

( Engman, CA; Zacharski, LR, 2008)

"Cancer has become a major problem in public health and the resulting bone metastases a worsening factor."

( Baslé, MF; Chappard, D; Cincu, C; Filmon, R; Nyangoga, H; Zecheru, T, 2009)

"Patients with malignancy have a 4-fold increase in the risk of developing a venous thrombosis and a 3-fold increase in risk of bleeding."

( Louzada, ML; Majeed, H; Wells, PS, 2009)

"These tumors have also responded well to boron neutron capture therapy."

( Johnson, A; Kabalka, GW; McCormack, MT; Miller, LF; Nichols, TL, 2009)

"Although cancers have altered glucose metabolism, termed the Warburg effect, which describes the increased uptake and conversion of glucose to lactate by cancer cells under adequate oxygen tension, changes in the metabolism of glutamine and fatty acid have also been documented."

( Dang, CV; Gao, P; Le, A, 2009)

"Epithelial tumors have been readily obtained by the implantation of embryo stomach tissue together with olive oil containing methylcholanthrene (with or without Scharlach R) in adult mice of homologous strain."

( Smith, WE, 1947)

"Cancer has become the number one cause of death amongst Americans, killing approximately 1,600 people per day."

( Brown, KC, 2010)

"A number of cancers have increased expression of Nampt/PBEF/visfatin, which regulates a variety of different signaling pathways such as PI3K/Akt, ERK1/2 and STAT3."

( Bi, TQ; Che, XM, 2010)

"Children with cancer have an increased susceptibility to influenza infection."

( Bate, J; Heath, PT; Hoschler, K; Miller, E; Morden, J; Sheasby, L; Taj, M; Yung, CF, 2010)

"Patients with cancer have an increased risk of VTE."

( Abletshauser, C; Bauersachs, R; Bramlage, P; Gerlach, HE; Haas, S; Melzer, N; Riess, H; Schellong, SM; Sieder, C; Tebbe, U, 2011)

"Cells of most human cancers have supernumerary centrosomes."

( Castiel, A; Cohen-Armon, M; Dantzer, F; Izraeli, S; Mittelman, L; Visochek, L, 2011)

"Many studies in cancer have identified alterations in the expression of proteins involved in the movement of Ca(2+) across the plasma membrane and subcellular organelles."

( Davis, FM; Monteith, GR; Roberts-Thomson, SJ, 2012)

"Patients with cancer have an impaired T cell response that can decrease the potential therapeutic benefit of cancer vaccines and other forms of immunotherapy."

( Ochoa, AC; Raber, P; Rodríguez, PC, 2012)

"Studies on HBO and cancer have up to recently focused on whether enhanced oxygen acts as a cancer promoter or not."

( Moen, I; Stuhr, LE, 2012)

"Cancer has become the leading cause of human death worldwide."

( He, Z; Luo, C; Sun, J; Wang, Y, 2013)

"The incidence of cancer has been rising steadily in the third world countries including India."

( Ganguly, S; Jana, U; Karmakar, R; Maiti, PK; Mitra, TN; Ray, A, 2012)

"Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cell lung cancer (NSCLC), and neuroblastoma."

( Adamson, PC; Ahern, C; Balis, FM; Blaney, SM; Ingle, AM; Laliberte, J; Lim, MS; Maris, JM; Mossé, YP; Rolland, D; Ruffner, K; Voss, SD; Weigel, BJ; Wilner, K, 2013)

"The incidence of cancer has been slowly declining in the developed countries, but increasing in the less developed and developing countries."

( Gangopadhyay, S; Maiti, PK, 2012)

"Patients with cancer have an increased risk for venous thrombosis."

( Geddings, JE; Mackman, N, 2013)

"Tumors have a greater reliance on anaerobic glycolysis for energy production than normal tissues."

( Arstad, E; Golay, X; Gonçalves, M; Johnson, SP; Lythgoe, MF; Parkes, HG; Pedley, RB; Rajkumar, V; Ramasawmy, R; Rega, M; Richardson, S; Thomas, DL; Torrealdea, F; Walker-Samuel, S, 2013)

"KDM4A-amplified tumors have increased copy gains for these same regions."

( Allis, CD; Black, JC; Cho, J; Daniels, DL; Dyson, NJ; Getz, G; Glass, K; Kim, J; Ladd, B; Lewis, PW; Manning, AL; Montagna, C; Murphy, N; Pineda, CM; Van Rechem, C; Whetstine, JR, 2013)

"Cancer has been a big challenge in the clinical research arena for many years."

( Chibber, S; Hassan, I; Naseem, I, 2013)

"Most malignant tumors have elevated levels of Tn, an O-GalNAc glycan."

( Bard, FA; Bard-Chapeau, EA; Chia, J; Clausen, H; Gill, DJ; Steentoft, C; Tham, KM; Wang, SC, 2013)

"The incidence of cancer has been increasing steadily in the developing world including India."

( Ganguly, S; Gayen, S; Pal, S; Purkait, R; Roy, BN; Samanta, T, 2012)

"Because many cancers have acquired mutations in DNA damage checkpoints or repair pathways, we hypothesized that these cancers may be susceptible to treatments that target compensatory pathways."

( Choi, K; Choi, Y; Fox, J; Hendrickson, EA; Kim, S; Li, L; Mejia, M; Muller, M; Myung, K; Oh, S; Ruangpradit, W; Saberi, A; Smith, S; Takeda, S; Wang, Y, 2014)

"Patients with cancer have an anabolic potential to be exploited early on in cachexia development."

( Chevalier, S; Winter, A, 2014)

"Several human tumors have been shown to have high levels of expression of OATP1B3 but not OATP1B1, the main transporter in liver cells."

( Daily, A; Moscow, JA; Niedermeyer, TH; Swiatecka-Hagenbruch, M, 2014)

"Cancers have dysfunctional redox regulation resulting in reactive oxygen species production, damaging both DNA and free dNTPs."

( Almlöf, I; Altun, M; Artursson, P; Axelsson, H; Baranczewski, P; Berglund, UW; Berntsson, RP; Bräutigam, L; Desroses, M; Djureinovic, T; Einarsdottir, BO; Eshtad, S; Evers, B; Gad, H; Gaugaz, FZ; Göktürk, C; Granelli, I; Gustafsson, R; Gustavsson, AL; Hagenkort, A; Häggblad, M; Hammarström, LG; Helleday, T; Henriksson, M; Höglund, A; Homan, EJ; Jacques, SA; Jacques-Cordonnier, MC; Jemth, AS; Jensen, AJ; Jeppsson, F; Johansson, F; Johansson, L; Kalderén, C; Koolmeister, T; Loseva, O; Lundbäck, T; Lundgren, B; Lundin, C; Martens, U; Nilsson, JA; Olofsson, R; Pham, T; Puigvert, JC; Saleh, A; Sanjiv, K; Schultz, N; Scobie, M; Stenmark, P; Ström, CE; Strömberg, K; Svensson, LM; Svensson, R; Vallin, KS; Vikingsson, S; Wallner, OA; Wiita, E, 2014)

"Because tumors have the added stress of hypoxia, the metabolic response to low oxygen may represent such a tumor-specific metabolic program."

( Denko, NC, 2014)

"Tumors have evolved numerous mechanisms by which they can escape from immune surveillance."

( Jia, ZH; Li, Z; Mao, XL; Meng, ZY; Tian, GF; Tian, J; Wu, ZZ; Yin, ZN; Zhang, HR; Zhang, LJ; Zhao, LQ, 2014)

"Patients with cancer have different immune profile in sepsis when compared with patients without cancer, as demonstrated for levels of cytokines, sTREM-1 and HMGB-1."

( Moura, AD; Pedroso, ÊR; Ravetti, CG; Teixeira, AL; Vieira, ÉL, 2015)

"Solid tumors have chaotic organization of blood vessels, disruptive nerve paths and muscle fibers that result in a hostile and heterogeneous microenvironment."

( Epel, B; Halpern, H; Kotecha, M; Majumdar, S; Triplett, W, 2014)

"Several types of tumors have abnormalities in arginine metabolism enzymes and completely rely on extracellular arginine to support necessary biological processes."

( Huang, J; Qiu, F; Sui, M, 2015)

"Cancers have been the leading cause of death worldwide and poor diet and physical inactivity are major risk factors in cancer-related deaths."

( Singh, S; Sunil Kumar, BV; Verma, R, 2017)

"Intriguingly, these cancers have changes in the global levels of the H3K27me2 and H3K27me3 modifications as well as genome-wide redistributions."

( Bracken, AP; Conway, E; Healy, E, 2015)

"The landscape of cancer has changed considerably in past several years, due mainly to aggressive screening, accumulation of data from basic and epidemiological studies, and the advances in translational research."

( Ahmad, A; Li, Y; Sarkar, FH, 2016)

"However, many tumors have developed adaptive mechanisms to circumvent the requirement for exogenous growth factors."

( Chen, Q; Chen, Y; Li, J; Li, X; Lin, Y; Ruan, Q; Wan, X; Yu, G; Zhang, G, 2016)

"In this context, cancer has become one of the most deadly diseases around the world, and despite many advances in theranostics techniques the treatment of cancer still remains an important problem."

( Augustine, S; Das, A; Malhotra, BD; Sharma, M; Singh, J; Srivastava, M, 2017)

"Cancers have increased threat to human health due to the limited treatment efficacy of chemotherapy and radiotherapy with a series of toxicity and side effects; therefore, the development and utilization of natural products with potential preventive and therapeutic efficacy, and less toxicity and side effects will be beneficial to promote the health of cancer patients."

( Chen, N; Fan, J; Kou, X, 2017)

"Therefore, cancer has been the main focus of recent research to uncover possible mitochondrial targets for therapeutic benefit."

( Dickerson, T; Jauregui, CE; Teng, Y, 2017)

"Given that many cancers have an environmental component, their occupational exposure to products of carbon combustion such as polycyclic aromatic hydrocarbons (PAHs) is of concern."

( Dickens, KE; Hewitt, FE; Houldsworth, PE; Martin, FL; Salden, M; Stec, AA; Watts, DP, 2018)

"Genomic analyses of cancer have identified recurrent point mutations in the RNA splicing factor-encoding genes SF3B1, U2AF1, and SRSF2 that confer an alteration of function."

( Abdel-Wahab, O; Agrawal, AA; Buonamici, S; Caleb, B; Chan, B; Csibi, A; Darman, R; Fekkes, P; Karr, C; Keaney, G; Klimek, V; Kumar, P; Lai, G; Lee, L; Lee, SC; Liu, X; Mackenzie, C; Meeske, C; Mizui, Y; Padron, E; Park, E; Pazolli, E; Peng, S; Prajapati, S; Sean, E; Seiler, M; Smith, PG; Taylor, J; Teng, T; Thomas, M; Wang, J; Warmuth, M; Yao, H; Yoshimi, A; Yu, L; Zhu, P, 2018)

"Breast cancer has led the way and endocrine agents used to treat it-notably tamoxifen and the aromatase inhibitors-have now been shown to have a substantial preventive effect as well."

( Cuzick, J, 2018)

"Information about cancer has to be delivered in an understandable form and to places where it reaches these communities."

( Berlin, J; Newton, P; Smith, D, 2018)

"Cancer has become an important public health issue in India."

( Keditsu, K; Meshram, N; Shankar, A; Srinivas, P; Thakur, R, 2018)

"Immunotherapy of cancer has finally materialized following the success of immune checkpoint blockade."

( Ohta, A, 2018)

"In recent years, cancer has become the most common human disease worldwide, and great attentions have been paid to clarifying the carcinogenesis and identifying new effective antitumor therapy."

( Sun, X; Yan, P, 2018)

"Patients whose tumors have genetic, metabolic, or imaging biomarker evidence of glutamine dependence should be prioritized as candidates for future clinical evaluations of novel DON prodrugs, given either as monotherapy or in rationally directed pharmacologic combinations."

( Lemberg, KM; Rais, R; Slusher, BS; Vornov, JJ, 2018)

"Cancer has been a significant threat to human health with more than eight million deaths each year in the world."

( Crawford, BM; Liu, Y; Vo-Dinh, T, 2018)

"Cancer has become the leading cause of death in many countries."

( Andersen, MØ; Arnspang, EC; Code, C; Notabi, MK; Popova, P, 2019)

"Tumors have evolved a variety of methods to reprogram conventional metabolic pathways to favor their own nutritional needs, including glutaminolysis, the first step of which is the hydrolysis of glutamine to glutamate by the amidohydrolase glutaminase 1 (GLS1)."

( Anderton, M; Bailey, A; Boyd, S; Brookfield, J; Cairnduff, C; Charles, M; Cheasty, A; Critchlow, SE; Culshaw, J; Ekwuru, T; Finlay, MRV; Hollingsworth, I; Jones, N; Leroux, F; Littleson, M; McCarron, H; McKelvie, J; Mooney, L; Nissink, JWM; Perkins, D; Powell, S; Quesada, MJ; Raubo, P; Sabin, V; Smith, J; Smith, PD; Stark, A; Ting, A; Wang, P; Wilson, Z; Winter-Holt, JJ; Wood, JM; Wrigley, GL; Yu, G; Zhang, P, 2019)

"We conclude that cancer has been recognized in India since antiquity."

( Mallath, MK; Smith, RD, 2019)

"Most people with cancer have a combination of treatments, such as surgery with chemotherapy and/or radiation therapy."

( Abdul Aziz, SA; Ismail, F; Lew, YL; Mohamed Shah, N, 2021)

"While research in cancer has largely focused on the neoplasm/tumor and the cancerous cells that make up the tumor, more recently, the existence, proliferation, differentiation, migration and invasion of cancer stem cells (CSCs) and the role that CSCs play in tumor initiation, progression, metastasis, drug resistance and relapse/recurrence of the disease has gained widespread interest in cancer research."

( Büsselberg, D; Samuel, SM; Satheesh, NJ, 2020)

"Chelating Cu from tumors has been verified as an effective and promising strategy for cancer therapy through antiangiogenesis."

( Chen, H; Chen, Q; Chu, Y; Guo, Q; Guo, Z; Jiang, C; Jiang, L; Li, C; Liu, P; Sun, T; Yu, H; Zhang, G; Zhang, Y; Zhou, W, 2020)

"Both these cancers have several risk factors, among which the claimed exposure presents only a minor, if any, increased risk."

( Dragani, TA, 2020)

"Liver cancer has become the third type of cancer that causes death; this is why the design of new chemotherapeutic drugs against this disease is a major need."

( Belhassan, A; Benlyas, M; Bouachrine, M; Lakhlifi, T; Zaki, H, 2021)

"In recent decades, cancer has been one of the leading causes of death worldwide."

( Ho, CT; Lai, CS; Pan, MH, 2020)

"Cancer has the ability to escape the immune system using different molecular actors."

( Cadassou, O; Cros-Perrial, E; Jordheim, LP; Strakhova, R, 2020)

"Tumors have increasingly been a spotlight because of their terrible trends and refractory characteristic."

( Lu, L; Tian, C; Tuo, Y; Xiang, M, 2020)

"Paradoxically, many cancers have increased dependency on NAD+."

( Allison, SJ; Griffiths, HBS; King, SJ; Williams, C, 2020)

"A number of cancers have been associated with inflammatory processes."

( Iqbal, A; Marszałek, K; Miękus, N; Podlacha, M; Puchalski, C; Świergiel, AH, 2020)

"Solid tumors have abnormal microcirculation that limits oxygen delivery and leads to a hypoxic tumor microenvironment."

( Spiess, BD, 2020)

"Cancer has been the second heath killer being next only to cardiovascular diseases in human society."

( Gao, H; Long, J; Tang, Z; Wan, Y, 2021)

"For their part, cancers have evolved to create conditions around their cells that eliminate their active apoptotic forms."

( Tsanov, H; Tsanov, V, 2021)

"Treatment of cancers has always been a challenge for physicians."

( Ala, M, 2021)

"Patients with cancer have played a key role in advocating for legal access to cannabis, but little is known about links between cancer and cannabis use or cannabis-related beliefs."

( Coughlin, LN; Cousins, MM; Ilgen, MA; Jagsi, R; Jannausch, ML, 2021)

"If, however, those cancers have functional GABA receptors that participate in GABAergic signaling, it raises an important question whether these signaling pathways might be targetable for therapeutic benefit."

( Bhattacharya, D; Gawali, VS; Kallay, L; Koehler, A; Krummel, DP; Sengupta, S; Stambrook, P; Toukam, DK, 2021)

"Cancer has become a serious disease threatening human health."

( Abu-Serie, MM; El Fawal, G; Mo, X; Wang, H, 2021)

"Cancer has become one of the main reasons for human death in recent years."

( Aramesh, N; Bagheri, AR; Bilal, M; Kim, HW; Xiao, J; Yan, B, 2021)

"Many neoplasms have been shown to have over activated Nrf2, strongly suggesting that it is responsible for tumors with a poor prognosis."

( Alam, W; Ayatollahi, J; Khan, H; Peirovi, N; Salemi, F; Saso, L; Shahcheraghi, SH, 2021)

"Breast cancer has strong developmental origins and maternal nutrition composition may influence later-life breast cancer risk in the offspring."

( Chen, M; Li, S; Li, Y; Li, Z; Sharma, M; Srinivasasainagendra, V; Tiwari, H; Tollefsbol, TO, 2022)

"Patients with cancer have a higher risk of renal dysfunction, which may be associated with increased risks of thrombotic or bleeding complications."

( Carrier, M; Mallick, R; Wang, TF; Wells, PS, 2022)

"Cancer has been one of the leading causes of death in India in the past decade."

( Bhadelia, A, 2021)

"Many cancers have an unusual dependence on glutamine."

( Alexander, PB; Li, QJ; Liang, Y; Mudgal, P; Pan, C; Qin, D; Tan, L; Thompson, JW; Wan, Y; Wang, XF; Wang, Y; Wu, H; Yin, T; Yuan, L, 2022)

"Cancer has long been considered a genetic disease characterized by a myriad of mutations that drive cancer progression."

( Choi, J; Gyamfi, J; Kim, J, 2022)

"The incidence of cancer has been increasing worldwide."

( Das, U; Dimmock, JR; Okudaira, N; Roayapalley, PK; Sakagami, H; Sharma, RK, 2022)

"Cancer has been identified as one of the leading causes of death worldwide."

( Alonso, C; Martín-Encinas, E; Palacios, F; Selas, A, 2022)

"Many tumors have increased sialic acid incorporation."

( Belmonte, P; Dong, H; Friedman, DJ; Kim Lee, HS; Kizerwetter, M; Rajcula, M; Shapiro, MJ; Shapiro, VS; Theodore, K, 2022)

"Accordingly, many cancers have been documented to silence expression of the ISYNA1 gene, which encodes the rate-limiting enzyme of inositol synthesis."

( Case, KC; Greenberg, ML; Schmidtke, MW, 2022)

"Cancer has become one of the leading causes of death worldwide."

( Gong, X; Guo, Y; Li, Y; Shi, L; Xu, J; Zhang, S, 2022)

"Tumors have a series of clinical biological signs with the following five main features: postoperative pain and cancerous pain; suppression of antitumor immunity; angiogenesis in tumors; proliferation, growth and metastasis of tumors; and mental depression."

( Chen, Q; Chen, S; Deng, S; Hu, P; Hu, X; Ling, C; Liu, X; Luo, B; Qiu, L; Wu, Q; Yuan, M, 2022)

"Tumors have developed the ability to survive at elevated ROS levels with significantly higher H2O2 levels than normal tissues."

( Amaldoss, MJN; Sorrell, CC, 2022)

"Since cancer has emerged as one of the most serious threats to human health, the highly sensitive determination of cancer cells is of significant importance to improve the accuracy of early clinical diagnosis."

( Lin, X; Qian, C; Sohan, ASMMF; Sun, X; Wan, X; Yin, B; Yue, W; Zeng, S, 2022)

"Cancer has presented to be the most challenging disease, contributing to one in six mortalities worldwide."

( Guha, S; Hazarika, S; Sivalingam, N; Sritharan, S, 2022)

"Tumors have long been known to rewire their metabolism to endorse their proliferation, growth, survival, and invasiveness."

( Bononi, G; Di Bussolo, V; Granchi, C; Masoni, S; Minutolo, F; Tuccinardi, T, 2022)

"Cancer has been recognized as one of the non-communicable diseases with an increasing number of new cases, higher morbidity, and higher mortality rates at the global level."

( Kaur, N; Kumar, D; Kumar, V; Sahu, S; Sharma, A; Sharma, V; Wadhwa, P, 2023)

"The incidence of cancer has been growing worldwide."

( Ansari, MJ; Jafarzadeh, E; Jalil, AT; Jawad, MA; Moslehi, M; Najafi, M; Rastegar-Pouyani, N; Rezaei, S; Taeb, S; Talebzadeh, P, 2023)

"Cancer has become a major challenge in the global disease burden."

( Cui, W; Li, B; Liu, L; Liu, S; Yan, F; Yan, S, 2022)

"Multiple cancers have been reported to be associated with angiogenesis and are sensitive to anti-angiogenic therapies."

( Chen, H; Gao, X; Li, J; Li, Y; Liu, J; Liu, P; Ren, Y; Song, S; Wang, B; Wang, H; Wang, R; Wang, Y; Zhang, M, 2023)

"Children with cancer have an increased risk for developing a venous thromboembolism (VTE) during their treatment course."

( Branchford, B; Liegl, M; Malec, L; Scheuermann, A; Simpson, P, 2023)

"Patients with cancer have increased risks of venous and arterial thromboembolism and/or atrial fibrillation, for which anticoagulation is commonly used."

( Wang, TF, 2022)

"Patients with cancer have a high risk of recurrent VTE and bleeding."

( Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Yamashita, A, 2023)

"Cancer has been a major health problem in the world in the past decades."

( Chen, D; Chen, L; Gu, Z; He, B; Li, Y; Lin, S; Yan, W; Zeng, Z, 2022)

"Patients with cancer have been reported to show elevated plasma concentrations of vitamin B12, thus causing uncertainties regarding safety of vitamin B12."

( Obeid, R, 2022)

"Cancer has recently increased the death toll worldwide owing to inadequate therapy and decreased drug bioavailability."

( Alalikhan, A; Hashemian, P; Hashemzadeh, A; Javid, H; Karimi-Shahri, M, 2023)

"Lactate in tumors has long been considered "metabolic junk" derived from the glycolysis of cancer cells and utilized only as a biomarker of malignancy, but is presently believed to be a pivotal regulator of tumor development, maintenance and metastasis."

( Chen, J; Shi, J; Wu, C; Zhu, Y, 2023)

"Patients with malignancy have higher risk of developing venous thromboembolism."

( Bodnar, L; Bodnar, P; Bodnar, T; Bodnar, Y; Klishch, I, 2022)

"Cancer has been considered as complex malignant consequence of genetic mutations that control the cellular proliferation, differentiation and homeostasis, thus making tumor treatment extremely challenging."

( Guo, Q; Meng, Y; Qiu, C; Shi, Q; Wang, C; Wang, J; Wu, Y; Xia, F; Xu, C; Zhang, J, 2023)

"Cancer has remained to be one of the major challenges in medicine and regarded as the second leading cause of death worldwide."

( AliAshrafzadeh, H; Jafarzadeh, E; Khodamoradi, E; Moazamiyanfar, R; Mouludi, K; Najafi, M; Rastegar-Pouyani, N; Rezaei, S; Taeb, S; Zhaleh, M, 2023)

"Tumors have considerable cellular heterogeneity that is impossible to explore with simple cell cultures."

( Beller, NC; Hummon, AB; Wang, Y, 2023)

"Cancer has become the primary cause of death worldwide, and anticancer drugs are used to combat this disease."

( Ahmad, FB; Woon, CK; Zamakshshari, NH, 2023)

"Solid tumors have developed robust ferroptosis resistance."

( Guan, Q; Qin, C; Qu, S; Su, W; Wang, Y; Wei, X; Xiang, J; Yang, Z; Yao, B; Zen, K; Zhao, D; Zhou, J, 2023)

"Malignant tumors have a unique tumor microenvironment (TME), which includes mild acidity, hypoxia, overexpressed reactive oxygen species (ROS), and high glutathione (GSH) levels, among others."

( Chen, L; Wang, Y; Yang, R; Yang, Y; Zhang, L; Zheng, X; Zhu, Y, 2023)

"Cancer has always posed a significant threat to human health, prompting extensive research into new treatment strategies due to the limitations of traditional therapies."

( Fu, Y; Li, W; Sun, J; Wang, Y, 2023)

Actions

Excerpt	Reference
"Neoplasia affecting the skeleton is an important cause of morbidity, which includes hypercalcaemia, bone pain and fracture."	( Kanis, JA; McCloskey, EV; O'Rourke, N; Taube, T, 1991)
"Malignant tumors can affect the integrity of the skeletal tissue and the homeostasis of the two main components of bone mineral, calcium (Ca) and inorganic phosphate (Pi)."	( Bonjour, JP; Rizzoli, R, 1989)
"The majority of cancers affecting HIV-infected subjects are those established as acquired immunodeficiency syndrome (AIDS)-defining: Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL), and invasive cervical cancer (ICC)."	( Barbarini, G; Barbaro, G, 2007)
"Drugs used to treat cancer may affect the skeleton in several ways, the most important being a decrease in sex steroid levels."	( Vestergaard, P, 2008)
"cancer-affected households) to households with similar socioeconomic and demographic characteristics (controls)."	( Engelgau, M; Fan, VY; Karan, A; Mahal, A, 2013)
"The 60% of tumors affected patients >65years of age and the future previsions are considering an amount of 70% after 2030."	( Berretta, M; Cacopardo, B; Lleshi, A; Michieli, M; Rupolo, M, 2013)
"Major tumors affected by genistein here reviewed are breast, prostate, colon, liver, ovarian, bladder, gastric, brain cancers, neuroblastoma and chronic lymphocytic leukemia."	( Daglia, M; Kasi, PD; Nabavi, SF; Nabavi, SM; Ravi, S; Russo, GL; Russo, M, 2016)
"Recently, cancer affects people's life more and more."	( Deng, L; Dong, J; Wang, G, 2018)
"For the cancer-affected patient's samples, the highest concentration among the OCP compounds was found for o,p-DDT (638."	( Al-Hussaini, M; Alawi, M; Masaad, M, 2018)
"Pain is common in cancer, affecting more than 70% of patients with advanced disease."	( Brogan, SE; Dalley, AP; Odell, DW; Sindt, JE, 2020)
"While, the anticancer impact of high doses of IVC remains debatable in spite of growing evidence that high dose vitamin C shows anti-tumorigenic activity by elevating the amount of reactive oxygen species (ROS) in cancer cells without meaningful toxicities."	( Abiri, B; Vafa, M, 2021)

Excerpt

Reference

"Neoplasia affecting the skeleton is an important cause of morbidity, which includes hypercalcaemia, bone pain and fracture."

( Kanis, JA; McCloskey, EV; O'Rourke, N; Taube, T, 1991)

"Malignant tumors can affect the integrity of the skeletal tissue and the homeostasis of the two main components of bone mineral, calcium (Ca) and inorganic phosphate (Pi)."

( Bonjour, JP; Rizzoli, R, 1989)

"The majority of cancers affecting HIV-infected subjects are those established as acquired immunodeficiency syndrome (AIDS)-defining: Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL), and invasive cervical cancer (ICC)."

( Barbarini, G; Barbaro, G, 2007)

"Drugs used to treat cancer may affect the skeleton in several ways, the most important being a decrease in sex steroid levels."

( Vestergaard, P, 2008)

"cancer-affected households) to households with similar socioeconomic and demographic characteristics (controls)."

( Engelgau, M; Fan, VY; Karan, A; Mahal, A, 2013)

"The 60% of tumors affected patients >65years of age and the future previsions are considering an amount of 70% after 2030."

( Berretta, M; Cacopardo, B; Lleshi, A; Michieli, M; Rupolo, M, 2013)

"Major tumors affected by genistein here reviewed are breast, prostate, colon, liver, ovarian, bladder, gastric, brain cancers, neuroblastoma and chronic lymphocytic leukemia."

( Daglia, M; Kasi, PD; Nabavi, SF; Nabavi, SM; Ravi, S; Russo, GL; Russo, M, 2016)

"Recently, cancer affects people's life more and more."

( Deng, L; Dong, J; Wang, G, 2018)

"For the cancer-affected patient's samples, the highest concentration among the OCP compounds was found for o,p-DDT (638."

( Al-Hussaini, M; Alawi, M; Masaad, M, 2018)

"Pain is common in cancer, affecting more than 70% of patients with advanced disease."

( Brogan, SE; Dalley, AP; Odell, DW; Sindt, JE, 2020)

"While, the anticancer impact of high doses of IVC remains debatable in spite of growing evidence that high dose vitamin C shows anti-tumorigenic activity by elevating the amount of reactive oxygen species (ROS) in cancer cells without meaningful toxicities."

( Abiri, B; Vafa, M, 2021)

Treatment

Excerpt	Reference
"The relevance of these observations to cancer immunotherapy is discussed."	( Stein-Werblowsky, R, 1975)
"Children with malignant solid tumors during therapy and children with leukemia during different stages of the disease often showed a slowing of less than 5% in the EM-test."	( Oehme, J; Ritter, J, 1978)
"Since the patient's response to cancer chemotherapy depends on immunocompetence which, in turn, is related to the nutritional state, adequate nutrition is the key to effective treatment."	( Jehn, U; Kohlschütter, B, 1978)
"Twenty-three cancer patients with cutaneous and/or systemic herpes zoster or herpes simplex infections were treated with parenteral acyclovir."	( Brigden, D; Clink, HM; Corringharn, R; Hoffbrand, AV; Janeson, B; Kay, HE; McElwain, TJ; Morgenstern, G; Powles, RL; Prentice, HG; Ross, MG; Selby, PJ; Thornton, R; Watson, JG, 1979)
"A randomized study in 20 patients with cancer was carried out to test the clinical efficacy of sodium-2-mercaptoethane sulfonate (ASTA D-7093; mesnum) as an agent to prevent urotoxic side effects (in particular, hemorrhagic cystitis) during cytostatic therapy with the oxazaphosphorines cyclophosphamide and ifosfamide."	( Brock, N; Burkert, H; Günther, U; Hoefer-Janker, H; Klein, HO; Mitrenga, D; Scheef, W; Schnitker, J; Voigtmann, R, 1979)
"Twenty-one patients (sixteen cancer patients receiving chemotherapy and/or radiotherapy, three with major abdominal traumatic injuries and four with paralytic ileus) were infused with 2 1/24 hours of a solution of 4."	( Angers, JW; Ching, N; Grossi, C; Jham, G; Mills, CJ; Nealon, TF; Zurawinsky, H, 1979)
"Of the 15 animals, 12 died with tumors induced by the treatment, half of them by the 41 st week; all 15 were dead at 58 weeks."	( Lijinsky, W; Taylor, HW, 1978)
"Patients with solid tumors who had received little or no prior chemotherapy and had good bone marrow reserve tolerated up to 6000 U/m2/24 hours X 5 days."	( Cuttner, J; Holland, JF; Nogeire, C; Ohnuma, T, 1978)
"Those patients with bladder cancer who did not respond to NCS therapy or exhibit any side effects even after 21 mg were found to have proteolytic activity in their sera which degraded NCS very rapidly as revealed by the fluorescence polarization technique."	( Maeda, H; Matsumoto, T; Ogata, J; Sakamoto, S, 1978)
"Twenty-three children with advanced cancer refractory to conventional therapy received weekly iv doses of neocarzinostatin for 5 weeks."	( Aur, RJ; Howarth, C; Pratt, CB; Rivera, G, 1978)
"The metabolic incorporation by tumors of this DNA-precursor indicates a potential value of this radiocompound for their detection, differentiation and follow-up of their evolution after therapy."	( Anghileri, LJ; Heidbreder, M; Mathes, R, 1977)
"The incidences of malignant tumors, hepatomas or modular hyperplasias, and benign tumors in halothane-treated mice were 7, 6, and 20 per cent, respectively; there were similar incidences of these lesions in control animals."	( Baden, JM; Kosek, JC; Mazze, RI; Rice, SA; Wharton, RS, 1979)
"13 patients with malignant tumors were treated by the radiosensitizer misonidazole (Ro 07-0582), total dosage 20-29 g."	( Kogelnik, HD; Mamoli, B; Müller, M; Rathkolb, O; Wessely, P, 1979)
"Immunotherapy against cancer in animals has been established."	( Eilber, FR; Holmes, EC; Morton, DL, 1975)
"Seven patients with metastatic tumors resistant to therapy with adriamycin, BCNU, plus cyclophosphamide received the same chemotherapy combined with amphotericin B."	( Klahr, C; Presant, CA; Santala, R, 1977)
"Fifty-four children with solid tumors were treated: 25 neuroblastoma, 9 rhabdomyosarcoma, 4 Ewing sarcoma, 2 testicular embryonal carcinoma, 2 retinoblastoma, and 12 miscellaneous tumors."	( Bryan, H; Nitschke, R; Starling, KA; Vats, T, 1978)
"Human cancer cells that had had high (greater than 160) tissue culture passages, when transplanted into antithymocyte-treated F344 newborn rats, caused induction of rat sarcomas in the rats within 2 or 3 subcultures, whereas human cancer cells with low (5-33) passages in vitro did not cause overt induction of rat sarcomas until after 5-10 subtransplantations."	( Bare, AL; Bare, RM; Djurickovic, D; Fish, DC; Huebner, RJ; Smith, GT; Trimmer, RW, 1979)
"Twenty-four patients with advanced cancer not reacting to conventional therapy were treated with 97 courses of i."	( Bartal, A; Cohen, Y; Honigman, J; Robinson, E, 1977)
"Therefore, cancer surgery acts as immunotherapy because it removes the cancer cells that produce the immunodepression and allows the patient's immune response to recover."	( Morton, DL, 1978)
"Drug combinations in cancer treatment are widely utilized because they frequently result in better therapeutic activity than the single treatments."	( Garattini, S; Spreafico, F, 1978)
"The therapeutic effect of drugs used in cancer chemotherapy has been augmented by their complexing or chemical linking to macromolecular carriers."	( Arnon, R, 1978)
"Malignant neoplasms may cause life-threatening complications requiring prompt diagnosis and emergency therapy."	( Stolinsky, DC, 1978)
"Antibiotic therapy in granulocytopenic cancer patients, the risk factors predisposing these patients to infection, and the signs, symptoms and types of infections occurring in these patients are reviewed."	( Hopefl, AW, 1979)
"The potential impact on cancer mortality from these treatment results is obvious."	( DeVita, VT; Weiss, RB, 1979)
"Ninety-two patients with cancer with 100 infectious episodes were treated with netilmicin sulfate, a new aminoglycoside."	( Bodney, GP; Yap, BS, 1979)
"One hundred and sixty-one cancer patients were nutritionally assessed prior to receiving oncological therapy (surgery, chemotherapy, and/or radiation therapy)."	( Blackburn, GL; Bothe, A; Harvey, KB, 1979)
"Five children with cancer treated with high dose cyclophosphamide experienced blurring of vision."	( Freeman, AI; Kende, G; Sirkin, SR; Thomas, PR, 1979)
"A 9-fold increased incidence of bladder cancer was found in the cyclophosphamide-treated group."	( Fairchild, WV; Gangai, MP; Solomon, HD; Spence, CR, 1979)
"Terminally ill cancer patients often derive great benefit from this treatment."	( Bürgi, H; Selz, B, 1979)
"Fifty one patients with terminal cancer suffering severe pains reluctant to other treatment have received morphine by mouth, in a regular regimen."	( Apchin, A; Belnat, P; Brulé, G; Domenge, C; Voisin, PM, 1979)
"The personal series consists of 140 cancer patients followed up over a period of some 3 years and submitted prior to the start of treatment to the DNCB skin test."	( Bianucci, P; De Rossi, O; Pastorino, G, 1979)
"The National Cancer Institute, in response to widespread public interest, undertook a retrospective analysis of Laetrile treatment."	( Byar, DP; Ellison, NM; Newell, GR, 1978)
"Adjuvant trials in cancer treatment present special problems in statistical analysis."	( Higgins, GA, 1978)
"153 patients with inoperable malignant tumors were treated by the so-called synchronization therapy with vincristine and ifosfamide."	( Hartwich, G; Lutz, H; Neidhardt, B, 1978)
"The treatment of cancer pain by psychotropic drugs is a method which has been employed for a long time [8] and in which the results obtained have appeared very interesting from the beginning: there is a high percentage of success, rapid action, absence of addiction, and although there are sometimes unpleasant side-effects, they are reversible when the treatment is stopped."	( Boudouresque, G; Bourhis, A; Fondarai, J; Pellet, W; Ponzio, J; Spitalier, JM, 1978)
"Seventy-two patients with advanced cancer were treated with combinations of heat and radiation in two groups: (a) heat + radiation, and (b) radiation + heat."	( George, R; Hornback, NB; Joe, BT; Marshall, C; Sayoc, E; Shidnia, H; Shupe, R, 1979)
"It is recommended that in future cancer therapy protocols test for circadian variability of white cell depression by varying treatment times systematically along the 24 h scale."	( Simpson, HW; Stoney, PJ, 1977)
"Late induction of malignancy can occur with either radiation or chemotherapy alone and, in some cases, this appears to be enhanced when they are combined."	( Fu, KK; Phillips, TL, 1977)
"Between 1967 and 1976, 269 tumors of the hand were treated."	( Flügel, M; Geldmacher, J, 1977)
"The intensive research on cancer treatment all over the world is leading to a rapid accumulation of experimental data about the action of single cytostatic drugs in tissue culture and on transplantable animal tumor systems, especially in rodents."	( Gross, R; Hirschmann, WD, 1976)
"One approach to effective cancer chemotherapy is to maximize the exposure of tumor cells to cytotoxic drugs while minimizing the exposure of sensitive normal cells to such agents."	( Juliano, RL, 1976)
"The treatment of breast and ovarian cancer brought the best results, improved by a synchronisation therapy."	( Siebner, H; Weber, W, 1976)
"Forty patients with generalized cancer complicated by water and electrolyte retention were treated with "medium" and "large" doses of furosemide and bumetanide with 35% and 40% objective positive response, respectively."	( Athanasiou, A; Dadiotis, L; Razis, DV, 1976)
"The treatment of cancer using fast neutrons was first attempted from 1938 to 1942, only a few years after the identification of the particle in 1932."	( Field, SB, 1976)
"Infections in the immunosuppressed cancer patient are caused by a wide variety of bacteria, viruses, fungi, and protozoa; many of these in the normal individual are saprophytes but will cause disease in the immunosuppressed patient, often with treatment failure."	( O'Loughlin, JM, 1975)
"Six patients with advanced cancer were treated with PTG (67 mg/m2 of body surface area intravenously) specifically labeled with tritium as the first dose of a weekly x 6 course."	( Allen, LM; Creaven, PJ, 1975)
"In patients with malignant tumors, changes in the blood count and morphological changes in the nucleoli in peripheral-blood lymphocytes were studied during treatment with Cytembena, Cyclophosphamide, or combinations of both drugs."	( Matĕjková, E, 1975)
"Sixty-seven patients with disseminated cancer were randomly allocated to treatment with continuous closed chest drainage removing all fluid for 72 hours (PD) or pleural drainage for 72 hours with the instillation into the pleural space of radioactive colloidal chromic phosphate (PD + 32P)."	( Baker, L; Caoili, EM; Izbicki, R; Vaitkevicius, VK; Weyhing, BT, 1975)
"Ninety-eight children with solid tumors resistant to conventional chemotherapy received adriamycin 90 mg/m2, either as a single intravenous injection or in 6 divided doses administered every 6 hours."	( George, S; Komp, DM; Lyon, GM; Ragab, AH; Starling, KA; Sutow, WW, 1975)
"Successfully, radically treated cancer patients with no detectable residues or metastases for at least 1 year had values (186 +/- 39; 76 +/-24) almost within the normal ranges (93 to 250 mg pectin equivalents per liter for CPA and 35 to 120 mg pectin equivalents per liter for SPA)."	( Huhtala, HJ; Rosengård, SA; Salmi, RE; Salo, EJ; Sandbacka, BO, 1976)
"Thirty six stage III cancer patients were treated with Ukrain, a semisynthetic drug derived from Chelidonium majus L."	( Brzosko, WJ; Manolakis, G; Meijer, D; Nowicky, JW; Vatanasapt, V, 1992)
"Sixty-four adult cancer patients entered this trial; all received a chemotherapy regimen containing cisplatin (greater than or equal to 60 mg/m2) and a combination of metoclopramide and dexamethasone for the control of acute emesis during the period from 0 to 24 h after cisplatin (day 1)."	( Bacchi, M; Bandini, N; Bella, M; Cocconi, G; Michiara, M; Monici, L; Passalacqua, R, 1992)
"Finally, the risk is discussed that cancer could be a side-effect of the use of retroviral vectors in human gene therapy."	( Weiss, RA, 1992)
"In testicular cancer, etoposide was shown to have a possible role in adjuvant therapy for refractory disease or as part of combination chemotherapy."	( Loehrer, PJ, 1992)
"Sixty patients with malignancy were enrolled in a study of high-dose chemotherapy and peripheral blood stem cell transplantation (PBSCT)."	( Bolton, A; Charles, P; Dale, BM; Gregg, A; Kotasek, D; Norman, JE; Pillow, A; Sage, RE; Shepherd, KM, 1992)
"289 consecutive cancer patients receiving cisplatin chemotherapy (much greater than 50 mg/m2) were randomised to receive one of the following intravenous antiemetic regimens: ondansetron 0."	( , 1992)
"Forty-seven patients with advanced cancer with moderate/severe pain, treated with regular doses of Ketogan tablets took part in an open phase 1 type pharmacologic/toxicologic study comparing Ketogan tablets and cetobem."	( Andersen, LS; Kjaer, M; Nielsen, H; Olsen, FE; Philipsen, J; Velander, G, 1992)
"Thirty-two cancer patients were given a 1-day course of chemotherapy consisting of etoposide (VP16), ifosfamide, and cisplatin (VIP; n = 46 cycles), followed by the combined sequential administration of recombinant human interleukin-3 (rhIL-3) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)."	( Bross, K; Brugger, W; Dern, P; Frisch, J; Kanz, L; Mertelsmann, R; Weber, B, 1992)
"Clinical success in the treatment of tumors with chemotherapy has significantly improved over the past several years."	( Henle, KJ; Mansouri, A; Nagle, WA, 1992)
"Among ovarian cancer cell lines tested, the enhancement of the activity of HuIFN by dipyridamole for HAC-2 and SHIN-3 cells was equivalent to or greater than that for 3 chemotherapy agents (adriamycin, vincristine, and a camptothecin derivative)."	( Fukazawa, I; Inaba, N; Isogai, E; Oiwa, Y; Saito-Ebihara, M; Sekiya, S; Sugano, I; Suzuki, N; Takakubo, Y; Yoshida, J, 1992)
"Odds ratios for cancer in the presence of administration of pethidine or of intramuscular vitamin K."	( Birmingham, K; Golding, J; Greenwood, R; Mott, M, 1992)
"Furthermore, a variety of pediatric tumors are responsive to RA in vitro, which provides additional rationale for a phase I evaluation of RA in children with cancer that is refractory to standard therapy."	( Adamson, PC; Aronson, L; Balis, FM; Fenton, RM; Feusner, J; Hammond, GD; Horowitz, ME; Murphy, RF; Reaman, G; Smith, MA, 1992)
"Twenty-eight cancer patients either received r-hGH for 3 days (GH group, n = 12, weight loss = 6 +/- 2%) or were not treated (control [CTL] group, n = 16, weight loss = 11 +/- 2%) before metabolic study."	( Brennan, MF; Burt, ME; Gonenne, A; Heslin, MJ; Newman, E; Pearlstone, DB; Wolf, RF, 1992)
"A review from Memorial Sloan-Kettering Cancer has shown that a new group of patients, those receiving corticosteroid therapy for brain neoplasm, are also at risk for the development of PCP and should receive PCP prophylaxis."	( Sepkowitz, KA, 1992)
"A third malignant neoplasm (dermal squamous cell carcinoma) was seen in a 64-year-old woman with rheumatoid arthritis after 13 months treatment with 7."	( Eisenlohr, H; Lydtin, H; Prechtel, K; Trenkwalder, P, 1992)
"Immunotherapy models using murine tumors or clinical experiments revealed that preadministration of immunostimulator such as OK-432, followed by chemotherapeutic agents such as cyclophosphamide, can induce host's non-cytotoxic fresh lymphocytes that act synergistically with cultured killer cells against autologous tumor cells."	( Harada, T; Ichinose, Y; Kan, N; Kodama, H; Moriguchi, Y; Ohgaki, K; Satoh, K; Yamasaki, S, 1992)
"Furthermore, in hormone-dependent cancers malignant cells may undergo massive apoptosis in response to hormone withdrawal or antihormone treatment."	( Bursch, W; Kraupp-Grasl, B; Oberhammer, F; Schulte-Hermann, R; Wagner, A, 1992)
"Pharmacokinetic data for six anticancer agents were compared in infants less than 1 year of age and children greater than 1 year of age treated at St Jude Children's Research Hospital."	( Crist, WM; Crom, WR; Evans, WE; Groom, S; McLeod, HL; Relling, MV; Rivera, GK; Rodman, JH; Silverstein, K, 1992)
"In this study, 11 cancer patients who experienced severe pain were treated with transdermal fentanyl."	( Herbst, LH; Strause, LG, 1992)
"A total of 35 previously treated cancer patients were enrolled in a phase I study of this compound."	( Alberts, DS; Brodar, F; Lam, KS; Matias, B; Modiano, M; Peng, YM; Sol Lucas, V; Tuttle, R; Wargin, W, 1992)
"Thirty-one patients with malignancy, anticoagulated for the treatment of venous thromboembolism (VTE) are reported."	( Chan, A; Woodruff, RK, 1992)
"Although WHO cancer pain relief is the first choice, nerve blocks and intraoperative radiotherapy, if indicated, must be taken into consideration in the early phase of the pain treatment."	( Fujita, N; Fuse, Y, 1992)
"As in the case of anticancer chemotherapy, it is hoped that combinations of drugs, which act against different steps in the viral replication cycle, might have synergistic potential."	( Margolese, RG; Wainberg, MA, 1992)
"Under the Cancer Preventive Program, Nocardia rubra cell-wall skeleton (N-CWS) was administered to 80 workers directly involved in the production of sulfur mustard and 66 workers engaged in work related to sulfur mustard production."	( Hozawa, S; Ishioka, S; Matsuzaka, S; Nishimoto, Y; Otake, M; Shigenobu, T; Yamakido, M; Yanagida, J, 1992)
"Twenty patients with advanced cancer for which there was no effective standard therapy or whose disease was refractory to standard therapy were treated with recombinant macrophage colony-stimulating factor (rM-CSF)."	( Childs, A; Groves, ES; Hudson, J; Konrad, M; Rudolph, AR; Zamkoff, KW, 1992)
"Hypercalcemia of malignancy is a commonly encountered serious clinical problem that often requires aggressive therapy."	( Fatemi, S; Rude, RK; Singer, FR, 1992)
"Advanced cancer is often accompanied by anaemia, which may worsen with concomitant administration of chemotherapy."	( Abels, RI, 1992)
"Fifteen patients with cancer pain (average age of 61 years) were treated with serial epidural phenol in glycerin injections."	( Finch, PM; Lovegrove, FT; Salmon, JB; Warwick, A, 1992)
"eight cancer patients treated with radiotherapy and/or chemotherapy (r/c cancer patients) and six chromium workers."	( Brochard, P; Jaurand, MC; Levy, F; Pilliere, F; Renier, A, 1992)
"On the basis of these findings cancer patients with pain unrelieved by oral opiates were treated for periods of 13 to 91 days with intrathecal octreotide 5-20 micrograms/h."	( Kroin, JS; Paice, JA; Penn, RD, 1992)
"We surveyed 550 cancer patients who experienced pain and were treated with morphine for a total of 22,525 treatment days."	( Grond, S; Jung, H; Meuser, T; Schug, SA; Stobbe, B; Zech, D, 1992)
"LASA can be useful for monitoring cancer patients during treatment, especially in combination with other tumor markers."	( Hilgers, J; Kenemans, P; Mensdorff-Pouilly, S; Schutter, EM; van Dijk, W; van Kamp, GJ; Visser, JJ, 1992)
"Fourteen patients with Adr-resistant tumors were treated with Adr and AM."	( de Vries, EG; Meijer, C; Mulder, NH; Mulder, PO; Nanninga, AG; Uges, DR; van der Graaf, WT; Vellenga, E, 1991)
"Of the ten head and neck cancer patients, five were found to have inappropriately low SIE levels before therapy, and two additional patients had a decrease of SIE levels during therapy, in one patient to an abnormally low level."	( Goldwasser, E; Smith, DH; Vokes, EE, 1991)
"Persistent severe cancer pain should be treated with opioid drugs, principally morphine."	( Twycross, RG; Zylicz, Z, 1991)
"Three modes of receptor-mediated cancer therapy were reviewed presenting our own data."	( Kanisawa, Y; Kondo, H; Niitsu, Y; Watanabe, N, 1990)
"Nine patients with terminal cancer were treated for pain with continuous subcutaneous injection of morphine via a portable battery-driven injection pump."	( Clemensen, SE; Hole, P; Nielsen, FB; Olesen, AS, 1990)
"Most cytotoxic drugs used in cancer therapy do not discriminate between neoplastic and normal proliferating cells."	( Martin, DS; Stolfi, RL, 1991)
"Treatment of cancer pain with opioids through an epidural catheter, with a portable infuser has been recorded in 20 patients retrospective."	( Jonsson, T; Linnemann, MU, 1991)
"In 48 patients with pain related to malignancy, a pain characterization was performed during oral opioid therapy."	( Hedner, T; Samuelsson, H, 1991)
"In 47 children with malignancy, zinc status, growth, and performance during standard treatment were compared with those in controls."	( Van Wouwe, JP; van Zuylen, L, 1991)
"We find that cancer patients given Type I or Type II IFNs can induce IDO which results in decreased serum Trp levels (20-50% of pretreatment) and increased urinary metabolites of the Kyn pathway (5 to 500 fold of pretreatment)."	( Borden, EC; Brown, RR; Datta, SP; Malone, DG; Ozaki, Y; Sondel, PM, 1991)
"As treatment regimens for cancer become more effective in prolonging a patient's life, and as cyclophosphamide receives increasing use for nonmalignant disorders, the potential for cyclophosphamide-induced cancers, particularly in the bladder, must be recognised."	( Fraiser, LH; Kanekal, S; Kehrer, JP, 1991)
"Clinical trials in cancer patients demonstrate that, compared with placebo, granisetron significantly reduces the incidence of nausea and vomiting for 24 hours after administration of high-dose cisplatin."	( Goa, KL; Plosker, GL, 1991)
"Eight patients with selected cancers were imaged prior to primary radiotherapy, and 3 returned for follow-up scans, for a total of 11 imaging studies."	( Evans, ML; Graham, MM; Grierson, JR; Griffin, TW; Koh, WJ; Krohn, KA; Lewellen, TK; Rasey, JS, 1992)
"Studies of cancer patients showed that transdermally administered fentanyl appears to be effective in the management of chronic, cancer-related pain."	( Calis, KA; Corso, DM; Kohler, DR, 1992)
"However, several other human tumors were resistant to Rh-123 laser therapy in vitro and in vivo."	( Castro, DJ; Fetterman, HR; Haghighat, S; Lufkin, RB; Saxton, RE; Soudant, J; Ward, PH, 1992)
"Six patients with ovarian cancer received 25 mg of HMFG1 monoclonal antibody coupled with 90Y-DOTA (doses of radioactivity, 15 to 25 mCi), administered i."	( Courtenay-Luck, NS; Epenetos, AA; Gooden, CS; Kosmas, C; McCall, MJ; Meares, CF; Snook, D, 1992)
"Neutropenic patients with cancer are traditionally treated with empiric antibiotic combinations when they become febrile."	( Anaissie, EJ; Berkey, P; Bodey, GP; Cabanillas, FF; Elting, L; Holmes, FA; Joshi, JH; Keating, MJ; Khardori, NM; Rolston, KV, 1992)
"It recommends that all cancer patients treated in this fashion be given an initial course of intravenous ascorbate followed by a maintenance oral dose to be continued indefinitely thereafter."	( Cameron, E, 1991)
"In this phase I study, 16 adult cancer patients were treated with concurrent 4-day continuous infusions of ifosfamide at 12 g/m2 and escalating doses of carboplatin (400-1600 mg/m2) to determine the major non-haematological dose-limiting toxicity of the combination."	( Ayash, LJ; Critchlow, J; Deary, J; Eder, JP; Elias, AD; Frei, E; Hunt, M; Schnipper, L; Weissman, L; Wheeler, C, 1991)
"14 patients with progressive advanced cancer, resistant to doxorubicin or epirubicin, were treated with the same anthracycline in combination with bepridil."	( Blokhuis, WM; de Jong, J; Giaccone, G; Maessen, PA; Pinedo, HM; Schuurhuis, GJ; van der Hoeven, JJ; van der Vijgh, WJ; van Kalken, CK, 1991)
"Etoposide is one of the few cancer chemotherapy agents that is schedule-dependent in both preclinical and clinical studies."	( Einhorn, LH, 1991)
"Eighteen patients with advanced solid tumors were treated in a phase I study of cisplatinum in combination with recombinant alpha-2a interferon (Roferon-A, Hoffman-LaRoche, Inc, Nutley, NJ)."	( Ajani, JA; Dhingra, HM; Dhingra, K; Gutterman, JU; Rothberg, JM; Talpaz, M, 1991)
"Clinical studies on cancer and psoriasis patients have shown that plasma and urinary homocysteine (Hcy) responds to methotrexate (MTX) therapy, indicating that Hcy in extracellular fluids may be an indicator of the antifolate effect."	( Christensen, B; Djurhuus, R; Refsum, H; Ueland, PM, 1991)
"Four of ten patients with colorectal cancer responded to the treatment (four partial responses), of whom three had been treated previously."	( Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S, 1991)
"Three patients with terminal malignancy reporting ineffective analgesia using systemic and subsequently spinal opiates were treated with subcutaneous infusion of 10% lidocaine hydrochloride."	( Brose, WG; Cousins, MJ, 1991)
"Ten patients with advanced cancer and breakthrough pain between the ages of 39 and 78 received oral transmucosal fentanyl citrate (10-15 micrograms/kg) 4 or 5 times each over 2 days (42 total administrations) in an open study."	( De Boer, JA; Fine, PG; Marcus, M; Van der Oord, B, 1991)
"Patients with ARF and haematological malignancy (excluding myeloma), presenting to a single unit over 10 years were analyzed to see if patients likely to benefit from intensive renal supportive therapy could be identified."	( Feehally, J; Harris, KP; Hattersley, JM; Walls, J, 1991)
"Twenty-three cancer patients undergoing therapy with interleukin-2 and lymphokine-activated killer cells were studied for evidence of complement activation and systemic neutrophil activation occurring during the course of therapy."	( Eberlein, TJ; Moore, FD; Rodrick, M; Schoof, DD, 1991)
"Although most experimental cancer models responds strikingly to treatment with polyamine antimetabolites--namely, inhibitors of various polyamine synthesizing enzymes--a real breakthrough in the treatment of human cancer has not yet occurred."	( Alhonen, L; Jänne, J; Leinonen, P, 1991)
"Photodynamic therapy of tumors with phthalocyanines (PC) as photosensitizers is described."	( Kwaśny, M, 1991)
"Forty patients with refractory solid tumors or non-Hodgkin's lymphoma were treated with high-dose cyclophosphamide, thiotepa, and carmustine (BCNU), followed by autologous stem cell rescue, in a phase I dose escalation study."	( Bitran, JD; Garner, M; Kaminer, LS; Moormeier, JA; Williams, SF, 1990)
"Not all cancer patients with pain, however, fail to get adequate treatment."	( Hill, CS, 1990)
"Survivors of childhood cancer who received anthracycline treatment have a high incidence of abnormal cardiac function."	( Steinherz, L; Steinherz, P, 1991)
"In murine tumors treated in vivo novobiocin markedly potentiates alkylating agent cytotoxicity without concomitant increases in host toxicity."	( Eder, JP; Schnipper, LE; Teicher, BA; Wheeler, CA, 1991)
"Fifty-four patients with inoperable cancers were treated with a combination of cisplatin and radiotherapy from May 1984 to February 1989."	( Bao, YH; Jiang, ZF; Wu, JD; Yuan, XC; Zhang, WJ, 1991)
"Decreases in spontaneous tumors have previously been seen in 2-year rodent studies in groups of animals that have a reduced body weight in comparison to controls, but the spectrum of reduction in spontaneous neoplasms after treatment with amphetamine is broader than has previously been observed."	( Dunnick, JK; Eustis, SL, 1991)
"Patients with refractory solid tumors and lymphomas were treated with a single 24-hour infusion of AZQ at 50 to 355 mg/m2 in dose escalations of 20%."	( Albain, K; Bansal, VK; Braud, E; Chun, HG; Koch, D; Lanzotti, VJ; McKenzie, RS; Potempa, LD; Stiff, PJ; Weidner, MK, 1991)
"Many patients with cancer enjoy long-term survival and are cured; others may live for extended periods while receiving specific treatment for cancer."	( Ganz, PA, 1990)
"The photodynamic therapy (PDT) of tumors involves illumination of the tumorous area following the administration of a tumor-localizing photodynamic sensitizer."	( Spikes, JD, 1990)
"A total of 29 patients with advanced malignancy were treated with recombinant interferon gamma (rIFN gamma, specific activity = 2."	( Avril, MF; Boue, F; Brandely, M; Le Chevalier, T; Paoletti, C; Pastran, Z; Sancho-Garnier, H; Sevin, D; Spielmann, M; Subirana, R, 1990)
"Endoscopic detection of small tumors is key to the early diagnosis and treatment of malignancy."	( Blackman, J; Herrera, HR; Hinshaw, JR; Lanzafame, RJ; Naim, JO; Rogers, DW, 1990)
"Life expectancy is poor in cancer-associated hypercalcemia even in patients who are actively treated."	( Boyle, IT; Campbell, J; Gallacher, SJ; Patel, U; Ralston, SH, 1990)
"Forty-three patients with advanced cancer were evaluated for the changes of absolute counts of peripheral blood lymphocytes and lymphocyte subsets during chemotherapy or chemoimmunotherapy."	( Kambe, M; Kanamaru, R; Mitachi, Y; Murakawa, Y; Okuno, M; Takahasi, H; Wakui, A, 1990)
"Thirty-two cancer patients being treated with cis-DDP-based chemotherapy for the first time were enrolled in the study and donated a baseline sample and at least one post-treatment sample of blood."	( Brandt-Rauf, P; Fischman, HK; Hemminki, K; Niman, HL; O'Dowd, K; Perera, F; Smith, S; Tang, MX; Toporoff, E; Tsai, WY, 1990)
"The untreated patients with lung cancer received 200 mg/m2 etoposide over 24 h in combination with 100 mg/m2 cisplatin, and the pretreated patients received 400 mg/m2 etoposide over 36 h as monotherapy."	( Miller, AA; Stewart, CF; Tolley, EA, 1990)
"In this study, 27 patients with solid tumors were treated with a combination of cyclophosphamide, thiotepa, and carboplatin (CTCb) in a phase I-II study."	( Burke, J; Eder, JP; Elias, A; Frei, E; Hunt, M; Schnipper, LE; Schryber, SM; Shea, TC; Siegel, R; Teicher, BA, 1990)
"Peripheral neuropathies in cancer patients may be caused by compression due to tumor invasion, by radiation injury, or by chemotherapy."	( Forman, A, 1990)
"Eighteen patients with advanced solid tumors received 37 courses of chemotherapy in a pilot study to determine safe drug concentrations for the three-drug infusion for 7 days."	( Mazur, RN; Mucenski, JW; Pugh, RP; Raju, RN; Shackney, SE; Simon, SR; Zidar, BL, 1990)
"In children with malignant tumors, the therapeutic activity of carboplatin at high doses, even in combination chemotherapy, deserves further studies."	( Castello, MA; Clerico, A; Dominici, C; Jenkner, A, 1990)
"Forty-two patients with advanced malignancy judged unlikely to respond to standard treatment received high-dose combination chemotherapy with cyclophosphamide, etoposide, and cisplatin in a phase I trial."	( Anderson, T; Kohler, W; Mangalik, A; Neidhart, JA; Plauche, A; Quenzer, RW; Rinehart, JJ; Stidley, C, 1990)
"Sixteen children with solid tumors resistant to conventional therapies were registered in a pilot Pediatric Oncology Group (POG) study that required the administration of HDAC at 3 g/m2 every 12 hours for four doses."	( Alvarado, C; Camitta, B; Fernbach, DJ; Krischer, J; Mahoney, DH; Tebbi, CK, 1990)
"Chemotherapeutic treatment for cancer has been successful in prolonging survival but it has also been demonstrated that survivors of cancer patients who had received chemotherapy with alkylating agents have an increased risk of second malignancies, mostly acute non-lymphatic leukemia."	( Hayashi, Y; Takahashi, M; Yoshimura, H, 1990)
"Conditioning regimens for solid tumors were multi-agent high-dose chemotherapy, mainly consisted of cyclophosphamide (CY) 120 mg/kg or melphalan 180mg/m2 and that for hematological malignancies were CY with fractionated total body irradiation (12 Gy)."	( Ohira, M, 1990)
"Nausea and emesis during cancer chemotherapy are very common, but can often be controlled with repetitive boli of antiemetic drugs."	( Naji, P; Osterwalder, B; Schuler, L; Senn, HJ; Wilder-Smith, CH, 1990)
"Fifty-four cancer patients, treated with diverse chemotherapy regimens, all including cisplatin (greater than = 50 mg/m2), received ICS 205-930 for a total of 165 courses."	( Antonacci, RA; Berruti, A; Dogliotti, L; Faggiuolo, R; Lancranjan, I; Ortega, C, 1990)
"In patients with cancer treated with cisplatin, carboplatin or methotrexate creatinine clearance calculated using the Cockcroft-Gault formula was compared with measured clearance and with the glomerular filtration rate."	( Atkinson, CH; Colls, BM; Fitzharris, BM; Frampton, CM; Robinson, BA, 1990)
"Fifty patients with advanced cancer were treated at dose levels that ranged from 100 to 1500 mg/m2/day."	( Baltzer, L; Dimaggio, JJ; Haines, I; Lee, SJ; Lowenthal, DA; Muindi, J; Stevens, YW; Walsh, TD; Warrell, RP; Yaldaei, S, 1990)
"Twenty-four cancer patients with diffuse interstitial pneumonitis (DIP) were randomized to undergo an open lung biopsy (OLB) within 8 hours of presentation (12 patients) or to receive empiric antimicrobial therapy (ET) with trimethoprim-sulfamethoxazole (TMP-SMX) erythromycin for a minimum of 4 days (12 patients)."	( Brower, S; Browne, MJ; Cotton, D; Gill, V; Glatstein, E; Gress, J; Hathorn, J; Hiemenz, J; Potter, D; Thaler, M, 1990)
"Patients with solid tumors are often anemic even before they undergo cytotoxic therapy."	( Abeloff, MD; Jones, RJ; Miller, CB; Piantadosi, S; Spivak, JL, 1990)
"We have treated 14 cancer patients with liposome-encapsulated doxorubicin (LED) at doses of 30, 45, 60, and 90 mg/m2."	( Alvord, WG; Forst, D; Potkul, LA; Rahman, A; Roh, JK; Treat, J; Woolley, PV, 1990)
"The genotoxicity of the alkylating anti-cancer drugs including cyclophosphamide (CP) has been examined previously by determining baseline SCEs in peripheral blood lymphocytes from treated cancer patients."	( Hansen, J; Jacobson-Kram, D; Kolodner, K; McDiarmid, MA; Strickland, PT, 1990)
"In this study, patients with advanced cancer were treated with DHAC administered as a 24-h constant i."	( Batist, G; Collins, JM; Curt, GA; Fine, RL; Huguenin, PN; Jenkins, J; Kelley, JA; Roth, JS, 1985)
"The effectiveness of sound cancer surgery and the importance of local disease control as an element in improving cure rates and palliation needs to be emphasised so that patients are not denied optimal treatment."	( Hughes, LE, 1985)
"In this malignancy, the HCG level suggests the diagnosis and stage, confirms response to therapy, and predicts relapse."	( Bates, SE; Longo, DL, 1985)
"In testicular cancer patients receiving adjuvant chemotherapy, a significant increase in serum (p less than 0."	( Hofbauer, J; Kratzik, C; Kuzmits, R; Legenstein, E; Ludwig, H; Szekeresz, T, 1986)
"Remarkable anticancer effects against various malignant solid tumors were observed using this targeting chemotherapy."	( Konno, T; Maeda, H; Matsumura, Y; Miyauchi, Y; Mizutani, J; Ohtsuka, N; Yamasaki, K, 1986)
"Immunotherapy against cancer gained popularity as a treatment modality based on the experimental model data that seemed to indicate that both specific stimulation of the immune response with antigen-bearing tumor cells and nonspecific stimulation with bacteria and other adjuvant-type compounds could enhance the existing immune response of the host and prevent recurrence or delay tumor growth."	( Niizu, Y; Urushizaki, I, 1986)
"Most human cancers are resistant to bleomycin a priori, however, and those which are initially sensitive frequently develop resistance to the drug during therapy."	( Sikic, BI, 1986)
"All patients treated to date had cancer, and all were suffering multisystem organ failure."	( Adams, F, 1988)
"Two important aspects of cancer that affect the way in which pain is managed are the cancer's treatability and components of its pathophysiology that themselves do not cause pain (the cancer's "nonpain" pathophysiology)."	( Levy, MH, 1989)
"The possibility and problems in cancer therapy using immunotoxin are discussed."	( Kitamura, K; Noguchi, A; Takahashi, T; Yamaguchi, T, 1989)
"Seventeen patients with advanced malignancy were treated with recombinant human granulocyte colony stimulating factor rhG-CSF (KRN 8601) infused intravenously over a period of 30 minutes once daily at the dose level/25 micrograms, 50 micrograms, 100 micrograms, 200 micrograms, 400 micrograms, 800 micrograms/m2 for 14 consecutive days, and the effect was compared to the period without rhG-CSF treatment."	( Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Mizunuma, N; Mukaiyama, T; Nagamine, D; Ogawa, M; Shinagawa, K; Tabata, M, 1989)
"A total of 173 female terminal cancer patients were randomized to treatment with daily 125 mg infusions of methylprednisolone sodium succinate or a matching placebo for a period of 8 consecutive weeks."	( Giongo, F; Lucchi, R; Popiela, T, 1989)
"Forty six episodes of infection in 43 cancer patients were treated with oral ciprofloxacin at a dose of 750 mg every 8 h."	( Bodey, GP; Cunningham, C; Haron, E; Holmes, F; Rolston, KV; Umsawasdi, T, 1989)
"A total of 28 patients receiving cancer chemotherapy with cisplatin-containing regimens (70-120 mg/m2) participated in an evaluation of the efficacy and safety of GR38032F for the prevention of acute nausea and vomiting."	( Bons, J; Brion, N; Droz, JP; Marty, M; Paule, B; Pouillart, P, 1989)
"Thirty-nine adults with solid tumors were treated on a Phase I study of menogaril administered i."	( Earhart, RH; Maroun, JA; Perrault, D; Stewart, DJ; Verma, S, 1989)
"Several thousand cancer patients with both early and advanced tumors have been treated to date with encouraging results."	( Dougherty, TJ, 1989)
"A patient with breast cancer was treated with adoptive immunotherapy of CTL because she had severe side effect from antineoplastics ."	( Kitsukawa, K, 1989)
"It is suggested that acid conditions in tumors might allow the development of new and relatively specific types of therapy which are directed against mechanisms which regulate pHi under acid conditions."	( Rotin, D; Tannock, IF, 1989)
"We evaluated 30 cancer patients who received immunotherapy with IL-2 or IL-2 plus lymphokine-activated killer (LAK) cells."	( Davis, CL; Denicoff, KD; Durkin, TM; Listwak, SJ; Lotze, MT; Quinlan, PE; Rosenberg, SA; Rubinow, DR, 1989)
"Almost three quarters of patients with cancer have severe pain, from invasion of the cancer itself, from effects of therapy, or from causes unrelated to the cancer (but often exacerbated by it)."	( Belgrade, MJ, 1989)
"Inadequate treatment of cancer pain with narcotics may stem, in part, from these events."	( Hill, CS, 1989)
"Acute and chronic malabsorption after cancer chemotherapy should be considered in patients, who are treated with enteral medication and nutrition."	( Borchard, F; Hürter, T; Reis, HE, 1989)
"One hundred forty-seven cancer patients were treated with intravenously administered ciprofloxacin, 200 mg every eight hours, as initial therapy for febrile episodes."	( Bodey, GP; Cunningham, C; Haron, E; Rolston, KV, 1989)
"Superficial human tumors have been studied by MRS to characterize their 31P spectra, and to measure metabolic changes during therapy."	( Boska, MD; Karczmar, GS; Meyerhoff, DJ; Shine, N; Speder, A; Valone, F; Weiner, MW; Wilkinson, M, 1989)
"Sixty-nine patients with malignant tumors receiving cancer chemotherapy, 90% including cis-platinum, were evaluated in a randomized crossover study for the antiemetic efficacy and the side effects of two antiemetic regimens: chlorpromazine (CPM) 2."	( Ben-Yosef, R; Biran, S; Brufman, G; Catane, R; Gez, E, 1989)
"Two patients with breast cancer who had multiple distant metastases and 2 pediatric patients are now alive with NED after 5 years of the treatment and seem to have been cured."	( Fujimoto, T; Kubota, M; Nakasaki, H; Norihisa, Y; Noto, T; Ohta, M; Okumura, A; Tajima, T; Tokuda, Y; Yokoyama, S, 1989)
"Seventeen of the 24 treated tumors (70%) had previously been irradiated."	( Clark, JR; Fraser, SM; Gelwan, LE; Hansen, J; Herman, TS; Jochelson, MS; Molnar-Griffin, BJ; Pfeffer, MR; Scott, PJ; Teicher, BA, 1989)
"Examination of electrocardiograms of cancer patients treated with a variety of doses and routes of OK-432 has revealed that none of 266 patients examined showed any significant change in electrocardiograms (ECGs) after OK-432 treatments, regardless of their pretreatment heart conditions (normal or abnormal ECGs)."	( Goya, T; Hayashi, Y; Sugisaki, T; Tanaka, J; Torisu, M; Yoshida, T, 1989)
"Thirty-three cancer patients remaining hypercalcemic after a 48-h rehydration period were included and monitored daily until normocalcemia or treatment failure was documented."	( Body, JJ; Borkowski, A; Magritte, A; Sculier, JP; Seraj, F, 1989)
"Fifty-two non-resectable and recurrent cancer patients with prior treatment, were entered in this study; 1 esophageal, 33 gastric, 1 duodenal, 4 colorectal, 2 pancreatic, 2 bile duct, and 9 breast cancer."	( Hattori, T; Jinushi, K; Kim, R; Niimoto, M; Saeki, K; Saeki, T; Toi, M; Yanagawa, E; Yoshinaka, K, 1989)
"The effect of cancer chemotherapy on dapsone (DDS) N-acetylation was explored in 28 patients with various malignancies."	( Harper, PG; Philip, PA; Rogers, HJ, 1989)
"A series of 252 patients with terminal cancer (mostly with bony metastases) were treated with epidural morphine."	( Hui, YL; Liew, E, 1989)
"Twelve Patients with malignant neoplasms were treated in twenty-five courses with high-dose Cisplatin and high-dose Bismuth Subnitrate."	( Kawamura, E; Morikawa, T, 1989)
"The more undifferentiated tumors took up more [125I]MIBG and may be more likely to respond to targeted radiotherapy with MIBG."	( Agrawal, M; Babich, JW; Carter, R; McElwain, TJ; Meller, ST; Moyes, JS, 1989)
"In 34 cancer patients with 40 neutropenic febrile episodes requiring broad-spectrum antimicrobial therapy, detailed dietary assessments revealed that deficient and severely deficient phylloquinone intakes (less than or equal to 70 and less than or equal to 25 micrograms/d) were identified during 88% and 38% of all days recorded, respectively."	( Conly, J; Loftson, J; Louie, T; Ramotar, K; Reid, E; Suttie, J, 1989)
"An open study of 47 patients with cancer pain treated with repeated doses of a controlled-release oral morphine tablet was conducted to assess the acceptability of this drug and develop guidelines for its use."	( Coyle, N; Foley, KM; Houde, RW; Lapin, J; Portenoy, RK, 1989)
"The impairment of cancer patients' nutritional status seems to depend primarily on the decrease of spontaneous oral intake as a consequence of the side effects of tumor therapy."	( Konkol, K; Mueller, JM; Ollenschlaeger, G; Schrappe-Baecher, M; Wickramanayake, PD, 1989)
"Being easy to use, these devices allow cancer patients to remain at home, whereas otherwise they would need to be hospitalized for effective treatment of pain."	( Buchser, E; Chapuis, G; Cosendey, BA; Dupasquier, G, 1989)
"Oral morphine therapy for cancer pain offers effective pain relief with minimal side effects in the majority of patients."	( Bhargava, K; Heranjal, R; Lobo, B; Vijayaram, S, 1989)
"The satisfactory treatment of cancer pain requires a variety of practical management strategies."	( Barnett, JB; Brigden, ML, 1987)
"When the breast cancer patients' macrophages were pretreated with these neuropeptides, enhancement in cytotoxicity was observed at 10(-10) M of [met]-enkephalin, and [leu]-enkephalin and at 10(-8) M and 10(-12) M of alpha-endorphin."	( Cameron, DJ, 1987)
"Pain in cancer patients is shown to arise in different ways, demanding a flexible approach to treatment."	( Böhme, K, 1988)
"One of the major problems in cancer chemotherapy is the development of drug resistance during treatment."	( Tsuruo, T, 1988)
"Meanwhile, attempts to treat the malignancy are initiated, including palliative radiation therapy for bony metastases."	( Fetchick, DA; Mundy, GR, 1986)
"Application of this therapy to tumors in the bronchus, bladder, skin, and several other sites has demonstrated both safety and efficacy, even in advanced cases."	( Dougherty, TJ, 1986)
"Twenty-two patients with advanced solid tumors were treated with a quinazoline folate antagonist, trimetrexate, to determine the toxicity spectrum, the maximal tolerated dose, and the pharmacokinetics of the drug."	( Baker, M; Bertino, JR; Cashmore, AR; Delap, R; Dreyer, RN; Ernstoff, M; Grillo-Lopez, A; Lin, JT; Marsh, JC; Whitfield, LR, 1987)
"Nineteen patients affected by solid tumors were included in the study, 5 of whom were treated with CMF, 4 with FEC, 4 with CEV, and 6 with CDDP."	( Barni, S; Crispino, S; Esposti, D; Esposti, G; Ferri, L; Fumagalli, G; Lissoni, P; Paolorossi, F; Rovelli, F; Tancini, G, 1987)
"Eighteen adult patients with solid tumors were treated with oral menogaril, a new anthracycline antibiotic active against human breast cancer after intravenous administration."	( Crespeigne, N; de Valeriola, D; Dodion, P; Joggi, J; Kenis, Y; Peeters, B; Piccart, M; Tueni, E; van Berchem, C; Wery, F, 1988)
"Eighteen adult patients with solid tumors were treated with oral menogaril, a new anthracycline antibiotic active against human breast cancer after intravenous administration."	( Crespeigne, N; de Valeriola, D; Dodion, P; Joggi, J; Kenis, Y; Peeters, B; van Berchem, C; Wery, F, 1988)
"Clinical studies have shown that cancer patients can develop learned aversions to a novel ice cream flavor when it is consumed before drug treatments that produce nausea and vomiting."	( Bernstein, IL, 1985)
"Models for potential indirect anticancer effects either by in-vivo administration or by in-vivo incubation plus passive transfer of T-cells are presented to be initiated in future clinical trials."	( Heinemann, V; Jehn, U, 1985)
"Anti-cancer agents suspended in Lipiodol have been proved to be effective in the targeting of chemotherapy for cancer of the digestive organs."	( Takahashi, T; Taniguchi, H; Yamaguchi, T, 1986)
"In small cell lung cancer initial high dose therapy followed by non-cross-resistant regimens may prove effective."	( Peters, W; Souhami, R, 1986)
"Fifty-four marijuana-naive cancer patients undergoing chemotherapy and about to use THC (delta-9-tetrahydrocannabinol) as an antiemetic for the first time were randomly assigned to one of two conditions: stress inoculation or placebo/information training."	( Roffman, RA, 1986)
"Thus, it is possible that tumors also pretreated with other drugs become resistant to growth inhibitory effects of ascorbate ions."	( Cercek, B; Cercek, L, 1987)
"Treatment of cancer patients often fails because of the resistance in the tumor to chemotherapeutic drugs."	( De Vries, EG; Hospers, GA; Mulder, NH, 1988)
"The role of IV melphalan in cancer chemotherapy is not well defined, despite its manageable toxicity and higher and more predictable blood levels following IV administration compared with oral administration."	( Cheson, BD; Leyland-Jones, B; Sarosy, G; Soochan, P, 1988)
"There are 5 patients with breast cancer who have been followed over 5 years after treatment."	( Kubota, M; Mitomi, T; Murakami, M; Nakamura, Y; Ohta, M; Shinozuka, T; Tajima, T; Tokuda, Y; Watanabe, K; Yokoyama, S, 1988)
"Sixty-five cancer patients pretreated with chemo or radiotherapy, with granulocytopenia less than 1000/mm3 and without fever, were entered into this study: 30 of them were submitted to prophylaxis with norfloxacin while the remaining 35 patients were used as a control group."	( Ameglio, F; Casali, A; Frasca, AM; Gallo Curcio, C; Modugno, G; Paoletti, G; Tonachella, R; Tropea, F; Verri, C, 1988)
"It is desirable for multidisciplinary cancer treatments to be concentrated as selectively as possible onto the cancer-bearing organs in order to augment the anticancer effects and minimize the untoward effects."	( Agishi, T; Fuchinoue, S; Honda, H; Nakazawa, H; Okumura, T; Teraoka, S, 1986)
"The growth of Meth A (MA) tumors was suppressed in tumor-antigen-specific manner in BALB/c mice immunized with mitomycin C-treated MA (MMC-MA) cells in saline or in Freund's complete adjuvant (FCA)."	( Himeno, K; Matsumoto, T; Miake, S; Mitani, M; Mori, K; Nomoto, K, 1986)
"Eight patients with cancer associated hypercalcaemia were treated with the combination of aminohydroxypropylidene diphosphonate and salmon calcitonin for six days."	( Alzaid, AA; Boyle, IT; Gardner, MD; Ralston, SH, 1986)
"A total of 24 patients with intractable cancer pain were evaluated as candidates for spinal morphine therapy."	( Hadley, MN; Shetter, AG; Wilkinson, E, 1986)
"in seven cancer patients over 10-day courses at doses of 10-90 g/day and 24-h urinary excretion of polyamines and decarboxylated-S-adenosylmethionine was determined before, during, and after treatment."	( Haegele, KD; Romijn, JC; Schechter, PJ; Sjoerdsma, A; Splinter, TA, 1987)
"Although other neural crest tumors may concentrate [131I]MIBG, this is not a consistent finding; however, it is useful to investigate which tumors do, as this may provide an alternative treatment modality for some patients."	( de Kraker, J; Hoefnagel, CA; Marcuse, HR; Voûte, PA, 1987)
"Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, greater than 11."	( Benson, AB; Bockman, RS; Citrin, DL; Greco, FA; Harvey, HA; Rasmussen, P; Schiller, JH; Siris, ES; Stock, JL; Witte, RS, 1987)
"Sampling of tumors before and after drug treatment is done by 4 mm disposable punch biopsy or forceps biopsy via subcutaneous tunneling."	( Gustavsson, BG; Spears, CP, 1988)
"In 2 patients with metastatic breast cancer who had not been pretreated with cytostatic agents, a partial remission was achieved lasting for 5 months."	( Kleeberg, UR; Miller, AA; Scheulen, ME; Schmidt, CG; Seeber, S, 1988)
"Twenty-three outpatients with cancer pain refractory to other methods of pain control were treated with epidural morphine (EM) delivered through a chronically placed percutaneous lumbar epidural catheter."	( Busch, EH; Downing, JE; Stedman, PM, 1988)
"Thirteen cancer patients with moderate to severe chronic pain of malignant origin on treatment with Ketogan tablets were included in an open non-randomized cross-over study comparing the analgesic effect, side effects and serum concentrations of Ketogan tablets and mixture."	( Kjaer, M; Nielsen, H, 1988)
"This study describes the development of neoplasms and the suppression of bone marrow stem cells following chronic administration of cytosine-arabinoside (ara-C) in Sprague-Dawley rats."	( Berger, MR; Schmähl, D, 1988)
"Four lymphoproliferative cancers occurred in the azathioprine treated group compared with two in the control group."	( Evans, SJ; Hazleman, B; Petrie, J; Silman, AJ, 1988)
"A total of 13 cancer patients were treated with Adoptive Chemoimmunotherapy (ACIT) using alloactivated HLA haploidentical lymphocytes."	( Hank, JA; Kohler, PC; Minkoff, DZ; Sondel, PM, 1988)
"Thirty-four patients with advanced neoplasms who had received interleukin-2 and LAK cells were followed for at least four weeks after treatment."	( Atkins, MB; Berkman, EM; Gould, JA; Kaplan, MM; Mier, JW; Parkinson, DR, 1988)
"Forty-four patients with advanced cancer were treated with IT OK-432 immunotherapy."	( Baba, N; Hattori, T; Kegoya, Y; Kuninobu, H; Toge, T; Yamaguchi, Y, 1988)
"We assessed the risk of occurrence of cancer associated with exposure to metronidazole in the 771 female residents of Rochester, Minnesota, who were treated with metronidazole for vaginal trichomoniasis during the period 1960 through 1969 and were followed up for a total of 12,628 person-years."	( Beard, CM; Dahlin, DC; Kurland, LT; Noller, KL; O'Fallon, WM, 1988)
"New therapeutic approaches to improving cancer treatment will most likely be coordinated with either chemotherapy or radiotherapy or combined chemotherapy and radiotherapy."	( Looney, WB, 1988)
"Fourteen patients with advanced cancer were treated at doses of 10-30 mg/m3."	( Bork, E; Hansen, HH; Vest, S, 1988)
"The sera of 138 cancer patients, taken before any therapy, were significantly lower than the corresponding normal or chronic disease controls."	( Gross, DJ; Gross, J; Margalioth, E; Simon, E; Szwarc-Bilotynski, L, 1988)
"Seventy-eight patients with cancer experienced 88 episodes of fever while neutropenic and were randomly assigned to receive empiric antibiotic therapy with cefoperazone 2 g intravenously every 12 hours and mezlocillin 4 g intravenously every six hours or imipenem/cilastatin 500 mg intravenously over 30 to 60 minutes every six hours."	( Black, D; Kirby, WM; Kwok, K; Miller, S; Mortimer, J, 1988)
"The effects on cancer development vary for different types of cancers, with type and dosage of hormone and probably also, insofar as breast cancer is concerned, with age and age at which treatment was begun."	( Bergkvist, L; Persson, I; Westerholm, B, 1988)
"Fifty-five ovarian cancer patients treated with melphalan during 1968-1978 were followed during 309 person years and studied with cytogenetic analyses."	( Einhorn, N; Eklund, G; Lambert, B, 1988)
"Eighty-four patients with refractory cancer received 12 dose escalations from 10-150 mg/m2 TCNU administered orally every 6 weeks."	( Cornbleet, MA; Kerr, ME; Leonard, RC; Macpherson, JS; Smyth, JF; Warrington, PS; Whelan, JM, 1987)
"Since neutropenia is common during cancer treatment, there is a continual risk of infection in cancer patients; thus it is important for medical oncologists to become aware of these complications and their management."	( Fujimoto, T, 1986)
"The influence of therapy for the first cancer on subsequent leukemia risk was determined by a case-control study conducted on 25 cases and 90 matched controls."	( Birch, J; Boice, JD; Fraumeni, JF; Hoover, RN; Meadows, AT; Oberlin, O; Stone, BJ; Stovall, M; Tucker, MA; Voûte, PA, 1987)
"Eighty-one febrile episodes in cancer patients with adequate neutrophil counts (greater than 1000/microliter) were treated with a double beta-lactam combination of ceftizoxime plus ticarcillin."	( Bodey, GP; Elting, L; Fainstein, V; Jones, PG; Rolston, KV, 1987)
"Thirty-four patients with cancer (30) or ARC (4) with severe T cell defect or imbalance persisting a long time after completion of any cytostatic treatment were treated by bestatin 30 mg/day 3 days per week during three weeks."	( Brienza, S; Canon, C; Mathé, G; Misset, JL; Musset, M; Reizenstein, P; Umezawa, H, 1986)
"Adoptive immunotherapy of human cancer was investigated in our institution as part of a National Cancer Institute extramural group study."	( Baker, H; Ciobanu, N; Dutcher, JP; Frank, O; Hutner, SH; Marcus, SL; Paietta, E; Strauman, J; Wiernik, PH, 1987)
"Most anticancer drugs are more toxic to proliferating cells and the fall and recovery of granulocyte counts after chemotherapy may be explained by the effect of drugs on rapidly proliferating precursor cells in the bone marrow."	( Tannock, IF, 1986)
"It has been postulated that tumors contain hypoxic cells of decreased radiation sensitivity, which limit curability with radiation therapy."	( Fischer, JJ; Martin, DF; Rockwell, S, 1986)
"The therapy for each of these tumors, with the exception of osteosarcoma, consisted of combination chemotherapy with or without radiotherapy and was started as soon after diagnosis as possible."	( Lampkin, BC; Wong, KY, 1986)
"The records of 147 cancer patients who received at least three courses of cisplatin-containing chemotherapy in the Arizona Cancer Center clinic between 1982 and 1985 were reviewed to determine the safety and tolerance of cisplatin administered in the outpatient setting."	( Alberts, DS; Brock, J, 1986)
"The numerical development of cancer cells during tumor growth and under current forms of therapy is quantitatively described as a fundament of a scientifically founded anticancer strategy."	( von Ardenne, M, 1986)
"Patients with specific types of cancer have achieved substantial prolongation of survival after successful cancer chemotherapy."	( Furue, H, 1987)
"One of the major causes of failure of cancer chemotherapy is the proliferation of specific drug-resistant tumor cells during treatment."	( Tsuruo, T, 1987)
"In this study, 12 patients with colon cancer were treated with thrice weekly thymosin fraction 5 at a dose of 120 mg/m2, and 10 patients with non-small-cell lung cancer received thymosin alpha 1 at 1."	( Beauregard, J; Dillman, RO; Royston, I; Zavanelli, MI, 1987)
"Urinary bladder cancer (six cyclophosphamide-treated patients, no control patients) and skin cancer (eight cyclophosphamide-treated patients, no control patients) were identified as differing statistically between the groups, and hematologic malignancy (five cyclophosphamide-treated patients, one control patient) showed a similar trend."	( Agarwal, AK; Baker, GL; Kahl, LE; Medsger, TA; Stolzer, BL; Zee, BC, 1987)
"Thirty cancer patients, who were diagnosed to be beyond the operable stage, were treated by intra-arterial anticancer agent infusion via an implantable vascular access device (VAD) combined with local hyperthermia and/or charcoal hemoperfusion."	( Agishi, T; Honda, H; Huchinoue, S; Kihara, K; Nakagawa, Y; Nakazawa, H; Oba, S; Ota, K; Teraoka, S, 1987)
"Thirty-seven patients with advanced cancer requiring oral administration of strong narcotics for pain control have been treated with one or other of two commercially-available, sustained-release morphine preparations."	( Sherman, LM, 1987)
"Seventeen patients with advanced cancer pain, treated with chronic epidural morphine, were studied."	( Hedner, T; Lindqvist, J; Nordberg, G; Samuelsson, H, 1987)
"Eleven non-resectable cancer patients have been successfully treated by means of a one-shot and continuous intra-arterial infusion chemotherapy, utilizing an implantable vascular access device (Catheter Access) connected to a continuous infusion pump (Nipro portable syringe infusion pump) via a non-corning needle (Nipro coreless needle set)."	( Agishi, T; Fuchinoue, S; Honda, H; Nakagawa, Y; Nakazawa, H; Ohta, K; Takahashi, K; Teraoka, S, 1987)
"Of 135 persons with cancer referred for psychotherapy, 76 per cent were found to have had a previous grief experience, and 60 per cent were suffering from unresolved grief for previous losses."	( Vachon, ML, 1987)
"Twelve patients with pain secondary to cancer were simultaneously administered both morphine (10 mg) and pethidine (50 mg) in 10 ml of normal saline via an epidural catheter inserted in the lumbar region (usually L2,3) and attached to a subcutaneously implanted portal reservoir."	( Armstrong, PJ; Cherry, DA; Cousins, MJ; Gourlay, GK; Plummer, JL, 1987)
"For certain classes of neoplasms, these parameters can be used for the early recognition of neoplasia and related to disease evolution and dissemination and to the results of therapy."	( Göhde, W; Mauro, F; Schumann, J; Teodori, L, 1986)
"Current treatment of cancer-related hypercalcemia is limited by agents of limited effectiveness or excessive toxicity."	( Alcock, NW; Bockman, RS; Skelos, A; Warrell, RP, 1986)
"Chronic cancer pain remains intractable by standard treatment in many patients and interferes with their mobility and independence."	( Handa, H; Konishi, T; Moritake, K; Nishioka, T; Suwa, H; Takaya, M; Umeda, S, 1986)
"Nineteen patients with urologic malignancy undergoing chemotherapy with cisplatin in combination with other agents were studied for the antiemetic efficacy of Timiperone."	( Kojima, S; Owada, F; Satake, I; Tari, K, 1986)
"for treatment of various human cancers, especially leukemias, even though the systemic availability of the drug given p."	( Creagan, ET; Hu, TC; Kovach, JS; Kvols, LK; Rubin, J; Schutt, AJ; Svingen, PA, 1986)
"Twenty-three patients with metastatic tumors received multiple chemotherapy regimens which included CIS platine (CDDP) by continuous ambulatory infusion for 4 successive days at a rate of 25 mg/m2/day repeated every 4 weeks."	( Benahmed, M; Renaux, J; Rouesse, J; Spielman, M, 1986)
"Fifteen cancer patients receiving cisplatin-containing chemotherapy participated in two antiemetic studies."	( Havsteen, H; Kjaer, M; Nielsen, H, 1986)
"In patients with cancer pain treated by continuous epidural opiate infusion (4."	( Gips, H; Hempelmann, G; Krumholz, W; Lüben, V; Müller, H; Zierski, J, 1986)
"Twenty cancer patients with severe chronic pain have been treated with intraventricular morphine sulfate."	( Hill, SC; Leavens, ME; Obbens, EAMT; Otis, F; Ruthenbeck, SS, 1987)
"Overall, the patients with cancer were pleased with their pain therapy, experienced few complications, and reported improved quality of life."	( Gershow, J; Glassberg, A; Kenefick, T; Krames, ES; Lyons, A; Taylor, P; Wilkie, D, 1985)
"High dose administration of anticancer drugs was discussed putting an emphasis on methotrexate and cytosine arabinoside."	( Takaku, F, 1985)
"This effect in cancer chemotherapy was studied in 31 patients with advanced ovarian cancer."	( Hrushesky, WJ, 1985)
"Therapeutic options in cancer treatment currently are few, and the benefits of potentially carcinogenic chemotherapy and radiotherapy continue to outweigh the risks."	( Coltman, CA; Dorr, FA, 1985)
"In all, 39 patients with advanced cancer were treated at doses of 2."	( Groth, S; Hansen, HH; Hansen, SW; Nissen, MH; Rørth, M; Sørensen, JB, 1985)
"The photodynamic therapy of tumors is based on a photosensitization reaction that produces oxygen-derived cytotoxic species."	( Freitas, I, 1985)
"Patients with hepatic cancers were treated with varying doses of DSM with mitomycin C coadministered into the hepatic artery to define a dose of DSM which produces acceptable toxicity with maximal hepatic drug deposition as determined by a reduction in systemic mitomycin C exposure."	( Ensminger, WD; Gyves, JW; Stetson, P; Walker-Andrews, S, 1985)
"Some of these solid tumors contain greater amounts of activity than do their normal equivalents, which encourages the use of inhibitors of this enzyme in conjunction with treatment of these tumors by 5-fluorouracil."	( Cha, S; el Kouni, MH; Naguib, FN, 1985)
"On the other hand, patients with larger tumors where the tumor dose cannot be increased more than 10% over conventional radiotherapy have not responded well to helium ion radiotherapy."	( Castro, JR; Char, D; Chen, GT; Collier, JM; Gauger, G; Gutin, P; Phillips, TL; Pitluck, S; Saunders, W; Zink, SR, 1985)
"The studied patient was elderly and had cancer of left breast, cancer of the head of the pancreas, history of blood transfusions, and was on tamoxifencitrate therapy for breast cancer."	( Barlas, AH, 1986)
"Although the pathophysiology of cancer cachexia is incompletely understood, it assumes considerable clinical relevance because malnutrition is a potentially treatable problem associated with poor outcome."	( Dempsey, DT; Mullen, JL, 1985)
"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications."	( Hazleman, B, 1985)
"Eleven dogs with spontaneous neoplasms were intensively treated with an immunoadsorption system consisting of a continuous flow centrifuge, Protein A-Sepharose columns, and a semi-automatic elution system."	( Branda, RF; Klausner, JS; Miller, WJ; O'Brien, TD, 1985)
"Seventy-eight infectious episodes in 75 cancer patients with adequate granulocyte counts were treated with cefotaxime."	( Bodey, GP; Bolivar, R; Elting, L; Fainstein, V; Jones, P; Rolston, K, 1985)
"Thirty-nine patients with metastatic neoplasms received a total of 127 treatment courses; two-thirds of the patients had received prior treatment with radiation therapy or chemotherapy; most of the latter treatment regimens included MTX or FUra."	( Benz, C; Cadman, E; DeGregorio, M; Holleran, W; Ignoffo, R; Lewis, B; Saks, S; Sambol, N, 1985)
"Only patient C (breast cancer) had received chemotherapy."	( Boulet, L; Dufour, M; Panasci, LC; St Germain, J, 1985)
"Eleven patients with advanced breast cancer and four with astrocytoma were treated with plasma perfused over columns containing staphylococcal Protein A (SPA)."	( Apuzzo, ML; Bertram, JH; Boquiren, D; Grunberg, SM; Hengst, JC; Kunkel, L; Nelson, J; Plotkin, D; Shulman, I; Waugh, WJ, 1985)
"Twenty-six out of 160 cancer patients referred to the Pain Division for pain assessment were selected for analgesia with long-term epidural morphine, so aiming to define its place amongst more traditional methods of treatment, such as drugs, nerve-blocks, neurosurgery or radiotherapy."	( Arnér, S; Bayer-Berger, MM, 1985)
"Possible ramifications to cancer chemotherapy are discussed."	( Tesmer, JG; Tobey, RA, 1985)
"A general review of the current use of cancer chemotherapeutic agents in the treatment of common types of cancer and an update of the state of the art of chemotherapeutic treatment of the late and early stages of breast cancer in 1984 are described."	( Wright, JC, 1985)
"Testicular and ovarian cancer patients receiving chemotherapy on the first course, and given cis-DDP in 21- or 28-day cycles (five days of drug infusion followed by two or three drug-free weeks) accumulated cis-DDP-DNA adducts in blood cell DNA as a function of dose."	( Litterst, CL; Ozols, RF; Poirier, MC; Reed, E; Yuspa, SH; Zwelling, LA, 1985)
"Fourteen cancer patients were administered 10 mg of morphine in 10 ml of normal saline via an epidural catheter inserted in the lumbar region (usually L2."	( Cherry, DA; Cousins, MJ; Gourlay, GK, 1985)
"In summary, a strategy of cancer chemotherapy predicated upon interference with RNA synthesis or increase in RNA catabolism is offered as a potential mechanism for establishing anti-angiogenesis, and as a promising alternative and adjunct to present methods."	( Blumberg, N, 1974)
"Eight other test compounds from the Cancer Chemotherapy National Service Center (CCNSC) were not toxic to cell growth, although two (4-biphenylcarboxylic acid and 1-[p-chlorobenzyl]-2-ethyl-5-methyl-indole-3-acetic acid) inhibited Crithidia alpha-glycerophosphate dehydrogenase below 1 mm."	( Bacchi, CJ; Ciaccio, EI; Koren, LE, 1969)
"Of 100 patients with small-cell lung cancer receiving an identical regimen of cyclophosphamide, doxorubicin, and vincristine, 40 were assigned to treatment with lithium concurrently."	( Dinwoodie, WR; Lyman, GH; Schocken, DD; Williams, CC, 1984)
"In untreated cancer patients, plasma and urine cAMP levels were similar to those of normal subjects, whereas plasma and urine cGMP levels were markedly higher."	( Baldini, L; Bamonti-Catena, F; Lombardi, L; Maiolo, AT; Mandelli, V; Peracchi, M; Polli, EE; Toschi, V, 1984)
"Undertreatment of cancer pain results not only from the limited expectations of patients but also from the inadequate knowledge of many physicians."	( Noyes, R, 1981)
"The treatment of chronic pain in cancer patients with analgesic drugs has been evaluated from the records of 70 hospital admissions."	( Heimpel, H; Merkle, W; Schreml, W, 1981)
"When gynecologic cancer is treated by either surgery or radiation therapy, definitive infertility usually results."	( Barber, HR, 1981)
"The management of pain in cancer patients requires experience and a therapy-protocol."	( Hoffmann, L, 1984)
"Intractable pain in six cancer patients was treated with lumbar intrathecal morphine (two patients) and intraventricular morphine (four patients)."	( Cech, DA; Hill, CS; Leavens, ME; Weston, JS; Weyland, JB, 1982)
"In nine of 11 (82%) instances, tumors were sensitive to a particular drug, and the patient had at least 50% regression of tumor following treatment with the tested drug."	( Burk, MW; Campbell, MA; Giuliano, AE; Kaiser, LR; Kern, DH; Mann, BD; Morton, DL, 1982)
"New agents used in cancer chemotherapy are continually appearing which, in turn, leads to newer patterns of toxicity."	( Seyfer, AE; Solimando, DA, 1983)
"Since 1970, we have carried out cancer chemotherapy and immunotherapy in cooperation with Japanese scientists, particularly Prof."	( Mathé, G, 1983)
"Many attempts in cancer immunotherapy have been made on the basis of advanced basic immunology."	( Yamamura, Y, 1983)
"A patient with a disseminated malignancy received 3 mg of synthetic beta-endorphin administered intrathecally by lumbar puncture."	( Cohen, MR; Dubois, M; Pickar, D, 1984)
"The majority of tumors treated were dermal breast cancer recurrences (21 cases), local recurrence of ENT squamous cell carcinomas (16 cases), and ENT cutaneous metastases of squamous cell carcinomas (9 cases)."	( Berns, MW; Burns, RG; Dahlman, A; Wile, AG, 1982)
"This paper provides an overview of cancer chemotherapy with special reference to the pharmacokinetics of the nitrosoureas."	( Wakui, A, 1982)
"Ten advanced cancer patients not amendable to conventional therapy were treated with high dose (greater than 500 mg/day, for 30 days) Medroxyprogesterone Acetate (MAP) both orally and intramuscularly, in order to evaluate a possible anabolic effect of this hormone."	( Angelelli, B; Camaggi, CM; Colalongo, F; Costanti, B; Giambiasi, ME; Lelli, G; Pannuti, F; Strocchi, E, 1983)
"The expanding use of cytotoxic drugs in cancer therapy has resulted in a confusing and increasingly frequent array of severe renal complications."	( Clarkson, AR; Healy, HG, 1983)
"Head and neck cancer patients received treatment to 114 sites with a complete response (CR) in 28, partial response (PR) in 42, stable disease (SD) in three, and no response (NR) in 34, and an undetermined response in seven."	( Baghdassarian, R; Berns, MW; Coffey, J; Mason, GR; Nahabedian, MY; Wile, AG, 1984)
"Ten advanced cancer patients (both with hormone-sensitive and non-hormone sensitive tumors) were treated with high dose medroxyprogesterone acetate (MAP, greater than 500 mg/day)."	( Angelelli, B; Lelli, G; Mondini, F; Monetti, N; Pannuti, F; Piana, E; Strocchi, E; Zanichelli, L, 1984)
"We investigated the incidence of second tumors after cytotoxic chemotherapy in 457 long-term survivors treated for choriocarcinoma or an invasive mole between 1958 and 1978."	( Bagshawe, KD; Booth, M; Dent, J; Rustin, F; Rustin, GJ; Salt, S, 1983)
"With assistance from the American Cancer Society, the State Medical Society, and volunteers and professionals in cancer research, the legislation was adapted to the existing legal and administrative framework."	( Joranson, DE; Treffert, DA, 1983)
"Since patients with advanced cancer are usually immunodeficient, they might benefit from therapy with thymic hormones, which have an immunorestorative effect in immunosuppressed laboratory animals."	( Beauregard, JC; Dillman, RO; Halliburton, BL; Royston, I; Wormsley, S; Zavanelli, MI, 1983)
"Thirty-seven adults with advanced cancer who were treated with cisplatin were randomly assigned to receive either synthetic long-acting ACTH (1 mg IM given 24 hours, 12 hours, and immediately preceding the administration of cisplatin) or a placebo given under the same conditions."	( Colbert, N; Izrael, V; Laugier, A; Lotz, JP; Pene, F; Schlienger, M; Stoppa-Lyonnet, D; Vannetzel, JM, 1983)
"The presence of hypoxic regions within tumors can be directly and indirectly inferred from invasive procedures such as oxygen electrode techniques and histologic study, respectively, but such information does not significantly contribute to current prescriptions given by oncologists for tumor treatment."	( Chapman, JD, 1984)
"Twenty-eight cancer patients were treated with intramuscular butorphanol tartrate, a new non-narcotic analgesic, for investigating its clinical benefits in controlling cancer pain."	( Ebina, A; Hayashi, I; Ito, T; Konno, K; Nagai, K; Nakai, Y; Sato, M, 1983)
"In other poor-prognosis tumors that are sensitive to chemotherapy, or can be debulked surgically, or locally irradiated, high-dose melphalan with ABMT given as late intensification therapy may significantly prolong time to relapse, and ultimately prolong survival."	( Boesen, E; Corringham, R; Gilmore, M; Prentice, HG, 1983)
"Patients with advanced cancer who had documented disease progression while receiving chemotherapy alone were subsequently treated with the same drug, by the same dose and route, combined with localized hyperthermia."	( Elliott, RS; Harrison, WH; Haskell, CM; Kaiser, LR; Morton, DL; Ramming, KR; Sarna, G; Silberman, AW; Storm, FK, 1984)
"Patients with malignant neoplasms who were receiving chemotherapy and renal transplant recipients who were receiving immunosuppressives were randomized to receive either clotrimazole (10 mg) or placebo troches three times a day in a prospective, double-blinded study."	( Dekker, PT; Nightingale, CH; Owens, NJ; Quintiliani, R; Schauer, PK; Schweizer, RT, 1984)
"In any event, for cancer treatment, it is important to determine which substances inhibit the arrest of circulating tumor cells and how to prevent hematogenous metastasis."	( Sone, S; Tsubura, E; Yamashita, T, 1983)
"However, the uptake of the anti-cancer drug into the tumor and its distribution throughout the body are influenced by a large number of factors: the method or route of administering the anti-cancer drug; rate of infusion; local blood flow; permeability of the blood vessels; structure and affinity of the drug; the metabolism of the drug and the speed of its breakdown and elimination."	( Taguchi, T, 1984)
"In a population of 51 ambulant cancer patients treated with doxorubicin-containing chemotherapy we conducted a double-blind cross-over randomized trial, comparing the anti-emetic efficacy of a combination of amitriptyline (25 mg p."	( Blijham, GH; Mellink, WA; van Deyk, WA, 1984)
"Most of these patients had solid tumors and were treated with an initial dose of mitoxantrone (12 to 14 mg/m2)."	( Crossley, RJ, 1984)
"To increase our understanding of cancer and improve cancer treatment on a rational basis we need to identify both qualitative and quantitative differences between normal and neoplastic tissue."	( Beaney, RP, 1984)
"Progress in the treatment of cancer with drugs has radically altered the clinical approach to patients with malignancy."	( Allegra, CJ; Chabner, BA; Curt, GA; Fine, RL; Yeh, GW, 1984)
"Cy is widely used for cancer chemotherapy."	( Ahmed, AR; Hombal, SM, 1984)
"Why do malignant tumors initially grow rapidly, then more slowly? What accounts for the different rats of growth among different tumors? Can the answers to these and related questions enable us to improve the results of cancer therapy? With advanced technology, we have come a long way in penetrating the mechanisms of tumor cell kinetics, but to date clinical strategies have not kept pace."	( Tannock, IF, 1983)
"This finding could be applied to cancer chemotherapy for enhancing drug delivery to tumor tissue selectively."	( Suzuki, M; Wakui, A, 1983)
"In this report the effects of anticancer agents on immune effector cells were analyzed and the possibility about the development of a reliable monitoring procedure for determining a potent treatment protocol was discussed."	( Saijo, N, 1983)
"The sperm production of 14 cancer patients who received doxorubicin was examined after cessation of therapy."	( Da Cunha, MF; Gordon, LA; Meistrich, ML; Ried, HL; Watchmaker, G; Wyrobek, AJ, 1983)
"This method is applied to cancer patients treated by cytotoxic chemotherapy with or without difluoromethylornithine (DFMO)."	( Belleville, F; Brossat, B; Metz, R; Nabet, P; Straczek, J, 1983)
"This finding was clinically applied to cancer chemotherapy for enhancing drug delivery to tumor tissue selectively."	( Sato, H; Wakui, A, 1984)
"Thirty six patients with advanced solid tumors (24 lung: 3 oat-cell, 14 squamous, 7 adenocarcinomas, 3 soft tissue sarcomas, 6 breast carcinomas; 1 seminoma; 2 ovarian adenocarcinomas) entered a phase II study of high-dose ifosfamide (IF) administered in combination with the uroprotective agent sodium 2-mercapto-ethane-sulfonate (Mesna)."	( Brema, F; Cinquegrana, A; Nobile, MT; Rosso, R; Santi, L, 1984)
"In a randomized crossover study 57 cancer patients receiving chemotherapy with high emetic potential were treated with low-dose levonantradol or standard-dose metoclopramide and crossed over to the other antiemetic drug in the next identical chemotherapy cycle."	( Altenburg, HP; Heim, ME; Queisser, W, 1984)
"With increasingly effective cancer chemotherapy, the control of chemotherapy-induced nausea and vomiting has become more important."	( Eyre, HJ; Ward, JH, 1984)
"As for the non-specific cancer immunotherapy concerned, the effect is limited and local use of immunopotentiators which could collect effector cells around tumor tissues might be the best way of cancer immunotherapy."	( Hamamoto, S; Hattori, T; Kameda, A; Niimoto, M; Seto, Y; Toge, T; Tomoda, S, 1984)
"For the treatment of cancer patients opioids can be administered epidurally."	( Bause, H; Blendl, M; Pothmann, W, 1984)
"All patients either had advanced tumors, or were in the terminal stage after repeated radiotherapy and chemotherapy."	( Abe, Y; Hong, SS; Kaneta, K; Matsuzawa, T, 1984)
"The effect of cesium therapy on various cancers is reported."	( Sartori, HE, 1984)
"25 patients with a malign neoplasia were treated with cytostatics."	( Borkenstein, J; Samonigg, H; Sterz, F, 1984)
"Eleven patients with advanced cancer were treated with SOAz, the first aziridino substituted inorganic heterocyclic compound to undergo phase I clinical trials."	( Mulder, NH; Rodenhuis, S; Schraffordt Koops, H; Sleijfer, DT; Van de Grampel, JC, 1984)
"Seventy-five percent of untreated cancer patients showed increased incorporation rates into the endogenous acceptor of serum."	( Aiginger, P; Kuzmits, R, 1984)
"Seven additional cancer patients were treated with probenecid prior to CP."	( Coleman, CN; Hirst, K; Jacobs, C; Rich, L; Weiner, MW, 1984)
"Thirty-four subsequent second malignant neoplasms were observed in 33 patients among those treated for Hodgkin's disease."	( DeVita, VT; Glatstein, E; Kelley, PA; Kinsella, TJ; Makuch, RW; Tester, WJ; Waller, B, 1984)
"A total of 20 cancer patients suffering chronic pain were treated with morphine chloride by intrathecal administration through a subcutaneous implanted reservoir."	( Ferrero Fernández, B; González Hernández, MJ; González Navarro, A; Molinero Aparicio, T; Ortíz González, JM; Simón Ascarza, I; Zimman Mansfeld, HM, 1984)
"The response rate was 54% in breast cancer patients receiving 4'e-Dx as first-line treatment, 25% in patients previously given chemotherapy without doxorubicin, and 11% in patients previously given chemotherapy with doxorubicin."	( Armand, JP; Cappelaere, P; Hurteloup, P; Mathé, G, 1983)
"In 8 cancer patients given 10 courses of treatment cisplatin caused a mean (+/- S."	( Howell, SB; Wung, WE, 1983)
"Thirty-five (8%) of 426 cancer patients receiving various combinations of antineoplastic chemotherapy qualified for the antibiotic treatment."	( Catane, R; Fuks, Z; Halpern, J; Sacks, T, 1983)
"Sixty-four patients with advanced solid tumors were treated with the drug combination of 4'-epi-DX and cis-dichlorodiammineplatinum (CDDP) at the doses of 40-60 and 50 mg/m2, respectively, every 21-28 days."	( Farabegoli, G; Ganzina, F; Giovannini, M; Martoni, A; Monetti, N; Pannuti, F; Tomasi, L, 1984)
"For the evaluation of cancer risks associated with immunodeficiencies experienced by patients with Hansen's disease (leprosy) and for the assessment of possible adverse effects of dapsone therapy, a follow-up study was conducted of 1,678 patients admitted to the National Hansen's Disease Center in Carville, La."	( Brinton, LA; Fraumeni, JF; Hoover, R; Jacobson, RR, 1984)
"Sixty-six patients with advanced solid tumors were treated with 4'-epi-doxorubicin at a dose of 90 mg/m2 by rapid IV injection every 21 days until the disease had progressed or to a maximum cumulative dose of 540 mg/m2."	( Bellanova, B; Camaggi, CM; Giovannini, M; Martini, A; Martoni, A; Monetti, N; Pannuti, F; Rossini, G; Tarquinii, M; Tomasi, L, 1984)
"Secondary tumors were noted in 8 out of 675 patients with Hodgkin's disease during remission following treatment."	( Shishkin, IP, 1984)
"Thirty-five patients with advanced cancers were treated with estramustine phosphate tablets (Estracyt)."	( Catane, R; Halpern, J, 1984)
"In experimental cancer chemotherapy using human tumor xenografts transplanted to nude mice, aclarubicin showed a moderate antitumor effect (retardation of tumor growth) and nearly the same spectrum of activity in vivo as Adriamycin (doxorubicin)."	( Abe, O; Ishibiki, K; Kubota, T; Kumai, K, 1984)
"Nineteen adult cancer patients each received 6-10 monthly treatments of doxorubicin and cisplatin."	( Hrushesky, WJ; Vukelich, M, 1984)
"Seventeen of 19 treated mice developed neoplasms; 7 of these immunosuppressed animals had 2 to 4 separate neoplasms."	( Anver, MR; Walker, SE, 1983)
"21 unilateral breast cancer patients taking different combinations of chemotherapeutic agents (cyclophosphamide, methotrexate, 6-fluorouracil, vincristine, and prednisone) were studied to determine how chemotherapy affected their granulocytes."	( Matamoros, MC; Van Dyke, CJ; Van Dyke, K; Walker, BK, 1983)
"The records of 714 neutropenic cancer patients who were treated with high doses of a combination of beta-lactam antibiotics were analyzed."	( Bodey, GP; Bolivar, R; Elting, L; Estey, EH; Fainstein, V; Keating, MJ; McCredie, KB, 1983)
"Twenty patients with malignant neoplasms given 2 cycles of a combination chemotherapy including cisplatinum and adriamycin received domperidone in one cycle and chlorpromazine in another cycle."	( Araki, Y; Seita, M; Tamura, K, 1983)
"The frequency of malignant neoplasms was studied in 248 psoriatics treated with a single, weekly, oral dose of methotrexate ranging from 5 to 25 mg."	( Jensen, H; Nyfors, A, 1983)
"Many human tumors treated by hyperthermia do not reach therapeutic temperatures (42 degrees C)."	( Graham, LS; Morton, DL; Olch, AJ; Silberman, AW; Storm, FK, 1983)
"Retinol was administered to 13 cancer patients in daily doses ranging from 100,000 units/m2 to 350,000 units/m2."	( Alberts, DS; Earnst, DL; Goodman, GE; Meyskens, FL, 1983)
"Sixty-nine tumors representing different histologic types including breast, lung, colon, ovarian, and cervical, as well as neoplasms of undiagnosed origin, were screened against N-MF (NSC-3051) and ECH (NSC-526417) simultaneously with five standard chemotherapeutic agents used clinically for treatment of the specific type of cancer."	( Bogden, AE; Cobb, WR; Griffin, TW; Kelton, DE; LePage, DJ; Reich, SD, 1983)
"One hundred children with cancer and bacterial sepsis were observed for one month after completion of antibiotic treatment for subsequent episodes of infection."	( Hughes, WT; Patterson, G, 1984)
"Regional cancer chemotherapy is a means of exploiting dose-response effects by delivering more drug to regionally confined tumors."	( Ensminger, WD; Gyves, JW, 1984)
"Fifteen patients with advanced solid tumors participated in a phase I study of a biochemically designed combination chemotherapy program which employed PALA and thymidine (TdR) with 5-FU."	( Casper, ES; Kemeny, N; Martin, DS; Michaelson, RA; Young, CW, 1984)
"Twenty-two patients with cancer and fever of undetermined origin for more than seven days were treated with naproxen to control fever when there was no evidence of infection after a careful initial evaluation, and in most cases, after failure of antibiotic therapy."	( Chang, JC; Gross, HM, 1984)
"15 patients with metastatic cancer were treated with Lonidamine, a substituted indazole carboxylic acid active against the Lewis lung and Sarcoma 180 tumors."	( Band, PR; Besner, JG; De Sanctis, A; Deschamps, M; Gervais, P; Leclaire, R, 1984)
"12 patients with metastatic cancer were treated with the substituted indazole carboxylic acid Lonidamine at oral daily doses of 270 mg/m2."	( Band, PR; Besner, JG; De Sanctis, A; Deschamps, M; Gervais, P; Leclaire, R, 1984)
"The organization of a multidisciplinary cancer treatment center is very heterogeneous in Europe."	( Littbrand, B, 1984)
"Ten patients with solid tumors were treated with continuous infusion of TdR at 34-75 g/m2/day for 3 to 5 days."	( Kraal, I; Leyva, A; Pinedo, HM; Schornagel, JH; Wadman, SK, 1984)
"The present intensification of cancer chemotherapy has resulted in increased toxicity."	( Gerhartz, H; Hiller, E, 1984)
"Individuals with cancer are subject to fluid and electrolyte imbalances because of the original disease process, therapy, and complications resulting from both the disease process and from therapy."	( Cunningham, SG, 1982)
"Results from testing three cancer patients before and after therapy correlate well with clinical evidence of the presence of tumor burden."	( Bennet, LR; Buffkin, DC; Juillard, GJ; Schwabe, AD; Verma, RC; Webber, MM, 1980)
"Seventeen patients with cancer or aplastic anemia received demeclocycline as treatment for hyponatremia."	( Trump, DL, 1981)
"Thirty-two patients with advanced cancer were treated in a phase I-II trial with ifosfamide plus mesnum."	( Falkson, G; Falkson, HC; Stapelberg, R; Van Dyk, JJ, 1982)
"Fifteen cases with advanced cancer were treated with UFD-1 (mixture of FD-1 and uracil under molar ratio of 1: 20) in a daily dose of 300 mg of FD-1."	( Furue, H, 1982)
"The levels of anticancer drugs in tissue were measured by bioassay method in 28 patients with gastrointestinal cancer, who were treated with intravenous administration of 500 mg of 5-FU combined with ANG-II during surgery."	( Kanno, H; Kikuchi, K; Kunii, Y; Takahashi, N, 1982)
"to rats induced mainly forestomach neoplasms and a few neoplasms of the duodenum, whereas similar treatment of rats with nitroso-2-hydroxypropylurea induced a high incidence of neoplasms of the thymus, some of the forestomach, and few at any other site."	( Lijinsky, W; Reuber, MD, 1983)
"Four cancer patients with severe chronic pain were treated with oral morphine with increasing doses during 5-8 months."	( Rane, A; Säwe, J; Svensson, JO, 1983)
"Thirteen patients with cancer being treated with high-dose methotrexate (MTX) chemotherapy (350-5,000 mg/6 h IV were entered in this study."	( Boublil, JL; Lalanne, CM; Milano, G; Namer, M; Renee, N; Schneider, M; Thyss, A, 1983)
"Constant infusion cancer chemotherapy is feasible, reliable, and safe."	( Bothe, A; Fine, N; Lokich, J; Perri, J, 1982)
"Investigation of retinoids for anticancer activity in humans, either in the chemopreventive or treatment mode, has been little studied."	( Meyskens, FL, 1982)
"Sixty-five patients with advanced solid tumors were treated with 4'epi-doxorubicin, a new analogue of doxorubicin (DXR)."	( Ferrazzi, E; Fiorentino, MV; Ganzina, F; Maraglino, G; Nicoletto, O; Pagnin, P; Vinante, O, 1982)
"The records of 32 cancer patients who were treated with heparin sodium and warfarin sodium for thromboembolic disease were reviewed."	( Karp, DD; Moore, FD; Osteen, RT; Steele, G; Wilson, RE, 1981)
"The clinical trial of K-247, an anticancer drug showing antitumor effect by new mechanism of action, was performed in a total of 22 patients with a variety of advanced cancers, consisting of 10 cases administered singly and 12 cases combined with other anticancer agents."	( Kakuta, H; Kanamaru, R; Kanbe, M; Mitachi, Y; Sato, T; Takahashi, K; Wakui, A, 1982)
"Eleven patients with a variety of solid tumors were treated with K-247 alone."	( Fukushima, M; Ota, K, 1982)
"Six patients with advanced cancer were treated with amygdalin (laetrile) at dosages similar to those employed by laetrile practitioners."	( Ames, MM; Kovach, JS; Moertel, CG; Moyer, TP; Rubin, JR; Tinker, JH, 1981)
"After a scrutiny of investigations in cancer patients, the conclusion emerges that, in a subsection of patients, mainly those with poor prospects, levamisole improves the prognosis after effective chemotherapy, radiotherapy or surgery when given in time and in an appropriate dosage."	( Amery, WK; Gough, DA, 1981)
"One hundred seventy-eight patients with cancer were treated with amygdalin (Laetrile) plus a "metabolic therapy" program consisting of diet, enzymes, and vitamins."	( Currie, VE; Davignon, JP; Fleming, TR; Jones, SE; Koch, R; Kvols, LK; Moertel, CG; Rubin, J; Sarna, G; Young, CW, 1982)
"Eighteen adult cancer patients with 21 episodes of staphylococcal bacteremia were treated with sequential intravenous and oral antimicrobial agents."	( Carney, DN; Fossieck, BE; Parker, RH, 1982)
"The usefulness of bestatin in cancer treatment has been suggested by clinical studies."	( Aoyagi, T; Umezawa, H, 1981)
"The anabolic profiles of 59 late-stage cancer patients responsive to hydrazine sulfate were examined; the drug had been given either as a sole agent or added to preexisting therapy to which the patients had become refractory."	( Gold, J, 1981)
"Patients with cancer and suspected sepsis were treated in a prospective, randomized trial with one of four cephalosporin-aminoglycoside combinations: cephalothin and tobramycin; cephalothin and gentamicin; cefamandole and tobramycin; or cefamandole and gentamicin."	( Armstrong, D; Brown, AE; Quesada, O, 1982)
"They recommended incorporation of cancer control functions into the organizational structure of the Ministry of Health as well as specific recommendations in education, prevention, and early detection, diagnosis, treatment, and epidemiologic studies."	( Puchkov, YI; Saunders, JF; Sutnick, AI, 1982)
"In anergic and malnourished cancer patients no curative surgical treatment was possible."	( Fritsch, A; Funovics, J; Huk, I; Roth, E; Schemper, M; Schulz, F; Winter, M, 1982)
"An unique combination treatment for cancer patients has been attempted in our department."	( Enomoto, K; Kodama, K; Okada, N; Sakurai, T; Suzuki, Y; Takimoto, M; Yokoi, H, 1982)
"Twenty-three cases of cancer patients were treated with FT-207 alone orally more than 52 weeks up to 199 weeks continuously with daily dose of 600-800mg with capsules, and 600-1200mg with enteric coated capsules, except one case with markedly light body weight (28kg)."	( Majima, H; Nishimura, A, 1982)
"Nutrition and cancer interact in a number of important ways and nutritional factors are increasingly recognized as relevant to both the prevention and treatment of cancer."	( Rivlin, RS, 1982)
"Drug treatment for cancer is now widely utilized and in selected neoplasms offers the opportunity for prolonged remission or even cure."	( Kiely, JM, 1981)
"A significant reduction of spontaneous tumors and prolongation of median survival was observed in mice given repeated injections of levamisole and of 100 microgram bestatin, compared with untreated aged mice and with mice given low doses of bestatin."	( Bruley-Rosset, M; Florentin, I; Kiger, N; Mathé, G; Schulz, JI, 1980)
"Treatment of cancer patients with Bestatin, a new immunomodulator increases the frequency of peripheral lymphocytes forming rosettes with sheep red blood cells (SRBC)."	( Blomgren, H; Wasserman, J, 1981)
"The findings suggest that astrocytoma tumors shed sialoglycolipids into the circulation, and their assay may be useful in monitoring oncological therapy."	( Hogan, EL; Koontz, DA; Lo, HS; Traylor, TD, 1980)
"Eighty-five patients with severe cancer pain despite large doses of opioids or with therapy-limiting side effects from opioids were randomized to receive, in a double-blind manner, 30 micrograms/h epidural clonidine or placebo for 14 days, together with rescue epidural morphine."	( Allin, D; Dubois, M; DuPen, S; Eisenach, JC; Miguel, R, 1995)
"In patients treated for thyroid cancer the damage to the salivary glands was revealed by an increase in TPA and amylase serum levels, dependent on the dose of 131-Iodine administered."	( Becciolini, A; Lanini, A; Porciani, S, 1994)
"Patients with advanced solid tumors were eligible if they had normal bone marrow, renal, and hepatic function and had not previously been treated with platinum compounds."	( Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL, 1994)
"We describe a patient with advanced cancer whose severe symptoms of congestive heart failure were successfully treated with dobutamine."	( Mercadante, S; Simonetti, MT, 1994)
"5 patients with metastatic tumors and 4 patients with hematological malignancies were treated either with G- or GM-CSF alone (5 micrograms/kg s."	( Bettelheim, P; Kasparu, H; Kolb, A; Krieger, O; Lutz, D, 1995)
"The side effects are most common in cancer patients treated with high dose morphine, and has been reported for all routes of administration."	( Jacobsen, LS; Jensen, NH; Olsen, AK; Sjøgren, P, 1995)
"Pain treatment for 17 pediatric cancer patients in our institution was evaluated and disirable cancer pain management for children was discussed."	( Hoshino, T; Kasai, H; Sasaki, K; Tsujinaga, H, 1995)
"Patients with advanced solid tumors and a maximum of one prior chemotherapy regimen for metastatic disease were eligible if they had a performance status of 0 to 1 and normal renal, hepatic, and bone marrow function."	( Brewster, L; Green, MR; Hargis, JB; Hollis, DR; Lilenbaum, RC; Miller, AA; O'Brien, SM; Ratain, MJ; Rosner, GL; Schilsky, RL, 1995)
"Thirteen patients with metastatic cancer received 30 cycles of therapy."	( Beitz, JG; Bigley, JW; Browne, MJ; Clark, JW; Cummings, FJ; Damowski, JW; Weitberg, AB, 1995)
"Nineteen cancer patients with chronic pain of moderate to severe intensity were randomized in a double-blind manner to 5 days of either 8-hourly or 12-hourly administration of controlled-release morphine (MS Contin, MSC), followed by the alternate schedule for 5 days."	( Harsanyi, Z; Latreille, J; Lemire, F; Mignault, GG; Richer, P; Stewart, JH; Viguié, F, 1995)
"Chronic anemia associated with cancer often causes poor quality of life and is often exacerbated by intensive treatment."	( Eguchi, K, 1995)
"In total, 126 patients with cancer, who had never received chemotherapy and who required at least two courses of moderately emetogenic non-cisplatin chemotherapy each lasting for a minimum of 5 days, were recruited into the study."	( Adams, M; Anderson, H; Barley, V; Boesen, E; de Bruijn, KM; Rüfenacht, E; Soukop, M; Trask, CW; Yosef, H, 1995)
"Patients with advanced solid tumors were administered LY231514 intravenously over 10 minutes, weekly for 4 weeks, every 42 days."	( Burris, HA; Corso, SW; Dorr, FA; Eckardt, JR; Fields, SM; Kuhn, JG; Langley, C; Rinaldi, DA; Rodriguez, G; Woodworth, JR, 1995)
"In those patients in whom systemic anti-cancer therapy is available, treatment with APD improves survival, but in all other patients the primary aim of treatment should be symptom control."	( A'Hern, RP; Hardy, JR; Ling, PJ, 1995)
"The WHO has created a Cancer Pain Relief Programme and developed guidelines for the treatment of cancer pain."	( Foley, KM, 1995)
"As a result, the extent of toxicity of cancer chemotherapy varies by 50% or more according to dosing time in mice or rats."	( Lévi, F, 1995)
"Eleven patients with germ cell cancer relapsing from a complete remission and 7 patients with refractory germ cell cancer and/or an unresectable partial remission received salvage chemotherapy with one to two courses of carboplatin (800 mg/m2) and etoposide (500 mg/m2 on days 1, 3, and 5), followed by either one or two courses of carboplatin (1600 mg/m2), cyclophosphamide (6 g/m2), and thiotepa (480 mg/m2) divided over 4 days with autologous bone marrow transplantation and/or peripheral stem cell support."	( Richel, DJ; Rodenhuis, S; Schornagel, JH; ten Bokkel Huinink, WW; van der Wall, E; Vlasveld, LT, 1995)
"Patients with refractory solid tumors (n = 51) were treated with a 48-h continuous intravenous infusion of menadione followed by a bolus intravenous dose of mitomycin C at the completion of the menadione infusion."	( Ahn, C; Akman, SA; Doroshow, JH; Leong, LA; Margolin, KA; Morgan, RJ; Raschko, JW; Somlo, G, 1995)
"There was increased risk of malignancy in the CYC-treated group, with 50 cancers found in 37 patients in the CYC group compared with 26 cancers in 25 of the control patients (P < 0."	( Agarwal, AK; Baker, GL; Cash, JM; Gallatin, A; Kahl, LE; Kwoh, CK; Medsger, TA; Radis, CD; Stolzer, BL; Wasko, MC, 1995)
"The risk of malignancy, particularly bladder cancer, in RA patients treated with oral CYC continues even 17 years after discontinuation of the drug."	( Agarwal, AK; Baker, GL; Cash, JM; Gallatin, A; Kahl, LE; Kwoh, CK; Medsger, TA; Radis, CD; Stolzer, BL; Wasko, MC, 1995)
"This study shows that cancer neuroimmunotherapy with low-dose IL-2 and the pineal hormone melatonin may prolong survival time and improve the quality of life of patients with metastatic solid tumours who do not respond to conventional therapies."	( Ardizzoia, A; Barni, S; Cazzaniga, M; Fossati, V; Frigerio, F; Lissoni, P; Tancini, G, 1995)
"These results indicate that, in cancer patients receiving long-term morphine treatment with stable doses, morphine has only a slight and selective effect on functions related to driving."	( Kalso, E; Matikainen, E; Ollila, J; Rosenberg, P; Vainio, A, 1995)
"In order to treat the cancer chronic pains, the morphine is the most relevant analgesic, since it has rapid, powerful and multiples possibilities of administration."	( Vedrenne, JB, 1993)
"In terminally ill cancer patients, the continuous intrathecal administration of morphine may be recommended if conventional pain relief fails."	( de Lange, JJ; Spoelder, EM; Wagemans, MF; Zuurmond, WW, 1993)
"Clinical usefulness of cytokines in cancer treatment has been described."	( Takaku, F, 1993)
"Thirty-four patients with cancer pain and no previous opioid treatment were randomized to receive morphine hydrochloride 10 mg orally or rectally (in the form of a microenema) for 2 days."	( Bruera, E; De Conno, F; Hanson, J; MacEachern, T; Ripamonti, C; Saita, L, 1995)
"Pursuant to this, the North Central Cancer Treatment Group has developed a series of clinical trials designed to study antidotes for these pathologic processes."	( Foote, RL; Loprinzi, CL; Michalak, J, 1995)
"Response rates in ovarian cancer range from 17% to 37% (according to extent of prior therapy); in gastric and pancreatic cancer, response rates of 26% and 29% have been reported, despite the fact that these diseases are notoriously resistant to chemotherapy."	( Kaye, SB, 1995)
"Chronic anemia of cancer can be corrected in approximately 50% of the cases by treatment with recombinant human erythropoietin (rHuEPO)."	( Fritz, E; Leitgeb, C; Ludwig, H; Pecherstorfer, M; Samonigg, H; Schuster, J, 1994)
"Children who had solid tumors and who were receiving highly emetogenic chemotherapy, including cisplatin, carboplatin, cyclophosphamide, and ifosfamide, were randomized (1:1) in a double-blind fashion to receive either OND 0."	( Alvarez, O; Bedros, A; Call, SK; Convy, L; Cook, L; Freeman, A; Halverson, J; Kalbermatter, O; Mick, K; Volsch, J, 1995)
"A significant number of cancer patients will require an alternate route of morphine administration at some point during their illness."	( Babul, N; Bruera, E; Darke, AC; Fainsinger, R; Harsanyi, Z; Spachynski, K, 1995)
"Mortality and cancer incidence among 999 neurological patients exposed to chronic alpha-particle irradiation from 232ThO2 (Thorotrast) administered for cerebral angiography in 1935-1947 was compared to that of 1480 similar patients examined with cerebral angiography without Thorotrast in 1946-1963 (controls)."	( Andersson, M; Carstensen, B; Storm, HH, 1995)
"Subcutaneous ports in paediatric cancer patients are reliable, safe, and durable and may offer an attractive alternative to external catheters for prolonged venous access and intensive treatment."	( Ane, M; Claeyssens, S; Fedacou, F; Guitard, J; Izard, P; Juricic, M; Krimou, A; Lemozy, J; Prere, MF; Rubie, H, 1995)
"A total of 37 patients with cancer were treated with oral dexniguldipine in increasing doses for up to 7 days."	( Boewer, C; Oldenkott, B; Rathgeb, F; Sybrecht, GW; Ukena, D; Wurst, W; Zech, K, 1995)
"Eleven patients with solid tumors for whom effective therapy was not available entered a phase I study of mitonafide given as a short intravenous (i."	( Benavides, A; Casado, A; Díaz-Rubio, E; López-Vega, JM; Martín, M, 1994)
"Several anticancer agents are dependent on oxygen to be cytotoxic, these drugs such as the iron-chelating peptide bleomycin are enhanced in antitumor activity by the co-administration of a PFCE/C."	( Teicher, BA, 1994)
"Anemia is common in cancer patients and may require treatment for symptomatic palliation."	( Henry, DH, 1994)
"Anemia is common in patients with cancer and is often exacerbated by myelosuppressive chemotherapy."	( Henry, DH, 1994)
"Hyperalgesia and allodynia in 4 cancer patients treated with morphine disappeared after discontinuing or substituting morphine with other opioid agonists."	( Jensen, NH; Jensen, TS; Sjøgren, P, 1994)
"The children with a malignant neoplasm were treated for emesis with tropisetron (5 mg o."	( Cordero di Montezemolo, L; Madon, E; Nasi, C; Rosso, P; Tonello, M; Valle, P; Vivenza, C, 1994)
"A total of 107 cancer patients were treated with 148 cycles of subcutaneous (SC) immunotherapy employing interleukin-2 (rIL-2) and/or interferon-alpha (rIFN-alpha)."	( Atzpodien, J; Fenner, M; Kirchner, H; Körfer, A; Lopez-Hänninen, E; Menzel, T; Poliwoda, H; Rudolph, P; Schomburg, A, 1994)
"The response rates achieved in these tumors are particularly impressive because heavily pretreated patients, and those who are refractory to prior standard chemotherapy, have had a high rate of objective responses to paclitaxel."	( Rowinsky, EK, 1994)
"The incidence of cancer in patients receiving low-dose cyclosporin, azathioprine and prednisolone was three of 45, in those given high-dose cyclosporin and prednisolone none of 23 and in those administered high-dose cyclosporin, nifedipine and prednisolone one of 29."	( Bell, PR; Butt, ZA; Donnelly, PK; Kehinde, EO; Morgan, JD; Petermann, A; Veitch, PS, 1994)
"A total of 20 patients with solid tumors completed a 4-week course of all-trans RA therapy."	( Kris, MG; Miller, VA; Muindi, JR; Rigas, JR; Tong, WP; Venkatraman, E; Warrell, RP, 1994)
"Methotrexate (MTX), one of the earliest cancer chemotherapy agents, continues to be used extensively in the treatment of leukemia and a variety of other tumors."	( Huennekens, FM, 1994)
"We compared the incidence of de novo tumors developing in 1165 primary adult renal allograft recipients treated with azathioprine (AZA)-prednisone (Pred)-antilymphocyte globulin (ALG) (CONV group) with that in 722 patients receiving cyclosporine (CSA) as part of double (CSA-Pred), triple (CSA-Pred-AZA), or quadruple-therapy (CSA-Pred-AZA-ALG) protocols."	( Dunn, DL; Gillingham, K; Gruber, SA; Matas, AJ; Sothern, RB; Stephanian, E, 1994)
"The so-called Cancer Multistep Therapy was conceived by the author in 1965."	( von Ardenne, M, 1994)
"Forty-eight adults with advanced malignancy received ICE chemotherapy by 96-hour continuous infusion."	( Antman, KH; Ayash, LJ; Elias, AD; Frei, E; Mazanet, R; McCauley, M; Schnipper, L; Schwartz, G; Tepler, I; Wheeler, C, 1994)
"The excess risk of cancer after chlorambucil appears to persist for 5 years after stopping this treatment."	( Dresch, C; Najean, Y; Rain, JD, 1994)
"Effective treatment of the underlying malignancy, with the resultant recovery from neutropenia, and the determination of the species of infecting Candida isolates are required for the prediction of the outcome of antifungal therapy."	( Akalin, HE; Akova, M; Aslan, S; Hayran, M; Kansu, E; Tekuzman, G; Telatar, H; Uzun, O, 1994)
"Present therapy for cancer patients is based primarily on tumor histology and anatomy."	( Griffin, TW; Koh, WJ; Laramore, GE; Rasey, JS, 1994)
"The rheumatic associations of cancer therapy are highlighted in this review."	( Brooks, PM; Conaghan, PG, 1994)
"Fifty-nine patients, with cancer refractory to conventional therapy, were entered in this phase I study, using a weekly schedule administration."	( Bugat, R; Chabot, GG; Culine, S; de Forni, M; Extra, JM; Gouyette, A; Madelaine, I; Marty, ME; Mathieu-Boué, A, 1994)
"One hundred patients with intolerable cancer pain were treated with intrathecal bolus injections of morphine(IT morphine)."	( Cheng, KI; Chu, KS; Tang, CS; Tseng, CK; Yip, NS; Yu, KL, 1993)
"Twelve patients with advanced cancer were included and begun on therapy with rIL-2, 1 x 10(6) U/m2 subcutaneously (SQ) daily for 5 days and levamisole beginning at 25 mg/m2 orally three times daily for 5 days."	( Buckner, JC; Call, TG; Creagan, ET; Frytak, S; Homburger, HA; Katzmann, JA; van Haelst-Pisani, C, 1994)
"Effectiveness of this approach for cancer treatment in vivo will depend on Rh123 tumor uptake kinetics and laser energy delivery via fiberoptics to the tumor site."	( Castro, DJ; Haghighat, S; Lufkin, R; Plant, D; Saxton, RE; Soudant, J, 1994)
"Cisplatin is one of the most active cancer treatment agents available."	( Abrahm, J; Cooley, ME; Davis, LE; DeStefano, M, 1994)
"The excess risk for cancer due to lifetime occupational exposure to 1,3-butadiene at the proposed US Occupational Safety and Health Administration standard of 2 ppm was estimated on the basis of a quantitative risk assessment."	( Bailer, AJ; Dankovic, DA; Smith, RJ; Stayner, LT, 1993)
"FDG-PET after anticancer treatment should be interpreted by considering the reaction due to the treatment and the partial volume artifact of PET caused by the limited spatial resolution."	( Arimizu, N; Imaseki, K; Itami, J; Okada, J; Oonishi, H; Uno, K; Yoshikawa, K, 1994)
"Patients with humoral hypercalcaemia of malignancy appear to respond less well to biphosphonate therapy than hypercalcaemic patients with osteolytic metastases."	( Body, JJ; Dumon, JC, 1994)
"Effective control of cancer pain can now be achieved in a high proportion of patients with rigorously applied pharmacologic treatment, reducing the need for more demanding invasive procedures."	( Patt, RB; Reddy, S, 1994)
"A total of 121 patients with cancer pain without gastric involvement participated in a 7-day treatment course and were allocated to receive either dipyrone 1 g (n = 41), dipyrone 2 g (n = 38) or morphine (n = 42)."	( Aliaga, L; Barutell, C; Gálvez, R; Moreno, J; Ortiz, P; Pallarés, J; Puerta, J; Rodríguez, M; Rull, M; Vidal, F, 1994)
"Twelve dogs with advanced stage tumors were administered a dose of 0."	( Castro, J; Madewell, BR; Ryu, J; Théon, AP, 1994)
"During the course of cancer treatment and as the disease progresses, symptoms may worsen and physical status may deteriorate."	( Given, B; Given, CW; Kurtz, JC; Kurtz, ME, 1994)
"2,124 cases of cancer diagnosed and/or treated in Penang between 1987-1990 were reported to the National Cancer Registry of Malaysia by hospitals in Penang."	( Chan, CK; Devaraj, T; Rasid, BK; Singh, J, 1994)
"Perceptions of cancer stressors and protective factors are predictors of stress experienced during treatment for childhood cancer were assessed in this study."	( DiIorio, C; Hockenberry-Eaton, M; Kemp, V, 1994)
"Twenty-three patients with various cancers were treated with doses of CPT-11 ranging from 400 to 600 mg/m2, administered as a 30-minute intravenous infusion every 3 weeks."	( Abigerges, D; Armand, JP; Chabot, GG; Cote, C; Da Costa, L; Fadel, E; Gandia, D; Hérait, P, 1994)
"One patient with head and neck cancer showed > 50% shrinkage of tumor mass for 6 weeks after treatment."	( Baker, M; Baptiste, J; Dennis, JW; Fernandes, B; Goss, PE, 1994)
"In this trial 324 chemotherapy-naive cancer patients, mostly females with breast cancer, were randomized to receive either placebo or ondansetron 1 mg, 4 mg, or 8 mg three times per day for 3 days."	( Burton, G; Ciociola, AA; Cubeddu, LX; Galvin, D; Meshad, M; Pendergrass, K; Ryan, T; York, M, 1994)
"CAI offers a new approach to cancer therapy, signal transduction therapy."	( Cole, K; Kohn, E, 1994)
"The use of morphine in the treatment of cancer pain is widely accepted among people taking care of cancer patients and concerned with pain relief."	( Lossignol, DA, 1993)
"Thirty-one cancer patients were treated with oral opioids, 180 mg morphine per 24 h (median)."	( Banning, AM; Christensen, CB; Pedersen, O; Sjøgren, P, 1994)
"In the 34 patients with advanced lung cancer, all-trans RA (45 mg/m2) was administered twice daily for 4 weeks, and, on days 2, 28, and 29, serial plasma samples were again obtained after a single 45-mg/m2 dose."	( DeGrazia, F; Francis, PA; Huselton, C; Kris, MG; Muindi, JR; Orazem, JP; Rigas, JR; Warrell, RP; Young, CW, 1993)
"An approach to anticancer therapy is suggested, using a hypothesis-based mechanism for the anti-cancer activity of retinoic acid."	( Beech, JA, 1993)
"The study included 30 cancer patients, who were randomized to treatment with IL-2 alone or IL-2 plus L-carnitine (1000 mg/day orally)."	( Barni, S; Galli, MA; Lissoni, P; Tancini, G, 1993)
"Thirty-six patients with cancer-associated hypercalcemia were treated with increasing doses (0."	( Clemens, MR; Ghielmini, M; Jaeger, P; Krahl, D; Manegold, C; Scharla, SH; Schöter, KH; Thiébaud, D; Wüster, C, 1993)
"Patients' awareness of the diagnosis of cancer and their perception of treatment intention and outcome were assessed independently by another investigator who was blind to the psychiatric diagnosis."	( Alexander, PJ; Dinesh, N; Vidyasagar, MS, 1993)
"Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia."	( Drenck, NE; Jensen, NH; Jensen, TS; Jonsson, T; Sjøgren, P, 1993)
"The measurement of oxygenation of human tumors and correlations with response to radiotherapy were the subjects of a recent workshop sponsored by the National Cancer Institute."	( Brown, JM; Phillips, TL; Stone, HB; Sutherland, RM, 1993)
"Justification for use of infusions in cancer chemotherapy has been slow in appearing with few studies proceeding to the comparative stage."	( DelaFlor-Weiss, E; Muggia, FM; Uziely, B, 1993)
"For this trial by the Cancer and Leukemia Group B (CALGB), cohorts of patients were treated with cyclophosphamide as a 1-hour intravenous infusion every 14 days; GM-CSF was given subcutaneously on days 3-10."	( Budman, DR; Egorin, MJ; Lichtman, SM; Norton, L; Ratain, MJ; Rosner, G; Schilsky, RL; Van Echo, DA; Vogelzang, NJ, 1993)
"To investigate whether childhood cancer is associated with intramuscular administration of vitamin K to newborn infants."	( Ekelund, H; Finnström, O; Gunnarskog, J; Källén, B; Larsson, Y, 1993)
"Odds ratios for cancer after intramuscular administration of vitamin K versus oral administration after stratification for year of birth."	( Ekelund, H; Finnström, O; Gunnarskog, J; Källén, B; Larsson, Y, 1993)
"The risk of cancer after intramuscular administration of vitamin K was not elevated compared with that after oral administration: odds ratios of 1."	( Ekelund, H; Finnström, O; Gunnarskog, J; Källén, B; Larsson, Y, 1993)
"Chiral anticancer agents which exist as a pair of enantiomers are commonly administered as racemic (50:50) mixtures of the two isomers."	( Wainer, IW, 1993)
"Thirty assessable patients with cancer refractory to conventional therapy were treated."	( Alberti, D; Arzoomanian, RZ; Cohen, JD; d'Oleire, F; Feierabend, C; Heiss, C; Longo, W; Robins, HI; Schmitt, CL; Tutsch, KD, 1993)
"The sample consisted of 127 adults with cancer who were to receive their first dose of chemotherapy (e."	( Dibble, SL; Dodd, MJ, 1993)
"One novel approach to cancer treatment involves targeting a cytotoxic agent to a cancer cell."	( Pastan, I; Theuer, CP, 1993)
"One hundred cancer patients receiving non-cisplatin containing chemotherapy were entered in a prospective study in which the efficacy of ondansetron was compared with standard antiemetic treatments in the prophylaxis of nausea and emesis."	( Flander, MK; Heikkinen, MI; Jantunen, IT; Kataja, VV; Kuoppala, TA; Teerenhovi, L, 1993)
"In 17 girls after the complex anti-neoplasm therapy we estimated the state of genital organs and the course of menorrhagia cycle together with plasma levels of beta-estradiol, progesterone and prolactin assessed by RIA."	( Bohdan, Z; Korzon, M; Kuźmińska, A; Wszelaki-Lass, E, 1993)
"Therefore, weight-losing cancer patients (n = 60), with normal liver and kidney function tests, were randomized to receive one of four drug treatments for 5 days: (a) Propranolol 80 mg x 2 (beta-adrenoceptor blockade); (b) Indomethacin 50 mg x 2 (prostaglandin synthesis inhibition); (c) Morphine 5 mg x 3 (pain relief) or (d) Placebo x 2."	( Hyltander, A; Körner, U; Lundholm, KG, 1993)
"Pharmacokinetic study of anticancer drug is essential for clinical application of cancer chemotherapy."	( Hagiwara, A; Takahashi, T; Taniguchi, H; Yamaguchi, T, 1993)
"Two patients, one with small cell lung cancer and one with breast cancer, had stable disease while receiving treatment for 5 and 6 months, respectively."	( Bjarnason, G; Bunting, P; DeAngelis, C; Erlichman, C; Goodman, P; Kerr, IG; Moore, M; Thiessen, JJ; Walker, S, 1993)
"Twelve cancer patients (aged 49-74 years) receiving doxorubicin (66 +/- 8 mg/m2) as a 1-hour intravenous infusion had serial serum samples (0-48 hours) obtained after the first and second courses of therapy."	( Piscitelli, SC; Rodvold, KA; Rushing, DA; Tewksbury, DA, 1993)
"In 10 patients with hypercalcemia of malignancy the levels of the midregional fragment of PTHrP in serum were determined by radioimmunoassay over 7 days during a calcium-lowering treatment with a single dose of the bisphosphonate BM 21."	( Blind, E; Meinel, T; Raue, F; Wüster, C; Ziegler, R, 1993)
"Eight children and young adults with cancer were evaluated serially using pure tone audiometry as well as registration of click-evoked otoacoustic emissions (EOAE) 1 day prior to therapy as well as after various numbers of doses of cisplatinum."	( Gutjahr, P; Schmitt, HJ; Zorowka, PG, 1993)
"Use of this test in cancer patients undergoing either chemotherapy or radiation therapy revealed evidence of early negative B12 balance that in some instances was induced by the treatment itself."	( Amin, J; Flener, V; Ramos, M; Tisman, G; Vanyo, L; Vu, T, 1993)
"Effective treatment of hypercalcemia of malignancy may improve patients' quality of life, although an episode of hypercalcemia is a poor prognostic indicator for survival."	( Hall, TG; Schaiff, RA, 1993)
"Thirty-five cancer patients, treated with chronic epidural morphine, were assayed for plasma and cerebrospinal fluid (CSF) minimum steady-state concentrations (Css min) of morphine (M), morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) by high performance liquid chromatography (HPLC)."	( Hedner, T; Michalkiewicz, A; Samuelsson, H; Venn, R, 1993)
"Eight new case histories of cancer patients plus two reported cases support the statement that therapy of cancer patients with CoQ10, which has no significant side effect, has allowed survival on an exploratory basis for periods of 5-15 years."	( Brown, R; Folkers, K; Judy, WV; Morita, M, 1993)
"All the cancer patients analyzed so far have shown the structural anomaly of the urinary chondroitin sulfate and this may be useful in the diagnosis and follow up of cancer therapy."	( Dietrich, CP; Martins, JR; Nader, HB; Sampaio, LO, 1993)
"Patients with advanced cancer frequently experience clinically significant anemia, which is often exacerbated by myelosuppressive chemotherapy."	( Bukowski, RM; Carey, RW; Case, DC; Fishkin, EH; Henry, DH; Jacobson, RJ; Jones, SE; Keller, AM; Kugler, JW; Nichols, CR, 1993)
"We studied 153 anemic cancer patients receiving cyclic combination chemotherapy in a prospective multicenter, double-blind, placebo-controlled trial."	( Bukowski, RM; Carey, RW; Case, DC; Fishkin, EH; Henry, DH; Jacobson, RJ; Jones, SE; Keller, AM; Kugler, JW; Nichols, CR, 1993)
"Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed."	( Bodey, GP; Lo, WK; Rolston, KV; Rubenstein, EB, 1993)
"Patients with breast cancer treated with MPA often report an improvement in appetite."	( Allbright, A; Downer, S; Joel, S; Plant, H; Slevin, M; Stubbs, L; Talbot, D, 1993)
"Seven patients with advanced cancer were treated weekly with 5-FU at increasing dosages starting at a dose of 600 mg/m2."	( Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1993)
"Thirty patients with advanced cancer, who were no longer receiving antineoplastic therapy, were randomly assigned to receive either L 75 mg/day or M 30 mg/day."	( Battaiotto, L; Corli, O; Cozzolino, A, 1995)
"In the present study a cancer risk assessment of occupational exposure to cyclophosphamide (CP), a genotoxic carcinogenic antineoplastic agent, was carried out following two approaches based on (1) data from an animal study and (2) data on primary and secondary tumors in CP-treated patients."	( Bos, RP; Kroese, ED; Sessink, PJ; van Kranen, HJ, 1995)
"In 34 cancer patients treated with chronic slow-release oral morphine, plasma and cerebrospinal fluid (CSF) minimum steady-state concentrations of morphine (M), morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) were determined by high-performance liquid chromatography (HPLC)."	( Hedner, T; Samuelsson, H; Wolff, T, 1995)
"PBPCs from six patients with solid tumors were recruited by standard-dose chemotherapy and subsequent administration of recombinant granulocyte colony-stimulating factor (G-CSF)."	( Brugger, W; Kanz, L; Lübbert, M; Mertelsmann, R, 1996)

Excerpt

Reference

"The relevance of these observations to cancer immunotherapy is discussed."

( Stein-Werblowsky, R, 1975)

"Children with malignant solid tumors during therapy and children with leukemia during different stages of the disease often showed a slowing of less than 5% in the EM-test."

( Oehme, J; Ritter, J, 1978)

"Since the patient's response to cancer chemotherapy depends on immunocompetence which, in turn, is related to the nutritional state, adequate nutrition is the key to effective treatment."

( Jehn, U; Kohlschütter, B, 1978)

"Twenty-three cancer patients with cutaneous and/or systemic herpes zoster or herpes simplex infections were treated with parenteral acyclovir."

( Brigden, D; Clink, HM; Corringharn, R; Hoffbrand, AV; Janeson, B; Kay, HE; McElwain, TJ; Morgenstern, G; Powles, RL; Prentice, HG; Ross, MG; Selby, PJ; Thornton, R; Watson, JG, 1979)

"A randomized study in 20 patients with cancer was carried out to test the clinical efficacy of sodium-2-mercaptoethane sulfonate (ASTA D-7093; mesnum) as an agent to prevent urotoxic side effects (in particular, hemorrhagic cystitis) during cytostatic therapy with the oxazaphosphorines cyclophosphamide and ifosfamide."

( Brock, N; Burkert, H; Günther, U; Hoefer-Janker, H; Klein, HO; Mitrenga, D; Scheef, W; Schnitker, J; Voigtmann, R, 1979)

"Twenty-one patients (sixteen cancer patients receiving chemotherapy and/or radiotherapy, three with major abdominal traumatic injuries and four with paralytic ileus) were infused with 2 1/24 hours of a solution of 4."

( Angers, JW; Ching, N; Grossi, C; Jham, G; Mills, CJ; Nealon, TF; Zurawinsky, H, 1979)

"Of the 15 animals, 12 died with tumors induced by the treatment, half of them by the 41 st week; all 15 were dead at 58 weeks."

( Lijinsky, W; Taylor, HW, 1978)

"Patients with solid tumors who had received little or no prior chemotherapy and had good bone marrow reserve tolerated up to 6000 U/m2/24 hours X 5 days."

( Cuttner, J; Holland, JF; Nogeire, C; Ohnuma, T, 1978)

"Those patients with bladder cancer who did not respond to NCS therapy or exhibit any side effects even after 21 mg were found to have proteolytic activity in their sera which degraded NCS very rapidly as revealed by the fluorescence polarization technique."

( Maeda, H; Matsumoto, T; Ogata, J; Sakamoto, S, 1978)

"Twenty-three children with advanced cancer refractory to conventional therapy received weekly iv doses of neocarzinostatin for 5 weeks."

( Aur, RJ; Howarth, C; Pratt, CB; Rivera, G, 1978)

"The metabolic incorporation by tumors of this DNA-precursor indicates a potential value of this radiocompound for their detection, differentiation and follow-up of their evolution after therapy."

( Anghileri, LJ; Heidbreder, M; Mathes, R, 1977)

"The incidences of malignant tumors, hepatomas or modular hyperplasias, and benign tumors in halothane-treated mice were 7, 6, and 20 per cent, respectively; there were similar incidences of these lesions in control animals."

( Baden, JM; Kosek, JC; Mazze, RI; Rice, SA; Wharton, RS, 1979)

"13 patients with malignant tumors were treated by the radiosensitizer misonidazole (Ro 07-0582), total dosage 20-29 g."

( Kogelnik, HD; Mamoli, B; Müller, M; Rathkolb, O; Wessely, P, 1979)

"Immunotherapy against cancer in animals has been established."

( Eilber, FR; Holmes, EC; Morton, DL, 1975)

"Seven patients with metastatic tumors resistant to therapy with adriamycin, BCNU, plus cyclophosphamide received the same chemotherapy combined with amphotericin B."

( Klahr, C; Presant, CA; Santala, R, 1977)

"Fifty-four children with solid tumors were treated: 25 neuroblastoma, 9 rhabdomyosarcoma, 4 Ewing sarcoma, 2 testicular embryonal carcinoma, 2 retinoblastoma, and 12 miscellaneous tumors."

( Bryan, H; Nitschke, R; Starling, KA; Vats, T, 1978)

"Human cancer cells that had had high (greater than 160) tissue culture passages, when transplanted into antithymocyte-treated F344 newborn rats, caused induction of rat sarcomas in the rats within 2 or 3 subcultures, whereas human cancer cells with low (5-33) passages in vitro did not cause overt induction of rat sarcomas until after 5-10 subtransplantations."

( Bare, AL; Bare, RM; Djurickovic, D; Fish, DC; Huebner, RJ; Smith, GT; Trimmer, RW, 1979)

"Twenty-four patients with advanced cancer not reacting to conventional therapy were treated with 97 courses of i."

( Bartal, A; Cohen, Y; Honigman, J; Robinson, E, 1977)

"Therefore, cancer surgery acts as immunotherapy because it removes the cancer cells that produce the immunodepression and allows the patient's immune response to recover."

( Morton, DL, 1978)

"Drug combinations in cancer treatment are widely utilized because they frequently result in better therapeutic activity than the single treatments."

( Garattini, S; Spreafico, F, 1978)

"The therapeutic effect of drugs used in cancer chemotherapy has been augmented by their complexing or chemical linking to macromolecular carriers."

( Arnon, R, 1978)

"Malignant neoplasms may cause life-threatening complications requiring prompt diagnosis and emergency therapy."

( Stolinsky, DC, 1978)

"Antibiotic therapy in granulocytopenic cancer patients, the risk factors predisposing these patients to infection, and the signs, symptoms and types of infections occurring in these patients are reviewed."

( Hopefl, AW, 1979)

"The potential impact on cancer mortality from these treatment results is obvious."

( DeVita, VT; Weiss, RB, 1979)

"Ninety-two patients with cancer with 100 infectious episodes were treated with netilmicin sulfate, a new aminoglycoside."

( Bodney, GP; Yap, BS, 1979)

"One hundred and sixty-one cancer patients were nutritionally assessed prior to receiving oncological therapy (surgery, chemotherapy, and/or radiation therapy)."

( Blackburn, GL; Bothe, A; Harvey, KB, 1979)

"Five children with cancer treated with high dose cyclophosphamide experienced blurring of vision."

( Freeman, AI; Kende, G; Sirkin, SR; Thomas, PR, 1979)

"A 9-fold increased incidence of bladder cancer was found in the cyclophosphamide-treated group."

( Fairchild, WV; Gangai, MP; Solomon, HD; Spence, CR, 1979)

"Terminally ill cancer patients often derive great benefit from this treatment."

( Bürgi, H; Selz, B, 1979)

"Fifty one patients with terminal cancer suffering severe pains reluctant to other treatment have received morphine by mouth, in a regular regimen."

( Apchin, A; Belnat, P; Brulé, G; Domenge, C; Voisin, PM, 1979)

"The personal series consists of 140 cancer patients followed up over a period of some 3 years and submitted prior to the start of treatment to the DNCB skin test."

( Bianucci, P; De Rossi, O; Pastorino, G, 1979)

"The National Cancer Institute, in response to widespread public interest, undertook a retrospective analysis of Laetrile treatment."

( Byar, DP; Ellison, NM; Newell, GR, 1978)

"Adjuvant trials in cancer treatment present special problems in statistical analysis."

( Higgins, GA, 1978)

"153 patients with inoperable malignant tumors were treated by the so-called synchronization therapy with vincristine and ifosfamide."

( Hartwich, G; Lutz, H; Neidhardt, B, 1978)

"The treatment of cancer pain by psychotropic drugs is a method which has been employed for a long time [8] and in which the results obtained have appeared very interesting from the beginning: there is a high percentage of success, rapid action, absence of addiction, and although there are sometimes unpleasant side-effects, they are reversible when the treatment is stopped."

( Boudouresque, G; Bourhis, A; Fondarai, J; Pellet, W; Ponzio, J; Spitalier, JM, 1978)

"Seventy-two patients with advanced cancer were treated with combinations of heat and radiation in two groups: (a) heat + radiation, and (b) radiation + heat."

( George, R; Hornback, NB; Joe, BT; Marshall, C; Sayoc, E; Shidnia, H; Shupe, R, 1979)

"It is recommended that in future cancer therapy protocols test for circadian variability of white cell depression by varying treatment times systematically along the 24 h scale."

( Simpson, HW; Stoney, PJ, 1977)

"Late induction of malignancy can occur with either radiation or chemotherapy alone and, in some cases, this appears to be enhanced when they are combined."

( Fu, KK; Phillips, TL, 1977)

"Between 1967 and 1976, 269 tumors of the hand were treated."

( Flügel, M; Geldmacher, J, 1977)

"The intensive research on cancer treatment all over the world is leading to a rapid accumulation of experimental data about the action of single cytostatic drugs in tissue culture and on transplantable animal tumor systems, especially in rodents."

( Gross, R; Hirschmann, WD, 1976)

"One approach to effective cancer chemotherapy is to maximize the exposure of tumor cells to cytotoxic drugs while minimizing the exposure of sensitive normal cells to such agents."

( Juliano, RL, 1976)

"The treatment of breast and ovarian cancer brought the best results, improved by a synchronisation therapy."

( Siebner, H; Weber, W, 1976)

"Forty patients with generalized cancer complicated by water and electrolyte retention were treated with "medium" and "large" doses of furosemide and bumetanide with 35% and 40% objective positive response, respectively."

( Athanasiou, A; Dadiotis, L; Razis, DV, 1976)

"The treatment of cancer using fast neutrons was first attempted from 1938 to 1942, only a few years after the identification of the particle in 1932."

( Field, SB, 1976)

"Infections in the immunosuppressed cancer patient are caused by a wide variety of bacteria, viruses, fungi, and protozoa; many of these in the normal individual are saprophytes but will cause disease in the immunosuppressed patient, often with treatment failure."

( O'Loughlin, JM, 1975)

"Six patients with advanced cancer were treated with PTG (67 mg/m2 of body surface area intravenously) specifically labeled with tritium as the first dose of a weekly x 6 course."

( Allen, LM; Creaven, PJ, 1975)

"In patients with malignant tumors, changes in the blood count and morphological changes in the nucleoli in peripheral-blood lymphocytes were studied during treatment with Cytembena, Cyclophosphamide, or combinations of both drugs."

( Matĕjková, E, 1975)

"Sixty-seven patients with disseminated cancer were randomly allocated to treatment with continuous closed chest drainage removing all fluid for 72 hours (PD) or pleural drainage for 72 hours with the instillation into the pleural space of radioactive colloidal chromic phosphate (PD + 32P)."

( Baker, L; Caoili, EM; Izbicki, R; Vaitkevicius, VK; Weyhing, BT, 1975)

"Ninety-eight children with solid tumors resistant to conventional chemotherapy received adriamycin 90 mg/m2, either as a single intravenous injection or in 6 divided doses administered every 6 hours."

( George, S; Komp, DM; Lyon, GM; Ragab, AH; Starling, KA; Sutow, WW, 1975)

"Successfully, radically treated cancer patients with no detectable residues or metastases for at least 1 year had values (186 +/- 39; 76 +/-24) almost within the normal ranges (93 to 250 mg pectin equivalents per liter for CPA and 35 to 120 mg pectin equivalents per liter for SPA)."

( Huhtala, HJ; Rosengård, SA; Salmi, RE; Salo, EJ; Sandbacka, BO, 1976)

"Thirty six stage III cancer patients were treated with Ukrain, a semisynthetic drug derived from Chelidonium majus L."

( Brzosko, WJ; Manolakis, G; Meijer, D; Nowicky, JW; Vatanasapt, V, 1992)

"Sixty-four adult cancer patients entered this trial; all received a chemotherapy regimen containing cisplatin (greater than or equal to 60 mg/m2) and a combination of metoclopramide and dexamethasone for the control of acute emesis during the period from 0 to 24 h after cisplatin (day 1)."

( Bacchi, M; Bandini, N; Bella, M; Cocconi, G; Michiara, M; Monici, L; Passalacqua, R, 1992)

"Finally, the risk is discussed that cancer could be a side-effect of the use of retroviral vectors in human gene therapy."

( Weiss, RA, 1992)

"In testicular cancer, etoposide was shown to have a possible role in adjuvant therapy for refractory disease or as part of combination chemotherapy."

( Loehrer, PJ, 1992)

"Sixty patients with malignancy were enrolled in a study of high-dose chemotherapy and peripheral blood stem cell transplantation (PBSCT)."

( Bolton, A; Charles, P; Dale, BM; Gregg, A; Kotasek, D; Norman, JE; Pillow, A; Sage, RE; Shepherd, KM, 1992)

"289 consecutive cancer patients receiving cisplatin chemotherapy (much greater than 50 mg/m2) were randomised to receive one of the following intravenous antiemetic regimens: ondansetron 0."

( , 1992)

"Forty-seven patients with advanced cancer with moderate/severe pain, treated with regular doses of Ketogan tablets took part in an open phase 1 type pharmacologic/toxicologic study comparing Ketogan tablets and cetobem."

( Andersen, LS; Kjaer, M; Nielsen, H; Olsen, FE; Philipsen, J; Velander, G, 1992)

"Thirty-two cancer patients were given a 1-day course of chemotherapy consisting of etoposide (VP16), ifosfamide, and cisplatin (VIP; n = 46 cycles), followed by the combined sequential administration of recombinant human interleukin-3 (rhIL-3) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)."

( Bross, K; Brugger, W; Dern, P; Frisch, J; Kanz, L; Mertelsmann, R; Weber, B, 1992)

"Clinical success in the treatment of tumors with chemotherapy has significantly improved over the past several years."

( Henle, KJ; Mansouri, A; Nagle, WA, 1992)

"Among ovarian cancer cell lines tested, the enhancement of the activity of HuIFN by dipyridamole for HAC-2 and SHIN-3 cells was equivalent to or greater than that for 3 chemotherapy agents (adriamycin, vincristine, and a camptothecin derivative)."

( Fukazawa, I; Inaba, N; Isogai, E; Oiwa, Y; Saito-Ebihara, M; Sekiya, S; Sugano, I; Suzuki, N; Takakubo, Y; Yoshida, J, 1992)

"Odds ratios for cancer in the presence of administration of pethidine or of intramuscular vitamin K."

( Birmingham, K; Golding, J; Greenwood, R; Mott, M, 1992)

"Furthermore, a variety of pediatric tumors are responsive to RA in vitro, which provides additional rationale for a phase I evaluation of RA in children with cancer that is refractory to standard therapy."

( Adamson, PC; Aronson, L; Balis, FM; Fenton, RM; Feusner, J; Hammond, GD; Horowitz, ME; Murphy, RF; Reaman, G; Smith, MA, 1992)

"Twenty-eight cancer patients either received r-hGH for 3 days (GH group, n = 12, weight loss = 6 +/- 2%) or were not treated (control [CTL] group, n = 16, weight loss = 11 +/- 2%) before metabolic study."

( Brennan, MF; Burt, ME; Gonenne, A; Heslin, MJ; Newman, E; Pearlstone, DB; Wolf, RF, 1992)

"A review from Memorial Sloan-Kettering Cancer has shown that a new group of patients, those receiving corticosteroid therapy for brain neoplasm, are also at risk for the development of PCP and should receive PCP prophylaxis."

( Sepkowitz, KA, 1992)

"A third malignant neoplasm (dermal squamous cell carcinoma) was seen in a 64-year-old woman with rheumatoid arthritis after 13 months treatment with 7."

( Eisenlohr, H; Lydtin, H; Prechtel, K; Trenkwalder, P, 1992)

"Immunotherapy models using murine tumors or clinical experiments revealed that preadministration of immunostimulator such as OK-432, followed by chemotherapeutic agents such as cyclophosphamide, can induce host's non-cytotoxic fresh lymphocytes that act synergistically with cultured killer cells against autologous tumor cells."

( Harada, T; Ichinose, Y; Kan, N; Kodama, H; Moriguchi, Y; Ohgaki, K; Satoh, K; Yamasaki, S, 1992)

"Furthermore, in hormone-dependent cancers malignant cells may undergo massive apoptosis in response to hormone withdrawal or antihormone treatment."

( Bursch, W; Kraupp-Grasl, B; Oberhammer, F; Schulte-Hermann, R; Wagner, A, 1992)

"Pharmacokinetic data for six anticancer agents were compared in infants less than 1 year of age and children greater than 1 year of age treated at St Jude Children's Research Hospital."

( Crist, WM; Crom, WR; Evans, WE; Groom, S; McLeod, HL; Relling, MV; Rivera, GK; Rodman, JH; Silverstein, K, 1992)

"In this study, 11 cancer patients who experienced severe pain were treated with transdermal fentanyl."

( Herbst, LH; Strause, LG, 1992)

"A total of 35 previously treated cancer patients were enrolled in a phase I study of this compound."

( Alberts, DS; Brodar, F; Lam, KS; Matias, B; Modiano, M; Peng, YM; Sol Lucas, V; Tuttle, R; Wargin, W, 1992)

"Thirty-one patients with malignancy, anticoagulated for the treatment of venous thromboembolism (VTE) are reported."

( Chan, A; Woodruff, RK, 1992)

"Although WHO cancer pain relief is the first choice, nerve blocks and intraoperative radiotherapy, if indicated, must be taken into consideration in the early phase of the pain treatment."

( Fujita, N; Fuse, Y, 1992)

"As in the case of anticancer chemotherapy, it is hoped that combinations of drugs, which act against different steps in the viral replication cycle, might have synergistic potential."

( Margolese, RG; Wainberg, MA, 1992)

"Under the Cancer Preventive Program, Nocardia rubra cell-wall skeleton (N-CWS) was administered to 80 workers directly involved in the production of sulfur mustard and 66 workers engaged in work related to sulfur mustard production."

( Hozawa, S; Ishioka, S; Matsuzaka, S; Nishimoto, Y; Otake, M; Shigenobu, T; Yamakido, M; Yanagida, J, 1992)

"Twenty patients with advanced cancer for which there was no effective standard therapy or whose disease was refractory to standard therapy were treated with recombinant macrophage colony-stimulating factor (rM-CSF)."

( Childs, A; Groves, ES; Hudson, J; Konrad, M; Rudolph, AR; Zamkoff, KW, 1992)

"Hypercalcemia of malignancy is a commonly encountered serious clinical problem that often requires aggressive therapy."

( Fatemi, S; Rude, RK; Singer, FR, 1992)

"Advanced cancer is often accompanied by anaemia, which may worsen with concomitant administration of chemotherapy."

( Abels, RI, 1992)

"Fifteen patients with cancer pain (average age of 61 years) were treated with serial epidural phenol in glycerin injections."

( Finch, PM; Lovegrove, FT; Salmon, JB; Warwick, A, 1992)

"eight cancer patients treated with radiotherapy and/or chemotherapy (r/c cancer patients) and six chromium workers."

( Brochard, P; Jaurand, MC; Levy, F; Pilliere, F; Renier, A, 1992)

"On the basis of these findings cancer patients with pain unrelieved by oral opiates were treated for periods of 13 to 91 days with intrathecal octreotide 5-20 micrograms/h."

( Kroin, JS; Paice, JA; Penn, RD, 1992)

"We surveyed 550 cancer patients who experienced pain and were treated with morphine for a total of 22,525 treatment days."

( Grond, S; Jung, H; Meuser, T; Schug, SA; Stobbe, B; Zech, D, 1992)

"LASA can be useful for monitoring cancer patients during treatment, especially in combination with other tumor markers."

( Hilgers, J; Kenemans, P; Mensdorff-Pouilly, S; Schutter, EM; van Dijk, W; van Kamp, GJ; Visser, JJ, 1992)

"Fourteen patients with Adr-resistant tumors were treated with Adr and AM."

( de Vries, EG; Meijer, C; Mulder, NH; Mulder, PO; Nanninga, AG; Uges, DR; van der Graaf, WT; Vellenga, E, 1991)

"Of the ten head and neck cancer patients, five were found to have inappropriately low SIE levels before therapy, and two additional patients had a decrease of SIE levels during therapy, in one patient to an abnormally low level."

( Goldwasser, E; Smith, DH; Vokes, EE, 1991)

"Persistent severe cancer pain should be treated with opioid drugs, principally morphine."

( Twycross, RG; Zylicz, Z, 1991)

"Three modes of receptor-mediated cancer therapy were reviewed presenting our own data."

( Kanisawa, Y; Kondo, H; Niitsu, Y; Watanabe, N, 1990)

"Nine patients with terminal cancer were treated for pain with continuous subcutaneous injection of morphine via a portable battery-driven injection pump."

( Clemensen, SE; Hole, P; Nielsen, FB; Olesen, AS, 1990)

"Most cytotoxic drugs used in cancer therapy do not discriminate between neoplastic and normal proliferating cells."

( Martin, DS; Stolfi, RL, 1991)

"Treatment of cancer pain with opioids through an epidural catheter, with a portable infuser has been recorded in 20 patients retrospective."

( Jonsson, T; Linnemann, MU, 1991)

"In 48 patients with pain related to malignancy, a pain characterization was performed during oral opioid therapy."

( Hedner, T; Samuelsson, H, 1991)

"In 47 children with malignancy, zinc status, growth, and performance during standard treatment were compared with those in controls."

( Van Wouwe, JP; van Zuylen, L, 1991)

"We find that cancer patients given Type I or Type II IFNs can induce IDO which results in decreased serum Trp levels (20-50% of pretreatment) and increased urinary metabolites of the Kyn pathway (5 to 500 fold of pretreatment)."

( Borden, EC; Brown, RR; Datta, SP; Malone, DG; Ozaki, Y; Sondel, PM, 1991)

"As treatment regimens for cancer become more effective in prolonging a patient's life, and as cyclophosphamide receives increasing use for nonmalignant disorders, the potential for cyclophosphamide-induced cancers, particularly in the bladder, must be recognised."

( Fraiser, LH; Kanekal, S; Kehrer, JP, 1991)

"Clinical trials in cancer patients demonstrate that, compared with placebo, granisetron significantly reduces the incidence of nausea and vomiting for 24 hours after administration of high-dose cisplatin."

( Goa, KL; Plosker, GL, 1991)

"Eight patients with selected cancers were imaged prior to primary radiotherapy, and 3 returned for follow-up scans, for a total of 11 imaging studies."

( Evans, ML; Graham, MM; Grierson, JR; Griffin, TW; Koh, WJ; Krohn, KA; Lewellen, TK; Rasey, JS, 1992)

"Studies of cancer patients showed that transdermally administered fentanyl appears to be effective in the management of chronic, cancer-related pain."

( Calis, KA; Corso, DM; Kohler, DR, 1992)

"However, several other human tumors were resistant to Rh-123 laser therapy in vitro and in vivo."

( Castro, DJ; Fetterman, HR; Haghighat, S; Lufkin, RB; Saxton, RE; Soudant, J; Ward, PH, 1992)

"Six patients with ovarian cancer received 25 mg of HMFG1 monoclonal antibody coupled with 90Y-DOTA (doses of radioactivity, 15 to 25 mCi), administered i."

( Courtenay-Luck, NS; Epenetos, AA; Gooden, CS; Kosmas, C; McCall, MJ; Meares, CF; Snook, D, 1992)

"Neutropenic patients with cancer are traditionally treated with empiric antibiotic combinations when they become febrile."

( Anaissie, EJ; Berkey, P; Bodey, GP; Cabanillas, FF; Elting, L; Holmes, FA; Joshi, JH; Keating, MJ; Khardori, NM; Rolston, KV, 1992)

"It recommends that all cancer patients treated in this fashion be given an initial course of intravenous ascorbate followed by a maintenance oral dose to be continued indefinitely thereafter."

( Cameron, E, 1991)

"In this phase I study, 16 adult cancer patients were treated with concurrent 4-day continuous infusions of ifosfamide at 12 g/m2 and escalating doses of carboplatin (400-1600 mg/m2) to determine the major non-haematological dose-limiting toxicity of the combination."

( Ayash, LJ; Critchlow, J; Deary, J; Eder, JP; Elias, AD; Frei, E; Hunt, M; Schnipper, L; Weissman, L; Wheeler, C, 1991)

"14 patients with progressive advanced cancer, resistant to doxorubicin or epirubicin, were treated with the same anthracycline in combination with bepridil."

( Blokhuis, WM; de Jong, J; Giaccone, G; Maessen, PA; Pinedo, HM; Schuurhuis, GJ; van der Hoeven, JJ; van der Vijgh, WJ; van Kalken, CK, 1991)

"Etoposide is one of the few cancer chemotherapy agents that is schedule-dependent in both preclinical and clinical studies."

( Einhorn, LH, 1991)

"Eighteen patients with advanced solid tumors were treated in a phase I study of cisplatinum in combination with recombinant alpha-2a interferon (Roferon-A, Hoffman-LaRoche, Inc, Nutley, NJ)."

( Ajani, JA; Dhingra, HM; Dhingra, K; Gutterman, JU; Rothberg, JM; Talpaz, M, 1991)

"Clinical studies on cancer and psoriasis patients have shown that plasma and urinary homocysteine (Hcy) responds to methotrexate (MTX) therapy, indicating that Hcy in extracellular fluids may be an indicator of the antifolate effect."

( Christensen, B; Djurhuus, R; Refsum, H; Ueland, PM, 1991)

"Four of ten patients with colorectal cancer responded to the treatment (four partial responses), of whom three had been treated previously."

( Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S, 1991)

"Three patients with terminal malignancy reporting ineffective analgesia using systemic and subsequently spinal opiates were treated with subcutaneous infusion of 10% lidocaine hydrochloride."

( Brose, WG; Cousins, MJ, 1991)

"Ten patients with advanced cancer and breakthrough pain between the ages of 39 and 78 received oral transmucosal fentanyl citrate (10-15 micrograms/kg) 4 or 5 times each over 2 days (42 total administrations) in an open study."

( De Boer, JA; Fine, PG; Marcus, M; Van der Oord, B, 1991)

"Patients with ARF and haematological malignancy (excluding myeloma), presenting to a single unit over 10 years were analyzed to see if patients likely to benefit from intensive renal supportive therapy could be identified."

( Feehally, J; Harris, KP; Hattersley, JM; Walls, J, 1991)

"Twenty-three cancer patients undergoing therapy with interleukin-2 and lymphokine-activated killer cells were studied for evidence of complement activation and systemic neutrophil activation occurring during the course of therapy."

( Eberlein, TJ; Moore, FD; Rodrick, M; Schoof, DD, 1991)

"Although most experimental cancer models responds strikingly to treatment with polyamine antimetabolites--namely, inhibitors of various polyamine synthesizing enzymes--a real breakthrough in the treatment of human cancer has not yet occurred."

( Alhonen, L; Jänne, J; Leinonen, P, 1991)

"Photodynamic therapy of tumors with phthalocyanines (PC) as photosensitizers is described."

( Kwaśny, M, 1991)

"Forty patients with refractory solid tumors or non-Hodgkin's lymphoma were treated with high-dose cyclophosphamide, thiotepa, and carmustine (BCNU), followed by autologous stem cell rescue, in a phase I dose escalation study."

( Bitran, JD; Garner, M; Kaminer, LS; Moormeier, JA; Williams, SF, 1990)

"Not all cancer patients with pain, however, fail to get adequate treatment."

( Hill, CS, 1990)

"Survivors of childhood cancer who received anthracycline treatment have a high incidence of abnormal cardiac function."

( Steinherz, L; Steinherz, P, 1991)

"In murine tumors treated in vivo novobiocin markedly potentiates alkylating agent cytotoxicity without concomitant increases in host toxicity."

( Eder, JP; Schnipper, LE; Teicher, BA; Wheeler, CA, 1991)

"Fifty-four patients with inoperable cancers were treated with a combination of cisplatin and radiotherapy from May 1984 to February 1989."

( Bao, YH; Jiang, ZF; Wu, JD; Yuan, XC; Zhang, WJ, 1991)

"Decreases in spontaneous tumors have previously been seen in 2-year rodent studies in groups of animals that have a reduced body weight in comparison to controls, but the spectrum of reduction in spontaneous neoplasms after treatment with amphetamine is broader than has previously been observed."

( Dunnick, JK; Eustis, SL, 1991)

"Patients with refractory solid tumors and lymphomas were treated with a single 24-hour infusion of AZQ at 50 to 355 mg/m2 in dose escalations of 20%."

( Albain, K; Bansal, VK; Braud, E; Chun, HG; Koch, D; Lanzotti, VJ; McKenzie, RS; Potempa, LD; Stiff, PJ; Weidner, MK, 1991)

"Many patients with cancer enjoy long-term survival and are cured; others may live for extended periods while receiving specific treatment for cancer."

( Ganz, PA, 1990)

"The photodynamic therapy (PDT) of tumors involves illumination of the tumorous area following the administration of a tumor-localizing photodynamic sensitizer."

( Spikes, JD, 1990)

"A total of 29 patients with advanced malignancy were treated with recombinant interferon gamma (rIFN gamma, specific activity = 2."

( Avril, MF; Boue, F; Brandely, M; Le Chevalier, T; Paoletti, C; Pastran, Z; Sancho-Garnier, H; Sevin, D; Spielmann, M; Subirana, R, 1990)

"Endoscopic detection of small tumors is key to the early diagnosis and treatment of malignancy."

( Blackman, J; Herrera, HR; Hinshaw, JR; Lanzafame, RJ; Naim, JO; Rogers, DW, 1990)

"Life expectancy is poor in cancer-associated hypercalcemia even in patients who are actively treated."

( Boyle, IT; Campbell, J; Gallacher, SJ; Patel, U; Ralston, SH, 1990)

"Forty-three patients with advanced cancer were evaluated for the changes of absolute counts of peripheral blood lymphocytes and lymphocyte subsets during chemotherapy or chemoimmunotherapy."

( Kambe, M; Kanamaru, R; Mitachi, Y; Murakawa, Y; Okuno, M; Takahasi, H; Wakui, A, 1990)

"Thirty-two cancer patients being treated with cis-DDP-based chemotherapy for the first time were enrolled in the study and donated a baseline sample and at least one post-treatment sample of blood."

( Brandt-Rauf, P; Fischman, HK; Hemminki, K; Niman, HL; O'Dowd, K; Perera, F; Smith, S; Tang, MX; Toporoff, E; Tsai, WY, 1990)

"The untreated patients with lung cancer received 200 mg/m2 etoposide over 24 h in combination with 100 mg/m2 cisplatin, and the pretreated patients received 400 mg/m2 etoposide over 36 h as monotherapy."

( Miller, AA; Stewart, CF; Tolley, EA, 1990)

"In this study, 27 patients with solid tumors were treated with a combination of cyclophosphamide, thiotepa, and carboplatin (CTCb) in a phase I-II study."

( Burke, J; Eder, JP; Elias, A; Frei, E; Hunt, M; Schnipper, LE; Schryber, SM; Shea, TC; Siegel, R; Teicher, BA, 1990)

"Peripheral neuropathies in cancer patients may be caused by compression due to tumor invasion, by radiation injury, or by chemotherapy."

( Forman, A, 1990)

"Eighteen patients with advanced solid tumors received 37 courses of chemotherapy in a pilot study to determine safe drug concentrations for the three-drug infusion for 7 days."

( Mazur, RN; Mucenski, JW; Pugh, RP; Raju, RN; Shackney, SE; Simon, SR; Zidar, BL, 1990)

"In children with malignant tumors, the therapeutic activity of carboplatin at high doses, even in combination chemotherapy, deserves further studies."

( Castello, MA; Clerico, A; Dominici, C; Jenkner, A, 1990)

"Forty-two patients with advanced malignancy judged unlikely to respond to standard treatment received high-dose combination chemotherapy with cyclophosphamide, etoposide, and cisplatin in a phase I trial."

( Anderson, T; Kohler, W; Mangalik, A; Neidhart, JA; Plauche, A; Quenzer, RW; Rinehart, JJ; Stidley, C, 1990)

"Sixteen children with solid tumors resistant to conventional therapies were registered in a pilot Pediatric Oncology Group (POG) study that required the administration of HDAC at 3 g/m2 every 12 hours for four doses."

( Alvarado, C; Camitta, B; Fernbach, DJ; Krischer, J; Mahoney, DH; Tebbi, CK, 1990)

"Chemotherapeutic treatment for cancer has been successful in prolonging survival but it has also been demonstrated that survivors of cancer patients who had received chemotherapy with alkylating agents have an increased risk of second malignancies, mostly acute non-lymphatic leukemia."

( Hayashi, Y; Takahashi, M; Yoshimura, H, 1990)

"Conditioning regimens for solid tumors were multi-agent high-dose chemotherapy, mainly consisted of cyclophosphamide (CY) 120 mg/kg or melphalan 180mg/m2 and that for hematological malignancies were CY with fractionated total body irradiation (12 Gy)."

( Ohira, M, 1990)

"Nausea and emesis during cancer chemotherapy are very common, but can often be controlled with repetitive boli of antiemetic drugs."

( Naji, P; Osterwalder, B; Schuler, L; Senn, HJ; Wilder-Smith, CH, 1990)

"Fifty-four cancer patients, treated with diverse chemotherapy regimens, all including cisplatin (greater than = 50 mg/m2), received ICS 205-930 for a total of 165 courses."

( Antonacci, RA; Berruti, A; Dogliotti, L; Faggiuolo, R; Lancranjan, I; Ortega, C, 1990)

"In patients with cancer treated with cisplatin, carboplatin or methotrexate creatinine clearance calculated using the Cockcroft-Gault formula was compared with measured clearance and with the glomerular filtration rate."

( Atkinson, CH; Colls, BM; Fitzharris, BM; Frampton, CM; Robinson, BA, 1990)

"Fifty patients with advanced cancer were treated at dose levels that ranged from 100 to 1500 mg/m2/day."

( Baltzer, L; Dimaggio, JJ; Haines, I; Lee, SJ; Lowenthal, DA; Muindi, J; Stevens, YW; Walsh, TD; Warrell, RP; Yaldaei, S, 1990)

"Twenty-four cancer patients with diffuse interstitial pneumonitis (DIP) were randomized to undergo an open lung biopsy (OLB) within 8 hours of presentation (12 patients) or to receive empiric antimicrobial therapy (ET) with trimethoprim-sulfamethoxazole (TMP-SMX) erythromycin for a minimum of 4 days (12 patients)."

( Brower, S; Browne, MJ; Cotton, D; Gill, V; Glatstein, E; Gress, J; Hathorn, J; Hiemenz, J; Potter, D; Thaler, M, 1990)

"Patients with solid tumors are often anemic even before they undergo cytotoxic therapy."

( Abeloff, MD; Jones, RJ; Miller, CB; Piantadosi, S; Spivak, JL, 1990)

"We have treated 14 cancer patients with liposome-encapsulated doxorubicin (LED) at doses of 30, 45, 60, and 90 mg/m2."

( Alvord, WG; Forst, D; Potkul, LA; Rahman, A; Roh, JK; Treat, J; Woolley, PV, 1990)

"The genotoxicity of the alkylating anti-cancer drugs including cyclophosphamide (CP) has been examined previously by determining baseline SCEs in peripheral blood lymphocytes from treated cancer patients."

( Hansen, J; Jacobson-Kram, D; Kolodner, K; McDiarmid, MA; Strickland, PT, 1990)

"In this study, patients with advanced cancer were treated with DHAC administered as a 24-h constant i."

( Batist, G; Collins, JM; Curt, GA; Fine, RL; Huguenin, PN; Jenkins, J; Kelley, JA; Roth, JS, 1985)

"The effectiveness of sound cancer surgery and the importance of local disease control as an element in improving cure rates and palliation needs to be emphasised so that patients are not denied optimal treatment."

( Hughes, LE, 1985)

"In this malignancy, the HCG level suggests the diagnosis and stage, confirms response to therapy, and predicts relapse."

( Bates, SE; Longo, DL, 1985)

"In testicular cancer patients receiving adjuvant chemotherapy, a significant increase in serum (p less than 0."

( Hofbauer, J; Kratzik, C; Kuzmits, R; Legenstein, E; Ludwig, H; Szekeresz, T, 1986)

"Remarkable anticancer effects against various malignant solid tumors were observed using this targeting chemotherapy."

( Konno, T; Maeda, H; Matsumura, Y; Miyauchi, Y; Mizutani, J; Ohtsuka, N; Yamasaki, K, 1986)

"Immunotherapy against cancer gained popularity as a treatment modality based on the experimental model data that seemed to indicate that both specific stimulation of the immune response with antigen-bearing tumor cells and nonspecific stimulation with bacteria and other adjuvant-type compounds could enhance the existing immune response of the host and prevent recurrence or delay tumor growth."

( Niizu, Y; Urushizaki, I, 1986)

"Most human cancers are resistant to bleomycin a priori, however, and those which are initially sensitive frequently develop resistance to the drug during therapy."

( Sikic, BI, 1986)

"All patients treated to date had cancer, and all were suffering multisystem organ failure."

( Adams, F, 1988)

"Two important aspects of cancer that affect the way in which pain is managed are the cancer's treatability and components of its pathophysiology that themselves do not cause pain (the cancer's "nonpain" pathophysiology)."

( Levy, MH, 1989)

"The possibility and problems in cancer therapy using immunotoxin are discussed."

( Kitamura, K; Noguchi, A; Takahashi, T; Yamaguchi, T, 1989)

"Seventeen patients with advanced malignancy were treated with recombinant human granulocyte colony stimulating factor rhG-CSF (KRN 8601) infused intravenously over a period of 30 minutes once daily at the dose level/25 micrograms, 50 micrograms, 100 micrograms, 200 micrograms, 400 micrograms, 800 micrograms/m2 for 14 consecutive days, and the effect was compared to the period without rhG-CSF treatment."

( Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Mizunuma, N; Mukaiyama, T; Nagamine, D; Ogawa, M; Shinagawa, K; Tabata, M, 1989)

"A total of 173 female terminal cancer patients were randomized to treatment with daily 125 mg infusions of methylprednisolone sodium succinate or a matching placebo for a period of 8 consecutive weeks."

( Giongo, F; Lucchi, R; Popiela, T, 1989)

"Forty six episodes of infection in 43 cancer patients were treated with oral ciprofloxacin at a dose of 750 mg every 8 h."

( Bodey, GP; Cunningham, C; Haron, E; Holmes, F; Rolston, KV; Umsawasdi, T, 1989)

"A total of 28 patients receiving cancer chemotherapy with cisplatin-containing regimens (70-120 mg/m2) participated in an evaluation of the efficacy and safety of GR38032F for the prevention of acute nausea and vomiting."

( Bons, J; Brion, N; Droz, JP; Marty, M; Paule, B; Pouillart, P, 1989)

"Thirty-nine adults with solid tumors were treated on a Phase I study of menogaril administered i."

( Earhart, RH; Maroun, JA; Perrault, D; Stewart, DJ; Verma, S, 1989)

"Several thousand cancer patients with both early and advanced tumors have been treated to date with encouraging results."

( Dougherty, TJ, 1989)

"A patient with breast cancer was treated with adoptive immunotherapy of CTL because she had severe side effect from antineoplastics ."

( Kitsukawa, K, 1989)

"It is suggested that acid conditions in tumors might allow the development of new and relatively specific types of therapy which are directed against mechanisms which regulate pHi under acid conditions."

( Rotin, D; Tannock, IF, 1989)

"We evaluated 30 cancer patients who received immunotherapy with IL-2 or IL-2 plus lymphokine-activated killer (LAK) cells."

( Davis, CL; Denicoff, KD; Durkin, TM; Listwak, SJ; Lotze, MT; Quinlan, PE; Rosenberg, SA; Rubinow, DR, 1989)

"Almost three quarters of patients with cancer have severe pain, from invasion of the cancer itself, from effects of therapy, or from causes unrelated to the cancer (but often exacerbated by it)."

( Belgrade, MJ, 1989)

"Inadequate treatment of cancer pain with narcotics may stem, in part, from these events."

( Hill, CS, 1989)

"Acute and chronic malabsorption after cancer chemotherapy should be considered in patients, who are treated with enteral medication and nutrition."

( Borchard, F; Hürter, T; Reis, HE, 1989)

"One hundred forty-seven cancer patients were treated with intravenously administered ciprofloxacin, 200 mg every eight hours, as initial therapy for febrile episodes."

( Bodey, GP; Cunningham, C; Haron, E; Rolston, KV, 1989)

"Superficial human tumors have been studied by MRS to characterize their 31P spectra, and to measure metabolic changes during therapy."

( Boska, MD; Karczmar, GS; Meyerhoff, DJ; Shine, N; Speder, A; Valone, F; Weiner, MW; Wilkinson, M, 1989)

"Sixty-nine patients with malignant tumors receiving cancer chemotherapy, 90% including cis-platinum, were evaluated in a randomized crossover study for the antiemetic efficacy and the side effects of two antiemetic regimens: chlorpromazine (CPM) 2."

( Ben-Yosef, R; Biran, S; Brufman, G; Catane, R; Gez, E, 1989)

"Two patients with breast cancer who had multiple distant metastases and 2 pediatric patients are now alive with NED after 5 years of the treatment and seem to have been cured."

( Fujimoto, T; Kubota, M; Nakasaki, H; Norihisa, Y; Noto, T; Ohta, M; Okumura, A; Tajima, T; Tokuda, Y; Yokoyama, S, 1989)

"Seventeen of the 24 treated tumors (70%) had previously been irradiated."

( Clark, JR; Fraser, SM; Gelwan, LE; Hansen, J; Herman, TS; Jochelson, MS; Molnar-Griffin, BJ; Pfeffer, MR; Scott, PJ; Teicher, BA, 1989)

"Examination of electrocardiograms of cancer patients treated with a variety of doses and routes of OK-432 has revealed that none of 266 patients examined showed any significant change in electrocardiograms (ECGs) after OK-432 treatments, regardless of their pretreatment heart conditions (normal or abnormal ECGs)."

( Goya, T; Hayashi, Y; Sugisaki, T; Tanaka, J; Torisu, M; Yoshida, T, 1989)

"Thirty-three cancer patients remaining hypercalcemic after a 48-h rehydration period were included and monitored daily until normocalcemia or treatment failure was documented."

( Body, JJ; Borkowski, A; Magritte, A; Sculier, JP; Seraj, F, 1989)

"Fifty-two non-resectable and recurrent cancer patients with prior treatment, were entered in this study; 1 esophageal, 33 gastric, 1 duodenal, 4 colorectal, 2 pancreatic, 2 bile duct, and 9 breast cancer."

( Hattori, T; Jinushi, K; Kim, R; Niimoto, M; Saeki, K; Saeki, T; Toi, M; Yanagawa, E; Yoshinaka, K, 1989)

"The effect of cancer chemotherapy on dapsone (DDS) N-acetylation was explored in 28 patients with various malignancies."

( Harper, PG; Philip, PA; Rogers, HJ, 1989)

"A series of 252 patients with terminal cancer (mostly with bony metastases) were treated with epidural morphine."

( Hui, YL; Liew, E, 1989)

"Twelve Patients with malignant neoplasms were treated in twenty-five courses with high-dose Cisplatin and high-dose Bismuth Subnitrate."

( Kawamura, E; Morikawa, T, 1989)

"The more undifferentiated tumors took up more [125I]MIBG and may be more likely to respond to targeted radiotherapy with MIBG."

( Agrawal, M; Babich, JW; Carter, R; McElwain, TJ; Meller, ST; Moyes, JS, 1989)

"In 34 cancer patients with 40 neutropenic febrile episodes requiring broad-spectrum antimicrobial therapy, detailed dietary assessments revealed that deficient and severely deficient phylloquinone intakes (less than or equal to 70 and less than or equal to 25 micrograms/d) were identified during 88% and 38% of all days recorded, respectively."

( Conly, J; Loftson, J; Louie, T; Ramotar, K; Reid, E; Suttie, J, 1989)

"An open study of 47 patients with cancer pain treated with repeated doses of a controlled-release oral morphine tablet was conducted to assess the acceptability of this drug and develop guidelines for its use."

( Coyle, N; Foley, KM; Houde, RW; Lapin, J; Portenoy, RK, 1989)

"The impairment of cancer patients' nutritional status seems to depend primarily on the decrease of spontaneous oral intake as a consequence of the side effects of tumor therapy."

( Konkol, K; Mueller, JM; Ollenschlaeger, G; Schrappe-Baecher, M; Wickramanayake, PD, 1989)

"Being easy to use, these devices allow cancer patients to remain at home, whereas otherwise they would need to be hospitalized for effective treatment of pain."

( Buchser, E; Chapuis, G; Cosendey, BA; Dupasquier, G, 1989)

"Oral morphine therapy for cancer pain offers effective pain relief with minimal side effects in the majority of patients."

( Bhargava, K; Heranjal, R; Lobo, B; Vijayaram, S, 1989)

"The satisfactory treatment of cancer pain requires a variety of practical management strategies."

( Barnett, JB; Brigden, ML, 1987)

"When the breast cancer patients' macrophages were pretreated with these neuropeptides, enhancement in cytotoxicity was observed at 10(-10) M of [met]-enkephalin, and [leu]-enkephalin and at 10(-8) M and 10(-12) M of alpha-endorphin."

( Cameron, DJ, 1987)

"Pain in cancer patients is shown to arise in different ways, demanding a flexible approach to treatment."

( Böhme, K, 1988)

"One of the major problems in cancer chemotherapy is the development of drug resistance during treatment."

( Tsuruo, T, 1988)

"Meanwhile, attempts to treat the malignancy are initiated, including palliative radiation therapy for bony metastases."

( Fetchick, DA; Mundy, GR, 1986)

"Application of this therapy to tumors in the bronchus, bladder, skin, and several other sites has demonstrated both safety and efficacy, even in advanced cases."

( Dougherty, TJ, 1986)

"Twenty-two patients with advanced solid tumors were treated with a quinazoline folate antagonist, trimetrexate, to determine the toxicity spectrum, the maximal tolerated dose, and the pharmacokinetics of the drug."

( Baker, M; Bertino, JR; Cashmore, AR; Delap, R; Dreyer, RN; Ernstoff, M; Grillo-Lopez, A; Lin, JT; Marsh, JC; Whitfield, LR, 1987)

"Nineteen patients affected by solid tumors were included in the study, 5 of whom were treated with CMF, 4 with FEC, 4 with CEV, and 6 with CDDP."

( Barni, S; Crispino, S; Esposti, D; Esposti, G; Ferri, L; Fumagalli, G; Lissoni, P; Paolorossi, F; Rovelli, F; Tancini, G, 1987)

"Eighteen adult patients with solid tumors were treated with oral menogaril, a new anthracycline antibiotic active against human breast cancer after intravenous administration."

( Crespeigne, N; de Valeriola, D; Dodion, P; Joggi, J; Kenis, Y; Peeters, B; Piccart, M; Tueni, E; van Berchem, C; Wery, F, 1988)

"Eighteen adult patients with solid tumors were treated with oral menogaril, a new anthracycline antibiotic active against human breast cancer after intravenous administration."

( Crespeigne, N; de Valeriola, D; Dodion, P; Joggi, J; Kenis, Y; Peeters, B; van Berchem, C; Wery, F, 1988)

"Clinical studies have shown that cancer patients can develop learned aversions to a novel ice cream flavor when it is consumed before drug treatments that produce nausea and vomiting."

( Bernstein, IL, 1985)

"Models for potential indirect anticancer effects either by in-vivo administration or by in-vivo incubation plus passive transfer of T-cells are presented to be initiated in future clinical trials."

( Heinemann, V; Jehn, U, 1985)

"Anti-cancer agents suspended in Lipiodol have been proved to be effective in the targeting of chemotherapy for cancer of the digestive organs."

( Takahashi, T; Taniguchi, H; Yamaguchi, T, 1986)

"In small cell lung cancer initial high dose therapy followed by non-cross-resistant regimens may prove effective."

( Peters, W; Souhami, R, 1986)

"Fifty-four marijuana-naive cancer patients undergoing chemotherapy and about to use THC (delta-9-tetrahydrocannabinol) as an antiemetic for the first time were randomly assigned to one of two conditions: stress inoculation or placebo/information training."

( Roffman, RA, 1986)

"Thus, it is possible that tumors also pretreated with other drugs become resistant to growth inhibitory effects of ascorbate ions."

( Cercek, B; Cercek, L, 1987)

"Treatment of cancer patients often fails because of the resistance in the tumor to chemotherapeutic drugs."

( De Vries, EG; Hospers, GA; Mulder, NH, 1988)

"The role of IV melphalan in cancer chemotherapy is not well defined, despite its manageable toxicity and higher and more predictable blood levels following IV administration compared with oral administration."

( Cheson, BD; Leyland-Jones, B; Sarosy, G; Soochan, P, 1988)

"There are 5 patients with breast cancer who have been followed over 5 years after treatment."

( Kubota, M; Mitomi, T; Murakami, M; Nakamura, Y; Ohta, M; Shinozuka, T; Tajima, T; Tokuda, Y; Watanabe, K; Yokoyama, S, 1988)

"Sixty-five cancer patients pretreated with chemo or radiotherapy, with granulocytopenia less than 1000/mm3 and without fever, were entered into this study: 30 of them were submitted to prophylaxis with norfloxacin while the remaining 35 patients were used as a control group."

( Ameglio, F; Casali, A; Frasca, AM; Gallo Curcio, C; Modugno, G; Paoletti, G; Tonachella, R; Tropea, F; Verri, C, 1988)

"It is desirable for multidisciplinary cancer treatments to be concentrated as selectively as possible onto the cancer-bearing organs in order to augment the anticancer effects and minimize the untoward effects."

( Agishi, T; Fuchinoue, S; Honda, H; Nakazawa, H; Okumura, T; Teraoka, S, 1986)

"The growth of Meth A (MA) tumors was suppressed in tumor-antigen-specific manner in BALB/c mice immunized with mitomycin C-treated MA (MMC-MA) cells in saline or in Freund's complete adjuvant (FCA)."

( Himeno, K; Matsumoto, T; Miake, S; Mitani, M; Mori, K; Nomoto, K, 1986)

"Eight patients with cancer associated hypercalcaemia were treated with the combination of aminohydroxypropylidene diphosphonate and salmon calcitonin for six days."

( Alzaid, AA; Boyle, IT; Gardner, MD; Ralston, SH, 1986)

"A total of 24 patients with intractable cancer pain were evaluated as candidates for spinal morphine therapy."

( Hadley, MN; Shetter, AG; Wilkinson, E, 1986)

"in seven cancer patients over 10-day courses at doses of 10-90 g/day and 24-h urinary excretion of polyamines and decarboxylated-S-adenosylmethionine was determined before, during, and after treatment."

( Haegele, KD; Romijn, JC; Schechter, PJ; Sjoerdsma, A; Splinter, TA, 1987)

"Although other neural crest tumors may concentrate [131I]MIBG, this is not a consistent finding; however, it is useful to investigate which tumors do, as this may provide an alternative treatment modality for some patients."

( de Kraker, J; Hoefnagel, CA; Marcuse, HR; Voûte, PA, 1987)

"Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, greater than 11."

( Benson, AB; Bockman, RS; Citrin, DL; Greco, FA; Harvey, HA; Rasmussen, P; Schiller, JH; Siris, ES; Stock, JL; Witte, RS, 1987)

"Sampling of tumors before and after drug treatment is done by 4 mm disposable punch biopsy or forceps biopsy via subcutaneous tunneling."

( Gustavsson, BG; Spears, CP, 1988)

"In 2 patients with metastatic breast cancer who had not been pretreated with cytostatic agents, a partial remission was achieved lasting for 5 months."

( Kleeberg, UR; Miller, AA; Scheulen, ME; Schmidt, CG; Seeber, S, 1988)

"Twenty-three outpatients with cancer pain refractory to other methods of pain control were treated with epidural morphine (EM) delivered through a chronically placed percutaneous lumbar epidural catheter."

( Busch, EH; Downing, JE; Stedman, PM, 1988)

"Thirteen cancer patients with moderate to severe chronic pain of malignant origin on treatment with Ketogan tablets were included in an open non-randomized cross-over study comparing the analgesic effect, side effects and serum concentrations of Ketogan tablets and mixture."

( Kjaer, M; Nielsen, H, 1988)

"This study describes the development of neoplasms and the suppression of bone marrow stem cells following chronic administration of cytosine-arabinoside (ara-C) in Sprague-Dawley rats."

( Berger, MR; Schmähl, D, 1988)

"Four lymphoproliferative cancers occurred in the azathioprine treated group compared with two in the control group."

( Evans, SJ; Hazleman, B; Petrie, J; Silman, AJ, 1988)

"A total of 13 cancer patients were treated with Adoptive Chemoimmunotherapy (ACIT) using alloactivated HLA haploidentical lymphocytes."

( Hank, JA; Kohler, PC; Minkoff, DZ; Sondel, PM, 1988)

"Thirty-four patients with advanced neoplasms who had received interleukin-2 and LAK cells were followed for at least four weeks after treatment."

( Atkins, MB; Berkman, EM; Gould, JA; Kaplan, MM; Mier, JW; Parkinson, DR, 1988)

"Forty-four patients with advanced cancer were treated with IT OK-432 immunotherapy."

( Baba, N; Hattori, T; Kegoya, Y; Kuninobu, H; Toge, T; Yamaguchi, Y, 1988)

"We assessed the risk of occurrence of cancer associated with exposure to metronidazole in the 771 female residents of Rochester, Minnesota, who were treated with metronidazole for vaginal trichomoniasis during the period 1960 through 1969 and were followed up for a total of 12,628 person-years."

( Beard, CM; Dahlin, DC; Kurland, LT; Noller, KL; O'Fallon, WM, 1988)

"New therapeutic approaches to improving cancer treatment will most likely be coordinated with either chemotherapy or radiotherapy or combined chemotherapy and radiotherapy."

( Looney, WB, 1988)

"Fourteen patients with advanced cancer were treated at doses of 10-30 mg/m3."

( Bork, E; Hansen, HH; Vest, S, 1988)

"The sera of 138 cancer patients, taken before any therapy, were significantly lower than the corresponding normal or chronic disease controls."

( Gross, DJ; Gross, J; Margalioth, E; Simon, E; Szwarc-Bilotynski, L, 1988)

"Seventy-eight patients with cancer experienced 88 episodes of fever while neutropenic and were randomly assigned to receive empiric antibiotic therapy with cefoperazone 2 g intravenously every 12 hours and mezlocillin 4 g intravenously every six hours or imipenem/cilastatin 500 mg intravenously over 30 to 60 minutes every six hours."

( Black, D; Kirby, WM; Kwok, K; Miller, S; Mortimer, J, 1988)

"The effects on cancer development vary for different types of cancers, with type and dosage of hormone and probably also, insofar as breast cancer is concerned, with age and age at which treatment was begun."

( Bergkvist, L; Persson, I; Westerholm, B, 1988)

"Fifty-five ovarian cancer patients treated with melphalan during 1968-1978 were followed during 309 person years and studied with cytogenetic analyses."

( Einhorn, N; Eklund, G; Lambert, B, 1988)

"Eighty-four patients with refractory cancer received 12 dose escalations from 10-150 mg/m2 TCNU administered orally every 6 weeks."

( Cornbleet, MA; Kerr, ME; Leonard, RC; Macpherson, JS; Smyth, JF; Warrington, PS; Whelan, JM, 1987)

"Since neutropenia is common during cancer treatment, there is a continual risk of infection in cancer patients; thus it is important for medical oncologists to become aware of these complications and their management."

( Fujimoto, T, 1986)

"The influence of therapy for the first cancer on subsequent leukemia risk was determined by a case-control study conducted on 25 cases and 90 matched controls."

( Birch, J; Boice, JD; Fraumeni, JF; Hoover, RN; Meadows, AT; Oberlin, O; Stone, BJ; Stovall, M; Tucker, MA; Voûte, PA, 1987)

"Eighty-one febrile episodes in cancer patients with adequate neutrophil counts (greater than 1000/microliter) were treated with a double beta-lactam combination of ceftizoxime plus ticarcillin."

( Bodey, GP; Elting, L; Fainstein, V; Jones, PG; Rolston, KV, 1987)

"Thirty-four patients with cancer (30) or ARC (4) with severe T cell defect or imbalance persisting a long time after completion of any cytostatic treatment were treated by bestatin 30 mg/day 3 days per week during three weeks."

( Brienza, S; Canon, C; Mathé, G; Misset, JL; Musset, M; Reizenstein, P; Umezawa, H, 1986)

"Adoptive immunotherapy of human cancer was investigated in our institution as part of a National Cancer Institute extramural group study."

( Baker, H; Ciobanu, N; Dutcher, JP; Frank, O; Hutner, SH; Marcus, SL; Paietta, E; Strauman, J; Wiernik, PH, 1987)

"Most anticancer drugs are more toxic to proliferating cells and the fall and recovery of granulocyte counts after chemotherapy may be explained by the effect of drugs on rapidly proliferating precursor cells in the bone marrow."

( Tannock, IF, 1986)

"It has been postulated that tumors contain hypoxic cells of decreased radiation sensitivity, which limit curability with radiation therapy."

( Fischer, JJ; Martin, DF; Rockwell, S, 1986)

"The therapy for each of these tumors, with the exception of osteosarcoma, consisted of combination chemotherapy with or without radiotherapy and was started as soon after diagnosis as possible."

( Lampkin, BC; Wong, KY, 1986)

"The records of 147 cancer patients who received at least three courses of cisplatin-containing chemotherapy in the Arizona Cancer Center clinic between 1982 and 1985 were reviewed to determine the safety and tolerance of cisplatin administered in the outpatient setting."

( Alberts, DS; Brock, J, 1986)

"The numerical development of cancer cells during tumor growth and under current forms of therapy is quantitatively described as a fundament of a scientifically founded anticancer strategy."

( von Ardenne, M, 1986)

"Patients with specific types of cancer have achieved substantial prolongation of survival after successful cancer chemotherapy."

( Furue, H, 1987)

"One of the major causes of failure of cancer chemotherapy is the proliferation of specific drug-resistant tumor cells during treatment."

( Tsuruo, T, 1987)

"In this study, 12 patients with colon cancer were treated with thrice weekly thymosin fraction 5 at a dose of 120 mg/m2, and 10 patients with non-small-cell lung cancer received thymosin alpha 1 at 1."

( Beauregard, J; Dillman, RO; Royston, I; Zavanelli, MI, 1987)

"Urinary bladder cancer (six cyclophosphamide-treated patients, no control patients) and skin cancer (eight cyclophosphamide-treated patients, no control patients) were identified as differing statistically between the groups, and hematologic malignancy (five cyclophosphamide-treated patients, one control patient) showed a similar trend."

( Agarwal, AK; Baker, GL; Kahl, LE; Medsger, TA; Stolzer, BL; Zee, BC, 1987)

"Thirty cancer patients, who were diagnosed to be beyond the operable stage, were treated by intra-arterial anticancer agent infusion via an implantable vascular access device (VAD) combined with local hyperthermia and/or charcoal hemoperfusion."

( Agishi, T; Honda, H; Huchinoue, S; Kihara, K; Nakagawa, Y; Nakazawa, H; Oba, S; Ota, K; Teraoka, S, 1987)

"Thirty-seven patients with advanced cancer requiring oral administration of strong narcotics for pain control have been treated with one or other of two commercially-available, sustained-release morphine preparations."

( Sherman, LM, 1987)

"Seventeen patients with advanced cancer pain, treated with chronic epidural morphine, were studied."

( Hedner, T; Lindqvist, J; Nordberg, G; Samuelsson, H, 1987)

"Eleven non-resectable cancer patients have been successfully treated by means of a one-shot and continuous intra-arterial infusion chemotherapy, utilizing an implantable vascular access device (Catheter Access) connected to a continuous infusion pump (Nipro portable syringe infusion pump) via a non-corning needle (Nipro coreless needle set)."

( Agishi, T; Fuchinoue, S; Honda, H; Nakagawa, Y; Nakazawa, H; Ohta, K; Takahashi, K; Teraoka, S, 1987)

"Of 135 persons with cancer referred for psychotherapy, 76 per cent were found to have had a previous grief experience, and 60 per cent were suffering from unresolved grief for previous losses."

( Vachon, ML, 1987)

"Twelve patients with pain secondary to cancer were simultaneously administered both morphine (10 mg) and pethidine (50 mg) in 10 ml of normal saline via an epidural catheter inserted in the lumbar region (usually L2,3) and attached to a subcutaneously implanted portal reservoir."

( Armstrong, PJ; Cherry, DA; Cousins, MJ; Gourlay, GK; Plummer, JL, 1987)

"For certain classes of neoplasms, these parameters can be used for the early recognition of neoplasia and related to disease evolution and dissemination and to the results of therapy."

( Göhde, W; Mauro, F; Schumann, J; Teodori, L, 1986)

"Current treatment of cancer-related hypercalcemia is limited by agents of limited effectiveness or excessive toxicity."

( Alcock, NW; Bockman, RS; Skelos, A; Warrell, RP, 1986)

"Chronic cancer pain remains intractable by standard treatment in many patients and interferes with their mobility and independence."

( Handa, H; Konishi, T; Moritake, K; Nishioka, T; Suwa, H; Takaya, M; Umeda, S, 1986)

"Nineteen patients with urologic malignancy undergoing chemotherapy with cisplatin in combination with other agents were studied for the antiemetic efficacy of Timiperone."

( Kojima, S; Owada, F; Satake, I; Tari, K, 1986)

"for treatment of various human cancers, especially leukemias, even though the systemic availability of the drug given p."

( Creagan, ET; Hu, TC; Kovach, JS; Kvols, LK; Rubin, J; Schutt, AJ; Svingen, PA, 1986)

"Twenty-three patients with metastatic tumors received multiple chemotherapy regimens which included CIS platine (CDDP) by continuous ambulatory infusion for 4 successive days at a rate of 25 mg/m2/day repeated every 4 weeks."

( Benahmed, M; Renaux, J; Rouesse, J; Spielman, M, 1986)

"Fifteen cancer patients receiving cisplatin-containing chemotherapy participated in two antiemetic studies."

( Havsteen, H; Kjaer, M; Nielsen, H, 1986)

"In patients with cancer pain treated by continuous epidural opiate infusion (4."

( Gips, H; Hempelmann, G; Krumholz, W; Lüben, V; Müller, H; Zierski, J, 1986)

"Twenty cancer patients with severe chronic pain have been treated with intraventricular morphine sulfate."

( Hill, SC; Leavens, ME; Obbens, EAMT; Otis, F; Ruthenbeck, SS, 1987)

"Overall, the patients with cancer were pleased with their pain therapy, experienced few complications, and reported improved quality of life."

( Gershow, J; Glassberg, A; Kenefick, T; Krames, ES; Lyons, A; Taylor, P; Wilkie, D, 1985)

"High dose administration of anticancer drugs was discussed putting an emphasis on methotrexate and cytosine arabinoside."

( Takaku, F, 1985)

"This effect in cancer chemotherapy was studied in 31 patients with advanced ovarian cancer."

( Hrushesky, WJ, 1985)

"Therapeutic options in cancer treatment currently are few, and the benefits of potentially carcinogenic chemotherapy and radiotherapy continue to outweigh the risks."

( Coltman, CA; Dorr, FA, 1985)

"In all, 39 patients with advanced cancer were treated at doses of 2."

( Groth, S; Hansen, HH; Hansen, SW; Nissen, MH; Rørth, M; Sørensen, JB, 1985)

"The photodynamic therapy of tumors is based on a photosensitization reaction that produces oxygen-derived cytotoxic species."

( Freitas, I, 1985)

"Patients with hepatic cancers were treated with varying doses of DSM with mitomycin C coadministered into the hepatic artery to define a dose of DSM which produces acceptable toxicity with maximal hepatic drug deposition as determined by a reduction in systemic mitomycin C exposure."

( Ensminger, WD; Gyves, JW; Stetson, P; Walker-Andrews, S, 1985)

"Some of these solid tumors contain greater amounts of activity than do their normal equivalents, which encourages the use of inhibitors of this enzyme in conjunction with treatment of these tumors by 5-fluorouracil."

( Cha, S; el Kouni, MH; Naguib, FN, 1985)

"On the other hand, patients with larger tumors where the tumor dose cannot be increased more than 10% over conventional radiotherapy have not responded well to helium ion radiotherapy."

( Castro, JR; Char, D; Chen, GT; Collier, JM; Gauger, G; Gutin, P; Phillips, TL; Pitluck, S; Saunders, W; Zink, SR, 1985)

"The studied patient was elderly and had cancer of left breast, cancer of the head of the pancreas, history of blood transfusions, and was on tamoxifencitrate therapy for breast cancer."

( Barlas, AH, 1986)

"Although the pathophysiology of cancer cachexia is incompletely understood, it assumes considerable clinical relevance because malnutrition is a potentially treatable problem associated with poor outcome."

( Dempsey, DT; Mullen, JL, 1985)

"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications."

( Hazleman, B, 1985)

"Eleven dogs with spontaneous neoplasms were intensively treated with an immunoadsorption system consisting of a continuous flow centrifuge, Protein A-Sepharose columns, and a semi-automatic elution system."

( Branda, RF; Klausner, JS; Miller, WJ; O'Brien, TD, 1985)

"Seventy-eight infectious episodes in 75 cancer patients with adequate granulocyte counts were treated with cefotaxime."

( Bodey, GP; Bolivar, R; Elting, L; Fainstein, V; Jones, P; Rolston, K, 1985)

"Thirty-nine patients with metastatic neoplasms received a total of 127 treatment courses; two-thirds of the patients had received prior treatment with radiation therapy or chemotherapy; most of the latter treatment regimens included MTX or FUra."

( Benz, C; Cadman, E; DeGregorio, M; Holleran, W; Ignoffo, R; Lewis, B; Saks, S; Sambol, N, 1985)

"Only patient C (breast cancer) had received chemotherapy."

( Boulet, L; Dufour, M; Panasci, LC; St Germain, J, 1985)

"Eleven patients with advanced breast cancer and four with astrocytoma were treated with plasma perfused over columns containing staphylococcal Protein A (SPA)."

( Apuzzo, ML; Bertram, JH; Boquiren, D; Grunberg, SM; Hengst, JC; Kunkel, L; Nelson, J; Plotkin, D; Shulman, I; Waugh, WJ, 1985)

"Twenty-six out of 160 cancer patients referred to the Pain Division for pain assessment were selected for analgesia with long-term epidural morphine, so aiming to define its place amongst more traditional methods of treatment, such as drugs, nerve-blocks, neurosurgery or radiotherapy."

( Arnér, S; Bayer-Berger, MM, 1985)

"Possible ramifications to cancer chemotherapy are discussed."

( Tesmer, JG; Tobey, RA, 1985)

"A general review of the current use of cancer chemotherapeutic agents in the treatment of common types of cancer and an update of the state of the art of chemotherapeutic treatment of the late and early stages of breast cancer in 1984 are described."

( Wright, JC, 1985)

"Testicular and ovarian cancer patients receiving chemotherapy on the first course, and given cis-DDP in 21- or 28-day cycles (five days of drug infusion followed by two or three drug-free weeks) accumulated cis-DDP-DNA adducts in blood cell DNA as a function of dose."

( Litterst, CL; Ozols, RF; Poirier, MC; Reed, E; Yuspa, SH; Zwelling, LA, 1985)

"Fourteen cancer patients were administered 10 mg of morphine in 10 ml of normal saline via an epidural catheter inserted in the lumbar region (usually L2."

( Cherry, DA; Cousins, MJ; Gourlay, GK, 1985)

"In summary, a strategy of cancer chemotherapy predicated upon interference with RNA synthesis or increase in RNA catabolism is offered as a potential mechanism for establishing anti-angiogenesis, and as a promising alternative and adjunct to present methods."

( Blumberg, N, 1974)

"Eight other test compounds from the Cancer Chemotherapy National Service Center (CCNSC) were not toxic to cell growth, although two (4-biphenylcarboxylic acid and 1-[p-chlorobenzyl]-2-ethyl-5-methyl-indole-3-acetic acid) inhibited Crithidia alpha-glycerophosphate dehydrogenase below 1 mm."

( Bacchi, CJ; Ciaccio, EI; Koren, LE, 1969)

"Of 100 patients with small-cell lung cancer receiving an identical regimen of cyclophosphamide, doxorubicin, and vincristine, 40 were assigned to treatment with lithium concurrently."

( Dinwoodie, WR; Lyman, GH; Schocken, DD; Williams, CC, 1984)

"In untreated cancer patients, plasma and urine cAMP levels were similar to those of normal subjects, whereas plasma and urine cGMP levels were markedly higher."

( Baldini, L; Bamonti-Catena, F; Lombardi, L; Maiolo, AT; Mandelli, V; Peracchi, M; Polli, EE; Toschi, V, 1984)

"Undertreatment of cancer pain results not only from the limited expectations of patients but also from the inadequate knowledge of many physicians."

( Noyes, R, 1981)

"The treatment of chronic pain in cancer patients with analgesic drugs has been evaluated from the records of 70 hospital admissions."

( Heimpel, H; Merkle, W; Schreml, W, 1981)

"When gynecologic cancer is treated by either surgery or radiation therapy, definitive infertility usually results."

( Barber, HR, 1981)

"The management of pain in cancer patients requires experience and a therapy-protocol."

( Hoffmann, L, 1984)

"Intractable pain in six cancer patients was treated with lumbar intrathecal morphine (two patients) and intraventricular morphine (four patients)."

( Cech, DA; Hill, CS; Leavens, ME; Weston, JS; Weyland, JB, 1982)

"In nine of 11 (82%) instances, tumors were sensitive to a particular drug, and the patient had at least 50% regression of tumor following treatment with the tested drug."

( Burk, MW; Campbell, MA; Giuliano, AE; Kaiser, LR; Kern, DH; Mann, BD; Morton, DL, 1982)

"New agents used in cancer chemotherapy are continually appearing which, in turn, leads to newer patterns of toxicity."

( Seyfer, AE; Solimando, DA, 1983)

"Since 1970, we have carried out cancer chemotherapy and immunotherapy in cooperation with Japanese scientists, particularly Prof."

( Mathé, G, 1983)

"Many attempts in cancer immunotherapy have been made on the basis of advanced basic immunology."

( Yamamura, Y, 1983)

"A patient with a disseminated malignancy received 3 mg of synthetic beta-endorphin administered intrathecally by lumbar puncture."

( Cohen, MR; Dubois, M; Pickar, D, 1984)

"The majority of tumors treated were dermal breast cancer recurrences (21 cases), local recurrence of ENT squamous cell carcinomas (16 cases), and ENT cutaneous metastases of squamous cell carcinomas (9 cases)."

( Berns, MW; Burns, RG; Dahlman, A; Wile, AG, 1982)

"This paper provides an overview of cancer chemotherapy with special reference to the pharmacokinetics of the nitrosoureas."

( Wakui, A, 1982)

"Ten advanced cancer patients not amendable to conventional therapy were treated with high dose (greater than 500 mg/day, for 30 days) Medroxyprogesterone Acetate (MAP) both orally and intramuscularly, in order to evaluate a possible anabolic effect of this hormone."

( Angelelli, B; Camaggi, CM; Colalongo, F; Costanti, B; Giambiasi, ME; Lelli, G; Pannuti, F; Strocchi, E, 1983)

"The expanding use of cytotoxic drugs in cancer therapy has resulted in a confusing and increasingly frequent array of severe renal complications."

( Clarkson, AR; Healy, HG, 1983)

"Head and neck cancer patients received treatment to 114 sites with a complete response (CR) in 28, partial response (PR) in 42, stable disease (SD) in three, and no response (NR) in 34, and an undetermined response in seven."

( Baghdassarian, R; Berns, MW; Coffey, J; Mason, GR; Nahabedian, MY; Wile, AG, 1984)

"Ten advanced cancer patients (both with hormone-sensitive and non-hormone sensitive tumors) were treated with high dose medroxyprogesterone acetate (MAP, greater than 500 mg/day)."

( Angelelli, B; Lelli, G; Mondini, F; Monetti, N; Pannuti, F; Piana, E; Strocchi, E; Zanichelli, L, 1984)

"We investigated the incidence of second tumors after cytotoxic chemotherapy in 457 long-term survivors treated for choriocarcinoma or an invasive mole between 1958 and 1978."

( Bagshawe, KD; Booth, M; Dent, J; Rustin, F; Rustin, GJ; Salt, S, 1983)

"With assistance from the American Cancer Society, the State Medical Society, and volunteers and professionals in cancer research, the legislation was adapted to the existing legal and administrative framework."

( Joranson, DE; Treffert, DA, 1983)

"Since patients with advanced cancer are usually immunodeficient, they might benefit from therapy with thymic hormones, which have an immunorestorative effect in immunosuppressed laboratory animals."

( Beauregard, JC; Dillman, RO; Halliburton, BL; Royston, I; Wormsley, S; Zavanelli, MI, 1983)

"Thirty-seven adults with advanced cancer who were treated with cisplatin were randomly assigned to receive either synthetic long-acting ACTH (1 mg IM given 24 hours, 12 hours, and immediately preceding the administration of cisplatin) or a placebo given under the same conditions."

( Colbert, N; Izrael, V; Laugier, A; Lotz, JP; Pene, F; Schlienger, M; Stoppa-Lyonnet, D; Vannetzel, JM, 1983)

"The presence of hypoxic regions within tumors can be directly and indirectly inferred from invasive procedures such as oxygen electrode techniques and histologic study, respectively, but such information does not significantly contribute to current prescriptions given by oncologists for tumor treatment."

( Chapman, JD, 1984)

"Twenty-eight cancer patients were treated with intramuscular butorphanol tartrate, a new non-narcotic analgesic, for investigating its clinical benefits in controlling cancer pain."

( Ebina, A; Hayashi, I; Ito, T; Konno, K; Nagai, K; Nakai, Y; Sato, M, 1983)

"In other poor-prognosis tumors that are sensitive to chemotherapy, or can be debulked surgically, or locally irradiated, high-dose melphalan with ABMT given as late intensification therapy may significantly prolong time to relapse, and ultimately prolong survival."

( Boesen, E; Corringham, R; Gilmore, M; Prentice, HG, 1983)

"Patients with advanced cancer who had documented disease progression while receiving chemotherapy alone were subsequently treated with the same drug, by the same dose and route, combined with localized hyperthermia."

( Elliott, RS; Harrison, WH; Haskell, CM; Kaiser, LR; Morton, DL; Ramming, KR; Sarna, G; Silberman, AW; Storm, FK, 1984)

"Patients with malignant neoplasms who were receiving chemotherapy and renal transplant recipients who were receiving immunosuppressives were randomized to receive either clotrimazole (10 mg) or placebo troches three times a day in a prospective, double-blinded study."

( Dekker, PT; Nightingale, CH; Owens, NJ; Quintiliani, R; Schauer, PK; Schweizer, RT, 1984)

"In any event, for cancer treatment, it is important to determine which substances inhibit the arrest of circulating tumor cells and how to prevent hematogenous metastasis."

( Sone, S; Tsubura, E; Yamashita, T, 1983)

"However, the uptake of the anti-cancer drug into the tumor and its distribution throughout the body are influenced by a large number of factors: the method or route of administering the anti-cancer drug; rate of infusion; local blood flow; permeability of the blood vessels; structure and affinity of the drug; the metabolism of the drug and the speed of its breakdown and elimination."

( Taguchi, T, 1984)

"In a population of 51 ambulant cancer patients treated with doxorubicin-containing chemotherapy we conducted a double-blind cross-over randomized trial, comparing the anti-emetic efficacy of a combination of amitriptyline (25 mg p."

( Blijham, GH; Mellink, WA; van Deyk, WA, 1984)

"Most of these patients had solid tumors and were treated with an initial dose of mitoxantrone (12 to 14 mg/m2)."

( Crossley, RJ, 1984)

"To increase our understanding of cancer and improve cancer treatment on a rational basis we need to identify both qualitative and quantitative differences between normal and neoplastic tissue."

( Beaney, RP, 1984)

"Progress in the treatment of cancer with drugs has radically altered the clinical approach to patients with malignancy."

( Allegra, CJ; Chabner, BA; Curt, GA; Fine, RL; Yeh, GW, 1984)

"Cy is widely used for cancer chemotherapy."

( Ahmed, AR; Hombal, SM, 1984)

"Why do malignant tumors initially grow rapidly, then more slowly? What accounts for the different rats of growth among different tumors? Can the answers to these and related questions enable us to improve the results of cancer therapy? With advanced technology, we have come a long way in penetrating the mechanisms of tumor cell kinetics, but to date clinical strategies have not kept pace."

( Tannock, IF, 1983)

"This finding could be applied to cancer chemotherapy for enhancing drug delivery to tumor tissue selectively."

( Suzuki, M; Wakui, A, 1983)

"In this report the effects of anticancer agents on immune effector cells were analyzed and the possibility about the development of a reliable monitoring procedure for determining a potent treatment protocol was discussed."

( Saijo, N, 1983)

"The sperm production of 14 cancer patients who received doxorubicin was examined after cessation of therapy."

( Da Cunha, MF; Gordon, LA; Meistrich, ML; Ried, HL; Watchmaker, G; Wyrobek, AJ, 1983)

"This method is applied to cancer patients treated by cytotoxic chemotherapy with or without difluoromethylornithine (DFMO)."

( Belleville, F; Brossat, B; Metz, R; Nabet, P; Straczek, J, 1983)

"This finding was clinically applied to cancer chemotherapy for enhancing drug delivery to tumor tissue selectively."

( Sato, H; Wakui, A, 1984)

"Thirty six patients with advanced solid tumors (24 lung: 3 oat-cell, 14 squamous, 7 adenocarcinomas, 3 soft tissue sarcomas, 6 breast carcinomas; 1 seminoma; 2 ovarian adenocarcinomas) entered a phase II study of high-dose ifosfamide (IF) administered in combination with the uroprotective agent sodium 2-mercapto-ethane-sulfonate (Mesna)."

( Brema, F; Cinquegrana, A; Nobile, MT; Rosso, R; Santi, L, 1984)

"In a randomized crossover study 57 cancer patients receiving chemotherapy with high emetic potential were treated with low-dose levonantradol or standard-dose metoclopramide and crossed over to the other antiemetic drug in the next identical chemotherapy cycle."

( Altenburg, HP; Heim, ME; Queisser, W, 1984)

"With increasingly effective cancer chemotherapy, the control of chemotherapy-induced nausea and vomiting has become more important."

( Eyre, HJ; Ward, JH, 1984)

"As for the non-specific cancer immunotherapy concerned, the effect is limited and local use of immunopotentiators which could collect effector cells around tumor tissues might be the best way of cancer immunotherapy."

( Hamamoto, S; Hattori, T; Kameda, A; Niimoto, M; Seto, Y; Toge, T; Tomoda, S, 1984)

"For the treatment of cancer patients opioids can be administered epidurally."

( Bause, H; Blendl, M; Pothmann, W, 1984)

"All patients either had advanced tumors, or were in the terminal stage after repeated radiotherapy and chemotherapy."

( Abe, Y; Hong, SS; Kaneta, K; Matsuzawa, T, 1984)

"The effect of cesium therapy on various cancers is reported."

( Sartori, HE, 1984)

"25 patients with a malign neoplasia were treated with cytostatics."

( Borkenstein, J; Samonigg, H; Sterz, F, 1984)

"Eleven patients with advanced cancer were treated with SOAz, the first aziridino substituted inorganic heterocyclic compound to undergo phase I clinical trials."

( Mulder, NH; Rodenhuis, S; Schraffordt Koops, H; Sleijfer, DT; Van de Grampel, JC, 1984)

"Seventy-five percent of untreated cancer patients showed increased incorporation rates into the endogenous acceptor of serum."

( Aiginger, P; Kuzmits, R, 1984)

"Seven additional cancer patients were treated with probenecid prior to CP."

( Coleman, CN; Hirst, K; Jacobs, C; Rich, L; Weiner, MW, 1984)

"Thirty-four subsequent second malignant neoplasms were observed in 33 patients among those treated for Hodgkin's disease."

( DeVita, VT; Glatstein, E; Kelley, PA; Kinsella, TJ; Makuch, RW; Tester, WJ; Waller, B, 1984)

"A total of 20 cancer patients suffering chronic pain were treated with morphine chloride by intrathecal administration through a subcutaneous implanted reservoir."

( Ferrero Fernández, B; González Hernández, MJ; González Navarro, A; Molinero Aparicio, T; Ortíz González, JM; Simón Ascarza, I; Zimman Mansfeld, HM, 1984)

"The response rate was 54% in breast cancer patients receiving 4'e-Dx as first-line treatment, 25% in patients previously given chemotherapy without doxorubicin, and 11% in patients previously given chemotherapy with doxorubicin."

( Armand, JP; Cappelaere, P; Hurteloup, P; Mathé, G, 1983)

"In 8 cancer patients given 10 courses of treatment cisplatin caused a mean (+/- S."

( Howell, SB; Wung, WE, 1983)

"Thirty-five (8%) of 426 cancer patients receiving various combinations of antineoplastic chemotherapy qualified for the antibiotic treatment."

( Catane, R; Fuks, Z; Halpern, J; Sacks, T, 1983)

"Sixty-four patients with advanced solid tumors were treated with the drug combination of 4'-epi-DX and cis-dichlorodiammineplatinum (CDDP) at the doses of 40-60 and 50 mg/m2, respectively, every 21-28 days."

( Farabegoli, G; Ganzina, F; Giovannini, M; Martoni, A; Monetti, N; Pannuti, F; Tomasi, L, 1984)

"For the evaluation of cancer risks associated with immunodeficiencies experienced by patients with Hansen's disease (leprosy) and for the assessment of possible adverse effects of dapsone therapy, a follow-up study was conducted of 1,678 patients admitted to the National Hansen's Disease Center in Carville, La."

( Brinton, LA; Fraumeni, JF; Hoover, R; Jacobson, RR, 1984)

"Sixty-six patients with advanced solid tumors were treated with 4'-epi-doxorubicin at a dose of 90 mg/m2 by rapid IV injection every 21 days until the disease had progressed or to a maximum cumulative dose of 540 mg/m2."

( Bellanova, B; Camaggi, CM; Giovannini, M; Martini, A; Martoni, A; Monetti, N; Pannuti, F; Rossini, G; Tarquinii, M; Tomasi, L, 1984)

"Secondary tumors were noted in 8 out of 675 patients with Hodgkin's disease during remission following treatment."

( Shishkin, IP, 1984)

"Thirty-five patients with advanced cancers were treated with estramustine phosphate tablets (Estracyt)."

( Catane, R; Halpern, J, 1984)

"In experimental cancer chemotherapy using human tumor xenografts transplanted to nude mice, aclarubicin showed a moderate antitumor effect (retardation of tumor growth) and nearly the same spectrum of activity in vivo as Adriamycin (doxorubicin)."

( Abe, O; Ishibiki, K; Kubota, T; Kumai, K, 1984)

"Nineteen adult cancer patients each received 6-10 monthly treatments of doxorubicin and cisplatin."

( Hrushesky, WJ; Vukelich, M, 1984)

"Seventeen of 19 treated mice developed neoplasms; 7 of these immunosuppressed animals had 2 to 4 separate neoplasms."

( Anver, MR; Walker, SE, 1983)

"21 unilateral breast cancer patients taking different combinations of chemotherapeutic agents (cyclophosphamide, methotrexate, 6-fluorouracil, vincristine, and prednisone) were studied to determine how chemotherapy affected their granulocytes."

( Matamoros, MC; Van Dyke, CJ; Van Dyke, K; Walker, BK, 1983)

"The records of 714 neutropenic cancer patients who were treated with high doses of a combination of beta-lactam antibiotics were analyzed."

( Bodey, GP; Bolivar, R; Elting, L; Estey, EH; Fainstein, V; Keating, MJ; McCredie, KB, 1983)

"Twenty patients with malignant neoplasms given 2 cycles of a combination chemotherapy including cisplatinum and adriamycin received domperidone in one cycle and chlorpromazine in another cycle."

( Araki, Y; Seita, M; Tamura, K, 1983)

"The frequency of malignant neoplasms was studied in 248 psoriatics treated with a single, weekly, oral dose of methotrexate ranging from 5 to 25 mg."

( Jensen, H; Nyfors, A, 1983)

"Many human tumors treated by hyperthermia do not reach therapeutic temperatures (42 degrees C)."

( Graham, LS; Morton, DL; Olch, AJ; Silberman, AW; Storm, FK, 1983)

"Retinol was administered to 13 cancer patients in daily doses ranging from 100,000 units/m2 to 350,000 units/m2."

( Alberts, DS; Earnst, DL; Goodman, GE; Meyskens, FL, 1983)

"Sixty-nine tumors representing different histologic types including breast, lung, colon, ovarian, and cervical, as well as neoplasms of undiagnosed origin, were screened against N-MF (NSC-3051) and ECH (NSC-526417) simultaneously with five standard chemotherapeutic agents used clinically for treatment of the specific type of cancer."

( Bogden, AE; Cobb, WR; Griffin, TW; Kelton, DE; LePage, DJ; Reich, SD, 1983)

"One hundred children with cancer and bacterial sepsis were observed for one month after completion of antibiotic treatment for subsequent episodes of infection."

( Hughes, WT; Patterson, G, 1984)

"Regional cancer chemotherapy is a means of exploiting dose-response effects by delivering more drug to regionally confined tumors."

( Ensminger, WD; Gyves, JW, 1984)

"Fifteen patients with advanced solid tumors participated in a phase I study of a biochemically designed combination chemotherapy program which employed PALA and thymidine (TdR) with 5-FU."

( Casper, ES; Kemeny, N; Martin, DS; Michaelson, RA; Young, CW, 1984)

"Twenty-two patients with cancer and fever of undetermined origin for more than seven days were treated with naproxen to control fever when there was no evidence of infection after a careful initial evaluation, and in most cases, after failure of antibiotic therapy."

( Chang, JC; Gross, HM, 1984)

"15 patients with metastatic cancer were treated with Lonidamine, a substituted indazole carboxylic acid active against the Lewis lung and Sarcoma 180 tumors."

( Band, PR; Besner, JG; De Sanctis, A; Deschamps, M; Gervais, P; Leclaire, R, 1984)

"12 patients with metastatic cancer were treated with the substituted indazole carboxylic acid Lonidamine at oral daily doses of 270 mg/m2."

( Band, PR; Besner, JG; De Sanctis, A; Deschamps, M; Gervais, P; Leclaire, R, 1984)

"The organization of a multidisciplinary cancer treatment center is very heterogeneous in Europe."

( Littbrand, B, 1984)

"Ten patients with solid tumors were treated with continuous infusion of TdR at 34-75 g/m2/day for 3 to 5 days."

( Kraal, I; Leyva, A; Pinedo, HM; Schornagel, JH; Wadman, SK, 1984)

"The present intensification of cancer chemotherapy has resulted in increased toxicity."

( Gerhartz, H; Hiller, E, 1984)

"Individuals with cancer are subject to fluid and electrolyte imbalances because of the original disease process, therapy, and complications resulting from both the disease process and from therapy."

( Cunningham, SG, 1982)

"Results from testing three cancer patients before and after therapy correlate well with clinical evidence of the presence of tumor burden."

( Bennet, LR; Buffkin, DC; Juillard, GJ; Schwabe, AD; Verma, RC; Webber, MM, 1980)

"Seventeen patients with cancer or aplastic anemia received demeclocycline as treatment for hyponatremia."

( Trump, DL, 1981)

"Thirty-two patients with advanced cancer were treated in a phase I-II trial with ifosfamide plus mesnum."

( Falkson, G; Falkson, HC; Stapelberg, R; Van Dyk, JJ, 1982)

"Fifteen cases with advanced cancer were treated with UFD-1 (mixture of FD-1 and uracil under molar ratio of 1: 20) in a daily dose of 300 mg of FD-1."

( Furue, H, 1982)

"The levels of anticancer drugs in tissue were measured by bioassay method in 28 patients with gastrointestinal cancer, who were treated with intravenous administration of 500 mg of 5-FU combined with ANG-II during surgery."

( Kanno, H; Kikuchi, K; Kunii, Y; Takahashi, N, 1982)

"to rats induced mainly forestomach neoplasms and a few neoplasms of the duodenum, whereas similar treatment of rats with nitroso-2-hydroxypropylurea induced a high incidence of neoplasms of the thymus, some of the forestomach, and few at any other site."

( Lijinsky, W; Reuber, MD, 1983)

"Four cancer patients with severe chronic pain were treated with oral morphine with increasing doses during 5-8 months."

( Rane, A; Säwe, J; Svensson, JO, 1983)

"Thirteen patients with cancer being treated with high-dose methotrexate (MTX) chemotherapy (350-5,000 mg/6 h IV were entered in this study."

( Boublil, JL; Lalanne, CM; Milano, G; Namer, M; Renee, N; Schneider, M; Thyss, A, 1983)

"Constant infusion cancer chemotherapy is feasible, reliable, and safe."

( Bothe, A; Fine, N; Lokich, J; Perri, J, 1982)

"Investigation of retinoids for anticancer activity in humans, either in the chemopreventive or treatment mode, has been little studied."

( Meyskens, FL, 1982)

"Sixty-five patients with advanced solid tumors were treated with 4'epi-doxorubicin, a new analogue of doxorubicin (DXR)."

( Ferrazzi, E; Fiorentino, MV; Ganzina, F; Maraglino, G; Nicoletto, O; Pagnin, P; Vinante, O, 1982)

"The records of 32 cancer patients who were treated with heparin sodium and warfarin sodium for thromboembolic disease were reviewed."

( Karp, DD; Moore, FD; Osteen, RT; Steele, G; Wilson, RE, 1981)

"The clinical trial of K-247, an anticancer drug showing antitumor effect by new mechanism of action, was performed in a total of 22 patients with a variety of advanced cancers, consisting of 10 cases administered singly and 12 cases combined with other anticancer agents."

( Kakuta, H; Kanamaru, R; Kanbe, M; Mitachi, Y; Sato, T; Takahashi, K; Wakui, A, 1982)

"Eleven patients with a variety of solid tumors were treated with K-247 alone."

( Fukushima, M; Ota, K, 1982)

"Six patients with advanced cancer were treated with amygdalin (laetrile) at dosages similar to those employed by laetrile practitioners."

( Ames, MM; Kovach, JS; Moertel, CG; Moyer, TP; Rubin, JR; Tinker, JH, 1981)

"After a scrutiny of investigations in cancer patients, the conclusion emerges that, in a subsection of patients, mainly those with poor prospects, levamisole improves the prognosis after effective chemotherapy, radiotherapy or surgery when given in time and in an appropriate dosage."

( Amery, WK; Gough, DA, 1981)

"One hundred seventy-eight patients with cancer were treated with amygdalin (Laetrile) plus a "metabolic therapy" program consisting of diet, enzymes, and vitamins."

( Currie, VE; Davignon, JP; Fleming, TR; Jones, SE; Koch, R; Kvols, LK; Moertel, CG; Rubin, J; Sarna, G; Young, CW, 1982)

"Eighteen adult cancer patients with 21 episodes of staphylococcal bacteremia were treated with sequential intravenous and oral antimicrobial agents."

( Carney, DN; Fossieck, BE; Parker, RH, 1982)

"The usefulness of bestatin in cancer treatment has been suggested by clinical studies."

( Aoyagi, T; Umezawa, H, 1981)

"The anabolic profiles of 59 late-stage cancer patients responsive to hydrazine sulfate were examined; the drug had been given either as a sole agent or added to preexisting therapy to which the patients had become refractory."

( Gold, J, 1981)

"Patients with cancer and suspected sepsis were treated in a prospective, randomized trial with one of four cephalosporin-aminoglycoside combinations: cephalothin and tobramycin; cephalothin and gentamicin; cefamandole and tobramycin; or cefamandole and gentamicin."

( Armstrong, D; Brown, AE; Quesada, O, 1982)

"They recommended incorporation of cancer control functions into the organizational structure of the Ministry of Health as well as specific recommendations in education, prevention, and early detection, diagnosis, treatment, and epidemiologic studies."

( Puchkov, YI; Saunders, JF; Sutnick, AI, 1982)

"In anergic and malnourished cancer patients no curative surgical treatment was possible."

( Fritsch, A; Funovics, J; Huk, I; Roth, E; Schemper, M; Schulz, F; Winter, M, 1982)

"An unique combination treatment for cancer patients has been attempted in our department."

( Enomoto, K; Kodama, K; Okada, N; Sakurai, T; Suzuki, Y; Takimoto, M; Yokoi, H, 1982)

"Twenty-three cases of cancer patients were treated with FT-207 alone orally more than 52 weeks up to 199 weeks continuously with daily dose of 600-800mg with capsules, and 600-1200mg with enteric coated capsules, except one case with markedly light body weight (28kg)."

( Majima, H; Nishimura, A, 1982)

"Nutrition and cancer interact in a number of important ways and nutritional factors are increasingly recognized as relevant to both the prevention and treatment of cancer."

( Rivlin, RS, 1982)

"Drug treatment for cancer is now widely utilized and in selected neoplasms offers the opportunity for prolonged remission or even cure."

( Kiely, JM, 1981)

"A significant reduction of spontaneous tumors and prolongation of median survival was observed in mice given repeated injections of levamisole and of 100 microgram bestatin, compared with untreated aged mice and with mice given low doses of bestatin."

( Bruley-Rosset, M; Florentin, I; Kiger, N; Mathé, G; Schulz, JI, 1980)

"Treatment of cancer patients with Bestatin, a new immunomodulator increases the frequency of peripheral lymphocytes forming rosettes with sheep red blood cells (SRBC)."

( Blomgren, H; Wasserman, J, 1981)

"The findings suggest that astrocytoma tumors shed sialoglycolipids into the circulation, and their assay may be useful in monitoring oncological therapy."

( Hogan, EL; Koontz, DA; Lo, HS; Traylor, TD, 1980)

"Eighty-five patients with severe cancer pain despite large doses of opioids or with therapy-limiting side effects from opioids were randomized to receive, in a double-blind manner, 30 micrograms/h epidural clonidine or placebo for 14 days, together with rescue epidural morphine."

( Allin, D; Dubois, M; DuPen, S; Eisenach, JC; Miguel, R, 1995)

"In patients treated for thyroid cancer the damage to the salivary glands was revealed by an increase in TPA and amylase serum levels, dependent on the dose of 131-Iodine administered."

( Becciolini, A; Lanini, A; Porciani, S, 1994)

"Patients with advanced solid tumors were eligible if they had normal bone marrow, renal, and hepatic function and had not previously been treated with platinum compounds."

( Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL, 1994)

"We describe a patient with advanced cancer whose severe symptoms of congestive heart failure were successfully treated with dobutamine."

( Mercadante, S; Simonetti, MT, 1994)

"5 patients with metastatic tumors and 4 patients with hematological malignancies were treated either with G- or GM-CSF alone (5 micrograms/kg s."

( Bettelheim, P; Kasparu, H; Kolb, A; Krieger, O; Lutz, D, 1995)

"The side effects are most common in cancer patients treated with high dose morphine, and has been reported for all routes of administration."

( Jacobsen, LS; Jensen, NH; Olsen, AK; Sjøgren, P, 1995)

"Pain treatment for 17 pediatric cancer patients in our institution was evaluated and disirable cancer pain management for children was discussed."

( Hoshino, T; Kasai, H; Sasaki, K; Tsujinaga, H, 1995)

"Patients with advanced solid tumors and a maximum of one prior chemotherapy regimen for metastatic disease were eligible if they had a performance status of 0 to 1 and normal renal, hepatic, and bone marrow function."

( Brewster, L; Green, MR; Hargis, JB; Hollis, DR; Lilenbaum, RC; Miller, AA; O'Brien, SM; Ratain, MJ; Rosner, GL; Schilsky, RL, 1995)

"Thirteen patients with metastatic cancer received 30 cycles of therapy."

( Beitz, JG; Bigley, JW; Browne, MJ; Clark, JW; Cummings, FJ; Damowski, JW; Weitberg, AB, 1995)

"Nineteen cancer patients with chronic pain of moderate to severe intensity were randomized in a double-blind manner to 5 days of either 8-hourly or 12-hourly administration of controlled-release morphine (MS Contin, MSC), followed by the alternate schedule for 5 days."

( Harsanyi, Z; Latreille, J; Lemire, F; Mignault, GG; Richer, P; Stewart, JH; Viguié, F, 1995)

"Chronic anemia associated with cancer often causes poor quality of life and is often exacerbated by intensive treatment."

( Eguchi, K, 1995)

"In total, 126 patients with cancer, who had never received chemotherapy and who required at least two courses of moderately emetogenic non-cisplatin chemotherapy each lasting for a minimum of 5 days, were recruited into the study."

( Adams, M; Anderson, H; Barley, V; Boesen, E; de Bruijn, KM; Rüfenacht, E; Soukop, M; Trask, CW; Yosef, H, 1995)

"Patients with advanced solid tumors were administered LY231514 intravenously over 10 minutes, weekly for 4 weeks, every 42 days."

( Burris, HA; Corso, SW; Dorr, FA; Eckardt, JR; Fields, SM; Kuhn, JG; Langley, C; Rinaldi, DA; Rodriguez, G; Woodworth, JR, 1995)

"In those patients in whom systemic anti-cancer therapy is available, treatment with APD improves survival, but in all other patients the primary aim of treatment should be symptom control."

( A'Hern, RP; Hardy, JR; Ling, PJ, 1995)

"The WHO has created a Cancer Pain Relief Programme and developed guidelines for the treatment of cancer pain."

( Foley, KM, 1995)

"As a result, the extent of toxicity of cancer chemotherapy varies by 50% or more according to dosing time in mice or rats."

( Lévi, F, 1995)

"Eleven patients with germ cell cancer relapsing from a complete remission and 7 patients with refractory germ cell cancer and/or an unresectable partial remission received salvage chemotherapy with one to two courses of carboplatin (800 mg/m2) and etoposide (500 mg/m2 on days 1, 3, and 5), followed by either one or two courses of carboplatin (1600 mg/m2), cyclophosphamide (6 g/m2), and thiotepa (480 mg/m2) divided over 4 days with autologous bone marrow transplantation and/or peripheral stem cell support."

( Richel, DJ; Rodenhuis, S; Schornagel, JH; ten Bokkel Huinink, WW; van der Wall, E; Vlasveld, LT, 1995)

"Patients with refractory solid tumors (n = 51) were treated with a 48-h continuous intravenous infusion of menadione followed by a bolus intravenous dose of mitomycin C at the completion of the menadione infusion."

( Ahn, C; Akman, SA; Doroshow, JH; Leong, LA; Margolin, KA; Morgan, RJ; Raschko, JW; Somlo, G, 1995)

"There was increased risk of malignancy in the CYC-treated group, with 50 cancers found in 37 patients in the CYC group compared with 26 cancers in 25 of the control patients (P < 0."

( Agarwal, AK; Baker, GL; Cash, JM; Gallatin, A; Kahl, LE; Kwoh, CK; Medsger, TA; Radis, CD; Stolzer, BL; Wasko, MC, 1995)

"The risk of malignancy, particularly bladder cancer, in RA patients treated with oral CYC continues even 17 years after discontinuation of the drug."

( Agarwal, AK; Baker, GL; Cash, JM; Gallatin, A; Kahl, LE; Kwoh, CK; Medsger, TA; Radis, CD; Stolzer, BL; Wasko, MC, 1995)

"This study shows that cancer neuroimmunotherapy with low-dose IL-2 and the pineal hormone melatonin may prolong survival time and improve the quality of life of patients with metastatic solid tumours who do not respond to conventional therapies."

( Ardizzoia, A; Barni, S; Cazzaniga, M; Fossati, V; Frigerio, F; Lissoni, P; Tancini, G, 1995)

"These results indicate that, in cancer patients receiving long-term morphine treatment with stable doses, morphine has only a slight and selective effect on functions related to driving."

( Kalso, E; Matikainen, E; Ollila, J; Rosenberg, P; Vainio, A, 1995)

"In order to treat the cancer chronic pains, the morphine is the most relevant analgesic, since it has rapid, powerful and multiples possibilities of administration."

( Vedrenne, JB, 1993)

"In terminally ill cancer patients, the continuous intrathecal administration of morphine may be recommended if conventional pain relief fails."

( de Lange, JJ; Spoelder, EM; Wagemans, MF; Zuurmond, WW, 1993)

"Clinical usefulness of cytokines in cancer treatment has been described."

( Takaku, F, 1993)

"Thirty-four patients with cancer pain and no previous opioid treatment were randomized to receive morphine hydrochloride 10 mg orally or rectally (in the form of a microenema) for 2 days."

( Bruera, E; De Conno, F; Hanson, J; MacEachern, T; Ripamonti, C; Saita, L, 1995)

"Pursuant to this, the North Central Cancer Treatment Group has developed a series of clinical trials designed to study antidotes for these pathologic processes."

( Foote, RL; Loprinzi, CL; Michalak, J, 1995)

"Response rates in ovarian cancer range from 17% to 37% (according to extent of prior therapy); in gastric and pancreatic cancer, response rates of 26% and 29% have been reported, despite the fact that these diseases are notoriously resistant to chemotherapy."

( Kaye, SB, 1995)

"Chronic anemia of cancer can be corrected in approximately 50% of the cases by treatment with recombinant human erythropoietin (rHuEPO)."

( Fritz, E; Leitgeb, C; Ludwig, H; Pecherstorfer, M; Samonigg, H; Schuster, J, 1994)

"Children who had solid tumors and who were receiving highly emetogenic chemotherapy, including cisplatin, carboplatin, cyclophosphamide, and ifosfamide, were randomized (1:1) in a double-blind fashion to receive either OND 0."

( Alvarez, O; Bedros, A; Call, SK; Convy, L; Cook, L; Freeman, A; Halverson, J; Kalbermatter, O; Mick, K; Volsch, J, 1995)

"A significant number of cancer patients will require an alternate route of morphine administration at some point during their illness."

( Babul, N; Bruera, E; Darke, AC; Fainsinger, R; Harsanyi, Z; Spachynski, K, 1995)

"Mortality and cancer incidence among 999 neurological patients exposed to chronic alpha-particle irradiation from 232ThO2 (Thorotrast) administered for cerebral angiography in 1935-1947 was compared to that of 1480 similar patients examined with cerebral angiography without Thorotrast in 1946-1963 (controls)."

( Andersson, M; Carstensen, B; Storm, HH, 1995)

"Subcutaneous ports in paediatric cancer patients are reliable, safe, and durable and may offer an attractive alternative to external catheters for prolonged venous access and intensive treatment."

( Ane, M; Claeyssens, S; Fedacou, F; Guitard, J; Izard, P; Juricic, M; Krimou, A; Lemozy, J; Prere, MF; Rubie, H, 1995)

"A total of 37 patients with cancer were treated with oral dexniguldipine in increasing doses for up to 7 days."

( Boewer, C; Oldenkott, B; Rathgeb, F; Sybrecht, GW; Ukena, D; Wurst, W; Zech, K, 1995)

"Eleven patients with solid tumors for whom effective therapy was not available entered a phase I study of mitonafide given as a short intravenous (i."

( Benavides, A; Casado, A; Díaz-Rubio, E; López-Vega, JM; Martín, M, 1994)

"Several anticancer agents are dependent on oxygen to be cytotoxic, these drugs such as the iron-chelating peptide bleomycin are enhanced in antitumor activity by the co-administration of a PFCE/C."

( Teicher, BA, 1994)

"Anemia is common in cancer patients and may require treatment for symptomatic palliation."

( Henry, DH, 1994)

"Anemia is common in patients with cancer and is often exacerbated by myelosuppressive chemotherapy."

( Henry, DH, 1994)

"Hyperalgesia and allodynia in 4 cancer patients treated with morphine disappeared after discontinuing or substituting morphine with other opioid agonists."

( Jensen, NH; Jensen, TS; Sjøgren, P, 1994)

"The children with a malignant neoplasm were treated for emesis with tropisetron (5 mg o."

( Cordero di Montezemolo, L; Madon, E; Nasi, C; Rosso, P; Tonello, M; Valle, P; Vivenza, C, 1994)

"A total of 107 cancer patients were treated with 148 cycles of subcutaneous (SC) immunotherapy employing interleukin-2 (rIL-2) and/or interferon-alpha (rIFN-alpha)."

( Atzpodien, J; Fenner, M; Kirchner, H; Körfer, A; Lopez-Hänninen, E; Menzel, T; Poliwoda, H; Rudolph, P; Schomburg, A, 1994)

"The response rates achieved in these tumors are particularly impressive because heavily pretreated patients, and those who are refractory to prior standard chemotherapy, have had a high rate of objective responses to paclitaxel."

( Rowinsky, EK, 1994)

"The incidence of cancer in patients receiving low-dose cyclosporin, azathioprine and prednisolone was three of 45, in those given high-dose cyclosporin and prednisolone none of 23 and in those administered high-dose cyclosporin, nifedipine and prednisolone one of 29."

( Bell, PR; Butt, ZA; Donnelly, PK; Kehinde, EO; Morgan, JD; Petermann, A; Veitch, PS, 1994)

"A total of 20 patients with solid tumors completed a 4-week course of all-trans RA therapy."

( Kris, MG; Miller, VA; Muindi, JR; Rigas, JR; Tong, WP; Venkatraman, E; Warrell, RP, 1994)

"Methotrexate (MTX), one of the earliest cancer chemotherapy agents, continues to be used extensively in the treatment of leukemia and a variety of other tumors."

( Huennekens, FM, 1994)

"We compared the incidence of de novo tumors developing in 1165 primary adult renal allograft recipients treated with azathioprine (AZA)-prednisone (Pred)-antilymphocyte globulin (ALG) (CONV group) with that in 722 patients receiving cyclosporine (CSA) as part of double (CSA-Pred), triple (CSA-Pred-AZA), or quadruple-therapy (CSA-Pred-AZA-ALG) protocols."

( Dunn, DL; Gillingham, K; Gruber, SA; Matas, AJ; Sothern, RB; Stephanian, E, 1994)

"The so-called Cancer Multistep Therapy was conceived by the author in 1965."

( von Ardenne, M, 1994)

"Forty-eight adults with advanced malignancy received ICE chemotherapy by 96-hour continuous infusion."

( Antman, KH; Ayash, LJ; Elias, AD; Frei, E; Mazanet, R; McCauley, M; Schnipper, L; Schwartz, G; Tepler, I; Wheeler, C, 1994)

"The excess risk of cancer after chlorambucil appears to persist for 5 years after stopping this treatment."

( Dresch, C; Najean, Y; Rain, JD, 1994)

"Effective treatment of the underlying malignancy, with the resultant recovery from neutropenia, and the determination of the species of infecting Candida isolates are required for the prediction of the outcome of antifungal therapy."

( Akalin, HE; Akova, M; Aslan, S; Hayran, M; Kansu, E; Tekuzman, G; Telatar, H; Uzun, O, 1994)

"Present therapy for cancer patients is based primarily on tumor histology and anatomy."

( Griffin, TW; Koh, WJ; Laramore, GE; Rasey, JS, 1994)

"The rheumatic associations of cancer therapy are highlighted in this review."

( Brooks, PM; Conaghan, PG, 1994)

"Fifty-nine patients, with cancer refractory to conventional therapy, were entered in this phase I study, using a weekly schedule administration."

( Bugat, R; Chabot, GG; Culine, S; de Forni, M; Extra, JM; Gouyette, A; Madelaine, I; Marty, ME; Mathieu-Boué, A, 1994)

"One hundred patients with intolerable cancer pain were treated with intrathecal bolus injections of morphine(IT morphine)."

( Cheng, KI; Chu, KS; Tang, CS; Tseng, CK; Yip, NS; Yu, KL, 1993)

"Twelve patients with advanced cancer were included and begun on therapy with rIL-2, 1 x 10(6) U/m2 subcutaneously (SQ) daily for 5 days and levamisole beginning at 25 mg/m2 orally three times daily for 5 days."

( Buckner, JC; Call, TG; Creagan, ET; Frytak, S; Homburger, HA; Katzmann, JA; van Haelst-Pisani, C, 1994)

"Effectiveness of this approach for cancer treatment in vivo will depend on Rh123 tumor uptake kinetics and laser energy delivery via fiberoptics to the tumor site."

( Castro, DJ; Haghighat, S; Lufkin, R; Plant, D; Saxton, RE; Soudant, J, 1994)

"Cisplatin is one of the most active cancer treatment agents available."

( Abrahm, J; Cooley, ME; Davis, LE; DeStefano, M, 1994)

"The excess risk for cancer due to lifetime occupational exposure to 1,3-butadiene at the proposed US Occupational Safety and Health Administration standard of 2 ppm was estimated on the basis of a quantitative risk assessment."

( Bailer, AJ; Dankovic, DA; Smith, RJ; Stayner, LT, 1993)

"FDG-PET after anticancer treatment should be interpreted by considering the reaction due to the treatment and the partial volume artifact of PET caused by the limited spatial resolution."

( Arimizu, N; Imaseki, K; Itami, J; Okada, J; Oonishi, H; Uno, K; Yoshikawa, K, 1994)

"Patients with humoral hypercalcaemia of malignancy appear to respond less well to biphosphonate therapy than hypercalcaemic patients with osteolytic metastases."

( Body, JJ; Dumon, JC, 1994)

"Effective control of cancer pain can now be achieved in a high proportion of patients with rigorously applied pharmacologic treatment, reducing the need for more demanding invasive procedures."

( Patt, RB; Reddy, S, 1994)

"A total of 121 patients with cancer pain without gastric involvement participated in a 7-day treatment course and were allocated to receive either dipyrone 1 g (n = 41), dipyrone 2 g (n = 38) or morphine (n = 42)."

( Aliaga, L; Barutell, C; Gálvez, R; Moreno, J; Ortiz, P; Pallarés, J; Puerta, J; Rodríguez, M; Rull, M; Vidal, F, 1994)

"Twelve dogs with advanced stage tumors were administered a dose of 0."

( Castro, J; Madewell, BR; Ryu, J; Théon, AP, 1994)

"During the course of cancer treatment and as the disease progresses, symptoms may worsen and physical status may deteriorate."

( Given, B; Given, CW; Kurtz, JC; Kurtz, ME, 1994)

"2,124 cases of cancer diagnosed and/or treated in Penang between 1987-1990 were reported to the National Cancer Registry of Malaysia by hospitals in Penang."

( Chan, CK; Devaraj, T; Rasid, BK; Singh, J, 1994)

"Perceptions of cancer stressors and protective factors are predictors of stress experienced during treatment for childhood cancer were assessed in this study."

( DiIorio, C; Hockenberry-Eaton, M; Kemp, V, 1994)

"Twenty-three patients with various cancers were treated with doses of CPT-11 ranging from 400 to 600 mg/m2, administered as a 30-minute intravenous infusion every 3 weeks."

( Abigerges, D; Armand, JP; Chabot, GG; Cote, C; Da Costa, L; Fadel, E; Gandia, D; Hérait, P, 1994)

"One patient with head and neck cancer showed > 50% shrinkage of tumor mass for 6 weeks after treatment."

( Baker, M; Baptiste, J; Dennis, JW; Fernandes, B; Goss, PE, 1994)

"In this trial 324 chemotherapy-naive cancer patients, mostly females with breast cancer, were randomized to receive either placebo or ondansetron 1 mg, 4 mg, or 8 mg three times per day for 3 days."

( Burton, G; Ciociola, AA; Cubeddu, LX; Galvin, D; Meshad, M; Pendergrass, K; Ryan, T; York, M, 1994)

"CAI offers a new approach to cancer therapy, signal transduction therapy."

( Cole, K; Kohn, E, 1994)

"The use of morphine in the treatment of cancer pain is widely accepted among people taking care of cancer patients and concerned with pain relief."

( Lossignol, DA, 1993)

"Thirty-one cancer patients were treated with oral opioids, 180 mg morphine per 24 h (median)."

( Banning, AM; Christensen, CB; Pedersen, O; Sjøgren, P, 1994)

"In the 34 patients with advanced lung cancer, all-trans RA (45 mg/m2) was administered twice daily for 4 weeks, and, on days 2, 28, and 29, serial plasma samples were again obtained after a single 45-mg/m2 dose."

( DeGrazia, F; Francis, PA; Huselton, C; Kris, MG; Muindi, JR; Orazem, JP; Rigas, JR; Warrell, RP; Young, CW, 1993)

"An approach to anticancer therapy is suggested, using a hypothesis-based mechanism for the anti-cancer activity of retinoic acid."

( Beech, JA, 1993)

"The study included 30 cancer patients, who were randomized to treatment with IL-2 alone or IL-2 plus L-carnitine (1000 mg/day orally)."

( Barni, S; Galli, MA; Lissoni, P; Tancini, G, 1993)

"Thirty-six patients with cancer-associated hypercalcemia were treated with increasing doses (0."

( Clemens, MR; Ghielmini, M; Jaeger, P; Krahl, D; Manegold, C; Scharla, SH; Schöter, KH; Thiébaud, D; Wüster, C, 1993)

"Patients' awareness of the diagnosis of cancer and their perception of treatment intention and outcome were assessed independently by another investigator who was blind to the psychiatric diagnosis."

( Alexander, PJ; Dinesh, N; Vidyasagar, MS, 1993)

"Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia."

( Drenck, NE; Jensen, NH; Jensen, TS; Jonsson, T; Sjøgren, P, 1993)

"The measurement of oxygenation of human tumors and correlations with response to radiotherapy were the subjects of a recent workshop sponsored by the National Cancer Institute."

( Brown, JM; Phillips, TL; Stone, HB; Sutherland, RM, 1993)

"Justification for use of infusions in cancer chemotherapy has been slow in appearing with few studies proceeding to the comparative stage."

( DelaFlor-Weiss, E; Muggia, FM; Uziely, B, 1993)

"For this trial by the Cancer and Leukemia Group B (CALGB), cohorts of patients were treated with cyclophosphamide as a 1-hour intravenous infusion every 14 days; GM-CSF was given subcutaneously on days 3-10."

( Budman, DR; Egorin, MJ; Lichtman, SM; Norton, L; Ratain, MJ; Rosner, G; Schilsky, RL; Van Echo, DA; Vogelzang, NJ, 1993)

"To investigate whether childhood cancer is associated with intramuscular administration of vitamin K to newborn infants."

( Ekelund, H; Finnström, O; Gunnarskog, J; Källén, B; Larsson, Y, 1993)

"Odds ratios for cancer after intramuscular administration of vitamin K versus oral administration after stratification for year of birth."

( Ekelund, H; Finnström, O; Gunnarskog, J; Källén, B; Larsson, Y, 1993)

"The risk of cancer after intramuscular administration of vitamin K was not elevated compared with that after oral administration: odds ratios of 1."

( Ekelund, H; Finnström, O; Gunnarskog, J; Källén, B; Larsson, Y, 1993)

"Chiral anticancer agents which exist as a pair of enantiomers are commonly administered as racemic (50:50) mixtures of the two isomers."

( Wainer, IW, 1993)

"Thirty assessable patients with cancer refractory to conventional therapy were treated."

( Alberti, D; Arzoomanian, RZ; Cohen, JD; d'Oleire, F; Feierabend, C; Heiss, C; Longo, W; Robins, HI; Schmitt, CL; Tutsch, KD, 1993)

"The sample consisted of 127 adults with cancer who were to receive their first dose of chemotherapy (e."

( Dibble, SL; Dodd, MJ, 1993)

"One novel approach to cancer treatment involves targeting a cytotoxic agent to a cancer cell."

( Pastan, I; Theuer, CP, 1993)

"One hundred cancer patients receiving non-cisplatin containing chemotherapy were entered in a prospective study in which the efficacy of ondansetron was compared with standard antiemetic treatments in the prophylaxis of nausea and emesis."

( Flander, MK; Heikkinen, MI; Jantunen, IT; Kataja, VV; Kuoppala, TA; Teerenhovi, L, 1993)

"In 17 girls after the complex anti-neoplasm therapy we estimated the state of genital organs and the course of menorrhagia cycle together with plasma levels of beta-estradiol, progesterone and prolactin assessed by RIA."

( Bohdan, Z; Korzon, M; Kuźmińska, A; Wszelaki-Lass, E, 1993)

"Therefore, weight-losing cancer patients (n = 60), with normal liver and kidney function tests, were randomized to receive one of four drug treatments for 5 days: (a) Propranolol 80 mg x 2 (beta-adrenoceptor blockade); (b) Indomethacin 50 mg x 2 (prostaglandin synthesis inhibition); (c) Morphine 5 mg x 3 (pain relief) or (d) Placebo x 2."

( Hyltander, A; Körner, U; Lundholm, KG, 1993)

"Pharmacokinetic study of anticancer drug is essential for clinical application of cancer chemotherapy."

( Hagiwara, A; Takahashi, T; Taniguchi, H; Yamaguchi, T, 1993)

"Two patients, one with small cell lung cancer and one with breast cancer, had stable disease while receiving treatment for 5 and 6 months, respectively."

( Bjarnason, G; Bunting, P; DeAngelis, C; Erlichman, C; Goodman, P; Kerr, IG; Moore, M; Thiessen, JJ; Walker, S, 1993)

"Twelve cancer patients (aged 49-74 years) receiving doxorubicin (66 +/- 8 mg/m2) as a 1-hour intravenous infusion had serial serum samples (0-48 hours) obtained after the first and second courses of therapy."

( Piscitelli, SC; Rodvold, KA; Rushing, DA; Tewksbury, DA, 1993)

"In 10 patients with hypercalcemia of malignancy the levels of the midregional fragment of PTHrP in serum were determined by radioimmunoassay over 7 days during a calcium-lowering treatment with a single dose of the bisphosphonate BM 21."

( Blind, E; Meinel, T; Raue, F; Wüster, C; Ziegler, R, 1993)

"Eight children and young adults with cancer were evaluated serially using pure tone audiometry as well as registration of click-evoked otoacoustic emissions (EOAE) 1 day prior to therapy as well as after various numbers of doses of cisplatinum."

( Gutjahr, P; Schmitt, HJ; Zorowka, PG, 1993)

"Use of this test in cancer patients undergoing either chemotherapy or radiation therapy revealed evidence of early negative B12 balance that in some instances was induced by the treatment itself."

( Amin, J; Flener, V; Ramos, M; Tisman, G; Vanyo, L; Vu, T, 1993)

"Effective treatment of hypercalcemia of malignancy may improve patients' quality of life, although an episode of hypercalcemia is a poor prognostic indicator for survival."

( Hall, TG; Schaiff, RA, 1993)

"Thirty-five cancer patients, treated with chronic epidural morphine, were assayed for plasma and cerebrospinal fluid (CSF) minimum steady-state concentrations (Css min) of morphine (M), morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) by high performance liquid chromatography (HPLC)."

( Hedner, T; Michalkiewicz, A; Samuelsson, H; Venn, R, 1993)

"Eight new case histories of cancer patients plus two reported cases support the statement that therapy of cancer patients with CoQ10, which has no significant side effect, has allowed survival on an exploratory basis for periods of 5-15 years."

( Brown, R; Folkers, K; Judy, WV; Morita, M, 1993)

"All the cancer patients analyzed so far have shown the structural anomaly of the urinary chondroitin sulfate and this may be useful in the diagnosis and follow up of cancer therapy."

( Dietrich, CP; Martins, JR; Nader, HB; Sampaio, LO, 1993)

"Patients with advanced cancer frequently experience clinically significant anemia, which is often exacerbated by myelosuppressive chemotherapy."

( Bukowski, RM; Carey, RW; Case, DC; Fishkin, EH; Henry, DH; Jacobson, RJ; Jones, SE; Keller, AM; Kugler, JW; Nichols, CR, 1993)

"We studied 153 anemic cancer patients receiving cyclic combination chemotherapy in a prospective multicenter, double-blind, placebo-controlled trial."

( Bukowski, RM; Carey, RW; Case, DC; Fishkin, EH; Henry, DH; Jacobson, RJ; Jones, SE; Keller, AM; Kugler, JW; Nichols, CR, 1993)

"Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed."

( Bodey, GP; Lo, WK; Rolston, KV; Rubenstein, EB, 1993)

"Patients with breast cancer treated with MPA often report an improvement in appetite."

( Allbright, A; Downer, S; Joel, S; Plant, H; Slevin, M; Stubbs, L; Talbot, D, 1993)

"Seven patients with advanced cancer were treated weekly with 5-FU at increasing dosages starting at a dose of 600 mg/m2."

( Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1993)

"Thirty patients with advanced cancer, who were no longer receiving antineoplastic therapy, were randomly assigned to receive either L 75 mg/day or M 30 mg/day."

( Battaiotto, L; Corli, O; Cozzolino, A, 1995)

"In the present study a cancer risk assessment of occupational exposure to cyclophosphamide (CP), a genotoxic carcinogenic antineoplastic agent, was carried out following two approaches based on (1) data from an animal study and (2) data on primary and secondary tumors in CP-treated patients."

( Bos, RP; Kroese, ED; Sessink, PJ; van Kranen, HJ, 1995)

"In 34 cancer patients treated with chronic slow-release oral morphine, plasma and cerebrospinal fluid (CSF) minimum steady-state concentrations of morphine (M), morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) were determined by high-performance liquid chromatography (HPLC)."

( Hedner, T; Samuelsson, H; Wolff, T, 1995)

"PBPCs from six patients with solid tumors were recruited by standard-dose chemotherapy and subsequent administration of recombinant granulocyte colony-stimulating factor (G-CSF)."

( Brugger, W; Kanz, L; Lübbert, M; Mertelsmann, R, 1996)

"Anti-cancer chemotherapy was continued."

( Donner, U; Hovi, L; Lindqvist, C; Saarinen, UM, 1996)

"Treatment of cancer associated hypercalcaemia is based on an initial phase of volume repletion with isotonic saline, followed by drug treatment to inhibit bone resorption."

( Ralston, SH, 1994)

"In solid tumors, CP, a vitamin K dependent enzyme could represent the selective target of the antimetastatic effects of warfarin treatment."

( Donati, MB, 1995)

"A total of 107 febrile neutropenic cancer patients were randomly assigned to empiric therapy with ticarcillin-clavulanate (4 g ticarcillin + 0."

( Abi-Said, D; Anaissie, EJ; Bodey, GP; Kantarjian, H; Karl, C; Legrand, C; Vadhan-Raj, S; Vartivarian, S, 1996)

"Dyspnea in patients with advanced cancer is a common symptom that is difficult to treat."

( Adams, L; Booth, S; Cox, NP; Guz, A; Kelly, MJ, 1996)

"In patients with metastatic colorectal cancer, approximately 18% to 27% of patients with 5-FU refractory disease and 15% to 32% of patients who are chemotherapy-naive respond to single agent therapy."

( Rothenberg, ML, 1996)

"Mucositis is a common toxicity of cancer chemotherapy."

( Anderson, PM; Skubitz, KM, 1996)

"Febrile neutropenic children with cancer were eligible for outpatient management with intravenous ceftriaxone therapy if they displayed selected low-risk criteria."

( Aquino, VM; Buchanan, GR; Mustafa, MM; Pappo, A; Tkaczewski, I, 1996)

"An increased risk of cancer has been reported in patients treated with azathioprine."

( Adeleine, P; Aimard, G; Confavreux, C; Grimaud, J; Moreau, T; Saddier, P, 1996)

"Three of the five evaluable tumors showed a significant response to our combined therapy."

( Goto, S; Kera, J; Sakai, S; Soma, GI; Suma, Y; Takeuchi, S, 1996)

"The treatment of cancer-associated pain in the terminally ill patient requires a vast knowledge of the available treatment modalities, but we also have to be aware of the fact that the continuous education of patients, nurses and doctors about the proper usage of these modalities is of paramount importance."

( Herrmann, R; Lohri, A, 1996)

"The efficacy of systemic cancer therapy rests on the ability of a toxin to be preferentially located in cancer cells, so that cancer cell kill is maximized and normal tissue spared."

( Allen, BJ; Blagojevic, N, 1996)

"Fifty-three patients with advanced cancer of variable histology with good prognostic features were treated in six cohorts."

( Conlon, KC; Creekmore, SP; Fenton, RG; Gause, BL; Holmlund, J; Janik, JE; Kopp, WC; Longo, DL; Sharfman, W; Smith, JW; Steis, RG; Sznol, M; Urba, WJ; VanderMolen, LA, 1996)

"Advances in diagnosis and treatment of cancer, as well as increased understanding of the mechanisms of the disease, have provided and will certainly continue to provide enormous benefit to affected individuals."

( Gaziano, JM; Hennekens, CH, 1996)

"The treatment of cancer patients has improved over the few past years."

( Catimel, G; Droz, JP, 1995)

"Four patients experiencing cancer pain with nociceptive and neuropathic components were treated with a continuous intrathecal administration of a mixture of ketamine (10 mg)-morphine (1-20 mg)-clonidine (30 micrograms)-lidocaine (20 mg) in 12 mL of normal saline, injected daily with an infusor (Baxter) pump."

( Lemos, D; Muller, A, 1996)

"To quantitate the relief of intractable cancer pain by the use of intraventricular morphine administration."

( Foroglou, G; Fountzilas, G; Karavelis, A; Selviaridis, P, 1996)

"Advances in diagnosis and treatment of cancer and cardiovascular disease as well as increased understanding of the mechanisms of the diseases have provided and will certainly continue to provide enormous benefit to affected individuals."

( Gaziano, JM, 1996)

"All patients had refractory solid tumors and had received prior cytotoxic treatment."

( Baker, LH; Earhart, RH; Flaherty, L; Foster, BJ; Kasunic, DA; LoRusso, PM; Poplin, E; Valdivieso, M; Wozniak, A; Zalupski, M, 1996)

"Eighteen patients with solid tumors refractory to all other known treatment modalities were entered."

( Dietzfelbinger, H; Hanauske, AR; Heim, ME; Keppler, KB; Niebch, G; Rastetter, J; Schilling, T, 1996)

"Using 98 plasma samples from cancer patients undergoing antineoplastic chemotherapy, we compared the activities of aspartate aminotransferase and alanine aminotransferase measured by two different methods, with and without the addition of pyridoxal-5'-phosphate to the assay medium."

( Facchetti, G; Franzini, C; Longoni, PD; Mastroianni, A, 1996)

"Patients with metastatic cancers were treated with GM-CSF at 5 micrograms/kg sc, days 1 to 7; leukaphereses were performed on days 6 and 7."

( Balcerzak, SP; Benzies, T; Triozzi, PL; Tucker, F, 1996)

"PKC activity was reduced in tumors derived from mice treated with either DXR or CGP 41251, but not from those derived from mice treated with the combination."

( Beltran, P; Fan, D; Fidler, IJ; Killion, JJ; O'Brian, CA; Wilson, MR; Yoon, SS, 1995)

"152 chemotherapy-naïve cancer patients were randomized in a double-blind manner to receive 2 or 5 mg tropisetron intravenously day 1 and orally days 2-6."

( de Bruijn, KM; de Vries, EG; Dullemond-Westland, AC; Nooy, M; Siegenbeek van Heukelom, L; van der Graaf, WT; van der Heul, C; van der Linden, GH; Wils, JA; Wymenga, AN, 1996)

"Sixteen patients with terminal cancer were treated subcutaneously or epidurally with continuous infusions of morphine using external multiday infusion pumps."

( Edén, T; Glimhall, BA; Ohlsson, LJ; Rydberg, TS; Thulin, LA, 1995)

"A significant number of cancer patients undergoing palliative radiotherapy experience treatment-related nausea and vomiting."

( Priestman, TJ, 1996)

"High-dose cisplatin chemotherapy for cancer patients induces an acute decrease of serum total calcium and serum ionized calcium and audiometric changes."

( Ascaso, C; Blanch, JL; Cuchi, MA; Estapé, J; Fírvida, JL; Grau, JJ, 1996)

"To develop a novel cancer gene therapy strategy based on suppression of tumor angiogenesis, we examined the feasibility of targeting and preferential killing of proliferating endothelial cells by use of the von Willebrand factor (vWf) promoter and herpes simplex virus thymidine kinase gene (HSV-TK)."

( Ide, H; Ikeda, Y; Ozaki, K; Saito, I; Sugimura, T; Terada, M; Yoshida, T, 1996)

"Number of cancer patients treated was not associated with attitudes toward the disclosure of information."

( Ekeberg, O; Falkum, E; Hytten, K; Kaasa, S; Loge, JH, 1996)

"For gastric cancer patients survival was improved by the adjuvant intraoperative radiotherapy compared with gastrectomy alone in those with advanced nodal or serosal involvement [P < 0."

( Abe, M; Nishimura, Y; Sasai, K; Shibamoto, Y; Takahashi, M, 1996)

"Of 115 cancer patients who fulfilled entry criteria for levels of distress, 45 patients were randomized to a fluoxetine treatment group (FA) and 46 patients to a placebo group (PA) after a 1-week placebo period designed to exclude placebo responders."

( Allilaire, JF; Blin, P; Bouhassira, M; Cordier, B; Desclaux, B; Fresco, R; Gauvain-Piquard, A; Guillibert, E; Mesters, P; Orth, JP; Piollet, I; Razavi, D; Salimpour, A; Saltel, P; Sechter, D; Smith, M; Trichard, C; Verra, M, 1996)

"This may offer new options for cancer immunotherapy."

( Uotila, P, 1996)

"This overview on glutamine, cancer and its therapy discusses some of the in vitro and in vivo work on glutamine and tumor growth, and summarizes animal and human data on the potential benefits of glutamine in the tumor-bearing host receiving radiation or chemotherapy."

( Klimberg, VS; McClellan, JL, 1996)

"Ten patients who suffered from severe cancer-related pain participated in a randomised, double-blind and cross-over study to compare the effectiveness and acceptability of epidural and subcutaneous administration of morphine."

( Heiskanen, T; Kalso, E; Rantio, M; Rosenberg, PH; Vainio, A, 1996)

"The treatment of severe cancer pain by intrathecal infusion of morphine and bupivacaine seems to be a promising method."

( Andersen, JS; Markers, PI; Valentin, N, 1996)

"In patients with LEMS who have cancer, effective treatment of the underlying tumor frequently produces marked improvement of weakness as well."

( Sanders, DB, 1995)

"Gene transfer for the treatment of cancer is a rapidly expanding field."

( Davis, BM; Gerson, SL; Koc, ON; Lee, K, 1996)

"In 25 cancer patients and 16 healthy subjects matched with regard to age, body mass index, and fat-free mass, indirect calorimetry was made before and after administration of a glucose load (75 g per subject, administered orally)."

( Gambardella, A; Paolisso, G; Tagliamonte, MR; Tortoriello, R; Varricchio, M, 1997)

"Patients with refractory cancer were treated with cyclophosphamide 600 mg/m2 on day 1, followed by topotecan given as a 30-minute infusion for 5 consecutive days."

( Anderson, S; Beidler, D; Belliveau, D; Burtness, BA; Cheng, YC; Fedele, J; Flynn, SD; Murren, JR; Pizzorno, G; Tocino, I; Zelterman, D, 1997)

"Sixteen patients with refractory cancer were treated (May 1992 to May 1995) with WBH alone during week 1) thereafter patients were randomized to receive either L-PAM alone on week 2 and L-PAM plus WBH on week 5, or the reverse sequence."

( Alberti, D; Arzoomanian, RZ; d'Oleire, F; Feierabend, C; Gillis, W; Kraemer, C; Kutz, M; Longo, W; Paul, D; Qu, RP; Robins, HI; Rushing, D; Spriggs, D; Stewart, JA; Tiggelaar, CL; Tutsch, KD; Wilding, G, 1997)

"Twenty-one evaluable patients with lung cancer have been treated to date."

( Berghorn, EJ; Creaven, PJ; Loewen, G; Meropol, NJ; Pendyala, L; Perez, RP; Raghavan, D, 1996)

"Twenty-three patients with advanced cancer were treated with a continuous infusion of EP using ambulatory pumps for 6 weeks followed by a 2-week rest."

( Creaven, PJ; Gunton, KE; Meropol, NJ; Noel, D; Pendyala, L; Schacter, LP; Soni, N, 1997)

"Twenty-nine patients with advanced malignancy who met standard eligibility criteria were treated with once-daily CAI given in cycles of 28 days."

( Alberti, D; Arzoomanian, RZ; Berlin, J; Cleary, J; Feierabend, C; Hutson, P; Rago, RP; Tutsch, KD; Wilding, G, 1997)

"The oxygenation status of R1H tumors decreased continuously from the start of the combined treatment, with increasing radiation dose and number of heat fractions."

( Kochs, E; Reeker, W; Zywietz, F, 1997)

"Early studies found that cancer patients in chronic oral opioid therapy had prolonged continuous reaction times, and that the opioids seemed to be mainly responsible for the prolongation."

( Sjøgren, P, 1997)

"In Montpellier Cancer Institute, first cancer pain patients received long-term intrathecal morphine as early as in 1979, and since then more than 400 patients have been treated."

( Gestin, Y; Pégurier, AM; Vainio, A, 1997)

"To report cancer cases in 426 rheumatoid arthritis patients treated with methotrexate, and determine whether there was an increased incidence of cancer compared with patients never treated with methotrexate (rheumatoid controls) and to the whole regional population."

( Bologna, C; Jorgensen, C; Picot, MC; Sany, J; Verdier, R; Viu, P, 1997)

"Lung cancer patients were treated with cisplatin and etoposide, breast cancer patients with mitoxantrone, and gastrointestinal tract tumor patients with 5-fluorouracil plus folates."

( Ardizzoia, A; Barni, S; Conti, A; Lissoni, P; Maestroni, G; Paolorossi, F; Tancini, G, 1997)

"In metastatic prostate cancer, our recent survey suggests the formation of a new paradigm: local field external-beam radiotherapy to the painful index site in combination with prophylactic administration of systemic radionuclides for clinically occult metastases."

( Ben-Josef, E; Porter, AT, 1997)

"Patients with solid tumors previously treated with no more than two prior chemotherapy regimens were given methotrexate intravenously on day 1, followed by paclitaxel, as a 24-hour infusion on day 2."

( Fossella, FV; Hong, WK; Huber, MH; Lee, JS; Lippman, SM; Newman, RA; Wester, M, 1996)

"The use of oxycodone to treat chronic cancer pain has been hampered by its short elimination half-life, which necessitates administration every 4 hours."

( Babul, N; Hagen, NA, 1997)

"To compare the occurrence of malignancy in patients with severe ocular inflammatory disease treated with systemic corticosteroids alone or with systemic immunosuppressive drugs with or without systemic corticosteroids."

( Akova, YA; Barney, N; Christen, W; Foster, CS; Lane, L; Messmer, E; Pedroza-Seres, M; Rodriguez, A; Tamesis, R, 1995)

"The rates of malignancy after initiation of drug therapy were compared using an exact test for incidence rate data."

( Akova, YA; Barney, N; Christen, W; Foster, CS; Lane, L; Messmer, E; Pedroza-Seres, M; Rodriguez, A; Tamesis, R, 1995)

"Certain types of cancer pain fail to respond well either to systemic drug therapy or to spinal opioids because of the occurrence of intolerable adverse effects."

( Ischia, S; Pinaroli, AM; Polati, E, 1996)

"Four patients developed neoplasia and three died suddenly a few days after receiving a CPM pulse but the causal relationship between CPM therapy and these poor outcomes is speculative."

( Devogelaer, JP; Houssiau, FA; Lauwerys, B; Lefèbvre, C; Martin, F, 1997)

"Drug resistance, a major obstacle to cancer chemotherapy, can be mediated by MDR-1/P-glycoprotein."

( Biedler, JL; Fojo, T; Knutsen, TA; Mickley, LA; Spengler, BA, 1997)

"The recent experience of the National Cancer Institute (Milan) in the follow-up of 189 lymphoma patient showed the major role of gallium scan, compared with MRI, in the study of the mediastinal region after treatment."

( Bombardieri, E; Gasparini, M; Monetti, N; Musumeci, R; Piffanelli, A; Spinelli, F; Tondini, C, 1996)

"Patients with advanced cancer either chemotherapy-naive or resistant to standard treatments received paclitaxel in a three-hour infusion followed by cisplatin, with or without the addition of r-HuG-CSF (5 micrograms/kg s."

( Casaretti, R; Comella, G; Comella, P; Daponte, A; De Rosa, L; Frasci, G; Gallipoli, A; Gravina, A; Parziale, A, 1997)

"Fifty-five patients with cancer (16 lung, 16 breast, 11 ovarian, 7 head and neck, 1 renal, 1 esophageal, 1 cervical, 1 soft-tissue sarcoma, and 1 of unknown primary), 25 of whom were pretreated, were entered into the study."

( Casaretti, R; Comella, G; Comella, P; Daponte, A; De Rosa, L; Frasci, G; Gallipoli, A; Gravina, A; Parziale, A, 1997)

"These studies confirm that cancer pain is inadequately treated for 51% of patients and identify among French physicians attitudinal barriers to the proper use of morphine."

( Larue, F, 1996)

"We prospectively evaluated 15 adult cancer patients being treated with adrenocorticosteroids (steroids) to determine the frequency and time course of "steroid myopathy."

( Batchelor, TT; DeAngelis, LM; Posner, JB; Taylor, LP; Thaler, HT, 1997)

"Topo I and II targeting anticancer agents such as camptothecins (CPT-II), epipodophyllotoxins (VP16 and VM26), and amsarcine are widely used in cancer chemotherapy."

( Furukawa, M; Harada, T; Kuwano, M; Tanaka, T, 1997)

"Photodynamic therapy (PDT) for cancer patients has developed into an important new clinical treatment modality in the past 25-years."

( Berg, K; Giercksky, KE; Kongshaug, M; Moan, J; Nesland, JM; Peng, Q; Warloe, T, 1997)

"A series of 279 cancer patients undergoing either chemotherapy and/or radiotherapy treatment for different tumor types was randomly allocated to receive either MPA or no treatment."

( Garosi, VL; Intini, C; Neri, B, 1997)

"A total of 27 patients with advanced cancer participated in a dose-escalation study in the first cycle of treatment with drug given i."

( Basser, RL; Cebon, J; Clarke, K; Geldard, H; Green, MD; Hill, JS; Kaye, AH; Maher, DW; Morgan, DJ; Park, SJ; Stylli, SS, 1997)

"All but 9 patients (with pancreatic cancer) had been previously treated with chemotherapy and all had extensive visceral disease."

( Calabresi, F; Ceribelli, A; Crecco, M; Oliva, C; Pollera, CF, 1997)

"Although cancer pain management has been highlighted in the lay and medical literature, physicians in training still demonstrate deficiencies in their knowledge about the pharmacology and bioequivalency of the opioid and the benefits of radiation therapy."

( Bartlett, NL; Mortimer, JE, 1997)

"Basic guidelines for cancer pain treatment can be found in many different handbooks published in the last years."

( De Conno, F; Polastri, D, 1997)

"A striking anti-cancer action of IP6 has been demonstrated both in vivo and in vitro, which is based on the hypotheses that exogenously administered IP6 may be internalized, dephosphorylated to IP(1-5), and inhibit cell growth."

( Cole, KE; Shamsuddin, AM; Vucenik, I, 1997)

"Anemia, frequently associated with cancer and cancer treatment, can use a variety of symptoms that diminish overall quality of life (QOL)."

( Cella, D, 1997)

"Untreated anemia is common in cancer patients."

( Glaspy, J, 1997)

"Many cancer patients in phase I clinical trials are treated at doses of chemotherapeutic agents that are below the biologically active level, thus reducing their chances for therapeutic benefit."

( Arbuck, SG; Christian, MC; Collins, J; Freidlin, B; Rubinstein, L; Simon, R, 1997)

"Further evidence for cancer and cardiac protection and antiatherogenic effects resulting from soybean isoflavones administration has been noted in various experimental animal models."

( Brandi, ML, 1997)

"As the number of terminal cancer patients receiving continuous intrathecal infusion of opioids and local anesthetics for relief of pain increases, we decided to investigate the post-mortem findings of the spinal cord, meninges and nerve roots of patients after continuous intrathecal administration of morphine and combined with bupivacaine."

( de Lange, JJ; Spoelder, EM; van der Valk, P; Wagemans, MF; Zuurmond, WW, 1997)

"In the shrinking, reoxygenation tumors with a Tc of 2 days, accelerated radiation therapy increased tumor control by 40%-80% over the control with conventional radiation therapy."

( Kocher, M; Müller, RP; Treuer, H, 1997)

"Fast-growing tumors that reoxygenate by shrinking are especially sensitive to acceleration and treatment breaks."

( Kocher, M; Müller, RP; Treuer, H, 1997)

"All children with tumors initiated regimen B, but only three, who had negative CMV detection and markedly decreased ALT levels, received full treatment; of the remaining two children, one recovered after only an initial course, and the other had therapy interrupted because of hepatic failure and died 9 days later."

( Bartmann, U; Castello, M; Clerico, A; Krzysztofiak, A; Nigro, G; Properzi, E; Valia, S, 1997)

"The anticancer therapy caused significant increases in the amount of all four DNA base modifications over control levels in the lymphocytes of most of the patients."

( Bialkowski, K; Foksinski, M; Jaruga, P; Olinski, R; Tujakowski, J, 1997)

"The risk for malignancy other than lymphoproliferative disorders does not seem to be elevated, although multiple sporadic malignancies have been reported in treated patients."

( Cash, JM; Kanik, KS, 1997)

"Thirty-three children with refractory cancer (stratified by age, < or = 12 and > 12 years) were treated with ATRA 3 consecutive days per week and IFN-alpha2a 3 x 10(6) U/m2 5 consecutive days per week, both repeated weekly."

( Adamson, PC; Balis, FM; Berg, SL; Blaney, SM; Feusner, J; Finklestein, JZ; Murphy, RF; O'Brien, M; Reaman, G, 1997)

"Modern cancer therapy produces substantial acute and chronic toxicity which impairs quality of life and limits the effectiveness of treatment."

( Trotti, A, 1997)

"Twenty-six cancer patients (pts) with chemotherapy-related neutropenic fever were treated with vancomycin 30 mg/m2/day i."

( Casali, A; Della Giulia, M; Di Lauro, L; Gionfra, T; Santini, S; Sega, FM; Vici, P, 1997)

"A history of cancer therapy threatening cognitive function (defined as > or = 18 gy of radiotherapy, intrathecal or high-dose systemic methotrexate, or both) was a marginally significant predictor of poorer-quality decision making in the first regression model."

( Finley, SM; Hobbie, WL; Hollen, PJ, 1997)

"The treatment of cancer patients with conventional chemotherapy is sometimes associated with severe systemic toxicity and only a minimal survival benefit."

( Harris, AL; Long, L; Mawer, EB; O'Byrne, KJ; Salisbury, AJ; Saunders, MP; Talbot, DC; Whitehouse, RM, 1997)

"The best laxative for terminal cancer patients treated with opioids still remains to be determined."

( Agra, Y; Calvo, MJ; Ferrari, M; González, M; Portugués, A; Sacristán, A, 1998)

"We treated 38 immunosuppressed cancer patients presenting to our ambulatory treatment center with VZV infections with intravenous acyclovir (500 mg/m2 8-hourly) in an ambulatory/home setting."

( Elting, L; Frisbee-Hume, S; Manzullo, E; Rodriguez, S; Rolston, KV; Rubenstein, EB, 1998)

"Ninety chemotherapy-naive cancer patients receiving cisplatin-based (> or = 50 mg/m2) chemotherapy participated in a randomized, double-blind, cross-over study comparing the safety and efficacy of granisetron (GRA) versus granisetron plus prednisolone (GRA + PRE)."

( Handberg, J; Hansen, HH; Herrstedt, J; Larsen, L; Wessel, V, 1998)

"Lung cancer trials have also confirmed the activity of both agents, although docetaxel appears to have slightly more promising activity in previously treated patients than paclitaxel."

( Eisenhauer, EA; Vermorken, JB, 1998)

"Butyrates have been studied as cancer differentiation agents in vitro and as a treatment for hemoglobinopathies."

( Conley, BA; Dover, G; Egorin, MJ; Fram, RJ; Rosen, DM; Sausville, EA; Tait, N; Van Echo, DA, 1998)

"Gender, age, cancer type, metastasis, initial pain intensity, nociceptive or neuropathic components and administration of adjuvant therapies were similar in both groups."

( Allaz, AF; Dayer, P; Desmeules, J; Kondo Oestreicher, M; Piguet, V, 1998)

"Eleven patients with advanced cancer refractory to standard therapy were treated with etoposide phosphate given over 1-2 hours on three consecutive days."

( Greco, FA; Hainsworth, JD; Utley, SM, 1997)

"Patients with advanced solid tumors refractory to standard therapy were enrolled at two institutions."

( Burris, HA; Diasio, R; Hohneker, J; Janisch, L; Khor, SP; Lucas, VS; Ratain, MJ; Schilsky, RL; Smetzer, L; Von Hoff, DD, 1998)

"Fifty-two patients with solid tumors had depressed white blood cell and neutrophil counts because of prior treatment with cytotoxic cancer chemotherapeutic drugs."

( Chang, RL; Conney, AH; Cui, YL; Han, ZT; He, LM; Newmark, HL; Sun, JZ; Tong, YK; Wang, TY; Zhang, H; Zhang, Y, 1998)

"The outcomes of cancer patients with radiotherapy have also improved considerably and organ preservation (e."

( Morgan, GW, 1998)

"The treatment of cancer pain with transdermal fentanyl can be performed as a long-term therapy and result in good pain relief."

( Donner, B; Raber, M; Strumpf, M; Zenz, M, 1998)

"Twenty-five cancer patients were treated with O6-Benzylguanine at a dose level of 10, 20, 40, and 80 mg/m2 intravenously (IV) over 1 hour."

( Dolan, ME; Fasanmade, AA; Paras, PR; Ratain, MJ; Roy, SK; Schilsky, RL, 1998)

"Adults with tumors appropriate for paclitaxel therapy who had abnormal liver function tests were eligible."

( Batist, G; Brown, TD; Budman, D; Egorin, MJ; Hohl, R; Jahan, TM; Kearns, CM; Ratain, MJ; Rosner, GL; Schilsky, RL; Venook, AP, 1998)

"Anemia is a common side effect of anticancer chemotherapy."

( Amadori, D; Armand, JP; Gamucci, T; Herrmann, R; Monfardini, S; Neri, B; Netter-Pinon, J; Nowrousian, MR; Oberhoff, C; Petry, KU; Rebmann, U; Tubiana-Mathieu, N; Voigtmann, R; Zwierzina, H, 1998)

"Adult patients with malignant solid tumors that were refractory to standard forms of chemotherapy were entered."

( Burris, H; Eckardt, JR; Fields, S; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; van Beurden, V; van der Burg, ME; Verweij, J; Von Hoff, DD, 1998)

"Two heavily pretreated ovarian cancer patients experienced reversible > or =grade 3 granulocytopenia."

( Alberti, D; Arzoomanian, RZ; Bailey, HH; Feierabend, C; Gould, MN; Pomplun, M; Ripple, GH; Stewart, JA; Tutsch, KD; Wilding, G, 1998)

"Surgical treatment of cancer patients did not modify the lymphocyte sensitivity to PGE2 after 1 week, but at 2 and 6 months after therapeutical treatment, the inhibition values of the parameters studied were almost similar or very similar to those of normal lymphocytes."

( Garipoli, C; Nicocia, G; Pitini, V; Sottile, A; Teti, D; Venza, I; Venza, M, 1998)

"Differences in cancer chemotherapy practices between Japan and USA are discussed as well."

( Rothenberg, ML, 1998)

"A group of 16 cancer patients were treated at doses of 0."

( Fleming, GF; Iyer, L; Janisch, L; Mani, S; Ratain, MJ; Schilsky, RL; Wang, X, 1998)

"Knowledge of cyclin D1's role in malignancy at the various sites, provides a basis on which future treatment directed against this molecule can proceed."

( Chetty, R; Donnellan, R, 1998)

"Three of four ovarian cancer patients demonstrated a drop in CA-125 serum concentrations during suramin treatment."

( Alberti, D; Arzoomanian, R; Cheng, AL; Church, D; Hutson, PR; Kehrli, N; Marnocha, R; Pomplun, M; Rago, R; Tutsch, KD; Wilding, G, 1998)

"Fifty patients with solid neoplasms were treated with TPT doses ranging from 0."

( Burris, HA; Eckardt, JR; Eckhardt, SG; Ganapathi, R; Hammond, LA; Hodges, S; Kuhn, JG; Rodriguez, GA; Rothenberg, ML; Rowinsky, EK; Von Hoff, DD; Weiss, GR, 1998)

"Treatment of cancer patients with thiol-containing antioxidants may improve the quality of life."

( Bärtsch, P; Benner, A; Breitkreutz, R; Dröge, W; Hack, V; Kinscherf, R; Röhrer, H; Taut, F, 1998)

"The study, conducted at a cancer center, included both a retrospective evaluation of patients undergoing highly emetogenic high-dose chemotherapy with peripheral blood stem-cell rescue between November 1994 and December 1995 and a concurrent evaluation of patients treated between January and May 1996."

( Finley, RS; Stull, DM; Trovato, JA, 1998)

"In multivariate analysis, the 10-year cancer mortality risk ratio associated with nifedipine therapy was 1."

( Behar, S; Boyko, V; Goldbourt, U; Jonas, M; Mandelzweig, L; Reicher-Reiss, H, 1998)

"Patients with advanced malignant tumors were treated within cohorts by one-hour infusional paclitaxel starting with 150 mg/m2 and stepwise escalation with 25 mg/m2 increments."

( Bauknecht, T; Häring, B; Hauns, B; Maier-Lenz, H; Meerpohl, HG; Mross, K; Unger, C, 1998)

"Patients with cancer have inappropriately low levels of endogenous erythropoietin for the degree of anemia and further suppression of erythropoiesis results from chemotherapy."

( Thatcher, N, 1998)

"The use of cytotoxic chemotherapy for cancer therapy has been very successful in the treatment and often cure of patients with particular neoplasms, such as testicular carcinomas and some lymphomas."

( Henner, WD; Kauvar, LM; Morgan, AS; Sanderson, PE, 1998)

"During the anticancer therapy the mean concentrations of serum albumin and prealbumin increased."

( Saarinen-Pihkala, UM; Taskinen, M, 1998)

"Breast cancer patients treated with the VIPE regimen (including pretreated women) had a significantly higher CFU-GM rate than patients treated with EC (P=0."

( Blumenstengel, K; Fricke, HJ; Höffken, K; Kath, R; Kunert, C; Sayer, HG; Vogel, W, 1998)

"Most cancer-patients should experience sufficient pain-management if existing recommendations for the pharmacological treatment of cancer-pain (e."

( Bautz, MT; Ensink, FB; Hanekop, GG; Hirn, AM; Kettler, D; Nass, S, 1998)

"To treat cancer pain patients appropriately, an interdisciplinary setting is essential."

( Bautz, MT; Beck, D; Ensink, FB; Hanekop, GG; Kettler, D, 1998)

"On the basis of this defect, anemic cancer patients, both adults and children, have been treated with recombinant human EPO (rHuEPO)."

( André, M; Beguin, Y; Bergmann, P; Buyse, M; Corazza, F; Devalck, C; Ferster, A; Fondu, P; Sariban, E, 1998)

"In bladder cancer, impressive single-agent activity of gemcitabine has also been seen, as well as in combination with cisplatin, initially in MVAC and platinum failures but more recently as first-line therapy both as a single agent and combined with cisplatin."

( Carmichael, J, 1998)

"The impact of cancer on the psychological well-being of newly diagnosed cancer patients before and during the course of radiotherapy was assessed in 70 consecutive cancer patients."

( Anantha, N; Chandra, PS; Channabasavanna, SM; Chaturvedi, SK; Rao, S; Reddy, BK; Sharma, S, 1998)

"Thirty-four patients with solid tumors, all of whom except three patients were pretreated, were treated at dose levels from 502 to 3,514 mg/m2 daily."

( Allman, D; Griffin, T; Kaye, S; Mackean, M; Osterwalder, B; Planting, A; Reigner, B; Schellens, J; Twelves, C; Verweij, J, 1998)

"Poor-risk solid tumors were treated with four courses of cyclophosphamide (4,200 mg/m2)/ doxorubicin (75 mg/m2), and three courses of ifosfamide (9,000 mg/m2)/etoposide (500 mg/m2)."

( Bajorin, D; Cheung, NK; Heller, G; Kramer, K; Kushner, BH; Meyers, PA; Polyak, T; Wollner, N, 1998)

"Patients had far advanced cancer, were far removed from chemotherapy or radiotherapy, and their nausea and emesis was not due to bowel obstruction, drug intake, or cranial, electrolytic, or metabolic causes."

( Befon, S; Liossi, C; Mystakidou, K; Vlachos, L, 1998)

"Seven children (1-15 years) with solid tumors were treated with long term epidural analgesia for refractory pain."

( Bernard, JL; Buttin, C; Camboulives, J; Coze, C; Fallouh, K; Gentet, JC; Marty, JY; Portas, M, 1998)

"The response of the human cancer strains HEp-2 (larynx carcinoma) and HL-60 (promyelocytic leukemia) cells to treatment with the CP-PG PGA1 in culture was investigated by evaluating the time-course of GSH synthesis and activity of enzymes of GSH metabolism, other than gamma-GCS, after PGA1 addition."

( Curi, R; de Bittencourt, PI; Miyasaka, CK; Williams, JF, 1998)

"A study was performed in low-risk cancer patients with chemotherapy-induced febrile neutropenia to determine the safety and efficacy of ceftriaxone given in an outpatient setting."

( Egerer, G; Jürgens, H; Karthaus, M; Kullmann, KH; Ritter, J, 1998)

"Patients with refractory solid tumors were eligible; however, only one previous chemotherapy regimen was allowed."

( Bernard, S; Brouwer, KL; Gonzalez, P; Lawrence, P; Letrent, SP; Mudd, PN; Radomski, KM; Socinski, MA; Steagall, A, 1998)

"Patients with advanced solid tumors and a maximum of one prior chemotherapy regimen for metastatic disease were eligible if they had a performance status of 0 to 1 and adequate renal, hepatic, and bone marrow function."

( Batist, G; Bernard, S; Egorin, MJ; Hollis, DR; Lilenbaum, RC; Miller, AA; Ratain, MJ; Rosner, GL; Schilsky, RL, 1998)

"Anemia is a frequent complication of cancer and its treatment and can have a significant impact on one's quality of life."

( Thomas, ML, 1998)

"Patients with cancer frequently develop anaemia, due either to the malignant disease itself or to its treatment."

( Nowrousian, MR, 1998)

"The anaemia associated with cancer can be effectively treated with recombinant human erythropoietin (rHuEpo) in about 60% of the patients."

( Beguin, Y, 1998)

"The possibility of natural cancer therapy has been recently suggested by advances in the knowledge of tumor immunobiology."

( Giani, L; Lissoni, P; Rovelli, F; Trabattoni, P; Zerbini, S, 1998)

"This study demonstrates that cancer pain patients given 6 to 12 tablets or capsules of fixed-dose combination analgesics can be equally well treated with CR oxycodone administered every 12 hr or IR oxycodone four times daily at the same total daily dose."

( Buckley, BJ; Croghan, MK; Johnson, BW; Kaiko, RF; Khojasteh, A; Moore, MR; Parris, WC; Reder, RF, 1998)

"The treatment of cancer pain includes various classes of molecules."

( Lossignol, D, 1998)

"Tegafur, an anticancer 5-FU prodrug suggested to be used by most of the patients who died, and SRV were orally administered to rats simultaneously once daily."

( Kato, A; Ogura, K; Okuda, H; Takubo, H; Watabe, T, 1998)

"Advanced cancer is commonly associated with significant anemia which worsens with the administration of cytotoxic drugs."

( Hakimali, A; Khan, ZK; Malik, IA; Rehman, G; Sabih, M, 1998)

"When the clinical responses for cancer chemotherapy were retrospectively compared with the in vitro sensitivities of the corresponding drugs on 16 patients who had measurable lesions, the correlation between the two was satisfactorily strong; the prediction accuracy for sensitivity was 83."

( Kitaoka, A; Muraoka, R; Tanigawa, N, 1997)

"Two patients with colorectal cancer, both previously treated with 5-FU, had partial responses."

( Allman, D; Bissett, D; Cassidy, J; Dirix, L; Griffin, T; Osterwalder, B; Reigner, B; Van Oosterom, AT, 1998)

"In untreated C3H tumors, the mean (+/- 1 SE) percentage of pO2 values < or = 2."

( Ehrnrooth, E; Horsman, MR; Ladekarl, M; Overgaard, J, 1998)

"Data exist in human ovarian cancer and in human gastric cancer that ERCC1 may be a useful marker for clinical drug resistance when platinum-based systemic chemotherapy is utilized."

( Reed, E, 1998)

"All children with cancer aged 1-17 years who had an episode of suspected or proven infection that required parenteral treatment at John Hunter Children's Hospital (JHCH) during 1994/95 were reviewed."

( Francis, L; Henry, RL; Jones, PD; Stuart, J, 1998)

"A cohort of 100 cancer patients who received or were scheduled to receive cisplatin or noncisplatin chemotherapy (50 per group) were then interviewed to measure the maximum WTP (net benefit) that they experienced with epoetin alfa."

( Dranitsaris, G; Ortega, A; Puodziunas, AL, 1998)

"Its ultimate role in ovarian cancer and other neoplasms awaits additional evaluation in combination with other agents and as first-line therapy."

( Cersosimo, RJ, 1998)

"Anemia can also be the result of cancer therapy, as is particularly prominent in patients with lung cancer receiving chemotherapy (incidence of anemia 20 to 50%)."

( Manegold, C, 1998)

"We have experienced cancer home chemotherapy in 90 cases of terminal cancer from August 1990 to May 1998."

( Nakamura, M; Sawada, K; Sawada, M; Suzuki, Y, 1998)

"Pharmacogenetic screening prior to anticancer drug administration may lead to identification of specific populations predisposed to drug toxicity or poor drug responses."

( Iyer, L; Ratain, MJ, 1998)

"OPTIMAL CHEMOTHERAPY DOSE: The goal of cancer chemotherapy is to eradicate the malignant disease while minimizing severe toxic effects."

( Brion, N; Paule, B, 1998)

"26 Italian hospitals specialising in cancer treatment."

( , 1999)

"The status of pain treatment for cancer patients in India is largely undocumented."

( Cleeland, CS; Mendoza, T; Saxena, A, 1999)

"Patients with solid tumors who were treated with conventional dose chemotherapy, presented with fever (axillary temperature >38 degrees C on 2 occasions or >38."

( Colomer, R; Cortés-Funes, H; García-Carbonero, R; Gómez, C; Hidalgo, M; Hornedo, J; Lumbreras, C; Perea, S; Ruiz, A; Trigo, JM, 1999)

"Therapy for cancer patients with biologically active immune modulators is attractive but has met with limited clinical success."

( Holcombe, RF; Li, A; Stewart, RM, 1998)

"A clinical audit of the treatment of cancer-related pain, ordered by Stockholm County Council and the Karolinska Institute, was performed at two Stockholm hospitals."

( Arnér, S; Killander, E; Westerberg, H, 1999)

"Strategies to improve traditional cancer therapy by modulation of the oxygenation status remain quite promising but more critical research and sophisticated clinical studies are necessary before its true potential is known."

( Feldmann, HJ; Molls, M; Vaupel, P, 1999)

"Patients with brain tumors can be safely treated with higher doses of docetaxel (23 mg/m2 twice a week) without toxicity."

( Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Schiza, S, 1999)

"Biological and gene therapy of cancer have become important components of clinical cancer research."

( Hersh, EM; Stopeck, AT, 1997)

"Patients with cancer are clearly at high risk for the development of venous thromboembolism (VTE), particularly during chemotherapy and surgery."

( Levine, MN; Rickles, FR, 1998)

"Successful pharmacologic treatment of cancer pain is founded upon careful assessment and measurement of pain before and during therapy."

( Jage, J; Weber, M, 1999)

"Patients with advanced cancer that was refractory or resistant to standard treatments were treated with paclitaxel, carboplatin, and topotecan; doses were escalated in sequential cohorts of patients."

( Burris, HA; Greco, FA; Hainsworth, JD; Morrissey, LH, 1999)

"Nine patients with refractory cancer were treated from October 1995 to June 1997."

( Alberti, D; Arzoomanian, RZ; d'Oleire, F; Feierabend, C; Gillis, W; Grosen, E; Katschinski, DM; Kraemer, C; Longo, W; Love, R; Morgan, K; Robins, HI; Rushing, D; Simon, K; Spriggs, D; Stewart, JA; Tiggelaar, CL; Wilding, G, 1999)

"The incidence of cancer was slightly higher in the patients receiving nifedipine than in those not being treated with a calcium antagonist, which is consistent with earlier reports; however, this increase was not statistically significant."

( Ishikawa, K; Kanamasa, K; Kimura, A; Miyataka, M; Takenaka, T, 1999)

"Advances in cancer pain research and management are an example of the advances that have occurred within the field of neuro-oncology, the medical discipline that includes the diagnosis and treatment of primary central nervous system neoplasms, metastatic and nonmetastatic neurological complications of cancer originating outside the nervous system, and pain associated with cancer."

( Foley, KM, 1999)

"We recruited 33 terminally ill cancer patients from three palliative care centers, all of whom had persistent dyspnea after rest and treatment with oxygen."

( Allard, P; Bernard, P; Lamontagne, C; Tremblay, C, 1999)

"Two patients with far-advanced cancer, near death, who were experiencing excruciating and intractable pain that was poorly responsive to rapidly escalating doses of morphine and hydromorphone were treated with low-dose intravenous ketamine (0."

( Fine, PG, 1999)

"Adults with incurable cancers of any histology requiring radiation therapy were eligible."

( Becerra, CR; Carbone, DP; Engel, J; Frenkel, EP; Lum, BL; Miles, D; Miller, R; Nurenberg, P; Renschler, MF; Rosenthal, DI; Young, S, 1999)

"Seventeen cancer patients who were no longer amenable to standard treatment were enrolled and were evaluable for DLT."

( Edler, L; Fiebig, HH; Frei, E; Hartung, G; Heeger, S; Heene, DL; Kränzle, M; Maier-Borst, W; Queisser, W; Schrenk, HH; Sinn, H; Stehle, G; Wunder, A, 1999)

"Progress in the treatment of solid tumors has been slow and sporadic."

( Chang, W; Kao, PN; Lee, KY; Qiu, D; Rosen, GD, 1999)

"A total of 427 cancer patients receiving cyclophosphamide chemotherapy participated in this multicenter, double-masked, double-dummy, parallel-group, randomized study comparing the antiemetic efficacy and safety of an 8-mg conventional ondansetron tablet (OT, n = 212) taken twice daily with an 8-mg orally disintegrating ondansetron tablet (ODT, n = 215) taken twice daily for 3 days."

( Curtis, P; Davidson, N; Erikstein, B; L'Esperance, B; Miller, I; Paska, W; Rapoport, B; Ruff, P, 1999)

"Anaemia is often exacerbated by cancer treatments, in particular routinely used cytotoxic chemotherapy."

( Ludwig, H, 1999)

"For most cancer patients, pain can be controlled with systemic analgesic and coanalgesic therapy in concert with treatment of their underlying cancer."

( Levy, MH, 1999)

"Large surveys of populations with cancer pain indicate that as many as 90% of patients can attain adequate relief of pain using optimal, systemic, opioid-based pharmacotherapy."

( Portenoy, RK, 1999)

"Guidelines for cancer pain management include nonsteroidal antiinflammatory drugs with opioids administered in a time-contingent manner."

( Lauretti, GR; Lima, IC; Pereira, NL; Prado, WA; Reis, MP, 1999)

"Resistance of cancer cells is the major limitation to the success of chemotherapy."

( Sikic, BI, 1999)

"Most solid tumors show resistance to current chemotherapy."

( Tomida, A; Tsuruo, T, 1999)

"Subcutaneous 9L/FPGS tumors responded as well to methotrexate given every third day as 9L tumors did to daily treatment."

( Aghi, M; Breakefield, XO; Kramm, CM, 1999)

"In low-risk patients with cancer who have fever and granulocytopenia, oral therapy with ciprofloxacin plus amoxicillin-clavulanate is as effective as intravenous therapy."

( Cometta, A; De Bock, R; Gaya, H; Kern, WV; Langenaeken, J; Paesmans, M, 1999)

"Transduction of cancer cells with herpes simplex virus thymidine kinase gene (HSVtk) followed by prodrug ganciclovir (GCV) treatment has been shown to induce apoptosis."

( Chao, Y; Hung, YM; Shih, YL; Wei, SJ; Yang, DM; Yang, WK, 1999)

"Patients with metastatic cancer who were not undergoing chemotherapy or radiotherapy and who had lost >5% of their body weight were eligible."

( Edelman, MJ; Gandara, DR; Gietzen, DW; Houston, J; Ishii, R; Lauder, I; Meyers, FJ; O'Mahony, M; Uhrich, M, 1999)

"Since cancer is incurable in many patients, palliation of symptoms and quality-of-life issues are important aspects of therapy."

( Bokemeyer, C; Hartmann, JT; Kanz, L; Kollmannsberger, C; Mayer, F, 1999)

"To test the anticancer properties of the water-insoluble derivative of camptothecin, 9-nitrocamptothecin (9-NC) against human breast, colon and lung cancer xenografts in nude mice when administered in liposome aerosol."

( Gilbert, BE; Giovanella, BC; Knight, V; Koshkina, NV; Waldrep, JC, 1999)

"Tumor growth was greatly reduced or tumors were undetectable after several weeks of treatment."

( Gilbert, BE; Giovanella, BC; Knight, V; Koshkina, NV; Waldrep, JC, 1999)

"Resistance to chemotherapy in cancer cells is mainly mediated by overexpression of P-glycoprotein (Pgp), a plasma membrane ATP-binding cassette (ABC) transporter which extrudes cytotoxic drugs at the expense of ATP hydrolysis."

( Baubichon-Cortay, H; Conseil, G; Dayan, G; Di Pietro, A; Jault, J; Krell, T; Steinfels, E; Trompier, D, 1999)

"The use of glutamine with cancer chemotherapy and radiotherapy seems to prevent gut and oral toxic side-effects, and may even increase the effectiveness of some chemotherapy drugs."

( Miller, AL, 1999)

"Most tumors are resistant to therapy by thymidylate synthase (TS) inhibitors due to their high levels of TS."

( Collins, JM; Katki, AG; Klecker, RW, 1999)

"Chemotherapy and radiation therapy for cancer often have severe side effects that limit their efficacy."

( Chernov, MV; Christov-Tselkov, K; Coon, JS; Gudkov, AV; Komarov, PG; Komarova, EA; Kondratov, RV, 1999)

"Staging of newly presenting cancer patients and restaging for treatment planning are reviewed here."

( Eary, JF, 1999)

"Fifty patients with advanced solid tumors and good performance status were treated with raltitrexed as a 15-min i."

( Allegra, CJ; Arbuck, SG; Chen, AP; Cullen, E; Goldspiel, B; Grem, JL; Hamilton, JM; Johnston, PG; Lawrence, D; McAtee, N; Sorensen, JM; Steinberg, SM; Takimoto, CH, 1999)

"In most cancer patients who are treated with opioid analgesics for pain control, the type of opioid needs to be changed at least once because of the presence of side effects or the need to escalate analgesic doses to toxic levels."

( Bruera, E; Neumann, CM, 1999)

"A similar number of patients with solid tumors (14 vs 15) and hematologic malignancies (five vs five) were treated in each group."

( Colby, C; Finkelstein, D; Fishman, J; McAfee, S; Sackstein, R; Spitzer, T, 1999)

"Twenty patients with cancer were selected for intrathecal treatment because of either side effects or inadequate relief during conventional pain treatment."

( Crul, BJ; van Dongen, RT; van Egmond, J, 1999)

"In head and neck cancer, we have found that gemcitabine doses far below the maximum tolerated dose for the drug when used alone significantly potentiate the toxicity of treatment."

( Eisbruch, A; Fields, MT; Lawrence, TS; McGinn, CJ; Shewach, DS, 1999)

"Patients with advanced cancer, performance status 0-2, and a normal left ventricular ejection fraction who had received up to 1 prior chemotherapy regimen were treated with epirubicin followed by a 3-hour infusion of paclitaxel repeated every 3 weeks."

( Bishop, JF; Francis, P; Ganju, V; Millward, MJ; Nawaratne, S; Rischin, D; Toner, GC; Webster, LK, 1999)

"Twenty-five patients with solid tumors received, after myeloblative chemotherapy, a total of 30 reinfusions of PBSC and/or bone marrow."

( Kema, IP; Mulder, NH; Smit Sibinga, CT; van der Graaf, WT; Vries, EG; Wymenga, AN, 1999)

"Patients with solid tumors refractory to standard therapy received continuous infusions of irinotecan by means of an ambulatory infusion pump."

( Beijnen, JH; Gruia, G; Herben, VM; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Vernillet, L, 1999)

"Patients with solid tumors refractory to standard therapy were entered onto the study."

( Beijnen, JH; Herben, VM; Hillebrand, MJ; Lieverst, J; Porro, MG; Schellens, JH; Schoemaker, NE; Schot, M; ten Bokkel Huinink, WW; van Gijn, R, 1999)

"Thirty-two patients with cancer refractory to conventional therapy were treated."

( Alberti, D; Arzoomanian, RZ; Cohen, JD; Feierabend, C; Jacobson, E; Katschinski, DM; Mehta, M; Olsen, M; Robins, HI; Tiggelaar, CL; Tutsch, K; Wilding, G, 1999)

"We report our experience with malignant tumors developing over 27 yr of treating IBD patients with 6MP."

( Fleisher, MR; Gleim, GW; Korelitz, BI; Mirsky, FJ; Warman, JI; Wisch, N, 1999)

"Twenty-one cancer patients requiring parenteral hydration were administered a 500 cc bolus of two-thirds dextrose (5%) and one-third normal saline solution subcutaneously at 08:00 and 16:00 hours during day 1 and day 2."

( Bruera, E; Calder, K; Hanson, J; Neumann, CM; Pituskin, E, 1999)

"To date, 14 patients with solid tumors have received 42 courses of treatment at a fixed gemcitabine dose of 1,000 mg/m2 on days 1 and 8 and escalating doses of MTA (200, 300, and 400 mg/m2) given 90 minutes after gemcitabine on day 1."

( Adjei, AA; Erlichman, C, 1999)

"We now know that hypoxia in solid tumors is not only a major problem for radiation therapy but also leads to resistance to most anticancer drugs and, importantly, appears to accelerate malignant progression and increase metastasis."

( Brown, JM, 1999)

"Forty-three children with cancer participated in this randomized, double-blind, placebo-controlled, crossover study in which nasal administration of midazolam spray,."

( Andréasson, S; Gordh, T; Kreuger, A; Ljungman, G; Sörensen, S, 2000)

"Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m(2), on Day 1 every 28 days."

( Baccala, P; Berg, D; Clark, JW; Finkelstein, D; Fuchs, CS; Grenon, N; Grossbard, ML; Lynch, TJ; Mayer, RJ; Ryan, DP; Seiden, MV, 2000)

"This is not an exception in cancer therapy; the conversion from hospital treatment to ambulatory and domiciliary treatment is promoted."

( Horimi, T; Morita, S; Shirasaka, T; Takahashi, I; Takasaki, M; Tsuji, A, 1999)

"Patients with advanced cancer were treated with CPT-11 (days 1, 8, and 15) and carboplatin (day 1) of a fixed-target area under the concentration-time curve (AUC) of 5 mg x min/ml."

( Fukuda, M; Kawabata, S; Kinoshita, A; Kohno, S; Nakatomi, K; Noguchi, Y; Oka, M; Soda, H; Takatani, H; Terashi, K; Tsukamoto, K; Tsurutani, J, 1999)

"Some important anticancer drugs contribute to dysfunction of the carnitine system in nontumor tissues, which is reversed by carnitine treatment, without affecting anticancer therapeutic efficacy."

( Barbarisi, A; Benatti, P; Calvani, M; Nicolai, R; Peluso, G; Reda, E, 2000)

"Forty-two patients with advanced solid tumors, most of whom had been previously treated, received docetaxel on day 1 as a 1-h i."

( Bartholomeus, S; Bleiberg, H; Brassinne, C; Cazenave, I; de Valeriola, D; Hennebert, P; Kerger, J; Kusenda, Z; Lefresne-Soulas, F; Piccart, M; Selleslags, J; Van Den Neste, E; Wythouck, H, 2000)

"One patient with metastatic colon cancer treated at the 500-mg bid dose had a 46% decrease in carcinoembryonic antigen levels, improvement in cough, and radiographically stable disease for 5 months."

( Belly, RT; Bol, CJ; Bowden, C; Chiao, J; Chow, C; Cowan, KH; End, DW; Gress, RE; Hakim, FT; Horak, ID; Kohler, DR; Kopp, WC; Kremer, AB; Larkin, G; Noone, M; Nussenblatt, RB; Piotrovsky, VK; Todd, A; Woestenborghs, R; Zujewski, J, 2000)

"Combined chemo-immunotherapeutical anti-cancer treatment seems to be more efficacious than chemotherapy alone, and the significant hematopoietic toxicity associated with most chemotherapeutical clinical trials can be reduced significantly by the addition of immunotherapy."

( Bodey, B; Kaiser, HE; Siegel, SE, 2000)

"In regards to cancer, there were possible benefits on total and prostate cancer in those with low baseline levels assigned to beta-carotene, a finding compatible with the Chinese Cancer Prevention Study for combined treatment with beta-carotene, vitamin E, and selenium in a poorly nourished population."

( Christen, WG; Gaziano, JM; Hennekens, CH, 2000)

"Anemia is a frequent complication of cancer and its treatment."

( Arun, B; Berkarda, B; Buyukunal, E; Demir, G; Demirelli, F; Mandel, NM; Ozguroglu, M; Serdengecti, S, 2000)

"Children with cancer who develop an episode of chemotherapy-induced febrile neutropenia usually are admitted to the hospital for intravenous empiric antibiotic therapy."

( Aquino, VM; Buchanan, GR; Herrera, L; Sandler, ES, 2000)

"Children with solid tumors refractory to conventional therapy received IRN by a 1-h i."

( Furman, WL; Hanna, SK; Houghton, PJ; Ma, MK; Radomski, KM; Santana, VM; Smith, AK; Stewart, CF; Zamboni, WC, 2000)

"Thirty-one patients with solid tumors stratified according to pretreatment were randomized to receive cisplatin/ifosfamide-based chemotherapy with or without amifostine (1000 mg absolute) given as a short infusion prior to cisplatin."

( Bokemeyer, C; Fels, LM; Hartmann, JT; Kanz, L; Knop, S; Stolte, H; van Vangerow, A, 2000)

"Patients with refractory solid tumors were treated with the combination of fractionated radiation therapy and multiple-dose intravenous tirapazamine to determine the toxicities and maximum tolerated dose of tirapazamine when given concurrently with radiation therapy."

( Buswell, L; Coleman, CN; Doherty, N; Loeffler, JS; Riese, N; Shulman, LN; von Roemeling, RW, 1999)

"To treat cancer pain, physicians often decide to jump directly from step 1 of the World Health Organization (WHO) analgesic ladder to step 3."

( Mattern, C; Uitendaal, MP; Vielvoye-Kerkmeer, AP, 2000)

"In the cancer dose-response modeling, each worker is treated as a separate experimental unit with his own unique dose."

( Bretzlaff, RS; de Jong, G; Sielken, RL; Stevenson, DE; Valdez-Flores, C, 1999)

"One hundred and thirty-five cancer patients admitted with low-risk neutropenic fever received a low-dose schedule of ceftazidime as infusional monotherapy over a total of 180 episodes."

( Clark, PI; Kelly, V; Marshall, E; Murray, A; O'Reilly, SM; Smith, DB, 2000)

"Six female non-heart-failure cancer patients treated with doxorubicin were included in a longitudinal study."

( Andre-Fouet, X; Beaune, J; Bontemps, L; Guastalla, JP; Itti, R; Janier, M; Landais, P; Lievre, M; Nony, P; Rebattu, P, 2000)

"A total of 101 cancer patients with 121 febrile neutropenia episodes were randomised to receive empirical treatment with i."

( Ferrant, A; Gérain, J; Humblet, Y; Longueville, J; Moreau, M; Straetmans, N; Symann, M; Vandercam, B; Wauters, G, 2000)

"Haemoglobin was measured in 444 cancer patients with different types and stages of cancer and treatment modalities."

( Glaus, A; Müller, S, 2000)

"New efforts in cancer therapy are being focused at various levels of signaling pathways."

( Berrie, CP; Brancaccio, A; Broggini, M; Falasca, M; Mascetta, G; Razzini, G; Vignati, S, 2000)

"Human colon cancer xenografts (146 x 12 mm(3)) in Balb / c nu / nu female mice were treated with 9."

( Aburano, T; Hiramatsu, T; Kinuya, S; Konishi, S; Michigishi, T; Shuke, N; Takayama, T; Tonami, N; Watanabe, N; Yokoyama, K, 2000)

"TS has been used as a target for cancer chemotherapy in the development of fluoropyrimidines such as 5-fluorouracil (5-FU) and 5-fluorodeoxyuridine and of novel folate-based TS inhibitors such as ZD1694 (Tomudex, Raltitrexed), ZD9331, LY231514 (ALIMTA, Pemetrexed), AG337 (Thymitaq, Nolatrexed) and AG331."

( Giaccone, G; Peters, GJ; Pinedo, HM; Van Triest, B, 2000)

"Patients with advanced cancer, WHO performance status 0-2, who had received up to one prior chemotherapy regimen were treated with gemcitabine on days 1 and 8 and docetaxel on day 8 repeated every 21 days."

( Bishop, J; Boyer, M; Davison, J; Emmett, E; McClure, B; Michael, M; Millward, M; Rischin, D; Smith, J; Zalcberg, J, 2000)

"Twenty-four patients with advanced cancer were treated with 5-Fluorouracil 600 mg/m2 intravenously and interferon-alfa-2b 3 MU subcutaneously both given weekly for 6 weeks followed by a 2-week hiatus."

( Casal, R; Quan, WD, 1996)

"The observed cancer patterns in this population establish that measures directed at prevention and early detection (linked with treatment) of cervix and head and neck cancers are of paramount importance for cancer control in this and other rural populations of India where three-fourths of the total population live."

( Cherian, J; Esmi, A; Jayaraman, R; Parkin, DM; Rajkumar, R; Sankaranarayanan, R, 2000)

"Phase II trials are warranted in tumors known to be responsive to 5-FU treatment."

( de Vries, MJ; Gall, H; Giaccone, G; Hanauske, AR; Noordhuis, P; Peters, GJ; Pinedo, HM; Schornagel, JH; Swart, MS; Turner, SL; van Groeningen, CJ, 2000)

"Adults with tumors appropriate for gemcitabine therapy and who had abnormal liver or renal function tests were eligible."

( Budman, D; Byrd, J; Egorin, MJ; Hawkins, M; Hohl, R; Hollis, D; Mani, S; Meropol, NJ; Ratain, MJ; Rosner, GL; Venook, AP, 2000)

"The impact of anemia on cancer patients undergoing chemotherapy is well established, but only recently has the prevalence of anemia in patients receiving radiotherapy received much attention."

( Harrison, LB; Ramdeen, B; Shasha, D; White, C, 2000)

"The efficacy of targeted cancer therapy relies on the ability of a toxin to be located in the target cancer cell."

( Allen, BJ, 1999)

"Patients with cancer who are treated with chemotherapy or receive a bone marrow transplant have an increased risk of acquiring fungal infections."

( Gotzsche, PC; Johansen, HK, 2000)

"Anaemia in cancer patients is multifactorial and may occur as a either a direct effect of the cancer, as a result of the cancer treatment itself, or due to chemical factors produced by the cancer."

( Filosto, S; Gebbia, V; Marrazzo, A; Mercadante, S, 2000)

"Seventy pediatric patients with cancer treated at the Hospital for Children and Adolescents, University of Helsinki, Finland, died while in terminal care and 30 children of therapy-related complications during active anticancer therapy in the period 1987-92."

( Hovi, L; Saarinen-Pihkala, UM; Sirki, K, 2000)

"Long-term survivors of childhood cancer treated with anthracyclines may have subclinical cardiac dysfunction undetectable at a baseline evaluation."

( Aricò, M; Bossi, G; Klersy, C; Lanzarini, L; Laudisa, ML, 2000)

"Radiation as a cancer treatment modality is of high physical precision but limited biological specificity."

( Wheldon, TE, 2000)

"39 adult cancer patients were enrolled with advanced/refractory disease not amenable to established treatments, PS

( Barbet, N; Buuren, IV; Capdeville, R; Choi, L; de Vries, EG; Dumez, H; Groen, HJ; Muskiet, F; Oosterom, AT; Paridaens, R; Seeghers, M; Uges, DR; van der Graaf, WT, 2000)

"In conclusion, in cancer patients with reduced HRQL, the start of morphine therapy had no major influence on aspects of HRQL other than pain."

( Borchgrevink, PC; Kaasa, S; Klepstad, P, 2000)

"Even when the guidelines for cancer pain management are followed, acute severe pain requiring immediate treatment will occur in some patients."

( Elsner, F; Radbruch, L; Sabatowski, R, 2000)

"Thirty-one patients with solid tumors stratified according to pretreatment were randomized to receive VIP- or TIP-chemotherapy with or without amifostine (910 mg/m2) given as a short infusion prior to cisplatin."

( Bokemeyer, C; Fels, LM; Hartmann, JT; Kanz, L; Knop, S; Stolt, H, 2000)

"We propose that ascorbate treatment of cancer should be reexamined by rigorous scientific scrutiny in the light of new evidence."

( Levine, M; Padayatty, SJ, 2000)

"There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment."

( Büller, HR; Gent, M; Ginsberg, J; Hutten, BA; Prins, MH; Tijssen, JG, 2000)

"Fourteen patients with various tumors were treated by conformal radiotherapy with a "tight" planning target volume (PTV) margin."

( Aoyama, H; Dosaka-Akita, H; Hashimoto, S; Kagei, K; Kitamura, K; Kunieda, T; Miyasaka, K; Nishioka, T; Shimizu, S; Shinohara, N; Shirato, H, 2000)

"This path stretches from cancer chemotherapy to nutritional toxicology, following the elusive thread that interconnects the metabolic network buried in the ground of any biological process."

( Carmona, A, 1999)

"We studied 29 patients with solid tumors, 14 of whom had breast cancer and all of whom were naive to bisphosphonate therapy."

( Body, JJ; Dumon, JC; Louviaux, I, 2000)

"Antihypertensive treatment may promote cancer through unknown mechanisms."

( Goldbourt, U; Grossman, E; Messerli, FH, 1999)

"The etoposide concentrations in four cancer patients treated with etoposide are also presented to demonstrate the clinical utility of this new method, which should aid the pharmacokinetically guided use of etoposide in clinical settings."

( Chen, CL; Uckun, FM, 2000)

"We report two cases of cancer pain treated with transcatheter thoracic epidural neurolysis using ethyl alcohol, and epidural histopathologic changes in the spinal cord observed in one of the patients."

( Hayashi, I; Odashiro, M; Sasaki, Y, 2000)

"A concept of cancer treatment proposes the conversion of tumor cells synchronously into the stage of unviable polykaryocytes, which leads to dissociation of the tumor substrate, reduction of the mass of tumor, and even to its resolution."

( Gedenidze, AV; Gogichadze, GK, 2000)

"Patients with solid malignant tumors refractory to standard treatment were given topotecan orally on a daily times five schedule repeated every 21 days."

( Akhtar, S; Beckman, RA; Doyle, E; Fields, SZ; Mould, DR; Wright, J, 2000)

"Ongoing research in cancer therapy has led to the development of antineoplastic agents which target specific components of the cell cycle."

( Dutcher, JP; Marcoullis, G; Novik, Y; O'Boyle, K; Secco, C; Wiernik, PH, 2000)

"Heterogeneity in human malignant tumors is a well-described phenomenon and of interest with regard to subpopulations with differences in clonality, metastatic potential, and response to therapy under different treatment regimes."

( Baumann, M; Horn, K; Könemann, S; Malath, J; Rübe, C; Rupek, T; Schuck, A; Vormoor, J; Willich, N, 2000)

"A total of 411 cancer patients (196 treated with meropenem and 215 treated with ceftazidime), who had 471 episodes of fever, participated in the trial."

( Berman, S; DePauw, B; Feld, R; Ho, W; Keating, A, 2000)

"As chemotherapy is used increasingly in cancer patients, HBV reactivation during cytotoxic treatment may become a more common problem."

( Chan, PK; Ho, WM; Hui, P; Johnson, PJ; Leung, NW; Steinberg, JL; Tam, JS; Yeo, W; Zee, B; Zhong, S, 2000)

"A survey of cancer treatment in a sample of hospitals > 100 beds conducted in 1998 compared with experience in the US showed that good progress has been achieved in Japan in the screening and early treatment of gastric cancer, and that the prognosis for breast cancer is better than in the West."

( Aiba, K; Akaza, H; Blackledge, G; Hinotsu, S; Isonishi, S; Kono, S; Mikami, O; Noguchi, S; Ogawa, O; Shibuya, M; Sone, S; Stribling, D; Tsuruo, T; Vose, B, 2000)

"One of the most widely used drugs in cancer chemotherapy is 5-fluorouracil (5-FU)."

( Kindler, HL; Schilsky, RL, 2000)

"From 1994 to April 1996 577 cancer patients were treated in our pain clinic according to WHO-Guidelines."

( Grond, S; Lehmann, KA; Loick, G; Radbruch, L; Sabatowski, R; Siessegger, M, 2000)

"Geriatric patients with cancer pain can be treated as effectively according to WHO-Guidelines as younger patients."

( Grond, S; Lehmann, KA; Loick, G; Radbruch, L; Sabatowski, R; Siessegger, M, 2000)

"Clinical studies in breast cancer and lymphoma suggest that serial FDG-PET studies allow the prediction of response early in the course of chemotherapy."

( Avril, N; Schwaiger, M; Weber, WA, 2000)

"The charts of 273 cancer patients were retrospectively analyzed in order (1) to evaluate the frequency of opioid change (OCH) when adjuvants (antiemetics/laxatives) were administered on a regular basis and co-analgesic medication as indicated by the specific type of pain, (2) to define risk factors for the request of OCH, and (3) to reveal settings in which OCH may not be recommended as a first-line therapeutic intervention."

( Bosse, B; Kloke, M; Kloke, O; Rapp, M, 2000)

"Thirty-six patients with relapsed solid tumors were treated and 109 courses were administered at doses ranging from 3 to 240 mg/m2."

( Booser, DJ; Cossum, P; Esparza-Guerra, L; Hortobagyi, GN; Perez-Soler, R; Priebe, W; Wu, QP; Zou, Y, 2000)

"A total of 26 patients with malignant tumors refractory to conventional treatment were enrolled in this phase I study; their median age was 62 years."

( Agelaki, S; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Reppa, D; Samonis, G; Souglakos, J; Vardakis, N, 2000)

"Inadequate pain management of cancer patients remains a striking problem despite impressive scientific progress in the knowledge of the pathophysiology, pathogenesis and therapy of pain."

( Berzlanovich, A; Fazeny, B; Hagmeister, H; Hauser, I; Mares, P; Marosi, C; Muhm, M; Wenzel, C, 2000)

"Major advances in cancer treatment have resulted from the use of drug combinations; for some combinations this raises the possibility of sinergistic neurotoxicity."

( Iñiguez, C; Larrodé, P; Mauri, JA; Mayordomo, JI; Morales, F; Trés, A, 2000)

"Patients with moderate to severe cancer pain and insufficient pain relief from nonopioid analgesics were treated with slow-release tramadol for initial dose finding and as a long-term treatment."

( Karthaus, M; Mertens, A; Petzke, F; Radbruch, L; Sabatowski, R, 2001)

"In vivo, these agonists exerted anti-cancer effects, and when given in combination with chemotherapy, they enhanced the chemotherapeutic index and acted as chemoprotective agents."

( Bar-Yehuda, S; Barer, F; Fishman, P; Ohana, G, 2001)

"Forty-four cancer patients with bone metastases or primary bone lesions were enrolled sequentially into 1 of 5 fixed ascending-dose treatment groups."

( Berenson, JR; Conde, F; Henick, K; Nishikubo, C; Rettig, M; Swift, RA; Vescio, R; Von Teichert, JM, 2001)

"C57BL/6 female mice bearing LLC tumors were given injections for 4 consecutive days with NM-3 (25 mg/kg/day) and treated with IR (20 Gy) for 2 consecutive days."

( Beckett, MA; Gupta, VK; Hari, DM; Hellman, S; Jaskowiak, NT; Kalluri, R; Koons, AM; Kufe, DW; Mauceri, HJ; Posner, MC; Reimer, C; Salloum, RM; Seetharam, S; Weichselbaum, RR, 2000)

"It is proposed that successful cancer chemotherapy requires the use of many agents to elevate ceramide levels adequately."

( Radin, NS, 2001)

"In recurrent germ-cell cancer, a "biplatin" regimen of oxaliplatin plus cisplatin was found to be effective salvage therapy."

( Lorusso, PM, 2000)

"Patients with refractory cancer or cancer for which no standard therapy was available were treated in escalating doses using an accelerated titration design."

( Averbuch, S; Bertucci, D; Douglass, E; Goh, BC; Hutchison, M; Mani, S; Ratain, MJ; Schilsky, RL; Smith, M; Smith, R; Vogelzang, NJ, 2001)

"Thirty-two patients with advanced solid cancers were treated at seven dose levels (12."

( Balkwill, F; Blackie, R; Braybrooke, JP; Caponigro, F; Dutreix, C; Ganesan, TS; Graf, P; Harris, AL; Kaye, SB; Man, A; McDonald, AC; Propper, DJ; Talbot, DC; Thavasu, P; Twelves, C, 2001)

"Twenty-two patients with advanced solid tumors, all previously treated, and with performance status < or = 2, were entered."

( Coyle, J; De Jager, R; Ducharme, MP; Dumas, P; Hoff, PM; Lassere, Y; Lee, JJ; Pazdur, R; Royce, ME, 2001)

"Improved means of cancer prevention and treatment remain key goals of global health programmes."

( Cross, ML; Gill, HS, 2000)

"Cohorts of three or more adult cancer patients were administered oral GTE with water after meals one or three times daily for 4 weeks, to a maximum of 6 months, depending on disease response and patient tolerance."

( Coldman, B; Glisson, BS; Hong, WK; Khuri, FR; Lee, JS; Newman, RA; Pisters, KM; Shin, DM, 2001)

"Guidelines for treatment of paediatric cancer pain recommend the usage of long-acting morphine."

( Lindena, G; Zernikow, B, 2001)

"A DPD-deficient phenotype among cancer patients, which has posed a serious problem in 5FU-based chemotherapy, was reported to be in part ascribed to germline mutations in dihydropyrimidine dehydrogenase (DPYD) gene."

( Akagi, K; Arai, Y; Kanda, Y; Yamaguchi, K, 2001)

"Male factor infertility as a result of cancer treatment is well treated with IVF or intracytoplasmic sperm injection, where indicated (32% delivery rate/cycle), with no difference between the frozen sperm banked before cancer treatment and fresh sperm produced after treatment."

( Ginsburg, ES; Jackson, KV; Yanushpolsky, EH, 2001)

"Patients with advanced solid tumors for whom no standard therapy was available could enter the study."

( Bol, CJ; Punt, CJ; Seifert, WF; van Maanen, L; Wagener, DJ, 2001)

"These studies demonstrated that KB tumors of [14C]NX211-treated mice had approximately 70-fold greater concentrations of [14C]lurtotecan at 24 h, respectively, compared to concentrations of [14C]lurtotecan of the KB tumors of [14C]lurtotecan-treated mice."

( Abbott, EA; Bendele, RA; Brown, EN; Desjardins, JP; Dihel, L; Emerson, DL; Hamilton, M; Leray, JD; Ptaszynski, M; Richardson, FC; Tomkinson, BE, 2001)

"Adult patients with refractory solid tumors were treated with DENSPM administered by intravenous infusion in 100 ml of normal saline over 30 minutes."

( Bender, JF; Streiff, RR, 2001)

"Fifty-nine cancer patients with bone metastases were enrolled sequentially into one of 8 treatment groups in the core protocol."

( Berenson, JR; Givant, E; Harvey, H; Hupkes, M; Lipton, A; Rosen, LS; Savage, A; Swift, R; Vescio, RA; VonTeichert, JM; Woo, M, 2001)

"However, cancer patients are often found to be immunosuppressed, which could be attributable to prior radiation, chemotherapy, or the tumor burden itself."

( Da Silva, DM; de Visser, KE; Fisher, SG; Kast, WM; Potkul, RK; Small, LA; Velders, MP, 2001)

"In addition to their desired anticancer effects, most cancer treatments may also cause transient toxicity, permanent organ damage, or death."

( Cheng, SC; Thall, PF, 1999)

"A total of 203 advanced-stage cancer patients suffering from different types of cancer who had exhausted all conventional forms of therapy were treated with the novel antitumor drug Ukrain over a period of 2."

( Aschhoff, B, 2000)

"Clinical and research oncologists, cancer nurses, and other healthcare professionals met to discuss the latest advances in prevention and treatment of cancers at the Eighth European Cancer Conference."

( Prescott, LM, 1995)

"Extracts from three of four tumors inhibited, dose- and time-dependently, (32)P-orthophosphate uptake by opossum kidney (OK) cells; maximum inhibition was about 45% of untreated control."

( Jonsson, KB; Jüppner, H; Mannstadt, M; Miyauchi, A; Stein, G; Yang, IM, 2001)

"In breast cancer cell cultures treated with cisplatin, ELISA absorbance increased only after treatment with drug concentrations 10-fold higher than concentrations inducing 95% growth inhibition."

( Frankfurt, OS; Krishan, A, 2001)

"Fifty-two consecutive cancer patients receiving oral morphine but with uncontrolled pain and/or moderate to severe opioid adverse effects were switched to oral methadone administered every 8 hours using different dose ratios."

( Boffi, R; Casuccio, A; Fulfaro, F; Gebbia, V; Groff, L; Mercadante, S; Ripamonti, C; Villari, P, 2001)

"In 18 patients with recurrent breast cancer who received docetaxel (D, 60 mg/m2) every 3 weeks as second line therapy after an anthracycline-based regimen, PNLs were investigated before and during the administration of D."

( Kuroi, K; Tanaka, C; Toi, M, 2001)

"54 patients with advanced malignancy refractory to chemotherapy were studied to evaluate efficacy and toxicity of continuous infusion of 5-fluorouracil (5FU) given for 3 weeks."

( Berger, R; Brenner, H; Ghodsizade, E; Katz, A; Rath, P; Tichler, T, 1999)

"In both SCC VII and EL4 tumors, maximum values of mitotic index (MI) and apoptosis frequency were observed 9 and 24 h after TXL administration, respectively."

( Hori, H; Kinashi, Y; Masunaga, SI; Murayama, C; Nagasawa, H; Nishimura, Y; Ono, K; Sadahiro, S; Suzuki, M; Takagaki, M; Tsuchiya, I; Uto, Y, 2001)

"In addition, for tumors that are susceptible to apoptosis after TXL administration alone, irradiation at the time of sufficient reoxygenation in tumors after TXL administration produces a greater radioenhancement effect on P cells."

( Hori, H; Kinashi, Y; Masunaga, SI; Murayama, C; Nagasawa, H; Nishimura, Y; Ono, K; Sadahiro, S; Suzuki, M; Takagaki, M; Tsuchiya, I; Uto, Y, 2001)

"Twenty-four patients with solid tumors, refractory to standard chemotherapy or for whom no effective therapy existed (age range 31-74; 7 female, 17 male; ECOG PS 0 = 12, 1 = 11, 2 = 1), received gemcitabine and CPT-11 weekly for four weeks out of every six weeks."

( Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Erlichman, C; Goldberg, RM; Kaufmann, SH; Okuno, SH; Pitot, HC; Rubin, J; Sloan, J, 2001)

"New concepts for the development of cancer treatment strategies that are based on the use of vitamin D(3) compounds are discussed in this manuscript."

( Reichrath, J, 2001)

"The association between atenolol and cancer death was analysed pooling three randomized controlled studies, including 1879 treated patients and 3078 non-treated patients, yielding a pooled OR of 1."

( Goldbourt, U; Grossman, E; Messerli, FH, 2001)

"Twenty-six patients with advanced solid tumors were treated with escalated doses of paclitaxel (starting dose 70 mg/m(2)/wk with increments of 10 mg/m(2)/wk) for 4 consecutive weeks every 6 weeks."

( Agelaki, S; Androulakis, N; Christodoulakis, M; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Samonis, G; Sarra, E; Souglakos, J, 2001)

"We report three patients with advanced cancer pain refractory to adjuvants and oral, intravenous, and epidural opioids, who achieved sustained pain relief after the repeated administration of diphenhydramine."

( Fischberg, D; Gonzales, G; Khjainova, N; Kornick, C; Santiago-Palma, J, 2001)

"Adoptive immunotherapy (AIT) of cancer with T lymphocytes may be limited by the need to activate tumor antigen-sensitized cells in vitro."

( Bear, HD; Cornell, D; Kyle, B; Roberts, J; Tombes, MB, 2001)

"Specific treatment of cancer remains essential to prevent TIH relapse."

( Lortholary, A, 2001)

"The role of epoetin alfa in anemic cancer patients receiving chemotherapy has grown as our understanding of the relationship between anemia and quality of life in this patient population has evolved."

( Gabrilove, JL, 2001)

"Patients with cancer are at risk for developing a variety of fluid and electrolyte disturbances caused by the disease process or by complications from therapy."

( Chan, GZ; Kapoor, M, 2001)

"Oral morphine treatment for cancer pain relief is established as central parts of 'WHO Regimen'."

( Kato, A; Kato, Y, 2001)

"The sequence of analgesic therapy for cancer pain should follow the WHO ladder regimen."

( Morimoto, M, 2001)

"384 neutropenic patients with cancer who had persistent fever that did not respond to antibiotic therapy."

( Boehme, A; Boogaerts, M; Bow, EJ; Chwetzoff, E; De Beule, K; Garber, G; Novitzky, N; Reboli, AC; Schwarer, AP; Winston, DJ, 2001)

"A total of 34 patients with advanced cancers were treated with gemcitabine and docetaxel on days 1 and 8 of each 21-day cycle according to the following dose escalation schedule: level 1, 800 and 30 mg/m2, respectively; level 2, 800 and 40 mg/m2; level 3, 1,000 and 40 mg/m2; and level 4, 1,250 and 40 mg/m2."

( Bhargava, P; Dahut, W; Figuera, M; Fried, K; Gehan, E; Hanfelt, J; Hawkins, MJ; Lefebvre, P; Marshall, JL; Rizvi, NA; Williams, M, 2001)

"The Nutritional Prevention of Cancer Trial found supplemental Se (200 microg/day, as Se-enriched yeast) to be associated with significant reductions in cancer risks in subjects with pre-treatment plasma Se concentrations below ca."

( Clark, LC; Combs, GF; Turnbull, BW, 2001)

"Most cancer patients will experience pain requiring opioid therapy during their illness."

( Bruera, ED; Gagnon, B; Hanson, J; Lawlor, PG; Mancini, IL; Pereira, JL, 2001)

"Photodynamic therapy (PDT) is a cancer treatment modality that is based on the administration of a photosensitiser, which is retained in tumour tissues more than in normal tissues, followed by illumination of the tumour with visible light in a wavelength range matching the absorption spectrum of the photosensitiser."

( Colussi, VC; Kinsella, TJ; Oleinick, NL; Sibata, CH, 2001)

"Children with refractory cancer (stratified by age, < or =12 and >12 years) were treated with p."

( Adamson, PC; Balis, FM; Gillespie, AF; Murphy, RF; Reaman, GH; Seibel, NL; Widemann, BC, 2001)

"Patients with advanced solid tumors were treated every 4 weeks with cisplatin on day 1 and Doxil on day 2."

( Gabizon, AA; Hubert, A; Lyass, O, 2001)

"Most metastatic tumors, such as those originating in the prostate, lung, and gastrointestinal tract, respond poorly to conventional chemotherapy."

( Epner, DE, 2001)

"The renal functions in pediatric cancer patients who received ifosfamide (IFO) treatment were evaluated and the risk factors related to IFO nephrotoxicity were determined."

( Ahn, HS; Cheong, HI; Choi, Y; Ha, IS; Hahn, H; Kang, HG; Lee, BS; Lee, JH; Shin, HY, 2001)

"These benefits were observed in cancer patients who were not receiving chemotherapy as well as those who were."

( Burdette-Radoux, S; Couture, F; Dolan, S; Kovacs, M; Lau, CY; McKenzie, M; Quirt, I; Robeson, C; Tang, SC, 2001)

"Patients with solid tumors not amenable to standard forms of therapy were eligible."

( Campone, M; Faber, MN; Fumoleau, P; Punt, CJ; Ravic, M; van de Walle, B, 2001)

"245 patients with cancer either receiving chemotherapy with cisplatin or who had received cisplatin-based chemotherapy within the previous 6 months."

( Ciotti, R; Dranitsaris, G; Labianca, R; Leung, P; Liaropoulos, L; Ortega, A; Quadri, A; Spinthouri, M, 2001)

"A human breast cancer metastasis model was employed to evaluate the in vivo efficacy of systemically administered, TfRscFv-immunolipoplex-mediated, p53 gene therapy in combination with docetaxel."

( Alexander, W; Chang, EH; Huang, CC; Pirollo, KF; Rait, A; Tang, WH; Xiang, LM; Xu, L, 2001)

"In the nude mouse breast cancer metastasis model, the combination of the p53 gene delivered by the systemic administration of the TfRscFv-immunolipoplex and docetaxel resulted in significantly improved efficacy with prolonged survival."

( Alexander, W; Chang, EH; Huang, CC; Pirollo, KF; Rait, A; Tang, WH; Xiang, LM; Xu, L, 2001)

"The sensitization of tumors to chemotherapy by this tumor-targeted and efficient p53 gene delivery method could lower the effective dose of the drug, correspondingly lessening the severe side effects, while decreasing the possibility of recurrence."

( Alexander, W; Chang, EH; Huang, CC; Pirollo, KF; Rait, A; Tang, WH; Xiang, LM; Xu, L, 2001)

"The potential role of histamine in cancer immunotherapy has been a subject of interest for more than a decade."

( Agarwala, SS; Sabbagh, MH, 2001)

"These compounds will alter cancer care as adjuncts to currently available treatment options."

( Goel, S; Mani, S; Perez-Soler, R, 2002)

"Recent clinical trials of cancer gene therapy have shown encouraging results for controlling localized tumors."

( Funakoshi, T; Goto, H; Hayashi, S; Kijima, T; Kimura, H; Kumagai, T; Nishino, K; Osaki, T; Tachibana, I; Takeda, Y; Yoneda, T, 2001)

"Hypoxia in tumors is associated with malignant progression, metastatic spread, and increased resistance to radiotherapy and chemotherapy."

( Adams, MA; Gofton, TE; Graham, CH; Matthews, NE; Maxwell, LR, 2001)

"The selective killing of cancer cells can be achieved by gene-directed enzyme pro-drug therapy (GDEPT)."

( Bilsland, A; Evans, TR; Glasspool, RM; Kakani, R; Keith, WN; Knox, RJ; Plumb, JA; Zhao, J, 2001)

"Acute cancer-related pain can be treated with fentanyl administered by continuous intravenous infusion (CII) in combination with patient-controlled analgesia (PCA)."

( Khojainova, N; Kornick, CA; Manfredi, PL; Payne, R; Primavera, LH; Santiago-Palma, J, 2001)

"Treatment of hypercalcemia of malignancy (HCM) is briefly reviewed, available treatments are compared, and treatment guidelines are presented."

( Davidson, TG, 2001)

"Anemia is a frequent complication of cancer and its associated treatment."

( Harrison, LB; Shasha, D, 2001)

( Dziambor, H; Hager, ED; Höhmann, D; Strama, H; Winkler, P, 2001)

"The treatment of cancer pain is improving, but pain remains a significant problem."

( Hewitt, DJ, 2001)

"Three terminal cancer patients with severe dyspnea were treated with nebulized furosemide."

( Shimoyama, M; Shimoyama, N, 2002)

"Eligible patients had advanced solid tumors that had failed to respond to standard therapy or for which no standard therapy was available, measurable or assessable disease, Karnofsky performance status > or = 70%, and acceptable organ function."

( Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ, 2002)

"Some non-cytotoxic drugs in cancer treatment, for example angiogenesis inhibitors, may be able to induce and maintain tumor dormancy."

( Sasaki, T, 2001)

"BMT is used in the treatment of solid tumors, hematologic diseases, and autoimmune disorders."

( Capria, S; Grieco, G; Iori, AP; Muscaritoli, M; Rossi Fanelli, F, 2002)

"Treatment of cancer is increasingly effective but is associated with short and long-term side effects."

( Clarkson, JE; Eden, OB; Worthington, HV, 2002)

"The efficacy of cancer gene therapy depends critically on "bystander effects" by which genetic modification of tumor cells results in killing of unmodified cells in the local microenvironment."

( Denny, WA; Helsby, NA; Hicks, KO; Hogg, A; Pullen, SM; Wilson, WR, 2002)

"The National Comprehensive Cancer Network (NCCN) of cancer centers has recommended that all patients aged 70 years and older treated with CHOP or cytotoxic chemotherapy of comparable intensity should receive prophylactic G-CSF administration, and that the hemoglobin concentration be maintained at >or=12 g/dl in elderly patients undergoing chemotherapy."

( Bokemeyer, C; Honecker, F; Kolb, G; Lipp, HP; Späth-Schwalbe, E; Wedding, U, 2002)

"Many cancer patients receiving radionuclide therapy have both bulk tumours, which are best treated with high-energy beta particles, and single spread cells or micrometastasis, which are preferably treated with low-energy electrons such as Auger and conversion electrons."

( Lubberink, M; Lundqvist, H; Tolmachev, V, 2002)

"Fatigue scores of the anemic cancer patients (at both baseline and upon completion of anemia therapy) were significantly worse compared with the scores of nonanemic cancer patients that, in turn, were worse compared with the scores of the general United States population (P < 0."

( Cella, D; Chang, CH; Lai, JS; Peterman, A; Slavin, M, 2002)

"However, the ability of cancer cells to become simultaneously resistant to different drugs--a trait known as multidrug resistance--remains a significant impediment to successful chemotherapy."

( Bates, SE; Fojo, T; Gottesman, MM, 2002)

"Patients with refractory solid tumors received ISIS 3521 as a 21-day continuous infusion administered simultaneously with 5-FU and LV given daily for 5 days repeated every 4-5 weeks (one cycle)."

( Dorr, FA; Geary, RS; Holmlund, JT; Kindler, HL; Kunkel, K; Mani, S; Ratain, MJ; Rudin, CM, 2002)

"Plasma collected from 29 autologous cancer donors and 33 normal allogeneic stem-cell donors following administration of mobilizing cytokines just prior to the first collection was assayed for TGF-beta1 using a sandwich-type ELISA."

( Hock, L; Kessinger, A; McGuire, TR; Sharp, JG, 2001)

"Data from trials in patients with cancer with a range of tumor types, whether receiving chemotherapy or not, indicate that darbepoietin-alpha is effective in alleviating anemia when dosed at intervals of once every 1, 2, or 3 weeks and may effect greater and more rapid responses than recombinant human erythropoietin."

( Smith, R, 2002)

"Treatment of anemic cancer patients with epoetin alfa results in significant reduction in transfusion requirements, increase in Hb levels, and improvements in QOL, regardless of whether the chemotherapy is platinum- or nonplatinum-based."

( Degos, L; Demetri, GD; Dicato, M; Glaspy, J, 2002)

"Time-patterned treatments of cancer involve two distinct lines of research."

( Claude, D; Goldbete, A, 2002)

"In addition to neuroendocrine tumors, somatostatin receptors have been identified on cancers of the central nervous system, breast, lung, and lymphatic tissue, and the use of radionuclide-labeled somatostatin analogues appeared promising for therapy as well as for diagnosis of such malignancies."

( Bodei, L; Chinol, M; Cremonesi, M; Paganelli, G, 2002)

"Forty-two cancer patients treated with oral sustained-release (SR) morphine were assessed for pain, sedation and other side effects related to morphine treatment."

( Andersen, G; Christrup, L; Hansen, SH; Jensen, NH; Sjøgren, P, 2002)

"The administration of anti-cancer agents is currently associated with significant toxicity and lack of tumour specificity."

( Ahmed, FY; Cassidy, J; Ferguson, MJ, 2001)

"Ninety percent of patients with cancer pain can be effectively treated with oral conservative medications."

( Lordon, SP, 2002)

"Ninety-five pediatric cancer patients with 120 febrile neutropenic episodes were randomized to receive empiric treatment with cefepime or ceftazidime."

( Chuang, YY; Huang, YC; Hung, IJ; Jaing, TH; Lin, TY; Yang, CP, 2002)

"Twenty-five consecutive cancer patients with bone metastases treated monthly with disodium pamidronate infusion were evaluated prospectively for circulating levels of vascular endothelial growth factor (VEGF), gamma-IFN, interleukin (IL)-6, and IL-8 at different time points: just before and after 1, 2, and 7 days after pamidronate infusion."

( Avvisati, G; Battistoni, F; Denaro, V; Dicuonzo, G; Gavasci, M; Salerno, A; Santini, D; Tonini, G; Vincenzi, B, 2002)

"131 patients with solid tumors were treated as outpatients with paclitaxel 75 mg/m(2) and carboplatin AUC 2-3 days 1, 8, 15 every 4 weeks irrespective of pretreatment and partly in neoadjuvant and multimodal concepts."

( Boehme, C; Cerny, T; D'Addario, G; Morant, R, 2002)

"The majority of experimental tumors responded to the melatonin treatment with growth inhibition."

( Karasek, M; Pawlikowski, M; Winczyk, K, 2002)

"Apart from cancer and organ transplant patients, who are treated by complicated, constantly changing protocols administered by special societies, the government does not distinguish between AIDS patients and other catastrophically ill patients; all are required to assume some costs for their drugs."

( , 1990)

"Seeley was a terminally ill cancer patient who smoked marijuana to control the side effects of chemotherapy."

( , 1997)

"Their use in cancer therapy result in a, pharmacological castration (i."

( Crispino, A; Crispino, L; Florio, S; Giordano, A; Pacilio, C; Pagnini, U, 2002)

"Included in the study were 270 cancer patients receiving their first day of chemotherapy."

( Bauer, S; Brockmöller, J; Kaiser, R; Papies, A; Possinger, K; Roots, I; Schelenz, C; Sezer, O; Tremblay, PB, 2002)

"A patient with anaplastic thyroid cancer had a complete response and is alive 30 months after treatment."

( Cooney, M; Dowlati, A; Jesberger, J; Lewin, JS; Makkar, V; McCrae, KR; Overmoyer, B; Petros, WP; Rafie, N; Remick, SC; Robertson, K; Stambler, B; Stratford, M; Taylor, A; Waas, J, 2002)

"Treatment of the cancer patient is multifaceted."

( Chaudhry, S; Ko, C, 2002)

"To optimize cancer outcomes, successful treatment of both the cancer and the "noncancer" issues is required."

( Chaudhry, S; Ko, C, 2002)

"Chemotherapy treated cancer patients are prone to neutropaenia and life-threatening infections."

( Grozinsky, S; Leibovici, L; Paul, M; Soares-Weiser, K, 2002)

"Cytokine therapy for cancer or viral diseases is accompanied by the development of depressive symptoms in a significant proportion of patients."

( Capuron, L; Dantzer, R; Maes, M; Miller, AH; Neveu, PJ; Ravaud, A, 2002)

"In serial specimens from cancer patients undergoing treatment, the change of tHcy coincided with the concentration of tumor markers."

( Wu, JT; Wu, LL, 2002)

"Sixty-eight cancer patients (25 colorectal, 26 lung and 17 ovarian cancer) presently undergoing chemotherapy participated in the study."

( Fleischhacker, WW; Greil, R; Hejna, M; Holzner, B; Huber, H; Kemmler, G; Kopp, M; Krajnik, G; Raderer, M; Sperner-Unterweger, B; Zeimet, A; Zöchbauer, S, 2002)

"Fatigue is often related to cancer, and that related to its treatment is the most commonly reported side effect of cancer treatment."

( Andrews, PL; Hickok, JT; Matteson, S; Morrow, GR; Roscoe, JA, 2002)

"Thirty-one cancers were observed in 30 patients treated with azathioprine (4."

( Fraser, AG; Jewell, DP; Orchard, TR; Robinson, EM, 2002)

"No increased risk of cancer diagnosis following azathioprine treatment was observed."

( Fraser, AG; Jewell, DP; Orchard, TR; Robinson, EM, 2002)

"Although most patients with cancer pain can attain a favorable balance between analgesia and side effects with a conventional approach to opioid therapy, a substantial minority cannot."

( Portenoy, RK; Vielhaber, A, 2002)

"A patient with non-small cell lung cancer previously treated with taxanes experienced a partial response lasting 4 months, and five patients had stable disease lasting > or =3 months."

( Algazy, K; Ellis, D; Enas, N; Gallagher, M; Hahn, S; Johnson, R; O'Dwyer, PJ; Schuchter, L; Stevenson, JP; Sun, W; Thornton, D; Vaughn, D, 2002)

"Treatment of human breast cancer and brain tumor cells with COBRA-1 caused destruction of microtubule organization and apoptosis."

( Ghosh, S; Liu, XP; Mao, C; Narla, RK; Navara, CS; Sudbeck, EA; Uckun, FM; Vassilev, AO, 2001)

"private practice) and treatment of cancer pain patients during the last three months shows a better result for GPs (84."

( Bautz, MT; Ensink, FB; Görlitz, A; Hanekop, GG; Voss, MC, 2002)

"(1) Some cancer patients suffer occasional breakthrough pain despite well-conducted opiate treatment, warranting the use of immediate-release oral morphine."

( , 2002)

"In addition to non-small cell lung cancer, phase II/III studies are currently investigating ZD1839 as monotherapy or in combination therapy against prostate, breast, head and neck, gastric, and colorectal tumors."

( Ranson, M, 2002)

"Children with cancer frequently develop anemia both from the disease and from chemo- and radiotherapy."

( Riccardi, R; Ruggiero, A, 2002)

"Thirty-seven children with solid tumors receiving treatment with platinum- or nonplatinum-based chemotherapy were treated with epoetin alfa and supplemental iron in a single-center, open-label, 28-week, case-control study."

( Kronberger, M; Zoubek, A, 2002)

"In established tumors with epigenetically repressed Fas, restoration of Fas activity either by transfection of fas or treatment with Trichostatin A (TSA), an inhibitor of histone deacetylase, suppresses tumor growth and restores chemosensitivity."

( Giaccia, AJ; Maecker, HL; Maecker, HT; Yun, Z, 2002)

"Thus, cancers that are most difficult to treat by classical methods may be most easily targeted with folate-linked therapeutics."

( Low, PS; Lu, Y, 2002)

"Several cancer gene therapy strategies have already been realized in vitro, as well as in vivo."

( Kissel, T; Kopecek, J; Merdan, T, 2002)

"6: Restaging of head and neck cancer with possibilities of curative treatment."

( Borrego Dorado, I; Vázquez Albertino, R, 2002)

"Nutritional support of cancer patients should ideally contribute to improve the immune defence, maintain the protein body pool and sensitize the tumour to oncologic treatments."

( Dupertuis, YM; Genton, L; Karsegard, V; Maisonneuve, N; Pichard, C; Uldry, C, 2002)

"Chemotherapy-naive patients with solid tumors treated with docetaxel-based chemotherapy were studied prospectively for the development of nonneutropenic infections."

( Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vlachonikolis, J, 2002)

"During a 2-year period, 680 cancer patients enrolled in 24 protocols received 2867 cycles of docetaxel-containing chemotherapy."

( Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vlachonikolis, J, 2002)

"All patients had tumors no longer amenable to established forms of treatment."

( Brunetto, AL; Costa, TD; Di Leone, L; Gregianin, LJ; Santos, PP; Schwartsmann, G, 2002)

"Preliminary data in patients with cancer suggest that concurrent chemotherapy may influence the pharmacokinetics of darbepoetin alfa."

( Stewart, CE; Zamboni, WC, 2002)

"In 70% of the cases of malignant neoplasms in pediatric patients antiblast therapy is used."

( Brandolini, C; Ferri, GG; Hatzopoulos, S; Montaguti, M; Pession, A; Prete, A, 2002)

"Anemia resulting from cancer or its treatment is an important clinical problem increasingly treated with the recombinant hematopoietic growth factor erythropoietin."

( Bennett, CL; Browman, GP; Cella, D; Djulbegovic, B; Goode, MJ; Gordon, MS; Jakubowski, AA; Lee, SJ; Lichtin, AE; Miller, CB; Rarick, MU; Regan, DH; Rizzo, JD; Seidenfeld, J; Woolf, SH, 2002)

"Immunosuppressants and anticancer agents, which improve the prognosis of survival or the quality of life of patients, induce temporary sterility in all treated patients and complete sterility in 50% of treated patients."

( Jegou, B; Velez De La Calle, JF, 1993)

"Fifty-five patients with advanced neoplasms were treated with flavopiridol at doses of 12, 17, 24, 30, 37."

( Arbuck, SG; Figg, WD; Headlee, D; Melillo, G; Messmann, R; Murgo, AJ; Sausville, EA; Senderowicz, AM; Swain, SM; Tan, AR; Zhai, S, 2002)

"Anemia resulting from cancer, or its treatment, is an important clinical problem increasingly treated with the recombinant hematopoietic growth factor erythropoietin."

( Bennett, CL; Browman, GP; Cella, D; Djulbegovic, B; Goode, MJ; Gordon, MS; Jakubowski, AA; Lee, SJ; Lichtin, AE; Miller, CB; Rarick, MU; Regan, DH; Rizzo, JD; Seidenfeld, J; Woolf, SH, 2002)

"With increasing numbers of cancer survivors, attention has been drawn to long-term complications of curative cancer treatment, including a range of metabolic disorders."

( Gietema, JA; Nuver, J; Postma, A; Sleijfer, DT; Smit, AJ, 2002)

"Anemia, common in people with cancer, can be due to the disease itself or to the associated therapy."

( Cella, D, 2002)

"Among 155 patients with breast cancer treated by Seishu Hanaoka the exact death dates of only five patients including Kan Aiya, the first to have received a tumour excision under general anesthesia are known to us and the remaining 149 patients remain unclarified concerning their death dates."

( Matsuki, A, 2002)

"Pretreatment of cancer cells with a cell-permeable SOD mimetic, Mn(II)-tetrakis(4-benzoic acid)porphyrin chloride, and transient transfection with the MnSOD gene resulted in a decreased effectiveness of PDT."

( Baranczyk-Kuzma, A; Czeczot, H; Golab, J; Grzela, T; Jakobisiak, M; Jalili, A; Kaminski, R; Kopec', M; Kozar, K; Makowski, M; Mroz, P; Nowis, D; Skrzycki, M; Wilczynski, GM, 2003)

"Patients with advanced cancer, World Health Organization (WHO) performance status 0 to 2, who had received up to one prior chemotherapy regimen were treated with docetaxel, epirubicin and cyclophosphamide repeated every 21 days."

( Ackland, SP; Clarke, S; Garg, MB; Millward, MJ; Rischin, D; Smith, J; Toner, GC; Zalcberg, J, 2002)

"A patient with metastatic gastric cancer at this dose level had a complete response and remained disease-free for more than 48 months after completing therapy."

( Alberti, D; Arzoomanian, R; Bailey, HH; Binger, K; Cleary, JF; Dresen, A; Feierabend, C; Marnocha, R; Simon, K; Thomas, JP; Tutsch, KD; Wilding, G, 2002)

"Pediatric cancer patients presenting with febrile neutropenia after non-myeloablative chemotherapy and who met institutional criteria for early hospital discharge following a minimum of 48-hr inpatient empiric intravenous ceftazidime were eligible for the study."

( Burns, JL; Coughlin, J; Friedman, DL; Hawkins, D; Park, JR; Pendergrass, T, 2003)

"As a high proportion (about 50%) of cancer patients undergoing radiotherapy are anemic prior to or during treatment, strategies to correct anemia and/or the resultant tumor hypoxia are increasingly being considered an important component of treatment."

( Harrison, LB; Homel, P; Shasha, D, 2002)

"Established Meth A tumors were rejected effectively with a single dose of B7RP-1-Fc, however, the treatment was less effective on larger tumors."

( Ara, G; Baher, A; Baikalov, C; Brisan, E; Camacho, R; Cattley, RC; Fong, D; Gaida, K; Goldman, H; Horan, T; Kohno, T; Moore, A; Storm, N; Van, G; Whoriskey, JS; Yoshinaga, SK; Zhang, M, 2003)

"The toxicity outcome of cancer patients receiving chemotherapy is difficult to predict."

( Alexandre, J; Falissard, B; Goldwasser, F; Gornet, JM; Gross-Goupil, M; Misset, JL; Nguyen, ML, 2003)

"Although dendritic cell (DC)-based cancer-specific immunotherapy is a potent strategy for various types of carcinomas, few clinical studies have yielded optimal antitumor effects."

( Mashino, K; Mori, M; Ohta, M; Sadanaga, N; Tanaka, F; Yamaguchi, H, 2002)

"Studies also are ongoing in solid tumors, as single agent therapy and in combination with standard agents such as carboplatin."

( Diggikar, S; Takimoto, CH, 2002)

"A total of 320 patients with gastric cancer, colorectal, esophageal cancer and liver cancer were randomized into ATFU group (study group) and FT207 group (control group) (a ratio of 2:1), treated with MMC + VP-16 + ATFU (FT-207), DDP + HCPT + ATFU (FT-207), DDP + VDS + ATFU (FT-207), and ADM + MMC + ATFU (FT-207) regimen, respectively."

( Feng, FY; Han, J; Li, L; Li, Q; Sui, GJ; Wang, PH; Zhang, Y; Zhang, YC; Zhang, ZH; Zhou, MZ; Zhu, YG, 2002)

"RCTs of adult patients with cancer and pain being treated with an opioid, and receiving either ketamine (any dose and any route of administration) or placebo or an active control."

( Bell, R; Eccleston, C; Kalso, E, 2003)

"TNP-470-treated tumors demonstrated a significant decrease of vascular volume, as well as a significant reduction in vascular and permeable regions, compared with volume-matched control tumors."

( Artemov, D; Bhujwalla, ZM; Kollars, P; Kristjansen, PE; Natarajan, K; Solaiyappan, M, 2003)

"The emergence of tumors resistant to anticancer agents has been recognized as one of the major obstacles to effective cancer chemotherapy."

( Akiyama, S, 2003)

"Fatigue, a common complaint of cancer patients, requires a multidisciplinary evaluation and treatment approach because of the multiple etiologies and contributing factors."

( Escalante, CP, 2003)

"The place of ET-receptor antagonists in cancer therapy for a range of malignancies merits further investigation."

( Bagnato, A; Battistini, B; Nelson, J; Nisen, P, 2003)

"Treatment of cancer cells with 1,25-dihydroxyvitamin D3 [1,25(OH)(2)D(3)] or its analogs induces growth arrest and expression of the cyclin-dependent kinase inhibitor p27(KIP1)."

( Lin, R; Miller, WH; Wang, TT; White, JH, 2003)

"Patients with transitional cell cancer (TCC) and other advanced malignancies were treated with G and P on days 1, 8, and 15 of each 28 day cycle."

( Butzbach, D; Cairdella, M; Capanna, T; DiPaola, RS; Dvorzhinski, D; Eid, J; Goodin, S; Rubin, E; Shih, JW; Todd, MB; Toppmeyer, D, 2003)

"Oxygen deficiency in tumors reduces the efficacy of nonsurgical treatment modalities."

( Beghein, N; Feron, O; Gallez, B; Grégoire, V; Jordan, BF; Sonveaux, P, 2003)

"The use of nucleoside analogues in anticancer and antiviral treatments is often impaired by the slow intracellular activation of these drugs."

( Konrad, M; Monnerjahn, C, 2003)

"It is important to augment the anti-cancer host response in cancer treatment."

( Okamoto, M; Sato, M, 2003)

"The characteristics of the first cancer, the patient's family history of cancer, and the treatment (type, cumulative dose of chemotherapy, schedule of etoposide administration, and radiation dose delivered to active bone marrow) were compared in the two groups."

( Bayle, C; Bernheim, A; Cayuela, JM; Chompret, A; de Vathaire, F; Hill, C; Lacour, B; Le Deley, MC; Leblanc, T; Raquin, MA; Shamsaldin, A; Sommelet, D; Vassal, G, 2003)

"Treatment of pain caused by cancer in Italy has been reported to be inadequate for more than a decade."

( Blengini, C; Joranson, DE; Ryan, KM, 2003)

"Anemia in cancer patients is frequent but often under-recognized and under-treated."

( Pirker, R; Smith, R, 2002)

"Thus, emerging rapidly are cancer treatment strategies based on an improved understanding of the specific cellular and molecular abnormalities of individual tumors."

( Bianco, C; Ciardiello, F; Harari, P; Helfrich, B; Raben, D; Weng, E, 2002)

"Patients undergoing cancer chemotherapy frequently suffer from mucositis, particularly if they become leukopenic (leucocytes <1000/microL)."

( Buth, C; Doelken, G; Kiefer, T; Kramer, A; Pitten, FA, 2003)

"Anemia in cancer may be secondary to blood loss, displacement of normal bone marrow cells by malignant cells, myelotoxic therapy, or the tumor itself."

( Gillespie, TW, 2003)

"Such data will help tailor cancer chemotherapy to an individual's predisposition in the near future."

( Hasegawa, Y, 2003)

"Compared with tumors from vehicle-treated mice, tumors from YC-1-treated mice were statistically significantly smaller (P<."

( Cho, YS; Chun, YS; Kim, J; Kim, MS; Lee, JC; Park, JW; Yeo, EJ, 2003)

"Patients with advanced solid tumors were randomized to gemcitabine-amifostine-cisplatin (GAP) or gemcitabine-cisplatin (GP) in Cycle 1 (C1) and then were crossed over to the other treatment in Cycle 2 (C2)."

( Haigentz, M; Hamilton, A; Hochster, H; Kim, M; Lee, J; Macapinlac, M; Mirchandani, D; Muggia, FM; Pavlick, A; Sewak, S; Sorich, J; Volm, M, 2003)

"Like previously described cancer-germline genes, the 5 genes were induced in cells treated with a demethylating agent."

( Boon, T; De Smet, C; Loriot, A, 2003)

"Patients with advanced malignancy are at an increased risk of cardiac arrhythmias, from their cancer and cardiotoxic treatments."

( Aapro, M; Bourke, JP, 2003)

"CT26 (a murine colon cancer cell line syngeneic with BALB/c) and CT26-bearing mice were treated with mitomycin C (MMC) intraperitoneally (i."

( Furumoto, K; Imamura, M; Inoue, N; Kan, T; Kondo, K; Yamasaki, S, 2003)

"Tamoxifen (TAM), a nonsteroidal anticancer agent, is used in the treatment of breast cancer."

( Davis, BA; Nagarkatti, N, 2003)

"Most importantly, tumors that arose in mice following subcutaneous injection of HSV-tk(+) human ES cells could be ablated in vivo by administration of ganciclovir."

( Benvenisty, N; Itskovitz-Eldor, J; Schuldiner, M, 2003)

"Three children with brain tumors were treated with MA to improve weight gain."

( Krawiecki, N; Mazewski, C; Meacham, LR, 2003)

"Seventy-four female cancer patients who received 13 varying chemotherapy regimens were included in a nonrandomized pilot study."

( Bjurberg, M; Gustavsson, A; Ridderheim, M, 2003)

"We included 242 cancer patients on their first day of chemotherapy."

( Brockmoller, J; Kaiser, R; Possinger, K; Roots, I; Rosler, N; Schelenz, C; Sezer, O; Tremblay, PB, 2003)

"The leading platinum compounds in cancer chemotherapy are cisplatin, carboplatin and oxaliplatin."

( Hartmann, JT; Lipp, HP, 2003)

"A recent approach to cancer treatment is destruction of malignant and non-malignant tumors by hormonally targeted lytic peptides."

( Bodek, G; Hansel, W; Jana, B; Zaleska, M; Ziecik, AJ, 2003)

"The impact of cisplatin on cancer chemotherapy cannot be denied."

( Au-Yeung, SC; Ho, YP; To, KK, 2003)

"To analyze the effect of cancer treatment on pregnancy, delivery and progeny of women survivors of childhood cancer, 18 of them (15 to 49 years of age) were interviewed, with diagnosis and treatment between july 1965 and December 1982 (15 from the Oncology Unit of the Children's Hospital of Buenos Aires and 3 from a private practice) and evaluated until December 2000."

( Pons, ML; Schwartz, L, 2003)

"A Phase I study involving 24 cancer patients in whom tumors were refractory to all other conventional therapies was conducted to determine the dose limiting toxicity, maximum tolerated dose, effectiveness, and pharmacokinetic parameters of this drug administered by 1-h IV infusion daily for five consecutive days every 3 weeks."

( Boinpally, RR; Gadgeel, SM; Heilbrun, LK; Jain, V; LoRusso, PM; Parchment, R; Redman, B; Wiegand, R; Wozniak, A; Zalupski, M, 2003)

"Treatment of tumors or normal tissues with Epothilone B at doses less than 10-8 mol/L was ineffective."

( Anthony, CT; Balster, DA; Frey, DJ; Harrison, LH; Lewis, JM; Maxwell, PJ; O'Leary, JP; Rothermel, J; Wang, YZ; Woltering, EA, 2003)

"In addition, cancers overexpressing EGFR respond poorly to both chemotherapy and radiation therapy."

( Bulgaru, AM; Goel, S; Mani, S; Perez-Soler, R, 2003)

"(1) For the treatment of cancer pain resistant to WHO step I and II analgesics, several oral morphine preparations are available, in immediate-release and sustained-release formulations."

( , 2003)

"The 5% incidence de novo tumors developing among patients treated with azathioprine and prednisolone (n = 241) was similar to the 5."

( Hídvégi, M; Járay, J; Langer, RM; Perner, F; Tóth, A; Végsö, G, 2003)

"These targets as anti-cancer therapy had emerged to be a new perspective for oncology."

( Dufresne, A; Gainet, M; Guardiola, E; Pivot, X, 2003)

"In 5-FU-based cancer chemotherapy, severe toxicities were observed at higher rates in patients who were heterozygous for a mutant DPYD allele, compared with toxicities in patients who were homozygous for the wild DPYD allele."

( Omura, K, 2003)

"Screening for cancer and evaluation of remote metastasis, recurrence, and effects of radio-chemotherapy are now performed clinically."

( Hatazawa, J; Higuchi, I; Nakamura, H, 2003)

"Oral administration of antibiotics [Cancer Res 56: 3752-3757, 1996; Clin Cancer Res 7: 1136-1141, 2001] or kampo medicine [Jpn J Cancer Res 86: 978-984, 1995; Jpn J Cancer Res 86: 985-989, 1995] to decrease beta-glucuronidase activity derived from bacteria in the large intestine was also reported to be successful in preventing delayed diarrhea."

( Kobayashi, K, 2003)

"Patients with cancer have a substantial risk of recurrent thrombosis despite the use of oral anticoagulant therapy."

( Baker, RI; Bowden, C; Gent, M; Haley, S; Julian, JA; Kakkar, AK; Kovacs, MJ; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2003)

"To test this hypothesis, 13 adult cancer patients were treated with intravenous (i."

( de Jonge, MJ; Gelderblom, H; Loos, WJ; Soepenberg, O; Sparreboom, A; van Boven-van Zomeren, DM; Verweij, J, 2003)

"Patients with advanced cancer who were treated in a Phase I study of OSI-774 underwent a biopsy of normal skin epidermis at baseline and after the last dose of drug in the first course of treatment."

( Bacus, S; Brattain, MG; deGraffenried, L; Hammond, LA; Hidalgo, M; Kreisberg, JI; Malik, SN; Rizzo, J; Rowinsky, EK; Siu, LL, 2003)

"Thirty per cent of cancer patients suffer from anemia before any treatment."

( Auclerc, G; Khayat, D; Meric, JB; Pommeyrol, A; Rixe, O, 2003)

"Unselected PBMC, collected from cancer patients undergoing apheresis prior to high-dose chemotherapy and autologous stem cell rescue, were expanded ex vivo in static cultures, without a stromal layer, in the presence of Flt3 ligand (Flt3L), a recombinant GM-CSF/IL-3 fusion protein (PIXY321), G-CSF and GM-CSF for 10 days."

( Goolsby, C; Guo, M; James, C; Miller, WM; Papoutsakis, ET; Patel, S; Winter, JN, 1999)

"Ten patients with recurrent solid tumors or tumors that were refractory to conventional treatment (two neuroblastomas, three rhabdomyosarcoma, two PNET/Ewing's sarcoma, one anaplastic astrocytoma, one soft tissue sarcoma and one synovial sarcoma) were included."

( Contra, T; Díaz Pérez, MA; Madero López, L; Pérez Martínez, A; Scaglione, C, 2003)

"In most of patients, cancer pain was relieved when they were treated."

( Cai, Z; Cao, J; Lian, Z; Liu, Z; Lü, X; Mu, Y; Ren, Z; Zhao, D; Zhou, W, 2001)

"EBV-based strategies for treating cancer include prevention of viral oncogene expression, inducing loss of the EBV episome, the purposeful induction of the lytic form of EBV infection, and enhancing the host immune response to virally encoded antigens."

( Israel, BF; Kenney, SC, 2003)

"Patients with intractable cancer pain often require non-pharmacological analgesic treatment that is accompanied by procedure-related pain."

( Nakaho, T; Ohara, T; Takahashi, M; Yamamoto, Y; Yamamuro, M, 2003)

"We reviewed the medical records of 118 cancer patients treated between 1999 and 2001 with cyclic chemotherapy plus epoetin alfa in 27 US community-based oncology practices."

( Brinkmannb, K; Fridman, M; Gupta, S; Harris Spiridonidis, C; Tannous, RE, 2003)

"Because survival for patients with oral cancer has not improved over the past 25 years, new approaches for treatment are needed."

( Bekele, BN; Bucana, CD; Doan, DD; Fidler, IJ; Greenberg, JS; Holsinger, FC; Jasser, SA; Myers, JN; Schiff, BA; Swan, EA; Younes, MN, 2003)

"JMAR human oral cancer cells were pretreated for 1 h with PKI166 and then stimulated with epidermal growth factor."

( Bekele, BN; Bucana, CD; Doan, DD; Fidler, IJ; Greenberg, JS; Holsinger, FC; Jasser, SA; Myers, JN; Schiff, BA; Swan, EA; Younes, MN, 2003)

"Patients with solid tumors not amenable to standard forms of treatment were eligible."

( Kamiya, Y; Kondoh, H; Matsumura, Y; Ono, H; Shimada, Y; Shirao, K; Tamura, T; Tanigawara, Y; Yamamoto, N, 2003)

"Chemotherapy treated cancer patients are prone to neutropaenia and life-threatening infections."

( Grozinsky, S; Leibovici, L; Paul, M; Soares-Weiser, K, 2003)

"Eighty-five in-patients with cancer undergoing chemotherapy were randomly divided into 2 groups: Nasea group (group A, n = 43, Nasea, ramosetron hydrochloride was injected intravenously 30 minutes before chemotherapy) and ondansetron group (group B, n = 42, ondamsetron was injected intravenously 30 minutes before chemotherapy)."

( Liu, DW; Liu, YY; Shan, XJ; Xie, XD; Zheng, ZD, 2003)

"Just as cancer chemotherapy began with the use of single agents and evolved into combination therapy, so immunotherapeutic agents have been combined with each other and with chemotherapy."

( Mitchell, MS, 2003)

"Patients with solid tumors (n = 29) treated for the first time with Doxil were evaluated for HSRs and concurrent C activation."

( Alving, CR; Chanan-Khan, A; Liebes, L; Muggia, FM; Rafique, NM; Savay, S; Szebeni, J, 2003)

"Fatigue is a common symptom of older cancer patients treated with antineoplastic medical treatment."

( Balducci, L; Jacobsen, PB; Respini, D; Thors, C; Tralongo, P, 2003)

"Growth of subcutaneous 9L rat tumors transduced ex vivo with TK-GFP gene was prevented when ganciclovir (GCV) treatment was initiated immediately after tumor inoculation."

( Hakkarainen, T; Loimas, S; Parkkinen, J; Pasanen, T; Tenhunen, A; Timonen, P; Wahlfors, J, 2003)

"Clinical trials in cancer patients either receiving or not receiving chemotherapy have demonstrated that darbepoetin alfa is safe and effective in alleviating anemia at dose intervals of once every 1, 2 or 3 weeks, and results suggest that it may achieve greater and more rapid responses than recombinant human erythropoietin in cancer patients."

( Cases, A, 2003)

"The dependence of cancer of the breast and prostate gland upon sex hormones has led to an attack on this problem by way of adrenalectomy with castration or by hypophysectomy when hormone treatment has failed."

( BAILEY, FW, 1956)

"The concept behind cancer treatment has evolved over the past decade from systemic, nonspecific, high-dose chemotherapy to targeted therapy and the introduction of cancer vaccines."

( Abou-Jawde, R; Alemany, C; Choueiri, T; Mekhail, T, 2003)

"The terms cancer, chemotherapy, monoclonal antibodies, targeted treatment, tyrosine kinase, epidermal growth factors, epidermal growth factor receptor, and cancer vaccines were used to search MEDLINE for English-language studies in humans, published between 1966 and March 2003."

( Abou-Jawde, R; Alemany, C; Choueiri, T; Mekhail, T, 2003)

"Targeted treatment and cancer vaccines are novel approaches in the treatment of cancer."

( Abou-Jawde, R; Alemany, C; Choueiri, T; Mekhail, T, 2003)

"Actinomycin D is an anti-cancer drug commonly used in the treatment of paediatric malignancies such as Wilms' tumour, Ewing's sarcoma and rhabdomyosarcoma."

( Boddy, AV; Errington, J; Griffin, MJ; Hale, J; Parry, A; Pearson, AD; Price, L; Sludden, J; Veal, GJ, 2003)

"The experience of treating cancer over the past several decades overwhelmingly demonstrates that the disease continues to evade the vast array of drugs and treatment modalities available in the twenty-first century."

( Ackerstaff, E; Bhujwalla, ZM; Glunde, K, 2003)

"Four cases of cancer patients whose intractable pain was treated by the authors using intrathecal neurolysis are presented."

( Candido, K; Stevens, RA, 2003)

"The same was noted in children with cancer exhibiting severe neoplasia and treated with chemotherapy."

( Solignac, M, 2003)

"Forty-two patients with advanced solid tumors were treated at four dose levels; parallel dose escalations were carried out in chemotherapy-naive and previously treated subjects."

( Doroshow, JH; Frankel, P; Galvin, I; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Longmate, J; Mack, PC; Martel, CL, 2003)

"As many tumors are driven by autocrine or paracrine growth through the type-I insulin-like growth factor receptor, mTOR is potentially an attractive target for molecular-targeted treatment."

( Houghton, PJ; Huang, S, 2004)

"Non-small cell lung cancer (NSCLC), ovarian and breast cancers, especially in advanced stages, are difficult to treat using chemotherapy, and novel treatments are required to improve the outcome for the large numbers of patients who relapse after receiving the most effective first- and second-line treatments currently available."

( Hainsworth, J; Janssens, J; Vergote, I, 2003)

"treatment arm and the breast cancer trial included a 3 mg oral treatment arm."

( Hainsworth, J; Janssens, J; Vergote, I, 2003)

"For colorectal cancer patients with unresectable liver metastases, chronotherapy with l-OHP + 5-FU + FA (folinic acid) has been reported to allow complete surgical resection of liver metastases, resulting in 39-50% 5-year survival."

( Eriguchi, M; Hisa, T; Levi, F; Nonaka, Y; Takeda, Y; Yanagie, H, 2003)

"Patients with advanced solid tumors were treated in an accelerated titration scheme."

( Bulgaru, A; Egorin, M; Goel, S; Harvey, E; Hochster, H; Ivy, P; Leibes, L; Lockwood, G; Mani, S; Muggia, F; Renshaw, G; Wadler, S; Zamboni, W, 2003)

"Anemia commonly occurs in patients with cancer or human immunodeficiency virus (HIV) infection as a result of the disease, its treatment, or both."

( Levine, AM, 2003)

"Research in cancer therapy and the elucidation of molecular pathways activated by fenretinide have also yielded clues about how this agent might be better used in a prevention setting."

( Crowell, J; Higley, H; Malone, W; Perloff, M; Sigman, C, 2003)

"Providing supplemental glutamine during cancer treatment has the potential to abrogate treatment-related toxicity."

( Corey, B; Savarese, DM; Savy, G; Vahdat, L; Wischmeyer, PE, 2003)

"Antiapoptotic activity of NF-kappaB in tumors contributes to acquisition of resistance to chemotherapy."

( Bottero, V; Ikawa, M; Li, Q; Tergaonkar, V; Verma, IM, 2003)

"Children who are treated for malignancy have been shown to have decreased bone mineral density."

( Bath, LF; Crofton, PM; Elmlinger, MW; Evans, AE; Kelnar, CJ; Ranke, MB; Wallace, WH, 2004)

"Delirium is a frequent complication of cancer treatment and is associated with a high incidence of morbidity and mortality."

( Fann, JR; Sullivan, AK, 2003)

"Patients with solid tumors who had either failed or were not amenable to established forms of treatment were eligible for the study."

( Calvert, H; Dittrich, C; Dumez, H; Faber, M; Fumoleau, P; Hanauske, A; Ravic, M; Wanders, J; Yule, M, 2003)

"E7070 has anticancer activity in pretreated patients."

( Calvert, H; Dittrich, C; Dumez, H; Faber, M; Fumoleau, P; Hanauske, A; Ravic, M; Wanders, J; Yule, M, 2003)

"Treatment of cancer cell lines with 1 ng/ml FK228 increased CAR RNA, alpha(v) integrin RNA, and histone H3 acetylation levels, and was associated with a 4-10-fold increase in the number of infected cells expressing the transgene."

( Aikou, T; Bates, S; Fojo, T; Fok, P; Goldsmith, ME; Kitazono, M, 2003)

"AA as therapy for cancer."

( Casciari, JJ; González, MJ; Hunninghake, RB; Jackson, JJ; Meng, X; Miranda-Massari, JR; Mora, EM; Riordan, HD; Riordan, NH; Rivera, A; Rosario, N; Taylor, P, 2003)

"Adults with tumors appropriate for irinotecan therapy and who had abnormal liver or renal function tests or had prior radiation to the pelvis were eligible."

( Budman, D; Byrd, J; Enders Klein, C; Fleming, G; Hohl, R; Hollis, D; Kastrissios, H; Leichman, CG; Marshall, J; Ramirez, J; Ratain, MJ; Rosner, GL; Venook, AP; Villalona, M, 2003)

"In an investigation by the Swedish Cancer Society, an expert group described the present status, critical issues and future aspects and potentials for each of nine major areas of radiation therapy research."

( Carlsson, J; Forssell-Aronsson, E; Glimelius, B, 2002)

"Among patients with Stage I-III cancer treated by radical resection with dissection of at least 10 lymph nodes, 40 patients who suffered recurrence/metastasis within 5 years post-operatively and 94 patients who did not have recurrence within 5 years were randomly selected."

( Inoue, H; Iwasaki, M; Makuuchi, H; Mukai, M; Nakasaki, H; Nishiumi, N; Ogoshi, K; Saito, Y; Sato, S; Tajima, T; Tokuda, Y, 2004)

"Therefore, in cancer patients receiving chemotherapy, the beneficial effects of epoetin alfa could be mediated not only through enhanced erythrocyte production but also via direct effects on the nervous system."

( Weiss, MJ, 2003)

"In an attempt to exploit MSI in cancer therapy, we constructed expression vectors carrying a thymidine kinase/blasticidin deaminase fusion gene downstream from a (C)(12) or an (A)(26) microsatellite and stably transfected these constructs into human cells in which the MMR status could be regulated by doxycycline."

( Cannavó, E; Cejka, P; Hemmerle, C; Jiricny, J; Marra, G; Storchova, Z, 2003)

"Solid tumors with areas of hypoxia are the most aggressive and difficult tumors to treat and are a major reason for treatment failure."

( Powis, G; Welsh, SJ, 2003)

"Breast cancer risk reduction and treatment trials were included."

( Braithwaite, RS; Chlebowski, RT; Col, NF; George, S; Hess, R; Lau, J, 2003)

"In preclinical cancer models, proteasome inhibitors induce apoptosis, have in vivo antitumor efficacy, and sensitize malignant cells and tumors to the proapoptotic effects of conventional chemotherapeutics and radiation therapy."

( Dees, EC; O'Neil, B; Orlowski, RZ; Voorhees, PM, 2003)

"Fifty-four pediatric cancer patients with a total of 100 febrile neutropenic episodes treated at China Medical College Hospital were randomized to receive meropenem or ceftazidime plus amikacin from January 2001 to April 2002."

( Chiu, HH; Hung, KC; Lin, HC; Peng, CT; Tsai, FJ; Tseng, YC; Wang, JH, 2003)

"These include novel tracers for cancer diagnosis and treatment capable of detecting hypoxia and angiogenesis."

( Alavi, A; Kung, JW; Zhuang, H, 2004)

"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors."

( Agrawal, N; Barkoczy, J; Bettegowda, C; Cheong, I; Dang, LH; Frost, P; Greenberger, L; Gurulingappa, H; Huso, D; Khan, S; Kinzler, KW; Loganzo, F; Parmigiani, G; Pettit, GR; Smith, AB; Vogelstein, B; Zhou, S, 2004)

"Inhibition of NHEJ can be exploited in cancer therapy in radio-sensitizing cancer cells."

( Błasiak, J; Pastwa, E, 2003)

"For patients without cancer, rates of therapy switching at 6 months were 10."

( Berger, A; Delea, TE; Goodman, S; Hoffman, DL; Oster, G; Seifeldin, R, 2004)

"Patients without cancer who receive CR oxycodone or transdermal fentanyl are less likely to switch therapy than those receiving CR morphine sulfate."

( Berger, A; Delea, TE; Goodman, S; Hoffman, DL; Oster, G; Seifeldin, R, 2004)

"The kind of malignancy and chemotherapeutic treatment were recorded, as was the date of treatment."

( Inghels, M; Mathijssen, J; Otten, HM; Prins, MH; Richel, DJ; Soesan, M; ten Cate, H, 2004)

"The pathogenesis of cancer anemia is complex and most of the time multifactorial; involving factors related to the tumor itself or its therapy."

( Abdel-Razeq, HN, 2004)

"For most advanced cancers the response rate to chemotherapy is about 50% in first-line treatments and about 15% in second- or third-line treatments; for example response rates of 25-50% have been observed for chemonaive patients with advanced non-small cell lung cancer treated with cisplatin or carboplatin in combination with gemcitabine or taxanes and in exceptional cases these rates are up to 80% with addition of radiotherapy."

( Boulikas, T; Vougiouka, M, 2004)

"Weight-losing untreated cancer patients had elevated resting energy expenditure compared to undernourished non-cancer patients (23."

( Bosaeus, I; Daneryd, P; Hyltander, A; Körner, U; Lundholm, K, 2004)

"Treatment of cancer is increasingly effective but is associated with short and long-term side effects."

( Clarkson, JE; Eden, OB; Worthington, HV, 2004)

"Current trends foretell the use of cancer treatments customized to each patient."

( Arteaga, CL; Roberts, RB; Threadgill, DW, 2004)

"In K1735-M2 and CT-26 tumors, a single treatment with IA-NP-(90)Y (14."

( Bednarski, MD; Choi, HS; Chu, P; Danthi, SN; Dechene, N; Doede, T; Knox, SJ; Lee, DY; Li, L; Ning, S; Pease, J; Shen, Z; Wartchow, CA, 2004)

"In experimental tumors, anti-vascular effects are seen within minutes of drug administration and rapidly lead to extensive ischemic necrosis in areas that are often resistant to conventional anti-cancer treatments."

( Price, P; West, CM, 2004)

"The treated tumors also showed a significant increase in apoptosis as determined by in situ end-labeling, and by poly ADP-ribose polymerase cleavage."

( Chiao, JW; Chung, FL; Conaway, CC; Liu, D; Ramaswamy, G; Wang, L; Wu, H, 2004)

"In 25 cancer patients treated with slow-release oral morphine and in 10 cancer patients treated with continuous infusion of morphine, plasma steady-state concentrations of morphine (M), morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G) were determined by high-performance liquid chromatography."

( Fujioka, H; Hashimoto, T; Izawa, K; Kobayashi, K; Masada, M; Ohashi, K; Tateishi, M; Yamaguchi, J, 2003)

"Solid tumors with disorganized, insufficient blood supply contain hypoxic cells that are resistant to radiotherapy and chemotherapy."

( Cawthorne, CJ; Demonacos, C; Dive, C; Erler, JT; Koritzinsky, M; Miller, C; Stratford, IJ; Williams, KJ; Wilson, C; Wouters, BG, 2004)

"Successful cancer gene therapy depends on the development of non-toxic, efficient, tumor cell- specific systemic gene delivery systems."

( Chang, EH; Ertem, G; Huang, W; Pirollo, KF; Rait, A; Xiang, L; Yu, B; Yu, W; Zhou, Q, 2004)

"The currently available treatment of cancer patients is based on the use of cytotoxic drugs and/or of ionizing radiations, which have potent antitumor activity, but also cause clinically relevant side effects, since they affect cellular targets that are common to both cancer cells and normal proliferating cells."

( Ciardiello, F; Damiano, V; Melisi, D; Tortora, G; Troiani, T, 2004)

"From 2% to 10% of cancer patients treated with 5-fluorouracil (5-FU) will develop symptomatic cardiotoxicity."

( Enderle, MD; Graeven, U; Pahlke, M; Petz, C; Schmiegel, W; Südhoff, T; Teschendorf, C, 2004)

"Therefore, direct targeting of TF in cancer should be considered in combination with other treatment modalities such as oncogene-directed therapies, antiangiogenic agents (e."

( Klement, P; May, L; Rak, J; Weitz, JI; Yu, JL, 2004)

"Patients with advanced or metastatic cancer were treated with once-daily oral BMS-275291 at doses escalating from 600 to 2400 mg/day."

( Conway, D; Daly, DJ; Gupta, E; Humphrey, JS; Hurwitz, H; Johnson, MD; Marshall, J; Ness, EA; Rizvi, NA; Sonnichsen, D; Williams, K, 2004)

"A consecutive sample of 48 cancer patients treated with oral morphine, who reported an acceptable basal analgesia and reported episodic pains, were selected for the study."

( Bianchi, M; Casuccio, A; Ferrera, P; Mercadante, S; Villari, P, 2004)

"The response of solid tumors to antitumor treatment generally declines markedly with treatment time."

( Liang, H; Sha, N, 2004)

"About one third of all cancer develops into a spread disease that is difficult to treat."

( Carlsson, J; Garske, U; Gedda, L; Kairemo, K; Lundqvist, H; Tolmachev, V, 2004)

"The Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire was translated into the Malayalam language complying with the standard cross-cultural translation methodology."

( Nair, MK; Pandey, M; Ramdas, K; Sebastian, P; Thomas, BC, 2004)

"Fifteen subjects with various cancer sites and psychiatric diagnoses were treated with bupropion SR (modal dose 150 mg) for up to 2 years."

( Cullum, JL; Pelletier, G; Simpson, JS; Wojciechowski, AE, 2004)

"administration of anticancer drugs, with continued selenium treatment for 7-21 days, depending on anticancer drugs under evaluation."

( Cao, S; Durrani, FA; Rustum, YM, 2004)

"Sixty-two cancer patients with chemotherapy were enrolled randomly into AB or BA group in cross-over pattern."

( Huang, XL; Li, X; Zhao, QC; Zhu, BD, 2004)

"Likewise in the non-cancer patient group duration of treatment did not influence the metabolite ratios."

( Andersen, G; Christrup, L; Hansen, SH; Jensen, NH; Sjøgren, P, 2004)

"In the cancer patient group neither dose nor treatment period seems to influence morphine glucuronidation."

( Andersen, G; Christrup, L; Hansen, SH; Jensen, NH; Sjøgren, P, 2004)

"Despite many advances in cancer treatment and the integration of supportive medications, including new and better drugs for pain management, antiemesis, infection, and reconstitution of the hematopoietic system, both toxic effects and the development of resistance in response to the treatment remain a major problem."

( Albers, A; Odoux, C, 2004)

"Cohorts of 3-6 pts with refractory cancer were treated with escalating doses of weekly IV bolus VRL (I -20."

( Budd, GT; Bukowski, RM; Elson, P; Ganapathi, R; Hutson, TE; Mekhail, T; Olencki, T, 2004)

"15/26 tumors had a pretreatment median pO(2) < or = 10 mmHg."

( Achermann, RE; Gassmann, M; Inteeworn, N; Kaser-Hotz, B; Ohlerth, SM; Rohrer Bley, C; Roos, M; Schärz, M; Wergin, MC, 2004)

"The efficacy of cancer therapy is compromised by the fact that there are currently no good ways to predict which patients will benefit from treatment."

( Eliason, JF; Megyeri, A, 2004)

"Across five trials of cancer patients on and off chemotherapy, hemoglobin response was associated with meaningful improvements in fatigue, which, in turn, was associated with improved physical, functional, emotional and overall well-being."

( Cella, D; Kallich, J; McDermott, A; Xu, X, 2004)

"After 13 weeks of growth, tumors in mevalonate-treated mice were significantly larger than tumors in saline-treated, control mice (1."

( Archer, MC; Duncan, RE; El-Sohemy, A, 2004)

"The anticancer efficacy of radiotherapy is, however, largely limited by its lack of tumor specificity and, consequently, normal tissue toxicity."

( Chen, AY; Chou, R; Gandara, D; Lau, D; Shih, SJ, 2004)

"25 outpatients with various advanced tumors who were refractory to standard therapies (23 subjects) or had refused, in whole or in part, conventional therapies (2 subjects) were treated with CRM197 injected subcutaneously in the abdominal wall, on alternate days, for 6 days."

( Buzzi, AM; Buzzi, G; Buzzi, S; Morisi, C; Pironi, F; Rubboli, D, 2004)

"We treated low-risk febrile neutropenic cancer patients utilizing two standard outpatient antibiotic pathways: oral ampicillin/clavulanate (500 mg) and ciprofloxacin (500 mg) or intravenous ceftazidime (2 g) and clindamycin (600 mg) every 8 h."

( Badrina, N; Benjamin, R; DeJesus, Y; Escalante, CP; Fernandez, S; Ho, V; Lam, T; Lee, EL; Manzullo, E; Rivera, E; Rolston, K; Valdres, R; Weiser, MA, 2004)

"Compared with other anti-cancer drugs, PX-478 had markedly improved regression, growth delay and log10 cell kill profiles, particularly against large tumors that are normally refractory to small molecule drug therapy."

( Figg, WD; Macpherson, GR, 2004)

"Patients with refractory solid tumors and performance status < or = 2 were treated with intravenous paclitaxel 50-110 mg/m(2) (Day 1), oral topotecan 0."

( Catapano, CV; Freeman, KD; Green, MR; Mushtaq, C; Oakhill, G; Pacheco, D; Rocha Lima, CM; Sherman, CA, 2004)

"In the case of cancer pain in particular, adequate therapy is a must."

( Thoma, R; Winter, E, 2004)

"The cardiotoxicity of anticancer agents can lead to significant complications that can affect patients being treated for various malignancies."

( Champion, C; Durand, JB; Ewer, MS; Gibbs, H; Lenihan, DJ; Swafford, J; Tong, AT; Yeh, ET; Yusuf, SW; Zafarmand, AA, 2004)

"We examined the rates of malignancy at 2 yr after transplantation in renal allograft patients receiving sirolimus (SRL) in continuous combination with cyclosporine (CsA), SRL as base therapy or SRL maintenance therapy after early withdrawal of CsA."

( Friend, P; Kreis, H; Mathew, T, 2004)

"Mice bearing 8-mm tumors were treated with C225 antibody at a dose of 1 mg given i."

( Ang, KK; Fan, Z; Hunter, N; Mason, K; Milas, L; Nakata, E, 2004)

"Patients with incurable solid tumors that expressed the target antigen for cantuzumab mertansine, CanAg, were treated with doses of cantuzumab mertansine ranging from 40 to 138 mg/m(2)."

( DeWitte, M; Erickson, J; Helft, PR; Hoke, FJ; Howard, M; Kindler, HL; Lambert, JM; Martino, HK; Pandite, L; Ratain, MJ; Russo, M; Schilsky, RL; Sprague, E; Williams, D, 2004)

"Forty-eight cancer patients treated with cisplatin-based chemotherapy were randomised in a double-blind manner to receive either supplementation with vitamin C, vitamin E and selenium dissolved in a beverage or to receive a placebo beverage."

( Cleton, FJ; Elsendoorn, TJ; Hopman, GD; Lentjes, EG; Osanto, S; Weijl, NI; Wipkink-Bakker, A; Zwinderman, AH, 2004)

"The successful treatment of cancer by boron neutron-capture therapy (BNCT) requires the selective delivery of relatively high concentration of 10B compounds to malignant tumor tissue."

( Chiba, M; Eriguchi, M; Ishida, O; Kasaoka, S; Kobayashi, H; Maruyama, K; Shinohara, A; Takizawa, T; Utoguchi, N; Yanagie, H, 2004)

"To determine the occurrence of cancer-related fatigue, the methods used to assess it, and the efficacy of the available treatments, we performed literature searches that identified English-language publications on these topics."

( Devine, D; Kupelnick, B; Lau, J; Lawrence, DP; Miller, K, 2004)

"Anaemia associated with cancer and cancer therapy is an important clinical factor in the treatment of malignant diseases."

( Bennet, C; Bohlius, J; Engert, A; Langensiepen, S; Piper, M; Schwarzer, G; Seidenfeld, J, 2004)

"However, a prospective evaluation of cancer patients treated with gemcitabine-based chemotherapy without neoplastic involvement of the thorax and without administration of radiotherapy has not been performed."

( Dafni, U; Dimopoulos, MA; Dimopoulou, I; Efstathiou, E; Kastritis, E; Lyberopoulos, P; Moulopoulos, LA; Papadimitriou, C; Roussos, C; Samakovli, A, 2004)

"Eligible patients with tumors accessible for core needle biopsy were treated with SU6668 at doses of 200 or 400 mg/m(2)/day."

( Abbruzzese, JL; Charnsangavej, CA; Davis, D; Faria, SC; Herbst, R; Hess, K; Hicks, M; Jackson, EF; Madden, T; McConkey, D; Scholz, C; Xiong, HQ, 2004)

"The role of ROS in cancer treatments and in the development of resistance to chemotherapy is now better understood."

( Renschler, MF, 2004)

"To address its potential in cancer treatment, we will also discuss the regulatory mechanisms of UPase gene expression and its induction in tumor tissues."

( Cao, D; Pizzorno, G, 2004)

"Patients with cancer-related anemia have an inadequate EPO response that is further impaired by cancer treatments such as chemotherapy."

( Bajetta, E; Bidoli, P; Buzzoni, R; De Candis, D; De Dosso, S; Del Vecchio, M; Ferrari, L; Ferrario, E, 2004)

"The most recent attempts at improving cancer treatment have taken the pharmacogenetic approach of identifying biochemical response determinants for response, so that patients with suboptimal determinants who unlikely to respond can be identified prior to treatment."

( Danenberg, PV, 2004)

"Epo therapy in anemic cancer patients is still a controversial issue, because of its possible action as a growth and an angiogenic factor."

( Buemi, M; Caccamo, C; Cavallaro, E; Floccari, F; Grasso, G; Nostro, L, 2005)

"The European Cancer Anaemia Survey (ECAS) was conducted to prospectively evaluate the prevalence, incidence and treatment of anaemia (haemoglobin <12."

( Barrett-Lee, P; Birgegård, G; Bokemeyer, C; Gascón, P; Kosmidis, P; Krzakowski, M; Ludwig, H; Nortier, J; Olmi, P; Schneider, M; Schrijvers, D; Van Belle, S, 2004)

"The continuous supplementation of anticancer therapies with the medical nutriment MSC helps to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers."

( Babosa, M; Borgulya, G; Fekete, G; Garami, M; Hauser, P; Hidvégi, M; Müller, J; Paksy, A; Schuler, D; Szabó, E, 2004)

"Targeted chemotherapy for cancer treatment offers a great potential advantage in tumour treatment due to greater specificity of delivery which leads to increased dose of the cytotoxin delivered to the tumour relative to the rest of the body."

( McEwan, J; McTavish, K; Nowotnik, D; Rice, J; Russell-Jones, G, 2004)

"Anemia in cancer patients is associated with reduced quality of life and local failure after radiation treatment."

( Henke, M; Pajonk, F; Sommer, A; Suwinski, R; Weil, A, 2004)

"The treatment of solid tumors by retroviral delivery of the herpes simplex virus thymidine kinase (TK) followed by ganciclovir (GCV) treatment has so far shown only limited success in patients."

( Caruso, M; de Campos-Lima, P; Qiao, J; Roy, V, 2005)

"We also examined apoptosis of cells in tumors at different time points after LTSL-DOX plus hyperthermia treatment and observed few apoptotic cells in tumor microvessels."

( Chen, Q; Dewhirst, MW; Tong, S; Yuan, F, 2004)

"Only two studies, one in breast cancer and the other in head and neck cancer, both of which used epoetin outside its approved indications, have observed a decrease in survival in epoetin-treated patients compared with controls."

( Dunst, J; Glaspy, J, 2004)

"The BReast cancer-Anaemia and the Value of Erythropoietin (BRAVE) trial is such a study, assessing the impact of epoetin beta on survival and QoL of patients with metastatic breast cancer scheduled to receive anthracycline- and/or taxane-based chemotherapy."

( Aapro, M; San Miguel, J, 2004)

"Patients with resistant cancers were treated with Doxil 50 mg/m2 every four weeks, and with VNB 15 mg/m2 on the same day."

( Jones, JJ; Laufman, LR; Rhodes, V; Rossi, K; Spiridonidis, CH; Wallace, K, 2004)

"All patients had advanced cancer refractory to standard treatment, performance status 0-2 and were without major organ dysfunction."

( Cole, C; Greystoke, A; Harries, M; Judson, I; Kaye, S; O'Donnell, A; Reade, S; Scurr, M; Twelves, C, 2004)

"For many years, the search for cancer therapy targets focused on the genetic changes associated with the transformation of normal cells into malignant cells."

( Bradbury, J, 2004)

"We screened 207 cancer pain patients on oral morphine treatment for four frequent OPRM1 gene polymorphisms."

( Baar, C; Borchgrevink, PC; Dale, O; Holthe, M; Kaasa, S; Klepstad, P; Krokan, HE; Rakvåg, TT; Skorpen, F; Vikan, T, 2004)

"In the design of ASOs for anticancer therapeutics in particular, the goal is often to enhance the cytotoxicity of traditional drugs toward cancer cells or to reduce the toxicity to normal cells to improve the therapeutic index of existing clinically relevant cancer chemotherapy drugs."

( Berg, RW; Jason, TL; Koropatnick, J, 2004)

"Patients with moderate-to-severe malignancy-related pain require opioid pharmacotherapy."

( Skaer, TL, 2004)

"Adults with moderate to severe cancer pain were stabilized for > or =3 days on morphine CR or oxycodone CR, and then treated for 7 days at their stabilized dose."

( Ahdieh, H; Slatkin, N; Sloan, P, 2005)

"Gastrointestinal stromal tumors (GISTs) express KIT and respond favorably to imatinib therapy."

( Bundi, M; Dimitrijevic, S; Dirnhofer, S; Kononen, J; Lugli, A; Mangialaio, S; Mirlacher, M; Sauter, G; Schraml, P; Simon, R; Went, PT, 2004)

"The nutritional status of 91 cancer patients was assessed at the time of diagnosis and follow-up assessments were carried out at the third and sixth week after initiating different treatment modalities to study the effect of type and duration of treatment on nutritional status."

( Prakash, J; Roy, RK; Usharani, K, 2004)

"The Cancer Profiling Arrays and the Cancer Cell Line Profiling Array demonstrated that MGC4175 is broadly expressed in various tissues with no significant difference of MGC4175 expression between chemotherapy naive tumor cells and normal cells."

( Brakora, KA; Duan, Z; Seiden, MV, 2004)

"Non-small-cell lung cancer cell lines were also evaluated for changes in proliferation and cyclin protein expression after erlotinib treatments."

( Biddle, A; Davis, TH; Desai, NB; Dmitrovsky, E; Dragnev, KH; Hamilton, M; Iwata, KK; Ma, Y; Memoli, N; Memoli, VA; Nugent, WC; Petty, WJ; Rigas, JR, 2004)

"In a mouse model bearing prostate cancer in which the cells were inoculated under the skin, B717/LIC-101 was administered subcutaneously around the tumor."

( Hirabayashi, K; Irimura, T; Ishiyama, K; Kashimori, I; Kitagawa, H; Naito, H; Nakagawa, S; Nogawa, M; Ohgi, T; Yamaguchi, T; Yano, J, 2004)

"Tumour hypoxia is a negative factor in cancer radiotherapy."

( Ito, M; Ogino, H; Shibamoto, Y; Sugie, C, 2004)

"This knowledge may lead to its use in cancer therapy."

( Lacy, A; O'Kennedy, R, 2004)

"Recent advances in cancer therapy have resulted in the development of drugs that target mechanisms involved in neoplastic change and angiogenesis."

( Von Pawel, J, 2004)

"Targeted cancer therapy is a promising strategy for the treatment of this disease."

( Raisch, KP; Safavy, A, 2005)

"Used to treat anemia of cancer, chemotherapy, and kidney disease, it has a three-fold longer serum half-life and increased in vivo activity, but decreased receptor-binding activity."

( Browne, J; Busse, L; Egrie, J; Elliott, S; Lorenzini, T; Ponting, I; Rogers, N, 2004)

"The management of cancer pain requires familiarity with a range of therapeutic strategies, including antineoplastic therapies, analgesic pharmacotherapy, and anesthetic, neurosurgical, psychological, and rehabilitation techniques."

( Cherny, NI, 2004)

"Virtually every modality used to treat cancer may cause fatigue, as can complications of the disease such as sleep disturbances, infections, malnutrition, hypothyroidism, and anemia."

( Lawrence, DP; Lipman, AJ, 2004)

"Molecular targeting strategies for cancer therapy are distinct from conventional chemotherapy and radiotherapy in their potential to provide increased tumor specificity."

( Harari, PM, 2004)

"Sixty-six patients with cancer-related pain entered an open multicentre study to examine the safety and efficacy of oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain."

( Busch, MA; Hanks, GW; Higgs, CM; Nugent, M, 2004)

"Intestinal dysfunction is frequent in cancer and during anti-cancer treatment."

( Andreassen, BU; Hartmann, B; Heilman, C; Holst, JJ; Michaelsen, KF; Paerregaard, A; Rechnitzer, C; Schmiegelow, K, 2005)

"In children treated with anti-cancer therapy, GLP-2 secretion seems to be normal if the enteral energy intake is sufficient."

( Andreassen, BU; Hartmann, B; Heilman, C; Holst, JJ; Michaelsen, KF; Paerregaard, A; Rechnitzer, C; Schmiegelow, K, 2005)

"Patients with advanced solid tumors who had received two or fewer prior chemotherapy regimens were eligible for trial."

( Cunningham, C; Grove, W; Kraker, A; Nemunaitis, J; Olivares, J; Olson, S; Pauer, LR; Williams, A, 2004)

"Electrochemotherapy (ECT) is a novel cancer treatment in which electric pulses (EPs) inducing cell membrane pored (electroporation) are used as a means of delivering antitumor drugs to the cytoplasm of cancer cells."

( Wang, Z; Yang, K; Yue, B, 2004)

"Its broad expression in tumors coupled with its role in resistance to chemotherapy-induced apoptosis make bcl-2 a rational target for anticancer therapy."

( Piro, LD, 2004)

"This review describes the candidate tumors eligible for such radiotherapy on the basis of their peptide receptor content and discusses factors in PRRT eligibility."

( Krenning, EP; Mäcke, HR; Reubi, JC, 2005)

"Although the vast majority of cancer patients obtain satisfactory pain relief from individualized systemic treatment, there remain the few whose pain is refractory to systemic treatments."

( Ballantyne, JC; Carwood, CM, 2005)

"NSAIDs are widely applied to treat cancer pain and are frequently combined with opioids in combination preparations for this purpose."

( Carr, DB; Goudas, L; Lau, J; McNicol, E; Strassels, SA, 2005)

"In most cancer patients pain can be successfully treated with pharmacological measures using opioid analgesics alone or in combination with adjuvant analgesics (coanalgesics)."

( Leppert, W; Łuczak, J, 2005)

"Mice cured of their tumors by combined CpG oligodeoxynucleotide 1826 plus radiotherapy were highly resistant to s."

( Ariga, H; Hunter, N; Krieg, AM; Mason, KA; Milas, L; Neal, R; Valdecanas, D; Whisnant, JK, 2005)

"Contemporary treatment of cancer (intensive chemotherapy, radiotherapy, radical surgery, stem cell transplantation) and severe non-neoplastic blood diseases resulted in significant improvement of treatment results."

( Balwierz, W, 2004)

"Colon cancer survival has improved with the addition of oxaliplatin to its treatment."

( Fojo, T; Muggia, FM, 2004)

"Seventy patients with advanced cancer and refractory emesis were treated with subcutaneous boluses of levomepromazine (median daily dose: 6."

( De Simone, GG; Eisenchlas, JH; Garrigue, N; Junin, M, 2005)

"There is a clear need in cancer treatment for a noninvasive imaging assay that evaluates the oxygenation status and heterogeneity of hypoxia and angiogenesis in individual patients."

( Krohn, KA; Rajendran, JG, 2005)

"In patients with metastatic cancer, no difference in mortality between the treatment groups was observed (72% and 69%, respectively; hazard ratio, 1."

( Baker, RI; Bowden, C; Gent, M; Julian, JA; Kakkar, AK; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2005)

"Patients with advanced malignancy were entered at different treatment levels according to symptom severity."

( A'Hern, R; Hardy, J; Kennett, A; Shah, S, 2005)

"GSE treated cancer cells exhibited apoptotic features as readily illustrated by morphological investigation, DNA fragmentation analysis and TUNEL labelling methods."

( Chan, AS; Cheng, CH; Cheng, GY; Cheung, F; Chui, CH; Kok, SH; Lai, KB; Lau, FY; Tang, JC; Teo, IT; Wong, RS; Yau, MY; Yeung, TT, 2005)

"Radioimmunotherapy of hematopoeitic cancers and micrometastases has been shown to have significant therapeutic benefit."

( Bao, A; Goins, B; Hevezi, JM; Otto, RA; Phillips, WT; Woolley, FR; Zhao, X, 2005)

"For the therapy of solid tumors, co-administration of angiotensin II (AngII) results in an increased uptake of drugs into the tumor interstitium."

( Agrawal, DK; Baranowska-Kortylewicz, J; Batra, SK; Chauhan, SC; Colcher, D; Goel, A; Jain, M; Kurizaki, T; Wittel, UA, 2005)

"Children with cancer often develop febrile illnesses after cytotoxic chemotherapy."

( Becker, KL; Bell, MJ; Dalton, H; Lawlor, C; Nylen, ES; Snider, RH; Stryjewski, GR; Wu, A, 2005)

"Fifteen chemotherapy- naive cancer patients were enrolled in Group A."

( Arslan, M; Demiray, M; Ercan, I; Evrensel, T; Kanat, O; Kurt, E; Manavoglu, O; Ozkan, A, 2005)

"Sixteen patients with solid tumors received 40 cycles of therapy at CA4P doses of 27 and 36 mg/m(2) together with carboplatin at area under the concentration-time curve (AUC) values of 4 and 5 mg min/mL."

( Bilenker, JH; Davis, L; Flaherty, KT; Gallagher, M; Giantonio, B; O'Dwyer, PJ; Rosen, M; Schnall, M; Stevenson, JP; Sun, W; Vaughn, D; Zimmer, R, 2005)

"We hypothesized that some tumors treated with multiple cytotoxic therapies may become more dependent on the HER1/EGFR signaling pathways for survival."

( Dai, Q; Iwata, KK; Kroog, G; Lia, M; Ling, YH; Perez-Soler, R; Zou, YY, 2005)

"For relief from cancer pain, we developed critical pathway (CP) as an effective strategy for the medical staff treating cancer patients."

( Hori, N; Konishi, T, 2005)

"For example, the assessment sheet of cancer pain is useful for treatment of pain and to equally recognize the patient's condition by each team."

( Hashizume, T, 2005)

"Eligible patients had solid tumors for which treatment with carboplatin/paclitaxel was appropriate."

( Arezzo, J; Bartley, P; Chia, M; Daly, M; Davis, ID; Green, M; Harrison, L; Kiers, L; MacGregor, L; Michael, M; Quinn, M; Rosenthal, M, 2005)

"The small cell lung cancer and fibrosarcoma cell lines pretreated with 5 microM ZOL showed a marked increase in sensitivity to lysis by gammadeltaT cells."

( Kimura, S; Kiyono, Y; Kuroda, J; Maekawa, T; Matsumoto, S; Nogawa, M; Sato, K; Segawa, H; Wada, H; Yokota, A; Yuasa, T, 2005)

"In metastatic breast cancer patients who had received prior treatment with an anthracycline-based regimen, a Phase III trial comparing the combination of capecitabine with docetaxel versus docetaxel alone demonstrated superior objective tumor RR (42% vs 30%, P = 0."

( Lindley, C; Walko, CM, 2005)

"Anemia is a common complication of cancer or anticancer therapy, with a significant negative impact on the functional status of patients and their quality of life (QOL)."

( Demetri, GD; Desai, J, 2005)

"Anemia resulting from cancer or chemotherapy is a common problem in oncology, and has been shown similarly to increase transfusion risk and decrease patient reported outcomes."

( Glaspy, J, 2005)

"Cancer and cancer therapy-associated anemia may have an impact on tumor response and overall survival."

( Bennett, CL; Bohlius, JF; Engert, A; Langensiepen, S; Schwarzer, G, 2005)

"In these primary brain tumors changes in urinary DiAcSpm were well correlated with the efficacy of treatments, recurrence of disease and increased malignancy of a tumor."

( Hiramatsu, K; Kariyone, K; Kawaguchi, M; Kawakita, M; Mori, T; Sasaki, Y; Shinoura, N; Takahashi, K; Tamamori, Y; Tanaka, T; Yamada, R, 2005)

"Most treatments for such cancer involve chemotherapy to induce the apoptotic process."

( Cotter, FE, 2004)

"Despite significant progress in cancer therapy, the outcome of the treatment is often unfavorable."

( Barczyk, K; Berdel, WE; Booy, EP; Ghavami, S; Kreuter, M; Los, M; Maddika, S; Pryjma, J; Roth, J, 2005)

"Combined treatment with BetA and anticancer drugs acted in concert to induce loss of mitochondrial membrane potential and the release of cytochrome c and Smac from mitochondria, resulting in activation of caspases and apoptosis."

( Debatin, KM; Fulda, S, 2005)

"Adult patients with advanced solid tumors were treated with docetaxel followed by irinotecan."

( Beringer, P; Garcia, AA; Iqbal, S; Jeffers, S; Lenz, HJ; Louie, S; Pujari, M, 2005)

"Anemia associated with cancer and cancer therapy is an important clinical and economic factor in the treatment of malignant diseases."

( Bennett, C; Bohlius, J; Engert, A; Langensiepen, S; Piper, M; Schwarzer, G; Seidenfeld, J, 2005)

"Certain types of pain associated with cancer may be difficult to treat with standard therapies, often resulting in intractable pain and suffering for the patient."

( Dunteman, ED, 2005)

"Six Japanese cancer patients treated with gemcitabine plus cisplatin were examined."

( Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kikura-Hanajiri, R; Kim, SR; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yamamoto, N; Yonemori, K; Yoshida, T, 2005)

"Following treatment of breast cancer patients with oral gefitinib (Iressa) 250 mg/d for > or = 14 days, gefitinib concentrations (mean, 7."

( Barnett, S; Bichat, F; Giles, PB; Guilbaud, N; Kemp, JV; Kendrew, J; McKillop, D; Partridge, EA; Patterson, AB; Spence, MP; Stephens, TC; Wood, PG, 2005)

"Urogenital cancer cell lines, SKRC, T24 and DU145, were treated with various concentrations of sodium nitroprusside (SNP), a NO donor."

( Kondo, H; Kuniyasu, H; Ohmori, H; Sasaki, T; Yoshida, K, 2005)

"Ten patients with neuropathic cancer pain, not responding to conventional opioid therapy, were treated with continuous intrathecal administration of meperidine."

( Kruis, MR; van der Vegt, MH; van Kan, HJ; Vranken, JH, 2005)

"However, in certain instances, tumors previously known to be resistant to specific single chemotherapeutic agents were shown to respond by the addition of NHS76/PEP(2) pretreatment."

( Epstein, AL; Hu, P; Khawli, LA, 2005)

"Sixty patients with cancer scheduled to receive moderately/highly emetogenic chemotherapy were pretreated 1 h before with 0."

( del Giglio, A; Moreno, J; Sahade, M, 2005)

"The ability to optimize treatments for cancer on the basis of relative risks for normal tissue injury has important implications in oncology, because higher doses of radiation might, in some diseases, improve both local control and survival."

( Anscher, MS; Brizel, DM; Chen, L; Dewhirst, MW; Folz, RJ; Huang, H; Kang, S; Larrier, N; Rabbani, Z; Samulski, TV; Vujaskovic, Z, 2005)

"Patients with advanced solid tumors or lymphoma were treated with MS-275 orally initially on a once daily x 28 every 6 weeks (daily) and later on once every-14-days (q14-day) schedules."

( Acharya, M; Chung, EJ; Elsayed, Y; Figg, WD; Headlee, D; Hwang, K; Kalnitskiy, M; Melillo, G; Monga, M; Murgo, A; Ryan, QC; Sausville, EA; Sparreboom, A; Trepel, JB; Ye, J; Zwiebel, J, 2005)

"However, cancer survivors are faced with the serious long-term effects of the different modalities of cancer treatments."

( Barton, DL; Loprinzi, CL; Molina, JR, 2005)

"The European Cancer Anaemia Survey (ECAS) has provided the most current, comprehensive, prospectively collected data on the incidence and prevalence of anemia among cancer patients, as well as important perspectives on anemia treatment and relationship of hemoglobin and performance status."

( Aapro, MS; Birgegård, G; Bokemeyer, C; Dicato, M; Drings, P; Hornedo, J; Krzakowski, M; Ludwig, H; Pecorelli, S; Schmoll, H; Schneider, M; Schrijvers, D; Shasha, D; Van Belle, S, 2005)

"This selective toxicity for cancer cells is the basis for the current enthusiasm for Apo2L/TRAIL as a potential novel anticancer therapy."

( Murphy, WJ; Sayers, TJ, 2006)

"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS)."

( Clarke, SJ; Li, KM; Rivory, LP, 2005)

"Metastasized cancer cells were isolated from the pleural fluids (n = 20) or ascites (n = 15) of patients, most of whom were refractory to chemotherapy."

( Duivenvoorden, W; Matthews, D; Richard, C; Th'ng, JP; Wright, PS; Yau, J, 2005)

"HCT116 human colon cancer cells and T47D human breast cancer cells were incubated with or without dimethyl fumarate or sulforaphane followed by mitomycin C or RH1 treatment, and cytotoxic activity was measured by a clonogenic (HCT116) or MTT assay (T47D)."

( Begleiter, A; Digby, T; Leith, MK; Thliveris, JA, 2005)

"Thirty patients with metastatic cancer were intravenously administered 500 mg/m2 HA in combination with escalating doses of DOX (30-60 mg/m2) or 5-FU (cumulative dose of 1,350-2,250 mg/m2 per cycle)."

( Brown, TJ; Ellis, A; Fox, RM; Gibbs, P; Heldin, P; Li, L; Rosenthal, MA; Uren, S; Wong, S, 2005)

"Chemoprevention is a promising anti-cancer approach with reduced secondary effects in comparison to classical chemotherapy."

( Blasius, R; Delhalle, S; Dicato, M; Diederich, M; Duvoix, A; Henry, E; Morceau, F; Schnekenburger, M, 2005)

"A histologic analysis of Calu-6 lung tumors treated with AZD2171 revealed a reduction in microvessel density within 52 hours that became progressively greater with the duration of treatment."

( Barnett, S; Barry, ST; Beck, S; Bigley, AL; Boffey, SJ; Brave, SR; Chester, R; Cooper, L; Curwen, JO; Dukes, M; Hennequin, LF; Jackson, JA; James, NH; Jürgensmeier, JM; Kendrew, J; Kilburn, LL; Ogilvie, DJ; Richmond, GH; Smith, NR; Taylor, ST; Valentine, PJ; Wadsworth, PF; Walker, M; Wedge, SR, 2005)

"Adult patients with tumors refractory to standard treatments received once-daily oral ZD6474 (50-600 mg) in 28-day cycles, until disease progression or unacceptable toxicity was observed."

( Barge, A; Basser, R; de Boer, R; Eckhardt, SG; Green, M; Holden, SN; Hurwitz, HI; Rischin, D; Rosenthal, MA; Wheeler, C, 2005)

"Most solid tumors contain hypoxic cells, and the amount of tumor hypoxia has been shown to have a negative impact on the outcome of radiotherapy."

( Begg, AC; Bussink, J; Kaanders, JH; Ljungkvist, AS; Raleigh, JA; Rijken, PF; van der Kogel, AJ, 2005)

"A variety of tumors developed in all groups, including the controls, but all were histologically similar to those known to occur spontaneously in F344 rats, and no statistically significant increase in the incidence of any type of neoplastic lesion was found for either sex in the treated groups."

( Hirose, M; Imazawa, T; Kanki, K; Kitamura, Y; Kuroiwa, Y; Nishikawa, A; Umemura, T, 2005)

"174 patients with cancer, who had undergone treatment within the last six months, answered the questionnaires and the Brief Version Zung Self-Rating Depression Scale (BZSDS)."

( Bhatia, S; Einhorn, LH; Hanna, A; Hanna, N; Juliar, BE; Monahan, P; Shafqat, A; Sledge, GW, 2005)

"We genotyped 207 Caucasian cancer patients on morphine treatment with respect to the Val158Met polymorphism and compared the morphine doses, serum concentrations of morphine and morphine metabolites between the genotype groups."

( Baar, C; Dale, O; Kaasa, S; Klepstad, P; Krokan, HE; Kvam, TM; Rakvåg, TT; Skorpen, F, 2005)

"Currently, the treatment of cancer has limitations and most cancer deaths result from the local invasion and distant metastasis of tumour cells."

( Hu, XF; Xing, PX, 2005)

"However, use of the NOS II gene in cancer therapy is problematic because of the double-edged nature of NO action."

( Huang, S; Lancaster, JR; Le, X; Wei, D; Xie, K, 2005)

"All patients with cancer should be evaluated for fatigue, and treatment options should be considered for those who are experiencing excessive levels of fatigue."

( Hickok, JT; Morrow, GR; Mustian, K; Roscoe, JA; Shelke, AR, 2005)

"Anaemia effects up to 90% of cancer patients, with more than 60% requiring blood transfusion during or after treatment."

( Engert, A, 2005)

"Fatigue can be a major problem for cancer patients receiving chemotherapy, and anaemia is known to be an important contributory factor."

( , 2005)

"Epidemiological cancer incidence (Statistic Austria 1999) were correlated with the number of patients receiving conventional radiotherapy."

( Auberger, T; Eiter, H; Hammer, J; Hawliczek, R; Hirn, B; Jäger, R; Knocke-Abulesz, TH; Krugmann, K; Lukas, P; Mayer, R; Mock, U; Nechville, E; Pakisch, B; Papauschek, M; Pötter, R; Raunik, W; Rhomberg, W; Sabitzer, H; Schratter-Sehn, A; Sedlmayer, F; Vutuc, C; Wedrich, I, 2004)

"Even for other types of tumors including prostate cancer, bone/soft tissue sarcoma and head/neck tumors, it was equally possible to apply the therapy in much shorter treatment times as compared to conventional RT regimen."

( Baba, M; Ezawa, H; Hasegawa, A; Kamada, T; Kandatsu, S; Kato, H; Kato, S; Kishimoto, R; Miyamoto, T; Mizoe, JE; Ohno, T; Sugawara, T; Tsuji, H; Tsujii, H; Yamada, S; Yanagi, T; Yasuda, S; Yoshikawa, K, 2004)

"Successful cancer patient survival and local tumor control from hadron radiotherapy warrant a discussion of potential secondary late effects from the radiation."

( Blakely, EA; Chang, PY, 2004)

"Patients with solid tumors received one of three escalating dose levels of daily celecoxib in combination with docetaxel and irinotecan administered on days 1 and 8 of an every 21-day cycle."

( Adjei, AA; Croghan, GC; Dy, GK; Furth, A; Hanson, LJ; Mandrekar, S; Okuno, SH; Peethambaram, PP, 2005)

"Studies of human tumors show that cells adapt to chemotherapy, but it has been largely assumed that clonal selection leads to the resistance of recurrent tumors."

( Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C, 2005)

"Thirty-six patients with advanced solid tumors were treated with various doses of AG-013736."

( Ashton, EA; Charnsangavej, C; Evelhoch, JL; Herbst, RS; Jackson, E; Kelcz, F; Lee, FT; Liu, G; McShane, TM; Ng, C; Park, JW; Pithavala, YK; Reich, SD; Rugo, HS; Steinfeldt, HM; Wilding, G; Yeh, BM, 2005)

"for the treatment of metastatic breast cancer (pegylated and non-pegylated liposomal doxorubicin) or AIDS-related Kaposi's sarcoma (pegylated liposomal doxorubicin and liposomal daunorubicin)."

( Beyer, U; Gnad-Vogt, SU; Hochhaus, A; Hofheinz, RD, 2005)

"The therapy of brain tumors has been limited by a lack of effective methods of drug delivery to the brain."

( Lesniak, MS, 2005)

"Four patients with advanced/metastatic cancer completed the study, receiving a single oral dose of 20 mg warfarin before the start of standard capecitabine treatment (day 1), and again during the third cycle of capecitabine (day 61)."

( Abt, M; Camidge, R; Cassidy, J; Grange, S; Jodrell, D; Reigner, B; Weidekamm, E, 2005)

"Around 3-5 million cancer patients receive radiotherapy worldwide every year."

( Bansal, M; Mohanti, BK, 2005)

"In head-and-neck cancer, the value of FDG-PET for radiation treatment planning is still under investigation."

( Grosu, AL; Jeremic, B; Molls, M; Picchio, M; Piert, M; Schratzenstaller, U; Schwaiger, M; Weber, WA; Zimmermann, FB, 2005)

"All 10 tumors with no VEGF were completely responsive (T(0)) to radiotherapy; 85% of those with VEGF and negative for Bcl-2 were responsive to therapy."

( Compton, CC; Nigam, N; Steele, R; Zlobec, I, 2005)

"However, in patients with "anemia of cancer" not being treated with chemotherapy, rhEPO appears less effective."

( Ganser, A; Heuser, M, 2006)

"Adenoviral vectors are widely used in cancer gene therapy."

( Curiel, DT; Gommans, WM; Haisma, HJ; Harmsen, MC; McLaughlin, PM; Rots, MG; van Eert, SJ; Yamamoto, M, 2006)

"Finally, leptin as a target for cancer treatment and prevention will be discussed."

( Garofalo, C; Surmacz, E, 2006)

"Seventeen patients with advanced solid tumors were treated with a median of two prior chemotherapy regimens."

( Azzoli, CG; Fury, MG; Kemeny, N; Kris, MG; Krug, LM; Rizvi, NA; Sharma, S; Wu, N, 2006)

"Records of 125 consecutive adult cancer patients (42 epoetin alpha, 40 epoetin beta, 43 darbepoetin alpha) receiving chemotherapy and erythropoietic treatment for anaemia, and treated between September 2003 and February 2004, were analysed."

( Hayward, C; Pujade-Lauraine, E; Richard, AJ; Sapède, C, 2005)

"PBL were obtained from 25 cancer patients (pre- and post-chemotherapy) and from 10 healthy persons, cultured and exposed to doxorubicin or cisplatin."

( Ciocca, DR; Drago, G; Ibarra, J; Nadin, SB; Vargas-Roig, LM, 2006)

"To translate this process to human cancer therapy, we conducted a phase I trial of administration of a tissue plasminogen activator (tPA) with a free sulfhydryl donor (mesna)."

( Cundiff, DL; Doll, JA; Jiang, K; Kuzel, TM; Martone, B; Rademaker, AW; Soff, GA; Wang, H, 2005)

"Fifteen patients with advanced solid tumors were treated."

( Cundiff, DL; Doll, JA; Jiang, K; Kuzel, TM; Martone, B; Rademaker, AW; Soff, GA; Wang, H, 2005)

"In the GEN-treated mice, tumors initially regressed significantly by 64% but regression ceased following prolonged treatment, resulting in final tumors that were significantly larger compared to negative control, ENL-, and END-treated mice, in part by increasing tumor cell proliferation."

( Chen, JM; Power, KA; Saarinen, NM; Thompson, LU, 2006)

"We used cancer cell lines and normal human endothelial and fibroblast cells to investigate the effect of pancratistatin treatment."

( Kekre, N; McNulty, J; Naderi, J; Pandey, S, 2005)

"In a retrospective study, patients with cancer and noncancer pain being treated with TD fentanyl or TD buprenorphine for at least 3 months between January 2001 and December 2003 were identified from the IMS Disease Analyzer-mediplus database, which contains all patient-related data documented from 400 medical practices in Germany."

( Nautrup, BP; Nuijten, M; Sittl, R, 2005)

"However, in non-small cell lung cancer (NSCLC), addition of ZD1839 (Iressa) to combination chemotherapy did not improve the therapeutic outcome."

( Arnold, D; Mueller, T; Pfeiffer, C; Pickan, V; Simon, H; Voigt, W, 2005)

"Nineteen patients with refractory cancer were treated."

( Adams, N; Barrera, D; Cunningham, C; Graham, S; Nemunaitis, J; Nugent, J; Senzer, N; Stewart, C, 2005)

"Palliative care is an important part of cancer treatment."

( Björk, O; Henter, JI; Kreicbergs, U; Onelöv, E; Steineck, G; Valdimarsdóttir, U, 2005)

"The success of molecular target-based cancer therapy exampled by Herceptin targeting Her2 indicates that cancer immunotherapy involves identifying and targeting key molecular drivers of cancer."

( Hu, XF; Xing, PX, 2005)

"radiotherapy plus amifostine for cancer treatment."

( Clark, LG; Clark, OA; Sasse, AD; Sasse, EC, 2006)

"High-dose cancer treatment protocols can induce a state of acute folate depletion which may lead to significant treatment-related toxicity."

( Boynton, A; Robien, K; Ulrich, CM, 2005)

"Intrinsic or acquired resistance to anticancer agents is a major obstacle to the success of chemotherapy."

( Igarashi, T; Izumi, H; Kohno, K; Matsuo, K; Miyamoto, N; Momii, Y; Niina, I; Uchiumi, T; Wakasugi, T; Yoshida, T, 2005)

"Specifically, so-called cancer testis antigens (CTAs) are intriguing targets for demethylation, since they are silenced in many hematopoietic disorders and may be reactivated by epigenetic therapy."

( Almstedt, M; Claus, R; Lübbert, M, 2005)

"We examined the neoplasms among 1008 renal transplant recipients treated at a single center with sirolimus-cyclosporine +/- prednisone."

( Kahan, BD; Katz, SM; Knight, RJ; Lai, D; Schoenberg, L; Van Buren, CT; Yakupoglu, YK, 2005)

"As more pediatric cancer patients survive for longer periods following treatment with cytotoxic agents, therapy-induced second malignant neoplasms (SMNs) have become a major concern."

( Meadows, AT, 2005)

"Anaemia is a common complication of cancer and its treatment."

( Gascón, P, 2005)

"Cell migration is a prerequisite for cancer invasion and metastasis, suggesting cell motility as a potential therapeutic target for cancer treatment."

( Han, DC; Koh, S; Kwon, BM; Lee, MY; Lee, S; Paik, YK; Shin, DS; Shin, KD; Son, KH, 2005)

"A large European survey of cancer patients (n = 15,367) reported that 67% had anaemia at some point during the survey, and that over 60% of these patients did not receive any treatment for their anaemia."

( Harper, P; Littlewood, T, 2005)

"The majority of patients with cancer will respond to epoetin therapy with an increase in haemoglobin levels."

( Beguin, Y; Glaspy, J, 2005)

"The early detection of tumors could increase the possibility of a favorable treatment outcome."

( Chrostek, L; Cylwik, B; Szmitkowski, M, 2005)

"In addition, lymphocytes from cancer patients undergoing oxaliplatin-based chemotherapy were assayed for the formation and repair of oxaliplatin-induced crosslinks."

( Almeida, GM; Duarte, TL; Jones, GD; Steward, WP, 2006)

"For cell lines and some NaBu-treated tumors we found histone H4 hyperacetylation."

( Arenas-Huertero, F; Armas-Pineda, C; Chico-Ponce de León, F; Lezama, P; Perezpeña-Diazconti, M; Recillas-Targa, F; Rodríguez-Salvador, J; Sosa-Sáinz, G, 2005)

"Chemotherapy using anticancer drugs induces serious the problem of multidrug resistance (MDR) in the cancer cells."

( Amino, N; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M, 2005)

"Eligible patients had advanced solid tumors that failed to respond to standard therapy or for which no standard therapy was available, including also the following criteria: measurable disease, Eastern Cooperative Oncology Group performance status of < or =2, and acceptable organ function."

( Carlisle, R; Goetz, A; Kwiatek, J; Posey, JA; Rizzo, J; Rowinsky, EK; Rudoltz, MS; Saif, MW; Simmons, P; Stevenson, S; Takimoto, CH; Tolcher, AW, 2005)

"Stealth anticancer nano-particle system can be regarded as a valuable drug deliver system to treat oral carcinoma."

( Chen, R; Chen, SW; Wan, YM; Yang, K, 2005)

"One of the standard treatments for cancer-associated thrombosis has been initial therapy with unfractionated heparin (UFH) followed by long-term therapy with an oral anticoagulant (i."

( Schwartz, RN, 2005)

"Results from long-term cancer bioassays in rodents show a statistically significant increase in the incidence of malignant and benign mammary gland tumors in female rats treated orally with DBCP compared to controls and some evidence of increased incidence of mammary fibroadenomas in DBCP low-dose treated female rats exposed by inhalation."

( Clark, HA; Snedeker, SM, 2005)

"Fifteen children and adolescents with cancer were treated with fluvoxamine 100 mg/day in an open prospective 8-week trial."

( Apter, A; Farbstein, I; Gothelf, D; Klein, A; Miller, O; Rubinstein, M; Shemesh, E; Weizman, A; Yaniv, I, 2005)

"This clinical profile suggests an anticancer gene therapy strategy in which solid tumors are transfected with the gene for E."

( Ealick, SE; Parker, WB; Sorscher, EJ; Zhang, Y, 2005)

"Although most advanced cancers are incurable, the majority of testicular germ cell tumors can be cured using cisplatin-based combination chemotherapy."

( Cummings, M; Hartley, JA; Köberle, B; Masters, JR; McGurk, CJ; Oliver, RT, 2006)

"Patients with cancer undergoing chemotherapy for at least 12 weeks (n=439) were randomly assigned, in a 2:1 ratio, to receive either dalteparin (5000 IU) or placebo, by subcutaneous injection, once daily for 16 weeks."

( Abecasis, NG; Baronius, W; Biakhov, M; Fountzilas, G; Garin, A; Giorgetti, C; Irwin, D; Karthaus, M; Kretzschmar, A; Kröning, H; Marschner, N; Reichardt, P; Slabber, C; Steger, GG; Südhoff, T, 2006)

"Anemia in cancer patients undergoing treatment is common and can cause debilitating symptoms such as fatigue and reduced exercise tolerance."

( Collins, G; Littlewood, T, 2005)

"Patients with cancer (N = 216) treated with chemotherapeutic regimens composed of highly or moderately emetogenic agents were examined for their antiemetic responses to tropisetron, ondansetron, or granisetron."

( Abali, H; Aynacioglu, AS; Babaoglu, MO; Bayar, B; Bozkurt, A; Celik, I; Kerb, R, 2005)

"In the treatment of advanced colorectal cancer, irinotecan has become one of the most important drugs, despite its sometimes unpredictable adverse effects."

( de Jong, FA; de Jonge, MJ; Mathijssen, RH; Verweij, J, 2006)

"In contrast to the cancer-promoting effect of folate deficiency in normal tissues, several lines of evidence indicate that folate depletion suppresses the progression of existing neoplasms and enhance the sensitivity of cancer cells to chemotherapy."

( Kim, YI; Novakovic, P; Sohn, KJ; Stempak, JM, 2006)

"Growth of FSaII tumors in the hind legs of C3H mice was determined after treating the host mice with i."

( Ahn, KJ; Ahn, SD; Boothman, DA; Choi, EK; Choi, J; Griffin, R; Ji, IM; Kim, EJ; Kook, YH; Lee, CK; Park, HJ; Song, CW; Williams, B, 2005)

"Systemic anticancer chemotherapy is immunosuppressive and mostly induces nonimmunogenic tumor cell death."

( Aucouturier, P; Casares, N; Chaput, N; Coutant, F; Garrido, C; Ghiringhelli, F; Hamai, A; Hervas-Stubbs, S; Kroemer, G; Métivier, D; Obeid, M; Pequignot, MO; Pichard, E; Pierron, G; Roux, S; Schmitt, E; Tesniere, A; Zitvogel, L, 2005)

"human ovarian OVCAR-3 tumors (a recognized difficult model to treat) in mice."

( Cartwright, GA; Darcy, PK; Hönemann, D; Kershaw, MH; Moeller, M; Power, BE; Prince, HM; Scott, AM; Smyth, FE; Smyth, MJ; Teng, MW; Trapani, JA; Westwood, JA, 2005)

"Twenty-five cancer patients treated with standard dosages of antiemetics and chemotherapies completed the study."

( Clemente, C; Leo, S; Riezzo, G; Russo, F, 2005)

"The use of radiation therapy for cancer is also associated with therapeutic challenges that are distinct from those that might be expected with antiangiogenic agents."

( O'Reilly, MS, 2006)

"All had tumors that had relapsed on, or were refractory to, conventional treatment, or for whom existing treatment options were considered ineffective."

( Cohn, RJ; McCowage, G; White, L; Ziegler, DS, 2006)

"Nine patients with advanced cancer suffering from idiopathic severe sweating were treated with gabapentin (600-1,800 mg/day)."

( Aielli, F; Aloisi, P; Cannita, K; Ficorella, C; Marchetti, P; Porto, C; Porzio, G; Ricevuto, E; Verna, L, 2006)

"Patients with cancer-related anemia have an inadequate Epo response that is further impaired by cancer treatments such as chemotherapy."

( Matsushita, T, 2006)

"Two and 7 days following treatment, tumors treated with 12-MTA showed a significant decrease in 5-hydroxyeicosatetraenoic acid (5-HETE) and a concomitant increase in 15-HETE levels while tumors treated with myristic acid exhibited a significant increase in prostaglandin E2 (PGE2) levels."

( Collin, P; Hicks, ME; Newman, RA; Van Pelt, CS; Wright, KC; Yang, P, 2005)

"Their effectiveness in cancer chemotherapy can be enhanced by delivering to tumors enzymes with improved prodrug reduction kinetics."

( Ackerley, DF; Barak, Y; Contag, CH; Lynch, SV; Matin, A; Thorne, SH, 2006)

"The nutritional needs of patients with cancer may differ from those of the healthy population due to hypermetabolism, impaired organ function, increased nutrient losses and therapy-related malnutrition."

( van Bokhorst-de van der Schueren, MA, 2005)

"We conclude that women with breast cancer or hematologic malignancy are more likely to develop GI GVHD after autologous transplantation, and that treatment with prednisone was effective."

( Adams, KM; Bensinger, W; Flowers, ME; Gooley, TA; Hockenbery, DM; Holmberg, L; Kikuchi, K; McDonald, GB; Schoch, HG, 2006)

"The incidence in cancer patients with pamidronate and zoledronate therapy is 4%-10%."

( Abu-Id, MH; Açil, Y; Gottschalk, J; Kreusch, T, 2006)

"Twenty-one patients with advanced cancers were treated with weekly intravenous administration of NV06 at escalating dose levels with 1-4 patients at each dose cohort."

( de Souza, PL; Howes, LG; Kelly, G; Liauw, W; Links, M; Pirabhahar, S, 2006)

"However, due to the heterogeneity of tumors, prior knowledge of the genetic and biochemical background of cancer cells will be required for effective targeted therapy."

( Blenis, J; Choo, AY, 2006)

"In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10."

( Giaccone, G; Savonije, JH; van Groeningen, CJ; Wormhoudt, LW, 2006)

"Fine needle aspiration biopsy of tumors was done at baseline and after 14 days of therapy for c-fos assessment."

( Bouaroud, N; Brahmer, J; Chan, A; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P, 2006)

"Breakthrough pain in patients with cancer is a common problem with characteristics that make it difficult to treat."

( Gordon, DB, 2006)

"The condition is caused either by the cancer itself or by cytotoxic treatment."

( Bohlius, J; Engert, A; Trelle, S; Weingart, O, 2006)

"In mice bearing various established tumors, including paclitaxel-resistant tumors, once daily oral administration of YM-359445 at doses of 0."

( Amino, N; Hisamichi, H; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M, 2006)

"The treatment of cancer patients with 5-fluorouracil (5FU)-based chemotherapy can be accompanied by severe and sometimes lethal toxicity."

( van Kuilenburg, AB, 2006)

"We examined the occurrence of neoplasms among 1008 renal transplant recipients treated with a sirolimus-cyclosporine (CsA) +/- prednisone (Pred) regimen."

( Buell, JF; Kahan, BD; Woodle, S; Yakupoglu, YK, 2006)

"Patients with moderate to severe malignancy-related pain frequently require the use of opioid pharmacotherapy."

( Skaer, TL, 2006)

"Emerging evidence suggests that cancer preventative agents might be combined with chemotherapy or radiotherapy for the more effective treatment of cancer."

( Li, Y; Sarkar, FH, 2006)

"Twenty-four consecutive selected cancer patients with scintigraphic and radiographic evidence of bone metastases were treated for the first time with a single infusion of 4 mg ZOL."

( Angeletti, S; Brown, JE; Budillon, A; Caraglia, M; Coleman, RE; Dicuonzo, G; Hannon, RA; Holen, I; La Cesa, A; Santini, D; Tonini, G; Vincenzi, B, 2006)

"The risk of cancer-associated thrombosis can be substantial, depending on tumor type, extent of cancer, and type of treatment."

( Pruemer, J, 2006)

"This minireview focuses on the anticancer potential of 1alpha,25(OH)2D3 and its analogues by summarizing the promising data from animal and human trials of 1alpha,25(OH)2D3 and some of the more interesting synthetic vitamin D analogues in the treatment of a variety of different animal cancer models and in human patients with advanced cancer."

( Jones, G; Masuda, S, 2006)

"Metastatic cancer is one of the main causes of cancer-related death since they rarely respond to available treatments."

( Cheung, HW; Chu, Q; Feng, H; Ling, MT; Tsao, SW; Wang, X; Wong, YC, 2006)

"The broad range of expression of cancer-testis antigens in various tumor types makes the proteins encoded by human MAGE gene family promising targets for anticancer immunotherapy."

( Pantel, K; Schwarzenbach, H; Wischnewski, F, 2006)

"The current belief today is that cancer may be prevented or treated by targeting specific cancer genes, signaling proteins, and transcription factors."

( Bode, AM; Dong, Z, 2006)

"Effective cancer pain management is influenced by the attitudes and knowledge of treating physicians."

( Corbex, M; Devi, BC; Tang, TS, 2006)

"Patients with solid tumors refractory to standard therapy were enrolled on this study."

( O'Leary, J; Sewak, S; Sorich, J, 2006)

"Treating cultured thoracic cancer cells with VA (0."

( Baras, A; Chua, A; Maxhimer, JB; Nguyen, DM; Schrump, DS; Shamimi-Noori, S; Yeow, WS; Ziauddin, MF, 2006)

"Fifty patients with advanced solid tumors were enrolled in this phase II trial, 43 of whom had received at least one prior chemotherapy regimen."

( Cano, PO; Germond, CJ; Lopez, PG; Noble, JC; Whissell, M; Young, SD, 2006)

"Patients had a diagnosis of nonmyeloid malignancy with > or = 8 weeks of planned chemotherapy, age >or = 18 years, and anemia (hemoglobin < or = 11 g/dL)."

( Boccia, RV; Bosserman, L; Glaspy, J; Hu, E; Lloyd, RE; Patel, R; Rossi, G; Tomita, D; Vadhan-Raj, S, 2006)

"The study sample consisted of 288 cancer patients randomly allocated (3:4 ratio) into two treatment groups: 120 patients received prophylactic antiemetic treatment with tropisetron and 168 patients received rescue tropisetron."

( Katsouda, E; Kouloulias, V; Linou, A; Mystakidou, K; Nikolaou, V; Parpa, E; Vlahos, L, 2006)

"Patients with cancer receiving myelosuppressive chemotherapy frequently develop anaemia; platinum-based chemotherapy, in particular, leads to reduced production of the bone marrow-stimulating hormone erythropoietin."

( Annemans, L; Moeremans, K; Repetto, L, 2006)

"In intermediate-risk breast cancer, complete hormonal blockade and chemotherapy provided similar outcomes."

( Bonneterre, J; Chollet, P; Clavère, P; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Monnier, A; Roché, H; Serin, D, 2006)

"Initial results showed that five of six cancer patients had decreased PKC activity following enzastaurin administration."

( Basche, M; Britten, CD; Carducci, M; Cook, CA; Eckhardt, SG; Green, LJ; Herbst, RS; Jaken, S; Marder, P; Musib, LC; Ray, C; Thornton, D, 2006)

"Histologic analysis of treated tumors confirmed spatial changes in cellularity as observed by fDM."

( Chenevert, TL; Hall, DE; Hoff, BA; Johnson, TD; McKeever, PE; Meyer, CR; Moffat, BA; Rehemtulla, A; Ross, BD, 2006)

"Anaemia is a common side-effect of malignancy and cancer therapy."

( Laird, J, 2006)

"We have observed the occurrence of some neoplasms in IBD patients who developed sustained leukopenia as a result of treatment with 6-MP."

( Bratcher, J; Disanti, W; Korelitz, BI; Panagopoulos, G; Rajapakse, RO, 2006)

"Targeted biologic therapy for cancer has evolved from the laboratory to active clinical protocols and applied clinical practice in selected patients."

( Agarwala, S; Argiris, A; Bergsland, E; Rugo, H; Wanebo, HJ, 2006)

"Tumor hypoxia induces cancer cell treatment resistance, angiogenesis, invasiveness, and overall poor clinical outcome."

( Verma, A, 2006)

"Despite the continuous improvement of cancer treatment protocols, altered testicular function and infertility frequently represent major adverse effects of oncologic treatments."

( Carli, MO; Ferlin, A; Foresta, C; Garolla, A; Pizzato, C; Selice, R, 2006)

"In vivo study showed that tumors exposed to the arsenic/emodin cotreatment had dramatically smaller sizes and weaker antioxidant capacity, compared with arsenic alone."

( Chen, Y; Hu, Q; Jing, Y; Li, H; Shi, G; Tang, X; Wang, Y; Yang, J; Yi, J, 2006)

"The National Cancer Institute has recognized that nanotechnology offers an extraordinary, paradigm-changing opportunity to make significant advances in cancer diagnosis and treatment."

( Cance, WG; Cuenca, AG; Delano, M; Grobmyer, SR; Hochwald, SN; Jiang, H, 2006)

"Important breakthroughs in cancer therapy include clinical application of antibodies, such as Rituximab, and small inhibitory molecules, such as Iressa and Velcade."

( Bremer, E; de Leij, L; Helfrich, W; Kroesen, BJ; van Dam, G, 2006)

"The coagulation system is activated in cancer and is further amplified by treatment with chemotherapy, radiation or surgery."

( Mousa, SA, 2006)

"In the ATBC Cancer Prevention Study Group, no statistically significant effect of treatment was seen for any cancer individually, and our pooled relative risk (regardless of tumor type) for alpha-tocopherol alone was 0."

( Coulter, ID; Hardy, ML; Hilton, LG; Morton, SC; Shekelle, PG; Tu, W; Valentine, D, 2006)

"Pretreatment of cancer cells with the noncytotoxic imidazoline 1d (10 nM) resulted in a significant increase in apoptosis and anticancer efficacy of the clinically significant DNA damaging agents camptothecin and cisplatin."

( Peddibhotla, S; Sharma, V; Tepe, JJ, 2006)

"In Phase I clinical trials in cancer therapy 3-AP had no cardiovascular, CNS or other major adverse effects."

( Ghanbari, HA; Jiang, ZG; Lebowitz, MS, 2006)

"A total of 310 patients with nonmyeloid malignancy and baseline hemoglobin (Hb)

( Charu, V; Gordan, LN; Henry, DH; Wilhelm, FE; Williams, D; Woodman, RC; Xie, J, 2006)

"Moreover, there are types of cancer, such as mesotheliomas, that cannot be treated at present."

( Dong, L; Neuzil, J; Tomasetti, M; Wang, XF; Wu, K; Zhao, Y, 2006)

"Targeting blood clotting reactions in cancer may provide a unique approach to cancer treatment."

( Rickles, FR, 2006)

"cerevisiae and cancer cells in vitro and in murine tumors in vivo treated with 5-fluorouracil."

( Brody, JR; Canto, MI; Gallmeier, E; Hruban, RH; Hucl, T; Kern, SE; Kulesza, P; Schulick, RD; Yoshimura, K, 2006)

"Anaemia associated with cancer and cancer therapy is an important clinical factor in the treatment of malignant diseases."

( Bayliss, S; Benett, CL; Bohlius, J; Brunskill, S; Djulbegovic, B; Engert, E; Hyde, C; Langensiepen, S; Piper, M; Sandercock, J; Schwarzer, G; Seidenfeld, J; Trelle, S; Weingart, O; Wilson, J, 2006)

"Twenty-six patients with advanced solid tumors were treated on four dosing cohorts starting at CI-1033 (50 mg/d) + docetaxel (75 mg/m2)."

( Arun, BK; Eder, JP; Eiseman, IA; Garland, LL; Hidalgo, M; Lenehan, PF; Lovalvo, JL; Mendelson, DS; Olson, SC; Ryan, DP, 2006)

"Phase II clinical trials in various cancers have been initiated as well as Phase I trials of combined therapy with 17-AAG."

( Sharp, S; Workman, P, 2006)

"The early observation that breast cancer patients, who were prescribed megestrol acetate as a cancer treatment, went on to increase their appetite and gain weight has given rise to a large number of clinical trials that have tested this progestational drug as a palliative agent for the cancer anorexia/weight loss syndrome."

( Jatoi, A; Mateen, F, 2006)

"A consecutive sample of 29 cancer patients, who were treated with TTS-BUP, reported an acceptable basal analgesia, and presented with episodic pains were selected for the study."

( Aielli, F; Casuccio, A; Ferrera, P; Mercadante, S; Porzio, G; Verna, L; Villari, P, 2006)

"In a process that can be considered as cancer therapy using a 'Trojan horse', when the nanoparticle conjugates are incubated with HeLa cells (a cervical cancer cell line), they are taken up thus delivering the phthalocyanine photosensitizer directly into the cell interior."

( Cook, MJ; Gavrilovic, J; Handsley, MM; Hone, DC; Russell, DA; Wieder, ME, 2006)

"We found that treatment of cancer cells with AGRO100 inhibits IKK activity and reduces phosphorylation of IkappaBalpha in response to tumor necrosis factor-alpha stimulation."

( Ball, MW; Barve, SS; Bates, PJ; Casson, LK; Girvan, AC; Jüliger, S; Klein, JB; Pierce, WM; Teng, Y; Thomas, SD, 2006)

"Eligible patients had advanced solid tumors, adequate organ function, and had not received anticancer therapy in the preceding 4 weeks."

( Abbruzzese, JL; Bogaard, K; Fukushima, M; Hoff, PM; Hong, DS; Kuwata, K; Lassere, Y; Mita, A, 2006)

"Phenytoin dosing is critical in cancer patients as to decreased absorption secondary to chemotherapy-induced gastrointestinal toxicity, increased phenytoin metabolism in the liver secondary to chemotherapy, extreme patient profile that falls outside the predicted pharmacokinetic population, frequent hypoalbuminaemia and polydrug treatment."

( Beijnen, JH; Boogerd, W; Huitema, AD; Joerger, M; Schellens, JH; van der Sande, JJ, 2006)

"Traditional anti-cancer treatments consist of chemotherapeutic drugs that effectively eliminate rapidly dividing tumor cells."

( Daniels, TR; Delgado, T; Helguera, G; Penichet, ML, 2006)

"Patients with cancer may have an absolute or functional iron deficiency as a result of their disease or its treatment."

( Henry, DH, 2006)

"Fatigue is common in cancer patients treated with chemotherapy, and it has detrimental effects on their quality of life."

( Cella, D, 2006)

"Anemia is common in many patients with cancer treated with chemotherapy."

( Crawford, J, 2006)

"In our ongoing efforts to combat cancer, peptide-based tumor vaccines are promising as one of the several alternatives used for cancer immunotherapy and immunoprevention."

( Mishra, S; Sinha, S, 2006)

"Fifty-four anemic cancer outpatients were treated with epoetin alpha over 26 weeks with an initial dose of 3 x 10,000 IU/week and further individually adapted dosage."

( Conrad, R; Geiser, F; Glasmacher, A; Hahn, C; Liedtke, R; Sauerbruch, T; Schmidt-Wolf, I, 2007)

"Children with newly diagnosed cancer, a CVL in a jugular vein and an expected treatment period of over 6 mo were eligible for the study."

( De Lange, C; Hogstad, EM; Holmstrøm, H; Ruud, E; Wesenberg, F, 2006)

"From 2001 to 2005, 39 pediatric cancer patients received 44 prophylactic ITC cycles; 102 trough plasma concentrations were measured after oral administration."

( Besuden, M; Bode, U; Fleischhack, G; Glasmacher, A; Hasan, C; Kreutzberg, S; Lampe, D; Simon, A; Vezmar, S, 2007)

"The level of hypoxia in primary tumors has been described to influence response to treatment."

( Achermann, R; Kaser-Hotz, B; Ohlerth, S; Rohrer Bley, C; Roos, M; Wergin, M, 2006)

"Of 101 women with cancer who met the inclusion criteria, 42 patients received DMPA, 39 patients received GnRH-a, and 20 patients remained untreated."

( Ben-Yehuda, D; Katz, D; Meirow, D; Or, R; Rabinovici, J; Shufaro, Y, 2006)

"Treatment of cancer cells with the demethylating agent 5-aza-2'-deoxycytidine results in CpG island hypomethylation, MBD release, and gene reexpression, reinforcing the notion that association of MBDs with methylated promoters is methylation-dependent."

( Alaminos, M; Ballestar, E; Esteller, M; Fraga, MF; Lopez-Serra, L; Setien, F, 2006)

"During the period of cancer diagnosis and active treatment, several small case series have revealed high rates of psychiatric difficulty in pediatric patients."

( Ahmad, N; Leavey, P; Portteus, A; Tobey, D, 2006)

"Activation of prodrugs for cancer treatments or antibiotic therapy are the most common applications."

( Berne, C; Betancor, L; Luckarift, HR; Spain, JC, 2006)

"These findings demonstrate the anticancer potential of betulinic acid and suggest that it may be taken into account as a supportive agent in the treatment of cancers with different tissue origin."

( Kaczor, J; Kandefer-Szerszeń, M; Rzeski, W; Sifringer, M; Stepulak, A; Szymański, M; Wejksza, K; Zdzisińska, B, 2006)

"Data from patients with noncancer or cancer pain treated with TD buprenorphine or TD fentanyl for at least 3 months between May 2002 and April 2005 were analyzed."

( Nuijten, M; Poulsen Nautrup, B; Sittl, R, 2006)

"Forty-six (46) patients with metastatic cancer to the liver from various solid tumors, with tumor progression despite polychemotherapy, were included."

( Campbell, J; Cheng, V; Fink-Bennett, D; Gates, VL; Lewandowski, RJ; Nagle, C; Qing, F; Salem, R; Savin, M; Sherpa, KM; Thie, J; Wong, CY, 2006)

"The first concerns the treatment of cancer by activating genome surveillance circuitry, namely checkpoint-pathway activation therapy."

( Li, CJ, 2006)

"Differential killing of the patient's cancer cells versus normal cells is a necessity for chemotherapy."

( Pardee, AB, 2006)

"The perfusion of tumors is a surrogate parameter of their viability and may mirror their response to therapy."

( Delorme, S; Krix, M, 2006)

"In this review we will focus on cancer therapy targeting integrin alphavbeta3 while other integrins (such as alpha5beta1, alphaIIbbeta3, alphavbeta5, alpha6beta4) will only be briefly mentioned when relevant."

( Cai, W; Chen, X, 2006)

"Long-term treatment options for cancer patients who experience VTE include vitamin K antagonists (VKAs), low molecular weight heparins (LMWHs), and inferior vena caval (IVC) filters."

( Streiff, MB, 2006)

"The importance of these new methods of cancer treatment necessitates further research into the dynamic interactions between cancer cells and therapeutic agents, as well as a means of analysing their relationship quantitatively."

( Abbott, LH; Michor, F, 2006)

""Second cancers" can be thought of in two general categories: (a) those occurring as a consequence of cancer treatment and (b) primary cancers that are thought to develop largely as a consequence of prior lifestyle habits (e."

( Cartmel, B; Mayne, ST, 2006)

"The guidelines in cancer pain management are concerned with the fact that pain may be under treated because of fear of addiction, and the guidelines in management of non-malignant pain patients include warnings of addiction."

( Højsted, J; Sjøgren, P, 2007)

"To be maximally effective, therapy of cancer must be directed against both the resting stem cells and the proliferating cells of the cancer."

( Sell, S, 2006)

"Ten patients with advanced stage solid tumors were treated with gemcitabine (1500 mg/m) as a 30-min intravenous infusion on days 1 and 8, followed by oxaliplatin (130 mg/m) as a 4-h intravenous infusion, on day 8 every 21 days."

( Georgoulias, V; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P, 2006)

"Numerous cancer patients fail standard chemotherapy or develop resistance to chemotherapy during the course of treatment."

( Duivenvoorden, WC; Richard, C; Th'ng, JP; Yau, J, 2006)

"Patients with solid tumors not amenable to standard forms of treatment were eligible."

( Fujisaka, Y; Horiike, A; Shimizu, T; Tamura, T; Yamada, Y; Yamamoto, N, 2006)

"Although being a heterogeneous disease, cancer has certain characteristic features which can be utilized for treatment with novel macromolecular therapeutics."

( Ogris, M, 2006)

"Many cancer patients treated with conventional therapies also try 'alternative' cancer treatments."

( Ernst, E; Lejeune, S; Milazzo, S, 2007)

"Recently, mass media reported cancer patients who were eager to receive the standard chemotherapy and requesting the regulatory authorities its quick approval."

( Sekine, N; Terada, K, 2006)

"Until recently, cancer therapy was based on three modalities: surgery, radiotherapy, and cytostatic chemotherapy."

( Knuth, A; Pestalozzi, BC; Stenner-Liewen, F; Zippelius, A, 2006)

"In vitro studies with various cancer cell lines have shown an increase in ROS and intracellular free zinc in cells treated with MGd."

( Magda, D; Miller, RA, 2006)

"Accurate staging of cancer is of fundamental importance to treatment selection and planning."

( Hicks, RJ; Lau, EW; Ware, RE, 2006)

"Breast cancer therapy trials often report serum lipid parameters, but assessing the quality and overall significance of the data can be difficult."

( Monnier, A, 2006)

"Among 103 cancer admissions with fever and neutropenia, treatment failure after initiating empiric fluconazole antifungal therapy occurred in 41% (95% confidence interval (CI) 31%-50%) of admissions."

( Bates, DW; Kumar, RN; Peterson, JF; Seger, DL; Yu, DT, 2006)

"Twenty-seven patients with advanced cancer were treated with daily oral gefitinib at 250 mg (n = 13) or 500 mg (n = 14) for 28 days."

( Baker, SD; Brahmer, J; Hidalgo, M; Karlsson, MO; Li, J; Spitz, A; Zhao, M, 2006)

"Their utility in cancer therapy has been demonstrated in specific cancer types."

( Bhat, PV; Brodeur, H; Mader, S; Parisotto, M, 2006)

"These carriers can selectively target cancer sites and carry large payloads, thereby improving cancer detection and therapy effectiveness."

( Ghandehari, H; Line, BR; Mitra, A; Nan, A, 2006)

"Patients with solid tumors treated with HDC and PBSCS, that developed fever and neutropenia (absolute neutrophil count < 500 cells/microL) were eligible, and randomly assigned to receive ceftazidime plus amikacin or cefepime."

( Amador, ML; Arcediano, A; Bazares, S; Castellano, D; Ciruelos, E; Cortés-Funes, H; González-Cortijo, L; Hornedo, J; Jimeno, A; Lumbreras, C; Paz-Ares, L; Robles, L, 2006)

"The most advanced aptamer in the cancer setting is AS1411, formerly known as AGRO100, which is being administered systemically in clinical trials."

( Ireson, CR; Kelland, LR, 2006)

"The types of tumors and their target organs found in this study were consistent with those observed in rats and mice administered DCE by gavage in a NCI study."

( Arito, H; Gotoh, K; Matsushima, T; Nagano, K; Senoh, H; Umeda, Y; Yamamoto, S, 2006)

"The angiogenic phenotype of malignant cancers has been established as a target for cancer therapy."

( Haviv, F; Henkin, J; Khanna, C; Majest, S; McKeegan, E; Rusk, A, 2006)

"Aim in cancer therapy is to increase the therapeutic ratio eliminating the disease while minimizing toxicity to normal tissues."

( Braun, K; Debus, J; Didinger, B; Hotz-Wagenblatt, A; Langowski, J; Müller, G; Strunz, AM; Waldeck, W; Wijenne, J, 2007)

"Anemia may result in cancer from either a bone marrow infiltration of cancer cells or a cytotoxic effect of chemotherapy and/or radiotherapy, or both."

( Milano, M; Schneider, M, 2007)

"A major challenge in cancer therapy is tumor drug resistance."

( Chan, TH; Chen, D; Dou, QP; Landis-Piwowar, KR; Milacic, V; Yan, B; Yang, H; Zhao, Y, 2006)

"The three studies evaluated untreated cancer patients, welders, and pathologists/anatomists exposed to formaldehyde."

( Baciuchka-Palmaro, M; Bonassi, S; Botta, A; Iarmarcovai, G; Orsière, T; Sari-Minodier, I, 2007)

"Fifty patients with malignant tumors undergoing their first chemotherapy were randomly divided into two groups, and each group received 0."

( Ai, B; Dong, M; Han, X; He, X; Huang, D; Liu, P; Shi, Y; Yang, S; Zhang, C; Zhou, S, 2007)

"The history of cancer chemotherapy and of the discipline of medical oncology has been that of drug discovery."

( Ribatti, D, 2007)

"Sufficient analgesia for cancer pain is sometimes difficult to achieve with conventional treatments."

( Oishi, K; Sakamoto, S; Shingu, K; Taguchi, H, 2007)

"When conventional cancer pain treatments are not successful, intrathecal betamethasone may be useful, as it probably induces long-lasting analgesia without adverse effects and improves activities of daily living, especially in patients with vertebral bone metastases."

( Oishi, K; Sakamoto, S; Shingu, K; Taguchi, H, 2007)

"With ranges of SSRIs cytotoxicity on cancer cells defined, limits in their possible applicability in cancer therapy is discussed."

( Conti, M; Frasnelli, M; Rosetti, M; Tesei, A; Zoli, W, 2006)

"p53 manipulations for cancer therapy have revealed the need for specificity of p53 activation and ability to spare body tissues."

( Bossi, G; Sacchi, A, 2007)

"Resistance to anticancer drugs can sometimes be overcome by combination treatment with other therapeutic drugs."

( Chung, HY; Kang, YH; Kim, CH; Lee, SJ; Lee, YS; Park, IC; Park, MT, 2007)

"PBLs from 10 healthy donors and 25 cancer patients (before and after three cycles of chemotherapy) were exposed to in vitro treatments: C (control), HS (heat shock at 42 degrees C), Do or Pt (doxorubicin or cisplatin alone), and HS+Do or HS+Pt (heat shock+doxorubicin or heat shock+cisplatin)."

( Ciocca, DR; Drago, G; Ibarra, J; Nadin, SB; Vargas-Roig, LM, 2007)

"In treated tumors, cells arrest in prometaphase, accumulate phosphohistone H3, and contain aberrant mitotic spindles."

( Adolf, GR; Baum, A; Garin-Chesa, P; Grauert, M; Gürtler, U; Hoffmann, M; Kraut, N; Krssák, M; Lénárt, P; Lieb, S; Peters, JM; Petronczki, M; Quant, J; Rettig, WJ; Steegmaier, M, 2007)

"However, the spectrum of cancers that can be treated with platinum agents is narrow and treatment efficacy suffers from side effects and resistance phenomena."

( Gust, R; Ott, I, 2007)

"One patient with colorectal cancer, previously treated with irinotecan, had a partial response."

( de Jonge, MJ; McGovern, D; Obach, R; Principe, P; Scott, L; Soepenberg, O; Th Planting, AS; Twelves, C; Verweij, J, 2007)

"An increase in the incidence of cancer among elderly people assigned to pravastatin therapy has been reported in a randomized controlled trial; however, this finding has been attributed to chance."

( Bonovas, S; Sitaras, NM, 2007)

"Patients with solid tumors who were not candidates for standard chemotherapy received escalating doses of carboplatin, gemcitabine, and irinotecan."

( Antonia, S; Chiappori, A; de Lima Lopes, G; Haura, E; Langevin, M; Lush, R; Rocha-Lima, CM; Simon, G; Sullivan, D, 2007)

"Patients who are diagnosed with cancer want advice on how they may alter their diet or which diet supplements they should take to augment chemotherapy."

( D'Incalci, M; Gescher, AJ; Steward, WP, 2007)

"However, anticancer drug resistance phenomena pose major obstacles towards curative cancer chemotherapy."

( Assaraf, YG, 2007)

"CAM interventions tested for cancer-related fatigue include acupuncture, aromatherapy, adenosine triphosphate infusions, energy conservation and activity management, healing touch, hypnosis, lectin-standardized mistletoe extract, levocarnitine, massage, mindfulness-based stress reduction, polarity therapy, relaxation, sleep promotion, support group, and Tibetan yoga."

( Barton, DL; Bauer, BA; Loprinzi, CL; Sood, A, 2007)

"First, cisplatin-treated human cancer cells undergo a prolonged G1 arrest before dying."

( Un, F, 2007)

"Targeting DNA methylation for cancer therapy has had a rocky history."

( Issa, JP, 2007)

"Patients with advanced, recurrent solid tumors who had received

( Aghajanian, C; Chi, DS; Colevas, AD; Derosa, F; Dizon, D; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Venkatraman, E, 2007)

"Febrile pediatric cancer patients with anticipated prolonged neutropenia were randomized between a regimen of once-daily ceftriaxone plus amikacin (C + A) and imipenem monotherapy (control)."

( Ahmed, IA; Ahmed, N; El-Beshlawy, A; El-Haddad, A; El-Mahallawy, HA; Nassif, S, 2007)

"We conclude that pediatric febrile cancer patients initially considered at risk for sepsis due to prolonged neutropenia can be re-evaluated at 72 hr for outpatient therapy."

( Ahmed, IA; Ahmed, N; El-Beshlawy, A; El-Haddad, A; El-Mahallawy, HA; Nassif, S, 2007)

"In patients with cancer, baseline levels of circulating prothrombotic, endothelial and platelet-derived MPs were similar to healthy controls and decreased significantly after administration of cisplatin."

( Amabile, N; Boulanger, CM; Eyer, S; Gerschheimer, C; Hayoz, D; Periard, D; Pugin, P, 2007)

"Hypoxic cells are common in tumors and contribute to malignant progression, distant metastasis and resistance to radiotherapy."

( Bussink, J; Kaanders, JH; Ljungkvist, AS; van der Kogel, AJ, 2007)

"Resistance of human cancers to current treatment regimens remains a challenge in oncology."

( Debatin, KM; Fulda, S, 2007)

"Twenty-four cancer patients were treated with i."

( de Bruijn, P; de Jong, FA; Engels, FK; Kitzen, JJ; Loos, WJ; Mathijssen, RH; Mathot, RA; Sparreboom, A; Verweij, J, 2007)

"Eighty-four Japanese patients with cancer who received irinotecan-based chemotherapy were enrolled."

( Ando, Y; Araki, K; Eodo, H; Fujita, K; Kodama, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W, 2007)

"One hundred six consecutive cancer outpatients with depressive symptoms were treated in a prospective, intention to treat, 4-week study, and were evaluated in single-blind with Montgomery Asberg rating scale for depression (MADRS), clinical global impression (CGI) and dosage record treatment emergent symptom scale (DOTES) to assess side effects of treatment."

( Berra, C; Binaschi, L; Borio, R; Torta, R, 2007)

"Our results suggest that cancer patients with deregulated Ras pathway tumors might benefit from FTS treatment."

( Blum, R; Elkon, R; Jacob-Hirsch, J; Kloog, Y; Rechavi, G; Shamir, R; Yaari, S; Zundelevich, A, 2007)

"Signal transduction therapy for cancer targets specific molecular elements that are essential for survival of the tumor."

( Klein, S; Levitzki, A, 2007)

"Among patients with advanced cancer not receiving antineoplastic therapy, the most frequent and severe symptoms were fatigue, pain, and lack of appetite."

( Krzyzanowska, MK; O'Carroll, A; Riechelmann, RP; Zimmermann, C, 2007)

"The care recipients had heterogeneous cancer diagnoses and were undergoing active treatment."

( Mehrotra, S; Sukumar, P, 2007)

"Anemia is frequently associated with cancer due to the disease itself and antineoplastic treatments."

( Beccaglia, P; Cartenì, G; Contillo, A; De Signoribus, G; Giannetta, L; Orecchia, S; Pezzella, G; Pinotti, G; Puglisi, F; Ucci, G; Vecchione, A, 2007)

"One aim of cancer gene therapy could be the induction of oxidative phosphorylation, the last metabolic step required by inflammation in order to differentiate the tissue that it produces."

( Aller, MA; Arias, J; Arias, JI, 2007)

"Treatment of cancer is increasingly effective but is associated with short and long term side effects."

( Clarkson, JE; Eden, OB; Worthington, HV, 2007)

"In primary tumors, such as cervix carcinomas, head and neck squamous cell carcinomas or rectum adenocarcinomas, elevated lactate levels as a mirror of a high glycolytic activity, are correlated even at the initial diagnosis with a high level of malignancy as indicated by increased formation of metastases or an elevated radiotherapy resistance."

( Mueller-Klieser, W; Sattler, UG; Walenta, S, 2007)

"Patients with advanced solid tumors, good performance status, normal organ function, and no potentially curative therapy were eligible for the trial."

( Bauer, KS; Bisacia, S; Dancey, J; Edelman, MJ; Smith, R; Wu, S, 2007)

"murine adenocarcinoma tumors at 0 and 24 h after administration."

( Angstadt, M; Bur, M; Dromi, S; Frenkel, V; Li, KC; Libutti, SK; Luk, A; Poff, J; Traughber, B; Wood, BJ; Xie, J, 2007)

"Thus, manipulation of NOx levels in tumors offers exciting opportunities to improve the effectiveness of cancer treatment."

( Hirst, DG; Robson, T, 2007)

"In this case, a stage III breast cancer patient undergoing dose-dense AC+T chemotherapy obtained a clear response equivalent to ESA treatment by using a pattern of simple oxygen breathing."

( Burk, R, 2007)

"In particular, we focus on Cancer Treatment Induced Bone Loss (CTIBL) and the musculo-skeletal complications that can occur in patients treated for extremity sarcoma."

( Aksnes, LH; Bruland, ØS, 2007)

"Similarly, human cancer-derived cell lines became more responsive to IFNalpha in conjunction with U0126 treatment."

( Ikeda, Y; Lee, PW; Mael, AA; Marcato, P; Noser, JA; Ohmine, S; Sakuma, R, 2007)

"Clarification of real role of ROS in cancer may shed light on the understanding of how impairment of mitochondria leads to malignant transformation of normal cells, and offer new types of strategies for cancer prevention and therapy."

( Lu, F, 2007)

"Encouraging anticancer activity was noted in patients with previously untreated non-small cell lung cancer."

( Argiris, AE; Belani, CP; Egorin, MJ; Lagattuta, TF; Musguire, LA; Parise, RA; Potter, DM; Ramalingam, SS; Ramananthan, RK; Ramanathan, RK; Stoller, RG; Zwiebel, JA, 2007)

"LNCaP and PC-3 prostate cancer cells stably overexpressing cyclin B1 are more sensitive to apoptosis induced by chemotherapy."

( Burnstein, K; de Las Pozas, A; Gomez, LA; Perez-Stable, C; Reiner, T, 2007)

"Strategies to treat cancer by restoring p53 tumor suppressor functions are being actively investigated."

( Carette, JE; Gerritsen, WR; Graat, HC; Kaspers, GJ; Schagen, FH; van Beusechem, VW; Vassilev, LT; Wuisman, PI, 2007)

"The treatment of adult cancer survivors who have had anthracycline-related cardiotoxicity has not been systematically studied."

( Alvarez, JA; Barry, E; Lipshultz, SE; Miller, TL; Scully, RE, 2007)

"Hypoxia is a common feature of solid tumors associated with therapy resistance, increased malignancy and poor prognosis."

( Begg, AC; Evelo, CT; Fung, G; Krishnan, S; Krishnapuram, B; Lambin, P; Magagnin, MG; Nuyten, DS; Rao, RB; Rouschop, KM; Seigneuric, R; Starmans, MH; van Erk, A; Wouters, BG, 2007)

"Twenty-three survivors of childhood cancer treated with cisplatin at our Unit from 1991 to 2004 performed tympanometry, pure tone audiometry, transient otoacoustic emissions, and distortion product otoacoustic emissions (DPOAE)."

( Brunetto, AL; Cigana, L; Coradini, PP; Rosito, LS; Selistre, SG, 2007)

"Interestingly, anticancer drugs appear to augment the antitumor effect of the vaccinia virus-mediated immunotherapy."

( Han, HD; Kang, TH; Kim, JH; Kim, TW; Noh, KH; Park, ES; Park, YS; Shin, BC; Song, CK, 2007)

"Twenty-seven pediatric inpatients with cancer (aged 7-18 years) who had severe pain requiring treatment with opioids and who received care in the Oncology Unit at the Children's Hospital at Westmead, Sydney, Australia participated in this study."

( Bergin, M; Collins, JJ; Finney, D; Friedrichsdorf, SJ; Stevens, M, 2007)

"When analyzed by intention to treat, cancer incidence was lower in the Ca + D women than in the placebo control subjects (P < 0."

( Davies, KM; Heaney, RP; Lappe, JM; Recker, RR; Travers-Gustafson, D, 2007)

"Information is lacking on therapies for cancer-related constipation among current medications approved by the US Food and Drug Administration (FDA)."

( Thomas, J, 2007)

"Patients with solid tumors previously treated with up to four chemotherapy regimens received a 3-h intravenous infusion of ixabepilone every 3 weeks."

( Fujisaka, Y; Fujiwara, Y; Klimovsky, J; Shimizu, T; Takayama, K; Tamura, T; Tokudome, T; Yamada, K; Yamada, Y; Yamamoto, N, 2008)

"Anemic patients with solid tumors received 150 microg/week of darbepoetin concomitantly with chemotherapy."

( Aldaud, A; Fandel, F; Hellmich, M; Lerchenmüller, C; Neise, M; Schmitz, S; Steinmetz, T; Totzke, U; Tsamaloukas, A; Weiligmann, C, 2007)

"Individuals with cancer are living longer, and the number of cancer treatment options provided at various points in the cancer continuum is growing; however, many treatments contribute to anemia."

( Bush, NJ; Hurter, B, 2007)

"A review of all patients with cancer treated with warfarin for venous thromboembolism (VTE) over a 1-year-period was carried out."

( Breathnach, OS; Davenport, C; Grogan, L; Morris, PG; O'callaghan, C; O'dwyer, D, 2007)

"Fifty-five patients with cancer and VTE were treated with warfarin from 07/04 to 06/05."

( Breathnach, OS; Davenport, C; Grogan, L; Morris, PG; O'callaghan, C; O'dwyer, D, 2007)

"In an analysis of various cancer cell lines, ovarian cancer cells were highly sensitive to combined treatment with cotylenin A and IFNalpha in terms of the inhibition of cell growth."

( Akimoto, M; Honma, Y, 2007)

"Patients with advanced cancer may develop cachexia, which is often treated with megestrol acetate (MA)."

( Bruera, E; Del Fabbro, E; Dev, R, 2007)

"A long-standing problem in cancer chemotherapy is the lack of tumor-specific treatments."

( Ojima, I, 2008)

"Patients with advanced cancer received a 14-day lead-in treatment with oral enzastaurin followed by subsequent 21-day cycles of daily enzastaurin, gemcitabine on days 1 and 8, and cisplatin on day 1."

( Beerepoot, LV; Beijnen, JH; Enas, N; Mehra, N; Musib, L; Radema, SA; Rademaker-Lakhai, JM; Schellens, JH; van Hal, G; van Maanen, R; Vermaat, JS; Visseren-Grul, CM; Voest, EE; Witteveen, EO, 2007)

"Patients with lung cancer on cancer treatment had lower FACT-An Trial Outcome Index than patients with breast cancer on treatment (mean values 71."

( Brandberg, Y; Bremberg, ER; Eksborg, S; Friesland, S; Hising, C, 2007)

"Partially responsive tumors exhibit increased Annexin signal when trastuzumab is combined with a cytotoxic agent (paclitaxel), which predicts subsequent tumor regression and suggests that imaging can guide therapy optimization."

( Bergquist, H; Gee, MS; Josephson, L; Mahmood, U; Upadhyay, R; Weissleder, R, 2007)

"The main cause of cancer treatment failure is the invasion of normal tissues by cancer cells that have migrated from a primary tumor."

( Makale, M, 2007)

"Seventeen patients with advanced solid tumors received 75 cycles of treatment."

( Chen, EX; Dancey, J; Duan, L; Duran, I; Hirte, H; Hotté, SJ; Lathia, C; MacLean, M; Pond, GR; Siu, LL; Turner, S; Walsh, S; Wright, JJ, 2007)

"Forty-one patients with advanced cancer disease were treated with an i."

( Drevs, J; Häring, B; Kratz, F; Medinger, M; Mross, K; Steinbild, S; Unger, C, 2007)

"Conventional cancer treatments rely on radiotherapy and chemotherapy."

( Amigorena, S; André, F; Apetoh, L; Barrat, FJ; Bourhis, J; Chompret, A; Clavel-Chapelon, F; Criollo, A; Delaloge, S; Ghiringhelli, F; Joulin, V; Kroemer, G; Levi, F; Lidereau, R; Maiuri, MC; Mignot, G; Mira, JP; Nogues, C; Obeid, M; Ortiz, C; Ryffel, B; Saftig, P; Saulnier, P; Tesniere, A; Tursz, T; Ullrich, E; Yang, H; Zitvogel, L, 2007)

"Patients with cancer, particularly those undergoing chemotherapy or radiotherapy, may develop oral mucositis."

( Darwish, M; Jiang, JG; Kirby, M; Robertson, P; Tracewell, W, 2007)

"In patients with solid tumors, FM content did not change during treatment."

( Barbosa-Cortés, L; López-Aguilar, E; Mejía-Aranguré, JM; Rivera-Márquez, H; Tapia-Rojas, M, 2007)

"While most of the attention in cancer therapy has been towards enhancing the death of tumor cells, the effect of dying tumors on the immune system has been less studied."

( Dhodapkar, MV; Spisek, R, 2007)

"The most common treatment of cancer pain consists of the use of regularly given oral analgesics."

( Arcuri, E; Mercadante, S, 2007)

"Included were patients with cancer for whom medical treatment options were restricted to supportive care, who had a life expectancy of less than 6 months, a World Health Organization performance status 1 or 2, and suffered from at least one of the following complaints: fatigue, anorexia or weight loss >5% over the previous 6 months."

( Beijer, S; Dagnelie, PC; Gielisse, EA; Hupperets, PS; Nijziel, MR; van den Beuken-van Everdingen, M; van den Borne, BE; van Henten, AM, 2007)

"Diabetes may negatively impact both cancer risk and outcomes of treatment."

( Singer, M, 2007)

"The National Comprehensive Cancer Network and American Society of Clinical Oncology guidelines for management of chemotherapy-associated nausea and vomiting cleary endorse the use of serotonin receptor antagonist; however, no single agent is preferred over the rest."

( Awan, FT; Chaudhary, L; Hamadani, M; Khan, JK; Kojouri, K; Ozer, H; Tfayli, A, 2007)

"Patients with cancer who develop thrombosis are more likely to experience a recurrence of VTE and have increased bleeding complications while receiving oral anticoagulant treatment."

( Goodin, S; Nishioka, J, 2007)

"Approximately 60% of anaemic cancer patients respond to epoetin treatment."

( Birgegård, G; Dahl, F; Glimelius, B; Landegren, U, 2007)

"Thirty-five adult cancer outpatients with mood depression, during chemotherapy, were enrolled to a 12-week trial with a flexible dose regime of sertraline."

( Caldera, P; Siri, I; Torta, R, 2008)

"Patients with refractory solid tumors and lymphoid malignancies were treated with oral MS-275 on a once weekly schedule for 4 weeks of a 6-week cycle."

( Chen, A; Chung, EJ; Conley, B; Donovan, E; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, M; Hwang, K; Kalnitskiy, M; Kummar, S; Lee, MJ; Maynard, K; Melillo, G; Murgo, AJ; Ryan, QC; Trepel, JB; Zwiebel, J, 2007)

"La autoantigen represents a promising cancer cell death target to determine chemotherapy response because its expression was selectively induced in dead cancer cells after DNA-damaging chemotherapy."

( Al-Ejeh, F; Brown, MP; Darby, JM, 2007)

"Basic research related to heavy-ion cancer therapy has been done at the Institute of Modern Physics (IMP), Chinese Academy of Sciences since 1995."

( Dai, Z; Jin, X; Li, Q; Liu, X; Xiao, G; Yan, Z, 2007)

"Some of cancer patients in capecitabine treatment who developed HFS, we recommended to apply henna."

( Guzin, G; Yucel, I, 2008)

"beta-Glucan as adjuvant to cancer chemotherapy and radiotherapy demonstrated the positive role in the restoration of hematopiesis following by bone marrow injury."

( Akramiene, D; Didziapetriene, J; Kevelaitis, E; Kondrotas, A, 2007)

"Imaging in a breast cancer patient showed FPAC localization in a primary tumor that responded to chemotherapy, while failure to localize in mediastinal disease corresponded with only partial response."

( Agarwal, R; Barrett, D; Bear, HD; Hirsch, JI; Kalen, JD; Kurdziel, KA; McCumiskey, JF; Wilson, JD, 2007)

"We identified 210 cancer patients with VRE bacteremia who had been treated between January 1996 and December 2004; 16 of these 210 had VR E."

( Chemaly, RF; Ghanem, G; Hachem, R; Jiang, Y; Raad, I, 2007)

"Patients with metastatic solid tumors or refractory lymphoma were treated with a starting dose of 4 mg/m2 intravenously administered over 1-h with a cycle defined as 3 weekly doses of SNS-032 every 21 days."

( Adelman, DC; Bible, K; Heath, EI; Lorusso, PM; Martell, RE, 2008)

"Camptothecin (CPT) is an anti-cancer drug with low solubility in aqueous solutions, which limits its efficacy during chemotherapy."

( Haverstick, K; Page, RL; Saltzman, WM; Ying, V, 2007)

"We also show that the KB tumors have high levels of shed mesothelin in their extracellular space; these levels increase with tumor size and, after Taxol treatment, dramatically fall in the drug-sensitive but not the drug-resistant tumors."

( Hassan, R; Pastan, I; Xiang, L; Zhang, Y, 2007)

"Eight patients with metastatic cancer were treated with DOX preceded by a 10 min i."

( Bast, A; Berkhof, J; Bronzwaer, JG; Bruynzeel, AM; Niessen, HW; van der Hoeven, JJ; van der Vijgh, WJ; van Groeningen, CJ, 2007)

"One of the major challenges facing cancer therapy today is achieving specificity."

( Cheong, I; Diaz, LA; Huang, X; Thornton, K; Zhou, S, 2007)

"Anemia is a frequent problem in cancer patients, especially in those treated with chemotherapy, and has an important negative impact on quality of life."

( Vansteenkiste, J; Wauters, I, 2007)

"Fifty-two patients with refractory tumors were accrued with a median age of 40 (range: 6-66), a median of 3 (1-6) prior chemotherapy regimens, and 3 (1-7) organs involved."

( Aldaz, A; Aramendía, JM; Aristu, J; Centeno, C; Hernández, M; Moreno, M; Nieto, Y; Pérez-Calvo, J; Rifón, J; Sayar, O; Viteri, S; Viúdez, A; Zafra, A; Zufia, L, 2007)

"Gemcitabine is an anticancer drug which is metabolized to a number of metabolites, administered using different dosing regimens and increasingly used in combination with oxaliplatin."

( Galettis, P; Jiang, X; Links, M; McLachlan, AJ; Mitchell, PL, 2008)

"Thirty-four incurable cancer patients with well controlled pain (NRSB4), treated by specialised palliative home care teams, with ongoing medication with the strong opioid paracetamol combination was recruited to this prospective clinical study."

( Axelsson, B; Stellborn, P; Ström, G, 2008)

"Numerous cancer drugs inhibit TR1, and this protein has been proposed as a target for cancer therapy."

( Carlson, BA; Gladyshev, VN; Hatfield, DL; Patterson, AD; Xu, XM; Yoo, MH, 2007)

"Anaemia has a high incidence in cancer patients, especially when it is a consequence of myelosuppressive treatments."

( Pelegrí, A, 2007)

"We have found that treatment of cancer cell lines expressing luciferase under control of the cytomegalovirus (CMV) promoter with staurosporine, doxorubicin, and paclitaxel results in a transient increase in bioluminescence, which is positively correlated with apoptosis and inversely correlated with cell viability."

( Barnes, JM; Cohen, MB; Henry, MD; Rokhlin, OW; Svensson, RU, 2007)

"The number of neoplasms in the mice treated with 5-ASA was significantly lower than that in the control mice."

( Endo, H; Fujisawa, T; Fujita, K; Ikeda, I; Inamori, M; Kubota, K; Nagashima, Y; Nakagama, H; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Tomimoto, A; Wada, K; Yoneda, M; Yonemitsu, K, 2007)

"Suicide cancer gene therapy with retroviral vector-producing cells was in the way of an adjuvant to the surgical resection of recurrent glioblastoma, although any benefit appeared to be marginal."

( Okada, T; Ozawa, K, 2008)

"Growth of solid tumors depends largely on the development of a functional vasculature, which has been the focus in anti-tumor therapy since Folkman in 1971 proposed that prohibiting the formation of new vessels could inhibit tumor growth."

( Eggermont, AM; Seynhaeve, AL; ten Hagen, TL, 2008)

"This would enhance the anticancer activity of current TNF-based locoregional regimens and would pave the way to the systemic administration of this cytokine and thus to a much wider clinical experimentation of TNF in the oncology field."

( Mocellin, S; Pilati, P; Rossi, CR, 2008)

"In paclitaxel-administered cancer patients, an association of CYP3A4*16B harboring the low activity allele *16 [554C > G (Thr185Ser)] has been shown with altered metabolite/paclitaxel area under the plasma concentration-time curve (AUC) ratios, suggesting a possible impact of *16B on the PK of other drugs."

( Fukushima-Uesaka, H; Hamaguchi, T; Kamatani, N; Kaniwa, N; Kunitoh, H; Kurose, K; Minami, H; Ohe, Y; Ohtsu, A; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tamura, T; Yamada, Y; Yamamoto, N; Yoshida, T, 2008)

"Medical problems associated with the malignancy or caused by the oncologic treatment are the main factors involved in bone loss."

( González Macías, J; Olmos Martínez, JM, 2007)

"These findings may be useful for cancer combinational therapy with erlotinib in the clinic."

( Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kim, IW; Peng, XX; Robey, RW; Shen, T; Shi, Z; Shukla, S; Si, QS, 2007)

"Eleven patients (larynx cancer, melanoma, breast cancer, T-cell lymphoma, renal cell carcinoma, Merkel cell carcinoma, and skin lymphoma) in addition to sirolimus therapy, underwent oncologic treatment, namely, surgery and/or chemotherapy."

( Boratyńska, M; Klinger, M; Patrzałek, D; Smolska, D; Watorek, E, 2007)

"Regarding cancer gene therapy, AAV vectors may be utilized to inhibit tumor angiogenesis, metastasis, and invasion."

( Ozawa, K, 2007)

"Targeting p53 for cancer therapy has been intensively pursued."

( El-Deiry, WS; Wang, W, 2008)

"CIPN is an important consequence of cancer treatment because of its potential impact on physical functioning and quality of life."

( Abbott, L; Aschenbrenner, J; Collins, M; Hart, C; Visovsky, C, 2007)

"Therefore, a clinical trial treating cancer patients with 1-MT has been started."

( Königsrainer, A; Löb, S, 2008)

"For HBV carrier cancer patients, an anti-viral therapy before their cancer chemotherapy seems to be very important."

( Chen, XY; Dong, JL; Huang, CY; Ma, LN; Sun, GZ, 2007)

"Anti-carcinogenic potential for cancer chemoprevention and anticancer therapy, which is one of the pleiotropic effects of resveratrol, is so called a new enlightenment of French Paradox."

( Liu, BL; Zhang, W; Zhang, X; Zhen, HN, 2007)

"The under treatment of cancer pain is still a major issue in both oncology and palliative medicine."

( Cleary, JF, 2007)

"Therapy-related cancer will remain a potential consequence of prolonged treatment for these generally non-life-threatening conditions."

( Attard, N; Karran, P, 2008)

"The therapeutic goal of cancer treatment has been to trigger tumor-selective cell death."

( Facchini, V; Kiss, R; Lefranc, F, 2007)

( Cork, MJ; Langley, RG; Luger, TA; Paul, C; Schneider, D, 2007)

"Pre-therapy CEC were detected in cancer patients and normal controls with mean concentrations of 0."

( Carroll, M; Frankel, P; Ruel, C; Smith-Powell, L; Synold, TW; Twardowski, PW; VanBalgooy, J, 2008)

"Adult patients with solid tumors refractory to existing treatments received a 10-min, single-dose intravenous infusion of ZD6126 every 14 or 21 days."

( Barge, AJ; Boerner, SA; DelProposto, ZS; DeLuca, PA; Evelhoch, JL; Gadgeel, SM; Jones, HK; LoRusso, PM; Wheeler, C; Wozniak, A, 2008)

"Long-term treatment of cancer patients having venous thromboembolism with low molecular weight heparin showed improved survival rate."

( Li, JP, 2008)

"The use of anticancer agents forms an important part for treatment of cancer of various types."

( Ho, JW, 2006)

"Multiple myeloma is the prototype of cancer where bortezomib has shown marked in vitro activity, which was followed by rapid translation to phase I, II and III clinical trials, and resulted in accelerated approval by the FDA for the treatment of patients with relapsed refractory disease."

( Ribatti, D; Roccaro, AM; Vacca, A, 2006)

"Also, combined therapy for tumors and tumor metastases comprised administration of integrin ligands and co-therapeutic agents have synergistic efficacy in isolated organ perfusion."

( Gouliamos, AD; Koukourakis, GV; Kouloulias, VE; Kouvaris, I; Petridis, AK, 2007)

"Patients with active cancer and anemia not receiving or planning to receive chemotherapy or radiotherapy were enrolled onto a phase III, multicenter, randomized, placebo-controlled study and administered placebo or DA 6."

( Aapro, MS; Chen, L; Ciuleanu, TE; Glaspy, JA; Lillie, T; Ludwig, H; Pintér, T; Smakal, M; Smith, RE, 2008)

"Patients (N = 89) with varying solid tumors and liver function were stratified into four groups according to serum total bilirubin and AST and were treated with escalating doses of imatinib."

( Belani, CP; Doroshow, JH; Egorin, MJ; Grem, JL; Hamilton, A; Hayes, MJ; Ivy, SP; LoRusso, PA; Mulkerin, DL; Murgo, AJ; Peng, B; Potter, DM; Ramanathan, RK; Remick, SC; Takimoto, CH, 2008)

"Finally, the results of LA use in human cancer chemotherapy and as chemopreventive agent are discussed in the light of LA future inclusion into chemotherapeutic protocols."

( Cojocel, C; Novotny, L; Rauko, P, 2008)

"Fifty-five cancer patients who received tropisetron for the prevention of acute chemotherapy-induced nausea and vomiting were enrolled into this single center, prospective study."

( Artac, M; Boruban, C; Eren, O; Genc, M; Yavas, O; Yazici, M, 2008)

"This method of cancer treatment does not require any chemotherapeutic agent to be applied."

( Kik, K; Lwow, F; Szmigiero, L, 2007)

"Compared to patients without cancer, patients with cancer receiving anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)."

( Akl, EA; Barba, M; Muti, P; Rohilla, S; Schünemann, HJ; Sperati, F; Terrenato, I, 2008)

"Finally, we evaluated recurrent cancers from patients whose primary BRCA2-mutated ovarian carcinomas were treated with cisplatin."

( Agarwal, MK; Couch, FJ; Farrugia, DJ; Friedman, C; Higgins, J; Jacquemont, C; Karlan, BY; Sakai, W; Swisher, EM; Taniguchi, T; Urban, N; Villegas, E, 2008)

"Poor oxygenation of solid tumors is a major indicator of adverse prognosis after standard treatment, e."

( Bache, M; Kappler, M; Said, HM; Staab, A; Vordermark, D, 2008)

"The resistance of many human cancers to immune-based therapies, including adoptive immunotherapy and the administration of therapeutic cancer vaccines, has been attributed to tumor-associated immune suppression, due in part to immunosuppressive molecules located within the tumor microenvironment."

( Blay, J; Conrad, DM; Furlong, SJ; Hoskin, DW; Mader, JS, 2008)

"This case-control study included 28 cancer patients concomitantly treated with Panicum Miliaceum and 56 patients receiving the same combinations of chemotherapy alone as a control group."

( Arnoffi, J; Biella, C; Casiraghi, M; Cerrone, R; Colombo, L; Galbiati, B; Gardani, G; Giani, L; Lissoni, P; Meregalli, M; Messina, G; Proserpio, E; Trabattoni, P; Travisi, O, 2007)

"Patients with advanced solid tumors and documented CanAg expression were treated with escalating doses of cantuzumab mertansine IV administered three-times a week in a 3 out of 4 weeks schedule."

( de Bono, J; Forero, L; Garrison, M; Hammond, LA; Hao, D; Howard, M; Lambert, JM; Pandite, L; Rodon, J; Smith, L; Takimoto, C; Tolcher, AW; Xie, H, 2008)

"Patients with cancer who received ESAs had increased VTE risks (334 VTE events among 4610 patients treated with ESA vs 173 VTE events among 3562 control patients; 7."

( Barnato, SE; Bennett, CL; Blau, CA; Courtney, DM; Djulbegovic, B; Dorr, DA; Edwards, BJ; Elverman, KM; Gleason, KJ; Henke, M; Kuzel, TM; Lai, SY; McKoy, JM; Raisch, DW; Samaras, AT; Silver, SM; Tallman, MS; Tigue, CC; Trifilio, SM; West, DP; Yarnold, PR, 2008)

"Prodrug 7 may be useful for selective cancer chemotherapy by a prodrug monotherapy (PMT) or antibody-directed enzyme prodrug therapy (ADEPT) strategy."

( Chen, CS; Chern, JW; Leu, YL; Wu, YJ, 2008)

"Oral administration of anticancer agents is preferred by patients for its convenience and potential for use in outpatient and palliative setting."

( Bromberg, L, 2008)

"Patients with solid tumors and no other curative treatment options were eligible."

( Baggstrom, MQ; Fracasso, PM; Govindan, R; Read, W; Suresh, R; Wildi, JD, 2008)

"Patients with cancer may receive erythropoiesis-stimulating agents (ESAs), including darbepoetin alfa (DA) or epoetin alfa (EA), to treat cancer-related anemia (CRA)."

( Berger, A; Edelsberg, J; Kallich, J; Oster, G, 2008)

"Treatment of several different cancer cell types with NSC348884 upregulated p53 (increased Ser15 phosphorylation) and induced apoptosis in a dose-dependent manner that correlated with apoptotic markers: H2AX phosphorylation, poly(ADP-ribose) polymerase cleavage and Annexin V labeling."

( Beeck, S; Cooke, L; Goldman, A; Mahadevan, D; Qi, W; Shakalya, K; Stejskal, A, 2008)

"Patients with cancer have an impaired T-cell response that can decrease the potential therapeutic benefit of cancer vaccines and other forms of immunotherapy."

( Ochoa, AC; Rodríguez, PC, 2008)

"Upon treatment of ovarian cancer TYK-nu cells with vitamin K2, superoxide is produced after two to three days, followed shortly thereafter by release of mitochondrial cytochrome c."

( Aiuchi, T; Nakaya, K; Shibayama-Imazu, T, 2008)

"Finally, under optimal conditions for cancer therapy, the DTX-HGC nanoparticles showed higher antitumor efficacy such as reduced tumor volume and increased survival rate in A549 lung cancer cells-bearing mice and strongly reduced the anticancer drug toxicity compared to that of free DTX in tumor-bearing mice."

( Hwang, HY; Kim, IS; Kim, YH; Kwon, IC, 2008)

"The total numbers of new cancer patients and total cancer patients (new and repeat) treated with radiotherapy in 2005 were estimated at approximately 162,000 and 198,000, respectively."

( Ikeda, H; Ito, H; Kamikonya, N; Koizumi, M; Masaki, H; Nagata, Y; Nishimura, T; Nishio, M; Numasaki, H; Sekiguchi, K; Shibuya, H; Tago, M; Teshima, T; Yamada, S, 2008)

"Patients with advanced solid tumors were treated with oxaliplatin 130 mg/m(2) intravenously on day 1, capecitabine 750-900 mg/m(2) twice daily orally for 14 days, and bortezomib 1."

( Beard, M; Cohen, SJ; Engstrom, PF; Langer, CJ; Lewis, NL; McLaughlin, S; Meropol, NJ; Weiner, LM, 2008)

"Here, we review recent findings that cancer cell sensitivity to TRAIL is greatly increased when the Bcl-2 family protein Mcl-1 is down-regulated by the Raf/vascular endothelial growth factor kinase inhibitor sorafenib, a Food and Drug Administration-approved cancer drug."

( El-Deiry, WS; Kim, SH; Ricci, MS, 2008)

"The first 20 years of anticancer photodynamic therapy (PDT) were based on the utility of the oligomeric mixture haematoporphyrin derivative (HpD) in various forms."

( Wainwright, M, 2008)

"Clinical trials in solid tumors and in acute myeloid leukemia have demonstrated the potential to improve treatment outcome when histamine dihydrochloride is combined with immunotherapy."

( Ho, AD; Perz, JB, 2008)

"Pain in older cancer patients is a common event, and many times it is undertreated."

( Bruera, E; Delgado-Guay, MO, 2008)

"Rather for several types of cancer a significantly reduced risk was observed, except for breast cancer in women treated with IS."

( Berthier, F; Clavelou, P; Danzon, A; de Seze, J; Debouverie, M; Defer, G; Gout, O; Lebrun, C; Rumbach, L; Vermersch, P; Wiertlevski, S, 2008)

"address in the current issue of Cancer Biology & Therapy, by examining the effects of combined treatment with radiation and HIV protease inhibitors."

( Bernhard, EJ; Brunner, TB, 2008)

"Evaluation of given cancer treatment, anthropometric and testicular size measurements, semen analysis, and measurement of gonadotrophins, testosterone, sex hormone-binding globulin (SHBG), and inhibin B were performed according to a protocol."

( Andersson, AM; Arola, M; Lähteenmäki, PM; Salmi, TT; Suominen, J; Toppari, J, 2008)

"Seven cell types, cancerous and noncancerous, were treated with lycopene from 0."

( Burgess, LC; Burgess, TP; Fischer, T; Klatt, K; Rice, E; Seekins, JR; Sticka, SJ, 2008)

"All S1 treated tumors and none of the controls exhibited complete or partial responses, and these responses continued for the entire observation period of 12 days."

( Awruch, J; Prucca, CG; Rivarola, VA; Strassert, C; Vittar, NB, 2008)

"To improve cancer chemotherapy, we need to understand the mechanisms that determine drug sensitivity in cancer and normal cells."

( Mitchison, T; Orth, JD; Shi, J, 2008)

"Eligibility criteria included stable cancer pain requiring opioid therapy, need for parenteral route, and normal cognition."

( Bruera, E; Hanson, J; Pereira, J; Tarumi, Y; Watanabe, S, 2008)

"LPA GPCRs regulate cancer cell proliferation, invasion, angiogenesis, and also biochemical resistance to chemotherapy- and radiotherapy-induced apoptosis."

( Gajewiak, J; Prestwich, GD; Serban, M; Xu, X; Yang, G; Zhang, H, 2008)

"Anemia is frequently experienced by cancer patients receiving chemotherapy and can negatively impact the patient's prognosis."

( Aapro, MS; Link, H, 2008)

"Thus an "old-age" disease such as cancer requires an "age-old" treatment."

( Aggarwal, BB; Anand, P; Jhurani, S; Kunnumakkara, AB; Sundaram, C, 2008)

"Fourteen human cancer cell lines with and without DNA MMR derived from carcinomas of the colon, bladder, ovary and prostate were treated with CAI, vehicle or control drugs (nifedipine and 5-flurouracil)."

( Friedlander, ML; Kohn, EC; Qu, XJ; Yang, JL; Yu, Y, 2008)

"Providing novel treatments to help cancer patients live longer and have better lives remains one of the biggest challenges of the pharmaceutical industry."

( Frieden, M; Ørum, H, 2008)

"Because most cancers are caused by dysregulation of as many as 500 different genes, agents that target multiple gene products are needed for prevention and treatment of cancer."

( Aggarwal, BB; Anand, P; Kunnumakkara, AB, 2008)

"Forty-nine patients with solid tumors were enrolled, and 48 were treated with plitidepsin (doses from 0."

( Bowman, A; García, M; Germá, JR; Gómez, J; Izquierdo, MA; Jimeno, J; Jodrell, D; López-Martin, JA; Martinez, M; Pardo, B; Smyth, JF, 2008)

"Chemotherapy for cancer can cause immunocompromise."

( Hesseling, PB; Labadarios, D; Stefan, DC; Wessels, G, 2008)

"The subjects were 56 cancer patients undergoing opioid therapy in hospitals belonging to the Symptom Control Research Group (SCORE-G)."

( Endo, R; Hisada, A; Itoh, T; Iwata, H; Kagaya, H; Kawade, Y; Kokubun, H; Nakamura, M; Sano, M; Shibasaki, Y; Shiokawa, M; Suzuki, T; Takase, H, 2008)

"Increased awareness of how to treat cancer pain is important go give a good treatment offer to all in Norway."

( Olsen, AS; Ottesen, S, 2008)

"For platinum-based anticancer drugs the interaction with serum proteins is regarded as an important contribution to the side effects accompanying chemotherapy."

( Groessl, M; Hartinger, CG; Jarosz, M; Keppler, BK; Polec-Pawlak, K, 2008)

"Differentiation among malignant tumors, benign tumors, and normal tissue is highly important in the diagnosis and treatment of many malignancies."

( Cao, X; Povoski, SP; Sun, D; Wang, B; Xu, RX, 2008)

"Patients with advanced or metastatic cancer refractory to standard therapy were eligible."

( Andre, VA; Beijnen, JH; Callies, S; Jansen, RS; Kloeker-Rhoades, S; Pluim, D; Rosing, H; Schellens, JH; Slapak, CA; Veltkamp, SA; Visseren-Grul, CM, 2008)

"Medical records of pediatric cancer patients treated with HD-MTX were reviewed retrospectively after follow-up of 1-10 years."

( Grönroos, MH; Irjala, K; Jahnukainen, T; Möttönen, M; Perkkiö, M; Salmi, TT, 2008)

"Recently, the use of SdFFF in cancer research has been studied in order to better understand major phenomena implicated in cancer development and therapy: apoptosis and differentiation."

( Battu, S; Bégaud-Grimaud, G; Beneytout, JL; Bertrand, J; Cardot, P; Jauberteau, MO; Liagre, B, 2008)

"More precisely, the French Plan cancer and the December 2004 << arrêté >> aim at << facilitating home-based chemotherapy by injection >> only << within the framework of a network of health in oncology >>, this in order to improve the quality of care and quality of life of patients."

( Barbarot, V; Courant-Menanteau, M; Lewden-Bernadac, B; Perrocheau, G; Thomare, P, 2008)

"It was also studied for treating some cancers and age-related macular degeneration and showed some promising findings."

( Heng, PW; Olivo, M; Saw, CL, 2008)

"Despite recent advances in cancer therapy, many malignant tumors still lack effective treatment and the prognosis is very poor."

( Haapa-aho, V; Järvinen, K; Korhonen, H; Pikkarainen, J; Pulkkinen, M; Seppälä, J; Tarvainen, T; Wirth, T, 2008)

"We conclude that a cancer gene therapy strategy based on a transcriptionally targeted viral vector expressing an inducible caspase allows for selective and controlled ablation of microvessels of histopathologically diverse tumor types."

( Dong, Z; Jin, T; Mantellini, MG; Nör, JE; Núñez, G; Song, W, 2008)

"In the treatment of tumors with thalidomide, a rationale for its use is that it inhibits angiogenesis."

( Sandoval, FG; Shannon, EJ, 2008)

"Fourteen patients with advanced solid tumors refractory to standard treatment were enrolled and received motesanib diphosphate 50 mg once daily from day 1 through 15."

( Chen, L; Heath, EI; Ingram, M; Lorusso, P; Malburg, L; McGreivy, J; Melara, R; Pilat, MJ; Sun, YN; Wiezorek, J; Yan, L, 2008)

"Monitoring direct targets of anticancer therapy might be superior to indirect size changes."

( de Langen, AJ; Lubberink, M; Marcus, JT; van den Boogaart, VE, 2008)

"Cells from 9 canine cancer cell lines were treated with dimethyl sulfoxide vehicle, OSU-HDAC42, or SAHA, then assays of cell viability were performed."

( Chen, CS; Kisseberth, WC; Kulp, SK; London, CA; Murahari, S, 2008)

"Patients who have cancer, particularly those undergoing chemotherapy, frequently become anemic."

( Glaspy, JA, 2008)

"These results suggest that epigenetic cancer therapy is possible for some cancers in combination with forced p53 activation."

( Asano, Y; Nakajima, W; Oda-Sato, E; Takeshita, T; Tanaka, N; Uehara, I; Yagi, S, 2008)

"Breast EMT6 tumors in mice were subjected to treatment by NaOH solution, hyperthermia and encapsulated sodium."

( Liu, J; Rao, W; Yang, Y; Zhang, H; Zhou, YX, 2008)

"Using sodium to ablate target tumors is potentially an effective, safe and low cost way to treat malignant tumors."

( Liu, J; Rao, W; Yang, Y; Zhang, H; Zhou, YX, 2008)

"Patients affected by tumors suffer from increased risk for treatment-related toxicities."

( Botturi, A; Bruzzone, MG; Ciceri, E; Erbetta, A; Potepan, P; Salmaggi, A; Sghirlanzoni, A; Silvani, A, 2008)

"These cancers are potential targets for selective chemotherapy with inhibitors of de novo adenine synthesis such as L-alanosine [L-2-amino-3-(N-hydroxy-N-nitrosamino) propionic acid]."

( Burris, HA; Kindler, HL; Oliff, IA; Sandler, AB, 2009)

"Items from the Functional Assessment of Cancer Therapy-Fatigue (FACT-F), Brief Fatigue Inventory (BFI), Fatigue Symptom Inventory (FSI), and items adapted from the Medical Outcomes Study SF-36 physical functioning scale were evaluated for inclusion in the measure."

( Cella, D; Foreman, AJ; Hays, RD; Kallich, JD; Mendoza, TR; Pasta, DJ; Stein, KD; Vadhan-Raj, S; Viswanathan, HN, 2008)

"The CTS plays a role in cancer processes and their treatments through the downregulation of malignant growth and the generation of large and predictable 24 hour changes in toxicity and efficacy of anti-cancer drugs."

( Altinok, A; Clairambault, J; Goldbeter, A; Lévi, F, 2008)

"New targets have been identified, but cancer therapy and the anti-cancer drug market still partly depend on anti-mitotic agents."

( Bermejo, M; Gonzalez-Alvarez, I; Kovacs, GG; Lau, P; Lehotzky, A; Merino, V; Orosz, F; Ovádi, J; Tokési, N, 2008)

"Clam cancer offers significant advantages over traditional models for genotoxic and non-genotoxic preclinical analysis of treatments for human cancers with a similar molecular basis."

( Böttger, SA; Walker, CW, 2008)

"Adults with cancer- or non-cancer-related chronic pain were switched from fentanyl transdermal reservoir patch to fentanyl transdermal matrix patch therapy without compromising efficacy; no differences in pain intensity or sleep interference scores were seen between the two formulations in an nonblind, multicentre, switching pilot study."

( Hoy, SM; Keating, GM, 2008)

"A major limitation in the treatment of cancers is the prevalence of chemoresistant tumors."

( Alvero, AB; Brown, D; Kelly, M; Leiser, A; Mor, G; Rossi, P; Rutherford, T, 2008)

"High-quality management of cancer pain depends on evidence-based standards for screening, assessment, treatment, and follow-up for general cancer pain and specific pain syndromes."

( Asch, SM; Dy, SM; Lorenz, KA; Naeim, A; Sanati, H; Walling, A, 2008)

"The experience of patients living with cancer and being treated with chemotherapy often includes the symptoms of nausea and vomiting."

( Asch, SM; Dy, SM; Lorenz, KA; Naeim, A; Sanati, H; Walling, A, 2008)

"Drugs used to treat cancer may affect the skeleton in several ways, the most important being a decrease in sex steroid levels."

( Vestergaard, P, 2008)

"There is a role for drug treatment of cancer-related fatigue, but no consensus has been reached on which drugs are useful."

( Hotopf, M; Minton, O; Richardson, A; Sharpe, M; Stone, P, 2008)

"Despite the improvements in cancer therapy during the past years, high-grade gliomas and many other types of cancer are still extremely resistant to current forms of therapy."

( Betzel, T; Hess, T; Reubi, JC; Roesch, F; Waser, B, 2008)

"Elucidation of the mechanisms of cancer cell elimination by PDT might help in establishing highly specific, non-genotoxic anti-cancer treatment of tomorrow."

( Bielawski, KP; Grulkowski, I; Krachulec, J; Selivanova, G; Zawacka-Pankau, J, 2008)

"Forty-seven cancer patients (23 elderly and 24 non-elderly) scheduled to receive HEC or MEC regimens who had experienced CINV grade 3-4 during the first chemotherapy course and for whom the same course of chemotherapy regimen was further scheduled were enrolled."

( Astara, G; Dessì, M; Lepori, S; Loi, C; Madeddu, C; Mantovani, G; Massa, E, 2009)

"Mice bearing LLC or Meth A tumors were treated with intratumoral or intravenous injections of Lip-MP and radiation."

( Diao, P; Ding, ZY; Du, XB; Fan, LY; Kan, B; Lang, JY; Li, HX; Li, T; Liu, L; Lu, Y; Mao, YQ; Wang, GQ; Wang, R; Wang, YS; Wei, YQ; Wen, YJ; Wu, HB; Xu, JR; Yang, HS; Yao, B; Yuan, ZP; Zhao, JM; Zhao, X, 2008)

"Treatment of mice with pancreatic cancer doubled their survival (P<0."

( Ala-Aho, R; Diaconu, I; Hakkarainen, T; Hemminki, A; Jalonen, H; Jokinen, M; Kähäri, VM; Kanerva, A; Kangasniemi, L; Koskinen, M; Moilanen, H; Pesonen, S; Stenman, UH; Toriseva, M; Ylä-Herttuala, S, 2009)

"Anaemia is common in cancer patients treated with chemotherapy."

( Alegre, A; Cassinello, J; Gasquet, JA; González, A; Mel, JR; Montesinos, J; Rodríguez, CA; Saigí, E; Salar, A; Sánchez, J, 2008)

"10 subjects with cancer who were currently receiving treatment and 10 additional subjects without cancer who were matched to the subjects with cancer based on gender and race were enrolled into the study."

( Cavallari, LH; Deyo, K; Molokie, RE; Momary, K; Neceskas, J; Patel, SR; Shord, SS; Viana, MA, 2008)

"Patients with advanced and incurable cancers are dealing with the emotional impact of a life-limiting illness, treatment decisions that are complex and frequently involve consideration of clinical trials, and the challenges of sustaining hope while also having realistic goals."

( Anderson, WG; Arnold, RM; Back, AL; Bunch, L; Marr, LA; Wallace, JA; Yang, HB, 2008)

"Caregiving, an important component of cancer patient treatment, may set forth a cascade of stress responses such as sympatho-adrenal activation, immuno-humoral changes and an unhealthy lifestyle, which could be hazardous to caregivers' health."

( Beltrami, S; Bruno, D; Cannone, V; Di Fede, G; Lucini, D; Malacarne, M; Pagani, M; Piazza, E; Pizzinelli, P, 2008)

"We reasoned that pretreatment of tumors with HDIs could enhance the replication and spread of OVs within malignancies."

( Abdelbary, H; Arguello, M; Atkins, H; Bell, JC; Bismar, TA; Breitbach, C; Diallo, JS; Falls, T; Hiscott, J; Kirn, D; Leveille, S; Nguyên, TL; Snoulten, VE; Stojdl, DF; Vähä-Koskela, MJ; Vanderhyden, BC; Werier, J; Yasmeen, A, 2008)

"Standard cytotoxic agents for treating cancer were developed based on their effectiveness to kill rapidly dividing cells, not on their ability to selectively kill cancer cells and spare normal tissue."

( Chan, DA; Giaccia, AJ, 2008)

"Although it is accepted that pediatric cancer treatment harbors a risk of gonadal damage, large cohort studies using up-to-date fertility markers are lacking."

( Dohle, GR; Hählen, K; Hakvoort-Cammel, FG; van Casteren, NJ; van den Heuvel-Eibrink, MM; van der Linden, GH, 2009)

"These findings may be useful for cancer combinational therapy with lapatinib in the clinic."

( Ambudkar, SV; Ashby, CR; Chen, LM; Chen, ZS; Dai, CL; Fu, LW; Huang, Y; Liang, YJ; Liu, DG; Robey, RW; Shi, CJ; Su, XD; Tiwari, AK; Wang, SR; Wu, CP, 2008)

"When LoVo tumors were treated with increasing radiation doses, more MSCs were found to migrate to them than to untreated tumors."

( Lawrence, TS; Livant, DL; Zielske, SP, 2009)

"Two different p53 wild-type cancer cell lines (U2OS and HCT116) treated with Nutlin-3a for 24 hours accumulated 2N and 4N DNA content, suggestive of G(1) and G(2) phase cell cycle arrest."

( Maki, CG; Moran, DM; Shen, H, 2008)

"A patient with pancreatic cancer treated at 100 mg/m(2) died on course one at day 18 with grade 3 hyperbilirubinemia and neutropenia, fever, and acute renal failure."

( Aherne, W; Atadja, P; de Bono, JS; Fong, P; Karavasilis, V; Kaye, S; Kristeleit, R; Mita, M; Pacey, S; Patnaik, A; Rowinsky, EK; Scott, JW; Shaw, H; Tolcher, A; Workman, P, 2008)

"Since these concentrations exhibit anticancer activities in vitro, this raises the controversial question of the re-evaluation of vitamin C in cancer treatment."

( Calderon, PB; Verrax, J, 2008)

"Gastrointestinal symptoms of cancer pain patients undergoing an opioid therapy are related to multifactorial causes."

( Kloecker, N; Mueller, M; Nadstawek, J; Schaefer, N; Schenk, M; Schroeck, A; Standop, J; Wirz, S; Wittmann, M, 2009)

"In adult patients with cancer and an acute venous thromboembolic event we sought to determine the rates of recurrent venous thromboembolism (VTE) and major hemorrhage when treated with prolonged LMWH therapy compared to vitamin-K antagonists."

( Louzada, ML; Majeed, H; Wells, PS, 2009)

"For anticancer therapy, stimulation of proapoptotic mitochondrial events in tumor cells and their suppression in surrounding normal cells represents a promising paradigm for new therapies."

( Atkinson, J; Bayir, A; Bayir, H; Belikova, NA; Borisenko, GG; Chapkin, RS; Greenberger, JS; Kagan, VE; Stoyanovsky, D; Tyurina, YY; Wipf, P, 2009)

"A total of 379 women developed invasive cancer (187 in the active treatment group and 192 in the placebo group)."

( Albert, CM; Buring, JE; Cook, NR; Gaziano, JM; Manson, JE; Zhang, SM, 2008)

"Published guidelines recommend holding cancer therapy if the rash is severe."

( Jatoi, A; Nguyen, PL, 2008)

"As conventional cancer therapies struggle with toxicity issues and irregular remedial efficacy, the preparation of novel gene therapy vectors could offer clinicians the tools for addressing the genetic errors of diseased tissue."

( Gunn, JW; Kievit, FM; Ratner, BD; Veiseh, O; Zhang, M, 2009)

"In dendritic cell (DC)-based cancer immunotherapy, it is important that DCs present peptides derived from tumor-associated antigens on MHC class I, and activate tumor-specific cytotoxic T lymphocytes (CTLs)."

( Kadowaki, N; Kodama, T; Maruyama, K; Namai, E; Oda, Y; Okada, N; Suzuki, R; Tachibana, K; Taira, Y; Utoguchi, N, 2009)

"In the present study, human cancer cell lines, DU-145 cells (androgen-insensitive prostate cancer cells), KB cells (human epidermoid cells), and human melanoma cell line, M14, were treated for 72 h with 0."

( Cardile, V; De Ioannes, A; Garbarino, J; Russo, A, 2009)

"Patients with solid tumors refractory to standard therapy received i."

( Animati, F; Beijnen, JH; Capriati, A; Crea, A; Schellens, JH; van den Heuvel, IJ; Veltkamp, SA; Voest, EE; Voogel-Fuchs, M; Witteveen, EO, 2008)

"A total of 78 untreated patients with cancer were included: 28 gastrointestinal system tumors (group 1), 27 respiratory system tumors (group 2), and 23 miscellaneus group of ovarian, renal, nasopharyngeal, mesothelioma, and unknown origin (group 3)."

( Akay, OM; Canturk, Z; Gulbas, Z; Mutlu, FS; Ustuner, Z, 2009)

"A severe limitation in cancer therapy is the often insufficient differentiation between malign and benign tissue using known chemotherapeutics."

( Alves, F; Krewer, B; Major, F; Müller, M; Schuberth, I; Schuster, HJ; Tietze, LF; von Hof, JM, 2008)

"Terminally ill cancer patients near the end of life may experience intolerable suffering refractory to palliative treatment."

( Casuccio, A; David, F; Ferrera, P; Intravaia, G; Mercadante, S; Villari, P, 2009)

"Thirty four patient pairs matched on cancer type and chemotherapy in pre- (retrospective; clinicians not using RESPOND) and post-cohorts (prospective; clinicians using RESPOND) followed over 4 months following EP treatment initiation."

( Aapro, M; Abraham, I; Albrecht, T; MacDonald, K; Muenzberg, M; Soubeyran, P; Turner, M; Van Erps, J; Warrinnier, H, 2009)

"Eligible patients had advanced solid tumors that failed to respond to standard therapy or for which no standard therapy was available, and met the following criteria: performance status ≤2 and acceptable organ function."

( Andoh, M; Fukuoka, M; Kawahara, M; Niitani, H; Yamamoto, N, 2009)

"The treatment of chemoresistant tumors represents an important challenge in the field of oncology."

( Barthomeuf, C; Bourguet-Kondracki, ML; Kornprobst, JM, 2008)

"Our findings show that cancer cells can survive after initiation of apoptosis, thereby revealing an unexpected potential escape mechanism of cancer cells from chemotherapy."

( Fung, MC; Tang, HL; Tang, HM; Yuen, KL, 2009)

"The aim of nutritional therapy in cancer patients is to prevent weight loss and to improve functional capacity and quality of life."

( Bayram, I; Celik, N; Erbey, F; Nelson, JL; Tanyeli, A, 2009)

"Heterogeneity of tumors dictates an individual approach to anticancer treatment."

( Gogvadze, V; Orrenius, S; Zhivotovsky, B, 2009)

"The use of anti-HIV drugs as cancer treatments is not new."

( Chow, WA; Guan, M; Jiang, C, 2009)

"and other treatment modalities in cancer patients who were admitted to an anesthesiology-based pain service."

( Bilgin, F; Dere, K; Ergin, A; Güzeldemir, ME; Orhan, ME, 2008)

"Conventional cancer treatment involves the use of surgery and cytotoxic chemotherapy and/or radiotherapy, which have the potential of harming normal, otherwise healthy, non-neoplastic cells."

( Choong, PF; Dass, CR; Tan, ML, 2009)

"Seventy eight cancer patients undergoing multiple-day chemotherapy of high (HEC) or moderate (MEC) emetic risk received granisetron, dexamethasone plus aprepitant during chemotherapy."

( Behlendorf, T; Jordan, K; Kinitz, I; Schmoll, HJ; Voigt, W; Wolf, HH, 2009)

"A total of 105 cancer patients receiving chemotherapy or radiotherapy were enrolled."

( Chen, SL; Huang, CC; Huang, MC; Lee, HS; Liu, WS; Shane, GT; Shen, YC; Tsai, JH; Tseng, HC; Wang, CK; Wu, TC; Yan, YY; Yang, CH; Zhuang, SR, 2009)

"Overall malignancy rates for adalimumab-treated patients were as expected for the general population."

( Burmester, GR; Dijkmans, BA; Gordon, K; Lovell, D; Mease, P; Panaccione, R; Pangan, AL; Perez, J, 2009)

"C57Bl/6 mice bearing subcutaneous B16 tumors were treated with CPA or PC-61 followed by 10 injections of low-dose IL-2."

( Coffey, M; Diaz, RM; Harrington, K; Kottke, T; Melcher, A; Pulido, J; Selby, P; Thompson, J; Vile, RG; Willmon, C, 2009)

( Fernandez Mauleffinch, LM; Glenny, AM; Pavitt, S; Walsh, T, 2009)

"PDT is well known as a practical cancer treatment using cytotoxicity of reactive oxygen species generated by the photochemical interaction."

( Arai, T; Hosokawa, S; Ito, A; Miyoshi, S; Soejima, K, 2008)

"Indeed, PAR expression correlates with cancer malignancy and clinical studies show that anticoagulant treatment is beneficial in cancer patients."

( Borensztajn, KS; Spek, CA, 2008)

"A fundamental assumption behind cancer rehabilitation in many Western societies is that cancer survivors can return to normal life by learning to deal with the consequences of their illness and their treatment."

( Hansen, HP; Tjørnhøj-Thomsen, T, 2008)

"It also efficiently treated tumors in mice with up to 40% complete remission."

( Bachmann, MH; Barak, Y; Contag, CH; Liang, W; Matin, A; Rao, J; Thorne, SH, 2009)

"The primary purpose of dose-banding for cancer chemotherapy is to reduce patient waiting times, but dose-banding also has additional benefits, such as reduced drug wastage, reduced stress for staff, and prospective quality control of infusions."

( Kaestner, SA; Sewell, GJ, 2009)

"Pain still afflicts most cancer patients, mainly in the metastatic phases, and undertreatment is well documented."

( Apolone, G; Caraceni, A; Corli, O; Deandrea, S; Greco, MT; Montanari, M, 2008)

"Vaccination with FasL-expressing tumors therefore enables the immune system to break tolerance to self-antigens, allowing identification of novel TACAs that can form the basis of future humoral anticancer therapy."

( Chen, PF; Newsom-Davis, TE; Screaton, GR; Simon, AK; Steinman, L; Wang, D; Wang, LX, 2009)

"The scale was administered to 257 cancer patients; the reliability and validity of the scale were examined using Cronbach's alpha and factor analysis, respectively."

( Han, SS; Kim, J; Puchalski, CM; Yong, J, 2008)

"The National Cancer Patient Registry was proposed as a database for cancer patients who seek treatment in Malaysia."

( Azura, D; Lim, GC, 2008)

"These findings may be useful for cancer combinational therapy with sunitinib in the clinic."

( Chen, ZS; Dai, CL; Fu, LW; Liang, YJ; Tiwari, AK; Tong, XZ; Wang, F; Wang, YS; Yan, YY, 2009)

"Thirty-six patients with metastatic cancer who had progressed on, or were ineligible for, standard chemotherapy received single-agent oral talactoferrin."

( Falchook, GS; Hayes, TG; Varadhachary, A, 2010)

"The European Pain in Cancer survey sought to increase understanding of cancer-related pain and treatment across Europe."

( Breivik, H; Cherny, N; Cohen, R; Collett, B; de Conno, F; Dow, L; Filbet, M; Foubert, AJ, 2009)

"Across Europe and Israel, treatment of cancer pain is suboptimal."

( Breivik, H; Cherny, N; Cohen, R; Collett, B; de Conno, F; Dow, L; Filbet, M; Foubert, AJ, 2009)

"Resistance of cancer cells to cytotoxic therapy can be caused by the activation of strong anti-apoptotic effectors, for example NF-kappaB."

( Brandely, M; de Jonge, MJ; Eskens, FA; Kitzen, JJ; Lamers, CH; Puozzo, Ch; Ter Steeg, J; van der Biessen, D; van Doorn, L; Verweij, J, 2009)

"Patients with solid tumors refractory to standard therapy were administered pertuzumab 5, 10, 15, 20 and 25 mg/kg intravenously once every 3 weeks."

( Fujisaka, Y; Fujiwara, Y; Shimizu, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N, 2009)

"Thirty-seven cases of cancer patients who had bad effect from anaesthetic drugs were received administration of intravenous flurbiprofen axetil with dose of 50 mg/5 ml/day."

( Chen, Z; Du, Y; Gu, K; Hao, J; Ning, J; Pan, Y; Sun, G; Wu, H, 2009)

"To examine anaemia management in cancer patients treated with erythropoiesis-stimulating agents (ESAs) in Europe."

( Aapro, M; Abraham, I; Albrecht, T; Bokemeyer, C; Ludwig, H; Macdonald, K; Soubeyran, P; Turner, M, 2009)

"A major obstacle for the efficacy of cancer gene therapy is the need to transduce a high proportion of tumor cells with genes that directly or indirectly cause their death."

( Alemany, R; Cascallo, M; Fillat, C; Martinez-Quintanilla, J, 2009)

"(18)F-FDG PET/CT is used for detecting cancer and monitoring cancer response to therapy."

( Dick, DW; Gambhir, SS; Goris, ML; Iagaru, A; Mittra, E; Quon, A; Yaghoubi, SS, 2009)

"Patients affected with advanced cancer were treated with palonosetron 250 mcg plus dexamethasone 20 mg before HEC."

( Giampaglia, M; Lorusso, V; Perrone, T; Petrucelli, L; Saracino, V; Spedicato, A, 2009)

"Targeted therapies are widely used in cancer because of their effectiveness, even in tumours that are resistant to conventional chemotherapy such as kidney or hepatocellular carcinomas."

( Dreyer, C; Faivre, S; Raymond, E, 2009)

"The most commonly treated tumors were gastrointestinal (60%), head and neck (22%) and breast (4%)."

( Saif, MW; Shah, AR; Shah, MM, 2009)

"Most recent advances in cancer treatment have come from the development of disease specific, molecular agents, many of which induce cell cycle arrest (cytostatic effect) instead of tumor cell death (cytotoxic effect)."

( Buck, AK; Dechow, T; Herrmann, K; Schwaiger, M; Shen, C; Wester, HJ, 2009)

"One hundred cancer patients (aged > or = 65 years) and 71 companions completed a recall questionnaire after a nursing consultation preceding chemotherapy treatment."

( Bensing, JM; Heeren, TJ; Jansen, J; van Dulmen, S; van Weert, JC; Wijngaards-de Meij, L, 2010)

"Patients with metastatic solid tumors (MST) with less than a complete response to chemotherapy (L-CR), a depressed immune system and elevated serum vascular endothelial growth factor (VEGF) lack defined treatment options."

( Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F, 2009)

"399 patients with solid tumors and Hb level of < or = 12 g/dl receiving chemotherapy were randomized to receive or not 10,000 IU epoetin-alpha thrice weekly."

( Aravantinos, G; Christodoulou, C; Dafni, U; Fountzilas, G; Janinis, J; Kalofonos, HP; Karina, M; Koutras, A; Papakostas, P; Samantas, E; Skarlos, D, 2009)

"Twenty-eight cancer patients were irradiated for intrathoracic, pelvic, or head and neck tumors and received simultaneous cisplatin containing chemotherapy."

( Engelhard, M; Erichsen, P; Grehl, S; Groneberg, M; Kaelberlah, HP; Pöttgen, C; Sak, A; Stuschke, M; Wierlemann, A, 2009)

"Conventional chemotherapy for cancer has limited specificity for cancer cells."

( Huq, A; Mascarenhas, D; Meeker, T; Singh, B, 2009)

"A total of 43 patients with chronic cancer pain without neuropathic origin aged between 18 and 76 years and receiving step 2 treatment according to the World Health Organization analgesic ladder were included."

( Aydinli, I; Keskinbora, K; Pekel, AF; Salihoglu, T; Sonsuz, A; Tasmacioglu, B, 2009)

"After anticancer treatment, anemia was reported in 54% of patients, mainly in gynecologic and lung cancer pts."

( Filipczyk-Cisarz, E; Lesniewski-Kmak, K; Nawrocki, S; Rybaltowski, M; Sierko, E; Staroslawska, E; Szczylik, C; Tujakowski, J; Wojtukiewicz, MZ, 2009)

"The treatment of BTP in cancer patients receiving opioids is principally based on the use of opioids, preferentially with a short onset."

( Casuccio, A; Fulfaro, F; Mercadante, S, 2009)

"This dilemma of copper implications in cancer therapy and heart hypertrophy dictates a comprehensive understanding of a patient's condition before an implementation of copper manipulation therapy for different diseases."

( Kang, YJ; Xie, H, 2009)

"In 18 patients with malignant tumors refractory to standard treatment, AdV/TK was injected on day 1 with dose escalation from 2."

( Guan, ZZ; Guo, Y; Li, S; Li, XL; Liao, H; Xu, F; Xu, R; Zhang, L; Zhang, Y; Zhao, HY; Zou, BY, 2009)

"These tumors have also responded well to boron neutron capture therapy."

( Johnson, A; Kabalka, GW; McCormack, MT; Miller, LF; Nichols, TL, 2009)

"Patients with cancer receiving highly emetogenic chemotherapy were enrolled in this single-blind randomized controlled study."

( Fujiwara, Y; Hashimoto, H; Hojo, T; Kaneko, M; Kato, Y; Katsumata, N; Kobayashi, Y; Satake, S; Takashima, A; Takeuchi, M; Yamamoto, H; Yonemura, M, 2009)

"The status of TDG expression in a cancer is therefore likely to determine its response to 5-FU-based chemotherapy."

( Focke, F; Kunz, C; Lettieri, T; Saito, Y; Schär, P; Schuermann, D; Selfridge, J, 2009)

"More studies of aspirin and cancer prevention are needed to define the lowest effective dose, the age at which to initiate therapy, the optimum treatment duration, and the subpopulations for which the benefits of chemoprevention outweigh the risks of adverse side-effects."

( Baron, JA; Brown, PH; Burn, J; Cuzick, J; Greenwald, P; Jankowski, J; La Vecchia, C; Meyskens, F; Otto, F; Senn, HJ; Thun, M, 2009)

"Score for all Functional Assessment of Cancer Therapy-Brain (FACT-BR) subscales (measuring quality of life), except social/family well-being, were improved (p < 0."

( Baum, L; Blackhall, L; Farace, E; Petroni, G; Shu, J, 2009)

"Treatment options for local cancer therapy are focused on indications where targeted activity may result in improved patient outcomes such as increased local control and decreased metastatic potential."

( Elstad, NL; Fowers, KD, 2009)

"Five patients with advanced breast cancer and 1 patient with metastatic lung cancer responded to the chemotherapy."

( Elson, P; Peereboom, D; Thomas Budd, G; Weiss, P; Wesolowski, R, 2010)

"For a cytotoxic cancer-treatment agent, TMZ has an acceptable safety profile."

( Hwu, WJ; Patel, SP; Trinh, VA, 2009)

"When treating cancer, cytotoxic agents are intended to exert their effect on rapidly proliferating cancer cells."

( Keely, NO; Meegan, MJ, 2009)

"Hyperthermia therapy for cancer has drawn more and more attention these days."

( Hou, CH; Hou, SM; Hsueh, YS; Lin, FH; Lin, J; Wu, HC, 2009)

"The extensive treatment of 21 human tumors with various dose levels of CZ48 has shown that this agent is highly effective against many different human tumors tested with a striking lack of toxicity."

( Cao, Z; Giovanella, B; Kozielski, A; Liu, X; Vardeman, D; Wang, Y, 2009)

"The first HDACi approved by the FDA for cancer therapy is suberoylanilide hydroxamic acid (SAHA, vorinostat, Zolinza), approved for treatment of cutaneous T-cell lymphoma."

( Marks, PA; Xu, WS, 2009)

"The hypoxic status of various solid tumors has been attributed as an indicator of adverse prognosis due to tumor progression toward a more malignant phenotype with increased metastatic potential and resistance to treatment."

( Kizaka-Kondoh, S; Konse-Nagasawa, H, 2009)

"The aim of anti-cancer therapy is induction of apoptosis in tumor cells."

( Büsselberg, D; Florea, AM, 2009)

"PDT in cancer therapy has been reviewed several times recently and many published reports have been showing promising results."

( Berg, K; Giercksky, KE; Norum, OJ; Selbo, PK; Weyergang, A, 2009)

"Patients with advanced refractory solid tumors were treated with escalating doses of YM155 administered by continuous i."

( Aoyama, Y; Ariyoshi, Y; Fukuoka, M; Hasegawa, Y; Hashimoto, Y; Kakihara, T; Masuda, N; Miyazaki, M; Morinaga, R; Nakagawa, K; Okamoto, I; Saito, T; Satoh, T; Taguchi, T; Terashima, M; Tsuya, A; Ueda, S; Watanabe, H, 2009)

"The development of efficient cancer immunotherapy strategies critically depends on our capacity to maximize anti-tumor effector T-cell responses."

( Barata, JT; Cardoso, BA; Correia, DV; d'Orey, F; deBarros, A; Grosso, AR; Lança, T; Martins, LR; Silva-Santos, B, 2009)

"One patient with gallbladder cancer previously treated with cisplatin and gemcitabine achieved a partial response lasting for >5 months, and eight patients achieved disease stabilization."

( Akashi, Y; Fukuoka, M; Miyazaki, M; Nakagawa, K; Okamoto, I; Ozaki, T; Satoh, T; Shimizu, T; Tamura, K, 2010)

"Planar imaging studies showed that tumors in the glioma-bearing mice administered with (99m)TcO(MAG(2)-3G(3)-dimer) can be visualized with excellent contrast as early as 15 min postinjection."

( Jia, B; Kim, YS; Liu, S; Shi, J; Wang, F; Wang, L; Zhai, S, 2009)

"Pretreatment of human colon and lung cancer cells with sulindac enhances killing by an oxidizing agent such as tert-butyl hydroperoxide (TBHP) or hydrogen peroxide."

( Binninger, D; Gamliel, E; Kesaraju, S; Marchetti, M; Resnick, L; Weissbach, H, 2009)

"The treatment of some cancer patients has shifted from traditional, non-specific cytotoxic chemotherapy to chronic treatment with molecular targeted therapies."

( Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B, 2009)

"Although cancer is considered to be a disease caused by DNA alterations, the high genetic variability of tumor cells makes it difficult to exploit these alterations for the treatment of cancer."

( López-Lázaro, M, 2009)

"Within the wider context of cancer immunotherapy, this Review also delineates how IDO could be exploited as a molecular target for therapeutic intervention in order to boost anti-cancer immunity."

( Bonanno, G; De Cristofaro, R; Rutella, S, 2009)

"beta-Glucans have been used to treat cancer and infectious disease for many years as biological response modifiers with varying and unpredictable efficacy."

( Gunn, L; Hansen, R; Liu, J; Yan, J, 2009)

"Future potential uses of bevacizumab in cancer therapy will be discussed."

( Cortés-Funes, H, 2009)

"A total of 493 patients with solid tumors receiving a first cycle of cisplatin > or =70 mg/m(2) were randomly assigned among six treatment arms."

( Bandekar, RR; Dediu, M; Grunberg, SM; Ramlau, R; Roila, F; Rolski, J; Russo, MW, 2009)

"Testing agents in cancers with multiple disease subtypes, in which the activity of a new treatment may vary between subtypes, presents statistical and logistical challenges."

( Crowley, J; Leblanc, M; Rankin, C, 2009)

"The findings for bladder cancer should be treated with caution as they relate to a relatively early period of follow-up and are based on very small numbers."

( Dost, A; Sorahan, T; Straughan, JK, 2009)

"Consecutive cancer patients scheduled for chemotherapy randomly received: acenocumarine 1 mg/day for 3 days before and 8 days after central vein catheter (CVC) insertion; dalteparin 5000 IU 2 h before and daily for 8 days after CVC insertion; no anticoagulant treatment (NT)."

( Balestreri, L; Bertuzzi, CA; Bidoli, E; De Cicco, M; Fabiani, F; Fantin, D; Malafronte, M; Matovic, M; Morassut, S; Pacenzia, R; Steffan, A; Veronesi, A, 2009)

"ESA treatment in cancer patients increased on study mortality and worsened overall survival."

( Bohlius, J; Brillant, C; Clarke, MJ; Djulbegovic, B; Egger, M; Engert, A; Fey, MF; Kluge, S; Moebus, V; Napoli, M; Piper, M; Rades, D; Ray-Coquard, I; Schmidlin, K; Schumacher, M; Schwarzer, G; Seidenfeld, J; Steensma, D; Thomas, G; Trelle, S; Untch, M; Weingart, O; Zwahlen, M, 2009)

"DNA was isolated from 85 advanced cancer patients treated with 300 or 350 mg/m2 irinotecan and genotyped for haplotype-tag polymorphisms across TOP1, PARP1, TDP1 and XRCC1."

( Hoskins, JM; Innocenti, F; McLeod, HL; Ratain, MJ; Rosner, GL, 2009)

"Significant advances in cancer treatment have been achieved with novel targeted and state-of-the-art treatments."

( Ahmad, A; de Azambuja, E; Metzger-Filho, O; Moulin, C, 2009)

"The data of 199 consecutive cancer patients treated with C-SLED were analyzed."

( Kumar, V; Lahoti, A; Madan, N; Nates, J; Price, K; Salahudeen, AK; Samuels, J; Xiao, L, 2009)

"Patients with solid tumors refractory to standard therapies or with no standard therapy available were enrolled."

( Bloem, JL; Christensen, O; de Jonge, MJ; Eskens, FA; Gelderblom, H; Kraetzschmar, J; Nortier, JW; Ouwerkerk, J; Rajagopalan, P; Steeghs, N; van Doorn, L; Verweij, J, 2009)

"In this study, we generated a dual cancer-specific targeting vector system by using PEGylation and the telomere reverse transcriptase (TERT) promoter and attempted to treat experimental metastases through systemic administration of the vectors."

( Eto, Y; Mizuguchi, H; Morishige, T; Mukai, Y; Nakagawa, S; Okada, N; Okada, Y; Watanabe, H; Yao, X; Yoshioka, Y, 2009)

"In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 led to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h, indicating effective Aurora-B inhibition in vivo."

( Arbitrario, JP; Belmont, BJ; Evanchik, MJ; Flanagan, WM; Fucini, RV; Hansen, SK; Harris, SO; Hashash, A; Hoch, U; Hogan, JN; Howlett, AR; Jacobs, JW; Lam, JW; Ritchie, SC; Romanowski, MJ; Silverman, JA; Stockett, DE; Taverna, P; Teague, JN; Zimmerman, KM, 2010)

"Doxorubicin is a common anticancer agent used in the treatment of a number of neoplasms, with the lifetime dose limited due to the potential for cardiotoxocity."

( Eikenberry, S, 2009)

"One of the main challenges of anti-cancer therapy is to specifically target these drugs to malignant cells."

( Devin, A; Diaz-Ruiz, R; Rigoulet, M; Uribe-Carvajal, S, 2009)

"The basic cancer pain management at our hospitalis based on WHO Cancer Pain Treatment Method-Opioid together with NSAIDs."

( Hirose, Y; Iwasaki, H; Matsuoka, H; Morita, T; Otsuka, M, 2009)

"Eligible patients were adults with cancer receiving a stable dose of long-term opioid treatment for the control of background pain."

( Colberg, T; Kaasa, S; Kaczmarek, Z; Kress, HG; Nolte, T; Orońska, A, 2009)

"In these opioid-tolerant patients with cancer, INFS at doses of 50, 100, and 200 microg was associated with an onset of activity at 10 minutes and effective treatment of breakthrough pain compared with placebo."

( Colberg, T; Kaasa, S; Kaczmarek, Z; Kress, HG; Nolte, T; Orońska, A, 2009)

"Clinical risk factors for cancer-associated VTE include primary tumor site, stage, initial period after diagnosis, presence and number of comorbidities, and treatment modalities including systemic chemotherapy, antiangiogenic therapy, and hospitalization."

( Connolly, GC; Khorana, AA, 2009)

"Today cancer treatment is not only a question of eliminating cancer cells by induction of cell death."

( Laszczyk, MN, 2009)

"Anti-cancer chemotherapy can be simultaneously lymphodepleting and immunostimulatory."

( Cleaver, AL; Currie, AJ; Degli-Esposti, MA; Lake, RA; Larma, I; Mahendran, S; Nowak, AK; Prosser, A; Robinson, BW; Salmons, J; Scalzo, AA; Smyth, MJ; van der Most, RG, 2009)

"The use of opioid for treatment of cancer pain has become common with the spread of the WHO method for relief of cancer pain."

( Watanabe, N; Yamamura, K; Yasuda, K; Yasumura, M, 2009)

"Treatment-emergent neoplasms judged to be malignant were included in this analysis."

( Home, PD; Lagarenne, P, 2009)

"Patients with solid tumors refractory to standard therapies or with no standard therapy available were enrolled."

( Carpinelli, P; de Jonge, MJ; Eskens, FA; Gelderblom, H; Laffranchi, B; Mariani, M; Nortier, JW; Ouwerkerk, J; Spinelli, R; Steeghs, N; van Noort, C; Verweij, J, 2009)

"Patients with advanced solid tumors were treated on a 3+3 trial design."

( Beatty, K; Bokar, J; Borden, E; Budd, GT; Bukowski, RM; Chen, HX; Cooney, MM; Dolwati, A; Dreicer, R; Elson, P; Garcia, JA; Ivy, P; Mekhail, T; Rini, BI; Triozzi, P; Tyler, A, 2009)

"Fifty-four normotensive advanced cancer patients underwent 24-hour ambulatory blood pressure monitoring before and between days 6 and 10 of sorafenib therapy."

( Black, HR; Elliott, WJ; Karrison, T; Kasza, KE; Maitland, ML; Moshier, K; Ratain, MJ; Sit, L; Stadler, WM; Undevia, SD, 2009)

"Twenty-three patients with malignancy resistant or refractory to standard treatment were enrolled into this study evaluating sagopilone doses from 0."

( Arnold, D; Behrmann, C; Giurescu, M; Kiewe, P; Lindemann, S; Reif, S; Schmoll, HJ; Thiel, E; Voigt, W; Wiesinger, H, 2009)

"Forty-five patients with advanced solid tumors and a median of 3 prior chemotherapy regimens (range 0-9), received 318 doses (median 5, range 1-34) of bortezomib and paclitaxel."

( Bekaii-Saab, T; Byrd, JC; Culler, K; Grever, MR; Lesinski, GB; Lucas, DM; Ramaswamy, B; Ruppert, AS; Schaaf, LJ; Shapiro, CL; Wilkins, D; Wright, JJ; Young, DC, 2010)

"The Childhood Cancer Survivor Study (CCSS) is a retrospective cohort study investigating health outcomes of 5+ year survivors diagnosed and treated between 1970 and 1986 compared to a sibling cohort."

( Aitken, CL; Blatt, J; Castleberry, RP; Kawashima, T; Mertens, AC; Mitby, P; Packer, RJ; Robison, LL; Sklar, CA; Stovall, M; Stratton, K; Waterbor, JW; Whelan, KF, 2010)

"This study in patients with cancer and anemia, who were receiving chemoradiation and were treated with epoetin alfa, examined the relationship between hemoglobin level and quality of life (QOL), change in hemoglobin and change in QOL, and incremental (1 g/dL) increase in hemoglobin and related incremental improvement in QOL."

( Cremieux, P; Harrison, L; Shasha, D, 2004)

"One patient with esophageal cancer and one with gastric cancer treated with RAD001 at 10 mg/day showed marked tumor responses."

( Doi, T; Kobayashi, K; Kurei, K; Miyazaki, M; Nakagawa, K; Ohtsu, A; Okamoto, I; Tsuya, A, 2010)

"Treatment of Japanese cancer patients with RAD001 may be undertaken with the expectation that previously determined pharmacokinetic and safety profiles apply."

( Doi, T; Kobayashi, K; Kurei, K; Miyazaki, M; Nakagawa, K; Ohtsu, A; Okamoto, I; Tsuya, A, 2010)

"Epigenetic therapy of cancer is based mostly on the usage of inhibitors of DNA methyltransferases (DNMTs), histone deacetylase (HDAC) inhibitors and anti-micro-RNA therapy."

( Brankovic-Magic, M; Magic, Z; Supic, G, 2009)

"Pediatric cancer treatment may imply an increased risk of hypogonadism, leading to metabolic disorders and osteoporosis."

( Cavallin-Ståhl, E; Giwercman, A; Giwercman, YL; Moëll, C; Relander, T; Romerius, P; Ståhl, O; Wiebe, T, 2009)

"Adult cancer patients receiving stable background opioid treatment and experiencing BTP episodes were recruited from 44 study centres in seven European countries (Austria, France, Germany, Italy, Poland, Spain and the United Kingdom); of the 196 patients enrolled, 139 were randomised to receive INFS followed by OTFC, or vice versa."

( Camba, MA; Colberg, T; Davies, A; Mercadante, S; Perkins, P; Poulain, P; Radbruch, L; Sitte, T, 2009)

"The treatment of VTE in patients with cancer, including those with intracranial malignancies, should be based on low-molecular-weight heparins administered at therapeutic doses for at least 3 months."

( Bosquet, L; Cajfinger, F; Debourdeau, P; Desmurs-Clavel, H; Elalamy, I; Elias, A; Farge, D; Grange, C; Hocini, H; Kassab-Chahmi, D; Legal, G; Levesque, H; Mahe, I; Meyer, G; Mismetti, P; Quéré, I, 2010)

"Although the treatment of cancer cachexia, a multifactorial syndrome, is more likely to yield success with a multitargeted approach; in the present study, we were able to show that a treatment, such as celecoxib, addressing a single target, albeit very important as chronic inflammation, could have positive effects."

( Antoni, G; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Massa, E; Panzone, F; Serpe, R, 2010)

"Paediatric cancer treatment includes a multidisciplinary intervention in all treatment phases, and particularly in the palliative phase."

( Catá del Palacio, E; Hernández Núñez-Polo, M; López Cabrera, A; Lorenzo González, R; Madero López, L; Martino Alba, R; Pérez Martínez, A, 2009)

"We recommend a triple vaccination in cancer patients (seasonal influenza, S-OIV, streptococus pneumoniae), if possible at least two weeks before beginning chemotherapy."

( Barrière, J; Coindard, G; Cua, E; Otto, J; Peyrade, F, 2009)

"Because most cancers are caused by deregulation of as many as 500 different genes, agents that target multiple gene products are needed for prevention and treatment of cancer."

( Das, K; Das, T; Sa, G; Saha, B, 2010)

"Five patients with bleeding from breast cancer under various circumstances were treated with this technique in 2008."

( Kakimoto, M; Okamura, T; Tokita, H; Yoshino, K, 2010)

"The treatment against cancer is being flooded by targeted therapies."

( Chaput, N; Ménard, C; Tursz, T; Zitvogel, L; Zoubir, M, 2010)

"glabrata were obtained from cancer patients who were at high risk for the development of oral candidiasis and who had been treated with topical chlorhexidine once a day."

( Lafleur, MD; Lewis, K; Qi, Q, 2010)

"Bloodless cancer operation and chemotherapy were not accompanied by serious complications."

( Kim, HJ; Kim, KH; Kim, SH; Kwon, HC; Kwon, KA; Lee, JH; Lee, KY; Lee, S; Oh, SY, 2010)

"The multidisciplinary cancer conference (MCC) provides an outlet for contributors in cancer care collectively to evaluate diagnosis and treatment options and to provide optimal patient care."

( Brown, P; Dobrow, MJ; Gagliardi, AR; Hong, NJ; Wright, FC, 2009)

"Chemotherapy can induce anticancer immune responses."

( Kepp, O; Kroemer, G; Martins, I; Métivier, D; Michaud, M; Perfettini, JL; Schlemmer, F; Senovilla, L; Séror, C; Tesniere, A; Zitvogel, L, 2009)

"The incidence of cancer or cancer death in the pravastatin and non-statin therapy groups was compared by multivariate Cox proportional hazard models stratified by trial."

( Hattori, Y; Iwashita, M; Kaburagi, J; Matsushita, Y; Ozawa, M; Saito, H; Sugihara, M; Yoshida, S, 2010)

"Untreated RIF-1 tumors were hypoxic with a tissue pO2 of 5-7 mmHg."

( Demidenko, E; Eastman, A; Hou, H; Khan, N; Lariviere, JP; Mupparaju, SP; Swartz, HM, 2009)

"HER family members are activated in cancer cells and are now considered to be useful molecular targets for cancer therapy."

( Kataoka, H, 2009)

"Several cancer treatment approaches, such as proteasome inhibitor Bortezomib and hsp90 inhibitor geldanamycin, involve activation of proteotoxic stress."

( Almasan, A; Banerjee, AK; Fairchild, RL; Gasparian, AV; Gorbachev, AV; Gudkov, AV; Gurova, KV; Komarov, AP; Neznanov, N; Neznanova, L, 2009)

"To evaluate pain management in cancer patients, a study was conducted examining the treatment circumstances and modalities of initial prescription level 3 analgesics used by 122 French cancer specialists."

( Causse, C; Delorme, T; Krakowski, I; Verrière, JL; Vuillemin, N, 2009)

"Albendazole is a potential anticancer agent that is currently under development for the treatment of cancer."

( Chin, M; Galettis, P; Liauw, W; Links, M; Morris, DL; Pourgholami, MH; Seef, J; Szwajcer, M, 2010)

"Patients with advanced solid tumors refractory to standard therapy were treated with escalating doses of Ang-(1-7) in cohorts of three patients."

( Gallagher, PE; McCoy, TP; Miller, AA; Petty, WJ; Tallant, EA; Torti, FM, 2009)

"Solid tumors contain microenvironmental regions of hypoxia that present a barrier to traditional radiotherapy and chemotherapy, and this work describes a novel approach to circumvent hypoxia."

( Bennewith, KL; Cairns, RA; Chang, DT; Denko, NC; Giaccia, AJ; Graves, EE, 2009)

"Pain still afflicts most cancer patients, mainly in the metastatic phases, and under-treatment is well documented."

( Apolone, G; Bertetto, O; Caraceni, A; Corli, O; De Conno, F; Greco, MT; Labianca, R; Maltoni, M; Mangano, S; Montanari, M; Negri, E; Nicora Maria, F; Torri, V; Zucco, F, 2009)

"These results suggest that the anticancer effect of S-1 can be predicted by performing UrBT 3 h after the initial oral S-1 administration."

( Asai, S; Ishii, Y; Suzuki, S; Takahashi, Y; Takayama, T, 2010)

"In general, most types of cancer pain are treatable following the guideline of Cancer Pain Relief well established by the WHO."

( Hattori, S; Sano, H; Tanaka, K; Yokota, M, 2009)

"In patients with cancer it appears that there is an excess of VTE recurrence after treatment with prophylactic doses that does not occur with full therapeutic doses."

( Cairols-Castellote, MA; Colomé, E; Iguaz, I; Martí-Mestre, X; Romera-Villegas, A; Vila-Coll, R, 2010)

"Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5)."

( Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC, 2010)

"Intererstingly, treatment of EACC tumors with active principles resulted in a significant elevation activity of key antioxidant enzymes (SOD, GST, tGPx, and LDH)."

( Aboul-Enein, KM; Aboul-Soud, MA; El-Shemy, HA; Kabash, A; Nassr-Allah, AA; Yagi, A, 2010)

"However, the resistance of cancer cells to the drugs remains a significant impediment to successful chemotherapy."

( Chen, C; Liang, XJ; Wang, PC; Zhao, Y, 2010)

"HeLa and human Panc1 cancer cells were treated with CNTs (24 h, 10 and 20 microg/ml), etoposide (6 h, 75 x 10(-6) M) and their combination."

( Agarwal, R; Ali, N; Biris, AR; Biris, AS; Dervishi, E; Fejleh, A; Galanzha, EI; Iancu, C; Iancu, DT; Karmakar, A; Li, Z; Mahmood, M; Mocan, L; Mocan, T; Xu, Y; Zharov, VP, 2009)

"Poor penetration of drugs into tumors is a major obstacle in tumor treatment."

( Agemy, L; Girard, OM; Hanahan, D; Karmali, PP; Kotamraju, VR; Mattrey, RF; Ruoslahti, E; Sugahara, KN; Teesalu, T, 2009)

"For some tumors, maximizing the bioavailability and dose intensity via intravenous (IV) administration may provide optimal clinical benefit."

( Boni, JP; Hug, B; Leister, C; Sonnichsen, D, 2009)

"Several aspects of cancer therapy would be involved."

( Baker, JR, 2009)

"For treated tumors, normalized (11)C-choline uptake decreased significantly 24 and 48 h after PDT, compared with the same tumors before PDT (P < 0."

( Chiu, SM; Fei, B; Wang, H; Wu, C, 2010)

"Since both wild-type and MDR cancer cells after pre-treatment with MDL 72527, a lysosomotropic compound, are sensitized to subsequent exposure to BSAO/spermine, it is conceivable that combined treatment with a lysosomotropic compound and BSAO/spermine would be effective against tumor cells."

( Agostinelli, E; Battaglia, V; Grancara, S; Saccoccio, S; Stevanato, R; Tempera, G; Toninello, A; Viceconte, N, 2010)

"Patients with solid tumors refractory or not amenable to conventional treatment were evaluated in a dose-escalation trial of PR-104 administered as a 1-h intravenous (IV) infusion every 3 weeks."

( Denny, WA; Gutheil, J; Jameson, MB; Patterson, AV; Pegram, M; Rischin, D; Wilson, WR, 2010)

"A number of anaemic cancer patients are not responsive to treatment with recombinant human erythropoietin (rHuEPO)."

( Alimonti, A; Borghesi, R; Brunetti, E; Di Palma, M; Mancino, G; Migliore, A; Pavese, I; Piergrossi, P; Piselli, P; Satta, F; Todi, F, 2010)

"The medication list of 200 consecutive cancer patients receiving intravenous chemotherapy was prospectively collected by means of the prescriptions (chemotherapy, supportive care, medications for comorbidities) and a questionnaire (over-the-counter products)."

( Beretz, L; Bergerat, JP; Lemachatti, J; Levêque, D, 2009)

"Triazole drugs are widely used in cancer patients for prophylaxis and treatment of life-threatening invasive fungal infections."

( Chandrasekar, PH; Cronin, S, 2010)

"Antiangiogenic cancer therapy can be achieved through the targeted delivery of antiangiogenic agents to the endothelial cells of tumor neovasculature."

( Chen, HZ; Fang, C; Lu, Q; Xie, J; Yu, DH, 2010)

"During the last few decades, cancer research has focused on the idea that cancer is caused by genetic alterations and that this disease can be treated by reversing or targeting these alterations."

( López-Lázaro, M, 2010)

"Chemoresistance is a major obstacle in cancer treatment."

( Blackburn, WH; Dickerson, EB; Kapa, LB; Lyon, LA; McDonald, JF; Smith, MH, 2010)

"However, little selectivity for cancer cells was observed, which raises concerns over their safety and efficacy in traditional treatment."

( Ashidi, JS; Efferth, T; Houghton, PJ; Hylands, PJ, 2010)

"For the cancer therapy, the anticancer drug, doxorubicin (DOX), was efficiently encapsulated into the AP-pH-PMs (DOX-AP-pH-PMs) with a higher loading efficiency."

( Bae, SM; Choi, K; Kim, IS; Kim, JH; Kim, K; Kim, MS; Koo, H; Kwon, IC; Lee, BH; Lee, DS; Park, RW; Shin, H; Wu, XL, 2010)

"HRP-expressing tumors showed a modest growth delay when treated with IAA compared with drug-vehicle controls."

( Dachs, GU; Hill, S; Stratford, MR; Tozer, GM; Tupper, J, 2010)

"Mice containing xenografted MDA-MB-435 tumors that are treated with the combined NR/LyP-1LP therapeutic system display significant reductions in tumor volume compared with individual nanoparticles or untargeted cooperative system."

( Bhatia, SN; Fogal, V; Kotamraju, VR; Park, JH; Ruoslahti, E; Sailor, MJ; von Maltzahn, G; Xu, MJ, 2010)

"Thus, a reevaluation of cancer metabolism considering glutamine catabolism with a better understanding of the tumor histological complexity is needed before cancer metabolism can be effectively targeted in therapy."

( Dang, CV, 2010)

"In some cancers, HIF-1 activity is constitutively elevated even in aerobic environments, making the cancer harder to treat and control."

( Barroso-Aranda, J; Contreras, F; McCarty, MF, 2010)

"Cancer and cancer treatments have both direct and indirect effects on physiologic, psychological, and interpersonal factors that can all impact negatively on sexual function and satisfaction."

( Basson, R; Incrocci, L; Krychman, M; Morales, AM; Sadovsky, R; Schover, L; Wang, R, 2010)

"Further, MDSCs from cancer patients treated with amiloride, a drug used to treat high blood pressure that also inhibits exosome formation, exhibited reduced suppressor functions."

( Apetoh, L; Boireau, W; Borg, C; Bruchard, M; Chalmin, F; Chauffert, B; De Thonel, A; Garrido, C; Ghiringhelli, F; Hamman, A; Ladoire, S; Lanneau, D; Martin, F; Mignot, G; Multhoff, G; Rébé, C; Remy-Martin, JP; Rouleau, A; Ryffel, B; Simon, B; Solary, E; Vincent, J; Zitvogel, L, 2010)

"We found that cancer cells with wild type p53 show a low level expression of survivin and are sensitive to treatment with bortezomib, while cancer cells with a mutant or null p53 show a high level expression of survivin and are resistant to bortezomib-mediated apoptosis induction."

( Calinski, D; Chanan-Khan, AA; Li, F; Ling, X; Zhou, M, 2010)

"Twenty cancer patients being treated with EGFRIs were included in the study."

( Antoniou, C; Katsambas, A; Kiagia, M; Nikolaou, C; Nikolaou, V; Stratigos, A; Syrigos, K, 2010)

"In a mouse model of cancer pain, significant anti-allodynic effect of Z-360 was observed after single and repeated oral administration of 100 and 300 mg/kg doses."

( Eta, R; Hamano, H; Hori, Y; Horii, T; Kawabata, Y; Kuraishi, Y; Orikawa, Y; Ozaki, T; Seto, K; Takei, M; Yoshii, K; Yoshinaga, K, 2010)

"Neuroablative techniques for cancer pain treatment have been used for more than a century."

( Erdine, S, 2009)

"In patients cured of pediatric malignancy chronic hepatitis C tends to run an indolent course during childhood and adolescence but more than 70% of treated and more than 80% of untreated cases children maintained HCV viremia."

( Bortolotti, F; Brugiolo, A; Carli, M; Cesaro, S; Guido, M; Petris, MG, 2010)

"Patients with advanced solid tumors refractory to standard therapy received a 30 min intravenous infusion of ABI-007 every 3 weeks without pre-medications at 200, 260 or 300 mg/m(2), respectively."

( Minami, H; Mukohara, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N, 2010)

"Successful therapy of cancer is frequently undermined by the development of paclitaxel resistance."

( Chatterjee, SK; Chung, I; Mu, CJ; Olsen, RR; Patel, N; Vrbanac, V; Waghorne, C; Zetter, BR, 2010)

"Fatigue is frequent in cancer patients undergoing chemotherapy."

( Adamsen, L; Andersen, C; Burmølle, SH; Madsen, KR; Midtgaard, J; Nielsen, B; Rørth, M; Stage, M, 2011)

"Many evolving treatments for cancer patients are based on the targeted delivery of therapeutic cargoes to and into cancer cells."

( Cicmil, N; Gariépy, J; Orava, EW, 2010)

"Most cancer patients receive radiotherapy during the course of their disease."

( Beckett, MA; Cohen, KS; Liang, H; Mauceri, HJ; Meng, Y; van Rooijen, N; Weichselbaum, RR, 2010)

"Starvation can protect mice, but not cancer cells, against high-dose chemotherapy [differential stress resistance (DSR)]."

( Bianchi, G; Cohen, P; Hwang, D; Lee, C; Longo, VD; Madia, F; Parrella, E; Raffaghello, L; Safdie, FM; Wei, M, 2010)

"Based on results of this plot, cancer patients fulfilling practice guideline criteria to receive erythropoiesis-stimulating agents (ESAs) were allocated to treatment with ESAs alone, iron alone or the combination of both."

( Breuer, F; Eggert, J; Eustermann, H; Rohrberg, R; Schmitz, S; Steinmetz, HT; Tessen, HW; Thomas, L; Tsamaloukas, A; Wiegand, J, 2010)

"Despite publication of numerous cancer pain management guidelines, undermedication appears to be a persistent problem for patients with painful bone metastases referred for radiotherapy."

( Barnes, E; Chow, E; Danjoux, C; DeAngelis, C; Kirou-Mauro, A; Mitera, G; Sahgal, A; Sanjeevan, T; Sinclair, E; Tsao, M; Wong, J; Zeiadin, N, 2010)

"It has been shown that human cancer cells are more sensitive to proteasome inhibition than normal cells, indicating that the proteasome could be a target of chemotherapy."

( Dou, QP; Liu, J; Yang, H, 2010)

"Pretreatment of the MRC-5 non-cancerous cells with the antioxidant N-acetylcysteine or 2,2,6,6-tetramethylpiperidine-1-oxyl suppresses the selenium-induced ATM activation and senescence."

( Cheng, WH; Kang, MM; Schoene, NW; Wu, M, 2010)

"The diagnosis and treatment of cancer is associated with substantial physical, psychological, and social morbidity."

( Bhatnagar, S; Chauhan, G; Mishra, S; Philip, FA; Singh Rana, SP; Singhal, V; Upadhyay, SP, 2010)

"Experiments were carried out on cancerous HeLa cells and blood serum using a double integrating sphere and a He-Ne laser to investigate the optical properties and cellular effects due to photodynamic therapy (PDT)."

( Atif, M; Firdous, S; Nawaz, M, 2010)

"For the cancer image and therapy, fluorescence dye, tetramethylrhodamine isothiocyanate (TRITC), or anticancer drug, camptothecin (CPT), was efficiently encapsulated into the pH-responsive polymeric micelles (pH-PMs) by a simple solvent casting method."

( Bae, SM; Jeong, SY; Kim, IS; Kim, JH; Kim, K; Kim, MS; Kwon, IC; Lee, DS; Lee, H; Min, KH; Park, RW; Park, S; Shin, H, 2010)

"Many advanced cancers receive cisplatin-based chemotherapy."

( Inokuchi, J; Kashiwagi, E; Kuroiwa, K; Naito, S; Seki, N; Shiota, M; Tada, Y; Tatsugami, K; Uchiumi, T; Yokomizo, A, 2010)

"Effective cancer therapy remains one of the most challenging tasks to the scientific community, with little advancement on overall cancer survival landscape during the last two decades."

( Greish, K, 2010)

"Current methods of treating cancer involve surgical removal of easily accessible tumors, radiation therapy, and chemotherapy."

( Day, ES; Halas, NJ; Morton, JG; West, JL, 2010)

"After treating the ovarian cancer cells with 11."

( Borrelli, A; Capasso, C; De Luca, V; Gori, E; Mancini, A; Mancini, R; Morelli, F; Schiattarella, A, 2011)

"Cases were defined as patients with cancer diagnosis after their second chemotherapy cycle (n = 30), and controls were subjects without cancer (n = 30)."

( Arrieta, O; Green-Renner, D; Laviano, A; Motola-Kuba, D; Rodríguez, C; Sánchez-Lara, K; Sosa-Sánchez, R, 2010)

"Changes of sweet DT and bitter RT in cancer patients under chemotherapy treatment were associated with lower energy and nutrient ingestion."

( Arrieta, O; Green-Renner, D; Laviano, A; Motola-Kuba, D; Rodríguez, C; Sánchez-Lara, K; Sosa-Sánchez, R, 2010)

"Sixteen patients with advanced solid tumors refractory to standard therapies were treated with escalating doses of oblimersen continuous, 120-h intravenous infusion given every 14 days, with a fixed-dose-rate intravenous infusion of gemcitabine administered on day 5 of each cycle."

( Advani, RH; Fisher, GA; Francisco, B; Galatin, PS; Julian, T; Losa, R; Sierra, MI; Sikic, BI, 2011)

"Several cancer-related clinical studies on nelfinavir as a single agent or in combination therapies have been launched and are expected to add to the usefulness of this versatile drug for cancer treatment strategies or other purposes."

( Brüning, A; Friese, K; Gingelmaier, A; Mylonas, I, 2010)

"About 25% of breast cancers harbor the amplified oncogene human epidermal growth factor receptor 2 (HER2) and are dependent on HER2 kinase function, identifying HER2 as a vulnerable target for therapy."

( Ahuja, D; Amin, DN; Blair, JA; Hann, B; Koch, KM; McMahon, M; Moasser, MM; Sergina, N; Shokat, KM; Wang, D, 2010)

"Although cancer vaccines are emerging as innovative methods for cancer treatment, these alone have limited potential for treating measurable tumor burden."

( Chang, MC; Chen, CA; Chen, YL; Cheng, WF; Chiang, YC; Ho, CM; Hsieh, CY; Sun, WZ; Syu, MH, 2010)

"In subcutaneous MDA-MB-435 human breast cancer xenograft models, RRV-mediated yCD and TK suicide gene therapy significantly suppressed tumor growth after prodrug administration."

( Lu, YC; Luo, YP; Tai, CK; Wang, YW, 2010)

"The most frequent cancer in patients treated with golimumab, in association or not with methotrexate, is the lung adenocarcinoma."

( Bartegi, A; Ben Amor, N; Bouaziz, A; Mnif, W; Zidi, I, 2011)

"Patients with advanced cancer refractory to standard therapy were treated with CA4P as a 10-min infusion, 20 h before carboplatin, paclitaxel, or paclitaxel, followed by carboplatin."

( Balkissoon, J; Boxall, J; Chaplin, DJ; Ganesan, TS; Gaya, A; Nathan, PD; Poupard, L; Rustin, GJ; Shreeves, G; Stratford, MR; Wang, D; Zweifel, M, 2010)

"In clinical practice, severe cancer pain often requires 3 step analgesics and alternative routes of administration, thus NSAIDs are usually abandoned."

( Cruto, M; Debernardi, F; Massucco, P; Moselli, NM; Savojardo, M, 2010)

"Development of cancer receptor-specific gold nanoparticles will allow efficient targeting/optimum retention of engineered gold nanoparticles within tumors and thus provide synergistic advantages in oncology as it relates to molecular imaging and therapy."

( Boote, E; Casteel, SW; Chanda, N; Cutler, C; Fent, GM; Kan, P; Kannan, R; Katti, K; Katti, KV; Kattumuri, V; Kulkarni, RR; Lever, JR; Robertson, JD; Shukla, R; Smith, CJ; Upendran, A; Zambre, A, 2010)

"In the era of targeted cancer therapy, cyanotoxins comprise a rich source of natural cytotoxic compounds with a potential to target cancers expressing specific uptake transporters."

( Briasoulis, E; Fokas, D; Kounnis, V; Sainis, I; Tzakos, AG; Vareli, K, 2010)

"Thirty-eight adult cancer pain patients participated in the study, which consisted of a run-in period for stabilization and two consecutive fixed-dose treatment periods of two weeks' duration each."

( Andersen, C; Burneckis, A; Jespersen, L; Ridgway, D; Sopata, M, 2010)

"The section "Investigations in urine of cancer treated patients" deals with speciation experiments on the Pt-metabolites excreted by the organism."

( Michalke, B, 2010)

"Breakthrough pain is caused by cancer, cancer complications, treatment or comorbidities."

( Davis, MP, 2010)

"Patients with solid tumors not amenable to standard forms of treatment were eligible."

( Fujisaka, Y; Horiike, A; Tamura, T; Yamada, Y; Yamamoto, N, 2010)

"We sought to describe the incidence of malignancy in patients treated with CsA for fibrosing interstitial pneumonia."

( Arakawa, N; Gushima, Y; Honda, M; Ichikado, K; Iwamoto, N; Kawamura, K; Kuda, T; Muranaka, H; Suga, M; Takaki, M, 2010)

"With regard to cancer treatment, replication competent oncolytic adenoviruses have been safe in humans, although their efficacy has been variable."

( Bauerschmitz, GJ; Cerullo, V; Diaconu, I; Escutenaire, S; Hemminki, A; Hernandez-Alcoceba, R; Kanerva, A; Pesonen, S, 2010)

"The advent of the targeted cancer therapies administered to patients, according to the results of molecular biology techniques (in particular, in situ hybridization, "polymerase chain reaction" amplification and sequencing), has modified the practice of the surgical pathology laboratories."

( Bordone, O; Butori, C; Coelle, C; Gavric-Tanga, V; Hofman, P; Hofman, V; Ilie, M; Lamy, A; Lassalle, S; Lespinet, V; Mari, M; Sabourin, JC; Selva, E, 2010)

"Signal transduction therapy for cancer targets signaling elements with key roles in cancer cell survival and proliferation, but with more minor roles in the survival of healthy cells."

( Klein, S; Levitzki, A, 2010)

"A number of drugs developed against cancer-specific molecular targets have been shown to offer survival benefits alone or in combination with standard treatments, especially for those cases in which tumor pathogenesis is dominated by a single molecular abnormality."

( Amstutz, RA; Hecker, RM; Niggli, FK; Schäfer, BW; Wachtel, M; Walter, D, 2010)

"Ten causative OOM tumors, including two resected from the patients participating in the octreotide administration study, were examined for expression of genes encoding SSTRs by quantitative real-time RT-PCR and immunohistochemistry."

( Goto, H; Hashimoto, J; Imanishi, Y; Inaba, M; Ishii, A; Kaji, H; Kobayashi, K; Komatsu, Y; Koyano, HM; Kurajoh, M; Miki, T; Miyauchi, A; Nagata, Y; Nishizawa, Y; Oba, K; Saito, T; Sugimoto, T; Ueda, T; Wakasa, K, 2010)

"Our results suggest that cancer-related dyspnea in ambulatory patients can be pharmacologically treated while its most probable specific cause is sought and/or while an etiology-oriented intervention is implemented."

( Castro, MA; Cerchietti, LC; Navigante, AH, 2010)

"The use of CTX in treating cancer patients is limited due to its severe toxicity induced mainly by oxidative stress."

( Kuttan, G; Pratheeshkumar, P, 2010)

"Only Simple and E45 fit the cancer agencies' definition of mild soap and could therefore be recommended for radiotherapy patients."

( Brown, P; Robertson, K, 2011)

"In AZD6244-resistant cancer cells, we observed the impaired nuclear localization of FOXO3a, reduced FOXO3a-mediated transcriptional activity, and decreased the expression of FOXO3a target gene Bim after cell treatment with AZD6244."

( Andreeff, M; Chang, CJ; Du, Y; Engelman, JA; Hortobagyi, GN; Hung, MC; Wang, Y; Wong, KK; Xia, W; Yang, JY, 2010)

"Personalized cancer medicine aims to develop individualized treatment options adapted to factors relevant for the prognosis of each patient."

( Efferth, T, 2010)

"A new paradigm in noncancer pain management has emerged, that of risk assessment and stratification in opioid therapy."

( Passik, SD; Rogak, LJ; Starr, TD, 2010)

"Furthermore, wild type HCT116 cancer cells had a higher incidence of cytotoxicity and apoptosis than securin-null HCT116 cells following treatment with baicalein."

( Chao, JI; Huang, HS; Jiang, RH; Liu, HF; Su, WC, 2010)

"As radiolabelled anticancer agents provide a potential means for personalized treatment planning, docetaxel was labelled with the positron emitter (11)C."

( Gerritsen, WR; Hendrikse, NH; Lammertsma, AA; Lubberink, M; Mooijer, MP; Rijnders, AY; Smit, EF; van der Hoeven, JJ; van der Veldt, AA; Windhorst, AD, 2010)

"Sunitinib PK was evaluated in eight cancer patients receiving sunitinib monotherapy in a "4 weeks on-2 weeks off" dose regimen."

( Baker, SD; Chen, Z; den Hartigh, J; den Hollander, M; Gelderblom, H; Guchelaar, HJ; König-Quartel, JM; Ploeger, BA; van Erp, NP; Zandvliet, AS, 2011)

"The paradigm of early breast cancer treated by epirubicin according to a branch of an actual clinical trial (the Trial of Principle, TOP trial) has been addressed."

( Desmedt, C; Dionysiou, DD; Georgiadi, ECh; Kolokotroni, EA; Stamatakos, GS, 2010)

"Combined diagnosis and therapy for cancer has been of great interest in medicine."

( Ahn, YC; Chen, Z; Kim, CS; Kwon, YJ; Shim, MS, 2010)

"After the diagnosis of malignancy, the patients were switched from calcineurin inhibitor-based immunosuppression to rapamycin (monotherapy, n = 3), or associated with steroids (n = 6) or with mycophenolate mofetil (n = 6)."

( Angelico, R; Anselmo, A; Bellini, MI; De Luca, L; Iaria, G; Manuelli, M; Perrone, L; Sforza, D; Tatangelo, P; Tisone, G, 2010)

"Both patients with metastatic cancer underwent chemotherapy but succumbed after 6 and 13 months."

( Angelico, R; Anselmo, A; Bellini, MI; De Luca, L; Iaria, G; Manuelli, M; Perrone, L; Sforza, D; Tatangelo, P; Tisone, G, 2010)

"Anemia in cancer patients is common, but often under-recognized and under-treated."

( Abdel-Razeq, H; Abdulelah, H; Amarin, R; Asawaeer, M; Hijjawi, S; Shaheen, H, 2010)

"As is common in cancer therapy, challenges with respect to treatment resistance emerge over time."

( Dunn, EF; Harari, PM; Wheeler, DL, 2010)

"Asymptomatic long-term cancer survivors treated with anthracycline were investigated for late anthracycline cardiotoxicity using dobutamine stress echocardiography (DSE) and tissue Doppler (TD) velocities."

( Ilhan, M; Karadeniz, C; Kula, S; Oguz, A; Oguz, D; Olguntürk, R; Pinarli, FG; Sedef Tunaoglu, F; Yildirim, A, 2010)

"As much as 28 patients with solid tumors underwent a total of 109 treatment cycles."

( Audrain, M; Bennouna, J; Bruzzoni-Giovanelli, H; Calvo, F; Galéa, C; Hiret, S; Levy, V; Rimbert, M; Rolland, F; Senellart, H; Sicard, H; Tiollier, J, 2010)

"A sample of 877 cancer patients beginning chemotherapy at 23 geographically separate University of Rochester Cancer Center (URCC) Community Clinical Oncology Program (CCOP) affiliates were assessed for fatigue."

( Esparaz, BT; Heckler, C; Hemstad, A; Hopkins, JO; Janelsins, M; Jean-Pierre, P; Mohile, S; Morrow, GR; Peppone, L; Roscoe, JA, 2010)

"Solid tumors in mice were specifically visualized after intravenous administration of ICG-loaded micelles."

( Chen, Y; Gombotz, WR; Kim, TH; Li, X; Mount, CW; Pun, SH, 2010)

"As many cancer therapies tend to be more effective in p53 WT patients, the higher sensitivity of p53-deficient tumors toward GSK461364A could potentially offer an opportunity to treat tumors that are refractory to other chemotherapies as well as early line therapy for these genotypes."

( Bachman, K; Bleam, M; Degenhardt, Y; Gilmartin, AG; Greshock, J; Halsey, W; Hughes, A; Jackson, J; Jing, J; Laquerre, S; Liu-Sullivan, N; Moy, C; Powers, S; Richter, M; Weber, B; Wooster, R; Zhang, X, 2010)

"Seventeen patients with advanced solid tumors signed consent and were treated on this study with at least one cycle."

( Bekaii-Saab, T; Kraut, EH; Serna, DS, 2011)

"Amongst 1159 patients with cancer treated at the Centro Infantil Boldrini from 2003 to 2007, 188 (16."

( Aguiar, Sdos S; Brandalise, SR; de Azevedo, AC; Pinheiro, VR; Rizzatti, M, 2010)

"Doxorubicin is a mainstay of cancer chemotherapy despite its clinical limitations that arise from its cardiotoxicity and the high incidence of multi-drug resistance."

( Effenberger-Neidnicht, K; Schobert, R, 2011)

"The majority of patients treated for cancer will have pain at some point in their journey."

( Balducci, L, 2010)

"Evidence-based treatment of cancer follows recommendations of international expert panels and includes indication-based surgery, chemotherapy, radiotherapy, hormone and antibody therapy."

( Beuth, J, 2010)

"OPC prevalence in treated cancer patients was high."

( Azria, D; Bastit, L; Gervais, H; Gligorov, J; Henni, M; Kahila, W; Lepille, D; Luporsi, E; Sasso, G; Varette, C, 2011)

"Patients with advanced cancer including breast cancer, hepatocellular cancer and urothelial cancer frequently receive a chemotherapy regimen containing doxorubicin."

( Eto, M; Itsumi, M; Naito, S; Shiota, M; Tada, Y; Takeuchi, A; Tatsugami, K; Uchiumi, T; Yokomizo, A, 2010)

"The main goals of cancer therapy include removing the primary tumor, preventing the spread of distant metastases, and improving survival and quality of life for the patients."

( Barnes, S; Nagy, TR; Virk-Baker, MK, 2010)

"Optimal gene therapy for tumors must deliver plasmid DNA (pDNA) or synthetic small interfering RNA (siRNA) to tumor cells with high efficiency and minimal toxicity."

( Hattori, Y, 2010)

"A call from the "cancer floor" sets a second-year psychiatric resident on a 42-year journey in treating patients with terminal illness."

( Klagsbrun, S, 2010)

"In addition, treating Z12 or cancer cell lines with either of these 2 inhibitors significantly decreased their secretion of TGFβ2."

( Kolattukudy, S; Lu, T; Stark, GR; Wan, Y; Yang, M, 2010)

"DNA-damaging agents are widely used in cancer treatment despite their lack of tumor specificity."

( Agarwal, R; Ali, R; Anderson, D; Auton, T; Cattell, E; Davies, S; Hartley, JA; Judson, I; Kerr, DJ; Knox, R; Middleton, MR; Midgley, R; Oppermann, U; Osawa, T; Sarker, D; Spanswick, VJ, 2010)

"For effective cancer gene therapy, systemic administration of tumor-targeting adenoviral (Ad) complexes is critical for delivery to both primary and metastatic lesions."

( Hwang, T; Kang, E; Kim, JH; Kwon, OJ; Lee, JM; Park, H; Park, Y; Yun, CO, 2010)

"The failure of solid tumors to respond to chemotherapy is a complicated and clinically frustrating issue."

( Kiesewetter, DO; Kurdziel, KA, 2010)

"Underlying malignancy and parenteral nutrition, which were associated with nutrition and the immune system, were found to affect the survival after 30 days of VCM therapy."

( Aoyama, T; Hayashi, H; Iida, H; Matsumoto, Y; Shimazaki, N; Umeda, K, 2010)

"Response to anticancer therapy is believed to be directly related to the concentration of the anticancer drug in the tumor itself."

( de Bruijn, P; Ghobadi Moghaddam-Helmantel, IM; Konings, IR; Loos, WJ; Mathijssen, RH; Sleijfer, S; van Dam, LM; Verweij, J; Wiemer, EA, 2011)

"Modern cancer treatment techniques, such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), have greatly increased the demand for more accurate treatment planning (structure definition, dose calculation, etc) and dose delivery."

( Chetty, IJ; Fragoso, M; Kumar, S; Liu, D; Movsas, B; Munther, A; Ryu, S; Wen, N, 2010)

"Patients with advanced solid tumors were treated."

( Adam, J; Ang, J; Bell, S; Calvert, H; de Bono, JS; Futreal, A; Plummer, R; Shahidi, M; Shaw, H; Spicer, J; Stephens, P; Stopfer, P; Temple, G; Uttenreuther-Fischer, M; Vidal, L; Yap, TA, 2010)

"Patients with advanced refractory solid tumors were treated with BIBF 1120 at oral doses of 150 to 250 mg twice daily."

( Arao, T; Kaiser, R; Kaneda, H; Konishi, K; Miyazaki, M; Morinaga, R; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Sarashina, A; Satoh, T; Terashima, M; Tsuya, A; Ueda, S, 2010)

"Oral cheek mucosal specimens from 52 cancer patients receiving chemotherapy were cultured on CHROMagar Candida plates for Candida identification."

( Lafleur, MD; Qi, C; Qi, QG; Sun, J, 2009)

"Response to analgesics, anticancer pharmacotherapy and pharmacotherapy of other cancer related symptoms vary broadly between individuals."

( Kleine-Brueggeney, M; Musshoff, F; Stamer, UM; Stuber, F, 2010)

"Catalytic therapy is a cancer treatment modality based on the generation of reactive oxygen species (ROS) through administration of ascorbate/medicinal herbal extracts and copper."

( Azmi, AS; Bhatt, SH; Hadi, SM; Shamim, U; Ullah, MF, 2010)

"With the population of cancer survivors nearing 12 million, an ever-increasing number of women will face vaginal health issues related to their disease and/or treatment."

( Carter, J; Goldfrank, D; Schover, LR, 2011)

"The application of nanotechnology for cancer therapy has received considerable attention in recent years."

( Acharya, S; Misra, R; Sahoo, SK, 2010)

"A total of 100 cancer patients who were receiving morphine therapy at the ORCI were interviewed to get information on morphine use."

( Ezekiel, D; Kamuhabwa, A, 2009)

"Anemia in cancer patients can result from a complex interaction of numerous factors including iron deficiency, inflammation, toxicity related to therapy and effect of cancer on the marrow."

( Arvedson, TL; Doellgast, G; Li, H; Molineux, G; Rose, MJ; Sasu, BJ, 2010)

"However, polyploidy may also render cancer cells more vulnerable to chemotherapy."

( Deo, D; Heimbrook, DC; Higgins, B; Kolinsky, K; Liu, JJ; Tovar, C; Vassilev, LT, 2010)

"In advanced cancer, the prevalence of fatigue is high and can be related to treatment or disease."

( Carmont, SA; Hardy, JR; Mitchell, GK; Nikles, CJ; O'Shea, A; Schluter, P; Vora, R, 2010)

"Untreated tumors showed homogeneous intra-group median values of all three parameters (k(1), k(2) and k(3)), whereas the parameters significantly increased in the tumors irradiated 24 h prior to (18)F-FDG PET."

( Aleksandersen, TB; Kristian, A; Malinen, E; Nilsen, LB; Olsen, DR; Qu, H; Ree, AH; Røe, K; Seierstad, T, 2010)

"Nude rats bearing human head and neck cancer and non-small cell lung cancer (NSCLC) xenografts were treated with intetumumab and fractionated local tumor radiotherapy."

( Knox, SJ; Marshall, DJ; Ning, S; Tian, J, 2010)

"Furthermore, tumors retained a higher amount of Dox in mice treated with the conjugate group compared to that of free Dox-treated group at the same dosage."

( Jon, S; Kim, IH; Lee, IH; Lee, JH; Park, TG; Yu, MK, 2011)

"Their proposed mechanisms of action in cancer therapy occur via stimulation of macrophages and priming of innate neutrophil complement receptor 3 for eliciting complement receptor 3-dependent cellular cytotoxicity of iC3b-opsonized tumor cells."

( Cai, Y; Ding, C; Hansen, R; Li, B; Mitchell, TC; Qi, C; Yan, J, 2010)

"Moreover, β-glucan-treated tumors had significantly more DC infiltration with the activated phenotype and significant levels of Th1-biased cytokines within the tumor microenvironment."

( Cai, Y; Ding, C; Hansen, R; Li, B; Mitchell, TC; Qi, C; Yan, J, 2010)

"Nineteen patients with varied solid tumors, who were not candidates for standard chemotherapy, were administered an escalating duration (6, 9 or 12 consecutive days) of oral etoposide (a 25 mg capsule three times daily) combined with carboplatin AUC5 administered on day 1, by a 30 min intravenous infusion, to define the maximum tolerated dose on the basis of the acute toxicities that were reported."

( Bazan, F; Chaigneau, L; Demarchi, M; Dobi, E; Ivanaj, A; Kalbacher, E; Maurina, T; Montange, D; Nguyen, T; Pivot, X; Royer, B; Thiery-Vuillemin, A; Villanueva, C, 2010)

"New anticancer agents are needed in order to overcome the resistance of cancer cells to standard chemotherapy."

( Oza, A; Stathis, A, 2010)

"An understanding of growth dynamics of tumors is important in understanding progression of cancer and designing appropriate treatment strategies."

( Bursac, Z; Eby, WM; Tabatabai, MA, 2010)

"On the other hand, cotreatment of cancer cells with cetuximab and the mTOR inhibitor rapamycin resulted in an Atg-dependent and lysosomal inhibition-sensitive death of cancer cells that show only growth inhibition or weak apoptosis after cetuximab treatment, indicating that cell death may be achieved by activating the autophagy pathway in these cells."

( Fan, Z; Li, X; Lu, Y; Pan, T, 2010)

"During anticoagulant therapy, cancer patients have a twofold to fourfold higher risk of recurrent VTE and major bleeding complications when compared to non-cancer patients."

( Prandoni, P, 2010)

"Eleven advanced cancer patients affected by malignant bowel obstruction (MBO) were treated at home with a combination of octreotide, metoclopramide, morphine, and dexamethasone."

( Aielli, F; Ficorella, C; Galletti, B; Porzio, G; Shoja E Razavi, G; Verna, L, 2011)

"Data on the treatment of breakthrough cancer pain (BTcP) in patients receiving methadone therapy are lacking."

( Arcuri, E; Ferrera, P; Mercadante, S, 2011)

"Intractable and untreatable pain from cancer remains a challenge for both patients and clinicians."

( Hoang, BX; Hoang, C; Levine, SA; Nguyen, PM; Pham, PT; Shaw, DG; Tran, DM; Tran, HD; Tran, HQ, 2010)

"Histone modification therapy of cancer is based on the generation of drugs able to interfere with the activity of enzymes involved in histone modifications: new drugs have recently been approved for use in cancer patients, clinically validating this strategy."

( Biancotto, C; Frigè, G; Minucci, S, 2010)

"Genistein sensitizes cancer cells to chemotherapy and radiation by modulating cell survival pathways."

( Dincaslan, H; Dogu, F; Kucuk, O; Ozyoruk, D; Sahin, K; Tacyildiz, N; Unal, E; Yavuz, G, 2010)

"A refractory esophageal cancer patient and a lung carcinoid tumor patient had an objective response and continued the study treatment for 5 and 12 months, respectively."

( Doi, T; Eguchi-Nakajima, T; Fuse, N; Hamaguchi, T; Kato, K; Matsumoto, S; Matsumura, Y; Ohtsu, A; Shimada, Y; Takanashi, M; Yamada, Y, 2010)

"Many difficult-to-treat solid cancer tumours and metastases have high-glucose uptake, usually under hypoxic conditions."

( Liebenberg, L; Mathews, EH; Pelzer, R, 2011)

"Cancer patients with solid tumors that experienced post chemotherapy thrombocytopenia with a nadir of < = 80,000 platelets/ml were eligible for this clinical trial."

( Daehler, M; Grutsch, JF; Gupta, D; Hall, JL; Levin, RD; Lis, CG, 2010)

"The knowledge of whether tumors express or do not express CXCR4 might be beneficial in determining appropriate treatment and monitoring."

( Chen, X; Farber, JM; Jacobson, O; Kiesewetter, DO; Weiss, ID, 2010)

"Mammary tumors, induced by inoculation of syngeneic BALB/c mice with BJMC3879luc2 cells, were subsequently treated with raloxifene at 0, 18 and 27 mg/kg/day using mini-osmotic pumps."

( Akamatsu, K; Kurose, H; Kusakabe, M; Li, ZL; Morimoto, J; Ohmichi, M; Otsuki, Y; Shibata, E; Shibata, MA, 2010)

"As mortality due to cancer continues to rise, advances in nanotechnology have significantly become an effective approach for achieving efficient drug targeting to tumour tissues by circumventing all the shortcomings of conventional chemotherapy."

( Acharya, S; Sahoo, SK, 2011)

"A combination cancer therapy was investigated via co-delivery of therapeutic gene encoding human tumor necrosis factor-related apoptosis-inducing ligand (pORF-hTRAIL) and doxorubicin (DOX) using a tumor-targeting carrier, peptide HAIYPRH (T7)-conjugated polyethylene glycol-modified polyamidoamine dendrimer (PAMAM-PEG-T7)."

( Han, L; Huang, R; Huang, S; Jiang, C; Li, J; Liu, S, 2011)

"ESAs should be avoided in patients with cancer not receiving concurrent chemotherapy, except for those with lower risk myelodysplastic syndromes."

( Arcasoy, MO; Bennett, CL; Bohlius, J; Brouwers, M; Evanchuk, D; Goode, MJ; Hurley, P; Jakubowski, AA; Regan, DH; Rizzo, JD; Seidenfeld, J; Somerfield, MR; Spivak, JL, 2010)

"ESAs should be avoided in patients with cancer not receiving concurrent chemotherapy, except for those with lower risk myelodysplastic syndromes."

( Arcasoy, MO; Bennett, CL; Bohlius, J; Brouwers, M; Evanchuk, D; Goode, MJ; Hurley, P; Jakubowski, AA; Regan, DH; Rizzo, JD; Seidenfeld, J; Somerfield, MR; Spivak, JL, 2010)

"The Functional Assessment of Cancer Therapy-Prostate (FACT-P) QoL questionnaire measured physical, social, emotional, and functional domains as well as sexual function."

( Fleishman, SB; Guarino, MJ; Homel, P; Khan, H; Mahajan, D; Mirzoyev, T; Mohammad, F; Rosenwald, V; Strebel-Amrhein, R; Suhail, MF; Suppiah, K; Wozniak, TF, 2010)

"In the long story of ONs for cancer therapy, the development of delivery strategies has led, in the last few years, to different opportunities to use the high therapeutic potential of these molecules in humans."

( De Rosa, G; De Stefano, D; Galeone, A, 2010)

"The reduction of cancer risk could be a further relevant reason for maintaining use of metformin in insulin-treated patients."

( Balzi, D; Barchielli, A; Colombi, C; Dicembrini, I; Giannini, S; Mannucci, E; Marchionni, N; Melani, C; Monami, M; Romano, D; Rotella, CM; Vitale, V, 2011)

"In murine tumors, ASA404 induces coordinated decreases in tumor blood flow, increases in vascular permeability and increases in vascular endothelial apoptosis, all occurring within 1 h of administration."

( Baguley, BC; McKeage, MJ, 2010)

"Patients with solid tumors refractory to standard therapy received LY2181308 (400, 600, or 750 mg) as a 3-h intravenous infusion for 3 consecutive days and thereafter once a week."

( Callies, S; Fujimoto, T; Goto, Y; Nokihara, H; Sekiguchi, R; Tamura, T; Tanioka, M; Uenaka, K; Yamada, K; Yamada, Y; Yamamoto, N, 2011)

"Chemotherapy is the major therapy for cancer in clinic."

( Cai, LP; Dong, M; Liu, WP; Mo, YQ; Tu, CH; Yang, DZ, 2011)

"For many solid tumors, anti-VEGF treatment offers greater clinical benefit when combined with chemotherapy."

( Carmeliet, P; Cauwenberghs, S; De Bock, K, 2011)

"disease and disease stage, cancer therapy and anti-anaemic treatment, including transfusions and the use of erythropoietin stimulating agents (ESA)."

( Beguin, Y; Bosly, A; Bries, G; Canon, JL; Van Belle, S; Verbeke, N; Wildiers, H, 2012)

"In several cancer cell lines, treatment with the DNA methyltransferase (Dnmt) inhibitor 5-Aza-dC effected expression of AID by TNF-α, and expression was further induced by additional treatment with histone deacetylase (HDAC) inhibitors with no stimulation."

( Hata, H; Nakadate, T; Tatemichi, M, 2011)

"Retinoic acid (RA) plays a role in cancer therapy."

( Kim, EJ; Park, UH; Um, SJ; Youn, HS, 2011)

"Many cancer-treating compounds used in chemotherapies, the so-called antimitotics, target the mitotic spindle."

( Galati, E; Piatti, S; Rossio, V, 2010)

"Seventeen patients with stage IV solid tumors were treated."

( Bommakanti, SV; Dudek, AZ; Gada, PD; Khatri, A; Kirstein, MN, 2011)

"Most sono/photosensitizers of cancer sonodynamic/photodynamic therapy (SDT/PDT), such as hypocrellin SL052, are water-insoluble, therefore restricting their clinical applications."

( Chen, J; Huang, M; Madiyalakan, R; Meng, Y; Swanson, E; Woo, T; Xing, JZ; Yang, X; Zou, C, 2010)

"Two cervical cancer cell lines, HeLa and Siha, an ovarian cancer cell line, SKOV3, and a non-small cell lung cancer cell line, A549, were treated with saikosaponins or cisplatin individually or in combination."

( Gao, LB; He, F; Lin, Y; Shi, F; Sun, H; Wang, Q; Wang, X; Yang, L; Zheng, XL; Zhong, YJ, 2010)

"The 20-year risk of cancer death (1634 deaths in 12 659 patients in three trials) remained lower in the aspirin groups than in the control groups (all solid cancers, HR 0·80, 0·72-0·88, p<0·0001; gastrointestinal cancers, 0·65, 0·54-0·78, p<0·0001), and benefit increased (interaction p=0·01) with scheduled duration of trial treatment (≥7·5 years: all solid cancers, 0·69, 0·54-0·88, p=0·003; gastrointestinal cancers, 0·41, 0·26-0·66, p=0·0001)."

( Belch, JF; Fowkes, FG; Meade, TW; Ogawa, H; Rothwell, PM; Warlow, CP, 2011)

"The study included 601 cancer patients treated with a 1 h infusion of docetaxel in monotherapy."

( Friberg, LE; Karlsson, MO; Quartino, AL, 2012)

"Patients with advanced/metastatic cancer were treated with once-weekly, 1- to 2-hour intravenous administration of MPC-6827 for 3 consecutive weeks every 28 days (1 cycle)."

( Akerley, W; Chhabra, A; Evans, BA; Hong, DS; Kurzrock, R; Mather, GG; Schabel, MC; Swabb, EA; Tsimberidou, AM; Uehara, C; Warren, T; Woodland, DP, 2010)

"Imaging of cycling hypoxia in tumors can provide capabilities to help plan appropriate treatment, by taking into account the magnitude and frequency of fluctuations and also their locations adjacent to normal tissue."

( Krishna, MC; Matsumoto, S; Mitchell, JB; Yasui, H, 2010)

"Prospective data on adult anaemic cancer patients receiving DA 500 µg Q3W during chemotherapy was collected."

( Braun, S; Eisterer, W; Erb, H; Haslbauer, F; Hussl, C; Jaeger, C; Sormann, S, 2011)

"For the treatment of cancer and hepatitis immunotherapeutic strategies have overall had limited clinical success."

( de Gruijl, TD; Janssen, HL; Scheper, RJ; Schneiders, FL; van den Eertwegh, AJ; van der Vliet, HJ; Verheul, HM; von Blomberg, BM; Woltman, AM, 2011)

"Thermotherapy consisting of heating tumors to death appears to be a suitable method to achieve tumor ablation in a noninvasive manner with minimal side effects but developments were hampered because of the lack of specificity of the heating method."

( Couvreur, P; Tsapis, N; Vauthier, C, 2011)

"Growth of xenograft tumors with BRCA1/2 mutations or with epigenetically silenced BRCA1 was reduced by AG014699 treatment, and combination treatment with AG014699 plus carboplatin was more effective than either drug alone."

( Curtin, NJ; Drew, Y; Edmondson, RJ; Hostomsky, Z; Kahn, S; Kyle, S; Los, G; Mukhopadhyay, A; Mulligan, EA; Plummer, ER; Thomas, HD; Vong, WT, 2011)

"Human cancer cells or xenograft tumors with mutated or epigenetically silenced BRCA1/2 were sensitive to AG014699 monotherapy, indicating a potential role for PARP inhibitors in sporadic human cancers."

( Curtin, NJ; Drew, Y; Edmondson, RJ; Hostomsky, Z; Kahn, S; Kyle, S; Los, G; Mukhopadhyay, A; Mulligan, EA; Plummer, ER; Thomas, HD; Vong, WT, 2011)

"A new strategy in the treatment of cancer has focused on targeting an essential cell metabolite, iron (Fe)."

( Bernhardt, PV; Kalinowski, DS; Kovacevic, Z; Lovejoy, DB; Richardson, DR; Sharpe, PC; Suryo Rahmanto, Y; Yu, Y, 2011)

"We found that E-3810 remained active in tumors rendered nonresponsive to the general kinase inhibitor sunitinib resulting from a previous cycle of sunitinib treatment."

( Bello, E; Berndt, A; Camboni, G; Cavalletti, E; Colella, G; D'Incalci, M; Damia, G; Giavazzi, R; Oliva, P; Scarlato, V; Serra, SC; Valbusa, G, 2011)

"Nanotechnology-based cancer treatment approaches potentially provide localized, targeted therapies that aim to enhance efficacy, reduce side effects, and improve patient quality of life."

( Bickford, LR; Coughlin, AJ; Day, ES; Drezek, RA; Hu, Y; Kennedy, LC; Lewinski, NA; West, JL, 2011)

"Breakthrough cancer pain (BTcP) has been defined as a transitory increase in pain intensity on a baseline pain of moderate intensity in patients on analgesic treatment regularly administered."

( Mercadante, S, 2011)

"Patients with advanced solid tumors were treated with CBP501 alone (D1/D8/D15, q4w, from 0."

( Bastos, BR; Borad, MJ; Eder, JP; Fernandez, C; Gordon, MS; Kawabe, T; Kufe, DW; Mendelson, DS; Pierceall, WE; Sato, H; Shapiro, GI; Sharma, S; Slough, S; Sutherland, W; Tibes, R; Vogelzang, NJ; Von Hoff, D; Wasserman, E; Weaver, D; Weiss, GJ; Wong, BY, 2011)

"PLP-L treatment resulted in smaller tumors and caused a significant drop in K(trans) 48 h post-treatment, which was maintained until one week after drug administration."

( Heisen, M; Kluza, E; Nicolay, K; Schiffelers, RM; Schmid, S; Storm, G; Strijkers, GJ; ter Haar Romeny, BM; van der Schaft, DW, 2011)

"Three isolated cases of malignancy were reported in cladribine-treated patients during the study; a fourth was reported during post-study surveillance."

( Comi, G; Cook, S; Giovannoni, G; Greenberg, SJ; Hamlett, A; Miret, M; Musch, B; Rammohan, K; Rieckmann, P; Sørensen, PS; Vermersch, P; Viglietta, V; Weiner, J, 2011)

"Current cancer chemotherapy relies heavily on cytotoxic agents, such as the taxanes and Vinca alkaloids, that interfere with the cellular machinery required for cell division and divert the cell down a pathway of programmed cell death."

( Cox, CD; Garbaccio, RM, 2010)

"Synthetic lethal approaches to cancer treatment have the potential to deliver relatively large therapeutic windows and therefore significant patient benefit."

( Ashworth, A; Hewish, M; Lord, CJ; Martin, SA; Sims, D, 2011)

"The decision for a patient with cancer to start heparin therapy for survival benefit should balance the benefits and downsides and integrate the patient's values and preferences."

( Akl, EA; Barba, M; Bryant, A; Dickinson, HO; Gunukula, S; Kuipers, S; Middeldorp, S; Schünemann, H; van Doormaal, FF; Yosuico, VE, 2011)

"Cell viability of murine kidney cancer cells (RENCA) was measured 24 hours following laser treatment with the previously mentioned laser parameters alone or with SWNHs."

( Campbell, TA; Do, T; Dorn, HC; Geohegan, DB; Manson, MK; More, KL; Puretzky, AA; Rouleau, CM; Rylander, CG; Rylander, MN; Sarkar, S; Whitney, JR; Young, T; Zhang, J, 2011)

"Data were collected from cancer patients in the Oncology Department of Sardjito Hospital, Yogyakarta, Indonesia, who were treated with cisplatin at the dosage ≥50 mg/m(2) as monotherapy or in combinations."

( Atthobari, J; Dwiprahasto, I; Gelderblom, H; Guchelaar, HJ; Hakimi, M; Kaptein, AA; Nortier, JW; Perwitasari, DA; Putter, H, 2011)

"Breakthrough pain in cancer patients can be very difficult to manage, primarily because of its heterogeneous and fleeting nature, so careful assessment is imperative to finding an adequate treatment regimen."

( Bobb, BT; Coyne, PJ, 2010)

"Thus, by combining different anticancer medicines as well as contrast imaging agents in NPs, we open the door toward generic conceptual framework for cancer treatment and diagnosis."

( Arias, JL; Couvreur, P; Desmaële, D; Dosio, F; Gillet, B; Gref, R; Othman, M; Reddy, LH; Zouhiri, F, 2011)

"As radio- and chemotherapy-based cancer treatments affect both tumors and healthy tissue, cancer immunotherapy attempts to specifically enhance the natural immune response to tumor cells."

( Acedo, P; Barber, DF; Cabrera, LI; Gutiérrez, L; Lázaro, FJ; Mejías, R; Morales, Mdel P; Pérez-Yagüe, S; Serna, CJ; Spada, R; Villanueva, A, 2011)

"In the breast and pancreatic cancer animal models, ultrasound-mediated therapy with paclitaxel-loaded PFCE nanoemulsions showed excellent therapeutic properties characterized by tumor regression and suppression of metastasis."

( Gao, Z; Gupta, R; Jeong, EK; Kennedy, AM; Kim, T; Liu, X; Mohan, P; Nam, KH; Parker, DL; Payne, A; Rapoport, N; Scaife, C; Shea, J; Todd, N, 2011)

"Patients with advanced solid cancers were treated with weekly, intravenous (i."

( Aherne, W; Arkenau, HT; Banerji, U; de Bono, JS; Eatock, MM; Hardcastle, A; Judson, I; Moreno-Farre, J; Pacey, S; Peachey, H; Raynaud, F; Roels, B; Walton, M; Wilson, RH; Workman, P; Zetterlund, A, 2011)

"The emergence of cancer stem cell theory has profound implications for cancer chemoprevention and therapy."

( Li, Y; Schwartz, SJ; Sun, D; Wicha, MS, 2011)

"We investigated 185 patients with cancer who were referred for isotope measurement of GFR with (51)Cr-EDTA before initiating chemotherapy treatment."

( Jeppesen, N; Rasmussen, K; Redal-Baigorri, B; Stokholm, KH, 2011)

"Warburg's in vivo studies of tumors further suggest that the dependency of tumors in vivo on glucose could be exploited for therapy, because reduction of arterial glucose by half resulted in a four-fold reduction in tumor fermentation."

( Dang, CV; Gao, P; Hamaker, M; Le, A; Sun, P, 2011)

"Despite advances in the management of cancer pain, through the application of modern, evidence-based, multimodality management and the availability of new treatment options, recent European surveys have indicated that the diagnosis and treatment of BTcP is still suboptimal."

( Dickman, A, 2011)

"Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)."

( Akl, EA; Barba, M; Gunukula, S; Muti, P; Schünemann, H; Sperati, F; Terrenato, I; Vasireddi, SR, 2011)

"The potential of gene therapy to treat cancer is currently limited by the low expression of therapeutic genes in the tumors."

( Aldawsari, H; Blatchford, DR; Dufès, C; Edrada-Ebel, R; Raj, BS; Tate, RJ; Tetley, L, 2011)

"Overall, there was no excess of cancer incidence with ARB therapy compared to controls in the 15 trials [4549 (6."

( , 2011)

"We review its use in cancer diagnosis, staging, restaging, and assessment of response to treatment."

( Lee, D; Shim, H; Zhu, A, 2011)

"Functional molecular imaging of MDR in cancer using single photon or positron emitters may be helpful to identify multidrug-resistant tumours and predict not only those patients who are resistant to treatment, with a clinically unfavourable prognosis, but also those who are susceptible to the development of drug toxicity or even certain tumours ."

( Dizdarevic, S; Peters, AM, 2011)

"An elevated initial GFR in a child with cancer, which normalizes after chemotherapy may indicate chemotherapy-induced decreased renal function, but can be due to normalization of an initially high GFR."

( Hjorth, L; Karpman, D; Wiebe, T, 2011)

"Three patients with cancer experienced severe side-effects after starting anti-neuropathic pain therapy."

( Engels, Y; Hekster, YA; Schalkwijk, A; Verhagen, CA; Vissers, KC, 2011)

"A major obstacle to successful cancer chemotherapy is drug resistance."

( Mendes, F; Paulo, A; Santos, I, 2011)

"In patients with moderate to severe cancer pain receiving treatment with opioid analgesics, the treatment was switched from the existing opioid analgesic to the 1-day fentanyl patch (the "1-day formulation"), and the efficacy and safety of the 1-day formulation were evaluated."

( Hanaoka, K; Sakata, H; Tomioka, T; Yoshimura, T, 2011)

"In patients with moderate to severe cancer pain, switching of opioid analgesic therapy to 1-day formulation therapy has been shown to be safe and useful, following rotation from other opioids, for controlling cancer pain."

( Hanaoka, K; Sakata, H; Tomioka, T; Yoshimura, T, 2011)

"When treating metastatic tumors, chemoresistance can cause problems."

( DeSimone, JM; Merkel, TJ, 2011)

"ESA-treated patients with cancer received a median initial dose 2."

( Diamantidis, CJ; Fink, JC; Hsu, VD; Parsa, A; Seliger, SL; Walker, L; Weir, MR; Zhang, AD, 2011)

"Like most other drugs employed in cancer therapy, it will be unlikely that Nutlin-3 will be used as a monotherapy."

( Bosco, R; Celeghini, C; Secchiero, P; Zauli, G, 2011)

"Solid tumors contain hypoxic regions in which cancer cells are often resistant to chemotherapy-induced apoptotic cell death."

( Blackhall, F; Brandenburg, M; Dempsey, C; Denneny, O; Dive, C; Harrison, LR; Hodgkinson, C; Makin, G; Micha, D; Morrow, CJ; Roberts, D; Simpson, KL; Yunus, Z, 2011)

"A major challenge in cancer biology is to monitor and understand cancer metabolism in vivo with the goal of improved diagnosis and perhaps therapy."

( Brindle, K; Chekmenev, EY; Comment, A; Cunningham, CH; Deberardinis, RJ; Green, GG; Kurhanewicz, J; Leach, MO; Malloy, CR; Rajan, SS; Rizi, RR; Ross, BD; Vigneron, DB; Warren, WS, 2011)

"In the cancer therapy effect prediction, both deltaTLG75 and deltaTLG50 were significantly higher than SUVmax by using receiver operating-characteristic (ROC) curve analysis."

( Fujita, S; Futami, S; Kiyohara, S; Nagamachi, S; Nishii, R; Tamura, S; Wakamatsu, H, 2010)

"To improve cancer immunotherapy, a better understanding of the weak efficiency of tumor-infiltrating T lymphocytes (TIL) is necessary."

( Avril, MF; Badoual, C; Bercovici, N; Cazes, A; Chapon, M; Damotte, D; Delongchamps, NB; Dieu-Nosjean, MC; Fouquet, S; Garcette, M; Gibault, L; Labroquère, K; Maubec, E; Prévost-Blondel, A; Randriamampita, C; Regnier, F; Salmon, H; Trautmann, A; Validire, P; Wang, SF; Zerbib, M, 2011)

"Outpatient cancer chemotherapy is increasing with the development of anticancer agents, and roles of medical staff are becoming more and more important in cancer chemotherapy."

( Iihara, H; Ishihara, M; Itoh, Y; Kawaguchi, Y; Kurahashi, S; Matsuura, K; Takahashi, T; Yoshida, K, 2012)

"Breakthrough cancer pain (BTcP) has been defined as a transitory increase in pain intensity on a baseline pain of moderate intensity in patients on regularly administered analgesic treatment."

( Mercadante, S, 2011)

"Pain is a major concern of cancer patients and a significant problem for therapy."

( Dang, HV; Ha, TV; Hoang, BX; Hoang, C; Luong, KN; Nguyen, PT; Pham, TD; Shaw, DG; Tran, DM; Tran, HD; Tran, HQ, 2011)

"An assessment of the anticancer potential of glufosfamide is of key importance in therapy."

( Mazur, L; Opydo-Chanek, M; Stojak, M, 2011)

"Hypoxia is a characteristic of tumors, is known to increase aggressiveness, and causes treatment resistance."

( Astner, ST; Bayer, C; Maftei, CA; Shi, K; Vaupel, P, 2011)

"Furthermore, Beclin 1 mutant tumors were significantly less responsive to chemotherapeutic treatment than were wild-type tumors."

( Ding, WX; Li, H; Sobol, RW; Stolz, DB; Sun, Q; Wang, P; Yin, XM; Yu, J; Zhang, L, 2011)

"To assess liver function in Nigerian cancer patients undergoing cytotoxic chemotherapy, with a view to contributing to the existing literature and possibly making recommendations for better management of the affected patients in Nigerian hospitals."

( Adamu, A; Adewuyi, SA; Akuyam, SA; Aliyu, IS; Dawotola, DA; Mai, A; Uchenna, OK, 2011)

"Patients with advanced cancer were assigned to receive either sirolimus or the VEGFR inhibitor alone for a 2-week lead-in period, followed by combination therapy."

( Cohen, EE; Fleming, GF; Gangadhar, TC; Geary, D; House, LK; Janisch, L; Kocherginsky, M; Maitland, ML; Ramirez, J; Ratain, MJ; Undevia, SD; Wu, K, 2011)

"At present, resources for cancer control in the ME countries as a whole are not only inadequate but directed almost exclusively to treatment."

( Daher, M, 2011)

"Even though conventional cancer therapies, comprising surgery and chemo- and radiotherapy, play an important role in the treatment of most solid tumours, successful therapeutic outcome is often limited due to high toxicity and related side-effects, as well as the development of multi-drug resistances."

( Kaminski, BM; Stein, JM; Steinhilber, D; Ulrich, S, 2012)

"Approximately 50-60% cancer patients in the United States utilize agents derived from different parts of plants or nutrients (complementary and alternative medicine), exclusively or concurrently with traditional therapeutic regime such as chemotherapy and/or radiation therapy."

( Anant, S; Dhar, A; Gutheil, WG; Ray, A; Reed, G, 2012)

"Its existence in human tumors can form the basis for explaining characteristics of cancer progression and metastasis, as well as certain cases of drug resistance and relapses after treatment."

( Gomes, LR; Labriola, L; Sogayar, MC; Terra, LF, 2011)

"A main obstacle for therapy of advanced cancers is that the outcome of metastasis depends on a complex interplay between malignant and host cells."

( Alonso, DF; Garona, J; Gomez, DE; Iannucci, NB; Ripoll, GV, 2011)

"When tumors reached 100 mm, mice were treated with CpG-C/vehicle, and 24 hours later the tumor was excised along with P+E/vehicle treatment."

( Ben-Eliyahu, S; Benish, M; Goldfarb, Y; Levi, B; Melamed, R; Sorski, L, 2011)

"Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)."

( Akl, EA; Barba, M; Gunukula, S; Muti, P; Schünemann, H; Sperati, F; Terrenato, I; Vasireddi, SR, 2011)

"The decision for a patient with cancer to start heparin therapy for survival benefit should balance the benefits and downsides and integrate the patient's values and preferences."

( Akl, EA; Barba, M; Bryant, A; Dickinson, HO; Gunukula, S; Kuipers, S; Middeldorp, S; Schünemann, H; van Doormaal, FF; Yosuico, VE, 2011)

"In most cancer patients, pain is successfully treated with pharmacological measures using opioid analgesics for moderate to severe pain (strong opioids) alone or in combination with adjuvant analgesics (coanalgesics)."

( Leppert, W, 2011)

"Dendritic cell (DC)-based cancer immunotherapy using tumor homogenate has been evaluated."

( Kambara, K; Kuwada, E; Noguchi, K; Tadaki, T, 2011)

"At present cancer treatment is still a confusing problem."

( Liu, K; Zhu, HL, 2011)

"Data from 246 cancer patients participating in a randomized placebo-controlled smoking cessation clinical trial were used to examine baseline predictors of end-of-treatment and six-month postbaseline smoking cessation outcomes."

( Langer, C; Leone, F; Martinez, E; Miyamoto, C; Schnoll, RA, 2011)

"Fatigue may be associated with cancer itself and with the treatment, particularly for therapies with neurotoxic side effects."

( Ran, S; Ray, MA; Toth, LA; Trammell, RA; Verhulst, S, 2011)

"Human tumors were xenografted into severe combined immunodeficient (SCID) mice and the cancer cell lines were treated with only paclitaxel or only metformin, or a combination of both drugs."

( Carvalheira, JB; Dias, MM; Osório-Costa, F; Rocha, GZ; Ropelle, ER; Rossato, FA; Saad, MJ; Vercesi, AE, 2011)

"Thrombosis in cancer patients is a frequent and difficult to treat condition."

( Belmont, L; Meyer, G, 2011)

"Importantly, in ABT-737-resistant cancer cells, the interaction between USP9X and Mcl-1, which was increased by ABT-737 treatment, could be disrupted by gemcitabine, thus resulting in enhanced ubiquitination and the subsequent degradation of Mcl-1 and ultimately in the synergism of these two drugs."

( Cai, TY; Dong, XW; He, QJ; Hu, YZ; Jiang, H; Lin, NM; Yang, B; Yang, LQ; Zhang, C; Zhu, H, 2011)

"Non-surgical cancer therapeutic strategies have focused primarily on direct killing of cancer cells by chemotherapy and/or radiation therapy."

( Bernhard, EJ, 2011)

"Sal sensitized radiation-treated cancer cells by inducing G2 arrest and causing DNA damage."

( Kang, HS; Kim, JH; Kim, S; Kim, WK; Ro, J; Yoon, K; Yoon, S, 2012)

"Most of the new anticancer treatments currently in developmental stage are based on targeted therapies, acting against numerous tumor cell abnormalities, like growth factors et their receptors, cell proliferation-inducing factors, molecules involved in DNA repair, cell death inducers, tumor invasion and angiogenesis."

( Geoerger, B; Leblond, P, 2011)

"Patients treated with opioid drugs for cancer pain experience different relief responses, raising the possibility that genetic factors play a role in opioid therapy outcome."

( Brunelli, C; Caraceni, A; Dragani, TA; Falvella, FS; Fladvad, T; Galvan, A; Kaasa, S; Klepstad, P; Knudsen, AK; Pigni, A; Skorpen, F, 2011)

"Since cancerous cells often display elevated protein synthesis and by-product disposal, inhibition of the protein degradation pathways is an emerging approach for cancer therapy."

( Dou, Z; Pan, JA; Ullman, E; Zong, WX, 2011)

"Cisplatin is a widely used cancer therapy drug that unfortunately has major side effects in normal tissues, notably nephrotoxicity in kidneys."

( Dong, G; Dong, Z; Huang, S; Jiang, M; Kumar, MV; Messing, RO; Pabla, N, 2011)

"Patients aged ≥18 years who had cancer and were being treated with CTH and antiemetic prophylaxis with palonosetron (Group 1) and other 5-HT(3) receptor antagonists (Group 2) for the first time between April 1, 2007, and March 31, 2009, were identified using a hospital-service database."

( Balu, S; Buchner, D; Craver, C; Gayle, J, 2011)

"In this study, patients with cancer who were treated with CTH and on antiemetic prophylaxis using palonosetron were found to have significantly lower CINV event rates than those receiving other 5-HT(3) receptor antagonists."

( Balu, S; Buchner, D; Craver, C; Gayle, J, 2011)

"Mammary tumors, induced by inoculation of BALB/c mice syngeneic with metastatic BJMC3879luc2 cells, were subsequently treated with α-mangostin at 0, 10 and 20 mg/kg/day using mini-osmotic pumps and histopathologically examined."

( Akamatsu, K; Akao, Y; Iinuma, M; Kurose, H; Morimoto, J; Okuno, Y; Otsuki, Y; Shibata, MA, 2011)

"Thyroid consequences of cancer therapy are multiple, better known after radiotherapy than after chemotherapy and recently described with targeted therapies."

( Borson-Chazot, F; Damatte-Fauchery, C; Nozières, C, 2011)

"Most patients with malignancy and neutropenia were successfully treated by all three drugs."

( Cornely, OA; Marty, FM; Pappas, PG; Stucker, F; Ullmann, AJ, 2011)

"Patients with advanced solid tumors refractory to and progressing after conventional therapies were treated with three different regimens of low-dose cyclophosphamide (CP) in combination with oncolytic adenovirus."

( Arstila, PT; Cerullo, V; Diaconu, I; Escutenaire, S; Haavisto, E; Hemminki, A; Holm, SL; Joensuu, T; Kanerva, A; Kangasniemi, L; Karioja-Kallio, A; Kauppinen, S; Koski, A; Laasonen, L; Oksanen, M; Partanen, K; Pesonen, S; Rajecki, M; Romano, V; Rouvinen, N; Tuuminen, T, 2011)

"It is well known that many cancer patients suffer from visceral pain, neuropathic pain and bone pain, not only during the terminal phase but also in the active treatment phase."

( Sumitani, M; Yamada, Y, 2011)

"Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)."

( Akl, EA; Barba, M; Gunukula, S; Muti, P; Schünemann, H; Sperati, F; Terrenato, I; Vasireddi, SR, 2011)

"Development of safe and effective cancer vaccine formulation is a primary focus in the field of cancer immunotherapy."

( Haddadi, A; Hamdy, S; Hung, RW; Lavasanifar, A, 2011)

"Sixteen patients with refractory solid tumors commonly exhibiting mitogen-activated protein kinase (MAPK) pathway activation were treated weekly with paclitaxel and bortezomib."

( Gounder, M; Kane, M; Karantza, V; Levinson, K; Lin, H; Lin, Y; Mehnert, JM; Moss, R; Poplin, E; Rubin, EH; Shih, WJ; Sovak, M; Stein, MN; Tan, AR; White, E, 2011)

"Platinum-based cancer drugs, such as cisplatin, are highly effective chemotherapeutic agents used extensively for the treatment of solid tumors."

( Aitken, JB; Ang, WH; Ascher, DB; Campomanes, P; De Luca, A; Dyson, PJ; Hancock, NC; Harris, HH; Italiano, LC; Lo Bello, M; Morton, CJ; Parker, LJ; Parker, MW; Rothlisberger, U, 2011)

"Patients were studied before their cancer treatment was started or 4 weeks after their treatment was completed or halted."

( Deutz, NE; Ferrando, A; Memelink, R; Safar, A; Schutzler, S; Spencer, H; van Helvoort, A; Wolfe, RR, 2011)

"These cancer stem cells (CSC) may also contribute to metastasis and treatment resistance."

( Korkaya, H; Liu, S; Wicha, MS, 2011)

"To retrospectively evaluate the rate of malignancy of focal fluorine-18 fluorodeoxyglucose (18F-FDG)-avid lesions without computed tomography (CT) correlate at whole-body positron emission tomography (PET)-CT in oncology patients, because better defining these abnormalities could potentially lead to improved patient management algorithms that rely on PET-CT for detection, staging, and treatment monitoring of malignancies."

( Hawkins, RA; Kumar, R; Wang, ZJ; Yeh, BM, 2011)

"This study explored cancer incidence rates in a large cohort of Israeli (Jewish and Arab) opioid-dependent individuals receiving methadone maintenance treatment (MMT), and how the incidences vary by ethnicity and sex."

( Barchana, M; Grinshpoon, A; Lipshitz, I; Ponizovsky, AM; Rosca, P; Weizman, A, 2011)

"Anemia, which is a common problem in cancer patients, has a negative effect on survival by decreasing the efficacy of chemotherapy and particularly of radiotherapy, as well as impairing the quality of life (QoL) of patients."

( Demirkaya, M; Durmaz, O; Sevinir, B, 2011)

"We found in mice and in cancer patients that administration of Gemcitabine induces a transient reduction in the percentage of regulatory T-cells among CD4-positive cells."

( Curioni, A; Knuth, A; Parvanova, I; Pascolo, S; Rettig, L; Samaras, P; Seidenberg, S, 2011)

"Cancer patients' knowledge about cancer and experiences with its treatment play an important role in long-term adherence in their disease management."

( Farooqui, M; Farooqui, MA; Hassali, MA; Seang, TB; Shafie, AA; Shatar, AK, 2011)

"For a variety of reasons, cancer pain is often undertreated, adversely affecting the quality of life for patients and caregivers."

( Induru, RR; Lagman, RL, 2011)

"Patients with advanced solid tumors were treated with 75 mg/m(2) cisplatin on day 1 and 1,250 mg/m(2) gemcitabine on days 1 and 8 of each 21-day cycle."

( Brendel, E; Kornacker, M; Kummer, G; Schultheis, B; Strumberg, D; Xia, C; Zeth, M, 2012)

"Patients with advanced or metastatic cancer were treated with escalating doses of LY2334737 monotherapy or in combination with continuous daily administration of 100 mg erlotinib."

( Beijnen, JH; Benhadji, KA; Callies, S; Garcia-Ribas, I; Jansen, RS; Koolen, SL; Kronemeijer, RH; Langenberg, MH; Nol, A; Schellens, JH; Slapak, CA; Voest, EE; Witteveen, PO, 2011)

"Human tumors often contain slowly proliferating cancer cells that resist treatment, but we do not know precisely how these cells arise."

( Darp, R; Dey-Guha, I; G Albeck, J; Leon, E; Petricoin, EF; Ramaswamy, S; Wittner, BS; Wolfer, A; Wulfkuhle, J; Yeh, AC, 2011)

"Hyperthermia, which is heating of tumors above 43°C for about 30min, has been known to modulate vascular permeability for enhanced chemotherapy."

( Elliott, AM; Huang, Q; Li, C; Melancon, MP; Shetty, A; Stafford, RJ, 2011)

"We observed 5,466 incident cancers; crude rates did not vary by treatment group."

( Korc, M; Liu, SK; Mackenzie, TA; Morden, NE; Skinner, J; Smith, J, 2011)

"However, novel anticancer strategies (including tyrosine kinase inhibitors and monoclonal antibodies, as well as antiangiogenetic treatments) are becoming relevant in veterinary medicine, too."

( Buchholz, J; Kaser-Hotz, B; Marconato, L; Ruess-Melzer, K, 2011)

"Multidrug resistance (MDR) in cancer is a phenomenon in which administration of a single chemotherapeutic agent causes cross-resistance of cancer cells to a variety of therapies even with different mechanisms of action."

( Beck, WT; Bleeker, NP; Das, SG; Doshi, JM; Hermanson, DL; Srinivasan, B; Tang, R; Xing, C, 2011)

"The growing number of cancer survivors combined with a looming shortage of oncology specialists will require greater coordination of post-treatment care responsibilities between oncologists and primary care physicians (PCPs)."

( Ayanian, JZ; Aziz, N; Earle, C; Ganz, PA; Han, PK; Klabunde, CN; Potosky, AL; Rowland, J; Smith, T; Stefanek, M, 2011)

"Children with solid tumors deemed to be poor risk at diagnosis and those who fail to respond or recur after chemotherapy have adverse outcomes."

( Alvaro, F; Cohn, RJ; McCowage, GB; Mrongovius, R; Oswald, C; White, L; Ziegler, DS, 2011)

"The first TCRs used in cancer gene therapy, DMF4 and DMF5, recognize two structurally distinct peptide epitopes of the melanoma-associated MART-1/Melan-A protein, both presented by the class I MHC protein HLA-A*0201."

( Baker, BM; Borbulevych, OY; Hossain, M; Santhanagopolan, SM, 2011)

"Neuropathic cancer pain (NCP), commonly encountered in clinical practice, may be cancer-related, namely resulting from nervous system tumor invasion, surgical nerve damage during tumor removal, radiation-induced nerve damage and chemotherapy-related neuropathy, or may be of benign origin, unrelated to cancer."

( Moka, E; Raptis, E; Siafaka, I; Sykioti, P; Vadalouca, A; Zis, P, 2012)

"Adding ZOL to anticancer therapy improved disease-free and overall survival in clinical trials in women receiving adjuvant endocrine therapy for breast cancer and in patients with newly diagnosed multiple myeloma."

( Lipton, A, 2011)

"Metformin users showed a lower risk of cancer-related mortality than not users or patients on diet only; this may represent another reason to choose metformin as a first-line therapy in T2DP."

( Appendino, G; Bo, S; Ciccone, G; Ghigo, E; Grassi, G; Rosato, R; Villois, P, 2012)

"Our study shows that in Indonesian cancer patients treated with highly cytostatic emetogenic, carriership of the CTG haplotype of the ABCB1 gene is related to an increased risk of delayed chemotherapy-induced nausea and vomiting."

( Baak-Pablo, RF; Gelderblom, H; Guchelaar, HJ; Hakimi, M; Mustofa, M; Nortier, JW; Perwitasari, DA; van der Straaten, RJ; Wessels, JA, 2011)

"In contrast, continuous growth of tumors was observed in the group treated with free Ce6."

( Kim, CW; Kim, YB; Lee, S; Oh, YK; Shim, G, 2011)

"The successful treatment of most cancers depends on early detection."

( Gao, Y; Li, N; Qiao, G; Tang, B; Yu, Z; Zhuo, L, 2011)

"Traditional cancer therapy can be successful in destroying tumors, but can also cause dangerous side effects."

( Bernabeu, E; Chiappetta, DA; Daniels, TR; Helguera, G; Holler, E; Kozman, M; Ljubimova, JY; Patel, S; Penichet, ML; Rodríguez, JA, 2012)

"We included 104 consecutive advanced cancer patients who were extensively pretreated with opioids."

( Jager, A; Janssen, PJ; Lieverse, PJ; Oldenmenger, WH; Taal, W; van der Rijt, CC, 2012)

"In advanced cancer patients with serious unstable cancer-related pain refractory to other opioids, continuous parenteral administration of hydromorphone often results in long-lasting adequate pain control and should be considered even after extensive pretreatment with opioids."

( Jager, A; Janssen, PJ; Lieverse, PJ; Oldenmenger, WH; Taal, W; van der Rijt, CC, 2012)

"A previous study of cancer-related neuropathic pain (NP) found that a 10-fold increase in pregabalin (PGB) use increased patients' satisfaction with treatment."

( Ciria, JP; Fernández, MC; Gonzálvez, ML; López-Gómez, V; Mańas, A; Masramon, X; Morillo, V; Pérez, M, 2011)

"It has enhanced the activity of anticancer treatments in preclinical models and early phase trials, although one Phase III trial result was negative and another is yet to be reported."

( Head, M; Jameson, MB, 2011)

"An outstanding problem in cancer therapy is the battle against treatment-resistant disease."

( Abu-Yousif, AO; Celli, JP; Evans, CL; Hasan, T; Klein, OJ; Park, YJ; Rizvi, I; Zheng, X, 2011)

"In chronic non-cancer pain patients pharmacological treatment is only one element of an interdisciplinary approach."

( Willimann, P, 2011)

"To develop a novel cancer vaccine using the targeting system of antigen protein to antigen-presenting cells (APCs) for efficient and safe cancer therapy."

( Fumoto, S; Higuchi, N; Kitahara, T; Kodama, Y; Kurosaki, T; Nakagawa, H; Nakamura, T; Nishida, K; Sasaki, H, 2012)

"Fifty patients with 76 malignant liver tumors treated by computed tomography (CT)-guided high-dose-rate brachytherapy (HDR-BT) were included in the study."

( Kropf, S; Lüdemann, L; Mohnike, K; Ricke, J; Seidensticker, M; Wust, P; Wybranski, C, 2011)

"Thirty patients with advanced solid tumors were treated in a standard 3 + 3 cohort design."

( Bauman, J; Belinsky, S; Fekrazad, M; Jones, D; Lee, SJ; Muller, C; Ravindranathan, M; Rutledge, T; Verschraegen, C, 2012)

"Currently, outpatient cancer chemotherapy has been commonly performed in Japan."

( Hino, K; Kudo, K; Sato, J; Takahashi, K, 2011)

"Thus, up to date management of cancer patients, in addition to other supportive care modalities, should also incorporate diagnostic methods and therapy of infections."

( Sinkó, J, 2011)

"Doxorubicin is a widely used anticancer drug in the treatment of solid tumors and leukemias."

( Boddy, AV; Jamieson, D, 2011)

"Specific cellular immunotherapy of cancer requires efficient generation and expansion of cytotoxic T lymphocytes (CTLs) that recognize tumor-associated self-antigens."

( Altvater, B; Juergens, H; Kailayangiri, S; Landmeier, S; Pscherer, S; Rossig, C; Savoldo, B, 2012)

"An orthotopic model of MDR human breast cancer was developed in nude mice and used to evaluate the safety and efficacy of nanoparticle treatment."

( Amiji, M; Duan, Z; Milane, L, 2011)

"Intensive cancer chemotherapy leads to significant bone loss, the underlying mechanism of which remains unclear."

( Foster, BK; Hopwood, B; Shandala, T; Shen Ng, Y; Xian, CJ; Yip, YC, 2012)

"This paves the way for a new selective cancer-targeting therapy, efficient in a wide range of human cancers."

( Castiel, A; Cohen-Armon, M; Dantzer, F; Izraeli, S; Mittelman, L; Visochek, L, 2011)

"In this study, we developed a cancer-targeting therangostics probe in a single system using an AS1411 aptamer - and miRNA-221 molecular beacon (miR-221 MB)-conjugated magnetic fluorescence (MF) nanoparticle (MFAS miR-221 MB) to simultaneously target to cancer tissue, image intracellularly expressed miRNA-221 and treat miRNA-221-involved carcinogenesis."

( Choi, KJ; Jo, MH; Kim, JK; Kim, S; Lee, M, 2012)

"This combination treatment of cancer-bearing mice was very effective against tumor xenograft from hormone-independent highly metastasized chemo-resistant human prostate cancer cells, suggesting that the combination treatment may provide a safe and effective alternative to genotoxin-based cancer therapies."

( Ellisman, M; Janssen, E; Kitada, S; Perkins, G; Reed, JC; Yamaguchi, R, 2011)

"UPase expressing colon 38 tumors implanted in UPase(-/-) mice revealed an improved therapeutic efficacy when treated with 5-FU and capecitabine because of the higher maximum tolerated dose for fluoropyrimidines achievable in UPase(-/-) mice."

( Cao, D; Flynn, S; Gach, M; Kim, B; McCabe, J; Pizzorno, G; Wan, L; Yan, R; Ziemba, A, 2011)

"The treatment of cancer often involves the use (or combination) of chemotherapeutic drugs, radiotherapy and interventional surgery (for solid and operable tumors)."

( De La Peña, H; Pastorin, G; Rajadas, J; Seifalian, A; Tan, A; Yildirimer, L, 2011)

"Although, nowadays, cancer treatment still relies heavily on conventional chemotherapy and surgery, with increasing evidence of novel biologic agents which demonstrate its higher anti-cancer activity and fewer side effects, more and more efforts have been spent on development of different types of novel agents."

( Chow, LW; Ong, EY; Yip, AY, 2012)

"VB-111 is novel agent for cancer that may have application as monotherapy and in combination with other therapies."

( Borden, EC; Triozzi, PL, 2011)

"Although cancer-associated anemia is caused by multiple factors, recombinant erythropoietin (rhuEpo) was widely used to treat and prevent this condition."

( Fink, D; Leo, C, 2011)

"Neuropathic pain in patients with cancer can be difficult to treat effectively."

( Abernethy, AP; Jett, LG; Pike, IM; Spruill, SE; True Kelly, A; Weinstein, SM, 2012)

"In cases of cancer pain patients with failed oral or transcutaneous opioid medication, sufficient pain reduction can be achieved with parenteral drug administration by PCA."

( Heine, J; Lux, EA, 2011)

"Doxorubicin is an anthracycline anticancer agent that is commonly used in the treatment of a variety of cancers, but its application is associated with severe side effects."

( Aben, RW; Hennink, WE; Lammers, T; Morita, K; Rijcken, CJ; Scheeren, HW; Storm, G; Talelli, M; van Nostrum, CF, 2011)

"MLT may benefit cancer patients who are also receiving chemotherapy, radiotherapy, supportive therapy, or palliative therapy by improving survival and ameliorating the side effects of chemotherapy."

( Fritz, H; Kennedy, DA; Mills, E; Seely, AJ; Seely, D; Tsui, T; Wu, P, 2012)

"Harnessing this process within cancer cells enables minimally invasive yet targeted cancer treatment."

( Gupta, AS; Master, AM; Oleinick, NL; Qi, Y, 2012)

"Photodynamic cancer therapy using Pc 4, a light activated and highly hydrophobic photosensitizer is demonstrated in this paper in vitro."

( Gupta, AS; Master, AM; Oleinick, NL; Qi, Y, 2012)

"Treatment of cancer cell lines with small interfering RNA targeting WHSC1 significantly knocked down its expression and resulted in the suppression of proliferation."

( Cho, HS; Daigo, Y; Field, HI; Hamamoto, R; Hayami, S; Iwai, Y; Kelly, JD; Maehara, Y; Masuda, K; Nakamura, Y; Neal, DE; Ponder, BA; Takawa, M; Toyokawa, G; Tsuchiya, E; Tsunoda, T; Yamane, Y; Yoshimatsu, M, 2011)

"However, as more human cancer cells are reported to be resistant to TRAIL treatment, it is important to develop new therapeutic strategies to overcome this resistance."

( Lu, Y; Shen, HM; Zhao, J, 2012)

"Multidrug resistance (MDR) in cancer, a major obstacle to successful application of cancer chemotherapy, is often characterized by over-expression of multidrug resistance-related proteins such as MRP1, P-gp or elevated glutathione (GSH) level."

( Banerjee, K; Basu, S; Chakraborty, P; Chatterjee, M; Choudhuri, SK; Efferth, T; Ganguly, A; Sen, R, 2012)

"No individual cancer site showed a substantial positive or negative association with VKA therapy in the prescription validation subset, the instrumental variable analysis, or the analysis with semi-Bayes adjustment."

( Ahern, TP; Lash, TL; Pedersen, L; Rothman, KJ; Sværke, C; Sørensen, HT, 2011)

"Because each cancer is a heterogeneous mix of cancer cells at different stages of development, we are faced with trying to treat many different diseased cells all at once."

( Perkins, G; Yamaguchi, R, 2012)

"In vitro, NP3 mediated PTA of both cancer cells and DOX release upon NIR laser treatment."

( Li, C; Liang, D; Liu, Y; Sood, AK; Van Pelt, CS; Wei, W; You, J; Zhang, G; Zhang, R; Zhong, M, 2012)

"The anticancer efficacy of these compounds may result from their use in monotherapy or in association with chemotherapeutic drugs."

( Russo, GL; Russo, M; Spagnuolo, C; Tedesco, I, 2010)

"Over-expression of HIF-1α in human tumors is associated with poor prognosis and poor therapeutic outcomes and HIF-1α has been suggested as a novel target for cancer therapy."

( Kim, HM; Lee, K, 2011)

"Effectiveness of nanomedicines in cancer therapy is limited in part by inadequate delivery and transport in tumor interstitium."

( Au, JL; Gao, Y; Lu, Z; Wang, J; Wientjes, MG, 2011)

"In this work, the anti-cancer drug Dox and therapeutic gene pTRAIL-loaded host-guest co-delivery system was assayed for the possibility of in vivo synergistically treating tumors."

( Fan, H; Hu, QD; Liang, WQ; Tang, GP; Xu, FJ; Yang, WT, 2012)

"The clinical cancer research community should cooperate and focus new studies on the use of a specific combination of antioxidant and chemotherapy or radiotherapy, and determine optimal doses for a specific cancer setting."

( Alladin, KP; Igbokwe, O; Nakayama, A; White, JD, 2011)

"NAT1 is up-regulated in several cancer types, and overexpression can lead to increased survival and resistance to chemotherapy."

( Butcher, NJ; Minchin, RF, 2012)

"Patients with chronic non-cancer pain and cancer pain treated at a tertiary pain center were screened for addiction using Portenoy's criteria and invited to answer the Danish version of the PMQ."

( Frich, L; Højsted, J; Kendall, S; Nielsen, PR; Sjøgren, P, 2011)

"The emergence of skin tumors in patients treated with sorafenib or with more recent BRAF inhibitors is an intriguing and potentially serious event."

( André, J; Arnault, JP; Boussemart, L; Druillennec, S; Dumaz, N; Eggermont, AM; Escudier, B; Eychène, A; Hollville, E; Kamsu-Kom, N; Lacroix, L; Larcher, M; Malka, D; Mateus, C; Robert, C; Sarasin, A; Soria, JC; Spatz, A; Tomasic, G; Vagner, S; Wechsler, J, 2012)

"Forty-one solid cancer patients received aprepitant, palonosetron and dexamethasone during a 3-day cisplatin-based chemotherapy."

( Gao, HF; Liang, Y; Wu, HY; Zhang, DS; Zhou, NN, 2013)

"A major issue relating to many cancers is the absence of effective chemotherapeutic agents; so that most often untreatable morbidity and death are prevalent once the cancer has been detected and has advanced."

( Costello, LC; Franklin, RB, 2012)

"The rationale for cancer neuroimmunotherapy consists of the possibility to enhance the efficacy of the various immunotherapeutic strategies by a concomitant administration of antitumor cytokines (namely IL-2), in addition to neuroendocrine endogenous molecules (namely the pineal indole hormones), able to stimulate the anticancer immunoresponse by amplifying the anticancer reaction and/or by counteracting the generation of immunosuppressive events."

( Lissoni, P; Rovelli, F, 2012)

"Over decades, cancer treatment has been mainly focused on targeting cancer cells and not much attention to host tumor microenvironment."

( Ahmad, A; Ali, S; Azmi, AS; Banerjee, S; Bao, B; Kong, D; Li, Y; Lum, LG; Sarkar, FH; Thakur, A, 2012)

"Autophagy is activated in cancer cells during chemotherapy and often contributes to tumor chemotherapy resistance."

( Chen, X; Ding, H; Wang, Y; Wu, L; Zen, K; Zhang, CY; Zhang, Q; Zhang, Y; Zou, Z, 2012)

"A total of 109 prospectively sampled cancer patients, receiving the first treatment with an EGFR inhibitor, were genotyped for functional EGFR polymorphisms and tagging variants in genes involved in receptor downstream signaling."

( Boeck, S; Heinemann, V; Kächele, V; Parmar, S; Paul, T; Rüdiger, S; Schumann, C; Seeringer, A; Seufferlein, T; Stingl, JC, 2013)

"Breast cancer survivors may experience long-term QoL comparable to the general population, even when suffering from substantial fatigue during treatment."

( Chang-Claude, J; Flesch-Janys, D; Heinz, J; Schmidt, ME; Steindorf, K; Vrieling, A, 2012)

"In the long lasting battle against cancer, Nature sometimes gives a helping hand to researchers to find new drugs for the treatment of diseases and improvement of patients' well-being."

( Chen, DY; Pouwer, RH; Richard, JA; Tseng, CC, 2012)

"Seventy-six cancer patients with normal cardiac function who received palonosetron for prevention of chemotherapy-induced nausea and vomiting were enrolled."

( Araz, M; Ata, OY; Dogan, U; Yavas, C; Yavas, G, 2012)

"Multidrug resistance (MDR) of cancer cells poses a serious obstacle to successful chemotherapy."

( Wesołowska, O, 2011)

"Here, we show that when cancer cells are treated with hypericin-based PDT (Hyp-PDT), they surface-expose both HSP70 and calreticulin (CRT)."

( Agostinis, P; Garg, AD; Krysko, DV; Vandenabeele, P, 2012)

"Cytotoxic drugs in cancer therapy are used with the expectation of selectively killing and thereby eliminating the offending cancer cells."

( Akporiaye, ET; Borodovsky, A; Hahn, T; Polanczyk, MJ; Ralph, SJ; Ramanathapuram, LV, 2013)

"The treatment of human cancer has been seriously hampered for decades by resistance to chemotherapeutic drugs."

( Baldi, A; Betti, G; Buglioni, S; Carocci, F; Citro, G; de Bazzichini, GM; Fais, S; Menicagli, F; Pantaleo, I; Spugnini, EP, 2011)

"VTE is a common entity in cancer patients and is managed with anticoagulant therapy, while tumour thrombosis requires aggressive multimodality management."

( Bal, C; Jeph, S; Kumar, R; Malhotra, A; Naswa, N; Patnecha, M; Reddy, RM; Sharma, P; Singh, H, 2012)

"Fifteen rabbits with Vx2 tumors within superficial thigh muscle were randomly assigned into three treatment groups: 1) free doxorubicin, 2) LTSL and 3) LTSL + MR-HIFU."

( Dreher, MR; Frenkel, V; Gacchina, CE; Jacobs, GC; Negussie, AH; Partanen, A; Ranjan, A; Sharma, KV; Wood, BJ; Woods, DL; Yarmolenko, PS, 2012)

"Poorly-differentiated cancer cells were generally more responsive to simvastatin than well-differentiated cancer cells, and the levels of HMGCR expression did not consistently correlate with response to statin treatment."

( Chakraborty, K; Harirforoosh, S; Hsi, L; Krishnan, K; Menter, DG; Newman, RA; Ramsauer, VP; Yang, P, 2011)

"Optical imaging of cancer would allow early diagnosis, evaluation of disease progression and therapy efficiency."

( Kumar, DS; Maekawa, T; Mohamed, MS; Nagaoka, Y; Poulose, AC; Raveendran, S; Veeranarayanan, S; Yoshida, Y, 2012)

"A refocused perspective of cancer metabolism that recognizes metabolic diversity within a tumor offers novel therapeutic targets by which cancer cells may be starved from their fuel sources, and thereby become more sensitive to traditional cancer treatments."

( Nakajima, EC; Van Houten, B, 2013)

"In the human tumors treated with conventional fractionated radiotherapy, the morphological and functional status of the vasculature is preserved, if not improved, during the early part of a treatment course and then decreases toward the end of treatment."

( Griffin, RJ; Hui, S; Levitt, SH; Park, HJ; Song, CW, 2012)

"In both rat and mouse breast cancer models, the dendrimer formulation gave equivalent antitumor efficacy when compared to the liposomal or solution doxorubicin formulations and administration of all three doxorubicin formulations resulted in a significant reduction (>75%) in tumor growth in both models at doses ranging from 2 to 10 mg/kg doxorubicin equivalents."

( Boyd, BJ; Cullinane, C; Kaminskas, LM; Kelly, BD; McLeod, VM; Owen, DJ; Porter, CJ; Sberna, G; Williamson, M, 2012)

"Erythropoietin may be lowered by cancer itself or because of chemoradiotherapy."

( Cartei, F; Cartei, G; Colombrino, E; Fiorica, F; Giraldi, T; Micucci, M; Plebani, M; Sanzari, MC; Zustovich, F, 2011)

"Advances in treatment options mean that cancer patients are living longer and pain interventions may have a role to play even early in the cancer diagnosis for better quality of analgesia."

( Bhaskar, AK, 2012)

"Selenium compounds are known as cancer preventive agents and are also able to ameliorate the toxicity associated with anti-cancer radiation and chemotherapy in mouse models."

( Antoch, MP; Chernov, MV; Comas-Soberats, M; Fedtsova, N; Gleiberman, AS; Gudkov, AV; Hu, Y; Jackson, M; Kuropatwinski, KK; Rustum, YM; Spengler, ML, 2011)

"Melatonin as an adjuvant therapy for cancer led to substantial improvements in tumor remission, 1-year survival, and alleviation of radiochemotherapy-related side effects."

( Ai, F; Dong, TF; Duan, CH; Fu, QL; Jin, BZ; Lu, YZ; Wang, YM, 2012)

"With specific relevance to cancer therapy, iron oxide nanoparticle-based therapy represents an important alternative to conventional chemotherapy, radiation, or surgery."

( Medarova, Z; Moore, A; Yigit, MV, 2012)

"As a target for cancer therapy it allows the simultaneous inhibition of several signalling pathways."

( Bantscheff, M; Boerno, ST; Dahl, A; Drewes, G; Fischer, A; Fröhlich, H; Gonzalez, C; Haupt, A; Joberty, G; Kerick, M; Lange, BM; Lappe, M; Lehrach, H; Schweiger, MR; Stehr, H, 2012)

"Sixty Japanese cancer patients being treated with a fentanyl transdermal reservoir system according to the current Japanese guidelines were enrolled."

( Kawakami, J; Mino, Y; Naito, T; Ohnishi, K; Takashina, Y; Yagi, T, 2012)

"Modeling cancer treatment has to take into account many cellular pathways usually leading to the construction of large mathematical models."

( Daskalaki, A; Hache, H; Herwig, R; Kühn, A; Lehrach, H; Li, J; Maschke-Dutz, E; Peycheva, S; Wierling, C, 2012)

"Of the 17 refractory colon cancer patients with a median of 3 prior treatments, stable disease was seen in 7 patients (41%)."

( Bayraktar, S; Ferrell, A; Flores, AM; Lucarelli, A; Macintyre, J; Poplin, EA; Raez, L; Rocha-Lima, CM; Rubin, EH; Tan, AR; Zojwalla, N, 2012)

"Astrocytomas are cancers of the brain in which high levels of extracellular glutamate plays a critical role in tumor growth and resistance to conventional treatments."

( Azmi, A; Benzaria, A; Di Scala, C; Graoudi, S; Maresca, M; Taïeb, N; Varini, K, 2012)

"An overview of GCPII/PSMA in cancer, as well as a discussion of imaging and therapy of prostate cancer using a wide variety of PSMA-targeting agents is provided."

( Cho, SY; Foss, CA; Kim, HJ; Mease, RC; Pomper, MG, 2012)

"Patients with cancer, irrespective of the stage of their disease, can require admission to the intensive care unit as a result of the complications of their underlying process or the surgical or pharmacological treatment provided."

( Abilés, J; Fernández-Ortega, JF; Planas, M, 2011)

"Knowledge of CNDAC mechanism identifies tumors that may be sensitized to sapacitabine, thus enabling a personalized treatment strategy."

( Kantarjian, H; Liu, X; Plunkett, W, 2012)

"We propose segmentation of tumors to determine tumor heterogeneity, potentially useful for dose-painting in radiotherapy and elucidating mechanisms of FDG uptake."

( de Geus-Oei, LF; Disselhorst, JA; Oyen, WJ; Visser, EP; Vriens, D, 2012)

"Colorectal and prostate cancer patients versus lung cancer patients and stage III versus stage IV patients were less likely to be treated with LMWH monotherapy."

( Aiello Bowles, EJ; Delate, T; Hornbrook, MC; Kushi, L; Ritzwoller, D; Schrag, D; Weeks, JC; Witt, DM, 2012)

"In anticancer therapy however, their potential is limited due to the resistance by various mechanisms."

( Brulikova, L; Hlavac, J; Hradil, P, 2012)

"Patients receiving chemotherapy for cancer are at increased risk for venous thromboembolism."

( Agnelli, G; Chaudhari, U; Fisher, W; George, DJ; Kakkar, AK; Lassen, MR; Lawson, F; Mismetti, P; Mouret, P; Turpie, AG, 2012)

"Patients with solid tumors who failed standard therapy or were candidates for gemcitabine-based therapy were eligible."

( Adjei, AA; Dy, GK; Eckhardt, SG; Jimeno, A; Ma, WW; Maniar, M; Messersmith, WA; Ren, C; Weekes, CD; Whitworth, A; Wilhelm, F, 2012)

"A significant proportion of cancer patients is treated using MeV electron radiation."

( Anton, M; Boillat, B; Vörös, S, 2012)

"Acquired resistance of cancer cells to various chemotherapeutic agents is known as multidrug resistance, and remains a critical factor in the success of cancer treatment."

( Matsubara, M; Minegaki, T; Okumura, K; Takahashi, M; Takara, K; Yamamoto, K; Yokoyama, T, 2012)

"Patients with thyroid cancer who had longer treatment duration also had a higher incidence of high-grade events, with a relative risk of 3."

( Bai, J; Chang, Y; Ding, C; He, J; Kang, E; Tang, L; Wu, S; Xu, X; Yue, L; Zang, J, 2012)

"Different cancer types and treatment durations may affect the risk of developing high-grade QTc interval prolongation."

( Bai, J; Chang, Y; Ding, C; He, J; Kang, E; Tang, L; Wu, S; Xu, X; Yue, L; Zang, J, 2012)

"They may serve as molecular markers for cancer prognosis and/or as therapeutic agents for treating immunodeficiencies, autoimmune diseases and malignancies."

( Derhovanessian, E; Ioannou, K; Livaniou, E; Samara, P; Tsitsilonis, OE, 2012)

"Resistance of cancer cells to chemotherapy and/or radiotherapy is a major challenge to current anticancer treatment."

( Chiang, IT; Hsu, FT; Hwang, JJ; Liu, YC, 2012)

"Patients with metastatic solid tumors who progressed on standard therapy received dasatinib orally daily and ixabepilone IV every 3 weeks at escalating doses using 3 + 3 design."

( Herbolsheimer, P; Jelinek, J; Kapoor, R; Perry, D; Smith, KL; Swain, SM; Verma, N; Veytsman, I, 2013)

"Childhood cancer survivors not receiving cardiotoxic treatments nevertheless have cardiovascular abnormalities, systemic inflammation, and an increased risk of atherosclerotic disease."

( Adams, MJ; Constine, LS; French, CA; Hinkle, AS; Landy, DC; Lipshultz, SE; Lipsitz, SR; Lopez-Mitnik, G; Miller, TL; Proukou, C; Rovitelli, AM, 2012)

"Drug targeting to tumors with limited toxicity and enhanced efficacy of drug is one of the important goals for cancer treatment pharmaceutics."

( Choi, EK; Choi, J; Chung, HK; Jeong, SY; Ju, EJ; Jung, J; Kim, HY; Lee, JS; Park, HJ; Park, J; Song, SY, 2012)

"In particular, three different cancer cells treated with AuNPs@SiNWs were completely destructed within 3 min of NIR irradiation, demonstrating the exciting potential of AuNPs@SiNWs for NIR hyperthermia agents."

( He, Y; Lee, ST; Lu, Y; Peng, F; Su, S; Su, Y; Wei, X; Xu, T; Zhong, Y, 2012)

"pH1N1 infection in pediatric cancer and SCT patients infrequently caused complications but commonly interrupted cancer treatment."

( Dix, D; Ethier, MC; Gassas, A; Johnston, DL; Portwine, C; Science, M; Sung, L; Tran, D; Yanofsky, R; Zelcer, S, 2012)

"Moreover, the alternative anticancer therapies based on thermal ablation and radiotherapy are discussed."

( Ali-Boucetta, H; Bianco, A; Da Ros, T; Fabbro, C; Kostarelos, K; Prato, M, 2012)

"Although many diseases, including cancer, hematological diseases, hypertension, heart failure, inflammation, sepsis, neurodegeneration, and sleep disorders, have been linked to abnormal endogenous CO metabolism and functions, CO administration has therapeutic potential in inflammation, sepsis, lung injury, cardiovascular diseases, transplantation, and cancer."

( Ascenzi, P; di Masi, A; Gullotta, F, 2012)

"Importantly, for breast and other cancers, when aggressive anti-tumor treatments are less effective, supportive approaches appear to become more useful."

( Spiegel, D, 2012)

"NK cells were detected in the tumors by histology after all three administration routes."

( Chen, Y; Foster, PJ; Mallett, CL; McFadden, C, 2012)

"Such cancers are very receptive to cytotoxic therapy because of increased mitotic rates."

( Mackiewicz, T, 2012)

"Patients with active cancer are often on chronic anticoagulation and frequently require interruption of this treatment for invasive procedures."

( Daniels, PR; Heit, JA; Hodge, DO; Litin, SC; McBane, RD; Slusser, JP; Sutkowska, E; Tafur, AJ; Wolny, E; Wysokinski, WE, 2012)

"For each indication, we tested active cancer and bridging heparin therapy as potential predictors of TE and major bleeding."

( Daniels, PR; Heit, JA; Hodge, DO; Litin, SC; McBane, RD; Slusser, JP; Sutkowska, E; Tafur, AJ; Wolny, E; Wysokinski, WE, 2012)

"Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a clinical challenge."

( Allende, S; Fallon, MT; Ganae-Motan, ED; McQuade, R; Portenoy, RK; Shaiova, L; Weinstein, S; Wright, S; Yanagihara, R, 2012)

"Molecular imaging of cancer using nanosized materials comprises an important part in diagnosis, therapy, and drug discovery in medical nanosciences."

( Georgoulias, P; Loudos, G; Psimadas, D; Valotassiou, V, 2012)

"In vitro trials carried out on KB cancer cells treated with IONCs of 19 nm have shown efficient hyperthermia performance, with cell mortality of about 50% recorded when an equilibrium temperature of 43 °C was reached after 1 h of treatment."

( Di Corato, R; Espinosa, A; Garcia-Hernandez, M; Gazeau, F; Guardia, P; Lartigue, L; Manna, L; Pellegrino, T; Wilhelm, C, 2012)

"Diagnosing tumors at an early stage when they are easily curable and may not require systemic chemotherapy remains a challenge to clinicians."

( Barback, CV; Blair, SL; Kono, Y; Kummel, AC; Liberman, A; Martinez, HP; Mattrey, RF; Ta, CN; Trogler, WC; Wu, Z, 2012)

"New approaches to folate-based cancer chemotherapy are described based on the targeted delivery of drugs to malignant cells."

( Goldman, ID; Visentin, M; Zhao, R, 2012)

"Female Balb/c mice bearing 4T1 breast cancer tumor were treated with a single i."

( Ahadi, F; Atyabi, F; Dinarvand, R; Khorramizadeh, MR; Taheri, A, 2012)

"DNA damage caused during cancer treatment can rapidly activate the ataxia telangiectasia-mutated (ATM) and ATM and Rad3-related (ATR)-dependent phosphorylation of Chk2 and Chk1 kinases, which are hallmarks of the DNA damage response (DDR)."

( Chang, FR; Chou, WC; Chuang, DW; Hunyadi, A; Lee, AY; Lin, WL; Liu, KY; Tseng, CN; Wang, HC; Wu, CC; Wu, YC, 2012)

"Greater percentages of MM and breast cancer patients were treated with ZOL."

( Henk, H; Kaura, S; Teitelbaum, A, 2012)

"Both STS and CAII are over-expressed in cancers and have become attractive targets for cancer treatment and molecular imaging of cancer."

( Gao, M; Miller, KD; Sledge, GW; Wang, M; Xu, L; Zheng, QH, 2012)

"The Functional Assessment of Cancer Therapy-Bone Marrow Transplant measures quality of life (QOL) in SCT patients."

( Garcia, CM; Mumby, PB; Stiff, PJ; Thilges, S, 2012)

"Cell proliferation, a main target in cancer therapy, is influenced by the surrounding three-dimensional (3D) extracellular matrix (ECM)."

( Ampe, C; Huyck, L; Van Troys, M, 2012)

"Effective targeting drug delivery for cancer therapy still remains a formidable challenge due to the complication and heterogeneity of malignant tumors."

( Fang, X; Han, L; Huang, Y; Qin, J; Shen, M; Wang, J; Yang, VC, 2012)

"In this study of cancer patients with MI, medical therapy with aspirin and β-blockers was associated with improved survival."

( Abbasi, N; Daher, IN; Daraban, N; Durand, JB; Lei, X; Yusuf, SW, 2012)

"Neuropathic pain frequently occurs in cancer patients, but no drug therapy has been established for this type of disorder."

( Fujisaka, Y; Kaneda, H; Koyama, A; Makimura, C; Matsuoka, H; Nakagawa, K; Okamoto, W; Otsuka, M; Tsurutani, J, 2012)

"Many tumors do not respond to drug treatment due to their resistance to undergo apoptosis thereby contributing to the development of cancer."

( de la Lastra, CA; Guerrero, JM; Packham, G; Sánchez-Hidalgo, M; Villegas, I, 2012)

"Except for some kind of cancers, no effective and/or definitive therapeutic treatment aimed to reduce or to retard the clinic and pathologic symptoms induced by AD and PD is presently available."

( Jimenez-Del-Rio, M; Velez-Pardo, C, 2012)

"The Global Cancer Genomics Consortium (GCGC) is an international collaborative platform that amalgamates cancer biologists, cutting-edge genomics, and high-throughput expertise with medical oncologists and surgical oncologists; they address the most important translational questions that are central to cancer research and treatment."

( , 2012)

"Patients with cancer often receive chemotherapeutic agents concurrently with other medications to treat comorbidity."

( Fujita, K; Ishida, H; Kato, Y; Miwa, K; Saji, S; Sasaki, T; Sasaki, Y; Sunakawa, Y; Yamashita, K, 2013)

"Chemonaive cancer patients receiving SSRI and antiemetic agents, including the 5-HT3 antagonist ondansetron and the neurokinin 1 (NK1) antagonist aprepitant for highly emetogenic chemotherapy (etoposide-platinum), were matched to control patients for the following variables: age, gender, primary tumor, past history of gestational emesis, chronic intake of benzodiazepines and/or corticosteroids, chronic alcohol intake, and aprepitant use."

( Boudou-Rouquette, P; Cessot, A; Coriat, R; Durand, JP; Gaillard, R; Giroux, J; Goldwasser, F; Mir, O; Ropert, S, 2012)

"Although cancer therapy is associated with many adverse effects, one of the primary concerns of young male cancer survivors is reproductive health."

( Cohen, LE; Constine, L; Duffey-Lind, E; Green, D; Hijiya, N; Kenney, LB; Lockart, B; Meacham, L; Metzger, ML; Shnorhavorian, M, 2012)

"During opioid treatment of cancer pain, constipation is one of the most prevalent and bothersome side effects."

( Borchgrevink, PC; Fredheim, OM; Skollerud, LM; Skurtveit, S; Svendsen, K, 2013)

"Understanding the complexity of cancer and of the underlying regulatory networks provides a new paradigm that tackles cancer development and treatment through a system biology approach, contemporarily acting on various intersecting pathways."

( Berrino, F; Gariboldi, M; Melani, C; Mogavero, A; Negri, T; Pasanisi, P; Pierotti, MA; Pilotti, S, 2013)

"By identifying VTE recurrence risk in cancer patients with VTE, we may be able to tailor treatment, improving clinical outcomes while minimizing costs."

( Carrier, M; Dao, V; Kovacs, MJ; Lazo-Langner, A; Lee, AY; Louzada, ML; Meyer, G; Ramsay, TO; Rodger, MA; Wells, PS; Zhang, J, 2012)

"As a result of advances in cancer diagnosis and treatment, young women within the reproductive-aged group are now more likely to survive cancer."

( Patel, A; Schwarz, EB, 2012)

"Here we discuss how tumors engage ER-signaling pathways to promote tumorigenesis and how manipulation of this process by anticancer drugs may contribute to cancer treatment."

( Martinon, F, 2012)

"Children with cancer were also evaluated after antineoplasic treatment (CAT, n = 17)."

( Brito, CX; Guerra, RN; Liberio, SA; Lima, MV; Mendonça, C; Mouchrek-Filho, JC; Nascimento, FR; Oliveira-Junior, JJ; Paim, DB; Pereira, AL, 2012)

"The future of anti-vascular cancer therapy may depend on finding new targets on "late" vessels, apart from those associated with the VEGF/VEGFR axis."

( Dvorak, HF; Nagy, JA, 2012)

"Patients with advanced solid tumors refractory to all standard treatments were administered a single oral dose of DHP107 on a dose-escalating schedule (60-600 mg/m(2)) during the first chemotherapy cycle, and intravenous paclitaxel 175 mg/m(2) during subsequent cycles."

( Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, H; Kim, KP; Kim, TW; Lee, JL; Lim, HS; Ryu, MH, 2013)

"In 20 patients with advanced cancer undergoing palliative (combination) chemotherapy, body weight, fat free mass (FFM), and cachexia were measured prior to the start and at 9 wk of treatment."

( Buskermolen, S; Heymans, MW; Kruizenga, HM; Langius, JA; Ligthart-Melis, GC; Verheul, HM, 2012)

"We identified 223 patients with cancer who developed MRSA BSIs between January 2001 and June 2009 and were treated with vancomycin."

( Adachi, JA; Chemaly, RF; Hachem, R; Mahajan, SN; Mulanovich, V; Raad, II; Rolston, KV; Shah, JN; Tverdek, F, 2012)

"Ophthalmologists need to be aware of cancer treatment-related eye disorders."

( Hendricks, D; Salvin, JH, 2012)

"Children and young adults with cancer who have completed treatment differ in the type and degree of renal damage they sustain."

( Adamkiewicz-Drożyńska, E; Aleksandrowicz, E; Balcerska, A; Kurylak, A; Owczarzak, A; Owczuk, R; Stefanowicz, J, 2012)

"More recently in colorectal cancer treatment the Epidermal Growth Factor receptor and its tumourigenic role has led to its targeting by using Cetuximab and Panitumumab."

( Haque, SU; Morton, D; Welch, H, 2012)

"In non-small cell lung cancer, median overall survival in eribulin-treated patients has been reported as 9."

( Scarpace, SL, 2012)

"Non-small cell lung cancer patients had improved response rates when treated with eribulin in open-label, nonrandomized, Phase II trials reported in abstract form."

( Scarpace, SL, 2012)

"Non-small cell lung cancer cells transiently transfected with an expression plasmid encoding pd1EGFP and treated with FZ showed an accumulation of the green fluorescent protein in the cells due to an increase in its half-life."

( Dogra, N; Mukhopadhyay, T, 2012)

"Chemotherapy remains the core of anticancer treatment."

( Adhikary, A; Bhattacharyya, P; DAS, T; Sa, G; Saha, S, 2012)

"Blood samples of cancer patients treated with a TDF patch for the alleviation of pain were collected at 24, 48, and 72 hours after application to evaluate population pharmacokinetics using the nonlinear mixed-effect model (NONMEM)."

( Ebinuma, K; Kokubun, H; Matoba, M; Takayanagi, R; Yago, K; Yamada, Y, 2012)

"Solid tumors such as hepatocellular carcinoma are very often not amenable to chemotherapy and radiotherapy."

( Aravalli, RN; Bischof, JC; Choi, J; Cressman, EN; Dong, J; Mehra, D; Mori, S, 2012)

"Patients with advanced solid tumors progressing on standard therapy were eligible."

( Chap, L; Hannah, A; Hudis, C; Jhaveri, K; Ma, W; Miller, K; Modi, S; Rosen, L; Schneider, B; Zhong, Z, 2012)

"Diverse death phenotypes of cancer cells can be induced by Photofrin-mediated photodynamic therapy (PDT), which has a decisive role in eliciting a tumor-specific immunity for long-term tumor control."

( Chi, LM; Chien, KY; Hsieh, YJ; Hsu, RM; Lin, SY; Lyu, PC; Sabu, S; Yu, JS, 2012)

"Platinum-based anticancer drugs are a mainstay of chemotherapy for many human malignancies."

( Liu, JJ; Lu, J; McKeage, MJ, 2012)

"Cachexia causes reduced cancer treatment tolerance and reduced quality and length of life, and remains an unmet medical need."

( Fearon, KC; Glass, DJ; Guttridge, DC, 2012)

"We also address the regression of tumors in response to cotreatment with conventional chemotherapeutics."

( Biavatti, MW; D'Herde, K; Grootjans, S; Kreuger, MR; Vandenabeele, P, 2012)

"Pancreatic cancer is a relatively rare malignancy with a very aggressive natural course, not restrained by the existing current treatments."

( Saif, MW; Strimpakos, AS; Syrigos, KN, 2012)

"Dying inpatients of a major cancer centre treated by an interdisciplinary team were eligible."

( Bueche, D; Cerny, T; Mao, MS; Renz, M; Strasser, F, 2013)

"Paclitaxel (PTX) is a potent anti-cancer chemotherapeutic agent and is widely used in the treatments of solid tumors, particularly of the breast and ovaries."

( Danhier, F; Danhier, P; De Preter, G; Gallez, B; Jordan, B; Karroum, O; Magotteaux, N; Préat, V; Ucakar, B, 2012)

"Moreover, cancer cells succumbing to a combination of chemotherapy plus CGs could vaccinate syngeneic mice against a subsequent challenge with living cells of the same type."

( Adjemian, S; André, F; Galluzzi, L; Ghiringhelli, F; Gidrol, X; Kepp, O; Kroemer, G; Locher, C; Ma, Y; Martins, I; Menger, L; Michaud, M; Mignot, G; Modjtahedi, N; Schlemmer, F; Shen, S; Sukkurwala, AQ; Sulpice, E; Vacchelli, E; Yamazaki, T; Zitvogel, L, 2012)

"In primary or secondary liver tumors, the (90)Y-labeled particles can be administered."

( Gabriel, M, 2012)

"Nanoparticles, an emerging platform for cancer therapy, have been shown to increase intracellular uptake of DOX with reduced side effects compared with conventional DOX formulations."

( Liang, W; Wang, Y; Wei, X; Zhang, C; Zhang, F, 2010)

"Given its pleiotropic effects on cancer biology, PKM2 represents an attractive target for cancer therapy."

( Luo, W; Semenza, GL, 2012)

"However, its potential in cancer therapy is limited by its poor bioavailability and its inability to specifically reach tumors at therapeutic concentrations after intravenous administration."

( Dufès, C, 2011)

"Understanding the metabolism of cancer cells may help to develop new anti-cancer treatments."

( Icard, P; Lincet, H, 2012)

"Demographic data, cancer type, duration of pain, side effects, visual analog scale (VAS) score, treatment assessment scale (TAS) score, TDF dosage, and the number of patients in whom therapy has been terminated were recorded."

( Ali, A; Alkan, I; Altan, A; Bilen, A, 2012)

"The TDF patch is a good choice for cancer pain treatment for both adult and geriatric patients."

( Ali, A; Alkan, I; Altan, A; Bilen, A, 2012)

"Advances in cancer treatment have greatly improved survival rates of children with cancer."

( Franco, VI; Harake, D; Henkel, JM; Lipshultz, SE; Miller, TL, 2012)

"The concept of treating cancer with antibody-drug conjugates (ADCs) has gained momentum with the favorable activity and safety of trastuzumab emtansine (T-DM1), SAR3419, and lorvotuzumab mertansine (IMGN901)."

( Erickson, HK; Lambert, JM, 2012)

"Hypoxic tumors are resistant to radiation, chemotherapy, and surgery."

( Maguire, D; O'Dell, W; Okunieff, P; Zhang, L; Zhang, M, 2013)

"Herein, we review the effects of anti-cancer agents that impact metabolism administered concurrently with autophagy inhibitors on immune cells and consider the implications for patient response to therapy."

( Hughson, LR; Lum, JJ; Poon, VI; Schlie, K; Townsend, KN; Westerback, A, 2012)

"The promises of a functional cancer therapy using GNPs have been extensively demonstrated, although the materials are still in their infancy stage and not surfaced to meet clinical standards."

( Ahmad, FJ; Ahmad, MZ; Akhter, S; Kok, RJ; Storm, G, 2012)

"The success of chemotherapy in cancer treatment is limited by scarce drug delivery to the tumor and severe side-toxicity."

( Alitalo, K; Anisimov, A; Baes, M; Carmeliet, P; D'hooge, J; Debackere, K; Deschoemaeker, S; Dettori, D; Finisguerra, V; Henze, AT; Hofmann, M; Jönsson, Y; Leite de Oliveira, R; Mazzone, M; Peeters, A; Roncal, C; Tack, E; Takeda, Y; Veschini, L, 2012)

"Since the invention of cancer radiotherapy, its primary goal has been to maximize lethal radiation doses to the tumor volume while keeping the dose to surrounding healthy tissues at zero."

( Allard, JF; Belmouaddine, H; Brastaviceanu, T; Houde, D; Huels, MA; Jay-Gerin, JP; Lemay, R; Lepage, M; Meesat, R; Paquette, B; Tanguay-Renaud, C; Tremblay, L; Wagner, JR, 2012)

"A sample of 329 Indian cancer patients were interviewed about their understanding of their illness (to assess awareness of a cancer diagnosis) and administered the following measures: the modified Rotterdam Symptom Checklist, the Hospital Anxiety and Depression Scale, and the Brief Illness Perceptions Questionnaire."

( Chittem, M; Harris, PR; Norman, P, 2013)

"Recent advances in the treatment of cancer involving therapeutic agents have shown promising results."

( Kim, JH; Magdoom, KN; Pishko, GL; Sarntinoranont, M, 2012)

"To investigate the incidence of cancer in arthritis patients treated with or without TNFα inhibitors (TNF-I)."

( Andersen, AR; Bennett, P; Dreyer, L; Hansen, TH; Hetland, ML; Jensen, DV; Juulsgaard Ellingsen, T; Linde, L; Lindegaard, HM; Loft, AG; Mellemkjær, L; Nordin, H; Omerovic, E; Poulsen, UE; Rasmussen, C; Schlemmer, A; Tarp, U, 2013)

"After adjusting for age, sex, primary cancer site, metastatic site, and cancer treatment, multiple logistic regression analyses for association between the events and "death within 48 h" revealed some significant changes: confused mental state, decreased blood pressure, increased pulse pressure, low oxygen saturation, death rattle, and decreased conscious level."

( Ahn, HY; Hwang, IC; Kim, KK; Park, SM; Shim, JY, 2013)

"The inhibitors of HIF-1 in cancer have provided us a new clue for the targeting cancer therapy."

( Hu, Y; Huang, H; Liu, J, 2013)

"45 patients with prostate cancer, breast cancer, bladder cancer, pancreatic cancer, lung cancer, thyroid cancer, skin cancer and B-cell lymphoma were treated at the Riordan Clinic by high doses of vitamin C (7."

( Casciari, J; Mikirova, N; Rogers, A; Taylor, P, 2012)

"IVC treatments on all aggressive stage cancer patients showed the poor response of treatment."

( Casciari, J; Mikirova, N; Rogers, A; Taylor, P, 2012)

"Here, we identified 10 human cancer cell lines (out of 16) with increased sensitivity to the anti-viral effects of IFN-α after treatment with the MEK inhibitor U0126, suggesting that the Ras/MEK pathway underlies their reduced sensitivity to IFN."

( Christian, SL; Codner, DA; Hirasawa, K; Komatsu, Y; Licursi, M; Pongnopparat, T; Zu, D, 2012)

"Comorbidity in cancer patients may influence treatment decisions, postoperative morbidity and ultimately, survival."

( Ba, R; Bhaduri, D; Bhatia, M; Chaudhary, RK; Hatti, S; Meva, J, 2013)

"Hyperthermia plays an important role in cancer therapy."

( Dewhirst, M; Huang, C; Li, C; Liu, F; Neill, D; Ouyang, R; Yan, B, 2012)

"(1) Hyperthermia: HCT116 colon cancer cells received water-submerged heating treatment at 42 or 44°C for 30 min; (2) gene amplification assay using N-(phosphoacetyl)-L-aspartate (PALA) selection of cabamyl-P-synthetase, aspartate transcarbarmylase, dihydro-orotase (cad) gene amplified cells; (3) southern blotting for confirmation of increased cad gene copies in PALA-resistant cells; (4) γH2AX immunostaining to detect γH2AX foci as an indication for DNA double strand breaks."

( Dewhirst, M; Huang, C; Li, C; Liu, F; Neill, D; Ouyang, R; Yan, B, 2012)

"One of the major challenges in cancer gene therapy is the identification of functionally relevant tumor-specific genes as the therapeutic targets."

( Hui, KM; Xia, H, 2012)

"During the last years novel anticancer treatments targeting specific molecules or genes involved in cancer development are being developed to improve outcome and reduce side-effects."

( Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ, 2012)

"Patients with cancer should be repeatedly screened for malnutrition and its risk factors during the diagnostic and therapeutic treatment trajectory."

( Beijer, S; Chua-Hendriks, J; de Graeff, A; Jager-Wittenaar, H; Vogel, J, 2012)

"Case studies incorporating aspects of cancer metabolism into therapy relevant applications and some potential new targets of cancer metabolism for novel cancer therapies are pointed out."

( Koch, M; Wiese, M, 2013)

"Patients with cancer have an impaired T cell response that can decrease the potential therapeutic benefit of cancer vaccines and other forms of immunotherapy."

( Ochoa, AC; Raber, P; Rodríguez, PC, 2012)

"In solid tumors the first PET response-adjusted treatment trials have been realized in adenocarcinoma of the esophagogastric junction."

( Arens, AI; de Geus-Oei, LF; Hutchings, M; Oyen, WJ; Vriens, D, 2012)

"Photothermal therapy (PTT) for cancer treatment is the use of heat between 41 degrees C and 45 degrees C to damage cancer cells."

( Chen, W; Hossu, M; Lakshmanan, SB; Ma, L; Yang, C; Zou, X, 2012)

"Glucocorticoids are widely used for cancer patients, although they can reduce the efficacy of anticancer treatment."

( Amtmann, E; Behrends, U; Boeckeler, E; Ehrhardt, H; Gündisch, S; Jeremias, I, 2012)

"A wide range of anti-cancer drugs in current use are associated with severe adverse effects, while deuterium-depleted water appears to have virtually no pharmacological side effects and is convenient to administer."

( Fang, W; Liu, C; Wang, H; Yang, H, 2012)

"Our work offers new prospect for cancer therapy using ATR inhibitors with the potential to decrease cellular adaptation in hypoxic tumors."

( Britton, S; Fallone, F; Muller, C; Nieto, L; Salles, B, 2013)

"Hemoglobin can rapidly decline in cancer patients receiving chemotherapy with hemoglobin levels around 10 g/dL, particularly in patients ≥65 years of age."

( Collins, H; Hulnick, S; Legg, J; Pirker, R; Pirolli, M; Quigley, J; Vansteenkiste, J, 2013)

"The analysis in the breast cancer MDA-MB-468 erlotinib-resistant and in lung cancer A549 cell lines of the molecular mechanism underlying the apoptosis induced by co-treatment highlighted that the accumulation of DNA defects and depletion of cIAP and XIAP activates the ripoptosome that ultimately activates caspases-8 and -10 and apoptosis."

( Guevara, T; Orzáez, M; Pérez-Payá, E; Sancho, M, 2012)

"The use of cannabinoids in cancer treatment is currently limited to chemo- and radio-therapy-associated nausea and cancer-associated pain apart from one trial on brain tumours in patients."

( Brown, I; Cascio, MG; Heys, SD; Pertwee, RG; Rotondo, D; Wahle, KW, 2013)

"Despite the coming of age of cancer immunotherapy, clinical benefits are still modest."

( Allard, B; Stagg, J; Turcotte, M, 2012)

"The Functional Assessment of Cancer Therapy (FACT)-EGFRI was developed to measure HRQL among patients receiving EGFRIs."

( Aneja, M; Berg, SR; Cella, D; Gandhi, M; Hlubocky, FJ; Lacouture, ME; Wagner, LI; Webster, K, 2013)

"This study provides evidence that cancer incidence in the first few years after starting metformin or sulphonylurea therapy in type 2 diabetes patients is not much affected by choice of hypoglycaemic drug class."

( Berlin, JA; Demissie, K; Marcella, SW; Qiu, H; Rhoads, GG, 2013)

"ROS render cancer cells more susceptible to subsequent heat treatment, which remarkably increases the degree of apoptotic cell death."

( Cheon, J; Choi, JS; Jeong, H; Preihs, C; Sessler, JL; Shin, TH; Yoo, D, 2012)

"Based on Warburg's theory that most cancer cells mainly depend on glycolysis for ATP generation, we hypothesize that, LC treatment would lead to disturbance of cellular metabolism and cytotoxicity in cancer cells."

( Dou, QP; Guan, L; Guo, H; Huang, H; Li, B; Li, X; Liao, S; Liu, C; Liu, J; Liu, N; Liu, S; Song, W; Wang, X; Xu, L; Yang, C; Zhang, C, 2012)

"Hypoxia-treated tumors showed increased vessel density, decreased interstitial distance, and delayed blood supply compared to control tumors."

( Gaustad, JV; Roa, AM; Rofstad, EK; Simonsen, TG, 2013)

"We studied 64 US cancer patients who received a single cycle of 75 mg/m of docetaxel monotherapy."

( Bies, RR; Egorin, MJ; Jiang, C; Kroetz, DL; Lewis, LD; Markova, S; McLeod, HL; Miller, AA; Owzar, K; Ratain, MJ, 2013)

"These transporters expel anti-cancer drugs and greatly impair therapeutic efficacy of chemotherapy."

( Lei, Y; Li, N; Ma, Y; Su, G; Tan, J; Wink, M, 2013)

"With an increasing population of cancer survivors, it is imperative to understand the treatment options available and outcomes for chemotherapy-related cardiomyopathy."

( Frangoul, H; Harrell, FE; Lenneman, AJ; Lenneman, CG; Sawyer, DB; Silverstein, C; Wang, L; Wigger, M, 2013)

"Resistance to anticancer drugs is a major obstacle to successful chemotherapy."

( Chen, X; Fang, W; Jin, J; Lang, L; Li, Y; Zhou, Q; Zhu, Z, 2012)

"A main problem of common cancer chemotherapy is the occurrence of severe side effects caused by insufficient selectivity of the applied drugs."

( Duefert, SC; Müller, M; Schmuck, K; Schuberth, I; Tietze, LF, 2013)

"The detection of tumors noninvasively, the characterization of their progression by defined markers and the monitoring of response to treatment are goals of medical imaging techniques."

( Durst, M; Düwel, S; Glaser, SJ; Haase, A; Köllisch, U; Menzel, MI; Otto, AM; Schilling, F; Schulte, RF, 2013)

"Anaemia associated with cancer and cancer therapy is an important clinical factor in the treatment of malignant diseases."

( Bohlius, J; Engert, A; Hyde, C; Mettler, A; Robert, N; Schwarzer, G; Seidenfeld, J; Tonia, T; Weingart, O, 2012)

"The risk of VTE in cancer is found to be further elevated by chemotherapy."

( Date, K; Greenman, J; Hall, J; Madden, LA; Maraveyas, A, 2013)

"The major challenges we are facing in cancer therapy with paclitaxel (PTX) are the drug resistance and severe side effects."

( Hu, LY; Li, X; Lu, MK; Wu, ZH, 2012)

"Chemoresistance is a major obstacle in cancer treatment."

( Desai, S; Fodstad, O; Khong, HT; Klos, KS; Liu, H; Liu, Z; McClellan, S; Schmitt, DC; Tan, M; Zhou, M, 2013)

"Anemia in cancer patients can be treated with red blood cell (RBC) transfusions."

( Corey-Lisle, P; Desrosiers, MP; Payne, K; Shreay, S, 2013)

"Liver, kidney, and hematological cancer, antineoplastic drugs, radiotherapy, steroid, immunosuppressive agents, granulocyte colony-stimulating factor, and thyroid inhibitors were defined as the exclusion criteria in consideration of influence on immune system or metabolism and excretion of morphine and oxycodone."

( Gotoh, K; Sakurada, T; Satoh, N; Suzuki, M; Watanabe, S, 2013)

"A large human cancer cell line panel screen (436 lines) revealed broad antiproliferative sensitivity and that cells harboring mutations in PI3KCA are generally more sensitive toward VS-5584 treatment."

( Amalini, C; Benes, C; Cheong, A; Chng, WJ; Dymock, B; Ethirajulu, K; Garnett, M; Goh, BC; Goh, KC; Hart, S; Jayaraman, R; Madan, B; McDermott, U; Mustafa, N; Nagaraj, H; Ng, BK; Novotny-Diermayr, V; Ong, LC; Pasha, KM; Tan, YC; Williams, M; Wood, JM, 2013)

"Recent studies using cancer cell and mouse models demonstrate a significant potential for SK1-targeting therapies to synergize with the effects of chemotherapy and radiotherapy; however, until recently the absence of clinically applicable SK1 inhibitors has limited the translation of these findings into patients."

( Alshaker, H; Böhler, T; Monteil, D; Ottaviani, S; Pchejetski, D; Sauer, L; Srivats, S, 2013)

"The anticancer activity the EOAS showed growth inhibitory activity on all cell lines when administered in a high concentration."

( Andrade-Silva, M; Cardoso, CA; de Carvalho, JE; Dos Santos, LA; Foglio, MA; Formagio, AS; Kassuya, CA; Vieira, Mdo C, 2013)

"In addition, in a mouse colorectal cancer model administration of nanoparticulate SN38 once weekly exhibited greater activity compared to daily or weekly administration of irinotecan."

( Al-Kasspooles, MF; Decedue, CJ; Henry, D; Howell, J; Niu, F; Roby, KF; Williamson, SK, 2013)

"(3) Irradiated tumors treated with ZnCP-I were mostly necrotized."

( Asahina, T; Hirano, T; Horiuchi, K; Kanayama, N; Kohmura, Y; Kohno, E; Murakami, H; Ooi, H; Ozawa, H; Sugihara, K; Tamura, N; Yaguchi, C, 2013)

"Cisplatin still has a central role in cancer chemotherapy, but is associated with the risk of toxicities, the most common of which is nephrotoxicity."

( Heidari, Z; Mashhadi, MA; Zakeri, Z, 2013)

"Forty-three patients with gastric cancer treated with neoadjuvant chemotherapy followed by curative resection between September 2011 and February 2012 were analyzed."

( Ang, J; Cao, CH; Chen, L; Hu, L; Huang, LN; Huang, PT; Wu, JX; Zheng, YX, 2012)

"Treated cancer patients were younger (P < 0."

( Azoulay, E; Besset, S; Canet, E; Lemiale, V; Lengliné, E; Maziers, N; Moreau, AS; Reuter, D; Schnell, D; Zafrani, L, 2013)

"The recent approval by the FDA of cancer vaccines and drugs that blockade immunological negative regulators has further enhanced interest in promising approaches of the immunotherapy of cancer."

( Ohta, A; Sitkovsky, M, 2013)

"Treated tumors are better differentiated as compared with those established in the control mice."

( Basavaraj, C; Chivukula, IV; James, R; Melarkode, R; Montero, E; Nair, P; Vishwakarma, S, 2012)

"These findings may be useful for cancer combinational therapy with BIRB796 in the clinic."

( Chen, XG; Chen, ZS; Fang, Y; Fu, LW; He, D; Liang, YJ; Qiu, HJ; Singh, S; Talele, TT; Wang, XK; Zhang, GQ; Zhao, XQ, 2013)

"The main outcome was incident cancer (ignoring non-melanoma skin cancer) during the scheduled treatment period (among participants who were still free of cancer)."

( Armitage, J; Baron, JA; Bennett, D; Bønaa, KH; Clarke, R; Collins, R; den Heijer, M; Ebbing, M; Galan, P; Gaziano, JM; Giovannucci, EL; Guarino, P; Halsey, J; Hankey, GJ; Jamison, R; Lewington, S; Logan, RF; Lonn, E; Manson, JE; Peto, R; Spence, JD; Ueland, PM; Vollset, SE, 2013)

"Cell treatment with gedunin leads to cancer cell death by apoptosis through inactivation of p23 and activation of caspase 7, which cleaves p23 at the C terminus."

( Blagg, BS; Chadli, A; Fauq, A; Miller, C; Patwardhan, CA; Peterson, LB, 2013)

"The National Cancer Institute (NCI) Best Case Series (BCS) Program provides an independent review of medical records, imaging, and pathology of cancer patients treated with unconventional therapies."

( Olaku, O; Santana, JM; White, JD; Zia, F, 2013)

"Inclusion criteria were cancer, febrile neutropenia, low risk of complications as predicted by a Multinational Association for Supportive Care in Cancer (MASCC) score > 20, ability to swallow, and ≤ one single intravenous dose of empiric antibiotic therapy before study drug treatment initiation."

( Akan, H; Akova, M; Aoun, M; Calandra, T; de Bock, R; Drgona, L; Kern, WV; Marchetti, O; Paesmans, M; Viscoli, C, 2013)

"Cell imaging and cancer therapy applications of such fluorescent MSNs were further explored."

( Liu, M; Tao, L; Wang, S; Wei, Y; Zhang, X; Zhang, Y, 2013)

"Forty-four Japanese cancer patients receiving cisplatin-based chemotherapy for the first time following oral aprepitant (125 mg on day 1 and 80 mg on days 2 and 3) were enrolled."

( Furuse, H; Hori, K; Hosokawa, S; Kawakami, J; Mineta, H; Mino, Y; Motohashi, S; Naito, T; Ozono, S, 2013)

"In contrast to existing anticancer therapies, inhibition of mitochondrial superoxide may represent a novel specific anticancer treatment with reduced cytotoxic side effects."

( Bikineyeva, A; Dikalov, SI; Dikalova, A; Grigor'ev, IA; Ivanov, S; Kirilyuk, IA; Nazarewicz, RR, 2013)

"Inefficiency of cancer chemotherapy to improve life expectancy in majority of patients raises serious concern and warrants development of novel therapeutic strategies."

( Bhaskar, S; Roy, A; Singh, MS; Upadhyay, P, 2013)

"Colon cancer cell lines HT29 (human) and MC26 (murine) were treated for 24 or 72 h with a range of MET concentrations (0-10 mM)."

( Habibollahi, P; Kuruppu, D; Loda, M; Mahmood, U; van den Berg, NS, 2013)

"Fifty patients with advanced cancer and predominant liver metastases were treated (median age, 58 years; 27 women, 23 men; median number of prior therapies, 3 [range 0-12])."

( Hess, KR; Hong, D; Naing, A; Nwosu, U; Tsimberidou, AM; Wheler, J; Wolff, RA; Ye, Y, 2013)

"Data from 5 monotherapy studies in cancer patients (n = 344) were pooled to investigate the relationship between Cτ and maximum ALT ≥ 3× the upper limit of normal (ULN), using a Bayesian logistic regression model incorporating an asymptote."

( Arumugham, T; de Souza, P; Suttle, AB, 2013)

"In support of the role of calpain II in cancer cells, transfection of calpain II expression vector or its activation by ionomycin enhanced the production of tRXRα, whereas treatment of cells with calpain inhibitors reduced the levels of tRXRα."

( Cai, S; Cao, X; Chen, J; Gao, W; Hu, M; Huang, M; Lin, B; Liu, J; Zeng, JZ; Zeng, Z; Zhang, XK; Zhou, H, 2013)

"The antioxidative and anticancer effects of these natural agents make them strong candidates for chemoprevention and/or therapy against human malignancies."

( Ahmad, A; Bao, B; Kong, D; Li, Y; Sarkar, FH, 2013)

"Five patients with advanced tumors treated with pre- or postoperative adjuvant radiotherapy were also included."

( Aibe, N; Kagiya, T; Kobayashi, K; Kodani, N; Koizumi, M; Nakamura, S; Tsubokura, T; Yamada, K; Yamazaki, H; Yoshida, K, 2013)

"From a consecutive sample of cancer patients admitted to an APRPCU for a period of 6 months, patients who had been administered opioids were included in this survey."

( Casuccio, A; Giarratano, A; Mercadante, S; Prestia, G; Ranieri, M, 2013)

"Treatment of cancer cells expressing wild-type p53 with RG7112 activated the p53 pathway, leading to cell-cycle arrest and apoptosis."

( Filipovic, Z; Garrido, R; Graves, B; Higgins, B; Kolinsky, K; Lee, E; Linn, M; Packman, K; Podlaski, F; Tardell, C; To, KH; Tovar, C; Vassilev, LT; Vu, B; Wovkulich, P; Xia, M, 2013)

"DPD-deficient cancer patients may be at risk of severe and sometimes lethal toxicity after the administration of 5-FU."

( Dołegowska, B; Ostapowicz, A, 2012)

"Many cancer patients fail to respond to chemotherapy because of the intrinsic resistance of their cancer to pro-apoptotic stimuli or the acquisition of the multidrug resistant phenotype during chronic treatment."

( Kiss, R; Mijatovic, T, 2013)

"The percentage of non-cancer patients receiving long-term opioid treatment has also increased over the period of the study."

( Ihle, P; Sabatowski, R; Schubert, I, 2013)

"With improvement in cancer survival rates, there has been a shift in attention toward management of long-term consequences of cancer therapy, including infertility."

( Dillon, KE; Dokras, A; Efymow, BL; Gracia, CR; Johnson, LN; Mainigi, MA; Sammel, MD, 2013)

"A key modality of non-surgical cancer management is DNA damaging therapy that causes DNA double-strand breaks that are preferentially toxic to rapidly dividing cancer cells."

( Engelward, BP; Floyd, S; Ge, J; Huang, Q; Mutamba, JT; Rowland, EA; Weingeist, DM; Wood, DK; Yaffe, MB, 2013)

"Patients with refractory cancer or cancer with no standard therapy received either once-daily (OD) or twice-daily (BID) oral AZD8330 on day 1 followed by a 7-day washout period and continuous dosing from day 8."

( Aamdal, S; Cavallin, M; Cohen, RB; Green, D; Kurzrock, R; Learoyd, M; Nyakas, M; Smith, I, 2013)

"Human cancer-derived cell lines are the most widely used models to study the biology of cancer and to test hypotheses to improve the efficacy of cancer treatment."

( Gillet, JP; Gottesman, MM; Varma, S, 2013)

"Intrathecal therapy (ITT) for cancer pain is characterized by high initial cost followed by low maintenance costs."

( Abiodun, A; Brogan, SE; Safarpour, R; Winter, NB, 2013)

"Neuropathic cancer pain (NCP) is a common manifestation of cancer and/or its treatment."

( Argyra, E; Melemeni, A; Raptis, E; Siafaka, I; Stavropoulou, E; Vadalouca, A, 2014)

"Hypoxia is a common feature of tumors and an important contributor to malignancy and treatment resistance."

( Bussink, J; Dubois, LJ; Keulers, TG; Koritzinsky, M; Lambin, P; Rouschop, KM; van den Beucken, T; van der Kogel, AJ; Wouters, BG, 2013)

"Carriers of drugs in cancer therapy are required to reduce side-effects of the drugs to normal cells."

( Cutting, SM; Hoang, TV; Huynh, HA; Nguyen, HA; Nguyen, VA; Ninh, NT; Pham, AT; Phan, TN, 2013)

"When administered in vitro to cancer cell lines, oxysterols invariably both slow down proliferation and provoke cell death."

( Bakalara, N; de Weille, J; Fabre, C, 2013)

"In part, cancer amelioration in treated mice suggested that long-term eRapa, like diet restriction, could be a pharmacological approach feasible for use in the clinic."

( Curiel, TJ; Livi, CB; Sharp, ZD, 2013)

"Furthermore, in the current state where cancer treatment will be shifting towards individualized medicine by targeted therapies, we will need to evaluate these modalities to establish an adequate measurement method and timing, and the evaluation method."

( Aramaki, T; Asakura, K; Bekku, E; Endo, M; Moriguchi, M; Sawada, A, 2013)

"Moreover, the ability to sensitize cancer cells suggested new and promising applications in chemotherapy."

( Paiva, AM; Pinto, MM; Sousa, E, 2013)

"Patients with advanced solid tumors were treated in a 3 + 3 escalation design."

( Bendell, JC; Burris, HA; Infante, JR; Jones, SF; Kuhn, JG; Kurkjian, C; McMeekin, S; Moore, K; Moreno, O; Pant, S, 2014)

"to analyze ES influence on anticancer activity and toxic reactions of cisplatin (CP) upon the use of carbon enterosorbent in 1 h after intravenous administration of cytostatic."

( Bardakhivskaya, KI; Ivanyuk, AA; Korotich, VG; Maslenniy, VN; Nikolaev, VG; Nikolaeva, VV; Sakhno, LA; Shevchuk, OO; Yurchenko, OV, 2013)

"With the development of cancer immunotherapy, cancer vaccine has become a novel modality for cancer treatment, and the important role of adjuvant has been realized recently."

( Chen, D; Chen, WR; Du, N; Gu, Y; Hode, T; Li, X; Min, M; Naylor, M; Nordquist, RE, 2013)

"We have recently developed a cancer-specific therapy, photoimmunotherapy, which uses an antibody-IR700 (phototoxic phthalocyanine dye) conjugate to bind to the cell membrane and near-infrared light to induce immediate and highly specific tumor killing in vivo."

( Choyke, PL; Kobayashi, H; Mitsunaga, M; Nakajima, T; Sano, K, 2013)

"None of tumors changed size within 24 h after photoimmunotherapy, although diffuse necrosis was observed in photoimmunotherapy-treated tumors."

( Choyke, PL; Kobayashi, H; Mitsunaga, M; Nakajima, T; Sano, K, 2013)

"All patients had received prior cancer therapy (median = 2, range = 1-11)."

( Beeram, M; Bekaii-Saab, T; Buchbinder, A; Lokiec, FM; Papadopoulos, KP; Patnaik, A; Rezaï, K; Schaaf, LJ; Tahiri, S; Tolcher, AW; Urien, S, 2013)

"An increasing number of cancer patients are using herbs in combination with conventional chemotherapeutic treatment."

( Du, J; Gu, C; Han, M; Lu, W; Qiao, J; Shang, W; Wang, W; Yin, W; Zhu, M, 2013)

"The Functional Assessment of Cancer Therapy-Anemia (FACT-An) was developed to measure the effect of anemia on quality of life (QOL) in cancer patients."

( Eguchi, H; Eguchi, K; Ishizawa, K; Kudo, S; Kurita, M; Mishima, Y; Morita, S; Ohashi, Y; Saito, M; Saito, Y; Seto, T; Shimozuma, K; Shishida, T; Ushiorozawa, N; Wasada, I; Yokomizo, Y, 2013)

"For folate receptor (FR) targeted anticancer therapy, novel folic acid (FA) conjugated cholesterol-modified glycol chitosan (FCHGC) micelles were synthesized and characterized by (1)H NMR, dynamic light scattering, transmission electron microscopy, and fluorescence spectroscopy."

( Che, X; Liu, P; Liu, Y; Lu, L; Wu, J; Xie, X; Xu, X; Yu, H; Yu, J, 2013)

"All the patients had cancer and were treated with 40-50 mg/day cisplatin."

( Arunkumar, PA; Belliyappa, MS; Mukund, H; Radheshyam, N; Viswanatha, GL, 2012)

"Cytotoxic therapy for patients with cancer frequently induces reversible, but long-lasting alopecia which might be prevented by scalp cooling."

( Breed, WP; Coebergh, JW; Nortier, JW; van de Poll-Franse, LV; van den Akker-van Marle, ME; van den Hurk, CJ, 2013)

"The Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor 18 (FACT-EGFRI-18) is a patient-reported outcomes questionnaire developed to assess the effect of EGFRI on patients."

( Boers-Doets, CB; Brakenhoff, JA; Bredle, JM; Epstein, JB; Gall, H; Gelderblom, H; Kaptein, AA; Lacouture, ME; Nortier, JW; Ouwerkerk, J; Schrama, NA, 2013)

"Most hypoxic tumors are insensitive to radiation, which is a major obstacle in the development of conventional radiotherapy for tumor treatment."

( Bu, W; Chen, F; Fan, W; He, Q; Liu, J; Ni, D; Peng, W; Shen, B; Shi, J; Xiao, Q; Xing, H; Zhang, S; Zhao, K; Zhou, L, 2013)

"The benefit of cancer chemotherapy based on alkylating agents is limited because of the action of DNA repair enzymes, which mitigate the damage induced by these agents."

( Barakat, KH; Bouledrak, K; Cohen, R; Cros-Perrial, E; Dumontet, C; El Sabeh, R; Heinrich-Balard, L; Jordheim, LP; Matera, EL; Perez-Pineiro, R; Tuszynski, J; Wishart, DS, 2013)

"Keywords including EGCG, cancer, chemotherapy, radiotherapy and side effects, were searched using PubMed and ScienceDirect databases to identify, analyze, and summarize the research literature on this topic."

( Dupertuis, YM; Lecumberri, E; Miralbell, R; Pichard, C, 2013)

"All ambulatory cancer patients receiving one or more intravenous cytotoxic treatments during the period October 2008 to April 2010 were included."

( de Wit, H; Janknegt, R; Peters, F; Schouten, H; van der Kuy, H; van Oijen, B, 2013)

"Deprivation of iron from neoplasmic and microbial cells by chelators could increase the prospect of improved treatments in cancer and infectious diseases."

( Kolnagou, A; Kontoghiorghe, CN; Kontoghiorghes, GJ, 2013)

"The MR-HIFU-treated tumors showed 4."

( Bitter, K; de Smet, M; Grüll, H; Heijman, E; Hijnen, NM; Langereis, S; van den Bosch, S, 2013)

"Recent research and development in cancer-targeted gold nanovectors shows promise for maximizing the efficacy of anti-cancer drugs while decreasing their harmful systemic effects in chemotherapy."

( Ahmad, FJ; Ahmad, MZ; Akhter, S; Anwar, M; Mallik, N; Rahman, Z, 2013)

"Understanding the consequences of cancer for energy metabolism is required in order to define strategies that both prevent and treat malnutrition."

( Demenice, R; dos Santos, JS; Jordão, AA; Leme, IA; Marchini, JS; Portari, GV; Rabito, EI, 2013)

"The treatment with GABA attenuates cancer cell growth in vitro."

( He, J; Huang, L; Li, J; Liu, J; Shen, J; Shi, X; Tang, H; Xiao, D; Zhang, H; Zhang, R; Zhang, X; Zheng, Y, 2013)

"Novel trends in cancer treatment research are focused on targeting the tumor microenvironment, thereby developing chemo-immunotherapeutic strategies which not only directly kill tumor cells, but also trigger the anti-tumor immune effector responses."

( Ashraf, M; Hussain, M; Javeed, A; Mukhtar, MM; Yuzhu, H, 2013)

"Patients with advanced or metastases cancer who had not received any effective routine conventional treatment or who had failed to respond to the existing conventional treatment were randomly assigned to receive either 45 mg/m(2) gambogic acid intravenously from Days 1 to 5 of a 2-week cycle (Group A), or 45 mg/m(2) every other day for a total of five times during a 2-week cycle (Group B)."

( Chi, Y; Cui, CX; Hu, JF; Wang, JW; Wang, YG; Wang, ZZ; Xiao, W; Xie, GR; Xiong, FX; Yang, L; Yu, H; Zhan, XK, 2013)

"A major tenet of cancer therapeutics is that combinations of anticancer agents with different mechanisms of action and different toxicities may be effective treatment regimens."

( Behrsing, H; Kaur, G; Millin, MD; Parchment, RE; Teicher, BA, 2013)

"Many patients receiving cancer treatment use micronutrient supplements, with the intention to complement their cancer treatment, or help them cope with the therapy- and disease-associated side-effects."

( Gröber, U; Holzhauer, P; Kisters, K; Mücke, R, 2013)

"The mean weight of the CT26 tumors was reduced in the group treated with genistein and radiation compared with the control group."

( Bae, MJ; Gong, EJ; Heo, K; Kim, JS; Kim, SD; Moon, C; Son, TG; Yang, K, 2013)

"After treatment of the three cancer cell lines with different doses of the (pro)enzymes for up to 7 days, we observed (i) growth inhibition in a dose-dependent manner, (ii) enhanced expression of β-catenin and E-cadherin and decreased expression of several epithelial-mesenchymal transition (EMT)-associated genes, such as Vimentin, Snail and Slug, (iii) differentiation of Caco-2 cells, including the appearance of cell-specific differentiated structures such as microvilli and tight junctions, the acquisition of a more regular polygonal morphology, and an increased expression of the intestinal differentiation markers alkaline phosphatase and cytokeratin 8, and (iv) differentiation of Panc1 cells, including the formation of cell aggregates, an increment on lamellar bodies and an increased expression of the pancreatic differentiation markers glucagon and insulin."

( García, MA; Kenyon, J; Marchal, JA; Perán, M; Tosh, D, 2013)

"Patients with cancer were more willing to accept strong and mild chemotherapy compared to the non-cancer group (88."

( Bee, PC; Gan, GG; Razali, RM, 2013)

"Within solid tumors, the distribution of doxorubicin, mitoxantrone and topotecan was limited to perivascular regions at 10 min after administration and the distance from blood vessels at which drug intensity fell to half was ~25-75 μm."

( Patel, KJ; Tannock, IF; Trédan, O, 2013)

"In subcutaneous A431 tumors in mice, pretreatment with Vit D induced the expression of C/EBPβ isoforms, and of coproporphyrinogen oxidase (CPO), a heme pathway enzyme responsible for the conversion of 5-aminolevulinic acid (ALA) into protoporphyrin IX (PpIX), the principal light-absorbing molecule during PDT."

( Anand, S; Hasan, T; Maytin, EV, 2013)

"In the advanced cancer setting, based on favorable results from phase III trials, everolimus is indicated for the treatment of advanced renal cell carcinoma, advanced neuroendocrine tumors of pancreatic origin, and advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer."

( Geberth, M; Grünwald, V; Hörsch, D; Janni, W; Lüftner, D; Pavel, ME; Weber, MM; Weikert, S, 2013)

"Here, we investigate the anticancer potential of a WEE1 inhibitor, independent of chemotherapy, and explore a possible cellular context underlying sensitivity to WEE1 inhibition."

( Benita, Y; Fawell, SE; Feldman, I; Gilliland, DG; Guertin, AD; Hirsch, HA; Hurd, MS; Li, J; Liu, Y; Long, B; Schuller, AG; Shumway, SD; Toniatti, C; Zawel, L, 2013)

"Since the efficiency of cancer therapy is not limited to the eradication of the tumour but rests also on the sparing of healthy tissue, a biodistribution study is required in order to determine whether the behaviour of the nanoparticles after intravenous injection is safe (no accumulation in healthy tissue, no uptake by phagocytic cell-rich organs (liver, spleen) and renal clearance)."

( Alric, C; Bazzi, R; Billotey, C; Janier, M; Kryza, D; Lux, F; Miladi, I; Perriat, P; Roux, S; Taleb, J; Tillement, O, 2013)

"No correlation between cancer and the insulin glargine treatment was proven in this study."

( Kvapil, M; Lacigová, S; Rusavý, Z, 2013)

"Nearly two thirds of all patients with cancer receive radiation therapy during the course of treatment, frequently resulting in acute skin and mucosal toxicities."

( Pace, MB; Radvansky, LJ; Siddiqui, A, 2013)

"NPs increase drug delivery to tumors to a certain extent, but the amount reaching tumors is only a small fraction of the total administered NPs because they depend on passive accumulation via the leaky vasculature surrounding tumors."

( Amoozgar, Z; Lin, Q; Park, J; Weidle, JH; Yeo, Y, 2013)

"Aggressive regrowth of recurrent tumors following treatment-induced dormancy represents a major clinical challenge for treatment of malignant disease."

( Boisgerault, N; Diaz, RM; Embry, A; Harrington, K; Kottke, T; Melcher, A; Pandha, H; Poeschla, E; Pulido, J; Rommelfanger-Konkol, D; Saenz, D; Selby, P; Thompson, J; Vile, R, 2013)

"Although the anticancer effects of garlic and its products have been demonstrated by a variety of studies; however, few studies were conducted to investigate the effects of garlic on the adverse effects of chemo/radiotherapy."

( Li, Y; Xie, KQ; Yu, LH; Zeng, T; Zhang, CL; Zhao, XL; Zhu, ZP, 2013)

"Children undergoing cancer therapy often receive aminoglycosides to treat febrile neutropenia or gram-negative infections."

( Bach, A; Chen, KS; Shoup, A; Winick, NJ, 2013)

"Reducing cancer-treatment toxicity was a largely ignored research agenda, which is now emerging as an active area of investigation."

( Prado, CM, 2013)

"This cancer-targeted design of SeNPs opens a new path for synergistic treating of cancer with higher efficacy and decreased side effects."

( Chen, T; Fan, C; He, L; Huang, Y; Liu, W; Wong, YS; Zheng, W, 2013)

"Gemcitabine (dFdC) mediated cancer treatment faces obstacles, due to its high hydrophilicity."

( Asthana, S; Chourasia, MK; Gupta, A; Konwar, R, 2013)

"Radiotherapy machine burden in a public cancer hospital in India increases the waiting time and 25% of advised patients do not comply with the prescribed treatment."

( Kaur, J; Mohanti, BK; Muzumder, S, 2013)

"Treating cancer cells with the EZH2 small molecular inhibitor, 3-Deazaneplanocin A (DZNep), restored DLC1 expression in different cancer cell lines, indicating that EZH2-mediated H3K27me3 epigenetic regulation of DLC1 was a common mechanism in human cancers."

( Au, SL; Lee, JM; Ng, IO; Wong, CC; Wong, CM, 2013)

"Therefore, natural agents could inhibit cancer progression, increase drug sensitivity, reverse EMT, and prevent metastasis though modulation of miRNAs, which will provide a newer therapeutic approach for cancer treatment especially when combined with conventional therapeutics."

( Li, Y; Sarkar, FH; Sethi, S, 2013)

"Hypoxic regions in tumors, therefore, represent attractive targets for cancer therapy."

( Ashoorzadeh, A; Ding, K; Guise, CP; Lin, WH; Mowday, AM; Patterson, AV; Smaill, JB; Wu, DH; Yuan, R, 2014)

"Large and established tumors were treated with CpG and/or CTX administered alone or in combination with CyaA-E7."

( Berraondo, P; Parra-Guillen, ZP; Ribba, B; Trocóniz, IF, 2013)

"The median for 19 untreated cancer subjects of similar age was significantly higher (175 picomoles desmosine/mg creatinine, p < 0."

( Ho, C; Sauter, E; Starcher, B, 2013)

"Patients with cancer who were treated with weekly gemcitabine were eligible."

( Kakudo, Y; Kameno, K; Kanai, M; Kim, YH; Kitano, T; Matsumoto, S; Mishima, M; Mori, Y; Nagai, H; Nakata, K; Nishimura, T; Sato, H; Takashima, S; Yamaguchi, T; Yanagihara, K; Yasuda, H, 2013)

"We balanced cohorts on risk factors for cancer outcomes based on comorbidities, comedication, and health care use during the prior 12 months using inverse probability of treatment weighting."

( Blonde, L; Buse, JB; Lavange, LM; Lim, S; Macdonald, E; Marquis, MA; Meigs, JB; Pate, V; Stürmer, T; Wang, R; Zhou, H, 2013)

"Results were consistent for breast cancer, prostate cancer, and colon cancer; various durations of treatment; and sensitivity analyses."

( Blonde, L; Buse, JB; Lavange, LM; Lim, S; Macdonald, E; Marquis, MA; Meigs, JB; Pate, V; Stürmer, T; Wang, R; Zhou, H, 2013)

"Pharmacokinetic study in cancer patients is an important component in dose administration choice."

( Jian, FB; Li, S; Liao, H; Zhan, J; Zou, BY, 2014)

"Treatment of cancer patients with chemotherapeutics like cyclophosphamide often causes alopecia as a result of premature and aberrant catagen."

( Bichsel, KJ; Forney, E; Gogia, N; Hammiller, B; Hansen, LA; Malouff, T; Pena, Z; Watson, P, 2013)

"Interestingly, cancer cells sometimes overadapt to the drug treatment environment, leading to a state in which cancer cells cannot survive without the drug."

( Mitsudomi, T; Suda, K, 2013)

"When HIV patients with a malignancy need treatment with erlotinib, there is a potential of as-yet-undefined drug-drug interaction."

( Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R, 2013)

"Nanoparticle-mediated hyperthermia for cancer therapy is a growing area of cancer nanomedicine because of the potential for localized and targeted destruction of cancer cells."

( Kaddi, CD; Phan, JH; Wang, MD, 2013)

"Chronic cancer pain is often refractory and difficult to treat."

( Bredlau, AL; Dworkin, RH; Korones, DN; Thakur, R, 2013)

"The majority of tumors treated with combined therapy regress significantly, while a small number of highly progressed tumors persist."

( Bronson, RT; Esfahani, S; Habibollahi, P; Kucherlapati, MH; Kucherlapati, RS; Mahmood, U; Still, ER; Wang, J, 2013)

"To evaluate the cancer-free survival of psoriasis patients who received methotrexate and cyclosporine treatment at the same time."

( Aydin, F; Canturk, T; Senturk, N; Turanli, AY; Yuksel, EP, 2014)

( Anghelescu, DL; Ehrentraut, JH; Faughnan, LG, 2013)

"The most frequent neoplasms were colorectal ones (12 cases in patients not treated with thiopurines but none in treated, P < 0."

( Cabello-Tapia, MJ; De Teresa-Galván, J; Gómez-García, M; Redondo-Cerezo, E; Sánchez-Capilla, AD, 2013)

"Medical records of patients with cancer treated with IVC at the Riordan Clinic were retrospectively reviewed."

( Casciari, J; Hunninghake, R; Mikirova, N; Riordan, N, 2013)

"Significant advances in cancer treatment have resulted from the targeted cancer therapy by understanding the process of malignant transformation."

( Yim, H, 2013)

"The ultimate goal of cancer chemotherapy is to achieve a cure without causing any adverse effects."

( Nagasaki, Y; Ozaki, Y; Thangavel, S; Yoshitomi, T, 2013)

"However, cancer patients treated with EGFR inhibitors (EGFRIs) frequently develop acneiform skin toxicities, which are a strong predictor of a patient's treatment response."

( Amberg, N; Ansari, P; Boelke, E; Buhren, BA; Fischer, JW; Gerber, PA; Harder, J; Holcmann, M; Homey, B; Kislat, A; Lichtenberger, BM; Mackenzie, C; Röck, K; Schröder, JM; Schrumpf, H; Sibilia, M; Smolle, V; Wollenberg, A, 2013)

"Patients with solid tumors refractory to standard therapies or with no standard treatment available were enrolled."

( Baselga, J; Burger, H; Carreras, MJ; de Jonge, MJ; Eskens, FA; Mizui, Y; O'Brien, JP; Piera, A; Ramos, FJ; Tabernero, J; Wiemer, EA, 2013)

"Claims of benefits of aromatherapy for cancer patients include reduced anxiety levels and relief of emotional stress, pain, muscular tension and fatigue."

( Boehm, K; Büssing, A; Ostermann, T, 2012)

"Local relapsed tumors following paclitaxel treatment proved to be paclitaxel-resistant and remained responsive to nab-paclitaxel."

( Baruchel, S; Elias, E; Kumar, S; Leadley, M; Marrano, P; Thorner, P; Zhang, L, 2013)

( Biermann, JS; Farooki, A; Fornier, MN; Gagel, RF; Gralow, JR; Kumar, R; Litsas, G; McKay, R; Podoloff, DA; Srinivas, S; Van Poznak, CH, 2013)

"More over, the prognosis of diabetic cancer patients on metformin therapy seems be better, than in diabetics without metformin treatment."

( Anděl, M; Skrha, P; Trnka, J, 2013)

"One method for improving cancer treatment is the use of nanoparticle drugs functionalized with targeting ligands that recognize receptors expressed selectively by tumor cells."

( Brown, KC; Gray, BP; McGuire, MJ, 2013)

"Most solid tumors are characterized by unstable perfusion patterns, creating regions of hypoxia that are detrimental to radiotherapy treatment response."

( Danhier, P; De Preter, G; De Saedeleer, CJ; Gallez, B; Jordan, BF; Karroum, O; Porporato, PE; Sonveaux, P, 2013)

"The major dilemma of cancer chemotherapy has always been a double-edged sword, producing resistance in tumor cells and life-threatening destruction of nontumorigenic tissue."

( Gupte, M; Sharma, VP; Tuck, AN; Williams, KJ, 2013)

"Genomic DNA from 672 cancer patients treated with 5-FU monotherapy and with documented toxicity according to WHO criteria was genotyped for 12 ABCC11 tag SNPs."

( Arlanov, R; Ishikawa, T; Klein, K; Lang, T; Magdy, T; Schwab, M; Toyoda, Y; Winter, S; Zanger, UM, 2013)

"The malignant disease itself, the cancer treatment and the presence of central venous catheters (CVCs) increase the risk of VTE."

( Kremer, LC; Schoot, RA; van de Wetering, MD; van Ommen, CH, 2013)

"In 29 patients with various malignant tumors there was carried out an estimation of Thiotriazoline efficacy in the treatment of hepatotoxicity in the process of combined chemoradiation therapy."

( Korytova, LI; Masliukova, EA; Meshechkin, AV; Sokurenko, VP; Zhabina, RM, 2013)

"PARP inhibitors are being evaluated in cancers with defective DNA repair mechanisms or in combination with cytotoxic therapy or radiation."

( Adamson, PC; Fox, E; Nguyen, VT; Norris, RE, 2014)

"Anemia in patients with cancer who are undergoing active therapy is commonly encountered and may worsen quality of life in these patients."

( Abbasi, S; Abdel-Razeq, H; Abdelelah, H; Jaber, R; Saadi, I, 2013)

"In MAb159-treated tumors, PI3K signaling was inhibited without compensatory MAPK pathway activation."

( Conti, PS; Dong, D; Gao, W; Gill, PS; Krasnoperov, V; Lee, AS; Li, D; Li, X; Li, Z; Liu, R; Liu, S; Louie, S; Mitra, SK; Wey, S; Zhou, Y; Zhu, G, 2013)

"The diabetes-cancer link has been hypothesized to rely on various hormonal (insulin, IGF1, adipokines), immunological (inflammation), or metabolic (hyperglycemia) characteristics of the disease and even on certain treatments."

( Chocarro-Calvo, A; De la Vieja, A; García-Jiménez, C; García-Martínez, JM, 2014)

"The Anemia Cancer Treatment study assessed hemoglobin (Hb) outcomes following treatment with erythropoiesis-stimulating agents (ESA) in anemic (Hb≤11g/dL) patients in Europe."

( Aapro, M; Abraham, I; Battistel, V; Bokemeyer, C; Ludwig, H; MacDonald, K; Soubeyran, P; Tharmarajah, S, 2013)

"In mouse xenograft models of human cancer, COH29 treatment reduced tumor growth compared with vehicle."

( Gaur, S; Horne, D; Hu, S; Hu, W; Smith, DL; Su, L; Synold, TW; Wu, J; Yen, Y; Yip, ML; Yuan, YC; Zhou, B, 2013)

"Dogs with solid tumors were administered toceranib at an intended target dose ranging from 2."

( Bernabe, LF; Kisseberth, WC; London, CA; Nguyen, S; Pennell, M; Portela, R; Yancey, MF, 2013)

"In the treatment of cancer, multidrug resistance (MDR) has been the major obstacle to the success of chemotherapy."

( Dong, H; Jia, M; Li, Y; Ou, Z; Ren, T; Wu, W, 2013)

"Their potential application in cancer treatment is promising."

( Ba, Q; Chu, R; Huang, C; Li, J; Wang, H; Yue, Q, 2013)

"Insights into the molecular drivers of cancer are providing opportunities for the development of new targeted treatments and more personalised approaches to cancer management."

( Day, RO; Kerridge, IH; Lewis, JR; Lipworth, WL, 2013)

"Using a mouse model for breast cancer, we confirm that inhibition of p38 MAPK cooperates with cisplatin treatment to reduce tumour size and malignancy in vivo."

( Canovas, B; Dolado, I; Igea, A; Nebreda, AR; Pereira, L, 2013)

"The success of anticancer therapy is limited due to the resistance caused by tumor cells to cytotoxic agents, which interfere with the effectiveness of various chemotherapeutic agents."

( Kaur, M; Kumar, R; Silakari, O, 2014)

"Although treatment of these cancers with tyrosine kinase inhibitors shows dramatic responses and durable disease control, drug resistance followed by clinical progression of disease eventually occurs in virtually all patients."

( Boggon, TJ; Lax, I; Mandel-Bausch, EM; Nelson, B; Pavlenco, A; Reshetnyak, AV; Schlessinger, J; Shi, X; Sidhu, SS; Suzuki, Y; Tome, F, 2013)

"As patients with cancer are living longer, there is a need to ensure that treatments used for palliative care are well tolerated and effective during long-term use."

( Ellershaw, JE; Perelman, M; Radbruch, L; Revnic, J; Taylor, D; Torres, LM, 2014)

"Forty-eight subjects with solid tumors were treated."

( Bannerji, R; Jou, YM; Kirschmeier, P; Nemunaitis, JJ; Small, KA; Statkevich, P; Yao, SL; Zhang, D; Zhu, Y, 2013)

"Given the essential role of OCTN2 in cancer cell uptake of chemotherapeutics, and thus treatment efficacy, pretreatment with a demethylating reagent is a possible strategy for optimizing pharmacotherapies against cancers."

( Fu, LJ; Lou, XY; Qu, J; Qu, Q; Wu, LX; Zhan, M; Zhang, YW; Zhou, HH, 2013)

"Bacteremia due to rESKAPE pathogens in cancer patients occurs mainly among those with comorbidities who have received prior antibiotic therapy and have a urinary tract source."

( Bodro, M; Boix, L; Calvo, M; Carratalà, J; Contra, A; Domingo-Domenech, E; Garcia-Vidal, C; Gudiol, C; Tubau, F, 2014)

"A retrospective analysis of all cancer patients attending the radiotherapy outpatient department (OPD) of a single unit during the period of January 2005 till December 2006 was conducted to know the geographical distribution and incidence of the most common cancers, their stage of presentation, treatment compliance among the patients and follow-up."

( Asthana, AK; Mandal, A; Nandi, M, 2013)

"There are many obstacles to effective cancer chemotherapy, including drug penetration and accumulation in tumors and drug systemic toxicity."

( Chiang, HH; Kohane, DS; Tong, R, 2013)

"To analyse the association between cancer incidence and oral diabetes therapy (biguanide, sulphonylurea, thiazolidinedione and meglitinide) in men and women with type 2 diabetes mellitus."

( Kashyap, SR; Kattan, MW; Raghavan, D; Sun, GE; Wells, BJ; Yip, K; Zimmerman, R, 2014)

"Differential anticancer drug delivery that selectively releases a drug within a tumor represents an ideal cancer therapy strategy."

( Bao, Y; Du, XJ; Jiang, Q; Tan, ZB; Wang, HX; Wang, J; Xiong, MH; Zhu, YH, 2013)

"Extensive central necrosis of tumors was evident by 12 h after treatment with CKD-516 (2."

( Cha, H; Cho, WJ; Dung, le TK; Lee, HY; Lee, SJ; Min, YJ; Moon, CH; Park, JW, 2014)

"New anticancer agents that target a single cell surface receptor, up-regulated or amplified gene product, or mutated gene, have met with some success in treating advanced cancers."

( Aldrich, J; Baker, A; Benson, H; Carpten, JD; Christoforides, A; Craig, DW; Demeure, MJ; Hostetter, G; Izatt, T; Kiefer, JA; Kurdoglu, A; Liang, WS; Marsh, V; Phillips, L; Reiman, R; Sinari, S; Von Hoff, DD; Weiss, GJ, 2013)

"Many cancer research efforts focus on exploiting genetic-level features that may be targeted for therapy."

( Baker, JH; Balbirnie, A; Bartels, KL; Cran, JD; Flanagan, EJ; Kyle, AH; Methot, SP; Minchinton, AI, 2013)

"Nanoparticles for cancer imaging and therapy have evolved rapidly during the last decade and it is expected that more and more will become clinical practise."

( Hu, SY; Huang, WB; Liu, ZA; Sun, NF; Tian, AL, 2014)

"Early diagnosis and treatment of cancer may curb the growing burden of the disease."

( Chauhan, AS; Hussain, MA; Mallick, D; Nayak, S; Pati, S, 2013)

"A therapy of cancer cells: Two-photon-triggered camptothecin delivery with nanoimpellers was studied in MCF-7 breast cancer cells."

( Blanchard-Desce, M; Charnay, C; Cheminet, N; Croissant, J; Derrien, G; Durand, JO; Gallud, A; Garcia, M; Gary-Bobo, M; Guardado-Alvarez, TM; Jarrosson, T; Lu, J; Maynadier, M; Mongin, O; Nyalosaso, JL; Peindy N'dongo, H; Raehm, L; Serein-Spirau, F; Tamanoi, F; Tarn, D; Zink, JI, 2013)

"For therapy of MDA-MB-435 tumors with paclitaxel protein-bound particles, a significant decrease was observed only with (18)F-alfatide II Bp value from kinetic analysis but not (18)F-FDG influx."

( Chen, X; Eden, HS; Guo, J; Guo, N; Kiesewetter, DO; Lang, L; Li, Q; Niu, G; Xie, Q, 2014)

"Pretreatment size tumors from each of the models were profiled for the levels of 27 protein markers of angiogenesis, SNP haplotype in 5 angiogenesis genes, and somatic mutation status for 11 genes implicated in tumor growth and/or vascularization."

( Goulart, A; Huang, H; Levin, N; Pavlicek, A; Pirie-Shepherd, S; Triana-Baltzer, G, 2013)

"Data on cancer incidence (follow-up 1998-2010), Cbl treatment, and prior diagnoses were obtained from medical registries."

( Arendt, JF; Nexo, E; Pedersen, L; Sørensen, HT, 2013)

"The use of selenium for anticancer therapy has been heavily explored during the last decade."

( Chen, T; Feng, Y; Su, J; Wu, H; Zhang, Y; Zhao, Z; Zheng, W, 2014)

"Current cancer therapy aims to exploit this epigenetic pathway by developing site-selective cAMP analogs."

( Ward, CS, 2014)

"Controlling anticancer drug activity and release on demand is very significant in cancer therapy."

( Cheng, Z; Dai, Y; Hou, Z; Li, C; Lin, J; Liu, J; Ma, P; Xiao, H; Yang, D; Yang, P; Yuan, Q, 2013)

"Subsequently, peritoneal tumors in a murine model of breast cancer metastasis were identified using OPAL after systemic administration of a tumor-selective fluorescent molecular probe."

( Achilefu, S; Akers, WJ; Gullicksrud, K; Mondal, S; Sarder, P; Sudlow, GP, 2013)

"The inhibition of cancer cell metastasis by graphene and graphene oxide might provide new insights into specific cancer treatment."

( Chen, C; Gao, X; Jia, Y; Wei, T; Yu, M; Zhang, B; Zhao, K; Zheng, J; Zhou, H; Zhou, T, 2014)

"In vitro treatment of thirteen cancer cell lines indicated that five cell lines (AGS, NCI-N87, HCT-8, A2780 and BxPC-3) are highly sensitive to MPA (IC50 < 0."

( Dun, B; He, M; Liu, H; Liu, X; Sharma, A; She, JX; Xu, H; Yi, B; Yu, H; Zeng, L, 2013)

"Patients with malignant solid tumors were assigned sequentially to one of ten dose-escalation cohorts of PNT2258 at 1, 2, 4, 8, 16, 32, 64, 85, 113, and 150 mg/m(2) administered intravenously on days 1 through 5 of each 21-day cycle."

( Amaya, A; Bisgaier, CL; Gaylor, SK; Messmann, RA; Moore, TD; Papadopoulos, KP; Patnaik, A; Rasco, DW; Rodrigueza, WV; Sooch, MP; Tolcher, AW; Woolliscroft, MJ, 2014)

"The impact of cancer treatment on ovarian function and fertility has been known since the 70s."

( Chabbert-Buffet, N; Daraï, É; Thomin, A; Torre, A, 2014)

"In this review, we summarize the anticancer effects of fucoxanthin through several different mechanisms including anti-proliferation, induction of apoptosis, cell cycle arrest and anti-angiogenesis, and its possible role in the treatment of cancer."

( Balasubramanian, MP; Nandakumar, N; Nishigaki, I; Rajendran, P; Rengarajan, T, 2013)

"Progress in cancer treatment means people will live longer with the sequelae of cancer and disease-directed treatments, and both the short- and long-term effects of opioid use must be considered."

( Davis, MP; Fielding, F; Sanford, TM, 2013)

"In recent years, efforts to improve cancer therapy have focused on developing new anticancer agents, such as mitocans."

( Angulo-Molina, A; Hernández, J; López-Malo, A; Reyes-Leyva, J, 2014)

"Apart from classical anti-cancer therapies such as surgery, chemotherapies, and radiotherapy, many new therapies are being developed or translated into clinical use."

( Li, F; Shi, X; Sun, Y; Wu, P; Zhang, Y; Zhu, Z, 2013)

"These data suggest that tumors displaying MET aberrations achieve plateau responses by MET monotherapy and do not receive further benefit by addition of cytotoxic treatments."

( Arnesano, A; Benvenuti, S; Comoglio, PM; Gentile, A; Lazzari, L; Trusolino, L, 2014)

"Only few human tumors express OCT2, its expression being apparently down-regulated by epigenetic modifications, suggesting that a protective therapy by competition for the transport of cisplatin by OCT2 may be generally feasible without affecting its antitumor potency."

( Ciarimboli, G, 2014)

"Compound 2 shows a good anticancer potential and it could represent an alternative to platinum-based drugs especially in the situation of standard treatment failure."

( Fischer-Fodor, E; Hey-Hawkins, E; Ilea, P; Imre-Lucaci, F; Krausz, LT; Lupan, I; Precup, CG; Schrepler, MP; Silaghi-Dumitrescu, L; Tatomir, C; Tudoran, LB; Vălean, AM; Virag, P, 2014)

"Aggressive tumors typically demonstrate a high glycolytic rate, which results in resistance to radiation therapy and cancer progression via several molecular and physiologic mechanisms."

( Champ, CE; Klement, RJ, 2014)

"Because many cancers have acquired mutations in DNA damage checkpoints or repair pathways, we hypothesized that these cancers may be susceptible to treatments that target compensatory pathways."

( Choi, K; Choi, Y; Fox, J; Hendrickson, EA; Kim, S; Li, L; Mejia, M; Muller, M; Myung, K; Oh, S; Ruangpradit, W; Saberi, A; Smith, S; Takeda, S; Wang, Y, 2014)

"In addition, their potential roles in cancer metabolism therapy will also be briefly discussed."

( Huang, W; Lei, QY; Wang, Z, 2014)

"Developing an effective treatment for cancer is still a challenge."

( Chen, H; Gao, Y; Huang, J; Tang, F; Zheng, B; Zhou, X, 2014)

"In this study, children with cancer (leukemia excluded) were evaluated for risk of severe infection complication, success of therapy and the relation between clinical and inflammatory parameters during neutropenic fever attacks."

( Arisoy, ES; Corapcioglu, F; Demirsoy, U; Karadogan, M; Karakurt, DG; Oncel, S, 2014)

"Opioid-treated adult cancer patients, experiencing 1 to 4 episodes of BTP per day, were included in the study."

( Bullier, F; Fricova, J; Harabisova, S; Novotna, S; Richterova, E; Trinquet, F; Valentova, K, 2014)

"In the context of cancer treatment, it involves breaking tolerance to a cancer-specific self-antigen and/or enhancing the existing anti-tumor immune response, be it specific or not."

( Rooke, R, 2014)

"Targeted therapy for the treatment of cancers using nanoparticles (NPs) decorated with transferrin (Tf) has been relatively successful, as several such nanocarriers are currently undergoing clinical trials."

( Chiu, RY; Kamei, DT; Liu, CT; Tsuji, T; Wang, J; Wang, SJ, 2014)

"Early detecting of cancer is critical to provide proper treatment and to improve survival of patients."

( Han, J; Kim, JH; Kim, JS; Lee, J; Lee, JH; Lim, JY; Pradhan, T; Ren, WX, 2014)

"To improve the anti-cancer efficacy and to counteract the side effects of chemotherapy, a variety of drug delivery systems have been invented in past decades, but few of these systems have succeeded in clinical trials due to their respective inherent shortcomings."

( Chen, J; Niu, R; Tian, R, 2014)

"Multidrug resistance (MDR) of tumors leads to fatal treatment outcome in many patients and novel drugs able to kill multidrug-resistant cells are urgently needed."

( Efferth, T; Khalid, H; Saeed, M; Sugimoto, Y, 2014)

"The detection and treatment of cancer has advanced significantly in the past several decades, with important improvements in our understanding of the fundamental molecular and genetic basis of the disease."

( Bergamaschi, A; Katzenellenbogen, BS; Mir, M; Popescu, G, 2014)

"Opioids are an effective treatment for cancer-related pain, yet substantial risk for substance abuse exits in the cancer population."

( Barclay, JS; Blackhall, LJ; Owens, JE, 2014)

"The inhibitory rate of S180 tumors in mice treated with 40 mg/kg BSF-A reached 62."

( Ding, X; Hou, W; Hou, Y; Li, J; Song, B; Wang, F; Wang, T; Xu, T; Zeng, Y; Zhong, J; Zhu, H, 2014)

"However, the ability of cancer cells to change their integrin repertoire in response to drug treatment renders this approach vulnerable to the development of resistance and paradoxical promotion of tumor growth."

( Patterson, LH; Sheldrake, HM, 2014)

"Understanding cancer-specific metabolism is important for identifying novel targets for cancer diagnosis and therapy."

( Fujibayashi, Y; Furukawa, T; Saga, T; Yoshii, Y, 2015)

"Current cancer management strategies fail to adequately treat malignancies with multivariable dose-restricting factors such as systemic toxicity and multi-drug resistance limiting therapeutic benefit, quality of life and complete long-term remission rates."

( Karagiannis, TC; Tortorella, S, 2014)

"386 adult patients with metastatic cancers refractory to at least one chemotherapy regimen, whom physicians identified as terminally ill at study enrollment and who subsequently died."

( Keating, NL; Prigerson, HG; Weeks, JC; Wright, AA; Zhang, B, 2014)

"386 adult patients with metastatic cancers refractory to at least one chemotherapy regimen, whom physicians identified as terminally ill at study enrollment and who subsequently died."

( Keating, NL; Prigerson, HG; Weeks, JC; Wright, AA; Zhang, B, 2014)

"216 (56%) of 386 terminally ill cancer patients were receiving palliative chemotherapy at study enrollment, a median of 4."

( Keating, NL; Prigerson, HG; Weeks, JC; Wright, AA; Zhang, B, 2014)

"The PTT study on cancer cells in vivo demonstrated that the WO3-x hierarchical nanostructures can generate enough heat for efficient photothermal therapy of cancer cells under the irradiation of a 915 nm laser with a power density of 1."

( An, L; Hu, J; Hua, Y; Li, B; Wang, Q; Yin, F; Zhang, B; Zhang, Y; Zou, R, 2014)

"Imaging spontaneous cancer cell metastasis or heterogeneous tumor responses to drug treatment in vivo is difficult to achieve."

( Blower, PJ; Diocou, S; Fruhwirth, GO; Mullen, GE; Ng, T, 2014)

"For hematological and solid malignancy patients undergoing chemotherapy, increases in HBV DNA and HCV RNA levels can be detected which may result in reactivation and hepatitis-related morbidity and mortality."

( Aykas, F; Basak, M; Karahan, S; Karaman, A; Oguz, A; Unal, D; Uslu, E, 2014)

"Edelfosine is mainly known for its anticancer properties, although it is also applied in the treatment of other diseases, like autoimmune, anti-HIV and antiparasitic."

( Dynarowicz-Latka, P; Hac-Wydro, K, 2014)

"Many types of cancer, for example glioblastoma, show resistance against current anti-cancer treatments."

( Gavish, M; Kugler, W; Veenman, L, 2014)

"Eighty subjects with solid tumors who were under standard chemotherapy regimens were randomly assigned to a bioavailability-boosted curcuminoids preparation (180 mg/day; n = 40) or matched placebo (n = 40) for a period of 8 weeks."

( Beiraghdar, F; Panahi, Y; Saadat, A; Sahebkar, A, 2014)

"30 patients with cancer accessed and administered a placebo of each product and were asked to rate them using 1-7 Likert agree-disagree scales and free-text responses, with regard to ease of access and administration, palatability and overall impression."

( England, R; Maddocks, M; Manderson, C; Wilcock, A; Zadora-Chrzastowska, S, 2011)

"Patients with cancer frequently experience chemotherapy-induced anaemia (CIA) and iron deficiency."

( Aapro, M; Beguin, Y; Bokemeyer, C; Glaspy, J; Hedenus, M; Littlewood, TJ; Ludwig, H; Mitchell, D; Österborg, A; Rzychon, B, 2014)

"This failure is seen in virtually all cancers treated with single-agent kinase inhibitors, most of which are not as dependent on a single signaling pathway such as BRaf-MEK-ERK in melanoma."

( Angus, SP; Graves, LM; Johnson, GL; Stuhlmiller, TJ; Zawistowski, JS, 2014)

"Effective therapy of the primary cancer consists the best current therapy for a given paraneoplastic syndrome."

( Fotopoulos, A; Kyritsis, AP; Sioka, C, 2014)

"Systemic cancer therapy can provide pain relief as a result of tumour shrinkage but recent studies suggest that benefit may also be as a consequence of modulation of pain signalling pathways."

( Gough, N; Linch, M; Miah, AB, 2014)

"In advanced cancers, oncological therapies must be considered as anti-pain treatments."

( Gough, N; Linch, M; Miah, AB, 2014)

"This laser-mediated, cancer-targeting platform can be widely used in cancer therapy."

( Chang, CC; Chang, YC; Chen, HW; Chen, JS; Chen, PH; Cheng, TM; Chou, CC; Chou, FH; Chu, HL; Ho, LP; Hsu, MH; Li, MP; Tsai, LY; Tseng, SH, 2014)

"Radiotherapy for the treatment of cancer is undergoing an evolution, shifting to the use of heavier ion species."

( Belard, A; Camphausen, KA; Krauze, A; O'Connell, JJ; Schlaff, CD, 2014)

"To compare the risk of solid cancer in patients with RA treated with TNFi to that in patients treated with non-biologic (synthetic) disease modifying antirheumatic drugs (sDMARDs)."

( Dixon, WG; Hyrich, KL; Low, AL; Lunt, M; Mercer, LK; Symmons, DP; Watson, KD, 2015)

"Rates of solid cancers in 11 767 patients without prior cancer who received TNFi were compared to those in 3249 patients without prior cancer treated with sDMARDs."

( Dixon, WG; Hyrich, KL; Low, AL; Lunt, M; Mercer, LK; Symmons, DP; Watson, KD, 2015)

"Pain is a symptom of cancer and is categorized in two forms: background pain to be treated with analgesics, and breakthrough cancer pain (BTcP), which needs drug treatment on demand."

( Oradei, M; Ruggeri, M; Turriziani, A, 2014)

"While cancer cell mitochondria mediate actions of many successful chemotherapeutics, little is known about mitochondrial response in mTOR-targeted anticancer therapy."

( Chen, Y; He, Q; Kim, JE; Shi, C; Yu, K, 2014)

"Pregnant patients with cancer are increasingly treated with anticancer drugs, although the specific impact of pregnancy-induced physiological changes on the pharmacokinetics (PK) of anticancer drugs and associated implications for optimal dose regimens remains unclear."

( Amant, F; Beijnen, JH; Han, S; Heyns, L; Huitema, ADR; Mhallem Gziri, M; Schellens, JHM; van Calsteren, K; van Hasselt, JGC, 2014)

"Patients with advanced solid tumors were treated with cabazitaxel 25 mg/m(2) every 3 weeks."

( Agarwala, SS; Baron, A; Chadjaa, M; Conkright, W; Dakhil, S; Daugaard, G; Machiels, JP; Maison-Blanche, P; Millard, F; Rottey, S; Sémiond, D; Sengeløv, L; Sharma, S; Shen, L; Soetekouw, PM; Van Veldhuizen, P; Wade, JL; Yachnin, J, 2014)

"Hypoxia is a hallmark of tumors leading to (mal-)adaptive processes, development of aggressive phenotypes and treatment resistance."

( Mayer, A; Vaupel, P, 2014)

"Treatment of cancer cells with strigolactone analogues was hallmarked by activation of the stress-related MAPKs: p38 and JNK and induction of stress-related genes; cell cycle arrest and apoptosis evident by increased percentages of cells in the sub-G1 fraction and Annexin V staining."

( Albanese, C; Feldman, AS; Kapulnik, Y; Koltai, H; Lee, H; Lee, RJ; Li, X; McDonough, S; Pollock, CB; Prandi, C; Ringer, L; Rodriguez, OC; Schlegel, R; Wang, VS; Yarden, RI, 2014)

"Mirtazapine was administered to 50 cancer patients with digestive symptoms in palliative care, and the data were retrospectively examined."

( Imai, E; Nishimura, D; Shibahara, H; Tokura, Y; Uematsu, N, 2014)

"In PC3 prostate cancer cells, RS-1-induced lethality was accompanied by the formation of microscopically visible RAD51 nuclear protein foci occurring in the absence of any DNA-damaging treatment."

( Bishop, DK; Budke, B; Connell, PP; Kozikowski, AP; Logan, HL; Mason, JM; Pawlowski, M; Weichselbaum, RR; Wu, M, 2014)

"With the majority of deaths from cancer because of their metastases, strategies to reduce this from occurring are at the forefront of treatment."

( Juneja, R, 2014)

"From the clinical editor: In this cancer treatment study clinical samples collected from patients were subjected to immunohistochemistry and pharmacogenomics."

( Chen, L; Davis, M; Gaur, S; Kretzner, L; Wang, Y; Wu, X; Yen, T; Yen, Y; Yuan, YC, 2014)

"The success of targeted cancer therapy largely relies upon the selection of target and the development of efficient therapeutic agents that specifically bind to the target."

( Bagia, C; Bai, M; Ding, Y; Janjic, JM; Jia, N; Shao, P; Zhang, S, 2014)

"Patients with advanced cancer need multiple drugs to control symptoms and to treat cancer and concomitant diseases."

( Kaasa, S; Klepstad, P; Kotlinska-Lemieszek, A; Paulsen, O, 2014)

"Patients with cancer treated with a World Health Organization Step III opioid use a high number of drugs."

( Kaasa, S; Klepstad, P; Kotlinska-Lemieszek, A; Paulsen, O, 2014)

"This was a retrospective study of adult cancer patients with septic shock who received low-dose HC therapy (200 mg/day)."

( Al-Shaer, M; AlNajjar, T; Hawari, F; Nazer, L; Rimawi, D, 2015)

"Treatment of chronic noncancer pain (CNCP) with high-dose opioids (HDOs) has burgeoned over the past 2 decades in the United States."

( Feeko, KJ; Kamen, LB, 2014)

"We aimed to analyse malignancy rates and predictors for the development of malignancies in a large German inflammatory bowel disease (IBD) cohort treated with thiopurines and/or anti-tumour necrosis factor (TNF) antibodies."

( Beigel, F; Brand, S; Breiteneicher, S; Göke, B; John, JM; Laubender, RP; Ochsenkühn, T; Schnitzler, F; Seiderer, J; Steinborn, A; Tillack, C; Van Steen, K, 2014)

"The overall incidence of FAEs in cancer patients treated with everolimus was 0."

( Abdel-Rasoul, M; Lustberg, M; Macrae, ER; Paskell, M; Shapiro, CL; Wesolowski, R, 2014)

"In patients with cancer, everolimus is associated with a small but significant increase in the odds of a treatment-related fatal events."

( Abdel-Rasoul, M; Lustberg, M; Macrae, ER; Paskell, M; Shapiro, CL; Wesolowski, R, 2014)

"Effective anticancer therapy can be achieved by designing a targeted drug-delivery system with high stability during circulation and efficient uptake by the target tumour cancer cells."

( Hoffman, AS; Jang, Y; Kim, IS; Kim, J; Kim, WJ; Lee, BH; Mi Lee, Y; Namgung, R; Rhee, YM; Sokkar, P, 2014)

"The association of cancer treatment, particularly chemotherapeutics, with nanotechnology is currently one of the most exciting areas of research."

( Durán, N; Fávaro, WJ; Marcato, PD, 2014)

"However, cancer treatment demands spatially and temporally controlled noninvasive therapy at the cell level because nonspecific toxicity often causes complicated side effects."

( Selvakumar, S; Shanmugam, V; Yeh, CS, 2014)

"Interaction between cancer cells and immune system critically affects development, progression and treatment of human malignancies."

( Hirt, C; Iezzi, G; Martin, I; Mele, V; Mengus, C; Muraro, MG; Papadimitropoulos, A; Spagnoli, GC; Terracciano, L, 2014)

"The (18)F-FDG PET/CT images of 43 cancer patients with both local recurrence (in-field) and distal metastases (out-field) after initial treatments were reviewed."

( Li, S; Li, W; Sun, L; Sun, X; Xing, L; Zhang, X; Zhao, F, 2014)

"Age, sex, cancer type, stage, and therapy, performance status, anemia status and treatment, and Hb concentrations were recorded for up to 18 weeks in a web-based registry."

( Hellebrand, E; Kindler, M; Kuhn, A; Lange, O; Steinmetz, T; Vehling-Kaiser, U, 2014)

"Recently, quercetin's effect in cancer prevention and treatment was recognized."

( Chen, LJ; Duan, X; Gou, ML; Huang, MJ; Men, K; Qian, ZY; Wei, XW; Wei, YQ, 2014)

"Successful anticancer therapy must consist of approaches that can target not only the differentiated cancer cells, but also cancer stem cells."

( Liu, T; Qiao, L; Shi, J; Zang, S, 2014)

"Therapeutic peptides offer important cancer treatment approaches."

( Kuna, M; Raucher, D; Ryu, JS, 2014)

"Burden of cancer is progressively increasing in developing countries like India which has also led to a steep rise in toxicity due to anti-cancer therapy."

( Gupta, S; Haresh, KP; Julka, PK; Mallick, S; Rath, GK; Raza, MW; Roy, S; Sharma, DN, 2014)

"For opioids used to treat cancer pain adverse event incidence rates were 25% for constipation, 23% for somnolence, 21% for nausea, 17% for dry mouth, and 13% for vomiting, anorexia, and dizziness."

( Derry, S; Moore, RA; Wiffen, PJ, 2014)

"The use of nanotechnology in cancer treatment offers exciting opportunities, including the possibility of destroying tumors with minimal damage to healthy tissue by novel targeted drug delivery systems."

( Gunduz, U; Khodadust, R; Mutlu, P; Onguru, O; Unsoy, G; Yalcin, S, 2014)

"This study identified a malignancy cohort of 25,322 patients who had never received morphine treatment."

( Kao, CH; Lee, CW; Liang, JA; Muo, CH; Sung, FC, 2014)

"The incidence of SDH in patients with cancer in Taiwan is associated with recent morphine treatment (≤6 months) and is dependent on the duration of morphine use."

( Kao, CH; Lee, CW; Liang, JA; Muo, CH; Sung, FC, 2014)

"Besides the anti-cancer activities, rocaglamides are also shown to protect primary cells from chemotherapy-induced cell death and alleviate inflammation- and drug-induced injury in neuronal tissues."

( Li-Weber, M, 2015)

"Patients ≥60 years of age with cancer were equally randomized into control (chemotherapy alone) or prophylactic (chemotherapy supplemented with 75 mg bicyclol, oral, daily) groups."

( Chen, S; Guan, M; Li, X; Wang, Y; Ying, H; Zhao, L; Zhou, J; Zhou, Y, 2014)

"Conversely, cancer cells with abundant endogenous intracellular dNTPs or treated with dNTP precursors were less responsive to autophagy induction by rapamycin, suggesting that autophagy and dNTP pool levels are regulated through a negative feedback loop."

( Ann, DK; Chen, L; Chen, W; Chen, YR; Hu, S; Kuo, ML; Tang, M; Yang, L; Yen, Y; Zhang, K; Zhang, L; Zhou, B, 2014)

"A brief introduction into cancer is given reflecting the different pathways this disease might be treated using chemotherapy using natural product analogs especially triterpenes."

( Csuk, R, 2014)

"In view of the current limitations of cancer chemotherapy, there has been resurgent interest in re-visiting glycolysis to determine whether tumors could be killed by energy deprivation rather than solely by strategies to inhibit proliferation."

( Al Hasawi, N; Alkandari, MF; Luqmani, YA, 2014)

"Patients with solid tumors for which gemcitabine was deemed an appropriate therapy were enrolled into one of two different dosing schedules (21-day dosing schedule: navitoclax administered orally on days 1-3 and 8-10,; and gemcitabine 1,000 mg/m(2) on days 1 and 8; 28-day dosing schedule: navitoclax administrated orally on days 1-3, 8-10, and 15-17; and gemcitabine 1,000 mg/m(2) on days 1, 8 and 15)."

( Busman, T; Cleary, JM; Franklin, C; Graham, A; Holen, K; Hurwitz, HI; Lima, CM; Mabry, M; Montero, AJ; Shapiro, GI; Uronis, H; Yang, J, 2014)

"It might be a novel and potent anticancer treatment by targeting P5 on the surface of cancer cells."

( Horibe, T; Kawakami, K; Okuno, Y; Torisawa, A, 2014)

"Quality pain management for cancer survivors is complicated by the fact that cancer-related pain can be due to the tumor, surgery, radiation, and/or chemotherapy."

( Schreiber, JA, 2014)

"Like most studies in patients with cancer pain, it was limited by its open-label, uncontrolled design, the number of patients lost in follow-up, and discontinuation of the treatment for several reasons."

( Adile, C; Aielli, F; Casuccio, A; Cortegiani, A; Dickenson, A; Mercadante, S; Porzio, G, 2014)

"A common approach to cancer therapy in clinical practice is the combination of several drugs to boost the anticancer activity of available drugs while suppressing their unwanted side effects."

( Jo, DE; Kang, BH; Lee, JE; Lim, J; Park, HK; Park, SA; Suh, PG, 2014)

"Gamitrinib sensitized various human cancer cells to doxorubicin treatment, and combination treatment with the two drugs synergistically increased apoptosis."

( Jo, DE; Kang, BH; Lee, JE; Lim, J; Park, HK; Park, SA; Suh, PG, 2014)

"Patients had advanced solid tumors for which ≥1 of these regimens was considered standard of care or for whom no other treatment options existed."

( Brana, I; Calles, A; Calvo, E; de Boer, CJ; LoRusso, PM; Puchalski, TA; Seetharam, S; Tabernero, J; Yee, LK; Zhong, B, 2015)

"Its key role in cancer promotes the development of a potent and selective inhibitor that might increase cancer cell death when combined with radiotherapy."

( Liu, Y; Yao, Y; Zhao, ZB, 2014)

"For small interfering RNA (siRNA)-based cancer therapies, we report an actively-targeted and stabilized polyion complex micelle designed to improve tumor accumulation and cancer cell uptake of siRNA following systemic administration."

( Christie, RJ; Fukushima, S; Kataoka, K; Low, SA; Matsumoto, Y; Miura, Y; Miyata, K; Naito, M; Nishiyama, N; Oe, Y; Toh, K, 2014)

"These include patients treated for cancer who no longer have evidence of disease (NED) and patients with chronic pain but no life-limiting illness (NLLI)."

( Archer, KJ; Cassel, B; Del Fabbro, E; Fletcher, D; Jennings, C; Skoro, N; Wang, A; Yanni, L, 2014)

"Compared with patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE."

( Akl, EA; Barba, M; Kahale, L; Muti, P; Neumann, I; Schünemann, H; Sperati, F; Terrenato, I, 2014)

"Despite its important role in cancer treatment, there is currently very limited available information concerning the clinical pharmacology of actinomycin D (Act D)."

( Boddy, AV; Cole, M; Errington, J; Hill, CR; Malik, G; Veal, GJ, 2014)

"Breast cancer is the most common cancer among women worldwide and novel therapeutic agents are needed to treat this disease."

( Ismail, P; Jabbarzadeh Kaboli, P; Ling, KH; Rahmat, A, 2014)

"Despite recent advances in cancer treatment, adverse effects related to cancer therapy remain a limiting factor for many patients."

( Botting, GM; Crees, Z; Devito, JT; Girard, J; Harrington, K; Puri, N; Rios, Z; Shearrow, C; Stone, AL; Uppada, SB; Wojdyla, L, 2014)

"Patients with advanced cancer were treated at the Immuno Biotech Treatment Centre with OA-GcMAF-based integrative immunotherapy in combination with a low-carbohydrate, high-protein diet, fermented milk products containing naturally-produced GcMAF, Vitamin D3, omega-3 fatty acids and low-dose acetylsalicylic acid."

( Branca, JJ; Morucci, G; Noakes, D; Pacini, S; Ruggiero, M; Smith, R; Taubmann, M; Thyer, L; Ward, E, 2014)

"Further cancer-specific controlling of HddSBL expression and animal studies may help to provide insights into a novel way of anti-cancer marine lectin gene therapy."

( Cui, L; Duan, X; Li, G; Luo, J; Wu, L; Yang, X, 2014)

"Targeting tumors with long-circulating nano-scaled carriers is a promising strategy for systemic cancer treatment."

( Cabral, H; Kataoka, K, 2014)

"The treatment of cancer pain is paramount to both medical practitioner and patient in order to maximize quality of life."

( Kaye, AD; Meserve, JR; Prabhakar, A; Urman, RD, 2014)

"A multifunctional copolymer-anticancer conjugate chitosan-graft-polyethyleneimine-candesartan (CPC) containing low molecular weight chitosan (CS) backbone and polyethyleneimine (PEI) arms with candesartan (CD) conjugated via an amide bond was fabricated as a targeted co-delivery nanovector of drug and gene for potential cancer therapy."

( Bao, X; Ding, Y; Jin, Y; Wang, C; Wang, W; Wang, X; Wang, Y; Zhou, J, 2014)

"Stratification by known cancer risk factors, history of cancer, other randomized treatment, and follow-up time showed no significant interactions."

( Bubes, V; Buring, JE; Christen, WG; Gaziano, JM; Glynn, RJ; Manson, JE; Sesso, HD; Wang, L, 2014)

"Depending on the type of cancer, physicians use the generally accepted schema of treatment, for example pharmacotherapy."

( Dołegowska, B; Jedrzychowska, A, 2013)

"Simultaneous targeted cancer imaging, therapy and real-time therapeutic monitoring can prevent over- or undertreatment."

( Ding, L; Ju, H; Li, X; Shen, Z; Tian, J; Yang, CJ; Yang, Y; Yu, JS; Zhu, Z, 2014)

"The application of nanotechnology in cancer treatment may also improve the efficacy of other known drugs, as a result of improved pharmacokinetic and pharmacodynamic profiles, similarly to paclitaxel."

( Carvalho, FL; Hernández-García, I; Hidalgo, M; Ramírez, N; Vera, R; Viúdez, A, 2014)

"Japanese patients with advanced solid tumors whose disease had progressed on at least one line of standard therapy, or for whom no standard therapy existed, were treated with AUY922 (intravenous, once-weekly, 28-day cycle, starting dose 8 mg/m(2))."

( Akimov, M; Boku, N; Doi, T; Fuse, N; Ohtsu, A; Onozawa, Y; Robson, M; Watanabe, J; Yamazaki, K; Yoshino, T, 2014)

"Breakthrough cancer pain (BTCP) is associated with decreased satisfaction with around-the-clock opioid therapy."

( Barker, J; Dillaha, L; Parikh, N; Rauck, R; Stearns, L, 2015)

"Among cancer patients, concomitant treatment with taxanes and younger age would seem to be risk factors for ICM-related ARs."

( Amadori, D; Aquilina, M; Barone, D; Carretta, E; Casadei, C; Della Luna, C; Farolfi, A; Gavelli, G; Gentili, N; Minguzzi, M; Nanni, O; Ragazzini, A, 2014)

"Survivors of childhood cancer frequently experience cancer-related cognitive dysfunction, commonly months to years after treatment for pediatric brain tumors, acute lymphoblastic leukemia (ALL), or tumors involving the head and neck."

( Castellino, SM; Lange, BJ; Ullrich, NJ; Whelen, MJ, 2014)

"The successful design and anticancer mechanistic studies of a series of cyclometalated Ir(III) complexes with histone deacetylase inhibitory and photodynamic therapy (PDT) activities are reported."

( Chen, MH; He, L; Ji, LN; Mao, ZW; Tan, CP; Ye, RR, 2014)

"Forty-six cancer patients diagnosed with solid tumors were enrolled to receive at least one cycle of highly emetogenic chemotherapy (HEC) every two to four weeks."

( Chanthawong, S; Sookprasert, A; Subongkot, S, 2014)

"With such important roles in cancer, CD73 has become an appealing therapy target."

( Dong, K; Gao, ZW; Zhang, HZ, 2014)

"Carboplatin is a platinum-based anticancer drug that has been long used to treat many types of solid cancer."

( Ando, Y; Hasegawa, Y; Shimokata, T; Yasuda, Y, 2014)

"The treatment of human cancer has been seriously hampered for decades by resistance to chemotherapeutic drugs."

( Buglioni, S; Carocci, F; Fais, S; Fanciulli, M; Francesco, M; Spugnini, EP; Vincenzi, B, 2014)

"Using biosimilar ESA for supportive cancer care yields significant savings and increases accessibility to primary antineoplastic therapy in a budget neutral way."

( Aapro, M; Abraham, I; Han, L; MacDonald, K; Sun, D, 2014)

"Doxorubicin, the potent anticancer drug, is widely used to treat various cancers."

( Mirza, AZ, 2015)

"We reviewed the anti-cancer effects of DCA, an orphan drug long used as an investigational treatment for various acquired and congenital disorders of mitochondrial intermediary metabolism."

( Kankotia, S; Stacpoole, PW, 2014)

"Statin therapy had to precede cancer diagnosis, if it occurred."

( Bigoloni, A; Bossolasco, S; Carbone, A; Castagna, A; Cossarini, F; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Poli, A; Salpietro, S; Spagnuolo, V, 2014)

"Patients with advanced solid tumors and platelets ≤300 × 10(9) /L receiving gemcitabine plus cisplatin or carboplatin (Group A) or gemcitabine monotherapy (Group B) were randomized 3:1 to receive eltrombopag or placebo at a starting dose of 100 mg daily administered on days -5 to -1 and days 2-6 starting from cycle 2 of treatment."

( Forget, F; Hartner, L; Johnson, BM; Karaszewska, B; Kumar, K; Mayer, B; Messam, CA; Mostafa Kamel, Y; Ramlau, R; Richards, DA; Safran, H; Winer, ES, 2015)

"Double targeting of nanoparticles to tumors by different mechanisms could be a promising translational approach for the management of therapeutic treatment and personalized therapy."

( Danhier, F; Gallez, B; Jacobs, D; Po, C; Préat, V; Schleich, N; Ucakar, B, 2014)

"Thirty-one patients with advanced neoplasms were treated with monthly cycles of perifosine loading doses of 300, 600, 900, 1,200 and 1,500 mg (dose levels 1 through 5, respectively) on days 1-2 depending on the actual dose of the initial cycle."

( Arbuck, SG; Chau, CH; Elsayed, YA; Figg, WD; Headlee, D; Hollingshead, M; Kalnitskiy, M; Melillo, G; Messman, R; Monga, M; Murgo, AJ; Peer, C; Ryan, QC; Sausville, EA; Senderowicz, AM; Shah, A, 2014)

"Patients with cancer who are treated with chemotherapy or receive a bone marrow transplant have an increased risk of acquiring fungal infections."

( Gøtzsche, PC; Johansen, HK, 2014)

"Specific cellular immunotherapy for cancer requires efficient generation and expansion of cytotoxic T lymphocytes (CTLs) that recognize tumor-associated antigens."

( Maekawa, R; Nakatsura, T; Nieda, M; Takahara, M; Tomiyama, M; Yoshikawa, T, 2014)

"However, rhuEpo-treated cancer patients show decreased survival rates and erythropoietin receptor (EpoR) expression has been found in patient tumour tissue."

( Doleschel, D; Fuge, F; Gremse, F; Kiessling, F; Lederle, W; Mottaghy, F; Rix, A; Wessner, A; Winz, O, 2015)

"The use of TDF for the treatment of cancer pain is not associated with impairment in cognitive performance."

( Ali, A; Bilen, A; Turgut, N; Türkmen, A; Unlü, N, 2014)

"The enhancement of the anti-cancer effect of chemotherapy with application of concurrent hyperthermia was noticed more than thirty years ago."

( Hervault, A; Thanh, NT, 2014)

"Patients with advanced solid tumors (n = 24) received doxorubicin 60 mg/m(2) and escalating doses of pantoprazole (80, 160, 240 and 360 mg) administered intravenously prior to doxorubicin."

( Bedard, PL; Brana, I; Chen, EX; Douglas, S; Haines, C; Lee, C; Ocana, A; Razak, AR; Siu, LL; Tannock, IF; Wang, L, 2014)

"Hypoxic regions in tumors are known to be resistant to chemotherapy and radiotherapy."

( Saji, H; Ueda, M, 2014)

"The enhanced anticancer effect was also verified by an enhanced apoptosis and reduced tumor cell proliferation following the treatment with the targeted micellar paclitaxel both in vitro and in vivo."

( Gillespie, JW; Mei, LA; Parmar, CK; Petrenko, VA; Praveen, KP; Torchilin, VP; Wang, T; Yang, S, 2014)

"The treatment of most cancers is still inadequate, despite tremendous steady progress in drug discovery and effective prevention."

( Bukhari, SN; Jantan, I; Seyed, MA, 2014)

"Different cancer cells exhibit altered sensitivity to metformin treatment."

( Chan, DK; Haugrud, AB; Miskimins, WK; Zhuang, Y, 2014)

"Multi-drug resistance (MDR) to cancer chemotherapy is a major obstacle to the effective treatment of tumors."

( Hu, Y; Li, C; Li, H; Li, M; Shu, X, 2014)

"The association between cancer and use of biologic therapy among rheumatoid arthritis (RA) patients remains controversial."

( Chang, YT; Chen, CC; Chen, DY; Chen, YJ; Ho, HJ; Kuo, KN; Liu, HN; Shen, JL; Wu, CY, 2014)

"Successful cancer gene therapy is dependent upon the development of nanocarriers that exhibit anti-cancer effects via delivery of nucleic acids to the target site in tumor tissue."

( Hama, S, 2014)

"A total of 10 cancer patients with VTE treated with the LMWH enoxaparin at a standard dose of 1 mg/kg every 12 h were enrolled."

( Gabizon, AA; Na'amad, M; Nasser, NJ; Weinberg, I, 2015)

"However, among cancer patients, the literature is conflicting about the real impact of metformin on survival and outcomes of cancer treatments."

( Barroso-Sousa, R; Glasberg, J; Miranda, VC; Riechelmann, RP, 2014)

"Comparative analysis of different cancer patients helps the treating oncologist/dentist to identify patients with a more imminent risk to develop an ONJ (i."

( Felsenberg, D; Gabbert, TI; Hoffmeister, B, 2015)

"While LCS101 increased cell death in cancer cells exposed to doxorubicin and 5-FU, it showed a protective effect on non-tumorigenic human epithelial cells from chemotherapy-induced cell death."

( Berger, R; Cohen, Z; Maimon, Y; Samuels, N; Yang, P; Yoeli-Lerner, M, 2015)

"We examined the changes in fatigue when cancer patients experiencing fatigue while undergoing chemotherapy were administered levocarnitine chloride."

( Matsunaga, N; Nakagawa, Y; Yanagawa, K, 2014)

"These differences between cancer cells and normal cells can be targeted to develop effective cancer therapy."

( Husain, MA; Ishqi, HM; Nehar, S; Rehman, SU; Sarwar, T; Tabish, M; Zubair, H, 2015)

"When an anticancer drug that has been conjugated to an ELP is administered, and focal hyperthermia applied, the thermoresponsive properties and enhanced permeability and retention effects of the ELP facilitate drug aggregation within tumor tissues."

( Raucher, D; Ryu, JS, 2015)

"Thousands of cancer patients are currently in clinical trials evaluating antiangiogenic therapy in the neoadjuvant setting, which is the treatment of localized primary tumors prior to surgical intervention."

( Attwood, K; Burns, P; Cruz-Munoz, WR; Ebos, JM; Hudson, JM; Jedeszko, C; Kerbel, RS; Lee, CR; Mastri, M; Tracz, A, 2014)

"Patients with advanced solid tumors refractory to standard therapy were eligible."

( Falchook, GS; Fu, S; Hong, DS; Huang, M; Janku, F; Jiang, Y; Kurzrock, R; Lin, Q; Naing, A; Parkhurst, K; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, R, 2015)

"Eligibility included ovarian cancer resistant to prior platinum; breast cancer with ≥ three chemotherapy regimens for metastatic disease; pancreatic cancer with prior gemcitabine treatment; or prostate cancer with progression on hormonal and one systemic therapy."

( Audeh, MW; Balmaña, J; Bowen, K; Domchek, SM; Fielding, A; Fried, G; Friedlander, M; Hubert, A; Kaufman, B; Loman, N; Mitchell, G; Rosengarten, O; Schmutzler, RK; Shapira-Frommer, R; Steiner, M; Stemmer, SM, 2015)

"Records of 138 consecutive cancer patients treated in hospice in 2010 were studied regarding the drugs given during their stay."

( Koivu, L; Pölönen, T; Salminen, E; Stormi, T, 2014)

"The treatment of cancer during pregnancy is challenging because of the involvement of two individuals and the necessity of a multidisciplinary approach."

( Amant, F; Claes, L; Han, S; Van Calsteren, K; Vandenbroucke, T; Verheecke, M, 2014)

"We analyzed myocardial injury in cancer patients who underwent doxorubicin chemotherapy and generated a doxorubicin-induced neonatal rat cardiomyocyte injury model and a mouse heart failure model."

( Cao, Y; Huang, X; Li, J; Li, M; Man, Y; Ruan, Y; Shen, T; Wang, S; Yu, W; Zhu, Y, 2014)

"Patients with refractory solid tumors were treated in a 3 + 3 dose escalation design."

( Bendell, JC; Burris, HA; Esquibel, V; Infante, JR; Jones, SF; Kurkjian, CD; Levin, W; Moore, KN; Moreno, O; Pant, S; Patel, MR, 2015)

"Anthracyclines are powerful anticancer agents and among the most important tools in the chemotherapy armamentarium of medical oncologists."

( Gabizon, AA; Patil, YP; Tahover, E, 2015)

"Our study proposes SM13 as anticancer compound to use for the treatment of p53-dependent tumours, even in the absence of p53 transcriptional activity."

( Bertamino, A; Campiglia, P; Ciccarelli, M; De Luca, N; Del Giudice, C; Gomez-Monterrey, I; Iaccarino, G; Illario, M; Novellino, E; Sorriento, D; Trimarco, B, 2015)

"Dyspnoeic patients with advanced cancer satisfying the selection criteria received (IV) Fentanyl and were evaluated for response 24 hours post-administration in a prospective observational study."

( Pang, GS; Qu, LM; Tan, YY; Yee, AC, 2016)

"Since the discovery of its anticancer activity in 1970s, cisplatin and its analogs have become widely used in clinical practice, being administered to 40-80% of patients undergoing chemotherapy for solid tumors."

( Mezencev, R, 2015)

"We assessed the proportion of cancer patients with PE actually treated with LMWH and the duration of anticoagulant treatment in the Netherlands."

( Büller, HR; Di Nisio, M; Hutten, BA; Kamphuisen, PW; Kleinjan, A, 2014)

"Many examples of anticancer drugs as paclitaxel, combretastatin, bryostatin and discodermolide have shown the importance of NP in the anticancer chemotherapy through many years."

( Dall'Acqua, S, 2014)

"Angiogenesis is a key feature of cancer development, thus it is a good target for cancer therapy."

( Al-Hilal, TA; Alam, F; Byun, Y; Chung, SW; Kim, HS; Lee, DS; Mahmud, F; Park, J; Seo, D, 2015)

"When tested in rats bearing C6 tumors, the TEN concentration in the tumors treated by the nanosuspensions was more than 20 times than that by the TEN solution at 2h."

( Duan, L; He, S; Li, Y; Yang, H; Zhang, R, 2015)

"The major goal of cancer therapy is to destroy cancer cells without harming normal cells."

( Chan, B; Lee, J; Manley, J; Singh, SR, 2015)

"Traditional antimitotic drugs for cancer chemotherapy often have undesired toxicities to healthy tissues, limiting their clinical application."

( Li, J; Qian, W; Santana-Santos, L; Shuda, M; Sobol, RW; Van Houten, B; Wang, J, 2015)

"The treatment of malignancy can markedly increase exposure of patients to elevated toxic iron species without the need for excess iron input from transfusion."

( Berdoukas, V; Coates, TD; Mainous, AG; Puliyel, M, 2015)

"These criteria were applied to 201 cancer patients treated with WHO step III "strong" opioids for 21 days."

( Corli, O; Greco, MT; Montanari, M; Roberto, A, 2015)

"The mainstay of cancer pain management is systemic pharmacotherapy."

( Chandrasena, C; Schug, SA, 2015)

"We treated A2780 (ovarian cancer) and HCT-116 (colorectal cancer) cell lines with FK866 in the presence and absence of nicotinic acid."

( Dong, S; Kuo, MS; Nikolayev, A; Tolstikov, V; Zhao, G, 2014)

"Increased rates of solid organ cancers post-liver transplantation have been reported, but the contribution of environmental factors and immunosuppressive therapy is not clear."

( Assenat, E; Bismuth, M; Carenco, C; Chanques, G; Danan, G; Duny, Y; Faure, S; Herrero, A; Jaber, S; Larrey, D; Navarro, F; Pageaux, GP; Ursic-Bedoya, J, 2015)

"Seventy-nine cancer patients (67 glioma and 12 solid tumor) enrolled in a first-in-human dose study and received the TGF-β inhibitor LY2157299 monohydrate (LY2157299) as monotherapy (n = 53) or in combination with lomustine (n = 26)."

( Azaro, A; Baselga, J; Carducci, M; Cleverly, AL; Corretti, M; Dolan, M; Fernández, MS; Gueorguieva, I; Kovacs, RJ; Lahn, MM; Maldonado, G; Pillay, NS; Romero, FL; Sepulveda-Sánchez, JM, 2015)

"The decision for a patient with cancer to start heparin therapy for survival benefit should balance the benefits and downsides, and should integrate the patient's values and preferences."

( Akl, EA; Ballout, RA; Barba, M; Bryant, A; Kahale, LA; Middeldorp, S; Schünemann, H; van Doormaal, FF; Yosuico, VE, 2014)

"Understanding oxygen fluctuation in a cancerous tumor is important for effective treatment, especially during radiotherapy."

( Hara, D; Ito, T; Kawasaki, A; Son, A; Tanabe, K, 2015)

"Relapsed small cell lung cancer (SCLC) has limited treatment options."

( Badve, S; Borghaei, H; Einhorn, L; Hanna, N; Jalal, SI; Koneru, K; Masters, GA; Prasad, N; Somaiah, N; Wu, J; Yu, Z; Zon, R, 2017)

"Several forms of skin cancer are successfully treated with the topical drug Imiquimod, which activates pDCs through toll-like receptor 7 engagement."

( Khaiboullina, SF; Lombardi, VC; Rizvanov, AA, 2015)

"Photodynamic therapy (PDT) of tumors causes skin photosensitivity as a result of unspecific accumulation behavior of the photosensitizers."

( Epple, M; Gräfe, S; Haedicke, K; Hilger, I; Kozlova, D; Teichgräber, U, 2015)

"This cross-sectional study included 109 cancer patients who had taken prescribed opioid analgesics for cancer-related pain in the past week and completed the Opioid-Taking sSelf-Efficacy Scale and European Organization for Research and Treatment of Cancer Quality of Life Group Questionnaire."

( Ding, SA; Liang, SY; Lin, CC; Liu, CY; Wu, WW, 2015)

"The study population comprised cancer patients whose first admission to a hospital for initial cancer treatment was in 2004."

( Chang, WP; Lin, CC, 2015)

"Amongst all the different treatments of cancer such as surgery, chemotherapy and radiation therapy, surgical resection is the most effective."

( Durfee, R; Kairdolf, B; Ren, J; Venugopalan, J; Wang, MD; Xu, J, 2014)

"Successful management of solid tumors in children requires imaging tests for accurate disease detection, characterization, and treatment monitoring."

( Daldrup-Link, HE; Donig, J; Link, M; Quon, A; Rosenberg, J; Uslu, L, 2015)

"The health burden related to cancer treatment will increase as this population expands and ages."

( Colan, SD; Franco, VI; Lipshultz, SE; Miller, TL; Sallan, SE, 2015)

"Many cancer patients receive supplemental ascorbate (vitamin C) in the belief that it synergizes the anticancer effects of chemotherapy and reduces its toxicity."

( Clemons, M; Hutton, B; Jacobs, C; Ng, T; Shorr, R, 2015)

"Investigating the molecular changes of cancer cell nucleus with drugs treatment is crucial for the design of new anticancer drugs, the development of novel diagnostic strategies, and the advancement of cancer therapy efficiency."

( Chang, Y; Huang, D; Li, H; Liang, C; Liang, L; Wang, H; Xu, S; Xu, W; Yang, YW, 2015)

"A total of 120 cancer patients was randomly divided into two groups, 60 patients took orally morphine sulfate sustained-release tablets in group A, and another 60 patients receiving the combination treatment of intravenous flurbiprofen axetil and opioid drugs in group B."

( Gao, JF; Ou, WL; Rao, ZG; Wang, J; Wang, ZG; Wu, TT; Yang, B; Yao, GQ; Zhang, BC, 2014)

"A promising strategy in anticancer therapy to overcome the resistance to certain antiangiogenic therapies is the tumor blood vessel normalization, which restores the physiological perfusion and oxygenation of tumor vasculature."

( Giraudo, E; Maione, F, 2015)

"Further characterization of tumors sensitive to MEK inhibitors holds great promise for optimizing drug therapy for patients with these tumors."

( Imoto, M; Kiga, M; Murakami, R; Nakanishi, T; Nakayama, A; Sasazawa, Y; Shikata, Y; Tashiro, E, 2015)

"Their impact in treatment of cancer, viral infections and cardiovascular diseases is discussed."

( Bryszewska, M; Majoral, JP; Mignani, S; Shakhbazau, A; Shcharbin, D; Shcharbina, N, 2015)

"Orthotopic patient-derived pancreatic cancer xenografts treated biweekly with gemcitabine via the device for 7 weeks experienced a mean log2 fold change in tumor volume of -0."

( Anders, CK; Bickford, LR; Brooks, CR; Byrne, JD; Darr, D; Deal, A; DeSimone, JM; Hyder, N; Jajja, MR; Keeler, AW; Lee, W; Little, RE; Luft, JC; Moffitt, RA; Napier, ME; Nelson, M; O'Neill, AT; Stack, C; Stack, R; Tepper, JE; Wagner, K; Wang, AZ; Yeh, JJ; Zamboni, WC, 2015)

"Because of increased incidence of cancer and the development of resistance after treatment with typical drugs, new insights into the mechanisms of action of individual compounds are extremely valuable."

( Marczak, A; Rogalska, A, 2015)

"Platinum compounds are a mainstay of cancer chemotherapy, with over 50% of patients receiving platinum."

( Johnstone, TC; Lippard, SJ; Suntharalingam, K, 2015)

"Using human breast cancer explants, in vitro cell lines, mouse in vivo studies and mathematical modelling, here we show that exposure to a taxane induces phenotypic cell state transition towards a favoured transient CD44(Hi)CD24(Hi) chemotherapy-tolerant state."

( Dhawan, A; Goldman, A; Goldman, D; Kohandel, M; Majumder, B; Majumder, PK; Ravi, S; Sengupta, S, 2015)

"Patient with cancer achieve the best pain control, and chronic obstructive pulmonary disease patients are the least likely to have their pain adequately treated."

( Babington, L; Beauchene, M; Romem, A; Scharf, SM; Tom, SE, 2015)

"Patients with cancer-related cachexia were treated with olanzapine (doses ranging from 2."

( Abdelrahim, M; Dalal, S; Falchook, GS; Fu, S; Hess, K; Hong, DS; Ilustre, A; Janku, F; Kurzrock, R; Naing, A; Ouyang, F; Wheler, J, 2015)

"Assumed cancer free patients, after cancer directed therapy (CDT), were assessed on the basis of a questionnaire developed by the investigators."

( Kaur, J; Mohanti, BK, 2015)

"The response to chemotherapy in cancer patients is frequently compromised by drug resistance."

( Aricioglu, RZ; Baumann, U; Borowski, SH; Bräutigam, M; Griesbeck, AG; Neudörfl, JM; Pietsch, M; Schenk, T; Sheikh, M; Teusch, N, 2015)

"By TUNEL immunofluorescent staining of tumors after NIR laser irradiation, we found that the co-therapy showed more apoptotic tumor cells than the other groups."

( Li, H; Li, W; Liao, J; Peng, J; Qian, Z; Wei, Y; Yang, Q; Zhang, X, 2015)

"Hypoxia in solid tumors is one of the seminal mechanisms for developing aggressive trait and treatment resistance in solid tumors."

( Krohn, KA; Rajendran, JG, 2015)

"Moreover, stratified by cancer site, treatment with carvedilol in the carvedilol cohort resulted in significantly lower incidence of stomach and lung cancers than in the noncarvedilol cohort."

( Kao, CH; Lin, CL; Lin, CS; Lin, WS, 2015)

"Many tumors exploit NO for survival and growth signaling, and also to thwart the effects of therapeutic treatments, including PDT."

( Girotti, AW, 2015)

"For the treatment of colon cancer patients with anti-EGFR-based drugs, the KRAS mutation status has to be determined to pre-select responders that will benefit from this medication."

( Chen, Y; Cialla-May, D; Clement, JH; Petersen, I; Pollok, S; Popp, J; Steinbach, C; Steinbrücker, C; Walther, K; Weber, K, 2015)

"Many patients with cancer experience moderate to severe pain that requires treatment with strong opioids, of which oxycodone and morphine are examples."

( Arnold, S; Bennett, MI; Bromham, N; Hilgart, JS; Schmidt-Hansen, M, 2015)

"Multidrug resistance (MDR) in cancer cells is a substantial limitation to the success of chemotherapy."

( Artzi, N; Conde, J; Oliva, N, 2015)

"We retrospectively reviewed adult cancer patients treated with cisplatin ≥60mg/m2 for at least four consecutive chemotherapy cycles from August 2011 to November 2013."

( Andrajati, R; Prasaja, Y; Sutandyo, N, 2015)

"This may limit further advances in cancer immunotherapy."

( Abbott, R; Belikoff, B; Cannici, R; Hatfield, SM; Jackson, EK; Karger, B; Kjaergaard, J; Ko, K; Kutok, JL; Lukashev, D; Ohta, A; Philbrook, P; Podack, ER; Rodig, S; Schreiber, TH; Sethumadhavan, S; Sitkovsky, MV; Thayer, M, 2015)

"Ascites accompanying a malignancy is often refractory to conventional treatment with saline diuretics, making it difficult to control."

( Akiyama, T; Aoki, Y; Hosokawa, I; Kato, A; Kawamoto, J; Kuboki, S; Mitsuhashi, N; Miyazaki, M; Nemoto, S; Nishino, H; Ohtsuka, M; Sasaki, K; Satoh, Y; Shimazaki, R; Shimizu, H; Shimizu, Y; Teranaka, R; Ueda, A; Yoichi, T; Yoshitomi, H, 2015)

"The hMFI-20 was administered to 200 cancer patients."

( Chandel, P; Choudhary, V; Khan, KA; Parganiha, A; Sultan, A, 2015)

"Radiofrequency (RF)-assisted cancer therapy is well-known in the medical field as it is non-hazardous and can penetrate tissues, enabling a deeply rooted cancer treatment."

( Jayakumar, R; Kim, YC; Rejinold, NS, 2015)

"Only 21% of VCF treated cancer patients had a strict contraindication to anticoagulation therapy."

( Brunson, A; Ho, G; White, R; Wun, T, 2015)

"Refractory cancer pain that does not respond to standard opioid and/or co-analgesic therapy occurs in 10-20 % of patients."

( Afsharimani, B; Good, P; Hardy, J; Kindl, K, 2015)

"technologies used in the field of Anticancer research at a level of drug discovery, development, diagnosis and treatment, which are illustrated in the form of novel substantive patent landscape maps."

( Dara, A; Sangamwar, AT, 2015)

"History of patients, including site of cancer, chemotherapy regime and dose of chemotherapy, was recorded."

( Jaffri, SA; Javaid, A; Munir, I; Nawaz, MK; Qazi, MH, 2015)

"Thus, sarcopenia in cancer patients with excessive fat mass (FM), entitled sarcopenic obesity, has gained greater relevance in clinical practice; it can negatively influence patients' functional status, tolerance to treatments & disease prognosis."

( Almeida, A; Pappalardo, G; Ravasco, P, 2015)

"We performed a subanalysis of cancer patients enrolled in a clinical trial that compared long-term (6 months) treatment with a low-molecular-weight heparin (LMWH) administered subcutaneously or with acenocoumarol."

( Colomé Nafría, E; Martí Mestre, X; Romera-Villegas, A; Vila Coll, R, 2015)

"An insight into the complex cancer pathophysiology reveals that a dependable amelioration of the disease could only be envisaged with a multipronged treatment approach."

( Iqbal, Z; Khuroo, T; Talegaonkar, S; Verma, D, 2015)

"CYP1B1 is recognized as a new target in cancer prevention and therapy."

( Cui, J; Cui, Q; Li, S; Meng, Q; Zhang, X; Zhou, W, 2015)

"Sex-dependent differences, ethnicity, cancer types and 5-FU-based chemotherapy regimens might affect the heterogeneity of genetic variants for predictive 5-FU-related toxicity."

( Lenz, HJ; Matsusaka, S, 2015)

"The increased risk of cancer associated with low levels of HDL cholesterol, low LDL cholesterol levels plus low triglyceride levels, and low levels of LDL cholesterol plus albuminuria can be reduced by treatment with metformin, renin-angiotensin system (RAS) inhibitors and statins, respectively."

( Chan, JC; Lee, HM; Yang, X, 2015)

"Many patients with cancer experience moderate to severe pain that requires treatment with strong analgesics."

( Arnold, S; Bromham, N; Hilgart, JS; Schmidt-Hansen, M; Taubert, M, 2015)

"Thus, DC-based cancer immunotherapy represents a powerful strategy."

( Gong, J; Ito, Z; Kajihara, M; Koido, S; Ohkusa, T; Takakura, K, 2015)

"To kill urothelial cancer cells while preserving healthy cells, this study used photothermal therapy (PTT)."

( Chen, CH; Chen, JJ; Wu, YJ, 2015)

( Feng, D; Hu, Y; Norton, JA; Tsung, K; Zhang, L, 2015)

"Traditional therapy for cancer is subject to some evident obstacles, including low effectiveness, resistance, systemic complication, etc."

( Cen, X; Fei, W; Jiang, Y; Liang, X; Tang, Y, 2015)

"Recommendations for management of cancer-related venous thromboembolism (VTE) in patients already receiving anticoagulant therapy are based on low-quality evidence."

( Ageno, W; Cheung, YW; de Sancho, M; Debourdeau, P; Falanga, A; Gallus, A; Hulegårdh, E; Kamphuisen, P; Le Gal, G; Lecumberri, R; Lee, A; Linkins, L; Molnar, S; Ortel, TL; Pasca, S; Ranta, S; Rigamonti, V; Schulman, S; Zondag, M, 2015)

"Patients with cancer and VTE despite anticoagulant therapy were reported to the registry."

"Although cisplatin is a widely used anticancer drug for treating various types of cancer, its clinical application is limited by severe systemic toxicities, such as nephropathy, hematologic toxicity, and gastrointestinal toxicity."

( Aiba, K; Arakawa, Y; Eto, S; Matsumoto, A; Nishikawa, K; Sakuyama, T; Tamura, M; Tanaka, Y; Yuda, M, 2015)

"Treatment of HER2(+) SK-BR-3 and BT-474 cancer cells with αPEG:αHER2 and the clinically used chemotherapeutic agent PEGylated liposomal doxorubicin for 3 hours enhanced the in vitro effectiveness of PEGylated liposomal doxorubicin by over two orders of magnitude."

( Burnouf, PA; Chen, BM; Cheng, TL; Chuang, KH; Huang, WC; Roffler, SR; Su, YC; Tung, HY; Yan, YT, 2015)

"In molecular-targeted cancer therapy, acquired resistance to gemcitabine is a major clinical problem that reduces its effectiveness, resulting in recurrence and metastasis of cancers."

( Bae, SJ; Kim, JK; Kim, SY; Kwon, K; Lee, YS; Noh, YH; Ryu, SW, 2015)

"Recent clinical trials in cancer therapy have demonstrated unprecedented responses through blockade of CTLA-4 and PD-1 immune checkpoint pathways."

( Horton, MR; Leone, RD; Powell, JD, 2015)

"In breast cancer patients, methylation of the SOX11 promoter was shown to correlate with estrogen receptor status, suggesting that SOX11 may be functionally re-expressed during treatment with HDAC inhibitors in specific patient subgroups."

( Andersson, E; Ek, S; Guldberg, P; Gustavsson, E; Holm, K; Kuci, V; Nordström, L; Ringnér, M, 2015)

"Patients suffering from cancer are often treated with a range of chemotherapeutic agents, but the treatment efficacy varies greatly between patients."

( Bødker, JS; Bøgsted, M; Dybkær, K; El-Galaly, TC; Falgreen, S; Johnsen, HE; Kjeldsen, MK; Laursen, MB; Nyegaard, M; Schmitz, A; Xu-Monette, ZY; Young, KH, 2015)

"The experience of cancer involves a significant series of treatment decisions."

( Davies, J; Hannigan, B; Kelly, D, 2015)

"For HT-1080 tumors, neither the treatments with FA-CPT-NDs nor those with the NDs lacking folate presented tumor growth inhibition."

( Chen, RC; Chen, WT; Kang, ST; Lin, JL; Wang, CH; Yeh, CK, 2015)

"Dihydroartemisinin (DHA) exhibits anticancer activities in a variety of cancer cells, but DHA alone are not effective enough for cancer therapy."

( Chen, SS; Hu, W; Lou, XE; Wang, Z; Zhou, HJ, 2015)

"The advent of cancer nanomedicine has forged new pathways for the enhanced imaging and treatment of a broad range of cancers using new classes of materials."

( Ho, D, 2015)

"Current anticancer chemotherapy relies on a limited set of in vitro or indirect prognostic markers of tumor response to available drugs."

( Baselga, J; Cima, MJ; Fuller, JE; Jonas, O; Landry, HM; Langer, R; Santini, JT; Tepper, RI, 2015)

"Furthermore, we show that treatment of cancer cells with Salinomycin under starvation conditions not only increases the apoptotic caspase activity, but also diminishes the protective autophagy normally triggered by the treatment with Salinomycin alone."

( Hallbeck, AL; Jain, MV; Jangamreddy, JR; Lotfi, K; Roberg, K; Łos, MJ, 2015)

"A polyelectrolyte microcapsule-based, cancer-targeting, and controlled drug delivery system has been developed as a multifunctional theranostic agent for synergistic cancer treatment."

( Chen, D; Chen, H; Di, Y; Gu, Y; Madrid, K; Tang, L; Tian, C; Zhang, M, 2015)

"Projections of cancer cases are particularly useful in developing countries to plan and prioritize both diagnostic and treatment facilities."

( Krishnan, SK; Ramnath, T; Shah, VP, 2015)

"Thus, both efficient cancer cell diagnostics and selective photoacoustic treatment can be realized with a single-particle formulation."

( Chen, Q; Wen, L; Xiang, L; Xing, D; Yang, S; Zhong, J, 2015)

"Repeated cancer treatments are common, owing to the aggressive and resistant nature of tumors."

( Chen, HL; Chia, WT; Chiu, YL; Chuang, EY; Hsiao, CW; Korupalli, C; Liao, ZX; Lin, KJ; Sung, HW; Wan, D, 2015)

"The treatment of cancer associated thrombosis is based on the use of low-molecular weight heparin for at least three to six months."

( Meyer, G, 2015)

"Photodynamic cancer therapy (PDT) uses non-toxic chemotherapeutic agents, photosensitizer (PS), to initiate a light-dependent and ROS-related cell death."

( Abrahamse, H; Mfouo-Tynga, I, 2015)

"A clinically useful PEGylated anticancer prodrug, MTX-PEG, was also developed as a tumor cell-specific targeting ligand for self-targeted cancer treatment."

( Hou, Z; Li, Y; Lin, C; Lin, J; Luo, F; Wu, H; Xie, L; Yu, F; Zhou, S, 2015)

"Various types of anticancer agents are used for its treatment, but unfortunately none of them is able to treat the cancer."

( Bhaskar, A; Chandra, S; Kumar, A; Kumar, M; Mukhopadhyay, K; Sasmal, D; Sharma, N, 2015)

"One possible reason is existence of cancer stem cells, which have self-renewal activity and resistance to chemotherapy and radiotherapy."

( Doi, T; Shitara, K, 2015)

"Oral, cervical and breast cancers, which are either preventable and/or amenable to early detection and treatment, are the leading causes of cancer-related morbidity and mortality in India."

( Anderson, BO; Basu, P; Belinson, JL; Bhatla, N; D'Cruz, A; Dhillon, PK; Gupta, PC; Jhulka, PK; Joshi, N; Kailash, U; Kapambwe, S; Katoch, VM; Kaur, P; Kaur, T; Krishnan, S; Mathur, P; Mehrotra, R; Prakash, A; Rajaraman, P; Sankaranarayanan, R; Selvam, JM; Seth, T; Shah, KV; Shastri, S; Siddiqi, M; Sivaram, S; Srivastava, A; Trimble, E, 2015)

"For many years, research on anticancer therapy has focussed almost exclusively on targeting cancer cells directly, to selectively kill them or restrict their growth."

( Abma, E; Daminet, S; de Rooster, H; Ni, Y; Smets, P, 2017)

"Pain remains a serious consequence of cancer and its treatment."

( Bruera, E; Paice, JA, 2015)

"Six patients, with solid tumors and thrombocytopenia that limits chemotherapy treatment, received eltrombopag during the study and it was observed a decrease in the delay of chemotherapy cycles (4."

( Cerezuela Fuentes, P; García Coronel, M; García Lagunar, MH; Gutiérrez-Meca Maestre, DP; Martínez Ortiz, MJ; Martínez Penella, M, 2015)

"The illumination of the tumors during PET imaging provoked a net decrease of (18)FDG uptake in tumors treated with AlPcS4 and a near total absence of (18)FDG uptake in tumors treated with ZnPcS2."

( Bentourkia, M; Boubacar, P; Lecomte, R; Sarrhini, O; van Lier, JE, 2015)

"The toxicity and cancer therapy effect of H-TiO2 -PEG NPs are relative systemically evaluated in vitro and in vivo."

( Brown, EM; Chen, G; Gong, A; Ren, W; Schaaf, P; Shi, Z; Wang, D; Wu, A; Yan, Y; Yu, H; Zeng, L; Zhao, J; Zou, B, 2015)

"In vivo, the tumors in mice were visualized using T1-weighted imaging after administration of the liposome."

( Chen, S; Li, H; Liu, M; Ren, L; Ye, C; Zhang, Z; Zhou, X, 2015)

"Human ovarian cancer cells (A2780), the corresponding cisplatin resistant cells (A2780cisR), and human embryonic kidney cells (HEK-293) were each incubated for 24 h and 72 h with [1](6+) and compared to untreated cells."

( Diserens, G; Furrer, J; Paul, LE; Vermathen, M; Vermathen, P, 2015)

"However, cancer gene therapy has been challenged by the inherent limitation of vectors that are able to deliver therapeutic genes to tumors specifically and efficiently following systemic administration."

( Asavarut, P; Hajitou, A; Lee, EL; Suwan, K; Syed, N; Yata, T, 2015)

"The highly effective anticancer agent doxorubicin (Dox) is a frontline drug used to treat a number of cancers."

( Jean, SR; Kelley, SO; Liyanage, SU; Riganti, C; Schimmer, AD; Tulumello, DV, 2015)

"Applications of biomaterials in cancer therapy has been limited to drug delivery systems and markers in radiation therapy."

( Premnath, P; Tan, B; Venkatakrishnan, K, 2015)

"Suicide gene therapy of cancer (SGTC) entails the introduction of a cDNA sequence into tumor cells whose polypeptide product is capable of either directly activating apoptotic pathways itself or facilitating the activation of pharmacologic agents that do so."

( Medin, JA; Nakagawa, R; Neschadim, A; Sato, T; Yanagisawa, T, 2015)

"There were 1 colon cancer patient, 1 retroperitoneal liposarcoma, 1 renal oncocytoma, 3 Kaposi sarcoma patients treated with cyclosporine; in those treated with Tac there were 1 basal cell carcinoma, 1 Kaposi sarcoma, 2 thyroid carcinoma, 1 breast carcinoma, 1 bladder carcinoma, 1 renal cell carcinoma, and 1 colon carcinoma patients."

( Ata, P; Demir, T; Eriş, C; Gökçe, AM; Kara, M; Özdemir, E; Ozel, L; Titiz, MI, 2015)

"Six hundred three cancer patients, treated with FL, have been retrospectively tested for eight DPYD polymorphisms (DPYD-rs3918290, DPYD-rs55886062, DPYD-rs67376798, DPYD-rs2297595, DPYD-rs1801160, DPYD-rs1801158, DPYD-rs1801159, DPYD-rs17376848) for association with Grade ≥3 toxicity, developed within the first three cycles of therapy."

( Berretta, M; Buonadonna, A; Cecchin, E; De Paoli, A; Dreussi, E; Gagno, S; Giodini, L; Lo Re, G; Lonardi, S; Mini, E; Miolo, G; Montico, M; Nobili, S; Pella, N; Roncato, R; Scalone, S; Toffoli, G, 2015)

"Taxanes are anti-cancer agents used to treat several types of solid tumours."

( de Bruijn, P; de Graan, AJ; de Jonge, E; Mathijssen, RH; Sparreboom, A; van der Holt, B; van Schaik, RH; Verweij, J; Wiemer, EA, 2015)

"Enhanced anticancer efficacy was demonstrated through the synergistic combination of promoted drug release upon ultraviolet (UV) light irradiation and photothermal therapy upon infrared (IR) irradiation."

( Gu, Z; Ligler, FS; Lu, Y; Mishra, SR; Mo, R; Neupane, B; Pacardo, DB; Rikard, SM; Tracy, JB; Wang, G, 2015)

"RBCs from cancer patients exhibited increased sensitivity to the prothrombotic effects of vitamin C, reflecting that intravenous gram-dose vitamin C therapy needs to be carefully revisited."

( Bae, ON; Chung, JH; Kang, S; Kim, I; Kim, K; Koh, SH; Lim, KM; Noh, JY; Shin, S, 2015)

"Many anticancer drugs have been proved effective against cancer cells as well as toxic to human tissues, which prevents sufficient doses from being administered to obtain a complete cure."

( Jiang, Z; Liu, R; Shen, Z; Wang, P; Yao, Y; Zhu, J, 2015)

"Immunotherapy as a treatment for cancer holds the promise of complete and durable tumor remission, yet the immunosuppressive environment created by many tumors, advanced patient age, and previous treatments with cytotoxic agents may limit the approach."

( Bryan, JK; Cohen, PA; Dietsch, GN; Gottardo, R; Hershberg, RM; Manjarrez, KL; Newkirk, M; Northfelt, DW; Ramanathan, RK; Randall, TD, 2015)

"The ability to selectively destroy cancer cells while sparing normal tissue is highly desirable during the cancer therapy."

( Bao, T; Dong, X; Gu, Z; Ma, X; Tian, G; Wang, Z; Yin, W; Yu, J; Zhang, X; Zhao, Y; Zheng, X, 2015)

"(1) In November 2011, 400 patients with cancer undergoing treatment at the University Medical Center Utrecht were surveyed to determine their use of fish oil supplements; 118 patients responded to the questionnaire (30%); (2) pharmacokinetic analysis of the 16:4(n-3) content of 6 fish oils and 4 fishes was carried out; (3) from April through November 2012, a healthy volunteer study was performed to determine 16:4(n-3) plasma levels after intake of 3 different brands of fish oil or 4 different fish species."

( Cirkel, GA; Daenen, LG; Gerrits, J; Houthuijzen, JM; Huitema, AD; Ishihara, K; Oosterom, I; Roodhart, JM; van Tinteren, H; Verhoeven-Duif, NM; Voest, EE, 2015)

"Currently, the use of nano silicon in cancer therapy is limited as drug delivery vehicles and markers in imaging, not as manipulative/controlling agents."

( Premnath, P; Tan, B; Venkatakrishnan, K, 2015)

"In particle therapy of hypoxic tumors, it may also be beneficial to redistribute the linear energy transfer (LET) so that the oxygen effect is minimized; so-called LET painting."

( Malinen, E; Søvik, Å, 2015)

"Notably, by screening cancer cell lines for growth defects after exposure to 5hmdC, we unexpectedly identify a subset of cell lines in which 5hmdC or 5fdC administration leads to cell lethality."

( Berridge, G; Goldin, R; Kessler, BM; Kriaucionis, S; Pugh, KM; Thézénas, ML; Zauri, M, 2015)

"Photodynamic therapy (PDT) is a cancer treatment modality in which a photosensitizing dye is administered and exposed to light to kill tumor cells via the production of reactive oxygen species (ROS)."

( Kanada, M; Okazaki, S; Terakawa, S; Yan, L; Zhang, J, 2015)

"This would support the model that cancer represents a revision back to ancient forms of life adapted to high fitness under extreme stress, and suggests that these ancient genes may be targets for cancer therapy."

( Austin, RH; Bussey, K; Davies, PC; Gatenby, RA; Khin, Z; Kim, HJ; Lambert, G; Pourmand, N; Sturm, JC; Wu, A; Zhang, Q, 2015)

"Novel biomarkers for cancer diagnosis and therapy selection are urgently needed to facilitate early detection and improve therapy outcomes."

( Gjerset, RA; Zhao, M, 2015)

"Due to increased numbers of young cancer patients and improved survival, the impact of anticancer treatments on fertility has become a major health concern."

( Ben-Aharon, I; Hasky, N; Levi, M; Shalgi, R; Stemmer, SM, 2015)

"We used treatment studies of implanted tumors in mice to demonstrate that the same inhibitory cells that abrogated an acute therapeutic T-cell response to established tumor did not inhibit the therapeutic response produced by memory T-cells."

( Bergman, I; Gao, Y; Whitaker-Dowling, P, 2015)

"The systematic administration of cancer targeting CMCs loaded with doxorubicin hydrochloride can significantly inhibit tumor growth in mouse xenografts, with significantly reduced toxicity compared to free drug."

( Gao, JQ; Han, LJ; Mao, ZW; Peng, LH; Wang, XR; Wu, JH; Zhang, CZ; Zhang, YH, 2015)

"The Hokusai VTE-cancer study is a randomised, open-label, clinical trial to evaluate whether edoxaban, an oral factor Xa inhibitor, is non-inferior to LMWH for treatment of VTE in patients with cancer."

( Beyer-Westendorf, J; Bleker, SM; Boda, Z; Büller, HR; Carrier, M; Chlumsky, J; Décousus, H; Di Nisio, M; Garcia, D; Gibbs, H; Grosso, MA; Kakkar, A; Kamphuisen, PW; Mercuri, MF; Monreal, M; Ockelford, P; Pabinger, I; Raskob, GE; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Weitz, JI, 2015)

"Integration of cancer cell imaging and therapy is critical to enhance the theranostic efficacy and prevent under- or overtreatment."

( Ju, H; Lei, J; Liu, J; Zhang, L, 2015)

"We included patients with cancer aged 18 years or older, who had not received moderately or highly emetogenic chemotherapy before, with a Karnofsky performance score of 60 or higher, and a predicted life expectancy of 4 months or longer."

( Arora, S; Chasen, MR; Gridelli, C; Modiano, MR; Navari, RM; Poma, A; Rapoport, BL; Schnadig, ID; Schwartzberg, LS; Urban, L, 2015)

"We enrolled patients with cancer aged 18 years or older, who had not previously been treated with cisplatin, with a Karnofsky performance score of 60 or higher, and a predicted life expectancy of 4 months or longer."

( Arora, S; Chasen, MR; Gridelli, C; Kansra, V; Modiano, MR; Navari, RM; Poma, A; Rapoport, BL; Schnadig, ID; Schwartzberg, LS; Urban, L, 2015)

"Efficacy of cancer pharmacotherapy depends upon drug exposure to the body and responsiveness of the tumor to the drug treatment."

( Tanigawara, Y, 2015)

"The subsequent photothermal therapy of cancer in vivo was achieved without inducing any observed side effects."

( Dai, Z; Jing, L; Li, Y; Liu, R; Peng, D; Tian, J, 2015)

"Adult patients with active cancer (defined as histologic diagnosis of cancer and receiving anticancer therapy or diagnosed with, or received such therapy, within the previous 6 months) and objectively documented proximal deep vein thrombosis (DVT) or pulmonary embolism, with a life expectancy greater than 6 months and without contraindications for anticoagulation, were followed up for 180 days and for 30 days after the last study medication dose for collection of safety data."

( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015)

"We retrospectively reviewed all cancer patients in whom anidulafungin treatment was immediately preceded by treatment with caspofungin and there existed clinical or laboratory evidence of hepatic damage or dysfunction at M."

( Jiang, Y; Jung, DS; Kontoyiannis, DP; Tverdek, FP, 2015)

"Photodynamic therapy (PDT) against cancer has gained attention due to the successful outcome in some cancers, particularly those on the skin."

( Bonavida, B; Della Pietra, E; Rapozzi, V, 2015)

"A large proportion of cancer deaths are preventable through early detection but there are a range of social, emotional, cultural and financial dimensions that hinder the effectiveness of cancer prevention and treatment efforts."

( Bumb, D; Dey, S; Dhillon, PK; Govil, J; Gupta, A; Krishnan, S, 2015)

"Immunotherapy of cancer is a promising therapeutic approach which aims to eliminate malignancies by inducing or enhancing an immune response against the tumor."

( Amidi, M; Fransen, MF; Hennink, WE; Kleinovink, JW; Ossendorp, F; Rahimian, S, 2015)

"Common adverse symptoms of cancer and chemotherapy are a major health burden; chief among these is pain, with opioids including transdermal fentanyl the mainstay of treatment."

( Barratt, DT; Dale, O; Kaasa, S; Klepstad, P; Somogyi, AA, 2015)

"Patients with advanced solid tumors or lymphoma were enrolled in a 3+3 dose escalation design with birinapant administered intravenously from 0."

( Adjei, AA; Amaravadi, RK; Graham, MA; Levin, M; Martin, LP; Schilder, RJ; Weng, DE, 2015)

"Then, the form of death of human cancer cells induced by treatment with biologically active phospholipids (BAPs) preparation was investigated."

( Chmelik, R; Collakova, J; Dostal, Z; Kollarova, V; Krizova, A; Slaba, M; Vesely, P, 2015)

"By 24h post-treatment, treated tumors appeared less condensed with widening of the stromal areas which increased at 48 and 72h."

( Beachy, SH; Fetterly, GJ; Gibbs, JF; Hylander, BL; Pitoniak, R; Prey, JD; Qiu, J; Repasky, EA; Sen, A; Ullas, S, 2015)

"Self-assembly of anticancer small molecules into nanostructures may represent an attractive approach to improve the treatment of experimental solid tumors."

( Fan, M; Li, Z; Liang, X; Shi, B; Wang, H; Yang, D, 2015)

"Olaparib is used to treat BReast CAncer susceptibility protein (BRCA)-associated, platinum-sensitive ovarian cancer."

( Cohen, AF; Goulooze, SC; Rissmann, R, 2016)

"In MGH-U3 bladder cancer xenografts, which contain both AKT1(E17K) and FGFR3(Y373C) mutations, AZD5363 monotherapy did not significantly reduce tumor growth, but tumor regression was observed in combination with the FGFR inhibitor AZD4547."

( Crafter, C; D'Cruz, CM; Davies, BR; Dudley, P; Guan, N; Hanson, L; Jacobs, V; Jacques, K; James, N; Jenkins, EL; Kodaira, M; Ladd, B; Lindemann, J; Logie, A; Tamura, K; Zinda, M, 2015)

"Further, DendGDP had improved anticancer activity when compared with doxorubicin or DendDP in an in vivo CT26 tumor xenograft model, ie, the volume of the CT26 tumor xenograft was significantly inhibited when compared with xenografts treated with doxorubicin or DendDP nanoparticles."

( Jeong, YI; Kang, DH; Lee, HC; Lee, SG; Lee, SJ; Oh, JS; Park, HK, 2015)

"The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected."

( Ashrani, A; Bockenstedt, PL; Chesney, C; Eby, C; Engh, AM; Fanikos, J; Fenninger, RB; Fogerty, AE; Gao, S; Goldhaber, SZ; Hendrie, P; Holmstrom, B; Kuderer, N; Lee, A; Lee, JT; Lovrincevic, M; McMillian, N; Millenson, MM; Neff, AT; Ortel, TL; Paschal, R; Shattil, S; Siddiqi, T; Smock, KJ; Soff, G; Streiff, MB; Wang, TF; Yee, GC; Zakarija, A, 2015)

"The different types of cancer, heterogeneity of populations and presence of comorbidity make it difficult to determine the benefits of metformin in cancer prevention and treatment."

( Cazzaniga, M; DeCensi, A; Dunn, BK; Gorlero, F; Lazzeroni, M; Provinciali, N, 2015)

"An ideal drug delivery system for cancer therapy should be equipped with extended circulation, improved tumor targeting and controlled drug release, as well as low toxicity from the carrier."

( Chen, D; Cheng, L; Hu, Q; Hu, W; Xu, M; Zhang, L; Zhu, Y, 2015)

"Although diverse cancer cell types are sensitive to oncolytic viruses, one of the major challenges of oncolytic virotherapy is that the sensitivity to oncolysis ranges among different cancer cell types."

( Cai, J; Chen, W; Fu, L; Gao, G; Hu, J; Li, K; Li, Y; Liang, J; Lin, Y; Lu, B; Mai, J; Qiu, J; Qiu, P; Su, X; Tai, PW; Tan, Y; Tang, L; Wang, F; Xiao, X; Xing, F; Yan, G; Yan, M; Yin, W; Zhang, H; Zhu, W, 2016)

"Although advances in cancer treatment have improved the 5-year survival rates, the same treatments, such as anthracyclines, that cure cancer also increase the risk for adverse cardiovascular effects."

( Franco, VI; Lipshultz, SE, 2015)

"Treatment options for treating cancer cachexia are limited."

( Criscitiello, C; Curigliano, G; Di Leo, M; Esposito, A; Gelao, L; Liuzzi, R; Locatelli, M; Massaro, M; Milani, A; Minchella, I; Pravettoni, G, 2015)

"Importantly, in several types of cancer HO-1/CO system exerts opposite activities, making the possible treatment more complicated."

( Dulak, J; Jozkowicz, A; Loboda, A, 2015)

"Forty-one patients with advanced solid tumors received single-dose LY monotherapy lead-in and 37 patients received LY (10-120 mg) plus pemetrexed/carboplatin (500 mg/m(2) and 5-6 AUC, respectively) across 8 dose levels every 21 days."

( Brail, LH; Burris, HA; Chow, KH; Cooksey, JF; Farrington, DL; Gray, JE; Infante, JR; Jackson, KA; Jones, SF; Simon, GR; Yeo, A; Zamek-Gliszczynski, MJ, 2015)

"More than 50% of all cancer patients receive radiation therapy."

( Berbeco, RI; Biancur, DE; Cameron, L; Detappe, A; Ireland, T; Kumar, R; Kunjachan, S; Makrigiorgos, GM; Motto-Ros, V; Sancey, L; Sridhar, S, 2015)

"Rhein is a potential cancer treatment agent."

( Bian, Y; Cao, H; Dong, S; Li, J; Liu, P; Sun, L; Sun, M; Sun, R; Wu, C; Xue, J; Zhou, H, 2017)

"Patients with documented cancers for whom erlotinib therapy was appropriate received erlotinib 150 mg orally once daily plus navitoclax 150 mg orally once daily, with navitoclax dose escalation via a continuous reassessment method model."

( Arzt, J; Busman, TA; Holen, KD; Kirschbrown, W; Lian, G; LoRusso, P; Rosen, LS; Rudersdorf, NS; Tolcher, AW; Vanderwal, CA, 2015)

"Nanosponges in cancer therapy, particularly cyclodextrin based nanosponges are brought up in this review."

( Bhosale, RR; Hani, U; Kulkarni, PK; Osmani, RA; Shanmuganathan, S, 2017)

"Biomedical imaging-guided cancer therapy should have capabilities of both accurate tumor diagnosis and high therapeutic efficacy for the personalized treatment."

( Chang, JH; Kang, J; Kim, H; Kim, J; Lee, H; Moon, H; Sim, C, 2015)

"In vivo cancer treatment study further uncovered that WS2:Gd(3+)-PEG could not only convert NIR light into heat for photothermal therapy (PTT) but also enhance the ionizing irradiation-induced tumor damage to boost radiation therapy (RT)."

( Cheng, L; Gong, H; Liu, Z; Shen, S; Yang, K; Yi, X; Yuan, C, 2015)

"In an area of limited successes in cancer therapy, our translation will pave the road to design stimulus environment responsive targeted PTT agents for the safe eradication of devastating cancer."

( In, I; Jeong, JH; Kim, SH; Lee, JE; Park, SY; Sharker, SM, 2015)

"Current cancer chemotherapy lacks specificity and is limited by undesirable toxic side-effects, as well as a high rate of recurrence."

( Boothman, DA; Gao, J; Huang, G; Huang, X; Ma, X; Moore, ZR, 2015)

"It possesses anti-cancer and anti-inflammatory activities in vitro and in vivo, and offers therapeutic benefits for treatment of metabolic syndromes."

( Chu, W; Liu, Y; Wei, P; Wei, T; Zhang, B, 2015)

"As an investigational cancer treatment, Toca 511 preferentially infects cancer cells without direct cell lysis and encodes an enhanced yeast cytosine deaminase that converts the antifungal drug 5-fluorocytosine to the anticancer drug, 5-fluorouracil."

( Burrascano, C; Diago, OR; Hogan, DJ; Ibanez, CE; Jolly, DJ; Ostertag, D; Twitty, CG, 2016)

"Advances in cancer immunotherapy in the pediatric field are needed in order to improve the prognosis of children with malignancies."

( Ammori, Y; Inoue, M; Ishihara, T; Kawa, K; Kondo, O; Koyama-Sato, M; Kuwae, Y; Nishikawa, M; Oji, Y; Oka, Y; Sawada, A; Sugiyama, H; Tsuboi, A; Yamada-Nakata, K; Yasui, M, 2016)

"The anticancer efficacy of these bio-inspired multifunctional smart magnetic nanoparticles was tested both in vitro and in vivo and found that these unique magnetic nanoplatforms can be established to endow for the next generation of nanomedicine for efficient and safe cancer therapy."

( GhavamiNejad, A; Jeong, YY; Kim, CS; Moon, M; Park, CH; Sasikala, AR; Thomas, RG; Unnithan, AR, 2015)

"Photodynamic therapy (PDT) is a cancer treatment modality that requires three components, namely light, dioxygen and a photosensitizing agent."

( Acherar, S; Barberi-Heyob, M; Boura, C; Chaimbault, P; Frochot, C; Gazzali, AM; Kamarulzaman, EE; Sibille, E; Vanderesse, R; Wahab, HA, 2015)

"The recurrence of colorectal cancer after chemotherapy is the leading cause of its high mortality."

( Deng, S; Gao, J; Guan, W; Han, W; Wang, X; Wu, M; Ye, H; Yu, Y; Zhang, Y; Zhu, S, 2015)

"Use of kinase inhibitors in cancer therapy leads invariably to acquired resistance stemming from kinase reprogramming."

( Chen, Y; Ding, J; Geng, M; Huang, M; Shen, A; Shen, YY; Sun, J; Wang, L; Wang, X; Yang, X, 2015)

"In this study, when CT26 and LL2 mouse cancer cells were treated with 6-nm anatase titanium dioxide NPs (TDNPs) without ultraviolet irradiation, oxidative stress and induction of inflammatory cytokines were observed."

( Fujii, K; Fujiwara, R; Kuniyasu, H; Luo, Y; Ohmori, H; Sasaki, T, 2015)

"In addition, the non-cancer and cancer risks, as well as the occupational exposure cancer risk, for workers exposed to emitted VOCs in workshop were reduced dramatically after the integrated technique treatment."

( An, T; Chen, J; Hu, Y; Huang, Y; Li, G; Li, Y, 2016)

"Unspecified cancer type and staging, fluctuated dose information and variants of targets across studies of berberine/ Coptidis Rhizoma impede their clinical use for cancer treatment."

( Feng, Y; Li, L; Tan, HY; Wang, N; Yuen, MF, 2015)

"Metabolic reprogramming renders cancer cells dependent on specific metabolic enzymes or pathways that could be exploited in cancer therapy."

( Baltazar, F; Granja, S; Martinho, O; Pinheiro, C; Reis, RM, 2015)

"The orthotopic liver cancer mice were established as deep-seated tumor model to investigate the anti-tumor effect of mitochondria-targeting TA therapy."

( Ding, W; Wen, L; Xing, D; Yang, S, 2016)

"All treated cancer cells showed significant (P<0."

( Abasi, M; Abbasi, MM; Akbarzadeh, A; Jahanban-Esfahlan, R; Sani, HM, 2015)

"Because tumors and other proliferating cells tend to exhibit a higher level of PpIX than normal cells after ALA incubation, ALA has been used as a prodrug to enable PpIX fluorescence detection and photodynamic therapy (PDT) of lesion tissues."

( Chen, B; Kraus, D; Palasuberniam, P; Yang, X, 2015)

"Anemia is a common issue in cancer patients and is largely undertreated with sub-optimal diagnoses of cause."

( Jang, JH; Jung, CW; Kim, K; Kim, SJ; Kim, WS; Park, S, 2015)

"The finding may open a new era in cancer therapy."

( Chen, B; Dai, W; He, B; Song, Q; Sun, J; Wang, X; Wang, Z; Zhang, H; Zhang, Q, 2016)

"Platinum-based anticancer drugs have been becoming one of the most effective drugs for clinical treatment of malignant tumors for its unique mechanism of action and broad range of anticancer spectrum."

( Chen, J; Dong, P; Fei, F; Gao, CZ; Wang, TS; Yang, B; Zhang, Y; Zhang, YJ, 2015)

"To explore further effects of cancer metabolism and epigenetic deregulation, DNA repair kinetics were examined in cells treated with metabolic intermediates, oncometabolites, and/or metabolic inhibitors by tracking resolution of double-strand breaks (DSB) in irradiated MCF7 breast cancer cells."

( Efimova, EV; Kozmin, SA; Kron, SJ; Labay, E; Shamsi, NA; Takahashi, S; Ulanovskaya, OA; Weichselbaum, RR; Wu, D, 2016)

"Response Evaluation Criteria In Solid Tumors (RECIST) evaluation after 3 cycles of therapy (27 patients) showed partial response in one (ovarian cancer), and stable disease in 18 patients."

( Alvfors, C; Berglund, Å; Gullbo, J; Hagberg, H; Harmenberg, J; Jerling, M; Lewensohn, R; Lisyanskaya, A; Nordström, E; Nygren, P; Orlov, S; Ringbom, M; Söderlind, K; Spira, J; Tholander, B; Ullén, A, 2015)

"The emerging roles of miRNAs in cancer-related inflammation and the potential to target miRNA signaling pathways for cancer therapy are also discussed."

( Guo, L; Huang, F; Li, J; Wang, S; Zhang, L; Zhang, Y, 2016)

"Photodynamic therapy (PDT)-generated cancer vaccine represents an attractive potential application of PDT, therapeutic modality destroying targeted lesions by localized photooxidative stress."

( Banáth, J; Korbelik, M; Saw, KM, 2015)

"To optimize synergistic cancer therapy, we rationally assemble an inorganic-organic nanocomplex using a folate-modified lipid bilayer spread on photosensitizer-entrapped mesoporous silica nanoparticle (MSN) coated gold nanorods (AuNRs)."

( Fei, J; Li, J; Qin, C; Wang, A; Yang, Y, 2015)

"Radiotherapy is a key component of cancer treatment."

( Caster, JM; Foote, M; Hyder, SN; Lara, H; Saripalli, S; Sethi, M; Tian, X; Wagner, KT; Wang, AZ; Wang, E; Zhang, L, 2015)

"Major current cancer strategies like surgery, radiotherapy, and chemotherapy are compromised due to major problem of recurrence, which usually lead to mortality."

( Li, H; Shi, AM; Tao, ZQ; Wang, YQ; Zhao, J, 2015)

"In p53-mutant tumors, cell cycle checkpoints are rewired, leading to dependency on the p38/MK2 pathway to survive DNA-damaging chemotherapy."

( Braun, CJ; Cameron, ER; Cannell, IG; Grant, RA; Hemann, MT; Merrick, KA; Morandell, S; Tsao, MS; Yaffe, MB; Zhu, CQ, 2015)

"The management and treatment of cancer-associated VTE are particularly challenging and, in many cases, are not guided by a high level of evidence."

( Ageno, W; Donadini, MP; Squizzato, A, 2016)

"There was no overall difference in cancer incidence by diabetes therapy (p = 0."

( Aragaki, AK; Chen, C; Chlebowski, RT; Gong, Z; Hou, L; Kuller, LH; LaMonte, MJ; LeBlanc, ES; Luo, J; Manson, JE; Rohan, TE; Tinker, LF; Vitolins, MZ; Wactawski-Wende, J, 2016)

"Studies have suggested increased cancer incidence associated with long-term dual antiplatelet therapy (DAPT) for acute coronary syndrome (ACS)."

( Armstrong, PW; Beaven, AW; Blackwell, KL; Cyr, DD; Eckart, D; Fox, KA; Houterloot, L; Morse, MA; Ohman, EM; Onken, JE; Prabhakaran, D; Ready, NE; Roe, MT; Schulte, PJ; Strickler, JH; White, HD; Winters, KJ; Wiviott, SD; Zafar, SY; Zamoryakhin, D, 2016)

"Multi-targeted prevention of cancer has emerged as a new paradigm for effective anti-cancer treatment."

( Khan, M; Ma, T; Maryam, A; Mehmood, T; Zhang, H, 2016)

"The treatment of cancer often fails due to the development of multidrug resistant (MDR) cancer cells."

( Boros, IM; Igaz, N; Kiricsi, M; Kónya, Z; Kovács, D; Madarász, D; Molnár, J; Rázga, Z; Spengler, G; Szőke, K; Tóth, T, 2016)

"Five hundred forty-one cancer patients receiving chemotherapy and experiencing fatigue (Brief Fatigue Inventory [BFI] item 3 of ≥3) were randomized to receive 200 mg modafinil (n = 260) or placebo (n = 281) daily from baseline (cycle 2) to posttest (cycle 4)."

( Conley, CC; Dakhil, S; Gross, H; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Palesh, OG; Peppone, LJ; Scalzo, AJ, 2016)

"Patients with cancer of the brain (n = 39), lung (n = 41), colon (n = 15) or pancreas (n = 17) were included before initiation of antitumor therapy."

( Ay, C; Kaider, A; Marosi, C; Pabinger, I; Quehenberger, P; Reitter, EM; Zielinski, C, 2016)

"The efficacy of radiotherapy on tumors is hampered by its devastating adverse effects on healthy tissue, particularly that of the gastrointestinal tract."

( Caz, V; de Miguel, E; Elvira, M; Grande, AG; Largo, C; Lopez-Plaza, B; Santamaria, M; Tabernero, M, 2015)

"The clinical response of 9 cancer patients of differing stages to the regular administration of large doses (25-100 g/d) of intravenous vitamin C (IVC; ascorbic acid) is outlined."

( Glenda, CS; Meng, LK; Raymond, YC, 2016)

"Finally, tested in a panel of cancer cells, the water-soluble form of 3a, compound 8, displayed antiproliferative effects in the range of 8-35 μM and increased H4K16 deacetylation, suggesting a possible role for SIRT1 activators in cancer therapy."

( Altucci, L; Atlante, S; Budriesi, R; Carafa, V; Carnevale, I; Cencioni, C; Del Bufalo, D; Gabellini, C; Gaetano, C; Mai, A; Mellini, P; Moniot, S; Nebbioso, A; Polletta, L; Saladini, S; Spallotta, F; Steegborn, C; Tafani, M; Tardugno, M; Trisciuoglio, D; Valente, S; Zwergel, C, 2016)

"In this study, mice with FaDu tumors were treated with the antibody therapy cetuximab or the chemotherapy cisplatin and imaged in vivo two days after treatment."

( Diggins, KE; Irish, JM; Shah, AT; Skala, MC; Walsh, AJ, 2015)

"However, the escape from senescence and cancer cell repopulation give rise to some doubts concerning the effectiveness of the senescence-induced anticancer therapy."

( Alster, O; Mosieniak, G; Piechota, M; Sikora, E; Sliwinska, MA; Strzeszewska, A; Sunderland, P; Was, H, 2015)

"We suppose that the anti-cancer treatment of solid tumours and leukaemias requires different types of drug conjugates."

( Cerny, V; Chytil, P; Etrych, T; Kabesova, M; Kovar, M; Pola, R; Rihova, B; Rossmann, P; Sirova, M; Strohalm, J; Tomala, J; Tomalova, B; Ulbrich, K, 2016)

"The nanococktail can actively target tumors via specific interaction of hyaluronic acid (HA) with CD44 receptors and respond to HAase-rich tumor microenvironment to induce intracellular cascade reaction for controlled therapy."

( Chen, WH; Cheng, SX; Feng, J; Hong, S; Lei, Q; Luo, GF; Qiu, WX; Wang, SB; Zeng, X; Zhang, XZ; Zheng, DW; Zhu, CH, 2016)

"Development of drug resistance to anticancer drugs is an important challenge for cancer treatment."

( Abnous, K; Hanafi-Bojd, MY; Jaafari, MR; Malaekeh-Nikouei, B; Ramezanian, N, 2016)

"MCF-7 breast cancer cells treated with curcumin were measured for 18F-fluorodeoxyglucose (18F‑FDG) uptake, lactate production, hexokinase activity, oxygen consumption rate (OCR), ROS production and mitochondrial membrane potential (MMP)."

( Cho, YS; Choe, YS; Jung, KH; Lee, JH; Lee, KH; Moon, SH; Park, JW, 2016)

"Anti-cancer treatments markedly improved the prognosis of patients, but unfortunately might be hampered by cardiotoxicity."

( Brunelli, C; Carbone, F; Di Iorio, C; Gigli, L; Montecucco, F; Nencioni, A; Rosa, GM; Tagliasacchi, MI, 2016)

"Cardiotoxicity of anti-cancer treatments is associated with development of heart failure."

( Brunelli, C; Carbone, F; Di Iorio, C; Gigli, L; Montecucco, F; Nencioni, A; Rosa, GM; Tagliasacchi, MI, 2016)

"As a result, radiotherapy of tumors with the 29 nm probe was the most potent."

( Cai, J; Cheng, D; Li, X; Liu, S; Shi, H; Su, H; Yang, Y; Zhang, C; Zhang, J; Zhang, L; Zhang, Y, 2016)

"Then, we have reported cancer preventive and treatment effects of polyphenols, especially focused in the green tea polyphenol (GTP) (-)-Epigallocatechin-3-gallate (EGCG)."

( Colomer, R; Lupu, R; Puig, T; Sarrats, A, 2017)

"Normal and cancerous ascites model rats were taken as the research objects and orally administered with different doses of vinegar-processed Kansui Radix for 7 d."

( Cao, LL; Ding, AW; Dou, ZH; Wang, WX; Wang, YH; Zhang, L, 2015)

"Patients (Pts) with advanced cancers were treated once (QD) or twice daily (BID) with escalating doses."

( Breazna, A; Bruce, JY; Goncalves, PH; Heath, EI; Liu, G; LoRusso, PM; Ricart, AD; Sadowski, E; Shalinsky, DR; Tortorici, M; Traynor, AM; Zhang, Y, 2016)

"To compare subsequent skin cancer formation in a mixed-organ cohort of OTRs who were or were not treated with sirolimus after developing a posttransplant index cancer of any type."

( Azzi, JR; Heher, EC; Hills, VM; Karia, PS; Schmults, CD, 2016)

"How to ablate tumors without using skin-harmful high laser irradiance remains an ongoing challenge for photothermal therapy."

( Gao, F; Hu, K; Liu, D; Piao, JG; Wang, L; Xiong, Y; Yang, L, 2016)

"Among different cytokines used for cancer immunotherapy, interleukin-12 (IL-12) has shown great ability as a powerful antitumor and antiangiogenic agent."

( Dehshahri, A; Keykhaee, M; Khalvati, B; Sadeghpour, H; Sheikhsaran, F, 2016)

"Unfortunately, many cancers initially respond to platinum treatment but when the tumor returns, drug resistance frequently occurs."

( Amable, L, 2016)

"The cardiotoxic effects of adjuvant cancer treatments (i."

( Ade, CJ; Black, CD; Brown, M; Caldwell, J; Didier, KD; Ederer, AK; Hardy, R; Larson, RD; Reiter, LK, 2016)

"In the clinic, patients with solid tumors that had progressed or failed to respond to previous therapies were treated with once-daily ASP9853 in combination with docetaxel once every 3 weeks to assess safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D) of the combination."

( Arai, Y; Dmuchowski, C; Fakhoury, A; Infante, JR; Krivoshik, A; LoRusso, P; Luke, JJ; Schuster, R; Shapiro, GI; Yamazaki, T, 2016)

"Therefore, in cancer treatment, both SWNT + LV pulse treatment followed by the injection of LIPO-DOX® and SWNT/DOX + LV pulse treatment can increase tumor inhibition and delay tumor growth."

( Lee, PC; Peng, CL; Shieh, MJ, 2016)

"Children with cancer or Langerhans cell histiocytosis who were receiving treatment or had completed therapy were eligible."

( Goldman, S; Haertling, T; Lai, JS; Rademaker, AW; Weinstein, J, 2016)

"The detection of cancer cells is extremely important for early diagnosis and clinical treatments."

( Chen, J; Chen, S; Cui, J; Gao, L; Li, H; Xu, P, 2016)

"Lenalidomide has synergistic anticancer effects when used with chemotherapy."

( Falchook, G; Fu, S; Hong, DS; Naing, A; Piha-Paul, S; Said, R; Tsimberidou, AM; Wheler, JJ; Ye, Y, 2016)

"Feasible treatment protocols for tumors that are diagnosed late and have grown to a relatively large size were identified."

( Finley, SD; Soto-Ortiz, L, 2016)

"Treatment of PC-3 prostate cancer cells with the most potent compound led to appreciable cell cycle arrest at a G1/G0 phase and cell apoptosis induction."

( Chen, C; Chen, G; Chen, QH; Wang, G; Wang, R; Zhang, Q; Zhang, X; Zheng, S; Zhong, Q, 2016)

"The unique survival kinetics of cancer immunotherapy was captured in the longitudinal predictions of the final analysis times."

( Chen, TT, 2016)

"Synergistic effects of anticancer drug and siRNA have displayed superior advantages for cancer therapy."

( Cao, H; Cheng, Q; Dong, A; Du, L; Han, S; Huang, Y; Liang, XJ; Liang, Z; Meng, L; Song, X; Wang, X; Wei, T; Wu, Y; Zheng, S; Zhou, J, 2016)

"Thus, metformin is emerging as a new cancer therapy or adjuvant anticancer drugs."

( Liu, KX; Xue, CJ, 2015)

"Participants were 303 consecutive adult cancer patients undergoing chemotherapy in an academic medical center."

( Atiliyana, MA; Beng, TS; Chan, CM; Fuang, HG; Thiagarajan, M; Yahaya, NA, 2016)

"Patients with advanced solid tumors were treated with 100 mg/m(2) irinotecan on days 1 and 8 of a 21-day cycle."

( Bell, T; Boerner, JL; Boerner, SA; Bowditch, A; Burger, A; Cai, D; Chen, AP; Cleary, JM; Ferry-Galow, K; Heilbrun, LK; Ji, J; Kinders, RJ; Li, J; LoRusso, PM; Marrero, AM; Parchment, RE; Pilat, MJ; Rubinstein, L; Sausville, EA; Shapiro, GI; Smith, D; Tolaney, SM; Wolanski, A; Zhang, J; Zhang, Y, 2016)

"We screened cancer patients' tumors for FA functional defects then aimed to establish the safety/feasibility of administering PARP inhibitors as monotherapy and combined with a DNA-breaking agent."

( Bekaii-Saab, T; Chen, A; Duan, W; Ji, J; Lustberg, M; Marshall, J; Rose, J; Schaaf, LJ; Shilo, K; Thurmond, J; Timmers, C; Villalona-Calero, MA; Westman, JA; Xiaobai, L; Zhao, W, 2016)

"The Warburg effect, which reflects cancer cells' preference for aerobic glycolysis over glucose oxidation, contributes to tumor growth, progression and therapy resistance."

( Cai, Q; Charles, S; Fu, X; Jin, Y; Kamarajugadda, S; Lim, S; Lu, J; Shenoy, AK; Tan, M; Tarrash, M; Trevino, JG; Zhang, Y, 2016)

"The anticancer activity of red ginseng is significantly increased, due to the production of active anticancer ginsenosides during the steaming treatment, compared with that of white ginseng."

( Anderson, S; DU, W; He, TC; Wang, CZ; Yuan, CS, 2016)

"Widely used anti-cancer treatments involving chemotherapeutic drugs result in cancer cell damage due to their strong interaction with DNA."

( Hepel, M; Hughes, T; Ilkhani, H; Li, J; Zhong, CJ, 2016)

"The severe cytotoxicity of cancer chemotherapy drugs limits their clinical applications."

( Chang, P; Gao, J; Huang, L; Liu, J; Qi, C; Shuai, X; Tao, K; Wang, G; Wang, L; Wang, Z; Xu, L, 2016)

"Colon26 tumors inoculated in the right shoulder were clearly visualized by SPECT 24h after administration."

( Homma, T; Kanazaki, K; Makino, A; Ono, M; Saji, H; Sano, K; Takahashi, A; Yamauchi, F, 2016)

"Timely and accurate diagnosis of cancer is crucial to cancer treatment."

( Chen, Y; Chu, PK; Guan, M; Li, Q; Li, W; Li, Y; Li, Z; Pan, H; Tong, L; Wang, H; Yu, XF; Zhang, W; Zhao, Y, 2016)

"Radiotherapy, a common cancer treatment, often adversely affects the surrounding healthy tissue and/or cells."

( Chen, HP; Chen, MH; Liu, TY; Tung, FI, 2016)

"Many therapies are available in cancer treatment such as chemotherapy, radiotherapy etc."

( Coşkun, GP; Küçükgüzel, ŞG, 2016)

"Taxane-type anticancer drugs, including paclitaxel and its semi-synthetic derivatives docetaxel and cabazitaxel, are widely applied to chemotherapy of malignancy like breast cancer, ovarian cancer, non-small cell lung cancer and prostate cancer."

( Chen, XX; Gao, F; Qu, XX; Tian, XC; Wang, D; Wen, G; Zhou, XL, 2016)

"Cancer site, cancer stage≥2, liver metastasis, chemotherapy, progesterone, being underweight or obese, hospitalization/nursing home confinement, CV catheter, and infection are independent risk factors for incident VTE in active cancer patients."

( Ashrani, AA; Bailey, KR; Gullerud, RE; Heit, JA; Marks, RS; Petterson, TM, 2016)

"In human neoplasms, miR-493-3p and Mad2 expression alterations correlated with advanced ovarian cancer forms and high miR-493-3p levels were associated with reduced survival of ovarian and breast cancer patients with aggressive tumors, especially in the paclitaxel therapy arm."

( Cárpen, O; Chen, P; Davidson, B; Elgaaen, BV; Hautaniemi, S; Huhtinen, K; Kallio, MJ; Lønning, PE; Mäki-Jouppila, J; Pruikkonen, S; Straume, AH; Tambe, M, 2016)

"The recognition of cancer cells is a key for cancer diagnosis and therapy, but the specificity highly relies on the use of biorecognition molecules particularly antibodies."

( Chen, HY; Liu, Z; Shen, X; Wang, S; Wang, W; Yin, D; Zhu, JJ, 2016)

"A total of 122 newly diagnosed cancer patients with seven cancer types were studied prior to their initial therapy."

( Gagnon, B; MacDonald, N; Murphy, J; Penafuerte, CA; Sirois, J; Tremblay, ML, 2016)

"Selective inhibition of cancer cells remains a challenge in chemotherapy."

( Du, X; Xu, B; Yamagata, N; Zhou, J, 2016)

"Treatment of MLH1-methylated colon cancer cell lines with the demethylating agent 5'-aza-2'-deoxycytidine induces the expression of MLH1 and sensitizes cancer cells to 5-fluorouracil."

( Gao, D; Guo, M; Herman, JG, 2016)

"The issue of multidrug resistance (MDR) cancer is one of the major barriers to successful chemotherapy treatment."

( Chiang, YC; Hsieh, YW; Hung, CC; Sheu, MJ; Teng, YN; Wang, RY, 2016)

"The efficacy of cancer drugs is often limited because only a small fraction of the administered dose accumulates in tumors."

( Blanco, E; Chen, L; Deng, X; Ensor, JE; Ferrari, M; Hu, Z; Huang, Y; Koay, E; Liu, H; Liu, J; Liu, X; Mai, J; Segura-Ibarra, V; Shen, H; Shen, J; Wu, S; Xu, R; Zhang, G, 2016)

"MSNs application in the field of cancer treatment has now become a hot research field of medicine."

( Han, FM; Liu, XQ; Mo, S; Wang, JY; Wang, ZM; Zhang, HM, 2015)

"During the irradiation, the cancer cells treated with 0."

( Araki, N; Hayashida, Y; Ikeda, Y; Kakehi, Y; Kato, T; Kawai, K; Sawada, K, 2016)

"The success of cancer treatment depends on the response to chemotherapeutic agents."

( Daglioglu, C; Okutucu, B, 2016)

"Patients with cancers of differing histologies that express certain biomarkers are likely to benefit from treatment with targeted therapies."

( Blay, JY; Buzyn, A; Cailliot, C; Deley, MC; Hoog-Labouret, N; Jimenez, M; Nowak, F; Pérol, D; Raynaud, J; Vassal, G, 2016)

"Since so many cancer patients consume amygdalin, and many clinicians administer it without clear knowledge of its mode of action, current knowledge has been summarized and the pros and cons of its use weighed."

( Blaheta, RA; Haferkamp, A; Juengel, E; Nelson, K, 2016)

"Ovarian cancer spheroids initially showed a decreased proliferation and after 14 days increased cell viability upon lycopene treatment, confirming the potential of lycopene to reduce cancer cell growth in short-term cultures and also indicate enhanced cell viability over prolonged exposure."

( Champ, S; Clements, JA; Feldthusen, J; Holzapfel, BM; Holzapfel, NP; Hutmacher, DW; Kaemmerer, E; Loessner, D; Rausch, T; Theodoropoulos, C, 2016)

"Patients with malignant tumors receiving chemotherapy, who had an intermediate risk of TLS or a high risk of TLS and were not scheduled to be treated with rasburicase, were enrolled and then randomized to febuxostat (60 mg/day) or allopurinol (300 or 200 mg/day)."

( Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T, 2016)

"The goal here is to detect and treat cancer cells by near-infrared fluorescence (NIRF) imaging and PDT synchronously."

( Fu, L; Jing, T; Liu, L; Ruan, Z; Yan, L, 2016)

"Chemotherapy is one of the major cancer treatment strategies, and it functions by targeting the physiological capabilities of cancer cells, including sustained proliferation and angiogenesis, the evasion of programmed cell death, tissue invasion and metastasis."

( Li, W; Liu, T; Liu, X, 2016)

"Noteworthy, cancer therapy is frequently hampered by drug resistance, which is also often associated with enhancement of tumor aggressiveness."

( Berger, W; Cichna-Markl, M; Englinger, B; Grillari, J; Heffeter, P; Körner, W; Kryeziu, K; Mohr, T; Pirker, C; Spitzwieser, M; Tav, K; van Schoonhoven, S; Weinmüllner, R, 2016)

"The anticancer activity of DDC is dependent on complexation with copper to form copper bis-diethyldithiocarbamate (Cu(DDC)2), a highly insoluble complex that has not been possible to develop for indications requiring parenteral administration."

( Anantha, M; Backstrom, I; Bally, MB; Chen, K; Edwards, K; Leung, A; Malhotra, A; Wehbe, M, 2016)

"Finding a smart cancer drug delivery carrier with long blood circulation, enhanced cancer targeting, and quick drug release in tumors is critical for efficient cancer chemotherapy."

( Chu, L; Deng, L; Dong, A; Huang, F; Huang, P; Liu, J; Liu, Q; Sun, Y; Yang, C; Zhang, Y; Zhou, J, 2016)

"In this paper we mainly report the anti-cancer effects of emodin according to the studies of the past five years, including four parts such as inhibit tumor growth, inhibit migration and invasion, enhance the efficacy of combination therapy, increase chemosensitivity and attenuated side effects."

( Lin, WF; Ling, CQ; Wang, C, 2015)

"Venous thromboembolism (VTE) and cancer are strongly associated, and present a major challenge in cancer patient treatment."

( Tieken, C; Versteeg, HH, 2016)

"The anticoagulant treatment of VTE in cancer patients is less effective with a three-fold increased risk of VTE recurrence compared to non-cancer patients, and it is less safe with more than double rates of major bleeding."

( Bauersachs, RM, 2016)

"A major goal of cancer nanotherapy is to use nanoparticles as carriers for targeted delivery of anti-tumour agents."

( Bjørkøy, A; de Lange Davies, C; Duivenvoorden, R; Fay, F; Fayad, ZA; Goode, B; Hak, S; Manuel Perez-Aguilar, J; Mulder, WJ; Pérez-Medina, C; Sanchez-Gaytan, BL; Weinstein, H; Zhao, Y, 2016)

"Treatment options for cancer patients have changed considerably in recent years with the introduction of variable gene mutation and targeted therapy."

( Guo, Z; Lloyd, RV, 2016)

"Platinum-based anticancer drugs play a central role in current cancer therapy."

( Cheng, Q; Liu, Y, 2017)

"Moreover, its potential value in cancer immunotherapy is also discussed in this work."

( Jin, H; Li, H; Sun, L, 2016)

"Anemia in patients with malignancy is common as a consequence of their disease and treatment."

( Carson, JL; Roubinian, N, 2016)

"Children on chemotherapy for solid tumors should be routinely screened for B19V infection by both serology and PCR."

( Gupta, S; Jain, A; Jain, P; Kant, R; Khan, DN; Kumar, A; Prakash, S; Seth, A, 2016)

"Oral agents for treatment of breast cancer include capecitabine, lafatinib, and palbociclib."

( Mann, J; Stein, J, 2016)

"Photodynamic therapy (PDT) of cancer is known for its limited number of side effects, and requires light, oxygen and photosensitizer."

( Esteves da Silva, JC; Magalhães, CM; Pinto da Silva, L, 2016)

"However, clinical success in cancer therapy remains elusive, mainly owing to suboptimal in vivo delivery of RNAi therapeutics such as small interference RNA (siRNA) to tumors."

( Bhasin, S; Farokhzad, OC; Ha, E; Li, Q; Liu, Y; Shi, J; Wu, J; Xu, X; Yu, M; Zhao, L; Zhu, X, 2016)

"can be exploited for cancer prevention and treatment."

( Burkard, M; Busch, C; Lauer, UM; Leischner, C; Pfeiffer, MM; Venturelli, S, 2016)

"Radiosensitizers are used in cancer therapy to increase the γ-irradiation susceptibility of cancer cells, including radioresistant hypoxic cancer cells within solid tumors, so that radiotherapy can be applied at doses sufficiently low to minimize damage to adjacent normal tissues."

( Ide, S; Kojima, S; Nakanishi, Y; Nishino, K; Tanamachi, K; Tanuma, S; Tsukimoto, M, 2016)

"Treating cancer is one of the big challenges of this century and it has become evident that single chemotherapeutic treatment is rarely effective."

( Lehr, T; Menche, D; Müller, R; Schneider, LS; Ulrich, M; von Schwarzenberg, K, 2016)

"Although treatments for cancer-related anorexia do exist, patients have sought complementary and alternative medicine including herbal remedies, due to safety concerns."

( Cheon, C; Huang, CW; Jang, BH; Ko, SG; Ko, Y; Park, S; Park, YL; Shin, YC, 2016)

"The NCI Cancer Therapy Evaluation Program sponsors hepatic dysfunction phase I clinical trials (HDCT) and phase 1 clinical trials (P1CT) to determine safe doses and schedules of antineoplastic therapeutics."

( Harris, PJ; Ivy, SP; Mansfield, AS; Rudek, MA; Smith, GL; Vulih, D, 2016)

"Adults with metastatic cancer were treated on 21-day cycles with alisertib (10, 20, 30, or 40 mg) twice daily on days 1 to 7 or days 1 to 5 and with docetaxel (75 or 60 mg/m(2) ) on day 1."

( Graff, JN; Hahn, NM; Higano, CS; Leonard, EJ; Sarantopoulos, J; Taylor, MH; Venkatakrishnan, K; Zhang, B; Zhou, X, 2016)

"In many cancers, aberrant Notch activity has been demonstrated to play a role in the initiation and maintenance of the neoplastic phenotype and in cancer stem cells, which may allude to its additional involvement in metastasis and resistance to therapy."

( Astudillo, L; Capobianco, AJ; Da Silva, TG; Han, X; Jin, K; Landgraf, R; Lee, E; Lopes, PE; MacKerell, AD; Neitzel, LR; Oashi, T; Orton, D; Robbins, DJ; VanWye, J; Wang, Z; Weaver, K; Zhu, X, 2016)

"In comparison, tumors treated with 2."

( Ackerman, SE; Chen, R; Cochran, JR; Currier, NV; Filsinger Interrante, M; Kintzing, JR; Sato, AK; Steiner, A, 2016)

"We describe a customizable approach to cancer therapy in which a gold nanoparticle (Au-NP) delivers a drug that is selectively activated within the cancer cell by the presence of an mRNA unique to the cancer cell."

( Gordon, DJ; Gordon, PM; Gossai, NP; Li, NS; Naumann, JA; Piccirilli, JA; Zamora, EA, 2016)

"Anaemia is common in cancer patients, with treatments including epoetins and blood transfusions."

( Douros, A; Garbe, E; Jobski, K; Kollhorst, B; Schink, T, 2016)

"Cohort members were incident cancer patients receiving first time treatment with epoetin or transfusion."

( Douros, A; Garbe, E; Jobski, K; Kollhorst, B; Schink, T, 2016)

"The treatment of pain associated with cancer should be tailored to the patient's personal preferences."

( de Graeff, A; Dijkstra, D; Jongen, JL; Mostovaya, I; van den Beuken-van Everdingen, MH; Vissers, KC, 2017)

"Conventional cancer treatment methods suffer from many limitations such as non-specificity and low efficacy in discrimination between healthy and cancer cells."

( Ghaznavi, H; Hosseini-Nami, S; Kamrava, SK; Samadian, H; Shakeri-Zadeh, A, 2016)

"Although many patients with cancer who smoke did not enroll in treatment, the side effect profile of varenicline and its effect on short-term cessation converge with what is seen in the general population."

( Blazekovic, S; Brubaker, TR; Hitsman, B; Hole, A; Kalhan, R; Langer, C; Leone, F; Patel, J; Price, S; Schnoll, R; Veluz-Wilkins, A; Wileyto, EP, 2017)

"The use of mangiferin for cancer treatment has attracted the attention of research groups around the World."

( Daglia, M; Núñez Selles, AJ; Rastrelli, L, 2016)

"Local recurrence following surgery in cancer treatment remains a major clinical challenge."

( Chen, X; Huang, Y; Jing, X; Liu, S; Qi, Y; Xie, Z; Zhang, Z; Zhou, D, 2016)

"Response Evaluation Criteria in Solid Tumors (RECIST) are commonly used to determine the efficacy of anti-cancer therapy in clinical trials."

( Bins, S; Cirkel, GA; de Jonge, MJ; Gadellaa-van Hooijdonk, CG; Langenberg, MH; Lolkema, MP; Schellens, JH; Sleijfer, S; Steeghs, N; Ubink, I; van Stralen, M; van Werkhoven, E; Veldhuis, WB; Voest, EE; Weeber, F; Willems, SM, 2016)

"Patients with any metastatic malignancy, without regular treatment options, were treated with the mTOR inhibitor everolimus."

"As a vital task in cancer therapy, accurately predicting the treatment outcome is valuable for tailoring and adapting a treatment planning."

( Denœux, T; Jardin, F; Lian, C; Ruan, S; Vera, P, 2016)

"The resulting anticancer treatment from RLNs-PTX was demonstrated a half-maximal inhibitory concentration of 0."

( Ding, Y; Gu, X; Hua, P; Shen, L; Wang, R; Yin, L; Zhou, J, 2016)

"With rising cancer survival rates, a greater proportion of patients are living with the side effects of their chemotherapy treatments."

( Daniel, SJ; Peleva, E; Waissbluth, S, 2017)

"These compounds hold promise for cancer therapy and have now entered clinical trials."

( Aggarwal, M; Agostino, SD; Avantaggiati, ML; Berry, D; Blandino, G; Chung, FL; Cruz, I; Dyba, M; Fu, Y; Jacobs, A; Kallakury, B; Mueller, SC; Saxena, R; Sinclair, E; Wang, X, 2016)

"This relationship is used in cancer therapy."

( Kłoczko, J; Ołdziej, AE; Romaniuk, W; Zińczuk, J, 2015)

"Targeted nanomedicine for cancer therapy has gained widespread popularity and is being extensively explored."

( Amin, ML; Kim, D; Kim, S, 2016)

"Treatment of unresectable primary cancer and their distant metastases, with the liver representing one of the most frequent location, is still plagued by insufficient treatment success and poor survival rates."

( Gai, Y; Kim, HS; Ludwig, JM; Sun, L; Xiang, G; Zeng, D, 2016)

"A new cancer diagnosis adds significant complexity and uncertainty to the management of pre-existing warfarin therapy."

( Ambrus, DB; Reisman, JI; Rose, AJ, 2016)

"F10 has strong potential for impacting cancer treatment because it displays high cytotoxicity toward proliferating malignant cells with minimal systemic toxicities thus providing an improved therapeutic window relative to traditional fluoropyrimidine drugs, such as 5-fluorouracil."

( Caudell, D; Debinski, W; Gmeiner, WH; Milligan, C; Pardee, TS, 2016)

"Rates of chronic non-cancer pain are increasing worldwide, with concerns regarding poorer access to specialist treatment services in remote areas."

( Bruno, R; Campbell, G; Degenhardt, L; Larance, B; Nielsen, S; Peacock, A, 2016)

"In this experimental study, cancer and normal cells behavior during an in vitro photodynamic therapy (PDT) under exposure of continuous wave (CW) and fractionated mode of laser with different irradiation power and time intervals was compared and investigated."

( Afsharan, H; Mollabashi, M; Montaseri, A; Navaeipour, F; Ranjbari, F; Rashidi, MR; Tajalli, H, 2016)

"Thus, high-performance cancer phototherapy with minimal side effects was afforded from synergistic PDT/PTT treatment and cancer-targeted accumulation of NGO-808."

( Li, C; Li, R; Luo, S; Shi, C; Tan, X; Wang, Y; Yang, Z; Zeng, Y, 2016)

"Because cancer vaccines require time to elicit an immune response, a delayed treatment effect is expected and is actually observed in drug approval studies."

( Hasegawa, T, 2016)

"We suggest that the treatment of cancer patients with APE can be oriented with the administration of a standard dose of fondaparinux until the next CT lung control (3 months)."

( Amato, B; Amato, M; Aprea, G; Bianco, T; Compagna, R; Danzi, M; de Franciscis, S; Gallelli, L; Milone, M; Rocca, A; Serra, R; Sivero, L; Vigliotti, G, 2016)

"In a murine cancer model, the PMPC conjugate completely inhibited tumor growth and cured 75% mice, whereas at the same dose, no mice treated with interferon-alpha or PEGASYS survived."

( Gao, W; Hu, J; Wang, G; Zhao, W, 2016)

"By developing this noninvasive cancer therapy, expectations to minimize toxicity of cancer treatment may become reality sooner."

( Ahmad, R; Fu, J; He, N; Li, S, 2016)

"Glo-1 has a dual role in cancer as a tumour suppressor protein prior to tumour development and mediator of multi-drug resistance in cancer treatment, implicating dicarbonyl glycation of DNA in carcinogenesis and dicarbonyl-driven cytotoxicity in mechanism of action of anticancer drugs."

( Rabbani, N; Thornalley, PJ; Xue, M, 2016)

"These data indicate that cancer patients treated with DTIC who possess any of the CYP1A1-T461N and I462V variants or the CYP1A2-F186L, D348N, I386F, R431W, and R456H variants are likely to have decreased prodrug activation, and hence may respond less favorably to DTIC treatment compared with individuals with wild-type CYP1A alleles."

( Korprasertthaworn, P; Lewis, BC; Miners, JO, 2016)

"To provide further improvements in anticancer therapy outcomes, novel molecular-targeted agents, immune checkpoint inhibitors, and other drugs are being developed, but 5-FU remains an attractive target that shows further potential for increased efficacy."

( Baba, H; Emi, Y; Iimori, M; Kakeji, Y; Kataoka, Y; Kitao, H; Maehara, Y; Niimi, S; Oki, E; Saeki, H; Shirasaka, T; Tokunaga, E, 2016)

"So, to design an efficacious cancer treatment strategy, it is essential to understand the interactions of natural molecules with their respective cellular targets."

( Kashyap, D; Mittal, S; Sak, K; Singhal, P; Tuli, HS, 2016)

"Survival analysis results of multiple cancer models confirmed that BF-rTK + GCV system has a wide field of application in solid tumor gene therapy."

( Hu, Q; Ma, Y; Song, F; Wang, C; Wu, J; Xie, T; Zeng, F, 2016)

"BALB/c nude bearing THP-1 tumors treated with 12 mg·kg(-1) of compound (2) showed a 92."

( Azeredo, NF; Borges, LJH; Bull, ÉS; Carvalho, ECQ; Fernandes, C; Freitas, WR; Horn, A; Jerdy, H; Kanashiro, MM; Lemos, LS; Resende, JALC, 2016)

"However, in anti-cancer therapy, HBO alone gives a limited curative effect and is typically not applied by itself."

( Matyja, E; Ostrowski, RP; Stępień, K, 2016)

"Hypoxic tumors are resistant to radiotherapy, motivating the development of tools to image local oxygen concentrations."

( Christodoulou, AG; Clifford, B; Epel, B; Halpern, HJ; Liang, ZP; Redler, G, 2016)

"The ultimate goal in cancer therapy and diagnosis is to achieve highly specific targeting to cancer cells."

( Feng, J; Hu, JJ; Qiu, WX; Yu, WY; Zhang, MK; Zhang, XZ; Zheng, DW; Zhu, JY, 2016)

"Adult patients with a cancer diagnosis who are admitted to the palliative care unit will be randomized into a treatment or placebo group."

( Agar, M; Bush, SH; Currow, DC; Lacaze-Masmonteil, N; Lawlor, PG; MacDonald, AR; McNamara-Kilian, MT; Momoli, F; Tierney, S, 2016)

"Architecting of various scaffolds for cancer treatment has become gradually increased in many years."

( Jain, SK; Kumar, D, 2016)

"Molecular profiling (MP) of tumors to identify biomarkers that predict potential outcomes with individual therapies is an emerging strategy to guide treatment decisions."

( Byrne, A; Dean, A; Hayden, I; Marinova, M, 2016)

"Hypoxia, a typical feature of solid tumors, remarkably restricts the efficiency of photodynamic therapy (PDT)."

( Fan, JX; Lei, Q; Li, B; Li, C; Li, CX; Xu, Z; Zhang, XZ; Zheng, DW, 2016)

"The aim of cancer treatment was palliative for metastatic patients (36 out of 63), or adjuvant or curative for patients with localized disease (27 out of 63)."

( Gemici, C; Mayadagli, A; Ozden, S; Ozyurt, H; Tepetam, H; Yaprak, G; Yetmen, O, 2016)

"Iv iron administration in cancer patients undergoing active oncologic treatment is an effective and safe measure for correction of anemia, and prevention of worsening of anemia."

( Gemici, C; Mayadagli, A; Ozden, S; Ozyurt, H; Tepetam, H; Yaprak, G; Yetmen, O, 2016)

"Owing to the complexity of cancer pathogenesis, conventional chemotherapy can be an inadequate method of killing cancer cells effectively."

( Biswas, S; Ghosh, B; Muddineti, OS, 2017)

"In all other cancer-associated hypocalcaemia, PTH is elevated, including significant renal impairment, critically ill patients, extensive cell destruction (rhabdomyolysis, tumour lysis, haemolysis), acute pancreatitis, adverse drug reactions, cancer or cancer treatment-related malabsorption syndromes, vitamin D deficiency, or osteoblastic metastases."

( Dubin, I; Gelber, M; Huber, R; Schattner, A, 2016)

"Pooled data from advanced end-stage cancer patients with OIC, despite laxatives, treated in two randomized (phase III and IV), placebo-controlled trials with MNTX were analyzed for overall survival (OS) in an unplanned post hoc analysis."

( Atkins, JT; Janku, F; Johnson, LK; Karp, DD; Moss, J; Singleton, PA, 2016)

"In cases of malignancy that are refractive to treatment, other therapies have been found to be effective for paraneoplastic itch, including selective serotonin reuptake inhibitors, mirtazapine, gabapentin, thalidomide, opioids, aprepitant, and histone deacetylase inhibitors."

( Rowe, B; Yosipovitch, G, 2016)

"We reviewed data of 4 cancer patients with resistant CMV or herpes simplex virus (HSV) infections and were treated with brincidofovir under emergency IND application."

( Ariza-Heredia, EJ; Chemaly, RF; El Chaer, F; El-Haddad, D; Gulbis, AM; Mulanovich, VE; Shah, DP; Shpall, EJ; Vanichanan, J, 2016)

"The most common method for cancer treatment is chemotherapy."

( Ansari, L; Hanafi-Bojd, MY; Malaekeh-Nikouei, B, 2016)

"After the sample was loaded with anticancer drug doxorubicin (DOX), the antitumor result in vitro indicates that YOHS-DOX might be effective in cancer treatment."

( Ge, K; Jia, G; Jin, Y; Li, Z; Liang, XJ; Liu, H; Sun, W; Zhang, C; Zhang, J, 2016)

"With the limitation of facilities for cancer treatment, the only effective way to tackle the rising and humongous cancer burden is focusing on preventable cancer cases."

( Bhandari, M; Devnani, B; Gandhi, AK; Kumar, P; Rath, GK, 2017)

"Hence, thalidomide is effective in cancer treatment due to the interaction between immune cells and tumor vasculature."

( Li, S; Lv, M; Shen, Y; Wang, F; Wang, X; Yang, J; Zhang, X, 2016)

"The treatment of VTE complications in cancer patients remains a difficult clinical task."

( Prandoni, P, 2017)

"Various cancers are related to obesity and proper understanding of their aetiology, especially their molecular tumour biology is important for early diagnosis and better treatment."

( Das, S; Teoh, SL, 2016)

"In the treatment of cancer with 5-fluorouracil, the administration of folates mechanistically leads to the formation of [6R]-5,10-methylene-tetrahydrofolate, and the increased concentration of this molecule leads to stabilization of the ternary complex comprising thymidylate synthase, 2'-deoxy-uridine-5'-monophosphate, and [6R]-5,10-methylene-tetrahydrofolate."

( Danenberg, PV; Gustavsson, B; Johnston, P; Lindberg, P; Moser, R; Odin, E; Peters, GJ; Petrelli, N, 2016)

"Only BA patents to treat cancer and inflammation are available."

( Ahmed, I; Al-Harrasi, A; Ali, Z; Csuk, R; Green, IR; Hussain, H; Khan, IA; Shamraiz, U, 2017)

"Today due to improvements in cancer treatment there is an increasing number of long-term cancer survivors, many of whom suffer from infertility caused by malignancy itself and chemo- or radiotherapy."

( Bardakhivskaya, KI; Bodnar, YY; Chekhun, VF; Datsko, TV; Nikolaev, VG; Posokhova, КА; Shevchuk, OO; Volska, AS, 2016)

"The synergistic cancer treatment performance was attributable to the effect of hyperthermia, which efficiently enhanced the radiosensitizing effect of hypoxic cancer cells that were resistant to ionizing radiation."

( Chen, Z; Gu, N; He, N; Jiang, YW; Jin, H; Liu, P; Ma, N; Myers, JN; Wu, FG; Wu, H; Zhang, X, 2016)

"Although all primary tumors continued to progress in time, this progression was slower than before treatment according to the contrast-enhanced ultrasound data."

( Cicchelero, L; de Rooster, H; Denies, S; Sanders, NN; Stock, E; Van Brantegem, L; Vanderperren, K, 2017)

"Efficient AuNR based cancer therapy requires efficient AuNR tumor delivery."

( Chen, X; Jacobson, O; Kiesewetter, DO; Niu, G; Song, J; Sun, X; Tong, X; Wang, Z, 2016)

"Intracranial hemorrhage (ICH) in cancer patients can result from tumor bleeding and from antitumor and anticoagulation therapy."

( García-Perdomo, HA; Oo, TH; Rojas-Hernandez, CM, 2017)

"Recognizing this need, Cancer Research UK (CRUK) and the European Organisation for Research and Treatment of Cancer (EORTC) assembled experts to review, debate and summarize the challenges of IB validation and qualification."

( Aboagye, EO; Adams, JE; Aerts, HJ; Barrington, SF; Beer, AJ; Boellaard, R; Bohndiek, SE; Brady, M; Brindle, KM; Brown, G; Buckley, DL; Chenevert, TL; Clarke, LP; Collette, S; Cook, GJ; deSouza, NM; Dickson, JC; Dive, C; Evelhoch, JL; Faivre-Finn, C; Gallagher, FA; Gilbert, FJ; Gillies, RJ; Goh, V; Griffiths, JR; Groves, AM; Halligan, S; Harris, AL; Hawkes, DJ; Hoekstra, OS; Huang, EP; Hutton, BF; Jackson, A; Jackson, EF; Jayson, GC; Jones, A; Koh, DM; Lacombe, D; Lambin, P; Lassau, N; Leach, MO; Lee, TY; Leen, EL; Lewis, JS; Liu, Y; Lythgoe, MF; Manoharan, P; Maxwell, RJ; McShane, LM; Miles, KA; Morgan, B; Morris, S; Ng, T; O'Connor, JP; Padhani, AR; Parker, GJ; Partridge, M; Pathak, AP; Peet, AC; Punwani, S; Reynolds, AR; Robinson, SP; Shankar, LK; Sharma, RA; Soloviev, D; Stroobants, S; Sullivan, DC; Taylor, SA; Tofts, PS; Tozer, GM; van Herk, M; Walker-Samuel, S; Wason, J; Waterton, JC; Williams, KJ; Workman, P; Yankeelov, TE, 2017)

"A more in-depth understanding of how cancer cells adapt to biguanide treatment may provide important therapeutic implications to achieve more effective and rational cancer therapies."

( Gan, B; Liu, X, 2016)

"As advances in cancer treatment have decreased cancer mortality, DOX-induced cardiomyopathy has become an increasing problem."

( Alitalo, K; Backman, JT; Degerman, J; Hulmi, JJ; Kerkelä, R; Kivelä, R; Mervaala, E; Miinalainen, I; Nissinen, TA; Räsänen, M; Siltanen, A, 2016)

"The heterogeneous responses of clonal cancer cells to treatment is understood to be caused by several factors, including stochasticity, cell-cycle dynamics, and different micro-environments."

( Balaban, NQ; Gefen, O; Pearl Mizrahi, S; Simon, I, 2016)

"After the year 2000, the treatment of cancer remarkably changed, including the development of outpatient cancer chemotherapy."

( Terada, T, 2016)

"Multidrug resistance (MDR), whereby cancer cells become resistant to the cytotoxic effects of various structurally and mechanistically unrelated chemotherapeutic agents, is a major problem in the clinical treatment of cancer."

( Brito, AM; Cavaco, MC; Gouveia, LF; Kreutzer, B; Pereira, C; Silva-Lima, B; Videira, M, 2017)

"Treatment of cancer patients with chemotherapeutic drugs is often associated with the occurrence of tumors with a multidrug resistance (MDR)."

( Chang, CS; Chen, CY; Huang, CF; Hung, CC; Lee, CY; Lin, CM; Lin, HC; Si Tou, TC, 2017)

"Type of cancer, treatment, age, and BMI were not significant predictors of bone pain."

( Abrams, M; Gavioli, E, 2017)

"In recent decades, advances in cancer treatment have led to a dramatic improvement in long term survival."

( Liang, T; Motan, T, 2016)

"Functional assessment of cancer therapy-general and functional assessment of chronic illness therapy-spiritual care was evaluated during the admission and at the time of discharge, two, four and 6 months following discharge from the hospital."

( Agarwal, V; Dalal, K; Sankhe, A; Sarve, P, 2017)

"It is an attractive target for cancer immunotherapy because its normal expression is limited to mesothelial cells, which are dispensable."

( Alewine, C; Hassan, R; Jaffee, EM; Le, DT; Pastan, I; Thomas, A, 2016)

"The detection of cancer cells through important molecular recognition target such as sialic acid is significant for the clinical diagnosis and treatment."

( Dervisevic, M; Isik, S; Sagir, T; Senel, M, 2017)

"active cancer or still undergoing anticancer therapy) beyond the initial 6 months of treatment, continuation of anticoagulation therapy for secondary prevention is usually recommended."

( Carrier, M; Prandoni, P, 2017)

"mTOR inhibitor treatment of solid cancers is associated with mTOR inhibitor-associated stomatitis (mIAS) a common, significant, dose-limiting toxicity, with aphthous-like lesions."

( Andreotta, PW; Lyng, G; Sonis, S, 2017)

"Several cancer therapy techniques are briefly introduced at the beginning."

( Cheng, J; Li, C; Wang, F; Yuan, Z, 2016)

"Topotecan (TPT), a potent anticancer camptothecin analog, is well described for the treatment of ovarian cancer, but has also anticancer activity against small-cell and non-small-cell lung cancer, breast cancer, and acute leukemia."

( Hurkat, P; Jain, A; Jain, SK; Saraf, S, 2016)

"Older cancer patients often wrestle with underlying heart disease during cancer therapy, whereas childhood cancer survivors are living long enough to face long-term unintended cardiac consequences of cancer therapies, including anthracyclines."

( Chen, JJ; Middlekauff, HR; Nguyen, KL; Wu, PT, 2017)

"An efficient cancer treatment results from the combination of Toll-like receptor agonists and phagocytosis stimulating ligands bound to the tumor cells."

( Caisová, V; Chmelař, J; Glaserová, S; Husníková, H; Jochmanová, I; Kopecký, J; Krejčová, G; Kumžáková, Z; Paďouková, L; Vácová, N; Vieru, A; Wolf, KI; Ženka, J, 2016)

"Given the complexity of tumors, several nanomaterial-based treatment modalities like chemotherapy (CT), photodynamic therapy (PDT) and photothermal therapy (PTT) have been developed for combating cancers."

( Feng, L; Liu, J; Liu, K; Liu, Z; Xu, L, 2017)

"The tumor-specific targeting of cancerostatics using polymer drug carriers represents a potential strategy to achieve an effective treatment with reduced side toxicity."

( Chytil, P; Etrych, T; Lidický, O; Říhová, B; Šírová, M; Strohalm, J; Tomala, J, 2017)

"Hypoxia-induced cancer stem cells have been known to be involved in tumour metastasis, resistance to chemo/radio therapy and tumour recurrence."

( Chen, Q; Han, C; Liu, Y; Song, L; Wang, D; Wang, K; Xie, X; Zhang, L; Zhou, Y; Zhu, H, 2016)

"In the G/P arm, patients with solid tumors or lymphoma were treated at four different DLs with a combination of gemcitabine (DL1: 750 mg/m, DL2-DL4: 1000 mg/m) and plitidepsin (DL1-DL2: 1."

( Alfaro, V; Aspeslagh, S; Bahleda, R; Extremera, S; Fudio, S; Gyan, E; Hollebecque, A; Salles, G; Soria, JC; Soto-Matos, A; Stein, M, 2017)

"The relationship of CTR1 to cancer prognosis remained significant in the subgroup of patients who underwent platinum-based chemotherapy, the patients with ovarian cancer and those with lung cancer."

( Cai, J; Sun, S; Wang, Z; Yang, Q; Zhao, S, 2017)

"A total of 78 cancer patients, who had delayed vomiting observed from 24 hours to 1 week after chemotherapy, were included in the study."

( Du, X; Han, Z; Jiang, G; Sun, X, 2016)

"An important limitation to successful cancer treatment with chemotherapeutics is the inability to achieve therapeutically effective drug concentrations while avoiding healthy tissue damage."

( Deng, Z; Duan, W; Li, F; Liu, X; Meng, L; Pan, M; Xiao, Y; Yan, F; Zheng, H, 2016)

"Metformin has utility in cancer prevention and treatment, though the mechanisms for these effects remain elusive."

( Carr, CE; Gygi, SP; Kacergis, MC; Li, M; Mou, F; Oshiro-Rapley, N; Paulo, JA; Soukas, AA; Talkowski, ME; Webster, CM; Wu, L; Zheng, B; Zhou, B, 2016)

"We give some background on personalized cancer treatment, the particular tumor chemosensitivity assay supported by the system, as well as some quality and legal issues related to such health systems."

( Alvarado, D; Báez, A; Bola Nos, C; López, G; López, M; Martinez, A; Mora, R; Quirós, S; Solano, A, 2017)

"However, multidrug resistance (MDR) of cancer cells has remained as a significant obstacle in the achievement of efficient chemotherapy."

( Chen, X; Kim, J; Kim, WJ; Yung, BC, 2017)

"Aggressive, desmoplastic tumors are notoriously difficult to treat because of their extensive stroma, high interstitial pressure, and resistant tumor microenvironment."

( Dayton, PA; Huang, L; Rojas, JD; Satterlee, AB, 2017)

"Anti-cancer treatment may reduce the fertile life span and induce premature menopause."

( Kaspers, GJ; Lambalk, CB; Overbeek, A; van den Berg, MH; van Dulmen-den Broeder, E; van Leeuwen, FE, 2017)

"Breast cancer survivors, those treated with procarbazine or other alkylating agents and those with a higher age at diagnosis are at highest risk of diminished ovarian function."

( Kaspers, GJ; Lambalk, CB; Overbeek, A; van den Berg, MH; van Dulmen-den Broeder, E; van Leeuwen, FE, 2017)

"In GQD-BTN-DOX treated cancer cells, the cytotoxicity was strongly dependent from cell uptake which was greater and delayed after treatment with GQD-BTN-DOX system with respect to what observed for cells treated with the same system lacking of the targeting module BTN (GQD-DOX) or with the free drug alone."

( Branca, C; Di Pietro, A; Galvagno, S; Giofré, SV; Iannazzo, D; Pistone, A; Romeo, R; Salamò, M; Visalli, G, 2017)

"The immune response to cancer vaccines was measured after treatment of C57BL/6J mice with two subcutaneous injections, seven days apart, of 50μg OVA encapsulated in particles composed of different polyanhydride copolymers with or without 25μg CpG ODN."

( Geary, SM; Goodman, JT; Narasimhan, B; Salem, AK; Wafa, EI, 2017)

"Combinational cancer therapy with photothermal conversion under near-infrared irradiation was shown to be a highly efficient cancer treatment."

( Jang, H; Kim, YK; Min, DH, 2017)

"About 26 patients with solid tumors were treated in four different dosing schedules."

( Badary, OA; Barrois, C; Cassier, P; Colomban, O; El-Demerdash, E; El-Madani, M; El-Shenawy, SM; Freyer, G; Gagnieu, MC; Guitton, J; Hommel-Fontaine, J; Ibrahim, BM; Lefort, T; Maillet, D; Peron, J; Rodriguez-Lafrasse, C; Tod, M; Valette, PJ; You, B, 2017)

"Platinum-based anti-cancer agents, which include cisplatin, carboplatin and oxaliplatin, are an important class of drugs used in clinical setting to treat a variety of cancers."

( McQuade, R; Nurgali, K; Rybalka, E; Stojanovska, V, 2017)

"In order to improve the sensitivity of tumors cells to radiation therapy, tumor hypoxia may theoretically be alleviated by increasing the oxygen delivery or by decreasing the oxygen consumption by tumor cells."

( Danhier, P; Gallez, B; Jordan, BF; Neveu, MA, 2017)

"Given cyclooxygenase's role in cancer pathways, we recommend dose-finding studies be undertaken before prospective clinical trials are conducted testing the currently unsubstantiated hypothesis that perioperative anti-inflammatory administration improves long-term cancer outcomes."

( Hiller, JG; Ho, KM; Kuruvilla, N; Millen, R; Ramsay, R; Riedel, B; Sampurno, S, 2017)

"The growth of tumors was inhibited with increasing serum retinol concentrations obtained post-administration of RP."

( Hasegawa, S; Imai, M; Li, C; Takahashi, N; Yamasaki, M, 2017)

"Chemotherapy-induced cancer cell secretomes promote resistance due, in part, to a predominant glycolytic energy metabolism, which drives aggressive cancer cell proliferation."

( Aldonza, MB; Hong, JY; Lee, SK, 2017)

"We included 60 patients (23 colon cancers, 36 kidney cancers, and 1 breast cancer) treated with axitinib (26 patients), sunitinib (27 patients), and other antiangiogenic treatments (7 patients)."

( Asselain, B; Benatsou, B; Bidault, S; Coiffier, B; Faivre, L; Girard, E; Koscielny, S; Lassau, N; Pitre-Champagnat, S, 2017)

"Many cancer patients have bone osteolysis that is refractory to state-of-the-art treatments, which block osteoclast activity with bisphosphonates or by inhibiting the receptor activator of nuclear factor κB ligand (RANKL) pathway."

( Anderson, N; Andrade, K; Fornetti, J; McHale, M; Miller, SC; Randall, RL; Waltz, SE; Welm, AL; Zhao, L, 2017)

"Both normal and cancerous cells, treated with drugs that block cytosine methylation of DNA, are preferentially killed by these drugs when they have p53 mutations and survive if they have a wild type protein."

( Levine, AJ, 2017)

"The multidrug resistance (MDR) of cancer cells has become a great barrier to the success of chemotherapy."

( Hadizadeh, F; Iman, M; Mollazadeh, S; Shamsara, J, 2017)

"However, exposure of noncancerous tissues to radiation continues to be a hindrance to safe and effective treatment of patients."

( Hargrove, D; Lu, X, 2017)

"In conclusion, anticancer effects of phytosterols have strongly been suggested and support their dietary inclusion to prevent and treat cancers."

( Abdel-Wahab, AF; Abduljaleel, Z; Afify, MA; Al-Allaf, FA; Al-Ghamdi, SS; Ali, A; Ibrahim, IAA; Khan, W; Md, S; Saluja, SS; Shahzad, N; Sharma, S, 2017)

"Their application in drug delivery, cancer treatment, catalysis and as antimicrobial agent has also been discussed."

( Husen, A; Siddiqi, KS, 2017)

"Targeting DNA methylation in cancer using DNA hypomethylating drugs reprograms tumor cells to a more normal-like state by affecting multiple pathways, and also sensitizes these cells to chemotherapy and immunotherapy."

( Issa, JJ; Kropf, P; Sato, T, 2017)

"However, survivors of brain tumors and any survivor who received high-dose neurotoxic treatment reported the lowest rates of achieving milestones of psychosexual development, whereas sexual and relationship status satisfaction were found to be related to relationship status."

( Bajwa, RPS; Gerhardt, CA; Hagedoorn, M; Keim, MC; Lehmann, V; Olshefski, RS; Tuinman, MA; Winning, AM, 2017)

"Interim data examining NTRK-rearranged tumors treated with entrectinib or LOXO-101 demonstrate encouraging activity, with patients achieving rapid and durable responses."

( Farago, AF; Holla, VR; Hong, DS; Khotskaya, YB; Meric-Bernstam, F; Mills Shaw, KR, 2017)

"Recently, co-delivery of siRNA and anticancer drugs has drawn much attention in the treatment of drug-resistant cancers."

( Capeling, M; Cheng, C; Sun, H; Yarovoy, I, 2017)

"However, cancer associated miRNAs has emerged only in recent years to support its applications in cancer therapy."

( Bishayee, A; Daglia, M; Nabavi, SF; Nabavi, SM; Pandima Devi, K; Rajavel, T, 2017)

"In 2011, Memorial Sloan Kettering Cancer Center (MSKCC) implemented the following guidelines in this setting: administer full dose enoxaparin for a platelet count > 50,000/mcL, half-dose enoxaparin for a platelet count of 25,000-50,000/mcL, and hold anticoagulation for a platelet count < 25,000/mcL."

( Mantha, S; Miao, Y; Parameswaran, R; Soff, GA; Wills, J, 2017)

"Targeting G-quadruplex DNAs for cancer treatment is a very promising prospect."

( Algara, T; Aparicio, S; Balasubramanian, S; Bally, MB; Banáth, J; Brenton, JD; Brown, GW; Caldas, C; Cescon, D; Chiu, DS; Di Antonio, M; Garcia, J; Hieter, P; Ho, B; Kabeer, F; Lai, D; Le, DD; Lin, SC; Mak, TW; Mathew, V; McKinney, S; O'Neil, NJ; Osako, T; Santos, ND; Saunders, DN; Shah, SP; Silvester, J; Soong, J; Soriano, P; Stirling, PC; Thu, K; Tsai, AH; Wei, V; Wong, J; Xian, J; Xu, H; Yap, D; Ye, FB; Zhang, A, 2017)

"• Efforts to improve cancer chemotherapy by exploiting the intrinsic differences between normal and neoplastic cells to achieve maximum effective drug delivery to target cancer cells through bioengineered chitosan nano delivery vectors are discussed."

( Kamath, PR; Sunil, D, 2017)

"Unearthing embryology-like processes in tumors may allow us to control organ-like tumor features such as tissue repair and revascularization and treat intratumoral heterogeneity."

( Akkari, L; Carmona-Fontaine, C; Deforet, M; Joyce, JA; Thompson, CB; Xavier, JB, 2017)

"The optimal duration and cancer risks of antiplatelet therapy following percutaneous coronary intervention (PCI) are unclear."

( Cabrera-Fuentes, HA; Cho, YR; Kim, MH; Kim, YD; Lee, K; Park, K; Park, TH; Serebruany, VL; Yoon, SC, 2017)

"Anti-cancer therapy efficacy in solid tumors mainly depends on drug transportation through the vasculature system and the extracellular matrix, on diffusion gradients and clonal heterogeneity within the tumor mass, as well as on the responses of the individual tumor cells to drugs and their interactions with each other and their local microenvironment."

( Liapis, E; Sakkalis, V; Tzamali, E; Tzedakis, G; Zacharakis, G, 2016)

"Advanced cancer patients represent a frail population, often requiring aggressive pain management, particularly in the late stage of disease, when untreated pain is one the most important causes of suffering."

( Mercadante, S, 2017)

"To make PDT more effective in cancer treatment while being patient-comfortable, herein, a hexylamine conjugated chlorin e6 (hCe6) as the photosensitizer together with a lipophilic near-infrared (NIR) dye 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide (DiR) are co-encapsulated into polyethylene glycol (PEG) shelled liposomes."

( Chao, Y; Chen, M; Chen, Q; Dong, Z; Feng, L; Liu, Z; Tao, D, 2017)

"Current clinical methods for cancer diagnosis and therapy have limitations, although survival periods are increasing as medical technologies develop."

( Key, J; Park, K, 2017)

"RSV-treated cancer cells may experience replication stress that can lead to cellular senescence or apoptosis."

( Gong, Y; Guo, H; Hou, D; Li, B; Liu, Q; Shao, C; Xu, X; Zhang, S; Zhang, X; Zhou, H; Zou, Y, 2017)

"Effective treatments for SUDs and cancer pain exist, and recovery can lead to improvements in multiple aspects of patients' lives."

( Chang, YP; Compton, P, 2017)

"One of the goals of cancer treatment is symptoms management especially at the end stage."

( Andrew, BN; Guan, NC; Jaafar, NRN, 2018)

"Considering both cancer's serious impact on public health and the side effects of cancer treatments, strategies towards targeted cancer therapy have lately gained considerable interest."

( Balanikas, EC; Boudouvis, AG; Dimitriou, NM; Georgakilas, AG; Lykakis, IN; Mantso, T; Mitsiogianni, M; Panayiotidis, MI; Pashos, G; Pavlopoulou, A; Tsekenis, G; Tsigaridas, G; Yannopapas, V, 2017)

"Rising cancer incidence and mortality in India emphasize the need to address the increasing burden of this disease and the stark inequities in access to radiotherapy and other essential medical treatments."

( Balogun, O; Dhillon, PK; Gandhi, AK; Grover, S; Gudi, S; Mahantshetty, U; Olson, AC; Puri, PM; Rath, GK; Rodin, D; Sharma, DN; Shrivastava, SK; Viswanathan, AN, 2017)

"The primary hurdle in the treatment of cancer is acquisition of resistance by the tumor cells toward multiple drugs and selectively targeting the cancer stem cells."

( Dewangan, J; Rath, SK; Srivastava, S, 2017)

"The current concepts and practice of cancer immunotherapy evolved from classical experiments that distinguished "self" from "non-self" and the finding that humoral immunity is complemented by cellular immunity."

( Farzaneh, F; Maher, J; Stambrook, PJ, 2017)

"Systemic delivery of an anti-cancer agent often leads to only a small fraction of the administered dose accumulating in target sites."

( Kodama, T; Komiya, A; Maruyama, S; Mori, S; Okajima, J; Oladipo, AO; Oluwafemi, OS; Songca, SP; Sukhbaatar, A, 2017)

"To verify its potentials in RNAi-based cancer therapy, the newly designed RAPSI nanoflower was further complexed with glycol chitosan (GC) derivatives, and systemically delivered to PC-3 xenograft tumors."

( Kim, HC; Kim, K; Kim, MJ; Kim, SH; Ku, SH; Kwon, IC; Lee, JH; Lee, SJ, 2017)

"To investigate the relative risk of cancer development in rheumatoid arthritis (RA) patients in Greece after taking into consideration treatment modalities."

( Katsoulis, M; Klinaki, E; La Vecchia, C; Trichopoulou, A, 2018)

"Besides cancer therapy, studies indicated that curcumin and some carbon materials could be used as radical scavengers that play an important role in the radioprotection of normal cells."

( Dong, X; Du, J; Gong, L; Gu, Z; Guo, Z; Tian, G; Xie, J; Yong, Y; Yu, S; Zhao, Y; Zhu, S, 2017)

( Kalalinia, F; Karimi-Sani, I, 2017)

"Histological sections of treated tumors have detected red blood cell extravasation within tumors treated with temperature-sensitive doxorubicin and ultrasound hyperthermia."

( Borowsky, AD; Curry, FE; Ferrara, KW; Fite, BZ; Foiret, JL; Ingham, ES; Kheirolomoom, A; Mahakian, LM; Seo, JW; Tam, SM, 2017)

"In this context, cancer has become one of the most deadly diseases around the world, and despite many advances in theranostics techniques the treatment of cancer still remains an important problem."

( Augustine, S; Das, A; Malhotra, BD; Sharma, M; Singh, J; Srivastava, M, 2017)

"Despite the newly treatment procedures, cancer is considered as the main health threat nowadays and, therefore, new therapeutic options such as traditional medicine should be investigated."

( Azimi-Nezhad, M; Farkhondeh, T; Samarghandian, S, 2018)

"Chemotherapy is widely used for cancer treatment, but its effectiveness is limited by drug resistance."

( Gujral, TS; Kirschner, MW, 2017)

"As advancing in chemotherapy for cancer treatment, cancer survivors live longer with opioid therapy."

( Nakatani, T, 2017)

"The common treatments for cancer include surgery, radiation, chemotherapy, targeted therapy and immunotherapy, while chemotherapy remains one of the most important treatments."

( Pu, X; Wei, Y; Zhao, L, 2017)

"Simultaneously, anti-cancer experiments demonstrate that the tumor can be ablated after treating with the MDV method for 4 days, demonstrating highly efficient anti-cancer effects."

( Kolios, M; Lu, G; Teng, Z; Wang, R; Wang, Y; Wang, Z; Zhang, N; Zheng, Y; Zhou, Y, 2017)

"We now propose cancer stromal targeting (CAST) therapy and diagnosis, using a cytotoxic agent or radioisotope conjugated to a monoclonal Ab directed at a specific inert constituent of the tumor stroma, as a new modality especially for invasive cancer."

( Matsumura, Y, 2017)

"Three stage III or IV cancer patients with cutaneous complications due to epidermal growth factor receptor (EGFR) inhibitors were treated with melanin and vascular-specific laser and light technologies."

( Kuo, KY; Kwong, B; Rahman, Z, 2017)

"In the case of cancer therapy, the studies are categorized in two main classes based on the conducted therapy strategies, including targeted drug delivery systems (DDS), and thermal ablation."

( Golbabaie, A; Kasaeian, A; Sheikhpour, M, 2017)

"Mouse breast cancer 4T1 cells were treated with these different SPIONs."

( Bertone, E; Borroni, E; Canuto, RA; Ferraris, S; Follenzi, A; Maggiora, M; Miola, M; Muzio, G; Puccinelli, MP; Ricci, M; Verné, E, 2017)

"The use of proteasome inhibitors for cancer therapy derives from the fact that tumor cells generally exhibit greater levels of proteotoxic stress than do normal cells, and thus cancer cells tend to be more sensitive to proteasome inhibition."

( Barnoud, T; George, DL; Herlyn, M; Leu, JI; Murphy, ME; Tian, T; Wei, Z; Zhang, G, 2017)

"Recent efforts in cancer stem cell (CSC) biology suggest that a subpopulation of tumor-initiating cells within the tumor bulk represents the root of tumor recurrence and therapy resistance."

( Che, N; Ma, S; Wong, TL, 2017)

"In vitro, cancer cell lines and mouse embryonic fibroblast cells were treated with different concentrations of pharmacological inhibitors for different times."

( Dorrance, A; Garzon, R; He, Z; Houghton, PJ; Hu, X; Liu, W; Shen, C, 2017)

"Drug-tolerant cancer cell subpopulations are responsible for relapse after chemotherapy."

( Ishida, K; Ito, C; Iwaya, T; Kobunai, T; Koizumi, Y; Konta, A; Kume, K; Nishizuka, SS; Nukatsuka, M; Ohmori, Y; Sato, KA; Takechi, T, 2017)

"Patients with cancer assigned for cisplatin chemotherapy were randomly divided into bee honey and royal jelly groups pretreated before the initiation and during cisplatin chemotherapeutic regimen and control group on cisplatin only."

( Abdelrahim, MEA; Abdullah, A; Bahaa, T; Emad, D; Gamal, B; Hussein, E; Mahfouz, E; Medhat, S; Osama, H; Sayed, D; Sayed, S; Tharwat, J, 2017)

"Intratumoral injection of anticancer drugs directly delivers chemotherapeutics to the tumor region, offering an alternative strategy for cancer treatment."

( Huang, R; Quan, D; Shen, L; Wang, T; Yang, X; Zhang, Z, 2017)

"Estimates of non-adherence to oral anti-cancer therapy range between 27% and 63% in studies of cancer patients."

( Ashkenazi, S; Dreyer, J; Leader, A; Raanani, P, 2017)

"Pain remains common in the setting of malignancy, occurring as a consequence of cancer and its treatment."

( Bennett, M; Paice, JA; Wallace, M, 2017)

"Our method is applicable to diverse cancer and treatment types and allows for a rational design of clinical trials."

( Chakrabarti, S; Michor, F, 2017)

"Radiation therapy alters tumors for enhanced TNP delivery in a TAM-dependent fashion, and these observations have implications for the design of next-generation tumor-targeted nanomaterials and clinical trials for adjuvant strategies."

( Adhikary, U; Chandra, R; Cuccarese, MF; Engblom, C; Kohler, RH; Miller, MA; Mohan, JF; Pfirschke, C; Pittet, MJ; Stapleton, S; Weissleder, R, 2017)

"Diabetic cancer patients are on additional therapy with anticancer drugs."

( Constante, SAR; de Rezende, AAA; Nepomuceno, JC; Oliveira, VC; Orsolin, PC; Spanó, MA, 2017)

"Most patients with advanced cancer will have pain requiring opioid therapy at some stage during their disease course."

( Hardy, JR; Pinkerton, R, 2017)

"A major challenge in cancer photodynamic therapy (PDT) is the poor tumor selectivity of the photosensitizer."

( Chen, Y; Feng, S; Gao, F; Liu, W; Wu, J, 2017)

"The emergence of oral targeted anticancer agents transformed several cancers into chronic conditions with a need for long-term oral treatment."

( Cardoso, E; Csajka, C; Schneider, MP; Widmer, N, 2018)

"Therefore, it has been suggested that cancer should be treated as a chronic disease, controlling its growth by providing continuous therapeutic pressure for long-term."

( Byun, Y; Cho, YS; Choi, JU; Chung, SW; Jeon, OC; Kim, GC; Kim, IS; Kim, JW; Kim, SW; Kim, SY; Kweon, S; Lee, BS; Lee, H; Mahmud, F, 2017)

"In this study, we evaluated whether cancer-related disease factors adversely influence smoking cessation treatment."

( Blazekovic, S; Carroll, AJ; Hitsman, B; Kalhan, R; Leone, FT; Schnoll, RA; Veluz-Wilkins, AK; Wileyto, EP, 2018)

"Tumor site, cancer treatment, and time since diagnosis did not predict any smoking cessation treatment outcomes."

( Blazekovic, S; Carroll, AJ; Hitsman, B; Kalhan, R; Leone, FT; Schnoll, RA; Veluz-Wilkins, AK; Wileyto, EP, 2018)

"Findings support National Comprehensive Cancer Network Clinical Practice guidelines that recommend smoking cessation treatment for all smokers with cancer, regardless of time since diagnosis."

( Blazekovic, S; Carroll, AJ; Hitsman, B; Kalhan, R; Leone, FT; Schnoll, RA; Veluz-Wilkins, AK; Wileyto, EP, 2018)

"One of the next challenges in cancer immunotherapy is the resistance of tumors to T-cell-based treatments through loss of MHC class I."

( Arens, R; Doorduijn, EM; Maas, S; Ossendorp, F; Salvatori, DC; Silvestri, S; Sluijter, M; van der Burg, SH; van Hall, T, 2017)

"Accumulating evidence suggest that cancer cells with mutated p53 often exhibit specific functional dependencies on secondary genes or pathways to survive, providing alternative targets to indirectly treat p53-mutant cancers."

( Brown, PH; Mazumdar, A; Savage, MI; Tahaney, WM; Zhao, D, 2017)

"Metastasis is responsible for most cancer-related deaths, but the current clinical treatments are not effective."

( Ali, MRK; Chen, K; El-Sayed, MA; Fang, N; Han, T; Tang, Y; Wu, R; Wu, Y; Xiao, H, 2017)

"Daily ANC in chemotherapy-treated cancer patients were simulated from a previously published population model describing docetaxel-induced myelosuppression."

( Friberg, LE; Karlsson, MO; Netterberg, I; Nielsen, EI, 2017)

"Iron-deficiency anemia and cancer-associated anemia are usually treated with supportive therapies."

( Barni, S; García-Erce, JA; Gascòn, P; Giordano, G; Mafodda, A; Múñoz, M; Pedrazzoli, P; Petrelli, F; Rosti, G, 2017)

"Anaemia in cancer patients undergoing chemotherapy is associated with decreased QoL."

( Christensen, IJ; Daugaard, G; Frandsen, KB; Johansson, PI; Mau-Sorensen, M; Norgaard, A; Yakymenko, D, 2018)

"Intensive cancer chemotherapy causes significant bone loss, for which the mechanisms remain unclear and effective treatments are lacking."

( Chen, KM; Hassanshahi, M; Howe, PR; Su, YW; Tang, Q; Xian, CJ, 2017)

"Here, a cancer targeted cascade bioreactor (designated as mCGP) was constructed for synergistic starvation and photodynamic therapy (PDT) by embedding glucose oxidase (GOx) and catalase in the cancer cell membrane-camouflaged porphyrin metal-organic framework (MOF) of PCN-224 (PCN stands for porous coordination network)."

( Cheng, H; Li, CX; Li, SY; Liu, WL; Qiu, WX; Wan, SS; Xie, BR; Zeng, JY; Zhang, L; Zhang, XZ, 2017)

"Results indicated that children with cancer who were on active treatment and who were posttreatment experienced clinically significant levels of pain."

( Barwick, M; Campbell, F; Chambers, CT; Fernandez, CV; Irwin, K; Jibb, LA; Nathan, PC; Parker, JA; Stinson, JN; Tutelman, PR; Witteman, HO, 2018)

"For children with malignancy, genotyping of the MTHFR C677T polymorphism is expected to be a useful tool in reducing toxicity and improving outcome in personalized MTX therapy."

( Li, XL; Liu, YW; Nie, XL; Wang, SZ; Wang, XL; Yu, XT; Zhao, LB; Zhu, C, 2018)

"An employee undergoing cancer treatment was prescribed metformin, a medication used in the treatment of type 2 diabetes and currently used as adjunct therapy for cancer."

( Lurati, AR, 2017)

"Efficient vaccine carriers for cancer immunotherapy require two functions: antigen delivery to dendritic cells (DCs) and the activation of DCs, a so-called adjuvant effect."

( Harada, A; Koiwai, K; Kono, K; Sakaguchi, N; Yoshizaki, Y; Yuba, E, 2017)

"Many NMMs exhibit effective anti-cancer activities and can be used as drugs or adjuvant agents to enhance the efficacy of chemotherapy and radiotherapy."

( Sui, G; Wall, NR; Zhong, C; Zu, Y, 2017)

"Neonatal tumors are different from tumors of the older children and knowledge gained from treating older children can not be extrapolated to neonates."

( Chandrasekaran, A, 2018)

"Our study insists that the neonatal tumors are distinct subset of pediatric tumors, requiring careful selection of treatment modalities and most of the solid tumors can be successfully managed if diagnosed and treated early."

( Chandrasekaran, A, 2018)

"Nurses in a National Cancer Institute-designated academic health center outpatient chemotherapy infusion suite were taught how to administer a hand massage to strengthen the nurse-patient relationship and improve patient experience, comfort, satisfaction, stress, and anxiety."

( Braithwaite, CM; Ringdahl, D, 2017)

"In case of solid tumors this is one of the reasons as to why genomic analysis from single tumor biopsy specimens underestimate the mutational burdens in such heterogeneous tumors thus contributing to treatment failure and drug resistance."

( Choudhury, P; Gupta, M, 2017)

"For the treatment of solid tumors, only allosteric mTOR inhibitors, such as everolimus and temsirolimus, are currently approved for clinical use."

( Janku, F, 2017)

"We show that the genomes of a cancer cell subpopulation that survives treatment with otherwise lethal drugs, the drug-tolerant persisters (DTPs), exhibit a repressed chromatin state characterized by increased methylation of histone H3 lysines 9 and 27 (H3K9 and H3K27)."

( Alag, N; Arnott, D; Chen, KB; Classon, M; Cuellar, T; Giresi, PG; Guler, GD; Haley, B; Hegde, G; Jackson, E; Jhunjhunwala, S; KaiWai Cheung, T; Kim, HJ; Liu, J; Nance, TL; Nichols, K; Pitti, R; Settleman, J; Stephan, JP; Tindell, CA; Webster, J; Wilson, C; Wongchenko, M; Yan, Y, 2017)

"We aimed to assess the overall cancer risk among contemporary menopausal hormone therapy (MHT) users in Sweden and the risk for different cancer types."

( Adami, HO; Brusselaers, N; Lagergren, J; Simin, J; Tamimi, R, 2017)

"While advances in biomedicine exist for cancer, its diagnosis and treatment still bring the threat of mortality to the forefront of spouses' lives."

( Chung, BPM; Leung, D; Leung, SM; Loke, AY, 2018)

"All patients with known advanced neoplasms admitted to Mater Health Services and St Vincent's Private Hospital Brisbane between January 2013 and October 2015; who were administered Diatrizoate Meglumine were included."

( Good, P; Hardy, J; Heng, S, 2018)

"According to US National cancer institute, it is anticipated to revolutionize the perspectives of cancer diagnosis and therapy."

( Al-Ani, LA; AlSaadi, MA; Hashim, NM; Julkapli, NM; Kadir, FA; Yehye, WA, 2017)

"Many cancer therapy regimes still rely heavily on the systemic administration of toxic chemotherapeutic agents."

( Jablonowski, LJ; Teraphongphom, NT; Wheatley, MA, 2017)

"Metastatic, solid tumor cancer patients receiving concomitant myelosuppressive chemotherapy and darbepoetin alfa with an associated hemoglobin <10 g/dL during 2011-2015 were identified."

( Chandler, D; Li, XS; Lin, J; MacLachlan, S; Nordstrom, BL; Pan, XL; Sharma, A; Xu, H, 2019)

"While surgery is at the foundation of cancer treatment, its access is limited in low-income countries."

( Barrero Castedo, C; Dewhirst, MW; Hu, F; Katz, DF; Madonna, M; Morhard, R; Mueller, JL; Nief, C; Ramanujam, N, 2017)

"Similar to many other anticancer therapies, photodynamic therapy (PDT) also suffers from the intrinsic cancer resistance mediated by cell survival pathways."

( Chang, Y; Fan, Z; Jin, Z; Kong, X; Li, X; Liu, X; Tu, L; Xue, B; Yan, D; Zhang, H; Zhang, L; Zhang, Y, 2017)

"Patients with cancer frequently experience unintended weight loss due to gastrointestinal (GI) dysfunction caused by the malignancy or treatment of the malignancy."

( Mattox, TW, 2017)

"Many people with cancer experience moderate to severe pain that requires treatment with strong opioids, such as oxycodone and morphine."

( Arnold, S; Bennett, MI; Bromham, N; Hilgart, JS; Schmidt-Hansen, M, 2017)

"It is not clear what kinds of cancer, treatments, and environment need prophylaxis for PCP."

( Ebara, M; Hasebe, S; Takemoto, S; Yakushijin, Y, 2017)

"Adult patients with malignancy requiring chemotherapy, hemoglobin (Hb) <12 g/dL and serum ferritin <100 mcg/mL, transferrin saturation <20% or hypochromic red blood cells >10% were randomized to intravenous (IV) iron sucrose or oral ferrous sulfate."

( Banavali, SD; Goud, S; Gupta, S; Joshi, A; Marfatia, S; More, S; Nakti, D; Noronha, V; Parikh, PM; Patil, VM; Prabhash, K; Punatar, S, 2018)

"Methods Forty-eight cancer patients treated with oral prochlorperazine were enrolled."

( Kagawa, Y; Kawakami, J; Naito, T; Tashiro, M, 2018)

"Thirty-nine palliative cancer patients with levels of 25-hydroxyvitamin D < 75 nmol/L were supplemented with vitamin D 4000 IE/day, and were compared to 39 untreated, matched "control"-patients from a previous study at the same ward."

( Bergqvist, J; Björkhem-Bergman, L; Helde-Frankling, M; Höijer, J, 2017)

"Vitamin D supplementation to palliative cancer patients is safe and improvement in pain management is noted as early as 1 month after treatment."

( Bergqvist, J; Björkhem-Bergman, L; Helde-Frankling, M; Höijer, J, 2017)

"However, the LC levels in end-stage cancer patients treated only with palliative care remained unclear."

( Fukushima, T; Gomi, D; Kobayashi, T; Koizumi, T; Mamiya, K; Matsushita, H; Sakamoto, A; Sekiguchi, N; Tsukahara, Y, 2017)

"The decision for a patient with cancer to start heparin therapy should balance the benefits and downsides, and should integrate the patient's values and preferences."

( Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Synnot, A; Terrenato, I; Yosuico, VED, 2017)

"Pt(II)-based anticancer drugs are widely used in the treatment of a variety of cancers, but their clinical efficacy is hindered by undesirable side effects and resistance."

( Cunningham, RM; DeRose, VJ, 2017)

"We found that ADR treatment of cancer cells in HG increased autophagy, as displayed by greater LC3II accumulation and p62 degradation compared to ADR-treated cells in low glucose."

( Baldari, S; Cirone, M; D'Orazi, G; Garufi, A; Pistritto, G; Toietta, G, 2017)

"The effect of systemic therapy on malignancy risk among patients with psoriasis is not fully understood."

( Fakharzadeh, S; Fiorentino, D; Galindo, C; Goyal, K; Ho, V; Hopkins, L; Langholff, W; Langley, RG; Lebwohl, MG; Leite, L; Srivastava, B, 2017)

"The use of cancer-relevant microRNA molecules as endogenous drug release stimuli is promising for personalized cancer treatment yet remains a great challenge because of their low abundance."

( He, X; Li, Z; Luo, X; Ma, N; Shen, X; Sun, Q; Wang, G; Wang, L; Yue, R, 2017)

"A promising strategy for cancer diagnosis and therapy is the development of an agent for multimodal imaging and treatment."

( Balalaeva, IV; Gavrina, AI; Grigoryev, IS; Klapshina, LG; Lermontova, SA; Muravieva, MS; Shirmanova, MV; Yuzhakova, DV; Zagaynova, EV, 2017)

"Macrophage recruitment to tumors after chemotherapy was visualized noninvasively by near-infrared fluorescence and single-photon emission CT imaging using F4/80-specific imaging probes."

( Bao, R; Gao, L; Jia, B; Lai, J; Liu, Z; Lu, D; Wang, F; Wang, Y; Yu, X; Zhang, C; Zhao, Y, 2017)

"Precise identification and detection of cancer cells using nanoparticle probes are critically important for early cancer diagnosis and subsequent therapy."

( Han, G; Liu, B; Liu, R; Liu, Z; Yang, L; Zhang, C; Zhang, R; Zhang, Z; Zhao, J; Zhao, T, 2017)

"In mouse xenograft models, cancer cells, where Cav-1 was attenuated, exhibited resistance to the antitumor effects of nab-paclitaxel therapy."

( Ben-Josef, E; Chakravarti, A; Chatterjee, M; Harbrecht, M; Palanichamy, K; Robb, R; Seum, S; Thirumoorthy, K; Vedaie, M; Williams, TM, 2017)

"Green tea prevents human cancer, and the combination of EGCG and anticancer drugs confers cancer treatment with tissue-agnostic efficacy."

( Fujiki, H; Rawangkan, A; Sueoka, E; Suganuma, M, 2017)

"Conventional treatment strategies for cancer cannot identify normal and cancer cells."

( Gao, T; Ning, L; Zhu, B, 2017)

"The quest for safer and more effective cancer treatments has led to the development of a plethora of innovative PTX formulations, many of which are currently undergoing clinical trials."

( Cui, H; Konstantopoulos, A; Porter, M; Wang, F; Zhang, P, 2017)

"Hyperthermia is an established anti-cancer treatment but is limited by tolerance of adjacent normal tissues."

( Gardner, HL; London, CA; Portela, R; Schoen, C; Schuh, EM, 2017)

"Our study revealed that C-GNPs with anticancer drugs or new compounds could be potentially applied for biomedical usage especially in cancer therapy."

( Barkhi, M; Daneshpour, M; Gholami, M; Khoshnevisan, K; Maleki, H; Samadian, H, 2018)

"Advanced stage cancer treatments are often invasive and painful-typically comprised of surgery, chemotherapy, and/or radiation treatment."

( Frieboes, HB; Huss, MK; Sims, LB; Steinbach-Rankins, JM, 2017)

"Molecularly targeted cancer therapies, specifically small-molecule protein kinase inhibitors, form an important part of cancer therapy."

( Li, Y; Liu, K; Ma, X; Shu, X; Sun, X; Wang, C; Wang, L; Yao, Y; Yuan, H; Zhang, J; Zhao, J, 2017)

"Thousands of cancer patients requiring radiotherapy do not have access to this treatment in the Brazilian public health system."

( Fernandes, GDS; Mendez, LC; Moraes, FY; Weltman, E, 2018)

"In the conventional non-invasive cancer treatments, such as photodynamic therapy (PDT) and photothermal therapy (PTT), light irradiation is precisely focused on tumors to induce apoptosis via the generation of reactive oxygen species (ROS) or localized heating."

( Du, D; Li, H; Lin, Y; Lu, Q; Luo, Y; Shi, Q; Song, Y; Ye, R; Zhu, C, 2017)

"Currently, four gene therapeutics, two cancer vaccines with genetic bases, and seven epigenetic medications are available for cancer treatment."

( Abdollahi, M; Rahmani, S, 2017)

"In ovarian cancer patients with a platinum treatment-free interval of 6-12 months treated with trabectedin + pegylated liposomal doxorubicin (PLD) or single-agent PLD, and retreated with platinum after relapse, overall survival was significantly prolonged in the trabectedin + PLD group."

( Ray-Coquard, I, 2017)

"Metformin treatment reduces the risk of cancer in type 2 diabetes patients."

( Junik, R; Muszyńska-Ogłaza, A; Olejniczak, H; Polaszewska-Muszyńska, M; Zarzycka-Lindner, G, 2017)

"Cancer is a complex disease where cancer stem cells (CSCs) maintain unlimited replicative potential, but evade chemotherapy drugs through cellular quiescence."

( Diwakar, BT; Korwar, AM; Paulson, RF; Prabhu, KS, 2017)

"Current treatments for cancer and the central nervous system diseases are limited, partly due to the difficulties posed by the insolubility, poor distribution of drugs among cells and lack of selectivity of drugs, the inability of drugs to cross cellular barriers and blood brain barrier (BBB)."

( Guo, Q; Li, YY; Shen, XT; Xu, SQ, 2017)

"However, resistance among cancer cells has emerged as a major barrier to effective treatment using DOX."

( Chen, C; Deng, X; He, G; Lu, L; Tao, X; Wu, D; Yan, S; Yao, H; Yi, H, 2018)

"Survivors of childhood cancer treated with anthracyclines carry the risk for developing late-onset cardiotoxicity."

( Babaoğlu, K; Başar, EZ; Çetin, S; Çorapçıoğlu, F; Deveci, M, 2018)

"However, most tumors ultimately become resistant to BRAF-targeted monotherapy."

( Hess, KR; Hong, DS; Meric-Bernstam, F; Sen, S; Subbiah, V, 2017)

"Hypoxia plays a central role in cancer progression and resistance to therapy."

( Ando, Y; Lee, SS; Raola, S; Shen, K; Ta, HP; Yen, DP, 2017)

"All patients had been treated for a malignancy with immune checkpoint inhibitors targeting PD-1 (nivolumab, pembrolizumab), PD-L1 (durvalumab), and/or CTLA-4 (ipilimumab, tremelimumab) at Memorial Sloan Kettering Cancer Center."

( Bass, AR; Smith, MH, 2019)

"At the end of life of cancer patients, sedation is sometimes needed, in order to palliate unbearable symptoms that other treatments fail to relieve."

( Beneton, A; Brosse, C; Magné, N; Morisson, S; Pacaut, C; Poenou, G; Vallard, A, 2017)

"FQ enhances the anticancer activity of several chemotherapeutics suggesting its potential application as an adjuvant to existing anticancer therapy."

( Biot, C; Delcourt, P; Dewailly, E; Dubois, C; Gordienko, D; Kondratska, K; Kondratskyi, A; Lemière, S; Prevarskaya, N; Skryma, R; Slomianny, C; Toillon, RA; Vanden Abeele, F, 2017)

"262 patients with malignant tumors, confirmed by pathological and radiological diagnosis as malignant tumor were randomly divided into 2 groups: the control group with chemotherapy; the treatment group with chemotherapy and 20 mg/d fluoxetine for six weeks."

( Dai, J; Liao, N; Shi, J; Tao, JQ, 2017)

"However, tumors arise, progress, and respond to therapy in the context of an intimate crosstalk with the host immune system, and many immunological functions rely on intact mitochondrial metabolism."

( Filigheddu, N; Galluzzi, L; Kroemer, G; Pedro, JMB; Porporato, PE, 2018)

"Chemotherapy is still one of the main cancer therapy treatments, but the curative effect of chemotherapy is relatively low, as such the development of a new cancer treatment is highly desirable."

( Chen, B; Liu, Z; Tang, H; Zhang, J, 2017)

"Personalized cancer therapy is based on a patient's tumor lineage, histopathology, expression analyses, and/or tumor DNA or RNA analysis."

( Benes, CH; Damon, LJ; Dardaei, L; Dastur, A; Dicecca, R; Engelman, JA; Farago, AF; Fintelmann, FJ; Friboulet, L; Gainor, JF; Greenberg, M; Held, MA; Kattermann, KE; Kodack, DP; Lee, D; Niederst, MJ; Parks, M; Piotrowska, Z; Riley, AK; Rizzo, C; Sequist, LV; Shaw, AT; von Flotow, F, 2017)

"Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN), which includes numbness, tingling, pain, cold sensitivity, and motor impairment in the hands and feet."

( Asare, M; Berenberg, J; Culakova, E; Fung, C; Gewandter, JS; Giguere, J; Heckler, CE; Janelsins, MC; Kamen, C; Kesler, SR; Kleckner, IR; Lin, PJ; Mohile, NA; Mustian, KM; Reddy, PS, 2018)

"Therefore, the cure efficiency of cancer chemotherapy depends not only on how the anticancer drug is delivered to its targets but also on the anticancer drug itself."

( Pinto, DCGA; Silva, AMS, 2017)

"Exosomes released from cancer cells support metastasis and growth of recipient cells and increase their resistance to chemotherapy."

( Alawadhi, H; El-Awady, R; Harati, R; Khan, FM; Saleh, E; Zimmermann, WH, 2018)

( Agrawal, S; Kumar, A; Moulik, NR, 2017)

"From cancer patients under chemotherapy we show that fucosylated AGP could be a clinically relevant biomarker for cancer progression or prognosis as well as for an early assessment of clinical response and treatment outcomes."

( Asao, T; Kaira, K; Kuwano, H; Yazawa, S; Yokobori, T, 2018)

"Eight patients with terminal cancer were treated with iAOR."

( Baldini, N; Inoue, K; Kusuzaki, K; Takai, S; Takai, T; Yoshimura, H, 2018)

"Oral cancers are extremely common among adults with increasing incidences due to human papillomavirus, while treatment modalities are limited."

( Abu El-Naaj, I; Bianco-Peled, H; Ghantous, Y; Goldfeder, M; Prinz, H; Schroeder, A; Shainsky, J; Shtenberg, Y, 2018)

"Its use in photodynamic therapy of tumors thus requires the development of methodologies for specific addressing of the photosensitizer to malignant cells while sparing normal tissue."

( Bilkis, I; Silman, I; Weiner, L, 2018)

"Children with newly diagnosed cancer who were admitted to our center were evaluated for serum selenium, iron, ferritin, C-reactive protein, vitamin B12, folate, and 25-OH vitamin D levels at presentation, and at the third and sixth months of cancer treatment."

( Bayhan, T; Demir, HA; Emir, S; Gunduz, M; Gurlek Gokcebay, D; Koc, N; Ozyoruk, D, 2018)

"To make systemic anti-cancer therapy (SACT) preparation more practicable, dose-banding approaches are currently being introduced in many clinical centres."

( Boddy, AV; Chatelut, E; Osborne, C; Paci, A; Veal, GJ; White-Koning, M, 2018)

"Nanomedicine have shown success in cancer therapy, but the pharmacological actions of most nanomedicine are often nonspecific to cancer cells because of utilization of the therapeutic agents that induce cell apoptosis from inner organelles."

( Ai, X; Jiang, Y; Pu, K; Xie, C; Xing, B; Zhen, X, 2018)

"Targeting key regulators of the cancer stem cell phenotype to overcome their critical influence on tumor growth is a promising new strategy for cancer treatment."

( Jackson, TL; Nazari, F; Nör, JE; Pearson, AT, 2018)

"Here, the current strategies of cancer therapy based on ferroptosis will be elaborated, the design considerations and the advantages and limitations are highlighted, and finally a future perspective on this emerging field is given."

( Chen, X; Shen, Z; Song, J; Wu, A; Yung, BC; Zhou, Z, 2018)

"Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE."

( Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE, 2018)

"The decision for a person with cancer to start LMWH therapy should balance the benefits and harms and consider the person's values and preferences."

( Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE, 2018)

"Importantly, cancer cells often develop resistance to chemotherapy, and formulating anticancer drugs into nanomedicines also helps overcome chemoresistance."

( Chen, Z; Cui, Z; Shi, Y; Zheng, Y, 2018)

"The treatment regimen for controlling cancer includes a number of approaches depending on the classification of the tumor."

( Valentovic, MA, 2018)

"Induction of oxidative stress in cancer cells is one of the cancer treatment strategies as controlled and targeted release of hydrogen peroxide can theoretically induce sufficient oxidative stress to kill cancer cells."

( Bay, BH; Gopalakrishnakone, P; Tan, KK, 2018)

"To develop a cancer targeting lactate attenuator in vivo for cancer phototherapy and inhibition of HIF-1, we report an aptamer modified photo-responsive nanoparticle (labeled as Mn-D@BPFe-A) for lactate oxidation and cancer phototherapy."

( Chen, QY; Gao, J; Huang, T; Lu, WL; Yang, H; Zhao, Y, 2018)

"Vascular supply of tumors is one of the main targets for cancer therapy."

( Akhmanova, A; Aviles, P; Bouchet, BP; Galmarini, CM; Guillen-Navarro, MJ; Martin, M; Martínez-Diez, M; Martinez-Leal, JF, 2018)

"During the last few decades, cancer has mushroomed as a major health issue; and almost all drugs used for its therapy are very toxic with lethal side effects."

( Afreen, A; Afzal, MN; Ahmed, Z; Khalid, N; Majeed, F; Malik, FZ, 2018)

"Currently cancer treatment is in large part non-specific with respect to treatment."

( Leblanc, RM; Pardo, J; Peng, Z, 2018)

"PDT has mostly been developed as a cancer therapy but can also be used as an antimicrobial approach against localized infections."

( Hamblin, MR, 2018)

"The major goal of cancer chemotherapy is to maximize the therapeutic efficacy of anticancer drugs, while minimizing their associated side effects."

( Choi, HG; Choi, JY; Gupta, B; Jeong, JH; Jin, SG; Kim, JO; Ramasamy, T; Yong, CS, 2018)

"In order to improve the effect of cancer therapy, the timely and accurate detection of the cancer is important and necessary."

( Gong, W; Hu, Z; Lai, Z; Li, J; Li, X; Liang, Y; Lu, X; Tan, J; Wang, Y; Zhao, Y; Zheng, R, 2018)

"The power of T cells for cancer treatment has been demonstrated by the success of co-inhibitory receptor blockade and adoptive T-cell immunotherapies."

( Campbell, E; Gallimore, A; Godkin, A; Hughes, E; Jones, E; Scurr, M, 2018)

"Forty-nine primarily solid-tumor cancer patients who failed standard therapy received weekly APFO doses (50-1200 mg) for 6 weeks."

( Barnett, AL; Church, TR; Convertino, M; Doyle, E; Elcombe, CR; Evans, TRJ; Liu, Y; MacPherson, IR; Olsen, GW; Samuel, LM, 2018)

"Improved understanding of cancer immunology has provided insight into the phenomenon of frequent tumor recurrence after initially successful immunotherapy."

( Aerts, JL; Bevers, S; Bialkowski, L; Heirman, C; Renmans, D; Thielemans, K; Tjok Joe, P; Van der Jeught, K, 2018)

"An understanding of the origin of cancer is critical for cancer prevention and treatment."

( Bjørge, T; Gissler, M; Glimelius, I; Grotmol, T; Kitahara, CM; Myrtveit Saether, SM; Ording, AG; Sköld, C; Sørensen, HT; Trabert, B; Troisi, R, 2018)

"For patients whose metastatic cancer did not respond to multiline chemotherapy or who were unwilling to receive chemotherapy, the use of TCEE as an adjuvant therapy to AmB resulted in tumor suppression and a delay in time to disease progression."

( Chang, CC; Chang, YJ; Chen, RJ; Chiou, HY; Kuo, LJ; Shi, YC; Su, CH; Tai, CJ; Tzao, C; Wu, CH, 2020)

"No significant differences in other cancers incidence in any duration of VPA treatment."

( Hsieh, TC; Lin, CC; Wu, LS, 2018)

"Photodynamic therapy is a promising cancer therapy modality but its application for deep-seated tumor is mainly hindered by the shallow penetration of visible light."

( Arellano, DL; Chauhan, K; Fournier, PGJ; Hirata, GA; Jain, A; Juárez, P; Sengar, P; Verdugo-Meza, A, 2018)

"Hyperthermia is an anti-cancer treatment in which the temperature of the malignant tumor is increased more than other adjacent normal tissues."

( Akbarzadeh, F; Khoshgard, K; Norouzi, H, 2018)

"In the case of cancers refractory to standard chemotherapy, and regarding our system of access to drugs illustrated by the PROFILER clinical trial, this approach allows the access to a therapeutic drug targeting specific biomarkers only in 7% of patients included."

( Albin, N; Mc Leer, A; Sakhri, L, 2018)

"Its administration against cancer pain is, however, tenable, albeit restricted to certain clinical situations."

( Mikus, G; Theile, D, 2018)

"In MRI-guided cancer radiotherapy, the dose perturbation effects for therapeutic beams are relatively obvious, and the beam energies of therapeutic beams have large impacts on the magnetic-induced dose perturbations with the presence of a 1."

( Bai, Y; Geng, C; Gong, C; Guan, F; Shao, W; Shu, D; Tang, X, 2018)

"Emerging PSi advances in the context of cancer immunotherapy are also highlighted."

( Ding, Y; Fontana, F; Hirvonen, JT; Li, W; Liu, D; Liu, Z; Santos, HA, 2018)

"Precision Medicine Guided Treatment for Cancer Pain is a pragmatic clinical trial that seeks to determine the utility of CYP2D6 genotype-guided opioid prescribing in patients with cancer."

( Cavallari, LH; Chang, YD; Clare-Salzler, M; Donovan, KA; George, TJ; Gong, Y; Gopalan, P; Hicks, JK; Langaee, T; McLeod, HL; Mosley, SA; Portman, DG; Rajasekhara, S; Schmit, J; Silver, N; Smith, JE; Soares, HP; Starostik, P; Starr, J, 2018)

"Immunotherapy is revolutionizing cancer treatment."

( Huang, AY; Kim, JA; Zhang, M, 2018)

"A total of 643 cancer patients (317 females and 326 males) with malignant biliary obstruction were treated with percutaneous drainage at our hospital between 1999 and 2016."

( Kallio, R; Niemelä, J; Ohtonen, P; Perälä, J; Saarnio, J; Syrjälä, H, 2018)

"The therapeutic performance of cancer radiotherapy is often limited by the overexpression of glutathione (GSH) in tumors and low radiation sensitivity of cancerous cells."

( Chen, X; Chen, Z; Cheng, X; Gu, N; Jia, HR; Jiang, YW; Liu, P; Ma, N; Wu, FG; Xia, LY; Zhang, X, 2018)

"Upregulation of MASTL in various cancers and its association with poor patient survival establishes it as an important drug target in cancer therapy."

( Ammarah, U; Bal, NC; Kumar, A; Misra, G; Pal, R, 2018)

"AGS (gastric cancer cell line), Caco-2 (colon cancer cell line) and T3M4 (pancreatic cancer cell line) were treated by cisplatin and different temperature setting (37 °C to 45 °C) either in isolation, or in combination."

( Barauskas, G; Cesna, V; Dambrauskas, Z; Gulbinas, A; Jasukaitiene, A; Naginiene, R; Paskauskas, S; Sukovas, A, 2018)

"A total of 42 cancer patients (41-63 years old) who received intravenous chemotherapy were randomized in a double-blind controlled trial at the National Cancer Institute in Thailand."

( Adulbhan, A; Bumrungpert, A; Nunthanawanich, P; Pavadhgul, P; Sirikanchanarod, A, 2018)

"Background Cancer patients with acute venous thromboembolism (VTE) receiving anticoagulant treatment have an increased bleeding risk."

( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2018)

"placebo among cancer patients on chemotherapy."

( Ades, S; Butenas, S; Callas, P; Cory, S; Cushman, M; Douce, D; Holmes, CE; Prior, S, 2018)

"Human melanoma (A7), prostate cancer (PC3), mouse fibrosarcoma (T241) and endothelial (MS1) cells were assayed for proliferation, migration, invasion and colony formation after treatment with calpeptin."

( Akyürek, LM; Ala, C; Alvandian, A; Bandaru, S; Devarakonda, S; Gökalp, S; Salimi, R; Yener, N, 2018)

"The only perspective trial found no cancer increase in patients treated with glargine."

( Belfiore, A; Frittitta, L; Manzella, L; Sciacca, L; Squatrito, S; Tumminia, A; Vella, V; Vigneri, R, 2018)

"Methods for treating cancer include surgery, radiotherapy and chemotherapy in addition to other specialized techniques."

( Bishayee, A; Khan, H; Mubarak, MS; Nabavi, SM; Saeedi, M, 2019)

"Key search terms were pediatric cancer, psycho-oncology, children with cancer + psychological intervention, or multimodal treatment, psychotherapy, cognitive training, behavioral, social skills+ feasibility study, pilot, randomized controlled trial, case study, systematic reviews."

( Bakhshi, S; Chadda, RK; Kaushal, T; Satapathy, S, 2018)

"However, its clinical application for cancer treatment was severely hindered by poor aqueous solubility and chemical instability."

( Du, S; Xiao, Y; Xiong, H; Xu, C; Yao, J; Yin, L; Zhou, J, 2018)

"Cancer cachexia negatively impacts cancer-related treatment options, quality of life, morbidity, and mortality, yet no established therapies exist."

( Chamberlain, A; Danesi, C; Dillon, EL; Durham, WJ; Gilkison, CR; Hatch, SS; Horstman, AM; Jupiter, DC; McCammon, S; Randolph, KM; Richardson, G; Sheffield-Moore, M; Urban, RJ; Willis, M; Wright, TJ, 2018)

"In patients with advanced cancer undergoing the early phase of standard of care therapy, adjunct testosterone improved lean body mass and was also associated with increased quality of life, and physical activity compared with placebo."

"Patients with various types of advanced cancer were enrolled if chemotherapy was scheduled or started in the previous 3 months."

( Berckmans, RJ; Büller, HR; Cesarman, G; Di Nisio, M; Hisada, Y; Kamphuisen, PW; Kleinjan, A; Mackman, N; Mahé, I; Nieuwland, R; Otten, HM; van Es, N, 2018)

"The treatment of SK-MEL-2 cancer cells with 6i showed apoptosis and morphological changes like cell shrinkage, cell wall deformation and reduced number of viable cells."

( Damale, MG; Gawhane, PA; Nikalje, AG; Sangshetti, JN; Tiwari, SV, 2018)

"Chemotherapy is used to treat most cancer patients, yet our understanding of factors that dictate response and resistance to such drugs remains limited."

( Bandyopadhyay, S; Barthelet, A; Harding, TC; Hu, HM; Kaushik, S; Lin, KK; Raponi, M; Robillard, L; Shah, KN; Simmons, AD; Zhao, X, 2018)

"Effective anti-cancer therapy is hurdled by the complicated extracellular and intracellular barriers, and thus a smart gene vector that can enable programmable gene delivery is highly demanded."

( Chen, Y; He, H; Wang, J; Wang, X; Xu, X; Yin, L, 2018)

"Local application of anticancer agents prolongs the presence time and increases the concentration of drug in the target place and therefore may reduce serious side effects compared to drug systemic administration."

( Bosakova, Z; Eckschlager, T; Hampejsova, Z; Hobzova, R; Hrabeta, J; Janouskova, O; Kopeckova, K; Plch, J; Sirc, J; Venclikova, K, 2018)

"We enrolled 150 cancer patients who underwent chemotherapy, which included irinotecan, in our outpatient chemotherapy center between October 2014 and January 2017."

( Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T, 2018)

"To enhance the anticancer activity, tumor penetration ability of the hybrid anticancer peptide, in this study, a TAT (RKKRRQRRR) peptide modified kla peptide (KLAKLAKKLAKLAK, with all D-amino acids), named kla-TAT, was co-administrated with the homing/penetrating peptide iRGD which could enhance the permeability of chemical drug in solid tumor and tumor vessel by co-administration."

( Chen, X; Chen, Y; Hu, C; Huang, Y, 2018)

"Children with cancer who die in high-acuity inpatient settings often experience a high burden of intensive therapy at the end of life."

( Baker, JN; Blazin, LJ; DeMarsh, S; Gushue, CA; Jerkins, J; Johnson, LM; Kaye, EC; Levine, DR; Lu, Z; Morrison, RR; Snaman, JM; Sykes, A, 2018)

"The great costs associated with curing cancer, through developing novel treatments and applying patented therapies, is an increasing burden to developed and developing nations alike."

( Fakih, O; Kane, D; Sanver, D; Thorne, JL, 2018)

"However, many cancer-cell types require exogenous methionine for survival and therefore methionine restriction is a promising avenue for treatment."

( Bertino, JR; Chaturvedi, S; Hoffman, RM, 2018)

"Delirium in patients with terminal cancer is irreversible and increases treatment resistance, which leads to a deterioration in quality of life."

( Fujii, R; Fukunaga, M; Hasuo, H; Kanbara, K; Sakuma, H; Uchitani, K, 2018)

"Ninety-seven patients with terminal cancer who were treated with intravenous chlorpromazine for irreversible delirium were included."

( Fujii, R; Fukunaga, M; Hasuo, H; Kanbara, K; Sakuma, H; Uchitani, K, 2018)

"With the coming of age of cancer immunotherapy, ectonucleotidases and adenosine receptors have emerged as novel therapeutic targets to enhance antitumor immune responses."

( Allard, B; Allard, D; Chrobak, P; Messaoudi, N; Stagg, J, 2019)

"A deeper understanding of SLC7A11 in cancer metabolism may identify new therapeutic opportunities to target this important amino acid transporter for cancer treatment."

( Gan, B; Koppula, P; Zhang, Y; Zhuang, L, 2018)

"Tumor vaccines for cancer prevention and treatment have attracted tremendous interests in the area of cancer immunotherapy in recent years."

( Chen, Q; Liu, Z; Peng, R; Sun, X; Xu, J; Xu, L; Yang, R; Zhao, Y, 2018)

"For image-guided cancer phototherapy, indocyanine green (ICG) is loaded into RGD-HBc VLP via a disassembly/reassembly pathway and electrostatic attraction with high efficiency."

( Bi, S; Chen, B; Chen, R; Nie, L; Ren, L; Shan, W; Ye, S; Zhang, Q; Zhao, J; Zhou, X, 2018)

"Active cancer was defined as a histologically confirmed malignancy, which was diagnosed or treated within the previous 6 months, or as a recurrent/ metastatic cancer."

( Bang, SM; Choi, WI; Hwang, HG; Kim, KH; Kim, SH; Kwon, YS; Lee, KW; Mun, YC; Nam, SH; Oh, D; Song, EK; Yhim, HY, 2019)

"Individual mice with 4T1 breast cancer were treated with either nanoparticle-delivered or free doxorubicin, with results demonstrating improved cancer kill efficacy of doxorubicin loaded nanoparticles in comparison to free doxorubicin."

( Brinker, CJ; Brocato, TA; Coker, EN; Cristini, V; Durfee, PN; Lin, YS; Townson, J; Wang, Z; Wyckoff, EF, 2018)

"Cancer cells in hypoxic tumors are remarkably resistant to photodynamic therapy."

( Huang, W; Xu, S; Yan, D; Zhang, C; Zhou, Y; Zhu, X, 2018)

"The drug reportedly not only has anticancer activity itself, but also increases cancer cells susceptibility to radiation therapy and, additionally, reduces long-term side effects of this therapy."

( Golunski, G; Piosik, J; Woziwodzka, A, 2018)

"In this study, key nanostructures for cancer therapy including gold nanoparticles, magnetite iron oxide nanoparticles, organic nanomaterials, and novel two-dimensional nanoagents such as MXenes are discussed."

( Elzatahry, AA; Hussein, EA; Nasrallah, GK; Zagho, MM, 2018)

"Immunotherapy of cancer has finally materialized following the success of immune checkpoint blockade."

( Ohta, A, 2018)

"To selectively kill the cancer stem cells conventional cancer therapies could be followed with a therapy based on inactivating human chronic gonadotrophin (HCG)."

( Li, CJ; Pardee, AB, 2018)

"One hundred twenty two consecutive ICU cancer patients with AKI treated with citrate-based CVVHD were prospectively evaluated in this prospective observational study."

( Bezerra, JS; Burdmann, EA; Caires, RA; Costa E Silva, VT; Costalonga, EC; Fukushima, JT; Hajjar, LA; Oikawa, L; Oliveira Coelho, F; Oliveira, APL; Soares, CM, 2018)

"Overall risk of first cancer was not associated with incomplete viral suppression; however, cancer remains a significant threat to HIV patients after treatment initiation."

( Achenbach, CJ; Althoff, KN; Cole, SR; Dittmer, DP; Eron, JJ; Lee, JS; Mathews, C; Miller, WC; Moore, RD; Richardson, DB, 2018)

"Targeting cancer metabolism and untuning the tumor metabolic machine has emerged as a promising strategy for cancer therapy."

( Cao, Q; Gan, Z; Hao, L; Ji, LN; Li, Z; Mao, ZW; Tong, YX; Yang, J; Zhang, H; Zhou, D, 2018)

"Patients with hematologic tumors, a neuropathic component of the index pain, and no treatment with opioid analgesics before RT were more likely to experience pain palliation after RT."

( Matsuyama, T; Ninomura, S; Oya, N; Saito, T; Tomitaka, E; Toya, R, 2018)

"In models of brain cancer and AML, tumor growth was potently inhibited in vivo following IACS-010759 treatment at well-tolerated doses."

( Ackroyd, J; Agip, AA; Al-Atrash, G; Asara, J; Bandi, M; Bardenhagen, J; Bristow, C; Carrillo, CC; Carroll, C; Chang, E; Ciurea, S; Cross, JB; Czako, B; Daver, N; de Groot, JF; Deem, A; DePinho, RA; Di Francesco, ME; Do, MG; Dong, JW; Draetta, GF; Feng, N; Gao, G; Gay, J; Gera, S; Giuliani, V; Greer, J; Han, J; Han, L; Heffernan, TP; Henry, VK; Hirst, J; Huang, S; Jiang, Y; Jones, P; Kang, Z; Khor, T; Konoplev, S; Konopleva, M; Lin, YH; Liu, G; Lodi, A; Lofton, T; Ma, H; Mahendra, M; Marszalek, JR; Matre, P; McAfoos, T; Molina, JR; Morlacchi, P; Muller, F; Mullinax, R; Peoples, M; Petrocchi, A; Protopopova, M; Rodriguez-Canale, J; Serreli, R; Shi, T; Smith, M; Sun, Y; Tabe, Y; Theroff, J; Tiziani, S; Toniatti, C; Xu, Q; Zhang, Q, 2018)

"Eligible patients were opioid-naïve cancer inpatients who received continuous oxycodone infusion as a treatment for dyspnea under the care of the palliative care team at Komaki City Hospital between November 2013 and December 2016."

( Deguchi, Y; Hirano, S; Kumon, A; Odagiri, T; Okumura, Y; Osada, T; Sakurai, A; Watanabe, H; Watanabe, N; Yamamoto, Y; Yamamura, K, 2018)

"The chemical treatment of cancer started with the realization that DNA damaging agents such as mustard gas present notable antitumoural properties."

( Fernandez-Capetillo, O; Lecona, E, 2018)

"Multidrug resistance (MDR), which leads tumors resistance to traditional anticancer drugs, can cause the failure of chemotherapy treatments."

( Adeli, M; Chen, W; Guday, G; Haag, R; Qiao, H; Tu, Z; Yan, Y, 2018)

"Chemophototherapy is an advanced cancer therapeutic that uses photothermal nanocarriers (NCs) responsive to near-infrared (NIR) light."

( Byeon, JH; Gautam, M; Kim, JO; Ku, SK, 2018)

"For development of targeted cancer therapy, attention is given to kinases rather than phosphatases inhibitors."

( Abdu-Allah, H; Al-Azawi, AM; El-Awady, R; El-Shorbagi, AN; Menon, V; Ramadan, W; Saleh, E; Tarazi, H; Vazhappilly, CG, 2019)

"The number of cancer survivors is exponentially increasing worldwide, due to both advances in cancer detection and treatment strategies, as well as the aging and growth of the population."

( Finet, JE; Wiggers, GA, 2018)

"Among cancer patients treated for tobacco dependence with varenicline, adherence is associated with smoking cessation."

( Bastian, J; Carroll, A; Crawford, G; Flitter, A; Hitsman, B; Jao, NC; Kalhan, R; Leone, F; Schnoll, R; Weisbrot, J, 2019)

"Sensitive detection of cancer cells is beneficial to the early diagnosis of cancer and individual treatment."

( Chen, D; Chen, L; Qin, W; Sun, D; Wang, Z; Zhang, Y; Zhou, L, 2018)

"However, the survival of adult cancer patients has improved with improved cancer diagnoses and treatments, and death education should be initiated before the dying stage."

( Luo, ZQ; Qiang, WM; Zhao, SX; Zheng, XN, 2018)

"In recent years, cancer has become the most common human disease worldwide, and great attentions have been paid to clarifying the carcinogenesis and identifying new effective antitumor therapy."

( Sun, X; Yan, P, 2018)

"Current anticancer drug discovery efforts focus on the identification of first-in-class compounds with a mode-of-action distinct from conventional DNA-targeting agents for chemotherapy."

( Ang, WH; Babak, MV; Cheong, MC; Chow, MJ; Gaiddon, C; Pastorin, G; Tan, KW, 2018)

"Patients with RAS-positive tumors respond poorly to chemotherapies and have a few treatment options."

( Fujisaka, Y; Furuse, J; Iwasa, T; Kitamura, H; Kurata, T; Nagashima, F; Nakagawa, K; Naruge, D; Okano, N; Shimizu, T, 2018)

"Targeting cancer metabolism for therapy has received much attention over the last decade with various small molecule inhibitors entering clinical trials."

( Bajpai, R; Shanmugam, M, 2018)

"Through this targeted cancer nanotherapy, cancer cells are killed with higher specificity, while the healthy cells are spared."

( Lee, LTO; Ma, X; Xiong, Y, 2018)

"Immunosuppressive tumors generally exhibit poor response to immune checkpoint blockade based cancer immunotherapy."

( Abbaraju, PL; Fu, J; Gu, Z; Jambhrunkar, M; Lei, C; Liu, Y; Song, H; Tang, J; Yang, Y; Yu, C; Zhang, M, 2018)

"Targeted cancer immunotherapy offers increased efficacy concomitantly with reduced side effects."

( Abdel-Rahman, N; Abraha, F; Bjerregaard-Andersen, K; Bousquet, PA; Burschowsky, D; Heggelund, JE; Hoås, HM; Høydahl, LS; Johannesen, H; Krengel, U; Løset, GÅ; Oscarson, S; Rojas, G, 2018)

"Various cancer therapeutic strategies have also been developed based on the catalytic chemistry of GOx: (1) the consumption of glucose provides an alternative strategy for cancer-starvation therapy; (2) the consumption of oxygen increases tumor hypoxia, which can be harnessed for hypoxia-activated therapy; (3) the generation of gluconic acid enhances the acidity of the tumor microenvironment, which can trigger pH-responsive drug release; (4) the generation of H2O2 increases the levels of tumor oxidative stress, and the H2O2 can be converted into toxic hydroxyl radicals that can kill cancer cells upon exposure to light irradiation or via the Fenton reaction."

( Fu, LH; Huang, P; Lin, J; Qi, C, 2018)

"Synergistic treatment of cancer can be achieved by combining chemotherapy with the photothermal effect of GNS."

( Chen, M; Cheng, Y; Feng, Q; Huang, L; Liang, F; Liu, S; Xu, C; Xu, P; Yang, X, 2018)

"The in vitro and in vivo anticancer results demonstrate that HA-PLGA@ART/ALA delivery system could provide a prospective comprehensive treatment strategy for cancer therapy."

( Hao, Y; Hu, Y; Li, L; Niu, M; Wang, L; Yin, Y; Zhang, Y; Zhang, Z; Zhao, H; Zheng, C, 2018)

"Many cancers are variably resistant to radiation treatment: some patients die within months, while others with the same tumour type and equivalent radiation protocol, survive for years."

( Doble, PA; Miklos, GLG, 2018)

"The overexpression of ABCB1 in cancer cells is a major factor contributing to the development of multidrug resistance (MDR) and treatment failure in cancer patients."

( Ambudkar, SV; Hsiao, SH; Hung, TH; Li, YQ; Murakami, M; Wu, CP; Wu, YS; Yeh, N, 2018)

"The efficacy of cancer chemotherapy can be generally restrained by the multiple drug resistance (MDR) of tumors, which is typically attributed to the upregulation of ATP-binding cassette (ABC) transporter proteins, such as P-glycoprotein (P-gp)."

( Chen, Z; Li, S; Li, T; Liu, Y; Qin, X; Shen, X; Wu, C; Xie, X; Yan, J; Yang, H, 2018)

"In line with the dependence of cancer on iron, we also discuss iron-dependent mechanisms as druggable pathways, as iron chelators have been considered for tumor therapy and new molecules currently proposed and studied as antineoplastic drugs may impinge on iron and its capacity to promote oxidative stress to have therapeutic value in cancer."

( Cairo, G; Gammella, E; Recalcati, S, 2019)

"Patients with lung cancer undergoing chemotherapy were included in this retrospective study where serum iron level, unsaturated iron-binding capacity (UIBC), total iron-binding capacity, and ferritin were available prior to and on days 2 and 8 of chemotherapy."

( Gemma, A; Kondo, H; Miya, T, 2018)

"Tumor-targeted delivery of anticancer agents using nanocarriers has been explored to increase the therapeutic index of cancer chemotherapy."

( Cho, JW; Kim, JH; Kim, JS; Kim, WJ; Nam, YS; Park, K; Seah, GL; Yang, MY; Yu, JH, 2018)

"Although most cancer patient cells initially respond well to the treatment, the clinical effectiveness declines over time as the cancer cells develop resistance to the drugs."

( Lambert, IH; Sørensen, BH, 2018)

"The eradication of cancer in a patient remains an elusive challenge despite advances in early detection and diagnosis, chemo- and immunotherapy, pinpoint radiation treatments, and expert surgical intervention."

( Hatamipour, M; Johnston, TP; Ramezani, M; Sahebkar, A; Tabassi, SAS, 2018)

"Most cancer and arthritis treatments affect normal cell function to cause significant adverse effects in patients."

( Blanco, FJ; Goldberg, GS; Krishnan, H; Miller, WT, 2019)

"In our study, obese and overweight cancer patients did not show a statistically significant difference in terms of effectiveness and toxicity compared to normal-weight cancer patients who were treated with carboplatin using their actual body weight with the Calvert formula and Cockcroft-Gault for CrCl estimation."

( Carrera Hueso, FJ; Gasent Blesa, JM; Grueso Cuesta, C; Moreno Royo, L; Poquet Jornet, JE; Valdivia Perez, A, 2019)

"Timely supportive care for cancer patients is advocated but these results suggest that older patients and those who do not receive anti-cancer treatment or opioid analgesics miss out."

( Bennett, MI; Craigs, CL; Hurlow, A; West, RM; Ziegler, LE, 2018)

"Rise in incidence of various cancers and growing adoption of biological therapy to avoid side effects of conventional cancer therapies is driving the growth of the cancer biotherapy market globally."

( Dhankhar, R; Gulati, P; Kapoor, RK; Kumar, S, 2018)

"ADI-based cancer therapy holds potential in treating liver, skin, lung, gastrointestinal, and blood cancer."

( Dhankhar, R; Gulati, P; Kapoor, RK; Kumar, S, 2018)

"psilocybin, LSD) in treating cancer-related psychiatric distress."

( Ross, S, 2018)

"In vivo studies further supported anticancer role for fraxinellone, demonstrating that fraxinellone treatment inhibited the growth of tumor xenografts."

( Jin, X; Li, MY; Ma, J; Mi, C; Wang, JY; Wang, Z; Xing, Y; Zhang, ZH; Zuo, HX, 2018)

"In this clinical trial, cancer patients who were suffering from chemotherapy-induced peripheral neuropathy comprised the study population."

( Alavi, A; Farshchian, N; Heydarheydari, S; Moradian, N, 2018)

"On the basis of the hypothesis that cancer immunotherapy, in particular with immune checkpoint inhibitors, increases the incidence of allergic-like immediate ARs to ICM with respect to "standard" cancer chemotherapy/targeted therapy (CHT) we retrospectively evaluated the incidence of CECT-related immediate ARs in cancer patients undergoing cancer treatments."

( Casadei, C; De Rosa, F; Farolfi, A; Gentili, G; Gentili, N; Guidoboni, M; Nanni, O; Petracci, E; Ridolfi, L; Rossi, A, 2018)

"Consecutive, 219 HBsAg-positive cancer patients treated with TDF (n = 106) or ETV (n = 113) for antiviral prophylaxis during chemotherapy with baseline serum creatinine (SCr) <1."

( Chao, Y; Hou, MC; Huang, YH; Lan, KH; Lee, IC; Li, CP; Lin, HC; Su, CW, 2018)

"In pathologies such as cancer, for instance, perfusion imaging and oxygen concentration are less well correlated, and oxygen concentration is independently correlated to radiotherapy response and overall treatment outcomes."

( Bonnitcha, P; Figtree, G; Grieve, S, 2018)

"It is estimated that more than half of cancer patients undergo radiotherapy during the course of their treatment."

( Farhood, B; Goradel, NH; Khanlarkhani, N; Mirtavoos-Mahyari, H; Mortezaee, K; Motevaseli, E; Musa, AE; Najafi, M; Nashtaei, MS; Salehi, E; Shabeeb, D, 2019)

"To overcome irradiation-dependence of cancer phototherapy, a near infrared aza-BODIPY-based photothermogenic photosensitizer BDY with 2-Pyridone group has been synthesized for imaging-guided photothermal synergistic sustainable photodynamic therapy."

( Dong, X; Huang, W; Huang, X; Ou, C; Shao, J; Si, W; Tang, Y; Wang, P; Wu, M; Xiao, W, 2018)

"Radiotherapy is a mainstay of cancer treatment since decades."

( Efferth, T; Fischer, N; Seo, EJ, 2018)

"Here we reviewed the literature on anticancer effects of plant-derived and synthetic cannabinoids, to better understand their mechanisms of action and role in cancer treatment."

( Dariš, B; Ferk, P; Knez, Ž; Tancer Verboten, M, 2019)

( Lemberg, KM; Rais, R; Slusher, BS; Vornov, JJ, 2018)

"Of the 36 patients with tumors that appeared after the onset of the disease, 20 patients had not been treated with immunomodulators or biologics."

( Bosca-Watts, MM; Cortes, X; Gil, R; Hervás, D; Huguet, JM; Iborra, M; Maroto, N; Paredes, JM, 2018)

"Because of different sensitivities of cancer cells for melatonin combination therapy, cancer-specific targeted therapy is also needed to be considered."

( Farhood, B; Hashemi Goradel, N; Khanlarkhani, N; Mortezaee, K; Najafi, M; Namjoo, Z; Nashtaei, MS; Salehi, E, 2019)

"Previously, we showed that KBV20C cancer cells highly resistant to Halaven® (HAL) were sensitized by co-treatment with fluphenazine (FLU)."

( Kim, HS; Kim, JY; Lee, BM; Tae, IH; Yoon, S, 2018)

"Therefore, developing new anti-cancer agents is crucial for cancer treatment."

( Akocak, S; Durgun, M; Gorgisen, G; Gulacar, IM; Kaya, Z; Koyuncu, I; Ozkol, H; Tuluce, Y, 2018)

"Common cancers cell lines were treated with copper complexes."

( Akocak, S; Durgun, M; Gorgisen, G; Gulacar, IM; Kaya, Z; Koyuncu, I; Ozkol, H; Tuluce, Y, 2018)

"Despite advances in cancer therapy, metastasis remains the dominate reason for cancer-related mortality."

( Guo, S; Huang, Q; Shen, Y; Shi, L; Wang, F; Wang, Y, 2018)

"Childhood cancer survivors treated with cisplatin, ifosfamide, or carboplatin are at risk for late kidney and blood pressure (BP) abnormalities."

( Harel-Sterling, M; Hessey, E; Huynh, L; McMahon, KR; Pizzi, M; Zappitelli, M, 2018)

"Adoptive T-cell treatments of solid cancers have evolved into a robust therapy with objective response rates surpassing those of standardized treatments."

( de Graaff, P; Debets, R; Govers, C; Wichers, HJ, 2018)

"Radiotherapy represents a major anti-cancer modality and effectively kills cancer cells through generation of reactive oxygen species (ROS)."

( De Ridder, M; Jiang, H; Wang, H, 2018)

"To treat the cancer there are a number of drugs existing in the market but no drug is found to be completely safe and effective."

( Giri, TK, 2019)

"In vitro anticancer effect and in vivo anticancer therapy was evaluated by CCK8 assay and MDA-MB231 tumor-bearing mice model."

( Cao, Y; Chen, Y; Gong, Y; Guo, Y; Li, P; Li, Y; Liu, F; Ran, H; Wang, Z, 2018)

"A promising therapeutic platform for cancer is offered by nanoparticle-mediated therapy."

( Crawford, BM; Liu, Y; Vo-Dinh, T, 2018)

"Its interplay with cancer development and treatment resistance is complicated and paramount for drug design since an autophagic response can lead to tumor suppression by enhancing cellular integrity and tumorigenesis by improving tumor cell survival."

( Cicero, AFG; Mohajeri, M; Panahi, Y; Sahebkar, A; Shakeri, A, 2019)

"A sample of 1,600 patients with cancer who were current inpatients or newly registered outpatients were recruited and administered a questionnaire that was based on the Brief Pain Inventory."

( Amon, JJ; Babu, S; Chaudhuri, P; Doyle, KE; El Nakib, SK; Jatua, D; Joshi, G; Kumarasamy, V; Kumari, DP; Lohman, D; Mohanthy, S; Palat, G; Rajagopal, MR, 2018)

"People with cancer may experience nausea and vomiting whilst receiving chemotherapy or radiotherapy, or whilst in the palliative phase of illness."

( Burton, MJ; Head, K; Naessens, K; Plugge, E; Sutherland, A; Ware, L; Wee, B, 2018)

"PRP has potential applications in cancer treatment and as an adjunct for other anticancer strategies."

( Chen, F; Chen, H; Ding, N; Ji, L; Liu, B; Meng, F; Qian, H; Sha, H; Xu, Q; Yu, L; Zhang, L; Zhou, Y; Zhu, A, 2018)

"To enhance anticancer efficacy and decrease side effects, the synergistic multi-agent therapy has now increasingly gotten great attention."

( Chen, L; Liu, L; Wang, J; Yin, L, 2018)

"Outcomes of anticancer therapy vary dramatically among patients due to diverse genetic and molecular backgrounds, highlighting extensive intertumoral heterogeneity."

( Bae, JS; Bordyuh, M; Cho, HJ; Choi, JW; Choi, MG; Choi, SW; Chu, T; Elliott, O; Iavarone, A; Jeong, BC; Kang, HJ; Kim, D; Kim, HC; Kim, J; Kim, KM; Kim, M; Kim, NKD; Kim, SH; Kim, ST; Kim, SY; Kong, DS; Kwon, YJ; Lee, IH; Lee, J; Lee, JE; Lee, JI; Lee, JK; Lee, JW; Lee, M; Lee, T; Liu, Z; Nam, DH; Oh, JW; Park, JO; Park, WY; Rabadan, R; Rosenbloom, DIS; Ryu, GH; Sa, JK; Seo, SW; Seo, YJ; Seol, HJ; Shim, YM; Shin, H; Shin, S; Shin, YJ; Sim, MH; Song, M; Song, SY; Verhaak, RGW; Wang, J; Yoon, Y; Zo, JI, 2018)

"The efficacy of a chemotherapy drug in cancer therapy is highly determined by the ability to control the rate and extent of its release in vivo."

( Chung, RJ; Dhawan, U; Li, YQ; Lin, C; Liu, WC; Liu, XR; Wu, KT; Wu, YC; Xu, M; Zhao, G, 2018)

"The emerging field of cancer immunotherapy requires and encourages close working between cellular and molecular pathology and clinical cancer treatment, while providing new hope for patients with cancers that may not have responded to conventional oncological treatments."

( Bateman, AC, 2019)

"We have reported that cancer patients treated with anthracycline-based or nonanthracycline chemotherapy developed an early impairment of myocardial relaxation at echocardiography or persistent elevations of the cardiac hormone B-type natriuretic peptide (BNP)."

( Annibali, O; Armento, G; Calabrese, V; Greco, C; Marchesi, F; Menna, P; Minotti, G; Reggiardo, G; Salvatorelli, E, 2018)

"For the combined therapy to breast cancer MCF-7 tumor, the co-delivery system of PCL-HPG-PEI600/DOX/pMMP-9 resulted in a much better inhibition effect on MCF-7 cell proliferation and migration in vitro as well as the suppression effect on MCF-7 tumors in vivo compared to those of single DOX or pMMP-9 formulation used."

( Kirk, TB; Ma, D; Wu, J; Xu, J; Xu, L; Xue, W; Zhou, X, 2018)

"The subcutaneous tumors in mice treated with modified MP formulations were measured for invasion fixation depth at 6 and 24 h after application."

( Hanioka, N; Murata, M; Ogawa, N; Shigeyama, M; Taguchi, M; Teramachi, H; Yamamoto, H, 2018)

"Advances in cancer therapy have led to a significant improvement of survival in most types of malignancies over the past few decades."

( Maurea, N; Riva, L, 2018)

"A continuous challenge in cancer management is to improve treatment efficacy and to diminish its side effects."

( Balacescu, O; Cruceriu, D; Rakosy, E, 2018)

"Because the most reliable therapy for cancer involves quantitative resection of all diseased tissue, considerable effort has been devoted to improving a surgeon's ability to locate and remove all malignant lesions."

( Gagare, P; Kularatne, SA; Liu, X; Low, PS; Mahalingam, SM; Myers, CH; Norshi, M; Singhal, S, 2018)

"Hypoxia in solid tumors may be a hindrance to effective treatments of tumors in achieving their therapeutic potential, especially for photodynamic therapy (PDT) which requires oxygen as the supplement substrate."

( Chung, HY; Hu, D; Sheng, Z; Song, R; Yao, S, 2018)

"In the mouse xenograft cancer model, the combination of CANA-loaded nanoparticles with radiotherapy (in the presence of an external magnetic field at the tumor site) exhibited higher antitumor activity compared with the combination of free CANA with radiotherapy."

( Angelopoulou, A; Avgoustakis, K; Bakandritsos, A; Hatziantoniou, S; Kakazanis, Z; Kardamakis, D; Khoury, N; Kolokithas-Ntoukas, A; Papaioannou, L; Papatheodorou, S; Zoumpourlis, V, 2018)

"It is the goal for the development of cancer target chemotherapy with specific recognition, efficient killing the tumor cells and tissues to avoid the intolerable side effects."

( Guo, DS; Liu, T; Qiao, Z; Wang, J; Yang, X; Zhang, P; Zhang, Z, 2019)

"The anticancer activity evaluation in vitro was performed using a method similar to the antibody-directed enzyme-prodrug therapy (ADEPT) method."

( Gao, H; Huang, G, 2018)

"The National Comprehensive Cancer Network guidelines suggest combination therapy of antiemetic agents."

( Abe, T; Hayashida, T; Kitagawa, Y; Maeda, H; Nagayama, A; Nakashoji, A; Seki, T; Takahashi, M; Takano, T; Yokoe, T, 2019)

"The combined application of the three cancer treatment approaches clearly demonstrated the feasibility of synergistic tri-modal therapy."

( Chae, A; Gil, YG; Jang, H; Kang, S; Kim, YK; Min, DH, 2018)

"Available data indicate that cancer patients use these products (along with standard treatments) more often than the general population."

( Gubili, J; Mao, JJ; Yeung, KS, 2018)

"While thermal ablation of various solid tumors has been demonstrated using high intensity focused ultrasound (HIFU), the therapeutic outcomes of this technique are still unsatisfactory because of common recurrence of thermally ablated cancers and treatment side effects due to the high ultrasound intensity and acoustic pressure requirements."

( Blum, NT; Cha, JN; Chattaraj, R; Goodwin, AP; Roy, S; Shi, D; Yildirim, A, 2018)

"Over the past few decades, cancer nanomedicine has been under intensive development for applications in drug delivery, cancer therapy, and molecular imaging."

( Du, JZ; Li, HJ; Wang, J, 2018)

"Not surprisingly, tumors differentially modulate factors involved in expressing these marks, contributing to both tumorigenesis and responses to alkylating chemotherapy."

( Bacolla, A; Brickner, JR; Chinnam, NB; Mosammaparast, N; Oyeniran, C; Tainer, JA; Thapar, R, 2019)

"'Targeted' or 'biological' cancer treatments rely on differential gene expression between normal tissue and cancer, and genetic changes that render tumour cells especially sensitive to the agent being applied."

( Ashton, TM; Herbert, KJ; Higgins, GS; Pirovano, G; Prevo, R, 2018)

"Opioids are commonly used to treat cancer-related pain, but carry the risk of severe side effects, limiting their use."

( Ahmedzai, SH; Eerdekens, MH; Kapanadze, S; Koch, ED; Kralidis, G; Meissner, W; Volkers, G, 2019)

"We thus retrospectively studied 350 cancer patients receiving anthracycline-based chemotherapy from 2001 to 2015 in our institution."

( Akashi, K; Fujino, T; Funakoshi, K; Hiasa, KI; Higo, T; Ide, T; Kamezaki, K; Ohtani, K; Sakamoto, I; Tsutsui, H, 2019)

"Developing drugs with anticancer activity and low toxic side-effects at low costs is a challenging issue for cancer chemotherapy."

( Akiyoshi, S; Hirose, L; Iwata, M; Kohara, H; Liao, J; Sawada, R; Tani, K; Yamanishi, Y, 2018)

"Significant progress has been made in cancer immunotherapy with checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)-programmed death-ligand 1 signaling pathways."

( Bao, R; Labadie, BW; Luke, JJ, 2019)

"To synthesize knowledge on cancer risks related to hormonal contraception and to propose recommendations on contraception during treatment and after cancer."

( Baffet, H; Laurence, V; Pragout, D; Raccah-Tebeka, B; Rousset-Jablonski, C, 2018)

"The field of cancer immunotherapy has been revolutionized with the use of immune checkpoint blockade antibodies such as anti-programmed cell death 1 protein (PD-1) and chimeric antigen receptor T cells."

( Chiang, CL; Kandalaft, LE, 2018)

"Although the cancer immunotherapy represents one of the most promising strategies for cancer treatment, the PD-1/PD-L1 pathway, which involves a receptor-ligand interaction, can induced immunosuppression by disabling tumor-infiltrating lymphocytes (TILs)."

( Cao, D; Huang, L; Kong, C; Li, H; Liang, L; Qin, H; Qu, X; Sun, Z; Wang, M; Wang, X; Xu, W; Yan, X; Zhang, Y, 2018)

"in-hospital treatment in children with cancer and febrile neutropenia (FN) with low risk of invasive bacterial infection (IBI)."

( Betanzos-Cabrera, Y; Gil-Veloz, M; Miranda-Novales, G; Pacheco-Rosas, DO; Solórzano-Santos, F; Villasís-Keever, MA, 2018)

"SOFBT in HCV-infected cancer patients is effective and safe, may permit access to investigational cancer therapy expanding treatment options, may induce remission of NHL, and may be used for 8 weeks."

( Angelidakis, G; Blechacz, B; Economides, MP; Granwehr, BP; Hosry, J; Jiang, Y; Kaseb, A; Kyvernitakis, A; Mahale, P; Miller, E; Naing, A; Raad, II; Samaniego, F; Torres, HA, 2019)

"In serial biopsies of melanoma tumors undergoing targeted therapy, the ensemble approach revealed enrichment of double-negative (DN) T cells."

( Diggins, KE; Doxie, DB; Ferrell, PB; Gama, V; Greenplate, AR; Irish, JM; Johnson, DB; Kelley, MC; Leelatian, N; McClanahan, DD; Oberholtzer, BK; Rasmussen, ML; Rathmell, JC; Roe, CE; Siska, PJ, 2019)

"Mice bearing A20-OVA lymphoma tumors were treated with OVA-loaded C3-liposomes, which led to reduced tumor growth in both treated and distal tumors in all mice."

( Francian, A; Kullberg, M; Mann, K; Martinson, H; Namen, S; Stanley, M, 2019)

"Limb edema of advanced cancer occasionally treated by physical therapy concerns patients with numerous comorbidities and precipitating factors."

( Gradalski, T, 2019)

"It suppresses cancer development in premalignant lesions in response to activated oncogenes and in tumors following therapy."

( Biran, A; Krizhanovsky, V; Porat, Z, 2019)

"In people with cancer, these drugs have emerged as attractive alternatives for the treatment of venous thromboembolism with the potential to overcome the limitations of low molecular weight heparin."

( Cabezón-Gutiérrez, L; Franco-Moreno, A; García-Navarro, M; Palka-Kotlowsa, M; Villamayor-Delgado, M, 2019)

"Nevertheless, chemoresistance in cancers has become an impediment in using cisplatin for cancer treatment."

( Abu, N; Hon, KW; Jamal, R; Jeyaraman, S, 2018)

"We find that the treatment of cancer would be far more effective if the two drugs are given non-overlappingly, with the chemotherapy drug at day 0 and anti-VEGF at day 7 in cycles of 21 days."

( Friedman, A; Lai, X, 2019)

"The study subjects were 168 cancer patients admitted to a university hospital for chemotherapy between October 2011 and December 2016: 58 patients who experienced intractable hiccups while on dexamethasone (cases) and 110 matched patients who received dexamethasone but did not experience hiccups (controls)."

( Kim, J; Oh, H; Seo, W, 2018)

"Recommended treatment for cancer-associated thrombosis is 3-6 months of low-molecular-weight heparin."

( Date, K; Hutchinson, A; Johnson, MJ; Maraveyas, A; Rees, S; Young, A, 2019)

"Three themes were found: experience of cancer-associated thrombosis, experience of anticoagulation and risk-benefit balance of the two modes of administration."

( Date, K; Hutchinson, A; Johnson, MJ; Maraveyas, A; Rees, S; Young, A, 2019)

"While many effective anticancer agents are available, the majority of drugs currently on the market are not specific, raising issues like the common side effects of chemotherapy."

( Mathias, F; Montana, M; Terme, T; Vanelle, P, 2019)

"Fatigue may be cause by all cancer treatments, maybe because the tissue damage or the build-up of dead cells derived products."

( Berretta, M; Cirrito, C; Del Pup, L; Lleshi, A; Pavanello, M; Tirelli, U, 2018)

"When transfected into lung cancer cells, the vector is able to express GADD45α upon resveratrol treatment, and subsequently leads to cell cycle arrest at the G2/M transition."

( Bhatia, D; Shi, Q, 2019)

"Suicide gene therapy of cancer (SGTC) involves the targeted or localized delivery of suicide transgene sequences into tumor cells by means of various gene delivery vehicles."

( Medin, JA; Neschadim, A, 2019)

"In patients with malignancy, sorafenib treatment combined with standard treatment significantly increases the risk of low-grade hemorrhagic events."

( Dai, C; Shao, JH; Wu, LQ; Yin, XB; Yu, X; Zhou, F, 2018)

"Probabilistic lifetime cancer risks and non-cancer risks of trihalomethanes (THMs) through ingestion, dermal contact, and inhalation exposure in 88 drinking water treatment plants (WTPs) with raw waters from five water systems (WSs) in Jiangsu Province were analyzed and compared."

( Engel, B; Wang, Y; Zhu, G, 2019)

"Patients with advanced cancer (no curable treatment options) with at least "moderate" nausea and/or one emetic episode within the last 24 h were included if they had not received chemotherapy or irradiation (last 2 weeks) and had no reversible causes of nausea/vomiting."

( Frandsen, KB; Groenvold, M; Harder, S; Herrstedt, J; Isaksen, J; Mondrup, L; Neergaard, MA; Sigaard, J, 2019)

"A link between cancer and inflammation and/or metabolic disorders has been well established and the therapy of these conditions with so-called pleiotropic drugs, which include non-steroidal anti-inflammatory drugs, statins and peroral antidiabetics, modulates a cancer risk too."

( Bojková, B; Kajo, K; Kubatka, P; Qaradakhi, T; Zulli, A, 2018)

"FGL1 is highly produced by human cancer cells, and elevated FGL1 in the plasma of cancer patients is associated with a poor prognosis and resistance to anti-PD-1/B7-H1 therapy."

( Badri, T; Boto, A; Chen, L; Chen, Y; Datar, I; Ji, L; Melero, I; Sanmamed, MF; Schalper, K; Su, TT; Sun, J; Sznol, M; Vignali, DAA; Wang, J; Yao, S; Yin, W; Zheng, L; Zhou, T; Zhu, G; Zhu, S, 2019)

"All patients had their cancer successful treated with no signs of recurrence."

( Ahmad, I; Cader, RA; Haron, SN; Mei Yee, AK; Yassin, A, 2018)

"Patients with advanced cancer refractory to standard treatment were eligible."

( Gerritse, SL; Honeywell, RJ; Labots, M; Peters, GJ; Rovithi, M; Ruijter, R; Ten Tije, AJ; Verheul, HMW; Voortman, J, 2019)

"Sixty-nine patients with advanced cancer, predominantly colorectal cancer (42%), were treated with this alternative dosing regimen."

( Gerritse, SL; Honeywell, RJ; Labots, M; Peters, GJ; Rovithi, M; Ruijter, R; Ten Tije, AJ; Verheul, HMW; Voortman, J, 2019)

"Oral mucositis (OM) induced by cancer chemotherapy has a high incidence and serious symptoms, which often force chemotherapy to be stopped."

( Makino, K; Shimamura, Y; Takeuchi, I; Terada, H, 2019)

"Eighteen patients with advanced tumors [lung (n = 9), colon (n = 8), and cervical (n = 1)] previously treated with at least two lines of chemotherapy including bevacizumab (n = 9, 50%) were enrolled."

( Jerome, M; Jones, B; Keef, J; Li, P; Madan, A; Miley, D; Paluri, R; Robert, F; Saleh, M, 2019)

"Patients with advanced cancer and no recent antineoplastic treatment were included in a prospective two-part study."

( Frandsen, K; Groenvold, M; Harder, S; Herrstedt, J; Isaksen, J; Jespersen, BA; Mondrup, L; Neergaard, MA; Sigaard, J, 2019)

"The current interest in cancer research is being shifted from individual therapy to combinatorial therapy."

( Abed, Z; Beik, J; Ghaznavi, H; Kamran Kamrava, S; Mahabadi, VP; Mirrahimi, M; Shakeri-Zadeh, A; Shiralizadeh Dezfuli, A; Shiri, I, 2019)

"Treating tumors with liposomal bicarbonate combined with a sub-therapeutic dose of doxorubicin achieved an improved therapeutic outcome, compared to mice treated with doxorubicin or bicarbonate alone."

( Abumanhal-Masarweh, H; Dahan, N; Kaneti, G; Koren, L; Krinsky, N; Lupu-Haber, Y; Schlesinger-Laufer, M; Schroeder, A; Shainsky-Roitman, J; Suss-Toby, E; Weiss-Messer, E; Yaari, Z; Zinger, A, 2019)

"Thus, an ever increasing number of cancer survivors search endocrinologic help in the form of hormone replacement therapy (HRT)."

( Deli, T; Jakab, A; Orosz, M, 2020)

"Improving therapeutic outcomes from cancer therapy is necessary for increasing patients' survival and quality of life."

( Farhood, B; Mirtavoos-Mahyari, H; Mortezaee, K; Motevaseli, E; Najafi, M; Rosengren, RJ; Sahebkar, A; Salehi, E, 2019)

"Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer."

( Casari, I; Desai, NM; Falasca, M; Massi, M; Simpson, PV, 2019)

"In this work, an anticancer drug, doxorubicin (Dox)-loaded liposome-holo-Lf nanocomposites, is developed for tumor targeting and imaging guided combined radiochemotherapy."

( Ling, C; Maiti, D; Min, Q; Qin, L; Xu, J; Yang, J; Yang, K; Zhang, Z, 2019)

"Existing cancer treatment strategies that target a single molecular pathway or cancer hallmark fail to fully resolve the problem."

( Fu, JY; Loh, HS; Mai, CW; Tham, SY, 2019)

"The current mode of treatment of cancer shows adverse effects on normal cells and also alter the cell signalling pathways."

( Allemailem, KS; Almatroudi, A; Alrumaihi, F; Alsahli, MA; Rahmani, AH, 2019)

"Low muscle mass in individuals with cancer has a profound impact on quality of life and independence and is associated with greater treatment toxicity and poorer prognosis."

( Fairman, CM; Galvão, DA; Hart, NH; Kendall, KL; Newton, RU; Taaffe, DR, 2019)

"An efficient nanosensitizer that makes cancer cells more sensitive to radiotherapy under a relatively low radiation dose would be highly desirable."

( Chen, Y; Li, N; Pan, W; Tang, B; Wang, J; Yu, L; Zhang, X, 2019)

"In breast cancer cells adapted to long-term paclitaxel treatment, we previously identified a new adaptive mechanism that contributes to resistance and involves high levels of tubulin tyrosination and long-chain polyglutamylation coupled with high levels of septin expression, especially that of SEPT9_i1."

( Baillet, A; Benoit, B; Cantaloube, I; Klipfel, L; Poüs, C; Salameh, J; Targa, B, 2019)

"Effective therapeutic interventions for cancer-induced and chemotherapy-induced cachexia must take into account the specific metabolic defects imposed by the pathological or pharmacological drivers of cachexia."

( Barreto, R; Bonetto, A; Couch, ME; O'Connell, TM; Pin, F, 2019)

"Basal-like breast cancer exhibits a triple-negative phenotype and has a poor prognosis, even with traditional chemical and anti-human epidermal growth factor receptor (HER) treatments."

( Chen, X; Liang, X; Mei, L; Miao, Q; Wang, C; Xie, Z; Xing, C; Ye, X; Zhang, H; Zhang, X, 2019)

"Hyperthermal therapy is an anticancer treatment mutually given with chemotherapy."

( Liu, L; Ma, Y; Sun, J; Wei, W; Yan, F; Zhao, Z, 2019)

"Immunotherapy for cancer treatment continues to evolve, and immune checkpoints have proven successful therapeutic targets."

( Basappa, NS; Chu, Q; Kolinsky, M; Lyddell, C; Roberts, J; Smylie, M; Walker, J; Ye, C, 2019)

"Central Nervous System (CNS) tumors have a poor survival prognosis due to their invasive and heterogeneous nature, in addition to the resistance to multiple treatments."

( Branco, V; Brito, MA; Carvalho, C; Pimentel, J, 2020)

"The current study included 229 new cancer cases and 229 controls matched for age (±1 year), sex, treatment group, and study site."

( Guo, H; Huo, Y; Li, J; Lin, T; Qin, X; Song, Y; Wang, B; Wang, J; Wang, X; Xu, X; Zhang, H; Zhang, Y, 2019)

"In addition to NSAIDs, an anticancer drug, paclitaxel, has considerable potential as an AD treatment."

( Lehrer, S; Rheinstein, PH, 2019)

"Pharmacotherapeutic approaches for cancer therapy-induced cognitive symptoms include CNS stimulants (eg, methylphenidate and modafinil), medications used in patients with memory impairment (eg, donepezil, memantine, and ginkgo biloba), and bone marrow supporting agents (eg, erythropoietin)."

( Dietrich, J; Karschnia, P; Parsons, MW, 2019)

"A small population of cancer stem cells (CSCs) were considered as a therapy target to reserve tumor relapse, resistance, and metastasis."

( Bai, L; Cao, F; Chen, C; Chen, H; Chuang, TH; Guo, J; He, H; Liu, Y; Luo, Y; Pan, Y; Si, Q; Song, M; Wang, S; Xiang, R; Zhu, R, 2019)

"Plasma MPs were isolated from cancer patients before and after treatment with VEGFi (pazopanib, sunitinib, or sorafenib)."

( Evans, TRJ; Jones, R; Montezano, AC; Neves, KB; Rios, FJ; Touyz, RM, 2019)

"Childhood cancer patients treated with platinums often develop hearing loss and the degree is classified according to different scales globally."

( Brooks, B; Carleton, B; Clemens, E; de Vries, ACH; van den Heuvel-Eibrink, MM; van Grotel, M, 2019)

"While older adults with cancer are more likely to develop chemotherapy-induced peripheral neuropathy (CIPN), the study aimed to determine if patient-reported and objective measures of CIPN differ by age among cancer survivors."

( Abrams, G; Chesney, MA; Conley, YP; Cooper, BA; Kober, KM; Levine, JD; Mazor, M; Miaskowski, C; Paul, SM; Schumacher, MA; Topp, K; Wong, ML, 2019)

"The variety of cancer therapy used in the present scenario have painful side effects, low effectiveness and high cost, which are some major drawbacks of the available therapies."

( Edison, TNJI; Kumar, P; LewisOscar, F; Pugazhendhi, A; Shanmugam, S; Shanmuganathan, R, 2019)

"It is foreseen that in near future cancer can be detected and/or treated at an early stage by utilizing biosurfactant conjugated GQDs."

( Bansal, S; Barnwal, RP; Chatterjee, M; Kaur, IP; Kumar, R; Kumari, U; Singh, G; Singh, J; Singh, S, 2019)

"A promising approach toward cancer therapy is expected to integrate imaging and therapeutic agents into a versatile nanocarrier for achieving improved antitumor efficacy and reducing the side effects of conventional chemotherapy."

( Chen, Z; Feng, Y; Li, S; Li, T; Liu, Y; Qin, X; Shen, X; Wu, C; Xie, X; Yang, H; You, F; Zhang, H; Zheng, C; Zhu, J, 2019)

"From this, targeted therapy for cancer stem cells may be one of the most promising strategies for comprehensive treatment of tumors in the future."

( Dai, Y; Hu, J; Li, H; Song, J; Xu, X; Yao, B; Yu, Y; Zhang, Y; Zhou, H; Zhu, L, 2019)

"To increase cancer immunotherapy success, PD-1 blockade must be combined with rationally selected treatments."

( Borst, J; Frijlink, E; Iglesias-Guimarais, V; Kroon, P; Schumacher, TN; van Buuren, MM; Verbrugge, I; Verheij, M; Volkov, A, 2019)

"We included participants with cancer-related dyspnoea when randomised to systemic corticosteroids (at any dose) administered for the relief of cancer-related dyspnoea or any other indication, compared to placebo, standard or alternative treatment."

( Duc, J; Good, P; Hardy, JR; Haywood, A; Khan, S; Rickett, K; Vayne-Bossert, P, 2019)

"Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism."

( Bauer, KA; Belani, CP; Burton, P; Eikelboom, J; Garcia, DA; Kakkar, AK; Kaul, S; Khorana, AA; Kuderer, NM; Liebman, HA; Lyman, GH; McBane, R; O'Reilly, EM; Patel, JN; Riess, H; Soff, GA; Streiff, MB; Vadhan-Raj, S; Vijapurkar, U; Wildgoose, P; Wun, T; Yimer, HA, 2019)

"In high-risk ambulatory patients with cancer, treatment with rivaroxaban did not result in a significantly lower incidence of venous thromboembolism or death due to venous thromboembolism in the 180-day trial period."

"Twelve patients with cancer receiving chemotherapy were included in the study."

( Blazkova, S; Costello, V; Dowling, M; Duggan, C; Leary, EO; Murphy, L; Yousif, AD, 2019)

"Despite the great advances in cancer therapy, the incidence and mortality rates of cancer remain high."

( Hadianamrei, R; Tomeh, MA; Zhao, X, 2019)

"Patients with solid cancers initiating first-line chemotherapy in 2010-2016 were included."

( Aagaard, T; Daugaard, G; Helleberg, M; Lundgren, J; Mocroft, A; Reekie, J; Roen, A; Sengeløv, H; Specht, L, 2020)

"Patients developing cancer treatment-related left ventricular dysfunction (CTrLVD) require a prompt therapy."

( Arboscello, E; Balbi, M; Bighin, C; Brunelli, C; Ghigliotti, G; Gualandi, F; Murialdo, R; Sarocchi, M; Sicbaldi, V; Spallarossa, P, 2018)

"Clinical chemotherapy for cancer is limited by the physiological barrier of tumors, resulting in low drug delivery to tumors, poor efficacy of drugs and inability to block tumor metastasis."

( Chen, G; He, Z; Li, X; Liu, J; Meng, Z; Miao, W; Ren, H; Wang, Y; Xu, Y, 2019)

"Here we report that treatment of cancer cells with cold physical plasma, an emerging and less aggressive tumor therapy, resulted in ROS generation which subsequently triggered the cleavage of HSP90."

( Azoitei, N; Bekeschus, S; Chiosis, G; Diepold, K; Lippert, M; Seufferlein, T, 2019)

"As the use of ICI for cancer therapy continues to expand, a myriad of immune-related adverse events (irAE) caused by these therapies are being recognized."

( Abdel-Wahab, N; Pundole, X; Suarez-Almazor, ME, 2019)

"Although a large number of cancer treatments are known to cause cardiovascular toxicity, they are still widely used because they are highly effective."

( Abdelgawad, IY; Grant, MKO; Zordoky, BN, 2019)

"The CXCR4-CXCL12 interaction in cancer elicits biological activities that result in tumor progression and has accordingly been the subject of significant investigation for detection and treatment of the disease."

( Aboagye, EO; Alam, IS; Barnes, C; Braga, M; Brickute, D; Carroll, L; Kaliszczak, MA; Lau, D; Nguyen, QD; Stevens, E; Trousil, S, 2019)

"Using peptide as an anti-cancer agent is a novel approach for cancer therapy possessing some advantages with respect to the chemotherapeutic drugs such as low toxicity, ease of synthesis, and high target specificity."

( Ganjalikhany, MR; Hemati, M; Jafari, S; Jafary, F; Moradi, A, 2019)

"Monitoring immune responses to solid cancers may be a better prognostic tool than conventional staging criteria, and it can also serve as an important criterion for the selection of individualized therapy."

( Kalina, T; Pelák, O; Pokrývková, B; Poláková, I; Šmahel, M; Tachezy, R; Thürner, D, 2019)

"On the other hand, PDT toward primary tumors enhances the immunotherapy-caused regression of the irradiation-free distant tumors."

( Feng, J; Li, CX; Li, X; Liu, T; Liu, WL; Song, W; Ye, JJ; Yu, WY; Zeng, JY; Zhang, XZ; Zou, MZ, 2019)

"Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited."

( Kocot-Kępska, M; Leppert, W; Mika, J; Wordliczek, J; Wrzosek, A; Zajączkowska, R, 2019)

"Thirty-nine of 327 patients (pts) with cancer who were treated with opioids suffered from OIC (overall prevalence 12%; 95%-CI: 8-15%)."

( Beeker, A; Berkhof, J; Neefjes, ECW; Rhodius, CA; Ten Oever, D; van den Berg, HP; van der Vliet, HJ; van der Vorst, MJDL; van der Wijngaart, H; Verheul, HMW, 2019)

"Cancer patients with cancer-associated thrombosis (CAT) are at an elevated risk of recurrent venous thromboembolism (VTE) and of major bleeding while receiving treatment with anticoagulation."

( Carrier, M; Kimpton, M, 2019)

"Certain subgroups of cancer patients may be at increased risk of major bleeding while on treatment with Xa inhibitors, when compared to low-molecular-weight-heparin (LMWH)."

( Carrier, M; Kimpton, M, 2019)

"Drug resistance is of great concern in cancer treatment because most effective drugs are limited by the development of resistance following some periods of therapeutic administration."

( Dou, B; Feng, Y; Qu, Y; Tan, H; Wang, D; Wang, N, 2019)

"Single‑agent targeted cancer therapy frequently fails due to acquired drug resistance."

( Chen, Y; Cui, G; Li, M; Meng, F; Yu, Z; Zhang, Y, 2019)

"Induction of cancer-specific cytotoxic T lymphocytes is crucially important to complement therapeutic effects of immune checkpoint inhibitors and to achieve efficient cancer immunotherapy."

( Harada, A; Miyazaki, M; Okubo, M; Yuba, E, 2019)

"Background Platinum-based anticancer drugs are widely used in the chemotherapy of human neoplasms."

( Makovec, T, 2019)

"A big challenge for CSC-based cancer therapy is the overexpression of therapeutic stress protein, heat shock protein 90 (Hsp90), which protects CSCs from further therapeutic-induced damage, leading to the failure of treatment."

( Li, H; Li, Z; Liu, D; Liu, Y; Peng, H; Suo, X; Yan, W; Yang, X; Zhang, J, 2019)

"Essential cancer medicine stock outs are occurring at an increasing frequency worldwide and represent a potential barrier to delivery of standard therapy in patients with cancer in low- and middle-income countries."

( Bilker, WB; DeMichele, A; Gross, R; Grover, S; Manshimba, P; Martei, YM; Monare, B; Ralefala, TB; Setlhako, DI; Shulman, LN, 2019)

"Primary exposure was the duration of cancer medicine stock out during a treatment cycle interval, when the cancer therapy was intended to be administered."

( Bilker, WB; DeMichele, A; Gross, R; Grover, S; Manshimba, P; Martei, YM; Monare, B; Ralefala, TB; Setlhako, DI; Shulman, LN, 2019)

"Each week of cancer therapy stock out poses a substantial barrier to receipt of high-quality cancer therapy in low- and middle-income countries."

( Bilker, WB; DeMichele, A; Gross, R; Grover, S; Manshimba, P; Martei, YM; Monare, B; Ralefala, TB; Setlhako, DI; Shulman, LN, 2019)

"Thus, GCPII is a viable target for cancer therapy, either alone or in combination with glutaminase inhibition."

( Antonio, MJ; Asaka, R; Betenbaugh, MJ; Camelo, F; Chaichana, KL; Elgogary, A; Gabrielson, E; Hartung, T; Hoang, G; Jung, JG; Kirsch, BJ; Kleensang, A; Le, A; Li, T; Marie, SK; Nabi, K; Nguyen, K; Nguyen, S; Nguyen, T; Quinones, A; Reyes, J; Sazeides, C; Shen, YA; Tan, J; Udupa, S; Wang, TL; Zhao, L, 2019)

"The incidence of bladder cancer, and of any other type of cancer, was not significantly increased by treatment with any SGLT-2i."

( Dicembrini, I; Mannucci, E; Monami, M; Nreu, B, 2019)

"Advances in cancer treatments have resulted in significant improvements in survival."

( Hardaway, BW, 2019)

"In patients with cancer, steady-state trough plasma pregabalin concentrations were altered with renal function, systemic inflammation, and opioid analgesic cotreatment."

( Kawakami, J; Naito, T; Yagi, T; Yoshikawa, N, 2019)

"Chemotherapy is the mainstay of cancer treatment."

( Jiang, S; Wang, K; Wang, M; Yu, F; Zhou, L, 2019)

"The risk of developing a malignancy during treatment is an important consideration, and many studies have been conducted to determine the magnitude of this risk."

( Casseres, RG; Dumont, N; Gottlieb, AB; Her, MJ; Kahn, JS; Rosmarin, D, 2019)

"Cell lines representing cancers of the ovary (SKOV-3), breast (MDA-MB-231), glia (U87MG), or prostate (LNCaP) were treated with cytostatic concentrations of mifepristone."

( Brandhagen, BN; Goyeneche, AA; Ritch, SJ; Telleria, CM, 2019)

"In diseases such as cancer where cell death inducing mechanisms, including apoptosis, are usually suppressed by genetic changes, the induction of alternative pathways leading to cell death could provide an attractive treatment strategy."

( Hrstka, R; Michalová, E; Skoupilová, H, 2018)

"p53 is the most mutated protein in cancer and the reactivation of its inactive mutated form represents one possibility for antitumor therapy."

( Galoczová, M; Vojtěšek, B; Zatloukalová, P, 2018)

"The 9474 reported lentinan-associated cancer treatment cases include lung cancer (3469 cases), gastric cancer (3039 cases), colorectal cancer (1646 cases), ovarian cancer (183 cases), cervical cancer (130 cases), Non-Hodgkin lymphoma (70 cases), pancreatic cancer (15 cases), cardiac cancer (15 cases), nasopharyngeal cancer (14 cases), duodenal cancer (1 case) and 110 cancer cases with no classifying patient information."

( Tian, Q; Zhang, L; Zhang, M; Zhang, Y, 2019)

"Many cancer patients on intensive chemotherapy lack vitamin C."

( Bos, GMJ; Lookermans, EL; Van Elssen, CHMJ; van Gorkom, GNY, 2019)

"We also show the plethora of anticancer drugs that specifically inhibit glutaminase isoenzymes for treating several sets of cancer."

( Alonso, FJ; Campos-Sandoval, JA; de Los Santos-Jiménez, J; Márquez, J; Matés, JM; Segura, JA, 2020)

"As traditional anticancer treatments fail to significantly improve the prognoses, exploration of therapeutic modalities is urgently needed."

( Bao, W; Gao, X; Li, F; Lu, GH; Lv, Y; Nie, W; Pu, K; Wei, W; Xie, HY; Zhang, F; Zhang, L, 2019)

"Managing pain in cancer survivors requires that oncologists understand the common painful syndromes that can occur from treatment or disease."

( Paice, JA, 2019)

"Twelve patients with solid tumors expressing NY-ESO-1 were treated using a 3 + 3 design."

( Ejadi, S; Gnjatic, S; Kenney, R; Kim-Schulze, S; Lu, H; Mahipal, A; Odunsi, K; Ter Meulen, JH, 2019)

"Furthermore, in some cancer cells, melatonin aids sensitizing cancer cells to therapy."

( Ahmadi, A; Farhood, B; Mortezaee, K; Musa, AE; Najafi, M; Potes, Y; Shabeeb, D, 2019)

"Effective cancer therapy can be achieved by designing a smart nanofiber system with the combination of chemotherapy and hyperthermia."

( Ebara, M; Lee, CM; Niiyama, E; Sakura, K; Uto, K, 2019)

"The efficacy of metformin in treating cancer has been extensively investigated since epidemiologic studies associated this anti-diabetic drug with a lower risk of cancer incidence."

( Gasparre, G; Iorio, M; Kurelac, I; Porcelli, AM; Umesh Ganesh, N, 2020)

"MATERIAL AND METHODS Human cervical cancer HeLa cells were treated with different concentrations of doxorubicin for 3 days, with or without subsequent extended culture in drug-free medium for 6 days."

( Hu, X; Zhang, H, 2019)

"This study involved 62 advanced cancer patients, with well-controlled background pain, who presented BTCP associated to routine radiotherapy procedures, treated with FPNS according to our protocol of administration."

( Aymar, N; Jiménez, E; Mena, A; Mestre, F; Ortiz, I; Pardo, J; Roncero, R; Vidal, M, 2019)

"In addition to effective cancer therapies like chemotherapy, radiotherapy and surgery, treatment based on traditional Chinese medicine (TCM) and combined TCM with western medicine has gradually gained attention in Oriental countries."

( Feng, Y; Hong, Y; Huang, Y; Lin, X; Shen, L; Zhu, J, 2019)

"The priming of tumors with ADI-PEG20 and DTX results in the stabilization of c-MYC potentiating the effect of GEM treatment via an increase in hENT1 expression."

( Chang, SF; Godec, A; Hawkins, WG; Hirbe, AC; Prudner, BC; Rathore, R; Robinson, AM; Van Tine, BA, 2019)

"Advances in cancer treatment have led to a growing number of survivors."

( Paice, JA, 2019)

"The main current treatment for cancer metastasis is chemotherapy targeting cancer cells' ability to proliferate."

( Ichijo, H; Morishita, K; Watanabe, K, 2019)

"Despite progress in treatments, cancer pain remains underestimated, poorly assessed and under-treated."

( Allano, G; Burnod, A; George, B; Lemaire, A; Maindet, C; Minello, C, 2019)

"Docetaxel (DTX) has been used in cancer treatments for several decades, but it results in many adverse apoptotic effects through excessive production of reactive oxygen species (ROS) in some tissue including the kidney and testes."

( Baş, E; Nazıroğlu, M, 2019)

"A relatively recent approach to cancer therapy involves the use of a natural process wherein small RNA molecules regulate gene expression in a pathway known as RNA interference (RNAi)."

( Revia, RA; Stephen, ZR; Zhang, M, 2019)

"in vitro studies on cancer therapy demonstrate that the combined treatment, compared with either chemotherapy or photothermal therapy alone, has better synergistic therapeutic effect."

( Chen, M; Chen, X; Deng, Y; Li, Y; Sang, R; Shi, J; Yang, W; Yang, Y, 2019)

"Targeting metabolic pathways for cancer treatment has been investigated as potential preventive or therapeutic methods."

( Cui, Q; Duan, K; Fei, Z; Liu, Q; Sun, Y; Xiong, W; Yang, Z; Yu, M; Zi, J, 2019)

"Data collected included primary malignancy, hospice enrollment, healthcare utilization, Oncology Care Model (OCM) enrollment, and clinical assessments at last office visit prior to a treatment decision before death."

( Holliday, R; Lynch, S; McNaughton, C; Moore, JH; Newport, K; Oyer, RA; Sivendran, S; Svetec, S; Wong, R, 2021)

"Of the 201 patients who died of cancer, 36 (17%) received anticancer therapy within the last 14 days of life."

( Holliday, R; Lynch, S; McNaughton, C; Moore, JH; Newport, K; Oyer, RA; Sivendran, S; Svetec, S; Wong, R, 2021)

"We discuss how conventional cancer therapies can be properly selected to set up combinatorial approaches with ICI leading to treatment improvement."

( Apetoh, L; Rivera Vargas, T, 2019)

"Because cancer cells often overexpress IAPs-a mechanism involved in the resistance to cancer therapy-SNIPERs could be used to kill cancer cells efficiently."

( Naito, M; Ohoka, N; Shibata, N, 2019)

"The impact of hypoxia on cancer therapeutics is significant: hypoxic tissue is 3× less radiosensitive than normoxic tissue, the impaired blood flow found in hypoxic tumor regions influences chemotherapy delivery, and the immune system is dependent on oxygen for functionality."

( Dewhirst, MW; Palmer, GM; Rickard, AG, 2019)

"Consecutive patients with active cancer and VTE, under treatment with bemiparin for at least 6 months, were recruited."

( Antonio, M; Domènech, P; Peñafiel, J; Peris, J; Pina, E; Rosselló, E; Tebe, C, 2020)

"Hyponatremia in cancer patients generally indicates advanced or severe disease but proper therapy that targets the underlying process can improve outcomes."

( Kitchlu, A; Rosner, MH, 2019)

"Purpose Cancer therapy-associated paronychia (CAP) is a frequent adverse event associated with cytotoxic and targeted therapies that may impact dosing of anticancer therapies and patient quality of life (QoL)."

( Anadkat, M; Barone, S; Capriotti, KD; Choi, J; Goldfarb, S; Kaffenberger, B; Kukoyi, O; Lacouture, M; McLellan, B, 2019)

"The heterogeneity and diversity of tumors seriously attenuate the curative outcome of single treatment modes."

( Dai, Z; Liu, X; Liu, Y; Wang, J; Wei, T, 2019)

"Treating cancer cell lines, intact animals with a variety of spontaneous cancers, and people with various cancers with mifepristone, has been found to inhibit cancer growth, and provide both palliation of symptoms and longevity possibly by suppressing this unique immunomodulatory protein."

( Check, D; Check, JH, 2019)

"Recent works have demonstrated anticancer properties of the FDA-approved drug ribavirin, a synthetic guanosine analogue and antiviral molecule used over the past four decades for the treatment of hepatitis C."

( Brem, H; Casaos, J; Choi, J; Felder, R; Gorelick, NL; Huq, S; Kast, RE; Lott, T; Serra, R; Skuli, N; Suk, I; Tyler, B; Xia, Y, 2019)

"The Hokusai VTE Cancer trial compared edoxaban with dalteparin for VTE treatment in patients with active cancer."

( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019)

"Delivery of anticancer drug to the tumor tissue is a major obstacle against successful chemotherapy, which is because of the toxicity and poor aqueous solubility of these drugs."

( Ganjali, S; Pirro, M; Sahebkar, A; Sarhadi, S, 2019)

"Intratumoral glucose depletion-induced cancer starvation represents an important strategy for anticancer therapy, but it is often limited by systemic toxicity, nonspecificity, and adaptive development of parallel energy supplies."

( Bejjanki, NK; Dou, J; Jiang, W; Khan, MI; Liu, H; Ma, Y; Tang, X; Wang, J; Wang, Q; Wang, Y; Xia, J; You, YZ; Zhang, G; Zhao, Y, 2019)

"HeLa cancer cells were treated with MB-loaded Au NC-mucin nanoparticles under irradiation of 640 nm light."

( Chattopadhyay, A; Dutta, D; Ghosh, SS; Sailapu, SK; Simon, AT, 2019)

"Co-treatment of colon cancer cells with Glutor and glutaminase inhibitor CB-839 very potently and synergistically inhibits cancer cell growth."

( Binici, A; Brand, S; Ceballos, J; Choidas, A; Karageorgis, G; Knauer, L; Nowacki, J; Reckzeh, ES; Schwalfenberg, M; Stroet, MCM; Strohmann, C; Waldmann, H; Ziegler, S, 2019)

"Together with its efficacy to eliminate cancer cells in vivo, Raptinal could be useful in difficult-to-treat cancer entities harboring defects in the intrinsic apoptosis pathway."

( Ehrenschwender, M; Heimer, S; Knoll, G; Schulze-Osthoff, K, 2019)

"Many cancers, including breast, ovarian, and lung cancer, are treated using taxane chemotherapy with curative intent."

( Andersen Hammond, E; Pitz, M; Shay, B, 2019)

"New roles for β-glucan in cancer therapy are also emerging through an evolving understanding that β-glucan is involved in a concept called trained immunity, where innate cells take on memory phenotypes."

( Geller, A; Shrestha, R; Yan, J, 2019)

"Dicycloplatin is a promising drug in cancer chemotherapy with less aggressive side-effects than those typically associated with cisplatin and carboplatin."

( Cecil, C; Crigger, C; Guo, YI; Hogan, T; Jiang, BH; Jiao, S; Liang, X; Morley, C; Salkini, MW; Washington, IM; Williams, DJ; Winn, AC; Yan, B; Yang, X; Yu, JJ; Zheng, J, 2019)

"Traditional cancer-therapeutic modalities such as chemotherapy suffer from the low therapeutic efficiency and severe side effects."

( Chen, Y; Dai, C; Hu, R; Lin, H; Liu, Z; Wang, C; Yu, L; Zhang, B, 2019)

"In 2000, concerns in patients with cancer arose attributable to associations of ESA use with increased mortality, thrombotic complications, and cerebrovascular accidents led to a change in US Food and Drug Administration oncology guidelines regarding limitation of ESA use for chemotherapy-induced anemia."

( Choi, MJ; Thavarajah, S, 2019)

"Successful cancer PDT relies on image guidance to ensure the treatment accuracy."

( Cao, Z; Fu, W; Gao, S; Lu, W; Qian, Y; Wang, X; Wei, G; Wu, W; Xiao, Z; Xu, J; Yu, S; Zhang, S; Zheng, B, 2019)

"The anticancer agents play an intriguing role in the treatment of cancers, while the severe anticancer scenario and the emergence of drug-resistant especially multidrug-resistant cancers create a huge demand for novel anticancer drugs with different mechanisms of action."

( Xu, Z; Zhang, L, 2019)

"Combating multidrug resistance (MDR) of tumors is still challenging for clinical chemotherapy, cocktail chemotherapy (CCT), and currently widely-studied nanodrug-based treatments."

( Ding, Y; Dong, CM; Du, C; Qian, J; Zhang, R, 2019)

"Efficient cancer therapy is sought not only for primary tumor treatment but also for the prevention of metastatic cancer growth."

( Jin, JO; Kwak, M; Lee, PCW; Oh, J; Park, HB; Xu, L; Zhang, W, 2019)

"Photodynamic therapy (PDT) is a cancer treatment involving the generation of reactive oxygen species (ROS) by laser irradiation of porphyrins that accumulate in cancer tissues."

( Ito, H; Kurokawa, H; Matsui, H, 2019)

"Further, integrating cancer therapy with untargeted metabolomic analysis would collectively offer clinical pertinence through facilitating early diagnosis and prognosis."

( Ahmad, F; Chen, X; Jiang, Z; Li, W; Liu, X; Mao, R; Wang, X; Yu, X, 2019)

"We investigated whether the response of cancer cells to antitumor treatment may be partially influenced by variation in expression of one-carbon metabolism genes."

( Krushkal, J; Min, DJ; Vural, S, 2019)

"Pediatric cancer and hematopoietic stem cell transplant patients (cancer and noncancer) who received continuous renal replacement therapy from January 2006 to July 2017 in the Netherlands."

( Cransberg, K; Dijkstra, S; Kneyber, MCJ; Lemson, J; Lilien, MR; Raymakers-Janssen, PAMA; Tibboel, D; van den Heuvel-Eibrink, MM; van Woensel, JBM; Wösten-van Asperen, RM, 2019)

"Of 1,927 PICU admissions of pediatric cancer and hematopoietic stem cell transplant patients, 68 of 70 evaluable patients who received continuous renal replacement therapy were included."

( Cransberg, K; Dijkstra, S; Kneyber, MCJ; Lemson, J; Lilien, MR; Raymakers-Janssen, PAMA; Tibboel, D; van den Heuvel-Eibrink, MM; van Woensel, JBM; Wösten-van Asperen, RM, 2019)

"PICU mortality of pediatric cancer and hematopoietic stem cell transplant patients requiring continuous renal replacement therapy is sadly high."

( Cransberg, K; Dijkstra, S; Kneyber, MCJ; Lemson, J; Lilien, MR; Raymakers-Janssen, PAMA; Tibboel, D; van den Heuvel-Eibrink, MM; van Woensel, JBM; Wösten-van Asperen, RM, 2019)

"Nanodrug-based cancer therapy is impeded by poor penetration into deep tumor tissues mainly due to the overexpression of hyaluronic acid (HA) in the tumor extracellular matrix (ECM)."

( Cui, T; Qin, H; Qu, X; Ren, J; Sun, Y; Yan, Z, 2019)

"Eligible patients had solid tumors or B-cell lymphomas with no available standard treatment regimen."

( Carver, J; Creasy, CL; Dhar, A; Frey, S; Giulino-Roth, L; Horner, T; Johnson, PWM; Khaled, A; Leonard, JP; Longley, J; Lopez, J; McCabe, MT; Michot, JM; Oh, C; Pene Dumitrescu, T; Ribrag, V; Stern, M; Wang, X; Winter, JN; Yap, TA, 2019)

"Forty-one patients (21 solid tumors, 20 lymphoma) received treatment."

"HER3 is a compelling target for cancer treatment; however, no HER3-targeted therapy is currently clinically available."

( Abe, M; Abe, Y; Agatsuma, T; Hashimoto, Y; Hayakawa, I; Hirotani, K; Iguchi, T; Ishizaka, T; Kagari, T; Kamai, Y; Kaneda, Y; Karibe, T; Koyama, K; Maeda, N; Morita, K; Murakami, M; Nakada, T; Nomura, T; Ogitani, Y; Shiose, Y; Ueno, S; Wakita, K; Zembutsu, A, 2019)

"HER3 is a compelling target for cancer treatment; however, no HER3-targeted therapy is currently clinically available."

"Many anticancer drugs have been developed for clinical usage till now, but the major problem is the development of drug-resistance over a period of time in the treatment of cancer."

( Khair, RR; Kumar, MS; Peters, GJ; Yadav, TT; Yergeri, MC, 2019)

"Aspirin is well-tolerated after radical cancer therapy."

( Adams, R; Berkman, L; Bridgewater, J; Cafferty, F; Cameron, D; Crossley, A; Din, F; Falk, S; Gilbert, D; Graham, J; Gupta, K; Henson, V; Hubner, R; Iveson, T; Jankowski, J; Joharatnam-Hogan, N; Khabra, K; Kunene, V; Kynaston, H; Langley, R; Patel, K; Pramesh, CS; Ring, A; Rowley, S; Sothi, S; Swinson, D; Thomas, A; Underwood, T; Warner, N; Wilson, R, 2019)

"5-Fluorouracil (5-FU) is an anticancer drug widely used to treat many cancers in the human body."

( Gupta, SK; Sharma, V; Verma, M, 2019)

"Colorectal cancer patients with T2DM treated with metformin as part of their diabetic therapy appear to have a superior OS and CS."

( Dulskas, A; Linkeviciute-Ulinskiene, D; Patasius, A; Smailyte, G; Urbonas, V; Zabuliene, L, 2019)

"At the same time, as the main cause of tumors, the abnormal activity of tyrosine kinase has become an important target for clinical treatment."

( Fang, DM; Gao, F; Yin, B; Zhou, XL, 2019)

"Notably, RECQL4ΔC cancer cells presented increased RPA2/RAD52 foci after cancer treatments."

( Kohzaki, M; Moritake, T; Okazaki, R; Ootsuyama, A; Sun, L, 2020)

"A long-anticipated cancer therapy would deliver the right type of therapeutic agents to the target in control with minimal systemic toxicity."

( Baigude, H; Ganbold, T; Han, J; Liu, L; Qi, Y; Wang, X, 2019)

"Active cancer treatment, defined as having chemotherapy, radiotherapy, cancer surgery, or hospitalization with a primary diagnosis of cancer, was evaluated from October 2015 to December 2016 allowing a ≥3-month look-back period for cancer diagnoses observed in the first quarter of 2016."

( Cochran, GT; Cole, ES; Donohue, JM; Gellad, WF; Gordon, AJ; Kelley, DK; Moyo, P; Sabik, LM, 2019)

"Among enrollees undergoing cancer treatment, with cancer but not in active treatment, and without cancer, the prevalence of high morphine milligram equivalents was 7."

( Cochran, GT; Cole, ES; Donohue, JM; Gellad, WF; Gordon, AJ; Kelley, DK; Moyo, P; Sabik, LM, 2019)

"Individuals with cancer, regardless of treatment status, had higher-risk opioid use based on Pharmacy Quality Alliance measures versus those without cancer."

( Cochran, GT; Cole, ES; Donohue, JM; Gellad, WF; Gordon, AJ; Kelley, DK; Moyo, P; Sabik, LM, 2019)

"Anticancer agents are critical for the cancer treatment, but side effects and the drug resistance associated with the currently used anticancer agents create an urgent need to explore novel drugs with low side effects and high efficacy."

( Liu, Y; Xu, Z; Zhao, SJ, 2019)

"Hypoxic tumours are a major problem for cancer photodynamic therapy."

( Banerjee, S; Blacque, O; Chao, H; Clarkson, GJ; Gasser, G; Huang, H; Malcomson, T; Paterson, MJ; Qiu, K; Sadler, PJ; Staniforth, M; Stavros, VG; Zhang, P, 2019)

"Cancer cells and mice models of cancer were treated with 5-ALA-PDT, MEK inhibitor or both MEK inhibitor and 5-ALA-PDT, and treatment efficacies were evaluated."

( Chelakkot, VS; Hirasawa, K; Rice, CP; Rutihinda, SG; Som, J; Yoshioka, E, 2019)

"Compared to conventional cancer therapy such as radiotherapy, surgery, and chemotherapy, we anticipate that this TNA-based polymeric system will work effectively in antisense cancer therapy and shortly start to play an important role in practical application."

( Han Chang, TJ; Lau, CH; Leung, HM; Liu, LS; Lo, PK; Tam, DY; Tin, C; Wang, F, 2019)

"Analyses of serum samples of cancer patients treated with cisplatin or carboplatin showed that Pt-chemotherapeutics were bound preferentially to HSA (around 80%)."

( Cemazar, M; Marković, K; Marković, S; Milačič, R; Ščančar, J; Sersa, G; Unk, M; Uršič, K; Vidmar, J; Žakelj, MN, 2020)

"As a novel treatment modality of tumors, hypothermal hyperthermia employed relatively lower temperature (<45 °C) to damage cancer cells with mild toxicity to normal tissues."

( Cai, Z; Guo, H; Liu, F; Liu, Y; Ouyang, B; Pang, Z; Ruan, S; Shen, S; Yu, X, 2019)

"It may provide a beneficial cancer therapy strategy in which the thermal and mechanical effects of ultrasound can intensify the therapeutic ratio of conventional chemotherapy methods."

( Abed, Z; Ahmadi, A; Ghaznavi, H; Irajirad, R; Khoei, S; Najafabad, BK; Shakeri-Zadeh, A; Sheervalilou, R; Shiran, MB, 2019)

"Smart drug delivery systems (SDDSs) for cancer treatment are of considerable interest in the field of theranostics."

( Ali, Z; Hou, Y; Ju, Y; Lin, J; Sheng, F; Wang, B; Wang, Z; Yin, H, 2019)

"Early detection of cancer is very critical because it can reduce the treatment risk and cost."

( Jahanian, A; Sanjabi, M, 2019)

"Combination therapy is an anticancer synergistic tool to overcome both cancer growth and resistance mechanisms."

( Campos-Sandoval, JA; Márquez, J; Matés, JM; Santos-Jiménez, JL, 2019)

"This review covers the effects of NO in cancer biology, NO releasing moieties which can be used for NO delivery, and current advances in the design of NO releasing biomaterials focusing on their applications for tumor therapy."

( Alimoradi, H; Gamble, AB; Giles, GI; Greish, K, 2019)

( Alfarsi, L; Craze, ML; El Ansari, R; Green, AR; Masisi, BK; Rakha, EA, 2020)

"In our quest for such a treatment for cancer we selected two phytochemicals namely resveratrol (RS) and ferulic acid (FA) that have gained wide attention in the field of medicine due to their array of properties."

( Balan, P; Indrakumar, J; Korrapati, PS; Murali, P, 2020)

"Melatonin is a natural agent with anti-cancer functions that has also been suggested as an adjuvant in combination with cancer therapy modalities such as chemotherapy, radiotherapy, immunotherapy and tumor vaccination."

( Farhood, B; Mirtavoos-Mahyari, H; Mortezaee, K; Motevaseli, E; Musa, AE; Najafi, M; Potes, Y; Shabeeb, D, 2019)

"SIGNIFICANCE: Cisplatin is pivotal for cancer treatment; however, nephrotoxicity limits its use."

( Jiang, W; Ma, T; Meng, X; Tang, X; Xu, Q; Zhang, C, 2020)

"The therapy of cancer continues to be a challenge aggravated by the evolution of resistance against current medications."

( Kropp, S; Proksch, P; Richter, L; Scheu, S, 2019)

"To achieve enhanced cancer therapy, a sequentially dynamic polymeric drug delivery system (ortho ester-linked PEGylated poly(disulfide)s-based micelle-doxorubicin (PS-g-OEMPEG-DOX)) is successfully constructed."

( Huang, Y; Li, D; Tang, R; Wang, J; Wang, X; Xu, Y; Yan, G, 2019)

"Most people with cancer have a combination of treatments, such as surgery with chemotherapy and/or radiation therapy."

( Abdul Aziz, SA; Ismail, F; Lew, YL; Mohamed Shah, N, 2021)

"The fight against cancer represents a great challenge for researchers and, for this reason, the search for new promising drugs to improve cancer treatments has become inevitable."

( Arizza, V; Lazzara, V; Luparello, C; Mauro, M; Vazzana, M, 2019)

"Thus, a specific anti-cancer effect can be achieved at high doses of vitamin C therapy."

( Aoki, I; Bakalova, R; Higashi, T; Miller, T; Zhelev, Z, 2020)

"It has a paramount impact on cancer growth, metastasis and has long been known as a major obstacle for cancer therapy."

( Kwon, I; Sahu, A; Tae, G, 2020)

"Herein, a computational study of cancer photothermal therapy using near-infrared radiation and graphene is presented using a Monte Carlo approach."

( Huang, J; Leng, S; Papavassiliou, DV; Shu, M; Wang, Y, 2020)

"Applied to cancer cells, the collective effect of the three modalities results in an extremely efficient treatment with nearly complete cell death (∼90%)."

( Aires, A; Cortajarena, AL; Holguín-Lerma, JA; Kosel, J; Lozano-Pedraza, C; Martínez-Banderas, AI; Merzaban, JS; Moreno, JA; Ooi, BS; Perez, JE; Quintanilla, M; Ravasi, T; Teran, FJ, 2019)

"Patients with advanced cancer often experience poor health-related quality-of-life (HRQoL) due to cancer and treatment-related side-effects."

( Finkelstein, E; Jacob, J; Kumari, P; Kumari, S; Malhotra, C; Ozdemir, S; Palat, G; Rapelli, V; Teo, I; Verghese, N, 2019)

"The limitations of anticancer drugs, including poor tumor targeting and weak uptake efficiency, are important factors affecting tumor therapy."

( Fu, Q; Gao, Y; Guo, F; Hong, W; Ji, X; Jin, C; Li, A; Wu, D; Yan, Q; Yang, G; Yang, Q, 2019)

"Anticoagulant therapy in patients with cancer with venous thromboembolism (VTE) increases the risk of both VTE recurrence and haemorrhagic complication."

( Fujita, H; Imai, K; Kawasaki, T; Matoba, S; Nakanishi, N; Okada, T; Sawada, T; Takai, S; Yamada, A; Yokota, I, 2019)

"As chemotherapy does not target the cancer stem cells, we conclude that the tumor cells recover due to the presence of cancer stem cells."

( Elliott, SL; Kose, E; Lewis, AL; Steinfeld, AE; Zollinger, EA, 2019)

"Studies of breast cancer therapy have examined the improvement of bispecific trastuzumab/pertuzumab antibodies interacting simultaneously with two different epitopes of the human epidermal growth factor receptor 2 (HER2)."

( Byalik, TE; Dorokhov, YL; Komarova, TV; Kosobokova, EN; Kosorukov, VS; Lipskerov, FA; Sheshukova, EV; Shindyapina, AV; Shpudeiko, PS, 2019)

"In summary, cancers carrying oncogenic RET alterations as a driver mutation could be collectively termed 'REToma' and treated with RET TKIs in a tissue-agnostic manner."

( Kohno, T; Nakaoku, T; Tabata, J, 2020)

"The efficacy of cancer chemotherapy is enhanced by induction of sustainable anti-tumor immune responses."

( Dubyak, GR, 2019)

"DNMT inhibition is actively pursued in cancer treatment, dominantly through the formation of irreversible covalent complexes between small molecular compounds and DNMTs that suffers from low efficacy and high cytotoxicity, as well as no selectivity towards different DNMTs."

( Adkins, GB; Duan, Y; Fang, J; Gao, L; Jimenez, LA; Lee, JY; Li, L; Ren, W; Song, J; Wang, L; Wang, Y; Yin, J; Zhong, W, 2019)

"The effectiveness of cancer treatment must be assessed early in the course of the therapy so that regimens can be tailored in an individualized manner."

( Basu, S; Parghane, RV, 2020)

"Children and adolescents with cancer need surgical interventions (ie, biopsy or major surgery) to diagnose, treat, or palliate their malignancies."

( Cata, JP; Kapoor, R; Lonnqvist, PA; Owusu-Agyemang, P, 2019)

"A patient non-adherence with oral anticancer agents is a well-recognized barrier to effective treatment."

( Chevrier, R; Chollet, P; Devaud, H; Dubray-Longeras, P; Durando, X; Kwiatkowski, F; Mouret-Reynier, MA; Poirier, C; Thivat, E; Vacher, L; van Praagh-Doreau, I, 2020)

"Hypoxia is a crucial factor in cancer therapy, determining prognosis and the effectiveness of treatment."

( Cao-Pham, TT; Fillée, C; Gallez, B; Heyerick, A; Jordan, BF; Joudiou, N; Tran-Ly-Binh, A, 2020)

"Also, arsenic increases the risk of tumors of bladder, lungs, kidneys and liver, according to the International Agency for Research on Cancer and the Food and Drug Administration."

( Arellano-Mendoza, MG; García-Montalvo, EA; Hernández-Zavala, A; Martínez-Castillo, M; Palma-Lara, I; Quintana-Pérez, JC; Tamay-Cach, F; Valenzuela-Limón, OL, 2020)

"The main modality to fight against cancer is surgery, radiotherapy, and chemotherapy, and more recently targeted therapy, gene therapy and immunotherapy, which play important roles in treating cancer patients."

( Cho, WC; Kobarfard, F; Kumar, P; Martins, N; Martorell, M; Pezzani, R; Rajabi, S; Redaelli, M; S Mileski, K; Salehi, B; Selamoglu, Z; Sharifi-Rad, J; Subhra Santra, T, 2019)

"A major challenge of cancer immunotherapy is the potential for undesirable effects on bystander cells and tumor-associated immune cells."

( Weiss, JM, 2020)

"In the case of cancer treatment, the plant species and its bioactive compounds target multiple pathways."

( Emami, SA; Taleghani, A; Tayarani-Najaran, Z, 2020)

"Metastasis is one of the main issues in cancer treatment and it has been documented that angiogenesis plays an important role in this process."

( Akbarzadeh, M; Fathi Maroufi, N; Fattahi, A; Nouri, M; Rashidi, MR; Vahedian, V, 2020)

"The treatment of cancer cells, HCT-116 and A-549, with CUR/FCt NPs lead to time-dependent decrement of cells' viability; the dead cells were 67."

( Al-Duais, MA; Alalawy, AI; Almutairi, FM; El Rabey, HA; Sakran, MI; Tayel, AA; Zidan, NS, 2020)

"For mRNA mediated cancer immunotherapy, Pam3 was incorporated as an adjuvant within lipid nanoparticles (LNPs) with OVA mRNA."

( Chang, J; Kim, MH; Kim, SY; Lee, H; Lee, K; Seo, Y, 2020)

"For local ablation of unresectable tumors, computed tomography-guided high-dose-rate brachytherapy (CT-HDRBT) is a minimally invasive therapeutic option involving CT-guided catheter placement and high-dose-rate irradiation with iridium-192."

( Böning, G; Büttner, L; Denecke, T; Gebauer, B; Jonczyk, M; Lüdemann, WM; Schnapauff, D; Wieners, G; Wust, P, 2020)

"Many patients who have cancer consider opioid-induced constipation (OIC) to be a burdensome side effect of opioid treatment."

( Akashi, Y; Fumita, S; Gamoh, M; Harada, T; Imai, H; Kizawa, Y; Noriyuki, T; Sato, H; Tokoro, A, 2020)

"Finally, the in vivo anticancer effect and safety of the combined therapy were also verified by the tumor-bearing mouse model."

( Gao, G; Guo, Y; Hu, P; Jiang, YW; Liu, JB; Lu, X; Wu, FG; Yu, XW; Zhang, X, 2020)

"GI dysmotility can occur due to the cancer itself or as a consequence of medical and surgical treatments."

( Shafi, MA, 2019)

"In advanced cancer patients, malignant cells invade and disseminate within normal cells and develop resistance to therapy with additional genetic mutations, which makes radical cure very difficult."

( Doi, H; Doi, T; Fujitani, H; Inoue, T; Kanai, M; Kawamura, T; Kawato, T; Kodama, T; Mizohata, E; Shimizu, Y; Shinoda, K; Sugiyama, A; Takahashi, K; Tanaka, T; Tatsumi, T; Yamashita, T; Yamatsugu, K, 2019)

"They are also potential candidates for cancer phototherapy including photothermal therapy (PTT) and photodynamic therapy (PDT) by virtue of extensive near-infrared absorbance."

( He, H; Jiang, S; Ling, G; Qin, L; Zhang, P, 2020)

"The currently practiced methods for cancer therapy have many defects, such as side effects, low curate rate, and discomfort for patients."

( Huang, X; Lin, Q; Wang, G; Xu, B; Xu, D; Xu, W; Yin, Y, 2019)

"To highlight their applications in cancer treatment, examples of therapeutic effects both in vitro and in vivo are presented."

( Huang, X; Lin, Q; Wang, G; Xu, B; Xu, D; Xu, W; Yin, Y, 2019)

"Four cancer and one normal cell lines were treated with a conventional drug (cisplatin) and a mitochondria-targeting agent (dequalinium chloride hydrate) separately and jointly."

( An, Q; Ball, KE; Smith, JR; Zaidieh, T, 2019)

"In addition, cancer cells with low levels of ROS may be more sensitive to the treatment, while cells with high levels of ROS may be more resistant."

( An, Q; Ball, KE; Smith, JR; Zaidieh, T, 2019)

"For accurate cancer diagnosis and targeted therapy, it is important to assess the localization of the affected area of cancers."

( Cai, W; Chen, Y; Du, T; Feng, H; Jiang, H; Liu, W; Pasquarelli, A; Wang, M; Wang, X; Weizmann, Y, 2020)

"Despite many efforts in the field of cancer therapy, this disease remains as the major reason of mortality all over the world."

( Abnous, K; Alibolandi, M; Ramezani, M; Taghavi, S; Taghdisi, SM, 2020)

"Resistance of cancer cells to chemotherapy is a significant clinical concern and mechanisms regulating cell death in cancer therapy, including apoptosis, autophagy or necrosis, have been extensively investigated over the last decade."

( Chan, WK; Dias, IRSR; Han, Y; Javed, MU; Law, BYK; Liu, L; Michelangeli, F; Mok, SWF; Qu, YQ; Wang, JR; Wong, VKW; Xu, SW; Xue, WW; Yao, XJ; Zeng, W; Zhang, H, 2019)

"Immunotherapy-based cancer treatment has revolutionized the era of cancer patients recuperation and it has brought a strong hope to treatment of some types of cancers."

( Bahrambeigi, S; Shafiei-Irannejad, V, 2020)

"Children with cancer need to be immunized against the common vaccine-preventable diseases after completion and sometimes during ongoing treatment of cancer."

( Arora, RS; Bansal, S; Chandra, J; Jog, P; Mandal, P; Moulik, NR; Sanjay, S; Shah, N, 2019)

"Patients with immune-infiltrated "hot" tumors demonstrate higher treatment response rates and improved survival."

( Abed, A; Aboelatta, MM; Aspromonte, SM; Bommareddy, PK; Broucek, JR; Buddhadev, S; Chesson, CB; Denzin, LK; Estupinian, R; Fidler, MJ; Giurini, EF; Goldufsky, JW; Guevara-Aleman, G; Gupta, KH; Gupta, V; Herzog, NL; Jhawar, SR; Kane, MP; Kaufman, HL; Kohlhapp, FJ; Kuzel, TM; Langenfeld, J; Lasfar, A; Lee, LY; Lee, M; Li, S; Malhotra, J; Marzo, AL; Medina, DJ; Newman, JH; Nowicki, C; Paras, J; Pepe, R; Rabson, AB; Redondo, RE; Reiser, J; Rossi, M; Rotter, D; Rudra, JS; Ruiz, ES; Sant'Angelo, DB; Schenkel, JM; Silk, AW; Singer, EA; Tarabichi, S; Thomas, PG; Wang, SJ; Zloza, A, 2020)

"One of the most studied sources for anticancer therapy is natural compounds and their derivates, like alkaloids, which are organic molecules containing nitrogen atoms in their structure."

( Arias-Calderón, M; Cancino, P; Rodríguez-Arce, E; Saldías, M; Silva-Matus, P, 2019)

"A series of early clinical studies of tumors in humans are ongoing at Dartmouth and Emory using electron paramagnetic resonance (EPR) oximetry to assess tumor oxygenation, initially and over time during either natural disease progression or treatment."

( Ali, A; Chen, EY; Flood, AB; Gallez, B; Lawson, VH; Liu, T; Schaner, PE; Schreiber, W; Swartz, HM; Vaupel, P; Williams, BB, 2020)

"However, data on the treatment of tumors with PDE5 inhibitors as well as the underlying mechanisms are as yet very scarce."

( Azoitei, N; Becher, A; Brunner, C; Chen, L; Chiosis, G; Cronauer, M; Diepold, K; Fehn, A; Liu, Y; Rouhi, A; Schmid, E; Seufferlein, T, 2020)

"Nevertheless, cancers are often able to circumvent chemotherapeutic interventions and become therapy resistant."

( Bayram, S; Forbes, M; Fürst, S; Kempa, S, 2020)

"Chemotherapy is important for cancer treatment, however, toxicities limit its use."

( Baker, D; Cole, T; Faccio, R; Faget, DV; Luo, X; Monahan, J; Murali, B; Ren, Q; Ricci, B; Schwarz, JK; Stewart, SA; Thotala, D; van Deursen, JM; Yao, Z, 2020)

"Specific focus on "redox cancer therapy" by targeting drugs to redox homeostasis of the cancer cells is growing rapidly."

( Bauri, AK; Chattopadhyay, S; Patro, BS; Tyagi, M, 2020)

"Ferroptosis-based cancer therapy strategies are promising, but how to effectively induce ferroptosis in cancer cells in vivo is still a question without clear answers."

( Han, W; Hou, H; Lv, H; Shaikh, AB; Shang, P; Wang, S; Wei, Y; Zhang, Z, 2020)

"The resistance of cancer cells to different therapies is one of the major stumbling blocks for successful cancer treatment."

( Maurya, SK; Shadab, GGHA; Siddique, HR, 2020)

"Effective management and treatment of cancer depend on developing novel antitumor drugs with the capability of targeting various molecular pathways."

( Ahmadi, Z; Ashrafizadeh, M; Rafiei, H, 2020)

"Multimodal cancer therapy has become a new trend in clinical oncology due to potential generation of synergistic therapeutic effects."

( Alamzadeh, Z; Beik, J; Ebrahimi, F; Ghalandari, B; Ghaznavi, H; Kamrava, SK; Komeili, A; Mirrahimi, M; Moustakis, C; Shakeri-Zadeh, A, 2020)

"The Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism (SELECT-D) trial demonstrated reduction in recurrent venous thromboembolism (VTE) but increased bleeding with rivaroxaban compared with dalteparin for treatment of acute VTE in cancer patients, at 6 months."

( Arif, A; Chapman, O; Dunn, JA; French, K; Hale, D; Hill, C; Hobbs, R; Kakkar, A; Levine, M; Lokare, A; Maraveyas, A; Maredza, M; Marshall, A; Petrou, S; Thirlwall, J; Wilkie, V; Young, AM, 2020)

"The occurrence and development of tumors is a multi-factor, multi-step, multi-gene pathological process, and its treatment has been the most difficult problem in the field of medicine today."

( Hu, CG; Luo, HL; Zhang, WJ; Zhu, ZM, 2020)

"As a novel modality for cancer treatment, CDT shows minimal invasiveness and high tumor specificity by responding to the acidic and the highly concentrated hydrogen peroxide microenvironment of tumor."

( Bajwa, SZ; Jin, Y; Khan, WS; Liu, X; Wang, W; Xu, Z; Yu, H, 2020)

"Our work provides a novel strategy for cancer therapy, using ND-conjugated cancer drugs, and the exploration of theranostic drug-delivery systems."

( Du, X; Li, L; Li, Y; Wang, S; Wei, S, 2020)

"A major impediment to successful cancer treatment is the inability of clinically available drugs to kill drug-resistant cancer cells."

( Arthur, G; Idowu, T; Nachtigal, M; Ogunsina, M; Samadder, P; Schweizer, F, 2020)

"Combination therapy for tumors is an important and promising strategy to improve therapeutic efficiency."

( Huang, M; Li, L; Li, S; Liu, H; Liu, X; Wang, Y; Xue, J; Zheng, K, 2020)

"Median time from anti-cancer therapy to CTRD was 41 [10; 141] months."

( Castro, A; Chaparro-Muñoz, M; López-Fernández, T; Lopez-Sendon, JL; Martín-Garcia, A; Martin-Garcia, AC; Martinez-Monzonis, A; Mitroi, C; Moliner, P; Sanchez, PL, 2020)

"Chemotherapy, a major cancer treatment approach, suffers seriously from multidrug resistance (MDR), generally caused by innate DNA repair proteins that reverse the DNA modification by anti-cancer therapeutics or trans-membrane efflux proteins that pump anti-cancer therapeutics out of the cytosol."

( Medarova, Z; Pantazopoulos, P; Yoo, B, 2020)

"The majority of cancers detected every year are treated with anti-cancer compounds."

( Dubois, J; Farce, A; Floquet, E; Ghinet, A; Rigo, B; Thuru, X, 2020)

"An ever-increasing number of cancer patients are being treated with checkpoint inhibitors such as anti-PD-1 antibodies, and a small percentage of these patients develop a psoriasis-like skin eruption or severe flares of prior psoriasis."

( Han, D; Huynh, M; Hwang, ST; Jena, PK; Sheng, L; Shi, Z; Wan, YY; Wu, X; Yu, S; Zhou, Y, 2020)

"We identified 78 invasive cancers among treated patients: rituximab 33 (incidence rate [IR] per 10,000 person-years = 34."

( Alping, P; Askling, J; Burman, J; Fink, K; Fogdell-Hahn, A; Frisell, T; Gunnarsson, M; Hillert, J; Langer-Gould, A; Lycke, J; Nilsson, P; Olsson, T; Piehl, F; Salzer, J; Svenningsson, A; Vrethem, M, 2020)

"The frequency of cancer amongst participants in the NAVIGATE ESUS randomized trial and the distribution of outcome events during treatment with aspirin and rivaroxaban were investigated."

"Chelating Cu from tumors has been verified as an effective and promising strategy for cancer therapy through antiangiogenesis."

( Chen, H; Chen, Q; Chu, Y; Guo, Q; Guo, Z; Jiang, C; Jiang, L; Li, C; Liu, P; Sun, T; Yu, H; Zhang, G; Zhang, Y; Zhou, W, 2020)

"To overcome the resistance of some cancer cells to this monotherapy, rationally designed combination modalities are needed."

( Bobak, YP; Fletcher, MT; Kunz-Schughart, LA; Shuvayeva, GY; Stasyk, OV; Vovk, OI, 2021)

"Childhood cancer therapy is associated with a significant risk of therapy-related cardiotoxicity."

( Korste, S; Michel, L; Mincu, RI; Mrotzek, SM; Neudorf, U; Rassaf, T; Totzeck, M, 2020)

"Advances in cancer treatment have led to significant improvements in long-term survival in many types of cancer, but heart dysfunction and heart failure, associated with cancer treatment, have also increased."

( Li, J; Peng, S; Qiao, Y; Zhang, Q; Zhang, Y, 2020)

"We analysed data of diabetic-cancer patients treated with high-dose cisplatin (> 50 mg/m2)-containing regimens."

( Fukasawa, H; Furuya, R; Ishibuchi, K; Iwakura, T; Kitamura, A; Yasuda, H, 2020)

"The prevalence of undertreated cancer pain remains high."

( Ho, JFV; Low, GSH; Tan, SB; Tho, LM; Wong, SL; Yaakup, H, 2020)

"Although the anti-cancer activity of colchicine and its derivatives has been established, none of them has found commercial application in cancer treatment due to side effects."

( Chambers, TC; Huczyński, A; Klejborowska, G; Maj, E; Moshari, M; Preto, J; Tuszynski, JA; Urbaniak, A; Wietrzyk, J, 2020)

"This study aimed to summarize the anti-cancer effects of clioquinol and its derivatives through a detailed literature and patent review and to review their potential re-uses in cancer treatment."

( Abdullah, Y; Dou, QP; Khan, H; Khan, R, 2020)

"Despite unprecedented progress in cancer chemoprevention, a vast number of cancers, however, remain an undefeatable challenge for treatment modalities."

( Chaubey, P; Murahari, M; Singh, V; Suvarna, V, 2020)

"Thereby targeting these PIKK kinases in cancer along with chemo/radiotherapy agents, can help in differential cytotoxicity towards cancer cell over the normal cell."

( Kirubakaran, S; Shaik, A, 2020)

"Given the growing number of cancers treated with 5-FU and the paucity of data regarding this ADR, we performed a retrospective national survey to better characterise 5-FU-induced hyperammonaemic encephalopathy."

( Boige, V; Boilève, A; Chouchana, L; Ducreux, M; Gaboriau, L; Hillaire-Buys, D; Hollebecque, A; Jozwiak, M; Lillo-Le Louët, A; Malka, D; Thomas, L, 2020)

"Personalized cancer vaccines based on neoantigens have become an important research direction in cancer immunotherapy."

( Heng, X; Hu, Q; Ji, X; Tang, L; Tian, Y; Yang, L; Zhang, R; Zhenyu, D; Zhou, B, 2020)

"Clinical manifestations of tumors indicate that malignant phenotypes developing in the hypoxic microenvironment lead to resistance to cancer treatment, rendering chemotherapy, radiotherapy, and photodynamic therapy less sensitive and effective in patients with tumor."

( Chen, H; Chen, J; Xue, F, 2020)

"A total of 69 cancer patients were identified, and the clinical characteristics and previous treatment were analyzed."

( Guo, JY; Li, JY; Li, TF; Liu, SY; Liu, XJ; Niu, CZ; Ren, ZG; Xuan, YY, 2020)

"Moreover, for the treatment of cancer in vivo, it achieved more effective antitumor performance along with minor side effects and systemic toxicity compared with cisplatin which is of great significance for the chemotherapeutic drug in the clinic."

( Jia, YY; Li, C; Wang, W; Zhang, BL; Zhang, JJ; Zhang, YX; Zhou, SY, 2020)

"Chelidonine suppresses NRAS-mutant cancer cell growth and could have utility as a new treatment for such malignancies."

( Chen, K; Chen, Z; Meng, Z; Qian, L; Wang, C; Wang, P, 2020)

"Among the 73 non-small cell lung cancer (NSCLC) patients treated, the objective response rate was 51 % (95 %CI = 38."

( Bebb, G; Bradbury, PA; Brown-Walker, P; Cabanero, M; Dennis, PA; Ellis, PM; Gauthier, I; Goffin, J; Goss, GD; Hao, D; Hilton, J; Hotte, S; Juergens, RA; Kollmannsberger, C; Laskin, J; Laurie, SA; Mates, M; Robinson, A; Seymour, LK; Smoragiewicz, M; Song, X; Sun, X; Tehfe, M; Tomiak, A; Tsao, MS; Tu, D; Wheatley-Price, P, 2020)

"Irinotecan treats a range of solid tumors, but its effectiveness is severely limited by gastrointestinal (GI) tract toxicity caused by gut bacterial β-glucuronidase (GUS) enzymes."

( Azcarate-Peril, MA; Bailey, ST; Bhatt, AP; Biernat, KA; Bultman, SJ; Creekmore, BC; Darr, DB; Gharaibeh, RZ; Letertre, MM; Montgomery, SA; Pellock, SJ; Redinbo, MR; Roach, JM; Roques, JR; Sartor, RB; Swann, JR; Wallace, BD; Walton, WG; Wilson, ID, 2020)

"To improve the efficiency of cancer treatment, the multifunctional nanocomposites MGO/FU-MI (MGO/FU-MI NCs) were used for combination chemotherapy and radiotherapy to verify its effectiveness in treating tumors."

( Dai, W; Kong, X; Peng, X; Quan, H; Xiang, Y; Yang, C, 2020)

"Last decade advances in cancer immunotherapy have reactivated the clinical interest on potential drug with TGF-β inhibition effect, combined with immunomodulating enhancer drugs."

( Aranda, F; Di Scala, M; Dotor, J; Gallo-Oller, G, 2020)

"During the study period, a total of 141 cancer patients were recruited, and their drug therapy regiment was thoroughly analyzed."

( Adib-Majlesi, M; Hajigholami, A; Moghaddas, A; Riechelmann, R; Sabzghabaee, AM, 2021)

"The development of effective agents for cancer therapy and inhibition of bacterial infection has drawn a great deal of interest."

( Chen, S; Cui, Y; Gao, D; He, J; Liu, K; Ma, G; Wang, J; Wang, L; Zhang, J; Zhang, Y, 2020)

"Oncolytic therapy is a fast-developing cancer treatment field based on the promising clinical performance from the selective tumor cell killing and induction of systemic antitumor immunity."

( Chen, E; Chen, W; Chen, X; Huang, D; Qian, H; Qiao, H; Tang, Q; Wang, Q; Zhang, J; Zhong, Y, 2020)

"Patients diagnosed with cancer in 2014, who were aged 20 years and older and those who underwent systemic anticancer treatment in 2014-15 were included."

( Higashi, T; Yamauchi, T; Yazaki, S, 2020)

"Targeted cancer therapy facilitates localizing the action of chemotherapeutic drugs at the tumor site enhancing the therapeutic efficacy and reducing the side effects to the healthy cells."

( Jain, S; Sahoo, SK; Singh, A, 2020)

"The main goals of cancer treatment are not only to eradicate the tumor itself but also to elicit a specific immune response that overcomes the resistance of tumor cells against chemo- and radiotherapies."

( Alexiou, C; Barras, A; Boukherroub, R; Frey, B; Gaipl, U; Janko, C; Muñoz, LE; Podolska, MJ; Szunerits, S, 2020)

"Despite breakthroughs achieved with cancer checkpoint blockade therapy (CBT), many patients do not respond to anti-programmed cell death-1 (PD-1) due to primary or acquired resistance."

( Boston, C; Brueckner, CT; Buckler, A; Capili, AD; Carven, GJ; Chapron, C; Dagbay, KB; Danehy, FT; Danek, N; Datta, A; Faucette, RR; Jackson, JW; Kalra, A; Lin, S; Littlefield, C; Martin, CJ; Nikiforov, A; Raman, P; Schürpf, T; Simpson, A; Streich, FC; Wawersik, S, 2020)

"Globimetulin B (2) selectively killed cancer cells with less toxicity to non-cancerous cells as compared to conventional doxorubicin therapy."

( Koert, U; Maza, HLD; McGaw, LJ; Mfotie Njoya, E; Mkounga, P; Nkengfack, AE, 2020)

"Solid tumors remain a major challenge for targeted therapeutic intervention strategies such as antibody-drug conjugates and immunotherapy."

( Al-Nakouzi, N; Daugaard, M; Khazamipour, N; Oo, HZ; Sorensen, PH; Steino, A; Ørum-Madsen, M, 2020)

"Patients with cancer who regularly engage in moderate-intensity exercise are more likely to have: fewer and less severe treatment-related side effects; a lower relative risk of developing other chronic diseases; and, in some cases, a lower relative risk of cancer recurrence and mortality."

( Cormie, P; Thornton-Benko, E; Trevaskis, M; Zopf, EM, 2020)

"The module of cancer treatment has undergone evolutionary changes by achieving crucial understanding on molecular, genetic, epigenetic and environmental adaptations by cancer cells."

( Bhatkar, D; Kumar, A; Roychoudhury, S; Sharma, NK, 2020)

"For the treatment of malignant tumors, drug nanocarriers with long blood circulation time and ability to target the tumor microenvironment are promising therapeutic abilities."

( Huang, J; Kang, Y; Li, D; Ou, K; Pang, J; Shi, F; Wu, J; Yan, B; Zhang, J; Zhang, X, 2019)

"The targeted delivery of anticancer drugs for improving the therapeutic efficacy and reducing the side effects has attracted great attention in cancer therapy."

( Cao, J; Chen, Y; Ge, Y; Guo, S; Huang, D; Ma, W; Qi, X; Shen, S; Wu, L; Zhang, X, 2019)

"Clinical cancer treatments [such as surgery, chemotherapy (CHT), radiotherapy (RT) and immunotherapy (IT)] are widely used but they have limited therapeutic effects and unavoidable side effects."

( Deng, J; Shen, P; Shen, Y; Wang, J; Webster, TJ; Wu, X, 2020)

"Patients with cancer treated with an intravenous or subcutaneous BMA, including pamidronate, zoledronic acid, or denosumab, at a tertiary care/safety net hospital in 2005 through 2015 were included in this retrospective review."

( Dennis, M; Jones, EA; Sarosiek, S; Weinberg, JM; White, PS, 2020)

"The incidence of DRONJ in cancer patients under treatment with denosumab ranged from 0."

( Bornstein, MM; Díaz-Parreño, SA; Helm, A; Limones, A; Molinero-Mourelle, P; Sáez-Alcaide, LM, 2020)

"Drug discovery in the scope of cancer therapy has been focused on conventional agents that nonselectively induce DNA damage or selectively inhibit the activity of key oncogenic molecules without affecting their protein levels."

( Barghout, SH, 2021)

"In this study, we treated cancer cells with metformin for diverse periods of time (0-24 h) and found that cell viability was decreased obviously."

( Bian, Y; Li, G; Ren, G; Zhang, Y; Zheng, Z, 2020)

"In order to improve the cancer therapy, it is essential to use the compounds that can overcome drug resistance and increase treatment efficiency."

( Gul, A; Keyvani-Ghamsari, S; Khorsandi, K, 2020)

"Despite its growing promise in cancer treatment, ferrotherapy has low therapeutic efficacy due to compromised Fenton catalytic efficiency in tumor milieu."

( Duan, H; Han, X; Huang, J; Jiang, Y; Li, J; Miao, Y; Pramanik, M; Pu, K; Sun, H; Upputuri, PK; Zhang, R; Zhao, X, 2020)

"Finally, we discuss cancer-related changes in lipid rafts and lipid composition, with a special focus on changes in glycosphingolipids and the possibility of using lipid therapy for cancer treatment."

( Kavaliauskiene, S; Sandvig, K; Skotland, T, 2020)

"The remarkable targeting capacity for cancer cells in combination with the synergistic effect of drug release and photothermal properties prove the great advantage of a combined chemo- and phototherapy based on graphene against cancer, opening the doors to future therapeutic applications of this type of material."

( Abellán, G; Bianco, A; Lucherelli, MA; Miyako, E; Reina, G; Yu, Y, 2020)

"Herein, an integrative strategy for cancer therapy against solid tumors is reported, in which alterations in the cleft of IS, following the secretion of acidic granular content, are utilized as a trigger for the delivery of chemotherapeutic drugs."

( Doh, J; Im, S; Jang, D; Jang, MH; Kang, Y; Kim, WJ; Lee, J; Lee, YM; Saravanakumar, G; Yang, ZY, 2020)

"Triple-negative breast cancer (TNBC) accounts for 10 to 20% of breast cancer, with chemotherapy as its mainstay of treatment due to lack of well-defined targets, and recent genomic sequencing studies have revealed a paucity of TNBC-specific mutations."

( Bhargava, R; Hu, Y; Lee, S; Lewis, MT; Loo, SK; Tan, Y; Wang, XS, 2020)

"In treatment of hypoxic tumors, oxygen-dependent photodynamic therapy (PDT) is considerably limited."

( Chou, T; Hu, W; Ren, L; Sun, J; Wang, H; Wang, J; Wang, Y; Zhang, B; Zhang, Q, 2020)

"In the treatment of malignant tumors, the combination of chemotherapy that can directly kill tumor cells and immunotherapy that can activate the body's immune system and regulate tumor microenvironments is becoming one of the most promising cancer treatments."

( Guo, Y; Hu, M; Hu, Q; Kong, L; Shang, L; Tu, K; Wang, M; Xu, M; Yu, Y; Zhang, Z, 2020)

"Gene delivery, one important cancer-therapy mode, still remains to be challenging because of the shortage of highly efficient and safe nonviral vectors."

( Caminade, AM; Cao, L; Chen, L; Fan, Y; Laurent, R; Li, J; Majoral, JP; Mignani, S; Qiu, J; Shi, X, 2020)

"SG also form in cancer cells, but studies investigating their formation upon treatment with chemotherapeutics are very limited."

( Adjibade, P; Gauthier, WN; Khandjian, EW; Ledoux, N; Mazroui, R; Nkurunziza, M; Simoneau, B, 2020)

"The diagnosis of cancer and photothermal therapy improve drastically with the implementation of nanotechnology."

( Ahmad, T; Al-Harrasi, A; Bashir, U; Farooq, U; Halim, SA; Iqbal, A; Khan, A; Sarwar, R, 2020)

"Chemo-phototherapy, as a promising cancer combination therapy strategy, has attracted widespread attention."

( Bai, L; Li, P; Li, S; Liu, H; Liu, S; Ma, J; Pan, X; Shen, H; Wu, Q; Zhang, F, 2020)

"Background : Cancer stem cell properties are highly relevant to the biology of treatment-resistant cancers."

( Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, Y; Shimada, M; Utsunomiya, T; Yamada, S, 2020)

"Mitochondrial OXPHOS dependency of cancer has been shown to underlie the development of resistance to chemotherapy and radiotherapy."

( Dey, S; Ghosh, P; Vidal, C; Zhang, L, 2020)

"Physicians treating patients with cancer are confronted with many challenges beginning with the initial diagnosis."

( Pomerantz, BJ, 2020)

"Cancer immunotherapy as a novel cancer therapeutic strategy has shown enormous promise."

( Bai, C; Jia, W; Li, L; Liu, S; Sun, Z; Wang, C; Wang, H; Zhao, Z; Zhen, M; Zhou, C, 2020)

"Recent cancer immunotherapy has attracted much attention due to high specificity and recurrence prevention of tumor."

( Kim, DH; Na, K; Seo, J, 2020)

"Vitamin C as a cancer therapy has a controversial history."

( Aoki, I; Bakalova, R; Higashi, T; Miller, T; Zhelev, Z, 2020)

"Active cancer was defined as a new diagnosis, treatment, progression or recurrence within 6 months before admission, or metastatic cancer."

( Iguchi, N; Izumi, T; Nanaura, H; Ozaki, M; Sugie, K, 2020)

"Liposomal drug delivery for cancer therapy can be limited due to drug leakage in circulation."

( Chen, HZ; Chen, ZJ; Dong, X; Fang, C; Feng, HY; Gao, Y; Lai, X; Liu, XL; Lovell, JF; Lu, Q; Yang, SC; Zhao, M; Zhu, MH; Zhu, XD, 2020)

"It is known that patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments."

( Addeo, A; Friedlaender, A; Obeid, M, 2020)

"The subjects were pediatric cancer patients who visited the emergency room at the Samsung Medical Center, Seoul, Korea, due to chemotherapy-induced febrile neutropenia, between January 2011 and December 2016."

( Huh, HJ; Kang, JM; Kim, YJ; Koo, HH; Lee, JW; Lee, NH; Lee, NY; Sung, KW; Yoo, KH, 2020)

"91 consecutive cancer patients planned for anthracycline treatment were enrolled and followed up for 12 months."

( Ishida, T; Misaka, T; Miyata, M; Nakazato, K; Oikawa, M; Takeishi, Y; Yaegashi, D; Yokokawa, T; Yoshihisa, A, 2020)

"The major problem associated with the cancer is its resistance to conventional therapy and a high relapse rate."

( Al Jaouni, SK; El-Far, AH; Mousa, SA; Tantawy, MA, 2020)

"Nanomedicines have shown success in cancer therapy in recent years because of their excellent solubility in aqueous solution and drug accumulation through controlled release in tumor tissues, but the preparation of most nanomedicines still requires ionic materials, surfactants or the amphiphilic structure to maintain nanoparticle stability and function."

( Guan, H; Jiang, T; Liu, J; Liu, X; Wang, X; Wu, G; Yin, R; Yu, M; Yu, R; Zhang, Y, 2020)

"The prospective importance of EGCG in cancer treatment is owed to its natural origin, safety, and low cost which presents it as an attractive target for further development of novel cancer therapeutics."

( Aggarwal, D; Aggarwal, V; Barwal, TS; Bishayee, A; Jain, A; Kaur, G; Pandey, A; Ritzer, EE; Sak, K; Srivastava, S; Tania, M; Tuli, HS; Varol, M, 2022)

"366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer."

( Bakouny, Z; Batist, G; Bekaii-Saab, T; Bilen, MA; Bouganim, N; Castellano, D; Choueiri, TK; de Lima Lopes, G; Del Prete, SA; Desai, A; Doroshow, DB; Egan, PC; Elkrief, A; Farmakiotis, D; Flora, D; Galsky, MD; Glover, MJ; Griffiths, EA; Grivas, P; Gulati, AP; Gupta, S; Hafez, N; Halfdanarson, TR; Hawley, JE; Hsu, CY; Hsu, E; Kasi, A; Khaki, AR; Kuderer, NM; Larroya, MB; Lemmon, CA; Lewis, C; Logan, B; Lyman, GH; Masters, T; McKay, RR; Mesa, RA; Mishra, S; Morgans, AK; Mulcahy, MF; Painter, CA; Panagiotou, OA; Peddi, P; Pennell, NA; Peters, S; Reynolds, K; Rini, BI; Rivera, DR; Rosen, LR; Rosovsky, R; Rubinstein, SM; Salazar, M; Schmidt, A; Shah, DP; Shah, SA; Shaya, JA; Shete, S; Shyr, Y; Steinharter, J; Stockerl-Goldstein, KE; Subbiah, S; Thompson, MA; Vinh, DC; Warner, JL; Wehbe, FH; Weissmann, LB; Wu, JT; Wulff-Burchfield, E; Xie, Z; Yeh, A; Yu, PP; Zhou, AY; Zubiri, L, 2020)

"Treatment of cancer with cisplatin can result in hearing loss."

( Govender, CD; Paken, J; Pillay, M; Sewram, V, 2020)

"Likely, cancer therapy in the NIR-II window could provide deeper penetration depth and higher exposure to laser over NIR-I."

( Han, Y; Li, J; Li, W; Peng, X; Qu, B; Zhang, R; Zhang, X, 2020)

"We enrolled patients with solid cancers who were treated at a single institute (Samsung Medical Center, South Korea), from April 2015 to July 2017, in this prospective single-arm Phase II clinical trial."

( Jang, JH; Jung, CW; Kim, K; Kim, SJ; Kim, WS; Kim, Y; Lee, J; Lee, SH; Park, S, 2020)

"As the number of cancer survivors increases due to early screening and modern (antineoplastic) treatments, cancer treatment associated cardiotoxicity (CTAC) is becoming an increasing health burden that affects survival and quality of life among cancer survivors."

( Aboumsallem, JP; Bracun, V; de Boer, RA; van der Meer, P, 2020)

"Within the setting of childhood cancer, there are defined groups of patients who present a particular challenge when dosing with carboplatin, including neonates and infants, those who are anephric, and poor prognosis patients receiving high-dose chemotherapy."

( Barnett, S; Kong, J; Makin, G; Veal, GJ, 2021)

"Chemotherapy has opened a new window in cancer therapy."

( Ashrafizadeh, M; Najafi, M; Tavakol, S; Zarrabi, A, 2022)

"Critically, the sensitivity of cancer cells to treatment depends on an unknown subset of a large number of biological features."

( Juraeva, D; Koras, K; Kreis, J; Mazur, J; Staub, E; Szczurek, E, 2020)

"Photodynamic therapy (PDT) against tumors was performed under 635 nm laser irradiation."

( He, P; Liu, R; Wang, W; Wen, S, 2020)

"The anticancer potential of ibuprofen has created a broad interest to explore the clinical benefits of ibuprofen in cancer therapy."

( Bao, Y; Du, R; Gao, W; Li, J; Luo, N; Shen, W; Wang, J; Yang, W; Zhang, X, 2020)

"This study aims to compare the risks of cancer among patients with type 2 diabetes mellitus (T2DM) on metformin-sulfonylurea dual therapy intensified with dipeptidyl peptidase 4 inhibitors (DPP4i), thiazolidinediones, or insulin."

( Chan, EWY; Lam, CLK; Man, KKC; Tse, ETY; Wong, CKH; Wong, ICK; Wu, T, 2020)

"Concurrent infection in cancer treatment is the leading cause of high cancer mortality that requires urgent action."

( Guo, J; Li, Y; Yang, Y; Yuan, Q; Zeng, B, 2020)

"Doxorubicin is a potent anticancer drug used to treat a variety of cancer types."

( Brunham, LR; Christidi, E; Davis, MK; Huang, H; Huang, K; Laksman, Z; Lin, E; Maillet, A; Shafaattalab, S; Tibbits, GF, 2020)

"The efficacy of nanoradiosensitizers in cancer therapy has been primarily impeded by their limited accessibility to radioresistant cancer cells residing deep inside tumor tissues."

( Chen, Z; Dou, J; Han, W; Jiang, W; Li, H; Li, S; Liu, H; Liu, Y; Wang, L; Wang, Q; Wang, Y; Xiao, L, 2020)

"Herein, C2C12 cancer cachexia model was established with C26 conditioned culture medium (CCM), then treated with magnolol to evaluate the pharmacological activity of magnolol in myotube atrophy."

( Chen, SZ; Ge, Z; Li, Y; Liu, D; Shang, Y, 2020)

"A unique phenomenon in solid tumors, the enhanced permeability and retention (EPR) effect is now well known in the development of macromolecular anticancer therapy."

( Ishida, T; Ishima, Y; Maruyama, T; Otagiri, M, 2020)

"Helenalin has shown its anti-cancer potential to treat multiple types of tumors, both in vitro and in vivo."

( Guarve, K; Kriplani, P, 2020)

"Only studies on head-neck cancer reported moderate agreement probably explained by the lack of reproducibility of the patients positioning between pre- and post-treatment FDG-PET/CT; and by the rigid registration process of images limited by post-therapeutic changes that highly affect anatomical landmarks."

( Abgral, R; Bourhis, D; Calais, J; Leclère, JC; Lucia, F; Salaün, PY; Schick, U; Vera, P, 2020)

"HCQ-HMSN-treated HCT116 colon cancer cells showed a 200-fold higher intracellular uptake of HCQ than that of free HCQ-treated cells, thereby effectively inhibiting the radiation-induced autophagy of cancer cells."

( Cheong, H; Cho, MH; Choi, Y; Lee, DE; Lee, SS; Li, Y, 2020)

"The number of cancer-associated VTE patients who received DOAC therapy was 334."

( Akiyama, E; Ebina, T; Hibi, K; Ishigami, T; Ishikawa, T; Iwahashi, N; Kimura, K; Kimura, Y; Kosuge, M; Maejima, N; Matsuzawa, Y; Minamimoto, Y; Ogino, Y; Okada, K; Tamura, K, 2020)

"In DOAC therapy for cancer-associated VTE, major bleeding prevention is important because it is an independent risk factor of death."

( Akiyama, E; Ebina, T; Hibi, K; Ishigami, T; Ishikawa, T; Iwahashi, N; Kimura, K; Kimura, Y; Kosuge, M; Maejima, N; Matsuzawa, Y; Minamimoto, Y; Ogino, Y; Okada, K; Tamura, K, 2020)

"Data from a large multicenter cohort of cancer-free patients investigated for OSA were linked to health administrative data to identify new-onset cancer."

( Bizieux-Thaminy, A; Blanchard, M; Gagnadoux, F; Gervès-Pinquié, C; Gosselin, C; Goupil, F; Humeau, MP; Justeau, G; Launois, S; Le Vaillant, M; Leclair-Visonneau, L; Masson, P; Meslier, N; Pigeanne, T; Trzepizur, W; Urban, T, 2020)

"Nuclear delivery of anticancer drugs, particularly dual complementary anticancer drugs, can significantly improve chemotherapy efficacy."

( Chen, Y; Li, X; Liang, C; Shi, Y; Wang, L; Xu, T; Yan, X; Yang, Z; Zheng, D, 2020)

"Among children on cancer chemotherapy with severe OM, ketamine mouthwash at a dose of 1 mg/kg did not significantly reduce OM pain."

( Bakhshi, S; Gupta, AK; Meena, JP; Pandey, RM; Prakash, S; Seth, R; Velpandian, T, 2020)

"Clinical strategies of cancer immunotherapy are briefly introduced and findings on apigenin linked to immunoregulatory roles in immunotherapy-associated aspects are brought together."

( Abdelbaset, GR; Ahmed, OM; Liu, H; Liu, S; Ullah, A; Xu, L; Yousuf, W; Zaky, MY; Zhang, Y, 2021)

"New anticancer therapeutic strategies, such as targeted therapies and immunotherapies, offer substantial benefits in the treatment of many neoplasms."

( Bonomini, M; Di Liberato, L; Morroni, M; Piscitani, L; Sirolli, V, 2020)

"In patients with active cancer, Apixaban, Edoxaban and Rivaroxaban are effective alternatives to treatment with LMWH."

( Ebner, M; Lankeit, M, 2020)

"The prevalence and mortality rates of cancer remain high despite significant progress in cancer therapy."

( Kumar, N; Mishra, I; Mishra, R; Sachan, N, 2020)

"Efforts in the field of anticancer therapy are increasingly focusing on the development of localized and selective treatments."

( Cassata, G; Cavallaro, G; Cicero, L; Giammona, G; Licciardi, M; Puleio, R; Scialabba, C; Varvarà, P, 2020)

"The anticancer agent 5-fluorouracil (5-FU) is cytotoxic and often used to treat various cancers."

( Hasegawa, M; Ito, SS; Kajihara, A; Kashino, G; Kikuchi, S; Kirita, T; Kitayoshi, F; Kobashigawa, S; Matsubayashi, M; Matsui, TK; Mori, E; Nakagawa, Y; Nakanishi, M; Nanaura, H; Sakaguchi, YM; Sugie, K; Takahashi, A; Tamaki, S, 2020)

"Substantial literature reports that cancer patients experience vitamin C deficiency associated with decreased oral intake, infection, inflammation, disease processes, and treatments such as radiation, chemotherapy, and surgery."

( Abiri, B; Vafa, M, 2021)

"One of the major issues in cancer radiotherapy (RT) is normal tissue toxicity."

( Beckham, W; Bromma, K; Chithrani, DB; Cicon, L, 2020)

"When applied to cancer treatment, Rh2 not only exhibits the anti-proliferation, anti-invasion, anti-metastasis, induction of cell cycle arrest, promotion of differentiation, and reversal of multi-drug resistance activities against multiple tumor cells, but also alleviates the side effects after chemotherapy or radiotherapy."

( Chen, N; Chu, S; Gao, Y; Hu, Y; Li, X; Lin, M; Liu, Y; Wang, H; Yang, S; Zhang, Y; Zhou, X, 2020)

"Finally, a pan-cancer review of publicly available data on genomic aberrations in the main enzymes involved in sterol biosynthesis and their transcription factors is reported, providing hitherto unexplored findings that may be the subject of future research in cancer metabolomics and tumor targeted treatment."

( Ballestrero, A; Bedognetti, D; Feltrin, S; Ferrando, L; Ravera, F; Traversone, N; Zoppoli, G, 2020)

"Despite the outstanding success of the cancer drug imatinib, one obstacle in prolonged treatment is the emergence of resistance mutations within the kinase domain of its target, Abl."

( Hoemberger, M; Kern, D; Pitsawong, W, 2020)

"Multidrug resistance (MDR) in cancer is one of the main limitations for chemotherapy success."

( M F Gonçalves, B; S P Cardoso, D; U Ferreira, MJ, 2020)

"Therefore, targeting EZH2 for cancer therapy is a hot research topic now and different types of EZH2 inhibitors have been developed."

( Du, W; Duan, R; Guo, W, 2020)

"Therapy against cancer remains a daunting issue for human health, despite remarkable innovations in many areas of pathology."

( Du, T; Jiang, H; Liu, W; Qambrani, A; Rehman, FU; Semcheddine, F; Shaikh, S; Tanziela, T; Wang, X, 2021)

"Despite advancements in cancer therapy and supportive care, childhood cancer survivors remain at risk for chronic morbidities associated with disease and treatment, such as hearing impairment (HI) and neurocognitive deficits."

( Armstrong, GT; Banerjee, P; Bass, JK; Brinkman, TM; Gajjar, A; Hudson, MM; Krull, KR; Liu, W; Merchant, TE; Mulrooney, DA; Pappo, AS; Robison, LL; Srivastava, D, 2020)

"T-cell-based cancer immunotherapies, such as immune checkpoint blockers (ICBs) and chimeric antigen receptor (CAR)-Tcells, have significant anti-tumor effects against certain types of cancer, providing a new paradigm for cancer treatment."

( Cha, JH; Jung, YS; Kim, K; Yang, WH, 2020)

"The treatment of patients with cancer should not be delayed, even in times of a pandemic."

( Ankolikar, S; Deshmukh, S; Gandhi, V; Gautam, P; Gawande, J; Gosavi, N; Naik, S; Patwa, R; Wagh, S; Watgaonkar, R; Zade, B, 2020)

"The mainstay of treatment in advanced cancer pain is opioids; however, non-opioid medications such as acetaminophen continue to be included in guidelines despite a lack of clear, convincing evidence for their use."

( Quirk, K; Smith, MA, 2020)

"Among them, cancer-related inflammation genes regulating curcumin-based molecules are a very promising target to overcome hurdles in the multimodality therapy of cancer."

( Harikrishnan, A; Khanna, S; Veena, V, 2021)

"All adult patients with solid tumors who received chemotherapy in their last 3 months of life and died in our hospital between January 2015 to June 2019 were included."

( Civelek, B; Özaslan, E; Sürel, AA; Urvay, S, 2021)

"We recruited 150 fasting patients with cancer (of 199 total recruited) from two cohorts, either prior to cancer surgery or during cancer chemo- or immunotherapy."

( Burgess, E; Dachs, GU; Morrin, HR; Nonis, M; Pearson, JF; Pullar, JM; Robinson, BA; Spencer, E; Vissers, MCM; White, R, 2020)

"This is also true with regards to cancer treatments and screening."

( Abrams, SL; Akula, SM; Basecke, J; Blalock, WL; Candido, S; Cervello, M; Cocco, L; Follo, MY; Lerpiriyapong, K; Libra, M; Martelli, AM; McCubrey, JA; Montalto, G; Notarbartolo, M; Piazzi, M; Ramazzotti, G; Ratti, S; Steelman, LS, 2020)

"For patients with metastatic cancer, treatment with palliative chemotherapy can lead to more aggressive end-of-life (EOL) care."

( Chen, ML; Cheng, WW; Gu, XL; Zhang, Z, 2020)

"Despite their efficacy, cancer cells can develop drug resistance leading to treatment failure and relapse."

( Dodani, SC; Gallenito, MJ; Meloni, G; Prakash, V; Qasim, TS; Tutol, JN, 2020)

"There are many types of hand tumors, and it is often difficult for imaging diagnosticians to make a correct diagnosis, which can easily lead to misdiagnosis and delay in treatment."

( Fang, J; Hu, X; Liu, Z; Lu, H; Zhou, H, 2020)

"Heat-treated cancer cells have thermo-resistance due to the up-regulated levels of heat shock proteins (HSP) resulting in low therapeutic efficiency and ineffective ablation of tumors."

( Li, R; Liu, L; Xue, F; Yi, T; Zhong, Y; Zou, Y, 2020)

"The stroma in solid tumors severely impedes drug delivery via systemic administration to cancer cells, especially when using nano-drug delivery systems."

( Fu, Q; Gu, Z; Jin, X; Lv, H; Zhang, Z, 2020)

"The therapeutic index of cytokines in cancer therapy can be increased by targeting strategies based on protein engineering with peptides containing the CNGRC (NGR) motif, a ligand that recognizes CD13-positive tumor vessels."

( Colombo, B; Corti, A; Curnis, F; Ferreri, AJM; Gasparri, AM; Monieri, M; Rrapaj, E; Sacchi, A, 2020)

"Opioids have been the foundation of cancer pain management for decades; however, there is a paucity of literature on long-term opioid therapy (LTOT) in cancer survivors."

( Bernacki, R; Fu, MR; Jones, KF; Lee, C; Merlin, JS; Paice, JA; Wood, LJ, 2021)

"In terms of cancer treatment, ursolic acid interacts with a number of molecular targets that play an essential role in many cell signaling pathways."

( Aderibigbe, BA; Khwaza, V; Oyedeji, OO, 2020)

"Specific doses of vitamin C can stop cancer cell glycolysis and block nitroso synthesis, indicating the potential of vitamin C in cancer treatment."

( Fu, J; Liu, J; Wu, T; Wu, Z, 2020)

"The widely recognized anti-cancer potential of aspirin has created a broad interest to explore the clinical benefits of aspirin in cancer therapy."

( Du, R; Luo, N; Shen, W; Xiang, R; Zhang, X, 2020)

"Over the past decade, cancer therapy has rapidly evolved from traditional approaches, such as surgery, chemotherapy, and radiotherapy, to revolutionary new treatment options with immunotherapy."

( Ma, R; Riker, AI; Xi, Y; Yi, B, 2020)

"In the treatment of hyponatremia in cancer patients, TpST was found to have more positive effects on blood sodium levels, length of hospital stay, hospital complications, and hyponatremia symptoms compared to ST."

( Basal, FB; Bilgetekin, I; Demirci, U; Erturk, I; Karacin, C; Karadurmus, N; Oksuzoglu, B, 2021)

"The usage of nanomaterials for cancer treatment has been a popular research focus over the past decade."

( Mondal, S; Sharma, H, 2020)

"The greatest challenge in cancer therapy is posed by drug-resistant recurrence following treatment."

( Jang, H; Kang, JH; Kim, HY; Kim, SY; Lee, H; Lee, JS; Lee, SH; Park, JB; Song, J; Woo, SM, 2020)

"The Children's Oncology Group (COG) Cancer Control and Supportive Care Neurotoxicity Subcommittee therefore conducted a survey of providers at COG institutions to determine perspectives on pediatric otoprotection practices and research surrounding three major themes: (1) prevalence of routine use of STS with cisplatin-based regimens, (2) application of audiometry to cisplatin therapy, and (3) preferred modalities for otoprotection research."

( Dvorak, CC; Esbenshade, AJ; Freyer, DR; Hardy, KK; Orgel, E; Thomas, SM; Ullrich, NJ, 2020)

"Currently, the major challenges for cancer immunotherapy are how to improve the response rate and overcome drug resistance."

( Chen, HJ; Huang, X; Jin, L; Lan, X; Lui, VWY; Pu, JJ; She, J; Su, YX; Xiao, H; Xie, X; Yu, Y; Zhu, W, 2020)

"To assess the risk of developing cancer in patients with rheumatoid arthritis (RA) exposed to non-TNF inhibitors (TNFi) biologics or tofacitinib therapy."

( Gao, D; Huang, H; Ji, L; Xie, W; Yang, X; Zhang, Z, 2020)

"Observational studies that reported cancer incidence in patients with RA treated with biologics or tofacitinib with active comparator of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or TNFi were eligible for inclusion."

( Gao, D; Huang, H; Ji, L; Xie, W; Yang, X; Zhang, Z, 2020)

"Particularly, in cancer therapy, the physicochemical properties of gold-based nanomaterials allow them to efficiently accumulate in the tumor tissue and then mediate the light-triggered thermal destruction of cancer cells with high spatial-temporal control."

( Correia, IJ; Gonçalves, ASC; Moreira, AF; Rodrigues, CF, 2020)

"Among the novel cancer treatment strategies, combination therapy is a cornerstone of cancer therapy."

( Darvishi, MH; Hashemzadeh, H; Khaledian, M; Nourbakhsh, MS; Saber, R, 2020)

"Comparison of the platinum uptake by cancer cells treated with the nanocapsule and with cisplatin evidenced superior uptake of platinum caused by the nanocapsule, which in HT-29 and HL-60 cells prevails by 21 and 31 times, respectively."

( Ahmedova, A; Mihaylov, L; Mihaylova, R; Mihaylova, V; Momekov, G; Momekova, D; Nihtianova, D; Paunova-Krasteva, T; Stoitsova, S; Stoykova, S; Yoshizawa, M, 2020)

"For treatment of cancer, single photothermal therapy (PTT) and PTT combined with other therapeutic modalities will be discussed."

( Chen, M; Chen, X; Li, J; Liu, Y; Zheng, N, 2020)

"Localized delivery of anticancer drugs is often the most useful therapeutic approach for the treatment of solid tumors."

( Collura, G; Condorelli, L; Fiorica, C; Giammona, G; Palumbo, FS; Pitarresi, G; Puleio, R, 2020)

"The release of anticancer drugs in systemic circulation and their associated toxicity are responsible for the poor efficacy of chemotherapy."

( Ansari, MN; Bajaj, A; Dasgupta, U; Jha, SK; Kumar, S; Medatwal, N; Pal, S; Rana, K; Verma, P, 2020)

"Within the tumors of treated patients, danvatirsen uptake was observed mainly in cells of the tumor microenvironment (TME)."

( Barrett, JC; Barry, S; Bommakanti, G; Cantin, S; Carnevalli, L; Collins, M; Deng, N; Fawell, S; Griffin, M; Grosskurth, S; Hughes, A; Magiera, L; McCoon, P; Mele, DA; Proia, TA; Reimer, C; Russell, D; Singh, M; Srinivasan, S; Woessner, R; Womack, C; Xie, M; Ye, M, 2020)

"Within the tumors of treated patients, danvatirsen uptake was observed mainly in cells of the tumor microenvironment (TME)."

"Thirty-four cancer patients undergoing radiotherapy, chemotherapy alone or combined treatment were investigated for oral Candida spp."

( Andrade, D; Bim, FL; Macedo, AP; Oliveira, VC; Sousa, ÁFL; Souza E Silva, VC; Watanabe, E, 2020)

"Epigenetic reprogramming of specific cancer-related pathways at the single-cell level is likely to underlie the remarkable efficacy of low-dose DNA demethylating therapy."

( Hattori, N; Takeshima, H; Ushijima, T; Wakabayashi, M; Yamashita, S; Yoda, Y, 2020)

"Maximizing the accumulation of anticancer medicine in the tumor is the priority to achieve minimal invasive cancer therapy, which raises high demands on tumor-targeting ability of drug delivery systems."

( Dong, C; Feng, C; Liang, S; Lin, Y; Liu, J; Lu, Y; Shi, S; Sun, M; Yang, Y, 2020)

"The early diagnosis and monitoring of cancers are key factors in effective cancer treatment."

( Jang, YO; Koo, B; Liu, H; Noh, GS; Qiao, Z; Shin, Y, 2020)

"Subjects with confirmed cancer who were naive to highly and moderately emetogenic chemotherapy (HEC and MEC) and were scheduled to receive intravenous (IV) anthracycline-cyclophosphamide (AC)-based MEC on the first day of chemotherapy were randomly assigned to receive oral ondansetron and oral dexamethasone plus either a single IV dose of fosaprepitant 150 mg (fosaprepitant regimen) or placebo (control regimen)."

( Beckford-Brathwaite, E; Green, S; Jordan, K; Khanani, S; Noga, SJ; Pong, A; Rapoport, BL; Vallejos, W; Weinstein, C, 2020)

"Triapine may be evaluated in cancer patients in the setting of HIV with emtricitabine or tenofovir treatment."

( Beumer, JH; Chaphekar, N; Chu, E; Guo, J; Jones, R; Joshi, A; Kiesel, BF; Kunos, CA; Taylor, S; Venkataramanan, R, 2020)

"Targeted delivery of anticancer drugs is one of the most promising methods for cancer therapy."

( Chen, G; Chen, Z; Li, X; Ma, X; Ren, X; Sun, Z; Yi, Z, 2020)

"In patients with pediatric cancer who are nearing the end of life, methadone is a valuable adjunctive therapy to treat nociceptive and neuropathic pain and to prevent opioid-induced hyperalgesia and opioid tolerance."

( Anghelescu, DL; Habashy, C; Hall, EA; Sauer, HE, 2021)

"However, due to their heterogeneity, cancer cells frequently display primary or acquired therapeutic resistance, thereby resulting in treatment failure."

( Cai, Y; Gao, M; Gong, Z; Guo, G; Huang, J; Peng, B; Wu, G; Xu, Z; Yan, Y; Zeng, S, 2020)

"Traditional cancer diagnosis strategies are not considered by most people until the last resort, which delays many cancer treatments leading to advanced stages."

( Li, D; Mei, X; Wang, G, 2020)

"Melanoma tumors in mice on the high-fructose diet were resistant to immunotherapy and showed increased expression of the cytoprotective enzyme heme oxygenase-1 (HO-1)."

( Bockerstett, KA; Burris, TP; DiPaolo, RJ; Donlin, MJ; Geraud, SC; Griffett, K; Khojandi, N; Klevorn, LE; Kuehm, LM; McCommis, KS; McLaughlin, NR; Nelson, AM; Piening, A; Preuss, ML; Pyles, KD; Teague, RM, 2021)

"This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment."

( Anderson, H; Corbett, R; Hitchings, E; Macfarlane, S; Mahoney, E; Narsinh, M; Natarajan, A; Naysmith, K; Ramadas, Y; Shum, M, 2020)

"Chemotherapy is widely used in cancer treatments."

( Alitheen, NB; Gan, BK; Ho, KL; Omar, AR; Rullah, K; Tan, WS; Yong, CY, 2020)

"The current trend of cancer therapy has changed from monotherapy to synergistic or combination therapies."

( Gao, N; Jing, J; Liu, Y; Su, S; Yang, C; Zhang, X, 2020)

"Many cancer centers have not fully implemented evidence-based tobacco treatment into routine care."

( Borderud, S; Cooley, ME; de León-Sanchez, S; Friedman, ER; Gonzalez, I; Holland, S; Hyland, KA; Irwin, KE; Kwon, D; Levy, DE; Malloy, L; Miller-Sobel, J; Muzikansky, A; O'Brien, M; Ostroff, JS; Park, ER; Partridge, AH; Perez, GK; Peterson, L; Pirl, WF; Ponzani, C; Rabin, J; Regan, S; Rigotti, NA; Sprunck, K; Temel, JS; Whitlock, CW, 2020)

"Treating cancer depends in part on identifying the mutations driving each patient's disease."

( Campbell, PA; Karimnezhad, A; Lo, B; Palidwor, GA; Perkins, TJ; Stewart, DJ; Thavorn, K, 2020)

"Nanotechnology applied to cancer treatment is a growing area of research in nanomedicine with magnetic nanoparticle-mediated anti-cancer drug delivery systems offering least possible side effects."

( Al-Arag, S; Amorim, CO; Cuisinier, F; Guha, M; Rauwel, E; Rauwel, P; Rosario, MS; Salehi, H, 2020)

"Combinatorial cancer therapies mediated by nanomaterials can potentially overcome the limitations of conventional treatments."

( Alves, CG; Correia, IJ; de Melo-Diogo, D; Lima-Sousa, R; Mó, I, 2020)

"Pro-drug activation, a modality of cancer therapy leads to Ganciclovir triphosphate (GCV-TP) incorporation into newly synthesized DNA resulting in cell death."

( Jain, V; Kamble, V; Nanda, A; Patel, H; Warawdekar, UM, 2021)

"The resistance to therapy of cancer cells is a challenge for achieving an appropriate therapeutic outcome."

( Afrashi, S; Ashrafizadeh, M; Farhood, B; Haghi-Aminjan, H; Moloudi, K; Musa, AE; Najafi, M; Taeb, S, 2021)

"The HepG2 and MCF7 cancer cells also had a significantly higher percentage of apoptosis and were more sensitive to gallic acid nanoparticle treatment in the cell migration assay."

( Azarian, MMS; Hassani, A; Hussain, SA; Ibrahim, WN, 2020)

"Nanoparticle technology in cancer chemotherapy is a promising approach to enhance active ingredient pharmacology and pharmacodynamics."

( Annereau, M; Bally, M; Corvis, Y; Fleury, T; Lai-Kuen, R; Lam, A; Martin, B; Mignet, N; Neri, G; Seguin, J, 2020)

"Patients receiving aggressive cancer treatment at the end of life elucidate significant gaps in quality cancer care, particularly the early involvement of dedicated palliative care."

( Gomez, TH; Santos, JL; Tan, X; Wilkerson, DH, 2021)

"In the context of cancer treatment within public health facility, younger survivors, households from B40 group and individual with educational attainment below the first level schooling in the Malaysian system of education are prone to greater financial toxicity."

( Chew, KS; Kueh, JS; Siew, KL; Wong, SS; Yap, SL, 2020)

"However, the majority of cancer patients still do not respond to checkpoint blockade immune therapy leading to an unmet need in tumor immunology research."

( Rothenberger, NJ; Somasundaram, A; Stabile, LP, 2020)

"Advanced stage cancer being treated with palliative intent vs others [30-day mortality 24%% vs 5%, odds ratio (OR) 5."

( Bagal, B; Bajpai, J; Banavali, S; Bhargava, P; Bonda, A; Cheriyalinkal Parambil, B; Chinnaswamy, G; Dhamne, C; Ghosh, J; Gokarn, A; Gulia, S; Gupta, S; Jain, H; Jobanputra, K; Joshi, A; Kapoor, A; Khattry, N; Kumar, A; Menon, N; Narula, G; Nayak, L; Noronha, V; Ostwal, V; Patil, VM; Prabhash, K; Prasad, M; Punatar, S; Ramaswamy, A; Rath, S; Roy Moulik, N; Sengar, M; Shah, MJ; Srinivas, S; Thorat, J; Vora, T, 2020)

"The mortality rates in cancer patients with COVID-19 who are receiving systemic anti-cancer therapy in LMICSs are marginally higher than that reported in unselected COVID-19 cohorts with prolonged time to viral negativity in a substantial number of patients."

"Patients with cancer have a higher risk to acquire the infection and worse prognosis as they have to attend more medical visits in healthcare institutions, receive medical and surgical treatments, and be subjected to diagnostic studies such as PET/CT in nuclear medicine services where the infection may be an incidental finding."

( González, E; Martí, A; Morón, S; Rojas, J, 2020)

"The future status of ferroptosis in cancer management is deliberated and strategies for treatment of therapy‑resistant cancers are discussed."

( He, B; Huang, Q; Huang, S; Liu, Y; Luo, Y; Xiao, J, 2021)

"The prevalence of cancer-related pain is 64% among patients with metastatic, advanced, or terminal cancer, 59% among patients undergoing anticancer treatment, and 33% among patients who completed curative treatment."

( Hozumi, J; Ikeda, K; Nishizawa, D; Sumitani, M, 2022)

"The co-presence of a malignant neoplasm and hyperostosis frontalis interna may be related to a hormonal imbalance, a possibility also suggested by atypical funerary treatment."

( Laffranchi, Z; Langer, R; Lombardo, P; Lösch, S; Milella, M, 2021)

"In a carefully monitored group of cancer survivors with persistent pain, chronic opioid therapy was safely managed during extended periods without significant opioid escalation or evidence of serious adverse events including aberrant behaviors."

( Fitzgibbon, D; Hsu, M; Lee, M; LeVoir, A; Posner, K, 2021)

"Baseline demographics, DAPT duration, malignancy type, stage, and treatment were retrospectively analyzed."

( Aziz, MK; Balanescu, DV; Cilingiroglu, M; Donisan, T; Hassan, S; Iliescu, C; Kim, P; Lopez-Mattei, J; Marmagkiolis, K; Ntim, W; Palaskas, N; Song, J, 2021)

"Of patients who resumed or started cancer treatment (chemotherapy, radiation therapy, or surgery) after PCI, all but one did so within 6 months of PCI, and most of them as early as 2 weeks."

( Aziz, MK; Balanescu, DV; Cilingiroglu, M; Donisan, T; Hassan, S; Iliescu, C; Kim, P; Lopez-Mattei, J; Marmagkiolis, K; Ntim, W; Palaskas, N; Song, J, 2021)

"Patients may resume cancer treatment <6 months after PCI."

( Aziz, MK; Balanescu, DV; Cilingiroglu, M; Donisan, T; Hassan, S; Iliescu, C; Kim, P; Lopez-Mattei, J; Marmagkiolis, K; Ntim, W; Palaskas, N; Song, J, 2021)

"Complexities in treating breast cancer with bone metastasis are enhanced by a vicious protumorigenic pathology, involving a shift in skeletal homeostasis toward aggressive osteoclast activity and polarization of immune cells supporting tumor growth and immunosuppression."

( Ashton, R; Deshane, JS; Hensel, JA; Khattar, V; Lee, JH; Ponnazhagan, S; Wang, H; Wang, Y, 2020)

"Treatment of cancer utilizing radiotherapy or chemotherapy actuates a few issues which incorporate spewing, sickness, unpalatable reactions, and so forth."

( Roy, A, 2021)

"However, due to the low selectivity of cancer cells, chemotherapy drugs produce a series of grievous side effects on normal cells."

( Guo, J; Hu, C; Peng, H; Wang, M, 2020)

"With the inspiration to develop new cancer nanotherapeutics by repurposing old drugs, in the current study, a novel two dimensional nanomedicine namely Mn doped, dihydroartemisinin (DHA) loaded layered double hydroxide (MnMgFe-LDH/DHA) with peroxide self-supplying properties for enhanced photothermal-chemodynamic therapy was proposed."

( Che, S; Chi, Y; Gao, F; Gu, Z; Guo, Z; Lu, J; Takuya, N; Xu, J; Xu, W; Yu, J; Zhang, J; Zhao, L, 2020)

"Platinum-based cancer therapy is restricted by dose-limiting side effects and is associated with elevation of growth differentiation factor 15 (GDF-15)."

( Bennett, D; Birnbaum, MJ; Breen, DM; Calle, RA; Collins, S; Esquejo, RM; He, T; Joaquim, S; Joyce, A; Kim, H; Lambert, M; Lin, L; Pettersen, B; Qiao, S; Rossulek, M; Weber, G; Wu, Z; Zhang, BB, 2020)

"Traditional anti-cancer treatments are far from satisfactory."

( Chen, YH; Jin, YC; Liu, YM; Tang, KZ, 2020)

"Metabolic cell labelling for cancer immunotherapy will also be discussed."

( Mooney, DJ; Wang, H, 2020)

"Inflammation can support or restrain cancer progression and the response to therapy."

( Bell, CR; Bonavita, E; Bromley, CP; Chiang, SC; Chikkanna-Gowda, CP; Davis, DM; Flanagan, E; Guerra, N; Jaillon, S; Jonsson, G; Mantovani, A; Mensurado, S; Moeini, A; Pelly, VS; Reis e Sousa, C; Rogers, N; Sahoo, S; Silva-Santos, B; Walwyn-Brown, K; Zelenay, S, 2020)

"Combination therapy of cancer cells by using HIF-1α siRNA-loaded SPION-TMC-HA NPs and E7046 also prevent proliferation, migration, invasion, angiogenesis, and colony formation of the cancer cells, remarkably."

( Abdpoor Sough, TS; Atyabi, F; Edalati, M; Fakkari Afjadi, J; Haeri, MS; Hajiramezanali, M; Hajizadeh, F; Heydarzadeh Asl, S; Izadi, S; Jadidi-Niaragh, F; Karpisheh, V; Masjedi, A; Mirzazadeh Tekie, FS; Nabi Afjadi, M; Sojoodi, M, 2021)

"Patients with cancer are at high risk of venous thromboembolic events, and this risk can be further increased in patients with certain cancer types and by cancer treatments."

( Carrier, M; Cohen, AT; Kavan, P; Khorana, AA; Meyer, G; Pabinger, I; Wells, P, 2020)

"The incidence and mortality of cancer continue to grow since the current medical treatments often fail to produce a complete and durable tumor response and ultimately give rise to therapy resistance and tumor relapse."

( Cui, G; Hou, Y; Meng, T; Shang, C; Shi, M, 2021)

"Across non-cancerous diagnoses, the intensity of treatment appeared consistent, which may indicate, that the awareness of palliative care is higher among oncologists than within other paediatric fields."

( Christiansen, CF; Darlington, AS; Johnsen, SP; Neergaard, MA; Schroeder, H; Wolff, S, 2021)

"used in cancer treatment due to the severe side effects associated with it."

( Sharma, R; Srivastava, N, 2021)

"Adverse drug reactions due to cancer chemotherapy negatively affect the quality of life (QoL) of cancer patients."

( Das, B; Nath, UK; Pasricha, RK; Ramasubbu, SK; Rawat, VS, 2021)

"Platinum (Pt)-based anticancer drugs such as cisplatin have been used to treat various cancers."

( Kim, CY; Lee, SY; Nam, TG, 2020)

"As a commonly used treatment method for cancer, chemotherapy is greatly limited by the side effects of chemotherapy drugs and the multiple drug resistance that develops."

( Huang, J; Li, Z; Wu, J, 2021)

"In mice with intradermal tumors that were orally administered ALA (200 mg/kg daily for 5 days), the tumor in each mouse was simultaneously irradiated (8 h/day for 5 days) using a wirelessly powered implantable green LED device (532 nm, 0."

( Fujie, T; Fujita, K; Kirino, I; Morimoto, Y; Sakanoue, K; Sugita, R; Takeoka, S; Uemoto, S; Yamagishi, K, 2020)

"A minority of cancer survivors with CIPN treated with duloxetine had a meaningful CIPN improvement, and tolerability was overall low."

( Argyriou, AA; Besora, S; Bruna, J; Calvo, M; Clapés, V; Gil-Gil, M; Izquierdo, C; Jiménez, L; Palmero, R; Pardo, B; Sala, R; Santos, C; Simó, M; Velasco, R, 2021)

"Higher ML deposition in tumors was associated with a reduction in lesion size and enhanced survival in animals treated with liposomal DXR, but not with DXR alone."

( Abakumov, MA; Chekhonin, VP; Garanina, AS; Lipatova, AV; Majouga, AG; Melnikov, PA; Naumenko, VA; Potashnikova, DM; Valikhov, MP; Vishnevskiy, DA; Vlasova, KY; Vodopyanov, SS, 2021)

"A systematic search of NTX in cancer therapy was conducted."

( Abd-Elsayed, A; Khajehdehi, N; Khan, JS; Kordbacheh, K; Liubchenko, K; Ma, F; Storey, M; Visnjevac, O; Visnjevac, T, 2021)

"Current progress in anticancer drugs offers a rise in isolation and clinical validation of numerous innovative developments and advances in anticancer therapy."

( Ouyang, S; Saeed, AFUH; Su, J, 2021)

"Nineteen patients treated for cancer pain with oral hydromorphone were reviewed in this study."

( Ishiki, H; Kiuchi, D; Sato, N; Satomi, E; Shimizu, M; Yoshida, T, 2020)

"The quality of cancer pain treatment in these hospitals was evaluated in August 2015, 2017 and 2019 by using an evaluation instrument containing eight domains."

( Fan, B; Li, P; Qin, W; Yang, Q; Yang, Y; Zhang, L, 2021)

"The discrepancy of surface receptors on cancerous and non-cancerous cells has been regarded as the mainstay of cancer-targeted therapy."

( Cai, K; Chen, Y; Cheng, J; Liu, X; Liu, Y; Wu, F; Yin, L; Zhang, Z; Zhao, Z, 2021)

"MCF-7 breast cancer cells were irradiated or received hyperthermia with or without treatment with suberosin."

( Ahmadi, A; Amini, P; Aryafar, T; Ashrafizadeh, M; Farhood, B; Khalafi, L; Mahdavi, SR; Musa, AE; Najafi, M; Nodooshan, SJ; Tavakoli, S, 2021)

"Suberosin has a potent anti-cancer effect when combined with radiotherapy or hyperthermia."

( Ahmadi, A; Amini, P; Aryafar, T; Ashrafizadeh, M; Farhood, B; Khalafi, L; Mahdavi, SR; Musa, AE; Najafi, M; Nodooshan, SJ; Tavakoli, S, 2021)

"In human cancers, ENPP1 expression correlates with reduced immune cell infiltration, increased metastasis, and resistance to anti-PD-1/PD-L1 treatment."

( Bakhoum, SF; Bareja, R; Bettigole, SE; Biswas, D; Cavallo, JA; Chatila, WK; Dhanota, N; DiPardo, BJ; Dorsaint, P; Duran, MA; Elemento, O; Gottesdiener, L; Hanna, MG; Hollmann, TJ; Humphries, MP; Izar, B; James, JA; Kalbasi, A; Kwon, J; Li, HW; Li, J; Li, P; Litchfield, K; Martin, ML; Melms, JC; Merghoub, T; Parkes, EE; Pauli, C; Powell, SN; Reis-Filho, JS; Riaz, N; Salto-Tellez, M; Shoushtari, AN; Sriram, RK; Su, SM; Swanton, C; Usaite, I; Vallabhaneni, S; Vasan, N; Wen, HY; Wolchok, JD, 2021)

"Adult cancer patients initiating treatment with EGFRIs were randomized to receive facial topical treatment with chloramphenicol 3% + prednisolone 0."

( Amitay-Laish, I; Ben-Aharon, I; Brenner, B; David, M; Davidovici, B; Flex, D; Hodak, E; Leshem, YA; Ollech, A; Peled, N; Popovtzer, A; Prag-Naveh, H; Purim, O; Snast, I; Stemmer, SM, 2021)

"With regard to cancer, melatonin's potential to suppress cancer initiation, progression, angiogenesis and metastasis as well as sensitizing malignant cells to conventional chemo- and radiotherapy are among its most interesting effects."

( Asghari, MH; Fallah, M; Hekmatirad, S; Moloudizargari, M; Moradkhani, F; Reiter, RJ, 2021)

"Despite advances in targeted cancer therapy, the fluoropyrimidines 5-fluorouracil (5FU) and capecitabine continue to play an important role in oncology."

( Galettis, P; Martin, JH; Schneider, JJ, 2021)

"Metastatic cancer is a persistent clinical enigma, which requires combination of several treatment modules."

( Diao, D; Huang, Y; Li, S; Luo, Z; Ren, P; Sun, J; Wan, Z; Xu, J; Zhang, B, 2021)

"Therefore, targeting TGFβ signaling for cancer therapy is challenging."

( Chen, J; Chen, XP; Ding, ZY; Li, S; Li, Z; Liu, S; Xiao, C; Yang, X; Zhang, BX, 2021)

"A system of integrated cancer care using psychosocial screening, opioid risk mitigation tools, opioid treatment agreements, and specialist expertise that cancer care providers can rely on to monitor POM use in conjunction with patient-centered communication to empower patients informed decision making in managing their cancer pain could address this critical gap in survivorship care."

( Chavez, MN; di Ciccone, BL; Gutierrez, A; Henderson, H; Lake, P; Marshall, VK; Pabbathi, S; Rajasekhara, S; Rigg, KK; Sherry, P; Tyson, DM, 2021)

"In patients with cancer, dysphagia has been attributed to local tumor invasion or as a complication from surgery, radiotherapy, and chemotherapy."

( Saraceni, C; Vaziri, H; Villavicencio Kim, J, 2022)

"We hypothesized that, during cancer therapy (DIECT), fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) imaging could be useful to predict dental inflammation with exacerbation."

( Asami, T; Dam, TT; Kim, M; Kurihara, J; Ogawa, M; Shimizu, T; Suzuki, K; Yamaguchi, T; Yokoo, S, 2021)

"Furthermore, CT-26 colon cancer cells were allografted subcutaneously into BALB/c mice, and α-pinene treatment then inhibited allografted tumor growth."

( Bin, BH; Brito, S; Cha, B; Jo, H; Kim, H; Kim, ST; Kwak, BM; Lee, MG, 2021)

"Gemcitabine is an anticancer drug used to treat a wide range of solid tumors and is a first-line treatment for pancreatic cancer."

( Hawryłkiewicz, A; Ptaszyńska, N, 2021)

"But, the evasion of apoptosis by tumors can cause acquired resistance to the therapy."

( Je, H; Kim, GB; Kim, IS; Kim, SR; Kim, W; Lee, EJ; Nam, GH, 2021)

"Combinational cancer therapy offers a promising strategy to overcome the limitations of single-drug treatment, including limited therapeutic efficacy, serious side effects, and low survival rate."

( Dai, F; Gou, S; Huang, Y; Ma, Y; Wang, C; Xiao, B; Xie, D, 2020)

"It can be caused by the cancer itself or by certain therapies like surgery, radiation or chemotherapy."

( Cata, JP; Gorur, A; Ramirez, MF, 2021)

"For both groups, the risk to develop cancer under treatment with different ASMs was analyzed using three different models (ever use vs."

( Hamer, HM; Kostev, K; Lang, JD; Mueller, TM; Reindl, C; Stritzelberger, J; Westermayer, V, 2021)

"While our understanding of tumors and how to treat them has advanced significantly since the days of Aminopterin and the radical mastectomy, cancer remains among the leading causes of death worldwide."

( Czarnowski, D, 2021)

"The treatment of cancer cachexia can be based on these three domains of the syndrome."

( Fonseca, GWPD; von Haehling, S, 2021)

"The role of zinc in cancer treatment has been discussed for some time, however without reaching an evidenced-based consensus."

( Büntzel, J; Dörfler, J; Hoppe, C; Huebner, J; Kutschan, S, 2021)

"However, effective cancer medication and therapy are still castles in the sky to researchers."

( Bose, B; Gauthaman, A; Moharana, P; Moorthy, A; Muthukumar, V; Paira, P; Ray Chaudhuri, S; Roy, N; Sen, U, 2021)

"Chemotherapy is a common strategy in cancer therapy, but its adverse effects and chemoresistance have limited its efficacy."

( Ashrafizadeh, M; Hushmandi, K; Najafi, M; Orouei, S; Saberifar, S; Salami, S; Zarrabi, A, 2021)

"We describe patients who developed cancer among a cohort of 886 MS patients on DMF treatment (2681 patient-years), with a median time of exposure of 39."

( Aladro-Benito, Y; Ayuso-Peralta, L; Cámara, PS; Costa-Frossard, L; Díaz-Díaz, J; Gómez-Moreno, M; Moreno-García, S; Oreja-Guevara, C; Pilo de la Fuente, B; Sabin-Muñoz, J; Sainz de la Maza, S; Sánchez-Seco, VG, 2021)

"Currently, major available AuNP-based cancer therapeutic approaches are the photothermal therapy (PTT) or photodynamic therapy (PDT)."

( Cioni, P; D'Acunto, M; Gabellieri, E; Presciuttini, G, 2021)

"Treatment of cancers has always been a challenge for physicians."

( Ala, M, 2021)

"Pain is common in advanced cancer is often refractory to standard treatment."

( Benkli, B; Chung, M; Huh, B; Qing, Y; Roldan, C; Wang, J, 2021)

"To improve the prognosis of cancer patients, methods of local cancer detection and treatment could be implemented."

( Alphandéry, E, 2021)

"Unfortunately, cancer patients are at higher risk of viral infection and more likely to develop serious complications due to their immunocompromised state, the fact that they are already administering multiple medications, as well as combined comorbidity compared to the general population."

( Amin, NS; El Tayebi, HM; Elgohary, S; Elkhodiry, AA; Stein, U, 2021)

"All of the solid 4T1 tumors disappeared, and tumor metastases were merely observed in the major organs of the tumor-bearing mice after administration of DGM-CuS@DOX and DGM-CuS@DOX-P with irradiation."

( Luo, X; Wang, P; Wang, Z; Wu, Z; Zhang, P, 2021)

"Conventional anti-cancer therapy can greatly improve survival however treatment resistance is still a major problem especially in metastatic disease."

( Abdullah, NA; Ammar, A; Md Hashim, NF; Muhamad Zakuan, N, 2021)

"The photodynamic anticancer activity of a photosensitizer can be further increased by co-administration of a flavonoid."

( Banerjee, UC; Bhaumik, J; Jain, S; Kalia, YN; Kirar, S; Kushwah, V; Mandal, N; Patel, G; Reddy, YN; Thakur, NS, 2021)

"Subgroup analysis showed that lung cancer was independently associated with targeted therapy (P<0."

( Chen, ML; Cheng, WW; Liu, MH; Zhang, Z, 2021)

"BBR effectively sensitizes refractory cancers to chemotherapy and radiotherapy by ameliorating the diverse events underlying therapy resistance."

( Devarajan, N; Ganesan, SK; Jayaraman, S; Mahendra, J; Palaniappan, H; Rajagopal, P; Venkatratnam, P, 2021)

"While challenging, treating cancer adequately during COVID-19 can be accomplished by adequate screening and testing, and religiously following the prevention guidelines."

( Akhtar, N; Azhar, T; Chakrabarti, D; Chaturvedi, A; Gupta, S; Kumar, V; Misra, S; Niranjan, P; Parveen, S; Qayoom, S; Rajan, S; Tiwari, S, 2021)

"Considering that cancer continues to be an important cause of death worldwide, several conventional anticancer treatments are widely used."

( Cardona-G, W; Castrillón-L, W; Herrera-R, A; Ramírez-Malule, H, 2021)

"Lapatinib, an FDA-approved drug for cancer treatment, has recently been identified as an mPGES-1 inhibitor."

( Zhan, CG; Zheng, F; Zhou, S, 2021)

"Furthermore, MTs implanted beside tumors allowed TK-hAMSCs migration towards tumor cells and, after GCV administration, inhibited tumor growth."

( Blanco, J; Blanco-Fernandez, B; Cano-Torres, I; Engel, E; Garrido, C; Guerra-Rebollo, M; Mateos-Timoneda, MA; Perez-Amodio, S; Rubi-Sans, G; Rubio, N; Sanchez-Cid, L, 2021)

"The understanding that tumors exploit these physiological mechanisms to avoid elimination has led to remarkable, but limited, success in the treatment of cancer through the use of biologics that interfere with the ability of cancers to suppress immune function."

( Mathew, D; Torres, RM, 2020)

"Propolis is a candidate for cancer treatment with its activity against different tumor cells and, has a wide spectrum of biological and pharmacological activities due to the diversity of its components."

( Akar, S; Cetin, EO; Demirozer, M; Karabey, F; Kilic, KD; Kirilmaz, L; Ors-Kumoglu, G; Ozden, I; Salmanoglu, DS; Sevimli-Gur, C; Uyanikgil, Y, 2022)

"Adult survivors of cancer who had completed cisplatin treatment."

( Anand, A; Baguley, DM; Hall, DA; Hennig, I; Kasbekar, AV; Prayuenyong, P, 2021)

"After 808 nm laser irradiation, CT26 cancer cells could be effectively ablated after the photothermal therapy of high-accumulated Bi@CCM NPs, and then the tumor tends to be eradicated after 12 days."

( Chen, Z; Geng, P; Jiang, Q; Lu, C; Macharia, DK; Ren, X; Sharjeel, A; Yan, H; Yang, S; Yu, N, 2021)

"Several approaches to cancer immunotherapy are being developed along this vector: deletion of tumor-infiltrating Tregs, inhibition of their homing to the tumor microenvironment, and functional downregulation of Tregs."

( Churov, A; Zhulai, G, 2021)

"In combating cancer, ultrasound (US)-triggered sonodynamic therapy (SDT) manifests a wide range of promising applications as a noninvasive treatment modality, thus showing potential to overcome the shortcomings and disadvantages of conventional photodynamic therapy (PDT)."

( Ding, S; Huang, C; Jiang, W; Wang, FB, 2021)

"The stability of anti-cancer drugs and the adverse drug reactions (ADRs) caused by drug-drug interactions (DDIs) are two major challenges of combination chemotherapy."

( Binks, BP; Chen, K; Qian, Y; Qiu, X; Wang, C; Yang, D, 2021)

"Due to the advantages in cancer diagnosis and treatments, survival rates of cancer patients rise and CIPN may occur even more frequently in the future."

( Baron, R; Diel, I; Maihöfner, C; Quandel, T; Tesch, H, 2021)

"Methods Patients with advanced solid tumors refractory to standard therapy were enrolled and treated in 2 dosing cohorts: weight-based (part A) and non-weight-based (part B)."

( Carlsen, M; Carvajal, RD; Chapman, SC; Dowlati, A; Hamid, O; Harvey, RD; Kauh, JSW; Klempner, SJ; Peterson, DA; Quinlan, T; Szpurka, AM; Wesolowski, R; Yu, D, 2021)

"Herein, we screened 12 anticancer drugs for combination with photodynamic therapy (PDT) using pheophorbide a (Pba)."

( Jang, SY; Koo, H; Kwon, S; Lee, D; Lee, Y; Park, E, 2021)

"Most patients with cancer experience pain at some point in the disease course due to the disease itself or its treatment, or both."

( Fielding, F; Lagman, RL; Najafi, S; Samala, RV, 2021)

"Opposite, when cancer patients are treated with antibodies blocking the inhibitory pathways, autoimmune diseases, including arthritis, develop as immune-related adverse events (IrAE)."

( Deleuran, B; Greisen, SR, 2021)

"Newly diagnosed metastatic cancer patients were recruited at the University of Chicago Medical Center and received spiritual support from a Spiritual Care Advocate during chemotherapy treatments."

( Arndt, N; Cipriano-Steffens, T; Cursio, JF; Fitchett, G; Garnigan-Peters, D; Gilliam, M; Hlubocky, F; Lassiter, RH; Malec, M; Pastor, RSO; Petty, LE; Phillips, L; Polite, B; Powell, J; Sumner, M, 2021)

( Cheng, Y; Cui, D; Fan, S; He, Y; Liu, Y; Niu, J; Tan, H; Wei, X; Xue, C; Zha, Y; Zhang, Y, 2021)

"Given that the median age of cancer diagnosis is 66 years and that immunotherapeutic interventions such as cancer vaccines are currently given in combination with or after other forms of treatments which themselves have immune-modulating potential such as surgery, chemotherapy and radiotherapy, the choice of adjuvants requires careful consideration in order to achieve the maximum immune response in a compromised environment."

( Cuzzubbo, S; Habra, K; Mangsbo, S; McArdle, SEB; Nagarajan, D; Pockley, AG, 2020)

"In patients with cancer, hyponatremia is associated with increased morbidity and mortality and can delay systemic therapy."

( Al-Othman, S; Blackhall, F; Brabant, G; Chatzimavridou-Grigoriadou, V; Higham, CE; King, J; Kyriacou, A; Trainer, PJ, 2021)

"The rapidly developing resistance of cancers to chemotherapy agents and the severe cytotoxicity of such agents to normal cells are major stumbling blocks in current cancer treatments."

( He, D; Hong, M; Li, J; Liu, Y; Sun, B; Wang, J; Wen, W, 2021)

"Kidney injury associated with cancer is common in multiple myeloma, tumor lysis syndrome, hematopoietic stem cell therapy, and chemotherapy."

( Chen, H; Li, R; Liu, Y; Ma, Y; Wang, X; Zhang, X; Zhao, X, 2021)

"Cisplatin is invaluable in childhood cancer treatment but its use is limited due to a permanent hearing loss (cisplatin-induced ototoxicity, CIO) adverse effect."

( Allison, WT; Babolmorad, G; Bhavsar, AP; Delyea, C; Domingo, IK; Latif, A; Pollock, NM; Rieger, AM, 2021)

"Hypoxic cancer cells within solid tumours show radio-resistance, leading to malignant progression in fractionated radiotherapy."

( Butterworth, KT; Date, H; Ishikawa, M; Matsuya, Y; McMahon, SJ; Naijo, S; Nara, I; Prise, KM; Saga, R; Sato, T; Yachi, Y, 2021)

"Among several strategies related to cancer therapy targeting the modulation of αβ-tubulin has shown encouraging findings, more specifically when this is achieved by inhibitors located at the colchicine binding site."

( Battastini, AMO; Costa, LT; de Fraga Dias, A; de Paula da Silva, CHT; Dos Santos, CBR; Federico, LB; Figueiró, F; Rosa, JMC; Silva, GM, 2020)

"In addition to cancer therapy, assessment of cancer prognosis, which can evaluate the success with treatment and chances of recovery as well as assist to make subsequent therapeutic schedule, is also remarkably indispensable and important."

( Ding, S; Gu, B; Jiang, P; Pang, W; Wang, D; Wei, X, 2021)

"These systems show good anticancer or antimicrobial effect in hypoxic environment and some of them possess specific imaging abilities providing precise guidance for treatment."

( Cui, X; Lee, CS; Lee, KW; Li, S; Li, X; Wan, Y, 2021)

"Treatment of adherent HT29 or HCC1937 cancer cells or suspension Jurkat or THP1 cells with a Chk1 inhibitor increased γH2AX in these cells."

( Brooks, T; Massey, AJ; Wayne, J, 2021)

"Recent cancer research is now utilizing the medicinal chemistry toolbox to tailor novel 'smart' carrier systems that can reduce the major limitations of chemotherapy ranging from non-specificity and ubiquitous biodistribution to systemic toxicity."

( Abdelmoneem, MA; Albericio, F; Elzoghby, AO; Haiba, NS; Khafaga, AF; Khalil, HH; Khattab, SN; Metawea, ORM; Noreldin, AE; Teleb, M, 2021)

"Implanted VX2 liver tumors in the hind limbs of 26 New Zealand White rabbits were treated using tracer amounts of either (a) 90Y-RadioGel™ or (b) 90Y-microparticles in phosphate-buffered saline (PBS) without the gel carrier."

( Fisher, DR, 2021)

"To improve the cure efficacy of cancer, nanozyme with enzyme-like activity has now been extensively investigated as a new strategy for tumor treatment."

( Chen, J; Fan, L; Gao, L; Huang, Y; Qian, X; Xi, J; Zhang, J, 2021)

"Various cancers treated with cisplatin almost invariably develop drug resistance that is frequently caused by substantial DNA repair."

( Chang, J; Chen, H; Chen, J; Guo, W; Liang, XJ; Wang, X; Xiao, H; Yuan, Y; Zhang, L; Zhao, Y, 2021)

"Income- and treatment-related cancer policies are needed to address the evidently high and unaffordable cancer treatment cost."

( Bahurupi, YA; Dhankhar, A; Kumari, R, 2021)

"Patients with active cancer, diagnosed with VTE and who received sequential treatment with dalteparin and rivaroxaban, were retrospectively reviewed."

( Chen, L; Chen, Q; Zhu, M; Zhuang, Z, 2021)

"The risk of malignancy in MS patients after AZA was similar to that of the general population and did not change with other DMTs sequential treatments."

( Benedetti, MD; Caputo, D; d'Arma, A; Di Tella, S; La Mantia, L; Lillini, R; Marangi, A; Mendozzi, L; Rovaris, M; Sant, M; Turatti, M, 2021)

"Patients on cancer chemotherapy, which has high occurrence of nausea and vomiting, were given either the low dose or the conventional dose of olanzapine for 3 days, in addition to some other antiemetic agents."

( Banerjee, S; Bhattacharya, B; Biswas, S; Dutta, P; M Navari, R; Mukhopadhyay, S, 2021)

"This paper aims to summarise the anticancer effect and molecular mechanisms modulated by hypericin-medicated photodynamic therapy and its potential role in the cancer treatment."

( Cruz, LJ; Dong, X; Fu, J; Gu, Z; Hao, Y; He, Y; Ni, J; Qu, C; Yin, X; You, L; Yu, Z; Zeng, Y; Zhang, Z, 2021)

"The preventable nature of cancer and the importance of a complex multi-level approach in anticancer therapy motivate the search for novel avenues of establishing the anticancer environment in the human body."

( Ruml, T; Vrzáčková, N; Zelenka, J, 2021)

"Overall, in different types of cancer mice models, the intratumoral and intravenous administration of HNTs-based nanoplatforms induced tumor growth inhibition without causing significant toxic effects."

( Nunes, C; Paiva-Santos, AC; Pereira, I; Reis, S; Saleh, M; Veiga, F, 2021)

"It is pivotal and remains challenge for cancer precision treatment to identify the survival outcome interactions between genes, cells and drugs."

( Cui, X; Han, L; Li, Y; Liu, Y; Song, B; Sun, W; Wang, H; Zhang, Y; Zhou, W, 2021)

"Overexpression of DUSP16 in cancer cells leads to increased resistance to cell death upon chemotherapy treatment."

( Cho, YL; DasGupta, R; Gascoigne, NRJ; Goh, BC; Kong, LR; Lee, FYX; Li, CW; Loo, JM; Low, HB; Png, CW; Schwarz, H; Shen, HM; Tan, IBH; Wong, ZL; Wu, B; Xiao, F; Xin, X; Xu, X; Yang, H; Zhang, Y, 2021)

"That is a problem because tumors, even ones derived from the same organ, are not homogeneous, patient-to-patient variability is common, and heterogeneity can occur even in the same patient, so monotherapy with one actively targeted agent is unlikely to be uniformly effective."

( Burgess, K; Usama, SM, 2021)

"The treatment of large established tumors remains a significant challenge and is generally hampered by poor drug penetration and intrinsic drug resistance of tumor cells in the central tumor region."

( Dong, E; Gan, J; Ji, G; Li, Q; Liu, B; Luo, H; Shen, Y; Wang, Y; Xu, L; Yang, H; Yang, Y; Yue, X; Zhang, G; Zhang, W, 2021)

"Dietary phytochemicals with anticancer properties have been gaining focus for cancer treatment since they have been found more effective in targeting cancer via regulating miRNAs expression."

( Ali, S; Almarshad, FM; Arafah, A; Rashid, S; Rehman, MU; Shoaib, A; Tabish, M; Wahab, S, 2021)

"While photodynamic therapy (PDT) of cancer has attracted much recent attention, its general applications are limited by the shallow tissue penetration depth of short-wavelength photons and the low oxygen contents in typical solid tumors."

( Chelora, J; Cui, X; Huang, YH; Huang, Z; Lee, CS; Li, S; Liang, Y; Tian, S; Wan, Y; Wei, WC; Wong, KT; Xiao, Y, 2021)

"Unfortunately, many types of cancers are extremely aggressive and untreatable since, in many cases, they are resistant to chemotherapy."

( Cadoná, FC; Dantas, RF; de Mello, GH; Silva-Jr, FP, 2022)

"Conventional chemotherapy used against cancer is mostly limited due to their non-targeted nature, affecting normal tissue and causing undesirable toxic effects to the affected tissue."

( Belbekhouche, S; Bourgoin-Voillard, S; Cascone, I; Cohen, JL; Courty, J; Ferrara, B; Habert, D; Houppe, C; Vallée, B, 2021)

"In animals that developed tumors, fluvastatin treatment inhibited tumor weight by 75% relative to vehicle control."

( Albarracin, C; Bedrosian, I; Bhardwaj, A; Embury, MD; Rojo, RD, 2021)

"After accumulation in cancer cells, PDA generates cytotoxic heat upon excitation of NIR light for photothermal therapy."

( Jiang, Y; Miao, P; Ouyang, N; Sun, M; Tang, Y, 2021)

"Detailed information of cancer treatment was available."

( Åkesson, KE; Elfving, M; Erfurth, EM; Giwercman, A; Henic, E; Mörse, H; Netterlid, A, 2021)

"During cancer development, tumor-associated macrophages (TAMs) dominatingly support disease progression and resistance to therapy by promoting tumor proliferation, angiogenesis, metastasis, and immunosuppression, thereby making TAMs a target for tumor immunotherapy."

( Chen, DG; Li, SC; Li, ZJ; Zhang, XM; Zhu, B, 2021)

"In paediatric cancer patients, switching tacrolimus administration route may result in reduced blood concentrations."

( Asakura, Y; Chiba, T; Endo, M; Goto, S; Hirai, D; Ito, S; Kudo, K; Miura, S; Nihei, S; Nishiya, N; Oyake, T; Ujiie, H, 2021)

"To explore the experiences of cancer diagnosis, treatment and care among people who self-identify as Roma or Gypsies and Travellers."

( Condon, L; Curejova, J; Fenlon, D; Leeanne Morgan, D, 2021)

"Increasing cancer drug prices present global challenges to treatment access and cancer outcomes."

( Ezeife, DA; Gyawali, B; Leighl, NB; Nirmalakumar, S, 2021)

"Sixty-two patients diagnosed with cancer under antiresorptive therapy answered three instruments from the European Organization for Cancer Research and Treatment (EORTC)."

( de Cassia Tornier, S; Macedo, FJ; Sassi, LM; Schussel, JL, 2021)

"Despite the undeniable improvement in cancer diagnostics and therapy, there is an urgent need for new therapeutic and preventive strategies with improved efficacy and fewer side effects."

( Coddou, C; Díaz-Muñoz, M; Madariaga, JA; Reyna-Jeldes, M; Vázquez-Cuevas, FG, 2021)

"Herein, to overcome such limitation, cancer cell membranes disguised biomimetic nanoreactors were elaborately established for synergetic cancer starvation therapy and cascade amplificated hypoxia activated chemotherapy."

( Liu, S; Shao, F; Tian, Z; Wu, Y, 2021)

"Radiation therapy is one of the main cancer treatment modalities applied in 50-70% of cancer patients."

( Abedi-Firouzjah, R; Dastranj, L; Dorri-Giv, M; Farhood, B; Khodaverdian, S; Mohammad Hosseini, S; Sheikholeslami, S; Souri, S; Zamani, H, 2021)

"To explore cancer occurrence following azathioprine therapy in myasthenia gravis patients in the long term, we searched Medline, EMBASE, and the Cochrane Library for terms related to azathioprine, myasthenia gravis and cancer occurrence."

( Jiang, B; Jin, T; Shi, T; Wang, M; Xu, B; Xu, L; Zhang, Z, 2021)

"Targeted therapy of cancer is considered as promising alternative approach to conventional chemotherapy and radiotherapy."

( Altmann, A; Giesel, F; Haberkorn, U; Kratochwil, C, 2021)

"Millions of patients with cancer pain are treated with prescription opioids each year."

( Bulls, HW; Chu, E; Goodin, BR; Liebschutz, JM; Merlin, JS; Schenker, Y; Wozniak, A, 2022)

"The striking metabolic overlap between cancer and neurological diseases sheds light on novel therapeutic strategies for cancer treatment."

( Gu, Y; Guo, S; Le, A; Qu, J, 2021)

"Even though cardiovascular diseases and cancer are usually studied independently [2-12], there are some striking overlaps between their metabolic behaviors and therapeutic targets, suggesting the potential application of cardiovascular disease treatments for cancer therapy."

( Hoang, G; Le, A; Nguyen, K, 2021)

"To overcome drug resistance in hypoxic tumors and the limitations of radiation impedance and radiation dose, we developed a nano-radiosensitizer to improve the efficacy of cancer radiotherapy."

( Chen, Q; Chen, T; He, L; Huang, J; Liu, X; Tang, Z; Yuan, Z, 2021)

"These cases where findings overlap with cancer pose a significant dilemma for diagnostic purposes, follow-up, and management leading to possible treatment delays, unnecessary repeat imaging and sampling, and patient anxiety."

( Ali, T; Bathini, VG; Edmiston, KL; Gerber, JM; McIntosh, LJ; Mittal, K; Rosen, MP; Walsh, WV; Whalen, GF, 2021)

"Seventeen cancer cell lines and multiple xenograft models bearing representative human solid tumors were subjected to 4'-thio-2'-deoxycytidine (T-dCyd) or control treatment."

( Difilippantonio, M; Doroshow, JH; Hollingshead, M; Kinders, RJ; Larenjeira, ABA; Nguyen, D; Rubinstein, L; Yang, SX, 2021)

"Chemotherapy and targeted agent anti-cancer efficacy is largely dependent on the proliferative state of tumours, as exemplified by agents that target DNA synthesis/replication or mitosis."

( Carnevalli, LS; Dunlop, CR; Fernández, SBQ; Jodrell, DI; Johnson, TI; Kottmann, D; Lau, A; Minteer, CJ; Richards, FM; Wallez, Y, 2021)

"The procoagulant state in cancer increases the thrombotic risk, and underlying cancer could affect treatment strategies and outcomes in patients with ischemic stroke."

( Ishibashi-Ueda, H; Kataoka, Y; Koga, M; Kusaka, H; Sonoda, K; Takahashi, JC; Toyoda, K; Yakushiji, Y, 2022)

"Major cancer management strategies include chemotherapy, surgical resection, and radiation."

( Ahmad, A; Khan, MA; Siddique, HR; Singh, D, 2021)

"A total of 373 cancer patients treated with ICIs were included and evaluated."

( Iiri, T; Kage, H; Kawai, T; Kume, H; Makita, N; Manaka, K; Miyagawa, T; Nagase, T; Nangaku, M; Sato, J; Sato, S; Sato, Y; Takeuchi, M; Watanabe, K; Yamada, D, 2021)

"Appealing cancer immunotherapy requires synchronous presentation of tumor antigens and immunoadjuvant."

( Cheng, H; Ding, Y; Han, G; Han, Y; Jiang, W; Jiang, Z; Jin, Y; Sun, B; Sun, C; Wang, G; Yuan, Z; Zhang, H; Zhou, J, 2021)

"We evaluated the prevalence and type of malignancy (diagnosed ≤12 months before SVT and/or ongoing therapy), demographics, and clinical and laboratory characteristics of the patients."

( Hajšmanová, Z; Hirmerová, J; Seidlerová, J; Šubrt, I, 2022)

"Breast cancer treatment needs to eradicate cancer cells and restore breast defects after surgical intervention."

( Chen, G; Chen, H; Chen, Y; Kawazoe, N; Sutrisno, L; Yang, Y; Yoshitomi, T, 2021)

"Diagnosis, treatment, and prediction of cancer progression require new targeting agents to specifically target cell surface receptors."

( Divsar, F; Fassihi, J; Hasani, Z; Mahani, M; Mahmoudi, F, 2021)

"The aim of immunomodulation in cancer therapy is boosting immune system cells including CD8+ T lymphocytes and natural killer (NK) cells, as well as suppression of immunosuppressive responses by macrophages and regulatory T cells (Tregs)."

( Chen, L; Musa, AE, 2021)

"With carcinogenesis mechanisms, cancer invasion, and metastasis remaining blurred, cancer diagnosis and novel drug delivery approaches should be developed urgently to enable management and treatment."

( Jia, L; Lugoloobi, I; Maniriho, H; Namulinda, T; Shi, X; Zhao, Y, 2021)

"We enrolled cancer patients who were treated with an irinotecan-containing regimen and did not have severe renal failure."

( Ariizumi, H; Fujita, KI; Hirasawa, Y; Ishida, H; Ishiguro, T; Kondo, Y; Kubota, Y; Kusuhara, H; Matsumoto, N; Ohkuma, R; Sasaki, Y; Tomoda, Y; Tsuboya, A; Tsunoda, T, 2021)

"To test this hypothesis, we treated tumors with DFMO, in either the presence or absence of additional PD-1 blockade, and subsequently analyzed their immunological and therapeutic responses."

( Bartee, E; Dryja, P; Fisher, C; Woster, PM, 2021)

"Once IPHG-DOX-penetrated 4T1 tumors are exposed to near-infrared irradiation, hyperthermia stress and photothermal therapy-elevated effective drug concentrations result in chemosensitization and prominent tumor suppression."

( Fu, Y; Shen, W; Wang, H; Yin, T; Zheng, Y; Zhou, J, 2021)

"We demonstrated the feasibility as a cancer-targeting and self-activating therapeutic nanoparticle in a pancreatic cancer xenograft mouse model, and it showed a superior therapeutic efficacy through ROS-induced therapy and drug-induced cell death."

( Jang, HJ; Kang, RH; Kim, D; Kim, JH; Kim, JS; Kim, NH; Kim, Y; Ko, HM; Lee, SH; Shim, I, 2021)

"The current treatment strategies for cancer therapy have posed many problems in achieving high efficacy."

( Ma, S; Raza, F; Shen, Q; Wei, Y; Zafar, H; Zhang, J, 2021)

""Acute renal failure and cancer treatment The interplay between cancer and acute kidney injury is intricate."

( Garcia, H; Grangé, S; Rafat, C, 2021)

"The diagnosis and treatment of cancer is one of the biggest medical challenges of the century."

( Chao, H; Chen, Y; Ji, L; Karges, J; Shen, J; Xiong, K, 2021)

"A sample of 210 end-of-life Italian cancer patients were assessed with the BFI, the Demoralization Scale (DS), the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being (FACIT-SP-12), the Functional Assessment of Cancer Therapy Scale-General Measure (FACT-G), and the Karnofsky performance status."

( Bovero, A; Ghiggia, A; Pierotti, V; Tesio, V, 2021)

"Despite advances in supportive care, cancer-related symptoms tend to be persistent regardless of cancer type, stage of disease, or treatment received."

( Cofini, V; Cortellini, A; Filetti, M; Giusti, R; Marchetti, P; Necozione, S; Pinato, DJ; Porzio, G; Trapani, D, 2021)

"The need for shared care in childhood cancer was perceived by Cankids and its partnering childhood cancer-treating centers in North and East India."

( Ahamad, N; Arora, RS; Bagai, P; Bagchi, B; Gomber, S; Gupta, H; Jain, P; Kumar, A; Mahajan, A; Radhakrishnan, N; Sahi, PK; Sharma, S; Singh, A, 2022)

"A prospective study was targeted on cancer patients receiving herbal therapy from a Traditional and Complementary Medicine (T&CM) clinic in a public hospital from 1st January 2016 to 31st August 2018."

( Ali, AB; Razali, NH; Suk Xian, N; Yong Sung, C, 2021)

"However, gender, cancer stage, cancer type, age, history of radiotherapy, and history of chemotherapy has no effect (p > 0."

( Ali, AB; Razali, NH; Suk Xian, N; Yong Sung, C, 2021)

"Herbal therapy did improve the QoL of cancer patients in the southern region of Peninsular Malaysia."

( Ali, AB; Razali, NH; Suk Xian, N; Yong Sung, C, 2021)

"Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with low survival rate and a lack of biomarkers and targeted treatments."

( Apostolidi, M; Gassaway, BM; Gaule, P; Muthusamy, V; Rimm, DL; Rinehart, J; Vathiotis, IA, 2021)

"The current cancer treatment scenario looks like aggravating tumor cell metabolism, causing the disease to progress even with greater intensity."

( Chawla, P; Chawla, V; Faruk, A; Negi, M, 2022)

"Successful cancer immunotherapy requires systemic immune activation."

( Bai, M; Jin, P; Li, J; Meng, X; Meng, Y; Wu, L; Yu, J, 2021)

"We also debate the dual role of NO in cancer and tumor progression and clinical approaches for inducible nitric oxide synthase (iNOS) based therapy against cancer."

( Ghaleno, HR; Hu, T; Liao, P; Miao, L; Nabavi, SM; Negintaji, S; Qi, Y; Safdari, M; Saghafi, F; Sahebnasagh, A; Shabani-Borujeni, M; Simal-Gándara, J; Sureda, A; Wang, M; Xiao, J, 2022)

"The major problems with cancer therapy are drug-induced side effects."

( Li, D; Zhang, J; Zhao, X, 2021)

"The study cohort comprised cancer survivors treated with VCR and/or DOX."

( Beltran, G; Brazell, A; Cost, NG; Gao, D; Gore, L; Hecht, SL; Holbrook, S; Iguchi, N; Malykhina, A; Quach, A; Wilcox, D, 2021)

"Recent studies have indicated that cancer treatment based on immunotherapy alone is not viable."

( Chang, HC; Chiu, HC; Chiu, YL; Kuo, TY; Lo, CL; Shueng, PW; Yen, YW; Yu, LY, 2021)

"However, many patients with incurable cancer have difficulty receiving oral administrations, which limits treatment options during disease progression."

( Fujii, R; Hasuo, H; Okada, M; Sakuma, H; Uchitani, K, 2021)

"Cervical cancer, one of the most common cancers affecting females in South Africa, commonly requires a cisplatin-based-treatment regimen, which has been associated with ototoxic side effects."

( Ayele, BT; Govender, CD; Paken, J; Pillay, M; Sewram, V, 2021)

"Fifty cervical cancer patients commencing with cisplatin chemotherapy underwent audiological assessments at a hospital in South Africa at various time intervals."

( Ayele, BT; Govender, CD; Paken, J; Pillay, M; Sewram, V, 2021)

"Multiple biological barriers in solid tumors severely restrict the penetration of nanomedicines, which is a main cause for therapeutic failure in traditional tumor treatment."

( Chen, Y; Li, ZH; Pan, P; Zeng, RY; Zhang, XZ, 2021)

"9 patients with ovarian cancer were examined during chemotherapy (6 courses), 40 patients with colon cancer, previously operated, were with malignant liver damage."

( Blindar, VN; Dobrovolskaya, MM; Sytov, AV; Zubrikhina, GN, 2021)

"The development of drug resistance in tumors is a major obstacle to effective cancer chemotherapy and represents one of the most significant complications to improving long-term patient outcomes."

( Feun, LG; Nguyen, DJM; Savaraj, N; Spector, SA; Theodoropoulos, G; Wangpaichitr, M; Wu, C, 2021)

"In complex diseases like cancer, single-agent approaches are often insufficient for an effective treatment, and drug combination therapies can be implemented."

( Correia, C; Ferreira, A; Lapa, R; Santos, J; Urtti, A; Vale, N; Yliperttula, M, 2021)

"Thus, in patients with cancer, alopecia can be iatrogenic (chemotherapies, endocrine therapies, targeted therapies, immunotherapies, radiotherapy, surgery) or directly the consequence of the disease itself (malnutrition, scalp metastases, paraneoplastic syndromes)."

( Baussard, L; Fiteni, F; Guichard, A; Le Vigouroux, S; Quesada, S, 2021)

"The Arg auxotrophic cancerous cells like hepatocellular carcinoma, human colon cancer, leukemia, and breast cancer cells are sensitive to ADE treatment due to low expression of crucial enzymes argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), and ornithine transcarbamylase (OCT)."

( Bansal, S; Kumari, N, 2021)

"Medical records of canine cancer patients were retrospectively reviewed and identified dogs were included in the following treatment categories: dogs which received RT to a portion of the abdomen and concurrent TOC (n = 19), abdominal RT alone (n-29), TOC alone (n = 20), or non-abdominal RT plus TOC (n = 9)."

( Boss, MK; LaRue, SM; Leary, D; Martin, T; Prebble, AR; Thamm, DH; Weishaar, KM, 2022)

"It also provides future perspectives on cancer therapy."

( Chung, IM; Rebezov, M; Rengasamy, KRR; Samynathan, R; Shariati, MA; Subramanian, U; Thirupathi, P; Thiruvengadam, M; Venkidasamy, B, 2023)

"Platinum-based anticancer drugs can inhibit the growth of cancer cells by disrupting DNA replication, which makes them widely applicable in clinics for treating tumors and cancers."

( Chen, H; Fang, Y; Huang, H; Wu, J; Xian, C; Xiong, F, 2021)

"The concept of using statins to treat cancer has been adopted since the 1990s In vitro and in vivo experiments and cohort studies using statins have been carried out to demonstrate their antitumor effects (such as proliferation and migration impairment) by influencing inflammatory and oxidative stress-related tumorigenesis."

( de Barros, ALB; Duarte, JA; Leite, EA, 2021)

"Despite its success against cancer, photothermal therapy (PTT) (>50 °C) suffers from several limitations such as triggering inflammation and facilitating immune escape and metastasis and also damage to the surrounding normal cells."

( Chen, B; Kankala, RK; Krastev, R; Li, X; Liu, Y; Long, R; Wang, P; Wang, S; Xiong, X; Yang, D; Zhang, Y; Zhu, M, 2021)

"Neuroendocrine neoplasms (NENs) are heterogeneous, and optimal treatment for aggressive grade 3 (G3) NENs remains undetermined."

( Becker, C; Bergsland, EK; Chan, DL; Chan, JA; Gadgil, R; Halfdanarson, TR; Hornbacker, K; Kelly, V; Kunz, PL; McGarrah, PW; Raj, NP; Reidy, DL; Singh, S; Thawer, A; Whitman, J; Wu, L, 2021)

"Cisplatin has been a mainstay of cancer chemotherapy since the 1970s."

( Tew, KD; Townsend, DM; Ye, ZW; Zhang, J, 2021)

"The aim of cancer immunotherapy is to reactivate autoimmune responses to combat cancer cells."

( Chauhan, A; Khan, T; Omri, A, 2021)

"One of the main current strategies for cancer treatment is represented by combination chemotherapy."

( Cimino, F; Citarella, A; Cristani, M; Micale, N; Molonia, MS; Saija, A; Speciale, A, 2021)

"Breast cancer consists of heterogenic subpopulations, which determine the prognosis and response to chemotherapy."

( Han, J; Kim, JH; Kim, JS; Lee, J; Sessler, JL; Verwilst, P; Won, M, 2021)

"Given that cancer cells consume a higher amount of iron than healthy ones, ferroptosis not only stands as an excellent alternative to trigger cell death and reverse drug-resistance, but also provides selectivity in therapy."

( Bakar-Ates, F; Ozkan, E, 2022)

"For breast cancer treatment, cerium oxide nanoparticles (CeONPs) can act as protectant for healthy cells against on-going radiotherapy."

( Akbar, I; Ashfaq, UA; Iqbal, M; Javaid, A; Zahra, D, 2021)

"Besides, the anticancer drug DOX was loaded to AS-nFAp:Gd/Tb so as to achieve the establishment of a multifunctional nano-probe that integrated the tumour diagnosis and treatment."

( Cai, X; Kong, T; Peng, S; Xiao, D; Yang, Y; Zhang, W; Zhou, R; Zhu, B, 2021)

"In this article, the anticancer mechanism of BA and its application in the treatment of tumour diseases are reviewed."

( Dong, S; Jiang, W; Li, X; Zhou, W, 2021)

"Complete treatment of cancer remains a major challenge today."

( Li, J; Liu, R; Liu, Y; Sang, L; Wang, D; Wang, T; Wang, Z, 2021)

"There are two severe obstacles in cancer immunotherapy."

( Chen, D; Chen, Y; Hu, H; Huang, Z; Li, W; Qiao, M; Shi, M; Zhang, J; Zhao, X, 2021)

"Among them, the incidence of comorbid tumors in RA is relatively high, resulting in a gradual increase in mortality; this poses a considerable challenge to clinical treatment."

( Chen, M; Deng, Y; Hu, M; Lai, X; Li, G; Liu, M; Sun, Y; Wang, S, 2021)

"In order to boost anticancer efficacy of indocyanine green (ICG)-mediated photothermal therapy (PTT) by promoting intracellular ICG delivery, the ICG-carrying hybrid polymeric nanoparticles were fabricated in this study by co-assembly of hydrophobic poly(lactic-co-glycolic acid) (PLGA) segments, ICG molecules, amphiphilic tocopheryl polyethylene glycol succinate (TPGS) and pH-responsive methoxy poly(ethylene glycol)-benzoic imine-1-octadecanamine (mPEG-b-C18) segments in aqueous solution."

( Chiang, WH; Chou, YH; Huang, SY; Ting, CW, 2021)

"The existence of cancer stem cells (CSCs) poses a major obstacle for the success of current cancer therapies, especially the fact that non-CSCs can spontaneously turn into CSCs, which lead to the failure of the treatment and tumor relapse."

( Haag, R; Li, W; Liu, C; Ma, X; Pan, Y; Parshad, B; Schwerdtle, T; Wu, A; Xing, J; Zhou, S, 2021)

"Over the years, cancer research has focused on different strategies to discover drugs and therapies to treat the metastatic stage of cancer."

( Gupta, R; Joshi, N; Kale, A; Nagotu, S; Parkar, H; Pathak, S, 2022)

"Despite much progress in cancer therapy, conventional chemotherapy can cause poor biodistribution and adverse side-effects on healthy cells."

( Jaimalai, T; Phetdee, C; Prangkio, P; Suyamud, C, 2021)

"Patients with cancer are using cannabis for self-treatment."

( Brønnum, D; Dalton, SO; Eckhoff, L; Herrstedt, J; Nielsen, SW; Ruhlmann, CH, 2022)

"The study of medicinal plants for cancer treatment has gained attention due to an increasing incidence of cancer worldwide and antineoplastics-related undesirable secondary effects."

( Ibarra-Berumen, J; Ordaz-Pichardo, C; Rosales-Castro, M, 2022)

"The ability to accurately diagnose cancer is the cornerstone of early cancer treatment."

( Duan, R; Li, Z; Liang, Z; Qu, L; Sun, Y; Yang, R; Zhang, K, 2021)

"Patients aged ≥ 21 years, aware of cancer diagnosis and receiving oncology treatment for Stage IV solid cancer were included in the study after obtaining written informed consent."

( Bhatnagar, S; Finkelstein, E; Maholtra, C; Ozdemir, S; Satija, A; Teo, I; Yang, GM, 2022)

"A hypoxic environment in tumors hampers the therapeutic efficacy of radiotherapy."

( Duan, Z; Gong, Q; Gu, L; Gu, Z; Li, X; Luo, K; Luo, Q; Zhang, H; Zhu, H, 2021)

"First, the functions of GSH in cancer cells are analyzed to elucidate the necessity of GSH depletion in cancer therapy."

( Liao, K; Niu, B; Pan, X; Quan, G; Wen, T; Wu, C; Zhou, Y, 2021)

"As a result, tumor growth of breast cancer 4T1 cells in vivo was significantly restrained and lung metastasis was potently decreased and almost eradicated, fully reflecting the advantages of organelle targeting combination therapy."

( Huang, Y; Li, Q; Li, X; Yang, J; Yang, N; Zhou, M; Zhou, Z, 2021)

"In this work, we thus show a cancer therapy based on gene interference-enhanced ferroptosis."

( Gao, J; Luo, T; Wang, J, 2021)

"Pin1 is an attractive target for cancer therapy due to its over-expression and/or activation in various types of cancer and the disorder of Proline directed phosphorylation."

( Chen, R; Ding, L; Liu, M; Yang, S; Zang, J; Zhao, J; Zhao, X, 2022)

"The natural affinity of macrophages to tumors, and their natural phagocytosis and ability to invade tumors, make them outstanding drug delivery vehicles for targeted tumor therapy."

( Bai, X; Chen, H; Chen, Y; Dai, Y; Feng, L; Feng, Y; Ji, Y; Jia, L; Sun, H; Wang, L; Zhang, C; Zhang, D, 2021)

"For symptomatic treatment of cancer patients with dyspnea, both pharmacologic and non-pharmacologic methods should be considered."

( Zemel, RA, 2022)

"Novel immunotherapies targeting cancer-associated truncated O-glycans Tn (GalNAcα-Ser/Thr) and STn (Neu5Acα2-6GalNacα-Ser/Thr) are promising strategies for cancer treatment."

( Aasted, MKM; Dabelsteen, S; Groen, A; Haue, AD; Pedersen, JW; Rømer, TB; Schnabel, J; Tan, E; Wandall, HH, 2021)

"Treating cancer with high efficacy while eliminating side effects has been the holy grail of cancer research."

( Chen, T; Isak, AN; Ma, Z; Pan, Q; Song, Y; Sun, F; Tang, X; Wang, H; Zhang, Q; Zhu, X, 2021)

"Finally, CaP@Fe-MOFs are used for cancer treatment in mice, alleviating the Ado-mediated immunosuppressive response and achieving tumor suppression."

( Chen, Y; Ji, C; Jia, Y; Liang, L; Sun, ZJ; Tan, J; Tan, W; Wang, W; Wang, X; Yang, LL; Yuan, Q; Zhang, L, 2021)

"Clinical observations of cancer patients treated with selinexor have reported high incidence of nausea and anorexia."

( Ahnert, JR; Albittar, AA; Dalal, S; Dev, R; Fu, S; Hui, D; Karp, DD; Liu, S; Meric-Bernstam, F; Naing, A; Piha-Paul, SA; Rubin, L; Tsimberidou, AM; Yap, TA; Zarifa, A; Zhong, LL, 2022)

"Immunohistochemistry of the tumors showed that CD8, GZMB, and IFN-γ were increased in the quercetin dihydrate-treated mice."

( Diao, A; Jing, L; Li, Y; Lin, J; Liu, Z; Tao, L; Yang, Y; Zhao, Q, 2021)

"Cancer cell death is the utmost aim in cancer therapy."

( Fu, X; Huang, Z; Li, M; Najafi, M; Tang, C, 2021)

"Advanced relapsed/refractory solid tumors following standard therapy or where the addition of selinexor to standard regimens deemed appropriate, were eligible."

( Carter, BW; Colen, R; Fu, S; Gong, J; Hong, DS; Janku, F; Karp, DD; McQuinn, L; Meric-Bernstam, F; Milton, DR; Naing, A; Piha-Paul, SA; Shah, J; Stephen, BA; Sulovic, S; Thein, KZ; Tsimberidou, A; Yap, TA, 2022)

"Then, ECDT-based multimodal anticancer therapy is discussed, including how to integrate these emerging Fenton reinforcement strategies for accelerating the development of multimodal anticancer therapy, as well as the synergistic mechanisms of ECDT and other treatment methods."

( Chen, X; Fan, S; Feng, L; Huang, X; Zhou, Y, 2021)

"Immunotherapy comes to the forefront of cancer treatments, resulting in impressive and durable responses but only in a fraction of patients."

( Medina, VA; Nicoud, MB; Sarasola, MP; Táquez Delgado, MA, 2021)

"Gas therapy is an emerging "green" cancer treatment strategy; however, its outcome often restricted by the complexity, diversity, and heterogeneity of tumor."

( Fu, LH; Hu, YR; Huang, P; Li, C; Li, Z; Lin, J; Sun, T; Wan, Y; Yin, W, 2021)

"Standard of care in treatment of cancer-related pain involves opioids in combination with non-steroidal anti-inflammatory drugs (NSAID)."

( Butcher, B; Clark, K; Currow, D; Fazekas, B; Hutchings, E; Rowett, D, 2022)

"We utilized a natural hydrophobic anti-cancer drug oleanolic acid (OA) and a photosensitizer chlorin e6 (Ce6) through self-assembly technology to form a carrier-free nanosensitizer OC for combined chemotherapy and SPDT for cancer treatment."

( Chen, H; Gao, Y; Li, Z; Shi, H; Yang, Y; Zheng, Y, 2021)

"DOX exerts strong anticancer activity and is commonly used to treat different cancers, including bone sarcomas, soft tissues, bladder, ovary, stomach, thyroid, breast, acute lymphoblastic leukemia, Hodgkin lymphoma, lung cancer, and myeloblastic leukemia."

( Gu, X; Li, Y; Sohail, M; Sun, Z; Xu, H, 2021)

"Undertreated cancer-related pain interferes with daily activities and increases morbidity and mortality."

( Cata, JP; Ramirez, MF; Rangel, FP, 2022)

"Malignant tumors are life-threatening, and chemotherapy is one of the common treatment methods."

( Li, J; Liu, M; Luo, R; Tan, T; Wang, R; Xie, T; Yin, L; Zeng, Y; Zeng, Z, 2021)

"Cardiovascular and cancer illnesses often co-exist, share pathological pathways, and complicate therapy."

( Bajpai, SK; Edwina, P; Roy, B; Sivasubramaniapandian, M; Vaibavi, SR; Vaippully, R, 2022)

"The development of small molecules as cancer treatments is still of both interest and importance."

( Chaloin, L; Charmelot, R; Cros-Perrial, E; Dumontet, C; Egron, D; Jordheim, LP; Peyrottes, S; Raza, MZ; Saulnier, S, 2022)

"Near-infrared-II (NIR-II) cancer photothermal therapy (PTT) has become more and more attractive as the NIR-II light shows a higher tissue penetrating depth, which leads to better anti-cancer effects."

( Cao, Z; Feng, M; Hou, X; Liu, J; Lu, Y; Zhang, X, 2021)

"Targeted cancer therapy has aroused the broad interest of researchers due to its accuracy in specific tumor targeting and its few side effects on normal cells."

( Ao, J; Liu, AA; Lv, C; Pang, DW; Tang, M; Wang, J, 2021)

"The included studies suggest that anticancer drug-incorporated zeolites/ZIFs can be used as alternative treatment options to enhance the efficacy of cancer treatment by mitigating the drawbacks of drugs under conventional treatment."

( Batu Eken, Z; Hao, J; Mravak-Stipetic, M; Ozer, F; Pavelić, K; Stavljenić Milašin, I, 2021)

"Irinotecan (CPT-11) is an anticancer agent widely used to treat adult solid tumours."

( Bies, RR; Cecchin, E; Cox, NJ; Etheridge, AS; Forrest, A; Innocenti, F; Karas, S; Mathijssen, RHJ; Mohlke, KL; Nickerson, DA; Toffoli, G, 2022)

"In 217 cancer patients treated with intravenous irinotecan single agent or in combination, germline DNA was used to interrogate the variation in 84 genes by next-generation sequencing."

( Bies, RR; Cecchin, E; Cox, NJ; Etheridge, AS; Forrest, A; Innocenti, F; Karas, S; Mathijssen, RHJ; Mohlke, KL; Nickerson, DA; Toffoli, G, 2022)

"While cancer cells expressing glutamate receptors frequently respond to riluzole treatment, numerous types of cancer cell lacking glutamate receptors unexpectedly responded to riluzole treatment as well."

( Blyufer, A; Lhamo, S; Mahajan, SS; Tam, C; Tariq, I; Thavornwatanayong, T, 2021)

"Even in sensitive cancer cells, though, biguanide treatment alone over a broad range of doses only inhibits cell replication without significantly affecting cell viability."

( Bharti, S; Bhujwalla, Z; Gabrielson, E; Tully, E; Woo, J, 2021)

"Radiotherapy (RT) is an important anti-cancer treatment modality that activates innate and adaptive immune responses."

( Bugno, J; Ding, X; Fu, YX; Hou, Y; Huang, X; Liang, HL; Rao, E; Vokes, E; Wang, J; Wang, L; Weichselbaum, RR; Yang, H; Yang, K; Yu, X; Zheng, W, 2021)

"Chemodynamic therapy (CDT), a novel cancer therapeutic strategy defined as the treatment using Fenton or Fenton-like reaction to produce •OH in the tumor region, was first proposed by Bu, Shi, and co-workers in 2016."

( Guo, Y; Jia, C; Wu, FG, 2022)

"The current study aimed to explore anticancer drug and P-gp inhibitor delivery as a promising strategy to efficiently treat colorectal cancer with MDR."

( Choi, WI; Hwang, Y; Lee, JS; Oh, H; Sung, D; Tae, G, 2022)

"Moreover, cancer is a kind of multifactorial disease, and therefore manipulating a single target may result in treatment failure."

( Fan, M; He, H; Hu, L; Qi, B; Shi, S; Song, X; Wang, F, 2022)

"In our study, advanced cancer patients can tolerate until 5000 μg of sodium selenite in combination with radiation and chemotherapy since the half-life of sodium selenite may be relatively short, and, further, selenium may accumulates more in cancer cells than that of normal cells, which may be toxic to the cancer cells."

( Choi, MC; Chung, AS; Kim, SJ; Park, JM, 2021)

"The treatment of hypercalcemia of malignancy (HCM) consists of enhancing renal calcium excretion, mostly through hydration with isotonic fluids and the use of antiresorptive therapies."

( Chakhtoura, M; El-Hajj Fuleihan, G, 2021)

"Extension of cancer prevention, equal, optimal treatment opportunities, and inclusion in clinical trials, akin to the younger population, must be encouraged."

( Brain, E; Cherian, M; Ganguli, A; Hariprasad, R; Mehrotra, R; Musolino, N; Nethan, S; Sullivan, R; Tullu, F, 2022)

"The incidence of cancer, which is the second leading cause of mortality globally, continues to increase, although continued efforts are being made to identify effective treatments with fewer side‑effects."

( Abraham, SJK; Dedeepiya, VD; Ikewaki, N; Iwasaki, M; Kisaka, T; Kumar, SRB; Kurosawa, G; Osawa, H; Preethy, S; Raghavan, K; Rao, KS; Senthilkumar, R; Srinivasan, S; Vaddi, S, 2022)

"In this open-label, uncontrolled study, cancer patients aged 2-19 years being treated with strong opioid analgesics were switched to fentanyl citrate patch for 2 weeks."

( Hashimoto, F; Hiyama, E; Okawa, K; Otaka, K; Terahara, T; Yamaguchi, S, 2021)

"This study aimed to understand Indian cancer patients' hopes and beliefs about the end of life, particularly focusing on how this informed their preferences regarding end-of-life treatment."

( Chittem, M; Eliott, J; Olver, I, 2022)

"We recently reported a cancer microenvironment-targeting therapy termed molecular block (MB) which induced cancer cell death by a pH-driven self-aggregation and cell membrane disruption at tumor microenvironment."

( Matsusaki, M; Nakamoto, M; Piantino, M, 2022)

"The drug resistance of cancer cells is a major concern in medical oncology, resulting in the failure of chemotherapy."

( Chatterjee, O; Chatterjee, S; Panda, S; Roy, L, 2022)

"Immunotherapy has become a powerful cancer treatment, but only a small fraction of patients have achieved durable benefits due to the immune escape mechanism."

( Chen, J; Chen, X; Fang, H; Guo, Z; Hu, Y; Li, Y; Lin, L; Tian, H, 2021)

"As a result, cancer therapy efficacy is improved significantly by applying all-in-one NPs to achieve synchronous chemoradiotherapy, as evidenced by studies evaluating cell viability, proliferation, and ROS production."

( Conde, J; Danafar, H; Ghaffarlou, M; Hosseinmirzaei, A; Mohammadi, A; Mousazadeh, N; Nosrati, H; Seidi, F; Sharafi, A, 2022)

"Despite advances in cancer therapy surgery remains one of the most important treatments for solid tumors; however, even with the development of better and less invasive surgical techniques, surgery is characterized by the increased risk of tumor metastasis, accelerated growth of pre-existing micrometastasis and cancer recurrence."

( Cata, JP; Ramirez, MF, 2021)

"Targeting solid tumors with absolute precision is a long-standing challenge in cancer immunotherapy."

( Gross, G; Savanur, MA; Weinstein-Marom, H, 2021)

"Here, metastatic cancer cells isolated from mouse models were resistant to paclitaxel treatment in vitro and in vivo when compared with parental cancer cells."

( Chen, X; Huang, C; Jin, S; Liang, H; Yuan, Y; Zhang, B; Zhang, W; Zhang, X; Zhao, J, 2022)

"Thus, improving the efficiency of cancer therapy is still a major challenge."

( Aoki, I; Hiraoka, N; Kato, N; Matsusaki, M; Nakatsuji, H; Okada, Y; Shibata, S; Shioji, Y, 2021)

"Importantly, cancer patients with low plasma histamine levels had a more than tripled objective response rate to anti-PD-1 treatment compared with patients with high plasma histamine."

( Fan, H; Gibbons, DL; Halpin, A; Kuo, WL; Lee, JJ; Li, H; Li, P; Li, Q; Pang, D; Ren, G; Saito, Y; Xiao, Y; Yagita, H; Yao, J; Yee, C; Yin, X; Yu, D; Yuan, X; Zhang, Y; Zhao, Z, 2022)

"Many present-day methods to treat cancer use drugs that can block a key molecule that is important for one or more of these characteristics and thus reduce side effects."

( Check, DL; Check, JH, 2021)

"Advances in the field of cancer immunotherapy have stimulated renewed interest in adenoviruses as oncolytic agents."

( Ashoorzadeh, A; Bai, SY; Guise, CP; Li, D; Mowday, AM; Patterson, AV; Singleton, DC; Smaill, JB; Syddall, SP; Wilson, WR, 2022)

"Mifepristone treatment for advanced cancer has demonstrated considerable improvement in both length and quality of life in patients who no longer have any other treatment options."

( Check, D; Check, JH, 2021)

"In recent years, cancer phototherapy has been extensively studied as noninvasive cancer treatment."

( Fan, Z; Ma, Y; Meng, M; Wang, S; Wang, W; Xi, R; Yin, Y; Zhao, H; Zhao, X, 2021)

"Overall, 115 patients with solid tumors and 93 with hematologic malignancies received treatment."

( Bauer, S; Carpio, C; Cassier, PA; Chatterjee, M; Chromik, J; de Vos, F; DeAngelo, DJ; Esteve, J; Fabre, C; Ferretti, S; Guerreiro, N; Halilovic, E; Kiladjian, JJ; Lin, CC; Mariconti, L; Meille, C; Minami, H; Mous, R; Pereira, B; Radhakrishnan, R; Steeghs, N; Stein, EM; Suarez, C; Tai, D; Yamamoto, N, 2022)

"Both human and veterinary cancer chemotherapy are undergoing a paradigm shift from a "one size fits all" approach to more personalized, patient-oriented treatment strategies."

( Balbo, S; Bartolomucci, A; Borgatti, A; Grant, M; Jacobs, F; Razzoli, M; Stornetta, A; Villalta, PW; Walters, K; Zordoky, B, 2021)

"Conventional cancer treatments have shown several unfavourable adverse effects, as well as an increase in anticancer drug resistance, which worsens the impending cancer therapy."

( Hakeem, KR; Zari, AT; Zari, TA, 2021)

"As a result of the difficulties of cancer detection and its treatment, the survival rate of patients is unclear."

( Abniki, M; Bakhtiari, A; Bazli, L; Esmaeilkhanian, A; Irani, M; Jafari Rad, A; Moghanian, A; Niazvand, F; Sharifianjazi, F, 2021)

"Targeted drug therapy against cancer has been introduced as a smart strategy to combat the unwanted side effects due to systemic administration of chemotherapeutics."

( Delavari, B; Ghasemi, A; Khoobi, M; Mahmoudi Aznaveh, H; Mamashli, F; Nikkhah, M; Pirhaghi, M; Saboury, AA; Toosi Moghadam, F, 2022)

"Hence, cascade multistage cancer treatment of "combined PTT and chemotherapy sensitization"-"penetration-enhanced PTT" is achieved, and tumor cells are comprehensively and effectively eliminated."

( Jiang, D; Liu, S; Qian, C; Shen, C; Wang, J; Yang, Z; Ye, W, 2022)

"The anti-cancer effects of IFD were evidenced by both the spectroscopic techniques and discriminated from the GMO-induced changes in the culture environment; moreover, a synergistic effect of IFD and GMO administration can be envisaged by the experimental results."

( Astolfi, P; Bramucci, M; Giorgini, E; Maggi, F; Notarstefano, V; Parlapiano, M; Pisani, M; Quassinti, L; Vaccari, L, 2022)

"Many cancers display altered cholesterol metabolism, and recent studies demonstrate that manipulating systemic cholesterol metabolism may be useful in improving immunotherapy responses."

( King, RJ; Mehla, K; Singh, PK, 2022)

"It could be a potential cancer therapy different from NO-induced apoptosis of tumor cells."

( He, Q; Hussain, M; Jin, G; Qu, M; Shi, W; Wu, X; Xu, C; Zeng, LH; Zhu, H, 2022)

"Primary tumors and metastasis were significantly inhibited when treated with "Nano-targeted cells"-based cocktail therapy."

( Cao, Y; Chen, Q; Li, L; Liu, S; Liu, W; Ran, H; Shang, T; Tan, M; Wang, Z; Xie, Z; Zhang, L; Zhang, W, 2021)

"Novel cancer therapies have exploited these particles as alternative adjuvant therapies to overcome the traditional limitations of radio and chemotherapy."

( Agner, T; Feltrin, FDS; Lona, LMF; Sayer, C, 2022)

"Thus, regulating the TME to improve cancer cell ablation efficiency has received extensive interest in oncotherapy."

( Chen, W; Deng, L; Li, H; Liu, YN; Ouyang, J; Tao, N; Wei, C; Wen, M; Zeng, K; Zhao, S, 2022)

"Despite the high frequency of cancer-related fatigue (CRF) and its debilitating effects on the quality of life of patients with advanced cancer, there are limited treatment options available."

( Basen-Engquist, K; Bruera, E; Busaidy, NL; Diaz Fleming, C; Hess, KR; Liu, DD; Lu, Z; Reuben, JM; Valero, V; Williams, JL; Yennurajalingam, S, 2021)

"The rising cost of cancer diagnosis and treatment has imposed a huge financial burden on the affected households."

( Jayaseelan, V; Maurya, PK; Murali, S; Pandjatcharam, J; Thulasingam, M, 2021)

"Malignant cells in advanced cancer often display multiple genetic mutations and become resistant to monotherapy."

( Aki, S; Ishii, M; Ishikawa, S; Kanai, M; Kaneko, Y; Katoh, H; Kawamura, T; Kodama, T; Miura, M; Ohkubo, K; Osawa, T; Sugiyama, A; Takahashi, K; Tatsumi, T; Yamashita, T; Yamatsugu, K, 2022)

"In this work, the anticancer vaccines were combined with cisplatin to treat HPV-induced tumors at advanced growth stages."

( Alves, RPDS; Aps, LRMM; Barros, TB; da Silva, JR; Diniz, MO; Ferreira, LCS; Moreno, ACR; Pagni, RL; Porchia, BFMM; Rocha, CRR; Rodrigues, KB; Sales, NS; Silva, MM; Silva, MO; Souza, PDC, 2022)

"Hypoxia, a common feature of most solid tumors, causes severe tumor resistance to chemotherapy and immunotherapy."

( Jiang, M; Liu, Y; Wang, K; Yuan, Y; Zhou, J; Zong, Q, 2022)

"However, cancers often develop resistance against drugs, leading to failure of treatment and recurrence of the disease."

( Asemi, Z; Maleki Dana, P; Sadoughi, F; Yousefi, B, 2022)

"Radiotherapy is the most widely used cancer treatment and improvements in its efficacy and safety are highly sought-after."

( Blaukat, A; Carr, MI; Chiu, LY; Czauderna, F; Guo, Y; Lan, Y; Lazorchak, AS; Marelli, B; Qi, J; Qin, G; Sun, Q; Vassilev, LT; Xu, C; Yu, H; Zenke, FT, 2022)

"On the other hand, cancer cells shape and train TME to support their development, respond to treatment and migration in an organism."

( Fattahi, MJ; Ghaderi, A; Haghshenas, MR, 2022)

"Advances in cancer therapy have resulted in more cancer therapy-related cardiac dysfunction (CTRCD), which is the main cause of death in older female survivors of breast cancer."

( Chen, Z; Li, T; Wang, L; Xi, Q, 2022)

"The impermeable barriers of solid tumors restrict the co-delivery of protein-based drugs and chemotherapeutics for cancer treatment."

( Chen, H; Lan, Z; Ma, M; Shafiq, M; Shen, J; Yu, H, 2022)

"Compared with the conventional cancer treatment, specifically targeting the well-known Achilles heel, the Warburg effect has attracted considerable attention."

( Guo, Y; Tam, KY; Zhou, Y, 2022)

"To demonstrate that cancer cells treated in vitro with a new class of potent ICD inducer, naphthylquinoxaline thymidine conjugate (NAP) followed by UVA irradiation would be able to act as an effective tumor immunotherapy directly."

( Yang, R; Zhou, Q; Zhou, S, 2022)

"The therapeutic potentials of treated cancer cell plus different vaccine adjuvants were assessed by in vivo liver tumor model and in vitro mixed lymphocyte reaction studies."

( Yang, R; Zhou, Q; Zhou, S, 2022)

"Unfortunately, in cancer patients, anemia, either as a complication of cancer progression or as the result of cancer treatment, undermines the expected therapeutic efficacy."

( Feng, W; Fu, Q; Ganz, T; Liu, S; Ren, L; Wang, S; Wei, S; Xu, Y; Zhang, Z; Zhu, J, 2022)

"Perceived cancer-related stigma can affect mental health and potentially treatment choices for patients with cancer."

( Bhaskar, A; Finkelstein, EA; Hapuarachchi, T; Joad, AK; Malhotra, C; Manalo, MF; Mariam, L; Ning, X; Ozdemir, S; Palat, G; Rahman, R; Teo, I; Tuong, PN, 2022)

"Despite advances in cancer diagnosis and treatment, mortality associated with this malignant disease is still a major challenge in the health system."

( Ansari, MJ; Kazemnezhad, K; Mahhengam, N; Olegovich Bokov, D; Setia Budi, H; Siahmansouri, H; Suksatan, W; Thangavelu, L, 2022)

"Currently, cancer patients with microbial infection are a severe challenge in clinical treatment."

( Cui, Z; Fu, A; Fu, C; Keerthiga, R; Li, X; Tong, T; Yang, X; Zhang, Y; Zhao, Z, 2022)

"Despite the rapid advance in anti-cancer treatment in recent years, the treatment to cancer-related pain remains largely unchanged."

( Zhang, H, 2022)

"Numerous studies have confirmed the anticancer effects of ferroptosis on a wide range of tumors, specifically in providing new perspectives for tackling drug resistance and treating refractory tumors."

( Dai, XF; Fan, J; Li, PD; Li, ZY; Wang, Y; Zhang, S; Zhou, MT, 2022)

"Most patients with cancer treated with everolimus experience stomatitis, which seriously affects the quality of life."

( Beijnen, JH; Dorlo, TPC; Huitema, ADR; Jacobs, BAW; Molenaar-Kuijsten, L; Rosing, H; Steeghs, N; Thijssen, B; Verheijen, RB, 2022)

"Targeted cancer therapy has become one of the most important medical methods because of the spreading and metastatic nature of cancer."

( Ai, J; Ga, L; Tong, X; Wang, Y, 2022)

"Paclitaxel, a drug routinely used in cancer chemotherapy, potentiates the in vivo toxicity of pyridostatin."

( Benainous, H; Biroccio, A; Bruna, A; De Visser, Y; Di Vito, S; Groelly, FJ; Kosova, AA; Leonetti, C; Porru, M; Ryan, A; Serra, V; Tarsounas, M; Zimmer, J, 2022)

"Because cancer is one of the highest causes of death globally, the discovery of immune checkpoint inhibitors by Honjo and Allison in cancer immunotherapy earned a Nobel Prize in 2018."

( Chen, W; MaruYama, T; Shibata, H, 2022)

"Some novel cancer therapy modalities such as immunotherapy or tumour vaccination therapy work based on the control of interactions within the tumour microenvironment (TME)."

( Lou, ZP; Ma, FY; Najafi, M; Yu, DL, 2022)

"Ionizing radiation is a pillar of cancer therapy that is deployed in more than half of all malignancies."

( Barcellos-Hoff, MH, 2022)

"The odds of all-cause and cancer-related mortality were consistently reduced among women who began menopausal hormone therapy ≤60 years, whereas the association with cardiovascular mortality was inconsistent."

( Brusselaers, N; Fornes, R; Khodir, H; Simin, J; Tamimi, RM, 2022)

"Metronomic chemotherapy in geriatric cancer patients exhibited grade 1 toxicity for haemoglobin."

( Durairaj, M; Lingeshwaran, GP; Mary Martin Daniel, PJ; Muhasaparur Ganesan, R; Srinivasan, K; Sureshkumar, K; Thiruvengadam, G, 2023)

"In multimodal cancer therapy, developing innovative multifunctional hybrid nanoparticles with significant potential is extensively considered."

( Davaran, S; Farahzadi, R; Fathi, E; Kadkhoda, J; Keramat, A, 2022)

"Cisplatin (CP) is an anticancer medication that is commonly used to treat solid tumors."

( Abd El-Emam, MM; Abdel-Rahman Mohamed, A; Bin Emran, T; El-Shetry, ES; Khater, SI; Metwally, MMM; Mostafa-Hedeab, G; Nassan, MA, 2022)

"The application of doxorubicin (DOX) in cancer therapy has been limited due to its drug resistance and poor internalization."

( Ashrafizadeh, M; Bikarannejad, P; Daneshi, S; Gholami, MH; Hashemi, M; Heydari Sheikh Hossein, H; Hushmandi, K; Khan, H; Kumar Thakur, V; Kumar, AP; Makvandi, P; Mirzaei, S; Mishra, YK; Mostafavi, E; Orive, G; Rabiee, N; Saebfar, H; Sharifi, E; Tay, FR; Vosough, M; Wang, Y; Zabolian, A; Zarrabi, A, 2022)

"Then, DOX resistance in cancer, GO-mediated photothermal therapy, and DOX delivery for cancer suppression are described."

"Recognizing cancer as a metabolic disorder could unravel key diagnostic and treatments markers that can impact approaches used in cancer management."

( Choi, J; Gyamfi, J; Kim, J, 2022)

"The clinical success of current cancer immunotherapy suggests that future anti-tumor therapy needs to consider its impact on the tumor-associated immune system."

( Brüne, B; Olesch, C; Weigert, A, 2022)

"Two key concerns exist in contemporary cancer chemotherapy in clinics: limited therapeutic efficiency and substantial side effects in patients."

( Han, J; Lu, Y; Xiong, J; Xiong, Q; Zang, Y; Zhang, W, 2022)

"Radiotherapy is a crucial cancer treatment, but its outcome is still far from satisfactory."

( Hać, A; Herman-Antosiewicz, A; Rak, J; Spisz, P; Zdrowowicz, M, 2022)

"Radiation therapy, a common cancer therapy, also interacts and alters one-carbon metabolism."

( Korimerla, N; Wahl, DR, 2022)

"As a cancer therapy adjuvant, melatonin could modulate TME oxidative stress levels and hypoxia, reverse pH gradient changes, reduce lipid peroxidation, and protect lipid raft compositions to suppress prion-mediated, non-Mendelian, heritable, but often reversible epigenetic adaptations that facilitate cancer heterogeneity, stemness, metastasis, and drug resistance."

( Loh, D; Reiter, RJ, 2022)

"Hypoxia in tumors results in resistance to both chemotherapy and radiotherapy treatments but affords an environment in which hypoxia-activated prodrugs (HAP) are activated upon bioreduction to release targeted cytotoxins."

( Anderson, RF; Hay, MP; Hong, CR; Qi, W; Stevenson, RJ; Yadav, P, 2022)

"Eligible patients had metastatic cancer receiving ≥2 prior treatments."

( Arkenau, HT; Boni, V; Dang, T; Fidler, MJ; Garcia-Corbacho, J; Hannah, A; Harding, JJ; Huisman, MC; Jalal, S; Kim, SK; Liu, JF; LoRusso, P; Lyman, SK; Menke van der Houven van Oordt, CW; Meric-Bernstam, F; Miedema, IHC; Nagasaka, M; Paton, V; Sanborn, RE; Spira, A; Sweis, RF; Uboha, N; van Dongen, GAMS; Vasiljeva, O; Vugts, DJ; Wang, S; Zein, IA; Zwezerijnen, GJC, 2022)

"In conclusion, resveratrol inhibited cancer cell survival, while knockdown of lncRNA H19 resulted in increased sensitivity to resveratrol therapy."

( Cheng, L; Huang, Y; Li, C; Li, T; Li, Y; Luo, Y; Wu, Z; Zhang, X; Zhao, Q; Zhou, K, 2022)

"Tumor microenvironment (TME)-activated cancer imaging and therapy is a key to achieving accurate diagnosis and treatment of cancer and reducing the side effects."

( Bai, Y; Hua, J; Liang, H; Wang, S; Zhang, L; Zhao, J; Zhao, S, 2022)

"The emerging area of gas-mediated cancer treatment has received widespread attention in the medical community."

( Gao, D; Guo, X; He, X; Jia, L; Ren, X; Wang, Y; Yang, Z; Zhao, Z, 2022)

"We identified treatment with OAC at cancer diagnosis and the following year and described the incidence of discontinuing or switching between warfarin and direct oral anti-coagulants (DOACs)."

( Grove, EL; Larsen, TB; Lip, GYH; Nielsen, PB; Ording, AG; Skjøth, F; Søgaard, M, 2022)

"Orally administrable anticancer nanomedicines are highly desirable due to their easy and repeatable administration, but are not yet feasible because the current nanomedicine cannot simultaneously overcome the strong mucus and villi barriers and thus have very low bioavailability (BA)."

( Fan, W; Geng, Y; Li, Z; Liu, Y; Piao, Y; Shao, S; Shen, Y; Sun, R; Tang, J; Tang, Y; Wang, G; Wei, Q; Xiang, J; Xie, T; Xu, L; Zhou, Q; Zhou, Z, 2022)

"Systemic treatments such as cancer vaccines harness antigen presenting cells (APCs) to activate T cells with tumor-associated antigens."

( Chen, H; Dai, X; Guo, B; Huang, L; Wang, Z; Yu, A, 2022)

"Accurate diagnosis of cancer cells directly affects the clinical treatment of cancer and can significantly improve the therapeutic effect of cancer patients."

( Chen, Y; Jiang, H; Liu, W; Liu, X; Lv, G; Wang, X; Ye, J, 2022)

"Surgery is an important treatment for cancer; however, local recurrence following macroscopically-complete resection is common and a significant cause of morbidity and mortality."

( Bloomquist, C; DeSimone, J; Foley, H; Hagan, CT; Kim, I; Knape, NM; Mecham, S; Wagner, KT; Wang, AZ; Warner, S, 2022)

"We collected 40 patients with solid tumors who received metformin for concomitant diabetes and nivolumab as anticancer therapy in four Italian Hospitals."

( Astore, S; Bassi, P; Bove, P; Bria, E; Buti, S; Ciccarese, C; Ferrara, MG; Foschi, N; Iacovelli, R; Iacovelli, V; Massari, F; Palermo, G; Primi, F; Rossi, E; Schinzari, G; Tortora, G, 2022)

"We prospectively monitored cancer patients from August 2017 to October 2019 receiving oncological treatments with SC, using the sensor-controlled system "DigniCap."

( Ebner, F; Hempel, D; Hempel, L; Keim, S; Milani, V; Retzer-Lidl, M; Wohlmuth, K, 2022)

"TGF-β blockade therapy for cancer has achieved some results but shows limited efficacy and side effects because these drugs are not selective and act on various types of cells throughout the body."

( Chen, X; Chen, Y; Guan, Y; Han, C; Jiang, L; Li, H; Ma, Y; Wei, W; Zhang, P; Zhang, Y, 2022)

"Active cancer was defined as a new diagnosis, treatment, progression, or recurrence within six months before admission or metastatic cancer."

( Iguchi, N; Izumi, T; Nanaura, H; Ozaki, M; Sugie, K, 2022)

"Patients with cancer-associated venous thromboembolism (VTE) have a high risk of VTE recurrence and anticoagulant treatment-related bleeding, but the correlation of these risks with the cancer stage is unclear."

( Agnelli, G; Becattini, C; Brenner, B; Cohen, AT; Connors, JM; Gussoni, G; Huisman, M; Munoz, A; Sanchez, O; Verso, M, 2022)

"Cancer stage was categorised by expert cancer physicians according to pre-specified criteria, and study outcomes were adjudicated by an independent committee unaware of cancer stage and treatment allocation."

( Agnelli, G; Becattini, C; Brenner, B; Cohen, AT; Connors, JM; Gussoni, G; Huisman, M; Munoz, A; Sanchez, O; Verso, M, 2022)

"We report a case of an advanced cancer patient cared receiving palliative care who developed severe facial edema after initiating a low dose of olanzapine in monotherapy."

( Bruera, E; Calaveiras, P; Costa, E; Daniel, AS; Ferreira, T; Julião, M; Lemos-Caldas, M; Sobral, MA, 2022)

"A patient with advanced cancer who presented with severe facial edema after initiating olanzapine for the treatment of her opioid use disorder."

( Bruera, E; Calaveiras, P; Costa, E; Daniel, AS; Ferreira, T; Julião, M; Lemos-Caldas, M; Sobral, MA, 2022)

"Due to its proven role in cancer development and immune regulation, gut microbiome has gained increasing expectation as a potential armamentarium to optimize immunotherapy with ICI."

( Antognelli, C; Aversa, F; Bellet, MM; Bereshchenko, O; Costantini, C; D'Onofrio, F; Gargaro, M; Giovagnoli, S; Nunzi, E; Pariano, M; Pieraccini, G; Puccetti, M; Renga, G; Ricci, M; Riuzzi, F; Romani, L; Santarelli, I; Stincardini, C, 2022)

"Chemotherapy is an important means of cancer treatment."

( Cai, Z; Ghaleb, H; Huang, W; Jiang, Y; Liu, Y; Qian, H; Qiu, Q; Shi, W; Yin, Z; Zhang, P; Zhou, J; Zou, F, 2022)

"Preventing depression in cancer patients on long-term opioid therapy should begin with depression screening before opioid initiation and repeated screening during treatment."

( Bates, N; Bello, JK; Osazuwa-Peters, N; Scherrer, JF; Sullivan, MD, 2022)

"Gene therapy can be used as a cancer therapy by affecting signaling networks participating in the aggressive behavior of tumors."

( Ang, HL; Aref, AR; Entezari, M; Hamblin, MR; Hashemi, M; Hushmandi, K; Kumar, AP; Mahabady, MK; Orouei, S; Paskeh, MDA; Saebfar, H; Samarghandian, S; Zarrabi, A, 2022)

"We obtained demographic, clinical, cancer type, and antineoplastic therapy data."

( Cadena, J; Chan, KHR; Gryshuk, AL; Hong, JC; Huang, FW; Kwon, DH; Nguyen, S; Ray, P; Soper, B, 2022)

"The recent development and prospects of cancer immunotherapy have led to diversification of the types of therapeutic agents used."

( Im, S; Kim, S; Kim, WJ; Lee, J, 2022)

"Multidrug resistance (MDR) to anticancer drugs remains a serious obstacle to the success of cancer chemotherapy."

( Choi, CY; Han, SI; Lee, TB; Lim, SC, 2022)

"The vulnerability of therapy-resistant cancers to ferroptosis provides an alternative way to overcome drug resistance."

( Li, X; Lin, H; OuYang, F; Pang, Y; Yan, J; Zhang, W; Zhou, J, 2022)

"Childhood cancers are usually treated with chemotherapy and radiation."

( Bahadoram, M; Bahadoram, S; Hassanzadeh, S; Keikha, A; Keikhaei, B; Mahmoudian-Sani, MR, 2023)

"Synergistic therapy for malignant tumors has been developed in the past."

( Li, B; Li, J; Liu, K; Lu, S; Su, J; Sun, J; Wang, F; Wei, Z; Zhang, H, 2022)

"As the impact of high glucose levels on cancer progression and therapy is a novel finding, further research is required."

( Cai, XJ; Li, TJ; Zhang, AB; Zhang, HY; Zhang, JY; Zhou, X, 2022)

"Immunotherapy of malignant cancers is now becoming one of representative approaches to overcome cancers."

( Bhuiyan, RH; Furukawa, K; Hamamura, K; Hashimoto, N; Kaneko, K; Kondo, Y; Ohkawa, Y; Ohmi, Y; Tajima, O; Yesmin, F, 2022)

"Opioid analgesics are the main stay for cancer pain management; however, long-term opioid treatment (L-TOT) may suppress the endocrine system."

( Abou-Kassem, D; Diasso, PDK; Kurita, GP; Sjøgren, P, 2022)

"Radiotherapy is a mainstay cancer therapy whose antitumor effects partially depend on T cell responses."

( Ahmed, A; Albrecht, D; Antonopoulos, W; Beckhove, P; Beikert, T; Bestvater, F; Brom, M; Cerwenka, A; Debus, J; Giese, NA; Griebel, P; Halama, N; Huber, PE; Jäger, D; Jiménez-Sánchez, A; Kraske, JA; Lenoir, B; Liao, B; Menevse, AN; Miller, M; Pahl, JHW; Pe'er, D; Perez, RL; Rosenstiel, P; Schmidt, G; Strobel, O; Suarez-Carmona, M; Tietz-Dahlfuß, A; Timke, C; Tran, F; von Bohlen Und Halbach, E; Walle, T, 2022)

"While not approved for cancer therapy, there are ongoing clinical trials to evaluate their safety and efficacy."

( Al-Zeidaneen, SA; Algwaiz, GF; Karim, NA; Mohsen, S; Nasef, N; Sobash, PT, 2022)

"Despite this increase, childhood cancer survivors (CCS) are at high risk of developing late complications such as nephrotoxicity due to chemotherapy."

( Aboelghar, HM; El-Deeb, SM; Elharoun, MS; Elsalam, HBA; Mahmoud, AAS; Zanaty, FM, 2022)

"Given the limitations of current cancer immunotherapy, there has been increasing interest in harnessing innate immune responses by nucleic acids and oligonucleotides."

( Meng, F; Wang, J; Yeo, Y, 2022)

"Adult cancer patients whose pain was previously stable with opioid analgesics and, based on clinical judgement, were able to convert to transdermal buprenorphine treatment were invited to participate."

( Chen, JS; Chen, ML; Hou, MM; Huang, TL; Huang, YM; Shen, WC; Wang, CH, 2023)

"They have been evaluated for their anticancer activity on cells and experimental animal models and used chemotherapy."

( Das, A; Gogoi, U; Pathak, K; Pathak, MP; Sahariah, JJ; Saikia, R; Samanta, A; Zothantluanga, JH, 2022)

"The desire for a cancer theranostic system with simultaneously accurate diagnosis and efficient therapy is undeniably interminable."

( Chen, B; Cheng, H; He, X; Huang, J; Jia, R; Ma, W; Sun, H; Wang, K; Wang, Y, 2022)

"Control of glucose metabolism in cancer cells has potential to serve as an anti-cancer therapy."

( Aftab, S; Khalid, Z; Shakoori, AR, 2022)

"Primary bone and joint cancers are rare and understudied, yet these neoplasms are difficult to treat and impact all age groups."

( Ananieva, EA; Betar, RA; Boyer, MP; Lim, D; Liu, D; Nilles, JD; Showalter, HA; Wilson, BD, 2023)

"Thus, their usefulness in the anticancer therapy is limited."

( Piechowiak, T; Skóra, B; Szychowski, KA, 2022)

"Apixaban therapy in patients with cancer and VTE is expected to increase as clinicians gain more experience and reassurance with data from real-world studies that are generally promising."

( Bolek, T; Galajda, P; Grilusová, K; Kubisz, P; Mikušová, V; Mokáň, M; Samoš, M; Škorňová, I; Stančiaková, L; Staško, J, 2021)

"Novel targets for cancer therapy have been identified and a methylase (KMT6A/EZH2), which produces the repressive H3K27me3 mark, and a demethylase (KDM1A/LSD1), which demethylates the active H3K4me2 mark, are now under clinical evaluation."

( Burchell, JM; Taylor-Papadimitriou, J, 2022)

"The improvement of cancer chemotherapy remains a major challenge, and thus new drugs are urgently required to develop new treatment regimes."

( Bachmeier, B; Dawood, M; Drif, A; Efferth, T; Hegazy, MF; Kadioglu, O; Kamounah, FS; Ooko, E; Saeed, MEM; Seo, EJ; Titinchi, SJ; Yücer, R, 2022)

"To further improve the efficiency of cancer treatment, combined therapy based on Cu-based NMs was introduced in detail."

( Dai, X; Qian, H; Wang, H; Wang, X; Wang, Y; Zhong, X, 2022)

"Titanium(IV) anticancer complexes are promising candidates for treatment of various cancers, and previous studies have pointed to possible interactions between Ti(IV) anticancer complexes and the serum proteins albumin and transferrin."

( Shpilt, Z; Tshuva, EY, 2022)

"Adolescents with cancer/family dyads were randomized into a clinical trial from July 2016 to April 2019 at a 2:1 ratio: intervention (n = 83); control (n = 43) to either 3 weekly sessions of FACE-TC (Lyon Advance Care Planning Survey; Next Steps: Respecting Choices Interview; Five Wishes, advance directive) or treatment as usual (TAU)."

( Baker, JN; Friebert, S; Jiang, J; Lyon, ME; Needle, J; Wang, J, 2022)

"Furthermore, when breast cancer xenograft models on nude mice were treated with EF-stimulated nanomedicine, the tumor-inhibition rate increases to 75%, which is 2."

( Jiao, Y; Liu, Z; Wang, Y; Wen, X; Yang, S; Zhu, Y, 2022)

"Multidrug-resistant isolates found in cancer patients and routine bacterial surveillance and study of their resistance patterns may guide successful antimicrobial therapy and improve the quality of care."

( Belay, G; Tigabu, A; Worku, M, 2022)

"Recent studies try to treat cancer by altering macrophages' polarization which damages tumor microenvironment and induces ferroptosis of cancer cells."

( Gao, W; Guo, L; Tang, TL; Wang, Y; Yan, M; Yang, Y, 2022)

"However, the success of cancer treatment is closely related to early diagnosis, identification, and effective treatment."

( Li, W; Li, Y; Liu, Y; Luo, D; Wang, S; Wang, Y; Yan, X; Zhang, Y; Zhu, P, 2022)

"Effective cancer immunotherapy requires physical contact of T cells with cancer cells."

( Bamba, T; Fukui, Y; Hattori, Y; Honma, T; Izumi, Y; Kanai, M; Kunimura, K; Nakamura, M; Oisaki, K; Sakata, D; Sakurai, T; Suematsu, M; Sugiura, Y; Takaya, D; Tatsuguchi, T; Togo, T; Uruno, T, 2022)

"The drugs used for cancer treatment have many drawbacks, as they damage both tumor and healthy cells and, in addition, they tend to be poorly soluble drugs."

( de Julián-Ortiz, JV; Díez-Sales, O; Nácher, A; Taléns-Visconti, R, 2022)

"Two key concerns exist in contemporary cancer chemotherapy: limited therapeutic efficiency and substantial side effects in patients."

( Han, J; Lu, Y; Xiong, J; Xiong, Q; Zang, Y; Zhang, W, 2022)

"Known cancer treatments are chemotherapy, surgery, radiation therapy, targeted hormonal therapy, or a combination of these methods."

"The problems with anticancer therapy are resistance and toxicity."

( Ivanova, S; Tsvetkova, D, 2022)

"Data on inpatient stays, cancer treatments, treatment decisions, and some background factors were retrieved from electronic records."

( Kataja, V; Lamminmäki, A; Länsimies, H; Tolppanen, AM; Tyynelä-Korhonen, K, 2022)

"In the clinic, oxygen saturation of tumors is usually achieved by the application of water-soluble ozone and hyperbaric oxygen therapy."

( Seledtsov, VI; von Delwig, AA, 2022)

"Radioisotope therapy (RIT) of cancer is restrained by the nonspecific distribution of radioisotope and ineptitude for metastatic tumors."

( Chen, H; Liu, T; Pei, P; Qi, Z; Yang, K; Yang, S; Zhang, Y, 2022)

"Photodynamic therapy (PDT) damages cancer cells via photosensitization using harmless laser irradiation."

( Aoki, H; Aoyama, M; Kataoka, H; Kimura, Y; Nishie, H; Nomoto, A; Otsuka, Y; Sakuragi, A; Soyama, T; Yano, S, 2022)

"Hydrogen can be used as an anti-cancer treatment."

( Chao, Y; Cheng, L; Gong, F; Gong, Y; Hao, Y; Lei, H; Liu, B; Liu, Z; Wang, X; Yang, N; Yang, X, 2022)

"GRPR is over-expressed in cancer cells and is a potential drug target for the treatment of cancer."

( He, M; Li, C; Meng, X; Wang, H; Yao, R; Yu, M; Zhu, Y, 2022)

"Bacteria-mediated cancer immunotherapy (BCI) robustly stimulates the immune system and represses angiogenesis, but tumor recurrence and metastasis commonly occur after BCI."

( Jiang, SN; Liu, X; Piao, L; Xu, H, 2022)

"Unfortunately, cancer cells can hijack this mechanism to survive under metabolic stress or develop drug resistance during chemotherapy."

( Chen, QL; Chen, XP; Dong, Y; Fu, J; Keon, KA; Li, M; Lu, JH; Lu, JJ; Rubinstein, JL; Shen, HM; Wang, SF; Zeng, SX; Zhang, S; Zhu, G, 2022)

"We aim to discuss the hematological cancer cases that opted for ovarian tissue cryopreservation (OTC) as fertility preservation before the gonadotoxic chemotherapy agent."

( Abdul Karim, AKB; Abu, MA; Ahmad, SM; Mat Jin, N; Mohd Faizal, A, 2022)

"Predictors of opioid use post cancer included prior opioid use, select comorbidities, use of nonopioid pain treatment adjuvants (muscle relaxants, sedative/hypnotics, anticonvulsants, antidepressants, and steroids), cancer site, and metastatic cancer."

( Fleming, SP; Le, TT; Simoni-Wastila, L, 2022)

"Due to drug resistance to current anticancer drugs, cancer incidence is rising, and seeking effective treatment is a major concern."

( Afzal, S; Banday, N; Farooq, S; Maqbool, M; Mir, PA; Mir, RH; Mohi-Ud-Din, R; Raza, SN, 2022)

"Side effects of chemotherapy in cancer patients need to be investigated in more detail."

( Abadi, H; Amirmoghaddami, H; Karamitanha, F; Moghaddam, Z; Rostami, M; Zeraatchi, A, 2022)

"Chemotherapy is a prime tool for cancer clinical therapy."

( Chang, J; Chen, M; Gong, X; Li, W; Lian, G; Peng, W; Qin, Y; Wang, T; Zhou, D, 2021)

"By hindering energy supply pathway for cancer cells, an alternative therapeutic strategy modality is put forward: tumor starvation therapy."

( Cui, X; Jia, F; Li, Y; Pan, Z; Wang, X; Wu, Y, 2022)

"Patients with active cancer have a 4-sevenfold increased risk for venous thromboembolism (VTE) especially during systematic anticancer treatment."

( Charalambakis, N; Kosmas, C; Lianos, E; Liatsos, AN; Mazlimoglou, E; Papageorgiou, G; Pouliakis, A; Simeonidis, D; Xynogalos, S; Ziras, N, 2022)

"Different cancer therapy modes employed, including chemotherapy and radiotherapy, have been reported to be significant in cancer management, but the side effects associated with these treatment strategies are still a health problem."

( A Alsahli, M; Alhumaydhi, FA; Almatroodi, SA; Babiker, AY; Khan, AA; Rahmani, AH; S M Aljohani, A, 2022)

"However, as with other types of cancer treatments, ICB-based immunotherapy is hampered by both innate and acquired drug resistance."

( Bu, MT; Chandrasekhar, P; Ding, L; Hugo, W, 2022)

"Many patients with a solid metastatic cancer are treated aggressively during their last month of life."

( Bundoc, F; Chaudhry, I; Finkelstein, E; Malhotra, C; Ozdemir, S; Teo, I, 2022)

"Traditional treatment strategies for cancer are unsatisfactory."

( He, W; Li, S; Liu, X; Meng, X; Peng, L; Xie, W; Yin, J, 2023)

"In the past three decades of cancer research, angiogenesis has been at its peak, where an anti-angiogenic agent inhibiting vascular endothelial growth factor acts as a promising substance to treat cancer."

( Nathan, J; Palanivel, G; Shameera, R, 2022)

"Numerous studies carried out on cancer cell lines and animal models demonstrated that millimolar vitamin C concentrations inhibit tumor cells viability, especially in association with chemotherapy."

( Astaras, C; Baudoux, N; Courtes, MG; Fernandez, E, 2022)

"Chez les patients atteints de cancer, l’administration d’une haute dose IV de vitamine C seule ne montre pas de signe d’activité antitumorale."

( Astaras, C; Baudoux, N; Courtes, MG; Fernandez, E, 2022)

"First-degree relatives of deceased cancer patients, interviewed by telephone, were asked if the treatments the patients received in their last month of life and their place of death corresponded to the patients' preferences."

( Bar-Sela, G; Bentur, N; Givon-Schaham, N; Tur-Sinai, A, 2023)

"Postoperative chemotherapy for gastric cancer often causes multidrug resistance (MDR), which has serious consequences for therapeutic effects."

( Cai, X; Hu, H; Li, H; Li, L; Li, N; Ma, J; Pang, L; Yi, T; Zeng, Y; Zhan, Y, 2022)

"Despite recent advances in cancer therapy, hard-to-reach, unidentified tumors remain a significant clinical challenge."

( Cresswell, GM; He, Y; Lanman, NA; Lyle, LT; Meng, F; Ratliff, TL; Wang, J; Yeo, Y, 2022)

"Despite patients with cancer having interest in seeking PDCs for symptom management, only a few initiated and continued therapy."

( Charbonneau, LF; De Angelis, C; Marchese, M; Peragine, C; Zhu, C, 2022)

"Various cancer therapies, such as surgery, radiotherapy, chemotherapy, and immunotherapy, have been used to treat cancer."

( Han, HD; Jang, GY; Kang, TH; Lee, JW; Lee, SE; Park, SH; Park, YM, 2022)

"Immunotherapy has revolutionized cancer therapy by reactivating tumour-resident cytotoxic lymphocytes."

( Belz, GT; McCulloch, TR; Rossi, GR; Schreuder, J; Souza-Fonseca-Guimaraes, F; Wells, TJ, 2022)

"The decision was made to stop systemic cancer treatment."

( Costantini, A; Fabre, L; Giroux-Leprieur, E; Magdelaine, P, 2022)

"They can stimulate or inhibit cancer cell proliferation and invasion, as well as interfere with cancer cell responses to drug treatments."

( Abdullah, RM; Al-Naqshabandi, MA; Alkasalias, T; Hama, HA; Housein, Z; Hussen, BM; Khudhur, ZO; Salihi, A, 2022)

"Twenty-one dogs diagnosed with various cancers were administered several doses of oral paclitaxel three times a month (group 1) or six times a month (group 2)."

( An, JH; Chae, HK; Chu, SN; Kang, K; Oh, YI; Park, S; Seo, K; Youn, HY, 2022)

"Persistent pain due to cancer and its treatment can be managed through multimodal care, although efforts to mitigate the opioid misuse epidemic have created challenges in access to appropriate treatment."

( Paice, JA, 2022)

"Achieving a complete response to cancer treatment is a severe challenge, and has puzzled humans for a long time."

( Cai, R; Chen, C; Li, X; Liu, T; Ovais, M; Ren, J; Wang, Z; Wen, S, 2022)

"Silver itself is a good anticancer and antibacterial agent and employing it with phytochemicals with anticancer properties, and nanotechnology can give the best approach for the treatment."

( Bhatt, A; Narwal, S; Rani, N; Redhu, R; Singla, RK, 2022)

"Radiotherapy (RT) is a conventional cancer therapeutic modality."

( Cao, T; Deng, T; Fu, Y; Gao, Y; Hou, Y; Li, X; Liu, Y; Peng, Y; Qi, X; Xie, L; Yin, L; Zhang, S; Zhu, Q, 2022)

"A shift in the paradigm of cancer pain treatment should be considered given the undertreatment rate, lack of benefits, and considerable risks associated with oral opioid medication in many patients who suffer from chronic cancer pain."

( Aubrun, F; Carvajal, G; Duarte, R; Dupoiron, D; Eldabe, S, 2022)

"Subgroup analysis based on type of cancer treatment given was done."

( Franco, PIG; Li, RK; Pandy, JGP, 2022)

"Immunotherapy is a valuable approach to cancer treatment as it is able to activate the immune system."

( Angelini, C; Argenziano, M; Cavalli, R; Giovarelli, M; Novelli, F; Occhipinti, S; Scomparin, A; Soster, M, 2022)

"Many people with cancer experience moderate to severe pain that requires treatment with strong opioids, such as oxycodone and morphine."

( Arnold, S; Bennett, MI; Bromham, N; Chi, Y; Hilgart, JS; Page, AJ; Schmidt-Hansen, M, 2022)

"A majority of cancers fail to respond to immunotherapy due to the immunosuppressive tumor microenvironment (TME), and metabolic regulation of the TME has been a promising strategy to improve immunotherapy."

( Cai, YJ; Li, B; Lin, MZ; Shuai, XT; Tian, LR; Xiao, ZC; Zhong, HH, 2022)

"We performed a post-hoc analysis of all cancer patients included in the prospective multicenter observational TROPIQUE study who received long-term treatment with tinzaparin for a first venous thromboembolism (VTE) event."

( Cajfinger, F; Crichi, B; Farge, D; Frere, C; Janus, N; Le Maignan, C; Marjanovic, Z; Rueda-Camino, JA; Spiess, N, 2022)

"Patients were eligible if they had cancer-related pain within the past 7 days, which was treated with strong opioids in the previous 7 days."

( Chang, MH; Kang, JH; Koh, SJ; Lee, KH; Oh, SY; Park, K, 2022)

"Using a 4T1 orthotopic breast cancer BALB/c mouse model, we observed that mineralized PB showed a significant temperature increase within the tumor, which led to better tumoricidal activity compared with CaP and PB when identical NIR treatment was applied."

( Chen, S; Ge, J; Iqbal, MZ; Kong, X; Ma, Z; Wang, S; Wang, Y; Xie, F; Yang, X; Zhang, Q; Zhao, R; Zhong, D, 2022)

"Therefore, DHP@M2 is suitable for cancer chemotherapy-sensitized immunotherapy."

( Du, T; Luan, Z; Wang, Y; Yang, K; Zhao, C, 2022)

"They are employed in the treatment of cancers, sarcomas, and hematologic malignancies."

( De Bruijn, EA; Harper, PG; Highley, MS; Landuyt, B; Prenen, H, 2022)

"The increase in metabolic plasticity of cancer cells' mitochondria and adaptive changes to the mitochondrial function are some of the mechanisms through which cancer cells resist chemotherapy."

( Gong, W; Hei, H; Li, Y; Liu, Y; Qin, J; Zhang, S, 2023)

"Agents that can sensitize the resistant cancer cells to the chemotherapeutic drug are currently the focus to improve the clinical efficiency of cancer therapy."

( Guha, S; Hazarika, S; Sivalingam, N; Sritharan, S, 2022)

"The resistance of cancer cells to cisplatin has dramatically blocked the further application of this drug in practical treatment settings."

( Deng, DP; Li, HM; Su, Y; Su, Z; Wang, MM, 2022)

"With increasing incidence of cancer worldwide and increasing burden of treatment over the patients with cancer, the caregivers of those patients with cancer also suffer from psychological distress which ultimately affects their Quality of Life (QOL)."

( Mandal, A; Rakesh, A; Ranjan, R; Shankar, A; Singh, D; Singh, P; Verma, M; Yadav, R, 2022)

"Caregiver Quality of Life Index-Cancer (CQOLC) Scale, employing standard 'forward-backforward' translation procedure, the English-language version of the questionnaire was translated into Hindi-language by experts and administered to each caregiver."

( Mandal, A; Rakesh, A; Ranjan, R; Shankar, A; Singh, D; Singh, P; Verma, M; Yadav, R, 2022)

"The design of nanomedicine for cancer therapy, especially the treatment of tumor metastasis has received great attention."

( Chen, JL; Chen, X; Gu, ZY; Jia, XH; Jiang, R; Li, J; Luo, KQ; Wang, L; Wu, X; Xu, YN; Yuan, G; Yuan, MH; Zhu, XM, 2022)

"After internalization by cancer cells, the acidic environment and localized heat generated by hyperthermia therapy would spur PDDFe to become loose and collapse to liberate its payload."

( Chen, L; Jin, Q; Lin, Q; Liu, J; Liu, N; Wu, L; Xiao, Z; Zhao, Y; Zhou, J; Zhu, X; Zuo, W, 2022)

"In patients with solid non-thyroid tumors, hypothyroidism is a common adverse event of radiotherapy, high-dose interleukin 2 (HD IL-2), interferon alpha (IFN-α), bexarotene, immune checkpoint inhibitors (ICPi), and tyrosine kinase inhibitors (TKIs), while chemotherapy may induce hypothyroidism more often than initially considered."

( Deligiorgi, MV; Trafalis, DT, 2022)

"Despite the many new possibilities, cancer pain treatment is not always effective and often poses a challenge for practitioners."

( Gorzewska, A; Janowiak, P; Lichodziejewska-Niemierko, M; Osowicka, M, 2022)

"In untreated cancerous mice, the percentage of splenic Th1 cells and plasma IFN-γ levels were lower (P<0."

( Hassan, ZM; Jafarzadeh, A; Nemati, M; Oladpour, O; Rezayati, MT; Taghipour, F; Taghipour, Z, 2022)

"Reactive oxygen species (ROS)-based cancer treatments have attracted much attention in recent years."

( Gao, Y; Li, N; Li, Y; Pan, W; Tang, B; Tang, K; Wang, S; Xu, H; Zhang, X, 2022)

"Approximately one in five cancer patients treated at reference hospitals in Mato Grosso reported having been exposed to pesticides, and one in ten were exposed to industrial dust and benzene, with greater exposure among men, older individuals, and those with lower level of education."

( Andrade, ACS; Correa, MLM; Galvão, ND; Machado, JMH; Pignati, WA; Silva, AMCD; Silva, NA; Soares, MR, 2022)

"Nanoparticles-based cancer therapeutics have offered a promising approach to treat cancer effectively while minimizing adverse events."

( Alle, M; Kim, JC; Lee, SH; Sharma, G, 2022)

"Conventional and targeted cancer therapies may induce a cellular senescence program termed therapy-induced senescence."

( Crescenzi, E; D'Incalci, M; Leonardi, A; Mellone, S; Pacifico, F; Stornaiuolo, M, 2022)

"The study was performed on human cancer cell lines treated with 2-APC, paclitaxel, and doxorubicin."

( Bikinieva, F; Boichuk, S; Galembikova, A; Mustafin, I; Ryzkin, S; Zykova, S, 2022)

"However, systemic cancer therapy with chemotherapy may also induce lung pneumonitis and fibrosis."

( Lai, X; Najafi, M, 2022)

"We aimed to evaluate the anti-cancer and immune system enhancing properties of Vitamin E succinate (VES) and methylselenic acid (MSA) administration on 4T1 breast tumor model under high-dose methotrexate (HDMTX) therapy and folinic acid (FA) rescue."

( Ahmadi, H; Akbari, ME; Barati, M; Davoodi, SH; Jabbari, M; Khaki Bakhtiarvand, V; Nikmehr, P; Shabani, M, 2022)

"Metastatic breast cancer poses great challenge in cancer treatment."

( Chen, WR; DeVette, CI; Hildebrand, WH; Hode, T; Hoover, AR; Krawic, JR; Lam, SSK; Liu, K; Medcalf, AD; Sun, XH; Welm, AL; West, CL, 2022)

"Polk-deficient tumors were controlled by cisplatin treatment and it significantly delayed tumor outgrowth and increased overall survival of tumor bearing mice."

( Beijersbergen, RL; Boadum, T; Buoninfante, OA; Catsman, JJI; de Groot, D; de Korte-Grimmerink, R; Jacobs, H; Kreft, M; Lieftink, C; Morris, B; Ormel, S; Pritchard, C; Proost, N; Shah, R; Siteur, B; Song, JY; Spanjaard, A; van de Ven, M; van den Berk, PCM; Zürcher, LM, 2022)

"The clinical success of anticancer therapy is usually limited by drug resistance and the metastatic dissemination of cancer cells."

( Han, W; Ren, L; Shi, K; Wang, H; Wang, Z; Xu, P; Yao, J, 2022)

"Functionally, treatment of breast cancer cells with the DNA methylation inhibitor 5-AzadC as well as silencing of DNA methyltransferase-1 (DNMT1) could decrease the abnormal hypermethylation of the MEG3 promoter, reverse MEG3 expression, inhibit cell proliferation and promote cell apoptosis."

( Chen, Z; Ding, H; Dong, M; Jin, L; Ma, X; Pan, T; Pan, W; Wu, D; Zhang, S, 2022)

"We developed a targeted enhanced cancer treatment method to camouflage HMMD by GOx-functionalized platelet (PLT) membranes (HMMD@PG)."

( Chen, B; Du, Y; Luan, J; Shen, Y; Wang, S; Zhang, M, 2022)

"Discovery of novel strategies for cancer immunotherapy including natural small molecules is needed."

( Cao, Z; Chen, C; Chen, G; Huang, J; Huang, M; Lei, H; Lu, Y; Ma, Y; Song, Y; Wu, F; Zhang, C; Zhang, L; Zhao, Y; Zhou, J, 2022)

"The characteristic hypoxia of solid tumors and inadequate oxygen supply become a key causation of the resistance to chemotherapy in cancer treatment."

( Chou, T; Gallaro, C; Halloran, M; Hu, W; Hu, X; Liang, L; Ren, L; Sun, J; Wang, H; Wang, J; Wang, Y; Zhang, B; Zhang, Q, 2022)

"Multidrug resistance (MDR) in cancer cells is a substantial limitation to the success of chemotherapy."

( Guo, Y; Tong, Z; Yang, D; Yao, C; Zhang, R; Zhao, J, 2022)

"Chemoresistance of cancer cells is a major problem in treating cancer."

( Najafi, M; Tang, Y; Wang, R; Zhao, S, 2022)

"Most high-priority cancer medicines identified by Indian oncologists are generic chemotherapy agents that provide substantial improvements in survival and are already included in WHO EML."

( Booth, CM; De Vries, EGE; Fundytus, A; Ganesan, P; Gyawali, B; Hopman, W; Ilbawi, A; Jalink, M; Lombe, D; Mathew, A; Moja, L; Pramesh, CS; Radhakrishnan, V; Roitberg, F; Sengar, M; Sullivan, R; Trapani, D, 2022)

"However, Black cancer patients are under-represented in music therapy trials."

( Cadwell, M; Casaw, C; Edwards, J; Li, QS; Lichtl, A; Liou, KT; Mao, JJ; Popkin, K; Yu, J, 2022)

"Early integration of palliative and cancer care improves the quality of life and is facilitated by discussions about the end of life after cessation of active cancer treatment between patients with advanced cancer and their physicians."

( Fujimori, M; Jinno, S; Majima, Y; Miyake, S; Mori, M; Okamura, M; Okusaka, T; Sato, A; Shirai, Y; Uchitomi, Y; Umehashi, M; Umezawa, S, 2022)

"Furthermore, chitin can be used in cancer treatment as a vehicle for delivering cancer drugs to a specific site and has an antiproliferative effect by reducing the viability of cells."

( Baharlouei, P; Rahman, A, 2022)

"Childhood cancer presents significant stress during diagnosis, treatment, and survivorship."

( Caterini, JE; Jones, HN; Nathan, PC; Rhind, SG; Wells, GD; White, GW, 2022)

"Breakthrough cancer pain (BTcP) refers to a sudden and transient exacerbation of pain, which develops in patients treated with opioid analgesics."

( Antenucci, N; Arcella, A; Boccadamo Pompili, SV; Font, J; Gradini, R; Liberatore, F; Llebaria, A; Luongo, L; Mascio, G; Nicoletti, F; Notartomaso, S; Scioli, M, 2022)

"So, new cancer treatment modalities are needed."

( El Sadieque, A; Elabd, S; Moustafa, ME; Shawki, MM, 2022)

( Hu, J; Li, C; Xiao, C; Zhu, L, 2022)

"Metal-nanocluster-mediated cancer diagnosis and therapy has drawn considerable attention in recent years due to the unique optical and photophysical properties of metal clusters."

( Jayasree, RS; Joseph, M; Nair, LV; Pathiripparambath, MSR; Tharayil, H, 2022)

"Drug resistance of cancer cells is a significant impediment to effective chemotherapy."

( Balakrishnan, AJ; Janardhanan, P; Pilankatta, R; Somasundaran, AK, 2022)

"Metabolomic profiling of tumors treated with DRP-104 revealed widespread changes indicative of the disruption of tumor anabolism and canonical cancer metabolism pathways; including altered glutamine metabolism while several immunosuppressive metabolites were decreased."

( Estok, TM; Wild, R; Yokoyama, Y, 2022)

"The treatment efficacy of anticancer drugs in complex physiological environments is still restricted by multi-drug resistance."

( Liu, Y; Ouyang, F; Shuai, Q; Zhang, L; Zhang, X, 2022)

"In Model 1, MCF-7 or T47D cancer cells were treated with Anastrozole, then exposed to whole blood and platelet-rich plasma, modelling platelet engagement in the tumour bed."

( Augustine, TN; Pather, K, 2022)

"Adults ≥18 years old with active cancer and evolving pain secondary to disease progression or treatment, whose symptoms were refractory to systemic opioids, and who underwent SCS trial followed by percutaneous implantation between 2016 and 2021 were included."

( Barzilai, O; Bulat, E; Chakravarthy, V; Crowther, J; Gulati, A; Rakesh, N, 2023)

"The nanolocks could eliminate the solid tumors through ferroptosis-sensitized chemotherapy under the guidance of photoacoustic imaging."

( Dong, X; Gan, L; Shao, J; Song, X; Su, Y; Wang, W; Wang, X; Zhao, Y; Zhong, L; Zhu, J, 2022)

"Treatment of subcutaneous MCA205 tumors associating gene transfer and low dose (10 mg/kg) chemotherapy resulted in inhibition of tumor progression."

( Antunes, F; Catani, JPP; Dariolli, R; Feitosa, VA; Hunger, A; Lana, MG; Medrano, RFV; Mendonça, SA; Rodrigues, EG; Salles, TA; Strauss, BE; Tamura, RE, 2022)

"Upon anticancer treatment, cancer cells can undergo cellular senescence, i."

( Bojko, A; Czarnecka-Herok, J; Herok, M; Mosieniak, G; Sikora, E; Sliwinska, MA; Strzeszewska-Potyrala, A; Targonska, A; Wolny, A, 2022)

"Precise anticancer therapies employing cytotoxic conjugates constitute a side-effect-limited, highly attractive alternative to commonly used cancer treatment modalities, such as conventional chemotherapy, radiotherapy or surgical interventions."

( Gędaj, A; Krzyścik, MA; Opaliński, Ł; Otlewski, J; Porębska, N; Poźniak, M; Zakrzewska, M; Żukowska, D, 2022)

"PDT is an anti-cancer therapy that relies on the light activation of non-toxic molecules-called photosensitizers-to generate ROS such as singlet oxygen."

( Monguzzi, A; Secchi, V; Villa, I, 2022)

"Since malignant tumor cancer cells overexpress the NK-1R, this combination therapy is a promising approach for the treatment of all kinds of cancer."

( Coveñas, R; Muñoz, M; Robinson, P, 2023)

"Conventional cancer therapies are chemotherapy, radiation, and surgery."

( Ahmadi, F; Asare-Addo, K; Ebrahimnejad, F; Ebrahimnejad, P; Nokhodchi, A; Pouya Hadipour Moghaddam, S; Sodagar-Taleghani, A, 2022)

"Then, an anti-cancer agent (curcumin) was loaded on the selected nano-platform to makes us able utilizing the synergistic effect of chemotherapy and photodynamic therapy simultaneously."

( Aghajanzadeh, M; Jashnani, S; Shahangian, SS; Shirini, F; Zamani, M, 2022)

"We used a novel model of anti-cancer treatment by the administration of L-NAME (30 mg/kg in a day, intraperitoneal) injected every third day for five weeks to rat model of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast tumor."

( Avtandilyan, N; Ginovyan, M; Javrushyan, H; Karapetyan, A; Trchounian, A, 2023)

"Despite the emergence of various cancer treatments, such as surgery, chemotherapy, radiotherapy, and immunotherapy, their use remains restricted owing to their limited tumor elimination efficacy and side effects."

( Goh, BH; Lim, HP; Low, LE; Sia, CS; Tey, BT, 2022)

"However, a new role in cancer therapy is emerging thanks to its outstanding catalytic properties, enabling novel approaches that are surveyed in this review."

( Bonet-Aleta, J; Garcia-Peiro, JI; Hueso, JL; Santamaria, J, 2022)

"Sixty subjects with advanced cancer requiring oxygen therapy from a grade 3, class A hospital in China were recruited and randomized (1:1) to traditional nasal catheter oxygen therapy or HFNC."

( Li, P; Ma, D; Xu, Z; Zhang, C, 2022)

"The only way to treat tumors is to detect them early so that the survival rate can be improved by early treatment."

( Li, P; Wei, J; Zhang, H; Zhu, R, 2022)

"Local cancer treatment by in situ injections of thermo-responsive hydrogels (HG) offers several advantages over conventional systemic anti-cancer treatments."

( Abasolo, I; Andrade, F; Durán-Lara, EF; Hide, D; Llaguno, M; Martell, M; Oliva, M; Rafael, D; Raurell, I; Roca-Melendres, MM; Schwartz, S; Vijayakumar, S, 2022)

"Patients undergoing therapy for cancer or autoimmune diseases are at higher risk of insufficient humoral immune response following COVID-19 vaccination."

( Ahlgrimm, M; Bewarder, M; Bittenbring, JT; Brill, K; Cetin, O; Christofyllakis, K; Kaddu-Mulindwa, D; Kiefer, M; Kos, IA; Lohse, S; Neumann, F; Smola, S; Thurner, L, 2022)

"The argument around cancer therapy is an old one."

( Barfar, A; Feyzizadeh, M; Nouri, Z; Sarfraz, M; Valizadeh, H; Zakeri-Milani, P, 2022)

"Chemo-thermotherapy, as a promising cancer combination therapy strategy, has attracted widespread attention."

( Cai, J; Cui, H; Gao, Y; Li, J; Li, K; Liu, S; Liu, Z; Shi, M; Wang, J; Zhang, Q, 2022)

"The majority of breast cancer patients is treated with breast-conserving surgery (BCS) combined with adjuvant radiation therapy."

( Basilion, JP; Bijlstra, OD; Burggraaf, J; Fallert, LC; Hilling, DE; Kuppen, PJK; Linders, DGJ; March, TL; Pool, M; Straight, B; Vahrmeijer, AL; Valentijn, ARPM; Walker, E, 2023)

"Drug repurposing opens new avenues in cancer therapy."

( Chandrasekaran, J; Elumalai, S; Kunjiappan, S; Murugesan, V; Pavadai, P; Theivendren, P, 2023)

"Anticoagulant treatment of pediatric cancer-associated venous thromboembolism (VTE) has not been prospectively evaluated."

( Brandão, LR; Hooimeijer, HL; Kenet, G; Kubitza, D; Lensing, AWA; Majumder, M; Male, C; Monagle, P; Palumbo, JS; Pap, AF; Prins, MH; Thelen, K; van Ommen, H; Willmann, S, 2022)

"DSF plays an important role in cancer treatment."

( Guo, Y; Li, Y; Shen, JW; Shen, Q; Sun, J; Sun, Y; Wei, Q; Xu, L, 2022)

"The growth of human cancer cell lines, including HeLa cells, are suppressed by lidocaine treatment."

( Haraguchi-Suzuki, K; Kawabata-Iwakawa, R; Saito, S; Suto, T; Suzuki, T; Takazawa, T, 2022)

"Evaluation of cancer therapy with imaging is crucial as a surrogate marker of effectiveness and survival."

( Endoh, H; Kaira, K; Oriuchi, N, 2022)

"Many cancer patients undergo non-gated chest computed tomography (NCCT) for cancer staging prior to treatment."

( Blaes, A; Brown, R; Chen, KA; Connett, J; Cullen, R; Gu, C; Hooks, M; Maganti, T; Nijjar, PS; Sandhu, G; Shenoy, C; Velangi, PS; Wang, M; Wiederin, J, 2022)

"Immunotherapeutic efficacy of tumors based on immune checkpoint blockade (ICB) therapy is frequently limited by an immunosuppressive tumor microenvironment and cross-reactivity with normal tissues."

( Dutta, D; Ge, Z; Japir, AAMM; Li, X; Lu, N; Zhou, Q, 2022)

"Therefore, cancer-specific medications seem to be the most desired and safe therapy."

( Kleczkowska, P; Laskowska, AK, 2022)

"STATEMENT OF SIGNIFICANCE: Cancer stem cells (CSCs), as an important part of tumor heterogeneity, can survive against conventional chemotherapy and initiate tumorigenesis, recurrence, and metastasis."

( Cui, Y; Fan, Y; Liang, J; Sun, Y; Tong, L; Xu, R; Yang, Y; Zhang, X; Zhao, M, 2022)

"The anticancer treatment is largely affected by the microenvironment of the tumors, which not only resists the tumors to the thermo/chemo-therapy, but also promotes their growth and invasion."

( Chen, Y; He, D; Zhang, Y; Zhang, Z; Zhu, J, 2022)

"Presently, the biggest hurdle to cancer therapy is the inevitable emergence of drug resistance."

( Fan, X; Fei, W; Li, C; Liu, Y; Qin, J; Wu, X; Xu, S; Ye, Y; Zheng, C, 2022)

"We found that treatment of cancer cells with the antitumor agent topotecan (TPT), an inhibitor of topoisomerase I (TOP1), induces DAMP secretion that triggers dendritic cell activation and cytokine production."

( Kitai, Y, 2022)

"Breast cancer is a prevalent female malignancy and tamoxifen remains the first-line treatment for breast cancer, but tamoxifen resistance is a frequent clinical problem."

( Dai, Z; Li, F; Li, M; Liu, J; Wang, B; Zhang, M; Zhang, W; Zhang, X, 2022)

"We aimed to calculate the risk of malignancy in patients with psoriasis who were treated with systemic medications."

( Chang, YT; Chou, YJ; Pan, TY; Wu, CY, 2022)

"Deep-seated tumors of the liver, brain, and other organ systems often recur after initial surgical, chemotherapeutic, radiation, or focal treatments."

( Bischof, JC; Etheridge, ML; Gangwar, L; Gao, Z; Garwood, M; Han, Z; Idiyatullin, D; Jagadeesan, BD; Kantesaria, S; Pasek-Allen, JL; Shao, Q, 2022)

"For many cancer patients, chemotherapy produces untreatable life-long neurologic effects termed chemotherapy-related cognitive impairment (CRCI)."

( Cheong, TC; Chiarle, R; Culhane, AJ; Jang, A; Jones, JK; Kanarek, N; Lehtinen, MK; Petrova, B; Shipley, FB; Wong, ET; Zawadzki, ME, 2022)

"During the combined treatment of tumors, the non-interfering transportation of drugs with different solubilities and the controllable sequential release are the main challenges."

( Cai, J; Gao, L; Gao, Y; Li, J; Li, K; Liu, S; Liu, Z; Shi, M; Yang, Y; Zhang, J; Zhang, Q, 2022)

"Here we review the NAD metabolism as a cancer therapy target."

( Carnero, A; Navas, LE, 2022)

"Today, cancer treatment is an important issue in the medical world due to the challenges and side effects of ongoing treatment procedures."

( Ajalli, N; Díez-Pascual, AM; Navaei-Nigjeh, M; Pourmadadi, M; Rashedi, H; Yazdian, F, 2022)

"Orthotopic HER2+ mammary tumors are established in immune-competent mice, followed by a single administration of lapatinib, a receptor tyrosine kinase inhibitor of HER2, to the mice that induces widespread, transient apoptosis in the tumor microenvironment."

( Werfel, TA, 2022)

"Different treatments, durations and cancer types were the main sources of heterogeneity."

( Bu, X; Chen, H; Fan, R; Li, X; Tan, Y; Wang, T; Yang, S, 2022)

"To assess for OIBD in people with cancer and people receiving palliative care the effectiveness and safety of mu-opioid antagonists (MOAs) versus different doses of MOAs, alternative pharmacological/non-pharmacological interventions, placebo, or no treatment."

( Candy, B; Jones, L; Larkin, PJ; Stone, P; Vickerstaff, V, 2022)

"In addition, patients with cancer-related pain treated with narcotic pain medications are at risk for nonmedical opioid use (NMOU)."

( Ganguly, A; Goschin, S; Harris, K; McFarland, DC; Michael, M, 2022)

"ER+ and ER- breast cancer cell lines were studied to compare their endogenous glucocorticoid activity as well as their metastatic ability in response to Dex treatment."

( Crozier, M; Ferraiuolo, RM; Fifield, BA; Hamm, C; Mailloux, E; Porter, LA; Ritchie, J; Sinha, I; Tubman, J; Zuccato, K, 2022)

"Once cancer cells are generated, TGF-β signaling is responsible for the orchestration of the immunosuppressive tumor microenvironment (TME) and supports cancer growth, invasion, metastasis, recurrence, and therapy resistance."

( Deng, S; Hu, T; Shi, X; Wang, S; Wu, D; Wu, F; Xu, H; Yang, J; Zeng, Q; Zhou, H, 2022)

"Sensitive and accurate detection of cancer cells is of great significance for the early diagnosis and treatment of cancer."

( Dong, M; Jiang, H; Li, J; Wang, JD; Wang, LB; Zhang, YT, 2022)

"Conventional treatments for cancer, such as chemotherapy, surgical resection, and radiotherapy, have shown limited therapeutic efficacy, with severe side effects, lack of targeting and drug resistance for monotherapies, which limit their clinical application."

( Jiang, JL; Li, C; Lin, JF; Shao, JW; Shen, ZC; Wu, PY; Zhang, BC; Zhang, WZ; Zou, JJ, 2022)

"In mice with HER2pos disseminated tumors, repeated administration of [225Ac]Ac-DOTA-2Rs15d significantly prolonged survival (143 days) compared to control groups (56 and 61 days) and to the group treated with HER2-targeting mAb trastuzumab (100 days)."

( Bruchertseifer, F; Caveliers, V; Covens, P; D'Huyvetter, M; Dekempeneer, Y; Lahoutte, T; Miller, BW; Morgenstern, A; Pruszyński, M; Rodak, M; Sevenois, MB; Wojewódzka, M, 2022)

"Conventional cancer treatment is mainly based on the surgical removal of the tumor followed by radiotherapy and/or chemotherapy."

( Kalenik, S; Komorowska, D; Radzik, T; Rodacka, A, 2022)

"The chemotherapy of tumors is frequently limited by the development of resistance and severe side effects."

( Bahramimehr, F; Boulos, JC; Dawood, M; Drif, A; Efferth, T; Khalid, SA; Shahhamzehei, N; Shan, L; Wasfi, M, 2022)

"Nanozymes are promising for precise cancer treatment, but are typically limited in terms of the low catalytic efficiency and the complexity in tumor microenvironment (TME)."

( Ågren, H; Chen, G; Du, J; Fang, X; Gerasimov, V; Jia, T; Li, D, 2022)

"Children with cancer have an increased risk for developing a venous thromboembolism (VTE) during their treatment course."

( Branchford, B; Liegl, M; Malec, L; Scheuermann, A; Simpson, P, 2023)

"Capacity was built at the spokes for cancer surgery and chemotherapy."

( Alajlani, M; Arvanitis, TN; Kommu, RS; Kumar, A; Kunnambath, R; Kuriakose, MA; Oswal, K; Pathak, S; Pradhan, A; Ramachandran, V; Rao, S; Rengaswamy, S; Sarvepalli, BK; Sharma, M, 2022)

"Malignant tumors of the eye can be successfully treated with radiotherapy, which, however, can lead to radiogenic side effects in the surrounding healthy tissues."

( Chronopoulos, A; Cremers, F; Grisanti, S; Kakkassery, V; Klassen, AM; Lüken, S; Rades, D; Ranjbar, M; Rommel, F; Zimbelmann, M, 2022)

"Photodynamic therapy (PDT) for cancer treatment has garnered tremendous attention with its promising non-invasiveness, low side effects, and spatiotemporal selectivity."

( Banerjee, S; Huang, H; Kumar, A; Wei, L; Zhang, Z, 2022)

"Several risk factors for insomnia in cancer patients have been recognized, including chronic pain and treatment with opioid."

( Akui, C; Hirose, M; Kimura, T, 2022)

"Non-inflamed tumors, including immune-excluded and immune-desert tumors, are commonly resistant to anti-PD-1/PD-L1 (α-PD-1/PD-L1) therapy."

( Chu, Q; Ge, H; Jiao, D; Niu, M; Wu, K; Wu, Y; Yan, Y; Yi, M; Zhang, J; Zhou, P; Zhu, S, 2022)

"Nanotechnology has been widely used in cancer treatment but only a small fraction (0."

( He, Z; Qi, W; Su, R; Wang, Y; Yan, X; You, S; Zhang, C; Zhang, J; Zhou, Y, 2022)

"From a total of 1318 patients with cancer who started anti-PD-1 treatment 8 cases and 16 controls were studied in this nested case-control study."

( Aerts, JGJV; Basak, EA; Bins, S; Chaker, L; de Joode, K; Feelders, RA; Joosse, A; Koolen, SLW; Mathijssen, RHJ; Oomen-de Hoop, E; Schreurs, MWJ; Uyl, TJJ; van den Berg, SAA; van der Leest, CH; van der Veldt, AAM; van der Wal, R, 2022)

"Although many types of cancers can be treated with surgery, alternatives such as photodynamic therapy with simultaneous use of photosensitive materials and illumination can also be used."

( Beigzadeh, AM; Ranjbar, S; Sharif, S; Vaziri, MRR, 2022)

"The creation of novel anticancer treatments for a variety of human illnesses, including different malignancies and dangerous microbes, also potentially depends on nanoparticles including silver."

( Anwer, ST; Fantoukh, OI; Imtiyaz, K; Khan, B; Mobashir, M; Naqvi, IH; Rizvi, MMA, 2022)

"HBsAg-positive cancer patients treated with ETV (n = 582), TDF (n = 200) and TAF (n = 188) during chemotherapy were retrospectively enrolled."

( Chao, Y; Hou, MC; Huang, YH; Lan, KH; Lee, IC; Li, CP; Lin, HC; Su, CW, 2022)

"Great advances in cancer treatment have been undertaken in the last years as a consequence of the development of new antitumoral drugs able to target cancer cells with decreasing side effects and a better understanding of the behavior of neoplastic cells during invasion and metastasis."

( De Lama-Odría, MDC; Del Valle, LJ; Puiggalí, J, 2022)

"When compared to normal cells, cancer cells have higher levels of ROS, and they are responsible for the maintenance of the cancer phenotype; this unique feature in cancer cells may, therefore, be exploited for targeted therapy."

( Al Azad, S; Bibi, S; Biswas, P; Biswas, PK; Chun, J; Dey, D; Hasan, MM; Hasan, MN; Khan, DA; Kim, B; Lily, NJ; Parvez, A; Rahaman, TI; Rahman, MA; Rahmatullah, M; Saha, K; Saha, S; Sohel, M, 2022)

"Cancer therapy through anticancer drugs and radiotherapy is associated with several side effects as well as tumor resistance to therapy."

( Amini, P; Dakkali, MS; Jafarzadeh, E; Johari, R; Khani, A; Khodamoradi, E; Moazamiyanfar, R; Mouludi, K; Najafi, M; Taeb, S, 2023)

"Patients diagnosed with cancer often experience pain during their treatment course, making it difficult to care for themselves and continue with their activities of daily living."

( Amatya, S; Cornett, EM; Cruz-Topete, D; Kaye, AD; Kelkar, N; Rosa, CM; Tran, A; Urits, I; Virgen, CG; Viswanath, O, 2022)

"The number of persons who have survived cancer has been increasing in India as elsewhere due to advances in detection and treatment of this disease."

( Dilip, TR; Guntupalli, AM; Maclennan, SJ; Selvamani, Y, 2022)

"Middle-aged and older cancer survivors, particularly those who underwent cancer diagnosis or treatment in the past 2 years, are at a significantly higher risk of experiencing poor self-reported health and other health challenges, suggesting the need for an integrated healthcare approach."

( Dilip, TR; Guntupalli, AM; Maclennan, SJ; Selvamani, Y, 2022)

"The breast cancer mouse models receiving combined therapy lived longer with higher average body weight and smaller tumor sizes."

( Ebrahimi, SO; Haji Ghasem Kashani, M; Hosseini, SS; Reiisi, S, 2023)

"Patients with cancer pain who were treated with opioids often have sensory abnormalities presented with reduced pain threshold and increased sensitivity to nociceptive stimuli."

( Li, BL; Li, HX; Wang, TH; Yan, T; Zheng, H, 2022)

"The translation of nanoparticles in cancer treatment is limited by their low drug-loading capacity, poor colloidal stability, insufficient tumor penetration, and uncontrolled drug release."

( Cui, H; Dai, P; Gao, J; Li, J; Li, K; Liu, Y; Mo, G; Sun, J; Zhang, Y; Zheng, K; Zhou, D; Zhou, Z, 2022)

"Arginine auxotrophic tumors are great candidates for arginine-starvation therapy."

( Hlozkova, K; Safrhansova, L; Starkova, J, 2022)

"In addition, the anticancer effects of fasting/FMD can also be tumor-independent and involve an immunotherapy-like activation of T cell-dependent attack of tumor cells."

( Di Tano, M; Longo, VD, 2022)

"Treatment of drug-resistant forms of cancer requires consideration of their hallmark features, such as abnormal cell death mechanisms or mutations in drug-responding molecular pathways."

( Agadzhanian, N; Dukhinova, M; Fedorov, V; Li, G; Shevtsov, M; Sun, Y; Tsymbal, S; Zhang, J, 2022)

"Photodynamic therapy (PDT)-mediated cancer immunotherapy is attenuated due to the dysfunction of T cells in immunosuppressive tumor microenvironment (TME)."

( Li, Y; Liu, X; Sun, X; Wang, D; Wang, J; Yi, W; Zhao, Z, 2023)

"Rapid, efficient, and precise cancer therapy is highly desired."

( Deng, CX; Guo, D; Lei, JH; Qu, S; Rong, D; Shen, HM; Tang, Z; Zhang, B; Zhang, T, 2022)

"Photoimmunotherapy is attractive for cancer treatment due to its spatial controllability and sustained responses."

( Hao, L; Liang, JH; Ling, YY; Mao, ZW; Tan, CP; Wang, WJ; Wu, XW; Zhang, H, 2022)

"Survivors of childhood cancer treated on contemporary treatment protocols have a significantly lower side-effect profile."

( Banavali, SD; Chinnaswamy, G; Goswami, S; Kurkure, PA; Prasad, M, 2022)

"We have demonstrated their anticancer properties both in vitro and in vivo comparing the results obtained with the administration of equivalent amounts of cisplatin, and showing a spectacular reduction of toxicity."

( Lujan, L; Martín-Duque, P; Martín-Pardillos, A; Sancho-Albero, M; Santamaria, J; Sebastian, V, 2022)

"This review hopes to generate new cancer therapy ideas and overcome drug resistance by modulating iron-sulfur clusters."

( Gu, Z; Le, Y; Liu, Z; Zhang, M; Zhao, H, 2022)

"Besides, as a local cancer treatment modality, PTT fails to inhibit metastasis of tumors."

( Lin, HH; Liu, JY; Wang, S; Wen, LF; Xu, G; Yang, XZ, 2023)

"Many cancer patients undergoing treatment experience cancer-related fatigue (CRF)."

( Danesi, CP; Dillon, EL; Durham, WJ; McGovern, KA; Randolph, KM; Sheffield-Moore, M; Urban, RJ; Wright, TJ, 2022)

"In addition to decreasing the risk of cancers, maintaining a healthy body mass index (BMI)/body weight and/or blood glucose levels within the normal range critically impacts the response to anti-cancer therapy among affected individuals."

( Büsselberg, D; Kubatka, P; Samuel, SM; Varghese, E, 2022)

"As hypoxic tumors show resistance to several clinical treatments, photosynthetic microorganisms have been recently suggested as a promising safe alternative for oxygenating the tumor microenvironment."

( Egaña, JT; Holmes, C; San Martín, S; Varas, J, 2022)

"SLs continue to be at the forefront of cancer drug discovery and are worth a joint interdisciplinary effort in order to leverage their potential in cancer therapy and prevention."

( Cheikh, IA; Darwiche, N; El-Baba, C; Ghantous, A; Saliba, NA; Youssef, A, 2022)

"Improving outcomes for cancer patients during treatment and monitoring for cancer recurrence requires personalized care which can only be achieved through regular surveillance for biomarkers."

( Cossins, LR; Greene, GW; Kapsa, RMI; Langley, DP; M Silva, S; Moulton, SE; Quigley, AF; Samudra, AN; Tothill, RW, 2022)

"It is verified that pretreatment of tumors with DXM can increase intratumorally micro-vessel density (delivery "unlocking") to enhance the tumor delivery efficiency of ZnPc@FOM-Pt and decrease HIF-1α expression."

( Cao, Y; Hao, JN; Jia, X; Jiang, C; Li, X; Li, Y; Mao, Y; Yang, Y; Zhang, P, 2023)

"Patients with advanced solid tumors were enrolled into dose-escalation cohorts and treated in 28-day cycles with oral SRA737 on days 2, 3, 9, 10, 16, and 17, and intravenous gemcitabine on days 1, 8, and 15."

( Anthoney, A; Arkenau, T; Banerji, U; Blagden, S; Carter, L; Garralda, E; Jones, R; Klencke, BJ; Kowalski, MM; Kristeleit, R; Moreno, V; Plummer, R; Roda, D; Roxburgh, P; Sarker, D; Walter, HS, 2023)

"In vivo imaging-guided PTT to A549 cancer shows precise treatment with little harm to normal cells, and PANI-Gel/Cu assemblies can disassemble into tiny particles (<15 nm) under laser irradiation."

( Gao, F; Li, JW; Si, QK; Wang, JY; Wang, LP; Xu, J; Zhang, F; Zhou, Y, 2022)

"In vivo imaging-guided PTT to A549 cancer shows precise treatment with little harm to normal cells, and PANI-Gel/Cu assemblies can disassemble into tiny particles (<15 nm) under laser irradiation."

( Gao, F; Li, JW; Si, QK; Wang, JY; Wang, LP; Xu, J; Zhang, F; Zhou, Y, 2022)

"In vivo imaging-guided PTT to A549 cancer shows precise treatment with little harm to normal cells, and PANI-Gel/Cu assemblies can disassemble into tiny particles (<15 nm) under laser irradiation."

( Gao, F; Li, JW; Si, QK; Wang, JY; Wang, LP; Xu, J; Zhang, F; Zhou, Y, 2022)

"MVBL sensitized MDA-MB-231 breast cancer cells to PTX, indicating that it can be used as an adjuvant to enhance the therapeutic effect of chemotherapy drugs."

( Cheng, Y; Deng, X; Jia, L; Li, S; Lian, S; Lu, Y; Wang, J; Zhai, S, 2022)

"MVBL may be used as an adjuvant drug in cancer therapy for improving the survival and quality of life of cancer patients."

( Cheng, Y; Deng, X; Jia, L; Li, S; Lian, S; Lu, Y; Wang, J; Zhai, S, 2022)

"MVBL sensitized MDA-MB-231 breast cancer cells to PTX, indicating that it can be used as an adjuvant to enhance the therapeutic effect of chemotherapy drugs."

( Cheng, Y; Deng, X; Jia, L; Li, S; Lian, S; Lu, Y; Wang, J; Zhai, S, 2022)

"MVBL may be used as an adjuvant drug in cancer therapy for improving the survival and quality of life of cancer patients."

( Cheng, Y; Deng, X; Jia, L; Li, S; Lian, S; Lu, Y; Wang, J; Zhai, S, 2022)

"MVBL sensitized MDA-MB-231 breast cancer cells to PTX, indicating that it can be used as an adjuvant to enhance the therapeutic effect of chemotherapy drugs."

( Cheng, Y; Deng, X; Jia, L; Li, S; Lian, S; Lu, Y; Wang, J; Zhai, S, 2022)

"MVBL may be used as an adjuvant drug in cancer therapy for improving the survival and quality of life of cancer patients."

( Cheng, Y; Deng, X; Jia, L; Li, S; Lian, S; Lu, Y; Wang, J; Zhai, S, 2022)

"Rapid and accurate detection of cancer and neurological diseases is a major issue that has received great attention recently to enable early therapy treatment."

( Chen, YY; Chiang, WH; Fedotov, PV; Kurniawan, D; Mousavi, SM; Obraztsova, ED, 2022)

"Rapid and accurate detection of cancer and neurological diseases is a major issue that has received great attention recently to enable early therapy treatment."

( Chen, YY; Chiang, WH; Fedotov, PV; Kurniawan, D; Mousavi, SM; Obraztsova, ED, 2022)

"Rapid and accurate detection of cancer and neurological diseases is a major issue that has received great attention recently to enable early therapy treatment."

( Chen, YY; Chiang, WH; Fedotov, PV; Kurniawan, D; Mousavi, SM; Obraztsova, ED, 2022)

"This study of NSCLC patients with cancer cachexia revealed consistent improvements in LBM, body weight, and appetite across most subgroups of anamorelin-treated patients."

( Komura, N; Naito, T; Takayama, K; Takiguchi, T, 2023)

"This study of NSCLC patients with cancer cachexia revealed consistent improvements in LBM, body weight, and appetite across most subgroups of anamorelin-treated patients."

( Komura, N; Naito, T; Takayama, K; Takiguchi, T, 2023)

"This study of NSCLC patients with cancer cachexia revealed consistent improvements in LBM, body weight, and appetite across most subgroups of anamorelin-treated patients."

( Komura, N; Naito, T; Takayama, K; Takiguchi, T, 2023)

"Herein, we construct a cancer cell-selective biomimetic metal-organic framework (MOF)-F platform for prodrug activation and enhanced synergistic chemodynamic therapy (CDT)."

( Liu, C; Liu, Z; Qu, X; Ren, J; Zhang, W; Zhao, C; Zhu, J, 2022)

"Herein, we construct a cancer cell-selective biomimetic metal-organic framework (MOF)-F platform for prodrug activation and enhanced synergistic chemodynamic therapy (CDT)."

( Liu, C; Liu, Z; Qu, X; Ren, J; Zhang, W; Zhao, C; Zhu, J, 2022)

"Herein, we construct a cancer cell-selective biomimetic metal-organic framework (MOF)-F platform for prodrug activation and enhanced synergistic chemodynamic therapy (CDT)."

( Liu, C; Liu, Z; Qu, X; Ren, J; Zhang, W; Zhao, C; Zhu, J, 2022)

"These studies reveal that cancer cells exploit collagen-consuming stromal cells for survival, exposing an important vulnerability across solid tumors with implications for developing improved anticancer therapy."

( Bajgain, P; Cuttitta, F; Dimitrov, DS; Dunleavey, JM; Emenaker, NJ; Feng, Y; Hilton, MB; Hsu, KS; Koogle, R; Lutz, EM; Morris, K; Rose, J; Saha, S; Seaman, S; St Croix, B; Szot, C; Tessarollo, L; Tomassoni-Ardori, F; Yang, L; Zhang, XM; Zhu, Z; Zudaire, E, 2022)

"Biomimetics plays an important role in cancer treatment since it can prolong the circulation of nanoparticles, enhance their delivery and retention in target tissues, and reduce the systemic toxicity of drugs and their carriers."

( Li, M; Li, Y; Lin, M; Lin, Y; Liu, Z; Long, H; Wu, C; Zhan, F; Zhang, Z, 2023)

"Combining siRNA and anticancer drugs can give synergistic effects in cancer cells, making them a significant gene-modification tool in cancer therapy."

( Ali, MS; Pogu, SV; Rengan, AK; Thanekar, AM; Yadav, DN, 2022)

"Combining siRNA and anticancer drugs can give synergistic effects in cancer cells, making them a significant gene-modification tool in cancer therapy."

( Ali, MS; Pogu, SV; Rengan, AK; Thanekar, AM; Yadav, DN, 2022)

"Combining siRNA and anticancer drugs can give synergistic effects in cancer cells, making them a significant gene-modification tool in cancer therapy."

( Ali, MS; Pogu, SV; Rengan, AK; Thanekar, AM; Yadav, DN, 2022)

"Photoactivatable cancer therapy has the significant advantage of a high spatiotemporal resolution, but most photoactivatable prodrugs require decoration with stoichiometric photocleavable groups, which are only responsive to ultraviolet irradiation and suffer from low reaction efficiency."

( Gao, M; Ling, X; Luo, G; Ma, L; Mazzone, G; Scoditti, S; Shao, H; Sicilia, E; Tang, BZ; Yang, X; Yao, M; Zhou, Z, 2022)

"Nano-immunotherapy improves breast cancer outcomes but not all patients respond and none are cured."

( Cabral, H; Chen, P; Costeas, P; Demetriou, P; Fukushima, S; Georgiou, P; Hashimoto, H; Hiroi, T; Ishii, G; Kataoka, K; Kojima, M; Koumas, L; Martin, JD; Michael, C; Mpekris, F; Nakagawa, Y; Panagi, M; Papageorgis, P; Papaphilippou, PC; Pierides, C; Samuel, R; Stylianopoulos, T; Stylianou, A; Voutouri, C, 2022)

"Nano-immunotherapy improves breast cancer outcomes but not all patients respond and none are cured."

"Oral cancer, one of the most common cancers, has unimproved 5-years survival rate in the last 30 years and the chemo/radiotherapy-associated morbidity."

( Awaad, AK; Essawy, MM; Mohamed, MM; Rafik, ST; Ramadan, OR; Raslan, HS, 2022)

"Oral cancer, one of the most common cancers, has unimproved 5-years survival rate in the last 30 years and the chemo/radiotherapy-associated morbidity."

( Awaad, AK; Essawy, MM; Mohamed, MM; Rafik, ST; Ramadan, OR; Raslan, HS, 2022)

"Oral cancer, one of the most common cancers, has unimproved 5-years survival rate in the last 30 years and the chemo/radiotherapy-associated morbidity."

( Awaad, AK; Essawy, MM; Mohamed, MM; Rafik, ST; Ramadan, OR; Raslan, HS, 2022)

"Patients with cancer pain treated with regular doses of nonsteroidal anti-inflammatory drugs or acetaminophen were enrolled and randomized (1:1) into morphine (group M) and oxycodone (group O) groups."

( Chiba, Y; Fujita, Y; Haratani, K; Hayashi, H; Koyama, A; Makimura, C; Matsuoka, H; Nakagawa, K; Nakura, M; Nishio, K; Ohtake, Y; Okuno, T; Sakai, K; Sakamoto, R; Takeda, M; Takegawa, N; Tanaka, K; Tsurutani, J; Yoshida, T, 2023)

"There is a need to readdress cancer therapy and include therapeutic strategies targeting multifactorial processes, including the application of multi-targeting drugs involving iron chelators and iron-chelator complexes."

( Kontoghiorghes, GJ, 2022)

"Finding the right combination of anticancer drugs and near-infrared (NIR) fluorophores is the key to targeted photothermal cancer treatment."

( Hyun, H; Jo, G; Kim, EJ; Park, MH, 2022)

"Finding the right combination of anticancer drugs and near-infrared (NIR) fluorophores is the key to targeted photothermal cancer treatment."

( Hyun, H; Jo, G; Kim, EJ; Park, MH, 2022)

"Finding the right combination of anticancer drugs and near-infrared (NIR) fluorophores is the key to targeted photothermal cancer treatment."

( Hyun, H; Jo, G; Kim, EJ; Park, MH, 2022)

"Platinum (Pt) resistance in cancer almost inevitably occurs during clinical Pt-based chemotherapy."

( Fang, C; Gu, H; Hu, X; Lee, J; Li, F; Ling, D; Ren, J; Sun, H; Zhang, B, 2022)

"Platinum (Pt) resistance in cancer almost inevitably occurs during clinical Pt-based chemotherapy."

( Fang, C; Gu, H; Hu, X; Lee, J; Li, F; Ling, D; Ren, J; Sun, H; Zhang, B, 2022)

"To uncover the effects of statins on cancer cells in vitro, we performed transcriptome and metabolome analyses on atorvastatin-treated statin-resistant and statin-sensitive lung cancer cells."

( Irie, N; Oltvai, ZN; Sugiura, A; Tashiro, J; Warita, K; Warita, T; Zhou, Y, 2023)

"To uncover the effects of statins on cancer cells in vitro, we performed transcriptome and metabolome analyses on atorvastatin-treated statin-resistant and statin-sensitive lung cancer cells."

( Irie, N; Oltvai, ZN; Sugiura, A; Tashiro, J; Warita, K; Warita, T; Zhou, Y, 2023)

"P2Y12R is involved in platelet-cancer cell crosstalk and become a potential target for anticancer therapy."

( Hu, JL; Zhang, WJ, 2023)

"P2Y12R is involved in platelet-cancer cell crosstalk and become a potential target for anticancer therapy."

( Hu, JL; Zhang, WJ, 2023)

"These nanoparticles have been used for cancer diagnosis and cancer treatments recently."

( Patil, SM; Tandon, N; Tandon, R, 2022)

"These nanoparticles have been used for cancer diagnosis and cancer treatments recently."

( Patil, SM; Tandon, N; Tandon, R, 2022)

"SMKI treatment in diabetic cancer patients reveals that certain SMKIs improve blood glucose levels and can mitigate insulin dependence or diabetic medication requirements in both type 1 diabetes (T1D) and type 2 diabetes (T2D)."

( Chan, DY; Duggan, BM; Marko, DM; Muzaffar, R; Schertzer, JD, 2023)

"Lung, prostate, and esophageal cancer persister cells remaining after treatments exhibited several hallmarks indicative of pyroptosis resistance."

( Berglund, A; Brown, J; El-Kenawi, A; Estrella, V; Gatenby, R; Johnson, J; Liu, M; Putney, RM; Yoder, SJ; Zhang, Y, 2023)

"Lung, prostate, and esophageal cancer persister cells remaining after treatments exhibited several hallmarks indicative of pyroptosis resistance."

( Berglund, A; Brown, J; El-Kenawi, A; Estrella, V; Gatenby, R; Johnson, J; Liu, M; Putney, RM; Yoder, SJ; Zhang, Y, 2023)

"The development of effective anticancer drugs is essential for chemotherapy that specifically targets cancer tissues."

( Fang, J; Harada, A; Islam, W; Niidome, T; Ono, K; Sawa, T; Shinozaki, K; Tsutsuki, H, 2022)

"The development of effective anticancer drugs is essential for chemotherapy that specifically targets cancer tissues."

( Fang, J; Harada, A; Islam, W; Niidome, T; Ono, K; Sawa, T; Shinozaki, K; Tsutsuki, H, 2022)

"Despite the arsenal of existing cancer therapies, the ongoing recurrence and new cases of cancer pose a serious health concern that necessitates the development of new and effective treatments."

( Charoenkwan, P; Hasan, MM; Lio', P; Moni, MA; Nantasenamat, C; Pipattanaboon, C; Shoombuatong, W, 2023)

"Despite the arsenal of existing cancer therapies, the ongoing recurrence and new cases of cancer pose a serious health concern that necessitates the development of new and effective treatments."

( Charoenkwan, P; Hasan, MM; Lio', P; Moni, MA; Nantasenamat, C; Pipattanaboon, C; Shoombuatong, W, 2023)

"Over half of cancer patients are subjected to radiotherapy, but owing to the deficient amount of reactive oxygen radicals (ROS) and DNA double-strand breaks (DSBs), a fair number of them suffer from radiotherapy resistance and the subsequent short-term survival opportunity."

( Chen, Y; Gao, C; Gao, Z; Gong, L; Han, S; Lu, Y; Ma, F; Ma, J; Tang, H; Wang, J; Xiao, W; Yan, J; Zhao, J, 2023)

"The need for innovative anticancer treatments with high effectiveness and low toxicity is urgent due to the development of malignancies that are resistant to chemotherapeutic agents and the poor specificity of existing anticancer treatments."

( Abdelhamid, IA; El-Shorbagy, HM; Ibrahim, SA; Sabet, S; WalyEldeen, AA, 2023)

"Rare subpopulations of cancer stem cells (CSCs) have the ability to self-renew and are the primary driving force behind cancer metastatic dissemination and the preeminent hurdle to cancer treatment."

( Chuang, YC; Kao, TW; Kuo, CC; Lee, HL; Shen, YA, 2022)

"Delivery of chemotherapeutics to cancer cells using polymeric micelles is a promising strategy for cancer treatment."

( Cheng, C; Mohamed, MA; Prasad, PN; Singh, A, 2022)

"Delivery of chemotherapeutics to cancer cells using polymeric micelles is a promising strategy for cancer treatment."

( Cheng, C; Mohamed, MA; Prasad, PN; Singh, A, 2022)

"Enhanced mechanical destruction of cancer cells via PMNs is confirmed both in vitro and in vivo under photomagnetic treatment."

( Cheng, Q; Cheng, Y; He, B; Li, J; Li, Y; Li, Z; Liu, Y; Lv, C; Ning, P; Shen, Y; Shi, Z; Tong, Y; Xu, C; Zhang, W; Zhou, R, 2023)

"Enhanced mechanical destruction of cancer cells via PMNs is confirmed both in vitro and in vivo under photomagnetic treatment."

( Cheng, Q; Cheng, Y; He, B; Li, J; Li, Y; Li, Z; Liu, Y; Lv, C; Ning, P; Shen, Y; Shi, Z; Tong, Y; Xu, C; Zhang, W; Zhou, R, 2023)

"Drug-resistant cancers exhibit complex molecular mechanisms to hit back therapy under pharmacological pressure."

( Dang, Q; Han, X; Li, H; Liu, L; Liu, Z; Lv, J; Xu, H; Zhang, Y; Zhou, Z; Zou, H, 2022)

"Drug-resistant cancers exhibit complex molecular mechanisms to hit back therapy under pharmacological pressure."

( Dang, Q; Han, X; Li, H; Liu, L; Liu, Z; Lv, J; Xu, H; Zhang, Y; Zhou, Z; Zou, H, 2022)

"Conventional cancer treatments like chemotherapy, radiotherapy, and surgery are associated with drug poisoning and poor prognosis."

( Ahmadifard, M; Fatemi, S; Kamali, MJ; Khoshghiafeh, A; Moradi, F; Salehi, M, 2023)

"Conventional cancer treatments like chemotherapy, radiotherapy, and surgery are associated with drug poisoning and poor prognosis."

( Ahmadifard, M; Fatemi, S; Kamali, MJ; Khoshghiafeh, A; Moradi, F; Salehi, M, 2023)

"Patients with cancer referred to an integrative oncology clinic use large numbers of DS with the potential for adverse effects and/or decreasing efficacy of treatments."

( Bauer, BA; Burckhard, JL; D'Andre, SD; Hofmann, MB; Loprinzi, CL; Montane, HN, 2022)

"Patients with cancer referred to an integrative oncology clinic use large numbers of DS with the potential for adverse effects and/or decreasing efficacy of treatments."

( Bauer, BA; Burckhard, JL; D'Andre, SD; Hofmann, MB; Loprinzi, CL; Montane, HN, 2022)

"To develop a next-generation anticancer metal-based drug, realize the multi-targeted combination therapy of protein drug and metal-based drug for cancer, solve their co-delivery challenges, and improve their in vivo targeting ability, we proposed to develop a multi-targeted anticancer metal-based agent exploiting the properties of the tumor microenvironment (TME) and of lactoferrin (LF)."

( Li, W; Li, Y; Liang, H; Yang, F; Yang, T; Zhang, J; Zhang, Z, 2023)

"This effect leads to the paradox that cancer treatment can rescue cells that were destined to die in the untreated tumour."

( Gordon Steel, G; Tannock, IF, 2023)

"Chemodynamic therapy (CDT) is a novel cancer therapeutic strategy."

( Duan, J; Kuang, Y; Li, C; Liao, T; Liu, Y; Xu, X, 2023)

"Prespecified on-treatment analyses for cancer-related AEs appeared to result in biased risk estimates in ASCEND-ND by preferentially under-counting events from patients assigned to darbepoetin."

( Atkins, MB; Barker, T; Blackorby, A; Carroll, K; Claggett, BL; Cobitz, AR; DiMino, T; Mallett, S; McCausland, FR; McMurray, JJV; Meadowcroft, A; Perkovic, V; Singh, AK; Snapinn, S; Solomon, SD; Wanner, C; Wiecek, A; Wittes, J, 2023)

"Local re-occurrence of cancer in patients with solid tumors is currently the most common reason for failure of treatment strategies."

( Chelvam, V; Krishnan, MA; Yadav, K, 2022)

"To examine the risk of cancer among people treated with ranitidine, we conducted a cohort study using the National Health Insurance Service-National Sample Cohort data (2002-2015) of South Korea."

( Cho, SI; Hwang, JE; Joung, KI; Oh, IS; Shin, JY, 2022)

"For treatment of MDR cancer, this study also proposed PCN-223-Fe loaded with an anticancer drug, irinotecan (CPT-11; i."

( Choy, YB; Han, JH; Ji, HB; Kim, CR; Kim, MJ; Kim, SN; Lee, C; Min, CH, 2023)

"Patients (n = 115) with cancer stages II-III, T2-3N0-1M0 were managed with comprehensiveconservative treatment."

( Baranovska, LM; Domina, EA; Glavin, OA; Ivankova, VS; Khrulenko, TV, 2022)

"Various cancer cells overexpress L-type amino acid transporter 1 (LAT1) to take up a large number of neutral amino acids such as phenylalanine and methionine, and LAT1 transporter should be a promising target for cancer diagnosis and therapy."

( Guo, H; Honda, Y; Kanamori, K; Matsui, M; Nishiyama, N; Nomoto, T; Takemoto, H; Voon, YM; Xu, W; Yamada, N, 2023)

"Among cancer survivors who have completed curative-intent treatment, the high prevalence and adverse consequences of chronic pain are well documented."

( Check, DK; Dinan, MA; Dunbar, TK; Farley, S; Fish, LJ; Jones, KF; Ma, J; Merlin, JS; O'Regan, A; Oeffinger, KC, 2023)

"Although new strategies for breast cancer treatment have yielded promising results, most drugs can lead to serious side effects when applied systemically."

( Cavalcante, RS; Cruz, LJ; de Araújo Júnior, RF; Eich, C; Gu, Z; He, Y; Schomann, T; Yu, Z, 2023)

"Terminal cancer patients already receiving opioid treatment participated in the 3-day study."

( Chen, YY; Chiu, GL; Huang, YT; Lai, WS; Lin, PC; Liu, IT; Su, PF; Tsai, JH, 2023)

"Despite the remarkable progress in cancer treatment up to now, we are still far from conquering the disease."

( Chae, HS; Hong, ST, 2022)

"Multidrug resistance (MDR) in cancer is one of the major obstacles of chemotherapy."

( Enyedy, ÉA; Kovács, H; May, NV; Nezafat Yazdi, Z; Özvegy-Laczka, C; Pivarcsik, T; Pósa, SP; Pósa, V; Spengler, G; Szakács, G; Szatmári, I; Tóth, S; Ugrai, I, 2022)

"The fact that cancer is one of the leading causes of death requires researchers to create new systems of effective treatment for malignant tumors."

( Abashkin, V; Bryszewska, M; Horodecka, K; Pędziwiatr-Werbicka, E; Shcharbin, D; Shmanai, V; Ulashchik, E; Zhogla, V, 2023)

"Deficiency of MAOA renders cancer cells resistant to ferroptosis upon 5-HT treatment."

( Chai, R; Chu, B; Cui, W; Du, L; Fu, X; Gu, W; Huang, B; Liang, CH; Liu, D; Wang, X; Yang, L; Yang, Y; Yin, C; Zhang, X; Zhang, Y; Zhuang, X, 2023)

"Studies assessing patients with cancer receiving psychedelics for the treatment of anxiety or depression."

( Dalo, J; Weisman, N; White, CM, 2023)

"Concordantly, F1,6P resensitizes cancer cells with chemotherapy resistance, impairs tumor growth and enhances chemosensitivity in mice, and impedes the growth of human tumor organoids."

( Cheng, Y; Duan, B; Fu, Y; Li, Y; Shang, M; Wang, T; Yu, Q; Zhang, K; Zhang, Y; Zhao, Y, 2023)

"Patients with various advanced cancers devoid of nuclear progesterone receptors (nPR) have demonstrated increased quality and length of life when treated with the PR modulator mifepristone, which likely works by interacting with membrane PRs (mPR)."

( Check, DL; Check, JH, 2023)

"The anticancer and antimetastatic effects of M@P-SOP were evaluated on a preclinical transplanted 4T1 tumor model by combining HIFU and immunotherapy."

( Cao, Y; Chen, Q; Cheng, C; Guo, X; He, H; Hu, Y; Li, F; Li, P; Lin, X; Tang, R; Wan, L; Wang, Q; Wu, N; Xiong, X; Zheng, M; Zhou, Y, 2023)

"PGA has superiority for cancer treatment because of its good biocompatibility, low immunogenicity, and modulated pH responsiveness."

( Li, Y; Lu, Y; Song, W; Xu, Y; Zhang, Y, 2024)

"The lack of selectivity of anticancer drugs limits current chemotherapy."

( Josa-Culleré, L; Llebaria, A, 2023)

"Adult patients with various types of cancer treated with apatinib were enrolled."

( Chen, KG; Guo, ZX; Kan, M; Li, Q; Li, Y; Liu, HY; Liu, XL; Shi, JY; Song, LL; van den Anker, J; Yang, XM; Ye, PP; Zhang, YH; Zhao, FR; Zhao, W, 2023)

"Tetraploidy is a hallmark of cancer cells, and tetraploidy-selective cell growth suppression is a potential strategy for targeted cancer therapy."

( Ishida-Ishihara, S; Kawamoto, E; Kuroda, T; Matsuo, K; Matsura, A; Mishra, M; Sakai, R; Sato, F; Shimada, M; Shimada, Y; Tamaoki, N; Uehara, R; Yaguchi, K; Yamamoto, T; Yoshizawa, K, 2023)

"Conventional cancer treatment modalities are often associated with major therapeutic limitations and severe side effects."

( Ali, MS; Hak, A; Rengan, AK; Sankaranarayanan, SA; Shinde, VR, 2023)

"The poor cancer immunotherapy outcome has been closely related to immunosuppressive tumor microenvironment (TME), which usually inactivates the antitumor immune cells and leads to immune tolerance."

( Hu, J; Jia, Y; Li, Z; Liu, R; Yang, X; Zeng, L; Zhang, L; Zhu, C, 2023)

"TMA related to cancer drugs disrupts the antineoplastic treatment course, increasing the risk of cancer progression."

( Aklilu, AM; Shirali, AC, 2023)

"Cancers, especially CNS tumors, and severe hematological disorders can affect spermatogonial quantity in prepubertal boys before treatment."

( Feijen, EAM; Goossens, E; Jahnukainen, K; Kremer, LMC; Masliukaite, I; Meissner, A; Ntemou, E; Repping, S; Soufan, AT; van de Wetering, M; van Pelt, AMM, 2023)

"The efficacy of cancer catalytic therapy is still hindered by the inefficient generation of reactive oxygen species (ROS)."

( Hu, Q; Jiang, Z; Li, L; Liu, Z; Tang, C; Wan, X; Wang, S; Yao, S; Zhao, Y; Zheng, M, 2023)

"The response of tumors to cisplatin treatment involves multiple physiological processes, and the efficacy of chemotherapy is limited by the intrinsic and acquired resistance of tumor cells."

( Han, B; Yue, P; Zhao, Y, 2023)

"In the p53 mutant breast cancer cell line MDA-MB-231, we show that Dox treatment significantly increases SK1 protein and S1P."

( Bonica, J; Clarke, CJ; Hannun, YA; Luberto, C; Obeid, LM, 2023)

"Tumor hypoxia drives resistance to many cancer therapies, including radiotherapy and chemotherapy."

( Bi, J; Bowman, KR; Boyce, H; Byrne, JD; Cook, AN; Dodd, RD; Feig, VR; Gutierrez, WR; Henry, MD; Mailloux, A; McGovern, M; Muller, BN; Otterbein, LE; Panchal, H; Ramos, AR; Rhodes, AC; Rytlewski, JD; Smith, MG; Traverso, G; Venkatachalam, V; Voltarelli, VA; Witt, E, 2023)

"Of 87 eligible cancer patients with neuropathic pain, 39 were recruited (47%), allocated to either the intervention (20 patients, virtual reality pain therapy software programme) or control (19 patients, viewing virtual reality videos)."

( Bogdanovych, A; Chow, H; Chua, W; Chuan, A; Dai, E; Haider, S; Hatty, M; Lan, A; Shelley, M, 2023)

"Due to the low radiation absorption of tumors, a high dose of ionizing radiation is often required during radiotherapy, which causes serious damage to normal tissues near tumors."

( Chen, W; Li, B; Liu, H; Shi, W; Wang, G; Wang, J; Wang, Y; Ye, M, 2023)

"We then emphasize how autophagy and cancer cells interacting with one another is a promising therapeutic target in cancer treatment."

( Islam, M; Kim, B; Parvez, MAK; Rahman, MA; Rahman, MS; Saikat, ASM, 2023)

"However, a lack of selectivity toward cancer cells and associated side effects with current treatment options has fueled continued efforts throughout the world to find better anticancer drugs."

( Rani J, J; Roy, S, 2023)

"Efficient cancer immunotherapy depends on selective targeting of high bioactivity therapeutic agents to the tumours."

( Gong, C; Huang, D; Kou, X; Li, Y; Liu, C; Wang, N; Wang, X; Wu, Q; Wu, X, 2023)

"Currently, cancer treatment mainly consists of surgery, radiotherapy, chemotherapy, immunotherapy, and molecular targeted therapy, of which radiotherapy is one of the major pillars."

( Fan, X; Ge, S; Su, Y; Yu, J; Yu, Y, 2023)

"The resistance of cancer cells to chemotherapeutic drugs greatly reduces the therapeutic effect in cancer patients, and the toxic side effects caused by chemotherapy also seriously affect the quality of life of patients."

( Feng, K; Li, P; Wang, L, 2023)

"The treatment modalities for cancer are various."

( Chai, J; Luan, J; Tian, Y; Wang, Y; Yang, K; Zhu, J, 2023)

"Gene therapy has long been proposed for cancer treatment."

( Alijas, S; Cascallar, M; de la Fuente, M; Gámez-Chiachio, M; Hurtado, P; López López, R; Lores, S; Moreno-Bueno, G; Piñeiro, R; Ramos-Nebot, C, 2023)

"Many types of human cancers are being treated with small molecule ATP-competitive inhibitors targeting the kinase domain of receptor tyrosine kinases."

( Besch, A; Marsiglia, WM; Mohammadi, M; Traaseth, NJ; Zhang, Y, 2023)

"This declining trend of cancer treatment among patients with advanced cancer stage at EoL was consistent among socio-demographic and clinical subgroups."

( Choi, JY; Jho, HJ; Kim, K; Park, B; Park, SJ, 2023)

"These PDTs do not efficiently treat tumors in hypoxic conditions."

( Bythell, BJ; Cimatu, KLA; Erasquin, U; Skelton, E; Sukul, A; White, J; Zuercher, A, 2023)

"During the treatment of cancer, 18% of patients use cannabis for symptom management."

( Alderman, B; Amano, K; Bouleuc, C; Case, AA; Crawford, GB; Davis, M; De Feo, G; Garsed, J; Hui, D; Mukhopadhyay, S; Sbrana, A; Tanco, K; To, J, 2023)

"Nanomedicines have been widely used for cancer therapy, while controlling their activity for effective and safe treatment remains a big challenge."

( Chen, D; Li, W; Liu, C; Su, L; Wang, X; Wu, S; Xu, C; Zhang, C, 2023)

"Electroacupuncture had no effects on cancer pain and its opioid treatment dosage."

( Hou, A; Jin, X; Liu, C; Liu, Y; Liu, Z; Lu, D; Sun, J; Sun, Y; Wang, W; Wang, Y; Yang, X; Yu, J; Yue, Z; Zang, Z; Zhou, K; Zhu, L, 2023)

"To design a proper cancer treatment, it is vital to study the thermal effect induced close to the gold nanoparticles, in the vicinity, and the cancerous tissue."

( Akbarzadeh, A; Etemadi, M; Golmohammadi, S; Rasta, SH, 2023)

"Metal complexes in cancer therapy have attracted much interest mainly because metals exhibit unique characteristics, such as redox activity, metal-ligand interaction, structure and bonding, Lewis acid properties etc."

( Grishina, M; Kumar Singh, A; Kumar, A; Kumar, P; Pal Yadav, J; Pathak, P; Singh, H; Sonawane, P; Verma, A, 2023)

"Interestingly, when treated with 4T1 cancer cells, DOX-encapsulated R-SIP (DR-SIP) induces the phosphorylation of eukaryotic translation initiation factor 2α and overexpression of ecto-calreticulin, resulting in endoplasmic reticulum-associated ICD."

( Dey, A; Jeon, J; Joo, H; Li, Y; Park, JH; Song, SH; Yoon, B, 2023)

"Existence of cancer stem cells (CSCs) are primarily responsible for chemoresistance, cancer reoccurrence and treatment failure in cancer patients."

( Anees, M; Kharbanda, S; Kumar, D; Mehrotra, N; Singh, H; Tiwari, S, 2023)

"Numerous cancer types exhibit overexpression of ErbB1 and ErbB2, which is linked to poor prognosis and causes resistance to ErbB1-targeted therapy."

( Chandrasekar, MJN; Nagarjuna, P; Nanjan, MJ; Patnaik, SK; Swaroop, AK, 2024)

"Here, we design a cancer-motivated upconversion nanomachine (UCNM) based on porous upconversion nanoparticles (p-UCNPs) for precise phototherapy."

( Gao, Y; He, B; Li, W; Luan, X; Pan, Y; Song, Y; Wang, X; Wang, Y; Zeng, F; Zhou, D, 2023)

"Breast cancer tissue samples were obtained before treatment and on Day 15 ± 5 of the first cycle of eribulin treatment."

( Ando, T; Asai, N; Fujii, K; Hayashi, T; Kobayashi, N; Nakano, S; Ushida, K; Utsumi, T, 2023)

"Despite the favorable roles of Qu in cancer therapy due to its numerous impacts on the cell signaling axis, its poor chemical stability and bioavailability, low aqueous solubility as well as short biological half-life have limited its clinical application."

( Aminianfar, A; Asemi, Z; Homayoonfal, M; Yousefi, B, 2024)

"Early cancer diagnoses and treatments have improved cancer survival rates, leading to a larger population of cancer patients and survivors."

( Farquhar-Smith, P; Lewis, CES; Schutzer-Weissmann, J, 2023)

"We present the status of cancer care across the state from the data collected by the investigators through public registries and personal communication to the concerned units to know the distribution of various services across the districts and give probable directives to improve on the present situation with emphasis on radiation therapy."

( Nishchith, VD; Palled, S; Srinivasan, D; Venugopal, B; Vijay, CR; Viswanath, L, 2023)

"Hence, autophagy has been targeted for cancer therapy."

( Hino, H; Hiramoto, M; Kokuba, H; Miyazawa, K; Takano, N; Tokuhisa, M; Yamada, Y, 2023)

"Approximately 18% of patients with cancer use cannabis at one time as palliation or treatment for their cancer."

( Alderman, B; Amano, K; Bouleuc, C; Case, AA; Crawford, GB; Davis, M; de Feo, G; Garsed, J; Hui, D; Mukhopadhyay, S; Sbrana, A; Tanco, K; To, J, 2023)

"Chemotherapy is an integral part of cancer management which is associated with phlebitis in around 70% of patients receiving intravenous chemotherapy infusion."

( Chaudhary, RK; Hegde, NN; Jacob, A; Mateti, UV; Shetty, V; Sudhakar, S, 2023)

"Charts of 12 298 cancer patients (4499 treated with prednisone equivalents) were analysed descriptively."

( Euler, S; Günther, MP; Riemann, PM; Schulze, JB; von Känel, R, 2023)

"We used datasets from the Cancer Cell Line Encyclopedia (CCLE) phase II project and treated metabolomic data as tensor predictors and data on gene expression of metabolic enzymes as confounding covariates."

( Huang, TH; Li, CI; Lin, PC; Shen, MR; Tsai, YS; Yeh, YM, 2023)

"Synthetic anticancer catalysts offer potential for low-dose therapy and the targeting of biochemical pathways in novel ways."

( Bolitho, EM; Bridgewater, HE; Coverdale, JPC; Romero-Canelón, I; Sadler, PJ, 2023)

"The application of nanoarchitectures in cancer therapy seems to be beneficial for the delivery of antitumor drugs."

( Asadi, S; Beiranvand, R; Entezari, M; Ertas, YN; Ettehadi, R; Haratian, N; Hashemi, M; Hushmandi, K; Jebali, A; Karimian, SS; Khorrami, R; Rashidi, M; Saebfar, H; Salimimoghadam, S; Sedghi, B; Taheriazam, A; Yousef Abad, GG; Zandieh, MA, 2023)

"Histopathology of breast tumors revealed better control of tumors in Met pre-treated groups treated with Dox than DMBA control group."

( Patel, PJ; Shah, JS, 2023)

"By directly harming cancer cells, radiotherapy (RT) is a crucial therapeutic approach for the treatment of cancers."

( Cao, L; Chen, K; Geng, H; Huang, Y; Liu, J; Liu, L, 2023)

"In total, 330 patients with incurable cancer, starting with opioids for pain management, will be randomized to treatment with either macrogol/electrolytes or magnesium hydroxide."

( Crul, M; de Graeff, A; de Klerk, G; Kistemaker, KRJ; Steegers, MAH; van de Ven, PM; van der Meulen, MP; van Zuylen, L, 2023)

"Nanoparticle-mediated cancer immunotherapy holds great promise, but more efforts are needed to obtain nanoformulations that result in a full scale activation of innate and adaptive immune components that specifically target the tumors."

( Chu, T; Hesemans, E; Izci, M; Mädler, L; Maksoudian, C; Manshian, BB; Naatz, H; Pokhrel, S; Richter, C; Rios Luci, C; Saffarzadeh, N; Soenen, SJ; Thieme, S; Wang, Y, 2023)

"Conventional cancer treatments no longer meet the needs of the health field due to the high rate of mutations and epigenetic factors that have caused drug resistance in tumor cells."

( Hosseini, SM; Mohammadnejad, J; Najafi-Taher, R; Ramakrishna, S; Tanhaei, M; Zadeh, ZB, 2023)

"In the relentless search for new cancer treatments, organoselenium compounds, and carbonic anhydrase (CA) inhibitors have emerged as promising drug candidates."

( Angeli, A; Astrain-Redin, N; Bonardi, A; Gratteri, P; Paoletti, N; Plano, D; Sanmartin, C; Supuran, CT, 2023)

"Therefore, we present the first anticancer combination of SDT and cuproptosis, which may inspire studies pursuing a rational multimodal treatment strategy."

( Chen, K; Liu, Y; Ning, X; Xu, Y; Zhou, A; Zhou, X, 2023)

"Meanwhile, in drug-resistant tumors, the efflux of anticancer therapeutic drugs via the drug efflux transporters on the plasma membrane of cancer cells can significantly decrease the intracellular drug concentration and lead to the failure of the drug treatment."

( Hao, SJ; Wu, FG; Zhu, YX, 2023)

"Finally, treatment of gold clusters on cancerous cells results in a significant decrease in the viability of irradiated cells to cobalt-60 beam."

( Amini, SM; Dinarvand, R; Jaafari, MR; Kharrazi, S; Rezayat, SM, 2023)

"Advanced cancer patients had different needs beyond receiving medical treatments."

( Cheong, MWL; Hamzah, E; Teoh, SL; Yong, ASJ, 2023)

"4) for ICD-based cancer therapy is constructed."

( Ding, Y; Hu, ZW; Liu, Q; Wang, L; Xie, L; Yang, Z; Zeng, S; Zhang, X; Zhang, Z, 2023)

"The ineffectiveness of traditional cancer therapies due to drug resistance, nontargeted delivery, and chemotherapy-associated adverse side effects has shifted attention to bioactive phytochemicals."

( Ki, JS; Pradhan, B, 2023)

"Drug addiction, a phenomenon where cancer cells paradoxically depend on continuous drug treatment for survival, has uncovered cell signaling mechanisms and cancer codependencies."

( Freedy, AM; Kissler, SM; Kwok, HS; Liau, BB; Morriss, JW; Siegenfeld, AP; Waterbury, AL, 2023)

"In patients with advanced cancer, radiation therapy is considered at various time points in the patient's clinical course from diagnosis to death."

( Johnstone, CA; Yerramilli, D, 2023)

"The effect of monotherapy in cancer is frequently influenced by the tumor's unique hypoxic microenvironment, insufficient drug concentration at the treatment site, and tumour cells' increased drug tolerance."

( Feng, L; Fu, Y; Li, B; Niu, X; Xu, J; Ye, H; Ye, X; You, Z, 2023)

"Older adults with advanced cancer are exposed to antibiotics but estimates of adverse drug events associated with antibiotic therapy are lacking."

( Allore, H; Datta, R; Doyle, M; Han, L; Juthani-Mehta, M; Quagliarello, V; Sanft, T, 2023)

"Breast cancer (BC) was induced in BALB/c mice, and then they received DC vaccine treated with lipopolysaccharide (LPS-mDCs), LPS with a 5 μM dose of CXB (LPS/CXB5-mDCs) and LPS with a 10 μM dose of CXB (LPS/CXB10-mDCs)."

( Ayoobi, F; Basirjafar, P; Gheitasi, M; Jafarzadeh, A; Khorramdelazad, H; Masoumi, J; Safdel, S; Taghipour, Z; Tavakoli, T; Yousefi, S; Zainodini, N; Zandvakili, R, 2023)

"31% of the patients received anticancer treatments within 30 days and 17% within the last 14 day before death."

( Anttonen, A; Hirvonen, O; Leskelä, RL; Nåhls, NS; Saarto, T, 2023)

"Patients with cancer who availed themselves of the spiritual care, psychology, and social work services, each profession in distinct ways, had significantly different outcomes in their EoL medical treatment, including undergoing fewer futile aggressive measures, having more time after their last active treatment, and using hospice services more."

( Bar-Sela, G; Baziliansky, S; Campisi-Pinto, S; Givoli, S; Illouz, S; Katra, D; Mitnik, I; Schultz, M; Ulitzur, N; Zalman, D, 2023)

"Further investigation revealed that cancer-associated fibroblasts (CAF) were the cell type most affected by treatment with canakinumab or gevokizumab in terms of change in gene expression."

( Baum, J; Charette, L; Choi, JE; Cremasco, V; Diwanji, R; Dranoff, G; Grauel, AL; Jayaraman, P; Laszewski, T; Martin, AM; Millholland, JM; Nguyen, B; O'Brien, NA; Pelletier, MR; Piquet, M; Pruteanu-Malinici, I; Rodrik-Outmezguine, V; Ruddy, DA; Sabatos-Peyton, C; Savchenko, A; Wong, CC; Wu, J; Xu, X; Yan, Z, 2023)

"However, IFNγ modulation for cancer therapy is still unsuccessful due to its complex effects on various host cells."

( Duan, X; Li, P; Lou, X; Ni, C; Qin, Z; Wan, J; Wang, L; Wang, R; Yao, X; Zhang, L, 2023)

"Among children on cancer chemotherapy, there was no decrease in the incidence of OM observed with oral zinc at a dose of 1 mg/kg/day."

( Gupta, A; Kumar Gupta, A; Makkar, H; Meena, JP; Pandey, RM; Seth, R; Shah, D; Velpandian, T, 2023)

"The therapy of solid tumors is always hampered by the intrinsic tumor physical microenvironment (TPME) featured with compact and rigid extracellular matrix (ECM) microstructures."

( Hu, L; Liu, T; Pei, P; Shen, W; Xie, Y; Yang, K; Yang, S; Zhang, Y; Zhou, H, 2023)

"Cytotoxicity results on cancer cell strains displayed higher cytotoxicity than complex 1 against treated cancer cells."

( Arjmand, F; Khan, HY; Roisnel, T; Tabassum, S; Zehra, S, 2023)

"The prime cause of cancer is essential for the prevention and diagnosis, yet the effects that influence tumor growth are more important for cancer treatment."

( Menchikov, LG; Popov, AV; Shestov, AA, 2023)

"Chemotherapy remains the mainstay of cancer treatment, and doxorubicin (DOX) is recommended as a first-line chemotherapy drug against cancer."

( Huang, H; Li, M; Li, N; Li, S; Li, T; Liu, Y; Lv, J; Qin, X; Wang, J; Wei, X; Wu, C; Yang, G; Yang, H; Zhang, H; Zhang, W; Zheng, Y, 2023)

"Patients with advanced cancer are prone to develop different opportunistic oral infection due to anti-cancer treatment or the malignancies themselves."

( Enersen, M; Fjeld, KG; Gay, CL; Herlofson, BB; Hove, LH; Kristoffersen, AK; Lerdal, A; Monsen, RE; Nordgarden, H; Tollisen, A, 2023)

"In the treatment of solid tumors, the complex barriers composed of cancer-associated fibroblasts (CAFs) prevent drug delivery and T cells infiltration into tumor tissues."

( Huang, Z; Li, X; Luo, Y; Wang, Y; Wu, J; Zhou, S, 2023)

"Tumor vaccine is a promising cancer treatment modality, however, the convenient antigens loading in vivo and efficient delivery of vaccines to lymph nodes (LNs) still remain a formidable challenge."

( Gao, H; Hu, H; Lei, L; Li, J; Li, Y; Lin, R; Xia, X; Yang, W; Zhang, H; Zhang, Y, 2023)

"Current knowledge of the anticancer effects of myricetin reveals its promise as a potentially bioactive chemical produced from plants for the prevention and treatment of cancer."

( Abdulabbas, HS; Garg, A; Kumar, S; Mishra, D; Rani, S; Sandhu, SS; Swamy, N; Tuli, HS, 2023)

"Common approaches to cancer treatment includes chemotherapy, hormone therapy, immunotherapy, radiation therapy etc."

( Amala Dev, AR; Sonia Mol, J, 2023)

"Radiotherapy is a common cancer treatment approach in clinical practice, yet its efficacy has been restricted by tumor hypoxia."

( Li, J; Qian, X; Wu, C; Yu, C; Zhang, J; Zhang, S; Zhao, M; Zheng, X; Zhu, A, 2023)

"Cancer theranostics that combines cancer diagnosis and therapy is a promising approach for personalized cancer treatment."

( Chang, Y; Ediriweera, GR; Fu, C; Jiang, X; Peng, H; Searles, DJ; Wang, Q; Whittaker, AK; Wu, M; Xu, X; Yu, Y; Zhen, X, 2023)

"These findings may benefit breast cancer patients undergoing Epirubicin chemotherapy."

( Adebisi, G; Owumi, SE, 2023)

"As an emerging cancer treatment strategy, ferroptosis is greatly restricted by excessive glutathione (GSH) in tumor microenvironment (TME) and low reactive oxygen species (ROS) generation efficiency."

( Han, ZY; Ji, P; Song, WF; Sun, YX; Zeng, JY; Zhang, XZ, 2023)

"In the AVERT trial enrolling ambulatory cancer patients receiving chemotherapy, we found no substantial differences in the efficacy or safety of apixaban thromboprophylaxis across obese and non-obese subjects."

( Carrier, M; Delluc, A; Di Nisio, M; Mallick, R; Porreca, E; Potere, N; Shivakumar, S; Tagalakis, V; Wang, TF; Wells, PS, 2023)

"In addition, anticancer drugs can modulate these cells and their interactions in favor of either cancer resistance or therapy."

( Alexis Ramírez-Coronel, A; Alsaikhan, F; Gupta, R; Hassan Jawhar, Z; Kadhim, MM; Khalimovna Mukhamedova, N; Najafi, M; Qasim Alasheqi, M; Ramaiah, P; Turki Jalil, A, 2023)

"RWD showed that in cancer patients using cannabis, the rate of reported symptomatic tachy- and brady-arrhythmias was significant (9%) but rarely led to invasive treatments."

( Laish-Farkash, A; Moisa, N; Vasilenko, L; Vorobiof, D, 2023)

"Chemotherapy treatments for cancer are always accompanied by a low concentration of drug delivered in the tumor area and severe side effects including systemic toxicity."

( Li, G; Ling, J; Liu, X; Lu, W; Pan, C; Shen, T; Sun, J; Sun, W; Xu, S; Zhang, J; Zheng, J, 2023)

"Chemotherapy treatments for cancer are always accompanied by a low concentration of drug delivered in the tumor area and severe side effects including systemic toxicity."

( Li, G; Ling, J; Liu, X; Lu, W; Pan, C; Shen, T; Sun, J; Sun, W; Xu, S; Zhang, J; Zheng, J, 2023)

"About 50% of cancer patients receive radiation therapy."

( Choghazardi, Y; Kazemzadeh, A; Naseri, P; Shahbazi-Gahrouei, D; Shahbazi-Gahrouei, S, 2023)

"Several NMT inhibitors used in cancer treatment are introduced."

( Qiao, Y; Wang, H; Wang, J; Xu, X, 2023)

"Treatment of metastatic cancer is one of the biggest challenges in anticancer therapy."

( Dytrych, P; Hajduch, J; Hoskovec, D; Jakubek, M; Kaplánek, R; Kejík, Z; Kučnirová, K; Martásek, P; Skaličková, M; Venhauerová, A; Veselá, K, 2023)

"Our results are discussed in light of cancer-associated endogenous stresses as exploitable tumor vulnerabilities and may inspire future clinical applications of CuET in oncology, including combinatorial treatments and focus on potential advantages of using certain validated drug metabolites, rather than old, approved drugs with their, often complex, metabolic profiles."

( Andújar-Sánchez, M; Arampatzis, S; Bartek, J; Bartkova, J; Björkman, A; Espinoza, JA; Fernandez-Capetillo, O; Kanellis, DC; Kosar, M; Lemmens, B; Li, X; Lindström, MS; Mistrik, M; Skrott, Z; Zisi, A, 2023)

"A syngeneic breast cancer mouse model was established by injecting 4T1-Luc mouse breast cancer cells into the fat pad of female BALB/c mice, and the extract was administered orally."

( Jang, YA; Kim, SK; Kim, YM; Kim, YN; Kwon, YJ; Lee, H; Lee, HS; Lee, JT; Seo, EB; Ye, SK, 2023)

"Despite their revolutionary success in cancer treatment over the last decades, immunotherapies encounter limitations in certain tumor types and patients."

( Dvorakova, T; Finisguerra, V; Formenti, M; Gallez, B; Mignion, L; Van den Eynde, BJ; Van Meerbeeck, P, 2023)

"EZH2 has been as a prominent target for cancer therapy and a growing number of potential targeting medicines have been developed."

( Liu, Y; Yang, Q, 2023)

"Ongoing cancer treatments did not correlate with a greater likelihood of receiving a transfusion (p=0."

( Albarini, M; Bergamaschi, L; Biassoni, V; Casanova, M; Catalano, I; Chiaravalli, S; Clerici, CA; Ferrari, A; Gattuso, G; Luksch, R; Massimino, M; Meazza, C; Nigro, O; Pellegatta, F; Podda, MG; Puma, N; Schiavello, E; Sironi, G; Spreafico, F; Terenziani, M; Visconti, G, 2023)

"Nanotheranostics advances anticancer management by providing therapeutic and diagnostic functions, that combine programmed cell death (PCD) initiation and imaging-guided treatment, thus increasing the efficacy of tumor ablation and efficiently fighting against cancer."

( Li, S; Li, W; Lo, H; Sun, H; Wu, K; Zeng, F; Zhang, Z; Zhao, X, 2023)

"Many patients with cancer started HFNC therapy at the point of imminent death."

( Heo, DS; Keam, B; Kim, JS; Kim, NH; Lee, SY; Shin, J; Yoo, SH, 2023)

"We retrospectively investigated cancer patients treated with ICIs between 2014 and 2021 and collected information about irAEs throughout their development, management, and clinical outcomes."

( Egashira, N; Hata, K; Hirota, T; Ieiri, I; Matsuda, K; Matsukane, R; Minami, H; Nakao, S; Suetsugu, K; Watanabe, H, 2023)

"The prevalence of irAEs varied by cancer type, but it was increased in regimens with longer treatment durations."

( Egashira, N; Hata, K; Hirota, T; Ieiri, I; Matsuda, K; Matsukane, R; Minami, H; Nakao, S; Suetsugu, K; Watanabe, H, 2023)

"In the treatment of cancer-associated thrombosis, direct oral anticoagulants (DOACs) have been found to be at least as effective as low-molecular weight heparins, which became the standard of care after several trials demonstrated superiority over vitamin K antagonists."

( Van Aelst, L; Van Cutsem, E; Van der Linden, L; Vanassche, T; Verhamme, P, 2023)

"Bacterial-based cancer immunotherapy has recently gained widespread attention due to its exceptional mechanism of rich pathogen-associated molecular patterns in anti-cancer immune responses."

( Narayanan, R; Thakker, DP, 2023)

"However, most cancer patients without TMB-H and dMMR do not benefit from ICB therapy."

( Chen, SY; Huang, CH; Huang, JL; Huang, YC; Lin, CS; Tseng, LC; Xu, JK, 2023)

"Targeting it is a potentially effective cancer prevention and treatment strategy in the clinic."

( Deng, X; Fu, J; Guo, Y; Guo, Z; Han, S; Hao, H; Jiao, Y; Wang, S; Yuan, Y, 2023)

"For the purpose of using polyphenols in cancer therapy, it would be helpful to have more in-depth knowledge about lncRNA modulation via resveratrol."

( Asemi, R; Asemi, Z; Davoodvandi, A; Hajijafari, M; Hakamifard, A; Homayoonfal, M; Rajabpoor Nikoo, N; Shafabakhsh, R; Sharifi, M, 2023)

"24 anticancer agents (20% of the oral market) have the potential to significantly interact with co-administered drugs."

( Levêque, D; Machkouri, C, 2023)

"All children with primary renal tumors (43%) underwent complete (n = 5) or partial nephrectomy (n = 1) before chemotherapy."

( Benedetti, DJ; Kao, PC; Ma, C; Marcus, KJ; Mullen, EA; Wong, CI, 2023)

"In children with HRR/INI- tumors, VDC-ICE chemotherapy was well-tolerated without excessive toxicities, even amongst young patients with solitary kidneys."

( Benedetti, DJ; Kao, PC; Ma, C; Marcus, KJ; Mullen, EA; Wong, CI, 2023)

"Most solid tumors are clinically treated using surgical resection, and the presence of residual tumor tissues at the surgical margins often determines tumor survival and recurrence."

( Qian, X; Qu, J; Teng, X; Xu, Y; Yang, J; Yang, Y; Zhu, W, 2023)

"In contrast, highly malignant 4T1 tumors demonstrated characteristics of a transient window of vascular normalization with an increase in tumor perfusion and permeability early after therapy initiation, followed by decreased perfusion and permeability parameters."

( Eisenblätter, M; Faber, C; Gerwing, M; Geyer, C; Hansen, U; Heindel, W; Helfen, A; Hoerr, V; Hoffmann, E; Höltke, C; Karst, U; Krähling, T; Kronenberg, K; Masthoff, M; Maus, B; Schinner, R; Wachsmuth, L; Wildgruber, M, 2023)

"When cancer treatments have similar oncologic outcomes, the number of days with in-person healthcare contact (""contact days'') can help contextualize expected time use with each treatment."

( Booth, CM; Chen, BE; Cheung, MC; Crump, M; Djurfeldt, MS; Gupta, A; Hay, AE; Shepherd, LE; Zhu, L, 2023)

"The pharmacological treatment of cancer-related pain is unsatisfactory."

( Artacho-Cordón, A; de la Nava, J; Huerta, MÁ; Nieto, FR, 2023)

"Early cancer diagnosis plays a critical role in improving treatment outcomes and increasing survival rates for certain cancers."

( Barros, AS; Caixeta, DC; Guedes, S; Sabino-Silva, R; Vitorino, R, 2023)

"Malnutrition in cancer patients is associated with increased treatment toxicity, reduced physical efficiency, and decreased survival."

( Caccialanza, R; Carnaghi, C; Gebbia, V; Guggino, R; Messina, A; Messina, S; Politi, MR; Sambataro, D; Scarpello, L, 2023)

"Recent advances in cancer treatment have significantly improved survival until adulthood."

( Aversa, L; Ballerini, MG; Bedecarrás, P; Bergadá, I; Correa Brito, L; Drelichman, G; Ferraro, C; Grinspon, RP; Gutiérrez, ME; Lopez Dacal, J; Morán, L; Prada, S; Rey, RA; Rodriguez, ME; Ropelato, MG; Soria, M, 2023)

"Adverse steps are taken to fund cancer treatment."

( Chaturvedi, P; Kumar K, A; Kuru, D, 2023)

"Data were collected from cancer patients evaluated for radiation therapy, age < 19, diagnosed from January 1990 to August 2019."

( Barredo, JC; Fine, JR; Isrow, DM; Kwon, D; Pinheiro, PS; Ransdell, JM; Reis, IM, 2023)

"Radiotherapy (RT) is one of the primary cancer treatment methods."

( Abdelrahman, IY; Afifi, MM; El-Gebaly, RH; Rageh, MM, 2023)

"Major challenges in current cancer chemotherapy include drug resistance, low efficacy and non-selectivity, resulting in undesirable side effects."

( Ambre, P; Coutinho, E; Gupta, C; Singh, P; Vaidya, S, 2023)

"Regrettably, most of the currently used cancer treatment approaches such as targeted therapy, chemotherapy, radiotherapy and surgery usually cause adverse complications including hair loss, bone density loss, vomiting, anemia and other complications."

( Alharbi, BF; Allemailem, KS; Almatroodi, SA; Almatroudi, A; Alrumaihi, F; Alwanian, WM; Khan, AA; Rahmani, AH, 2023)

"We examined the progression of cancers depending on body mass index, blood glucose levels, the presence and therapy of type 2 diabetes, over and above analyzed changes in glycemic and nutritional status in relation to tumor stage, further more prevalence of diabetes mellitus."

( Bánhegyi, RJ; Beke, S; Mátrai, ÁA; Rácz, B; Veréb, B, 2023)

"However, a significant percentage of cancer patients are resistant to CDDP treatment."

( Abbaszadegan, MR; Khalili-Tanha, G; Moghbeli, M; Navaei, ZN; Zangouei, AS, 2021)

"One main obstacle to targeted cancer therapies is the immunosuppressive tumor microenvironment, which can facilitate tumor growth and induce resistance to antitumor treatments."

( Fang, Q; Jiang, G; Xiang, Z, 2023)

"A crucial element of cancer treatment is radiation therapy that is used to destroy tumors and cancer cells through radiation."

( Ali, SW; Fatima, N; Hameed, A; Jabeen, A; Qazi, AS; Safdar, W; Tariq, MR, 2023)

"SFRT can be an effective modality for tumors which are otherwise challenging to manage with conventional radiation therapy techniques or for patients who have limited treatment options."

( Ahmed, SK; Corbin, KS; Deufel, CL; Finley, RR; Grams, MP; Haddock, MG; Kavanaugh, JA; Lang, KG; Lester, SC; Ma, DJ; Owen, D; Park, SS; Petersen, IA; Spreiter, SS, 2023)

"Once tumors were established, we initiated treatment with fulvestrant or vehicle, followed by external beam RT one week later."

( Bates, AM; Burkel, BM; Emma, SE; Jin, WJ; Morris, ZS; Nystuen, EJ; O'Leary, KA; Ponik, SM; Schuler, LA; Sriramaneni, RN; Sumiec, EG, 2023)

"Despite resistance of TC11 tumors to anti-estrogen therapy alone, fulvestrant slowed tumor regrowth following RT, and significantly altered multiple immune populations in the irradiated TME."

( Bates, AM; Burkel, BM; Emma, SE; Jin, WJ; Morris, ZS; Nystuen, EJ; O'Leary, KA; Ponik, SM; Schuler, LA; Sriramaneni, RN; Sumiec, EG, 2023)

"In the chemotherapy processes, anti-cancer drugs can be encapsulated in a stimuli-responsive coating which is capable of being functionalized by diverse ligands to increase the biocompatibility and control drug release behavior in a targeted drug delivery system."

( Ghaemi, A; Pandey, S; Pourmadadi, M; Rahdar, A; Rajabzadeh-Khosroshahi, M; Shaghaghi, M; Shamsabadipour, A, 2023)

"The immune-excluded tumors (IETs) show limited response to current immunotherapy due to intrinsic and adaptive immune resistance."

( Guan, Q; Hou, B; Huang, L; Lai, Y; Pan, J; Wang, F; Wang, H; Wang, J; Xu, Z; Yu, H; Zhou, M, 2023)

"The effective application of STMN1 in cancer prognosis and treatment requires further understanding of this protein."

( Dong, C; Guo, H; Li, S; Liang, X; Liu, R; Lu, Y; Tang, J; Wu, J; Yao, W; Zhang, H, 2023)

"CNL monotherapy of 4T1 tumors yielded significant intratumoral bioactive C6 accumulation by the EPR effect, but tumor growth was not controlled."

( Deering, T; Fox, T; Kester, M; Price, RJ; Sheybani, ND; Thim, EA; Vass, LR, 2023)

"In addition, more solid tumors, especially subcutis sarcomas, were observed in the pre-treatment rats (26."

( Matsuu-Matsuyama, M; Nakashima, M; Shichijo, K; Tsuchiya, T, 2023)

"Glutathione (GSH) consumption-enhanced cancer therapies represent important potential cancer treatment strategies."

( Chen, Y; Ding, X; Du, J; Gu, J; Li, Y; Liu, J; Sun, H; Wei, S; Xu, J; Yan, A; Yu, S; Zang, M; Zhang, Y, 2023)

"The solid tumors are characterized with oxidative stress and metabolic reprogramming, which has been independently used for targeted tumor monotherapy."

( Dai, Y; Jing, W; Man, S; Meng, X; Shen, Y; Wang, L; Yao, Y; Zhao, D; Zhao, N; Zhao, Y, 2023)

"Therefore, we can better comprehend cancer biology by developing a mechanistic understanding of curcumin, which will also inspire the scientific community to develop new pharmacological models, and exploration of emerging directions to revitalize application of natural products in cancer therapy."

( Haque, S; Hussain, A; Jain, A; Kumar, A; Saini, AK; Saini, RV; Sak, K; Sethi, G; Sharma, U; Tuli, HS; Uttam, V, 2023)

"We report a terminally ill cancer patient who was diagnosed with opioid withdrawal syndrome (OWS) based on symptoms centered around restlessness and sweating that developed 43 days after administration of naldemedine for OIC."

( Ishida, M; Onishi, H; Ooya, Y; Sakimoto, T; Sato, R; Takahashi, T; Uchida, N; Yamaguchi, T, 2023)

"Adults undergoing cancer treatment at a National Cancer Institute-designated cancer center completed measures of sociodemographic characteristics, cannabis use, use modalities, reasons for use, perceived harms/benefits of use, physical and psychological symptoms, and other substance/medication use."

( Alexander, AC; Azizoddin, DR; Boozary, LK; Cohn, AM; Henson, CE; Holman, LL; Kendzor, DE; Moore, KN; Sifat, MS; Ulahannan, SV, 2023)

"Among adults undergoing cancer treatment, 26% reported cannabis use in the past 30 days."

( Alexander, AC; Azizoddin, DR; Boozary, LK; Cohn, AM; Henson, CE; Holman, LL; Kendzor, DE; Moore, KN; Sifat, MS; Ulahannan, SV, 2023)

"Pancreatic cancer (PC) is a malignant disease of gastrointestinal tract in which chemotherapy and radiotherapy are main tools in its treatment, and recently, nanocarriers have been emerged as promising structures in its therapy."

( Ahjel, S; Ahsan, M; Akhavan-Sigari, R; Allela, OQB; Ameen, F; Amin, AH; Arias-Gonzáles, JL; Baher, H; Carlos Cotrina-Aliaga, J; Chaitanya, M; Gilmer Rosales Rojas, G; Lakshmaiya, N; Li, Y; Mahdi, MH; Saadh, MJ, 2023)

"Calcium ion therapy is a potential anticancer treatment."

( Liu, XH; Xie, BR; Ye, JJ; Yu, Y; Zhang, XZ; Zhong, Z, 2023)

"The promising combination for cancer treatment is with immunotherapy."

( Panaampon, J; Saengboonmee, C; Zhou, Y, 2023)

"While there are cancer-specific guidelines for the treatment of pain, widespread publication and policy changes in response to the opioid epidemic have drastically impacted perceptions of opioid use."

( Cuthbert, C; Harsanyi, H; Schulte, F, 2023)

"Patients with metastatic cancer who are receiving increased opioid prescribing may have difficult-to-treat pain and may benefit from multidisciplinary pain management strategies to supplement opioid prescription and improve outcomes."

( Cheung, WY; Cuthbert, C; Harper, A; Harsanyi, H; Jarada, TN; Lupichuk, S; Quan, ML; Xu, Y; Yang, L, 2023)

"It is expected to effectively treat cancer through its tumor-suppressor function, as mitochondria are the intracellular energy factory and a binding site of reactive oxygen species production, closely related to ferroptosis."

( Cheng, X; He, J; Ke, M; Liu, S; Wang, Q; Wang, Z; Xiao, Y; Zhang, J; Zhang, L, 2023)

"Oncolytic viruses exploited for cancer therapy have been developed to selectively infect, replicate, and kill cancer cells to inhibit tumor growth."

( Cashen, M; Daggett-Vondras, J; Enow, JA; Everts, A; Gutierrez-Jensen, AD; Hossain, M; Karr, TL; Kilbourne, J; Lowe, K; McFadden, G; Rahman, MM; van Oosterom, F, 2023)

"At present, cancer remains one of the leading causes of human death worldwide, and surgery, radiotherapy and chemotherapy are still the main methods of cancer treatment."

( Liu, SY; Qi, K; Sun, B; Zhang, M, 2023)

"Due to the complexity of tumors, multimodal therapy for them has always been of concern to researchers."

( Hao, Y; Liu, X; Ma, S; Mao, C; Yang, H; Zhang, S; Zhao, W, 2023)

"Gene therapy and nucleic acid-based cancer diagnosis play important roles in cancer theranostic, but their applicability is challenged by the low cellular uptake and enzymatic degradation."

( Chen, Y; Li, D; Liang, Y; Liang, Z; Ma, G; Wang, L, 2023)

"The aim was to estimate who died due to cancer, to report use of chemotherapy (CT) in the last 3 months of life, and to describe clinical-epidemiological characteristics of these patients."

( Carretero, M; Diaz, MH; Grande Ratti, MF; Ibañez Ledesma, LG; Martínez, BJ; Pasquinelli, R; Torres Gomez, F, 2023)

"Combination therapy is widely used in cancer medicine due to the benefits of drug synergy and the reduction of acquired resistance."

( Avrutin, Y; Azagury, DM; Gluck, BF; Harris, Y; Niezni, D; Sason, H; Shamay, Y, 2023)

"'Active cancer' was defined as a malignancy diagnosed within the previous weeks with planned or ongoing anticancer therapy."

( Aissaoui, N; Bataille, V; Biendel, C; Bonello, L; Bonnefoy, E; Bourenne, J; Cariou, A; Champion, S; Combaret, N; Curtiaud, A; Delmas, C; Gantzer, J; Gerbaud, E; Harbaoui, B; Khachab, H; Kurtz, JE; Lamblin, N; Lattuca, B; Leurent, G; Levy, B; Lim, P; Marchandot, B; Merdji, H; Puymirat, E; Quentin, C; Roubille, F; Schneider, F; Schurtz, G; Seronde, MF; Vanzetto, G, 2023)

"Despite advances in cancer treatment, immune checkpoint blockade (ICB) only achieves complete response in some patients, illustrating the need to identify resistance mechanisms."

( Cai, Y; Cen, X; Chen, Z; Huang, J; Liang, Y; Liu, X; Shan, B; Wang, D; Wang, F; Wu, R; Wu, Y; Xia, H; Xie, B; Xie, Y; Zeng, L; Zhang, C; Zhou, J, 2023)

"Flavonoids effectively treat cancer, inflammatory disorders (cardiovascular and nervous systems), and oxidative stress."

( Abu-Izneid, T; Ahmad, I; Alhumaydhi, FA; Aljohani, ASM; Aljohani, MSM; Bashir, K; Bin Emran, T; Gondal, TA; Hemeg, HA; Imran, M; Khan, IN; Nath, N; Rauf, A; Thiruvengadam, M, 2023)

"Because cancer progression is closely related to oxidative processes at the cellular level, we further applied the surface treatment of tannic acid drug-delivery nanocarriers."

( Jeong, S; Jung, J; Ku, M; Park, JH; Seo, S; Yang, J; Yoon, N; Youn, HS, 2023)

"PRMT5 is upregulated in a variety of tumors and promotes tumorigenesis and tumor cell proliferation and metastasis, making it a potential tumor therapy target."

( Guo, C; Han, C; Hou, X; Wang, Z; Wu, L; Zhao, L; Zheng, X, 2023)

"As for pediatric cancer, many cancer of the AYA generation were treated with radiation therapy as the multidisciplinary treatment."

( Soejima, T, 2023)

"Furthermore, its anticancer potential has been suggested to be a promising alternative in cancer treatment or management through the modulation of signal transduction pathways, which includes apoptosis, cell cycle, angiogenesis, ERK/MAPK, signal transducer, and the activator of transcription and other cell signaling molecules."

( Anwar, S; Babiker, AY; Rahmani, AH, 2023)

"Since cancer is a continuously increasing concern for the general population, more efficient treatment alternatives ought to be developed."

( Andronescu, E; Bîrcă, AC; Chircov, C; Dănciulescu, LA; Neacșu, IA; Oprea, OC; Trușcă, RD, 2023)

"Patients with cancer who cannot tolerate opioids or not responding to conventional treatment may benefit from epidural analgesia."

( Chen, HY; Hsieh, YL; Lin, CR; Wang, CF, 2023)

"Mannose has anticancer activity that inhibits cell proliferation and enhances the efficacy of chemotherapy."

( Dohmae, N; Freeze, HH; Harada, Y; Higashiyama, S; Hiratsuka, T; Hirayama, A; Ikeda, S; Imagawa, Y; Maeda, K; Miyoshi, E; Mizote, Y; Murai, J; Nishida, M; Ohkawa, Y; Suzuki, T; Tahara, H; Taniguchi, N; Udono, H; Ueda, A, 2023)

"Although this principle also applies to cancer cells, a specific sugar called mannose not only inhibits cancer cell division but also makes them more sensitive to chemotherapy."

"With traditional cancer treatment (including chemotherapy, radiotherapy, phototherapy), nanozyme catalytic therapy exhibited a synergistic effect for limiting the growth of tumors."

( He, L; Liu, J; Liu, S; Wang, Q; Yang, P, 2023)

"The misdiagnosis of tumors due to insufficient penetration depth or signal interference and damage to normal tissues due to indiscriminate treatment are the biggest challenges in using photothermal agents for clinical translation."

( An, L; Chang, Q; Li, K; Liu, D; Liu, H; Tian, Q; Wang, M; Zhang, H; Zhang, X; Zhang, Z, 2023)

"Ferroptosis holds great potential in cancer treatment, but its efficacy is severely limited by a low Fenton reaction efficacy."

( Guo, M; Hou, G; Li, Z; Qian, J; Suo, A; Wang, J; Wang, Y; Xu, W, 2023)

"Etoposide (ETO), a popular anticancer drug that inhibits topoisomerase II enzymes, may be administered more effectively and efficiently due to nanomedicine."

( Arshad, R; Behzadmehr, R; Fathi-Karkan, S; Ghotekar, S; Pandey, S; Rahdar, A; Ramezani, A, 2023)

"Systemic anticancer therapy (SACT) includes different treatment modalities that can be effective in treating cancer."

( Geyer, T; Groissenberger, I; Jutz, F; Kreye, G; Le, NS; Tschurlovich, L, 2023)

"Microtubules are a well-known target in cancer chemotherapy because of their critical role in cell division."

( Rathinasamy, K; Sebastian, J, 2023)

"With regards to changes in cancer stem cell markers, CD44 showed low levels after 5-fluorouracil administration."

( Doki, Y; Eguchi, H; Fujino, S; Hamabe, A; Hata, T; Horie, M; Miyoshi, N; Nagae, A; Ogino, T; Sasaki, M; Sekido, Y; Takahashi, H; Uemura, M; Yachida, S; Yamamoto, H, 2023)

"For the treatment against refractory tumors, such as the recurrence after chemotherapy, the treatment should target the emerging specific population such as CD44 (or CD44v9) and proliferative cancer cells."

( Doki, Y; Eguchi, H; Fujino, S; Hamabe, A; Hata, T; Horie, M; Miyoshi, N; Nagae, A; Ogino, T; Sasaki, M; Sekido, Y; Takahashi, H; Uemura, M; Yachida, S; Yamamoto, H, 2023)

"Pediatric cancer survivors often experience long-term adverse health conditions or late effects, including hearing loss, that are attributable to cancer therapy."

( Clay, S; Doss, J; Fang, Z; Moore, B; Musso, A; Norman, M; Prasad, P; Sheets, G; Tsien, F; Umrigar, A, 2023)

"This study identified pediatric cancer survivors between 2 and 24 years of age with treatment protocol information and audiological evaluations."

( Clay, S; Doss, J; Fang, Z; Moore, B; Musso, A; Norman, M; Prasad, P; Sheets, G; Tsien, F; Umrigar, A, 2023)

"In patients currently receiving cancer treatment, 12% had significant hearing loss."

( Clay, S; Doss, J; Fang, Z; Moore, B; Musso, A; Norman, M; Prasad, P; Sheets, G; Tsien, F; Umrigar, A, 2023)

"To find a novel target for anticancer therapy, the UPS has been an active area of research since the FDA's first approval of a proteasome inhibitor bortezomib in 2003 for treating multiple myeloma (MM)."

( Hwang, S; Kim, YJ; Lee, Y; Park, J; Shin, H; Song, EJ, 2023)

"To restore effective apoptosis in tumors, we propose that the administration of citrate could inhibit ATP production, activate caspase-8 (a key necroptosis inhibitor), and downregulate key anti-apoptotic proteins (Bcl-xL and MCL1)."

( Alifano, M; Icard, P; Simula, L, 2023)

"Childhood cancer therapy may cause long-term effects."

( Jahnukainen, K; Korhonen, M; Koskela, M; Madanat-Harjuoja, LM; Tainio, J, 2023)

"In breast cancer, dysregulated TP53 expression signatures are a better predictor of chemotherapy response and survival outcomes than TP53 mutations."

( Avery-Kiejda, KA; Groen, K; Morten, BC; Steffens Reinhardt, L; Wawruszak, A; Zhang, X, 2023)

"The anthracycline anti-cancer drugs are intensely used in the clinic to treat a wide variety of cancers."

( Codée, JDC; Neefjes, JJC; Overkleeft, HS; van der Marel, GA; van der Zanden, SY; van Gelder, MA; Vriends, MBL; Wagensveld, RA; Wander, DPA, 2023)

"The major challenge in cancer therapy is the development of cancer resistance and relapse."

( Alanazi, AS; Alanazi, MM, 2023)

"Chemotherapy is a common cancer treatment strategy."

( Han, B; Hu, J; Huang, J; Kai, G; Sheng, M; Sun, C; Yang, R; Zhang, J, 2024)

"The risk of malignancy in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX) and biological disease-modifying antirheumatic drug (bDMARD) combination therapy is unknown."

( Inose, R; Muraki, Y; Nakamura, A; Omi, R; Takeno, S, 2023)

"Immunotherapy for breast cancer has not gained significant success."

( Basu, A; Bhoumick, A; Chatterjee, A; Das, K; Ghosh, A; Paul, S; Sen, P, 2023)

"In a mouse model of breast cancer, tumor cell-specific PAR2 depletion leads to PD-L1 downregulation and increases anti-PD-1 immunotherapy efficacy."

( Basu, A; Bhoumick, A; Chatterjee, A; Das, K; Ghosh, A; Paul, S; Sen, P, 2023)

"Platinum based anticancer chemotherapeutic drugs can kill tumor cells by damaging DNA through chemotherapy."

( Cai, K; Cheng, S; Lei, K; Li, H; Li, J; Zhai, J; Zhou, P, 2023)

"While most cancer patients with end-of-life (EOL) care receive antibiotic treatments, antibiotic use should be decided appropriately considering the benefits, side effects, resistance, and cost effects."

( Choi, S; Ji, JG; Jung, KH; Kim, H; Kwon, MK; Lee, M; Son, HJ; Woo, CY, 2023)

"PET may be a useful tool for anal canal cancer therapy planning and provides valuable prognostic information."

( Kohan, A; Mesci, A; Metser, U; Mirshahvalad, SA; Murad, V; Ortega, C; Veit-Haibach, P, 2023)

"This review discusses the role of Zn in cancer and its associated components, such as Zn-related proteins, their potential as biomarkers and the use of Zn-based strategies for tumor treatment."

( Bendellaa, M; Busser, B; Coll, JL; Deniaud, A; Lelièvre, P; Sancey, L, 2024)

"The role of ROS in breast cancer warrants continued investigation, in relation to both pathogenesis and treatment of breast cancer."

( Alcantara, CA; Asif, A; Chorbajian, A; Glassman, I; Goulding, A; Le, N; Mirhosseini, M; Singh, M; Venketaraman, V; Vu, A, 2023)

"In patients with cancer with isolated distal deep vein thrombosis, 12 months was superior to 3 months for an edoxaban treatment with respect to the composite outcome of a symptomatic recurrent VTE or VTE-related death."

( Akamatsu, D; Chatani, R; Dohi, K; Fujita, M; Hashimoto, G; Hosoi, Y; Ikeda, N; Ikeda, S; Jujo, K; Kim, K; Kimura, T; Minami, Y; Mo, M; Mori, K; Morimoto, T; Muraoka, N; Nakanishi, N; Nishikawa, T; Nishimoto, Y; Ogihara, Y; Otsui, K; Oyakawa, T; Sato, Y; Shikama, A; Shoji, M; Sueta, D; Takada, T; Tanabe, Y; Tsubata, Y; Tsukahara, K; Umetsu, M; Yamashita, Y; Yoshikawa, Y, 2023)

"Although cancer immunotherapy has made encouraging progress, clinical therapeutic efficiency is often modest due to inadequate immunogenicity and immune resistance."

( Hu, C; Li, H; Man, R; Tang, B; Xia, M; Yu, Z, 2023)

"There is still unmet medical need in cancer treatment mainly due to drug resistance and adverse drug events."

( Chua, HM; Goh, HP; Kifli, N; Ming, LC; Moshawih, S, 2023)

"Half of the patients with cancer who undergo radiation therapy do so with palliative intent."

( Davis, MP; Gupta, M; Lagerman, B; Liu, E; Mackley, H; Panikkar, R; Vanenkevort, E; Wojtowicz, M; Young, A, 2023)

"The serious threat that cancer poses to human health highlights the significance of early detection and effective treatment."

( Duo, YY; Liu, SL; Pang, DW; Wang, ZG; Zhao, L; Zhu, H, 2023)

"The therapeutic effect of cancer immunotherapy is restrained by limited patient response rate caused by 'cold' tumors with an intrinsically immunosuppressive tumor microenvironment (TME)."

( Feng, X; He, Y; Lei, J; Li, G; Liang, H; Ma, L; Tan, L; Yang, C; Zhang, W; Zhang, X, 2023)

"Ten patients with ER + breast cancer were employed in this study, six of whom had neoadjuvant chemotherapy and four of whom did not."

( Baek, M; Choi, Y; Han, W; Jeon, SY; Jon, S; Kim, HS; Lee, D; Lee, HB; Lee, S; Ryu, S; Song, J; Yoon, SH, 2023)

"The improved survival rates after cancer treatment necessitate the inclusion of fertility preservation procedures as part of the comprehensive care for patients, taking into consideration their age."

( Ancelle, A; Barbotin, AL; Brugnon, F; Bubenheim, M; Daudin, M; Dumont, L; Feraille, A; Giscard d'Estaing, S; Liard, A; Mirallié, S; Rives, N; Rondanino, C; Roux, C; Schneider, P, 2023)

"(Pre)pubertal boys with cancer diagnosis who had been offered TTF prior to conditioning treatment for hematopoietic stem cell transplantation were included in the study."

( Ancelle, A; Barbotin, AL; Brugnon, F; Bubenheim, M; Daudin, M; Dumont, L; Feraille, A; Giscard d'Estaing, S; Liard, A; Mirallié, S; Rives, N; Rondanino, C; Roux, C; Schneider, P, 2023)

"To advance cancer treatment, we have developed a novel composite material consisting of conjugated polymer dots (CPDs) and Prussian blue (PB) particles, which were immobilized on, and encapsulated within, silica particles, respectively."

( Jo, S; Kim, S; Lee, H; Lee, S; Lee, TS; Lee, WJ; Lim, J; Park, JH; Yang, JK, 2023)

"The global incidence of cancer and available cancer-directed therapy options is increasing rapidly, presenting patients and clinicians with more complex treatment decisions than ever before."

( Doyon, K; Epstein, AS; Ferrell, BR; Levoy, K; McDarby, M; Parker, PA; Rosa, WE; Rosenberg, AR; Sanders, JJ; Sullivan, DR, 2023)

"The sensitivity of cancer cells to ferroptosis induction varies based on their metabolic, genetic, and signalling pathways, prompting the use of combination therapy."

( Ghadi, R; Jain, S; Kuche, K; Patel, M; Yadav, V, 2023)

"Nanomaterial-based cancer therapy has recently emerged as a new therapeutic modality with the advantages of minimal invasiveness and negligible normal tissue toxicity over traditional cancer treatments."

( Chen, H; Chu, X; Duan, M; Hou, H; Li, SL; Liu, P; Liu, Y; Zhang, Y, 2023)

"A major cause of cancer recurrence following chemotherapy is cancer dormancy escape."

( Bakhtiary, M; Bhasin, MK; Bhasin, SS; Cheemarla, NR; Ganesan, R; Krishnan, U; Sukhatme, VP; Thomas, BE, 2023)

"The worldwide prevalence of cancer and its significantly rising risks with age have garnered the attention of nanotechnology for prompt detection and effective therapy with minimal or no adverse effects."

( Meher, MK; Packirisamy, G; Poluri, KM; Tripathi, DK; Unnikrishnan, BS, 2023)

"The rabbit VX2 breast cancer model was established and received HIFU treatment with complete ablation (100% tumor volume) and incomplete ablation (about 80% tumor volume) under real-time B-ultrasound monitoring."

( Du, Y; Feng, X; Li, J; Liao, H; Wang, Q; Yang, M; Zhang, Z, 2023)

"Given the key roles of cancer associated fibroblasts (CAFs) in shaping tumor stroma, this study shows a CAF-associated ITGB1-inactivating peptide-enriched membrane nanodelivery system (designated as PMNPs-D) to simultaneously target CAFs and tumor cells for boosted chemotherapy through promoted drug perfusion."

( Ji, P; Liu, H; Liu, P; Liu, Z; Luo, GF; Shang, Z; Yu, L; Zhang, SM; Zhang, XZ, 2023)

"Although combination cancer therapy has been beneficial in providing cancer drug sensitivity, targeted delivery of drugs appears to be more efficient."

( Zou, J, 2023)

"Liver cancer, a malignancy with a rising global incidence, poses a significant challenge in achieving effective treatment outcomes."

( Am, AE; Hua, Z; Huang, S; Tan, M; Wang, K, 2023)

"Focusing on cancer, we also provide a comprehensive summary of recently developed KDM1 inhibitors and related preclinical and clinical studies to provide a better understanding of the mechanisms of action and applications of these KDM1-specific inhibitors in therapeutic treatment."

( Mao, F; Shi, YG, 2023)

"We searched our database for cancer survivors subjected to ovarian decortication and chemotherapy at least 3 years previously."

( Cano, A; Hidalgo, JJ; Monllor-Tormos, A; Ortiz, E; Pellicer, A; Peña, CJ; Sánchez-Serrano, M; Vila, MJ; Zolfaroli, I, 2023)

"Accordingly, anticancer compounds are essential for chemotherapy-resistant cancer cells."

( Alam, W; Aschner, M; Ghanbari, F; Hassani, S; Khan, H; Lotfi, M; Popović-Djordjević, J; Shahcheraghi, SH, 2023)

"Pathophysiological barriers in "cold" tumors seriously limit the clinical outcomes of chemoimmunotherapy."

( Dong, J; Duan, B; Huang, K; Li, C; Li, J; Sun, M; Yang, R; Zhang, F; Zhi, F; Zhou, Z, 2023)

"Microbial-based cancer treatments are an emerging field, with multiple bacterial species evaluated in animal models and some advancing to clinical trials."

( Artemov, D; Flavahan, K; Ittig, SJ; Jain, SK; Kasper, CA; Ordonez, AA; Parveen, S; Saupe, F; Shin, H; Turner, ML, 2023)

"Patients with advanced solid tumors who had progressed on approved systemic therapy, were enrolled into 2 successive dose escalation cohorts, fruquintinib 3 mg (n = 7) or 5 mg (n = 7), orally, once daily (QD), 3 weeks on and 1 week off (3/1) with a 3 + 3 design followed by a dose expansion cohort at the RP2D 5 mg dose (n = 6)."

( Chien, C; Gonzalez, M; Kania, M; Schelman, W; Ukrainskyj, S; Wang-Gillam, A; Yang, Z; Yeckes-Rodin, H, 2023)

"Photothermal therapy (PTT) is a novel cancer treatment using a photoabsorber to cause hyperthermia to kill tumors by laser irradiation."

( Hong, H; Im, HJ; Jeon, M; Kim, H; Kim, M; Lee, C; Lee, W; Piao, Y, 2023)

"In late-stage cancer, the cancer itself or the side effects of cancer treatment are known to affect the hemoglobin (Hgb) levels or emotions of patients."

( Chang, WP; Chung, MH, 2023)

"Among the emerging cancer therapeutic methods, nanocatalytic therapy through the rational design of nanozymes is considered to be a promising strategy."

( Hu, Q; Li, L; Wang, S; Zhang, Z; Zhao, Y; Zhong, S, 2023)

"The impact of bacteria on cancer progression and treatment is becoming increasingly recognized."

( Cho, MY; Han, EH; Hong, KS; Karan, S; Kim, HM; Lee, H; Park, HS; Sessler, JL, 2023)

"Ionizing radiation is a frequently used cancer therapy to kill malignancies."

( Hua, J; Li, H; Li, J; Liu, R; Ren, Y; Wang, J; Wang, WA; Yang, P; Zhang, Q; Zhang, T; Zhou, H, 2023)

"The dependency of cancer cells on iron increases their susceptibility to ferroptosis, thus providing new opportunities for patients with treatment-resistant tumors."

( Gan, B; Huang, S; Wang, X; Zhang, P; Zhang, Q; Zhang, Y; Zhao, M, 2023)

"Nanomaterial-based cancer therapy faces significant limitations due to the complex nature of the tumor microenvironment (TME)."

( Chang, C; Chen, Y; He, R; Liu, A; Lu, B; Yang, P; Zhang, Y, 2023)

"Gastric cancer, a gastrointestinal tumor with high morbidity and lethality, is often treated using strategies that are not as effective as they could be due to the locally advanced stage."

( Cao, Y; Jin, S; Song, P; Wang, D; Yin, N; Zhang, H; Zhang, S, 2023)

"X-PDT is one of the novel cancer treatment approaches that uses high penetration X-ray radiation to activate photosensitizers (PSs) placed in deep seated tumors."

( Hosseini, FS; Naghavi, N; Sazgarnia, A, 2023)

"Patients with metastatic cancer face a relatively high opioid burden, which increases over time, even among those who receive palliative radiation therapy."

( Arabandi, PR; Carroll, NV; Fernandez, EV; Slade, AN, 2023)

"Platinum-based anticancer agents have revolutionized oncological treatments globally."

( Ahn, S; Bao, K; Choi, HS; Kang, H; Kim, J; Park, SH; Stiles, WR; Yamashita, A; Zeng, L, 2023)

"Up to five hospitals for cancer treatment across the country."

( Kuru, D, 2023)

"Analysis of treated tumors demonstrates that targeting of a Toll-like receptor 7 agonist inhibits Treg expression of FOXP3, PD-1, CTLA4, and HELIOS, resulting in 40-80% reduction in tumor growth and repolarization of other tumor-infiltrating immune cells to more inflammatory phenotypes."

( Alfar, R; Finnell, R; Johnson, A; Low, PS; Napoleon, JV; Shahriar, I; Walchle, C, 2023)

"Nonapoptotic ferroptosis is a promising cancer treatment which offers a solution to the multidrug resistance of conventional apoptosis-induced programmed cancer cell death therapies."

( Bai, LP; Jiang, ZH; Wang, CY; Yang, Z; Yin, T; Zhang, W; Zhao, Y; Zhou, M; Zhu, GY, 2023)

"Pro-tumoral macrophages in lung tumors present a significant challenge in immunotherapy."

( Bao, Q; Guo, Y; Hu, P; Shi, J, 2023)

"sinense in the treatment of breast cancer."

( Ewing, RM; Tang, X; Wang, J; Wang, S; Wang, Y; Williamson, PTF; Zhao, H, 2023)

"sinense in cancer treatment."

( Ewing, RM; Tang, X; Wang, J; Wang, S; Wang, Y; Williamson, PTF; Zhao, H, 2023)

"The antitumor immune response of cancer immunotherapy is a cascade of cancer-immunity cycles (CIC)."

( An, M; Bi, J; Cao, Y; Li, J; Liang, Q; Liu, Y; Yang, J; Zhang, J; Zhang, X, 2023)

"Combined multimodal therapy for breast cancer is a promising therapeutic approach to increase treatment efficacy and reduce systemic toxicity."

( He, F; Jiang, X; Li, N; Wang, H; Wu, Z; Xiao, W; Zhang, W, 2023)

"Aerobic glycolysis is critical for cancer progression and can be exploited in cancer therapy."

( Deng, J; Hao, Q; Huang, Y; Lu, H; Wang, C; Wu, H; Wu, X; Xiong, C; Xiong, J; Zhou, X; Zuo, Z, 2023)

"A total of 86 patients with malignant tumors treated in Anhui No."

( Chen, M; Chen, MY; Cheng, XP; Cui, WX; Zhang, H, 2023)

"Wild-type p53 cancer therapy-induced senescent cells frequently engulf and degrade neighboring ones inside a massive vacuole in their cytoplasm."

( Bongarzone, I; Bresci, A; Ghislanzoni, S; Kang, JW; Kobayashi-Kirschvink, KJ; Masella, A; Polli, D; So, PTC, 2023)

"Although cancer therapy has evolved significantly over the years, numerous challenges persist on the path to effectively combating this multifaceted disease."

( Bardelčíková, A; Čižmáriková, M; Michalková, R; Mirossay, L; Mojžiš, J; Mojžišová, G; Zigová, M, 2023)

"Similar observations in human cancer cell lines suggest that TFOs could be broadly applicable to mitigate drug resistance, one of the major difficulties in treating cancer."

( Balázsi, G; Cohen, J; Coraci, D; Cross, E; Farquhar, K; Helenek, C; Krzysztoń, R; Lin, A; Mu, Q; Tompkins, C; Wan, Y; Wang, J, 2023)

"An orthotropic breast cancer model was established by injecting EO771 breast cancer cells into the mammary fat pad of mice intraperitoneally administered ketamine (30 mg/kg, daily) for 68 days."

( Chen, KB; Chen, L; Chen, LK; Chen, SS; Huang, ZX; Shih, CH, 2023)

"The current prevalence of cancerous diseases necessitates the exploration of materials that can effectively treat these conditions while minimizing the occurrence of adverse side effects."

( Abu-Serie, MM; Ali, SM; El Fawal, G; Elessawy, NA, 2023)

"Most cancer patients are more interested in using this non-mainstream medicine to complement their conventional treatment than as an alternative."

( De Vriese, C; Lechon, AS; Mathieu, V; Pochet, S; Rondeaux, S; Schils, A; Souard, F; Van Laethem, JL, 2023)

Timeframe	Studies, This Condition (%)	All Conditions %
pre-1990	26953 (27.04)	23.3326
1990's	9204 (9.23)	12.5806
2000's	17439 (17.49)	18.1394
2010's	30615 (30.71)	28.8240
2020's	15470 (15.52)	9.53

Timeframe

Studies, This Condition (%)

All Conditions %

pre-1990

26953 (27.04)

23.3326

1990's

9204 (9.23)

12.5806

2000's

17439 (17.49)

18.1394

2010's

30615 (30.71)

28.8240

2020's

15470 (15.52)

9.53

Drug	Relationship Strength	Studies	Trials
acetylcarnitine	medium	5	2
dinitrochlorobenzene	medium	57	1
ethylene dichloride	medium	2	1
2,3-dihydroxybenzoic acid	low	1	0
chloroacetaldehyde	medium	6	3
ethylene chlorohydrin	low	3	0
alpha-hydroxyglutarate	medium	53	1
alpha-ketoglutaric acid	low	1	0
2-phosphoglycerate	low	4	0
2,3-diphosphoglycerate	low	5	0
2,5-dichlorophenol	low	1	0
alpha-ketoadipic acid	low	1	0
protocatechuic acid	medium	4	1
3-cyanopyridine	low	1	0
3-hydroxyanthranilic acid	low	2	0
3-hydroxykynurenine	low	2	0
acetoacetic acid	low	1	0
phosphoserine	low	38	0
3-phenylpropionic acid	low	1	0
cysteine sulfinic acid	low	1	0
n-carbamoyl-beta-alanine	low	1	0
gamma-aminobutyric acid	medium	76	17
4-hydroxybenzaldehyde	low	1	0
4-hydroxybenzoic acid	low	2	0
aminolevulinic acid	low	119	0
5-hydroxytryptophan	medium	15	1
phosphoribosyl-n-formylglycineamide	low	1	0
ethylene glycol	medium	11	1
acetic acid	low	32	0
acetaldehyde	medium	55	4
acetamide	low	4	0
acetone	low	18	0
acetyl phosphate	low	4	0
adenine	medium	169	11
adipic acid	low	2	0
agmatine	low	4	0
allantoin	low	6	0
curdlan	low	9	0
ammonium hydroxide	medium	53	4
anthranilic acid	low	8	0
arsenic acid	low	7	0
quinacrine	medium	59	3
beta-alanine	low	19	0
benzaldehyde	medium	7	1
benzene	medium	199	1
benzoic acid	low	9	0
benzyl alcohol	low	1	0
betaine	low	15	0
bromide	low	23	0
1-butanol	low	10	0
butyric acid	low	16	0
cadaverine	low	15	0
carbamates	medium	69	13
carbamic acid	low	1	0
carbamyl phosphate	low	2	0
ureidosuccinic acid	low	1	0
carbon monoxide	medium	72	1
formic acid	low	12	0
aminooxyacetic acid	low	2	0
carnitine	medium	67	15
catechol	low	17	0
methane	medium	339	4
chlordecone	low	5	0
chloroacetic acid	low	1	0
choline	medium	128	3
aconitic acid	low	2	0
citric acid, anhydrous	medium	95	4
chlorine	medium	117	3
hydrochloric acid	medium	22	1
coproporphyrinogen iii	low	1	0
coumarin	medium	52	4
4-hydroxymandelic acid	low	1	0
salicylic acid	medium	171	9
phloroglucinol	low	14	0
gallic acid	medium	45	1
4-nitrophenylphosphate	low	1	0
octanoic acid	low	4	0
indoleacetamide	low	1	0
2-nitropropane	low	2	0
hydrogen sulfide	medium	76	1
4-aminophenol	low	1	0
nornicotine	low	1	0
dihydrolipoic acid	low	3	0
trimethylenediamine	low	2	0
3-hydroxybutyric acid	medium	14	1
bupropion	medium	18	7
sorbitol	low	1	0
n(1)-methylnicotinamide	low	2	0
guaiacol	low	13	0
hippuric acid	low	2	0
2-aminoadipic acid	low	1	0
taxifolin	low	1	0
2-keto-4-methylthiobutyric acid	low	2	0
methylmalonic acid	medium	13	1
n(1)-acetylspermidine	low	3	0
n(g),n(g')-dimethyl-l-arginine	low	3	0
malic acid	low	4	0
propionaldehyde	low	1	0
phosphoglycolate	low	1	0
hydrogen selenide	low	3	0
1-aminocyclopropane-1-carboxylic acid	low	1	0
arsenous acid	low	1	0
phosphonoacetic acid	medium	37	8
3,4-dihydroxyphenylacetic acid	low	3	0
aminocaproic acid	medium	16	1
dibenzofuran	low	5	0
creatine	medium	55	3
cytosine	medium	170	7
lactic acid	medium	579	5
5,6-dihydroorotate	low	1	0
dihydrouracil	low	8	0
diacetyl	low	6	0
diethyl phosphate	low	2	0
dihydrolipoamide	low	1	0
dihydroxyacetone phosphate	low	3	0
dihydroxyacetone	low	1	0
dimethylamine	low	2	0
dimethyl sulfoxide	medium	99	8
ethanolamine	low	11	0
formaldehyde	medium	392	1
formamide	low	2	0
3-phosphoglycerate	low	8	0
hexachlorocyclohexane	low	4	0
glutaric acid	low	1	0
glycine	medium	235	19
glyceraldehyde	low	9	0
glycerol	medium	122	11
alpha-glycerophosphoric acid	low	3	0
glycolic acid	low	6	0
glyoxylic acid	low	1	0
carbonic acid	low	2	0
hydrogen cyanide	low	14	0
hydrogen carbonate	medium	64	2
dalteparin	medium	177	67
histamine	medium	151	6
homogentisic acid	low	3	0
hydrogen	medium	84	4
hydroquinone	low	10	0
hydroxylamine	low	5	0
imidazole	low	34	0
indole	low	20	0
indoleacetic acid	low	41	0
iodine	medium	416	1
itaconic acid	low	6	0
arabitol	low	1	0
dihydroxyphenylalanine	medium	31	1
kynurenine	medium	99	3
2,3,4,5-tetrahydroxypentanal	low	4	0
lactaldehyde	low	2	0
thioctic acid	medium	43	3
malonic acid	low	5	0
racemethionine	low	22	0
pyruvaldehyde	low	48	0
methanol	medium	124	2
phytic acid	low	20	0
inositol	low	31	0
melatonin	medium	331	23
croton oil	low	60	0
n-acetylserotonin	low	3	0
acetanilide	low	2	0
naphthalene	low	19	0
naringenin	low	1	0
nickel	medium	201	2
niacinamide	medium	374	72
niacin	medium	69	1
nitrates	medium	111	4
nitric acid	low	6	0
nitroxyl	medium	21	1
nitrites	medium	100	3
nitrous oxide	medium	43	4
n,n-dimethylaniline	low	1	0
1-octanol	low	3	0
hydroxide ion	low	8	0
orotic acid	low	27	0
oxaloacetic acid	low	3	0
oxalic acid	medium	5	1
oxamic acid	low	4	0
4-aminobenzoic acid	low	24	0
4-hydroxyphenylpyruvic acid	low	1	0
4-nitrophenol	low	1	0
triphosphoric acid	low	12	0
palmitic acid	medium	28	1
parathion	low	2	0
pentachlorophenol	low	13	0
phenanthrene	low	12	0
phenol	medium	67	2
phenylpyruvic acid	low	2	0
phenylacetaldehyde	low	1	0
phenylacetic acid	medium	13	7
phenethylamine	low	1	0
phosphoric acid	low	6	0
phosphoenolpyruvate	low	9	0
phosphorylcholine	medium	59	7
phosphorylethanolamine	medium	17	3
phthalic acid	low	17	0
picolinic acid	low	3	0
porphobilinogen	low	12	0
diphosphoric acid	low	4	0
pqq cofactor	low	2	0
propylene glycol	medium	4	2
1-propanol	low	8	0
propionic acid	low	6	0
pteridines	medium	64	10
purine	medium	111	1
putrescine	low	68	0
pyrazinamide	low	4	0
pyrazole	low	15	0
pyridine	low	23	0
pyridoxal	low	10	0
pyridoxal phosphate	low	20	0
pyridoxine	medium	55	3
pyrogallol	low	8	0
pyruvic acid	low	115	0
quinolinic acid	low	4	0
thiosulfates	medium	22	3
sarcosine	medium	10	1
selenic acid	low	3	0
selenious acid	medium	10	1
sulfites	medium	60	1
spermidine	low	90	0
spermine	medium	112	5
succinic acid	medium	37	2
sulfuric acid	low	5	0
sulfur dioxide	medium	36	2
taurine	medium	44	3
thiophane	low	1	0
thiamine	low	52	0
thymine	medium	75	10
toluene	medium	54	1
trimethyloxamine	low	11	0
trimethylamine	low	3	0
tryptophan	low	1	0
tryptamine	low	4	0
uracil	medium	223	32
uric acid	medium	163	6
urea	medium	191	17
vanillin	low	9	0
xanthine	low	10	0
isopentenyl pyrophosphate	low	5	0
isocitric acid	low	7	0
catechin	low	2	0
2-amino-5-phosphonovalerate	low	2	0
8-hydroxy-2-(di-n-propylamino)tetralin	low	1	0
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid	low	2	0
alpha-methyl-4-carboxyphenylglycine	low	1	0
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid	low	1	0
4-iodo-2,5-dimethoxyphenylisopropylamine	low	1	0
1-hydroxy-3-amino-2-pyrrolidone	low	1	0
ibotenic acid	low	1	0
normetanephrine	low	3	0
n(8)-bromoacetyl-n(1)-3'-(4-indolyloxy)-2'-hydroxypropyl-1,8-diamino-4-menthane	low	1	0
sk&f-38393	low	1	0
vanilmandelic acid	low	15	0
menthol	low	11	0
perillic acid	medium	3	1
5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate	low	1	0
mandelic acid	low	16	0
1,10-diaminodecane	low	1	0
1,10-phenanthroline	medium	20	1
1,2-dimethylhydrazine	low	7	0
1,3-diethyl-8-phenylxanthine	low	1	0
1,3-dipropyl-8-cyclopentylxanthine	low	2	0
1,3-dipropyl-8-(4-sulfophenyl)xanthine	low	1	0
1,5-dihydroxyisoquinoline	low	1	0
pk 11195	low	4	0
1-(2-methoxyphenyl)piperazine	low	1	0
1-(2-trifluoromethylphenyl)imidazole	low	1	0
1-aminocyclohexanecarboxylic acid	low	1	0
1-aminobenzotriazole	low	3	0
1-anilino-8-naphthalenesulfonate	medium	72	2
1-methylimidazole	low	1	0
edelfosine	medium	23	1
pd 173074	low	7	0
14,15-epoxy-5,8,11-eicosatrienoic acid	low	1	0
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one	low	1	0
hoe 33342	low	1	0
2,2'-dipyridyl	low	25	0
2,4,5-trichlorophenoxyacetic acid	medium	53	1
2,4-dichlorophenoxyacetic acid	low	56	0
2,4-dichlorophenoxyacetic acid methyl ester	low	1	0
4-(2,4-dichlorophenoxy)butyric acid	low	1	0
2,4-dinitrophenol	low	8	0
gw 2433	low	1	0
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	low	18	0
2-aminofluorene	low	7	0
2-hydroxysaclofen	low	1	0
mercaptoethanol	medium	28	3
pyrithione	low	3	0
2-aminoethoxydiphenyl borate	low	3	0
3,4-dichloroisocoumarin	low	2	0
zopolrestat	low	1	0
3,4-methylenedioxyamphetamine	low	30	0
n-methyl-3,4-methylenedioxyamphetamine	medium	3	1
amitrole	low	10	0
phaclofen	low	1	0
3-aminobenzamide	low	11	0
tramiprosate	low	2	0
aminopropionitrile	low	7	0
3-bromo-7-nitroindazole	low	1	0
3-methylcholanthrene	low	400	0
enprofylline	low	1	0
3-nitropropionic acid	low	2	0
ro 5-4864	low	1	0
4,5,6,7-tetrabromo-2-azabenzimidazole	low	1	0
4,5,6,7-tetrahydroisoxazolo(4,5-c)pyridin-3-ol	low	1	0
4-amino-1,8-naphthalimide	low	4	0
4-aminopyridine	low	4	0
p-chloromercuribenzoic acid	low	1	0
chlorocresol	low	2	0
homovanillic acid	low	8	0
4-hydroxybenzoic acid hydrazide	low	1	0
4-nonylphenol	low	3	0
4-phenyl-3-furoxancarbonitrile	low	1	0
5,5-dimethyl-1-pyrroline-1-oxide	low	3	0
phenytoin	medium	29	5
5,7-dichlorokynurenic acid	low	1	0
5,8,11,14-eicosatetraynoic acid	low	1	0
5-dimethylamiloride	low	1	0
5-(n,n-hexamethylene)amiloride	low	2	0
ethylisopropylamiloride	low	2	0
5-fluoroindole-2-carboxylic acid	low	2	0
hydroxyindoleacetic acid	medium	45	6
5-methoxytryptamine	medium	5	3
6,7-dichloroquinoxaline-2,3-dione	low	1	0
phenanthridone	low	3	0
6-chloromelatonin	low	1	0
6-hydroxymelatonin	low	3	0
6-methoxytryptoline	low	1	0
6-nitroso-1,2-benzopyrone	low	1	0
7,8-dihydroxyflavone	low	1	0
7-(2-chloroethyl)theophylline	low	1	0
7-chlorokynurenic acid	low	2	0
etofylline	low	1	0
7-nitroindazole	low	2	0
8-(4-sulfophenyl)theophylline	low	1	0
8-cyclopentyl-1,3-dimethylxanthine	low	2	0
8-phenyltheophylline	low	1	0
oxyquinoline	medium	34	2
tacrine	low	2	0
ro 48-8071	low	1	0
acemetacin	low	1	0
acephate	low	1	0
acetaminophen	medium	96	20
salophen	low	4	0
acetarsol	low	1	0
acetazolamide	medium	64	1
acetochlor	low	3	0
acetohexamide	low	1	0
acetohydroxamic acid	low	1	0
acetyl-dl-leucine	low	1	0
n-acetyltryptophan	low	1	0
2-acetamido-3-(4-hydroxyphenyl)propanoic acid ethyl ester	low	1	0
6-acetylaminocaproic acid	low	2	0
acridone	low	4	0
4-(acetylamino)benzeneacetic acid	low	1	0
beta-aminoethyl isothiourea	low	18	0
ag 127	low	1	0
ag 1295	low	1	0
rtki cpd	low	1	0
tyrphostin a23	low	1	0
tyrphostin 25	low	2	0
tyrphostin a1	low	1	0
1-aminoindan-1,5-dicarboxylic acid	low	1	0
aritmina	low	1	0
aklomide	low	1	0
alachlor	low	9	0
alaproclate	low	1	0
albendazole	medium	8	2
albuterol	low	5	0
alendronate	medium	21	3
alfuzosin	low	2	0
alosetron	low	1	0
alpha-cyano-4-hydroxycinnamate	low	2	0
alpha-methyltyrosine methyl ester	low	1	0
alpha-methylornithine	low	1	0
tocopheroxy radical	low	1	0
alprazolam	medium	7	3
althiazide	low	1	0
altretamine	medium	33	5
aluminum fluoride	low	2	0
am 251	low	1	0
amantadine	medium	13	2
ametantrone	low	5	0
amfonelic acid	low	1	0
diatrizoic acid	low	12	0
amifostine anhydrous	medium	156	25
3-(2'-aminobenzhydryloxy)tropane	low	1	0
aminoglutethimide	low	4	0
pimagedine	low	4	0
p-aminohippuric acid	medium	6	1
ampyrone	low	1	0
theophylline	medium	24	4
2-aminothiazole	low	3	0
amiodarone	low	10	0
dan 2163	low	1	0
amitriptyline	medium	28	7
amlexanox	low	2	0
amlodipine	low	10	0
amobarbital	low	5	0
amoxapine	low	3	0
amsacrine	medium	42	6
anastrozole	medium	7	1
anethole trithione	low	3	0
aniracetam	low	1	0
anisindione	low	1	0
antazoline	low	2	0
9-anthroic acid	low	1	0
anthralin	low	5	0
antipyrine	medium	9	1
2-amino-4-phosphonobutyric acid	low	1	0
acetovanillone	low	3	0
arecoline	low	1	0
aristolochic acid i	low	24	0
aspirin	medium	481	51
astemizole	low	6	0
atenolol	medium	13	2
alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate	low	1	0
atrazine	low	12	0
aurintricarboxylic acid	low	6	0
azasetron	medium	4	3
azathioprine	medium	196	18
azelaic acid	low	3	0
azinphosmethyl	low	1	0
azobenzene	low	39	0
aztreonam	medium	24	14
baclofen	medium	17	1
barbital	low	5	0
bay-k-8644	low	1	0
bencyclane	low	1	0
bendiocarb	low	1	0
bendroflumethiazide	low	1	0
benefin	low	2	0
benserazide	low	1	0
bentazone	low	2	0
benzamide	low	11	0
benzethonium	low	2	0
benzo(a)pyrene	medium	153	1
benzocaine	low	3	0
benzothiazide	medium	14	2
benzyl benzoate	low	1	0
benzyl isothiocyanate	low	8	0
butylbenzyl phthalate	low	1	0
bepridil	low	3	0
berberine	low	56	0
diminazene	low	2	0
5-methoxypsoralen	low	4	0
beta-naphthoflavone	low	2	0
propiolactone	low	3	0
bethanechol	low	1	0
2,5-di-tert-butylhydroquinone	low	1	0
bay h 4502	low	2	0
bisacodyl	low	1	0
bisbenzimidazole	low	6	0
bisindolylmaleimide i	low	3	0
bisoprolol	medium	2	1
bml 190	low	1	0
bohemine	low	2	0
brimonidine	low	1	0
bromazepam	low	1	0
bromhexine	low	1	0
bromopride	low	1	0
bromisovalum	low	1	0
broxyquinoline	low	2	0
bufexamac	low	1	0
buformin	low	4	0
bumetanide	low	4	0
bunazosin	low	1	0
bupivacaine	medium	52	9
buspirone	medium	3	1
busulfan	medium	185	24
butacaine	low	1	0
butamben	low	2	0
cacodylic acid	low	8	0
caffeine	medium	117	6
verapamil	medium	97	10
beta-glycerophosphoric acid	low	1	0
camphor, (+-)-isomer	low	4	0
candesartan cilexetil	low	2	0
candesartan	medium	10	1
cannabinol	low	1	0
carbamazepine	medium	17	2
carbetapentane	low	1	0
carbofuran	low	2	0
carbazilquinone	low	8	0
carisoprodol	low	2	0
carmofur	low	11	0
carmustine	medium	128	27
carprofen	low	4	0
carvedilol	medium	14	5
carbonyl cyanide m-chlorophenyl hydrazone	low	4	0
cefuroxime	medium	4	1
celecoxib	medium	112	19
cefixime	medium	5	4
cetyltrimethylammonium ion	low	9	0
cgp 37157	low	2	0
cgs 12066	low	1	0
cgs 15943	low	1	0
chetomin	low	2	0
chelerythrine	low	6	0
chloral hydrate	low	9	0

Drug

Indicated

Relationship Strength

Studies

Trials

acetylcarnitine

medium

dinitrochlorobenzene

medium

ethylene dichloride

medium

2,3-dihydroxybenzoic acid

low

chloroacetaldehyde

medium

ethylene chlorohydrin

low

alpha-hydroxyglutarate

medium

alpha-ketoglutaric acid

low

2-phosphoglycerate

low

2,3-diphosphoglycerate

low

2,5-dichlorophenol

low

alpha-ketoadipic acid

low

protocatechuic acid

medium

3-cyanopyridine

low

3-hydroxyanthranilic acid

low

3-hydroxykynurenine

low

acetoacetic acid

low

phosphoserine

low

3-phenylpropionic acid

low

cysteine sulfinic acid

low

n-carbamoyl-beta-alanine

low

gamma-aminobutyric acid

medium

4-hydroxybenzaldehyde

low

4-hydroxybenzoic acid

low

aminolevulinic acid

low

119

5-hydroxytryptophan

medium

phosphoribosyl-n-formylglycineamide

low

medium

low

medium

low

low

low

medium

low

low

low

low

medium

low

low

medium

low

medium

medium

low

low

low

low

low

low

low

medium

low

low

low

medium

low

low

medium

low

medium

low

low

medium

low

citric acid, anhydrous

medium

chlorine

medium

117

hydrochloric acid

medium

coproporphyrinogen iii

low

coumarin

medium

4-hydroxymandelic acid

low

medium

low

medium

4-nitrophenylphosphate

low

low

low

low

medium

low

low

low

low

3-hydroxybutyric acid

medium

bupropion

medium

sorbitol

low

n(1)-methylnicotinamide

low

low

low

low

low

2-keto-4-methylthiobutyric acid

low

methylmalonic acid

medium

n(1)-acetylspermidine

low

n(g),n(g')-dimethyl-l-arginine

low

low

low

low

low

1-aminocyclopropane-1-carboxylic acid

low

arsenous acid

low

phosphonoacetic acid

medium

3,4-dihydroxyphenylacetic acid

low

medium

low

medium

medium

medium

low

low

low

low

low

dihydroxyacetone phosphate

low

low

low

medium

low

medium

low

low

hexachlorocyclohexane

low

low

medium

low

medium

alpha-glycerophosphoric acid

low

low

low

low

low

medium

medium

medium

low

medium

low

low

low

low

low

medium

low

low

dihydroxyphenylalanine

medium

kynurenine

medium

2,3,4,5-tetrahydroxypentanal

low

low

medium

low

low

low

medium

low

low

medium

low

low

low

low

low

medium

medium

medium

medium

low

medium

medium

medium

low

low

low

low

low

medium

low

low

4-hydroxyphenylpyruvic acid

low

low

low

medium

low

low

low

medium

low

low

medium

low

low

low

medium

phosphorylethanolamine

medium

low

low

low

low

low

medium

low

low

medium

medium

low

low

low

low

low

low

medium

low

low

low

medium

medium

low

medium

medium

low

medium

medium

low

medium

medium

low

low

medium

medium

low

low

low

low

medium

medium

medium

low

low

isopentenyl pyrophosphate

low

isocitric acid

low

catechin

low

2-amino-5-phosphonovalerate

low

8-hydroxy-2-(di-n-propylamino)tetralin

low

alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

low

alpha-methyl-4-carboxyphenylglycine

low

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid

low

4-iodo-2,5-dimethoxyphenylisopropylamine

low

1-hydroxy-3-amino-2-pyrrolidone

low

ibotenic acid

low

normetanephrine

low

n(8)-bromoacetyl-n(1)-3'-(4-indolyloxy)-2'-hydroxypropyl-1,8-diamino-4-menthane

low

low

low

low

medium

5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate

low

mandelic acid

low

1,10-diaminodecane

low

1,10-phenanthroline

medium

1,2-dimethylhydrazine

low

1,3-diethyl-8-phenylxanthine

low

1,3-dipropyl-8-cyclopentylxanthine

low

1,3-dipropyl-8-(4-sulfophenyl)xanthine

low

1,5-dihydroxyisoquinoline

low

pk 11195

low

1-(2-methoxyphenyl)piperazine

low

1-(2-trifluoromethylphenyl)imidazole

low

1-aminocyclohexanecarboxylic acid

low

1-aminobenzotriazole

low

1-anilino-8-naphthalenesulfonate

medium

1-methylimidazole

low

edelfosine

medium

pd 173074

low

14,15-epoxy-5,8,11-eicosatrienoic acid

low

1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one

low

hoe 33342

low

2,2'-dipyridyl

low

2,4,5-trichlorophenoxyacetic acid

medium

2,4-dichlorophenoxyacetic acid

low

2,4-dichlorophenoxyacetic acid methyl ester

low

4-(2,4-dichlorophenoxy)butyric acid

low

2,4-dinitrophenol

low

gw 2433

low

2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine

low

low

low

medium

low

2-aminoethoxydiphenyl borate

low

3,4-dichloroisocoumarin

low

zopolrestat

low

3,4-methylenedioxyamphetamine

low

n-methyl-3,4-methylenedioxyamphetamine

medium

low

low

low

low

low

3-bromo-7-nitroindazole

low

3-methylcholanthrene

low

400

enprofylline

low

3-nitropropionic acid

low

ro 5-4864

low

4,5,6,7-tetrabromo-2-azabenzimidazole

low

4,5,6,7-tetrahydroisoxazolo(4,5-c)pyridin-3-ol

low

4-amino-1,8-naphthalimide

low

4-aminopyridine

low

p-chloromercuribenzoic acid

low

chlorocresol

low

homovanillic acid

low

4-hydroxybenzoic acid hydrazide

low

4-nonylphenol

low

4-phenyl-3-furoxancarbonitrile

low

5,5-dimethyl-1-pyrroline-1-oxide

low

phenytoin

medium

5,7-dichlorokynurenic acid

low

5,8,11,14-eicosatetraynoic acid

low

5-dimethylamiloride

low

5-(n,n-hexamethylene)amiloride

low

ethylisopropylamiloride

low

5-fluoroindole-2-carboxylic acid

low

hydroxyindoleacetic acid

medium

5-methoxytryptamine

medium

6,7-dichloroquinoxaline-2,3-dione

low

low

low

low

low

6-nitroso-1,2-benzopyrone

low

7,8-dihydroxyflavone

low

7-(2-chloroethyl)theophylline

low

7-chlorokynurenic acid

low

etofylline

low

7-nitroindazole

low

8-(4-sulfophenyl)theophylline

low

8-cyclopentyl-1,3-dimethylxanthine

low

low

medium

low

low

low

low

medium

low

low

medium

low

low

low

low

low

2-acetamido-3-(4-hydroxyphenyl)propanoic acid ethyl ester

low

6-acetylaminocaproic acid

low

acridone

low

4-(acetylamino)benzeneacetic acid

low

beta-aminoethyl isothiourea

low

low

low

low

low

low

low

1-aminoindan-1,5-dicarboxylic acid

low

low

low

low

low

medium

low

medium

low

low

alpha-cyano-4-hydroxycinnamate

low

alpha-methyltyrosine methyl ester

low

alpha-methylornithine

low

low

medium

low

medium

low

low

medium

low

low

low

medium

3-(2'-aminobenzhydryloxy)tropane

low

low

low

medium

low

medium

low

low

low

medium

low

low

low

low

medium

medium

low

low

low

low

low

low

medium

2-amino-4-phosphonobutyric acid

low

low

low

low

medium

low

medium

alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate

low

atrazine

low

aurintricarboxylic acid

low

medium

medium

low

low

low

medium

medium

low

low

low

low

low

low

low

low

low

low

medium

low

medium

low

benzyl isothiocyanate

low

butylbenzyl phthalate

low

low

low

low

low

low

low

low

2,5-di-tert-butylhydroquinone

low

bay h 4502

low

bisacodyl

low

bisbenzimidazole

low

bisindolylmaleimide i

low

medium

low

low

low

low

low

low

low

low

low

low

low

low

medium

medium

medium

low

low

low

medium

medium

beta-glycerophosphoric acid

low

camphor, (+-)-isomer

low

candesartan cilexetil

low

medium

low

medium

low

low

low

low

low

medium

low

medium

carbonyl cyanide m-chlorophenyl hydrazone

low

medium

medium

medium

cetyltrimethylammonium ion

low

low

low

low

low

low

low

medium

medium

low

medium

low

low

low

medium

medium

low

low

low

low

low

chromone-2-carboxylic acid

low

low

medium

low

low

low

low

medium

low

low

low

medium

medium

medium

5,7-dimethoxycoumarin

low

low

medium

low

low

low

medium

low

low

low

medium

medium

medium

4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide

low

low

low

medium

low

colchicine, (+-)-isomer

low

conduritol epoxide

low

coumaphos

low

2-(2-hydroxyethylsulfanyl)-3-methyl-1,4-naphthoquinone

low

low

low

low

low

low

low

medium

low

medium

dimethyl 2,3,5,6-tetrachloroterephthalate

low

low

low

low

low

low

medium

low

low

medium

low

low

medium

low

low

medium

low

medium

low

low

low

low

low

low

low

medium

dichlorodiphenyl dichloroethylene

low

medium

low

low

low

low

3,4-dihydroxybenzohydroxamic acid

medium

diethyl pyrocarbonate

low

low

medium

medium

dihydrocytochalasin b

low

3,3'-diindolylmethane

low

low

low

low

low

low

low

medium

low

low

medium

low

low

medium

low

low

low

medium

2-amino-7-phosphonoheptanoic acid

low

racemetirosine

medium

thiorphan

low

2,3-dimethoxy-1,4-naphthoquinone

low

medium

medium

low

low

low

low

medium

low

low

low

low

low

low

low

low

low

low

medium

low

medium

medium

medium

medium

low

low

low

low

low

eicosapentaenoic acid ethyl ester

medium

low

medium

low

low

low

medium

carbonyl cyanide p-trifluoromethoxyphenylhydrazone

low

low

low

low

low

low

medium

low

medium

low

medium

123

low

low

low

medium

low

low

medium

medium

medium

medium

low

low

low

low

medium

258

medium

low

medium

medium

low

low

low

low

low

low

low

low

medium

low

medium

medium

low

4-amino-5-hexynoic acid

low

gemfibrozil

medium

gentamicin

medium

2,5-dihydroxybenzoic acid

low

low

medium

low

low

low

low

low

low

medium

low

low

low

medium

low

1-(5-isoquinolinesulfonyl)-2-methylpiperazine

low

1-(5-isoquinolinesulfonyl)piperazine

low

low

low

low

medium

medium

low

low

low

low

low

low

4-fluorohexahydrosiladifenidol

low

low

low

low

medium

low

low

hexamethylene bisacetamide

medium

low

medium

medium

medium

low

low

low

medium

medium

medium

low

low

medium

low

low

medium

low

low

low

medium

medium

low

medium

indirubin-3'-monoxime

low

low

medium

medium

medium

low

low

low

medium

low

low

medium

medium

low

medium

low

low

medium

low

low

1-methyl-3-isobutylxanthine

low

isocarboxazid

low

isoflurane

medium

isoniazid

medium

4-piperidinecarboxylic acid

low

low

low

low

low

4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline

low

whi p154

low

jl 18

low

7-amino-4-chloro-3-methoxy-2-benzopyran-1-one

low

juglone

low

staurosporine aglycone

low

low

medium

low

medium

medium

medium

medium

low

low

low

low

2-amino-3-phosphonopropionic acid

low

low

low

low

low

medium

low

medium

low

low

medium

medium

low

low

low

low

low

medium

medium

low

medium

low

low

low

low

2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one

low

low

low

low

medium

low

low

medium

low

medium

meclofenamate sodium anhydrous

low

medium

medium

low

medium

low

low

low

low

low

low

low

low

medium

low

medium

low

low

low

low

medium

low

low

low

medium

low

low

medium

low

low

medium

3-Hydroxy-alpha-methyl-DL-tyrosine

low

3,7-bis(dimethylamino)phenothiazin-5-ium

low

methyl methanesulfonate

low

medium

medium

low

low

medium

medium

low

low

medium

medium

medium

low

medium

medium

low

medium

low

medium

low

low

medium

low

n(1),n(11)-diethylnorspermine

medium

deet

low

n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide

low

n-bromoacetamide

low

ethylmaleimide

low

2-[[2-formamido-4-(methylthio)-1-oxobutyl]amino]propanoic acid

low

n-formylmethionylphenylalanine

low

low

low

low

medium

low

low

low

low

low

medium

low

low

low

medium

medium

low

low

low

low

low

low

medium

low

low

low

low

medium

medium

low

low

low

medium

low

low

medium

low

5-nitro-2-(3-phenylpropylamino)benzoic acid

low

ns 2028

low

ns 1619

low

n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide

low

low

low

medium

low

medium

low

medium

medium

111

medium

1,2-cyclohexanediamine

low

low

low

low

medium

low

low

low

low

low

medium

medium

low

low

low

low

medium

medium

medium

low

low

low

low

low

low

low

low

low

low

low

low

medium

low

low

low

low

medium

low

low

low

medium

medium

phenolsulfonphthalein

low

low

low

medium

low

low

medium

phenylmethylsulfonyl fluoride

low

phloretin

low

phorate

low

phosalone

low

phthalylsulfathiazole

low

low

low

low

low

low

low

medium

low

low

piperidine-4-sulfonic acid

low

medium

low

low

medium

low

low

low

low

medium

low

low

low

medium

medium

low

low

low

medium

low

low

low

medium

medium

medium

low

low

low

low

low

low

low

low

medium

low

low

low

low

medium

low

medium

low

low

low

low

low

low

low

medium

low

1,2,5,8-tetrahydroxy anthraquinone

low

medium

low

low

low

low

low

resorcinol monoacetate

low

low

medium

low

medium

low

low

4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone

low

medium

low

low

low

low

butyl phosphorotrithioate

low

low

low

low

low

low

low

low

low

low

low

low

medium

low

medium

medium

medium

medium

low

low

s-nitroso-n-acetylpenicillamine

low

low

medium

low

medium

low

low

low

low

low

low

low

low

low

low

medium

medium

low

low

succinylsulfathiazole

low

low

low

low

low

low

low

low

medium

sulfamethoxypyridazine

low

low

low

low

low

low

low

low

medium

low

medium

medium

low

2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol

low

medium

low

medium

low

low

medium

medium

1,4-bis(2-(3,5-dichloropyridyloxy))benzene

low

low

medium

low

low

medium

low

low

low

low

low

low

tetraisopropylpyrophosphamide

low

tetrahydroxy-1,4-quinone

low

3-hydroxyaspartic acid

low

medium

low

low

2,4-thiazolidinedione

low

medium

low

low

medium

medium

low

low

low

low

medium

medium

medium

low

8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate

low

low

low

medium

medium

low

low

(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid

low

ici 136,753

low

tranexamic acid

medium

2-phenylcyclopropan-1-amine

low

medium

low

low

low

low

low

low

2,2',2''-trichlorotriethylamine

low

medium

medium

low

medium

low

low

low

low

medium

medium

low

low

low

low

low

low

low

medium

low

low

low

low

low

medium

low

low

low

8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine

low

xanthurenic acid

low

2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2h-tetrazolium hydroxide

low

xylazine

low

1,4-phenylenebis(methylene)selenocyanate

low

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole

low

low

low

medium

low

medium

low

medium

hydrocortisone acetate

low

low

medium

low

medium

low

lysergic acid diethylamide

medium

low

low

low

low

medium

low

medium

medium

low

procaine hydrochloride

low

low

low

low

low

3,3',5-triiodothyroacetic acid

low

3,3',5-triiodothyropropionic acid

low

dichloroisoproterenol

low

isoproterenol hydrochloride

low

hydroxyproline

medium

histamine dihydrochloride

low

thyroxine

medium

153

dibenzylchlorethamine

low

dextroamphetamine

medium

carbachol

low

norethindrone acetate

medium

medium

low

low

low

low

low

low

low

low

medium

low

low

methylprednisolone acetate

low

oxandrolone

low

androsterone

low

etiocholanolone

low

dehydroepiandrosterone

medium

promazine hydrochloride

low

1,2,5,6-dibenzanthracene

low

nad

low

hydroxyacetylaminofluorene

low

2-acetylaminofluorene

low

medium

low

medium

medium

low

pilocarpine hydrochloride

low

pilocarpine

medium

dimethylphenylpiperazinium iodide

low

low

low

low

low

racepinephrine hydrochloride

low

(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride

low

methyldimethylaminoazobenzene

low

isoflurophate

low

dimethylmyleran

low

hexamethonium bromide

low

biguanides

medium

cystamine dihydrochloride

low

carbon tetrachloride

low

cantharidin

low

tetraethylammonium chloride

low

alanine

medium

serine

medium

255

desoxycorticosterone acetate

low

benz(a)anthracene

low

135

4-nitroquinoline-1-oxide

low

medium

medium

medium

medium

low

low

medium

low

low

low

low

medium

low

testosterone propionate

low

tubocurarine

low

9,10-dimethyl-1,2-benzanthracene

low

low

medium

low

promethazine hydrochloride

low

tetrabenazine

low

puromycin aminonucleoside

low

adenosine diphosphate

medium

cephalothin

medium

triphenylethylene

low

2,3,4,6-tetrachlorophenol

medium

uridine

medium

117

uridine monophosphate

low

low

medium

medium

medium

medium

low

low

low

low

tolazoline hydrochloride

low

medium

medium

low

p-dimethylaminoazobenzene

low

low

medium

low

acetylcholine chloride

low

low

low

low

low

methoxamine hydrochloride

low

methoxamine

low

adenosine monophosphate

low

papaverine hydrochloride

low

methicillin

low

n,n-dimethyltryptamine

low

low

medium

medium

low

low

medium

low

low

ethyl methanesulfonate

low

methacholine chloride

low

aniline

low

2-aminoisobutyric acid

low

dimethylnitrosamine

low

androstenedione

low

carbaryl

low

cytidine monophosphate

low

low

medium

medium

low

thonzylamine monohydrochloride

low

methionine

medium

243

1,2-dipalmitoylphosphatidylcholine

low

medium

low

low

low

yohimbine hydrochloride

low

gallamine triethiodide

low

cytidine

medium

cytidine triphosphate

medium

low

low

low

low

low

low

low

low

medium

medium

fluocinolone acetonide

low

triamcinolone diacetate

low

gliotoxin

low

sodium citrate, anhydrous

medium

low

medium

low

low

medium

17-alpha-hydroxyprogesterone

low

quinacrine monohydrochloride

low

chlorpromazine hydrochloride

low

tubercidin

low

ampicillin

medium

mannitol

medium

cytarabine hydrochloride

low

cytarabine

medium

302

dithionitrobenzoic acid

low

medium

low

medium

low

medium

low

low

4-hydroxypropiophenone

low

histidine

medium

117

n-pentanol

low

1,1,1-trichloroethane

low

medroxyprogesterone acetate

medium

low

low

medium

medium

low

low

low

dichlorodiphenyldichloroethane

low

low

low

medium

low

medium

low

lidocaine hydrochloride

low

medium

low

low

medium

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

medium

low

low

low

low

low

low

low

low

low

low

bromotrichloromethane

low

tert-butyl alcohol

low

methanesulfonic acid

low

trichloroacetaldehyde

low

trifluoroethanol

low

tert-butylhydroperoxide

low

low

low

low

low

triamcinolone acetonide

medium

medium

low

low

medium

low

hexachlorocyclopentadiene

low

low

low

medium

medium

3-mercaptopropionic acid

low

low

low

low

low

low

low

low

low

low

chloroacetyl chloride

low

low

medium

low

medium

low

low

low

medium

low

low

tetrabromobisphenol a

low

low

low

low

low

low

low

low

1-amino-2,4-dibromoanthraquinone

low

purpurin

low

1,4-dihydroxyanthraquinone

low

rhodamine b

medium

benzanthrone

low

1-amino-2-methylanthraquinone

low

low

low

low

medium

3-methylsalicylic acid

low

medium

low

low

low

9,10-phenanthrenequinone

low

syrosingopine

low

2,6-dihydroxyanthraquinone

low

low

low

low

low

low

low

1-naphthalenesulfonic acid

low

pyocyanine

low

n-nitrosodiphenylamine

low

acriflavine chloride

low

1-hydroxy-2-naphthoic acid

low

low

low

medium

low

low

low

medium

low

low

low

2,4,6-trichlorophenol

low

n-vinyl-2-pyrrolidinone

medium

2-tert-butyl-4-hydroxyanisole

low

anthranilamide

low

2-nitrotoluene

low

1-chloro-2-nitrobenzene

low

2,3,5-triiodobenzoic acid

low

picryl chloride

low

picric acid

low

2,4-dinitrobenzenesulfonic acid

low

low

low

low

low

low

1-naphthylphenylamine

low

low

low

low

low

low

beta-glucono-1,5-lactone

low

pyrogallol 1,3-dimethyl ether

low

quinoxalines

medium

101

1,2,3,4-tetrahydroisoquinoline

low

low

low

low

low

3,3'-dichlorobenzidine

low

3,3'-diaminobenzidine

low

low

low

low

low

low

low

medium

low

low

4,4'-dihydroxybiphenyl

low

low

low

low

low

low

low

low

low

2-methyl-4-chlorophenoxyacetic acid

low

low

low

low

low

low

low

low

low

4-chloro-1,2-diaminobenzene

low

2,4,5-trichlorophenol

low

dilactide

low

allyl methacrylate

low

styrene oxide

low

1,2-dibromo-3-chloropropane

low

2,3-dibromopropanol

low

1,2,3-trichloropropane

low

1,3-dichloro-2-propanol

low

low

low

low

medium

low

2,4-di-tert-butylphenol

low

lactobionic acid

low

sulfosalicylic acid

low

1,3-ditolylguanidine

low

phosphoribosyl pyrophosphate

medium

o-aminoazotoluene

low

ethyl methacrylate monomer

low

ethylene dimethacrylate

low

low

low

low

low

low

pyrrolidonecarboxylic acid

medium

low

low

low

low

low

low

low

low

low

4-bromophenacyl bromide

low

low

low

low

low

4-hydroxyacetophenone

low

dimethyl-4-toluidine

low

4-chloronitrobenzene

low

4-nitroaniline

low

4-(dimethylamino)benzaldehyde

low

low

low

medium

low

low

low

low

low

low

medium

low

methylenebis(chloroaniline)

low

pyridostigmine bromide

medium

4-benzylphenol

low

4,4'-diphenylmethane diisocyanate

low

4,4'-diaminodiphenylmethane

low

di-(4-aminophenyl)ether

low

2-benzylpyridine

low

dicyclohexylamine

low

diglycidyl resorcinol ether

low

low

low

low

low

low

low

medium

low

4-vinyl-1-cyclohexene dioxide

low

low

low

low

low

low

low

low

low

low

low

low

low

chloromethyl methyl ether

low

dimethyldioctadecylammonium

low

2-methylpentane

low

vinyl acetate

low

methyl isobutyl ketone

low

low

low

low

low

low

medium

low

low

low

low

medium

low

low

low

low

low

low

low

low

low

medium

low

medium

n,n'-methylenebisacrylamide

low

medium

low

low

low

dimethylethylenediamine

low

low

low

low

low

low

low

low

bis(2-chloroethyl)ether

low

low

low

low

low

stearyltrimethylammonium

low

triethylene glycol

low

decanaldehyde

low

undecanoic acid

low

tetraethylenepentamine

low

lauryl acetate

low

ergotamine

low

methylergonovine

low

imipramine hydrochloride

low

neostigmine bromide

low

n(1)-acetylphenylhydrazine

low

phenformin

low

propylene

low

2,2,2-trichloroethanol

low

chlorendic acid

low

oxyphenisatin acetate

low

low

low

low

low

low

low

low

low

diethylhexyl phthalate

low

low

low

low

low

2'-hydroxyacetophenone

low

medium

low

low

low

low

low

low

low

low

ethyl-p-hydroxybenzoate

low

low

low

low

low

3-tert-butyl-4-hydroxyanisole

low

2,4-dinitrotoluene

low

vanillic acid

low

triethylamine

low

benzethonium chloride

low

2-amino-5-nitrothiazole

low

sulfan blue

low

suramin sodium

low

pyrazolanthrone

low

piperidolate hydrochloride

low

1,4-naphthoquinone

low

pamoic acid

low

diatrizoate meglumine

low

meglumine

medium

dioxybenzone

low

2,2',4,4'-tetrahydroxybenzophenone

low

captan

low

folpet

low

phenyl 4-aminosalicylate

low

iodohippuric acid

low

peucedanin

low

uridine diphosphate glucose

low

low

medium

low

low

methapyrilene hydrochloride

low

neozone

low

oxythiamine

low

1,3-diphenyl-1-triazene

low

phenazopyridine hydrochloride

low

tetrracaine hydrochloride

low

2-aminothiophenol

low

ziram

low

dextrothyroxine

medium

amprolium hydrochloride

low

carzenide

low

shikimic acid

medium

chelidamic acid

low

4-nitrosodimethylaniline

low

nitrilotriacetic acid

low

4,4'-thiodianiline

low

aminoethylpiperazine

low

monuron

low

pentamidine isethionate

low

low

low

medium

low

low

low

low

low

low

low

monomethylarsonic acid

low

low

low

low

low

low

diphenhydramine hydrochloride

medium

medium

low

medium

low

medium

low

low

low

low

low

medium

thiamine pyrophosphate

low

phenetidine

low

cysteamine hydrochloride

low

methylene dimethanesulfonate

low

low

low

low

low

low

medium

indeno(1,2,3-cd)pyrene

low

7h-dibenzo(c,g)carbazole

low

low

low

low

low

low

low

low

low

low

low

medium

178

medium

low

medium

low

medium

low

low

low

low

medium

medium

medium

medium

medium

low

low

low

medium

low

low

low

propantheline bromide

low

nitroblue tetrazolium

medium

triphenyltetrazolium

low

calcium gluconate

medium

ephedrine

low

allylisopropylacetamide

low

low

medium

medium

chlormadinone acetate

low

benactyzine

low

pirinitramide

low

hydralazine hydrochloride

low

ethamivan

low

pargyline hydrochloride

low

hydroxyamphetamine hydrobromide

low

4-hydroxyphenyllactic acid

low

perfluorodecalin

low

dexamethasone 21-phosphate

medium

evans blue

low

apomorphine hydrochloride, anhydrous

low

monocrotaline

low

testosterone enanthate

low

low

low

low

medium

low

low

low

perfluorooctanoic acid

medium

carbutamide

low

orphenadrine hydrochloride

low

methylthioinosine

medium

pseudoephedrine hydrochloride

low

3-acetylpyridine

low

2,2,2-trifluoroethyl methacrylate

low

low

low

low

low

2-chloro-1,1-difluoroethylene

low

nandrolone decanoate

medium

aminoimidazole carboxamide

medium

methysergide

low

bucladesine

low

kynuramine

low

thymidine monophosphate

low

2-fluoroethanol

low

citrulline

low

betamethasone

medium

4-hydroxyphenobarbital

low

prenylamine

medium

hexafluorobenzene

low

benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide

low

trifluoroacetic anhydride

low

low

low

low

low

low

low

low

medium

thiazolidine-4-carboxylic acid

medium

1,2-dihydronaphthalene

low

low

low

low

low

low

low

low

medium

low

low

low

low

low

medium

medium

low

medium

low

chenodeoxycholic acid

low

low

low

low

low

medium

low

low

low

low

low

low

low

low

low

medium

low

low

medium

low

low

phosphoadenosine phosphosulfate

low

low

low

low

low

low

low

low

low

low

low

indole-3-carbaldehyde

low

medium

low

low

low

low

low

low

low

low

salicylaldehyde isonicotinoyl hydrazone

low

low

low

low

low

low

2,4-pyridinedicarboxylic acid

low

dipicolinic acid

low

oxanilic acid

low

4-hydroxyphenylethanol

low

low

low

low

medium

medium

low

low

low

medium

low

low

low

low

low

low

low

medium

low

low

low

medium

medium

low

low

medium

low

tetrahydrozoline hydrochloride

low

low

low

low

low

low

low

low

medium

medium

uridine diphosphate n-acetylglucosamine

low

cellobiose

low

3',5'-dichloromethotrexate

low

apronalide

low

1,2,3,4-tetrahydro-1-naphthalenol

low

syringic acid

low

acetylsalicylsalicylic acid

low

herniarin

low

furothiazole

low

thiamine monophosphate

low

low

low

low

low

low

methoxyhydroxyphenylglycol

low

medium

low

low

low

low

dicyclohexylcarbodiimide

low

low

low

low

medium

low

low

decamethonium dibromide

low

low

low

low

low

medium

low

low

medium

bis(chloromethyl) ether

low

cadmium acetate

low

myristic acid

low

triethylenephosphoramide

medium

trinitrobenzenesulfonic acid

low

eosine yellowish-(ys)

low

phenalen-1-one

low

2-thymotic acid

low

lucanthone hydrochloride

low

gentian violet

low

amitriptyline hydrochloride

low

resazurin

low

naphazoline hydrochloride

low

trimellitic anhydride

low

low

medium

low

low

low

medium

low

low

4-chloromercuribenzenesulfonate

low

trimesic acid

low

tripalmitin

low

benzylhydrazine

low

glycyl-glycyl-glycine

low

glycidol

low

doxylamine succinate

low

4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol

low

glycerylphosphorylcholine

low

carbamylhydrazine monohydrochloride

low

3-chloro-2-methylprop-1-ene

low

diepoxybutane

low

2-hydroxybutyric acid

low

low

low

low

low

1,4-naphthohydroquinone

low

congo red

low

1,2-dihydroxynaphthalene

low

low

low

low

low

isoxsuprine hydrochloride

low

low

low

low

low

low

toluene 2,4-diisocyanate

low

terpinolene

low

4-acetylbenzoic acid

low

diphenylamine

medium

betaine hydrochloride

low

bethanechol chloride

low

iodobenzene

low

levulinic acid

low

methyl n-butyl ketone

low

low

low

low

medium

medium

low

low

low

low

low

low

low

low

n-hydroxy-1-naphthylamine

low

low

medium

low

low

low

low

low

low

low

4-methoxy-3-phenylenediamine

low

nitrosomethylurethane

low

low

low

medium

low

low

2,6-dichloro-4-nitrophenol

low

3-hydroxybenzeneacetic acid

low

low

low

low

low

low

low

1,1,1,2-tetrachloroethane

low

2-sulfobenzoic acid

low

bulbocapnine

low

dicarbethoxydihydrocollidine

low

c.i. 42510

low

brilliant green

low

Berberine chloride (TN)

low

phendimetrazine

low

2-pyrrolecarboxylic acid

low

ethyl tert-butyl ether

low

benzydamine

medium

erythromycin stearate

low

erythromycin

medium

4-propylphenol

low

formal glycol

low

dehydroepiandrosterone sulfate

low

low

low

low

medium

low

low

medium

low

low

low

2-methyl-5-nitroimidazole

low

2-fluoroadenine

low

methoxytryptophol

medium

sterculic acid

low

hydroxychloroquine sulfate

low

n-methyl-n-formylhydrazine

low

ethylnitrosourea

low

eptc

low

1,2-cyclohexanedione

low

2,3-dimethylmaleic anhydride

low

9-methylanthracene

low

9,10-dimethylanthracene

low

low

medium

medium

low

Mecamylamine hydrochloride

low

naphthyl acetate

low

1-phenylazo-2-naphthol

low

n-hydroxy-4-acetylaminostilbene

low

dihydrotestosterone propionate

low

dipipanone

low

phentyrin

low

vinblastine

low

alpha-fluoro-beta-alanine

low

hydroxyethyl methacrylate

low

n-nitrosobutylurea

low

2-chloroethylamine

low

2-phenylbenzothiazole

low

1,4-androstadiene-3,17-dione

low

diphenoxylate

low

amaranth dye

low

hexafluoroisopropanol

low

low

low

low

low

low

low

low

low

nitrosobenzylmethylamine

low

3-hydroxy-1-benzopyran-2-one

low

1,2,3,4-tetrahydrocarbazole

low

low

low

low

medium

258

medium

low

low

low

low

cyproheptadine hydrochloride (anhydrous)

low

canrenone

low

estradiol valerate

low

cytidine diphosphate choline

low

rhodamine 6g

low

methylphosphonic acid

low

pentadecanoic acid

low

5-methoxyindole

low

2-phenylpyridine

low

deoxycytidine monophosphate

low

low

low

low

low

low

low

benzylhydrazine dihydrochloride

low

phenylglyoxal

low

4-(4-nitrobenzyl)pyridine

low

nicotinamide mononucleotide

low

dimethoxon

low

metformin hydrochloride

low

n-nitrosodiethanolamine

low

1,3-propane sultone

low

pyridine-2-carboxaldehyde

low

2-acetylpyridine

low

tetramethylpyrazine

low

4,4'-dimethyl-2,2'-bipyridine

low

4-n-bis(2-chloroethyl)aminobenzoic acid

low

decabromobiphenyl ether

low

low

low

low

low

low

low

low

medium

low

medium

low

medium

medium

low

low

low

low

medium

low

medium

medium

low

low

low

low

low

low

low

low

low

sorbitan monostearate

low

low

medium

low

medium

medium

medium

low

low

low

medium

low

low

low

bisphenol a-glycidyl methacrylate

low

2,4-dinitrothiocyanatobenzene

low

daminozide

low

vincamine

low

fenchol

low

methyl tert-butyl ether

low

4-n-Butylphenol

low

diethylcarbamazine citrate

low

low

medium

low

low

low

low

low

low

medium

(4-tert-Butyl-phenoxy)-acetic acid

low

azacyclonol

low

2,2'-biphenol

low

pentachloromethylthiobenzene

low

stearylamine

low

4-nitrothiophenolate

low

5 alpha-androstane-3 alpha,17 beta-diol

low

4-chlorophenylacetic acid

low

ethyldimethylaminopropyl carbodiimide

low

tetrachloroisophthalonitrile

medium

paraquat

low

picloram

low

pristane

low

2'-deoxyadenosine triphosphate

low

s,n,n'-tripropylthiocarbamate

medium

2-tert-butylhydroquinone

low

5-hydroxyindole

low

ethoglucid

low

beta-hydroxymyristic acid

low

dronabinol

medium

112

methionine sulfoximine

medium

n-tetradecylamine

low

amiloride hydrochloride, anhydrous

low

low

low

low

low

azetidyl-2-carboxylic acid

low

flumethasone

medium

betamethasone valerate

low

2,4-diacetylphloroglucinol

low

fluometuron

low

azaribine

low

diallyl disulfide

low

hydrocortisone hemisuccinate

low

n-isopropylacrylamide

low

benzylguanidine

low

menthol

low

phenethyl isothiocyanate

medium

low

low

low

low

methylprednisolone hemisuccinate

medium

low

low

low

low

low

dexamethasone sodium phosphate

low

low

low

low

low

low

medium

low

low

low

antazoline hydrochloride

low

sulfur hexafluoride

low

7,12-dihydroxymethylbenz(a)anthracene

low

direct blue 6

low

uridine diphosphate glucuronic acid

low

acadesine

low

1,2-benzisothiazoline-3-one

low

n,n-dimethylacrylamide

low

thiocholchicine

low

mebeverine hydrochloride

low

hydroxyphenytoin

low

n-methylamino-2-nitro-4-n',n'-bis(2-hydroxyethyl)aminobenzene

low

n-methylcolchiceinamide, (s)-isomer

low

2-(dimethylamino)ethyl methacrylate

low

squaric acid

low

2-amino-4,5,6,7-tetrahydrobenzothiazole

low

thymine glycol

low

uridine diphosphate galactose

low

clopidol

low

dichloroacetonitrile

low

4-nitroimidazole

low

benzo(a)pyrene-3,6-quinone

low

midodrine hydrochloride

low

doxifluridine

medium

dicloxacillin

medium

colchicenamide

low

p-chloro-o-toluidine hydrochloride

low

ornithylaspartate

low

octachlorodibenzo-4-dioxin

low

2,2-bis(bromomethyl)-1,3-propanediol

low

fluorescein-5-isothiocyanate

low

9-anilinoacridine

low

benzolamide

low

sabinene

low

2,3-diketogulonic acid

low

improsan

medium

mannose

low

5-methoxyindoleacetic acid

low

trimethylcolchicinic acid methyl ether

low

dithiothreitol

medium

clidinium bromide

low

palmatine

low

pentaerythrityl triacrylate

low

3-methoxy-4-aminoazobenzene

low

medium

low

low

low

uridine diphosphate xylose

low

cyclic cmp

low

acedoben

low

dimethyl trisulfide

low

meclofenoxate hydrochloride

low

5-methylchrysene

low

tranylcypromine

low

2-(aminomethyl)pyridine

low

todralazine

low

streptomycin

low

carbonates

low

butylhydroxybutylnitrosamine

low

low

low

low

low

low

2-amino-1,3,4-thiadiazole

low

nitroxoline

low

5-azacytosine

low

4-acetylaminobiphenyl

low

pn 401

medium

2-acetamidophenanthrene

low

dimethylnitramine

low

clonidine hydrochloride

low

cladribine

medium

hyaluronoglucosaminidase

low

mono-(2-ethylhexyl)phthalate

low

low

low

low

low

2,4,5-trimethoxybenzaldehyde

low

n-hydroxy-4-acetylaminobiphenyl

low

2,2'-diamino-1,1'-dinaphthyl

low

nitracrine

low

carbenicillin

medium

1-naphthalenemethanol

low

carbenicillin disodium

low

1,3-dithiolane

low

2,3,4,5-tetrachlorophenate

low

trimetazidine

low

dexpropranolol

low

buthionine sulfoximine

medium

low

low

low

low

mexiletine hydrochloride

low

1,3-diphenylisobenzofuran

low

dihydrostreptomycin sulfate

low

aseanostatin p5

low

1-nitropyrene

low

beclomethasone dipropionate

low

vidarabine

medium

diadenosine tetraphosphate

low

low

low

low

medium

low

stearoyl-2-lactylic acid

low

low

low

medium

low

low

acetoxyacetylaminofluorene

low

suxamethonium chloride

low

chlorphenamidine

low

cyclobenzaprine hydrochloride

low

4-(4-dimethylaminophenylazo)benzoic acid

low

n-methylaspartate

low

nimorazole

medium

enbucrilate

low

octyl 2-cyanoacrylate

low

low

low

low

low

low

low

low

1-(4-carboxyphenyl)-3,3-dimethyltriazene

medium

1-phenyl-3,3-dimethyltriazene

low

metoclopramide hydrochloride

low

low

low

low

low

medium

low

medium

medium

medium

medium

low

medium

low

low

low

medium

low

low

medium

low

low

low

low

medium

low

medium

low

low

medium

medium

low

low

low

medium

medium

low

medium

low

medium

medium

medium

low

medium

low

medium

low

low

low

low

medium

medium

low

low

low

medium

low

low

low

low

medium

titanium tetrachloride

low

usnic acid

low

phosphoric acid, trisodium salt

low

low

low

low

low

propionylpromazine hydrochloride

low

medium

264

medium

low

medium

low

low

medium

low

medium

monoethylglycinexylidide

medium

low

medium

low

low

calcium phosphate, dibasic, anhydrous

low

calcium phosphate, monobasic, anhydrous

low

medium

low

low

medium

low

medium

low

medium

low

low

low

low

medium

medium

low

low

low

low

low

low

low

low

calcium pyrophosphate

low

thallium chloride

low

butylated hydroxyanisole

low

glycerol 1-stearate

low

ethinyl estradiol-norgestrel combination

low

galactose

medium

poloxalene

medium

hexamethyldisiloxane

low

hexadimethrine bromide

low

low

low

low

medium

low

medium

low

low

medium

1,3-dichloro-1-propene

low

medium

low

low

low

low

4-chloro-7-nitrobenzofurazan

low

low

medium

low

low

low

low

medium

medium

low

low

low

medium

low

low

low

low

low

low

low

low

low

arabinofuranosylcytosine triphosphate

low

dimethyl alpha-ketoglutarate

low

procion blue mx-r

low

3-hydroxybenzo(a)pyrene

low

2',3-dimethyl-4-aminobiphenyl

low

low

medium

low

medium

desmethylmisonidazole

medium

mopidamol

medium

diacerein

low

1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea

medium

medium

low

low

low

tiletamine hydrochloride

low

low

low

low

low

low

low

medium

low

benserazide hydrochloride

low

low

medium

low

low

low

low

low

trimethylolpropane triacrylate

low

cephalexin

medium

1-methyladenosine

low

2,3-dihydroxyquinoxaline

low

low

medium

low

low

ferric nitrilotriacetate

low

n'-nitrosonornicotine

low

tetradecanoylphorbol acetate

medium

193

levamisole hydrochloride

low

low

low

low

low

2-amino-3-hydroxypyridine

low

fluoroboric acid

low

gold tetrachloride, acid

low

fluorides

medium

116

acridine half-mustard

low

danazol

low

tomatine

low

18-crown-6

low

9-hydroxybenzo(a)pyrene

low

low

low

low

low

low

low

low

low

low

low

medium

low

low

neohesperidin dihydrochalcone

low

low

medium

low

low

medium

low

fludarabine phosphate

medium

cyanazine

low

phosphotyrosine

low

mercuric oxide

low

disopyramide phosphate

low

2,6-diaminopurine

low

carbimazole

low

2-bromoergocryptine mesylate

low

medium

low

low

low

medium

low

low

cetylpyridinium chloride anhydrous

medium

low

low

low

low

low

low

low

low

low

low

tris(2,3-dibromopropyl)phosphate

low

low

low

medium

low

low

low

butylated hydroxytoluene

low

low

low

low

low

low

medium

low

medium

medium

bisbenzimidazole trihydrochloride

low

8-bromo cyclic adenosine monophosphate

medium

pronamide

low

transferrin

medium

270

rose bengal b disodium salt

low

normeperidine

low

fanft

low

tridemorph

low

aluminum oxide hydroxide

low

n-nitrosoiminodiacetic acid

low

clobetasol propionate

low

low

medium

medium

medium

low

medium

low

adenylyl imidodiphosphate

low

azoxymethane

low

minaprine dihydrochloride

low

cefazolin

medium

allura red ac dye

low

poly-n,n-dimethyl-n,n-diallylammonium chloride

low

frentizole

low

sodium azide

low

azides

medium

adenosine diphosphate ribose

low

low

medium

low

low

4-ketocyclophosphamide

low

medium

low

low

medium

low

low

low

low

medium

medium

low

medium

low

medium

low

low

low

medium

medium

medium

medium

medium

medium

340

low

buspirone hydrochloride

low

low

medium

149

medium

low

6-hydroxybenzo(a)pyrene

low

propafenone hydrochloride

low

promegestone

low

dobutamine

medium

ticarcillin

medium

1,2,7,8-tetrachlorodibenzo-p-dioxin

low

pcb 180

low

etazolate hydrochloride

low

n,n'-bis(2-hydroxybenzyl)ethylenediamine-n,n'-diacetic acid

low

low

medium

medium

medium

phorbol 12,13-dibutyrate

low

thiocholine

low

fluorescamine

low

2,3,4,2',3',4'-hexachlorobiphenyl

low

aroclor 1016

low

anft

low

10-carboxymethyl-9-acridanone

low

low

low

low

low

n-(2-hydroxypropyl)methacrylamide

low

low

low

medium

low

low

low

medium

low

medium

medium

low

medium

diethylmethylnitrosourea

low

vinclozolin

low

2,3,7,8-tetrabromodibenzo-4-dioxin

low

n-acetyl-4-benzoquinoneimine

medium

vecuronium bromide

low

ng-nitroarginine methyl ester

low

low

low

low

low

1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril

low

hyalodendrin

low

permethrin

low

chlorodiphenyl (54% chlorine)

low

quisqualic acid

low

decamethrin

low

pirfenidone

low

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid

low

mefloquine

low

diisopropanolnitrosamine

low

medium

low

low

low

low

nicardipine hydrochloride

low

3,3',5,5'-tetramethylbenzidine

low

meglitinide

low

7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide

low

acodazole

low

5'-palmitoyl cytarabine

low

low

medium

low

medium

n-(2-cyanoethylene)urea

low

medium

low

low

medium

2-hydroxybenzo(a)pyrene

low

desflurane

medium

2,3,4,7,8-pentachlorodibenzofuran

low

low

low

medium

low

low

low

enkephalin, methionine

medium

medium

low

medium

low

2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone

low

nitrosobis(2-oxopropyl)amine

low

low

low

low

medium

medium

triciribine phosphate

medium

captopril

medium

cefoperazone

medium

staurosporine

low

terazosin hydrochloride anhydrous

low

medium

low

medium

low

n-(2-chloroethyl)-n-nitrosoacetamide

low

4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone

low

low

medium

low

low

medium

medium

low

ranitidine hydrochloride

low

low

low

low

medium

2-amino-6-methyldipyrido(1,2-a-3',2'-d)imidazole

low

low

low

medium

low

medium

medium

low

low

medium

mitoxantrone hydrochloride

low

low

medium

medium

low

medium

medium

low

low

low

medium

medium

low

2-amino-3-methylimidazo(4,5-f)quinoline

low

n-(4-nitrophenacyl)imidazole

low

3-chloro-4-(dichloromethyl)-5-hydroxy-2(5h)-furanone

low

enoximone

low

loceryl

low

mono-n-butyltin

low

azelastine hydrochloride

low

medium

low

low

medium

low

low

medium

medium

atomoxetine hydrochloride

low

atomoxetine

low

ci 906

low

quinapril

low

raloxifene hydrochloride

low

5-benzylacyclouridine

low

medium

low

medium

medium

quinpirole hydrochloride

low

1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea

low

low

medium

medium

low

low

low

low

low

sarafloxacin hydrochloride

low

low

medium

low

medium

medium

medium

low

medium

low

1,2-dihydroxy-epoxy-1,2,3,4-tetrahydro-5-methylchrysene

low

low

medium

medium

low

medium

low

medium

medium

low

medium

low

low

medium

medium

medium

low

low

low

pioglitazone hydrochloride

low

medium

low

low

medium

mibefradil dihydrochloride

low

low

low

medium

n(1),n(14)-bis(ethyl)homospermine

medium

pivalyloxymethyl butyrate

medium

medium

188

medium

low

technetium tc 99m mertiatide

low

low

medium

medium

medium

atorvastatin calcium anhydrous

low

atorvastatin

medium

lamivudine

medium

duloxetine hydrochloride

medium

irinotecan

medium

508

170

aptiganel hydrochloride

low

low

medium

low

low

3-iodobenzylguanidine

medium

medium

low

medium

medium

low

medium

medium

medium

Pronetalol hydrochloride

low

safranal

low

phenelzine sulfate

low

nitroaniline

low

2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole

low

2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone

low

octyl gallate

low

sudan black b

low

triphenylsulfonium ion

low

pyranine

low

gadolinium chloride

low

erionite

low

4-propionyloxy-4-phenyl-n-methylpiperidine

low

medium

low

low

low

ruthenium chloride (rucl3)

low

medium

low

low

low

2-amino-3,4-dimethylimidazo(4,5-f)quinoline

low

2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline

low

sudan iii

low

acridine orange

low

benzylaminopurine

low

trifluoromethanesulfonic acid

low

eramide

low

isothiocyanic acid

medium

ammonium peroxydisulfate

low

low

low

low

medium

medium

low

low

urea formaldehyde foam

low

octyl glucoside

low

fluoxetine hydrochloride

low

desferrioxamine b mesylate

low

propranolol hydrochloride

low

bupropion hydrochloride

low

halofuginone

medium

diltiazem hydrochloride

low

venlafaxine hydrochloride

medium

dt 5061

low

trazodone hydrochloride

medium

trovafloxacin

low

verapamil hydrochloride

low

doxazosin mesylate

low

terfenadine

low

sertraline hydrochloride

low

4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol

low

3,4,5,3',4'-pentachlorobiphenyl

low

2,4(1h,3h)-quinazolinedione

low

efavirenz

low

nelfinavir

medium

amantadine hydrochloride

low

aluminum phosphate

low

methionine methyl ester

medium

glucose, (beta-d)-isomer

medium

115

anisodamine

low

lincomycin monohydrochloride

low

meclizine monohydrochloride

low

mevastatin

low

acid citrate dextrose

low

bupivacaine hydrochloride

low

spectinomycin dihydrochloride

low

bts 54 524

low

dihydrochalcone

low

chloroquine diphosphate

low

2',7'-dichlorofluorescein

low

ursolic acid

medium

n-methylnicotinamide

low

3-aminoisobutyric acid

low

low

low

low

low

medium

thymidine 5'-triphosphate

low

medium

low

low

low

medium

low

medium

medium

medium

low

low

low

guanidine thiocyanate

low

diacetylfluorescein

low

ibacitabine

low

2',3'-dideoxythymidine triphosphate

low

diphenylcyclopropenone

low

methylthymidine

low

2'-deoxyuridylic acid

low

epigallocatechin gallate

medium

211

n-acetylaspartic acid

medium

2-phenyloxazolone

low

cholesteryl sulfate

low

protolichesterinic acid

low

fluorexon

low

cholesteryl succinate

medium

gallocatechol

low

psicofuranine

low

2,4-diaminoquinazoline

low

2'-deoxycytidine 5'-triphosphate

low

25-hydroxycholesterol

low

1-methylinosine

low

6-sulfatoxymelatonin

low

10,10'-dimethyl-9,9'-biacridinium

low

3'-amino-3'-deoxyadenosine

low

leucine methyl ester

low

chlorin

low

phosphoramidic acid

low

1,2-dipalmitoyl-3-phosphatidylethanolamine

low

aica ribonucleotide

low

5-bromo-4-chloroindoxyl acetate

low

thomsen-friedenreich antigen

low

salvin

low

1,2-dipalmitoylphosphatidylglycerol

low

1,2-distearoyllecithin

low

bathocuproine

low

aconitic anhydride

low

flavopereirine

low

5-bromo-4-chloro-3-indolyl beta-galactoside

low

nile red

low

metaperiodate

low

xanthyletine

low

lissamine rhodamine b

low

rhodamine 110

low

neocuproine

low

1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose

low

tris(2,2'-bipyridine)ruthenium(II)

low

low

low

low

low

2-oxothiazolidine-4-carboxylic acid

low

o-(6)-methylguanine

low

surfactin peptide

low

dobutamine hydrochloride

low

ephedrine hydrochloride

low

desipramine hydrochloride

low

dopamine hydrochloride

low

proadifen hydrochloride

low

pyrrolidine dithiocarbamate

low

o-4-methylthymine

low

peroxynitric acid

low

glutathione disulfide

low

secoisolariciresinol

low

hypusine

low

triciribine

low

4-nitrobenzylthioinosine

low

triptonide

low

sinefungin

low

iopamidol

medium

sulconazole, mononitrate, (+-)-isomer

low

n-acetyl-5-aminosalicylic acid

low

7-hydroxydehydroepiandrosterone

low

4-aminomethylbenzoic acid

low

glucose-1-phosphate

low

cephalosporin c

medium

111

16-hydroxytestosterone

low

tetraiodothyroacetic acid

low

quassin

low

cedrol

low

tomatidine

low

trioctyl phosphine oxide

low

2,2'-dithiodiethanesulfonic acid

medium

low

low

low

low

medium

low

low

low

low

low

4-aminobenzoic acid-n-xyloside

low

medium

low

medium

low

low

methoxy-morpholinyl-doxorubicin

medium

medium

medium

low

medium

low

low

medium

low

low

low

trihexyphenidyl hydrochloride

low

methacycline

low

oxyphencyclimine hydrochloride

low

thioridazine hydrochloride

low

diphenylpyraline hydrochloride

low

bergenin

low

procainamide hydrochloride

low

siquil

low

mepivacaine hydrochloride

low

tetramethylputrescine

low

omega-aminocaprylic acid

low

n-acetylproline

low

boron nitride

low

sotalol hydrochloride

low

oxymetazoline hydrochloride

low

dexfenfluramine

low

ay-20694

low

alprenolol hydrochloride

low

iridium radioisotopes

medium

low

low

medium

low

medium

low

low

low

low

low

5-aminoisophthalic acid

low

2-bromo-4'-nitroacetophenone

low

16-fluoroestradiol

low

4-(diethylamino)benzaldehyde

low

4-amino-6-chloro-1,3-benzenedisulfonamide

low

low

low

low

low

low

fluphenazine hydrochloride

low

estradiol-3,4-quinone

low

2,4-diaminopyrimidine

low

1,7-phenanthroline

medium

pyrrolo(1,2-a)quinoxaline

low

pyrazolo(3,4-d)pyrimidine

low

benzofurazan

low

piaselenole

low

1h-imidazo(4,5-b)pyridine

low

benzo-1,2,3-thiadiazole

low

medium

low

low

tryptamine monohydrochloride

low

low

low

low

low

low

low

2,4,6-trihydroxyacetophenone

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

chloroethylaminouracil

low

duroquinone

low

delphinidin

low

5,6,7,8-tetrahydro-1-naphthol

low

2,6-dimethoxy-1,4-benzoquinone

low

coproporphyrin i

low

sesamol

low

1,2-dithiol-3-thione

low

dyclonine hydrochloride

low

disulphane

low

trimethobenzamide monohydrochloride

low

4-aminoquinoline

low

suberosin

low

clomipramine hydrochloride

low

amiloride hydrochloride

low

prazosin hydrochloride

low

mianserin hydrochloride

low

miconazole nitrate

low

alfatradiol

low

econazole nitrate

low

1,3-bis(4-carboxyphenoxy)propane

low

fluorodeoxyglucose f18

medium

1,421

sertraline

medium

lomefloxacin hydrochloride

low

fenspiride hydrochloride

low

nilverm

low

sanguinarine chloride

low

picosulfate sodium

medium

rilmenidine

low

ropinirole hydrochloride

low

medium

low

low

delta sleep-inducing peptide

low

low

low

low

medium

medium

low

medium

low

low

low

low

low

low

low

1,3,5-trimethoxybenzene

low

phenylazide

low

4-aminobenzyl alcohol

low

beta-hydroxyisovaleric acid

medium

2,6-dihydroxypyridine

low

5-aminovaleric acid hydrochloride

low

1,2,3,4-tetrahydroquinoline

low

resorufin

low

fructose-6-phosphate

low

pentafluorobenzaldehyde

low

2,4-disulfamyl-5-trifluoromethylaniline

low

4(5)-phenylimidazole

low

5-fluoropyrimidine

low

n,n-dimethyl-4-anisidine

low

low

low

low

low

low

3-chloroperbenzoic acid

low

low

low

low

low

low

5-hydroxymethylcytosine

low

2-hydroxychavicol

low

2,2',2''-terpyridine

low

leucyl-glycyl-glycine

low

n-acetylglutamic acid

low

low

low

low

medium

low

dihydroergotamine mesylate

low

low

low

low

low

6-amino-1-hydroxyhexane-1,1-diphosphonate

low

ranolazine hydrochloride

low

low

low

medium

low

low

low

low

low

guanfacine hydrochloride

low

pirenzepine dihydrochloride

low

tocophersolan

low

labetalol hydrochloride

low

acecainide hydrochloride

low

loperamide hydrochloride

low

maprotiline hydrochloride

low

protoporphyrin ix, disodium salt

low

trichlorosucrose

low

bay i 7433

medium

phenylalanine

low

16-bromoepiandrosterone

low

medium

low

low

medium

low

low

medium

low

medium

low

low

low

medium

low

low

datelliptium chloride

medium

acemannan

low

prednisolone phosphate

low

low

medium

low

low

low

medium

medium

3-octadecanamido-2-ethoxypropylphosphocholine

low

7-hydroxystaurosporine

medium

low

low

low

low

medium

low

low

low

low

low

chelerythrine chloride

low

low

low

low

low

low

low

low

low

low

low

low

medium

low

low

low

deoxyaminopteroic acid

low

low

medium

low

low

low

low

pentazirinocyclodiphosphathiazene

low

zaluzanin C

low

pacein

low

methyl fluorone black

low

alantolactone

low

alpha-lapachone

low

nsc 361456

medium

5-nitro-1,10-phenanthroline

low

5-methyl-1,10-phenanthroline

low

cryptand 2.2

low

1,10-phenanthroline-5,6-dione

low

bathophenanthroline

low

cyclopentenyl cytosine

medium

nsc 251635

low

2-aminobenzenesulfonamide

low

indole-2-carboxylic acid

low

neplanocin a

low

methylene violet

low

haloprogin

low

medicarpin, (6as-cis)-isomer

low

serpentine (alkaloid)

low

tetrandrine

low

3-deazaneplanocin

low

tosyllysine chloromethyl ketone

low

low

low

low

low

low

low

dehydrocostus lactone

low

low

low

low

low

low

low

low

low

low

5-(n-methyl-n-isobutyl)amiloride

low

strictinin

low

1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride

low

amperozide hydrochloride

low

pyrrolidine dithiocarbamic acid

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

thiazole-4-carboxamide adenine dinucleotide

low

low

low

low

low

1,1,1-trifluoro-2,4-pentanedione

low

carbohydrazide

low

oxazolidin-2-one

medium

pramoxine hydrochloride

low

ceric oxide

low

sodium oxide

low

cupric selenide

low

3,4,7,8-tetramethyl-1,10-phenanthroline

low

perfluorooctane sulfonic acid

low

triphenylmethylphosphonium

low

low

medium

low

low

low

s-methylisothiourea sulfate

low

1-(2-chloroethyl)-1-nitrosourea

low

4-aminopyrazolo(3,4-d)pyrimidine

low

2-aminoethylmethacrylate

low

2-hydroxyfluorene

low

n-acetylhistidine

low

p-Aminobenzamidine dihydrochloride

low

2,4-dihydroxy-6-methylbenzoic acid ethyl ester

low

2-(methylamino)isobutyric acid

low

phenylalanyl-phenylalanyl-phenylalanine

low

octadecyl palmitate

low

c.i. direct red 80

low

2-(2-aminoethyl)pyridine

low

3-tritylthio-l-alanine

low

low

low

low

low

5-(3-methyl-1-triazeno)imidazole-4-carboxamide

medium

1-pyrenebutyrate

low

bendamustine hydrochloride

medium

n-(hydroxymethyl)nicotinamide

low

sofosbuvir

low

2,4,6-tripyridyl-s-triazine

low

spinochrome a

low

4'-methoxyflavone

low

4-phenyl-1,2,4-triazoline-3,5-dione

low

low

medium

low

low

5-hydroxymethyluracil

low

2-aminopyrazine

low

imidazo(1,2-a)pyridine

low

piperazine-n,n'-bis(2-ethanesulfonic acid)

low

naphtho(2,3-b)furan-4,9-dione

low

tricine

low

n-hydroxysuccinimide

low

1-methylxanthine

low

benzamidine hydrochloride

low

6-amino-5-bromouracil

low

trans-4-methylcyclohexylamine

low

n-hydroxy-4-aminobiphenyl

low

3,7-dimethyl-7-octen-1-ol

medium

7-nitro-1h-indole-2-carboxylic acid

low

leucyl-alanine

low

gamma-glutamine-4-nitroanilide

low

s-benzyl-l-cysteine-4'-nitroanilide

low

pentaerythritol tetra(3-mercaptopropionate)

low

low

low

medium

medium

low

low

5-chloroindole-2-carboxylate

low

3,4-dihydroxyphenylethanol

low

low

low

low

low

low

low

lanthanum trifluoride

low

1-(2-hydroxyethyl)-1-nitrosourea

low

3-(trimethoxysilyl)propylamine

low

orphenadrine citrate

low

d-aspartic acid

low

5-(biotinamido)pentylamine

low

acetaminophen sulfate ester

medium

acetaminophen glucuronide

medium

7-deoxyadriamycin aglycone

low

acetaminophen mercapturate

medium

albendazole sulfoxide

low

adriamycinol

medium

acetaminophen cysteine

medium

ketorolac tromethamine

medium

clarithromycin

medium

8-hydroxyquinoline glucuronide

low

5-amino-1,3,4-thiadiazole-2-sulfonamide

low

4-aminoquinazoline

low

primin

low

bromates

low

1-cyclohexyl-3-(2-(4-morpholinyl)ethyl)carbodiimide

low

2,4,6-trimorpholino-1,3,5-triazine

low

dicyclohexyl-18-crown-6

low

tebuconazole

low

imidacloprid

low

alpha-tocopherol acetate

low

cholest-5-ene-3,4-diol

medium

we 201

low

4,4-trimethylenedipyridine

low

sdds

low

5-Chloro-1H-indole-2,3-dione

low

low

low

low

low

4,5-dimethoxy-2-nitrobenzaldehyde

low

5-thio-d-glucose

low

1,8-bis(dimethylamino)naphthalene

low

va 061

low

kampirone

low

5,7-dimethoxyflavone

low

methionine sulfoximine

low

medium

low

low

medium

low

low

1-aminocyclobutanecarboxylic acid

low

altersolanol a

low

carbetapentane citrate

low

cinchonine

low

fibrinogen

medium

349

n,n'-dibenzoylcystine

low

phentolamine mesylate

low

17-alpha-hydroxypregnenolone

low

low

low

low

low

low

cholestanol, (3alpha, 5beta)-isomer

low

low

low

low

low

low

low

low

6-phosphogluconic acid

low

cholestane-3,5,6-triol, (3beta, 5alpha, 6beta)-isomer

low

prochlorperazine edisylate salt

low

cadmium telluride

medium

goethite

low

oxybutynin hydrochloride

low

inermin

low

acid green 50

low

3,4-dihydroxyphenylglycol

low

low

low

medium

low

low

5-(3-hydroxyphenyl)-5-phenylhydantoin

low

acetylsalicylic acid lysinate

low

9-hydroxyellipticine

low

nimustine

low

4-n,n-dimethylaminoazobenzene-4'-sulfonyl chloride

low

low

low

low

low

low

medium

low

low

low

low

low

low

prilocaine hydrochloride

low

adenosine 5'-methylenediphosphate

low

n(6)-benzyladenosine

low

D-dopa

low

fluoromisonidazole

low

7-amino-4-methylcoumarin

low

levobupivacaine

medium

phenylacetylglutamine

medium

3-aminobenzeneboronic acid

low

5-((2-aminoethyl)amino)naphthalene-1-sulfonic acid

low

low

medium

low

low

low

low

medium

medium

11-hydroxyprogesterone, (11alpha)-isomer

low

low

low

low

low

low

low

low

low

low

low

cycloadiphenine hydrochloride

low

low

low

low

low

3,5-diiodothyronine, (l)-isomer

low

16-dehydropregnenolone

low

n(alpha)-acetyllysine

low

5-methylcytidine

low

rac-glycerol 1-monodecanoate

low

firefly luciferin

low

4,4'-azobis(4-cyanovaleric acid)

low

dextromoramide

low

alanyltyrosine

low

perezone

low

tolperisone hydrochloride

low

low

low

low

low

low

di-tert-butylperoxy-3,3,5-trimethylcyclohexane peroxide

low

titanium nitride (tin)

low

dimyristoylphosphatidic acid

low

bis(2,4,5-trichloro-6-carbopentoxyphenyl)oxalate

low

phenylisopropyladenosine

low

4-desacetylvinblastine-3-carboxhydrazide

medium

hexamethonium chloride

low

1-(2-thiazolylazo)-2-naphthol

low

arabitol

medium

erythrose

low

3-hydroxydodecanoic acid

low

low

low

low

low

low

mercury cadmium telluride

low

1-(ethan-1-ol)-2-methyl-3-hydroxypyridin-4-one

low

1-(2-pyridinyl)piperazine

low

alpha-tocopherol phosphate

low

low

low

low

medium

low

low

1-phenazinecarboxylic acid

low

osajin

low

2,2',4,4'-tetrabromodiphenyl ether

low

4-mercaptobenzoate

low

2,2-dimethyl-beta-alanine

low

low

low

low

low

6-(4-nitrobenzylthio)guanosine

low

6'-o-methylguanosine

low

phosphoramide mustard

medium

olivacine

medium

2-(4-hydroxyphenyl)-5,6,7,8-tetrahydroxy-4H-1-benzopyran-4-one

low

dipin

low

6,7-dichloroquinoline-5,8-dione

low

low

low

low

low

low

10-hydroxycamptothecin

medium

5-iodotubercidin

low

3,5,7,3',4'-pentamethoxyflavone

low

1,3,4-oxadiazole

low

Koenimbine

low

s-(2,4-dinitrophenyl)glutathione

low

3-aminopropylphosphonic acid

low

oxoglaucine

low

hydroxybenzindazole

low

6-methoxyflavanone

low

1-(1-naphthyl)ethylamine

low

1-methyltryptophan

low

n-(hippuryl)phenylalanine

low

trimeperidine

low

5-formyl-2'-deoxyuridine

low

5'-n-methylcarboxamideadenosine

low

quindoline

low

n-glycylglutamic acid

low

6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline)

medium

tetrathiafulvalene

low

diosgenin

low

isosteviol

low

sarsasapogenin, (3beta,5alpha,25r)-isomer

low

n-succinimidyl-3-(4-hydroxyphenyl)propionate

low

3,7-dimethyl-1-propargylxanthine

low

mollisin

low

lecanoric acid

low

Lup-20(29)-en-28-al, 3beta-hydroxy-

low

zpck

low

5,6-dihydro-5-azacytidine

low

4-hydroxycyclophosphamide

medium

at 1258

low

4-methoxydalbergione

low

phorbolol myristate acetate

low

pyrimidin-2-one beta-ribofuranoside

low

low

low

low

low

low

alpha-glutamyltryptophan

low

1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol

medium

combretastatin

medium

enkephalinamide-met, ala(2)-

low

fangchinoline

low

8-chloro-cyclic adenosine monophosphate

medium

malabaricone c

low

2'-chloro-2'-deoxyadenosine

low

coumarin 6

low

isophosphamide mustard

low

low

low

low

low

low

low

medium

low

7-amino-4-trifluoromethylcoumarin

low

n-hydroxysuccinimide suberic acid ester

low

selenazofurin

low

n-succinimidyl 3-(2-pyridyldithio)propionate

low

bimolane

medium

Eupatoriochromene

low

5-chloro-2'-deoxycytidine

low

leukogen

low

safrole oxide

low

6-(6-methoxy-1,3-benzodioxol-5-yl)-7-furo[3,2-g][1]benzopyranone

low

low

low

low

low

medium

low

low

tetrahydrodeoxycorticosterone

low

3 alpha,17 alpha-dihydroxy-5 beta-pregnan-20-one

low

methyl mannoside, (alpha-d)-isomer

low

low

low

low

medium

deoxy-5-methylcytidylic acid

low

benzyloxyamine

low

1,2-distearoylphosphatidylethanolamine

low

lambertianic acid

low

2,3-bis(4-hydroxyphenyl)-propionitrile

low

alexidine dihydrchloride

low

hedione

low

4-fluoroglutamic acid

medium

low

low

medium

p-methoxy-n-methylphenethylamine

low

3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine

low

medium

medium

medium

low

1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acid

low

aflatoxin b1-2,3-oxide

low

yttrium radioisotopes

medium

133

mizoribine

low

1-amino-1,3-dicarboxycyclopentane

low

low

low

low

medium

arginyl-glycyl-aspartic acid

medium

247

calcium phosphate, dibasic, dihydrate

low

medium

low

medium

low

medium

medium

low

medium

low

low

2-amino-3,7,8-trimethylimidazo(4,5-f)quinoxaline

low

4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol

low

s-nitrosoglutathione

low

bosentan anhydrous

low

n-nitrosothiazolidine-4-carboxylic acid

low

cp-55,940

low

diacetyldichlorofluorescein

low

vanoxerine

low

3,3',4,4',5,5'-hexabromobiphenyl

low

2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine

low

norverapamil

low

fluo-3

low

1,n(6)-ethenoadenine

medium

methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate

low

indolactam v

low

paxilline

medium

beauvericin

low

fructose 2,6-diphosphate

low

medium

low

medium

medium

low

1,n(6)-ethenodeoxyadenosine

low

low

low

low

low

medium

3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate

low

4'-(9-acridinylamino)methanesulfonanilide

low

cv 3988

low

cgp 35348

low

beta-carboline-3-carboxylic acid methyl ester

low

bismuth nitrate

low

22-hydroxycholesterol

low

inositol 1-phosphate

low

aldophosphamide

low

4'-(9-acridinylamino)methanesulfon-o-anisidide

low

inositol-1,3,4,5-tetrakisphosphate

low

dimyristoylphosphatidylglycerol

low

3,n(4)-ethenodeoxycytidine

low

arginyl-glycyl-aspartyl-serine

low

fusarochromanone

low

saikosaponin d

low

6-hydroxydopa

low

n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide

medium

perindopril

medium

hypotaurine

low

nantradol

medium

1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane

low

low

low

low

low

1,n(2)-propanodeoxyguanosine

low

low

low

low

medium

low

low

1-hydroxymethylmidazolam

medium

2'-5'-oligoadenylate trimer

low

n(delta)-(n-methyl-n-nitrosocarbamoyl)-l-ornithine

low

medium

low

low

low

low

betaxolol hydrochloride

low

catechin

low

hydroxycotinine

low

1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine

low

s-methylthiocitrulline

low

fingolimod hydrochloride

low

low

low

low

medium

cobaltiprotoporphyrin

low

low

low

low

low

low

low

alpha-methylphenylalanine

low

low

low

medium

low

low

medium

low

low

medium

carboxyamido-triazole

medium

ecteinascidin 743

medium

kt 6149

medium

kt 5823

low

1-hexadecyl-2-acetyl-glycero-3-phosphocholine

low

4'-deoxy-4'-iododoxorubicin

low

low

medium

low

low

glutarylphenylalanine-4-nitroanilide

low

leucinol

low

anecortave acetate

low

anserine

low

6-methyl-2-ethyl-3-hydroxypyridine

low

3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione

medium

n-(2-hydroxypropyl)-n-nitrosourea

low

1-phenyl-2-decanoylamino-3-morpholino-1-propanol

low

2,3-bis(3'-hydroxybenzyl)butyrolactone

low

diclofenac hydroxyethylpyrrolidine

low

7-o-(2,6-dideoxy-2-fluoro-alpha-talopyranosyl)adriamycinone- 14-beta-alaniate hydrochloride

medium

indolo(3,2-b)carbazole

low

3',4'-dichlorobenzamil

low

medium

low

medium

low

low

low

selenomethylselenocysteine

medium

3-deoxyglucosone

low

16-hydroxyestrone

low

dechloroethylcyclophosphamide

low

aluminum phthalocyanine

medium

ibuprofen, (r)-isomer

low

thromboxanes

low

dodecyl-beta-d-maltoside

low

low

low

low

low

11-hydroxytestosterone

low

1-(carboxymethylthio)tetradecane

low

zinc coproporphyrin iii

low

1,2-dimyristoylphosphatidylethanolamine

low

benzoylphenylalanyl-alanyl-proline

low

norbuprenorphine

low

n-hydroxy-2-aminopyrene

low

nitroacridine 3582

low

wr 33278

low

toosendanin

low

10-n-nonylacridinium orange

low

low

low

low

medium

5-(tetradecyloxy)-2-furancarboxylic acid

low

dihydro-dids

low

phenylalanyl-prolyl-arginine-chloromethyl ketone

low

3,5-dibromo-4-nitrosobenzenesulfonate

low

annamycin

low

3beta-(n-(n',n'-dimethylaminoethane)carbamoyl)cholesterol

low

sophocarpine

low

2-aminobicyclo(2,2,1)heptane-2-carboxylic acid

low

cp 65,526

medium

2-iodomelatonin

low

nitisinone

low

bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii)

low

low

low

low

low

low

low

medium

low

low

low

1-(6-hydroxy-2-isopropenyl-1-benzofuran-5-yl)-1-ethanone

low

obacunone

low

janus green

low

3-mercaptopicolinic acid

low

cynaropicrin

low

1'-acetoxychavicol acetate

low

thiodigalactoside

low

ak 2123

medium

clofarabine

medium

silicon phthalocyanine pc4

low

low

low

low

low

low

benzo(a)pyrene-3,6-quinol

low

low

low

low

medium

low

low

low

medium

low

medium

low

tris(2-carboxyethyl)phosphine

low

gallopamil hydrochloride

low

cyasterone

low

s-lactoylglutathione

low

ah 6809

low

muramylnac-ala-isogln-lys-tripeptide

low

pefloxacin mesylate

low

n'-(2-chloroethyl)-n-(2-(methylsulfonyl)ethyl)-n'-nitrosourea

medium

gamma-glutamylaminomethylsulfonic acid

low

buthionine sulfoximine

low

medium

low

low

low

low

low

low

low

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid

medium

low

low

low

low

low

low

1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine

low

(20s)-20-hydroxycholesterol

low

dansyllysine

low

24-hydroxycholesterol

low

perftoran

low

2-aminoacridone

low

rhenium-186 hedp

medium

5-fluorodihydrouracil

low

low

low

low

low

medium

gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate

low

6-heptyne-2,5-diamine

low

sulforhodamine 101

low

(3-dimyristyloxypropyl)(dimethyl)(hydroxyethyl)ammonium

low

triiodothyronine sulfate

low

ru 24926

low

tryptophan methyl ester

low

san 58035

low

kallidin, des-arg(10)-

low

iodosulpride

low

benzyl-alpha-n-acetylgalactosamine

low

5-chloromethylfluorescein diacetate

low

saccharolactone

low

efaproxiral

medium

n-acetylputrescine

low

n,n-dimethyl-3,3-diphenyl-1-methylallylamine

low

n-benzyloxycarbonylprolylprolinal

low

gossylic nitrile-1,1'-diacetate

low

low

low

low

low

4'-demethylepipodophyllotoxin

low

chaetoglobosins

low

profenamine hydrochloride

low

low

low

low

low

low

low

low

medium

medium

low

low

medium

low

aminolevulinic acid hydrochloride

low

9-methoxycamptothecin

low

tazobactam

medium

gefitinib

medium

253

hemoregulatory peptide 5b

low

n(8)-acetylspermidine

low

1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine

low

dimyristoylphosphatidylserine

low

2,3-bis(3'-hydroxybenzyl)butane-1,4-diol

low

nnc 711

low

phosphocitrate

low

3-iodo-alpha-methyltyrosine

low

4-carboxyfluorescein

low

aerobactin

low

galactosyl-(1-3)galactose

low

c & b metabond

low

n(6)-carboxymethyllysine

low

technetium tc 99m hydroxymethylene diphosphonate

low

angiotensin ii, des-phe(8)-

medium

omega-(4-iodophenyl)pentadecanoic acid

low

glycyl-arginyl-glycyl-aspartyl-serine

low

23-seleno-25-homotaurocholic acid

low

n,n-dimethylarginine

low

2-(2-(5-carboxy)oxazole)-5-hydroxy-6-aminobenzofuran-n,n,o-triacetic acid

low

htr composite

low

cyclic adp-ribose

low

h-d-phe-pip-arg-pna

low

bis(sulfosuccinimidyl)suberate

low

3-tyr-octreotide

low

antibiotic g 418

low

4-iodoamphetamine

low

interleukin-1beta (163-171)

low

glycerophosphoethanolamine

low

1-((3,5-dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone

low

hydroxycitric acid

low

lysyl-aspartyl-glutamyl-leucine

low

glycylglutamine

low

4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide

low

indium tris(tropolonate)

low

pristanic acid

low

5-((4,6-dichloro-1,3,5-triazin-2-yl)amino)fluorescein

low

alanylglutamine

medium

gamma-glutamylcysteine

low

naadp

low

vadimezan

medium

27-hydroxycholesterol

low

tyrosyl-isoleucyl-glycyl-seryl-arginine

low

3-carboxy-4-methyl-5-propyl-2-furanpropionic acid

low

e 64

low

dimethyl dithiobispropionimidate

low

low

low

low

low

low

4-azido-7-phenylpyrazolo-(1,5a)-1,3,5-triazine

low

3-deazaguanosine

low

1,4,7-triazacyclononane-n,n',n''-triacetic acid

low

4-carbamoylimidazolium 5-olate

low

azetidine-2,4-dicarboxylic acid

low

phosphonium choline

low

teloxantrone

medium

nsc 224070

low

n-acetyl-demethylmuramyl-alanyl-isoglutamine

low

chloroterpyridineplatinum(ii)

low

6-methoxypurine arabinoside

low

16-hydroxycleroda-3,13(14)-dien-15,16-olide

low

phosphocyclocreatine

low

solutol hs 15

low

8-oxo-dado

low

valyl-glycyl-valyl-alanyl-prolyl-glycine

low

hypothiocyanite ion

low

glycerophosphoinositol 4,5-bisphosphate

low

3-ft

low

n-acetylneuraminosyl(alpha2-6)lactosamine

low

di-n-desethylamiodarone

low

dibutyryl cyclic-3',5'-cytidine monophosphate

low

502u83

medium

idb 1031

low

3'-deamino-3'-hydroxydaunorubicin

low

3-azidopyrimethamine

low

rb 6145

low

n-succinimidyl-5-iodo-3-pyridinecarboxylic acid

low

blonanserin

low

o,o'-diacetylhematoporphyrin

low

9-methoxy-n(2)-methylellipticinium

low

4-amino-3-(5-chloro-2-thienyl)butyric acid

low

n'-(2-chloroethyl)-n-(2-(methylsulfinyl)ethyl)-n'-nitrosourea

low

7-goniofufurone

low

indatraline

low

disialosyl galactosyl globoside

low

1-acetyl-3,2-toluyl-5-fluorouracil

medium

low

low

low

low

phenylalanyl-phenylalanyl-arginine chloromethyl ketone

low

lestaurtinib

medium

2'-deoxy-3',5'-di-o-acetyl-5-fluoro-3-(3-methylbenzoyl)uridine

low

ay 25545

low

sn 23862

low

l 012

low

6-chloropenicillanic acid s-sulfoxide

low

1-(7-(2-hydroxyethyl)dodecahydro-3a-methyl-1h-benz(e)inden-3-yl)ethanone

low

cytidine monophosphate-n-glycoloylneuraminic acid

low

methotrexate

medium

1,183

2,3-bis-(palmitoyloxy)-2-propyl-n-palmitoyl-cysteinylserine

low

1-(2-allylphenoxy)-3-((8-bromoacetylamino-4-menthane-1-yl)amino)-1-propanol

low

low

low

low

low

low

low

n-(5-(2,3-dihydrobenzofuryl)sulfonyl)-n'-(3,4-dichlorophenyl)urea

medium

(76br)-3-bromobenzylguanidine

low

3-fluoro-alpha-fluoromethyltyrosine

low

s-4-bromobenzylglutathione cyclopentyl diester

low

protosappanin a

low

hx 600

low

4-nitrophenyl 2-fluoropropionate

low

low

low

low

low

low

low

low

low

2-methacryloyloxyethyl phosphorylcholine

low

4'-deoxydoxorubicinol

low

adenosine-n(6)-diethylthioether-n'-pyridoximine 5'-phosphate

low

ici 204448

low

s-nitrosocaptopril

low

1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine

low

n-succinimidyl 3-(trimethylstannyl)benzoate

low

antiprimod

low

4-hydroxy-25-desoxyneorollinicin

low

3-mercapto-3,3-cyclopentamethylenepropionic acid

low

medium

medium

low

low

2-methoxyisobutylisonitrile

low

2',2'-difluorodeoxycytidine 5'-triphosphate

medium

ly 195448

low

talotrexin

low

2'-methyl-2'-deoxycytidine

low

low

low

low

low

low

low

n-(3-phenyl-n-propyl)-1-phenyl-2-aminopropane

low

3-methoxy-7h-8-methyl-11-((3'-amino)propylamino)benzo(e)pyrido(4,3-b)indole

low

pyridinium 3-methoxyestra-1,3,5(10)-trien-6-yl sulfate

low

4-amino-1-(6-chloro-2-pyridyl)piperidine hydrochloride

low

sk&f 104976

low

5-ethylamino-9-diethylaminobenzo(a)phenothiazinium

low

7-(4'-(2-nitroimidazole-1-yl)butyl)theophylline

low

bibw 22

low

n-methyl-n-2-(methylsulfinyl)ethylpropionic acid amide

low

c 1311

medium

way 123398

low

omega-n-hydroxymethylarginine

low

n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide

low

n',n''-diacetylspermine

low

osw 1

low

diammine platinum(ii) dilactate

low

3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan

low

l 733060

low

omega-n-methylarginine

low

b 581

low

5,8-dihydroxy-3-methyl-4-(9h)-naphtho(2,3-c)furanone

low

abiraterone

medium

7,7'-(carbonyl-bis(imino-n-methyl-4,2-pyrrolcarbonylimino(n-methyl-4,2-pyrrol)carbonylimino))-bis(1,3-naphthalenedisulfonic acid)

medium

kw 2189

medium

ivabradine

low

l 741742

low

8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine

low

hexestrol diphosphate

low

ge 68

low

sonepiprazole

low

2,7,8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychroman

low

5'-(4-fluorosulfonylbenzoyl)adenosine

low

5'-(sulfonylbenzoyl)adenosine

low

yakuchinone-a

low

5-carboxyfluorescein diacetate

low

imidazolecarboxamide

low

l 741626

low

1-hydroxymethylmidazolam glucuronide

medium

1-(4-bromoacetamidobenzyl)edta

low

n-hydroxysulfosuccinimide

low

16-fluoro-5-androsten-17-one

low

fr 66973

low

5,11-dimethyl-5h-indolo(2,3-b)quinoline

low

medium

medium

medium

low

nisoxetine hydrochloride

low

low

low

low

medium

medium

low

low

ng-nitroarginine methyl ester

low

tilarginine acetate

low

valerylsalicylate

low

alpha-guanidinoglutaric acid

low

3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-isomer

low

cd 437

low

ompi

low

gyrophoric acid

low

3-(2'-deoxyribofuranosyl)pyrimido(1,2-a)purin-10(3h)-one

low

hexa-peri-hexabenzocoronene

low

low

low

medium

low

low

1,3,5-triaza-7-phosphaadamantane

low

phytol

low

imidazole-4-acetic acid hydrochloride

low

proline

low

cucurbitaceae

low

harmalol hydrochloride

low

low

low

medium

low

tris-(1,10-phenanthroline)ruthenium

low

8-chloroadenosine

low

withangulatin a

low

gl 331

low

10-propargyl-10-deazaaminopterin

medium

docetaxel

low

docetaxel anhydrous

medium

616

193

2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a

low

medium

medium

medium

low

low

medium

low

3-nitroso-2-oxazolidone

low

platinum(ii) 1,2-diaminocyclohexane malonate

low

nsc-141549

low

5-vinyl-2'-deoxyuridine

low

peptide elongation factor 2

low

3,4-epithiobutanenitrile

low

levofloxacin

medium

aclacinomycin

low

ezetimibe

medium

4-boronophenylalanine

medium

rb 90740

low

ertapenem

low

2'fluoro-2'-deoxyuridine

low

2'-deoxycytidine diphosphate

low

5-fluorouridine 5'-phosphate

low

benzoyl l-arginine methyl ester

low

phenylalanylarginine

low

4-aminophenylalanine

low

5-methoxytryptophan

low

6-carboxyfluorescein diacetate

low

low

medium

medium

low

low

low

low

low

medium

oleanolic acid 3-acetate

low

tyrosinamide

low

6-o-galactopyranosylgalactose

low

low

low

low

low

medium

2-chloro-2-deoxyglucose

low

damvar

low

phosphorodithioic acid

low

prolyl-prolyl-glycine

low

glycylphenylalanine 2-naphthylamide

low

5-hydroxy-3',4',6,7-tetramethoxyflavone

low

imidazole-4-carboxamide

medium

medium

low

medium

low

low

low

dexmethylphenidate hydrochloride

medium

bazedoxifene

low

10-deacetylbaccatine iii

low

centchroman

low

hyoscyamine

low

idazoxan hydrochloride

low

phorbols

low

isoguvacine hydrochloride

low

4-methoxyhonokiol

low

chamaejasmine

low

8-methoxymethyl-3-isobutyl-1-methylxanthine

low

atractylenolide iii

low

cryptolepine monohydrochloride

low

acetylneurotensin (8-13)

low

naproxen

medium

canertinib dihydrochloride

medium

canertinib

medium

cinacalcet

medium

birb 796

low

technetium tc 99m citrate

low

medium

low

low

low

methyl 5-aminolevulinate

low

schizandrin b

low

satavaptan

low

n-(4-(n-((2,4-diaminofuro(2,3-d)pyrimidin-5-yl)methyl)amino)benzoyl)glutamic acid

low

l 739749

low

25-hydroxyprotopanaxadiol

low

medium

low

low

medium

low

low

low

low

medium

dialuminum magnesium tetraoxide

low

neodymium oxide

low

yttria

low

gadolinium oxide

low

lead titanate zirconate

low

karounidiol

low

mdl 74156

medium

celastrol methyl ester

low

medium

low

low

low

low

medium

gadolinium (+3) acetate

low

bisdequalinium

low

aristololactam-glucoside

low

low

medium

low

low

low

medium

ketobemidone, n,n-dimethyl-3,3-diphenyl-1-methylallylamine drug combination

low

miltirone

low

oxidopamine hydrochloride

low

cirsiliol

low

cryptotanshinone

low

fenton's reagent

low

n,n'-bis(2-pyridylmethylene)-1,4-butanediamine (n,n',n'',n''')-cu(ii)diperchlorate

low

cyc 202

medium

carbodiimides

low

Serotonin hydrochloride

low

n-phthaloylglutamic acid

low

low

low

low

low

3,5-dimethoxy-4'-hydroxystilbene

low

3,5-diiodothyropropionic acid

low

liensinine

low

saicar

low

4'-demethyldesoxypodophyllotoxin

low

ly 181984

low

benzo-tepa

low

testololactone

low

dimethylsulfonioacetate

low

low

low

low

low

2-phenyl-4-oxohydroquinoline

low

cloperastine hydrochloride

low

low

low

low

low

n(6)-(n-threonylcarbonyl)adenosine

low

low

low

low

low

low

low

low

low

1,3-dipropyl-7-methylxanthine

low

tylophorinidine

low

2,4,5-trihydroxypentanoic acid gamma-lactone

low

4,5-dibromo-2-pyrrolic acid

low

2-dodecylcyclobutanone

low

dihydroguaiaretic acid

low

ag 3-5

low

jolkinolide a

low

jolkinolide b

low

8-aminohexylamino camp

low

n-acetyl-1,6-diaminohexane

low

7-hydroxyamoxapine

low

isovitexin

low

cirsilineol

low

2-deoxy-2-fluorogalactose

low

lhrh, lys(6)-

low

glyceollin

low

platycodin d

low

beta-cyclodextrin-benzaldehyde

low

low

low

low

low

medium

low

naphthalenesulfonamide

low

6-deoxy-n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminoglucose

low

1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane

low

arginyl-tryptophyl-n-methylphenylalanyl-tryptophyl-leucyl-methioninamide

medium

sialyl-le(a) oligosaccharide

low

lysyl-arginyl-alanyl-lysyl-alanyl-lysyl-threonyl-threonyl-lysyl-lysyl-arginine

low

yttrium ethylenediaminetetra(methylenephosphonic acid)

low

sdz mrl 953

medium

1-(3-astatobenzyl)guanidine

low

atx 70

low

n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid

low

doranidazole

medium

isoindigotin

low

thymidine 5'-diphosphate

low

low

low

low

low

calcium pyrophosphate

low

tartrazine

low

cupric hydroxide

low

tetraphenylphosphonium

low

mirestrol

low

histidinol

low

diadenosine triphosphate

low

4'-hydroxyflavanone

low

pridinol mesylate

low

matrine, (5beta)-isomer

low

paromomycin

low

phosphorodiamidic acid

low

quinonyl-mdp-66

low

anidulafungin

low

avasimibe

low

technetium tc 99m pentetate

medium

5-formamidoimidazole-4-carboxamide ribotide

low

diethylenetriaminetetraacetic acid

low

metaperiodate

low

thiophosphoric acid

medium

clorazepate dipotassium

medium

amplex red

low

anacardic acid

low

leucodin

low

(22r)-22-hydroxycholesterol

low

trimethylsilyldiazomethane

low

n-n-propylnorapomorphine

low

urapidil monohydrochloride

low

22s-hydroxycholesterol

low

butyltriphenylphosphonium

low

pectolinarin

low

boswellic acid

low

beta-solamarine

low

5-hydroxymethyldeoxycytidine monophosphate

low

threitol

low

symmetric dimethylarginine

low

magnolin

low

aminopterin

medium

aminobutane bisphosphonate

low

elenolic acid

low

4-(2-aminoethyl)benzenesulfonamide

low

azepexole, dihydrochloride

low

17 alpha-hydroxyprogesterone caproate

low

low

medium

low

low

2,5-dimethoxy-4-iodoamphetamine hydrochloride

low

isopulegol

low

lysylproline

low

s-adenosyl-3-thiopropylamine

low

low

low

low

low

low

medium

low

manganese (iii) hematoporphyrin

low

lixivaptan

low

campesterol

low

methyl 4-azidophenylacetimidate

low

triptophenolide

low

1-nitrohydroxyphenyl-n-benzoylalanine

low

dimethylethylsilylimidazole

low

low

low

medium

low

low

low

low

low

low

medium

low

low

low

low

medium

medium

low

low

erlotinib hydrochloride

medium

medium

low

low

medium

low

medium

low

medium

indisetron hydrochloride

low

low

low

low

low

low

low

low

(2S)-5,7-dihydroxy-6,8-dimethylflavanone

low

(R)-atenolol

low

cucurbitacin iia

low

memantine hydrochloride

low

medioresinol

low

aceglutamide

low

(2R,3S)-2-(3,4-dimethoxyphenyl)-5,7-dimethoxy-3,4-dihydro-2H-1-benzopyran-3-ol

low

topsentin a

low

melagatran

low

s-benzoylmercaptoacetyltriglycine

low

scutellarin

low

hydroxycitric acid

low

dimethylarsinous acid

low

low

low

low

low

low

5-hydroxy-7,8-dimethoxyflavone

low

1,4,7-triazacyclononane

low

5'-deoxy-5'-iodouridine

low

n-bromoacetylethanolamine phosphate

low

2'-deoxytubercidin-5'-triphosphate

low

n(4)-adenosyl-n(4)-methyl-2,4-diaminobutanoic acid

low

low

low

low

low

low

low

low

low

3,7-diazabicyclo(3.3.1)nonane

low

low

low

low

low

medium

medium

(s-dinitrophenyl)-6-mercaptopurine riboside triphosphate

low

2-anilino-5-thiazolinone

low

succinylproline

low

3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine

low

3-(2'-pyridyldithio)benzyldiazoacetate

low

ranatachykinin a

low

cucurbit(6)uril

low

pi 083

low

n-(3-pyridylmethyl)adriamycin

low

palmarumycin cp(1)

low

rhinacanthone

low

n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide

medium

tripelennamine citrate

low

low

low

low

low

low

low

benfluorex hydrochloride

low

gabaculine hydrochloride

low

n-demethyltramadol

low

(-)-gallocatechin gallate

low

etiron monohydrobromide

low

4-methoxyphenylboronic acid

low

low

medium

low

low

low

procyclidine hydrochloride

low

medium

medium

low

low

2-(4-morpholinoanilino)-6-cyclohexylaminopurine

low

low

low

medium

medium

low

low

medium

medium

colistimethate sodium

low

medium

low

medium

low

low

medium

low

n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide

medium

diflomotecan

medium

regadenoson

low

alanyl-glutamyl-aspartyl-glycine

low

phenoxodiol

medium

1-methylpropyl-2-imidazolyl disulfide

medium

N-hydroxy-2-phenylacetamide

low

low

low

low

low

low

1-Anilino-9,10-dioxo-2-anthroic acid

low

sitosterol, (3beta)-isomer

low

low

medium

low

low

low

low

alpha-(trichloromethyl)-4-pyridineethanol

low

fludrocortisone acetate

low

cholesterol alpha-oxide

low

gossypol acetic acid

medium

carzinophilin

low

methandriol

low

norethindrone enanthate

low

nandrolone phenpropionate

low

mezlocillin

low

3-cyanoindole

low

cellulose triacetate

low

5,6-dimethoxy-3H-isobenzofuran-1-one

low

acetoxycycloheximide

low

colchiceine

low

2-(4-aminophenyl)benzothiazole

low

2-methylthioadenosine

low

3-nitrotyrosine

low

5-Fluoroisatin

low

epinastine

low

5-hydroxymethylfurfural

low

n-hydroxy-2,2-diphenylacetamide

low

vinblastine sulfate

low

vincaleukoblastine

low

5 alpha-androstane-3 beta,17 beta-diol

low

n-acetylcolchinol

low

blastmycin

low

estradiol-17 beta-3-methyl ether

low

cortol

low

lanosterol

low

21-hydroxypregnenolone

low

low

low

low

low

low

medium

medium

low

low

low

low

low

medium

chondocurine (1beta)-(+-)-isomer

low

khellactone

low

potassium bromide

low

sodium bromide

low

4-[(1,3-dimethyl-2,6-dioxo-7H-purin-8-yl)methylamino]benzoic acid

low

coronopilin

low

2-phenylethylenesulfonamide

low

low

medium

medium

low

3-(3-pyridinyl)propanoic acid

low

1-(2,4-Dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone

low

5',5',5'-trifluoroleucine

low

lupeol

low

telocinobufagin

low

n,n'-bis(salicylidene)-1,6-hexanediamine

low

n-methylserotonin oxalate salt

low

low

low

low

low

low

low

6-methylpurine 2'-deoxyriboside

low

phenesterin

low

gaillardin

low

23,24-dihydrocucurbitacin b

low

low

low

low

low

low

low

low

low

medium

low

low

medium

low

medium

low

medium

medium

low

low

low

medium

low

low

low

medium

2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one

low

medium

low

low

low

low

low

low

low

low

low

low

medium

low

low

low

low

low

3,4-dihydroxyphenylpropionic acid

low

indole-3-acetonitrile

low

6-fluorouracil

low

2'-fluorothymidine

medium

annonacin

low

4-oxy-6-(4-oxybezoyloxy)dauc-8,9-en

low

nsc606985

low

3,5-bis(benzylidene)-4-piperidone

low

erianin

low

adozelesin

medium

nsc 617145

low

trimethoprim, sulfamethoxazole drug combination

medium

diethoxy-(1-phenyl-1,3-butanedionato)titanium (iv)

medium

cercosporin

low

4,5,7-trihydroxy-9,10-dioxo-2-anthracenecarboxylic acid

low

acylfulvene

low

7-ethyl-7-hydroxy-10h-1,3-dioxolo(4,5-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-8,11(7h,12h)-dione

low

ledoxantrone

medium

ku 2285

low

paullone

low

5,3'-dihydroxy-3,6,7,8,4'-pentamethoxyflavone

low

o-(chloroacetylcarbamoyl)fumagillol

medium

halenaquinone

low

2,5-bis(5-hydroxymethyl-2-thienyl)furan

low

diba-1

low

murrayafoline a

low

nsc 663284

low

tris(2-pyridylmethyl)amine

low

3-(9-acridinylamino)-5-hydroxymethylaniline

low

low

medium

low

low

low

low

taurochenodeoxycholic acid

low

1,4,7,10-tetraazacyclododecane-1,7-diacetic acid

low

nsc681152

low

bortezomib

medium

263

2-(2-nitro-1h-imidazol-1-yl)-n-(2,2,3,3,3-pentafluoropropyl)acetamide

medium

aminoflavone

low

isochamaejasmin

low

neocryptolepine

low

7-methoxy-4-methyl-1-benzopyran-2-one

low

low

low

medium

low

medium

low

low

low

low

low

low

low

3-bromoacetylamino benzoylurea

low

4-(3-(2-nitro-1-imidazolyl)-propylamino)-7-chloroquinoline hydrochloride

low

low

low

medium

low

low

low

medium

n,n-dimethyl-n-(18f)fluoromethyl-2-hydroxyethylammonium

low

indoximod

low

cimadronate

low

dihydropyridines

medium

4-2-Aminoethyl-morpholine

low

nsc 23766

low

povidone-iodine

medium

5-amino-8-hydroxyquinoline

low

low

low

low

medium

medium

low

low

low

medium

243

low

low

medium

6-methylthiopurine ribonucleoside-5'-phosphate

medium

xr5944

medium

s-adenosylhomocysteine

low

5'-methylthioadenosine

low

low

low

low

glycerate 1,3-biphosphate

low

sorbose

low

arabinose

low

n-acetylneuraminic acid

medium

low

medium

medium

low

low

medium

polygalacturonic acid

low

elastin

low

carnosine

medium

mevalonic acid

medium

formiminoglutamic acid

low

low

low

low

medium

low

low

low

medium

low

low

low

low

s-adenosyl-3-methylthiopropylamine

low

7-dehydrocholesterol

low

inositol 1,4,5-trisphosphate

low

glutamyl-glutamic acid

low

low

low

low

low

low

low

low

low

low

tosylphenylalanyl chloromethyl ketone

low

tartaric acid

low

alpha-aminobutyric acid

low

medium

low

low

low

ketodihydrosphingosine

low

nicotinamide-beta-riboside

low

n-glycolylneuraminic acid

low

nitroarginine

low

mannosamine

low

willardiine

low

5-methyldeoxycytidine

low

inositol 3-phosphate

low

222

n-acetylglucosamine-1-phosphate

low

adenosine 5'-o-(3-thiotriphosphate)

low

24,25-dihydrolanosterol

low

low

low

low

low

low

low

low

low

low

low

low

low

low

medium

low

low

medium

low

trimeprazine tartrate

low

low

low

medium

low

low

low

low

low

medium

acebutolol hydrochloride

low

perindopril erbumine

low

miglitol

low

amiodarone hydrochloride

low

mometasone furoate

low

dicyclomine hydrochloride

low

metyrosine

low

nortriptyline hydrochloride

low

erythromycin estolate

low

paromomycin sulfate

low

terconazole

low

bacampicillin hydrochloride

low

medium

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

medium

low

low

low

low

low

low

5,6,7-trimethoxyflavone

low

low

low

medium

low

low

low

low

4-hydroxy-3-(3-methyl-2-butenyl)acetophenone

low

low

low

low

low

low

low

low

acetylleucyl-leucyl-norleucinal

low

s-(4-azidophenacyl)glutathione

low

1-alpha-terpineol

low

bq 123

low

n-formylmethionine leucyl-phenylalanine

medium

hydroxylamine hydrochloride

low

low

low

low

medium

3,5-dihydroxyphenylglycine

low

low

low

low

low

low

low

low

low

doxorubicin hydrochloride

low

halcinonide

low

metrizamide

low

medigoxin

low

erythromycin ethylsuccinate

low

vinpocetine

low

amcinonide

low

flumethasone pivalate

medium

tibolone

low

dihydroergocristine monomesylate

low

medium

low

low

low

low

low

low

medium

medium

medium

low

low

low

n-acetylneuraminic acid

low

farnesol

medium

phosphoramidon

low

3-hydroxy-3-methylglutaryl-coenzyme a

low

medium

medium

low

low

low

alpha-D-fructofuranose 1,6-bisphosphate

low

low

low

medium

medium

farnesyl pyrophosphate

low

low

medium

low

low

medium

1,4-dideoxy-1,4-iminoarabinitol, (2r-(2alpha,3beta,4beta))-isomer

low

eicosapentaenoic acid

medium

medium

medium

medium

low

medium

low

medium

5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol

low

medium

low

medium

low

low

2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl)propionic acid

low

cefoxitin

low

geranylgeranyl pyrophosphate

low

low

medium

low

low

low

medium

n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea

low

y 27632

low

cytidine monophosphate n-acetylneuraminic acid

low

adenosine-5'-(n-ethylcarboxamide)

low

low

medium

medium

benzene-1,3,5-tricarboxamide

low

epothilone a

medium

107

eptifibatide

low

7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine

low

6-bromoindirubin-3'-oxime

low

low

low

medium

low

low

low

low

low

medium

low

medium

medium

medium

1,4-dideoxy-1,4-imino-d-arabinitol

low

colfosceril palmitate

low

sm 8668

medium

phorbol-12,13-didecanoate

low

teniposide

low

texas red

low

cladribine triphosphate

low

low

medium

medium

low

low

low

low

low

medium

low

low

medium

low

low

5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide

low

tiazofurin

low

aphidicolin

low

3-(1-deoxyribofuranosyl)benzamide

low

arsphenamine

low

5-carboxy-8-hydroxyquinoline

low

azaserine

medium

melphalan

medium

358

1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione

low

enkephalin, leucine

medium

benzyloxycarbonylleucyl-leucyl-leucine aldehyde

low

ic9564

low

tenofovir

low

prinomastat

low

Epigallocatechin 3,5-Digallate

low

low

low

medium

medium

low

5-ethynyl-2'-deoxyuridine

low

low

medium

low

medium

low

beta, beta-dimethylacrylshikonin, (+)-isomer

low

acetylshikonin

low

shikonin

low

elatol

low

6,8-diprenylgenistein

low

low

low

low

medium

3-((4-azidophenyl)dithio)propionic n-hydroxysuccinimide

low

2'-c-methylcytidine

low

evp 4593

low

2,3-bis(bromomethyl)quinoxaline-1,4-dioxide

medium

isoxanthohumol

low

5-fluoro-2'-deoxycytidine

medium

Phe-Tyr

low

sodium thiocyanate

low

potassium permanganate

low

sodium bicarbonate

medium

potassium bicarbonate

low

potassium perchlorate

low

sodium chlorate

low

ammonium acetate

low

sodium dichloroacetate

low

arsenic trioxide

low

zn(ii)-phthalocyanine

medium

2,2,5,5-tetramethyl-1-pyrrolidinyloxy-3-carboxylic acid

low

low

low

medium

low

low

low

cholestane-3,5,6-triol

low

thiacremonone

low

bromochloroacetic acid

medium

233

11-mercaptoundecanoic acid

low

trimedlure

low

calix(4)arene

low

2-tetradecylcyclobutanone

low

4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

2-hydroxycinnamic acid

low

trans-4-coumaric acid

low

low

low

low

medium

low

low

low

medium

low

medium

low

low

low

low

low

low

low

medium

low

low

low

low

phenyl-n-tert-butylnitrone

low

low

low

low

low

4-dimethylaminostilbene

low

dibenzylidene acetone

low

picibanil

medium

2-methoxycinnamaldehyde

low

p-hydroxycinnamaldehyde

low

low

low

low

low

low

low

low

low

low

low

low

low

flavin-adenine dinucleotide

low

medium

low

medium

medium

medium

low

low

low

low

low

low

low

medium

low

medium

low

low

iothalamate meglumine

low

ferlixit

medium

mitobronitol

medium

tropisetron hydrochloride

low

tropisetron

medium

sodium metabisulfite

medium

Reactive blue 2

low

(2'-(benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)ethylamide)

low

hydrastine, (r-(r*,s*))-isomer

low

5,6-dichloro-1-ethyl-1,3-dihydro-2h-benzimidazol-2-one

low

prednisolone hemisuccinate

low

quinidine sulfate

low

isopropyl thiogalactoside

medium

n-octyl-beta-d-thioglucopyranoside

low

tiamulin

low

methylthio-dadme-immucillin-a

low

low

medium

low

low

low

low

ipratropium bromide anhydrous

low

methamilane methiodide

low

physostigmine salicylate

low

pilocarpine nitrate

low

r 59949

low

n(6)-cyclopentyladenosine

low

methylatropine nitrate

low

low

medium

low

low

medium

medium

medium

low

low

low

3,3',4,5'-tetrahydroxystilbene

low

bemesetron

low

benzoylacrylic acid

low

alpha-methyltryptophan, (l)-isomer

low

1-methyltryptophan

medium

thioinosine

medium

6-methoxy-2-(3-methoxyphenyl)-1-benzopyran-4-one

low

jrf 12

low

phenylthiourea

low

(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide

low

crotamiton

low

(S)-(-)-pindolol

low

levosulpiride

medium

5-(2-bromovinyl)uracil

low

L-histidine 2-naphthylamide

low

3,6-dihydroxyflavone

low

3,7-dimethoxyflavone

low

6-methoxy-2-(4-methoxyphenyl)-1-benzopyran-4-one

low

3',4'-dimethoxyflavone

low

2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-1-benzopyran-4-one

low

(2S)-7-hydroxyflavanone

low

low

low

low

low

low

low

4-fluorophenyl-L-alanine

low

3-(3,4-dimethoxyphenyl)propenoic acid

low

(E)-2-methoxycinnamic acid

low

5-phenyl-1,3,4-oxadiazole-2-thiol

low

3,4,5-trimethoxycinnamic acid

low

vanilmandelic acid

low

isoferulic acid

low

1-(2-hydroxy-5-methylphenyl)-3-phenyl-1,3-propanedione

low

ethyl ferulate

low

urocanic acid

low

2-(1-piperidinylmethyl)phenol

low

2,6-bis(benzimidazol-2-yl)pyridine

low

4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol

low

4-acetylaminostilbene

low

3-(5-methoxy-2,2-dimethyl-1-benzopyran-8-yl)-3-oxopropanoic acid

low

purine-nucleoside phosphorylase

low

ethyl 2,4-dihydroxybenzoate

low

low

medium

low

low

low

5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-(4-methoxyphenyl)isoxazole

low

low

low

low

low

medium

low

low

low

low

low

low

N-(4-chlorophenyl)-7,8-dimethoxy-1-oxo-2-benzothiopyran-3-carboxamide

low

3-(n-benzylsulfamoyl)-4-bromo-n-(4-bromophenyl)benzamide

low

low

low

low

medium

low

low

3-cyano-4-phenyl-6-(3-bromo-6-hydroxyphenyl)-2-pyridone

low

N-[(2-fluorophenyl)methyl]-2-thiophenecarboxamide

low

low

low

low

low

5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one

low

medium

low

low

low

3-phenyl-2H-1,4-benzoxazine

low

low

medium

low

low

medium

low

low

low

low

low

n-(fluorenyl-9-methoxycarbonyl)leucine

low

allylthiourea

low

tosylarginine methyl ester

low

aurapten

low

n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide

low

low

low

low

medium

low

low

low

medium

N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide

low

N-[2-[5-(1,3-benzothiazol-2-yl)-3-ethyl-1-phenyl-2-benzimidazol-3-iumyl]ethenyl]-N-methylaniline

low

phenacylamine monohydrochloride

low

thioguanine anhydrous

medium

low

low

low

low

(1R,2S)-tranylcypromine hydrochloride

low

s-phenyl-n-acetylcysteine

low

tacrine hydrochloride

low

1-n-methyl-5-thiotetrazole

medium

low

medium

low

low

2-amino-5-mercapto-1,3,4-thiadiazole

low

medium

low

low

medium

low

4-bromotetramisole, oxalate (1:1), salt(s)-isomer

low

low

low

low

low

low

p-aminosalicylic acid monosodium salt

low

digoxin

medium

6-thioguanosine

low

3-hydroxybenzylhydrazine hydrochloride

low

1,6-anhydro-beta-glucopyranose

low

ccg 1423

low

1-(3-chlorophenyl)biguanide hydrochloride

low

mecysteine hydrochloride

low

4-chlorophenylalanine methyl ester, hydrochloride, (dl)-isomer

low

epsilon-tert-butyloxycarbonyl-lysine

low

capsazepine

low

fumonisin b1

low

fumonisin b2

low

1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole

low

diphenyleneiodium chloride

low

azetidine-2,4-dicarboxylic acid, (cis)-isomer

low

tamoxifen citrate

low

tamoxifen

medium

205

4-vinylphenyl boronic acid

low

nadp

low

140

pimagedine hydrochloride

low

1,1-diphenyl-2-picrylhydrazyl

low

Betaine Aldehyde Chloride

low

yoda 1

low

bi-78d3

low

ethionamide

low

5-carboxytetramethylrhodamine succinimidyl ester

low

5-carboxytetramethylrhodamine

low

6-carboxytetramethylrhodamine

low

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium

low

3-(4-acetylphenyl)-2-aminopropanoic acid

low

perfluoro-1,4,7,10,13-pentaoxacyclopentadecane

low

stattic

low

3,4-diaminocyclobut-3-ene-1,2-dione

low

sc 514

low

N-(1H-indol-5-yl)-2-thiophenecarboxamide

low

2-oxo-4,6-dithiophen-2-yl-1H-pyridine-3-carbonitrile

low

low

medium

low

low

low

methyl-thiohydantoin-tryptophan

low

apcin

low

4,6-dimorpholino-n-(4-nitrophenyl)-1,3,5-triazin-2-amine

low

10074-g5

low

oreoselone

low

N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide

low

6-(4-hydroxyphenyl)-2-thioxo-2,3-dihydro-4(1h)-pyrimidinone

low

eskazine

low

k 858

low

1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane

low

N-[4-[[[4-(4-methoxyphenyl)-4-oxanyl]methylamino]-oxomethyl]phenyl]-2-furancarboxamide

low

low

low

medium

medium

low

medium

beta-2'-deoxythioguanosine

low

low

low

low

medium

low

low

low

low

low

medium

alpha-2'-deoxythioguanosine

low

2'-deoxy-2'-methylenecytidine

low

low

low

low

low

low

4-diphenylacetoxy-n-methylpiperidine methiodide

low

Avocadyne

low

5-amino-2,4,6-triiodoisophthalic acid

low

n-bromotaurine

low

6,7-dichloro-3-hydroxy-2-quinoxalinecarboxylic acid

low

2-(allylthio)pyrazine

low

medium

medium

medium

low

medium

medium

low

low

medium

low

low

low

low

medium

low

low

medium

low

low

4-thiouridine triphosphate

low

low

low

medium

low

low

low

low

low

5-mercapto-1,3,4-thiadiazole

low

ra vii

medium

2,2'-bipyridyl-6-carbothioamide

low

6-thioguanylic acid

low

1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester

low

androstane-3,17-diol glucuronide

low

2-thioxo-4-thiazolidinecarboxylic acid

low

low

low

medium

low

2,2-dimethyl-5-hydroxy-1-pyrrolidinyloxy

low

mdl 72527

low

rtki cpd

low

2'-cyano-2'-deoxyarabinofuranosylcytosine

low

ethylenediamine platinum(ii) malonate

low

2,4-dinitrofluorobenzene sulfonic acid

low

didimethylsulfoxide dichloroplatinum(ii)

low

asperlicin

low

1-(4-hydroxybenzyl)imidazole-2-thiol

low

1-(2-(2-(4-pyridyl)-2-imidazoline-1-yl)ethyl)-3-(4-carboxyphenyl)urea

low

e 7010

medium

win 33377

medium

nicotine n-glucuronide

medium

2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide

low

2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid

low

low

medium

medium

low

low

medium

low

low

medium

low

low

low

low

low

ritodrine hydrochloride

low

3-deoxyvasicine, hydrochloride

low

low

low

medium

low

trequinsin hydrochloride

low

dasatinib

medium

ha 1100

low

emetine dihydrochloride

low

low

low

medium

low

low

low

low

low

5-methoxycarbonylmethyluridine

low

6-fluoropyridoxal

low

n-(4-acetamidobenzoyl)-l-glutamic acid

low

2,3,4-tri-o-acetylarabinopyranosyl isothiocyanate

low

arginyl-glycyl-aspartyl-phenylalanine

low

1-(3-chloro-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone

low

7-deoxy-13-dihydroadriamycinone

low

medium

medium

low

medium

low

low

2-fluoro-2-deoxyglucose-6-phosphate

medium

medium

low

low

medium

low

3-hydroxy-6-cholen-24-oic acid

low

low

low

medium

low

low

low

6,7,8-trimethoxycoumarin

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

1,6-dimethyl-3-propylpyrimido[5,4-e][1,2,4]triazine-5,7-dione

low

benzatropine methanesulfonate

low

phosphothreonine

low

cambinol

low

nsc 117199

low

n-(3-oxododecanoyl)homoserine lactone

low

sb 203186

low

n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea

low

ovalbumin

low

171

5-iodo-2'-deoxyuridine triphosphate

low

n-acetylgalactosaminyl-1-4-n-acetylglucosamine

low

gw 7647

low

sodium dodecyl sulfate

medium

blister

low

bromohydrin pyrophosphate

medium

5-chloro-7-[1-piperidinyl(2-pyridinyl)methyl]-8-quinolinol

low

ro 41-0960

low

crocin

low

galactomannan

low

5-chloro-7-[(4-ethyl-1-piperazinyl)-(3-pyridinyl)methyl]-8-quinolinol

low

cgp 13501

low

dimethyldithiocarbamate

low

Angolensin

low

nefurthiazole

low

n-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-3-methoxybenzamide

low

mtt formazan

low

chloramine-t

low

2-[4-[oxo(thiophen-2-yl)methyl]phenyl]propanoic acid methyl ester

low

l 663536

low

brl 15572

low

N-(4-methylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide

low

low

low

low

low

6-bromo-3'-nitroflavone

low

6-cyano-7-nitroquinoxaline-2,3-dione

low

2,4-dinitrophenylhydrazine

low

6-hydrazinopyridine-3-carboxylic acid

low

zinc protoporphyrin ix

low

3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3h)-quinazolinone

low

2-amino-6-methyl-4-(3-pyridinyl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile

low

sb 225002

low

or486

low

fg 9041

low

2,5-dihydroxy-4-methoxybenzophenone

low

2,4-dihydroxyheptadec-16-ynyl acetate

low

low

low

low

low

low

low

tetramethylrhodamine isothiocyanate

low

4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione

low

low

low

low

low

low

medium

low

low

low

low

low

hydroxyethylcellulose

low

low

low

medium

low

low

low

medium

low

4-mercaptophenylboronic acid

low

5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione

low

icodextrin

low

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide

low

7-lysylalanyl-4-methylcoumarinamide

low

rhodamine 123

medium

N-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide

low

4-hydroxy-5-methyl-3(2h)-furanone

low

low

low

low

low

low

low

low

low

1,3,5-tris(4-hydroxyphenyl)-4-propyl-1h-pyrazole

low

low

low

low

low

low

iodoazomycin arabinoside

low

tetrathiomolybdate

medium

nor-beta-lapachone

low

7-methoxy-2-(4-methoxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one

low

low

low

low

low

low

quercetin 3-o-glucuronide

low

low

low

low

medium

medium

medium

medium

medium

low

low

low

low

low

low

arachidonyltrifluoromethane

low

low

low

low

medium

medium

7,3'-dihydroxy-4'-methoxyisoflavone

low

low

medium

low

low

low

medium

medium

vitamin k semiquinone radical

medium

medium

medium

low

low

low

medium

2'-hydroxyformononetin

low

hymecromone

low

daphnetin

low

8,11,14-eicosatrienoic acid

low

luteolin-7-glucoside

low

rosin

low

quercetin 3-o-methyl ether

low

apigetrin

low

furylfuramide

low

alprostadil

medium

5-hydroxy-6,8,11,14-eicosatetraenoic acid

low

low

low

low

medium

low

medium

quercetin 3-o-glucopyranoside

low

medium

low

low

low

9-deoxy-delta-9-prostaglandin d2

low

9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin d2

low

6-ketoprostaglandin f1 alpha

low

6-ketoprostaglandin e1

low

arachidonic acid omega-9 hydroperoxide

low

medium

low

medium

low

low

low

medium

medium

medium

low

low

low

low

low

low

low

low

brompheniramine maleate

low

chlorpheniramine maleate

low

clemastine fumarate

low

methylergonovine maleate

low

carboprost

low

mycophenolate mofetil

low

medium

low

low

low

low

low

low

low

low

low

low

medium

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

medium

low

low

low

low

low

medium

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

7-hydroxy-6,4'-dimethoxyisoflavone

low

coumestrol

low

daidzein

low

polydatin

low

Pinosylvin methyl ether

low

low

low

low

low

low

low

low

caffeic acid phenethyl ester

low

low

low

low

low

low

4'-methoxy-3',5,7-trihydroxyisoflavone

low

low

low

medium

low

low

low

low

medium

low

low

low

low

low

low

low

low

low

low

low

low

low

low

4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid

low

4,4'-dinitro-2,2'-stilbenedisulfonic acid

low

8-epi-prostaglandin f2alpha

medium

glyceryl 2-arachidonate

low

selachyl alcohol

low

n,n-dimethylsphingenine

low

low

low

low

low

low

low

4,4'-dihydroxystilbene

low

low

medium

medium

medium

xylometazoline hydrochloride

low

flunarizine hydrochloride

low

ketotifen fumarate

low

carbinoxamine maleate

low

low

medium

low

medium

cis-flupenthixol dihydrochloride

low

hydrocortisone valerate

low

9,11-linoleic acid

low

trans-10,cis-12-conjugated linoleic acid

low

9-hydroxy-10,12-octadecadienoic acid

low

13-hydroxy-9,11-octadecadienoic acid

low

15-keto-13,14-dihydroprostaglandin f2alpha

low

thromboxane b2

medium

5-oxo-6,8,11,14-eicosatetraenoic acid

low

low

low

low

low

1-monooleoyl-rac-glycerol

low

menaquinone 6

medium

sphingosine 1-phosphate

medium

126

n-palmitoylsphingosine

low

ceramide 1-phosphate

low

1,25-dihydroxy-24-oxo-vitamin d3

low

low

low

low

medium

low

medium

low

low

phenoxybenzamine hydrochloride

low

phenylephrine hydrochloride

low

low

low

low

low

3-amino-1,4-dimethyl-5h-pyrido(4,3-b)indole

low

3-amino-1-methyl-5h-pyrido(4,3-b)indole

low

low

low

low

medium

low

low

low

medium

medium

medium

low

low

low

low

medium

low

medium

medium

low

medium

medium

medium

medium

low

3',4',7-trihydroxyisoflavone

low

6,7,4'-trihydroxyisoflavone

low

6alpha-hydroxy-17beta-estradiol

low

low

low

medium

low

low

medium

low

vitamin a acid ethylamide

low

fenretinide

medium

ro26-4550

low

N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide

low

geldanamycin

low

N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose

low

low

low

low

low

17-(dimethylaminoethylamino)-17-demethoxygeldanamycin

medium

lobeline

low

morphine

medium

1,249

265

oregon green 488 carboxylic acid

low

pactamycin

low

as 605240

low

su 9516

low

4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid

low

l-2-(carboxypropyl)glycine

low

low

low

low

low

deamino arginine vasopressin

low

medium

low

medium

low

low

low

low

low

low

low

low

low

15-deoxy-delta(12,14)-prostaglandin j2

low

lacidipine

low

lysophosphatidic acid

low

lysophosphatidylcholines

low

magnesium trisilicate

low

mdl 100907

low

n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester

low

low

medium

low

low

low

low

11-dehydrocorticosterone

low

low

low

low

low

low

low

low

low

low

low

10-hydroxy-2-decenoic acid

low

1,2-oleoylphosphatidylcholine

low

low

low

low

low

low

low

low

kaempferol 3-o-rhamnoside

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

medium

low

low

low

3-deoxysappanchalcone

low

MeJA

low

muromonab-cd3

low

5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one

low

artemetin

low

salazinic acid

low

5,4'-dihydroxy-3,6,7-trimethoxyflavone

low

low

low

low

low

low

low

low

low

low

low

low

medium

low

low

low

low

1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)-

medium

low

low

low

low

low

low

alpha-cyano-4-hydroxycinnamic acid

low

low

low

medium

low

medium

medium

medium

low

low

medium

low

7-hydroxycoumarin-3-carboxylic acid

low

low

low

low

medium

low

low

low

medium

ergosterol-5,8-peroxide

low

low

low

low

low

low

medium

low

low

medium

12-hydroxy-5,8,10,14-eicosatetraenoic acid

low

13-hydroperoxy-9,11-octadecadienoic acid

low

15-hydroxy-5,8,11,13-eicosatetraenoic acid

low

8-(3-chlorostyryl)caffeine

low

alpha-cyano-3-hydroxycinnamate

low

bay 11-7082

low

bay 11-7085

low

methyl 2,5-dihydroxycinnamate

low

indanocine

low

diamide

low

rg 14620

low

2,4,3',5'-tetramethoxystilbene

low

methyl-3-methoxy-4-hydroxystyryl ketone

low

5,7-dihydroxy-4-methylcoumarin

low

low

low

low

low

7,8-dihydroxy-4-methylcoumarin

low

flavokawain b

low

1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one

low

8-oxo-7,8-dihydrodeoxyguanine

low

low

low

low

low

low

low

low

low

low

low

medium

low

medium

medium

medium

low

medium

low

medium

low

low

medium

4-hydroxyaminoquinoline-1-oxide

low

naltrexone

medium

morphine-6-glucuronide

medium

dextromethorphan

medium

dextrorphan

medium

nalbuphine hydrochloride

low

low

medium

medium

medium

low

low

low

low

medium

medium

low

low

medium

low

methylazoxymethanol acetate

low

geldanamycin

low

musk

low

1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-butenone

low

3,7,11,15-tetramethyl-2-hexadecen-1-ol

low

2,7,11-cembratriene-4,6-diol

low

octa-2,4,6-trienoic acid

medium

low

low

low

low

low

5-(4-methoxybenzylidene)thiazolidine-2,4-dione

low

plastoquinone

low

diphenylhexatriene

low

2',4'-dihydroxychalcone

low

low

low

low

low

low

5,6-dichloro-1H-imidazo[4,5-b]pyrazine-2-carboxylic acid

low

puerarin

low

7-hydroxymethotrexate

low

eleostearic acid

low

ajoene

low

quinocetone

low

3,4',5-trimethoxystilbene

low

low

low

medium

low

low

low

low

low

low

low

low

low

n-methylscopolamine bromide

low

sinomenine

low

dimyristoylphosphatidylcholine

low

low

low

low

low

low

2-deoxyribose 1-phosphate, (alpha-d-erythro)-isomer

low

low

low

low

low

medium

low

low

low

low

medium

medium

medium

dextromethorphan hydrobromide

low

enalaprilat anhydrous

low

6-o-monoacetylmorphine

low

low

low

low

low

2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid

low

gamma-mangostin

low

n-hydroxy-n'-aminoguanidine

low

naloxone hydrochloride

low

imidapril

low

4',7,8-trihydroxyisoflavone

low

low

low

low

low

s-trans,trans-farnesylthiosalicylic acid

medium

low

low

low

low

low

medium

low

low

low

low

low

low

medium

low

low

1,3,5,6-tetrahydroxyxanthone

low

2-acetylpyridine thiosemicarbazone

low

glyfoline

low

guajavarin

low

Norartocarpetin

low

24-ethyl-4-cholesten-3-one

low

succinyl-trialanine-4-nitroanilide

low

pachymic acid

low

morphine-3-glucuronide

medium

dermorphin

low

naltrexone hydrochloride

low

benzoporphyrin d

low

enkephalin, ala(2)-mephe(4)-gly(5)-

low

lespenefril

low

strontium radioisotopes

low

stercobilin

low

caesium-137

low

sinigrin

low

3,3'-dipropyl-2,2'-thiadicarbocyanine

low

troxerutin

low

talaporfin

medium

neuromedin c

low

naltrindole benzofuran

low

pregabalin

medium

ll d42067 alpha

low

capuramycin

low

seryl-isoleucyl-lysyl-valyl-alanyl-valinamide

low

3,3'-diheptyloxycarbocyanine

low

homocastasterone

low

3,8-dihydroxy-6h-dibenzo(b,d)pyran-6-one

low

1,3-dihydroxy-xanthone

low

alvimopan anhydrous

low

baohuoside i

low

zinc(ii) tetrakis(4-carboxyphenyl)porphine

low

low

low

low

medium

low

low

low

2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one

low

vx680

medium

9-Hydroxycalabaxanthone

low

n-acetylsphingosine

low

crotonyl-coenzyme a

low

triolein

low

docosapentaenoic acid

medium

low

low

low

low

(1S,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-[oxo-(3,4,5-trimethoxyphenyl)methoxy]-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid methyl ester

low

guanabenz acetate

low

guanabenz

low

1-[4-[4-[[(2R)-2-(2,4-dichlorophenyl)-2-(1-imidazolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]ethanone

low

nylidrin hydrochloride

low

triprolidine hydrochloride anhydrous

low

phentolamine

low

epicinchonine

low

ethaverine hydrochloride

low

famotidine

low

fenoterol

low

fendiline hydrochloride

low

tiapridex

low

bromhexine hydrochloride

low

mephentermine sulfate

low

methylbenzethonium chloride

low

quipazine maleate

low

n-(2-aminoethyl)-4-chlorobenzamide hydrochloride

low

nab-365

low

tulobuterol hydrochloride

low

low

low

low

low

low

3,3'-dihexyl-2,2'-oxacarbocyanine

low

3,3'-dioctadecylindocarbocyanine

low

ap 10

low

carbocyanines

low

165

25-hydroxyvitamin d 2

medium

salubrinal

low

3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one

low

low

medium

low

low

medium

low

low

medium

n,n,n-trimethyl-1-(4-stilbenoxy)-2-propylammonium iodide

low

cinidon-ethyl

low

1,2-dielaidoylphosphatidylethanolamine

low

gw-5074

low

6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one

low

low

low

low

low

low

low

low

7-chloro-4-hydroxy-2-phenyl-1,8-naphthyridine

low

c.i. fluorescent brightening agent 28

low

3',4',5',3,4,5-hexamethoxy-chalcone

low

4,4'-diisothiocyanostilbene-2,2'-disulfonic acid

low

12-o-retinoylphorbol-13-acetate

low

gr 46611

low

proguanil

low

3,5-dihydroxy-4'-methoxystilbene

low

12-o-undecadienoylphorbol-13-acetate

low

flavokawain C

low

22,23-dihydroavermectin b(1)a

low

ma-1

medium

monorden

low

coomassie brilliant blue

low

low

low

low

medium

low

low

low

low

low

medium

medium

medium

low

medium

low

low

low

low

low

medium

low

low

low

1,1-diethyl-2-hydroxy-2-nitrosohydrazine

low

aluminum hydroxide, magnesium hydroxide, drug combination

medium

technetium tc 99m stannous pyrophosphate

low

venalot

low

clinoptilolite

medium

bismuth germanium oxide

low

boron-10 atom

low

palonosetron

medium

(3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

low

low

low

low

low

medium

low

(-)-catechin-3-O-gallate

low

sinequan

low

homatropine hydrobromide, (endo-(+-)-isomer)

low

dihydroergotoxine

low

clebopride maleate

low

vancomycin hydrochloride

low

moxisylyte hydrochloride

low

low

low

low

low

low

low

low

low

low

low

5-aminolevulinic acid hexyl ester

low

era-923

low

robenacoxib

low

ferrous fumarate

low

norpseudoephedrine hydrochloride, (s-(r*,s*))-isomer

low

beta-aminopropionitrile fumarate

low

low

low

low

low

low

low

24,25-dihydroxyvitamin d 3

low

flupirtine

low

cilastatin

medium

tezacitabine

medium

zimelidine hydrochloride

low

sclerotiorin

low

1-palmitoyl-2-oleoylphosphatidylcholine

low

low

low

low

low

low

ethyldeshydroxysparsomycin

low

oxotremorine sesquifumarate

low

low

low

low

low

low

low

medium

low

12-o-tetradeca-2,4,6,8-tetranoylphorbol-13-acetate

low

manoalide

low

1,2-dioleoyloxy-3-(trimethylammonium)propane

low

pectenotoxin 2

low

dioleoyl phosphatidylethanolamine

low

n-(2-hydroxyethyl)retinamide

low

low

low

low

low

low

low

n-(1-(2,3-dioleyloxy)propyl)-n,n,n-trimethylammonium chloride

low

microcystin rr

low

5-(2-iodovinyl)-2'-deoxyuridine

low

low

low

low

low

9-oxo-15-hydroxy-delta 7,10,13-prostatrienoic acid methyl ester

low

neo-gambogic acid

low

1,2-dioleoylphosphatidylserine

low

retinylidene dimedone

low

nsc 262266

medium

ganglioside gm3 lactone

low

low

low

medium

low

1,25-dihydroxy-16-ene-vitamin d3

low

glidobactin a

low

lactosyl lysosphingolipid

low

smr 2

low

e 3330

low

n,n,n-trimethylsphingosine

low

erucylphosphocholine

low

ethyl o-(n-(4-carboxyphenyl)carbamoyl)mycophenolate

low

pregna-4,17-diene-3,16-dione

low

medium

low

low

low

low

1,3'-diethyl-4,2'-quinolylthiacyanine iodide

low

poriferasterol monoglucoside

low

zeatin riboside

low

n(4)-oleylcytosine arabinoside

low

curdione

low

sphingosyl beta-glucoside

low

medium

low

low

low

low

low

low

hydroxysafflor yellow a

low

4,7,10,13,16,19-docosahexaenoic acid dopamine conjugate

low

low

medium

medium

low

medium

medium

13-oxo-9,11-octadecadienoic acid

low

fr 901464

low

5-(2-iodovinyl)-1-(2'-fluoro-2'-deoxyuridine)

low

low

low

low

low

pregna-4,17-diene-3,16-dione, (17z)-isomer

low

ganglioside, gd2

medium

asialo gm1 ganglioside

low

medium

medium

medium

low

low

low

low

i(3)so3-galactosylceramide

low

medium

low

low

low

low

technetium tc 99m pyrophosphate

low

19-hydroxycholesterol

low

brazilein

low

belotecan

medium

su 11248

low

(1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one

low

low

low

low

medium

medium

low

low

low

low

low

2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole

low

low

medium

low

low

nipecotic acid, (s)-isomer

low

glucoraphanin

medium

stigmasterol 3-o-beta-d-glucopyranoside

low

scopolamine hydrobromide

low

protriptyline hydrochloride

low

n(4)-chloroacetylcytosine arabinoside

low

n-(3-(cyclohexylidene-(1h-imidazol-4-ylmethyl))phenyl)ethanesulfonamide

low

n-(4-amino-2-chlorophenyl)phthalimide

low

cb 34

low

b 43

low

(8R)-7-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,13,14-triol

low

(8R)-7-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,13,14-triol

low

3-(6-chloro-3-pyridazinyl)-3,8-diazabicyclo(3.2.1)octane

low

2-(3,3-diphenylpropylamino)acetamide

low

4-(2-(phenylsulfonylamino)ethylthio)-2,6-difluorophenoxyacetamide

low

low

low

low

low

s-nitroso-n-acetylpenicillamine

low

low

low

low

low

low

low

low

low

low

low

(6aS,12aS)-9-hydroxy-2,3-dimethoxy-8-(3-methylbut-2-enyl)-6a,12a-dihydro-6H-[1]benzopyrano[3,4-b][1]benzopyran-12-one

low

1-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-oxolanyl]-5-(trifluoromethyl)pyrimidine-2,4-dione

low

Retusin 7-Methyl Ether

low

tehranolide

low

17-hydroxyjolkinolide b

low

gw 610

low

nifurtimox

low

ispinesib

medium

6-hydroxybenzothiazide-2-sulfonamide

low

peplomycin

low

epinephrine bitartrate

low

bicuculline methobromide

low

6 beta-hydroxycortisol

low

butylscopolammonium bromide

medium

androst-16-en-3-one

low

butaclamol hydrochloride

low

medium

medium

low

low

low

acetyl isogambogic acid

low

Garcinolic acid

low

3-hydroxy-4-methoxybenzaldehyde thiosemicarbazone

low

medium

low

medium

low

medium

low

low

low

low

low

low

low

low

low

tiapamil hydrochloride

medium

teroxirone

low

8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide

low

low

low

low

low

medium

medium

low

low

morpholinoanthracycline mx2

medium

low

low

medium

medium

medium

low

low

medium

low

d-phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide

low

ski 2053r

medium

dutasteride

low

combretastatin a-4 disodium phosphate

low

medium

low

medium

low

low

medium

medium

medium

low

medium

low

medium

docosahexaenoyl-paclitaxel

low

low

low

medium

low

medium

low

low

medium

medium

medium

medium

medium

medium

low

medium

low

low

low

medium

low

low

low

medium

low

4-acetamido-N-(2-amino-5-thiophen-2-ylphenyl)benzamide

low

low

low

low

low

low

low

leucyl-leucine-methyl ester

low

acetylcarnitine

low

staurosporine

medium

N-(3-methylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide

low

thymodepressin

low

N-(4-fluorophenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide

low

3-methyl-n-(3-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)isoxazole-5-carboxamide

low

dioleoylphosphatidic acid

low

low

low

low

low

low

low

low

low

low

low

low

low

medium

low

9h-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-n-(1-methylethyl)-

medium

tws 119

low

((3z)-n-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1h-pyrrol-2-yl)methylene)-n-methyl-2-oxo-2,3-dihydro-1h-indole-5-sulfonamide)

low

low

medium

low

low

low

low

low

low

medium

low

proguanil hydrochloride

low

cefmenoxime

medium

3-aminopyridine-2-carboxaldehyde thiosemicarbazone

medium

gs-7340

low

doxorubicin(6-maleimidocaproyl)hydrazone

medium

furaltadon monohydrochloride, (s)-isomer

low

low

low

medium

low

medium

low

low

low

gemifloxacin mesylate

low

cefoselis

low

naloxone benzoylhydrazone

low

poloxin

low

ferrihydrite

low

s-allylcysteine

low

s-allylmercaptocysteine

low

clasto-lactacystin beta-lactone

low

2-methyl-6-(phenylethynyl)pyridine hydrochloride

low

iniparib

medium

2-hydroxy-9-cis-octadecenoic acid

low

ave-8063

low

amiprilose

low

(R)-fluoxetine hydrochloride

low

phenylahistin

low

am 555s

medium

n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide

low

s-(1,2-dicarboxyethyl)glutathione

low

low

low

medium

low

low

medium

amoxicillin-potassium clavulanate combination

medium

medium

low

low

medium

low

acth (4-7), pro-gly-pro-

low

low

low

low

low

medium

medium

low

low

6-methylsulfinylhexyl isothiocyanate

low

thiophenfurin

low

6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol

low

low

low

low

low

low

low

low

medium

medium

medium

low

medium

low

medium

medium

medium

medium

low

low

seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide

low

omacor

medium

jasplakinolide

low

ro 28-2653

low

ezetimibe, simvastatin drug combination

medium

efatutazone

medium

sincalide

low

18f-fluoroethyl-l-tyrosine

low

3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one

low

tapentadol

medium

technetium tc 99m diphosphonate

low

low

low

low

low

1-(2-deoxy-beta-ribofuranosyl)-5-iodo-2-pyrimidinone

medium

rumbrin

low

ml 00253764

low

ly 450139

low

4-trimethylammonio-3-((tetradecylcarbamoyl)amino)butyrate

low

low

low

low

medium

low

low

medium

low

low

medium

medium

medium

medium

7-monohydroxyethylrutoside

medium

gnetin h

low

ppi-0903

low

4-anisyltetrazolium blue

low

low

medium

low

medium

low

desmethylselegiline hydrochloride

low

3-morpholino-sydnonimine monohydrochloride

low

low

low

low

low

medium

low

low

low

low

medium

low

low

low

4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acid

low

low

medium

low

low

low

low

low

low

low

medium

medium

1,3-bis(bis(pyridin-2-ylmethyl)amino)propan-2-ol

low

tafluposide

low

lipid a

medium

conagenin

low

4-methylene-2-octyl-5-oxofuran-3-carboxylic acid

low

dehydroxymethylepoxyquinomicin

low

treosulfan

medium

sr 4554

medium

22-hydroxyacuminatine

low

promestriene

low

qx-314 bromide

low

3-hydroxy-4,3',4',5'-tetramethoxychalcone

low

(S)-fluoxetine hydrochloride

low

pi103

low

3,5-bis(2-fluorobenzylidene)piperidin-4-one

low

low

low

medium

low

low

medium

low

low

medium

4-(n-(s-glutathionylacetyl)amino)phenylarsenoxide

medium

low

medium

low

medium

low

low

medium

low

thymic humoral factor gamma 2

low

medium

low

medium

low

1-(2-methoxyphenyl)piperazine hydrochloride

low

PI3-Kinase alpha Inhibitor 2

low

y 27632, dihydrochloride, (4(r)-trans)-isomer

low

5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride

low

low

low

low

low

low

low

ornithine alpha-ketoglutarate

low

low

medium

medium

low

medium

medium

n-((2s)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3- dimethyl-l-valinamide

medium

low

medium

low

low

low

3,9-bis((ethylthio)methyl)-k-252a

medium

casopitant

medium

msi 1436

low

secoisolariciresinol diglucoside

low

low

medium

low

medium

medium

2-deoxy-2-((18)F)fluoro-beta-D-glucose

low

ammonium trichloro(dioxoethylene-o,o'-)tellurate

low

low

low

medium

medium

low

n-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2h)-carboxamide

low

tocotrienols

low

(2s,3as,7as)-1-(((r,r)-2-phenylcyclopropyl)carbonyl)-2-((thiazolidin-3-yl)carbonyl)octahydro-1h-indole

low

n-desmethyltopotecan

low

rucaparib

medium

noscapine hydrochloride

low

medium

low

low

medium

medium

6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)-

medium

low

medium

low

low

low

low

low

low

medium

medium

low

low

medium

low

low

low

medium

1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride

low

aq4n

medium

chir 99021

low

ym 201636

low

1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole

low

acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide

medium

low

low

low

low

low

low

low

low

low

low

low

low

medium

low

low

low

low

low

low

low

low

low

low

low

low

arachidonoylserotonin

low

low

low

low

low

2'-deoxy-4'-thiocytidine

low

5'-deoxy-5-fluorocytidine

medium

3'-hydroxypterostilbene

low

low

low

low

low

low

low

low

low

low

low

low

low

low

medium

low

low

medium

medium

4-hydroxy-n-desmethyltamoxifen

low

low

low

low

low

low

2,4,2',4'-Tetrahydroxychalcone

low

medium

low

low

medium

medium

low

levodopa methyl ester hydrochloride

low

low

medium

low

low

prasugrel hydrochloride

medium

low

low

medium

medium

low

1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine

low

balicatib

low

gw 799388

low

benalfocin hydrochloride

low

low

low

low

low

low

low

5-fluorouridine 5'-triphosphate

medium

low

medium

low

medium

11 beta-hydroxyandrosterone

low

trans-sodium crocetinate

low

binimetinib

medium

xenon-129 atom

low

3,4-methylenedioxy-3',4',5'-trimethoxy chalcone

low

low

medium

medium

low

medium

low

low

low

low

low

low

low

erucylphospho-n,n,n-trimethylpropylammonium

low

pyranicin

low

7-aminoactinomycin d

low

2-acetylfuranonaphthoquinone

low

eudistomin u

low

luotonin a

low

di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone

low

2-hydroxyestriol

low

fauc 213

low

sb 204990

low

6-(3'-(1-adamantyl)-4'-hydroxyphenyl)-5-chloronaphthalenecarboxylic acid

low

ngr peptide

medium

angiotensin amide

low

3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole

low

low

low

medium

medium

low

benoxathian hydrochloride

low

((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1h-inden-5-yl)oxy)acetic acid, (+)-isomer

low

(1,2-bis(1,2-benzisoselenazolone-3(2h)-ketone))ethane

low

low

low

low

low

n-cyclopropyl adenosine-5'-carboxamide

low

low

low

low

low

homatropine methylbromide

low

ly 411575

low

nh 125

low

bms 599626

low

1,4-o-diferuloylsecoisolariciresinol

low

hellebrin

low

(S)-Isosclerone

low

cis-3,4',5-trimethoxy-3'-aminostilbene

low

di-2-pyridyl ketone isonicotinoyl hydrazone

low

low

low

medium

low

low

medium

low

medium

2'-benzoyloxycinnamaldehyde

low

low

low

low

low

glycerol phenylbutyrate

low

renieramycin m

low

3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxylic acid

low

medium

low

low

low

n'-(10h-indolo(3,2-b)quinolin-11-yl)-n,n-dimethylpropane-1,3-diamine

low

zeylenone

low

isomalyngamide a

low

vinflunine

medium

4,5-diaminofluorescein

low

low

low

low

low

low

medium

2,3-dihydro-3beta-methoxy withaferin A

low

5,15-diphenylporphine

low

low

low

low

low

medium

low

low

low

low

low

low

low

medium

8-oxo-2'-deoxyadenosine

low

low

low

medium

low

low

low

bis(2-pyridyl)methylamine

low

low

low

low

low

cyclic diadenosine phosphate

low

sarcodonin g

low

bakkenolide b

low

regorafenib

medium

acetyl-11-ketoboswellic acid

low

ym 155

low

kyp 2047

low

calpain inhibitor iii

low

protopanaxadiol, (3beta,12beta)-isomer

low

6-o-carboxypropyl-alpha-tocotrienol

low

low

low

low

medium

low

low

low

low

low

low

4-(2-((1r)-1-(((4-chlorophenyl)sulfonyl)-2,5-difluoroanilino)ethyl)-5-fluorophenyl)butanoic acid

low

low

low

low

low

low

low

low

low

buprenorphine, naloxone drug combination

low

medium

medium

medium

low

medium

medium

medium

low

low

low

medium

low

low

low

low

medium

medium

medium

low

low

medium

medium

linoleic acid hydroperoxide

low

potassium cyanate

low

karwinskia toxin t-514

low

mitoquinone

low

cannabidiol hydroxyquinone

low

low

low

medium

low

technetium tc 99m disofenin

low

nutlin-3a

low

danusertib

medium

2-methylene-3-hexylbutanedioic acid

low

low

low

low

medium

low

low

medium

medium

medium

low

low

5-(2,2-difluorobenzo(1,3)dioxol-5-ylmethylene)thiazolidine-2,4-dione

low

fr 180204

low

arq 197

medium

GR 127935 hydrochloride

low

low

low

low

low

medium

3-bromo-2-oxopropionate-1-propyl ester

low

low

medium

low

low

low

medium

low

medium

monomethyl auristatin e

medium

2,5-dimethylcelecoxib

low

medium

low

medium

low

low

low

sitagliptin phosphate

low

low

low

medium

low

medium

medium

low

low

medium

low

medium

pyrazolo(1,5-a)pyrimidine

low

low

low

low

low

medium

low

2,4,3',5'-tetrahydroxystilbene

low

low

low

low

medium

low

low

low

medium

low

low

medium

low

medium

low

low

low

low

low

low

low

low

low

medium

low

medium

147

medium

low

low

low

low

low

low

low

low

3',4'-anhydrovinblastine

medium

alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc

low

corannulene

low

aplyronine a

low

td-5108

low

2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose

low

low

medium

medium

medium

low

low

technetium tc 99m exametazime

low

telomestatin

low

at 13387

medium

ly2603618

medium

1-aminocyclopropane-1-carboxylic acid hydrochloride

low

alaproclate hydrochloride

low

ubenimex

low

3-chloroalanine hydrochloride, (l-ala)-isomer

low

dsp 4 hydrochloride

low

calcimycin

low

(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzodioxan hydrochloride

low

2-cyclooctyl-2-hydroxyethylamine hydrochloride

low

cirazoline monohydrochloride

low

dihydroouabain

low

adtn

low

apocodeine hydrochloride, (r)-isomer

low

Dihydro-beta-erythroidine hydrobromide

low

lilly 78335

low

efaroxan hydrochloride

low

fenoldopam hydrobromide

low

1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride

low

guvacine hydrochloride

low

7-hydroxy-2-n,n-dipropylaminotetralin hydrobromide

low

8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide, (r)-isomer,

low

1-(2-(4-(4-fluoro-benzoyl)-piperidin-1-yl)-ethyl)-3,3-dimethyl-1,2-dihydro-indol-2-one

low

4-iodoclonidine

low

dextrothyroxine

medium

4-methylpyrazole monohydrochloride

low

tele-methylhistamine

low

alpha-methyltyrosine methyl ester, monohydrochloride

low

octoclothepine maleate

low

2-(n-phenethyl-n-propyl)amino-5-hydroxytetralin hydrochloride

low

du 24565

low

2-methoxyidazoxan hydrochloride

low

ro 25-6981

low

sk&f 77434

low

3-[(6aR,9R,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-yl]-1,1-diethylurea

low

wk-x-34

low

veliparib

medium

ku-0060648

low

s-tetradecanoyl-coenzyme a

low

delta-1-pyrroline-5-carboxylate

low

sepharose

low

indocyanine green

medium

232

scopolamine hydrobromide

medium

low

low

low

medium

low

medium

low

medium

medium

benzoyl-ile-glu-gly-arg-p-nitroanilide

low

lhrh, ala(6)-gly(10)-ethylamide-

low

medium

low

low

low

inositol 3,4,5-trisphosphate

low

low

low

low

low

low

medium

low

low

low

5-ethoxycarbonyl-5-methyl-1-pyrroline n-oxide

low

thienopyridine

medium

arabinofuranosyluracil

medium

2-phenylquinazoline

low

demethylcantharidin

low

n-methylpyridine-2-carboxamide

low

low

low

medium

low

low

2alpha,3beta-dihydroxy-20(29)-lupen-28-oic acid

low

low

low

low

low

low

low

low

low

cannogenin thevetoside

low

low

low

low

low

low

low

low

low

low

low

low

low

low

low

medium

low

low

low

1-deoxynojirimycin hydrochloride

low

low

low

low

medium

medium

5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4h-1-benzopyran-4-one

low

low

low

low

low

chikusetsu saponin iva

low

2',2'-difluoro-2'-deoxyuridine

medium

low

low

low

low

low

low

low

7-n-(4-hydroxyphenyl)mitomycin c

low

low

low

low

low

low

low

low

low

5-Hydroxymethylcytidine

low

low

low

low

low

low

low

low

low

low

low

low

low

5-formyl-2'-deoxycytidine

low

win 62577

low

ankaflavin

low

2,3-dihydrowithaferin A

low

low

low

medium

low

low

medium

low

low

low

quinoline-3-carboxamide

low

pluramycin

low

3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide

low

cyanidin-3-o-beta-glucopyranoside

low

low

medium

low

medium

low

low

medium

medium

low

low

low

medium

low

n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide

medium

low

medium

medium

low

medium

medium

clindamycin hydrochloride

low

low

low

low

low

low

low

low

low

motesanib diphosphate

low

3,4-dimethoxy-n-((2,2-dimethyl-2h-chromen-6-yl)methyl)-n-phenylbenzenesulfonamide

low

low

low

low

medium

low

2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone

low

low

low

medium

low

low

medium

low

low

low

atrial natriuretic factor

medium

tachyplesin peptide, tachypleus tridentatus

low

tannins

low

magainin 2 peptide, xenopus

low

low

low

low

medium

low

(dtpa-phe(1))-octreotide

medium

low

low

low

low

glycoprotein e2, hepatitis c virus

medium

gala peptide

low

peptide i

low

ro 25-1553

low

pyrrhocoricin protein, pyrrhocoris apterus

low

low

low

low

low

medium

low

medium

medium

low

medium

low

medium

low

low

ceca1 protein, drosophila

low

low

low

low

low

low

low

low

low

low

low

low

low

low

medium

medium

low

low

low

medium

medium

glucagon-like peptide 1

low

low

low

low

low

low

low

msh, 4-nle-7-phe-alpha-

low

cbp 501

medium

c-peptide

low

gastrin 17

low

natriuretic peptide, c-type

low

low

low

low

medium

low

medium

medium

low

low

low

low

medium

medium

low

low

rv 538, (r-(r*,r*))-isomer

low

3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (1s-cis)-isomer

low

low

low

medium

medium

low

medium

medium

medium

low

low

medium

medium

low

low

phenylmercuric acetate

low

bis(tri-n-butyltin)oxide

low

4-aminophenylmercuriacetate

low

low

low

low

low

medium

medium

medium

medium

low

9-methylstreptimidone

low

cnf 2024

low

ku 0063794

low

14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene

low

medium

low

low

low

low

low

low

low

low

low

low

low

medium

low

N-(2-aminophenyl)-2-pyrazinecarboxamide

low

medium

low

low

low

low

cilastatin, imipenem drug combination

medium

2,3,4,10-tetrahydro-7,10-dimethyl-2,4-dioxobenzo(g)pteridine

low

igk

low

iminobiotin

low

3,4-dihydroxyphenylethanol-elenolic acid dialdehyde

low

rhenium(v)dimercaptosuccinic acid

low

alpha-amanitin

low

calpain

low

sodium cyanoborohydride

low

citric acid, iron, sorbitol drug combination

medium

hydromorphone-3-glucuronide

medium

lucifer yellow

low

2'-fluorothymidine

low

idarubicinol

medium

4-borono-2-fluorophenylalanine

low

sapogenins

low

theaflavin-3,3'-digallate

low

n,n'-bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine n,n'-diacetic acid

low

hydroxyoctadecadienoic acid

low

guanidine isothiocyanate

low

low

low

low

low

low

low

low

low

low

low

23-hydroxybetulinic acid

low

low

medium

medium

low

low

2',3',4'-trihydroxyflavone

low

technetium tc 99m sestamibi

medium

15-amino-4,7,10,13-tetraoxapentadecanoic acid

low

potassium borohydride

low

kw-2478

low

balanophonin

low

mo 113

low

15-deoxyprostaglandin j2

low

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine

low

cep 8983

medium

meglumine ioxithalamate

low

low

medium

medium

low

medium

low

medium

potassium aminobenzoate

low

low

low

medium

low

low

low

low

low

low

low

low

taurocholic acid, monosodium salt

low

low

low

low

low

low

low

low

4-hydroxymercuribenzoate

low

sodium nitrite

low

raltegravir potassium

medium

amphotericin b, deoxycholate drug combination

medium

low

low

low

low

low

low

low

potassium phenethicillin

low

low

low

low

medium

low

5-hydroxydecanoic acid, monosodium salt

low

merocyanine dye

medium

ro13-9904

medium

cr 1409

low

sodium pertechnetate tc 99m

low

low

low

low

cortisol succinate, sodium salt

low

piperacillin, tazobactam drug combination

medium

chiniofon

medium

quinupristin

medium

quinupristin-dalfopristin

low

medium

low

low

low

gadofosveset trisodium

low

medium

low

low

low

(E)-1,7-Bis(4-hydroxyphenyl)hept-4-en-3-one

low

low

low

low

low

medium

low

medium

low

low

low

phosphatidylinositol 4-phosphate

low

medium

low

low

low

low

low

low

medium

medium

medium

medium

low

low

low

low

medium

low

low

low

medium

low

medium

low

medium

low

low

low

low

medium

medium

low

low

10-methoxy-9-nitrocamptothecin

low

medium

medium

low

low

low

medium

low

sorbitan monopalmitate

low

low

low

low

medium

medium

low

low

medium

low

low

medium

low

low

n-alpha-benzoyl-n5-(2-chloro-1-iminoethyl)-l-ornithine amide

low

navitoclax

medium

pervanadate

low

sns 314

low

isocombretastatin a-4

low

low

low

medium

medium

low

low

4,4-difluoro-4-bora-3a,4a-diaza-s-indacene

low

quetiapine fumarate

medium

doxo-emch

medium

s-(1,2-dicarboxyethyl)cysteine

low

chlorin e4

low

n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide

low

ter 199

low

cardiovascular agents

medium

115

oprozomib

medium

ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4h-chromene-3-carboxylate

low

low

medium

medium

low

medium

low

medium

low

low

low

medium

medium

low

low

low

medium

medium

N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide

low

low

medium

medium

medium

low

medium

low

low

medium

low

low

low

medium

medium

medium

medium

low

medium

low

low

6-diazo-5-oxonorleucine

low

s-ethylcysteine

low

n-fluoroacetyl-n-(2,5-dimethoxybenzyl)-2-phenoxyaniline

low

nvp-bep800

low

(2-phenylthiazol-4-yl)-(3,4,5-trimethoxyphenyl)methanone

low

pf 3758309

low

pyridostatin

low

to-pro-3

low

n-methyl-4-(4-(3-(trifluoromethyl)benzamido)phenoxy)picolinamide

low

gdc 0980

low

cx 5461

low

wye 125132

low

3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1h-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1h-indole-5-carboxylic acid

low

azd2014

medium

(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol

medium

pf 8380

low

kurarinone

low

salicortin

low

4'-geranyloxyferulic acid

low

peptones

low

4-hydroxy-5-nitrophenyl acetic acid

low

plx4032

medium

2,3-bis(2-hydroxyethylsulfanyl)-(1,4)naphthoquinone

low

gsk 1363089

medium

arry-334543

low

GDC-0623

low

triiodothyronine, reverse

low

low

low

low

low

low

medium

2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide

low

medium

low

low

medium

low

medium

low

low

low

4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester

low

arry 520

medium

piperidines

medium

359

6-[(3-methoxyphenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone

low

6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone

low

medium

low

low

medium

medium

5-hydroxymethyl-2'-deoxyuridine

low

low

low

medium

low

medium

medium

low

medium

low

medium

low

3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline

low

cp 466722

low

scopadulciol

low

2,3-dihydro-3beta-O-sulfate withaferin A

low

low

low

medium

low

low

n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

medium

low

medium

low

low

low

low

[5-[4-[(5-methyl-2-furanyl)methylamino]-6-quinazolinyl]-2-furanyl]methanol

low

low

medium

low

medium

medium

medium

medium

low

low

5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine

medium

medium

medium

low

low

low

low

low

low

low

low

14-o-phosphonooxymethyltriptolide

low

medium

low

medium

low

low

low

medium

medium

low

low

low

low

low

medium

low

low

low

medium

low

low

low

low

6-phosphogluconolactone

low

dinaciclib

medium

lgk974

medium

1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone

low

fructose-1,6-diphosphate

low

low

medium

medium

low

low

low

medium

low

low

low

low

low

low

medium

medium

medium

low

N-(4,6-dimethyl-2-pyridinyl)-4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarbothioamide

low

low

low

low

low

low

medium

low

low

low

low

low

low

medium

medium

low

medium

methyl 1-hydroxy-6-phenyl-4-(trifluoromethyl)-1h-indole-2-carboxylate

low

low

low

medium

low

medium

medium

dimethylaminomicheliolide

low

rugulactone

low

gephyronic acid

low

3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea

low

nvp-cgm097

medium

landomycin e

low

vasoactive intestinal peptide

low

moverastin a

low

phosphomannopentaose sulfate

medium

natriuretic peptide, brain

medium

low

low

medium

low

medium

low

medium

low

low

low

medium

low

medium

medium

low

o-(2-fluoroethyl)tyrosine

medium

low

low

medium

4-hydroxy-6-methyl-2-pyrone

low

low

medium

low

oxytetracycline, anhydrous

low

medium

low

low

medium

low

medium

medium

4-hydroxy-3-(4-hydroxyphenyl)-5-methoxy-8,8-dimethyl-6-(3-methylbut-2-enyl)-2-pyrano[2,3-h][1]benzopyranone

low

medium

low

low

low

low

medium

medium

low

ethyl 1-benzyl-3-hydroxy-2(5h)-oxopyrrole-4-carboxylate

low

warfarin

medium

515

metastat

medium

ascorbate-2-phosphate

low

gimeracil

medium

6-o-palmitoylascorbic acid

low

demeclocycline

low

phenprocoumon

medium

pyrvinium pamoate

low

oxytetracycline hydrochloride

low

citrinin

low

tetrocarcin a

low

zilascorb

medium

chlortetracycline hydrochloride

low

low

low

low

low

medium

low

low

low

methacycline monohydrochloride

low

ethyl biscoumacetate

low

hispidin

low

minocycline hydrochloride

low

demeclocycline hydrochloride

low

tigecycline

low

vulpinic acid

low

2,4-dihydroxypyridine

low

ascorbyl monolaurate

low

tetracycline hydrochloride

low

low

low

medium

low

low

medium

low

low

low

low

medium

low

low

low

medium

low

carboxyphthalato-1,2-diaminocyclohexaneplatinum

low

2'-hydroxy-5,9-dimethyl-2-allyl-6,7-benzomorphan

low

copper indium diselenide

low

n,n'-bis(pyridoxal-5-phosphate)ethylenediamine-n,n'-diacetic acid

low

whitlockite

low

betalains

low

gpi0100

low

epidermal growth factor

medium

low

medium

low

low

low

gastrin-releasing peptide

medium

medium

medium

low

low

low

transforming growth factor beta

medium

1,075

phytoestrogens

medium

semaglutide

low

antimony potassium tartrate

low

cep-32496

low

calicheamicin gamma(1)i

low

low

low

medium

low

3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid

low

low

low

low

medium

low

low

low

low

medium

low

low

medium

medium

low

low

low

low

low

low

medium

low

low

medium

low

low

low

low

medium

low

3-fluoro-2-(4-((2-nitro-1h-imidazol-1-yl)methyl)-1h-1,2,3-triazol-1-yl)propan-1-ol

medium

low

low

low

low

2-ethylphenyl 4-(3-ethylureido)benzenesulfonate

low

low

low

low

low

low

low

low

low

low

medium

low

low

globotriaosylceramide

low

hydrazino nicotinamide

low

carboxyethyl-hydroxychroman

low

low

medium

low

low

low

low

medium

low

medium

low

3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester

low

n2-(1h-indazole-5-yl)-n6-methyl-3-nitropyridine-2,6-diamine

low

low

low

low

low

low

low

low

low

low

low

low

medium

thymic factor, circulating

medium

medium

low

low

low

low

low

leu-ser-lys-leu peptide

low

trp-lys-tyr-met-val-met

medium

2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2h-chromen-6-yl)ethanone

low

low

low

low

medium

medium

medium

low

low

low

low

low

low

technetium tc 99m lidofenin

low

3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide

medium

low

low

medium

low

low

low

low

low

low

9-(1-methyl-4-pyrazolyl)-1-[1-(1-oxoprop-2-enyl)-2,3-dihydroindol-6-yl]-2-benzo[h][1,6]naphthyridinone

low

low

low

low

low

cobra cardiotoxin proteins

medium

DDR1-IN-1

low

hirudin

low

technetium tc 99m depreotide

low

medium

medium

low

medium

low

low

contraceptives, postcoital

low

low

low

low

low

lysophosphatidylinositol

low

low

low

low

medium

medium

low

low

low

low

medium

technetium tc 99m sulfur colloid

low

nov 002

low

CCT251545

low

cefiderocol

low

3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid

low

low

low

low

low

low

low

low

low

low

low

medium

tetracarboxyphenylporphine

low

asbestos, crocidolite

low

medium

low

medium

low

low

low

benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone

low

low

low

low

medium

low

low

low

medium

1 alpha,24-dihydroxyvitamin d3

low

aqua regia

low

indolicidin

low

glucagon-like peptide 2

low

snx 482

low

calpastatin

low

angiotensin i

medium

antimicrobial peptide ib-367

medium

low

low

low

low

ferric oxide, saccharated

low

contrast agent p792

low

unipr129

low

germacranolide

low

gadoxetic acid disodium

low

cobamamide

low

hyaluronoglucosaminidase

medium

low

low

low

medium

low

medium

medium

low

low

low

low

low

d-ala(2),mephe(4),met(0)-ol-enkephalin

low

low

low

low

low

low

low

low

medium

4-acetylantroquinonol b

low

low

low

low

low

low

low

low

low

medium

medium

ferric ammonium citrate

low

humulin s

low

glucosaminylmuramyl-2-alanine-d-isoglutamine

medium

medium

medium

medium

low

low

low

low

low

medium

low

transforming growth factor alpha

medium

as 1411

medium

lysergic acid

low

nickel ferrite

low

monomethylauristatin f

medium

dihydroxythiobinupharidine

low

low

low

medium

flavin mononucleotide

low

low

low

low

low

low

low

low

low

low

medium

low

low

medium

low

low

low

low

low

low

zinc naphthalocyanine

low

oxybiotin

low

sparsomycin

low

fusarenon-x

low

phenanthroindolizidine

low

lutetium orthosilicate

medium

phenanthroquinolizidine

low

ritterazine b

low

2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone

medium

phenylbutazone, propyphenazone drug combination

low

asbestos, amosite

low

tremolite

low

gallium ga 68 dotatate

low

carboxymethyl-beta-cyclodextrin

low

orabase

medium

technetium tc 99m medronate

low

technetium tc-99m tetrofosmin

low

low

low

medium

medium

low

low

low

low

low

medium

medium

low

amyloid beta-peptides

low

lutetium lu 177 dotatate

low

low

medium

low

medium

medium

low

low

low

low

low

low

low

low

technetium tc 99m dimercaptosuccinic acid

low

11-dehydrosinulariolide

low

factor a

low

fucosyl gm1 ganglioside

low

low

low

low

low

tetra(4-n-methylpyridyl)porphine

low

low

low

low

medium

low

low

low

low

medium

100

8-oxodeoxyguanosine triphosphate

low

cyclic gmp

low

sepiapterin

low

deoxyguanosine

medium

2'-deoxyguanosine 5'-phosphate

low

deoxyguanosine triphosphate

low

dihydrofolate

low

guanosine diphosphate

low

guanosine pentaphosphate

low

guanosine monophosphate

low

guanosine triphosphate

low

guanine

medium

298

guanosine

medium

guanosine tetraphosphate

low

low

low

medium

low

low

medium

low

low

low

guanosine 5'-o-(3-thiotriphosphate)

low

low

low

low

low

low

medium

medium

low

medium

low

medium

medium

low

medium

low

low

low

low

medium

medium

5,10-methylenetetrahydrofolic acid

low

vardenafil

low

2-methyl-6-(4-methoxyphenyl)-3,7-dihydroimidazo(1,2-alpha)pyrazin-3-one

low

kf38789

low

2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone

low

salicylaldehyde benzoyl hydrazone

low

low

low

low

medium

n-(4(n-((2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-l-glutamic acid

low

2,2'-(hydroxynitrosohydrazono)bis-ethanamine

low

low

low

low

low

pterine-6-carboxylic acid

low

thiolactomycin

low

1843u89

medium

5,10,15,20-tetrakis(4-methoxyphenyl)porphyrin

low

10-formyldihydropteroylglutamate

low

5,10-methenyltetrahydrofolate

low

diazeniumdiolate

low

2'-o-methylguanosine

low

8-hydroxyguanosine

low

5,11-methenyltetrahydrohomofolate

low

4-hydroxyquinazoline

low

2,4-diaminohypoxanthine

low

noc 18

low

alanosine

medium

2-amino-4-hydroxy-6-formylpteridine

low

bl 4162a

low

forodesine

low

9-((2-phosphonylmethoxy)ethyl)guanine

low

tegaserod

low

norclozapine

low

isatoribine anhydrous

low

pyridoxal isonicotinoyl hydrazone

low

low

medium

medium

7-deaza-2'-deoxyguanosine

low

5,10,15,20-tetra(4-pyridyl)porphyrin

low

low

medium

medium

low

medium

medium

low

low

medium

medium

low

low

low

low

vardenafil dihydrochloride

low

azilsartan

low

5,6,7,8-tetrahydrofolic acid

low

6-hydroxymethylpterin

low

low

low

low

low

low

8-bromocyclic gmp, sodium salt

low

8-bromocyclic gmp

low

ag-879

low

8-hydroxyguanine

low

2-carboxyarabinitol 1-phosphate

low

sb-590885

low

hesperadin

low

trypan blue

low

acyclovir monophosphate

low

5-(4-aminophenyl)-10,15,20-triphenylporphyrin

low

nintedanib

medium

7-bromoindirubin-3'-oxime

low

tn 16

low

ec20 folate peptide

low

2-(4-methoxyphenyl)-1H-quinazolin-4-one

low

zd 9331

medium

alpha,beta,gamma,delta-tetrakis(4-n-trimethylaminophenyl)porphine

low

methylnitronitrosoguanidine

low

bis(3',5')-cyclic diguanylic acid

low

8-hydroxy-2'-deoxyguanosine

medium

low

low

low

low

low

low

medium

medium

5,8-dideazaisofolic acid

low

10-formyltetrahydrofolate

medium

guanylyl-(3'-5')-guanosine

low

debromohymenialdisine

low

pyridoxal thiosemicarbazone

low

low

low

medium

low

low

low

medium

cyclic guanosine monophosphate-adenosine monophosphate

low

npt 15392

low

3,n(4)-ethanocytosine

low

formycins

low

8-nitroguanine

low

galloflavin

low

5-methyltetrahydrofolate

medium

gossylic iminolactone

low

9-deazahypoxanthine

low

hydrazinocurcumin

low

alpha-cyclopiazonic acid

low

8-oxyguanine

low

9-arabinofuranosylguanine

low

n(2),n(2)-dimethylguanosine

low

cytidylyl-3'-5'-guanosine

low

capromab pendetide

low

deoxycytidylyl-(3'-5')-deoxyguanosine

low

carbadox

low

apogossypolone

low

3'-deoxyinosine

low

ganciclovir triphosphate

low

low

low

low

low

low

low

low

low

low

cyclic guanosine monophosphate-adenosine monophosphate

low

low

low

low

low

medium

medium

low

low

medium

low

medium

low

n(delta)-(5-methyl-4-oxo-2-imidazolin-2-yl)ornithine

low

sparstolonin b

low

liproxstatin-1

low

n2-ethyl-2'-deoxyguanosine

low

8-nitroguanosine

low

7-methyl-2'-deoxyguanosine 3'-monophosphate

low

3,7-dihydro-6-(4-(2-(n'-(5-fluoresceinyl)thioureido)ethoxy)phenyl)-2-methylimidazo-(1,2-a)pyrazin-3-one

low

low

low

low

low

low

low

low

low

low

low

low

butylcycloheptylprodigiosin

low

ARS-1620

low

sotorasib

medium

4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one

medium

hematoporphyrin ix dimethylester

low

low

medium

low

low

medium

fructooligosaccharide

low

manganese-zinc ferrite

low

zinc(ii) phthalocyanine trisulfonic acid

low

low

low

low

low

low

low

lorvotuzumab mertansine

medium

n-glycolylneuraminyllactosylceramide

low

ferric carboxymaltose

medium

low

low

low

medium

low

low

2-met-4-(4-nitro)-phe-5-pronh2-enkephalin

medium

low

low

low

low

medium

low

low

low

low

medium

low

low

low

low

low

technetium tc 99m-ethylenedicysteine

low

low

low

low

low

antimony sodium gluconate

low

low

low

low

low

medium

low

low

chloroaluminum tetrasulfophthalocyanine

low

aluminum tetrasulfophthalocyanine

medium

aluminum phthalocyanine disulfonate

low

phosphorus radioisotopes

medium

187

1,24-dihydroxyvitamin d2

medium

low

low

low

low

medium

low

medium

low

medium

low

low

medium

low

low

low

medium

low

Protein Targets (6,470)

Protein	Potency Measurements	Inhibition Measurements	Activation Measurements	Drugs
Glucose-6-phosphate 1-dehydrogenase	0	6	0	6
Pyruvate kinase PKM	0	29	11	47
Proteasome subunit beta type-5	0	42	0	44
Mu-type opioid receptor	0	116	33	167
Alpha-synuclein	170	36	2	208
Delta-type opioid receptor	0	88	24	134
Kappa-type opioid receptor	0	92	24	136
6-phosphogluconate dehydrogenase, decarboxylating	0	11	0	11
Beta-secretase 1	0	54	2	57
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	0	22	196	219
Enoyl-acyl-carrier protein reductase	0	26	0	26
3-oxoacyl-acyl-carrier protein reductase	0	15	0	15
Beta-hydroxyacyl-ACP dehydratase precursor (Fatty acid synthesis protein)	0	16	0	16
Genome polyprotein	0	13	5	18
Heat shock protein HSP 90-beta	0	32	26	64
Hepatocyte growth factor receptor	0	63	189	255
Sigma non-opioid intracellular receptor 1	0	43	4	47
Lysosomal alpha-glucosidase	0	13	0	13
Chain A, Cruzipain	270	0	0	270
endonuclease IV	284	0	0	284
glp-1 receptor, partial	458	0	0	458
thioredoxin reductase	789	0	0	789
USP1 protein, partial	683	0	0	683
TDP1 protein	1568	0	0	1568
Smad3	409	0	0	409
estrogen-related nuclear receptor alpha	1292	0	0	1292
Parkin	138	0	0	138
euchromatic histone-lysine N-methyltransferase 2	1278	0	0	1278
Bloom syndrome protein isoform 1	555	0	0	555
vitamin D3 receptor isoform VDRA	539	0	0	539
chromobox protein homolog 1	826	0	0	826
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	258	0	0	258
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	269	0	0	269
geminin	1339	0	0	1339
survival motor neuron protein isoform d	538	0	0	538
lamin isoform A-delta10	1029	0	0	1029
neuropeptide S receptor isoform A	273	0	0	273
Rap guanine nucleotide exchange factor 4	124	0	0	124
Ataxin-2	539	0	0	539
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	555	0	0	555
Chain A, ATP-DEPENDENT DNA HELICASE Q1	230	0	0	230
PPM1D protein	461	0	0	461
glucocerebrosidase	214	0	0	214
nuclear receptor ROR-gamma isoform 1	614	0	0	614
DNA polymerase kappa isoform 1	426	0	0	426
Interferon beta	1044	0	0	1044
G1/S-specific cyclin-E1	0	51	0	54
Cyclin-dependent kinase 2	0	121	206	333
Tyrosine-protein kinase ZAP-70	0	20	67	87
Protein-tyrosine kinase 2-beta	0	10	199	209
Hepatocyte growth factor receptor	0	1	0	1
Thioredoxin reductase 1, cytoplasmic	0	12	0	12
Thioredoxin reductase 1, cytoplasmic	0	10	0	11
Thioredoxin reductase 3	0	7	0	7
Thioredoxin reductase 2, mitochondrial	0	7	0	7
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	771	0	0	771
Gamma-aminobutyric acid type B receptor subunit 2	0	4	4	8
Gamma-aminobutyric acid receptor subunit alpha-1	0	49	28	78
Gamma-aminobutyric acid receptor subunit beta-1	0	35	4	40
Gamma-aminobutyric acid receptor subunit gamma-2	0	44	23	68
Gamma-aminobutyric acid receptor subunit rho-1	0	2	5	13
Gamma-aminobutyric acid receptor subunit beta-3	0	43	11	55
Gamma-aminobutyric acid receptor subunit rho-2	0	1	4	11
Gamma-aminobutyric acid receptor subunit alpha-5	0	42	15	58
Gamma-aminobutyric acid receptor subunit alpha-3	0	42	11	54
Gamma-aminobutyric acid receptor subunit alpha-2	0	42	13	56
Gamma-aminobutyric acid receptor subunit beta-2	0	39	21	61
Gamma-aminobutyric acid receptor subunit alpha-4	0	35	5	41
Gamma-aminobutyric acid receptor subunit alpha-6	0	40	5	46
Gamma-aminobutyric acid type B receptor subunit 1	0	4	4	8
Chain A, Beta-lactamase	479	0	0	479
retinoic acid nuclear receptor alpha variant 1	1042	0	0	1042
estrogen nuclear receptor alpha	1581	0	0	1581
G	701	0	0	701
cytochrome P450 2D6	735	0	0	735
Lysine-specific demethylase 4E	0	22	0	23
aryl hydrocarbon receptor	589	0	0	589
guanine nucleotide-binding protein subunit alpha-15	0	10	10	20
trace amine-associated receptor 1	0	10	10	20
Lysine-specific demethylase 6B	0	11	0	11
Lysine-specific histone demethylase 1A	0	42	2	45
Voltage-dependent calcium channel gamma-2 subunit	551	0	0	551
HLA class I histocompatibility antigen, B alpha chain	701	0	0	701
Glutamate receptor 2	595	21	10	638
Amine oxidase [flavin-containing] A	0	125	1	130
Amine oxidase [flavin-containing] B	0	105	2	109
Lysine-specific demethylase 5C	0	8	0	8
Lysine-specific histone demethylase 1B	0	3	0	3
Inositol hexakisphosphate kinase 1	701	0	0	701
Lysine-specific demethylase 4C	0	15	0	15
Lysine-specific demethylase 2A	0	9	0	9
Lysine-specific demethylase 3A	0	5	0	5
cytochrome P450 2C9, partial	701	0	0	701
Hsf1 protein	0	0	28	37
peripheral myelin protein 22 isoform 1	421	0	0	421
potassium voltage-gated channel subfamily H member 2 isoform d	579	0	0	579
glycogen synthase kinase-3 beta isoform 1	0	0	29	29
DNA polymerase iota isoform a (long)	609	0	0	609
cytochrome P450 3A4 isoform 1	818	0	0	818
Gamma-aminobutyric acid receptor subunit pi	818	81	19	919
Gamma-aminobutyric acid receptor subunit beta-1	818	81	19	919
Gamma-aminobutyric acid receptor subunit delta	818	81	19	919
Gamma-aminobutyric acid receptor subunit gamma-2	818	82	21	922
Gamma-aminobutyric acid receptor subunit alpha-5	818	82	19	920
Gamma-aminobutyric acid receptor subunit alpha-3	818	81	19	919
Gamma-aminobutyric acid receptor subunit gamma-1	818	82	19	920
Gamma-aminobutyric acid receptor subunit alpha-2	818	81	20	920
Gamma-aminobutyric acid receptor subunit alpha-4	818	81	19	919
Gamma-aminobutyric acid receptor subunit gamma-3	818	81	19	919
Gamma-aminobutyric acid receptor subunit alpha-6	818	81	19	919
Gamma-aminobutyric acid receptor subunit alpha-1	818	84	21	924
Gamma-aminobutyric acid receptor subunit beta-3	818	82	19	920
Gamma-aminobutyric acid receptor subunit beta-2	818	81	21	921
GABA theta subunit	818	81	19	919
Gamma-aminobutyric acid receptor subunit epsilon	818	81	19	919
Tubulin alpha-1A chain	0	23	5	30
Tubulin beta chain	0	18	5	23
cytochrome P450 family 3 subfamily A polypeptide 4	974	0	0	974
Potassium channel subfamily K member 3	0	11	0	11
Potassium voltage-gated channel subfamily A member 3	0	7	1	8
Potassium voltage-gated channel subfamily A member 5	0	9	1	10
Nuclear receptor ROR-gamma	232	7	11	250
Oxysterols receptor LXR-alpha	0	10	17	29
Oxysterols receptor LXR-beta	0	10	12	24
Prolyl endopeptidase	0	11	0	11
Prolyl endopeptidase	0	21	0	21
Neuraminidase	0	35	0	36
67.9K protein	450	0	0	450
Neuraminidase	0	9	0	9
Cytochrome P450 2C9	0	219	8	238
aldehyde dehydrogenase 1 family, member A1	964	0	0	964
Muscarinic acetylcholine receptor M2	0	133	11	154
Muscarinic acetylcholine receptor M4	0	122	7	135
Muscarinic acetylcholine receptor M5	0	120	8	132
Muscarinic acetylcholine receptor M1	0	136	15	161
Muscarinic acetylcholine receptor M3	0	127	10	142
Muscarinic acetylcholine receptor	0	11	4	16
Luciferase	551	0	0	551
nonstructural protein 1	295	0	0	295
Receptor-type tyrosine-protein phosphatase beta	0	1	0	14
Bone morphogenetic protein receptor type-1B	0	2	194	196
Membrane-associated progesterone receptor component 1	0	0	133	133
Serine/threonine-protein kinase PLK4	0	18	201	219
ATP-dependent RNA helicase DDX3X	0	0	182	182
Pyridoxal kinase	0	0	182	184
Citron Rho-interacting kinase	0	2	198	200
Serine/threonine-protein kinase Chk1	0	31	200	231
Aurora kinase A	0	69	204	273
Cyclin-G-associated kinase	0	9	200	209
Ephrin type-B receptor 6	0	0	191	191
Peroxisomal acyl-coenzyme A oxidase 3	0	0	182	182
Receptor-interacting serine/threonine-protein kinase 2	0	13	198	211
Mitotic checkpoint serine/threonine-protein kinase BUB1	0	1	163	164
Dynamin-like 120 kDa protein, mitochondrial	0	0	182	182
Eukaryotic translation initiation factor 5B	0	0	131	131
Rho-associated protein kinase 2	0	15	197	212
Serine/threonine-protein kinase ULK1	0	2	191	193
Serine/threonine-protein kinase/endoribonuclease IRE1	0	11	195	206
Ribosomal protein S6 kinase alpha-5	0	10	200	210
U5 small nuclear ribonucleoprotein 200 kDa helicase	0	1	182	183
Ribosomal protein S6 kinase alpha-4	0	4	199	203
Serine/threonine-protein kinase 16	0	1	199	200
Serine/threonine-protein kinase 10	0	5	198	203
Serine/threonine-protein kinase D3	0	20	200	222
Structural maintenance of chromosomes protein 2	0	0	181	181
Mitogen-activated protein kinase kinase kinase 6	0	1	191	192
Mitogen-activated protein kinase kinase kinase kinase 4	0	4	198	202
Serine/threonine-protein kinase LATS1	0	1	198	199
Serine/threonine-protein kinase PAK 4	0	17	198	215
Tyrosine-protein kinase ABL1	0	82	205	293
Epidermal growth factor receptor	0	197	212	410
High affinity nerve growth factor receptor	0	27	188	215
Guanine nucleotide-binding protein G(i) subunit alpha-2	0	0	139	139
ADP/ATP translocase 2	0	0	182	182
Protein kinase C beta type	0	45	185	232
Insulin receptor	0	48	199	248
Tyrosine-protein kinase Lck	0	78	203	282
Tyrosine-protein kinase Fyn	0	62	199	261
Cyclin-dependent kinase 1	0	103	182	293
Glycogen phosphorylase, liver form	0	3	182	185
Tyrosine-protein kinase Fes/Fps	0	8	200	208
Adenine phosphoribosyltransferase	0	0	140	140
Tyrosine-protein kinase Yes	0	22	198	220
Tyrosine-protein kinase Lyn	0	28	198	226
Proto-oncogene tyrosine-protein kinase receptor Ret	0	47	199	246
Insulin-like growth factor 1 receptor	0	52	200	252
Signal recognition particle receptor subunit alpha	0	0	159	159
Cytochrome c1, heme protein, mitochondrial	0	0	178	178
Tyrosine-protein kinase HCK	0	18	198	216
Platelet-derived growth factor receptor beta	0	71	201	273
Serine/threonine-protein kinase A-Raf	0	5	175	180
Glycogen phosphorylase, brain form	0	3	180	183
Breakpoint cluster region protein	0	26	187	219
Serine/threonine-protein kinase pim-1	0	44	204	254
Fibroblast growth factor receptor 1	0	64	202	271
DNA topoisomerase 2-alpha	0	30	154	207
Cyclin-dependent kinase 4	0	67	195	265
ADP/ATP translocase 3	0	0	180	180
Inosine-5'-monophosphate dehydrogenase 2	0	9	160	171
Proto-oncogene tyrosine-protein kinase Src	0	101	199	301
cAMP-dependent protein kinase type II-alpha regulatory subunit	0	0	173	173
Serine/threonine-protein kinase B-raf	0	37	203	242
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	0	2	198	200
Ribosyldihydronicotinamide dehydrogenase [quinone]	0	24	185	209
Tyrosine-protein kinase Fer	0	6	198	204
Protein kinase C alpha type	0	60	188	252
cAMP-dependent protein kinase catalytic subunit alpha	0	37	199	236
General transcription and DNA repair factor IIH helicase subunit XPD	0	0	182	182
Casein kinase II subunit alpha'	0	39	199	238
Ras-related protein Rab-6A	0	0	173	173
Ephrin type-A receptor 1	0	3	172	175
Multifunctional protein ADE2	0	0	182	182
cAMP-dependent protein kinase catalytic subunit gamma	0	26	148	174
cAMP-dependent protein kinase catalytic subunit beta	0	26	198	224
Ferrochelatase, mitochondrial	0	0	184	184
Ribosomal protein S6 kinase beta-1	0	13	185	198
Tyrosine-protein kinase JAK1	0	27	201	231
Beta-adrenergic receptor kinase 1	0	2	186	188
Probable ATP-dependent RNA helicase DDX6	0	0	178	178
Mitogen-activated protein kinase 3	0	29	198	228
MAP/microtubule affinity-regulating kinase 3	0	1	198	199
Deoxycytidine kinase	0	2	182	193
Phosphatidylinositol 3-kinase regulatory subunit alpha	0	30	2	33
Mitogen-activated protein kinase 1	0	50	202	252
Ephrin type-A receptor 2	0	19	198	217
Ephrin type-B receptor 2	0	11	201	212
Non-receptor tyrosine-protein kinase TYK2	0	18	202	223
UMP-CMP kinase	0	0	102	105
Phosphatidylethanolamine-binding protein 1	0	0	145	145
Wee1-like protein kinase	0	3	199	202
Heme oxygenase 2	0	1	177	178
S-adenosylmethionine synthase isoform type-2	0	1	166	167
DnaJ homolog subfamily A member 1	0	0	182	182
RAC-alpha serine/threonine-protein kinase	0	48	201	251
RAC-beta serine/threonine-protein kinase	0	18	199	217
Dual specificity protein kinase TTK	0	8	142	150
DNA replication licensing factor MCM4	0	0	174	174
Myosin-10	0	1	131	132
Dual specificity mitogen-activated protein kinase kinase 2	0	20	198	218
Receptor-type tyrosine-protein kinase FLT3	0	90	200	292
Bone morphogenetic protein receptor type-1A	0	3	198	201
Activin receptor type-1B	0	7	198	205
TGF-beta receptor type-1	0	15	200	215
TGF-beta receptor type-2	0	4	189	193
Electron transfer flavoprotein subunit beta	0	0	143	143
Tyrosine-protein kinase CSK	0	20	198	218
Glycine--tRNA ligase	0	0	182	182
Protein kinase C iota type	0	21	197	219
Exosome RNA helicase MTR4	0	0	182	182
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	0	68	79	149
Serine/threonine-protein kinase mTOR	0	54	73	128
Tyrosine-protein kinase Tec	0	6	199	205
Tyrosine-protein kinase ABL2	0	7	199	206
Tyrosine-protein kinase FRK	0	8	198	206
G protein-coupled receptor kinase 6	0	6	110	116
Tyrosine-protein kinase SYK	0	28	205	233
26S proteasome regulatory subunit 6B	0	3	182	185
Mitogen-activated protein kinase 8	0	16	201	217
Mitogen-activated protein kinase 9	0	11	201	212
Dual specificity mitogen-activated protein kinase kinase 4	0	3	120	123
Dual specificity mitogen-activated protein kinase kinase 3	0	4	198	202
Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	4	0	150	154
Casein kinase I isoform alpha	0	15	195	211
Casein kinase I isoform delta	0	18	199	218
MAP kinase-activated protein kinase 2	0	15	195	210
Elongation factor Tu, mitochondrial	0	0	182	182
Cysteine--tRNA ligase, cytoplasmic	0	0	144	144
Casein kinase I isoform epsilon	0	15	200	215
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	0	0	181	181
Dual specificity protein kinase CLK1	0	11	188	199
Dual specificity protein kinase CLK2	0	5	172	177
Glycogen synthase kinase-3 alpha	0	43	198	241
Glycogen synthase kinase-3 beta	0	97	202	299
Cyclin-dependent kinase 7	0	37	200	238
Cyclin-dependent kinase 9	0	52	199	252
Ras-related protein Rab-27A	0	0	169	169
Interleukin-1 receptor-associated kinase 1	0	3	195	198
Ribosomal protein S6 kinase alpha-3	0	11	198	209
Serine/threonine-protein kinase Nek2	0	8	198	206
Serine/threonine-protein kinase Nek3	0	2	195	197
Dual specificity mitogen-activated protein kinase kinase 6	0	4	198	202
LIM domain kinase 1	0	7	198	205
LIM domain kinase 2	0	7	198	205
Mitogen-activated protein kinase 10	0	35	197	232
Tyrosine--tRNA ligase, cytoplasmic	0	0	180	180
5'-AMP-activated protein kinase subunit gamma-1	0	3	186	190
Ephrin type-B receptor 3	0	3	198	201
Ephrin type-A receptor 5	0	2	196	198
Ephrin type-B receptor 4	0	14	199	213
Ephrin type-A receptor 4	0	3	198	201
Adenylate kinase 2, mitochondrial	0	0	180	183
Adenosine kinase	0	4	177	183
Ras-related protein Rab-10	0	0	177	177
Actin-related protein 3	0	1	178	179
Actin-related protein 2	0	0	167	167
GTP-binding nuclear protein Ran	0	0	182	182
Casein kinase I isoform gamma-2	0	6	171	177
Cyclin-dependent kinase 3	0	8	194	203
Cyclin-dependent kinase 6	0	26	180	208
Cyclin-dependent-like kinase 5	0	55	198	254
Cyclin-dependent kinase 16	0	2	199	202
Cyclin-dependent kinase 17	0	2	180	183
ATP-dependent 6-phosphofructokinase, platelet type	0	0	168	168
Dual specificity mitogen-activated protein kinase kinase 1	0	37	198	235
DNA topoisomerase 2-beta	0	12	189	216
Protein kinase C theta type	0	29	190	221
Activin receptor type-1	0	6	198	204
Macrophage-stimulating protein receptor	0	15	196	211
Focal adhesion kinase 1	0	24	199	223
Protein kinase C zeta type	0	29	94	124
Protein kinase C delta type	0	37	202	241
Tyrosine-protein kinase BTK	0	23	202	225
Activated CDC42 kinase 1	0	8	199	207
Epithelial discoidin domain-containing receptor 1	0	11	199	210
Potassium voltage-gated channel subfamily H member 2	0	279	2	286
Mitogen-activated protein kinase kinase kinase kinase 2	0	3	195	198
Serine/threonine-protein kinase 4	0	3	199	203
5'-AMP-activated protein kinase catalytic subunit alpha-1	0	3	203	207
Dual specificity mitogen-activated protein kinase kinase 5	0	3	195	198
Mitogen-activated protein kinase 7	0	2	194	196
Serine/threonine-protein kinase PAK 2	0	6	186	192
Serine/threonine-protein kinase 3	0	3	198	201
Mitogen-activated protein kinase kinase kinase 1	0	3	195	198
Integrin-linked protein kinase	0	0	162	162
Rho-associated protein kinase 1	0	17	196	213
Non-receptor tyrosine-protein kinase TNK1	0	1	199	200
Serine/threonine-protein kinase ATR	0	18	82	100
Calcium/calmodulin-dependent protein kinase type II subunit gamma	0	5	198	203
Calcium/calmodulin-dependent protein kinase type II subunit delta	0	5	198	203
Activin receptor type-2B	0	0	196	196
Bone morphogenetic protein receptor type-2	0	2	198	200
Protein-tyrosine kinase 6	0	9	198	207
cGMP-dependent protein kinase 1	0	5	198	203
Cyclin-dependent kinase 13	0	5	194	200
Inhibitor of nuclear factor kappa-B kinase subunit epsilon	0	7	197	204
Maternal embryonic leucine zipper kinase	0	11	198	209
Structural maintenance of chromosomes protein 1A	0	0	165	165
Chromodomain-helicase-DNA-binding protein 4	0	0	169	169
Peroxisomal acyl-coenzyme A oxidase 1	0	0	146	146
Ephrin type-A receptor 7	0	2	178	180
Delta(24)-sterol reductase	0	0	179	179
Ribosomal protein S6 kinase alpha-1	0	12	198	210
Dual specificity testis-specific protein kinase 1	0	1	176	177
Myosin light chain kinase, smooth muscle	0	11	197	208
Mitogen-activated protein kinase 11	0	15	196	211
Serine/threonine-protein kinase STK11	0	3	194	197
Serine/threonine-protein kinase N1	0	4	198	202
Serine/threonine-protein kinase N2	0	5	198	203
Mitogen-activated protein kinase 14	0	86	203	289
Calcium/calmodulin-dependent protein kinase type IV	0	1	192	193
Mitogen-activated protein kinase kinase kinase 11	0	3	197	200
Discoidin domain-containing receptor 2	0	14	198	212
AP2-associated protein kinase 1	0	5	199	204
Myosin light chain kinase 3	0	2	189	191
Putative heat shock protein HSP 90-beta 2	0	0	174	174
Rab-like protein 3	0	0	157	157
Serine/threonine-protein kinase MRCK alpha	0	1	195	196
Serine/threonine-protein kinase MRCK gamma	0	1	186	187
Acyl-CoA dehydrogenase family member 10	0	0	163	163
Serine/threonine-protein kinase N3	0	1	109	110
Serine/threonine-protein kinase ULK3	0	1	195	196
Rapamycin-insensitive companion of mTOR	0	8	0	8
Uncharacterized protein FLJ45252	0	0	182	182
Acyl-CoA dehydrogenase family member 11	0	0	160	160
Serine/threonine-protein kinase/endoribonuclease IRE2	0	1	179	180
Serine/threonine-protein kinase MARK2	0	2	199	201
ATP-dependent RNA helicase DHX30	0	0	124	124
Serine/threonine-protein kinase TAO1	0	1	194	195
STE20-related kinase adapter protein alpha	0	0	178	178
Myosin-14	0	0	162	162
AarF domain-containing protein kinase 1	0	0	182	182
ATP-dependent RNA helicase DDX42	0	0	151	151
Mitogen-activated protein kinase kinase kinase kinase 3	0	3	198	201
MAP kinase-activated protein kinase 5	0	7	194	201
Regulatory-associated protein of mTOR	0	13	1	14
Misshapen-like kinase 1	0	3	131	134
Atypical kinase COQ8A, mitochondrial	0	0	198	198
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	0	0	193	193
Mitogen-activated protein kinase 15	0	1	198	199
Serine/threonine-protein kinase Nek9	0	1	198	199
Serine/threonine-protein kinase Nek7	0	1	139	140
ATP-dependent RNA helicase DDX1	0	0	176	176
Mitogen-activated protein kinase kinase kinase kinase 1	0	1	195	196
Aurora kinase B	0	84	200	285
MAP/microtubule affinity-regulating kinase 4	0	2	179	181
Serine/threonine-protein kinase Nek1	0	2	198	200
PAS domain-containing serine/threonine-protein kinase	0	2	125	127
Calcium/calmodulin-dependent protein kinase kinase 2	0	2	199	201
EKC/KEOPS complex subunit TP53RK	0	0	182	182
Dual specificity testis-specific protein kinase 2	0	0	105	105
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	0	14	199	213
Mitogen-activated protein kinase kinase kinase 5	0	7	198	205
Mitogen-activated protein kinase kinase kinase 3	0	1	195	196
Target of rapamycin complex 2 subunit MAPKAP1	0	8	0	8
Eukaryotic translation initiation factor 2-alpha kinase 1	0	0	193	193
Target of rapamycin complex subunit LST8	0	14	1	15
Nucleolar GTP-binding protein 1	0	0	172	172
Serine/threonine-protein kinase D2	0	2	198	200
NUAK family SNF1-like kinase 2	0	2	194	196
RNA cytidine acetyltransferase	0	0	182	182
Serine/threonine-protein kinase SIK2	0	2	198	200
STE20-like serine/threonine-protein kinase	0	4	199	203
Serine/threonine-protein kinase TAO3	0	1	195	196
dCTP pyrophosphatase 1	0	2	182	184
Dual specificity protein kinase CLK4	0	3	152	155
Casein kinase I isoform gamma-1	0	9	195	204
Serine/threonine-protein kinase PAK 6	0	6	141	147
Phenylalanine--tRNA ligase beta subunit	0	0	182	182
Isoleucine--tRNA ligase, mitochondrial	0	0	106	106
BMP-2-inducible protein kinase	0	0	200	200
Obg-like ATPase 1	0	0	147	147
Midasin	0	0	178	178
Interleukin-1 receptor-associated kinase 4	0	4	195	199
Mitogen-activated protein kinase kinase kinase 20	0	5	198	203
Cyclin-dependent kinase 12	0	6	182	189
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	0	1	171	172
Serine/threonine-protein kinase pim-2	0	13	143	156
Serine/threonine-protein kinase 26	0	3	195	198
Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	0	0	152	152
Serine/threonine-protein kinase NLK	0	3	195	198
5'-AMP-activated protein kinase subunit gamma-2	0	1	182	184
Serine/threonine-protein kinase TBK1	0	13	196	209
Septin-9	0	0	182	182
Ribosomal protein S6 kinase alpha-6	0	3	198	201
TRAF2 and NCK-interacting protein kinase	0	3	194	197
Serine/threonine-protein kinase TAO2	0	1	195	196
Serine/threonine-protein kinase ICK	0	1	183	184
RAC-gamma serine/threonine-protein kinase	0	14	197	211
Serine/threonine-protein kinase 38-like	0	1	117	118
Serine/threonine-protein kinase SIK3	0	2	195	197
Mitogen-activated protein kinase kinase kinase 2	0	1	195	196
Thyroid hormone receptor-associated protein 3	0	0	135	135
Dual specificity tyrosine-phosphorylation-regulated kinase 1B	0	7	99	106
Mitogen-activated protein kinase kinase kinase kinase 5	0	3	198	201
Receptor-interacting serine/threonine-protein kinase 3	0	4	182	186
Serine/threonine-protein kinase MRCK beta	0	2	198	200
Interleukin-1 receptor-associated kinase 3	0	0	198	198
Serine/threonine-protein kinase 24	0	2	160	162
Casein kinase I isoform gamma-3	0	1	199	200
Mitogen-activated protein kinase kinase kinase 4	0	0	198	198
Chain A, HADH2 protein	487	0	0	487
Chain B, HADH2 protein	487	0	0	487
dopamine D1 receptor	66	0	0	66
RGS12	29	0	0	29
ClpP	51	0	0	51
ATAD5 protein, partial	559	0	0	559
NFKB1 protein, partial	220	0	0	220
GLS protein	521	0	0	521
Thrombopoietin	174	0	0	174
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	323	0	0	323
hypothetical protein, conserved	90	0	0	90
regulator of G-protein signaling 4	436	0	0	436
arylsulfatase A	362	0	0	362
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)	161	0	0	161
D(1A) dopamine receptor	213	0	0	213
guanine nucleotide-binding protein G(i) subunit alpha-1 isoform 1	27	0	0	27
mitogen-activated protein kinase 1	452	0	0	452
flap endonuclease 1	351	0	0	351
serine/threonine-protein kinase mTOR isoform 1	180	0	0	180
M-phase phosphoprotein 8	343	0	0	343
muscarinic acetylcholine receptor M1	310	0	0	310
pyruvate kinase PKM isoform b	48	0	0	48
Ornithine decarboxylase	48	3	0	53
D	0	72	1	78
D(3) dopamine receptor	0	55	0	57
D(2) dopamine receptor	0	23	0	23
D(1B) dopamine receptor	0	36	0	36
D(4) dopamine receptor	0	43	1	44
D(1A) dopamine receptor	94	7	0	101
D(2) dopamine receptor	0	122	13	142
D	0	19	0	19
2,3-bisphosphoglycerate-independent phosphoglycerate mutase	27	0	0	27
ATP-dependent phosphofructokinase	457	0	0	457
cytochrome P450 2D6 isoform 1	324	0	0	324
cellular tumor antigen p53 isoform a	350	0	0	350
cytochrome P450 2C9 precursor	294	0	0	294
lethal factor (plasmid)	360	0	1	361
Histamine H2 receptor	512	14	8	550
Chain A, Ferritin light chain	457	0	0	457
Microtubule-associated protein tau	791	0	0	792
thyroid stimulating hormone receptor	571	0	0	571
atrial natriuretic peptide receptor 1 precursor	86	0	0	86
atrial natriuretic peptide receptor 2 precursor	96	0	0	96
ras-related protein Rab-9A	226	0	0	226
Transient receptor potential cation channel subfamily V member 1	0	14	7	21
Transient receptor potential cation channel subfamily V member 1	0	23	20	50
GLI family zinc finger 3	1030	0	0	1030
nuclear receptor subfamily 1, group I, member 3	907	0	0	907
Spike glycoprotein	464	13	35	512
importin subunit beta-1 isoform 1	215	0	0	215
snurportin-1	215	0	0	215
histone-lysine N-methyltransferase 2A isoform 2 precursor	161	0	0	161
GTP-binding nuclear protein Ran isoform 1	130	0	0	130
urokinase-type plasminogen activator precursor	301	0	0	301
plasminogen precursor	301	0	0	301
urokinase plasminogen activator surface receptor precursor	301	0	0	301
TAR DNA-binding protein 43	324	2	0	326
Sodium channel protein type 1 subunit alpha	1	10	0	11
Sodium channel protein type 2 subunit alpha	1	15	0	16
Beta-2 adrenergic receptor	0	55	31	87
Sodium channel protein type 3 subunit alpha	1	10	0	11
Beta-1 adrenergic receptor	0	58	25	83
5-hydroxytryptamine receptor 1A	0	71	24	99
Beta-3 adrenergic receptor	0	51	23	74
5-hydroxytryptamine receptor 1A	0	176	23	207
5-hydroxytryptamine receptor 1B	0	122	11	134
Inositol monophosphatase 1	261	0	0	261
IDH1	456	0	0	456
Rap guanine nucleotide exchange factor 3	140	0	0	140
dual specificity tyrosine-phosphorylation-regulated kinase 1A isoform 1	3	0	0	3
dual specificity protein kinase CLK2 isoform 2	1	0	0	1
dual specificity tyrosine-phosphorylation-regulated kinase 1B isoform p69	1	0	0	1
dual specificity protein kinase CLK4	4	0	0	4
Dual specificity protein kinase CLK3	0	4	136	140
cytochrome P450 2C19 precursor	299	0	0	299
Polyunsaturated fatty acid lipoxygenase ALOX15B	309	22	0	331
Sodium-dependent dopamine transporter	0	74	6	80
Glutamate receptor ionotropic, NMDA 1	5	76	16	122
Lysosomal Pro-X carboxypeptidase	0	4	0	4
Glutamate receptor ionotropic, NMDA 2A	1	72	13	111
Glutamate receptor ionotropic, NMDA 2B	1	79	13	119
Glutamate receptor ionotropic, NMDA 2C	1	73	12	112
Sodium-dependent dopamine transporter	0	170	8	180
Glutamate receptor ionotropic, NMDA 2D	1	67	12	105
Glutamate receptor ionotropic, NMDA 3B	1	67	12	105
Glutamate receptor ionotropic, NMDA 3A	1	67	12	105
transcriptional regulator ERG isoform 3	126	0	0	126
Guanine nucleotide-binding protein G	190	0	0	190
Chain A, JmjC domain-containing histone demethylation protein 3A	400	0	0	400
nuclear factor erythroid 2-related factor 2 isoform 2	397	0	0	401
Beta-2 adrenergic receptor	0	13	3	19
Beta-1 adrenergic receptor	0	17	7	28
Beta-3 adrenergic receptor	0	10	3	13
Chain A, RNA-directed RNA polymerase NS5	0	15	0	15
Nrf2	71	0	0	71
WRN	77	0	0	77
LacZ protein (plasmid)	0	5	4	9
fatty acid synthase	0	6	0	6
C-C chemokine receptor type 6	0	6	0	6
serine/threonine-protein kinase PLK1	152	1	2	155
DNA polymerase eta isoform 1	213	0	0	213
rac GTPase-activating protein 1 isoform a	0	25	0	25
DNA dC->dU-editing enzyme APOBEC-3G isoform 1	84	22	0	106
Glycoprotein hormones alpha chain	54	0	0	54
NAD(P)H dehydrogenase [quinone] 1	0	0	0	14
Ghrelin O-acyltransferase	0	9	0	9
Chain A, 2-oxoglutarate Oxygenase	648	0	0	648
alpha-galactosidase	125	0	0	125
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	443	0	0	443
5-hydroxytryptamine receptor 3E	0	18	4	24
5-hydroxytryptamine receptor 3B	0	19	5	26
5-hydroxytryptamine receptor 2C	0	90	15	108
D(2) dopamine receptor	0	164	17	194
5-hydroxytryptamine receptor 2A	0	129	19	151
Alpha-1B adrenergic receptor	0	179	27	207
Alpha-1D adrenergic receptor	0	101	27	131
5-hydroxytryptamine receptor 1D	0	31	11	44
5-hydroxytryptamine receptor 1F	0	31	11	43
5-hydroxytryptamine receptor 2B	0	85	15	100
5-hydroxytryptamine receptor 7	0	32	11	43
Alpha-1B adrenergic receptor	0	39	16	64
D(3) dopamine receptor	1	183	10	202
Alpha-1A adrenergic receptor	0	190	29	220
5-hydroxytryptamine receptor 3A	0	35	7	45
5-hydroxytryptamine receptor 6	0	125	1	132
Beta-2 adrenergic receptor	0	5	1	6
5-hydroxytryptamine receptor 3D	0	18	4	24
5-hydroxytryptamine receptor 3C	0	18	4	24
apical membrane antigen 1, AMA1	196	0	0	196
Alpha-2B adrenergic receptor	0	75	19	95
Alpha-2C adrenergic receptor	0	75	18	94
Alpha-2A adrenergic receptor	0	77	18	96
Phospholipase D1	0	4	0	4
Chain A, Putative fructose-1,6-bisphosphate aldolase	313	0	0	313
PAX8	0	0	0	34
phosphopantetheinyl transferase	480	0	0	480
thioredoxin glutathione reductase	206	0	0	206
bromodomain adjacent to zinc finger domain 2B	350	0	0	350
LAP4	0	0	10	10
neutrophil cytosol factor 1	0	10	0	10
runt-related transcription factor 1 isoform AML1b	27	0	0	27
core-binding factor subunit beta isoform 2	27	0	0	27
polyadenylate-binding protein 1	0	14	0	14
DNA polymerase beta	215	0	0	215
heat shock protein HSP 90-alpha isoform 2	0	17	0	59
tumor susceptibility gene 101 protein	33	0	0	33
lethal(3)malignant brain tumor-like protein 1 isoform I	86	0	0	86
Vpr	97	0	0	97
muscleblind-like protein 1 isoform 1	246	0	0	246
DNA dC->dU-editing enzyme APOBEC-3F isoform a	62	0	0	62
heat shock protein 90, putative	0	0	0	42
hypoxia-inducible factor 1 alpha subunit	383	0	0	383
AR protein	1326	0	0	1326
peroxisome proliferator-activated receptor delta	637	0	0	637
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	726	0	0	726
Nitric oxide synthase, brain	0	14	0	16
BRCA1	70	0	0	70
serine-protein kinase ATM isoform a	55	0	0	55
NPC intracellular cholesterol transporter 1 precursor	176	0	0	176
Polyphenol oxidase 2	0	94	1	112
Serine/threonine-protein kinase PAK 1	0	14	67	81
Dopamine beta-hydroxylase	0	3	0	3
Dopamine beta-hydroxylase	0	6	0	8
Dopamine beta-hydroxylase	0	2	0	2
5-hydroxytryptamine receptor 4	0	14	11	27
P53	61	0	0	61
exodeoxyribonuclease V subunit RecD	0	15	0	15
exodeoxyribonuclease V subunit RecB	0	16	0	16
exodeoxyribonuclease V subunit RecC	0	16	0	16
Ubiquitin carboxyl-terminal hydrolase 7	0	3	1	4
Ubiquitin carboxyl-terminal hydrolase 47	0	2	0	2
huntingtin isoform 2	176	0	0	176
Protein kinase C gamma type	0	33	3	38
Protein kinase C eta type	0	29	71	102
Protein kinase C epsilon type	0	36	71	109
Serine/threonine-protein kinase D1	0	25	69	96
Adenosine receptor A3	0	137	12	153
MO15-related protein kinase Pfmrk	0	17	0	17
glucocorticoid receptor [Homo sapiens]	923	0	0	923
peroxisome proliferator activated receptor gamma	722	0	0	722
vitamin D (1,25- dihydroxyvitamin D3) receptor	629	0	0	629
thyroid hormone receptor beta isoform a	386	0	0	386
nuclear factor erythroid 2-related factor 2 isoform 1	1006	0	0	1006
histone acetyltransferase KAT2A isoform 1	426	0	0	426
Peroxisome proliferator-activated receptor alpha	32	20	36	91
peripheral myelin protein 22	438	0	0	438
Metabotropic glutamate receptor 8	0	8	0	10
Metabotropic glutamate receptor 6	0	8	7	18
Glutamate receptor 1	50	24	10	96
Glutamate receptor 3	50	21	9	92
Glutamate receptor 4	50	21	9	92
Glutamate receptor ionotropic, kainate 1	1	18	2	27
Metabotropic glutamate receptor 1	0	7	6	13
Metabotropic glutamate receptor 2	0	2	5	7
Metabotropic glutamate receptor 3	0	4	4	8
Metabotropic glutamate receptor 4	0	2	8	10
Metabotropic glutamate receptor 5	0	6	6	12
Metabotropic glutamate receptor 6	0	1	6	7
Metabotropic glutamate receptor 7	0	1	5	6
Metabotropic glutamate receptor 5	0	14	5	22
Glutamate receptor ionotropic, kainate 2	1	16	3	26
Glutamate receptor ionotropic, kainate 3	1	22	0	29
Metabotropic glutamate receptor 8	0	0	3	3
Glutamate receptor ionotropic, kainate 4	1	13	0	20
Metabotropic glutamate receptor 1	0	16	7	26
Metabotropic glutamate receptor 2	0	13	8	24
Metabotropic glutamate receptor 7	0	6	4	13
Metabotropic glutamate receptor 3	0	5	2	10
Metabotropic glutamate receptor 4	0	13	7	23
Glutamate receptor ionotropic, kainate 5	1	13	0	20
pregnane X receptor	170	0	0	170
SUMO-1-specific protease	0	6	0	6
RAR-related orphan receptor gamma	1017	0	0	1017
SUMO1/sentrin specific peptidase 7	0	6	0	6
caspase 7, apoptosis-related cysteine protease	231	0	0	231
estrogen receptor 2 (ER beta)	629	0	0	629
progesterone receptor	676	0	0	676
farnesoid X nuclear receptor	624	0	0	624
pregnane X nuclear receptor	966	0	0	966
caspase-3	231	0	0	231
Histone H2A.x	472	0	0	472
hemoglobin subunit beta	36	0	0	36
thyroid hormone receptor beta isoform 2	1009	0	0	1009
histone deacetylase 9 isoform 3	187	0	0	187
caspase-3 isoform a preproprotein	0	16	1	17
glycogen synthase kinase-3 alpha	0	0	0	28
sentrin-specific protease 8	0	7	0	7
Cellular tumor antigen p53	913	10	0	923
ATPase family AAA domain-containing protein 5	377	0	0	377
Cytochrome P450 3A4	0	292	17	336
Cytochrome P450 2D6	0	207	7	223
Cytochrome P450 4Z1	0	1	0	1
Chain A, Glutamate [NMDA] receptor subunit zeta 1	0	3	0	3
Chain A, Glutamate [NMDA] receptor subunit zeta 1	0	3	0	3
Chain A, Glutamate [NMDA] receptor subunit zeta 1	0	3	0	3
cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 7	0	0	0	15
Chain A, Phenylethanolamine N-methyltransferase	0	0	4	4
Chain A, Phenylethanolamine N-methyltransferase	0	0	4	4
Chain A, Phenylethanolamine N-methyltransferase	0	0	4	4
Chain A, Phenylethanolamine N-methyltransferase	0	0	4	4
Chain A, Phenylethanolamine N-methyltransferase	0	0	4	4
Chain A, Phenylethanolamine N-methyltransferase	0	0	4	4
Chain A, Phenylethanolamine N-methyltransferase	0	0	4	4
Chain A, Phenylethanolamine N-methyltransferase	0	0	4	4
Chain A, Phenylethanolamine N-methyltransferase	0	0	4	4
Chain A, Phenylethanolamine N-methyltransferase	0	0	4	4
Chain A, Phenylethanolamine N-methyltransferase	0	0	4	4
Chain A, Phenylethanolamine N-methyltransferase	0	0	4	4
Chain A, Phenylethanolamine N-methyltransferase	0	0	4	4
Urokinase-type plasminogen activator	0	22	1	23
Cationic trypsin	0	16	0	16
Coagulation factor VII	0	17	0	17
Tissue factor	0	22	0	23
Neutrophil cytosol factor 1	0	9	2	11
Tryptase beta-2	0	4	0	4
Nitric oxide synthase, endothelial	0	12	0	14
Nitric oxide synthase, brain	0	24	1	27
Nitric oxide synthase, inducible	0	17	1	23
Kappa-type opioid receptor	0	52	9	77
Mu-type opioid receptor	0	79	12	98
Tyrosine-protein kinase	0	0	2	2
Chain B, pheromone binding protein	0	0	1	1
Chain A, pheromone binding protein	0	0	1	1
acid sphingomyelinase	94	0	0	94
fibroblast growth factor 22 isoform 1 precursor	0	0	0	7
Mitogen-activated protein kinase 13	0	14	63	77
Beta-lactamase	0	23	0	23
Transthyretin	0	26	25	58
Fatty acid-binding protein, intestinal	0	13	5	18
Fatty acid-binding protein, adipocyte	0	10	5	15
Cyclin-A2	0	67	2	71
Cannabinoid receptor 1	0	36	9	45
Choline O-acetyltransferase	0	6	0	6
Mitogen-activated protein kinase 12	0	14	70	84
Fatty acid-binding protein 5	0	6	2	8
Fatty acid-binding protein 5	0	0	3	3
pyruvate kinase	67	0	0	67
Endothelin receptor type B	24	12	1	37
Endothelin-1 receptor	24	8	2	34
phosphoglycerate kinase	64	0	0	64
G2/mitotic-specific cyclin-B2	0	39	0	46
G2/mitotic-specific cyclin-B1	0	78	0	85
G2/mitotic-specific cyclin-B	0	25	0	25
Glycogen synthase kinase-3 beta	0	18	0	18
Cyclin-dependent kinase 5 activator 1	0	53	0	53
G2/mitotic-specific cyclin-B3	0	39	0	46
Cyclin-dependent kinase 1	0	25	0	25
retinoid X nuclear receptor alpha	847	0	0	847
thyroid stimulating hormone receptor	502	0	0	502
Choline O-acetyltransferase	0	7	0	11
Alpha-mannosidase	0	6	1	7
Trehalase	0	3	0	3
lysosomal alpha-glucosidase preproprotein	146	0	0	146
Trehalase	0	1	0	1
Maltase-glucoamylase, intestinal	0	16	0	16
Trehalase	0	3	0	3
Lysosomal acid glucosylceramidase	0	5	1	6
Alpha-galactosidase A	0	1	0	1
Alpha-glucosidase MAL62	0	5	0	5
Lactase-phlorizin hydrolase	0	2	0	2
Lysosomal alpha-glucosidase	0	16	0	16
Beta-glucosidase A	0	1	0	1
Sucrase-isomaltase, intestinal	0	12	0	12
Sucrase-isomaltase, intestinal	0	13	0	13
Beta-glucosidase	0	1	0	1
Protein-lysine 6-oxidase	0	8	0	8
Alpha-mannosidase 2	0	3	0	3
Glycogen debranching enzyme	0	2	0	2
Glycogen debranching enzyme	0	2	0	2
Alpha-glucosidase MAL32	0	4	0	4
Oligo-1,6-glucosidase IMA1	0	7	0	7
Alpha-glucosidase MAL12	0	10	0	10
Alpha-amylase	0	1	0	1
Trehalose synthase/amylase TreS	0	1	0	1
Lactase-phlorizin hydrolase	0	3	0	3
Neutral alpha-glucosidase AB	0	3	1	4
Ceramide glucosyltransferase	0	2	0	2
Lysosomal acid glucosylceramidase	0	1	0	1
Probable maltase-glucoamylase 2	0	9	0	9
Beta-glucosidase	0	1	0	1
Cytosolic beta-glucosidase	0	1	0	1
Non-lysosomal glucosylceramidase	0	3	0	3
Putative alpha-glucosidase	0	1	0	1
Killer cell lectin-like receptor subfamily B member 1A	0	2	0	2
Early activation antigen CD69	0	2	0	2
Platelet-activating factor receptor	14	12	0	28
L-lactate dehydrogenase A chain	0	16	3	19
Neuraminidase	0	4	0	4
L-lactate dehydrogenase A chain	0	3	1	4
L-lactate dehydrogenase B chain	0	10	0	10
Tyrosine-protein phosphatase non-receptor type 1	0	104	4	112
activating transcription factor 6	452	0	0	452
v-jun sarcoma virus 17 oncogene homolog (avian)	545	0	0	545
heat shock protein beta-1	435	0	0	435
Chain A, High-affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	0	1	0	1
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	0	1	0	1
Chain A, Phosphodiesterase 9A	0	1	0	1
Chain A, Class I phosphodiesterase PDEB1	0	1	0	1
Chain A, High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A	0	1	0	1
Chain A, cGMP-dependent 3',5'-cyclic phosphodiesterase	0	1	0	1
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase catalytic domain, Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha chimera	0	1	0	1
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase catalytic domain, Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha chimera	0	1	0	1
Chain A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A	0	1	0	1
Chain A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A	0	1	0	1
Phosphodiesterase	0	11	0	11
cGMP-dependent 3',5'-cyclic phosphodiesterase	0	27	0	27
Monocarboxylate transporter 4	0	5	0	8
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A	0	12	0	12
cGMP-specific 3',5'-cyclic phosphodiesterase	0	36	2	39
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A	0	6	0	6
Renin	0	21	3	24
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	0	13	0	13
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	0	9	0	10
cAMP-specific 3',5'-cyclic phosphodiesterase 4C	0	9	0	10
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	0	9	0	11
Adenosine receptor A1	8	97	6	134
Adenosine receptor A3	0	36	0	36
Adenosine receptor A2a	0	78	26	121
Adenosine receptor A2b	0	36	14	65
Adenosine receptor A2b	0	45	7	73
Adenosine receptor A1	0	65	16	97
Adenosine receptor A2a	0	79	12	128
Sodium-dependent serotonin transporter	0	61	6	69
Adenosine receptor A2a	0	10	1	11
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'	0	7	1	8
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	0	9	0	10
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	0	25	0	26
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	0	13	0	13
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	0	24	0	25
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	0	8	0	8
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	0	34	1	38
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	0	42	1	44
cGMP-inhibited 3',5'-cyclic phosphodiesterase B	0	35	0	36
Voltage-dependent L-type calcium channel subunit alpha-1C	0	75	0	76
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	0	8	0	8
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	0	26	0	27
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	0	37	0	38
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	0	8	0	8
Phosphodiesterase	0	1	0	1
Phosphodiesterase	0	8	0	8
cAMP-specific 3',5'-cyclic phosphodiesterase 7B	0	8	0	8
Large neutral amino acids transporter small subunit 1	0	16	0	18
Epoxide hydrolase 1	0	0	0	5
Glutaminyl-peptide cyclotransferase	0	13	0	13
Glutaminyl-peptide cyclotransferase	0	7	0	7
Fumarate hydratase	424	0	0	424
EWS/FLI fusion protein	678	0	0	679
polyprotein	424	0	0	424
Spike glycoprotein	0	13	35	48
Replicase polyprotein 1ab	0	48	36	84
Transmembrane protease serine 2	0	13	35	48
Procathepsin L	0	30	36	66
Replicase polyprotein 1a	0	30	37	67
Replicase polyprotein 1ab	0	17	35	52
Replicase polyprotein 1ab	0	93	41	134
Replicase polyprotein 1ab	0	164	49	213
Thioredoxin	0	2	0	2
Angiotensin-converting enzyme 2	0	20	36	56
Dihydrofolate reductase	0	45	0	49
Indoleamine 2,3-dioxygenase 1	0	50	3	56
Indoleamine 2,3-dioxygenase 1	0	16	0	16
Tryptophan 2,3-dioxygenase	0	6	0	6
Indoleamine 2,3-dioxygenase 2	0	6	0	6
Thyroid hormone receptor beta	0	12	0	12
Xanthine dehydrogenase/oxidase	0	63	0	64
Diacylglycerol kinase alpha	0	4	0	4
Sulfotransferase 1A1	0	0	0	14
Prostaglandin G/H synthase 1	0	26	0	29
Prostaglandin G/H synthase 2	0	12	0	14
DNA repair and recombination protein RadA	0	0	4	4
Cytochrome P450 1A2	0	171	6	188
Cytochrome P450 2A6	0	38	6	45
Polyunsaturated fatty acid 5-lipoxygenase	0	30	0	39
Cytochrome P450 2A5	0	10	0	11
UDP-glucuronosyltransferase 1A1	0	35	0	50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	447	0	0	447
Kelch-like ECH-associated protein 1	0	4	8	13
Histone acetyltransferase KAT8	0	6	0	8
Chain A, Obp14	0	0	1	1
Chain A, Obp14	0	0	1	1
Chain A, Obp14	0	0	1	1
interleukin 8	156	0	0	156
15-lipoxygenase, partial	325	0	0	325
SMAD family member 2	362	0	0	362
SMAD family member 3	362	0	0	362
Caspase-7	125	0	0	125
caspase-3	125	0	0	125
nuclear factor NF-kappa-B p105 subunit isoform 1	80	0	7	87
Integrin beta-3	244	20	4	269
Integrin alpha-IIb	244	16	2	263
M-phase inducer phosphatase 2	0	18	0	18
Acetylcholinesterase	0	171	5	180
eyes absent homolog 2 isoform a	56	0	0	56
C-terminal-binding protein 2	0	8	1	9
G-protein coupled receptor 84	0	8	10	19
acetylcholinesterase	455	0	0	455
nonstructural protein 1	0	16	0	16
heat shock protein 90	0	0	22	22
TPA: protein transporter TIM10	0	15	0	15
TPA: protein transporter TIM23	0	11	0	11
tumor necrosis factor	19	1	0	20
Galanin receptor type 2	0	1	2	3
Carboxypeptidase A1	0	3	0	3
Thermolysin	0	9	0	10
Amyloid-beta precursor protein	32	59	6	101
C-C chemokine receptor type 1	0	6	7	13
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	0	20	2	25
Protein farnesyltransferase subunit beta	0	19	2	22
C-C chemokine receptor type 5	0	12	10	23
C-C chemokine receptor type 8	0	0	7	7
Metallo-beta-lactamase VIM-13	0	3	0	11
Snake venom metalloproteinase neuwiedase	0	2	0	2
Collagenase ColG	0	3	0	3
Beta-lactamase VIM-1	0	3	0	11
MSRA protein	0	2	2	4
Phospholipase C, gamma 1	0	6	0	6
Phospholipase C, beta 3 (phosphatidylinositol-specific)	0	6	0	6
photoreceptor-specific nuclear receptor	0	12	0	12
green fluorescent protein, partial	0	7	0	7
histone-lysine N-methyltransferase NSD2 isoform 1	0	0	0	7
transactivating tegument protein VP16 [Human herpesvirus 1]	0	19	0	19
tyrosyl-DNA phosphodiesterase 2	0	4	0	4
Coagulation factor XII	0	24	0	24
Cholinesterase	0	86	1	89
Liver carboxylesterase 1	0	36	0	48
RNA-editing ligase 1, mitochondrial	0	5	0	5
putative polyprotein	0	9	0	9
MPI protein	0	12	0	12
phosphomannomutase 2	0	2	0	2
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	0	12	0	15
3-oxo-5-alpha-steroid 4-dehydrogenase 1	0	7	0	7
3-oxo-5-alpha-steroid 4-dehydrogenase 2	0	6	0	6
Caspase-3	0	10	1	12
Caspase-7	59	1	1	66
Monoglyceride lipase	0	4	0	4
large T antigen	0	49	6	55
Cocaine esterase	0	27	0	29
Liver carboxylesterase 1	0	15	0	15
Tyrosine-protein phosphatase non-receptor type 22	0	6	0	6
pyruvate kinase PKM isoform a	35	0	0	35
Vif	0	17	0	18
Tat	0	14	0	14
replicative DNA helicase	0	0	0	30
recombinase A	0	0	30	32
Papain	0	11	0	11
Receptor-type tyrosine-protein phosphatase C	0	5	0	5
Adenosine receptor A1	0	20	0	20
Genome polyprotein	0	12	0	12
Phenylethanolamine N-methyltransferase	0	14	0	16
Phenylethanolamine N-methyltransferase	0	2	1	4
CD44 antigen	0	0	1	1
CD44 antigen	0	1	1	2
Nicotinamide N-methyltransferase	0	9	0	9
Genome polyprotein	0	6	4	10
Prothrombin	0	8	0	8
Coagulation factor X	0	23	0	23
Genome polyprotein	0	4	0	4
Alpha-amylase 1A	0	10	0	10
5'-nucleotidase	0	11	1	13
Squalene monooxygenase	0	9	0	10
Ectonucleoside triphosphate diphosphohydrolase 1	0	4	0	4
Anthrax toxin receptor 2	0	13	0	13
Xanthine dehydrogenase/oxidase	0	38	1	43
Neuraminidase	0	2	0	2
5'-nucleotidase	0	5	0	5
Cytochrome P450 1B1	0	79	2	83
Chain A, Breast cancer type 1 susceptibility protein	25	0	0	25
Chain A, Casein kinase II subunit alpha	0	1	0	1
dual specificity mitogen-activated protein kinase kinase 1	4	0	0	4
RAF proto-oncogene serine/threonine-protein kinase isoform b	7	0	0	7
ubiquitin carboxyl-terminal hydrolase 2 isoform a	161	0	0	161
Tissue-type plasminogen activator	0	14	0	14
Plasminogen activator inhibitor 1	0	7	1	9
Urokinase-type plasminogen activator	0	9	0	9
Casein kinase II subunit alpha	0	3	0	3
Type-1A angiotensin II receptor	4	14	6	24
Type-1B angiotensin II receptor	4	16	1	21
Type-2 angiotensin II receptor	4	16	1	21
DNA repair protein RAD52 homolog	0	14	0	14
Casein kinase II subunit beta	0	40	3	43
Casein kinase II subunit beta	0	3	0	3
Casein kinase II subunit alpha	0	51	72	123
Disintegrin and metalloproteinase domain-containing protein 17	120	18	0	138
Integrase	0	56	5	62
Cytochrome P450 1A1	0	3	7	13
Aryl hydrocarbon receptor	0	2	12	15
Broad substrate specificity ATP-binding cassette transporter ABCG2	0	106	13	125
Chain A, Urea transporter	0	1	0	1
Cytochrome P450 1A1	0	68	4	73
Chain A, Pr10.2b	0	0	1	1
luciferase	23	0	0	23
Bifunctional epoxide hydrolase 2	0	29	0	29
Epoxide hydrolase B	0	1	0	1
putative alpha-glucosidase	7	0	0	7
Neuronal acetylcholine receptor subunit alpha-7	0	14	9	23
Vasopressin V2 receptor	0	0	0	3
Adenosine receptor A1	0	9	5	16
Adenylate cyclase type 5	0	11	0	12
Adenylate cyclase type 1	0	2	1	6
Rev	0	4	0	4
Female germline-specific tumor suppressor gld-1	0	4	0	4
Integrin beta-1	0	12	0	12
Muscarinic acetylcholine receptor M1	0	57	21	85
Polyunsaturated fatty acid 5-lipoxygenase	0	83	2	87
Muscarinic acetylcholine receptor M2	0	54	21	82
Integrin alpha-4	0	6	0	6
C-8 sterol isomerase	0	12	0	12
Delta-type opioid receptor	0	68	11	87
Mu-type opioid receptor	0	89	12	105
Kappa-type opioid receptor	0	26	11	39
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	0	13	1	14
Sigma intracellular receptor 2	0	15	0	15
Sigma intracellular receptor 2	0	23	1	24
Vesicular acetylcholine transporter	0	8	0	8
Sigma non-opioid intracellular receptor 1	1	147	8	158
Sigma non-opioid intracellular receptor 1	0	29	10	40
isocitrate dehydrogenase 1, partial	44	0	0	44
beta-2 adrenergic receptor	35	0	7	42
polyunsaturated fatty acid lipoxygenase ALOX12	102	0	0	102
Estrogen receptor	1	79	24	111
Angiotensin-converting enzyme	0	36	1	38
Valosin-containing protein	0	8	0	8
Apoptotic peptidase activating factor 1	0	10	0	10
cell division cycle 42 (GTP binding protein, 25kDa), partial	0	0	11	11
jumonji domain containing 2C, partial	0	0	0	5
jumonji domain containing 2A	0	0	0	3
galactokinase	21	0	0	21
phospholipase A2 precursor	0	8	0	8
nuclear receptor corepressor 2 isoform 2	0	4	0	4
fructose-bisphosphate aldolase A	15	0	0	15
caspase-9 isoform alpha precursor	0	10	0	10
glyceraldehyde-3-phosphate dehydrogenase isoform 1	9	2	0	11
sphingosine 1-phosphate receptor 2	0	1	0	1
mothers against decapentaplegic homolog 3 isoform 1	0	4	0	4
dual specificity tyrosine-phosphorylation-regulated kinase 1A	0	0	0	28
cysteine protease ATG4B isoform a	0	8	0	8
peroxisome proliferator-activated receptor gamma isoform 2	0	4	0	4
tyrosine-protein phosphatase non-receptor type 22 isoform 1	0	6	0	6
4-(cytidine 5'-phospho)-2-C-methyl-D-erithritol kinase	5	0	0	5
streptokinase A precursor	0	0	66	66
tyrosine-protein phosphatase non-receptor type 7 isoform 2	0	10	0	10
Tyrosyl-DNA phosphodiesterase 2	0	7	3	10
Estrogen receptor	0	4	34	39
DNA-(apurinic or apyrimidinic site) endonuclease	0	14	4	18
Estrogen receptor beta	0	2	34	37
Chain A, Pentaerythritol Tetranitrate Reductase	0	0	1	1
Chain A, Pentaerythritol Tetranitrate Reductase	0	0	1	1
Chain A, PENTAERYTHRITOL TETRANITRATE REDUCTASE	0	0	1	1
Aromatase	0	83	0	96
corticotropin-releasing hormone receptor 2	0	8	9	17
corticotropin releasing factor-binding protein	0	8	9	17
Glycogen phosphorylase, muscle form	0	23	0	23
Protein kinase C alpha type	0	14	0	14
Glucoamylase, intracellular sporulation-specific	0	1	0	1
Protein kinase C delta type	0	14	0	14
Protein kinase C epsilon type	0	14	0	14
Protein kinase C zeta type	0	14	0	14
Glycogen phosphorylase, liver form	0	4	0	4
Alpha-mannosidase 2C1	0	3	1	4
Protein kinase C gamma type	0	15	0	15
Protein kinase C beta type	0	17	0	17
Beta-mannosidase	0	2	0	2
Protein kinase C eta type	0	14	0	14
Protein kinase C theta type	0	14	0	14
Alpha-mannosidase 2	0	1	0	1
Beta-galactosidase	0	3	0	3
IAG-nucleoside hydrolase	0	1	0	1
Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase	0	1	0	1
Thioredoxin reductase 2, mitochondrial	0	8	0	8
thyrotropin-releasing hormone receptor	92	0	0	92
DNA topoisomerase 1	0	23	8	54
Carbon monoxide dehydrogenase small chain	0	0	2	2
Dual specificity protein phosphatase 1	0	6	0	6
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	0	8	1	9
Dual specificity protein phosphatase 6	0	6	0	6
Histone-lysine N-methyltransferase EHMT2	0	23	2	26
Histone-lysine N-methyltransferase EHMT1	0	14	0	14
Beta-lactamase	0	2	0	2
botulinum neurotoxin type A	0	0	1	1
botulinum neurotoxin type F, BoNT/F	0	0	1	1
Poly [ADP-ribose] polymerase 2	0	6	0	6
Poly [ADP-ribose] polymerase 1	0	33	12	48
Protein mono-ADP-ribosyltransferase PARP15	0	9	0	9
MSH	0	0	0	8
Caspase 6, apoptosis-related cysteine peptidase	0	0	0	11
Rac1 protein	0	0	10	10
delta-type opioid receptor	0	3	11	14
mu-type opioid receptor isoform MOR-1	0	0	35	35
DNA repair and recombination protein RAD54-like isoform 1	0	0	0	8
dual specificity protein phosphatase 3	0	5	0	5
nuclear receptor coactivator 3 isoform 1	0	1	0	1
5-hydroxytryptamine receptor 5A	0	0	5	5
dual specificity protein phosphatase 6	0	6	0	6
Caspase-9	0	7	0	10
Caspase-8	0	0	0	3
Protein disulfide-isomerase A6	0	0	0	1
Neuronal acetylcholine receptor subunit alpha-4	58	39	7	106
Neuronal acetylcholine receptor subunit beta-2	58	37	7	104
Stimulator of interferon genes protein	0	0	1	1
Trypsin	0	12	0	16
Stimulator of interferon genes protein	0	1	8	9
Dihydrofolate reductase	0	15	0	17
Dihydrofolate reductase	0	12	0	15
caspase-1 isoform alpha precursor	77	1	0	78
Folate receptor alpha	0	4	0	4
Reduced folate transporter	0	5	0	5
Proton-coupled folate transporter	0	5	0	6
Myc proto-oncogene protein	0	7	2	10
Protein max	0	1	2	3
Hypoxia-inducible factor 1-alpha	0	25	3	29
Chain A, Retinaldehyde-binding protein 1	0	0	1	1
Chain A, Retinaldehyde-binding protein 1	0	0	1	1
Androgen receptor	0	150	1	153
Corticosteroid 11-beta-dehydrogenase isozyme 1	0	7	1	8
Corticosteroid 11-beta-dehydrogenase isozyme 2	0	3	1	4
Polyunsaturated fatty acid lipoxygenase ALOX15	0	42	0	42
Polyunsaturated fatty acid lipoxygenase ALOX15	0	25	0	26
Polyunsaturated fatty acid lipoxygenase ALOX12	0	21	0	22
Tyrosine-protein kinase JAK2	0	45	104	153
Cyclin-K	0	7	0	7
Cyclin-dependent kinase-like 5	0	0	139	139
Cyclin-H	0	34	0	34
CDK-activating kinase assembly factor MAT1	0	28	0	28
Cyclin-A1	0	40	1	43
Platelet-activating factor acetylhydrolase	0	9	1	12
Long-chain-fatty-acid--CoA ligase 5	0	0	124	124
prostaglandin E2 receptor EP2 subtype	3	0	0	7
Transient receptor potential cation channel subfamily A member 1	0	7	47	59
Peroxisome proliferator-activated receptor gamma	0	31	62	97
Glucose-6-phosphate 1-dehydrogenase	0	23	1	25
Sex hormone-binding globulin	0	3	35	38
Lysine-specific demethylase 4B	0	5	0	5
Heat shock protein HSP 90-alpha	0	38	41	81
Cholesteryl ester transfer protein	0	4	2	6
Lysine-specific demethylase 5A	0	12	1	13
Endoplasmin	0	10	5	15
Endothelial PAS domain-containing protein 1	0	14	1	16
nuclear receptor subfamily 1, group I, member 2	150	0	0	150
Glucocorticoid receptor	1	84	9	120
Glycine receptor subunit alpha-1	0	73	0	73
Corticosteroid-binding globulin	0	21	0	22
Glycine receptor subunit beta	0	72	0	72
Glycine receptor subunit alpha-2	0	74	0	74
Glycine receptor subunit alpha-3	0	72	0	72
Chain A, THYMIDYLATE SYNTHASE	0	1	0	1
Thymidylate synthase	0	3	0	3
Thymidylate synthase	0	18	0	21
Dihydrofolate reductase	0	19	5	25
Folylpolyglutamate synthase, mitochondrial	0	1	0	9
Bifunctional dihydrofolate reductase-thymidylate synthase	0	10	0	11
7,8-dihydro-8-oxoguanine triphosphatase	0	12	3	15
Myeloperoxidase	0	20	0	20
Carbonic anhydrase 12	0	123	3	171
Carbonic anhydrase 1	0	239	3	310
Carbonic anhydrase 2	0	269	12	347
Plasma kallikrein	0	10	2	29
Carbonic anhydrase 3	0	68	2	98
Carbonic anhydrase 4	0	137	2	176
Carbonic anhydrase 6	0	96	3	139
Histamine H1 receptor	0	23	2	25
Carbonic anhydrase 5A, mitochondrial	0	107	4	154
Histamine H1 receptor	0	114	8	127
Carbonic anhydrase	0	48	0	63
Carbonic anhydrase 7	0	107	3	148
Carbonic anhydrase	0	26	0	43
Carbonic anhydrase 9	0	156	3	207
Carbonic anhydrase	0	24	0	41
Carbonic anhydrase-like protein, putative	0	0	0	19
Carbonic anhydrase	0	23	0	43
Carbonic anhydrase	0	31	0	51
Carbonic anhydrase	0	24	0	41
Carbonic anhydrase 15	0	63	0	81
Carbonic anhydrase 13	0	62	0	94
Histamine H4 receptor	0	21	7	29
Carbonic anhydrase 14	0	78	2	120
Carbonic anhydrase 5B, mitochondrial	0	81	2	126
Protein S100-A4	0	0	4	4
M-phase inducer phosphatase 1	0	15	0	15
Telomerase reverse transcriptase	0	19	1	20
Bromodomain-containing protein 4	0	28	14	44
72 kDa type IV collagenase	0	48	0	50
Matrix metalloproteinase-9	0	38	1	39
Neutrophil collagenase	0	10	0	10
Collagenase 3	0	21	0	24
TCRAV4S1, partial	0	2	0	2
aryl hydrocarbon receptor nuclear translocator	0	0	0	11
integrase, partial	0	16	0	16
lens epithelium-derived growth factor p75	0	16	0	16
Myeloid cell leukemia sequence 1 (BCL2-related)	0	3	0	3
alkaline phosphatase, intestinal	0	8	9	17
alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproprotein	0	13	7	20
intestinal alkaline phosphatase precursor	0	14	2	16
transforming acidic coiled-coil-containing protein 3	0	0	0	11
alkaline phosphatase, germ cell type preproprotein	0	8	9	17
bcl-2-like protein 1 isoform Bcl-X(L)	0	3	0	3
albumin precursor	0	2	0	2
Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2	0	5	0	5
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3	0	5	0	5
Beta-glucuronidase	0	2	0	2
Poly [ADP-ribose] polymerase tankyrase-1	0	18	6	24
Beta-glucuronidase	0	6	0	6
Tubulin beta-2B chain	0	31	3	40
Similar to alpha-tubulin isoform 1	0	27	3	36
Similar to alpha-tubulin isoform 1	0	27	2	35
Poly [ADP-ribose] polymerase tankyrase-2	0	17	12	29
Chain A, Serine/threonine-protein Kinase 12-a	0	1	0	1
Dual specificity mitogen-activated protein kinase kinase 1	0	2	0	2
Serine/threonine-protein kinase PLK1	0	56	136	194
Aurora kinase C	0	22	70	92
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1	0	2	0	2
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1	0	2	0	2
Chain A, Methyltransferase Wbdd	0	1	0	1
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	0	48	71	120
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	0	9	0	9
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	0	11	64	75
5-hydroxytryptamine receptor 4	0	158	8	166
Proteinase-activated receptor 1	0	6	2	10
Bromodomain-containing protein 2	0	13	4	17
5-hydroxytryptamine receptor 2A	0	192	15	213
5-hydroxytryptamine receptor 2C	0	193	11	205
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	0	1	0	1
Type-1 angiotensin II receptor	0	11	3	14
5-hydroxytryptamine receptor 2B	0	203	8	213
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	0	3	0	3
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	0	46	71	120
Serine/threonine-protein kinase mTOR	0	2	0	2
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	0	55	70	126
DNA-dependent protein kinase catalytic subunit	0	40	7	47
Serine-protein kinase ATM	0	19	1	20
Bromodomain-containing protein 3	0	11	4	15
Serine/threonine-protein kinase pim-3	0	8	70	78
Phosphoinositide 3-kinase regulatory subunit 5	0	5	0	5
Serine/threonine-protein kinase PLK3	0	26	69	95
Serine/threonine-protein kinase PLK2	0	23	63	86
Proton-coupled amino acid transporter 1	0	28	0	29
transient receptor potential cation channel subfamily V member 1	43	0	0	43
5-hydroxytryptamine receptor 2A	0	0	27	27
Aldo-keto reductase family 1 member B1	0	200	0	200
Alpha-2A adrenergic receptor	0	190	14	211
Sodium-dependent noradrenaline transporter	0	211	32	244
Sodium-dependent serotonin transporter	0	185	15	202
Retinal dehydrogenase 1	0	6	0	6
Signal transducer and activator of transcription 3	0	18	6	25
Protein cereblon	0	27	5	41
Stromelysin-1	0	25	8	33
Cruzipain	0	29	0	29
Cysteine protease	0	9	0	9
Cysteine proteinase falcipain 2a	0	6	0	6
Pteridine reductase 1	0	9	0	9
Chain A, Glutamate receptor 2	0	1	0	1
N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase	0	3	0	3
Xanthine dehydrogenase	0	1	0	1
Cyclin-C	0	9	1	10
Cyclin-dependent kinase 8	0	15	68	84
Cyclin-C	0	0	1	1
Cyclin-dependent kinase 8	0	0	2	2
Cyclin-dependent kinase 19	0	6	68	75
Cell division cycle 7-related protein kinase	0	6	101	107
Serine/threonine-protein kinase 38	0	1	104	105
Eukaryotic peptide chain release factor GTP-binding subunit ERF3B	0	0	43	43
Calcium/calmodulin-dependent protein kinase type 1G	0	1	84	85
Carbonic anhydrase	0	0	0	22
Carbonic anhydrase	0	40	0	40
Carbonic anhydrase	0	24	0	24
Carbonic anhydrase	0	33	0	33
Carbonic anhydrase	0	33	0	33
Carbonic anhydrase	0	20	0	20
Beta-carbonic anhydrase 1	0	34	0	34
Carbonic anhydrase 2	0	30	0	30
Carbonic anhydrase, alpha family	0	26	0	26
Carbonic anhydrase 4	0	33	0	38
Chain A, Tryptase beta-2	0	1	0	1
Chain A, Tryptase beta-2	0	1	0	1
Chain A, Tryptase beta-2	0	1	0	1
Chain A, Trypsin	0	1	0	1
Chain A, Tryptase beta-2	0	1	0	1
Membrane primary amine oxidase	0	5	0	5
Transcriptional activator protein LasR	0	4	1	5
Regulatory protein RhlR	0	3	0	4
Membrane primary amine oxidase	0	4	0	6
Pteridine reductase, putative	0	1	0	1
UDP-glucuronosyltransferase 1A4	0	15	0	37
Transient receptor potential cation channel subfamily M member 2	0	6	1	7
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1	0	30	1	31
Transient receptor potential cation channel subfamily V member 3	0	3	3	7
Transient receptor potential cation channel subfamily V member 2	0	4	3	8
Chain A, Arginase-1	0	1	0	1
Chain A, Arginase-1	0	1	0	1
Arginase-1	0	2	0	2
Nitric oxide synthase, inducible	0	27	0	28
Phosphatidylinositol 4-kinase alpha	0	20	0	23
Phosphatidylinositol 4-kinase type 2-beta	0	15	0	18
Phosphatidylinositol 4-kinase type 2-alpha	0	16	0	19
Phosphatidylinositol 4-kinase beta	0	22	66	91
Botulinum neurotoxin type A	0	13	0	13
Alpha-2B adrenergic receptor	0	168	9	183
Prostaglandin G/H synthase 1	0	98	0	99
[tau protein] kinase	0	9	0	9
Cannabinoid receptor 1	0	9	4	14
E3 ubiquitin-protein ligase XIAP	0	14	6	20
Alpha-1A adrenergic receptor	0	44	18	73
Peroxisome proliferator-activated receptor delta	0	11	20	36
Adenosine receptor A1	0	5	0	5
Adenosine receptor A2a	0	3	0	3
Adenosine receptor A2b	0	2	1	6
Adenosine receptor A3	0	5	2	7
NPYLR7B	0	0	21	21
vasopressin V1b receptor	9	0	0	9
eukaryotic translation initiation factor 2-alpha kinase 3 isoform 1 precursor	0	0	3	3
relaxin receptor 1 isoform 1	22	0	0	22
high affinity choline transporter 1 isoform a	0	15	0	15
relaxin receptor 2 isoform 1	9	0	0	9
Endoplasmin	0	14	7	22
Adenosine deaminase	0	8	0	16
Ghrelin O-acyltransferase	0	2	0	2
Dihydroorotate dehydrogenase (quinone), mitochondrial	0	16	2	19
Chain A, BCL-2-RELATED PROTEIN A1	0	0	16	23
hepatitis C virus polyprotein	7	0	0	7
bcl-2-like protein 11 isoform 1	0	0	16	16
Bcl-2-like protein 11	0	3	0	8
Reverse transcriptase/RNaseH	0	39	15	78
Nuclear factor NF-kappa-B p105 subunit	0	31	2	37
Substance-P receptor	0	26	0	35
Quinone oxidoreductase	0	0	0	20
Dihydroorotate dehydrogenase	0	16	0	16
Carbonic anhydrase 13	0	31	3	41
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase	0	15	0	15
glucose-6-phosphate 1-dehydrogenase isoform b	0	15	0	15
Disabled homolog 2-interacting protein	0	1	0	1
Estrogen receptor beta	1	46	19	68
Adenylate cyclase type 10	0	1	0	1
hypothetical protein CAALFM_CR05890CA	0	0	0	9
H3 histone acetyltransferase	0	0	0	9
Peptidyl-prolyl cis-trans isomerase FKBP5	0	3	4	7
Melatonin receptor type 1A	0	13	3	16
Melatonin receptor type 1A	0	5	2	7
Melatonin receptor type 1B	0	11	3	14
Melatonin receptor type 1C	0	5	2	7
Melatonin receptor type 1B	0	5	2	7
C-terminal-binding protein 1	16	0	2	18
interferon gamma precursor	0	0	0	25
Prostaglandin D2 receptor	0	3	1	4
Prostaglandin D2 receptor 2	0	5	1	6
Protein skinhead-1	0	8	0	8
Sulfotransferase 1E1	0	0	0	2
Sulfotransferase 1A1	0	4	1	8
Sulfotransferase 2A1	0	2	0	3
LysR family transcriptional regulator	0	0	1	1
Phenol oxidase	0	2	0	2
Chymase	0	5	0	5
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	0	7	2	9
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	0	8	1	9
eukaryotic translation initiation factor 4 gamma 1 isoform 4	0	9	0	9
eukaryotic translation initiation factor 4E isoform 1	0	9	0	9
Cathepsin L2	0	3	0	3
Tubulin beta-4A chain	0	32	12	49
Tubulin beta chain	0	32	12	49
Tubulin alpha-3C chain	0	34	12	51
Tubulin alpha-1B chain	0	34	12	51
Tubulin alpha-4A chain	0	34	12	51
Tubulin beta-4B chain	0	32	12	49
Tubulin beta-3 chain	0	33	12	50
Tubulin beta-2A chain	0	32	12	49
Tubulin beta-8 chain	0	32	12	49
Tubulin alpha-3E chain	0	34	12	51
Tubulin alpha-1A chain	0	34	12	51
Tubulin alpha-1C chain	0	34	12	51
Tubulin beta-6 chain	0	32	12	49
Tubulin beta-2B chain	0	32	12	49
Tubulin beta-1 chain	0	34	13	52
chaperonin GroEL	8	0	0	8
Quinolone resistance protein NorA	0	7	0	9
Bcl-2-like protein 1	0	32	10	42
Alcohol dehydrogenase E chain	0	11	1	13
Alcohol dehydrogenase S chain	0	11	1	13
D-amino-acid oxidase	0	3	2	5
D-amino-acid oxidase	0	11	2	13
Olfactory receptor 51E2	0	1	12	13
Prostaglandin E synthase	0	19	0	19
Inhibitor of nuclear factor kappa-B kinase subunit beta	0	26	61	88
3-phosphoinositide-dependent protein kinase 1	0	22	70	92
RAF proto-oncogene serine/threonine-protein kinase	0	32	69	103
Platelet-derived growth factor receptor alpha	0	54	73	127
Vascular endothelial growth factor receptor 1	0	51	69	121
Fibroblast growth factor receptor 2	0	28	67	97
Fibroblast growth factor receptor 4	0	22	67	92
Fibroblast growth factor receptor 3	0	31	69	102
Vascular endothelial growth factor receptor 3	0	46	67	114
Vascular endothelial growth factor receptor 2	0	137	74	218
Tyrosine-protein kinase JAK1	0	1	0	1
Tyrosine-protein kinase JAK3	0	47	73	124
Angiopoietin-1 receptor	0	30	71	101
Nuclear receptor subfamily 1 group I member 2	0	7	46	56
Tyrosinase	0	36	0	37
Nuclear factor erythroid 2-related factor 2	0	4	10	20
Bile salt export pump	0	691	0	695
Histone deacetylase 8	0	84	11	102
Chain A, PROTEIN (HYDROXYNITRILE LYASE)	0	1	0	1
Chain A, PROTEIN (HYDROXYNITRILE LYASE)	0	1	0	1
Methionine aminopeptidase 1	0	4	2	6
Deoxyhypusine hydroxylase	0	4	0	4
Transmembrane prolyl 4-hydroxylase	0	3	5	8
PINK1	40	0	0	40
RPL19A	0	0	5	5
LMP1 [Human herpesvirus 4]	0	0	0	12
Polyphenol oxidase 1	0	4	0	4
Nuclear receptor ROR-alpha	0	1	0	1
Nuclear factor NF-kappa-B p100 subunit	0	24	0	26
Transcription factor p65	0	37	2	45
Chain A, Neutrophil gelatinase-associated lipocalin	0	0	1	1
Matrilysin	0	18	0	18
Prolyl 4-hydroxylase subunit alpha-1	0	15	0	15
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6	0	9	0	9
Alpha-(1,3)-fucosyltransferase 7	0	9	0	9
CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1	0	9	0	9
Glutamate receptor ionotropic, NMDA 2D	0	15	4	19
Glutamate receptor ionotropic, NMDA 3B	0	14	4	18
Glutamate receptor ionotropic, NMDA 1	0	24	6	30
Glutamate receptor ionotropic, NMDA 2A	0	23	6	29
Glutamate receptor ionotropic, NMDA 2B	0	21	7	29
Glutamate receptor ionotropic, NMDA 2C	0	15	4	19
Glutamate receptor ionotropic, NMDA 3A	0	14	4	18
hexokinase-4 isoform 1	30	0	0	30
glucokinase regulatory protein	30	0	0	30
Dual specificity mitogen-activated protein kinase kinase 7	0	3	64	67
Single-stranded DNA cytosine deaminase	22	0	0	22
Beta-nerve growth factor	0	1	0	1
Tumor necrosis factor receptor superfamily member 16	0	1	0	1
TSHR protein	11	0	0	11
Albumin	0	5	2	8
Dihydrofolate reductase	0	7	0	7
Dihydrofolate reductase	0	4	0	4
Dihydrofolate reductase	0	12	0	13
m7GpppX diphosphatase	0	1	0	1
Pyruvate dehydrogenase E1 component subunit alpha, mitochondrial	0	1	0	1
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial	0	1	0	1
Chain A, Carbonic anhydrase 2	0	3	0	3
Chain A, Carbonic anhydrase 2	0	3	0	3
Chain A, Carbonic anhydrase 2	0	3	0	3
Delta-type opioid receptor	0	74	8	92
Carbonic anhydrase	0	23	0	23
Delta carbonic anhydrase	0	23	0	23
Kynurenine 3-monooxygenase	0	2	0	2
Lysine-specific demethylase 6A	0	6	0	6
Lysine-specific demethylase 4A	0	10	2	12
Peptidyl-prolyl cis-trans isomerase A	0	5	1	6
Aspartyl/asparaginyl beta-hydroxylase	0	9	0	9
Beta-lactamase	0	3	0	4
Lysine-specific demethylase 4D	0	2	0	2
Lysine-specific demethylase 7A	0	4	0	4
Prolyl 4-hydroxylase	0	18	0	18
Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial	0	2	0	2
Prolyl hydroxylase EGLN2	0	4	5	11
Lysine-specific demethylase 5D	0	3	0	3
Alpha-ketoglutarate-dependent dioxygenase FTO	0	10	0	10
Egl nine homolog 1	0	13	12	27
Prolyl hydroxylase EGLN3	0	2	5	9
Hypoxia-inducible factor 1-alpha inhibitor	0	9	0	11
Lysine-specific demethylase 5B	0	4	0	4
Histone lysine demethylase PHF8	0	6	0	6
Tyrosinase	0	20	0	20
Pentachlorophenol 4-monooxygenase	0	0	3	3
Neuronal proto-oncogene tyrosine-protein kinase Src	0	3	0	4
Solute carrier family 28 member 3	0	8	0	8
short transient receptor potential channel 6 isoform 1	0	0	18	18
POsterior Segregation	0	0	23	25
Zinc finger protein mex-5	0	0	22	26
Chain A, Sarcoplasmic/endoplasmic reticulum calcium ATPase 1	0	0	1	1
alternatively spliced Trp4	0	0	8	8
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2	0	3	0	3
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2	0	6	0	6
Sarcoplasmic/endoplasmic reticulum calcium ATPase 3	0	5	0	5
Aminopeptidase N	0	11	0	11
Guanine deaminase	0	5	0	6
hexokinase HKDC1	0	3	1	4
Cytidine deaminase	0	3	0	8
RNA-directed RNA polymerase	0	6	6	16
Thymidine kinase, cytosolic	0	12	0	22
AAA family ATPase	0	0	0	3
Chain A, ANAEROBIC RIBONUCLEOTIDE-TRIPHOSPHATE REDUCTASE LARGE CHAIN	0	0	2	2
Chain A, ANAEROBIC RIBONUCLEOTIDE-TRIPHOSPHATE REDUCTASE LARGE CHAIN	0	0	2	2
S-adenosylmethionine synthase isoform type-1	0	2	0	4
S-adenosylmethionine synthase isoform type-2	0	1	0	3
P2Y purinoceptor 1	0	0	5	5
P2Y purinoceptor 11	0	1	6	7
Chain A, Protein (thymidylate Synthase)	0	0	1	1
Chain A, Thymidylate Synthase	0	0	1	1
Chain A, Thymidylate Synthase	0	0	1	1
Chain A, Thymidylate Synthase	0	0	1	1
Chain A, Thymidylate Synthase	0	0	2	2
Chain A, Thymidylate Synthase	0	0	2	2
Chain A, Thymidylate Synthase	0	0	2	2
Chain A, Thymidylate Synthase	0	0	2	2
Chain A, Thymidylate Synthase	0	0	2	2
Chain A, Thymidylate Synthase	0	0	1	1
Chain A, Thymidylate Synthase	0	0	1	1
Thymidylate synthase	0	7	0	10
Thymidylate synthase	0	10	1	14
Thymidylate synthase	0	14	0	19
Thymidylate kinase	0	3	0	5
Gonadotropin-releasing hormone receptor	0	4	1	5
Thymidylate kinase	0	9	0	12
Thymidylate synthase	0	1	0	1
Deoxyuridine triphosphatase, putative	0	1	0	1
Acetylcholinesterase	0	12	1	13
Androgen receptor	1	56	12	91
Aldo-keto reductase family 1 member C3	0	30	0	30
Histamine H1 receptor	0	15	9	26
DNA polymerase beta	0	13	0	13
DNA polymerase beta	0	6	0	6
DNA polymerase lambda	0	3	0	3
60 kDa chaperonin	0	42	0	42
60 kDa heat shock protein, mitochondrial	0	50	0	50
Genome polyprotein	0	5	0	5
10 kDa heat shock protein, mitochondrial	0	50	0	50
Thiosulfate sulfurtransferase	0	47	0	47
60 kDa chaperonin	0	52	0	52
10 kDa chaperonin	0	52	0	52
Sterol O-acyltransferase 1	0	12	0	12
NPC1-like intracellular cholesterol transporter 1	0	1	5	6
Alpha-crystallin B chain	0	0	2	2
3-hydroxy-3-methylglutaryl-coenzyme A reductase	0	16	3	19
Integrin alpha-V	0	9	2	11
Sterol regulatory element-binding protein 2	0	2	0	2
Oxysterol-binding protein 2	0	0	1	1
Zinc finger protein GLI1	0	8	0	8
Receptor-type tyrosine-protein phosphatase F	0	7	0	7
Receptor-type tyrosine-protein phosphatase alpha	0	4	0	4
Low molecular weight phosphotyrosine protein phosphatase	0	10	0	10
Tyrosine-protein phosphatase non-receptor type 6	0	15	0	15
Tyrosine-protein phosphatase non-receptor type 7	0	9	0	9
Dual specificity protein phosphatase 3	0	9	0	9
Tyrosine-protein phosphatase non-receptor type 11	0	20	1	25
Tyrosine-protein phosphatase non-receptor type 13	0	1	0	1
Dual specificity protein phosphatase CDC14A	0	1	0	1
Fibroblast growth factor receptor 4	0	4	0	4
Smoothened homolog	0	14	3	17
chaperonin-containing TCP-1 beta subunit homolog	16	0	0	16
Sphingosine kinase 2	0	12	0	13
Sphingosine kinase 1	0	10	0	11
Prostaglandin G/H synthase 1	0	72	5	78
Prostaglandin G/H synthase 2	0	36	0	37
FAD-linked sulfhydryl oxidase ALR	0	0	0	18
Guanylate cyclase soluble subunit beta-2	0	0	1	2
Guanylate cyclase soluble subunit alpha-2	0	0	1	2
Guanylate cyclase soluble subunit alpha-1	0	0	2	3
Guanylate cyclase soluble subunit beta-1	0	0	2	3
Histone acetyltransferase p300	0	18	3	22
CREB-binding protein	8	6	4	18
Lysine-specific demethylase 3B	0	1	0	1
Lysine-specific demethylase 2B	0	2	0	2
Nicotinamidase	0	3	0	3
Bifunctional dihydrofolate reductase-thymidylate synthase	0	6	0	6
Poly [ADP-ribose] polymerase 1	0	2	0	2
Transporter	0	38	4	43
Beta-lactamase	0	5	0	9
Beta-lactamase	0	10	0	19
Angiotensin-converting enzyme	0	20	1	21
Beta-lactamase TEM	0	12	0	19
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2	0	13	0	13
4-aminobutyrate aminotransferase, mitochondrial	0	10	0	11
D-aspartate oxidase	0	8	0	8
Protein mono-ADP-ribosyltransferase PARP3	0	5	11	19
Sodium- and chloride-dependent GABA transporter 1	0	10	0	10
Sodium- and chloride-dependent GABA transporter 2	0	9	0	9
Sodium- and chloride-dependent GABA transporter 3	0	9	0	9
Sodium- and chloride-dependent betaine transporter	0	6	0	6
Gamma-aminobutyric acid receptor subunit rho-3	0	0	2	7
Gamma-aminobutyric acid type B receptor subunit 2	0	7	0	7
1-deoxy-D-xylulose 5-phosphate reductoisomerase	0	6	0	6
Gamma-aminobutyric acid type B receptor subunit 1	0	6	0	6
Ribonucleoside-diphosphate reductase subunit M2	0	1	0	3
CDGSH iron-sulfur domain-containing protein 1	0	25	0	25
Amine oxidase [flavin-containing] A	0	23	4	30
Nitric oxide synthase, endothelial	0	6	1	9
Solute carrier family 22 member 6	0	41	0	56
Solute carrier family 22 member 8	0	32	0	48
Solute carrier family 22 member 8	0	20	0	27
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1	0	1	0	1
Baculoviral IAP repeat-containing protein 5	0	0	1	1
5-hydroxytryptamine receptor 3A	0	3	3	6
Inosine-5'-monophosphate dehydrogenase 1	0	7	0	9
Chain A, INOSINE-ADENOSINE-GUANOSINE-PREFERRING NUCLEOSIDE HYDROLASE	0	1	0	1
Adenosylhomocysteinase	0	11	0	16
Purine nucleoside phosphorylase	0	11	1	14
Histone-lysine N-methyltransferase EZH2	0	12	2	15
Calpain-1 catalytic subunit	0	8	0	8
D-amino-acid oxidase	0	0	1	1
Aldo-keto reductase family 1 member B1	0	79	0	82
Sorbitol dehydrogenase	0	10	0	10
Serine racemase	0	7	0	7
Angiotensin-converting enzyme	0	88	0	89
L-lactate dehydrogenase B chain	0	1	1	4
Cytochrome P450 2E1	0	12	1	14
Chain A, Phenazine biosynthesis protein phzF	0	0	1	1
Chain A, PROTOCATECHUATE 3,4-DIOXYGENASE	0	2	0	2
Chain M, PROTOCATECHUATE 3,4-DIOXYGENASE	0	2	0	2
Chain A, PROTOCATECHUATE 3,4-DIOXYGENASE	0	2	0	2
Chain M, PROTOCATECHUATE 3,4-DIOXYGENASE	0	2	0	2
Chain A, PROTOCATECHUATE 3,4-DIOXYGENASE	0	2	0	2
Chain M, PROTOCATECHUATE 3,4-DIOXYGENASE	0	2	0	2
Chain A, PROTOCATECHUATE 3,4-DIOXYGENASE	0	2	0	2
Chain M, PROTOCATECHUATE 3,4-DIOXYGENASE	0	2	0	2
Chain A, PROTOCATECHUATE 3,4-DIOXYGENASE	0	2	0	2
Chain M, PROTOCATECHUATE 3,4-DIOXYGENASE	0	2	0	2
Chain A, Protocatechuate 3,4-dioxygenase	0	2	0	2
Chain M, Protocatechuate 3,4-dioxygenase	0	2	0	2
Calcium/calmodulin-dependent protein kinase type II subunit alpha	0	5	0	5
Tetraspanin	0	1	0	1
Estrogen receptor	0	0	4	4
Estrogen receptor beta	0	0	4	4
Monocarboxylate transporter 2	0	6	0	6
Solute carrier family 22 member 20	0	28	0	28
Solute carrier family 22 member 6	0	28	0	29
Free fatty acid receptor 1	0	0	8	8
Free fatty acid receptor 4	0	0	4	4
ATP-dependent translocase ABCB1	0	145	36	227
Calmodulin-1	0	12	2	14
Fatty acid synthase	0	27	0	27
Dipeptidyl peptidase 3	0	14	0	14
HSP40, subfamily A [Plasmodium falciparum 3D7]	0	0	0	21
Kynureninase	0	0	0	1
POU domain, class 2, transcription factor 1	0	1	0	11
Phosphoenolpyruvate carboxykinase, cytosolic [GTP]	0	3	0	3
Beta-lactamase	0	4	0	6
Chain A, DNA-3-methyladenine glycosylase I	0	0	1	1
Chain A, DNA-3-METHYLADENINE GLYCOSYLASE I	0	0	1	1
Chain A, Dna-3-methyladenine Glycosylase I	0	0	1	1
Chain A, VP39	0	0	1	1
Chain A, VP39	0	0	1	1
Chain A, VP39	0	0	1	1
Chain A, VP39	0	0	1	1
Coenzyme A biosynthesis bifunctional protein CoaBC	0	1	0	1
Pancreatic triacylglycerol lipase	0	24	0	26
Aldo-keto reductase family 1 member B1	0	5	0	5
Inositol polyphosphate multikinase	0	12	0	12
Inositol hexakisphosphate kinase 2	0	12	0	12
endoribonuclease toxin MazF	0	0	7	7
Delta-aminolevulinic acid dehydratase	0	3	0	3
Isocitrate lyase 1	0	2	0	2
Isocitrate lyase	0	3	0	3
Isocitrate lyase	0	1	0	1
Tubulin--tyrosine ligase	0	2	0	2
DNA polymerase iota	0	1	0	1
DNA polymerase kappa	0	3	0	3
DNA polymerase eta	0	4	0	4
DNA polymerase III, partial	40	0	0	40
Chain A, Aspartate Aminotransferase	0	0	2	2
Chain B, Aspartate Aminotransferase	0	0	2	2
Chain A, Aspartate Aminotransferase	0	0	2	2
Chain B, Aspartate Aminotransferase	0	0	2	2
Chain A, Aspartate aminotransferase	0	0	2	2
Chain B, Aspartate aminotransferase	0	0	2	2
Chain A, Aspartate aminotransferase	0	0	2	2
Chain A, Aspartate aminotransferase	0	0	2	2
Chain A, Aspartate aminotransferase	0	0	2	2
Chain B, Aspartate aminotransferase	0	0	2	2
Kinesin-like protein KIF11	0	18	3	21
DNA topoisomerase type IB small subunit	0	0	1	1
DNA topoisomerase I	0	0	1	1
Aryl hydrocarbon receptor	0	1	2	3
G-protein coupled receptor 84	0	0	1	1
Proliferating cell nuclear antigen	0	7	0	7
Calcium dependent protein kinase	0	1	0	1
serine/threonine-protein kinase 33 isoform a	0	0	13	14
Dipeptidyl peptidase 4	0	12	0	12
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1	0	11	0	11
Lactoylglutathione lyase	0	25	0	25
Arginase-1	0	4	0	4
Thyroid hormone receptor alpha	0	7	6	13
Thyroid hormone receptor beta	0	7	6	13
Retinoic acid receptor RXR-alpha	0	15	29	51
Sodium/bile acid cotransporter	0	17	1	19
Solute carrier organic anion transporter family member 1C1	0	6	0	6
electroneutral potassium-chloride cotransporter KCC2	0	0	5	5
mu opioid receptor, partial	0	0	3	3
kappa-type opioid receptor isoform 1	0	5	2	7
Chymotrypsinogen A	0	19	0	20
Neutrophil elastase	0	29	0	30
Cathepsin G	0	10	1	11
Rhomboid protease GlpG	0	1	0	1
Lysosomal protective protein	0	5	0	6
Fatty acid synthase	0	5	0	5
Rhomboid protease AarA	0	1	0	1
Rhomboid protease GluP	0	1	0	1
Rhomboid-related protein 3	0	1	0	1
Liver carboxylesterase	0	4	0	4
Rhomboid-related protein 1	0	1	0	1
Chain A, Penicillin Amidohydrolase	0	3	0	3
Chain B, Penicillin Amidohydrolase	0	3	0	3
Chain A, Penicillin Amidohydrolase	0	3	0	3
Chain B, Penicillin Amidohydrolase	0	3	0	3
Chain A, Penicillin Amidohydrolase	0	3	0	3
Chain B, Penicillin Amidohydrolase	0	3	0	3
Chain A, Penicillin Amidohydrolase	0	3	0	3
Chain B, Penicillin Amidohydrolase	0	3	0	3
Chain A, Penicillin Amidohydrolase	0	3	0	3
Chain B, Penicillin Amidohydrolase	0	3	0	3
Chain A, Penicillin Amidohydrolase	0	3	0	3
Chain B, Penicillin Amidohydrolase	0	3	0	3
Chain A, Penicillin Amidohydrolase	0	3	0	3
Chain B, Penicillin Amidohydrolase	0	3	0	3
Chain A, Protocatechuate 3,4-dioxygenase	0	0	1	1
Chain M, Protocatechuate 3,4-dioxygenase	0	0	1	1
Olfactory receptor class A-like protein 1	0	0	3	3
3-oxoacyl-	0	2	0	2
5-hydroxytryptamine receptor 6	0	12	10	22
5-hydroxytryptamine receptor 5A	0	11	10	21
5-hydroxytryptamine receptor 5B	0	11	10	21
5-hydroxytryptamine receptor 3A	0	32	12	44
5-hydroxytryptamine receptor 3B	0	31	12	43
5-hydroxytryptamine receptor 7	0	47	2	51
Aryl hydrocarbon receptor	0	2	0	2
Prostaglandin G/H synthase 2	0	126	64	194
Transient receptor potential cation channel subfamily A member 1	0	14	16	30
5'-AMP-activated protein kinase subunit beta-1	0	3	4	8
Neuronal acetylcholine receptor subunit alpha-3	0	16	5	23
Neuronal acetylcholine receptor subunit alpha-2	0	9	3	13
Neuronal acetylcholine receptor subunit beta-3	0	8	4	13
Neuronal acetylcholine receptor subunit beta-4	0	16	5	23
Substance-P receptor	0	6	0	6
Neuromedin-K receptor	0	1	2	3
Substance-K receptor	0	4	4	8
Neuronal acetylcholine receptor subunit alpha-5	0	8	3	12
Substance-K receptor	0	67	0	67
Substance-P receptor	0	26	4	30
Neuromedin-K receptor	0	8	2	11
Neuronal acetylcholine receptor subunit alpha-6	0	10	4	15
Neuronal acetylcholine receptor subunit alpha-9	0	8	3	12
Neuronal acetylcholine receptor subunit alpha-7	0	22	10	33
Neuronal acetylcholine receptor subunit alpha-10	0	8	3	12
Multidrug resistance-associated protein 1	0	31	4	45
cGMP-dependent 3',5'-cyclic phosphodiesterase	0	8	0	8
Microtubule-associated protein tau	0	14	1	17
Acetylcholinesterase	0	20	1	21
Dipeptidyl peptidase 4	0	37	3	45
Mitogen-activated protein kinase kinase kinase 9	0	7	67	74
Protein delta homolog 1	0	3	6	9
Mitogen-activated protein kinase kinase kinase 10	0	3	67	70
S100A4, partial	0	0	0	2
Chain A, Macrophage migration inhibitory factor	0	1	0	1
Chain C, Macrophage migration inhibitory factor	0	1	0	1
Macrophage migration inhibitory factor	0	28	2	31
Death-associated protein kinase 1	0	17	67	84
Gamma-aminobutyric acid receptor subunit pi	0	33	0	33
Gamma-aminobutyric acid receptor subunit delta	0	33	1	34
Gamma-aminobutyric acid receptor subunit epsilon	0	33	0	33
Gamma-aminobutyric acid receptor subunit gamma-1	0	33	0	33
Gamma-aminobutyric acid receptor subunit gamma-3	0	33	0	33
Gamma-aminobutyric acid receptor subunit theta	0	33	0	33
Presenilin-1	0	15	7	23
Presenilin-2	0	14	5	20
Gamma-secretase subunit APH-1B	0	14	5	20
Nicastrin	0	14	6	21
Gamma-secretase subunit APH-1A	0	14	6	21
Gamma-secretase subunit PEN-2	0	15	6	23
Chain A, Retinoic acid receptor beta	0	0	1	1
Retinoic acid receptor alpha	0	13	14	34
Retinoic acid receptor beta	0	13	15	34
Retinoic acid receptor gamma	0	12	15	33
Retinoic acid receptor RXR-beta	0	9	10	19
Cellular retinoic acid-binding protein 1	0	3	0	5
Retinoic acid receptor RXR-gamma	0	9	10	19
Carbonic anhydrase 5A, mitochondrial	0	11	0	11
Carbonic anhydrase	0	15	0	15
Nuclear receptor subfamily 0 group B member 2	0	1	0	1
Tumor necrosis factor	0	6	4	10
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	0	33	3	37
cAMP-specific 3',5'-cyclic phosphodiesterase 4C	0	27	0	27
cGMP-specific 3',5'-cyclic phosphodiesterase	0	8	0	8
Transitional endoplasmic reticulum ATPase	0	4	1	5
Sphingosine kinase 2	0	1	0	1
protein artemis isoform a	0	1	0	1
M1-family alanyl aminopeptidase	0	8	0	8
Cyclin-dependent kinase 10	0	1	52	54
ALK tyrosine kinase receptor	0	36	93	130
Chain A, TGF-beta receptor type-1	0	1	0	1
tyrosine-protein kinase Yes	126	0	0	126
Serine/threonine-protein kinase 25	0	1	67	68
Serine/threonine-protein kinase RIO3	0	0	67	67
Serine/threonine-protein kinase DCLK1	0	2	67	69
Muscle, skeletal receptor tyrosine-protein kinase	0	2	67	69
Death-associated protein kinase 3	0	5	68	73
NUAK family SNF1-like kinase 1	0	13	68	81
Serine/threonine-protein kinase PAK 3	0	5	67	72
Serine/threonine-protein kinase 17B	0	4	67	71
Cyclin-dependent kinase 14	0	3	67	71
Receptor tyrosine-protein kinase erbB-2	0	81	72	153
Macrophage colony-stimulating factor 1 receptor	0	38	69	107
Proto-oncogene tyrosine-protein kinase ROS	0	15	69	84
Tyrosine-protein kinase Fgr	0	9	103	112
Mast/stem cell growth factor receptor Kit	0	63	81	144
Myosin light chain kinase, smooth muscle	0	2	35	37
Insulin receptor-related protein	0	3	67	70
Interferon-induced, double-stranded RNA-activated protein kinase	0	10	67	77
Cyclin-dependent kinase 11B	0	1	67	69
Activin receptor type-2A	0	0	67	67
Ephrin type-A receptor 3	0	3	70	73
Ephrin type-A receptor 8	0	2	67	69
Leukocyte tyrosine kinase receptor	0	5	68	74
Tyrosine-protein kinase receptor UFO	0	15	67	82
Mitogen-activated protein kinase 4	0	0	67	67
Tyrosine-protein kinase receptor Tie-1	0	1	67	68
Serine/threonine-protein kinase receptor R3	0	3	87	90
Tyrosine-protein kinase TXK	0	6	69	75
Tyrosine-protein kinase Blk	0	15	69	84
Cytoplasmic tyrosine-protein kinase BMX	0	15	70	85
cAMP-dependent protein kinase catalytic subunit PRKX	0	3	68	71
5'-AMP-activated protein kinase catalytic subunit alpha-2	0	2	69	72
Ephrin type-B receptor 1	0	2	67	69
Serine/threonine-protein kinase SIK1	0	4	67	71
Tubulin alpha-1A chain	0	0	35	35
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta	0	0	67	67
SRSF protein kinase 2	0	1	67	68
Tyrosine-protein kinase receptor TYRO3	0	4	67	71
Cyclin-dependent kinase 18	0	2	80	83
Tyrosine-protein kinase ITK/TSK	0	13	69	82
Myotonin-protein kinase	0	4	67	71
Tyrosine-protein kinase Mer	0	9	110	119
cGMP-dependent protein kinase 2	0	1	67	68
Receptor-interacting serine/threonine-protein kinase 1	0	6	68	74
Calcium/calmodulin-dependent protein kinase type II subunit beta	0	7	67	74
Calcium/calmodulin-dependent protein kinase type 1	0	2	68	70
Ribosomal protein S6 kinase alpha-2	0	4	68	72
NT-3 growth factor receptor	0	7	68	75
BDNF/NT-3 growth factors receptor	0	14	70	84
Mitogen-activated protein kinase 6	0	0	69	69
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform	0	1	67	68
Serine/threonine-protein kinase TNNI3K	0	1	67	68
Serine/threonine-protein kinase Nek5	0	1	67	68
Serine/threonine-protein kinase tousled-like 2	0	2	67	69
Serine/threonine-protein kinase 32C	0	1	67	68
Myosin light chain kinase family member 4	0	1	67	68
Calcium/calmodulin-dependent protein kinase type 1D	0	2	68	70
Serine/threonine-protein kinase BRSK2	0	3	69	72
Serine/threonine-protein kinase DCLK2	0	1	68	69
Calcium/calmodulin-dependent protein kinase kinase 1	0	1	67	68
Casein kinase I isoform alpha-like	0	1	67	68
Myosin-IIIa	0	1	67	68
Ankyrin repeat and protein kinase domain-containing protein 1	0	0	67	67
Serine/threonine-protein kinase BRSK1	0	2	67	69
Myosin-IIIb	0	1	67	68
Atypical kinase COQ8B, mitochondrial	0	0	67	67
SRSF protein kinase 1	0	2	67	69
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha	0	0	67	67
Serine/threonine-protein kinase RIO1	0	0	67	67
MAP kinase-interacting serine/threonine-protein kinase 1	0	10	67	77
Testis-specific serine/threonine-protein kinase 1	0	2	67	69
Serine/threonine-protein kinase 33	0	2	67	69
Serine/threonine-protein kinase DCLK3	0	0	67	67
Myosin light chain kinase 2, skeletal/cardiac muscle	0	1	67	68
Tyrosine-protein kinase Srms	0	1	67	68
MAP kinase-interacting serine/threonine-protein kinase 2	0	14	68	82
Serine/threonine-protein kinase Nek6	0	6	67	73
Serine/threonine-protein kinase LATS2	0	1	67	68
Serine/threonine-protein kinase 36	0	1	67	68
Serine/threonine-protein kinase 32B	0	1	67	68
Serine/threonine-protein kinase MARK1	0	3	67	70
Serine/threonine-protein kinase PAK 5	0	6	67	73
eIF-2-alpha kinase GCN2	0	1	67	68
Serine/threonine-protein kinase 17A	0	4	68	72
Ephrin type-A receptor 6	0	1	67	68
Death-associated protein kinase 2	0	2	68	70
Serine/threonine-protein kinase tousled-like 1	0	1	67	68
Cyclin-dependent kinase 11A	0	0	67	67
Calcium/calmodulin-dependent protein kinase type II subunit alpha	0	8	67	75
Kappa-type opioid receptor	0	17	6	27
Mu-type opioid receptor	0	26	4	35
Aldehyde dehydrogenase, mitochondrial	0	5	1	6
Aldehyde dehydrogenase, dimeric NADP-preferring	0	1	0	1
Aldehyde dehydrogenase family 1 member A3	0	1	0	1
Chain A, REPLICASE POLYPROTEIN 1AB	0	1	0	1
Cytochrome P450 2A13	0	9	6	15
Phospholipase D2	0	2	0	2
Steroid hormone receptor ERR2	0	2	0	2
Progesterone receptor	0	22	10	35
Estrogen receptor	0	5	7	16
Estrogen-related receptor gamma	0	4	3	7
Estrogen-related receptor gamma	0	1	0	1
Phospholipase D1	0	2	0	2
Inhibitor of nuclear factor kappa-B kinase subunit alpha	0	13	61	74
Histone deacetylase 3	0	83	8	98
Histone deacetylase 4	0	75	7	90
Histone deacetylase 1	0	97	15	120
Histone deacetylase 7	0	71	6	84
Histone deacetylase 2	0	88	12	108
Polyamine deacetylase HDAC10	0	60	6	73
Histone deacetylase 11	0	60	5	72
Histone deacetylase 6	0	92	14	114
Histone deacetylase 9	0	68	5	80
Histone deacetylase 5	0	74	5	86
Chain A, Poly(adp-ribose) Polymerase	0	2	0	2
Chain A, Poly(adp-ribose) Polymerase	0	2	0	2
Chain A, Poly(adp-ribose) Polymerase	0	2	0	2
Thiopurine S-methyltransferase	0	6	1	7
Succinate-semialdehyde dehydrogenase, mitochondrial	0	7	0	7
Dihydropteroate synthase	0	0	1	1
Chain A, Toluene-4-monooxygenase system protein A	0	1	0	1
Trypsin-1	0	21	0	21
Histone acetyltransferase KAT2B	0	7	0	7
Leucine-rich repeat serine/threonine-protein kinase 2	0	11	61	72
Potassium channel subfamily K member 2	0	13	17	30
Acetylcholinesterase	0	17	0	19
Potassium voltage-gated channel subfamily A member 1	0	6	2	8
Acetylcholinesterase	0	73	1	76
cAMP-dependent protein kinase catalytic subunit alpha	0	13	0	13
Beta-casein	0	2	0	2
Phospholipase A2	0	5	2	7
Alkaline phosphatase, tissue-nonspecific isozyme	0	1	0	1
ATP-binding cassette sub-family C member 3	0	441	0	442
Multidrug resistance-associated protein 4	0	449	0	457
Canalicular multispecific organic anion transporter 1	0	430	0	433
Secreted chorismate mutase	0	6	0	6
voltage-dependent T-type calcium channel subunit alpha-1H isoform a	0	0	4	4
Muscarinic acetylcholine receptor M3	0	49	21	76
Muscarinic acetylcholine receptor M4	0	48	20	74
Muscarinic acetylcholine receptor M5	0	47	20	73
Muscarinic acetylcholine receptor DM1	0	5	0	5
Chain A, Trichosurin	0	0	1	1
Solute carrier organic anion transporter family member 1B3	0	101	0	113
Solute carrier organic anion transporter family member 1B1	0	104	0	117
Chymotrypsin-like elastase family member 1	0	3	0	3
Chymotrypsin-C	0	4	0	4
Chain X, Dimeric dihydrodiol dehydrogenase	0	1	0	1
Testosterone 17-beta-dehydrogenase 3	0	14	0	14
Chain A, Nadph Dehydrogenase 1	0	0	1	1
D(1A) dopamine receptor	0	125	11	143
Carbonic anhydrase	0	11	0	11
Toll-like receptor 2	0	2	0	2
Cathepsin H	0	1	0	1
Cathepsin B	0	2	0	2
M18 aspartyl aminopeptidase	0	10	0	10
cathepsin L1	0	8	0	8
Purine nucleoside phosphorylase	0	0	8	8
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	0	13	0	14
5-hydroxytryptamine receptor 2C	0	8	0	9
5-hydroxytryptamine receptor 2A	0	5	0	6
5-hydroxytryptamine receptor 5A	0	14	0	15
Chain A, Carbonic anhydrase 2	0	1	0	1
Cannabinoid receptor 1	0	43	11	66
Cannabinoid receptor 2	0	32	12	55
G-protein coupled bile acid receptor 1	0	6	29	35
Fatty-acid amide hydrolase 1	2	41	0	44
Monoglyceride lipase	0	9	0	9
Fatty acid synthase	0	10	0	10
Induced myeloid leukemia cell differentiation protein Mcl-1	0	48	3	51
GALC protein	94	0	0	94
3-alpha-hydroxysteroid dehydrogenase	0	0	0	2
Equilibrative nucleoside transporter 1	0	18	0	18
Adenosine kinase	0	1	0	3
Chain A, Sulfotransferase 1A1	0	1	0	1
Chain A, Sulfotransferase 1A1	0	1	0	1
Endolysin	0	0	8	8
Protein-tyrosine-phosphatase	0	0	0	1
Serum paraoxonase/arylesterase 1	0	15	0	15
Tyrosine-protein phosphatase non-receptor type 5	0	0	0	1
1-deoxy-D-xylulose-5-phosphate synthase	0	1	0	1
Glutathione reductase, mitochondrial	0	19	0	24
Thioredoxin glutathione reductase	0	2	0	2
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain A, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
Chain B, AROMATIC AMINO ACID AMINOTRANSFERASE	0	0	1	1
NAD-dependent protein deacylase sirtuin-5, mitochondrial	0	15	1	21
Albumin	0	25	35	79
Vascular endothelial growth factor A	0	0	3	3
P2Y purinoceptor 2	0	2	12	14
P2Y purinoceptor 4	0	0	6	6
Carnitine O-palmitoyltransferase 2, mitochondrial	0	4	0	4
Carnitine O-palmitoyltransferase 2, mitochondrial	0	6	0	6
Carnitine O-palmitoyltransferase 1, liver isoform	0	2	0	2
Carnitine O-palmitoyltransferase 1, liver isoform	0	6	0	6
Carnitine O-palmitoyltransferase 1, muscle isoform	0	3	0	3
Carnitine O-palmitoyltransferase 1, muscle isoform	0	6	0	6
GTP-binding protein Rheb	0	0	2	2
Chain A, Cell division protein kinase 2	0	1	0	1
Casein kinase II subunit alpha 3	0	24	2	26
Sodium- and chloride-dependent GABA transporter 1	0	18	0	18
Sodium- and chloride-dependent GABA transporter 2	0	18	0	18
Sodium- and chloride-dependent GABA transporter 3	0	15	0	15
Sodium- and chloride-dependent betaine transporter	0	15	0	15
Accessory gene regulator protein A	0	3	0	3
Tumor necrosis factor receptor superfamily member 1A	0	2	0	2
NLRP3 protein	0	2	0	2
nuclear receptor subfamily 0 group B member 1	0	19	0	19
Urease subunit alpha	0	23	0	23
Urease subunit beta	0	23	0	23
Cytochrome P450 2B1	0	9	0	12
Cytochrome P450 144	0	0	7	7
Steroid C26-monooxygenase	0	0	9	9
Steroid C26-monooxygenase	0	0	7	7
Lanosterol 14-alpha demethylase	0	0	2	2
Lanosterol 14-alpha demethylase	0	0	5	5
UDP-glucuronosyltransferase 2B15	0	0	0	2
Gag-Pol polyprotein	0	13	1	14
Calcitonin gene-related peptide 1	0	2	0	2
Phosphatidylinositol 3-kinase catalytic subunit type 3	0	15	7	22
Prothrombin	0	27	9	38
Plasminogen	0	21	2	23
Coagulation factor XI	0	4	0	4
Vitamin K-dependent protein C	0	8	0	8
Trypsin-2	0	15	0	15
Sodium/hydrogen exchanger 1	0	10	0	10
Sodium/hydrogen exchanger 3	0	7	0	7
Trypsin-3	0	16	0	16
Sodium channel protein type 5 subunit alpha	0	54	0	54
Sodium/hydrogen exchanger 5	0	6	0	6
Renin	0	3	0	3
Endochitinase A1	0	3	0	3
90-kda heat shock protein beta HSP90 beta, partial	0	17	0	17
Catechol O-methyltransferase	0	9	1	12
CPG DNA methylase	0	5	0	5
Uridine phosphorylase 1	0	1	0	1
Uridine phosphorylase 1	0	0	1	4
Protein-glutamine gamma-glutamyltransferase 2	0	13	0	13
Methylcytosine dioxygenase TET2	0	4	1	5
Thymidine phosphorylase	0	8	0	9
Thymidine phosphorylase	0	9	1	18
calcineurin A1, putative	0	0	8	8
estrogen receptor beta isoform 1	0	11	0	11
ADAM10	0	2	0	2
PPP5C protein, partial	0	2	0	2
serine/threonine-protein phosphatase PP1-alpha catalytic subunit isoform 3	0	2	0	2
disintegrin and metalloproteinase domain-containing protein 17 isoform 1 preproprotein	0	2	0	2
protein AF-9 isoform a	0	0	0	15
Hepcidin	0	1	0	1
Glutathione S-transferase P	0	7	0	7
Sodium/hydrogen exchanger 2	0	3	0	3
Solute carrier family 22 member 4	0	5	0	5
Chain A, Deoxycytidine kinase	0	1	0	1
Chain A, Deoxycytidine kinase	0	1	0	1
Chain A, 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase	0	0	1	1
Chain C, 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase	0	0	1	1
Chain A, 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase	0	0	1	1
Chain A, 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase	0	0	1	1
Chain C, 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase	0	0	1	1
Chain A, 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase	0	0	1	1
2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase	0	1	3	4
Janus kinase 2 (a protein tyrosine kinase)	0	5	0	5
Orotidine 5'-phosphate decarboxylase	0	5	0	5
Uridine 5'-monophosphate synthase	0	4	0	4
Bifunctional purine biosynthesis protein ATIC	0	10	0	11
Cytochrome P450 2C19	0	145	3	154
Sialidase-2	0	21	0	21
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Chain A, Leukotriene A-4 hydrolase	0	3	0	3
Leukotriene A-4 hydrolase	0	27	2	30
DNA repair protein RAD51 homolog 1	0	0	1	1
Chain A, Mitogen-activated protein kinase 3	0	1	0	1
Adenosine kinase	0	1	0	1
Adenosine kinase	0	2	0	2
Adenosine kinase	0	1	0	1
Histone-lysine N-methyltransferase, H3 lysine-79 specific	0	12	4	16
NAD	0	6	0	11
Chain A, Pantothenate synthetase	0	0	1	1
Chain A, Pantothenate synthetase	0	0	1	1
Chain A, Pantothenate synthetase	0	0	1	1
Chain A, Pantothenate synthetase	0	0	1	1
Chain A, Pantothenate synthetase	0	0	1	1
Chain A, Pantothenate synthetase	0	0	1	1
Chain B, Pantothenate synthetase	0	0	1	1
Chain A, Pantothenate synthetase	0	0	1	1
Pantothenate synthetase	0	4	1	5
Potassium voltage-gated channel subfamily A member 2	0	0	1	1
Potassium voltage-gated channel subfamily A member 3	0	0	1	1
Potassium voltage-gated channel subfamily A member 6	0	0	1	1
Potassium voltage-gated channel subfamily C member 1	0	0	1	1
5-hydroxytryptamine receptor 1D	0	19	0	25
5-hydroxytryptamine receptor 1B	0	15	3	19
Cholecystokinin receptor type A	0	8	4	12
Gastrin/cholecystokinin type B receptor	0	6	4	10
5-hydroxytryptamine receptor 4	0	9	4	15
Transient receptor potential cation channel subfamily M member 8	0	7	5	15
Thymidine kinase, cytosolic	0	3	0	6
Pannexin-1	0	3	0	3
Oxoeicosanoid receptor 1	0	4	1	5
Thymidine phosphorylase	0	2	0	2
Canalicular multispecific organic anion transporter 1	0	10	0	14
Bile acid receptor	0	19	12	31
Trifunctional purine biosynthetic protein adenosine-3	0	6	0	6
Bifunctional purine biosynthesis protein ATIC	0	1	0	1
Signal transducer and activator of transcription 1-alpha/beta	0	4	1	5
CAD protein [Includes: Glutamine-dependent carbamoyl-phosphate synthase	0	0	0	1
Dihydroorotate dehydrogenase (quinone), mitochondrial	0	0	0	1
Apoptosis regulator Bcl-2	0	34	8	42
Bcl2-associated agonist of cell death	0	7	1	8
Chain A, N-methyl-D-aspartate Receptor Subunit 1	0	3	0	3
Chain A, N-methyl-D-aspartate Receptor Subunit 1	0	3	0	3
Chain A, N-methyl-D-aspartate Receptor Subunit 1	0	3	0	3
Cyclin-T1	0	46	0	46
Genome polyprotein	0	5	0	5
Cyclic AMP-responsive element-binding protein 1	0	0	0	2
steroidogenic factor 1	0	15	0	15
Dihydrofolate reductase	0	2	0	2
Cytochrome P450 11B1, mitochondrial	0	4	0	4
Histidine decarboxylase	0	2	5	7
ELAV-like protein 1	0	3	1	4
Mcl-1	0	20	0	20
envelope glycoprotein	0	4	0	4
core protein, partial	0	3	0	3
Caspase-1	6	21	1	30
Tyrosine-protein kinase transforming protein Abl	0	3	0	3
Calmodulin-sensitive adenylate cyclase	0	1	0	1
Heat shock-related 70 kDa protein 2	0	1	0	1
Heat shock cognate 71 kDa protein	0	0	6	6
S-methyl-5'-thioadenosine phosphorylase	0	1	1	4
Protein arginine N-methyltransferase 5	0	8	3	11
Indolethylamine N-methyltransferase	0	3	0	3
Catechol O-methyltransferase	0	3	0	3
Methylosome protein 50	0	3	2	5
Spermidine synthase	0	2	0	2
5-methylthioadenosine/S-adenosylhomocysteine deaminase	0	0	0	3
2-oxoglutarate receptor 1	0	3	0	3
Heat shock protein hsp-16.2	0	2	0	2
Nuclear hormone receptor family member daf-12	0	3	5	8
oxysterols receptor LXR-beta isoform 1	0	3	5	8
Chain A, Glutathione S-transferase P	0	0	1	1
Chain A, Glutathione S-transferase P	0	0	1	1
Glutathione S-transferase Mu 2	0	1	0	1
Fatty-acid amide hydrolase 1	0	20	0	21
Geranylgeranyl pyrophosphate synthase	0	10	0	12
Farnesyl pyrophosphate synthase	0	20	1	21
Glycogen synthase kinase-3 beta	0	10	0	10
[Tau protein] kinase	0	10	0	10
matrix metalloproteinase-14 preproprotein	0	4	0	4
melanocortin receptor 4	0	4	4	8
Casein kinase I isoform alpha	0	4	0	4
G1/S-specific cyclin-D1	0	52	0	53
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	0	16	2	18
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	0	11	0	11
Dual specificity tyrosine-phosphorylation-regulated kinase 2	0	8	61	69
Glutamate receptor 1	0	12	4	16
Glutamate receptor 2	0	13	4	17
Glutamate receptor 3	0	9	4	13
Glutamate receptor 4	0	12	3	15
Methylated-DNA--protein-cysteine methyltransferase	0	5	0	7
Dehydrogenase/reductase SDR family member 9	0	2	0	2
Solute carrier organic anion transporter family member 2A1	0	4	0	11
transcription factor p65 isoform 1	0	0	7	7
Estrogen receptor beta	0	4	7	15
Dihydroorotase	0	0	1	1
Mas-related G-protein coupled receptor member X2	0	0	16	16
Pancreatic alpha-amylase	0	4	0	4
Chain A, 6-PHOSPHOGLUCONATE DEHYDROGENASE	0	0	1	1
6-phosphogluconolactonase	0	0	1	1
nuclear receptor coactivator 1 isoform 1 [Homo sapiens]	0	8	0	8
nuclear receptor coactivator 3 isoform a	0	8	0	8
UDP-glucose 6-dehydrogenase	0	2	0	2
UDP-glucuronosyltransferase 1A1	0	2	0	2
Sialidase	0	21	0	21
Tryptophan 2,3-dioxygenase	0	1	0	1
Tryptophan 2,3-dioxygenase	0	11	0	12
estrogen receptor alpha, partial	0	0	1	1
Estrogen receptor 1	0	7	2	9
toll-like receptor 9	0	5	0	5
inositol monophosphatase 1	3	0	0	3
Beta lactamase (plasmid)	0	12	0	12
GTP-binding protein (rab7)	0	0	9	9
ras protein, partial	0	0	9	9
Ras-related protein Rab-2A	0	0	9	9
Vesicular glutamate transporter 3	0	4	0	4
Vitamin D3 receptor	0	11	11	27
D(3) dopamine receptor isoform e	15	0	0	15
kallikrein-7 isoform 1 preproprotein	0	0	1	1
Glyceraldehyde-3-phosphate dehydrogenase, glycosomal	0	7	0	7
ERAP1 protein	0	0	0	3
Glyceraldehyde-3-phosphate dehydrogenase	0	15	0	15
Seed linoleate 13S-lipoxygenase-1	0	20	0	28
Small conductance calcium-activated potassium channel protein 3	0	8	2	10
Cholinesterase	0	56	0	58
Zn finger protein	0	2	0	2
Aldo-keto reductase family 1 member B10	0	29	0	33
17-beta-hydroxysteroid dehydrogenase type 1	0	10	0	11
Aldo-keto reductase family 1 member B1	0	13	0	13
17-beta-hydroxysteroid dehydrogenase type 2	0	13	0	13
G1/S-specific cyclin-E2	0	13	0	16
Cyclin-dependent kinase 1	0	3	0	3
Cystic fibrosis transmembrane conductance regulator	0	2	10	12
Ribonuclease T	0	0	0	4
Cell death-related nuclease 4	0	0	0	4
Nitric oxide synthase, endothelial	0	1	0	1
Chain A, Tyrosine 3-monooxygenase	0	1	0	1
Solute carrier family 15 member 1	0	48	5	54
Solute carrier family 15 member 1	0	18	0	20
Solute carrier family 15 member 2	0	22	0	22
Solute carrier family 15 member 2	0	32	0	33
aryl hydrocarbon receptor	0	0	1	1
nuclear receptor subfamily 1 group I member 2 isoform 1	0	0	1	1
Amine oxidase [flavin-containing] B	0	37	1	40
Amine oxidase [flavin-containing] B	0	7	0	8
Heat shock 70 kDa protein 1A	0	4	2	6
Endoplasmic reticulum chaperone BiP	0	3	2	5
26S proteasome non-ATPase regulatory subunit 14	0	7	0	7
cAMP-dependent protein kinase type I-alpha regulatory subunit	0	0	2	2
cAMP-dependent protein kinase type II-beta regulatory subunit	0	0	2	2
cAMP-dependent protein kinase catalytic subunit beta isoform 1	0	0	2	2
cAMP-dependent protein kinase catalytic subunit beta isoform 3	0	0	2	2
Translocator protein	0	27	6	34
Alpha-1D adrenergic receptor	0	137	14	160
5-hydroxytryptamine receptor 7	0	43	0	44
D	0	7	0	7
5-hydroxytryptamine receptor 2A	0	5	0	5
Lysosomal alpha-glucosidase	0	3	0	3
Chain A, Avidin	0	0	2	2
Chain A, Avidin	0	0	2	2
Chain B, Avidin	0	0	2	2
COP9 signalosome complex subunit 5	0	1	0	1
Adenosine receptor A1	0	4	0	4
Thymidine kinase 2, mitochondrial	0	4	0	4
Thymidine kinase	0	3	0	3
Diacylglycerol kinase 1	0	1	0	1
Thymidine kinase	0	5	0	6
Deoxynucleoside kinase	0	3	0	3
Ricin	0	4	0	4
Purine nucleoside phosphorylase	0	1	4	9
Chain B, PURINE NUCLEOSIDE PHOSPHORYLASE	0	0	1	1
Ubiquitin carboxyl-terminal hydrolase isozyme L3	0	5	0	5
XBP1	0	9	0	9
RAD51	0	6	0	6
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2, isoform CRA_a	0	0	5	5
mitogen-activated protein kinase kinase kinase kinase 2 isoform 1	0	0	3	3
DNA damage-inducible transcript 3 protein	0	9	0	9
DNA repair protein RAD52 homolog isoform a	0	0	0	22
mitogen-activated protein kinase kinase kinase 3 isoform 1	0	0	3	3
Transient receptor potential cation channel subfamily M member 4	0	1	0	1
Sphingosine-1-phosphate receptor 4	0	1	0	1
PTK2B protein tyrosine kinase 2 beta	0	2	0	2
perilipin-5	0	20	0	20
perilipin-1	0	20	0	20
sphingosine 1-phosphate receptor 1	0	1	0	1
protein-arginine deiminase type-4	0	4	0	4
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform a	0	20	0	20
Chain A, Heat shock protein HSP 90-alpha	0	1	0	1
Chain A, Heat shock protein HSP 90-alpha	0	1	0	1
Heat shock protein 75 kDa, mitochondrial	0	13	0	14
TWIK-related acid-sensitive K+ channel	0	1	0	1
Kcnk3 channel	0	1	0	1
potassium voltage-gated channel subfamily H member 2 isoform a	0	1	0	1
potassium channel subfamily K member 9	0	1	0	1
Potassium channel subfamily K member 5	0	1	0	1
Potassium channel subfamily K member 17	0	1	0	1
Potassium channel subfamily K member 9	0	3	0	3
Potassium channel subfamily K member 9	0	6	0	6
5'-AMP-activated protein kinase subunit beta-2	0	1	3	5
5'-AMP-activated protein kinase catalytic subunit alpha-1	0	0	1	1
5'-AMP-activated protein kinase subunit gamma-3	0	1	2	4
ubiquitin-conjugating enzyme E2 N	0	29	0	29
Bcl-2-like protein 2	0	12	0	12
Histamine H3 receptor	0	21	3	25
G1/S-specific cyclin-D3	0	13	0	14
Choline-phosphate cytidylyltransferase A	0	0	90	90
MAP kinase-activated protein kinase 3	0	3	62	65
Uncharacterized aarF domain-containing protein kinase 5	0	0	107	107
Homeodomain-interacting protein kinase 1	0	8	61	69
Nuclear receptor corepressor 2	0	29	0	29
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	0	6	1	7
Steroid 17-alpha-hydroxylase/17,20 lyase	0	15	0	15
Steroid 21-hydroxylase	0	2	0	2
Steroid 17-alpha-hydroxylase/17,20 lyase	0	4	0	4
Cytochrome P450 11B1, mitochondrial	0	9	0	9
Cytochrome P450 11B2, mitochondrial	0	10	0	10
Monocarboxylate transporter 10	0	1	0	5
Leukotriene C4 synthase	0	0	61	61
Peripheral plasma membrane protein CASK	0	0	61	61
Mitogen-activated protein kinase kinase kinase 13	0	0	61	61
Mitogen-activated protein kinase kinase kinase 7	0	3	64	67
Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	0	0	61	61
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma	0	0	61	61
Serine/threonine-protein kinase OSR1	0	0	61	61
Serine/threonine-protein kinase Chk2	0	10	62	72
Wee1-like protein kinase 2	0	0	65	65
Uncharacterized serine/threonine-protein kinase SBK3	0	0	61	61
Serine/threonine-protein kinase MAK	0	1	61	62
Receptor tyrosine-protein kinase erbB-3	0	15	61	76
G protein-coupled receptor kinase 4	0	1	61	62
Megakaryocyte-associated tyrosine-protein kinase	0	1	61	62
Serine/threonine-protein kinase Nek4	0	1	61	62
Hormonally up-regulated neu tumor-associated kinase	0	0	61	61
Receptor-interacting serine/threonine-protein kinase 4	0	0	61	61
Cell division control protein 2 homolog	0	0	61	61
Calcium-dependent protein kinase 1	0	1	61	62
Serine/threonine-protein kinase PknB	0	0	61	61
Cyclin-dependent kinase-like 1	0	0	61	61
Mitogen-activated protein kinase kinase kinase 12	0	1	61	62
Serine/threonine-protein kinase PRP4 homolog	0	0	61	61
Receptor tyrosine-protein kinase erbB-4	0	29	63	92
Rhodopsin kinase GRK1	0	2	61	63
Serine/threonine-protein kinase SBK1	0	1	61	62
Mitogen-activated protein kinase kinase kinase 19	0	1	62	63
Dual serine/threonine and tyrosine protein kinase	0	2	61	63
Mitogen-activated protein kinase kinase kinase 15	0	0	61	61
Serine/threonine-protein kinase VRK2	0	1	61	62
Cyclin-dependent kinase-like 3	0	3	61	64
Serine/threonine-protein kinase NIM1	0	4	61	65
Serine/threonine-protein kinase ULK2	0	2	61	63
Homeodomain-interacting protein kinase 4	0	5	61	66
Serine/threonine-protein kinase Nek11	0	1	61	62
Serine/threonine-protein kinase 35	0	0	61	61
Rhodopsin kinase GRK7	0	1	61	62
Serine/threonine-protein kinase 32A	0	0	61	61
Cyclin-dependent kinase-like 2	0	0	61	61
Serine/threonine-protein kinase Sgk3	0	1	61	62
Cyclin-dependent kinase 15	0	1	61	63
Serine/threonine-protein kinase RIO2	0	0	61	61
Transient receptor potential cation channel subfamily M member 6	0	0	61	61
Homeodomain-interacting protein kinase 2	0	5	63	68
Homeodomain-interacting protein kinase 3	0	7	61	68
SNF-related serine/threonine-protein kinase	0	1	61	62
STE20/SPS1-related proline-alanine-rich protein kinase	0	1	61	62
SRSF protein kinase 3	0	1	61	62
Microtubule-associated serine/threonine-protein kinase 1	0	0	61	61
low molecular weight phosphotyrosine protein phosphatase isoform c	0	6	0	6
Beta-adrenergic receptor kinase 2	0	1	1	2
Calcium/calmodulin-dependent protein kinase type 1B	0	1	1	2
Bcl-2-related protein A1	0	7	1	8
Chain A, Apoptosis regulator Bcl-X	0	1	0	1
BH3-interacting domain death agonist	0	5	0	5
Induced myeloid leukemia cell differentiation protein Mcl-1 homolog	0	1	1	2
Apoptosis regulator BAX	0	1	1	2
Bcl-2 homologous antagonist/killer	0	5	1	6
Bcl-2-binding component 3, isoforms 1/2	0	1	0	1
Bcl-2-like protein 10	0	2	0	2
Potassium voltage-gated channel subfamily E member 1	0	19	0	19
Potassium voltage-gated channel subfamily KQT member 1	0	21	0	21
Potassium voltage-gated channel subfamily D member 3	0	13	0	13
Major prion protein	0	0	9	9
Trypanothione reductase	0	26	0	31
Solute carrier family 22 member 6	0	39	0	46
UDP-glucuronosyltransferase 1A9	0	4	0	17
Bile salt export pump	0	81	0	84
Myoglobin	0	1	0	1
UDP-glucuronosyltransferase 1-6	0	17	0	23
Arachidonate 5-lipoxygenase-activating protein	0	6	1	7
Cytochrome P450 2J2	0	70	0	72
toxin B	0	0	0	2
Nicotinate phosphoribosyltransferase	0	14	0	14
14 kDa phosphohistidine phosphatase	0	8	0	8
Chain A, CARBONIC ANHYDRASE II	0	0	1	1
Chain A, CARBONIC ANHYDRASE II	0	0	1	1
Chain A, CARBONIC ANHYDRASE II	0	0	1	1
Chain A, Carbonic Anhydrase Ii	0	0	1	1
Chain A, Carbonic Anhydrase Ii	0	0	1	1
Chain A, Endochitinase	0	2	0	2
Chain A, Endochitinase	0	2	0	2
Chain A, Endochitinase	0	2	0	2
Chain A, Class Iii Chitinase Chia1	0	1	0	1
Chain A, Carbonic anhydrase 13	0	1	0	1
Chain A, Carbonic anhydrase II	0	3	0	3
Chain A, Carbonic anhydrase 2	0	3	0	3
Chain A, Carbonic anhydrase 2	0	3	0	3
Chain A, Carbonic anhydrase 2	0	3	0	3
Chain A, Carbonic anhydrase 2	0	3	0	3
Chain A, Carbonic anhydrase 2	0	3	0	3
Chain A, Carbonic anhydrase 2	0	3	0	3
Chain A, Carbonic anhydrase 2	0	3	0	3
Chain A, Carbonic anhydrase 2	0	3	0	3
Chain A, Carbonic anhydrase 2	0	1	0	1
Chain A, Carbonic anhydrase	0	1	0	1
Chain B, Carbonic anhydrase	0	1	0	1
Chain A, Carbonic anhydrase 2	0	1	0	1
Carbonic anhydrase-related protein 11	0	1	0	3
Carbonic anhydrase 2	0	5	2	7
Cathepsin B	0	3	0	3
Steryl-sulfatase	0	7	0	9
Cytochrome P450 2C8	0	38	2	42
Cytochrome P450 2B6	0	32	2	38
Endochitinase	0	2	0	2
Carbonic anhydrase	0	2	0	2
Corticosteroid 11-beta-dehydrogenase isozyme 1	0	5	1	6
Squalene synthase	0	7	0	8
Carbonic anhydrase 3	0	17	0	17
Multidrug resistance-associated protein 1	0	3	0	3
Acidic mammalian chitinase	0	2	0	2
Carbonic anhydrase 7	0	1	0	1
Carbonic anhydrase	0	18	0	18
Carbonic anhydrase	0	2	0	2
Carbonic anhydrase 2, isoform A	0	2	0	2
Free fatty acid receptor 3	0	0	3	3
Free fatty acid receptor 2	0	2	2	4
Fibrinogen C domain-containing protein 1	0	2	0	2
Leukocyte surface antigen CD47	0	0	1	1
Urease	0	7	0	8
Lethal factor	0	15	0	15
Succinyl-diaminopimelate desuccinylase	0	8	0	8
Peptide deformylase	0	2	0	2
Urease subunit gamma	0	1	0	1
Urease subunit beta	0	1	0	1
Urease subunit alpha	0	1	0	1
Urease subunit beta	0	2	0	2
caspase recruitment domain family, member 15	0	6	0	6
receptor-interacting serine/threonine-protein kinase 2 isoform 1	0	6	0	6
N-alpha-acetyltransferase 50	0	0	2	2
Ubiquitin carboxyl-terminal hydrolase 2	0	6	0	6
Ubiquitin carboxyl-terminal hydrolase isozyme L1	0	4	0	4
Ubiquitin carboxyl-terminal hydrolase 15	0	2	0	2
Ubiquitin carboxyl-terminal hydrolase isozyme L5	0	3	0	3
Solute carrier family 22 member 5	0	2	0	4
cardiac alpha tropomyosin	0	2	1	3
troponin I, cardiac muscle	0	2	1	3
troponin T, cardiac muscle isoform 3	0	2	1	3
troponin C, slow skeletal and cardiac muscles	0	2	1	3
Putative glycosyltransferase WbgO	0	0	0	1
Calpain small subunit 1	0	1	0	1
Cathepsin B	0	23	1	24
Calpain-1 catalytic subunit	0	6	0	6
ATP-citrate synthase	0	6	0	7
Synaptic vesicular amine transporter	0	10	1	11
Platelet glycoprotein VI	0	4	5	10
karyopherin alpha 2 (RAG cohort 1, importin alpha 1), isoform CRA_b	0	0	3	3
LANA	0	0	0	8
insulin-degrading enzyme isoform 1	0	0	8	8
Arginase	0	13	0	15
Chain A, Peptide deformylase 1B, chloroplastic	0	1	0	1
Chain A, Peptide deformylase 1B, chloroplastic	0	1	0	1
Interstitial collagenase	0	35	2	39
Neprilysin	0	5	0	5
Neprilysin	0	5	0	5
Aminopeptidase N	0	9	0	9
Peptide deformylase	0	1	0	1
Meprin A subunit beta	0	2	0	2
Peptide deformylase 1A, chloroplastic/mitochondrial	0	2	0	2
Peptide deformylase, mitochondrial	0	2	0	2
Peptide deformylase	0	2	0	2
Histone deacetylase 6	0	1	0	1
NAD-dependent protein deacetylase sirtuin-2	0	21	2	23
NAD-dependent protein deacetylase sirtuin-1	0	18	2	25
Chain E, Purine nucleoside phosphorylase	0	1	0	1
Thymidine kinase	0	8	0	9
Solute carrier family 22 member 1	0	103	0	126
POU domain, class 2, transcription factor 2	0	1	0	3
Thymidine kinase	0	1	0	1
Prostaglandin reductase 1	0	2	0	4
Aspartate aminotransferase, cytoplasmic	0	5	1	6
Glycine receptor subunit alpha-1	0	4	13	17
Pup--protein ligase	0	1	0	1
Phosphoribosyl pyrophosphate synthase-associated protein 2	0	1	0	2
Adenylate kinase isoenzyme 1	0	0	0	3
Capsid protein	0	1	5	6
Chain A, MTA/SAH nucleosidase	0	1	0	1
Chain A, Ribosome-inactivating protein alpha-trichosanthin	0	0	1	1
Chain A, Ricin A chain	0	0	1	1
Chain A, Ribosome-inactivating protein 3	0	0	1	1
Chain A, Membrane lipoprotein tmpC	0	0	3	3
Chain A, Membrane lipoprotein tmpC	0	0	3	3
Chain A, Membrane lipoprotein tmpC	0	0	3	3
Chain A, Structure of PAE2307 in complex with adenosine	0	0	1	1
Chain B, Structure of PAE2307 in complex with adenosine	0	0	1	1
Chain A, ADENOSINE RECEPTOR A2A	0	2	0	2
Chain A, ADENOSINE RECEPTOR A2A	0	2	0	2
Chain A, tRNA (guanine-N(1)-)-methyltransferase	0	0	1	1
Chain A, Uncharacterized protein MJ0883	0	0	1	1
signal transducer and activator of transcription 6, interleukin-4 induced	16	0	0	16
Sodium/nucleoside cotransporter 1	0	5	0	5
Calcium dependent protein kinase	0	1	0	1
Sodium/nucleoside cotransporter 2	0	6	0	6
Phosphoglycerate kinase 1	0	3	0	3
Adenosine deaminase	0	3	0	4
Avidin	0	0	1	1
Adenosine deaminase	0	2	0	3
Phosphoglycerate kinase 2	0	3	0	3
Streptavidin	0	0	2	2
Adenylate kinase 2, mitochondrial	0	2	0	3
Adenylate kinase isoenzyme 1	0	2	0	3
Equilibrative nucleoside transporter 2	0	4	0	4
Adenosine transporter 1	0	1	0	2
5'-nucleotidase	0	6	0	6
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1	0	2	0	2
Glycine--tRNA ligase	0	3	0	3
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1	0	1	0	1
Chain A, DNA polymerase III subunit gamma	0	0	1	1
Chain D, DNA polymerase III subunit gamma	0	0	2	2
Chain D, DNA polymerase III subunit gamma	0	0	2	2
P2X purinoceptor 1	0	1	5	6
P2X purinoceptor 2	0	2	2	4
P2X purinoceptor 1	0	4	3	7
P2X purinoceptor 4	0	1	4	5
P2X purinoceptor 5	0	0	3	3
P2X purinoceptor 6	0	0	3	3
P2X purinoceptor 3	0	5	4	9
P2Y purinoceptor 12	0	4	3	7
Chain A, Heat Shock Protein 90	0	0	1	1
Chain A, GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE	0	0	1	1
Chain B, GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE	0	0	1	1
Chain A, EOSINOPHIL-DERIVED NEUROTOXIN	0	1	0	1
Chain A, EOSINOPHIL-DERIVED NEUROTOXIN	0	1	0	1
Chain A, EOSINOPHIL-DERIVED NEUROTOXIN	0	1	0	1
Chain A, Myosin Ie Heavy Chain	0	0	1	1
Chain A, Preprotein translocase secA	0	0	1	1
Chain A, Ribonuclease pancreatic	0	1	0	1
Chain A, Ribonuclease pancreatic	0	1	0	1
Chain A, Ribonuclease pancreatic	0	1	0	1
Chain A, Ribonuclease pancreatic	0	1	0	1
Chain A, Ribonuclease pancreatic	0	1	0	1
Chain A, Phosphoribosylformylglycinamidine synthase	0	1	0	1
Chain A, nucleoside diphosphate kinase A	0	0	1	1
Chain B, nucleoside diphosphate kinase A	0	0	1	1
Chain A [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 3	0	0	1	1
Chain A [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 3	0	0	1	1
Chain A, Kinesin-like protein KIF11	0	1	0	1
HPr kinase/phosphorylase	0	0	1	1
ATP-dependent molecular chaperone HSP82	0	4	2	7
2-dehydropantoate 2-reductase	0	3	5	8
Pyruvate kinase PKM	0	0	0	1
Pyruvate kinase PKLR	0	0	0	1
Heat shock cognate 71 kDa protein	0	0	1	1
P2Y purinoceptor 1	0	1	5	6
P2Y purinoceptor 6	0	1	7	8
Sensor protein kinase WalK	0	2	0	2
P2X purinoceptor 2	0	1	3	4
Chain A, Glycogen Phosphorylase B	0	0	1	1
Chain B, Glycogen Phosphorylase B	0	0	1	1
Chain A, ADP-dependent glucokinase	0	1	0	1
Chain A, Ribonuclease pancreatic	0	2	0	2
Chain A, Ribonuclease pancreatic	0	2	0	2
Chain A, phosphodiesterase-nucleotide pyrophosphatase	0	1	0	1
Chain A, GLYCOGEN PHOSPHORYLASE B	0	0	1	1
Chain B, GLYCOGEN PHOSPHORYLASE B	0	0	1	1
Chain A, GLYCOGEN PHOSPHORYLASE B	0	0	1	1
2'-deoxynucleoside 5'-phosphate N-hydrolase 1	0	1	0	1
2'-deoxynucleoside 5'-phosphate N-hydrolase 1	0	1	0	1
Fructose-1,6-bisphosphatase 1	0	3	0	3
Alkaline phosphatase, tissue-nonspecific isozyme	0	9	0	10
Fructose-1,6-bisphosphatase 1	0	8	0	9
Inosine-5'-monophosphate dehydrogenase	0	1	0	2
GTP:AMP phosphotransferase AK3, mitochondrial	0	0	0	1
Adenosine deaminase-like protein	0	0	0	1
Protease	0	28	8	52
Histamine H3 receptor	4	7	2	14
Chain A, Endoplasmin	0	0	1	1
thyrotropin-releasing hormone receptor	2	0	0	2
Transmembrane domain-containing protein TMIGD3	0	2	0	2
Aflatoxin B1 aldehyde reductase member 3	0	1	0	1
Endoplasmin	0	0	1	1
Chain A, Carbamoyl-phosphate Synthase	0	1	0	1
Chain A, Potassium-transporting ATPase B chain	0	0	1	1
Platelet-derived growth factor receptor beta	0	12	0	12
Dihydrofolate reductase	0	16	0	17
Platelet-derived growth factor receptor alpha	0	10	0	10
Chain A, Lck Kinase	0	1	0	1
Chain A, Tyrosine-protein kinase Lyn	0	1	0	1
Chain A, Tyrosine-protein kinase Lyn	0	1	0	1
Skn7p	0	0	0	8
amino acid transporter AGP1	0	0	2	2
Proto-oncogene tyrosine-protein kinase Src	0	15	5	20
Proto-oncogene tyrosine-protein kinase LCK	0	6	0	6
Transient receptor potential cation channel subfamily M member 8	0	10	3	13
Dynamin-1	0	6	0	6
Receptor-type tyrosine-protein phosphatase eta	0	7	0	7
Receptor protein-tyrosine kinase	0	8	0	8
Tyrosyl-DNA phosphodiesterase 1	0	16	0	16
Ephrin type-A receptor 3	0	1	0	1
Isocitrate dehydrogenase [NADP] cytoplasmic	0	8	3	11
Isocitrate dehydrogenase [NADP], mitochondrial	0	2	0	2
Solute carrier family 22 member 2	0	46	0	57
Polyamine oxidase 1	0	1	0	1
Solute carrier family 22 member 3	0	26	0	31
Solute carrier family 22 member 3	0	5	0	7
Nischarin	0	6	0	6
Solute carrier family 22 member 1	0	35	0	45
Deoxyhypusine synthase	0	1	0	1
Solute carrier family 22 member 2	0	30	0	36
kelch-like ECH-associated protein 1	0	0	0	11
Prostaglandin E2 receptor EP1 subtype	0	4	3	7
Prostaglandin E2 receptor EP4 subtype	0	4	1	6
Prostaglandin E2 receptor EP3 subtype	0	5	2	8
Prostaglandin E2 receptor EP2 subtype	0	4	2	6
Prostacyclin receptor	0	7	3	10
Histidine triad nucleotide-binding protein 1	0	0	1	1
RuvB-like 1	0	3	0	3
Alanine racemase, biosynthetic	0	0	0	1
Adenosine deaminase	0	1	0	2
Transcriptional activator Myb	0	8	0	8
UDP-N-acetylglucosamine 1-carboxyvinyltransferase	0	6	0	6
UDP-N-acetylglucosamine 1-carboxyvinyltransferase	0	6	0	6
Sterol 14-alpha demethylase	0	6	3	9
Methionine aminopeptidase	0	7	0	7
Beta-2 adrenergic receptor	0	2	9	17
Beta-2 adrenergic receptor	0	16	17	35
Mineralocorticoid receptor	1	14	7	24
Mineralocorticoid receptor	0	2	1	3
Solute carrier organic anion transporter family member 1A1	0	12	0	26
Echinoderm microtubule-associated protein-like 4	0	7	3	11
Chain A, farnesyl pyrophosphate synthase	0	1	0	1
Hypoxanthine-guanine phosphoribosyltransferase	0	2	0	2
Farnesyl pyrophosphate synthase	0	7	0	7
Farnesyl pyrophosphate synthase	0	3	0	3
Alpha-1A adrenergic receptor	0	6	3	9
Alpha-1A adrenergic receptor	0	11	4	15
Pepsin A	0	3	0	3
Renin-1	0	1	0	1
Renin	0	2	0	2
Cathepsin D	0	4	0	4
Renin	0	1	0	1
Protease	0	28	8	38
retinoic acid receptor alpha isoform 1	0	2	0	2
retinoic acid receptor RXR-alpha isoform a	0	2	0	2
Retinoic acid receptor alpha	0	3	3	6
Retinoic acid receptor gamma	0	2	3	5
Retinoic acid receptor beta	0	2	3	5
Nuclear receptor subfamily 4 group A member 1	0	0	6	6
Cellular retinoic acid-binding protein 2	0	0	3	3
Retinoic acid receptor RXR-alpha	0	3	7	10
Retinoic acid receptor RXR-beta	0	2	6	8
Retinoic acid receptor RXR-gamma	0	2	6	8
Type-2 angiotensin II receptor	0	13	2	15
Cellular retinoic acid-binding protein 1	0	0	3	3
Retinoic acid receptor RXR-alpha	0	0	3	3
RmtA	0	5	0	5
Protein arginine N-methyltransferase 1	0	13	0	15
Class A sortase SrtA	0	8	0	8
Transient receptor potential cation channel subfamily A member 1	0	0	10	10
Mitochondrial 2-oxodicarboxylate carrier	0	2	0	2
Hypoxanthine-guanine phosphoribosyltransferase	0	3	0	9
Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase	0	2	0	2
Nuclear receptor ROR-gamma	0	2	0	2
Shiga toxin subunit A	0	2	0	2
Histamine H3 receptor	0	7	1	17
Chain A, Xcogt	0	0	1	1
Chain A, Xcogt	0	0	1	1
Chain A, Xcogt	0	0	1	1
Tyrosine-protein phosphatase 1	0	6	0	6
Transient receptor potential cation channel subfamily M member 8	0	3	1	4
Tissue alpha-L-fucosidase	0	6	0	6
P2Y purinoceptor 12	0	15	0	15
Prolyl endopeptidase FAP	0	6	0	6
Dipeptidyl peptidase 8	0	8	0	8
Dipeptidyl peptidase 9	0	6	0	6
Dipeptidyl peptidase 2	0	5	0	5
calpain II, partial	0	4	0	4
Cathepsin G	0	1	0	1
Neutrophil elastase	0	1	0	1
Myeloblastin	0	1	0	1
Glutamate receptor 1	0	2	1	4
Glutamate receptor 2	0	2	0	3
Glutamate receptor ionotropic, kainate 1	0	5	2	7
Excitatory amino acid transporter 1	0	6	0	7
Excitatory amino acid transporter 2	0	5	0	6
Excitatory amino acid transporter 3	0	5	0	6
Glutamate receptor ionotropic, kainate 2	0	5	2	7
Glutamate receptor ionotropic, kainate 3	0	4	0	4
Glutamate receptor ionotropic, kainate 4	0	2	0	2
Glutamate receptor ionotropic, kainate 5	0	5	0	5
Glutamate receptor 4	0	2	0	3
Glutamate receptor 3	0	2	0	3
3-hydroxy-3-methylglutaryl-coenzyme A reductase	0	2	0	2
Cannabinoid receptor 2	0	7	7	14
Monocarboxylate transporter 1	0	3	0	5
G-protein coupled receptor 35	0	21	20	41
Chain A, Solute-binding protein	0	0	2	2
Chain A, Solute-binding protein	0	0	2	2
Chain B, SusD	0	0	2	2
Chain A, SusD	0	0	2	2
Chain A, SusD	0	0	2	2
Chain B, Putative Glucanohydrolase Pep1a Glge Isoform 1	0	1	0	1
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1	0	4	0	4
26S proteasome non-ATPase regulatory subunit 1	0	0	0	1
Solute carrier organic anion transporter family member 2A1	0	5	0	10
Prolyl 4-hydroxylase subunit alpha-1	0	0	0	2
Solute carrier family 22 member 7	0	9	0	16
Carboxylic ester hydrolase	0	1	0	1
Cytochrome P450 3A6	0	1	0	1
UDP-glucuronosyltransferase 2B7	0	16	0	36
Thromboxane-A synthase	0	32	0	32
UDP-glucuronosyltransferase 2B10	0	14	0	14
Glutathione S-transferase omega-1	0	8	0	8
Gamma-aminobutyric acid receptor subunit alpha-1	0	9	0	15
Gamma-aminobutyric acid receptor subunit beta-1	0	9	0	15
Gamma-aminobutyric acid receptor subunit alpha-2	0	8	0	14
Gamma-aminobutyric acid receptor subunit alpha-3	0	8	0	14
Gamma-aminobutyric acid receptor subunit alpha-4	0	8	0	14
Gamma-aminobutyric acid receptor subunit gamma-2	0	8	0	14
Cholecystokinin receptor type A	1	12	0	13
Cholecystokinin receptor type A	0	7	0	7
Prostaglandin E2 receptor EP3 subtype	0	3	0	3
Prostaglandin E2 receptor EP4 subtype	0	3	1	4
Prostaglandin E2 receptor EP1 subtype	0	3	0	3
Nuclear receptor subfamily 4 group A member 2	0	2	9	11
Nuclear receptor subfamily 4 group A member 2	0	0	2	2
Nuclear receptor subfamily 4 group A member 2	0	0	2	2
Prostaglandin E2 receptor EP2 subtype	0	3	1	4
Solute carrier organic anion transporter family member 2B1	0	2	0	4
Solute carrier organic anion transporter family member 3A1	0	0	0	2
Chain A, Glycogen Synthase Kinase-3 Beta	0	3	0	3
Chain B, Glycogen Synthase Kinase-3 Beta	0	3	0	3
Chain A, Glycogen Synthase Kinase-3 Beta	0	3	0	3
fMet-Leu-Phe receptor	0	5	0	5
hepatocyte nuclear factor 4-alpha isoform 2	0	8	0	8
Chain A, Protein (glycogen Phosphorylase)	0	1	0	1
Nucleoside diphosphate kinase B	0	0	14	15
Dual specificity protein kinase CLK1	0	6	0	6
G1/S-specific cyclin-D2	0	3	0	4
Cyclin homolog	0	7	0	7
La-related protein 7	0	1	0	1
Matrix protein 2	0	1	2	3
Matrix protein 2	0	2	3	5
Multidrug and toxin extrusion protein 1	0	56	0	56
Cytosol aminopeptidase	0	5	0	5
Leucyl-cystinyl aminopeptidase	0	2	0	2
Glutamyl aminopeptidase	0	1	0	1
Leukotriene B4 receptor 1	1	10	2	14
hypothetical protein SA1422	0	2	0	2
Group 10 secretory phospholipase A2	0	1	0	1
Phospholipase A2	0	1	0	1
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1	0	2	0	2
Phospholipase A2, membrane associated	0	5	0	6
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1	0	1	0	1
Cytosolic phospholipase A2	0	3	0	3
Placenta growth factor	0	0	1	1
Delta-type opioid receptor	0	1	0	1
5-hydroxytryptamine receptor 1D	0	2	0	2
Poly [ADP-ribose] polymerase 2	0	13	11	27
Protein Mdm4	0	7	0	7
E3 ubiquitin-protein ligase Mdm2	2	24	8	34
Hepatocyte growth factor receptor	0	3	0	3
Chain A, Hepatocyte growth factor receptor	0	1	0	1
Chain A, Hepatocyte growth factor receptor	0	1	0	1
Solute carrier organic anion transporter family member 2B1	0	20	0	27
Thrombopoietin receptor	0	0	1	1
Adiponectin receptor protein 2	0	0	1	1
Adiponectin receptor protein 1	0	0	1	1
Aminoglycoside 3'-phosphotransferase	0	0	0	4
Chain U, UROKINASE-TYPE PLASMINOGEN ACTIVATOR	0	1	0	1
Chain A, UROKINASE-TYPE PLASMINOGEN ACTIVATOR	0	1	0	1
Chain A, UROKINASE-TYPE PLASMINOGEN ACTIVATOR	0	1	0	1
Sodium/hydrogen exchanger 1	0	4	0	5
Amiloride-sensitive sodium channel subunit alpha	0	1	0	1
Sodium/hydrogen exchanger 2	0	5	0	5
Acid-sensing ion channel 1	0	5	0	5
Acid-sensing ion channel 3	0	1	0	1
Sodium/hydrogen exchanger	0	2	0	2
serine/threonine-protein kinase D1 isoform 2	0	1	0	1
Muscarinic receptor M1	0	1	0	1
Chain A, PLASMINOGEN	0	0	2	2
Chain A, PLASMINOGEN	0	0	2	2
Chain A, Apolipoprotein	0	0	1	1
Sterol O-acyltransferase 1	0	9	0	9
Cholesterol side-chain cleavage enzyme, mitochondrial	0	1	1	2
Triosephosphate isomerase	0	4	0	4
Cholesterol side-chain cleavage enzyme, mitochondrial	0	1	0	1
Aromatase	0	2	2	4
Cytochrome P450 11B2, mitochondrial	0	2	0	2
Cystathionine gamma-lyase	0	9	1	11
Cystathionine beta-synthase	0	4	0	4
Lysyl oxidase homolog 2	0	1	0	1
Protein-lysine 6-oxidase	0	1	0	1
Lysyl oxidase homolog 2	0	1	0	1
Lysyl oxidase homolog 3	0	4	0	4
Lysyl oxidase homolog 4	0	4	0	4
Lysyl oxidase homolog 2	0	6	0	6
Folylpolyglutamate synthase, mitochondrial	0	2	0	6
Solute carrier organic anion transporter family member 1A3	0	5	0	12
ORF73	0	0	13	14
Eyes absent homolog 2	0	4	0	4
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2	0	2	0	2
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1	0	2	0	2
microphthalmia-associated transcription factor isoform 9	0	10	0	10
Voltage-dependent L-type calcium channel subunit alpha-1C	0	18	0	18
Solute carrier organic anion transporter family member 1A4	0	10	0	22
Voltage-dependent L-type calcium channel subunit alpha-1F	0	54	0	54
Lysine-specific demethylase PHF2	0	1	0	1
Thyroid hormone receptor alpha	0	2	0	2
ATP-dependent translocase ABCB1	0	38	0	38
ATP-dependent translocase ABCB1	0	38	6	45
D(4) dopamine receptor	0	74	7	88
Histamine H2 receptor	0	77	3	81
Endothelin-1 receptor	0	22	1	24
B2 bradykinin receptor	0	6	1	9
Melanocortin receptor 4	0	14	1	15
Melanocortin receptor 5	0	20	1	21
Sodium channel protein type 1 subunit alpha	0	17	0	17
Sodium channel protein type 4 subunit alpha	0	19	0	22
Squalene synthase	0	2	0	3
C-C chemokine receptor type 2	0	11	0	11
Melanocortin receptor 3	0	12	1	13
C-C chemokine receptor type 4	0	7	0	7
Sodium channel protein type 7 subunit alpha	0	12	0	12
Voltage-dependent L-type calcium channel subunit alpha-1D	0	54	0	54
Voltage-dependent L-type calcium channel subunit alpha-1S	0	54	0	54
Squalene monooxygenase	0	3	0	3
Sodium channel protein type 9 subunit alpha	0	23	0	23
Sodium channel protein type 2 subunit alpha	0	19	0	19
NAD-dependent protein deacetylase sirtuin-3, mitochondrial	0	7	5	12
Sodium channel protein type 3 subunit alpha	0	19	0	19
Sodium channel protein type 11 subunit alpha	0	11	0	11
Sodium channel protein type 8 subunit alpha	0	14	0	14
Sodium channel protein type 10 subunit alpha	0	13	0	13
Albumin	0	0	17	17
Alpha-2C adrenergic receptor	0	146	13	166
D(1B) dopamine receptor	0	23	0	27
UDP-glucuronosyltransferase 1A3	0	0	0	13
Voltage-dependent N-type calcium channel subunit alpha-1B	0	17	4	21
Nuclear receptor subfamily 3 group C member 3	0	65	0	65
NEDD8-activating enzyme E1 regulatory subunit isoform a	0	2	0	2
NEDD8-conjugating enzyme Ubc12	0	2	0	2
Voltage-dependent L-type calcium channel subunit alpha-1C	0	18	0	19
Potassium channel subfamily K member 2	0	4	0	4
Beta-lactamase	0	2	0	7
Beta-lactamase	0	2	0	11
Beta-lactamase	0	0	0	10
Beta-lactamase	0	3	0	14
Beta-lactamase	0	0	0	5
Beta-lactamase SHV-1	0	2	0	8
Beta-lactamase SHV-1	0	5	0	15
Beta-lactamase	0	3	0	13
B2 metallo-beta-lactamase	0	0	0	10
Beta-lactamase	0	2	0	9
Beta-lactamase	0	1	0	8
Beta-lactamase	0	2	0	8
Beta-lactamase	0	0	0	8
Synaptojanin-2	0	5	0	5
Synaptojanin-1	0	5	0	5
Chain A, Mutant Al2 6e7p9g	0	0	1	1
Beta-lactamase	0	4	0	10
Beta-lactamase	0	3	0	11
Beta-lactamase	0	1	0	10
Metallo-beta-lactamase type 2	0	1	2	12
Metallo-beta-lactamase VIM-11	0	0	0	9
Metallo-beta-lactamase VIM-2	0	0	0	9
Beta-lactamase	0	1	0	12
Metallo-beta-lactamase	0	0	0	9
Beta-lactamase	0	3	0	11
Beta-lactamase OXA-7	0	0	0	8
Beta-lactamase	0	2	0	7
Beta-lactamase	0	2	0	7
Beta-lactamase	0	2	0	7
Efflux transporter	0	1	0	5
Beta-lactamase	0	1	0	8
Beta-lactamase Toho-1	0	0	0	5
Beta-lactamase	0	1	0	5
Class D beta-lactamase	0	3	0	8
Metallo-beta-lactamase	0	0	0	7
Beta-lactamase	0	3	0	10
Beta-lactamase	0	2	3	10
Metallo-b-lactamase	0	0	0	18
Carbapenem-hydrolyzing beta-lactamase KPC	0	5	0	14
Beta-lactamase class B VIM-2	0	2	2	22
Inner centromere protein	0	8	1	9
Aldehyde oxidase 1	0	4	0	4
Aldehyde oxidase	0	15	0	17
Aldehyde oxidase 1	0	7	0	7
Taste receptor type 2 member 16	0	0	4	8
Probable linoleate 9S-lipoxygenase 5	0	1	0	1
Histone acetyltransferase KAT5	0	3	0	3
SUMO-activating enzyme subunit 1	0	4	0	4
Fatty-acid amide hydrolase 1	0	3	0	4
Fatty acid-binding protein, liver	0	7	0	7
Corticotropin-releasing factor receptor 2	0	4	0	4
Lanosterol 14-alpha demethylase	0	24	2	27
Cannabinoid receptor 2	0	7	3	10
Transient receptor potential cation channel subfamily V member 2	0	12	7	19
Hexokinase-2	0	2	0	2
Beta-glucuronidase	0	4	0	4
Gastrin/cholecystokinin type B receptor	1	9	2	13
Chain A, retinol dehydratase	0	1	0	1
Triosephosphate isomerase, glycosomal	0	1	0	1
Atrial natriuretic peptide receptor 3	0	2	0	2
Type-1 angiotensin II receptor	0	1	1	2
Type-1 angiotensin II receptor	0	18	6	31
Cytochrome P450 130	0	0	3	3
Cytochrome P450 130	0	0	3	3
Glucose transporter	0	6	0	6
Hexose transporter 1	0	6	0	6
Solute carrier family 2, facilitated glucose transporter member 1	0	13	1	14
5-lipoxygenase	0	10	0	10
Ornithine decarboxylase	0	0	0	3
30S ribosomal protein S6	0	12	3	16
30S ribosomal protein S7	0	12	3	16
50S ribosomal protein L15	0	12	3	16
50S ribosomal protein L10	0	12	3	16
50S ribosomal protein L11	0	12	3	16
50S ribosomal protein L7/L12	0	12	3	16
50S ribosomal protein L19	0	12	3	16
50S ribosomal protein L1	0	12	3	16
50S ribosomal protein L20	0	12	3	16
50S ribosomal protein L27	0	12	3	16
50S ribosomal protein L28	0	12	3	16
50S ribosomal protein L29	0	12	3	16
50S ribosomal protein L31	0	12	3	16
50S ribosomal protein L31 type B	0	12	3	16
50S ribosomal protein L32	0	12	3	16
50S ribosomal protein L33	0	12	3	16
50S ribosomal protein L34	0	12	3	16
50S ribosomal protein L35	0	12	3	16
50S ribosomal protein L36	0	12	3	16
30S ribosomal protein S10	0	12	3	16
30S ribosomal protein S11	0	12	3	16
30S ribosomal protein S12	0	12	3	16
30S ribosomal protein S13	0	12	3	16
30S ribosomal protein S16	0	12	3	16
30S ribosomal protein S18	0	12	3	16
30S ribosomal protein S19	0	12	3	16
30S ribosomal protein S20	0	12	3	16
30S ribosomal protein S2	0	12	3	16
30S ribosomal protein S3	0	12	3	16
30S ribosomal protein S4	0	12	3	16
30S ribosomal protein S5	0	12	3	16
30S ribosomal protein S8	0	12	3	16
30S ribosomal protein S9	0	12	3	16
50S ribosomal protein L13	0	12	3	16
50S ribosomal protein L14	0	12	3	16
50S ribosomal protein L16	0	12	3	16
50S ribosomal protein L23	0	12	3	16
30S ribosomal protein S15	0	12	3	16
50S ribosomal protein L17	0	12	3	16
50S ribosomal protein L21	0	12	3	16
50S ribosomal protein L30	0	12	3	16
50S ribosomal protein L6	0	12	3	16
30S ribosomal protein S14	0	12	3	16
30S ribosomal protein S17	0	12	3	16
30S ribosomal protein S1	0	12	3	16
50S ribosomal protein L18	0	12	3	16
50S ribosomal protein L2	0	12	3	16
50S ribosomal protein L3	0	12	3	16
50S ribosomal protein L24	0	12	3	16
50S ribosomal protein L4	0	12	3	16
50S ribosomal protein L22	0	12	3	16
50S ribosomal protein L5	0	12	3	16
30S ribosomal protein S21	0	12	3	16
50S ribosomal protein L25	0	12	3	16
50S ribosomal protein L36 2	0	12	3	16
Mitochondrial succinate dehydrogenase subunit C	0	1	0	1
Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial	0	1	0	1
Dihydroorotate dehydrogenase (fumarate)	0	5	0	5
Dihydroorotate dehydrogenase	0	8	0	8
Chain A, Proto-oncogene tyrosine-protein kinase Src	0	1	0	1
Chain A, Proto-oncogene tyrosine-protein kinase Src	0	1	0	1
Cell division cycle protein 20 homolog	0	0	1	1
DNA polymerase catalytic subunit	0	1	0	1
DNA polymerase catalytic subunit	0	2	0	2
DNA polymerase catalytic subunit	0	2	0	2
DNA polymerase catalytic subunit	0	2	0	2
DNA polymerase alpha catalytic subunit	0	3	1	4
DNA polymerase delta catalytic subunit	0	2	0	2
DNA polymerase catalytic subunit	0	2	0	2
DNA polymerase subunit gamma-1	0	1	1	2
Chain A, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase	0	2	0	2
Chain B, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase	0	2	0	2
Chain A, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase	0	2	0	2
Chain B, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase	0	2	0	2
Chain A, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase	0	2	0	2
Chain B, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase	0	2	0	2
Chain A, Transthyretin	0	0	5	5
Chain A, Transthyretin	0	0	5	5
Chain A, Transthyretin	0	0	5	5
Chain A, Transthyretin	0	0	5	5
Chain B, Transthyretin	0	0	5	5
Chain A, Transthyretin	0	0	5	5
Chain B, Transthyretin	0	0	5	5
Chain A, Casein kinase II subunit alpha	0	2	0	2
Chain A, Casein kinase II subunit alpha	0	2	0	2
Chain A, Casein Kinase Ii Subunit Alpha	0	2	0	2
Lysozyme C-1	0	2	0	2
Beta-glucuronidase	0	4	0	4
Mucin-1	0	1	0	1
Peroxisome proliferator-activated receptor gamma	0	1	27	28
Homeobox protein Nkx-2.5	0	2	0	2
Lactoperoxidase	0	4	0	11
Transcription factor GATA-4	0	2	0	2
Substance-K receptor	0	19	0	19
NACHT, LRR and PYD domains-containing protein 3	0	5	0	5
Myocilin	0	0	2	2
Prenyltransferase homolog	0	0	0	5
Carboxylic ester hydrolase	0	9	0	11
NADPH oxidase 4	0	5	0	5
Short transient receptor potential channel 5	0	6	1	7
Programmed cell death protein 1	0	4	0	4
Programmed cell death 1 ligand 1	0	4	0	4
Chain A, Coagulation factor X (EC 3.4.21.6) (Stuart factor) (Stuart-Prower factor)	0	1	0	1
Coagulation factor X	0	1	0	1
C-C chemokine receptor type 5	0	3	0	3
Tryptophan 5-hydroxylase 1	0	7	0	7
Substance-P receptor	0	2	0	2
Monocarboxylate transporter 1	0	1	1	2
Chain A, ADIPOCYTE LIPID-BINDING PROTEIN	0	0	1	1
Chain A, SERUM ALBUMIN	0	0	2	2
Chain A, SERUM ALBUMIN	0	0	2	2
Calmodulin	0	3	7	11
Cytosolic phospholipase A2 gamma	0	3	0	3
Cytosolic phospholipase A2	0	1	0	1
Cytosolic phospholipase A2 beta	0	1	0	1
Muscarinic acetylcholine receptor M1	0	4	4	10
Muscarinic acetylcholine receptor M3	0	1	3	8
Muscarinic acetylcholine receptor M2	0	1	1	8
Chain E, LYSINE, ARGININE, ORNITHINE-BINDING PROTEIN	0	0	3	3
Chain E, LYSINE, ARGININE, ORNITHINE-BINDING PROTEIN	0	0	3	3
Chain E, LYSINE, ARGININE, ORNITHINE-BINDING PROTEIN	0	0	3	3
Cationic amino acid transporter 3	0	2	0	2
Vasopressin V2 receptor	0	15	3	19
Oxytocin receptor	0	5	4	9
Vasopressin V1a receptor	0	3	3	7
Vasopressin V1a receptor	0	20	4	24
Vasopressin V1b receptor	0	4	3	7
Vasopressin V2 receptor	0	0	1	1
Vasopressin V1b receptor	0	4	1	7
Translocator protein	0	4	0	6
Oxytocin receptor	0	3	1	4
Vasopressin V2 receptor	0	6	2	9
Integrin alpha-5	0	7	0	7
Integrin beta-5	0	3	0	3
Integrin alpha-2	0	1	0	1
Integrin alpha-3	0	1	0	1
Integrin beta	0	1	1	2
Glycoprotein IIb	0	1	1	2
3-hydroxy-3-methylglutaryl-coenzyme A reductase	0	15	0	15
Multidrug and toxin extrusion protein 2	0	30	0	30
NS5	0	2	5	7
Adenosylhomocysteinase	0	1	0	1
E3 ubiquitin-protein ligase Mdm2 isoform a	0	1	3	4
GTPase KRas	0	9	2	12
Quinone oxidoreductase	0	1	0	1
Synaptic vesicle membrane protein VAT-1 homolog	0	1	0	1
Reticulon-4	0	1	0	1
14-3-3 protein eta	0	0	1	1
Cysteine protease falcipain-2	0	1	0	1
Forkhead box protein O1	0	1	0	1
Chain A, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	0	1	0	1
Chain A, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	0	1	0	1
Alternative oxidase, mitochondrial	0	2	0	2
Chain A, Hyaluronidase, phage associated	0	1	0	1
Hyaluronate lyase	0	1	0	1
Solute carrier family 23 member 1	0	1	0	1
Pancreatic alpha-amylase	0	11	0	15
Tyrosine-protein phosphatase non-receptor type 2	0	16	0	16
Neutral amino acid transporter A	0	7	0	7
Neutral amino acid transporter B(0)	0	7	0	7
Amino acid transporter	0	7	0	7
Excitatory amino acid transporter 4	0	2	0	2
Glutamate transporter homolog	0	0	2	2
Chain A, Phospholipase A2 isoform 3	0	0	1	1
Prostaglandin-H2 D-isomerase	0	3	0	3
Fatty acid-binding protein, liver	0	18	2	20
Glutathione hydrolase 1 proenzyme	0	1	0	1
Urotensin-2 receptor	0	2	0	2
4-aminobutyrate aminotransferase, mitochondrial	0	3	0	3
Rho-associated protein kinase 2	0	5	0	5
Polycomb protein EED	0	8	2	10
HLA class I histocompatibility antigen, A alpha chain	0	1	7	8
Somatostatin receptor type 2	0	8	1	9
Somatostatin receptor type 4	0	8	0	8
Somatostatin receptor type 3	0	8	1	9
Somatostatin receptor type 5	0	8	1	9
Heparanase	0	2	7	9
Baculoviral IAP repeat-containing protein 3	0	7	3	10
Baculoviral IAP repeat-containing protein 2	0	9	4	13
Cyclin-Y	0	2	0	2
Ras-related C3 botulinum toxin substrate 1	0	4	10	14
Ribosomal protein S6 kinase beta-2	0	3	0	3
Beta-1 adrenergic receptor	0	6	12	21
Patatin-like phospholipase domain-containing protein 2	0	1	0	1
Patatin-like phospholipase domain-containing protein 2	0	1	0	1
Nociceptin receptor	0	8	3	12
Krueppel-like factor 10	0	1	0	1
Transporter	0	10	0	10
Insulin receptor	0	10	0	10
Dipeptidyl peptidase 4	0	4	0	4
Dihydroorotate dehydrogenase	0	6	0	6
Cytochrome b	0	1	0	1
Dihydroorotate dehydrogenase (quinone), mitochondrial	0	4	0	5
Sterol O-acyltransferase 2	0	7	0	7
Endothelin receptor type B	0	17	1	18
Endothelin receptor type B	0	1	0	1
Atrial natriuretic peptide receptor 1	0	2	1	3
Atrial natriuretic peptide receptor 1	0	0	1	1
cystic fibrosis transmembrane conductance regulator	0	8	0	9
Muscarinic acetylcholine receptor M4	0	4	1	6
NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial	0	1	0	1
Cytochrome c oxidase subunit NDUFA4	0	1	0	1
Acyl carrier protein, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1	0	1	0	1
NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2	0	1	0	1
NADH dehydrogenase [ubiquinone] iron-sulfur protein 5	0	1	0	1
NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1	0	1	0	1
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 subunit C2	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10	0	1	0	1
NADH-ubiquinone oxidoreductase chain 1	0	1	0	1
NADH-ubiquinone oxidoreductase chain 2	0	1	0	1
NADH-ubiquinone oxidoreductase chain 3	0	1	0	1
NADH-ubiquinone oxidoreductase chain 4L	0	1	0	1
NADH-ubiquinone oxidoreductase chain 4	0	1	0	2
NADH-ubiquinone oxidoreductase chain 5	0	1	0	1
NADH-ubiquinone oxidoreductase chain 6	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7	0	1	0	1
NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial	0	1	0	1
NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8	0	1	0	1
NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial	0	1	0	1
Amine oxidase [flavin-containing] A	0	3	0	4
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 2	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 3	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 4	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12	0	1	0	1
Complex I intermediate-associated protein 30, mitochondrial	0	1	0	1
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9	0	1	0	1
Microphthalmia-associated transcription factor	0	0	0	9
Complement component C9	0	1	0	1
DNA-3-methyladenine glycosylase	0	4	0	4
Cystathionine gamma-lyase	0	1	0	1
DNA polymerase iota	0	3	0	3
Cysteine protease ATG4B	0	6	0	6
Thromboxane A2 receptor	0	2	2	8
Leukotriene B4 receptor 2	1	4	5	11
Sterol O-acyltransferase 1	0	1	2	3
Acyl-CoA:cholesterol acyltransferase	0	6	0	6
Chain A, VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2	0	3	0	3
Chain A, VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2	0	3	0	3
Chain A, VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2	0	3	0	3
Chain A, VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2	0	3	0	3
Chain A, VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2	0	3	0	3
Histone-lysine N-methyltransferase SMYD3	0	2	0	2
N-lysine methyltransferase SMYD2	0	4	1	5
Pirin	0	5	0	5
Heat shock factor protein 1	0	7	1	8
DNA (cytosine-5)-methyltransferase 1	0	16	1	17
Calcitonin gene-related peptide type 1 receptor	0	2	0	2
Protein-arginine deiminase type-4	0	18	0	19
Orotidine 5'-phosphate decarboxylase	0	1	0	1
Signal transducer and activator of transcription 5A	0	3	0	3
Chain A, Diaminopimelate decarboxylase	0	1	0	1
Chain B, Diaminopimelate decarboxylase	0	1	0	1
Nuclear receptor corepressor 1	0	7	0	7
Chain A, Tyrosine-protein kinase BTK	0	1	0	1
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	0	5	0	5
Protein farnesyltransferase subunit beta	0	5	0	5
Squalene synthase	0	1	0	1
V-type proton ATPase subunit S1	0	1	0	1
Vacuolar proton pump subunit B	0	1	0	1
Cytochrome P450 11B1, mitochondrial	0	8	0	8
Prostaglandin G/H synthase 2	0	19	0	22
Linoleate 9S-lipoxygenase-4	0	3	0	3
Receptor-type tyrosine-protein phosphatase S	0	4	0	4
Prostaglandin G/H synthase 1	0	21	0	24
Polyunsaturated fatty acid lipoxygenase ALOX15B	0	1	0	1
Cathepsin S	0	1	0	1
Cathepsin D	0	6	0	7
Cathepsin S	0	4	1	5
Cathepsin K	0	8	0	8
Cathepsin K	0	3	0	3
Nucleoside diphosphate kinase, mitochondrial	0	0	1	1
Glutaryl-CoA dehydrogenase, mitochondrial	0	0	1	1
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase	0	2	0	2
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase	0	2	0	2
Nuclear factor erythroid 2-related factor 2	0	0	0	3
Kelch-like ECH-associated protein 1	0	0	0	2
Nuclear factor erythroid 2-related factor 2	0	0	0	1
Low affinity immunoglobulin epsilon Fc receptor	0	2	0	2
Matrix metalloproteinase-14	0	10	0	10
Snake venom metalloproteinase BaP1	0	3	0	3
Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase	0	0	3	3
NACHT, LRR and PYD domains-containing protein 3	0	9	0	9
Prolyl 3-hydroxylase OGFOD1	0	2	0	2
Chain A, Dual specificity mitogen-activated protein kinase kinase 1	0	1	0	1
shiga toxin 1 variant A subunit	5	0	0	5
shiga toxin 1 B subunit	5	0	0	5
Voltage-dependent L-type calcium channel subunit alpha-1D	0	12	0	13
Voltage-dependent L-type calcium channel subunit alpha-1S	0	11	0	12
Vitamin D-binding protein	0	2	0	2
3-oxoacyl-[acyl-carrier-protein] synthase 3	0	5	0	5
Acyl-protein thioesterase 1	0	2	0	2
Proteasome subunit beta type-11	0	10	0	11
26S proteasome non-ATPase regulatory subunit 11	0	3	0	3
26S proteasome non-ATPase regulatory subunit 12	0	3	0	3
Proteasome subunit alpha type-7	0	10	0	11
26S proteasome non-ATPase regulatory subunit 3	0	3	0	3
26S proteasome regulatory subunit 6A	0	3	0	3
Proteasome subunit beta type-1	0	16	0	18
Proteasome subunit alpha type-1	0	10	0	11
Proteasome subunit alpha type-2	0	10	0	11
Proteasome subunit alpha type-3	0	10	0	11
Proteasome subunit alpha type-4	0	10	0	11
Proteasome subunit beta type-8	0	12	0	13
Proteasome subunit beta type-9	0	11	0	12
Proteasome subunit alpha type-5	0	10	0	11
Proteasome subunit beta type-4	0	10	0	11
Proteasome subunit beta type-6	0	10	0	11
26S proteasome regulatory subunit 7	0	3	0	3
Proteasome subunit beta type-10	0	11	0	12
26S proteasome non-ATPase regulatory subunit 8	0	3	0	3
Proteasome subunit beta type-3	0	10	0	11
Proteasome subunit beta type-2	0	16	0	18
26S proteasome non-ATPase regulatory subunit 7	0	3	0	3
26S proteasome non-ATPase regulatory subunit 4	0	3	0	3
26S proteasome complex subunit SEM1	0	3	0	3
Proteasome subunit alpha type-6	0	10	4	15
26S proteasome regulatory subunit 4	0	3	0	3
26S proteasome regulatory subunit 8	0	3	0	3
26S proteasome regulatory subunit 10B	0	3	0	3
26S proteasome non-ATPase regulatory subunit 2	0	3	0	3
26S proteasome non-ATPase regulatory subunit 6	0	3	0	3
Proteasomal ubiquitin receptor ADRM1	0	3	0	3
Proteasome subunit alpha-type 8	0	10	0	11
Proteasome subunit beta type-7	0	10	0	11
26S proteasome non-ATPase regulatory subunit 1	0	3	0	3
26S proteasome non-ATPase regulatory subunit 13	0	3	0	3
Cytochrome P450 3A5	0	21	3	26
Histone deacetylase	0	6	0	6
Zinc finger protein mex-5	0	0	1	1
Ubiquitin-like modifier activating enzyme 2	0	6	0	6
SUMO1 activating enzyme subunit 1	0	6	0	6
SUMO-conjugating enzyme UBC9	0	6	0	6
Chain B, SARS CORONAVIRUS MAIN PROTEINASE	0	1	0	1
Poly(ADP-ribose) glycohydrolase	0	1	0	1
Kallikrein-5	0	1	0	1
DNA (cytosine-5)-methyltransferase 1 isoform b	0	2	0	2
Acetylcholinesterase	0	15	0	15
Chain A, Integrase	0	1	0	1
Chain A, Integrase	0	1	0	1
Chain A, T4 LYSOZYME	0	0	1	1
Chain A, GCN4P1	0	0	1	1
Chain B, GCN4P1	0	0	1	1
Chain C, GCN4P1	0	0	1	1
Chain A, T4 LYSOZYME	0	0	1	1
Chain A, T4 LYSOZYME	0	0	1	1
Chain A, Replicase polyprotein 1ab	0	2	0	2
Chain A, 3C-like proteinase	0	2	0	2
Acyl-protein thioesterase 1	0	1	0	1
Acyl-protein thioesterase 2	0	1	0	1
enteropeptidase precursor	4	0	0	4
KiSS-1 receptor	0	1	0	1
Chain A, GTPase KRas, isoform 2B	0	0	1	1
Chain A, GTPase KRas, isoform 2B	0	0	1	1
Chain A, Oxygen-insensitive Nad(p)h Nitroreductase	0	1	0	1
Chain B, Oxygen-insensitive Nad(p)h Nitroreductase	0	1	0	1
Chain A, ODORANT-BINDING PROTEIN	0	3	0	3
Chain A, ODORANT-BINDING PROTEIN	0	3	0	3
Chain B, Odorant-binding Protein	0	3	0	3
Chain A, ODORANT-BINDING PROTEIN	0	3	0	3
Chain A, ODORANT-BINDING PROTEIN	0	3	0	3
Chain A, ODORANT-BINDING PROTEIN	0	3	0	3
Chain A, Kemp eliminase KE59 R1 7/10H	0	1	0	1
Chain A, Kemp eliminase KE59 R13 3/11H	0	1	0	1
Chain A, Kemp eliminase KE59 R13 3/11H	0	1	0	1
Polymerase acidic protein	0	6	3	9
Hormone-sensitive lipase	0	3	0	3
Malate dehydrogenase, cytoplasmic	0	9	0	9
Chain A, PROTEIN (TRYPSIN)	0	1	0	1
Chain A, PROTEIN (TRYPSIN)	0	1	0	1
Membrane primary amine oxidase	0	0	0	2
Amiloride-sensitive amine oxidase [copper-containing]	0	2	0	3
Amine oxidase [flavin-containing] B	0	12	0	15
Cytokinin dehydrogenase 1	0	0	0	1
5-hydroxytryptamine receptor 3B	0	6	0	6
Calpain-9	0	5	0	5
Calpain-2 catalytic subunit	0	4	0	4
NF-kappa-B inhibitor alpha	0	2	1	3
Envelope glycoprotein	0	0	7	7
Neuraminidase	0	11	0	11
Aldo-keto reductase family 1 member C2	0	16	0	16
D(2) dopamine receptor isoform long	3	0	0	3
Cell division protein FtsZ	0	2	2	8
NAD(+) hydrolase SARM1	0	8	0	8
Carboxylic ester hydrolase	0	17	0	17
Cytochrome P450 2B4	0	1	0	1
Interleukin-6	0	1	0	1
Sodium- and chloride-dependent GABA transporter 3	0	5	0	5
Sodium- and chloride-dependent GABA transporter 2	0	3	0	3
NADPH--cytochrome P450 reductase	0	1	0	1
Mucosa-associated lymphoid tissue lymphoma translocation protein 1	0	2	0	2
protein Mdm4 isoform 1	0	1	0	1
Breast cancer type 1 susceptibility protein	0	1	0	1
BRCA1-associated RING domain protein 1	0	1	0	1
Neuraminidase	0	2	0	2
Chain A, D-MALTODEXTRIN BINDING PROTEIN	0	0	1	1
Chain A, Limit Dextrinase	0	0	1	1
Chain A, Alpha-hemolysin	0	0	1	1
Chain B, Alpha-hemolysin	0	0	1	1
Chain C, Alpha-hemolysin	0	0	1	1
Chain D, Alpha-hemolysin	0	0	1	1
Chain E, Alpha-hemolysin	0	0	1	1
Chain F, Alpha-hemolysin	0	0	1	1
Chain G, Alpha-hemolysin	0	0	1	1
Chain A, Betaine ABC transporter permease and substrate binding protein	0	0	1	1
Chain A, Osmoprotection protein (ProX)	0	0	1	1
Chain A, Glycine betaine/carnitine/choline-binding protein	0	0	2	2
Chain A, Glycine betaine/carnitine/choline-binding protein	0	0	2	2
Chain A, Glycine betaine/carnitine/choline-binding protein	0	0	2	2
Chain A, Glycine betaine/carnitine/choline-binding protein	0	0	2	2
galanin receptor type 3	0	4	0	4
Solute carrier family 22 member 11	0	15	0	23
Env polyprotein	0	0	3	3
Phosphodiesterase isozyme 4	0	1	0	1
Non-structural protein 1	0	5	0	5
Cytochrome P450 26A1	0	3	1	4
Cytochrome P450 26B1	0	2	0	2
Peroxisome proliferator-activated receptor alpha	0	3	14	17
Peroxisome proliferator-activated receptor delta	0	0	9	9
Transcription initiation factor TFIID subunit 1	0	1	1	2
Nucleosome-remodeling factor subunit BPTF	0	0	1	1
Bromodomain testis-specific protein	0	8	6	14
Mitogen-activated protein kinase 1	0	6	0	6
Dipeptidyl peptidase 1	0	6	0	6
Integrin beta-2	0	2	1	3
Intercellular adhesion molecule 1	0	2	1	3
Integrin alpha-L	0	5	2	7
Integrin beta-7	0	1	0	1
STAT3, partial	0	3	2	5
signal transducer and activator of transcription 1-alpha/beta isoform alpha	0	3	2	5
Carbonyl reductase [NADPH] 1	0	12	0	14
Chain A, Avidin	0	0	1	1
Chain A, Protein (streptavidin)	0	0	1	1
Chain B, Protein (streptavidin)	0	0	1	1
Chain A, Streptavidin	0	0	1	1
Chain D, Streptavidin	0	0	1	1
Chain A, Streptavidin	0	0	1	1
Chain D, Streptavidin	0	0	1	1
Chain A, Streptavidin	0	0	1	1
Chain D, Streptavidin	0	0	1	1
Chain A, Streptavidin Complex With Biotin	0	0	1	1
Chain D, Circularly Permuted Core-streptavidin E51/a46	0	0	1	1
Chain A, Core-streptavidin	0	0	1	1
Chain D, Core-streptavidin	0	0	1	1
Chain A, Core-streptavidin	0	0	1	1
Chain D, Core-streptavidin	0	0	1	1
Chain A, Core-streptavidin	0	0	1	1
Chain D, Core-streptavidin	0	0	1	1
Chain A, Core-streptavidin	0	0	1	1
Chain D, Core-streptavidin	0	0	1	1
Chain A, Avidin	0	0	1	1
Chain A, Streptavidin	0	0	1	1
Chain B, Streptavidin	0	0	1	1
Chain A, Streptavidin	0	0	1	1
Chain B, Streptavidin	0	0	1	1
Chain A, p38 MAP kinase	0	0	1	1
Chain A, p38 MAP kinase	0	0	1	1
Serine/threonine-protein kinase Sgk1	0	7	0	7
Tyrosine-protein kinase ABL1	0	8	0	8
Heat shock protein beta-1	0	1	0	1
G protein-coupled receptor kinase 5	0	4	0	4
Mitogen-activated protein kinase 14	0	1	2	3
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1	0	3	0	3
Testis-specific serine/threonine-protein kinase 2	0	2	0	2
Serine/threonine-protein kinase WNK2	0	2	0	2
Peptidyl-prolyl cis-trans isomerase FKBP1A	0	9	4	13
Peptidyl-prolyl cis-trans isomerase FKBP4	0	5	0	5
Baculoviral IAP repeat-containing protein 7	0	2	2	4
Stimulator of interferon genes protein	0	3	9	12
RocR	0	1	0	1
G-protein coupled receptor 35 isoform a	0	1	0	1
G-protein coupled receptor 55	0	6	1	7
Multidrug resistance protein CDR1	0	1	0	1
Sarcoplasmic/endoplasmic reticulum calcium ATPase 3	0	1	0	1
Chain A, Protein kinase C, iota	0	1	0	1
Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform	0	1	0	1
cAMP-dependent protein kinase catalytic subunit alpha	0	3	0	3
Serine/threonine-protein kinase LMTK3	0	4	0	4
Beta-1 adrenergic receptor	0	5	1	6
Chain A, Estrogen-related receptor gamma	0	0	1	1
Chain A, Estrogen-related receptor gamma	0	0	2	2
Chain A, Estrogen-related receptor gamma	0	0	2	2
Chain A, Estrogen-related receptor gamma	0	0	2	2
Myosin-2 heavy chain, non muscle	0	1	0	1
Myosin-2 heavy chain	0	1	0	1
Myosin IC heavy chain	0	1	0	1
Myosin-9	0	1	0	1
Unconventional myosin-X	0	1	0	1
Myosin-7	0	1	0	1
Unconventional myosin-Ib	0	1	0	1
Myosin-4	0	1	0	1
Myosin-14	0	1	0	1
Nonmuscle myosin heavy chain	0	1	0	1
Unconventional myosin-Va	0	1	0	1
Myosin heavy chain, non-muscle	0	1	0	1
Unconventional myosin-XV	0	1	0	1
Protein mono-ADP-ribosyltransferase PARP14	0	4	3	7
Protein mono-ADP-ribosyltransferase PARP10	0	5	5	10
Protein mono-ADP-ribosyltransferase PARP8	0	0	3	3
Protein mono-ADP-ribosyltransferase PARP16	0	2	5	7
Protein mono-ADP-ribosyltransferase PARP12	0	4	3	7
Protein mono-ADP-ribosyltransferase PARP4	0	5	5	10
GTPase HRas	0	4	0	5
Geranylgeranyl transferase type-1 subunit beta	0	10	1	13
Cysteinyl leukotriene receptor 1	0	8	0	8
Insulin-like growth factor 1 receptor	0	2	0	2
RAC-alpha serine/threonine-protein kinase	0	1	0	1
Chain A, hepatocyte growth factor receptor	0	1	0	1
High affinity immunoglobulin gamma Fc receptor I	0	2	0	2
Nonstructural protein 5A	0	2	3	5
Glycine receptor subunit alpha-2	0	2	0	2
Neuronal acetylcholine receptor subunit beta-2	0	16	4	22
Neuronal acetylcholine receptor subunit alpha-4	0	15	4	20
Sclerostin	0	1	0	1
Phospholipase A2, major isoenzyme	0	3	0	3
Phospholipase A2	0	3	0	3
Chain H, Proteasome component PUP1	0	1	0	1
Chain I, Proteasome component PUP3	0	1	0	1
Chain K, Proteasome component PRE2	0	1	0	1
Chain L, Proteasome component C5	0	1	0	1
Chain K, Proteasome component PRE2	0	1	0	1
Chain L, Proteasome component C5	0	1	0	1
Chymotrypsinogen B	0	7	0	7
Proteasome subunit beta type-8	0	1	0	1
Lon protease homolog, mitochondrial	0	1	0	1
ATP-dependent Clp protease proteolytic subunit	0	2	2	4
Endothelin receptor type B	0	0	1	1
Deoxyhypusine synthase	0	1	0	1
Endothelin-1 receptor	0	4	0	4
Nucleophosmin	0	5	0	5
Glycogen phosphorylase, muscle form	0	4	0	4
Tyrosine-protein kinase Blk	0	2	0	2
Platelet-derived growth factor receptor alpha	0	3	0	3
Platelet-derived growth factor receptor beta	0	4	0	4
D(3) dopamine receptor	0	2	1	3
Signal transducer and activator of transcription 3	0	4	0	5
Multidrug resistance-associated protein 6	0	0	0	1
Solute carrier organic anion transporter family member 1A5	0	0	0	11
Solute carrier organic anion transporter family member 1B2	0	1	0	7
Protection of telomeres protein 1	0	1	0	1
B2 bradykinin receptor	0	1	0	1
B1 bradykinin receptor	0	4	0	4
major prion protein preproprotein Prp precursor	0	2	0	2
Gamma-aminobutyric acid	0	2	4	6
Gamma-aminobutyric acid receptor subunit alpha-6	0	2	4	6
Gamma-aminobutyric acid receptor subunit gamma-2	0	2	4	6
Gamma-aminobutyric acid receptor subunit delta	0	2	4	6
Gamma-aminobutyric acid receptor subunit alpha-2	0	2	4	6
Gamma-aminobutyric acid receptor subunit alpha-3	0	2	4	6
Gamma-aminobutyric acid receptor subunit gamma-3	0	2	4	6
Gamma-aminobutyric acid receptor subunit beta-1	0	2	4	6
Gamma-aminobutyric acid receptor subunit alpha-1	0	5	4	9
Gamma-aminobutyric acid receptor subunit beta-3	0	2	4	6
Gamma-aminobutyric acid receptor subunit alpha-5	0	2	4	6
Gamma-aminobutyric acid receptor subunit pi	0	2	4	6
Gamma-aminobutyric acid receptor subunit alpha-4	0	2	4	6
Gamma-aminobutyric acid receptor subunit theta	0	2	4	6
Gamma-aminobutyric acid receptor subunit gamma-1	0	2	4	6
Alpha-1B adrenergic receptor	0	0	4	4
G protein-activated inward rectifier potassium channel 1	0	0	3	3
Chain A, CARBONIC ANHYDRASE IV	0	1	0	1
Vascular endothelial growth factor receptor 2	0	7	0	7
Thymidine kinase	0	3	0	4
Thymidine kinase	0	0	0	7
Chain A, Dihydroneopterin aldolase	0	1	0	1
Chain A, Dihydroneopterin aldolase	0	1	0	1
Chain A, Dihydroneopterin aldolase	0	1	0	1
Chain A, Dihydroneopterin aldolase	0	1	0	1
Chain A, Dihydroneopterin aldolase	0	1	0	1
Chain A, Dihydroneopterin aldolase	0	1	0	1
Chain A, Dihydroneopterin aldolase	0	1	0	1
MEP2	0	0	4	4
Taste receptor type 2 member 10	0	0	3	5
Cytochrome P450 3A7	0	8	0	8
leucine aminopeptidase	0	1	0	1
M17 leucyl aminopeptidase	0	2	0	2
M1-family alanyl aminopeptidase	0	2	0	2
M17 leucyl aminopeptidase	0	3	0	3
Solute carrier family 12 member 2	0	1	0	1
Chain A, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	0	1	0	1
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	0	3	0	3
Serine/threonine-protein kinase mTOR	0	2	1	3
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	0	4	0	4
Potassium channel subfamily K member 3	0	2	0	2
Acetylcholine receptor subunit alpha	0	7	3	10
Acetylcholine receptor subunit gamma	0	7	3	10
Acetylcholine receptor subunit beta	0	7	3	10
Neuronal acetylcholine receptor subunit beta-4	0	8	5	14
Neuronal acetylcholine receptor subunit alpha-3	0	9	5	15
Acetylcholine receptor subunit delta	0	7	3	10
Alpha-2A adrenergic receptor	0	5	0	5
MCOLN3 protein	0	0	1	1
transient receptor potential cation channel, subfamily N, member 1	0	0	1	1
Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	0	9	0	9
Mu-type opioid receptor	0	1	1	2
Chain A, Nitrile Hydratase alpha subunit	0	1	0	1
Chain B, Nitrile Hydratase beta subunit	0	1	0	1
Methyl-accepting chemotaxis protein NahY	0	0	6	6
Cyclic GMP-AMP synthase	0	4	0	4
UDP-glucuronosyltransferase 1A10	0	3	0	10
Acyl-CoA desaturase 1	0	7	0	7
Kinesin-1 heavy chain	0	5	0	5
Coiled-coil domain-containing protein 6	0	7	0	7
SAFB-like transcription modulator	0	1	0	1
RNA polymerase beta subunit (EC 2.7.7.6), partial	0	4	0	4
Lipoxygenase	0	2	0	2
Hyaluronidase-1	0	4	0	4
BiP isoform A	0	1	0	1
Aldo-keto reductase family 1 member A1	0	5	0	5
Aldo-keto reductase family 1 member C4	0	10	0	10
Aldo-keto reductase family 1 member C1	0	14	0	14
Chain A, Glycogen Phosphorylase	0	1	0	1
Chain A, Glycogen phosphorylase, liver form	0	0	2	2
Chain A, glycogen phosphorylase, liver form	0	0	2	2
Chain A, Glycogen phosphorylase, liver form	0	0	2	2
Chain A, Glycogen phosphorylase, liver form	0	0	2	2
Chain A, Chitinase	0	1	0	1
Glycogen phosphorylase, muscle form	0	1	0	1
Chitotriosidase-1	0	4	1	5
Palmitoleoyl-protein carboxylesterase NOTUM	0	3	3	6
Endochitinase B1	0	4	1	5
type-1 angiotensin II receptor	0	4	0	4
apelin receptor	0	5	0	5
Chain A, Vitamin D Nuclear Receptor	0	0	1	1
Vitamin D3 receptor	0	0	1	1
Vitamin D-binding protein	0	0	1	1
Vitamin D3 receptor	0	1	1	3
Vitamin D3 receptor	0	0	2	2
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial	0	5	1	6
Vitamin D3 receptor	0	1	1	2
Vitamin D3 receptor A	0	0	2	2
SUMO-1	0	6	0	6
bcl-2-related protein A1	0	9	0	9
Transcriptional activator protein LuxR	0	4	0	4
Calpain-1 catalytic subunit	0	1	0	1
Pro-cathepsin H	0	5	0	5
Falcipain 2B	0	1	0	1
Serine/threonine-protein phosphatase PP1-gamma catalytic subunit	0	3	0	3
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B	0	4	0	4
NAD-dependent protein deacetylase HST2	0	6	0	6
Sphingomyelin phosphodiesterase 3	0	1	0	1
DNA topoisomerase	0	1	0	1
Type-2 restriction enzyme ScaI	0	1	0	1
Deoxyribonuclease-2-alpha	0	1	0	1
Deoxyribonuclease-1	0	1	0	1
Type-2 restriction enzyme PstI	0	1	0	1
Type-2 restriction enzyme EcoRI	0	1	0	1
DNA ligase	0	2	0	2
Heterogeneous nuclear ribonucleoprotein A1	0	0	2	2
Type-2 restriction enzyme BamHI	0	1	0	1
Somatostatin receptor type 1	0	7	0	7
Type-2 restriction enzyme HindIII	0	1	0	1
Ribonuclease pancreatic	0	3	0	3
DNA topoisomerase 1	0	3	1	5
DNA topoisomerase 1	0	1	0	1
DNA topoisomerase type IB small subunit	0	0	1	1
Chain A, Cyclin-dependent kinase 9	0	1	0	1
Sodium/glucose cotransporter 1	0	6	4	10
Sodium/glucose cotransporter 2	0	6	4	10
1,3-beta-D-glucan synthase catalytic subunit	0	2	0	2
NEDD8-activating enzyme E1 regulatory subunit	0	2	3	5
NEDD8-activating enzyme E1 catalytic subunit	0	1	3	4
Cytochrome P450 2C11	0	3	0	3
N-acylethanolamine-hydrolyzing acid amidase	0	5	0	5
Heat sensitive channel TRPV3	0	1	2	3
Transient receptor potential cation channel subfamily V member 4	0	3	6	9
G-protein coupled receptor 55	0	1	4	6
Diacylglycerol lipase-alpha	0	6	0	6
G-protein coupled receptor 6	0	0	1	1
Transient receptor potential cation channel subfamily V member 4	0	3	3	6
Inhibin alpha chain	0	1	0	1
Transient receptor potential cation channel, subfamily V, member 3	0	0	1	1
Protein phosphatase 1B	0	2	0	2
Chain A, Beta-lactoglobulin	0	0	1	1
Chain A, Beta-lactoglobulin	0	0	1	1
UDP-3-O-acyl-N-acetylglucosamine deacetylase	0	0	1	1
NADH-ubiquinone oxidoreductase chain 1	0	3	0	3
Chain A, angiotensin converting enzyme	0	1	0	1
Chain A, angiotensin converting enzyme	0	1	0	1
EEF1AKMT4-ECE2 readthrough transcript protein	0	3	0	3
Leukotriene A-4 hydrolase	0	1	0	1
Endothelin-converting enzyme 1	0	5	0	5
Beta-lactamase	0	3	0	3
Phospho-N-acetylmuramoyl-pentapeptide-transferase	0	1	0	1
Phospho-N-acetylmuramoyl-pentapeptide-transferase	0	1	0	1
UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase	0	1	0	1
Frizzled-8	0	0	1	1
P2X purinoceptor 4	0	5	1	6
kallikrein-5 preproprotein	0	1	0	1
Dihydroxyacetone phosphate acyltransferase	0	0	0	3
Lactoperoxidase	0	2	0	2
Chain A, PAPAIN	5	0	0	5
Chain A, serum paraoxonase	0	1	0	1
COUP transcription factor 2 isoform a	0	3	0	3
ATP-diphosphohydrolase 1	0	1	0	1
Proteasome subunit beta type-2	0	1	0	1
Proteasome subunit beta type-1	0	1	0	1
Sodium/hydrogen exchanger 1	0	3	0	3
Sodium/hydrogen exchanger 3	0	1	0	1
Sodium/hydrogen exchanger 3	0	1	0	1
Sodium/hydrogen exchanger 2	0	1	0	1
Acid ceramidase	0	3	0	3
Acid ceramidase	0	1	0	1
Sulfide:quinone oxidoreductase, mitochondrial	0	1	0	1
Glutathione reductase	0	3	0	3
Solute carrier family 22 member 5	0	0	0	2
Solute carrier family 22 member 16	0	0	0	1
Solute carrier family 22 member 21	0	0	0	1
Solute carrier family 22 member 5	0	0	0	2
Pancreatic triacylglycerol lipase	0	4	0	4
Complement C5	0	0	3	3
Toll-like receptor 4	0	3	0	3
Potassium channel subfamily K member 10	0	1	0	1
Neuraminidase	0	1	0	1
Sialidase-3	0	6	0	6
Chain A, Protein kinase CK2, alpha Subunit	0	1	0	1
Chain A, PROTEIN KINASE CK2, alpha SUBUNIT	0	1	0	1
Chain A, Protein Kinase Ck2, Alpha Subunit	0	1	0	1
Chain A, Neutrophil gelatinase-associated lipocalin	0	0	1	1
3-dehydroquinate synthase	0	2	0	3
Potassium-transporting ATPase subunit beta	0	3	0	4
Potassium-transporting ATPase alpha chain 1	0	3	0	4
Autoinducer 2-binding periplasmic protein LuxP	0	5	0	5
Coagulation factor XIII A chain	0	2	0	2
Translocator protein	0	11	4	17
Glutaminase kidney isoform, mitochondrial	0	1	0	1
Glutaminase kidney isoform, mitochondrial	0	1	1	2
DNA (cytosine-5)-methyltransferase 3A	0	1	1	2
Virulence sensor histidine kinase PhoQ	0	1	1	2
ATP-dependent molecular chaperone HSC82	0	4	0	4
Histidine kinase	0	3	0	3
Protein Wnt-3a	0	2	0	2
Cyclin-dependent kinase 19	0	0	1	1
carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 isoform 1	0	10	0	10
Solute carrier family 22 member 7	0	8	0	12
Beta-lactamase	0	4	0	9
Beta-lactamase	0	0	0	3
Metallo-beta-lactamase VIM-19	0	0	0	8
Beta-lactamase	0	3	0	9
Beta-lactamase	0	0	0	3
Beta-lactamase	0	0	0	3
Beta-lactamase	0	1	0	4
Beta-lactamase	0	3	0	9
Metallo-beta-lactamase VIM-2	0	0	0	8
Beta-lactamase	0	0	0	5
BlaVIM-1	0	0	0	7
Beta-lactamase	0	0	0	4
Beta-lactamase	0	2	0	8
Solute carrier family 22 member 8	0	12	0	15
Insulin-degrading enzyme	0	5	0	5
Glutathione peroxidase 1	0	1	0	1
Microsomal glutathione S-transferase 1	0	1	0	1
Beta-lactamase	0	4	0	7
Beta-lactamase	0	0	0	3
DNA dC->dU-editing enzyme APOBEC-3A isoform a	0	3	0	3
L-ornithine N(5)-monooxygenase	0	1	1	2
Receptor-type tyrosine-protein phosphatase epsilon	0	4	0	4
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN	0	1	0	1
Regulator of G-protein signaling 17	0	4	2	6
Chain A, Carbonic anhydrase II	0	1	0	1
Cytochrome c oxidase subunit 1	0	2	0	2
Cytochrome c oxidase subunit 2	0	1	0	1
Catechol O-methyltransferase	0	1	0	1
Cytochrome c oxidase subunit 2	0	7	0	7
Prostaglandin G/H synthase 1	0	6	0	6
Prostaglandin G/H synthase 2	0	15	0	16
Prostaglandin G/H synthase 1	0	2	0	2
Cyclooxygenase-2	0	3	0	3
Chain A, Endoglucanase B	0	1	0	1
Chain A, cellulase	0	0	2	2
Chain A, cellulase	0	0	2	2
Chain A, Cellulose 1,4-beta-cellobiosidase	0	0	1	1
Nuclear receptor coactivator 4	0	2	0	2
IGF-like family receptor 1	0	0	1	1
Beta-lactamase OXA-10	0	0	0	2
Beta-lactamase	0	0	0	4
Beta-lactamase IMP-1	0	0	0	4
Beta-lactamase	0	0	0	4
Beta-lactamase OXA-1	0	3	0	5
Beta-lactamase	0	1	0	5
Casein kinase 1, delta tv1	0	2	0	2
Protein kinase C-like 1	0	1	0	1
Serine/threonine-protein kinase haspin	0	5	0	5
Cadherin-1	0	4	0	4
Transcription factor 4	0	2	0	2
Adenomatous polyposis coli protein	0	3	0	3
Catenin beta-1	0	9	1	10
Transcription factor 7-like 2	0	4	0	4
Transcription factor ETV6	0	2	0	2
Gonadotropin-releasing hormone receptor	0	2	1	3
Caspase-2	0	0	2	3
Tyrosine-protein kinase BTK	0	2	0	2
Mitochondrial sodium/calcium exchanger protein	0	1	0	1
Dual specificity tyrosine-phosphorylation-regulated kinase 3	0	4	0	4
Eukaryotic translation initiation factor 4E	0	1	1	2
Cyclin-dependent kinase 5, regulatory subunit 1 (p35)	0	0	0	4
CDK5	0	0	0	4
Serine/threonine-protein kinase SMG1	0	1	0	1
Chain A, STROMELYSIN-1	0	1	0	1
Chain A, COLLAGENASE 3	0	1	0	1
Chain A, Heat shock protein HSP 90-alpha	0	0	1	1
Chain A, Heat shock protein HSP 90-alpha	0	0	1	1
Chain A, Heat shock protein HSP 90-alpha	0	0	1	1
Stromal cell-derived factor 1	0	1	0	1
Polyunsaturated fatty acid 5-lipoxygenase	0	3	0	3
Sortase A	0	3	0	3
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2	0	1	0	1
Aromatic-L-amino-acid decarboxylase	0	4	0	4
Alanine aminotransferase 1	0	0	0	4
Cell division control protein 42 homolog	0	6	0	6
4-hydroxy-2-oxoglutarate aldolase, mitochondrial	0	2	0	2
Ileal sodium/bile acid cotransporter	0	7	0	8
Bile acid receptor	0	1	3	4
Histone-lysine N-methyltransferase SUV39H1	0	6	0	6
Tyrosine-protein phosphatase YopH	0	2	0	2
Nicotinamide phosphoribosyltransferase	0	8	3	11
Methionine--tRNA ligase, mitochondrial	0	0	1	1
CAAX prenyl protease	0	0	0	3
Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	0	4	0	5
Spermine oxidase	0	2	0	2
Riboflavin-binding protein	0	2	3	5
Histidine-rich protein PFHRP-II	0	8	0	9
Spike glycoprotein	0	4	3	7
DNA ligase 1	0	1	0	1
Calcium-dependent protein kinase 1	0	1	1	2
DNA ligase A	0	1	0	1
Phosphoethanolamine N-methyltransferase	0	2	0	2
Cysteine proteinase falcipain 2a	0	1	0	1
citrate synthase 2, partial	0	0	3	3
Beta-galactosidase	0	0	5	5
MBT domain-containing protein 1	0	3	0	3
Lethal(3)malignant brain tumor-like protein 4	0	3	0	3
Lethal(3)malignant brain tumor-like protein 3	0	3	0	3
Chloroquine resistance transporter	0	5	0	5
Lethal(3)malignant brain tumor-like protein 1	0	3	0	3
NADPH oxidase 1	0	7	0	7
Snq2p	0	0	0	14
Adenylate cyclase type 1	0	4	0	4
Major prion protein	0	1	1	2
Cys-loop ligand-gated ion channel	0	1	0	1
Sphingomyelin phosphodiesterase	0	3	0	3
Adenylate cyclase type 3	0	4	0	4
Adenylate cyclase type 2	0	4	1	5
Adenylate cyclase type 4	0	4	0	4
Pleiotropic ABC efflux transporter of multiple drugs	0	14	0	28
Adenylate cyclase type 8	0	4	0	4
Gastrin/cholecystokinin type B receptor	0	6	0	6
Adenylate cyclase type 6	0	4	0	4
Adenylyl cyclase 7	0	4	0	4
Acetylcholinesterase	0	1	0	1
Carboxylic ester hydrolase	0	1	0	1
twin arginine protein translocation system - TatA protein	0	0	0	9
Cholesterol 24-hydroxylase	0	2	3	5
G-protein coupled bile acid receptor 1	0	1	0	1
Chain A, Acetylcholinesterase	0	0	2	2
Chain A, Acetylcholinesterase	0	0	2	2
Chain A, Acetylcholinesterase	0	0	2	2
Chain A, Acetylcholinesterase	0	0	2	2
Chain A, Acetylcholinesterase	0	0	2	2
Chain A, Acetylcholinesterase	0	0	2	2
Chain A, Acetylcholinesterase	0	0	2	2
Chain A, Putative Glycine Betaine-binding Abc Transporter Protein	0	0	1	1
Chain A, PUTATIVE GLYCINE BETAINE-BINDING ABC TRANSPORTER PROTEIN	0	0	1	1
Chain A, Choline-binding protein	0	0	1	1
Solute carrier family 22 member 1	0	8	0	10
Solute carrier family 22 member 2	0	6	0	7
Sodium- and chloride-dependent creatine transporter 1	0	1	0	1
High affinity choline transporter 1	0	1	0	1
High affinity choline transporter 1	0	1	0	1
Trypanothione reductase	0	3	0	3
Chain A, Glycogen phosphorylase, muscle form	0	1	0	1
Chain A, Glycogen phosphorylase, muscle form	0	1	0	1
15-hydroxyprostaglandin dehydrogenase [NAD(+)]	0	1	0	1
Dipeptidase 1	0	1	0	1
Integrin beta-6	0	1	0	1
Glutamine synthetase	0	1	0	1
Potassium-transporting ATPase alpha chain 1	0	3	0	3
Potassium-transporting ATPase subunit beta	0	3	0	3
Extracellular calcium-sensing receptor	0	0	1	1
Peroxisome proliferator-activated receptor alpha	0	0	4	4
DNA gyrase subunit B	0	2	0	2
DNA gyrase subunit A	0	2	0	2
DNA gyrase subunit B	0	6	0	9
DNA gyrase subunit A	0	12	0	17
DNA gyrase subunit B	0	12	1	17
DNA topoisomerase 4 subunit A	0	2	0	2
DNA topoisomerase 4 subunit B	0	2	0	4
DNA topoisomerase 4 subunit A	0	5	0	7
DNA gyrase subunit A	0	6	0	9
Multidrug resistance protein MdtK	0	0	3	3
DNA gyrase subunit B	0	10	0	12
DNA gyrase subunit A	0	12	0	14
Enoyl-[acyl-carrier-protein] reductase [NADH]	0	4	0	9
DNA topoisomerase 4 subunit A	0	2	0	2
DNA topoisomerase 4 subunit B	0	2	0	2
Renin	0	4	0	4
Sodium-dependent noradrenaline transporter	0	5	0	5
Sodium-dependent serotonin transporter	0	5	0	5
Sodium-dependent dopamine transporter	0	8	0	8
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, Proto-oncogene Tyrosine-protein Kinase Src	0	3	0	3
Chain A, N5-carboxyaminoimidazole ribonucleotide mutase	0	0	1	1
Chain B, N5-carboxyaminoimidazole ribonucleotide mutase	0	0	1	1
Chain A, N5-carboxyaminoimidazole ribonucleotide mutase	0	0	1	1
Chain B, N5-carboxyaminoimidazole ribonucleotide mutase	0	0	1	1
Beta-lactamase	0	3	0	3
3-dehydroquinate dehydratase	0	0	1	1
3-dehydroquinate dehydratase	0	0	1	1
General amino-acid permease GAP1	0	0	0	1
Beta-lactamase	0	3	0	3
Beta-lactamase	0	1	0	1
Beta-lactamase	0	1	0	1
Beta-lactamase	0	2	0	2
luciferase	0	0	0	2
Glucocorticoid receptor	0	5	2	8
Type IV secretion-like conjugative transfer relaxase protein TraI	0	2	0	2
Macrophage metalloelastase	0	5	0	5
Trypanothione reductase	0	1	0	1
Translocator protein	0	2	0	2
Alpha-2B adrenergic receptor	0	6	0	8
Alpha-2C adrenergic receptor	0	6	0	8
Alpha-2A adrenergic receptor	0	6	0	8
Nischarin	0	9	0	9
Sigma non-opioid intracellular receptor 1	0	3	0	3
Amine oxidase [flavin-containing] A	0	8	0	9
Sigma intracellular receptor 2	0	1	0	1
Intermediate conductance calcium-activated potassium channel protein 4	0	2	0	2
Heme oxygenase 1	0	7	0	7
Heme oxygenase 2	0	7	0	7
C-X-C chemokine receptor type 1	0	11	0	11
Mycocyclosin synthase	0	0	3	3
Nuclear receptor subfamily 1 group I member 3	0	4	0	4
Sterol 14-alpha demethylase	0	0	5	5
Indoleamine 2,3-dioxygenase 2	0	9	0	9
14-alpha sterol demethylase	0	0	5	6
Cysteinyl leukotriene receptor 1	0	16	3	19
Methionine aminopeptidase 2	0	8	0	8
5-hydroxytryptamine receptor 3A	0	7	0	7
D(2) dopamine receptor	0	2	0	2
D(2) dopamine receptor	0	6	0	6
5-hydroxytryptamine receptor 2B	0	5	0	5
5-hydroxytryptamine receptor 1A	0	5	0	5
Chain A, Heat shock protein HSP 90-alpha	0	1	0	1
Chain A, CHIMERA OF IG KAPPA CHAIN: HUMAN CONSTANT REGION AND MOUSE VARIABLE REGION	0	0	1	1
Chain B, CHIMERA OF IG GAMMA-1 CHAIN: HUMAN CONSTANT REGION AND MOUSE VARIABLE REGION	0	0	1	1
Chain H, Fab M82G2, Heavy chain	0	0	1	1
Chain L, Fab M82G2, Light chain	0	0	1	1
Chain H, Fab M82g2, Heavy Chain	0	0	1	1
Chain L, Fab M82g2, Light Chain	0	0	1	1
Fatty acid-binding protein, heart	0	3	0	3
Muscarinic acetylcholine receptor M2	0	1	3	4
Cytochrome P450 2D1	0	7	0	7
Cytochrome P450 2D26	0	8	0	8
Cytochrome P450 2D3	0	8	0	8
Cytochrome P450 2D4	0	8	0	8
AMP deaminase 3	0	1	0	1
Adenosine deaminase	0	2	0	2
Vesicular acetylcholine transporter	0	3	0	3
Tubulin polymerization-promoting protein	0	0	1	1
Adenylate cyclase type 8	0	1	1	2
Relaxin receptor 1	0	0	1	1
Nuclear receptor subfamily 1 group I member 2	0	0	16	16
B2 bradykinin receptor	0	6	0	6
Dihydrofolate reductase	0	4	0	4
Beta-galactosidase	0	2	0	3
PH domain leucine-rich repeat-containing protein phosphatase 2	0	1	0	1
Chain A, Carbonic anhydrase 2	0	0	1	1
Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial	0	0	0	1
interleukin-8 isoform 1 precursor	0	2	0	2
Taste receptor type 2 member 46	0	0	4	4
Exportin-1	0	3	1	4
NAD-dependent histone deacetylase SIR2	0	4	0	8
N-arachidonyl glycine receptor	0	3	2	5
Sodium- and chloride-dependent creatine transporter 1	0	1	0	1
Sodium-dependent phosphate transport protein 2B	0	2	0	2
HLA class II histocompatibility antigen gamma chain	0	2	0	2
ALK tyrosine kinase receptor	0	2	0	2
Angiopoietin-1 receptor	0	1	0	1
Lysine--tRNA ligase	0	4	2	6
Macrophage-stimulating protein receptor	0	1	0	1
Mixed lineage kinase domain-like protein	0	0	1	1
Aurora kinase A-interacting protein	0	2	0	2
Alkaline phosphatase, germ cell type	0	3	0	3
G protein-coupled receptor GPR35	0	0	3	3
G-protein coupled receptor 35	0	0	2	2
Cathepsin B-like cysteine protease	0	1	0	1
Tyrosine-protein phosphatase non-receptor type 9	0	1	0	1
1-acyl-sn-glycerol-3-phosphate acyltransferase beta	0	2	0	2
Sonic hedgehog protein	0	5	1	7
Sonic hedgehog protein	0	9	4	14
Lymphocyte antigen 96	0	0	2	2
Platelet-activating factor receptor	0	9	1	10
Protein phosphatase 1A	0	1	0	1
Solute carrier organic anion transporter family member 1A2	0	1	0	10
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform	0	1	0	1
Ecdysone receptor	0	3	0	3
Chain A, Homo sapiens cyclin-dependent kinase 2	0	1	0	1
Chain C, Cell division protein kinase 2	0	1	0	1
Chain C, Cell division protein kinase 2	0	1	0	1
Dual specificity protein kinase CLK2	0	3	0	3
Dual specificity protein kinase CLK3	0	3	0	3
Dual specificity protein kinase CLK4	0	3	0	3
cGMP-dependent protein kinase 1	0	1	0	1
Synapsin-1	0	2	0	2
Casein kinase I isoform alpha	0	1	0	1
Cyclin-dependent-like kinase 5	0	1	0	1
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	0	3	0	3
Cyclin-dependent kinase 20	0	1	0	2
Multidrug resistance-associated protein 5	0	4	0	5
Interferon regulatory factor 3	0	0	1	1
Eukaryotic initiation factor 4A-I	0	3	2	5
Peptidyl-prolyl cis-trans isomerase FKBP3	0	1	0	1
Peptidyl-prolyl cis-trans isomerase FKBP14	0	1	0	1
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4	0	1	0	1
Smoothened homolog	0	4	3	7
Transcription intermediary factor 1-alpha	0	3	0	3
E3 ubiquitin-protein ligase TRIM33	0	3	0	3
Uridine-cytidine kinase 1	0	1	0	1
D-alanine--D-alanine ligase	0	1	0	1
UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase	0	1	0	1
scavenger receptor class B member 1 isoform 1	0	0	0	3
Interleukin-2	0	1	0	1
Peptidylglycine alpha-amidating monooxygenase	0	1	0	3
fMet-Leu-Phe receptor	0	4	2	7
Peptidyl-prolyl cis-trans isomerase B	0	1	1	2
Calcineurin subunit B type 1	0	1	0	1
Peptidyl-prolyl cis-trans isomerase FKBP1B	0	1	2	3
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	0	3	0	3
Peptidyl-prolyl cis-trans isomerase D	0	3	1	4
Non-lysosomal glucosylceramidase	0	0	0	2
Cytochrome P450 3A43	0	6	0	6
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	0	2	0	2
Sodium/potassium-transporting ATPase subunit beta-1	0	3	0	3
Sodium/potassium-transporting ATPase subunit alpha-4	0	3	0	3
Histone-lysine N-methyltransferase SETD7	0	14	0	14
Protein-S-isoprenylcysteine O-methyltransferase	0	2	0	2
Asparagine synthetase [glutamine-hydrolyzing]	0	0	0	1
Probable deoxycytidylate deaminase	0	0	0	2
Enoyl-[acyl-carrier-protein] reductase [NADH]	0	4	0	4
Cdk-related protein kinase 6	0	1	0	1
Protein kinase domain-containing protein	0	1	0	1
Mitogen-activated protein kinase	0	1	0	1
Proline--tRNA ligase	0	1	0	1
Calcium-dependent protein kinase 4	0	2	0	2
Lysine--tRNA ligase	0	1	0	1
Uridine-cytidine kinase 1	0	0	0	2
Ribonucleoside-diphosphate reductase large subunit	0	1	0	3
2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase	0	0	3	3
Ribonucleoside-diphosphate reductase subunit M2 B	0	0	0	2
Seminal ribonuclease	0	2	0	2
Beta-galactoside alpha-2,6-sialyltransferase 1	0	1	0	1
CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase	0	1	0	1
Orotidine 5'-phosphate decarboxylase	0	2	0	2
Beta-galactoside alpha-2,6-sialyltransferase 1	0	0	0	1
Chain A, Glucose-1-phosphate cytidylyltransferase	0	1	0	1
Chain B, CTP synthase	0	1	0	1
Glucose-1-phosphate cytidylyltransferase	0	1	0	1
Acetylcholine receptor subunit alpha	0	6	2	8
Acetylcholine receptor subunit beta	0	6	2	8
Acetylcholine receptor subunit gamma	0	6	2	8
Acetylcholine receptor subunit delta	0	6	3	9
Solute carrier family 2, facilitated glucose transporter member 3	0	1	0	1
Solute carrier family 2, facilitated glucose transporter member 4	0	2	0	2
Chain A, Actin-5C	0	0	1	1
Deoxycytidine kinase	0	0	0	1
Phosphatidylcholine:ceramide cholinephosphotransferase 2	0	3	0	3
Alpha-tocopherol transfer protein	0	0	1	1
Serine protease hepsin	0	5	0	5
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1	0	1	0	1
Growth factor receptor-bound protein 2	0	1	0	2
Growth factor receptor-bound protein 2	0	1	0	1
Gamma-butyrobetaine dioxygenase	0	4	2	6
Chain B, Retinoid X receptor, alpha	0	0	1	1
Casein kinase II subunit alpha	0	2	0	2
Serine/threonine-protein kinase SULU	0	1	0	1
Protein DBF4 homolog A	0	4	0	4
Sodium/glucose cotransporter 2	0	1	1	2
Sodium/myo-inositol cotransporter 2	0	2	0	2
Solute carrier family 5 member 4	0	2	0	2
Glandular kallikrein	0	1	0	1
6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase	0	1	0	1
Platelet-activating factor acetylhydrolase	0	1	0	1
Chain A, Pol Polyprotein	0	1	0	1
Chain A, Pol Polyprotein	0	1	0	1
Chain B, Pol Polyprotein	0	1	0	1
Chain A, Pol Polyprotein	0	1	0	1
Chain B, Pol Polyprotein	0	1	0	1
Chain A, HIV-1 Protease	0	1	0	1
Chain B, HIV-1 Protease	0	1	0	1
Chain A, protease	0	1	0	1
Chain B, protease	0	1	0	1
Chain A, Protease	0	1	0	1
Chain B, Protease	0	1	0	1
Chain A, Protease	0	1	0	1
Chain B, Protease	0	1	0	1
Chain A, Protease	0	1	0	1
Chain B, Protease	0	1	0	1
Chain A, Protease (Retropepsin)	0	0	1	1
Chain B, Protease (Retropepsin)	0	0	1	1
Chain A, Protease (Retropepsin)	0	0	1	1
Chain B, Protease (Retropepsin)	0	0	1	1
Chain A, HIV-1 Protease	0	1	0	1
Chain B, HIV-1 Protease	0	1	0	1
Chain A, HIV-1 Protease	0	1	0	1
Chain B, HIV-1 Protease	0	1	0	1
Chain A, HIV-1 Protease	0	1	0	1
Chain B, HIV-1 Protease	0	1	0	1
Chain A, HIV-1 Protease	0	1	0	1
Chain B, HIV-1 Protease	0	1	0	1
Chain A, HIV-1 Protease	0	1	0	1
Chain B, HIV-1 Protease	0	1	0	1
Chain A, HIV-1 Protease	0	1	0	1
Chain B, HIV-1 Protease	0	1	0	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	1	0	1
Chain B, Protease	0	1	0	1
Chain A, HIV-1 protease	0	0	1	1
Chain B, HIV-1 protease	0	0	1	1
Chain A, HIV-1 protease	0	0	1	1
Chain B, HIV-1 protease	0	0	1	1
Chain A, HIV-1 Protease	0	0	1	1
Chain B, HIV-1 Protease	0	0	1	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	1	0	1
Chain B, Protease	0	1	0	1
Chain A, Protease	0	1	0	1
Chain B, Protease	0	1	0	1
Chain A, Protease	0	1	0	1
Chain B, Protease	0	1	0	1
Chain A, Protease	0	1	0	1
Chain B, Protease	0	1	0	1
Chain A, Protease	0	1	0	1
Chain B, Protease	0	1	0	1
Chain A, HIV-1 protease	0	1	0	1
Chain B, HIV-1 protease	0	1	0	1
Chain A, HIV-1 protease	0	1	0	1
Chain B, HIV-1 protease	0	1	0	1
Chain A, HIV-1 protease	0	1	0	1
Chain B, HIV-1 protease	0	1	0	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Pol polyprotein	0	1	0	1
Chain B, Pol polyprotein	0	1	0	1
Gag-Pol polyprotein	0	8	0	8
Gag-Pol polyprotein	0	10	1	11
Gag-Pol polyprotein	0	1	0	1
Myelin transcription factor 1	0	2	0	2
Breakpoint cluster region protein	0	2	0	2
NF-kappa-B essential modulator	0	2	1	3
Transcription factor AP-1	0	8	1	9
Chain A, Calmodulin	0	0	1	1
Acetylcholine-binding protein	0	2	1	3
Phospholipase B	0	1	0	1
Chain A, Odorant binding protein	0	0	1	1
Chain B, Odorant binding protein	0	0	1	1
Flavin reductase (NADPH)	0	0	6	6
Ubiquitin carboxyl-terminal hydrolase 5	0	1	0	1
Probable ubiquitin carboxyl-terminal hydrolase FAF-X	0	1	0	1
Gem-associated protein 4	0	1	0	1
Glucose-6-phosphate 1-dehydrogenase	0	2	0	2
ATP-binding cassette sub-family C member 11	0	0	0	2
Solute carrier organic anion transporter family member 1A1	0	0	0	3
Chain A, STEROID DELTA-ISOMERASE	0	0	1	1
Steroid Delta-isomerase	0	0	1	1
Thymidine kinase 2	0	1	0	1
Deoxycytidylate deaminase	0	0	0	1
AAA family ATPase	0	0	0	1
Sterol O-acyltransferase 1	0	2	0	2
Chain A, Dutpase	0	0	1	1
Chain A, Dutpase	0	0	1	1
Chain B, Dutpase	0	0	1	1
Chain A, Dutpase	0	0	1	1
Chain B, Dutpase	0	0	1	1
Small conductance calcium-activated potassium channel protein 2	0	3	0	3
Small conductance calcium-activated potassium channel protein 1	0	3	0	3
Small conductance calcium-activated potassium channel protein 3	0	1	0	1
NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial	0	4	0	4
Acyl carrier protein, mitochondrial	0	4	0	4
RGS7, partial	0	0	1	1
regulator of G-protein signaling 4	0	0	1	1
regulator of G-protein signaling 19	0	0	1	1
regulator of G-protein signaling 16	0	0	1	1
Acid-sensing ion channel 3	0	4	0	4
C-X-C chemokine receptor type 2	0	9	0	9
Nuclear receptor subfamily 2 group E member 1	0	0	6	6
Trace amine-associated receptor 1	0	0	2	2
Trace amine-associated receptor 1	0	0	5	5
Trace amine-associated receptor 1	0	0	9	9
Trace amine-associated receptor 1	0	1	7	8
Inhibitor of growth protein 2	0	1	0	1
caspase 7, apoptosis-related cysteine peptidase	0	0	1	1
metallo beta-lactamase	0	2	0	2
metallo-beta-lactamase IMP-1	0	2	0	2
glutathione S-transferase, partial	0	0	1	1
BZLF2	0	5	0	5
P2Y purinoceptor 4	0	0	2	2
P2Y purinoceptor 1	0	0	1	1
Bis(5'-adenosyl)-triphosphatase	0	0	0	1
Alpha-1-acid glycoprotein 1	0	0	0	1
Sphingosine-1-phosphate lyase 1	0	2	0	2
ATP-binding cassette sub-family C member 8	0	5	2	7
ATP-sensitive inward rectifier potassium channel 11	0	6	2	8
Cathepsin B	0	3	0	3
DNA (cytosine-5)-methyltransferase 3-like	0	5	0	5
DNA (cytosine-5)-methyltransferase 3A	0	7	1	8
Acetylcholinesterase	0	2	0	2
Interleukin-8	0	4	0	4
UDP-glucuronosyltransferase 1A7	0	2	0	6
NAD	0	1	0	1
ATP phosphoribosyltransferase	0	2	0	2
Proprotein convertase subtilisin/kexin type 7	0	2	0	2
Retinal dehydrogenase 1	0	1	0	1
UDP-glucose 4-epimerase	0	4	0	4
High mobility group protein B1	0	0	4	4
2-amino-3-carboxymuconate-6-semialdehyde decarboxylase	0	4	0	4
Chain A, DigA16	0	0	2	2
Chain A, DigA16	0	0	2	2
Sodium/potassium-transporting ATPase subunit alpha-1	0	10	0	11
Sodium/potassium-transporting ATPase subunit beta-1	0	10	0	11
Sodium/potassium-transporting ATPase subunit alpha-3	0	7	0	8
Sodium/potassium-transporting ATPase subunit beta-2	0	7	0	8
Sodium/potassium-transporting ATPase subunit alpha-2	0	10	0	11
Sodium/potassium-transporting ATPase subunit alpha-1	0	3	0	3
Potassium-transporting ATPase alpha chain 2	0	1	0	2
Sodium/potassium-transporting ATPase subunit beta-3	0	7	0	8
Sodium/potassium-transporting ATPase subunit gamma	0	7	0	8
Sodium/potassium-transporting ATPase subunit alpha-4	0	7	0	8
Solute carrier organic anion transporter family member 4C1	0	3	0	6
Sodium/potassium-transporting ATPase subunit alpha-2	0	2	0	2
Sodium/potassium-transporting ATPase subunit alpha-3	0	2	0	2
Solute carrier organic anion transporter family member 4C1	0	0	0	2
Solute carrier organic anion transporter family member 1A4	0	0	0	1
ADP-ribose glycohydrolase MACROD2	0	1	0	1
3-hydroxyanthranilate 3,4-dioxygenase	0	1	0	1
3-hydroxyanthranilate 3,4-dioxygenase	0	1	0	1
Chain A, HTH-type transcriptional regulator qacR	0	0	1	1
Chain B, HTH-type transcriptional regulator qacR	0	0	1	1
Chain A, PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN (PROBABLY DEOR-FAMILY)	0	0	1	1
Chain B, PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN (PROBABLY DEOR-FAMILY)	0	0	1	1
Dihydrofolate synthase/folylpolyglutamate synthase	0	1	0	1
Proto-oncogene c-Fos	0	2	0	2
Chain A, GLUTAMATE RECEPTOR SUBUNIT 2	0	3	0	3
Chain A, Glutamate Receptor Subunit 2	0	3	0	3
Chain B, Glutamate Receptor Subunit 2	0	3	0	3
Chain A, Glutamate receptor 2	0	1	0	1
Chain A, Glutamate receptor 2	0	1	0	1
Chain A, Glutamate receptor	0	1	0	1
Chain A, Sex Hormone-Binding Globulin	0	0	1	1
Progesterone receptor	0	1	0	1
Sex hormone-binding globulin	0	1	0	1
Androgen receptor	0	1	3	4
Neuropeptide FF receptor 2	0	0	0	4
Chain A, ALDOLASE	0	0	1	1
Histamine H1 receptor	0	1	0	1
Cereblon isoform 4	0	11	0	11
Insulin-like growth factor-binding protein 5	0	0	1	1
Furin	0	1	0	1
Diamine acetyltransferase 1	0	2	0	3
Acid-sensing ion channel 1	0	1	0	1
Acid-sensing ion channel 2	0	1	0	1
Niemann-Pick C1 disease protein, partial	1	0	0	1
Prostaglandin F2-alpha receptor	0	2	0	2
Prostaglandin F2-alpha receptor	0	2	2	4
Prostaglandin F2-alpha receptor	0	0	1	1
Solute carrier organic anion transporter family member 2A1	0	2	0	2
Prostaglandin E2 receptor EP4 subtype	0	1	1	2
Prostaglandin E2 receptor EP2 subtype	0	1	1	2
Solute carrier family 22 member 7	0	0	0	2
Histamine N-methyltransferase	0	1	0	4
Calcium release-activated calcium channel protein 1	0	4	0	4
Protein orai-2	0	1	0	1
Protein orai-3	0	1	0	1
Ornithine transcarbamylase, mitochondrial	0	2	0	2
Nociceptin receptor	0	3	1	4
Metallo-beta-lactamase type 2	0	1	0	1
Metallo-beta-lactamase type 2	0	1	0	1
Metallo-beta-lactamase L1 type 3	0	2	0	2
Chain A, limonene-1,2-epoxide hydrolase	0	1	0	1
Chain A, Epoxide hydrolase	0	1	0	1
Tripeptidyl-peptidase 2	0	1	0	1
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta	0	7	2	9
3',5'-cyclic-AMP phosphodiesterase	0	7	0	7
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha	0	6	0	6
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma	0	6	0	6
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta	0	6	0	6
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma	0	6	0	6
Exopolyphosphatase PRUNE1	0	1	0	1
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A	0	9	0	9
Phosphodiesterase	0	5	0	5
X-linked inhibitor of apoptosis	0	1	0	1
polypyrimidine tract-binding protein 1 isoform a	2	0	0	2
bifunctional UDP-N-acetylglucosamine pyrophosphorylase/glucosamine-1-phosphate N-acetyltransferase	0	4	0	4
Carbamate kinase	0	1	0	1
Gasdermin-D	0	2	0	2
Gasdermin-D	0	2	0	2
plectin 1	0	2	0	2
Photosystem II protein D1	0	1	0	1
Growth hormone-releasing hormone receptor	0	1	0	1
Nucleotide-binding oligomerization domain-containing protein 2	0	3	0	3
Chain A, FATTY ACID-BINDING PROTEIN, BRAIN	0	0	2	2
Chain A, Fatty Acid-binding Protein, Brain	0	0	2	2
Epoxide hydrolase 1	0	3	0	3
Chain A, PFV integrase	0	1	0	1
Chain A, PFV integrase	0	1	0	1
Chain A, PFV integrase	0	1	0	1
Integrase	0	1	1	2
Cholinesterase	0	5	0	5
Acetylcholine receptor subunit epsilon	0	3	1	4
Bone morphogenetic protein 4	0	1	0	1
Chain A, CARBONIC ANHYDRASE II	0	1	0	1
Chain A, CARBONIC ANHYDRASE II	0	1	0	1
Chain A, CARBONIC ANHYDRASE II	0	1	0	1
14-3-3 protein gamma	0	2	0	2
UDP-galactopyranose mutase	0	0	0	1
Lysophosphatidylserine lipase ABHD12	0	2	0	2
Monoacylglycerol lipase ABHD6	0	2	0	2
N-acetyltransferase Eis	0	3	0	3
Toll-like receptor 7	0	0	1	1
Toll-like receptor 7	0	1	5	8
3-oxo-5-alpha-steroid 4-dehydrogenase 1	0	3	0	3
3-oxo-5-alpha-steroid 4-dehydrogenase 2	0	5	0	5
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase	0	2	0	2
Cysteine protease falcipain-3	0	2	0	2
Cysteine protease falcipain-3	0	1	0	1
Splicing factor 3B subunit 3	0	3	1	4
Hydroxycarboxylic acid receptor 2	0	4	1	5
Arrestin, beta 1	0	1	0	1
hexokinase	0	3	0	3
hexokinase-1 isoform HKI	0	0	1	1
phosphoethanolamine/phosphocholine phosphatase isoform 1	0	2	0	2
Sulfhydryl oxidase 1	0	1	0	1
Toxin B	0	1	0	1
Structural capsid protein	0	1	0	1
Ultraspiracle	0	4	0	4
20-hydroxy-ecdysone receptor	0	4	0	4
Ecdysone receptor	0	1	0	1
Protein ultraspiracle	0	1	0	1
Ultraspiracle	0	1	0	1
20-hydroxy-ecdysone receptor	0	1	0	1
Ultraspiracle protein	0	1	0	1
20-hydroxy-ecdysone receptor	0	1	0	1
neuropeptide Y receptor type 1	0	3	1	4
neuropeptide Y receptor type 2	0	3	1	4
UDP-glucuronosyltransferase 2B17	0	0	0	1
Substance-P receptor	0	0	1	1
Chain A, POL POLYPROTEIN	0	1	0	1
Chain A, POL POLYPROTEIN	0	1	0	1
Chain B, POL POLYPROTEIN	0	1	0	1
Chain A, POL POLYPROTEIN	0	1	0	1
Chain B, POL POLYPROTEIN	0	1	0	1
Chain A, Pol Polyprotein	0	1	0	1
Chain B, Pol Polyprotein	0	1	0	1
Microsomal triglyceride transfer protein large subunit	0	2	0	2
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120	0	1	0	1
Fructose-1,6-bisphosphatase 1	0	0	0	2
Reverse transcriptase	0	2	2	4
Chain A, Protein (peroxisome Proliferator Activated Receptor (ppar-delta))	0	1	0	1
Serine/threonine-protein kinase ULK3	0	0	6	6
Serine/threonine-protein kinase 3	0	0	5	5
Chain A, Liver Fatty Acid Binding Protein	0	0	1	1
Chain A, Casein kinase II subunit alpha	0	1	0	1
acetyl-CoA acetyltransferase/HMG-CoA reductase	0	1	0	1
unnamed protein product	0	2	0	2
heat shock 70kDa protein 1A	0	3	0	3
Aldehyde oxidase 1	0	3	0	3
heat shock cognate 71 kDa protein isoform 1	0	3	0	3
heat shock cognate 71 kDa protein isoform 2	0	3	0	3
Glutathione S-transferase Mu 1	0	2	0	2
Mitogen-activated protein kinase kinase kinase 8	0	6	0	6
DNA primase	0	4	0	4
Tyrosine-protein kinase Lyn	0	1	0	1
Polypeptide N-acetylgalactosaminyltransferase 2	0	3	2	5
ELAV-like protein 3	0	5	0	5
Tyrosine-protein kinase Fgr	0	1	0	1
Glutathione S-transferase	0	1	0	1
Translin-associated protein X	0	1	0	1
likely tRNA 2'-phosphotransferase	0	2	0	2
Macrophage-expressed gene 1 protein	0	2	0	2
Serine hydrolase RBBP9	0	1	0	1
Chain A, PROTEIN KINASE CK2, ALPHA SUBUNIT	0	1	0	1
Chain A, Casein kinase II, alpha chain	0	1	0	1
Chain A, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase	0	0	1	1
Chain B, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase	0	0	1	1
3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ	0	4	0	4
Protein tyrosine phosphatase type IVA 3	0	2	0	2
Genome polyprotein	0	1	0	1
Angiotensin-converting enzyme	0	1	0	1
Angiotensin-converting enzyme 2	0	1	0	1
Dihydropyrimidine dehydrogenase [NADP(+)]	0	1	0	1
Opioid receptor, delta 1b	0	2	0	2
Opioid receptor homologue	0	2	0	2
Proenkephalin-B	0	0	1	1
Mu-type opioid receptor	0	2	0	2
V-type proton ATPase subunit B, brain isoform	0	1	0	1
RISC-loading complex subunit TARBP2	0	0	1	1
Histone deacetylase 8	0	9	2	11
Histone deacetylase-like amidohydrolase	0	6	1	7
Eukaryotic elongation factor 2 kinase	0	4	0	4
Putative nucleoside diphosphate kinase	0	0	7	7
Eukaryotic translation initiation factor 2-alpha kinase 3	0	2	0	2
Chain A, Troponin C, slow skeletal and cardiac muscles	0	0	1	1
Chain A, Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	0	0	1	1
Chain A, POLYMERASE PA	0	1	0	1
Chain A, Polymerase Pa	0	1	0	1
Chain A, Polymerase Pa	0	1	0	1
Chain A, Polymerase Pa	0	1	0	1
Chain A, Polymerase Pa	0	1	0	1
NAD kinase	0	3	1	4
Phosphoglycerate mutase 1	0	4	0	4
3-oxoacyl-[acyl-carrier-protein] reductase	0	1	0	1
Macrophage migration inhibitory factor	0	1	0	1
[Histone H3]-lysine	0	1	0	1
Histone-binding protein RBBP4	0	3	0	3
Polycomb protein SUZ12	0	6	0	6
Zinc finger protein AEBP2	0	2	0	2
Histone-lysine N-methyltransferase EZH1	0	5	0	5
Protein arginine N-methyltransferase 7	0	2	0	2
Prolyl 4-hydroxylase, beta polypeptide	0	0	0	5
HRAS, partial	0	0	0	1
Voltage-dependent anion-selective channel protein 2	0	0	1	1
Cystine/glutamate transporter	0	6	0	6
Adenylate cyclase	0	2	0	2
Solute carrier family 22 member 4	0	1	0	2
epidermal growth factor receptor isoform a precursor	3	3	0	6
Corticosteroid 11-beta-dehydrogenase isozyme 1	0	2	0	2
Serine/threonine-protein kinase B-raf	0	4	0	4
Alpha-1A adrenergic receptor	0	2	0	2
Motilin receptor	0	0	1	1
Motilin receptor	0	1	1	2
Chitinase B	0	1	0	1
ERAP2 protein	0	0	0	2
leucyl-cystinyl aminopeptidase [Mus musculus]	0	0	0	2
Sodium/bile acid cotransporter	0	1	0	6
Solute carrier organic anion transporter family member	0	0	0	2
Chain A, GLUTATHIONE TRANSFERASE A1-1	0	1	0	1
Chain A, Glutathione S-transferase P1-1	0	1	0	1
Chain A, Glutathione S-transferase P1-1	0	1	0	1
Chain B, Glutathione S-transferase P1-1	0	1	0	1
Hematopoietic prostaglandin D synthase	0	4	0	4
Glutathione S-transferase A1	0	1	0	1
Chain A, HEAT SHOCK PROTEIN HSP 90-ALPHA	0	0	1	1
Chain A, HEAT SHOCK PROTEIN HSP 90-ALPHA	0	0	1	1
Chain A, Heat Shock Protein Hsp 90-alpha	0	0	1	1
Chain A, HEAT SHOCK PROTEIN HSP 90-ALPHA	0	0	1	1
Chain A, HEAT SHOCK PROTEIN HSP 90-ALPHA	0	0	1	1
Chain A, HEAT SHOCK PROTEIN HSP 90-ALPHA	0	0	1	1
FATTY-ACID-CoA LIGASE FADD28 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE)	0	0	0	7
Voltage-dependent calcium channel subunit alpha-2/delta-1	0	3	0	3
Voltage-dependent T-type calcium channel subunit alpha-1I	0	4	1	5
Chain A, Carbonic anhydrase 2	0	1	0	1
Aldo-keto reductase family 1 member A1	0	5	0	5
Aldo-keto reductase family 1 member A1	0	4	0	4
T cell receptor, partial	3	0	0	3
bcr	0	3	0	3
phospholipase A2, group III	0	3	0	3
rac GTPase-activating protein 1 isoform a	0	3	0	3
rho GTPase-activating protein 1	0	3	0	3
Taste receptor type 2 member 38	0	0	4	10
Chain H, IGG1-KAPPA DB3 FAB (HEAVY CHAIN)	0	1	0	1
Chain L, IGG1-KAPPA DB3 FAB (LIGHT CHAIN)	0	1	0	1
Chain H, IGG1-KAPPA DB3 FAB (HEAVY CHAIN)	0	1	0	1
Chain L, IGG1-KAPPA DB3 FAB (LIGHT CHAIN)	0	1	0	1
Chain H, IGG1-KAPPA DB3 FAB (HEAVY CHAIN)	0	1	0	1
Chain L, IGG1-KAPPA DB3 FAB (LIGHT CHAIN)	0	1	0	1
Acetylcholine receptor subunit delta	0	1	0	1
Acetylcholine receptor subunit alpha	0	1	0	1
Acetylcholine receptor subunit gamma	0	1	0	1
Acetylcholine receptor subunit beta	0	1	0	1
Regulatory protein E2	0	0	2	2
DNA topoisomerase 2	0	0	0	2
DNA topoisomerase 2-alpha	0	0	0	1
Ubiquitin carboxyl-terminal hydrolase isozyme L3	0	3	0	3
Ubiquitin carboxyl-terminal hydrolase isozyme L1	0	3	0	3
Luciferin 4-monooxygenase	0	7	1	9
TGF-beta receptor type-1	0	3	0	3
NPC1-like intracellular cholesterol transporter 1	0	1	0	1
Chain D, PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA	0	1	0	1
Protein farnesyltransferase subunit beta	0	1	0	2
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	0	1	0	2
Geranylgeranyl pyrophosphate synthase	0	4	0	5
Chain E, cAMP-dependent protein kinase, alpha-catalytic subunit	0	3	0	3
Chain I, cAMP-dependent protein kinase inhibitor, alpha form	0	3	0	3
Chain B, Rho-associated protein kinase 1	0	3	0	3
Chain A, Rho-associated protein kinase 1	0	3	0	3
Chain A, Rho-associated protein kinase 1	0	3	0	3
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit	0	2	0	2
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit	0	2	0	2
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit	0	2	0	2
Chain I, cAMP-dependent protein kinase inhibitor alpha	0	2	0	2
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit	0	2	0	2
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit	0	2	0	2
Chain I, cAMP-dependent protein kinase inhibitor alpha	0	2	0	2
Chain A, Rho-associated protein kinase 1	0	3	0	3
cAMP-dependent protein kinase catalytic subunit alpha isoform Calpha1	0	0	0	2
cAMP-dependent protein kinase catalytic subunit alpha	0	4	1	5
C-C motif chemokine 2	0	3	0	3
Rho-associated protein kinase 2	0	3	0	3
5-hydroxytryptamine receptor 2A	0	3	0	3
Cathepsin B	0	2	0	2
procathepsin L isoform 1 preproprotein	0	3	0	3
fructose-bisphosphate aldolase	0	2	0	2
Caspase-4	0	7	0	8
Caspase-5	0	7	0	8
Fatty acid-binding protein, liver	0	2	2	4
Retinol-binding protein 4	0	1	5	6
Prosaposin	0	0	1	1
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	0	1	0	1
Sphingosine 1-phosphate receptor 1	0	3	3	6
RCG53912, isoform CRA_a	0	0	0	1
Sphingosine kinase 1	0	0	0	1
Chain B, Cell division protein kinase 6	0	1	0	1
Chain A, Nicotinamide phosphoribosyltransferase	0	0	1	1
Chain B, Nicotinamide phosphoribosyltransferase	0	0	1	1
Chain A, Nicotinamide phosphoribosyltransferase	0	0	1	1
Chain B, Nicotinamide phosphoribosyltransferase	0	0	1	1
Chain A, Nicotinamide phosphoribosyltransferase	0	1	0	1
Chain B, Nicotinamide phosphoribosyltransferase	0	1	0	1
Nicotinamide phosphoribosyltransferase	0	3	2	5
Potassium voltage-gated channel subfamily D member 2	0	3	0	3
Lanosterol 14-alpha demethylase	0	1	3	5
Chain A, PROTEIN (TRANSTHYRETIN)	0	0	1	1
Chain B, PROTEIN (TRANSTHYRETIN)	0	0	1	1
Transcription factor SOX-18	0	3	0	3
Transcriptional enhancer factor TEF-3	0	3	2	5
Potassium channel subfamily K member 18	0	1	1	2
Acid-sensing ion channel 5	0	0	1	1
Voltage-dependent T-type calcium channel subunit alpha-1G	0	3	2	5
Voltage-dependent T-type calcium channel subunit alpha-1H	0	4	1	5
Voltage-dependent L-type calcium channel subunit beta-1	0	1	0	1
Voltage-dependent calcium channel subunit alpha-2/delta-1	0	1	0	1
Voltage-dependent N-type calcium channel subunit alpha-1B	0	2	0	2
Chain H, 4-4-20 (ig*g2a=kappa=) Fab Fragment	0	0	1	1
Chain L, 4-4-20 (ig*g2a=kappa=) Fab Fragment	0	0	1	1
Chain A, Uracil Phosphoribosyltransferase	0	1	0	1
Potassium voltage-gated channel subfamily C member 1	0	1	0	1
Gastrin/cholecystokinin type B receptor	0	1	0	1
Ubiquitin carboxyl-terminal hydrolase 1	0	5	0	5
WD repeat-containing protein 48	0	5	0	5
Potassium voltage-gated channel subfamily KQT member 3	0	0	1	2
Potassium voltage-gated channel subfamily KQT member 2	0	0	1	2
Serine hydroxymethyltransferase, mitochondrial	0	6	0	6
Potassium voltage-gated channel subfamily KQT member 4	0	0	0	1
Potassium voltage-gated channel subfamily KQT member 5	0	0	0	1
Arylacetamide deacetylase	0	2	0	5
Arylacetamide deacetylase	0	0	0	2
Arylacetamide deacetylase	0	0	0	2
Cytochrome P450 1A2	0	4	2	10
Chain A, Dihydrofolate reductase	0	0	1	1
Multidrug resistance associated protein	0	2	0	6
Interleukin-2	0	1	3	4
Chain A, MTA/SAH nucleosidase	0	1	0	1
Chain B, MTA/SAH nucleosidase	0	1	0	1
Chain A, MTA/SAH nucleosidase	0	1	0	1
Chain B, MTA/SAH nucleosidase	0	1	0	1
Chain A, 5'-methylthioadenosine nucleosidase	0	1	0	1
Chain B, 5'-methylthioadenosine nucleosidase	0	1	0	1
Chain A, 5'-methylthioadenosine nucleosidase	0	1	0	1
Chain B, 5'-methylthioadenosine nucleosidase	0	1	0	1
Chain A, PURINE NUCLEOSIDE PHOSPHORYLASE	0	1	0	1
Chain A, PURINE NUCLEOSIDE PHOSPHORYLASE	0	1	0	1
Chain B, PURINE NUCLEOSIDE PHOSPHORYLASE	0	1	0	1
Chain A, uridine phosphorylase, putative	0	0	1	1
Chain B, uridine phosphorylase, putative	0	0	1	1
Chain A, Uridine phosphorylase putative	0	0	1	1
Chain B, Uridine phosphorylase putative	0	0	1	1
Chain A, Purine nucleoside phosphorylase	0	0	1	1
Chain A, IAG-nucleoside hydrolase	0	1	0	1
Chain A, IAG-nucleoside hydrolase	0	1	0	1
Purine nucleoside phosphorylase	0	1	0	1
Purine nucleoside phosphorylase	0	1	0	1
Tubulin polymerization-promoting protein	0	1	0	1
Beta-tubulin	0	4	0	4
Chain A, probable fosfomycin resistance protein	0	0	1	1
Chain B, probable fosfomycin resistance protein	0	0	1	1
Advanced glycosylation end product-specific receptor	0	1	3	4
Nuclear receptor subfamily 2 group C member 2	0	2	0	3
Phospholipase A-2-activating protein	0	7	0	7
Guanine nucleotide-binding protein subunit alpha-11	0	2	0	2
Guanine nucleotide-binding protein G(q) subunit alpha	0	2	0	2
Guanine nucleotide binding protein q polypeptide	0	2	0	2
Menin	0	1	1	2
Lecithin retinol acyltransferase	0	2	0	2
Protein Rev	0	1	2	3
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	0	2	2	4
Protein farnesyltransferase subunit beta	0	2	2	4
Fucose-binding lectin PA-IIL	0	3	0	3
CD209 antigen	0	3	0	3
Steroid hormone receptor ERR1	0	5	0	5
Methionine aminopeptidase 1	0	1	0	1
NADP-dependent malic enzyme, mitochondrial	0	0	0	2
Histone-arginine methyltransferase CARM1	0	4	0	4
Protein arginine N-methyltransferase 6	0	3	0	3
Holo-[acyl-carrier-protein] synthase	0	1	0	1
Chain A, Type Iii Chloramphenicol Acetyltransferase	0	1	0	1
Protein-serine O-palmitoleoyltransferase porcupine	0	2	1	3
P-selectin	0	2	0	2
Lipopolysaccharide heptosyltransferase 1	0	1	0	1
PA-I galactophilic lectin	0	0	2	2
Jacalin	0	0	1	1
Protein disulfide-isomerase	0	2	0	2
Chain A, ACETYLCHOLINESTERASE	0	1	0	1
Chain A, Acetylcholinesterase	0	1	0	1
L-selectin	0	1	0	1
E-selectin	0	1	0	1
Ribonuclease HI	0	3	0	3
Thioredoxin, mitochondrial	0	1	0	1
Sodium- and chloride-dependent GABA transporter 1	0	5	1	9
Sodium- and chloride-dependent taurine transporter	0	2	0	2
Sodium- and chloride-dependent betaine transporter	0	4	0	4
4-aminobutyrate aminotransferase, mitochondrial	0	2	1	4
Chain A, Glycogen phosphorylase, muscle form	0	1	0	1
Glutathione hydrolase 1 proenzyme	0	0	1	2
Asc-type amino acid transporter 1	0	3	0	3
Zinc finger protein GLI1	0	2	0	2
Zinc finger protein GLI2	0	2	0	2
Max-like protein X	0	1	0	1
Heat shock protein HSP 90	0	2	0	2
Putative heat shock protein HSP 90-alpha A4	0	2	0	2
Heat shock protein 90, putative	0	0	1	1
Chain A, DEOXYNUCLEOSIDE KINASE	0	1	0	1
Chain A, Estrogen receptor 1 (alpha)	0	1	0	1
Chain A, Transthyretin	0	0	1	1
Chain A, Transthyretin	0	0	1	1
Ornithine decarboxylase	0	2	0	2
Solute carrier family 2, facilitated glucose transporter member 4	0	4	0	4
Cystic fibrosis transmembrane conductance regulator	0	0	1	1
NH(3)-dependent NAD(+) synthetase	0	4	0	4
beta-amyloid peptide, A beta {N-terminal} [human, cerebrospinal fluid, conditioned medium of mixed-brain cell cultures, Peptide Partial, 33 aa]	1	0	0	1
alpha synuclein, partial	1	0	0	1
Phosphatidylcholine:ceramide cholinephosphotransferase 1	0	2	0	2
Acetolactate synthase catalytic subunit, mitochondrial	0	1	0	1
Mycothiol S-conjugate amidase	0	2	0	2
E3 ubiquitin-protein ligase RNF31	0	1	0	1
RanBP-type and C3HC4-type zinc finger-containing protein 1	0	1	0	1
Sharpin	0	1	0	1
Glucagon-like peptide 1 receptor	0	0	1	1
Glucagon-like peptide 1 receptor	0	3	3	6
Glucagon receptor	0	0	1	1
Glucagon receptor	0	0	1	1
Peroxiredoxin-1	0	0	1	1
Asialoglycoprotein receptor 1	0	1	1	2
Chain A, Slr1257 protein	0	0	1	1
Chain A, Glucosamine--fructose-6-phosphate aminotransferase [isomerizing]	0	1	0	1
Bifunctional aspartokinase/homoserine dehydrogenase 1	0	1	0	1
Excitatory amino acid transporter 3	0	0	0	1
Glutamate racemase	0	0	0	1
Metabotropic glutamate receptor 8	0	2	2	4
Glutamate carboxypeptidase 2	0	5	0	6
Glutamate racemase	0	0	0	1
Chain A, Glutamine Binding Protein	0	0	1	1
Glutamate carboxypeptidase 2	0	1	0	1
Chain A, Protein (aspartate Aminotransferase)	0	0	2	2
Chain A, Aspartate Aminotransferase	0	0	2	2
Glutathione reductase	0	1	0	3
ATP-binding cassette sub-family C member 9	0	2	1	3
ATP synthase subunit beta, mitochondrial	0	1	0	1
ATP synthase subunit delta, mitochondrial	0	1	0	1
ATP synthase subunit gamma, mitochondrial	0	1	0	1
ATP synthase subunit epsilon, mitochondrial	0	1	0	1
Cholesteryl ester transfer protein	0	1	0	1
Chain B, EUKARYOTIC TRANSLATION INITIATION FACTOR 4E	0	0	1	1
Sodium- and chloride-dependent glycine transporter 1	0	2	0	2
Sodium- and chloride-dependent glycine transporter 2	0	3	0	3
Bile salt export pump	0	0	0	4
Corticosteroid 11-beta-dehydrogenase isozyme 2	0	1	0	1
Lactoylglutathione lyase	0	1	0	1
High mobility group protein B1	0	0	0	1
4-hydroxy-tetrahydrodipicolinate synthase	0	1	0	1
Chain A, 3-phosphoshikimate 1-carboxyvinyltransferase	0	1	0	1
Chain A, 3-phosphoshikimate 1-carboxyvinyltransferase	0	1	0	1
Glutamine synthetase	0	1	0	1
Cytochrome P450 71B1	0	1	0	2
Glutamine synthetase	0	1	0	1
2-dehydro-3-deoxyphosphooctonate aldolase	0	1	0	1
Nicotinamide phosphoribosyltransferase	0	2	0	2
Malate dehydrogenase, mitochondrial	0	2	0	2
Malate dehydrogenase, cytoplasmic	0	2	0	3
L-lactate dehydrogenase B chain	0	2	0	2
Type 1 InsP3 receptor isoform S2	4	0	0	4
L-lactate dehydrogenase	0	2	0	2
L-lactate dehydrogenase	0	2	0	2
L-lactate dehydrogenase B chain	0	2	0	2
L-lactate dehydrogenase	0	2	0	2
Inosine-5'-monophosphate dehydrogenase	0	1	0	1
Targeting protein for Xklp2	0	4	0	4
4-aminobutyrate aminotransferase, mitochondrial	0	1	0	1
Growth hormone secretagogue receptor type 1	0	2	1	3
Chain A, Bromodomain-containing Protein 4	0	0	1	1
Chain A, BROMODOMAIN-CONTAINING PROTEIN 2	0	1	0	1
Chain A, BROMODOMAIN-CONTAINING PROTEIN 2	0	1	0	1
ATPase family AAA domain-containing protein 2	0	0	2	2
Protein phosphatase 1D	0	1	0	1
Histone-lysine N-methyltransferase 2D	0	1	0	1
Protein arginine N-methyltransferase 3	0	2	0	2
DNA (cytosine-5)-methyltransferase 3B	0	1	0	1
Histone-lysine N-methyltransferase 2A	0	6	0	6
Histone-binding protein RBBP7	0	2	0	2
Histone-lysine N-methyltransferase SETMAR	0	1	0	1
Histone-lysine N-methyltransferase 2C	0	1	0	1
Histone-lysine N-methyltransferase SUV39H2	0	2	0	2
Histone-lysine N-methyltransferase 2B	0	1	0	1
Chain A, Bromodomain-containing protein 4	0	0	1	1
RAC-alpha serine/threonine-protein kinase	0	1	0	1
5'-AMP-activated protein kinase catalytic subunit alpha-2	0	1	0	1
Rho-associated protein kinase 1	0	1	0	1
Chain A, Proto-oncogene Serine/threonine-protein Kinase Pim-1	0	1	0	1
Chain A, Proto-oncogene Serine/threonine Protein Kinase Pim-1	0	1	0	1
Chain A, Proto-oncogene Serine/threonine Protein Kinase Pim-1	0	1	0	1
Chain A, Proto-oncogene Serine/threonine Protein Kinase Pim-1	0	1	0	1
2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase	0	0	3	3
Chain A, Probable hydrogenase nickel incorporation protein hypB	0	0	1	1
Chain B, Probable hydrogenase nickel incorporation protein hypB	0	0	1	1
Chain A, ELONGATION FACTOR TU (EF-TU)	0	0	1	1
Chain A, Elongation Factor G	0	0	1	1
Chain A, ADP-RIBOSYLATION FACTOR-LIKE PROTEIN 3	0	0	1	1
Chain A, Eukaryotic peptide chain release factor GTP-binding subunit	0	0	1	1
Chain A, ras-related C3 botulinum toxin substrate 1 isoform Rac1b	0	0	1	1
Chain A, ras-related C3 botulinum toxin substrate 1 isoform Rac1b	0	0	1	1
Chain A, interferon-inducible GTPase	0	0	1	1
Chain A, interferon-inducible GTPase	0	0	1	1
Chain A, Elongation factor 2	0	0	1	1
Chain A, Guanine nucleotide-binding protein G(i), alpha-1 subunit	0	0	1	1
Ras-related protein Rab-7a	0	0	2	2
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT5	0	1	0	1
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase 9	0	4	0	4
Chain A, Hypoxanthine Phosphoribosyltransferase	0	2	0	2
Chain A, HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE	0	2	0	2
Chain A, HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE	0	0	2	2
Chain B, HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE	0	0	2	2
Chain A, HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE	0	0	2	2
Chain A, Xanthine phosphoribosyltransferase	0	0	1	1
Histidine triad nucleotide-binding protein 1	0	0	1	1
Chain A, Uracil Phosphoribosyltransferase	0	0	1	1
Chain B, Uracil Phosphoribosyltransferase	0	0	1	1
Chain C, Uracil Phosphoribosyltransferase	0	0	1	1
Chain A, BDNF/NT-3 GROWTH FACTORS RECEPTOR	0	1	0	1
Chain A, BDNF/NT-3 GROWTH FACTORS RECEPTOR	0	1	0	1
Chain A, BDNF/NT-3 GROWTH FACTORS RECEPTOR	0	1	0	1
Macrophage colony-stimulating factor 1 receptor	0	3	0	3
Pre-mRNA-processing factor 19	0	0	1	1
Dual specificity tyrosine-phosphorylation-regulated kinase 4	0	2	0	2
Kinesin-like protein KIF15	0	1	0	1
Receptor tyrosine-protein kinase erbB-2	0	1	0	1
Coelenterazine h 2-monooxygenase	0	0	0	1
Chain E, C-amp-dependent Protein Kinase	0	1	0	1
Chain I, Protein Kinase Inhibitor Peptide	0	1	0	1
Chain E, C-amp-dependent Protein Kinase	0	1	0	1
Chain E, C-amp-dependent Protein Kinase	0	1	0	1
Chain I, Protein Kinase Inhibitor Peptide	0	1	0	1
cAMP-dependent protein kinase type II-alpha regulatory subunit	0	1	0	1
cAMP-dependent protein kinase catalytic subunit beta	0	1	0	1
cAMP-dependent protein kinase type II-beta regulatory subunit	0	1	0	1
Adenylosuccinate synthetase isozyme 2	0	1	0	1
AP-2 complex subunit sigma	0	1	0	1
Zinc finger protein 664	0	1	0	1
STE24	0	0	0	3
Chain A, Dual specificity tyrosine-phosphorylation-regulated kinase 1A	0	1	0	1
CDC-like kinase 1, isoform CRA_c	0	0	0	3
Sodium-dependent dopamine transporter	0	1	0	1
Neuromedin-B receptor	0	2	0	3
Chain E, Fibrin beta chain	0	3	0	3
Vesicular acetylcholine transporter	0	2	0	2
Choline kinase	0	2	0	2
Chain A, TYROSINE PHOSPHATASE	0	1	0	1
Chain A, Tyrosine Phosphatase	0	1	0	1
Aurora kinase B-A	0	3	0	3
small ubiquitin-related modifier 2 isoform b precursor	0	1	0	1
N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D	0	2	0	2
N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D	0	1	0	1
Eukaryotic initiation factor 4A-III	0	1	1	2
Eukaryotic initiation factor 4A-I	0	1	0	1
Eukaryotic initiation factor 4A-II	0	1	0	1
ATP-dependent RNA helicase DHX29	0	1	0	1
Chain A, CARBONIC ANHYDRASE II	0	0	1	1
Chain A, Protein (female-specific Histamine Binding Protein 2)	0	0	1	1
Histamine H3 receptor	0	2	0	2
Histamine N-methyltransferase	0	2	0	2
Equilibrative nucleoside transporter 4	0	0	0	1
Histamine H4 receptor	0	1	2	3
Histamine H4 receptor	0	2	3	5
Histamine H4 receptor	0	1	0	1
Chain A, HISTIDINE-BINDING PROTEIN	0	0	1	1
Histidine-binding periplasmic protein	0	0	1	1
Histidinol dehydrogenase	0	0	0	1
Chloride channel isoform 1	0	1	1	2
Intestinal-type alkaline phosphatase	0	6	0	6
Chain A, TGF-beta receptor type I	0	1	0	1
Chain A, TGF-beta receptor type I	0	1	0	1
Phosphatidylcholine-sterol acyltransferase	0	0	1	1
G-protein coupled receptor 1	0	0	1	1
N-glycosylase/DNA lyase	0	5	0	5
Glucocorticoid receptor	0	1	2	3
Chain A, Carbonic anhydrase 2	0	2	0	2
Chain A, Carbonic anhydrase 2	0	2	0	2
Chain A, Carbonic anhydrase 2	0	2	0	2
Toll-like receptor 9	0	1	0	1
ATP-citrate synthase	0	2	0	2
Uracil nucleotide/cysteinyl leukotriene receptor	0	5	0	5
Capsid scaffolding protein	0	1	0	1
Glutamine synthetase	0	1	0	1
Oleandomycin glycosyltransferase	0	0	0	1
Glycogen synthase kinase 3	0	3	0	3
Chain A, Phospholipase A2	0	0	1	1
Chain A, Phospholipase A2 VRV-PL-VIIIa	0	0	1	1
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial	0	0	1	1
Corticotropin-releasing factor receptor 1	0	2	0	2
2-5A-dependent ribonuclease	0	3	0	4
Chain A, Purine-nucleoside Phosphorylase	0	1	0	1
Chain C, Xanthine dehydrogenase/oxidase	0	0	1	1
Dehydrogenase/reductase SDR family member 9	0	1	0	1
DNA-dependent protein kinase catalytic subunit	0	1	0	1
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	0	2	0	2
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	0	2	0	2
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	0	2	0	2
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	0	2	0	2
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	0	2	0	2
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	0	2	0	2
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	0	2	0	2
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	0	2	0	2
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	0	2	0	2
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	0	2	0	2
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	0	2	0	2
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	0	2	0	2
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	0	2	0	2
Sodium channel protein type 9 subunit alpha	0	1	0	1
Cysteinyl leukotriene receptor 2	0	5	1	6
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	0	1	0	1
Chain A, Adam 17	0	0	1	1
Disintegrin and metalloproteinase domain-containing protein 17	0	2	0	2
Matrix metalloproteinase-15	0	2	0	2
Matrix metalloproteinase-16	0	2	0	2
Disintegrin and metalloproteinase domain-containing protein 33	0	1	0	1
Prostacyclin receptor	0	1	1	2
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL	0	1	0	1
Chain A, Tyrosine-protein kinase SYK	0	1	0	1
BCR/ABL p210 fusion protein	0	1	0	1
Mast/stem cell growth factor receptor Kit	0	2	0	2
Mitogen-activated protein kinase kinase kinase 14	0	4	0	4
P2X purinoceptor 7	0	3	1	4
Transmembrane protease serine 4	0	2	0	2
Beta-lactamase	0	0	0	1
Metallo-beta-lactamase type 2	0	0	0	1
Toll-like receptor 8	0	0	3	5
Tyrosine-protein kinase JAK2	0	1	1	2
Chain A, Cell Division Protein Kinase 2	0	1	0	1
Chain A, CELL DIVISION PROTEIN KINASE 2	0	1	0	1
Chain A, Cell Division Protein Kinase 2	0	1	0	1
Chain A, CELL DIVISION PROTEIN KINASE 2	0	1	0	1
Chain A, CELL DIVISION PROTEIN KINASE 2	0	1	0	1
Chain A, CELL DIVISION PROTEIN KINASE 2	0	1	0	1
Chain A, CELL DIVISION PROTEIN KINASE 2	0	1	0	1
Chain A, CELL DIVISION PROTEIN KINASE 2	0	1	0	1
Chain A, CELL DIVISION PROTEIN KINASE 2	0	1	0	1
Chain A, CELL DIVISION PROTEIN KINASE 2	0	1	0	1
Chain A, CELL DIVISION PROTEIN KINASE 2	0	1	0	1
Chain A, CELL DIVISION PROTEIN KINASE 2	0	1	0	1
Chain A, CELL DIVISION PROTEIN KINASE 2	0	1	0	1
Chain A, Cell Division Protein Kinase 2	0	1	0	1
Chain A, PROTEIN (PROTEASE)	0	1	0	1
Chain B, PROTEIN (PROTEASE)	0	1	0	1
Chain A, PROTEIN (PROTEASE)	0	1	0	1
Chain B, PROTEIN (PROTEASE)	0	1	0	1
Chain A, HIV-1 PROTEASE	0	1	0	1
Chain B, HIV-1 PROTEASE	0	1	0	1
Chain A, HIV-II PROTEASE	0	1	0	1
Chain B, HIV-II PROTEASE	0	1	0	1
Chain A, POL polyprotein	0	0	1	1
Chain B, POL polyprotein	0	0	1	1
Chain A, POL polyprotein	0	0	1	1
Chain B, POL polyprotein	0	0	1	1
Chain A, POL polyprotein	0	0	1	1
Chain B, POL polyprotein	0	0	1	1
Chain A, POL polyprotein	0	0	1	1
Chain B, POL polyprotein	0	0	1	1
Chain A, protease RETROPEPSIN	0	1	0	1
Chain B, protease RETROPEPSIN	0	1	0	1
Chain A, protease RETROPEPSIN	0	1	0	1
Chain B, protease RETROPEPSIN	0	1	0	1
Chain A, protease RETROPEPSIN	0	1	0	1
Chain B, protease RETROPEPSIN	0	1	0	1
Chain A, POL polyprotein	0	2	0	2
Chain B, POL polyprotein	0	2	0	2
Chain A, POL polyprotein	0	2	0	2
Chain B, POL polyprotein	0	2	0	2
Chain A, HIV-1 protease	0	1	0	1
Chain B, HIV-1 protease	0	1	0	1
Chain A, Pol polyprotein	0	1	0	1
Chain B, Pol polyprotein	0	1	0	1
Chain A, Pol polyprotein	0	1	0	1
Chain B, Pol polyprotein	0	1	0	1
Chain A, Pol polyprotein	0	1	0	1
Chain B, Pol polyprotein	0	1	0	1
Chain A, Pol polyprotein	0	1	0	1
Chain B, Pol polyprotein	0	1	0	1
Chain A, Hiv-1 Protease	0	1	0	1
Chain B, Hiv-1 Protease	0	1	0	1
Chain A, Hiv-1 Protease	0	1	0	1
Chain B, Hiv-1 Protease	0	1	0	1
Chain A, Hiv-1 Protease	0	1	0	1
Chain B, Hiv-1 Protease	0	1	0	1
Gag-Pol polyprotein	0	4	0	4
Gag polyprotein	0	2	0	2
Gag-Pol polyprotein	0	5	0	5
Gag-Pol polyprotein	0	5	0	5
Thromboxane-A synthase	0	1	0	4
Protease	0	1	0	1
Malate dehydrogenase	0	6	0	6
Kit ligand	0	1	0	1
Protein kinase C delta type	0	2	1	3
RAS guanyl-releasing protein 1	0	1	0	1
Trp operon repressor	0	0	3	3
Bifunctional dihydrofolate reductase-thymidylate synthase	0	4	0	4
Kynurenine--oxoglutarate transaminase 1	0	1	0	1
Chain A, membrane-associated prostaglandin E synthase-2	0	1	0	1
C-X-C chemokine receptor type 3	0	5	0	5
Prostaglandin D2 receptor	0	2	0	2
Survival motor neuron protein	0	0	0	1
Chain A, ADENOSINE DEAMINASE	0	1	0	1
Chain A, ADENOSINE DEAMINASE	0	1	0	1
Chain A, hypoxanthine phosphoribosyltransferase	0	0	1	1
Chain A, hypoxanthine phosphoribosyltransferase	0	0	1	1
Chain A, Hypoxanthine-guanine phosphoribosyltransferase	0	1	0	1
Chain B, Pulmonary surfactant-associated protein D	0	1	0	1
Chain A, Pulmonary surfactant-associated protein D	0	1	0	1
Beta-adrenergic receptor kinase 1	0	3	0	3
Chain A, BETA-SPECTRIN	0	0	1	1
Chain A, Phospholipase C Delta-1	0	0	1	1
Chain A, Inositol 1,4,5-trisphosphate receptor type 1	0	0	1	1
Inositol-trisphosphate 3-kinase A	0	2	0	2
Inositol 1,4,5-trisphosphate receptor type 1	0	0	2	2
Inositol 1,4,5-trisphosphate receptor type 2	0	1	0	1
Inositol 1,4,5-trisphosphate receptor type 3	0	1	1	2
Inositol polyphosphate-5-phosphatase A	0	1	0	1
Inositol 1,4,5-trisphosphate receptor type 1	0	1	1	2
Chain A, Tyrosine-protein Kinase Btk	0	0	1	1
Chain A, Bruton's Tyrosine Kinase	0	0	1	1
Chain A, DUAL ADAPTOR OF PHOSPHOTYROSINE AND 3-PHOSPHOINOSITIDES	0	0	1	1
Cytohesin-3	0	0	1	1
Chain A, Acetylcholinesterase	0	1	0	1
protein quaking isoform 1	0	1	0	1
Chain A, HYALURONATE LYASE	0	1	0	1
Chain A, meta-Cleavage product hydrolase	0	1	0	1
Free fatty acid receptor 3	0	0	3	3
Formamidopyrimidine-DNA glycosylase	0	1	0	1
Endonuclease III-like protein 1	0	1	0	1
Putative FAD-containing monooxygenase MymA	0	1	0	1
Dihydrofolate reductase	0	3	0	3
Endonuclease 8-like 1	0	1	0	1
Butyrophilin subfamily 3 member A1	0	1	3	5
Chain A, beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Chain A, Beta-galactosidase	0	1	0	1
Beta-galactosidase	0	1	0	1
Beta-2 adrenergic receptor	0	1	1	2
Beta-3 adrenergic receptor	0	0	1	1
Taste receptor type 2 member 39	0	0	1	1
Taste receptor type 2 member 40	0	0	1	1
Taste receptor type 2 member 41	0	0	1	1
Taste receptor type 2 member 43	0	0	1	1
Taste receptor type 2 member 31	0	1	4	5
Taste receptor type 2 member 45	0	0	1	1
Taste receptor type 2 member 30	0	0	1	1
Taste receptor type 2 member 19	0	0	1	1
Taste receptor type 2 member 20	0	0	1	1
Taste receptor type 2 member 50	0	0	1	1
Taste receptor type 2 member 60	0	0	2	2
Taste receptor type 2 member 42	0	0	1	1
Taste receptor type 2 member 14	0	0	2	3
Taste receptor type 2 member 13	0	0	2	2
Taste receptor type 2 member 9	0	0	2	2
Taste receptor type 2 member 8	0	0	1	1
Taste receptor type 2 member 7	0	0	1	1
Taste receptor type 2 member 5	0	0	1	1
Taste receptor type 2 member 4	0	0	2	2
Taste receptor type 2 member 3	0	0	1	1
Taste receptor type 2 member 1	0	0	2	2
Kinesin-like protein KIFC1	0	2	0	2
Voltage-dependent L-type calcium channel subunit alpha-1C	0	1	0	1
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2	0	0	1	1
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1	0	0	1	1
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	0	0	1	1
Poly [ADP-ribose] polymerase tankyrase-2	0	1	0	1
Poly [ADP-ribose] polymerase tankyrase-1	0	1	0	1
Proto-oncogene Wnt-3	0	0	1	1
Chain A, cAMP-dependent protein kinase catalytic subunit alpha	0	1	0	1
Chain B, cAMP-dependent protein kinase inhibitor alpha	0	1	0	1
Chain A, cAMP-dependent protein kinase catalytic subunit alpha	0	1	0	1
Chain B, cAMP-dependent protein kinase inhibitor alpha	0	1	0	1
Vascular endothelial growth factor receptor 2	0	1	0	1
G1/S-specific cyclin-D1	0	1	0	1
Cyclin-dependent kinase 4	0	1	0	1
Casein kinase I isoform delta	0	2	0	2
Nucleoprotein TPR	0	1	0	1
Legumain	0	1	0	1
Procathepsin L	0	1	0	1
Caspase-3	0	1	0	1
Chain A, Bromodomain-containing protein 4	0	0	1	1
Chain A, Bromodomain testis-specific protein	0	0	1	1
Bromodomain-containing protein 1	0	1	0	1
DNA damage-binding protein 1	0	3	2	6
Sphingosine 1-phosphate receptor 2	0	3	2	6
Sphingosine 1-phosphate receptor 4	0	3	1	4
Sphingosine 1-phosphate receptor 2	0	1	0	1
Sphingosine 1-phosphate receptor 3	0	3	2	5
Sphingosine 1-phosphate receptor 5	0	3	1	4
Xaa-Pro dipeptidase	0	1	0	1
Prolyl endopeptidase	0	5	0	5
Chain A, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase	0	1	0	1
Chain B, (3R)-hydroxymyristoyl-acyl carrier protein dehydratase	0	1	0	1
Protein E6	0	4	0	4
Chain A, Glutamate receptor 2	0	0	2	2
Chain A, Glutamate receptor 2	0	0	2	2
Chain C, Glutamate receptor 2	0	0	2	2
3-oxoacyl-[acyl-carrier-protein] synthase 3	0	1	1	2
Gap junction alpha-1 protein	0	1	0	1
Gap junction beta-2 protein	0	1	0	1
Synaptic vesicular amine transporter	0	6	1	7
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	0	2	0	2
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	0	2	0	2
Camphor 5-monooxygenase	0	0	0	1
Cholesterol side-chain cleavage enzyme, mitochondrial	0	1	0	1
Cytochrome P450 2A2	0	1	0	1
Cytochrome P450 7A1	0	1	0	1
Cytochrome P450 4F2	0	4	0	4
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial	0	1	0	1
Cytochrome P450 7A1	0	1	0	1
Lanosterol 14-alpha demethylase	0	2	0	2
Tyrosinase	0	1	1	2
Uncharacterized protein YOR062C	0	1	0	1
Tyrosinase	0	1	0	1
Chain A, Prolyl Endopeptidase	0	1	0	1
Chain A, Prolyl Endopeptidase	0	1	0	1
Chain A, PROLYL ENDOPEPTIDASE	0	1	0	1
Chain A, Prolyl Endopeptidase	0	1	0	1
Prolyl endopeptidase FAP	0	4	0	4
Prolyl endopeptidase	0	2	0	2
Angiotensin II type-2 receptor	0	1	0	1
Prostaglandin E synthase 2	0	2	0	2
Leukotriene C4 synthase	0	2	0	2
Leukotriene C4 synthase	0	0	0	1
Beta-secretase 2	0	1	0	1
5-hydroxytryptamine receptor 1E	0	3	0	4
Chain A, Protein farnesyltransferase/geranylgeranyltransferase type I alpha subunit	0	1	0	1
Chain B, Protein farnesyltransferase beta subunit	0	1	0	1
Chain A, Protein farnesyltransferase/geranylgeranyltransferase type I alpha subunit	0	1	0	1
Chain B, Geranylgeranyl transferase type I beta subunit	0	1	0	1
GTPase NRas	0	1	0	1
Protein farnesyltransferase subunit beta	0	3	0	3
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha	0	3	0	3
bioA	0	0	0	2
Chain A, Lectin	0	0	1	1
Chain A, Lectin	0	0	1	1
Chain A, Lectin	0	0	1	1
Chain A, Lectin	0	0	1	1
Chain A, ERYTHRINA CRISTA-GALLI LECTIN	0	0	1	1
Chain A, ERYTHRINA CRISTA-GALLI LECTIN	0	0	1	1
Chain A, Galectin-3	0	0	1	1
Chain A, Anti-tumor lectin	0	1	0	1
Galectin-3	0	1	0	1
Galectin-9	0	0	3	3
Galectin-8	0	0	4	4
Beta-galactoside-binding lectin	0	1	0	1
Galectin-1	0	1	3	5
Galectin-3	0	1	1	2
Galectin-3	0	1	3	6
Galectin-7	0	0	3	3
Alpha 1,4 galactosyltransferase	0	0	0	1
Trans-sialidase	0	2	0	2
WD repeat-containing protein 5	0	5	1	7
Cytosolic endo-beta-N-acetylglucosaminidase	0	3	0	3
Chain A, Epidermal growth factor receptor	0	1	0	1
Ubiquitin-like modifier-activating enzyme 1	0	1	0	1
neurotensin receptor type 1	0	0	3	3
Actin	0	1	0	1
Actin, alpha skeletal muscle	0	1	0	1
Neuronal acetylcholine receptor subunit beta-4	0	3	0	3
Neuronal acetylcholine receptor subunit beta-2	0	3	1	4
P2X purinoceptor 7	0	1	0	1
matrix metalloproteinase 1, partial	0	0	2	2
Dihydroorotate dehydrogenase (quinone), mitochondrial	0	2	0	2
DNA-binding protein Ikaros	0	0	2	7
Zinc finger protein Aiolos	0	0	2	2
Chain A, AMINOPEPTIDASE	0	2	0	2
Chain A, AMINOPEPTIDASE	0	2	0	2
Chain A, Leucine Aminopeptidase	0	1	0	1
Chain A, HTH-type transcriptional regulator qacR	0	0	1	1
Chain B, HTH-type transcriptional regulator qacR	0	0	1	1
Chain A, HTH-type transcriptional regulator qacR	0	0	1	1
Chain B, HTH-type transcriptional regulator qacR	0	0	1	1
Chain A, HTH-type transcriptional regulator qacR	0	0	1	1
Chain A, HTH-type transcriptional regulator qacR	0	0	1	1
Chain B, HTH-type transcriptional regulator qacR	0	0	1	1
Chain A, HTH-type transcriptional regulator qacR	0	0	1	1
Chain B, HTH-type transcriptional regulator qacR	0	0	1	1
Plasminogen	0	1	0	1
Hepatocyte growth factor activator	0	3	1	4
Transmembrane protease serine 6	0	1	0	1
Cysteine protease	0	2	0	2
Suppressor of tumorigenicity 14 protein	0	4	0	4
Alkaline phosphatase, placental type	0	1	0	1
Alkaline phosphatase, tissue-nonspecific isozyme	0	3	0	3
Intestinal-type alkaline phosphatase	0	2	0	2
Synaptic vesicle glycoprotein 2A	0	2	0	2
Neurotensin receptor type 2	0	4	3	7
SLC16A10 protein	0	0	0	5
CAAX prenyl protease 2 isoform 2	0	0	0	1
Serine/threonine-protein kinase PLK1	0	1	0	1
Chain A, NUCLEAR RECEPTOR ROR-BETA	0	1	0	1
Protein-serine O-palmitoleoyltransferase porcupine	0	3	0	3
Dipeptidyl peptidase 9	0	2	0	2
Dipeptidyl peptidase IV	0	3	0	3
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial	0	1	0	1
N-formyl peptide receptor 2	0	1	3	4
Ephrin type-A receptor 2	0	2	0	2
Protein polybromo-1	0	1	3	4
Phosphoribosylglycinamide formyltransferase	0	1	0	1
Trifunctional purine biosynthetic protein adenosine-3	0	4	0	4
Chain A, Protein farnesyltransferase alpha subunit	0	1	0	1
Chain B, Protein farnesyltransferase beta subunit	0	1	0	1
Geranylgeranyl transferase type-1 subunit beta	0	1	0	1
Geranylgeranyl transferase type-1 subunit beta	0	2	0	2
Protein farnesyltransferase alpha subunit	0	2	0	2
CAAX farnesyltransferase subunit beta	0	2	0	2
Chain A, protease	0	1	0	1
Chain B, protease	0	1	0	1
Chain A, protease	0	0	1	1
Chain B, protease	0	0	1	1
Chain A, protease	0	0	1	1
Chain B, protease	0	0	1	1
Chain A, protease	0	0	1	1
Chain B, protease	0	0	1	1
Chain A, protease	0	0	1	1
Chain B, protease	0	0	1	1
Chain A, protease	0	0	1	1
Chain B, protease	0	0	1	1
Chain A, Protease	0	1	0	1
Chain B, Protease	0	1	0	1
Chain A, Protease	0	1	0	1
Chain B, Protease	0	1	0	1
Chain A, Protease	0	1	0	1
Chain B, Protease	0	1	0	1
Chain A, PROTEASE RETROPEPSIN	0	1	0	1
Chain B, PROTEASE RETROPEPSIN	0	1	0	1
Chain A, Protease Retropepsin	0	1	0	1
Chain B, Protease Retropepsin	0	1	0	1
Chain A, Protease Retropepsin	0	1	0	1
Chain B, Protease Retropepsin	0	1	0	1
Gag-Pol polyprotein	0	3	0	3
CAAX prenyl protease 1 homolog	0	1	0	1
Plasmepsin V	0	2	0	2
Sodium-dependent neutral amino acid transporter B(0)AT2	0	2	0	2
5-hydroxytryptamine receptor 2C	0	0	1	1
Type-1 angiotensin II receptor	0	2	1	3
Chain A, Antigen Cd11a (p180)	0	1	0	1
Queuine tRNA-ribosyltransferase	0	1	0	1
histidine kinase	0	1	0	1
Chemotaxis protein CheA	0	1	0	1
Cytosol aminopeptidase	0	2	0	2
DNA topoisomerase 1	0	1	0	1
Signal peptide peptidase-like 2A	0	1	0	1
Transcription factor HES-1	0	1	0	1
Sodium-dependent dopamine transporter	0	1	0	1
Chain A, Ribulose-1,5 bisphosphate carboxylase/oxygenase large subunit N-methyltransferase, chloroplast	0	1	0	1
Chain A, Ribulose-1,5 bisphosphate carboxylase/oxygenase large subunit N-methyltransferase, chloroplast	0	1	0	1
Lysophosphatidic acid receptor 6	0	0	1	1
Lysophosphatidic acid receptor 4	0	0	1	1
Lysophosphatidic acid receptor 1	0	0	2	2
Lysophosphatidic acid receptor 4	0	0	1	1
Lysophosphatidic acid receptor 5	0	0	1	1
Lysophosphatidic acid receptor 2	0	0	1	1
Lysophosphatidic acid receptor 3	0	0	1	1
Chain A, Oligo-peptide Binding Protein	0	1	0	1
Rhodopsin	0	1	1	2
Chain A, Retinoic acid receptor RXR-alpha	0	0	1	1
Chain A, Peroxisome proliferator-activated receptor gamma	0	0	1	1
Sialidase A	0	3	0	3
Phosphatidylcholine:ceramide cholinephosphotransferase 1	0	1	0	1
Phosphatidylcholine:ceramide cholinephosphotransferase 2	0	1	0	1
Carboxylic ester hydrolase	0	1	0	1
Chain A, Phosphoenolpyruvate carboxykinase	0	1	0	1
D-aspartate oxidase	0	1	0	1
D-aspartate oxidase	0	1	0	1
Serine racemase	0	3	0	3
Chain A, Maltodextrin-binding Protein	0	1	0	1
Chain A, maltose/maltodextrin-binding protein	0	0	1	1
Chain A, Maltodextrin-binding Protein	0	1	0	1
Chain A, Maltodextrin Binding Protein	0	1	0	1
Sphingomyelin phosphodiesterase	0	1	0	1
Phosphatidylcholine 2-acylhydrolase	0	1	0	1
Acidic phospholipase A2 beta	0	1	0	1
Phospholipase A2, membrane associated	0	2	0	2
Acidic phospholipase A2 2	0	3	0	3
C-C chemokine receptor type 5	0	1	0	1
Chain A, A disintegrin and metalloproteinase with thrombospondin motifs 5	0	1	0	1
Chain A, Catalytic Domain of ADAMTS-5	0	1	0	1
Chain A, A disintegrin and metalloproteinase with thrombospondin motifs 5	0	1	0	1
Zinc metalloproteinase dpy-31	0	1	0	1
Zinc metalloproteinase dpy-31	0	1	0	1
Matrix metalloproteinase-20	0	1	0	1
A disintegrin and metalloproteinase with thrombospondin motifs 4	0	2	0	2
Stromelysin-2	0	1	0	1
Matrix metalloproteinase-25	0	1	0	1
Matrix metalloproteinase-26	0	1	0	1
A disintegrin and metalloproteinase with thrombospondin motifs 5	0	1	0	1
Matrix metalloproteinase-24	0	1	0	1
Seed linoleate 9S-lipoxygenase	0	1	0	1
Lipoxygenase	0	1	0	1
REST corepressor 1	0	1	0	1
Prostate-specific antigen	0	1	0	1
Calmodulin-domain protein kinase 1	0	1	0	1
Chain H, Prothrombin	0	1	0	1
Chain H, Prothrombin	0	1	0	1
Melatonin receptor type 1C	0	0	1	1
Large neutral amino acids transporter small subunit 1	0	2	0	2
Vitamin K-dependent gamma-carboxylase	0	0	0	1
Solute carrier family 22 member 12	0	5	0	5
UDP-glucose 6-dehydrogenase	0	1	0	1
Hydroxyacid oxidase 1	0	1	0	1
Multidrug transporter MdfA	0	3	0	3
NS3, partial	0	1	0	1
Chain A, Methionyl-tRNA synthetase	0	0	1	1
Chain A, Methionyl-tRNA synthetase	0	0	1	1
Chain A, Aminopeptidase	0	1	0	1
Chain A, Methionine aminopeptidase	0	1	0	1
S-ribosylhomocysteine lyase	0	1	0	1
Adenylate cyclase type 5	0	1	0	2
G-protein coupled receptor homolog US28	0	0	1	1
G protein-coupled receptor	0	0	1	1
Chain B, DIHYDROFOLATE REDUCTASE	0	0	1	1
Chain B, DIHYDROFOLATE REDUCTASE	0	0	1	1
Chain B, DIHYDROFOLATE REDUCTASE	0	0	1	1
ATP-binding cassette sub-family C member 3	0	1	0	3
Thymidylate synthase	0	5	0	5
Folate receptor beta	0	3	0	3
Bifunctional dihydrofolate reductase-thymidylate synthase	0	3	0	3
Dihydrofolate reductase	0	3	0	3
dTDP-4-dehydrorhamnose reductase	0	1	0	1
Catechol O-methyltransferase	0	0	0	2
Chain A, Agglutinin alpha chain	0	0	1	1
Chain A, Agglutinin alpha chain	0	0	1	1
Concanavalin-A	0	1	0	1
Type 1 fimbrin D-mannose specific adhesin	0	1	1	2
C-type lectin domain family 4 member M	0	1	0	1
luteinizing hormone receptor	2	0	0	2
Dihydrolipoyl dehydrogenase, mitochondrial	0	1	0	4
Dihydrolipoyl dehydrogenase	0	1	0	2
DNA topoisomerase I	0	0	0	1
Seed linoleate 9S-lipoxygenase-3	0	1	0	1
Serine/threonine-protein phosphatase	0	1	0	1
Protein tyrosine phosphatase receptor type C-associated protein	0	1	0	1
Chain A, MTA/SAH nucleosidase	0	1	0	1
Chain B, MTA/SAH nucleosidase	0	1	0	1
Chain A, MTA/SAH nucleosidase	0	1	0	1
Chain B, MTA/SAH nucleosidase	0	1	0	1
5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase	0	1	0	1
5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase	0	0	1	1
5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase	0	1	1	2
5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase	0	2	0	2
5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase	0	0	1	1
5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase	0	2	1	3
Chain A, Histamine N-methyltransferase	0	2	0	2
Chain A, Histamine N-methyltransferase	0	2	0	2
Chain A, Histamine N-methyltransferase	0	2	0	2
Chain A, Histamine N-methyltransferase	0	2	0	2
Thioredoxin reductase	0	1	0	1
Flavodoxin	0	0	0	2
Sodium channel protein type 1 subunit alpha	0	1	0	1
Sodium channel protein type 9 subunit alpha	0	1	0	1
G-protein coupled receptor	0	1	0	1
5-hydroxytryptamine receptor 1A	0	0	3	3
Kynurenine 3-monooxygenase	0	3	0	3
Sodium channel protein type 4 subunit alpha	0	1	0	1
Voltage-dependent L-type calcium channel subunit beta-3	0	1	0	1
Cytochrome P450 1A2	0	1	0	1
methionyl-tRNA synthetase, putative	0	2	0	2
Chain A, PROGESTERONE RECEPTOR	0	1	0	1
Glucocorticoid receptor	0	1	0	1
Tegument protein VP16	0	0	1	1
Progesterone receptor	0	0	1	1
Glucocorticoid receptor	0	1	0	1
Lysosomal alpha-mannosidase	0	2	0	2
Alpha-glucosidase	0	1	0	1
S-adenosylmethionine decarboxylase proenzyme	0	1	0	2
S-adenosylmethionine decarboxylase proenzyme	0	2	0	3
Chain A, Probable serine/threonine-protein kinase pknB	0	1	0	1
Serine/threonine-protein kinase WNK3	0	1	0	1
Caspase-14	0	0	0	1
Caspase-6	0	0	0	1
Inactive caspase-12	0	0	0	1
Caspase-10	0	0	0	1
Melanocortin receptor 4	0	2	2	4
Phospholipid hydroperoxide glutathione peroxidase	0	0	1	1
Glucose-6-phosphate dehydrogenase	0	1	0	1
Bifunctional glucose-6-phosphate 1-dehydrogenase/6-phosphogluconolactonase	0	1	0	1
Aurora kinase A	0	7	0	7
Aurora kinase B	0	1	0	1
Iodotyrosine deiodinase	0	0	1	1
Tyrosine 3-monooxygenase	0	1	0	1
Tyrosine 3-monooxygenase	0	2	0	2
Iodotyrosine deiodinase 1	0	0	1	1
Chain A, HEAT SHOCK PROTEIN 90	0	0	1	1
Chain A [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1	0	1	0	1
Chain A [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 3	0	1	0	1
Chain A, Atp-dependent Molecular Chaperone Hsp82	0	0	1	1
Chain A, Atp-dependent Molecular Chaperone Hsp82	0	0	1	1
Chain B, Type 2 DNA topoisomerase 6 subunit B	0	0	1	1
Chain A, Virulence sensor histidine kinase phoQ	0	0	1	1
Proto-oncogene tyrosine-protein kinase Src	0	1	0	1
Islet amyloid polypeptide	0	1	0	1
Low molecular weight phosphotyrosine protein phosphatase	0	1	0	1
Solute carrier family 22 member 12	0	1	0	1
Nociceptin receptor	0	2	0	2
Mu-type opioid receptor	0	1	0	1
UDP-glucuronosyltransferase 1A8	0	0	0	7
Phosphotyrosine protein phosphatase	0	4	0	4
Low molecular weight protein-tyrosine phosphatase A	0	3	0	3
Tyrosine-protein phosphatase non-receptor type 12	0	2	0	2
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1	0	1	0	1
DNA gyrase subunit B	0	2	0	2
Melanocortin receptor 3	0	0	1	1
Melanocortin receptor 3	0	1	2	3
Melanocortin receptor 5	0	1	1	2
Melanocyte-stimulating hormone receptor	0	2	1	3
Melanocyte-stimulating hormone receptor	0	1	1	2
Chain A, Isoleucyl-tRNA synthetase	0	1	0	1
Isoleucine--tRNA ligase	0	1	0	1
L-cysteine:1D-myo-inositol 2-amino-2-deoxy-alpha-D-glucopyranoside ligase	0	2	0	2
Chain A, Inosine-5'-Monophosphate Dehydrogenase 2	0	1	0	1
Inosine-5'-monophosphate dehydrogenase	0	1	0	2
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1	0	2	0	2
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1	0	2	0	2
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1	0	2	0	2
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1	0	2	0	2
Chain A, Pancreatic alpha-amylase	0	1	0	1
Chain A, Pancreatic alpha-amylase	0	1	0	1
Tyrosine-protein kinase transforming protein Fps	0	1	0	1
Solute carrier family 2, facilitated glucose transporter member 2	0	2	0	2
Solute carrier family 2, facilitated glucose transporter member 4	0	2	0	2
DNA primase TraC	0	1	0	1
Aldo-keto reductase family 1 member C21	0	5	0	5
Toll-like receptor 2	0	2	0	2
DnaK protein homolog	0	2	0	5
molecular chaperone DnaK	0	0	0	1
Carboxypeptidase B2	0	2	0	2
Prostaglandin E synthase	0	1	0	1
LuxR family transcriptional regulator	0	0	1	1
arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 isoform 2	0	1	0	1
Glycogen synthase kinase-3 beta	0	2	2	4
Nitric oxide synthase, endothelial	0	1	0	1
Aldehyde dehydrogenase 1 family, member A1	1	0	0	1
glutathione S-transferase	1	0	0	1
D-3-phosphoglycerate dehydrogenase	0	1	1	2
Peroxisomal multifunctional enzyme type 2	1	0	0	1
Thymidylate synthase	0	3	0	3
Sialin	0	2	0	3
Sialic acid-binding Ig-like lectin 7	0	1	1	2
Chain A, SusD homolog	0	0	1	1
Neuraminidase	0	5	0	5
Sialidase-4	0	5	0	5
Sialidase-1	0	4	0	4
Sepiapterin reductase	0	1	0	1
Tryptophanase	0	1	0	1
Prolyl endopeptidase	0	2	0	2
Chymotrypsin-like elastase family member 1	0	1	0	1
Prolyl endopeptidase	0	1	0	1
Formyl peptide receptor-related sequence 1	0	0	1	1
FML2_HUMAN	0	0	1	1
Chain A, Venom Allergen 2	0	0	1	1
Elastase	0	1	0	1
Glucose-dependent insulinotropic receptor	0	0	1	1
Glucose-dependent insulinotropic receptor	0	0	1	1
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	0	0	0	2
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	0	0	0	1
Tyrosyl-DNA phosphodiesterase 2	0	1	0	1
Tyrosyl-DNA phosphodiesterase 2	0	1	0	1
Chain B, Interleukin-2	0	1	0	1
Chain A, Interleukin-2	0	1	0	1
Interleukin-2 receptor subunit alpha	0	2	2	5
Chain A, mRNA CAPPING ENZYME	0	1	0	1
Chain A, Ribulose-1,5 bisphosphate carboxylase/oxygenase	0	0	3	3
Chain A, Ribulose-1,5 bisphosphate carboxylase/oxygenase large subunit N-methyltransferase	0	0	3	3
Chain A, Ribulose-1,5 bisphosphate carboxylase/oxygenase large subunit N-methyltransferase	0	0	3	3
Chain A, Ribulose-1,5 bisphosphate carboxylase/oxygenase large subunit N-methyltransferase	0	0	3	3
Adenosine receptor A1	0	2	1	3
Chain B, Exotoxin A	0	0	1	1
Chain B, Exotoxin A	0	0	1	1
Chain B, Exotoxin A	0	0	1	1
Glutamate dehydrogenase 1, mitochondrial	0	2	0	3
ubiquitin-like modifier-activating enzyme 1	0	1	0	1
ubiquitin-conjugating enzyme E2 variant 1 isoform a	0	1	0	1
Complement C1r subcomponent	0	1	0	1
Complement C1s subcomponent	0	2	0	2
DNA (cytosine-5)-methyltransferase 3B	0	5	0	5
DNA polymerase I, thermostable	0	1	0	1
Chain A, Cholix toxin	0	1	0	1
Beta-hexosaminidase subunit alpha	0	2	0	3
Chain A, Hth-type Transcriptional Regulator Ttgr	0	0	2	2
Chain A, Hth-type Transcriptional Regulator Ttgr	0	0	2	2
Chain A, Mitogen-activated protein kinase 14	0	1	0	1
Chain A, Mitogen-activated protein kinase 14	0	1	0	1
Chain A, Mitogen-activated protein kinase 14	0	1	0	1
Chain A, Mitogen-activated protein kinase 14	0	1	0	1
Chain A, Mitogen-activated protein kinase 14	0	1	0	1
Chain A, Mitogen-activated protein kinase 14	0	1	0	1
Chain A, Mitogen-activated protein kinase 14	0	1	0	1
Chain A, Mitogen-activated protein kinase 14	0	1	0	1
Chain A, Mitogen-activated protein kinase 14	0	1	0	1
G protein-activated inward rectifier potassium channel 2	0	0	1	1
G protein-activated inward rectifier potassium channel 4	0	0	1	1
G protein-activated inward rectifier potassium channel 1	0	0	1	1
Corticotropin-releasing factor receptor 1	0	1	1	2
Corticotropin-releasing factor receptor 2	0	1	1	2
Protein Tat	0	1	0	1
Protein Rev	0	1	0	1
Chain A, ASPARTYLPROTEASE	0	1	0	1
Chain B, ASPARTYLPROTEASE	0	1	0	1
Microsomal glutathione S-transferase 1	0	1	0	1
Adenosylhomocysteinase	0	1	0	2
Adenosylhomocysteinase	0	3	0	3
Neuromedin-K receptor	0	1	1	2
Substance-K receptor	0	2	0	2
Substance-K receptor	0	2	0	2
Neuropeptide Y receptor type 1	0	2	0	2
Neuropeptide Y receptor type 2	0	2	0	2
Neurotensin receptor type 1	0	0	1	1
Neurotensin receptor type 2	0	2	1	4
Myelin basic protein	0	0	1	1
Neurotensin receptor type 1	0	3	1	5
Neurotensin receptor type 1	0	3	4	9
Sortilin	0	2	0	2
Chain B, Hiv-1 Reverse Transcriptase	0	1	0	1
Chain A, Hiv-1 Reverse Transcriptase	0	1	0	1
Chain A, Hiv-1 Reverse Transcriptase	0	1	0	1
Chain A, Hiv-1 Reverse Transcriptase	0	1	0	1
Chain B, Hiv-1 Reverse Transcriptase	0	1	0	1
Chain A, Reverse transcriptase/ribonuclease H	0	1	0	1
Gag-Pol polyprotein	0	1	0	1
Imidazoleglycerol-phosphate dehydratase	0	1	0	1
Ryanodine receptor 1	0	1	0	1
Exoribonuclease H	0	3	0	3
Cardiac ryanodine receptor 2	0	1	0	1
Signal transducer and activator of transcription 5B	0	2	0	2
Hydroxycarboxylic acid receptor 3	0	0	1	1
Hydroxycarboxylic acid receptor 2	0	0	1	1
Hydroxycarboxylic acid receptor 2	0	1	1	2
Chain A, NAD-dependent deacetylase	0	1	0	1
NAD-dependent protein deacetylase sirtuin-6	0	3	1	5
NAD-dependent protein deacetylase	0	1	0	1
Equilibrative nucleoside transporter 1	0	1	0	1
Anoctamin-1	0	2	0	2
Neuronal acetylcholine receptor subunit alpha-4	0	2	1	3
Neuronal acetylcholine receptor subunit alpha-4	0	1	0	1
Acetylcholine receptor subunit beta-like 2	0	2	0	2
Neuronal acetylcholine receptor subunit alpha-5	0	0	2	2
Neuronal acetylcholine receptor subunit alpha-7	0	4	0	4
Neuronal acetylcholine receptor subunit beta-3	0	1	1	2
Neuronal acetylcholine receptor subunit alpha-2	0	1	0	1
Neuronal acetylcholine receptor subunit alpha-6	0	1	1	2
Neuronal acetylcholine receptor subunit alpha-5	0	2	0	2
Liver carboxylesterase B-1	0	1	0	1
Neuronal acetylcholine receptor subunit beta-3	0	2	0	2
Neuronal acetylcholine receptor subunit alpha-3	0	2	0	2
Soluble acetylcholine receptor	0	1	0	1
Neuronal acetylcholine receptor subunit alpha-2	0	2	0	2
Neuronal acetylcholine receptor subunit alpha-6	0	2	0	2
Voltage-dependent L-type calcium channel subunit alpha-1C	0	1	0	1
Voltage-dependent L-type calcium channel subunit alpha-1S	0	1	0	1
Voltage-dependent L-type calcium channel subunit alpha-1D	0	1	0	1
Voltage-dependent L-type calcium channel subunit alpha-1F	0	1	0	1
Chain A, Phospholipase A2 isoform 3	0	0	1	1
Voltage-dependent L-type calcium channel subunit beta-4	0	2	0	2
Voltage-dependent P/Q-type calcium channel subunit alpha-1A	0	2	0	2
Voltage-dependent calcium channel gamma-3 subunit	0	2	0	2
Voltage-dependent L-type calcium channel subunit beta-3	0	2	0	2
Voltage-dependent calcium channel subunit alpha-2/delta-1	0	3	0	4
Voltage-dependent calcium channel gamma-7 subunit	0	2	0	2
Voltage-dependent L-type calcium channel subunit beta-1	0	2	0	2
Voltage-dependent calcium channel gamma-1 subunit	0	2	0	2
Voltage-dependent L-type calcium channel subunit beta-2	0	2	0	2
Voltage-dependent R-type calcium channel subunit alpha-1E	0	2	0	2
Voltage-dependent calcium channel subunit alpha-2/delta-4	0	2	0	2
Voltage-dependent calcium channel subunit alpha-2/delta-3	0	2	0	2
Voltage-dependent calcium channel gamma-8 subunit	0	2	0	2
Voltage-dependent calcium channel gamma-6 subunit	0	2	0	2
Voltage-dependent calcium channel subunit alpha-2/delta-2	0	3	0	3
Voltage-dependent calcium channel gamma-4 subunit	0	2	0	2
Voltage-dependent calcium channel gamma-5 subunit	0	2	0	2
Voltage-dependent calcium channel gamma-2 subunit	0	2	0	2
Protein mono-ADP-ribosyltransferase PARP11	0	1	2	3
Pyruvate-flavodoxin oxidoreductase	0	1	0	1
4-hydroxyphenylpyruvate dioxygenase	0	1	0	1
4-hydroxyphenylpyruvate dioxygenase	0	1	0	1
4-hydroxyphenylpyruvate dioxygenase	0	1	0	1
Sodium/iodide cotransporter	0	3	0	3
Nitric oxide synthase, inducible	0	2	0	2
Nitric oxide synthase, brain	0	2	0	2
Chain B, Cathepsin B	0	1	0	1
Nociceptin receptor	0	1	3	4
Chain A, Glutathione-requiring prostaglandin D synthase	0	1	0	1
sentrin-specific protease 1	0	1	0	1
Mediator of RNA polymerase II transcription subunit 25	0	1	0	1
Tubulin beta 8B	0	0	1	1
Chain A, Gyrase	0	0	1	1
DNA gyrase subunit B	0	1	0	1
DNA gyrase subunit B	0	1	0	1
Cell division inhibitor SulA	0	0	0	1
DNA topoisomerase 4 subunit B	0	1	0	1
DNA topoisomerase	0	1	0	1
Microtubule-associated proteins 1A/1B light chain 3B	0	2	1	3
Microtubule-associated proteins 1A/1B light chain 3A	0	2	1	3
Tyrosine-protein kinase Lyn	0	1	0	1
Mitogen-activated protein kinase 10	0	1	0	1
Calcium-activated potassium channel subunit alpha-1	0	1	0	2
Calcium-activated potassium channel subunit beta-1	0	0	0	1
Acyl-homoserine lactone acylase PvdQ	0	1	0	1
Ras-related C3 botulinum toxin substrate 1	0	1	0	1
M-phase inducer phosphatase 3	0	4	0	4
N-lysine methyltransferase KMT5A	0	1	1	2
Signal transducer and activator of transcription 1	0	1	0	1
Dual specificity protein phosphatase 5	0	2	0	2
Chain A, CYCLIN-DEPENDENT PROTEIN KINASE 2	0	2	0	2
Chain A, CYCLIN-DEPENDENT PROTEIN KINASE 2	0	2	0	2
mitogen-activated protein kinase 3 isoform 1	0	0	0	1
Endothelial lipase	0	2	0	2
E3 ubiquitin-protein ligase Mdm2	0	2	0	2
E3 ubiquitin-protein ligase Mdm2	0	2	0	2
Chain A, Hepatocyte growth factor receptor	0	1	0	1
Solute carrier family 22 member 19	0	0	0	1
Cathepsin Z	0	1	0	1
Cathepsin F	0	1	0	1
Protein mono-ADP-ribosyltransferase PARP6	0	2	0	2
Neurogenic locus notch homolog protein 1	0	1	0	1
Hemagglutinin [Cleaved into: Hemagglutinin HA1 chain; Hemagglutinin HA2 chain]	0	0	1	1
Chain A, Adipocyte Lipid-binding Protein	0	0	1	1
Chain A, MUSCLE FATTY ACID BINDING PROTEIN	0	0	2	2
Chain A, MUSCLE FATTY ACID BINDING PROTEIN	0	0	2	2
Chain A, MUSCLE FATTY ACID BINDING PROTEIN	0	0	2	2
putative potassium channel subunit	0	0	1	1
Chain A, MAP KINASE P38	0	2	0	2
Chain A, PROTEIN (MAP KINASE P38)	0	2	0	2
Chain A, PROTEIN (MAP KINASE P38)	0	2	0	2
Chain A, Protein (map Kinase P38)	0	2	0	2
Chain A, Extracellular Regulated Kinase 2	0	2	0	2
Chain A, Extracellular Regulated Kinase 2	0	2	0	2
Bifunctional cytochrome P450/NADPH--P450 reductase	0	0	1	1
Bombesin receptor subtype-3	0	0	1	1
ATP-dependent Clp protease proteolytic subunit, mitochondrial	0	0	2	2
Interleukin-6 receptor subunit alpha	0	1	0	1
Thyrotropin-releasing hormone receptor	0	1	0	1
Glycine receptor subunit alpha-4	0	1	0	1
Leukotriene B4 receptor 1	0	1	0	1
Phosphatidylserine lipase ABHD16A	0	1	0	1
Lipoprotein lipase	0	1	0	1
Hepatic triacylglycerol lipase	0	1	0	1
Neutral cholesterol ester hydrolase 1	0	1	0	1
Diacylglycerol lipase-alpha	0	1	0	1
Diacylglycerol lipase-beta	0	1	0	1
Acyl-protein thioesterase 2	0	1	0	1
Chain A, ARGINASE 1	0	1	0	1
Chain A, Arginase 1	0	1	0	1
Chain A, ARGINASE 1	0	1	0	1
Chain A, L-ARGININE\\:GLYCINE AMIDINOTRANSFERASE	0	1	0	1
Solute carrier family 2, facilitated glucose transporter member 9	0	2	2	4
Neuraminidase	0	4	0	4
Neuraminidase	0	4	0	4
Acyl-CoA desaturase 1	0	3	0	3
Neuraminidase	0	4	0	4
Neuraminidase	0	4	0	4
Neuraminidase	0	2	0	2
Neuraminidase	0	2	0	2
Cytochrome P450 11B2, mitochondrial	0	1	0	1
von Hippel-Lindau disease tumor suppressor	0	1	0	1
Epidermal growth factor receptor	0	4	0	4
Chain H, Igg2b-kappa 40-50 Fab (heavy Chain)	0	1	0	1
Chain L, Igg2b-kappa 40-50 Fab (light Chain)	0	1	0	1
Chain A, Na, K-ATPase alpha subunit	0	0	1	1
Kruppel-like factor 5	0	1	0	1
Sodium/potassium-transporting ATPase subunit alpha-1	0	1	0	1
Sodium/potassium-transporting ATPase subunit beta-3	0	1	0	1
MecA	0	1	0	1
Protoporphyrinogen oxidase	0	1	0	1
Chain A, Pyruvate kinase, M2 isozyme	0	1	0	1
Chain A, Phosphonopyruvate hydrolase	0	1	0	1
Chain A, Phosphoenolpyruvate-protein phosphotransferase	0	1	0	1
Chain A, CITRATE SYNTHASE	0	0	1	1
Chain B, CITRATE SYNTHASE	0	0	1	1
Prolyl 4-hydroxylase subunit alpha-1	0	2	0	2
L-lactate dehydrogenase C chain	0	1	0	1
L-lactate dehydrogenase A chain	0	1	0	1
L-lactate dehydrogenase A chain	0	1	0	1
L-lactate dehydrogenase	0	1	0	1
Bifunctional epoxide hydrolase 2	0	1	0	1
Bifunctional epoxide hydrolase 2	0	1	0	1
Chain A, Bacterial leucyl aminopeptidase	0	1	0	1
Oxytocin receptor	0	0	1	1
Plasminogen activator inhibitor 1	0	0	1	1
Chain B, Cell division protein kinase 6	0	1	0	1
Chain B, Cell division protein kinase 6	0	1	0	1
Genome polyprotein	0	1	0	1
Chain A, Fatty acid-binding protein, adipocyte	0	1	0	1
Protein Tat	0	0	2	2
NAD-dependent protein deacetylase sirtuin-7	0	2	0	2
Type II pantothenate kinase	0	0	0	1
Type III pantothenate kinase	0	0	0	1
Chain A, cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	0	1	0	1
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	0	2	0	2
Photosystem I iron-sulfur center	0	0	0	1
Pyrroline-5-carboxylate reductase 1, mitochondrial	0	1	0	1
Rhodopsin kinase GRK1	0	1	0	1
G protein-coupled receptor kinase 5	0	1	0	1
Beta-adrenergic receptor kinase 1	0	0	0	1
Testosterone 17-beta-dehydrogenase 3	0	1	0	1
Nuclear receptor subfamily 4 group A member 3	0	1	0	1
Peroxiredoxin-like 2A	0	1	0	1
Protein kinase C alpha type	0	2	0	2
Fructose-1,6-bisphosphatase 1	0	2	0	2
Fibroblast growth factor receptor 1	0	1	0	1
Fibroblast growth factor receptor 2	0	1	0	1
Fibroblast growth factor receptor 3	0	1	0	1
calcium-dependent protein kinase 1	0	1	0	1
protein kinase 6	0	1	0	1
Chain A, Protein (fibroblast Growth Factor (fgf) Receptor 1)	0	1	0	1
Gastrin-releasing peptide receptor	0	1	0	2
Chain A, Proto-oncogene tyrosine-protein kinase ABL1	0	1	0	1
Chain A, Proto-oncogene tyrosine-protein kinase ABL1	0	1	0	1
Chain A, Proto-oncogene tyrosine-protein kinase ABL1	0	1	0	1
Chain A, Proto-oncogene tyrosine-protein kinase ABL1	0	1	0	1
Chain A, Proto-oncogene tyrosine-protein kinase ABL1	0	1	0	1
Dual specificity mitogen-activated protein kinase kinase 2	0	1	0	1
Dual specificity mitogen-activated protein kinase kinase 1	0	1	0	1
Chymotrypsin-like elastase family member 2A	0	3	0	3
Chain A, Thymidylate Synthase	0	1	0	1
Chain A, Thymidylate Synthase	0	1	0	1
Chain A, Thymidylate Synthase	0	1	0	1
Serine hydroxymethyltransferase, cytosolic	0	1	1	2
Beta-lactamase 1	0	0	0	1
Chain C, Respiratory nitrate reductase 1 gamma chain	0	1	0	1
Protein S100-B	0	1	1	2
Protein S100-B	0	0	1	1
Acrosin	0	1	0	1
Protein tyrosine phosphatase type IVA 2	0	1	0	1
Protein tyrosine phosphatase type IVA 1	0	1	0	1
Chain A, CATHEPSIN D	0	1	0	1
Chain B, CATHEPSIN D	0	1	0	1
Chain A, PLASMEPSIN II	0	1	0	1
Chain E, ENDOTHIAPEPSIN	0	1	0	1
Chain E, RHIZOPUSPEPSIN	0	1	0	1
Chain E, ENDOTHIAPEPSIN	0	1	0	1
Chain E, ENDOTHIAPEPSIN	0	1	0	1
Chain E, RHIZOPUSPEPSIN	0	1	0	1
Chain E, RHIZOPUSPEPSIN	0	1	0	1
Candidapepsin-2	0	1	0	1
Pepsin A-5	0	1	0	1
Gag-Pro polyprotein	0	1	0	1
Cathepsin E	0	1	0	1
Plasmepsin-1	0	1	0	1
Plasmepsin-2	0	1	0	1
Disintegrin and metalloproteinase domain-containing protein 9	0	1	0	1
Plasmepsin 4	0	1	0	1
NACHT, LRR and PYD domains-containing protein 1 isoform 1	0	1	0	1
Aldehyde oxidase 1	0	2	0	2
Aldehyde oxidase 1	0	2	0	2
Ubiquitin-like modifier-activating enzyme 6	0	1	0	1
Ubiquitin-like modifier-activating enzyme ATG7	0	1	0	1
Ubiquitin-like modifier-activating enzyme 1	0	1	0	1
NEDD8	0	1	0	1
SUMO-activating enzyme subunit 2	0	1	0	1
Chain A, HEPATOCYTE GROWTH FACTOR RECEPTOR	0	1	0	1
Chain A, HEPATOCYTE GROWTH FACTOR RECEPTOR	0	1	0	1
Chain A, HEPATOCYTE GROWTH FACTOR RECEPTOR	0	1	0	1
Chain A, HEPATOCYTE GROWTH FACTOR RECEPTOR	0	1	0	1
cGMP-specific 3',5'-cyclic phosphodiesterase	0	4	0	4
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2	0	1	0	1
Acyl-CoA	0	1	0	1
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2	0	1	0	1
Probable global transcription activator SNF2L2	0	0	2	2
Transcription activator BRG1	0	0	2	2
Bromodomain-containing protein 9	0	0	3	3
Bromodomain-containing protein 7	0	0	3	3
Chain A, Focal adhesion kinase 1	0	1	0	1
B-cell lymphoma 6 protein	0	0	1	1
Fibroblast growth factor 1	0	0	3	3
Fibroblast growth factor 2	0	1	2	3
Cyclin-dependent kinase 2-associated protein 2	0	1	0	1
calcium-dependent protein kinase 4	0	1	0	1
Poly [ADP-ribose] polymerase 1	0	1	0	1
Chain A, Immunoglobulin	0	0	1	1
Chain B, Immunoglobulin	0	0	1	1
Muscarinic acetylcholine receptor M5	0	1	1	3
Chain A, TRYPSIN	0	1	0	1
Chain A, TRYPSIN	0	1	0	1
Chain A, TRYPSIN	0	1	0	1
Chain A, TRYPSIN	0	1	0	1
Chain A, TRYPSIN	0	1	0	1
Chain A, TRYPSIN	0	1	0	1
Chain A, Lysozyme	0	0	1	1
Chain A, Lysozyme	0	0	1	1
Chain A, Lysozyme	0	0	1	1
Chain A, Lysozyme	0	0	1	1
Chain A, Ferritin light chain	0	0	2	2
Chain A, Ferritin light chain	0	0	2	2
Chain A, Ferritin light chain	0	0	2	2
Chain A, Ferritin light chain	0	0	2	2
Chain A, Ferritin light chain	0	0	2	2
Chain A, Ferritin light chain	0	0	2	2
Chain A, Ferritin light chain	0	0	2	2
Thymidylate synthase	0	1	0	1
Alpha-1B adrenergic receptor	0	5	0	5
Trace amine-associated receptor 5	0	0	4	4
Retinoid isomerohydrolase	0	1	0	1
Retinoid isomerohydrolase	0	1	0	1
Retinoid isomerohydrolase	0	1	0	1
Myeloblastin	0	1	0	1
Chain A, PROTEIN (CATECHOL OXIDASE)	0	1	0	1
Sodium/hydrogen exchanger 9B2	0	1	0	1
Sodium/glucose cotransporter 1	0	1	0	1
Proto-oncogene vav	0	0	1	1
Transient receptor potential cation channel subfamily V member 4	0	0	1	1
Chain A, NUCLEOSIDE DIPHOSPHATE KINASE	0	0	1	1
Chain A, phosphoenolpyruvate carboxykinase, cytosolic	0	1	0	1
Chain A, Phosphoenolpyruvate Carboxykinase, Cytosolic	0	1	0	1
Chain A, TRIOSEPHOSPHATE ISOMERASE	0	1	0	1
Chain A, METHYLGLYOXAL SYNTHASE	0	1	0	1
Chain F, METHYLGLYOXAL SYNTHASE	0	1	0	1
Chain A, TRIOSEPHOSPHATE ISOMERASE	0	1	0	1
Chain B, TRIOSEPHOSPHATE ISOMERASE	0	1	0	1
Chain A, triosephosphate isomerase, glycosomal	0	1	0	1
Chain A, Triosephosphate Isomerase	0	1	0	1
Chain B, Triosephosphate Isomerase	0	1	0	1
Chain A, Triosephosphate Isomerase	0	1	0	1
Chain A, Enolase	0	1	0	1
Chain A, Methylglyoxal synthase	0	1	0	1
Chain F, Methylglyoxal synthase	0	1	0	1
Chain A, Triosephosphate Isomerase	0	1	0	1
Chain A, Alkaline Phosphatase	0	1	0	1
Chain A, ALKALINE PHOSPHATASE	0	1	0	1
Fe(3+)-Zn(2+) purple acid phosphatase	0	2	0	2
Chain E, THERMOLYSIN	0	1	0	1
Chain E, Thermolysin	0	1	0	1
Neprilysin	0	5	0	5
Acetylcholinesterase	0	1	0	1
Chain D, PROTEIN (PHOSPHOGLYCERATE MUTASE 1)	0	1	0	1
Chain A, PROTEIN (PHOSPHOGLYCERATE MUTASE 1)	0	1	0	1
Chain A, Beta-arrestin 1	0	0	1	1
Chain A, PHOSPHOTIDYLINOSITOL 3 KINASE 59F	0	1	0	1
Chain A, PHOSPHOTIDYLINOSITOL 3 KINASE 59F	0	1	0	1
Chain A, PHOSPHOTIDYLINOSITOL 3 KINASE 59F	0	1	0	1
Chain A, PHOSPHOTIDYLINOSITOL 3 KINASE 59F	0	1	0	1
4-hydroxyphenylpyruvate dioxygenase	0	1	0	1
CDGSH iron-sulfur domain-containing protein 1	0	2	0	2
Peroxisome proliferator-activated receptor gamma	0	1	0	1
CDGSH iron-sulfur domain-containing protein 2	0	2	0	2
Transforming growth factor beta-1 proprotein	0	2	0	2
Mothers against decapentaplegic homolog 3	0	2	0	2
Dihydrofolate reductase	0	3	0	4
Dihydrofolate reductase	0	3	0	3
Dihydrofolate reductase	0	6	0	6
Dihydrofolate reductase	0	2	0	2
Cytochrome P450 4B1	0	3	0	3
Cytochrome P450 2A7	0	3	0	3
Cytochrome P450 2F1	0	3	0	3
Transcriptional enhancer factor TEF-1	0	1	1	2
Cytochrome P450 2C18	0	4	0	4
Cytochrome P450 4F8	0	3	0	3
Cytochrome P450 4A11	0	3	0	3
Cytochrome P450 4F3	0	3	0	3
Transcriptional enhancer factor TEF-4	0	1	0	1
Cytochrome P450 4A22	0	3	0	3
Vitamin D 25-hydroxylase	0	3	0	3
Cytochrome P450 2U1	0	3	0	3
Cytochrome P450 2W1	0	3	0	3
Cytochrome P450 2S1	0	3	0	3
Transcriptional enhancer factor TEF-5	0	1	0	1
Tubulin alpha chain-like 3	0	2	0	2
Tubulin alpha-8 chain	0	2	0	2
C-X-C chemokine receptor type 4	0	1	0	1
Atypical chemokine receptor 3	0	0	1	1
C-X-C chemokine receptor type 4	0	4	2	9
Chain A, B-Raf proto-oncogene serine/threonine-protein kinase	0	1	0	1
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1	0	1	0	1
Chain A, Basic fibroblast growth factor receptor 1	0	1	0	1
Chain A, AKAP9-BRAF fusion protein	0	1	0	1
Dual specificity mitogen-activated protein kinase kinase 4	0	0	1	1
Regulatory protein E2	0	0	1	1
Regulatory protein E2	0	0	1	1
Calcium-activated potassium channel subunit alpha-1	0	1	0	1
E3 ubiquitin-protein ligase ZFP91	0	0	0	1
Sentrin-specific protease 1	0	4	0	4
Sterol 14-alpha-demethylase	0	0	2	2
14-alpha sterol demethylase	0	0	2	2
14-alpha sterol demethylase	0	0	2	2
Sodium/potassium/calcium exchanger 4	0	1	1	2
Sodium/potassium/calcium exchanger 2	0	1	1	2
Oxygen-insensitive NAD(P)H nitroreductase	0	0	0	3
Beta-casein	0	2	0	2
Alpha-2A adrenergic receptor	0	2	0	2
Glutamine synthetase	0	0	1	1
Pannexin-1	0	1	0	1
Vascular cell adhesion protein 1	0	1	0	1
Chain H, ALPHA-THROMBIN	0	0	1	1
Chain A, Transcriptional regulator qacR	0	0	1	1
Chain A, Transcriptional regulator qacR	0	0	1	1
Chain A, TETR FAMILY TRANSCRIPTIONAL REPRESSOR LFRR	0	0	1	1
Major pollen allergen Bet v 1-A	0	0	1	1
Histamine H2 receptor	0	1	0	1
Glutamate 5-kinase	0	0	0	1
Free fatty acid receptor 2	0	0	1	1
NADH-cytochrome b5 reductase 3	0	1	0	1
Thyroid peroxidase	0	1	0	1
WEE1 homolog (S. pombe)	0	0	1	2
cyclin B1	0	0	1	1
urokinase-type plasminogen activator isoform 1 preproprotein	1	0	0	1
Chain A, Protocatechuate 3,4-dioxygenase alpha chain	0	0	1	1
Chain B, Protocatechuate 3,4-dioxygenase beta chain	0	0	1	1
Coproheme decarboxylase	0	0	1	1
GMP synthase [glutamine-hydrolyzing]	0	1	0	1
Chain A, Protein (ricin)	0	1	0	1
Chain A, Protein (ricin)	0	1	0	1
Interleukin-5	0	1	0	1
Interleukin-5	0	1	0	1
Interleukin-5 receptor subunit alpha	0	1	0	1
Puromycin-sensitive aminopeptidase	0	3	0	3
Cdc2	0	2	0	2
Chain A, PUTRESCINE-BINDING PROTEIN	0	0	1	1
Chain A, S-ADENOSYLMETHIONINE DECARBOXYLASE ALPHA CHAIN	0	1	0	1
Chain B, S-ADENOSYLMETHIONINE DECARBOXYLASE BETA CHAIN	0	1	0	1
Chain A, S-ADENOSYLMETHIONINE DECARBOXYLASE ALPHA CHAIN	0	1	0	1
Chain B, S-ADENOSYLMETHIONINE DECARBOXYLASE BETA CHAIN	0	1	0	1
Chain A, Mitogen-activated protein kinase 10	0	1	0	1
Chain A, Mitogen-activated protein kinase 10	0	1	0	1
Chain A, Mitogen-activated protein kinase 10	0	1	0	1
Trans-sialidase	0	1	0	1
Bifunctional dihydrofolate reductase-thymidylate synthase	0	1	0	1
Beta-hexosaminidase subunit beta	0	1	0	1
Bifunctional dihydrofolate reductase-thymidylate synthase	0	2	0	2
Bifunctional dihydrofolate reductase-thymidylate synthase	0	2	0	2
Multidrug and toxin extrusion protein 1	0	1	0	1
Cytidine deaminase	0	1	0	1
Chain A, dATP pyrophosphohydrolase	0	1	0	1
Chain A, Adenylate cyclase type 5	0	1	0	1
Chain B, Adenylate cyclase type 2	0	1	0	1
Monocarboxylate transporter 2	0	0	0	1
Fumarate reductase	0	1	0	1
Chain A, Mitogen-activated protein kinase 8	0	1	0	1
Mitogen-activated protein kinase 8	0	1	0	1
oxytocin receptor	0	0	2	2
Chain A, APH(2')-Id	0	1	0	1
glucose-6-phosphate dehydrogenase	0	1	0	1
N	0	1	0	1
DNA-directed RNA polymerase subunit alpha	0	1	0	1
DNA-directed RNA polymerase subunit omega	0	1	0	1
DNA-directed RNA polymerase subunit beta'	0	1	0	1
DNA-directed RNA polymerase subunit beta	0	1	0	1
Multidrug resistance protein 1a	0	0	0	1
Advanced glycosylation end product-specific receptor	0	0	1	1
Chain A, Glutamate Receptor 2	0	1	0	1
Chain A, Glutamate Receptor 2	0	1	0	1
Diacylglycerol kinase alpha	0	2	0	2
Diacylglycerol kinase alpha	0	1	0	1
Gastric inhibitory polypeptide receptor	0	1	0	1
Chain A, Thymidylate Synthase	0	1	0	1
Chain B, Thymidylate Synthase	0	1	0	1
Chain A, THYMIDYLATE SYNTHASE	0	1	0	1
Chain A, THYMIDYLATE SYNTHASE	0	1	0	1
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3	0	1	0	1
Vascular endothelial growth factor receptor 3	0	2	0	2
Synaptic vesicular amine transporter	0	3	0	3
Chromaffin granule amine transporter	0	1	0	1
Chain A, Bacterial regulatory proteins, tetR family	0	0	1	1
Chain A, Troponin C, slow skeletal and cardiac muscles	0	0	1	1
N1L	0	1	0	1
Chain A, Cellular retinoic acid-binding protein 2	0	0	1	1
Chain A, Cellular retinoic acid-binding protein 2	0	0	1	1
Chain A, PLASMA RETINOL-BINDING PROTEIN PRECURSOR	0	0	1	1
Beta-lactoglobulin	0	0	1	1
Polymerase basic protein 2	0	0	1	1
RNA-directed RNA polymerase catalytic subunit	0	0	1	1
Genome polyprotein	0	0	1	1
Chain A, 6,7-Dimethyl-8-ribityllumazine Synthase	0	0	1	1
Chain B, 6,7-Dimethyl-8-ribityllumazine Synthase	0	0	1	1
Chain H, Immunoglobulin Igg1 Heavy chain	0	0	1	1
Chain L, Immunoglobulin Igg1 Lambda Light Chain	0	0	1	1
Chain A, DODECIN	0	0	1	1
Chain A, DODECIN	0	0	1	1
Chain C, DODECIN	0	0	1	1
Chain E, DODECIN	0	0	1	1
DNA-directed RNA polymerase subunit beta	0	1	0	1
DNA-directed RNA polymerase subunit beta	0	1	0	1
Scavenger receptor class B member 1	0	1	0	1
4-hydroxy-3-methylbut-2-enyl diphosphate reductase	0	1	0	1
Farnesyl diphosphate synthase	0	1	0	1
H	0	2	0	2
Phosphotransferase	0	1	0	1
Farnesyl diphosphate synthase	0	1	0	1
Chain A, HIV-1 PROTEASE	0	1	0	1
Chain B, HIV-1 PROTEASE	0	1	0	1
Chain A, Endothiapepsin	0	1	0	1
Chain A, Endothiapepsin	0	1	0	1
Chain A, Activated Factor Xa Heavy Chain	0	1	0	1
Serine/threonine-protein kinase VRK1	0	1	0	1
Chain A, Transthyretin	0	0	1	1
Chain B, Transthyretin	0	0	1	1
Chain A, Transthyretin	0	0	1	1
Chain B, Transthyretin	0	0	1	1
Chain A, Transthyretin	0	0	1	1
Squalene--hopene cyclase	0	1	0	1
Lanosterol synthase	0	1	0	1
Chain A, interleukin-2	0	0	1	1
Prostaglandin G/H synthase 2	0	1	0	1
Cytochrome c oxidase subunit 1	0	1	0	1
Transporter	0	1	0	1
Sodium-dependent serotonin transporter	0	1	0	1
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	0	4	0	4
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	0	4	0	4
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	0	4	0	4
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	0	4	0	4
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	0	4	0	4
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	0	4	0	4
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	0	4	0	4
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	0	4	0	4
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	0	4	0	4
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	0	4	0	4
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	0	4	0	4
Chain B, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	0	4	0	4
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase	0	4	0	4
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase	0	4	0	4
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	0	1	0	1
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	0	1	0	1
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	0	1	0	1
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	0	1	0	1
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	0	1	0	1
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	0	1	0	1
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	0	1	0	1
Phosphodiesterase	0	2	0	2
Retina-specific copper amine oxidase	0	2	0	2
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B	0	4	0	4
Histone deacetylase 6	0	4	1	5
Protein translocase subunit SecA 1	0	1	0	1
Protein translocase subunit SecA 2	0	1	0	1
Thrombin	0	0	1	1
UDP-galactopyranose mutase	0	0	2	2
UDP-galactopyranose mutase	0	0	2	2
Choline kinase alpha	0	1	0	1
GDH/6PGL endoplasmic bifunctional protein	0	1	0	1
Protein mono-ADP-ribosyltransferase PARP9	0	0	1	1
Neuromedin-U receptor 2	0	0	2	2
Low-density lipoprotein receptor	0	1	0	1
Fibronectin	0	1	0	1
Proprotein convertase subtilisin/kexin type 9	0	1	0	1
nucleotide exchange factor GrpE	0	1	0	1
Chain A, ADENINE-N6-DNA-METHYLTRANSFERASE TAQI	0	0	2	2
Chain A, Adenine-n6-dna-methyltransferase Taqi	0	0	2	2
Chain A, Histamine N-Methyltransferase	0	1	0	1
Chain A, Histamine N-Methyltransferase	0	1	0	1
Chain A, Modification Methylase Rsri	0	0	1	1
Chain A, Modification Methylase Rsri	0	0	1	1
Chain A, Ermc' Methyltransferase	0	2	0	2
Chain A, Ermc' Rrna Methyltransferase	0	2	0	2
Chain A, Uroporphyrin-III C-methyltransferase	0	1	0	1
Chain B, ADENINE-N6-DNA-METHYLTRANSFERASE TAQI	0	0	2	2
tRNA (cytosine(38)-C(5))-methyltransferase	0	2	2	4
Adenosylhomocysteinase	0	0	0	1
Histone-lysine N-methyltransferase NSD2	0	2	0	2
rRNA adenine N-6-methyltransferase	0	1	0	1
tRNA (guanine-N(1)-)-methyltransferase	0	0	1	1
Histone-lysine N-methyltransferase SETDB1	0	1	0	1
Retinoblastoma-binding protein 5	0	1	0	1
tRNA (guanine-N(1)-)-methyltransferase	0	0	1	1
N6-adenosine-methyltransferase catalytic subunit	0	1	0	1
Histone-lysine N-methyltransferase KMT5C	0	1	0	1
Protein dpy-30 homolog	0	1	0	1
Histamine N-methyltransferase	0	0	0	1
tRNA (guanine-N(1)-)-methyltransferase	0	0	1	1
Set1/Ash2 histone methyltransferase complex subunit ASH2	0	1	0	1
Met repressor	0	0	2	2
Histone H3K27 methylase	0	0	0	1
Protein-L-isoaspartate(D-aspartate) O-methyltransferase	0	2	0	2
Protein-S-isoprenylcysteine O-methyltransferase	0	1	0	1
Chain A, Lysr-type Regulatory Protein	0	0	1	1
Chain A, Lysr-type Regulatory Protein	0	0	1	1
Chain A, Lysr-type Regulatory Protein	0	0	1	1
Chain A, 146aa long hypothetical transcriptional regulator	0	0	1	1
Chain A, Anthranilate phosphoribosyltransferase	0	1	0	1
Chain A, Anthranilate phosphoribosyltransferase	0	1	0	1
Chain A, Anthranilate phosphoribosyltransferase	0	1	0	1
Chain B, Anthranilate phosphoribosyltransferase	0	1	0	1
Chain C, Anthranilate phosphoribosyltransferase	0	1	0	1
Chain A, Anthranilate phosphoribosyltransferase	0	1	0	1
Anthranilate phosphoribosyltransferase	0	1	0	1
Tyrosine-protein phosphatase YopH	0	1	0	1
Ubiquitin-like domain-containing CTD phosphatase 1	0	1	0	1
B-cell CLL/lymphoma 9 protein	0	2	0	2
Chain A, Hiv-1 Protease	0	1	0	1
Chain B, Hiv-1 Protease	0	1	0	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Protease	0	0	1	1
Chain B, Protease	0	0	1	1
Chain A, Proto-oncogene tyrosine-protein kinase Src	0	1	0	1
Tau-tubulin kinase 1	0	1	0	1
Tau-tubulin kinase 2	0	1	0	1
Chain A, Erk2	0	1	0	1
Mitogen-activated protein kinase 2	0	1	0	1
P2X purinoceptor 7	0	1	0	1
Transient receptor potential cation channel subfamily M member 1	0	1	0	1
Adenylate cyclase type 6	0	1	0	1
Adenylate cyclase type 3	0	1	0	1
Adenylate cyclase type 9	0	1	0	1
D(1) dopamine receptor	0	1	0	1
Adenylate cyclase type 7	0	1	0	1
Adenylate cyclase type 2	0	1	0	1
Adenylate cyclase type 4	0	1	0	1
C-X-C chemokine receptor type 2	0	1	0	1
Collagenase ColH	0	1	0	1
Lanosterol synthase	0	1	0	1
Chain A, Porphobilinogen Synthase	0	1	0	1
Chain A, Porphobilinogen Synthase	0	1	0	1
Chain A, Porphobilinogen Synthase	0	1	0	1
Cell division control protein 42 homolog	0	1	0	1
Type-1 angiotensin II receptor	0	1	0	1
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET	0	1	0	1
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET	0	1	0	1
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET	0	1	0	1
vasopressin V1a receptor	0	0	1	1
Vascular endothelial growth factor receptor 1	0	2	0	2
Vascular endothelial growth factor receptor 2	0	3	0	3
1,25-dihydroxyvitamin D-3 receptor	0	1	0	1
Protein Red	0	1	0	1
Proteinase-activated receptor 2	0	1	1	2
Chain A, POL polyprotein	0	0	1	1
Chain B, POL polyprotein	0	0	1	1
Chain A, POL polyprotein	0	0	1	1
Chain B, POL polyprotein	0	0	1	1
Chain A, POL polyprotein	0	0	1	1
Chain B, POL polyprotein	0	0	1	1
Chain A, POL polyprotein	0	0	1	1
Chain B, POL polyprotein	0	0	1	1
Chain A, POL polyprotein	0	0	1	1
Chain B, POL polyprotein	0	0	1	1
Thymidine phosphorylase	0	1	0	1
Thymidine phosphorylase	0	1	0	1
Protein arginine N-methyltransferase 1	0	1	0	1
Chain A, Hepatocyte growth factor receptor	0	1	0	1
Chain A, Hepatocyte growth factor receptor	0	1	0	1
Chain A, Shikimate kinase	0	0	1	1
Chain A, 3-phosphoshikimate 1-carboxyvinyltransferase	0	1	0	1
Chain A, 3-phosphoshikimate 1-carboxyvinyltransferase	0	1	0	1
Pyruvate kinase PKLR	0	1	0	1
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase	0	0	1	1
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase	0	0	1	1
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase	0	0	1	1
cGMP-specific 3',5'-cyclic phosphodiesterase	0	3	2	5
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma	0	3	0	3
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha	0	3	0	3
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'	0	3	0	3
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma	0	3	0	3
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta	0	3	0	3
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma	0	1	0	1
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta	0	3	0	3
Cholecystokinin receptor type A	0	1	0	1
mRNA cap guanine-N7 methyltransferase	0	1	0	1
Glycine N-methyltransferase	0	1	0	1
RNA guanine-N7 methyltransferase activating subunit	0	1	0	1
Peptidyl-prolyl cis-trans isomerase FKBP1A	0	1	0	1
Programmed cell death protein 4	0	1	1	2
Chain A, Ribosomal protein S6 kinase alpha-3	0	0	1	1
Putative nitroreductase	0	2	0	4
Nitroreductase A	0	2	0	2
Corticotropin releasing hormone receptor 2	0	2	0	2
Laccase	0	1	0	1
Beta-lactamase	0	1	0	2
Protein-serine/threonine kinase	0	1	0	1
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	0	1	0	1
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	0	1	0	1
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	0	1	0	1
Somatostatin receptor type 5	0	1	0	1
Somatostatin receptor type 1	0	1	0	1
Somatostatin receptor type 2	0	1	0	1
Somatostatin receptor type 3	0	1	0	1
Somatostatin receptor type 5	0	1	0	1
Somatostatin receptor type 4	0	1	0	1
Chain A, Mitogen-activated protein kinase 14	0	0	1	1
Chain A, Mitogen-activated protein kinase 14	0	0	1	1
Chain A, Mitogen-activated protein kinase 14	0	0	1	1
Chain A, Mitogen-activated protein kinase 14	0	0	1	1
Chain A, Mitogen-activated protein kinase 14	0	0	1	1
Chain A, Mitogen-activated protein kinase 14	0	0	1	1
Chain A, Mitogen-activated protein kinase 14	0	0	1	1
RuvB-like 2	0	1	1	2
Chain A, Acetyl-CoA carboxylase 2	0	0	1	1
Cyclic AMP-dependent transcription factor ATF-1	0	1	0	1
Ubiquitin carboxyl-terminal hydrolase 10	0	1	0	1
Ubiquitin carboxyl-terminal hydrolase 13	0	1	0	1
Sulfate anion transporter 1	0	0	0	1
C-X-C chemokine receptor type 5 isoform 1	0	1	0	1
Endoglycoceramidase II	0	0	0	1
5-hydroxytryptamine receptor 1E	0	1	0	1
sphingosine 1-phosphate receptor 3	0	1	0	1
D(3) dopamine receptor	0	1	0	1
5-hydroxytryptamine receptor 7	0	1	0	1
D(4) dopamine receptor	0	1	0	1
D(1B) dopamine receptor	0	1	0	1
Chain A, Mineralocorticoid receptor	0	1	0	1
Chain A, Mineralocorticoid receptor	0	1	0	1
Orexin receptor type 1	0	2	0	3
Nuclear receptor subfamily 1 group D member 1	0	2	3	5
Nuclear receptor subfamily 1 group D member 2	0	2	0	2
Chain A, Serine/threonine-protein kinase Chk1	0	1	0	1
Chain A, Serine/threonine-protein kinase Chk1	0	1	0	1
Chain A, Serine/threonine-protein kinase Chk1	0	1	0	1
Chain E, Camp-dependent Protein Kinase	0	1	0	1
Chain A, Tyrosine-protein kinase ZAP-70	0	1	0	1
Chain A, Tyrosine-protein kinase SYK	0	1	0	1
Chain A, Protein kinase C, theta type	0	1	0	1
Chain X, Proto-oncogene tyrosine-protein kinase Fyn	0	1	0	1
Chain A, Serine/threonine-protein kinase TAO2	0	1	0	1
Casein kinase II subunit alpha'	0	1	0	1
Cyclin-T2	0	1	0	1
Retinoblastoma-associated protein	0	1	0	1
Cyclin-dependent kinase 1	0	1	0	1
Insulin receptor	0	1	0	1
Cyclin-O	0	1	0	1
Hexokinase-4	0	1	0	1
Phosphorylase b kinase regulatory subunit alpha, liver isoform	0	1	0	1
Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform	0	1	0	1
Mitogen-activated protein kinase 1	0	1	0	1
Casein kinase II subunit beta	0	1	0	1
Mitogen-activated protein kinase kinase kinase 21	0	1	0	1
Casein kinase II subunit alpha	0	1	0	1
Testis-specific serine/threonine-protein kinase 1	0	1	0	1
Kinase suppressor of Ras 2	0	1	0	1
Serine/threonine-protein kinase Nek8	0	1	0	1
Casein kinase II subunit alpha'-interacting protein	0	1	0	1
Kinase suppressor of Ras 1	0	1	0	1
Protein odd-skipped-related 1	0	1	0	1
Phosphorylase b kinase regulatory subunit beta	0	1	0	1
Lymphokine-activated killer T-cell-originated protein kinase	0	1	0	1
Testis-specific serine/threonine-protein kinase 3	0	1	0	1
Testis-specific serine/threonine-protein kinase 6	0	1	0	1
Serine/threonine-protein kinase WNK1	0	1	0	1
Inactive tyrosine-protein kinase PEAK1	0	1	0	1
Serine/threonine-protein kinase Sgk2	0	1	0	1
Chain A, Ribosomal protein S6 kinase alpha-1	0	1	0	1
Chain X, Tyrosine-protein kinase Lyn	0	1	0	1
Chain A, Dual specificity protein kinase TTK	0	0	1	1
Chain A, Dual specificity protein kinase TTK	0	0	1	1
Zinc finger protein GLI2	0	2	0	2
Rho guanine nucleotide exchange factor 1	0	1	0	1
DNA repair and recombination protein RAD54-like	0	0	1	1
Sentrin-specific protease 6	0	1	0	1
Sentrin-specific protease 2	0	1	0	1
Protein-arginine deiminase type-1	0	1	0	1
Protein-arginine deiminase type-3	0	1	0	1
Protein-arginine deiminase type-2	0	1	0	1
Glycine receptor subunit beta	0	1	0	1
Chain A, Cell division protein kinase 2	0	1	0	1
Chain A, Cell division protein kinase 2	0	1	0	1
Chain A, Cell division protein kinase 2	0	1	0	1
Chain A, Cell division protein kinase 2	0	1	0	1
Solute carrier family 13 member 3	0	1	0	1
Chain A, MALTOPORIN	0	0	1	1
Chain B, MALTOPORIN	0	0	1	1
Metallo-beta-lactamase type 2	0	2	0	2
Protein argonaute-2	0	0	3	3
ATP-dependent 6-phosphofructokinase	0	2	0	2
Dihydropteroate synthase	0	2	0	2
Chain A, Glutathione S-transferase	0	1	0	1
Transcription regulator protein BACH1	0	1	0	1
Transcription factor MafK	0	1	0	1
PSMD14 protein	0	2	0	2
drug resistance protein 2	0	0	1	1
TPA: prothrombin	0	2	0	2
72 kDa type IV collagenase isoform 1 preproprotein	0	2	0	2
D(2) dopamine receptor	0	1	0	1
Ectonucleoside triphosphate diphosphohydrolase 2	0	1	0	1
Ectonucleoside triphosphate diphosphohydrolase 1	0	1	0	1
Ectonucleoside triphosphate diphosphohydrolase 8	0	1	0	1
Ectonucleoside triphosphate diphosphohydrolase 3	0	1	0	1
Orexin receptor type 2	0	2	0	2
Orexin receptor type 1	0	1	0	1
Orexin receptor type 2	0	1	0	1
Chain A, Alpha-mannosidase Ii	0	1	0	1
Chain A, ALPHA-MANNOSIDASE II	0	1	0	1
Chain A, Alpha-mannosidase Ii	0	1	0	1
Mannosyl-oligosaccharide alpha-1,2-mannosidase IA	0	2	0	2
Alpha-mannosidase 2	0	1	0	1
Alpha-1,2-mannosidase family protein	0	1	0	1
Putative alpha-1,2-mannosidase	0	1	0	1
Alpha-1,2-mannosidase, putative	0	1	0	1
Putative alpha-1,2-mannosidase	0	1	0	1
Putative alpha-1,2-mannosidase	0	1	0	1
Putative alpha-1,2-mannosidase	0	1	0	1
Putative alpha-1,2-mannosidase	0	1	0	1
Glycoside hydrolase family 92	0	1	0	1
Glycoside hydrolase family 92	0	1	0	1
Alpha-1,2-mannosidase	0	1	0	1
Putative alpha-1,2-mannosidase	0	1	0	1
Alpha-1,2-mannosidase, putative	0	1	0	1
Putative alpha-1,2-mannosidase	0	1	0	1
Alpha-1,2-mannosidase	0	1	0	1
Alpha-1,2-mannosidase, putative	0	1	0	1
Putative alpha-1,2-mannosidase	0	1	0	1
Putative alpha-1,2-mannosidase	0	1	0	1
Alpha-1,2-mannosidase	0	1	0	1
Putative alpha-1,2-mannosidase	0	1	0	1
Putative alpha-1,2-mannosidase	0	1	0	1
Putative alpha-1,2-mannosidase	0	1	0	1
Putative alpha-1,2-mannosidase	0	1	0	1
Alpha-1,2-mannosidase family protein	0	1	0	1
alpha-1,2-Mannosidase	0	1	0	1
Forkhead box protein O3	0	0	1	1
Chain A, Oxysterols receptor LXR-beta	0	1	0	1
Chain A, Oxysterols receptor LXR-beta	0	1	0	1
Nuclear receptor ROR-alpha	0	3	1	4
Oxysterols receptor LXR-beta	0	0	1	1
Oxysterols receptor LXR-beta	0	0	1	1
Nuclear receptor ROR-beta	0	2	1	3
Chain A, ACETYLCHOLINESTERASE	0	1	0	1
Chain A, liver Carboxylesterase I	0	1	0	1
Gastrotropin	0	0	1	1
Collagenase 3	0	1	0	1
Chain A, FOCAL ADHESION KINASE 1	0	1	0	1
Chain A, FOCAL ADHESION KINASE 1	0	1	0	1
Chain A, FOCAL ADHESION KINASE 1	0	1	0	1
Chain A, FOCAL ADHESION KINASE 1	0	1	0	1
Chain A, Epidermal growth factor receptor	0	1	0	1
Chain A, Receptor tyrosine-protein kinase erbB-2	0	1	0	1
Chain A, Receptor tyrosine-protein kinase erbB-2	0	1	0	1
Chain A, PROTEIN (CRABP-I)	0	1	0	1
Chain A, PROTEIN (CRABP-II)	0	1	0	1
Chain A, PROTEIN (CRABP-II)	0	1	0	1
DNA topoisomerase 1	0	1	0	1
Chain A, CES1 protein	0	1	0	1
Emopamil-binding protein-like	0	2	0	2
7-dehydrocholesterol reductase	0	1	1	2
Heat-shock protein	0	1	0	1
menin isoform 1	1	0	0	1
Chain A, Prostatic Acid Phosphatase	0	1	0	1
Sodium/bile acid cotransporter	0	0	0	1
Ileal sodium/bile acid cotransporter	0	0	0	1
Ileal sodium/bile acid cotransporter	0	0	0	1
Solute carrier organic anion transporter family member 4A1	0	0	0	2
Beta-lactamase	0	1	0	1
Cytochrome P450 14alpha-demethylase	0	0	2	2
Stromal interaction molecule 1	0	1	0	1
Chain A, Peroxisome proliferator-activated receptor gamma	0	1	0	1
Chain A, Peroxisome proliferator-activated receptor gamma	0	1	0	1
cGMP-gated cation channel alpha-1	0	0	1	1
Tetracycline resistance protein, class B	0	0	0	1
Ras guanyl-releasing protein 3	0	0	1	1
Solute carrier family 22 member 3	0	0	0	1
Solute carrier family 22 member 4	0	0	0	1
Chain A, Multidrug-efflux Transporter 1 Regulator Bmrr	0	0	1	1
Alpha-enolase	0	1	0	1
Chain A, Pyridoxal kinase	0	1	0	1
Chain A, Pyridoxal Kinase	0	1	0	1
Serine palmitoyltransferase 1	0	0	1	1
Serine palmitoyltransferase 2	0	1	0	1
Chain A, Methionine aminopeptidase	0	1	0	1
Chain A, ykoF	0	0	1	1
Chain B, ykoF	0	0	1	1
Chain A, ThiT	0	0	1	1
Thiamine transporter ThiT	0	0	1	1
Transketolase	0	0	1	1
Thiamine-binding periplasmic protein	0	0	1	1
1-deoxy-D-xylulose-5-phosphate synthase	0	0	1	1
1-deoxy-D-xylulose-5-phosphate synthase	0	0	1	1
Chain D, HEAT-LABILE ENTEROTOXIN	0	1	0	1
Chain E, HEAT-LABILE ENTEROTOXIN	0	1	0	1
Chain D, Heat-labile Enterotoxin	0	1	0	1
Chain E, Heat-labile Enterotoxin	0	1	0	1
Chain A, Galectin-1	0	0	1	1
Chain A, Galectin-1	0	0	1	1
Galectin-2	0	0	1	1
Galectin-1	0	0	1	1
Galectin-4	0	0	1	1
nucleotide-binding oligomerization domain-containing protein 1 isoform 1	0	1	0	1
Chain A, BETA-KETOACYL-[ACYL CARRIER PROTEIN] SYNTHASE I	0	0	1	1
Chain A, 3-OXOACYL-[ACYL-CARRIER-PROTEIN] SYNTHASE 1	0	0	1	1
Chain A, 3-OXOACYL-[ACYL-CARRIER-PROTEIN] SYNTHASE 1	0	0	1	1
Chain B, 3-OXOACYL-[ACYL-CARRIER-PROTEIN] SYNTHASE 1	0	0	1	1
3-oxoacyl-[acyl-carrier-protein] synthase 1	0	1	0	1
3-oxoacyl-[acyl-carrier-protein] synthase 3	0	1	0	1
3-oxoacyl-[acyl-carrier-protein] synthase 2	0	1	0	1
3-oxoacyl-[acyl-carrier-protein] synthase 2	0	0	1	1
Neprilysin	0	1	0	1
Urease subunit alpha	0	1	0	1
Thymidine kinase	0	2	0	4
Thymidine kinase	0	1	0	3
Nucleoside diphosphate kinase A	0	0	0	1
Chain A, Deoxynucleoside kinase	0	1	0	1
Chain A, Thymidylate Synthase	0	0	1	1
Thymidine phosphorylase	0	1	0	1
Chain X, Thyroid hormone receptor beta-1	0	0	2	2
Chain X, Thyroid hormone receptor beta-1	0	0	2	2
Malate dehydrogenase, mitochondrial	0	1	0	1
Monocarboxylate transporter 8	0	0	0	1
Solute carrier organic anion transporter family member 1C1	0	0	0	1
P2Y purinoceptor 13	0	1	0	1
Chain B, Protein farnesyltransferase beta subunit	0	1	0	1
Integrin subunit alpha 2b	0	1	0	1
Integrin beta-3	0	1	0	1
Chain A, Adam 17	0	1	0	1
Chain A, Tyrosine-protein kinase	0	1	0	1
Chain A, Tyrosine-protein kinase	0	1	0	1
Chain A, Tyrosine-protein kinase JAK2	0	1	0	1
Tyrosine-protein kinase JAK3	0	1	0	1
Tyrosine-protein kinase JAK2	0	1	0	1
Tyrosine-protein kinase JAK3	0	1	0	1
Chain A, Carbonic anhydrase 1	0	1	0	1
Carbonic anhydrase 2	0	1	0	1
Acrosin	0	1	0	1
Cell division protein FtsZ	0	1	0	1
Cell division protein FtsZ	0	0	1	1
cathepsin S isoform 1 preproprotein	0	1	0	1
Chain A, RIO-type serine/threonine-protein kinase Rio1	0	0	1	1
Spermidine synthase, putative	0	1	0	1
Spermidine synthase	0	1	0	1
REST corepressor 3	0	2	0	2
Chain A, X-ray structure of the sucrose-phosphatase (SPP) from Synechocystis sp.PCC6803 in complex with trehalose	0	1	0	1
Chain A, X-ray structure of the sucrose-phosphatase (SPP) from Synechocystis sp.PCC6803 in complex with cellobiose	0	1	0	1
Chain A, X-ray structure of the sucrose-phosphatase (SPP) from Synechocystis sp.PCC6803 in complex with maltose	0	1	0	1
Trehalose-phosphatase	0	1	0	1
Nitroreductase	0	0	0	1
Chain A, Nuclear Receptor ROR-beta	0	1	0	1
Chain A, HDLP (HISTONE DEACETYLASE-LIKE PROTEIN)	0	1	0	1
Chain B, HDLP (HISTONE DEACETYLASE-LIKE PROTEIN)	0	1	0	1
Chain A, Histone deacetylase 7a	0	1	0	1
Chain A, Histone deacetylase 7a	0	1	0	1
Histone deacetylase	0	2	0	2
unnamed protein product	0	0	0	1
Histone deacetylase 1	0	5	0	5
Histone deacetylase 3	0	1	0	1
Histone deacetylase 2	0	1	0	1
Histone deacetylase 1	0	2	0	2
Histone deacetylase	0	2	0	2
Histone deacetylase 4	0	1	0	1
Polyamine deacetylase HDAC10	0	1	0	1
Histone deacetylase 3	0	2	0	2
Histone deacetylase 7	0	1	0	1
Histone deacetylase 8	0	1	0	1
Histone deacetylase 11	0	1	0	1
HD2 type histone deacetylase HDA106	0	6	0	6
Histone deacetylase 9	0	1	0	1
Histone deacetylase 7	0	2	0	2
Histone deacetylase 6	0	2	0	2
Histone deacetylase 4	0	2	0	2
Histone deacetylase 5	0	1	0	1
Histone deacetylase	0	2	0	2
Chain A, enoyl-acyl carrier reductase	0	1	0	1
Chain C, enoyl-acyl carrier reductase	0	1	0	1
Chain A, enoyl-acyl carrier reductase	0	1	0	1
Chain C, enoyl-acyl carrier reductase	0	1	0	1
Chain A, enoyl-acyl carrier reductase	0	1	0	1
Chain C, enoyl-acyl carrier reductase	0	1	0	1
Chain A, Repressor	0	0	1	1
Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	0	1	0	1
Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	0	1	0	1
Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI	0	2	0	2
Enoyl-acyl carrier reductase	0	1	0	1
Enoyl-ACP reductase II	0	1	0	1
Delta	0	1	0	1
Cycloeucalenol cycloisomerase	0	1	0	1
Sterol-8,7-isomerase	0	1	0	1
Thialysine N-epsilon-acetyltransferase	0	0	0	1
Chain A, Dihydrofolate Reductase	0	0	1	1
Chain A, Dihydrofolate reductase	0	1	0	1
Chain A, dihydrofolate reductase (DHFR)	0	1	0	1
Chain A, Dihydrofolate reductase	0	1	0	1
Chain A, Dihydrofolate reductase	0	1	0	1
Dihydrofolate reductase type 1	0	1	0	2
Dihydrofolate reductase	0	1	0	1
Dihydrofolate reductase type 1 from Tn4003	0	1	0	1
Bifunctional dihydrofolate reductase-thymidylate synthase	0	1	0	1
Dihydrofolate reductase	0	1	0	1
Dihydrofolate reductase	0	1	0	1
Dihydrofolate reductase	0	1	0	1
Forkhead box protein M1	0	2	0	2
Chain A, CARBONIC ANHYDRASE II	0	1	0	1
5-hydroxytryptamine receptor 4	0	0	0	1
Strictosidine synthase	0	0	0	1
5-hydroxytryptamine receptor 5A	0	1	0	1
Chain A, Trp Rna-binding Attenuation Protein	0	0	1	1
Chain K, Trp Rna-binding Attenuation Protein	0	0	1	1
Chain B, tryptophanyl-tRNA synthetase	0	0	1	1
Chain C, Tryptophanyl-tRNA synthetase II	0	0	1	1
Tryprostatin B synthase	0	0	0	1
Polyamine deacetylase HDAC10	0	1	0	1
Chain A, Purine nucleoside phosphorylase	0	1	0	1
Chain A, Purine nucleoside phosphorylase DeoD-type	0	1	0	1
Myc proto-oncogene protein	0	1	0	1
Transcription factor AP-1	0	1	0	1
Chain A, CHORISMATE MUTASE	0	1	0	1
Chain A, TYROSYL-tRNA SYNTHETASE	0	0	1	1
Chain A, Carbonic anhydrase 2	0	1	0	1
Chain A, Carbonic anhydrase 2	0	1	0	1
Chain A, Carbonic anhydrase 2	0	1	0	1
Chain A, Carbonic anhydrase 2	0	1	0	1
Chain A, Carbonic anhydrase 2	0	1	0	1
Chain A, Bacterial leucyl aminopeptidase	0	1	0	1
Aminopeptidase B	0	2	0	2
M1 family aminopeptidase	0	2	0	2
Cytosol aminopeptidase	0	2	0	2
Aminopeptidase N	0	1	0	1
Interleukin-1 receptor antagonist protein	0	1	0	1
Aminopeptidase N	0	2	0	2
Bacterial leucyl aminopeptidase	0	2	0	2
Endoplasmic reticulum aminopeptidase 2	0	1	0	1
Aminopeptidase B	0	1	0	1
Endoplasmic reticulum aminopeptidase 1	0	1	0	1
Photinus pyralis luciferase	1	0	0	1
Golgi-associated PDZ and coiled-coil motif-containing protein isoform b	0	0	0	1
Histone acetyltransferase GCN5	0	1	0	1
Histone acetyltransferase RTT109	0	1	0	1
Spindlin-1	0	1	0	1
Chain A, Uracil-DNA Glycosylase	0	1	0	1
Fatty-acid amide hydrolase 2	0	1	0	1
CAD protein	0	0	0	1
Chain A, Cytidine Deaminase	0	1	0	1
UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit	0	1	0	1
P2Y purinoceptor 14	0	0	4	4
P2Y purinoceptor 6	0	0	1	1
Beta-1,4-galactosyltransferase 1	0	0	0	1
N-acetyllactosaminide alpha-1,3-galactosyltransferase	0	0	0	1
Chain A, orotidine 5'-monophosphate decarboxylase	0	1	0	1
Chain B, orotidine 5'-monophosphate decarboxylase	0	1	0	1
Chain A, orotidine 5'-monophosphate decarboxylase	0	1	0	1
Chain A, orotidine monophosphate decarboxylase	0	1	0	1
Chain A, orotidine monophosphate decarboxylase	0	1	0	1
Chain B, orotidine monophosphate decarboxylase	0	1	0	1
Chain B, PyrR bifunctional protein	0	0	1	1
N-acetyllactosaminide alpha-1,3-galactosyltransferase	0	1	0	1
P2Y purinoceptor 2	0	1	1	2
P2Y purinoceptor 2	0	0	1	1
Basic phospholipase A2 1	0	1	0	1
Hemagglutinin	0	0	1	1
Basic phospholipase A2 PLA-A	0	1	0	1
Acidic phospholipase A2 EC-I	0	1	0	1
Valacyclovir hydrolase	0	0	0	1
Chain A, Carbonic anhydrase II	0	1	0	1
Chain A, Arginase 1	0	1	0	1
Aldo-keto reductase family 1 member A1	0	1	0	1
Aldo-keto reductase family 1 member B7	0	2	0	2
D-alanyl-D-alanine dipeptidase	0	1	0	1
Chain A, Heat shock protein HSP 90-alpha	0	1	0	1
Chain A, Heat shock protein HSP 90-alpha	0	1	0	1
Chain A, Heat shock protein HSP 90-alpha	0	1	0	1
Chain A, HEAT SHOCK PROTEIN HSP 90-ALPHA	0	0	1	1
Glycoprotein	0	1	0	1
Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7	0	1	0	1
Dipeptidyl peptidase 4	0	1	0	1
Chain A, RETINOL BINDING PROTEIN	0	0	1	1
Chain A, Histone deacetylase-like amidohydrolase	0	1	0	1
Chain A, Histone deacetylase-like amidohydrolase	0	1	0	1
Gli1	0	1	0	1
protein Wnt-3a precursor	0	1	0	1
Leukotriene A-4 hydrolase	0	1	0	1
Renin	0	1	0	1
Histone deacetylase	0	1	0	1
Putative alpha-1-antitrypsin-related protein	0	1	0	1
Receptor-interacting serine/threonine-protein kinase 1	0	1	0	1
Vitamin K epoxide reductase complex subunit 1-like protein 1	0	1	0	1
Vitamin K epoxide reductase complex subunit 1	0	1	0	1
Vitamin K epoxide reductase complex subunit 1-like protein 1	0	1	0	1
Vitamin K epoxide reductase complex subunit 1	0	2	0	2
Arachidonate 5-lipoxygenase	0	1	0	1
Telomere resolvase ResT	0	1	0	1
Chain A, glutamate receptor 2	0	1	0	1
Chain A, glutamate receptor 2	0	1	0	1
Chain A, glutamate receptor 2	0	1	0	1
Chain A, glutamate receptor 2	0	1	0	1
ADP-ribosylation factor GTPase-activating protein 1	0	1	0	1
Chain A, Tankyrase-2	0	0	1	1
Chain A, Tankyrase-1	0	1	0	1
Chain A, Tankyrase-1	0	1	0	1
Protein Wnt-3a	0	1	0	1
Axin-2	0	0	1	1
Chain A, Heat Shock Protein Hsp 90-alpha	0	1	0	1
Chain A, Heat Shock Protein Hsp 90-alpha	0	1	0	1
Chain A, Heat Shock Protein Hsp 90-alpha	0	1	0	1
1-phosphatidylinositol 3-phosphate 5-kinase	0	1	1	2
Farnesyl diphosphate synthase	0	2	0	2
Chain A, Guanine nucleotide-binding protein G(i) subunit alpha-1/Guanine nucleotide-binding protein G(q) subunit alpha chimeric protein	0	1	0	1
Chain B, Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1	0	1	0	1
Guanine nucleotide-binding protein G(o) subunit alpha	0	1	0	1
Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas	0	1	0	1
Piezo-type mechanosensitive ion channel component 1	0	0	1	1
Chain A, Neuraminidase	0	1	0	1
Chain A, Neuraminidase	0	1	0	1
Chain A, Neuraminidase	0	1	0	1
Chain A, Neuraminidase	0	1	0	1
Chain A, Neuraminidase	0	1	0	1
Chain A, Neuraminidase	0	1	0	1
Chain A, NEURAMINIDASE	0	1	0	1
Chain A, Neuraminidase	0	1	0	1
Neuraminidase	0	1	0	1
Sialidase-1	0	1	0	1
Neuraminidase	0	1	0	1
Neuraminidase	0	1	1	2
Neuraminidase	0	1	0	1
Neuraminidase	0	1	0	1
Neuraminidase	0	1	0	1
Neuraminidase	0	1	0	1
Neuraminidase	0	1	0	1
Alkaline phosphatase, tissue-nonspecific isozyme	0	1	0	1
Chain A, Phosphodiesterase 4D	0	1	0	1
Chain A, cytokinin-specific binding protein	0	0	1	1
Histidine kinase 4	0	0	1	1
Histidine kinase 3	0	0	1	1
Ectonucleoside triphosphate diphosphohydrolase 1	0	0	0	1
Tumor necrosis factor ligand superfamily member 11	0	1	0	1
Chain A, Cytosol aminopeptidase	0	1	0	1
Amine oxidase [flavin-containing]	0	1	0	1
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Synonyms(8)

Research Excerpts

Overview

Context

Actions

Treatment

Research

Studies (99,681)

Protein Targets (6,470)

Benign Neoplasms

Synonyms(8)

Research Excerpts

Overview

Context

Actions

Treatment

Research

Studies (99,681)

Drugs Studied (10,501)

Protein Targets (6,470)